text,label,seq_length,text_4mer,text_5mer,text_6mer,text_7mer,annotation,orig_index
GTAATT TAATTC AATTCC ATTCCT TTCCTT TCCTTA CCTTAC CTTACC TTACCT TACCTG ACCTGA CCTGAA CTGAAA TGAAAC GAAACG AAACGT AACGTA ACGTAA CGTAAG GTAAGC TAAGCC AAGCCG AGCCGA GCCGAA CCGAAA CGAAAA GAAAAA AAAAAA AAAAAC AAAACG AAACGT AACGTC ACGTCA CGTCAG GTCAGC TCAGCT CAGCTT AGCTTT GCTTTC CTTTCG TTTCGG TTCGGT TCGGTG CGGTGG GGTGGC GTGGCG TGGCGG GGCGGA GCGGAG CGGAGT GGAGTT GAGTTT AGTTTG GTTTGT TTTGTT TTGTTG TGTTGA GTTGAG TTGAGG TGAGGG GAGGGG AGGGGA GGGGAT GGGATT GGATTG GATTGT ATTGTG TTGTGA TGTGAT GTGATA TGATAG GATAGG ATAGGC TAGGCG AGGCGA GGCGAC GCGACA CGACAT GACATT ACATTA CATTAC ATTACT TTACTA TACTAT ACTATT CTATTT TATTTT ATTTTG TTTTGA TTTGAG TTGAGC TGAGCC GAGCCA AGCCAG GCCAGG CCAGGC CAGGCT AGGCTG GGCTGT GCTGTG CTGTGA TGTGAC GTGACA TGACAT GACATT ACATTA CATTAG ATTAGT TTAGTG TAGTGG AGTGGA GTGGAA TGGAAA GGAAAG GAAAGT AAAGTG AAGTGT AGTGTG GTGTGA TGTGAA GTGAAA TGAAAC GAAACC AAACCG AACCGG ACCGGA CCGGAA CGGAAC GGAACA GAACAT AACATC ACATCA CATCAG ATCAGG TCAGGC CAGGCC AGGCCG GGCCGT GCCGTA CCGTAG CGTAGC GTAGCA,3,142,GTAA TAAT AATT ATTC TTCC TCCT CCTT CTTA TTAC TACC ACCT CCTG CTGA TGAA GAAA AAAC AACG ACGT CGTA GTAA TAAG AAGC AGCC GCCG CCGA CGAA GAAA AAAA AAAA AAAA AAAC AACG ACGT CGTC GTCA TCAG CAGC AGCT GCTT CTTT TTTC TTCG TCGG CGGT GGTG GTGG TGGC GGCG GCGG CGGA GGAG GAGT AGTT GTTT TTTG TTGT TGTT GTTG TTGA TGAG GAGG AGGG GGGG GGGA GGAT GATT ATTG TTGT TGTG GTGA TGAT GATA ATAG TAGG AGGC GGCG GCGA CGAC GACA ACAT CATT ATTA TTAC TACT ACTA CTAT TATT ATTT TTTT TTTG TTGA TGAG GAGC AGCC GCCA CCAG CAGG AGGC GGCT GCTG CTGT TGTG GTGA TGAC GACA ACAT CATT ATTA TTAG TAGT AGTG GTGG TGGA GGAA GAAA AAAG AAGT AGTG GTGT TGTG GTGA TGAA GAAA AAAC AACC ACCG CCGG CGGA GGAA GAAC AACA ACAT CATC ATCA TCAG CAGG AGGC GGCC GCCG CCGT CGTA GTAG TAGC AGCA,GTAAT TAATT AATTC ATTCC TTCCT TCCTT CCTTA CTTAC TTACC TACCT ACCTG CCTGA CTGAA TGAAA GAAAC AAACG AACGT ACGTA CGTAA GTAAG TAAGC AAGCC AGCCG GCCGA CCGAA CGAAA GAAAA AAAAA AAAAA AAAAC AAACG AACGT ACGTC CGTCA GTCAG TCAGC CAGCT AGCTT GCTTT CTTTC TTTCG TTCGG TCGGT CGGTG GGTGG GTGGC TGGCG GGCGG GCGGA CGGAG GGAGT GAGTT AGTTT GTTTG TTTGT TTGTT TGTTG GTTGA TTGAG TGAGG GAGGG AGGGG GGGGA GGGAT GGATT GATTG ATTGT TTGTG TGTGA GTGAT TGATA GATAG ATAGG TAGGC AGGCG GGCGA GCGAC CGACA GACAT ACATT CATTA ATTAC TTACT TACTA ACTAT CTATT TATTT ATTTT TTTTG TTTGA TTGAG TGAGC GAGCC AGCCA GCCAG CCAGG CAGGC AGGCT GGCTG GCTGT CTGTG TGTGA GTGAC TGACA GACAT ACATT CATTA ATTAG TTAGT TAGTG AGTGG GTGGA TGGAA GGAAA GAAAG AAAGT AAGTG AGTGT GTGTG TGTGA GTGAA TGAAA GAAAC AAACC AACCG ACCGG CCGGA CGGAA GGAAC GAACA AACAT ACATC CATCA ATCAG TCAGG CAGGC AGGCC GGCCG GCCGT CCGTA CGTAG GTAGC TAGCA,GTAATT TAATTC AATTCC ATTCCT TTCCTT TCCTTA CCTTAC CTTACC TTACCT TACCTG ACCTGA CCTGAA CTGAAA TGAAAC GAAACG AAACGT AACGTA ACGTAA CGTAAG GTAAGC TAAGCC AAGCCG AGCCGA GCCGAA CCGAAA CGAAAA GAAAAA AAAAAA AAAAAC AAAACG AAACGT AACGTC ACGTCA CGTCAG GTCAGC TCAGCT CAGCTT AGCTTT GCTTTC CTTTCG TTTCGG TTCGGT TCGGTG CGGTGG GGTGGC GTGGCG TGGCGG GGCGGA GCGGAG CGGAGT GGAGTT GAGTTT AGTTTG GTTTGT TTTGTT TTGTTG TGTTGA GTTGAG TTGAGG TGAGGG GAGGGG AGGGGA GGGGAT GGGATT GGATTG GATTGT ATTGTG TTGTGA TGTGAT GTGATA TGATAG GATAGG ATAGGC TAGGCG AGGCGA GGCGAC GCGACA CGACAT GACATT ACATTA CATTAC ATTACT TTACTA TACTAT ACTATT CTATTT TATTTT ATTTTG TTTTGA TTTGAG TTGAGC TGAGCC GAGCCA AGCCAG GCCAGG CCAGGC CAGGCT AGGCTG GGCTGT GCTGTG CTGTGA TGTGAC GTGACA TGACAT GACATT ACATTA CATTAG ATTAGT TTAGTG TAGTGG AGTGGA GTGGAA TGGAAA GGAAAG GAAAGT AAAGTG AAGTGT AGTGTG GTGTGA TGTGAA GTGAAA TGAAAC GAAACC AAACCG AACCGG ACCGGA CCGGAA CGGAAC GGAACA GAACAT AACATC ACATCA CATCAG ATCAGG TCAGGC CAGGCC AGGCCG GGCCGT GCCGTA CCGTAG CGTAGC GTAGCA,GTAATTC TAATTCC AATTCCT ATTCCTT TTCCTTA TCCTTAC CCTTACC CTTACCT TTACCTG TACCTGA ACCTGAA CCTGAAA CTGAAAC TGAAACG GAAACGT AAACGTA AACGTAA ACGTAAG CGTAAGC GTAAGCC TAAGCCG AAGCCGA AGCCGAA GCCGAAA CCGAAAA CGAAAAA GAAAAAA AAAAAAC AAAAACG AAAACGT AAACGTC AACGTCA ACGTCAG CGTCAGC GTCAGCT TCAGCTT CAGCTTT AGCTTTC GCTTTCG CTTTCGG TTTCGGT TTCGGTG TCGGTGG CGGTGGC GGTGGCG GTGGCGG TGGCGGA GGCGGAG GCGGAGT CGGAGTT GGAGTTT GAGTTTG AGTTTGT GTTTGTT TTTGTTG TTGTTGA TGTTGAG GTTGAGG TTGAGGG TGAGGGG GAGGGGA AGGGGAT GGGGATT GGGATTG GGATTGT GATTGTG ATTGTGA TTGTGAT TGTGATA GTGATAG TGATAGG GATAGGC ATAGGCG TAGGCGA AGGCGAC GGCGACA GCGACAT CGACATT GACATTA ACATTAC CATTACT ATTACTA TTACTAT TACTATT ACTATTT CTATTTT TATTTTG ATTTTGA TTTTGAG TTTGAGC TTGAGCC TGAGCCA GAGCCAG AGCCAGG GCCAGGC CCAGGCT CAGGCTG AGGCTGT GGCTGTG GCTGTGA CTGTGAC TGTGACA GTGACAT TGACATT GACATTA ACATTAG CATTAGT ATTAGTG TTAGTGG TAGTGGA AGTGGAA GTGGAAA TGGAAAG GGAAAGT GAAAGTG AAAGTGT AAGTGTG AGTGTGA GTGTGAA TGTGAAA GTGAAAC TGAAACC GAAACCG AAACCGG AACCGGA ACCGGAA CCGGAAC CGGAACA GGAACAT GAACATC AACATCA ACATCAG CATCAGG ATCAGGC TCAGGCC CAGGCCG AGGCCGT GGCCGTA GCCGTAG CCGTAGC CGTAGCA,"ID   Y1496_MYCTO             Reviewed;         336 AA.
AC   P9WPZ0; L0T711; P63577; P71777;
DT   16-APR-2014, integrated into UniProtKB/Swiss-Prot.
DT   25-MAY-2022, sequence version 2.
DT   05-FEB-2025, entry version 49.
DE   RecName: Full=Probable GTPase MT1543;
DE            EC=3.6.-.-;
GN   OrderedLocusNames=MT1543;
OS   Mycobacterium tuberculosis (strain CDC 1551 / Oshkosh).
OC   Bacteria; Bacillati; Actinomycetota; Actinomycetes; Mycobacteriales;
OC   Mycobacteriaceae; Mycobacterium; Mycobacterium tuberculosis complex.
OX   NCBI_TaxID=83331;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=CDC 1551 / Oshkosh;
RX   PubMed=12218036; DOI=10.1128/jb.184.19.5479-5490.2002;
RA   Fleischmann R.D., Alland D., Eisen J.A., Carpenter L., White O.,
RA   Peterson J.D., DeBoy R.T., Dodson R.J., Gwinn M.L., Haft D.H., Hickey E.K.,
RA   Kolonay J.F., Nelson W.C., Umayam L.A., Ermolaeva M.D., Salzberg S.L.,
RA   Delcher A., Utterback T.R., Weidman J.F., Khouri H.M., Gill J., Mikula A.,
RA   Bishai W., Jacobs W.R. Jr., Venter J.C., Fraser C.M.;
RT   ""Whole-genome comparison of Mycobacterium tuberculosis clinical and
RT   laboratory strains."";
RL   J. Bacteriol. 184:5479-5490(2002).
CC   -!- FUNCTION: Probable GTPase. May also bind and hydrolyze ATP. May
CC       function as chaperone (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Homodimer. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the SIMIBI class G3E GTPase family. ArgK/MeaB
CC       subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAK45810.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000250|UniProtKB:P9WPZ1};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AE000516; AAK45810.1; ALT_INIT; Genomic_DNA.
DR   PIR; C70712; C70712.
DR   AlphaFoldDB; P9WPZ0; -.
DR   SMR; P9WPZ0; -.
DR   KEGG; mtc:MT1543; -.
DR   PATRIC; fig|83331.31.peg.1660; -.
DR   HOGENOM; CLU_043725_2_2_11; -.
DR   Proteomes; UP000001020; Chromosome.
DR   GO; GO:0005737; C:cytoplasm; IEA:TreeGrafter.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005525; F:GTP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003924; F:GTPase activity; IEA:InterPro.
DR   CDD; cd03114; MMAA-like; 1.
DR   Gene3D; 1.10.287.130; -; 1.
DR   Gene3D; 1.20.5.170; -; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   InterPro; IPR005129; GTPase_ArgK.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   NCBIfam; TIGR00750; lao; 1.
DR   PANTHER; PTHR23408:SF3; METHYLMALONIC ACIDURIA TYPE A PROTEIN, MITOCHONDRIAL; 1.
DR   PANTHER; PTHR23408; METHYLMALONYL-COA MUTASE; 1.
DR   Pfam; PF03308; MeaB; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
PE   3: Inferred from homology;
KW   ATP-binding; Chaperone; GTP-binding; Hydrolase; Nucleotide-binding;
KW   Reference proteome.
FT   CHAIN           1..336
FT                   /note=""Probable GTPase MT1543""
FT                   /id=""PRO_0000426868""
FT   BINDING         67..75
FT                   /ligand=""GTP""
FT                   /ligand_id=""ChEBI:CHEBI:37565""
FT                   /evidence=""ECO:0000250""
FT   BINDING         209
FT                   /ligand=""GTP""
FT                   /ligand_id=""ChEBI:CHEBI:37565""
FT                   /evidence=""ECO:0000250""
FT   BINDING         245..247
FT                   /ligand=""GTP""
FT                   /ligand_id=""ChEBI:CHEBI:37565""
FT                   /evidence=""ECO:0000250""
SQ   SEQUENCE   336 AA;  36459 MW;  8B4AACF079CE66C7 CRC64;
     MAMMAASHDD DTVDGLATAV RGGDRAALPR AITLVESTRP DHREQAQQLL LRLLPDSGNA
     HRVGITGVPG VGKSTAIEAL GMHLIERGHR VAVLAVDPSS TRTGGSILGD KTRMARLAVH
     PNAYIRPSPT SGTLGGVTRA TRETVVLLEA AGFDVILIET VGVGQSEVAV ANMVDTFVLL
     TLARTGDQLQ GIKKGVLELA DIVVVNKADG EHHKEARLAA RELSAAIRLI YPREALWRPP
     VLTMSAVEGR GLAELWDTVE RHRQVLTGAG EFDARRRDQQ VDWTWQLVRD AVLDRVWSNP
     TVRKVRSELE RRVRAGELTP ALAAQQILEI ANLTDR
//
",30542
ATCCAC TCCACG CCACGC CACGCG ACGCGT CGCGTG GCGTGC CGTGCT GTGCTT TGCTTT GCTTTG CTTTGT TTTGTT TTGTTA TGTTAA GTTAAG TTAAGC TAAGCG AAGCGT AGCGTT GCGTTT CGTTTG GTTTGG TTTGGA TTGGAC TGGACT GGACTG GACTGG ACTGGA CTGGAC TGGACT GGACTC GACTCT ACTCTT CTCTTG TCTTGA CTTGAA TTGAAA TGAAAA GAAAAT AAAATC AAATCC AATCCT ATCCTA TCCTAT CCTATA CTATAC TATACT ATACTA TACTAG ACTAGG CTAGGG TAGGGG AGGGGG GGGGGT GGGGTG GGGTGA GGTGAA GTGAAC TGAACT GAACTA AACTAA ACTAAA CTAAAG TAAAGA AAAGAA AAGAAT AGAATA GAATAA AATAAT ATAATG TAATGC AATGCG ATGCGG TGCGGT GCGGTT CGGTTT GGTTTG GTTTGT TTTGTA TTGTAG TGTAGA GTAGAA TAGAAA AGAAAG GAAAGC AAAGCT AAGCTT AGCTTC GCTTCA CTTCAA TTCAAC TCAACA CAACAC AACACA ACACAT CACATA ACATAC CATACG ATACGT TACGTG ACGTGT CGTGTC GTGTCA TGTCAA GTCAAA TCAAAC CAAACC AAACCT AACCTG ACCTGC CCTGCA CTGCAT TGCATT GCATTA CATTAT ATTATT TTATTA TATTAG ATTAGC TTAGCA TAGCAG AGCAGA GCAGAC CAGACA AGACAA GACAAA ACAAAT CAAATT AAATTC AATTCT ATTCTC TTCTCA TCTCAG CTCAGC TCAGCT CAGCTC AGCTCT GCTCTT CTCTTC TCTTCA CTTCAC TTCACG TCACGA CACGAC,0,145,ATCC TCCA CCAC CACG ACGC CGCG GCGT CGTG GTGC TGCT GCTT CTTT TTTG TTGT TGTT GTTA TTAA TAAG AAGC AGCG GCGT CGTT GTTT TTTG TTGG TGGA GGAC GACT ACTG CTGG TGGA GGAC GACT ACTC CTCT TCTT CTTG TTGA TGAA GAAA AAAA AAAT AATC ATCC TCCT CCTA CTAT TATA ATAC TACT ACTA CTAG TAGG AGGG GGGG GGGG GGGT GGTG GTGA TGAA GAAC AACT ACTA CTAA TAAA AAAG AAGA AGAA GAAT AATA ATAA TAAT AATG ATGC TGCG GCGG CGGT GGTT GTTT TTTG TTGT TGTA GTAG TAGA AGAA GAAA AAAG AAGC AGCT GCTT CTTC TTCA TCAA CAAC AACA ACAC CACA ACAT CATA ATAC TACG ACGT CGTG GTGT TGTC GTCA TCAA CAAA AAAC AACC ACCT CCTG CTGC TGCA GCAT CATT ATTA TTAT TATT ATTA TTAG TAGC AGCA GCAG CAGA AGAC GACA ACAA CAAA AAAT AATT ATTC TTCT TCTC CTCA TCAG CAGC AGCT GCTC CTCT TCTT CTTC TTCA TCAC CACG ACGA CGAC,ATCCA TCCAC CCACG CACGC ACGCG CGCGT GCGTG CGTGC GTGCT TGCTT GCTTT CTTTG TTTGT TTGTT TGTTA GTTAA TTAAG TAAGC AAGCG AGCGT GCGTT CGTTT GTTTG TTTGG TTGGA TGGAC GGACT GACTG ACTGG CTGGA TGGAC GGACT GACTC ACTCT CTCTT TCTTG CTTGA TTGAA TGAAA GAAAA AAAAT AAATC AATCC ATCCT TCCTA CCTAT CTATA TATAC ATACT TACTA ACTAG CTAGG TAGGG AGGGG GGGGG GGGGT GGGTG GGTGA GTGAA TGAAC GAACT AACTA ACTAA CTAAA TAAAG AAAGA AAGAA AGAAT GAATA AATAA ATAAT TAATG AATGC ATGCG TGCGG GCGGT CGGTT GGTTT GTTTG TTTGT TTGTA TGTAG GTAGA TAGAA AGAAA GAAAG AAAGC AAGCT AGCTT GCTTC CTTCA TTCAA TCAAC CAACA AACAC ACACA CACAT ACATA CATAC ATACG TACGT ACGTG CGTGT GTGTC TGTCA GTCAA TCAAA CAAAC AAACC AACCT ACCTG CCTGC CTGCA TGCAT GCATT CATTA ATTAT TTATT TATTA ATTAG TTAGC TAGCA AGCAG GCAGA CAGAC AGACA GACAA ACAAA CAAAT AAATT AATTC ATTCT TTCTC TCTCA CTCAG TCAGC CAGCT AGCTC GCTCT CTCTT TCTTC CTTCA TTCAC TCACG CACGA ACGAC,ATCCAC TCCACG CCACGC CACGCG ACGCGT CGCGTG GCGTGC CGTGCT GTGCTT TGCTTT GCTTTG CTTTGT TTTGTT TTGTTA TGTTAA GTTAAG TTAAGC TAAGCG AAGCGT AGCGTT GCGTTT CGTTTG GTTTGG TTTGGA TTGGAC TGGACT GGACTG GACTGG ACTGGA CTGGAC TGGACT GGACTC GACTCT ACTCTT CTCTTG TCTTGA CTTGAA TTGAAA TGAAAA GAAAAT AAAATC AAATCC AATCCT ATCCTA TCCTAT CCTATA CTATAC TATACT ATACTA TACTAG ACTAGG CTAGGG TAGGGG AGGGGG GGGGGT GGGGTG GGGTGA GGTGAA GTGAAC TGAACT GAACTA AACTAA ACTAAA CTAAAG TAAAGA AAAGAA AAGAAT AGAATA GAATAA AATAAT ATAATG TAATGC AATGCG ATGCGG TGCGGT GCGGTT CGGTTT GGTTTG GTTTGT TTTGTA TTGTAG TGTAGA GTAGAA TAGAAA AGAAAG GAAAGC AAAGCT AAGCTT AGCTTC GCTTCA CTTCAA TTCAAC TCAACA CAACAC AACACA ACACAT CACATA ACATAC CATACG ATACGT TACGTG ACGTGT CGTGTC GTGTCA TGTCAA GTCAAA TCAAAC CAAACC AAACCT AACCTG ACCTGC CCTGCA CTGCAT TGCATT GCATTA CATTAT ATTATT TTATTA TATTAG ATTAGC TTAGCA TAGCAG AGCAGA GCAGAC CAGACA AGACAA GACAAA ACAAAT CAAATT AAATTC AATTCT ATTCTC TTCTCA TCTCAG CTCAGC TCAGCT CAGCTC AGCTCT GCTCTT CTCTTC TCTTCA CTTCAC TTCACG TCACGA CACGAC,ATCCACG TCCACGC CCACGCG CACGCGT ACGCGTG CGCGTGC GCGTGCT CGTGCTT GTGCTTT TGCTTTG GCTTTGT CTTTGTT TTTGTTA TTGTTAA TGTTAAG GTTAAGC TTAAGCG TAAGCGT AAGCGTT AGCGTTT GCGTTTG CGTTTGG GTTTGGA TTTGGAC TTGGACT TGGACTG GGACTGG GACTGGA ACTGGAC CTGGACT TGGACTC GGACTCT GACTCTT ACTCTTG CTCTTGA TCTTGAA CTTGAAA TTGAAAA TGAAAAT GAAAATC AAAATCC AAATCCT AATCCTA ATCCTAT TCCTATA CCTATAC CTATACT TATACTA ATACTAG TACTAGG ACTAGGG CTAGGGG TAGGGGG AGGGGGT GGGGGTG GGGGTGA GGGTGAA GGTGAAC GTGAACT TGAACTA GAACTAA AACTAAA ACTAAAG CTAAAGA TAAAGAA AAAGAAT AAGAATA AGAATAA GAATAAT AATAATG ATAATGC TAATGCG AATGCGG ATGCGGT TGCGGTT GCGGTTT CGGTTTG GGTTTGT GTTTGTA TTTGTAG TTGTAGA TGTAGAA GTAGAAA TAGAAAG AGAAAGC GAAAGCT AAAGCTT AAGCTTC AGCTTCA GCTTCAA CTTCAAC TTCAACA TCAACAC CAACACA AACACAT ACACATA CACATAC ACATACG CATACGT ATACGTG TACGTGT ACGTGTC CGTGTCA GTGTCAA TGTCAAA GTCAAAC TCAAACC CAAACCT AAACCTG AACCTGC ACCTGCA CCTGCAT CTGCATT TGCATTA GCATTAT CATTATT ATTATTA TTATTAG TATTAGC ATTAGCA TTAGCAG TAGCAGA AGCAGAC GCAGACA CAGACAA AGACAAA GACAAAT ACAAATT CAAATTC AAATTCT AATTCTC ATTCTCA TTCTCAG TCTCAGC CTCAGCT TCAGCTC CAGCTCT AGCTCTT GCTCTTC CTCTTCA TCTTCAC CTTCACG TTCACGA TCACGAC,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",10996
CCCTCT CCTCTT CTCTTT TCTTTG CTTTGA TTTGAG TTGAGA TGAGAC GAGACA AGACAG GACAGC ACAGCT CAGCTC AGCTCC GCTCCC CTCCCA TCCCAT CCCATC CCATCT CATCTC ATCTCG TCTCGT CTCGTT TCGTTA CGTTAC GTTACG TTACGC TACGCC ACGCCA CGCCAT GCCATT CCATTC CATTCA ATTCAT TTCATG TCATGC CATGCA ATGCAG TGCAGG GCAGGT CAGGTC AGGTCG GGTCGG GTCGGT TCGGTA CGGTAT GGTATT GTATTT TATTTA ATTTAA TTTAAC TTAACC TAACCG AACCGA ACCGAC CCGACA CGACAA GACAAG ACAAGG CAAGGA AAGGAA AGGAAT GGAATT GAATTT AATTTC ATTTCG TTTCGC TTCGCT TCGCTA CGCTAC GCTACC CTACCT TACCTT ACCTTA CCTTAG CTTAGG TTAGGA TAGGAC AGGACC GGACCG GACCGT ACCGTT CCGTTA CGTTAT GTTATT TTATTG TATTGT ATTGTT,3,88,CCCT CCTC CTCT TCTT CTTT TTTG TTGA TGAG GAGA AGAC GACA ACAG CAGC AGCT GCTC CTCC TCCC CCCA CCAT CATC ATCT TCTC CTCG TCGT CGTT GTTA TTAC TACG ACGC CGCC GCCA CCAT CATT ATTC TTCA TCAT CATG ATGC TGCA GCAG CAGG AGGT GGTC GTCG TCGG CGGT GGTA GTAT TATT ATTT TTTA TTAA TAAC AACC ACCG CCGA CGAC GACA ACAA CAAG AAGG AGGA GGAA GAAT AATT ATTT TTTC TTCG TCGC CGCT GCTA CTAC TACC ACCT CCTT CTTA TTAG TAGG AGGA GGAC GACC ACCG CCGT CGTT GTTA TTAT TATT ATTG TTGT TGTT,CCCTC CCTCT CTCTT TCTTT CTTTG TTTGA TTGAG TGAGA GAGAC AGACA GACAG ACAGC CAGCT AGCTC GCTCC CTCCC TCCCA CCCAT CCATC CATCT ATCTC TCTCG CTCGT TCGTT CGTTA GTTAC TTACG TACGC ACGCC CGCCA GCCAT CCATT CATTC ATTCA TTCAT TCATG CATGC ATGCA TGCAG GCAGG CAGGT AGGTC GGTCG GTCGG TCGGT CGGTA GGTAT GTATT TATTT ATTTA TTTAA TTAAC TAACC AACCG ACCGA CCGAC CGACA GACAA ACAAG CAAGG AAGGA AGGAA GGAAT GAATT AATTT ATTTC TTTCG TTCGC TCGCT CGCTA GCTAC CTACC TACCT ACCTT CCTTA CTTAG TTAGG TAGGA AGGAC GGACC GACCG ACCGT CCGTT CGTTA GTTAT TTATT TATTG ATTGT TTGTT,CCCTCT CCTCTT CTCTTT TCTTTG CTTTGA TTTGAG TTGAGA TGAGAC GAGACA AGACAG GACAGC ACAGCT CAGCTC AGCTCC GCTCCC CTCCCA TCCCAT CCCATC CCATCT CATCTC ATCTCG TCTCGT CTCGTT TCGTTA CGTTAC GTTACG TTACGC TACGCC ACGCCA CGCCAT GCCATT CCATTC CATTCA ATTCAT TTCATG TCATGC CATGCA ATGCAG TGCAGG GCAGGT CAGGTC AGGTCG GGTCGG GTCGGT TCGGTA CGGTAT GGTATT GTATTT TATTTA ATTTAA TTTAAC TTAACC TAACCG AACCGA ACCGAC CCGACA CGACAA GACAAG ACAAGG CAAGGA AAGGAA AGGAAT GGAATT GAATTT AATTTC ATTTCG TTTCGC TTCGCT TCGCTA CGCTAC GCTACC CTACCT TACCTT ACCTTA CCTTAG CTTAGG TTAGGA TAGGAC AGGACC GGACCG GACCGT ACCGTT CCGTTA CGTTAT GTTATT TTATTG TATTGT ATTGTT,CCCTCTT CCTCTTT CTCTTTG TCTTTGA CTTTGAG TTTGAGA TTGAGAC TGAGACA GAGACAG AGACAGC GACAGCT ACAGCTC CAGCTCC AGCTCCC GCTCCCA CTCCCAT TCCCATC CCCATCT CCATCTC CATCTCG ATCTCGT TCTCGTT CTCGTTA TCGTTAC CGTTACG GTTACGC TTACGCC TACGCCA ACGCCAT CGCCATT GCCATTC CCATTCA CATTCAT ATTCATG TTCATGC TCATGCA CATGCAG ATGCAGG TGCAGGT GCAGGTC CAGGTCG AGGTCGG GGTCGGT GTCGGTA TCGGTAT CGGTATT GGTATTT GTATTTA TATTTAA ATTTAAC TTTAACC TTAACCG TAACCGA AACCGAC ACCGACA CCGACAA CGACAAG GACAAGG ACAAGGA CAAGGAA AAGGAAT AGGAATT GGAATTT GAATTTC AATTTCG ATTTCGC TTTCGCT TTCGCTA TCGCTAC CGCTACC GCTACCT CTACCTT TACCTTA ACCTTAG CCTTAGG CTTAGGA TTAGGAC TAGGACC AGGACCG GGACCGT GACCGTT ACCGTTA CCGTTAT CGTTATT GTTATTG TTATTGT TATTGTT,"ID   YCX91_PHAAO             Reviewed;          91 AA.
AC   Q3BAI2;
DT   25-JUL-2006, integrated into UniProtKB/Swiss-Prot.
DT   22-NOV-2005, sequence version 1.
DT   05-FEB-2025, entry version 27.
DE   RecName: Full=Uncharacterized protein ORF91;
OS   Phalaenopsis aphrodite subsp. formosana (Moth orchid).
OG   Plastid; Chloroplast.
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliopsida; Liliopsida; Asparagales; Orchidaceae;
OC   Epidendroideae; Vandeae; Aeridinae; Phalaenopsis.
OX   NCBI_TaxID=308872;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=cv. Taisugar TS-97;
RX   PubMed=16207935; DOI=10.1093/molbev/msj029;
RA   Chang C.-C., Lin H.-C., Lin I.-P., Chow T.-Y., Chen H.-H., Chen W.-H.,
RA   Cheng C.-H., Lin C.-Y., Liu S.-M., Chang C.-C., Chaw S.-M.;
RT   ""The chloroplast genome of Phalaenopsis aphrodite (Orchidaceae):
RT   comparative analysis of evolutionary rate with that of grasses and its
RT   phylogenetic implications."";
RL   Mol. Biol. Evol. 23:279-291(2006).
CC   -!- SUBCELLULAR LOCATION: Plastid, chloroplast.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY916449; AAW82572.1; -; Genomic_DNA.
DR   RefSeq; YP_358636.1; NC_007499.1.
DR   AlphaFoldDB; Q3BAI2; -.
DR   GeneID; 3741793; -.
DR   GO; GO:0009507; C:chloroplast; IEA:UniProtKB-SubCell.
DR   AntiFam; ANF00025; Antisense to 23S rRNA.
PE   4: Predicted;
KW   Chloroplast; Plastid.
FT   CHAIN           1..91
FT                   /note=""Uncharacterized protein ORF91""
FT                   /id=""PRO_0000246135""
SQ   SEQUENCE   91 AA;  10596 MW;  C770491A1FF96EE8 CRC64;
     MQVVRIFTDM SISPSLSPRQ CPDRYAFRAG RNLPDKEFRY LRTVLVTAAV HRGFGRRLPC
     HQVTNFLDLP ALGRRQPPYM VLRLCGDLCF W
//
",21687
AACATG ACATGG CATGGA ATGGAC TGGACG GGACGT GACGTC ACGTCC CGTCCC GTCCCC TCCCCG CCCCGT CCCGTC CCGTCG CGTCGT GTCGTC TCGTCA CGTCAA GTCAAG TCAAGC CAAGCG AAGCGC AGCGCA GCGCAA CGCAAG GCAAGG CAAGGA AAGGAC AGGACT GGACTA GACTAC ACTACG CTACGA TACGAG ACGAGC CGAGCT GAGCTC AGCTCG GCTCGT CTCGTC TCGTCG CGTCGA GTCGAC TCGACA CGACAT GACATT ACATTG CATTGA ATTGAC TTGACT TGACTC GACTCG ACTCGG CTCGGA TCGGAC CGGACG GGACGA GACGAA ACGAAT CGAATT GAATTC AATTCG ATTCGT TTCGTT TCGTTT CGTTTC GTTTCG TTTCGC TTCGCT TCGCTG CGCTGA GCTGAT CTGATG TGATGA GATGAA ATGAAC TGAACG GAACGA AACGAT ACGATG CGATGA GATGAC ATGACG TGACGG GACGGT ACGGTG CGGTGA GGTGAG GTGAGA TGAGAT GAGATC AGATCC GATCCG ATCCGC TCCGCA CCGCAA CGCAAC GCAACG CAACGA AACGAC ACGACC CGACCT GACCTC ACCTCA CCTCAA CTCAAG TCAAGG CAAGGT AAGGTT AGGTTC GGTTCC GTTCCC,3,112,AACA ACAT CATG ATGG TGGA GGAC GACG ACGT CGTC GTCC TCCC CCCC CCCG CCGT CGTC GTCG TCGT CGTC GTCA TCAA CAAG AAGC AGCG GCGC CGCA GCAA CAAG AAGG AGGA GGAC GACT ACTA CTAC TACG ACGA CGAG GAGC AGCT GCTC CTCG TCGT CGTC GTCG TCGA CGAC GACA ACAT CATT ATTG TTGA TGAC GACT ACTC CTCG TCGG CGGA GGAC GACG ACGA CGAA GAAT AATT ATTC TTCG TCGT CGTT GTTT TTTC TTCG TCGC CGCT GCTG CTGA TGAT GATG ATGA TGAA GAAC AACG ACGA CGAT GATG ATGA TGAC GACG ACGG CGGT GGTG GTGA TGAG GAGA AGAT GATC ATCC TCCG CCGC CGCA GCAA CAAC AACG ACGA CGAC GACC ACCT CCTC CTCA TCAA CAAG AAGG AGGT GGTT GTTC TTCC TCCC,AACAT ACATG CATGG ATGGA TGGAC GGACG GACGT ACGTC CGTCC GTCCC TCCCC CCCCG CCCGT CCGTC CGTCG GTCGT TCGTC CGTCA GTCAA TCAAG CAAGC AAGCG AGCGC GCGCA CGCAA GCAAG CAAGG AAGGA AGGAC GGACT GACTA ACTAC CTACG TACGA ACGAG CGAGC GAGCT AGCTC GCTCG CTCGT TCGTC CGTCG GTCGA TCGAC CGACA GACAT ACATT CATTG ATTGA TTGAC TGACT GACTC ACTCG CTCGG TCGGA CGGAC GGACG GACGA ACGAA CGAAT GAATT AATTC ATTCG TTCGT TCGTT CGTTT GTTTC TTTCG TTCGC TCGCT CGCTG GCTGA CTGAT TGATG GATGA ATGAA TGAAC GAACG AACGA ACGAT CGATG GATGA ATGAC TGACG GACGG ACGGT CGGTG GGTGA GTGAG TGAGA GAGAT AGATC GATCC ATCCG TCCGC CCGCA CGCAA GCAAC CAACG AACGA ACGAC CGACC GACCT ACCTC CCTCA CTCAA TCAAG CAAGG AAGGT AGGTT GGTTC GTTCC TTCCC,AACATG ACATGG CATGGA ATGGAC TGGACG GGACGT GACGTC ACGTCC CGTCCC GTCCCC TCCCCG CCCCGT CCCGTC CCGTCG CGTCGT GTCGTC TCGTCA CGTCAA GTCAAG TCAAGC CAAGCG AAGCGC AGCGCA GCGCAA CGCAAG GCAAGG CAAGGA AAGGAC AGGACT GGACTA GACTAC ACTACG CTACGA TACGAG ACGAGC CGAGCT GAGCTC AGCTCG GCTCGT CTCGTC TCGTCG CGTCGA GTCGAC TCGACA CGACAT GACATT ACATTG CATTGA ATTGAC TTGACT TGACTC GACTCG ACTCGG CTCGGA TCGGAC CGGACG GGACGA GACGAA ACGAAT CGAATT GAATTC AATTCG ATTCGT TTCGTT TCGTTT CGTTTC GTTTCG TTTCGC TTCGCT TCGCTG CGCTGA GCTGAT CTGATG TGATGA GATGAA ATGAAC TGAACG GAACGA AACGAT ACGATG CGATGA GATGAC ATGACG TGACGG GACGGT ACGGTG CGGTGA GGTGAG GTGAGA TGAGAT GAGATC AGATCC GATCCG ATCCGC TCCGCA CCGCAA CGCAAC GCAACG CAACGA AACGAC ACGACC CGACCT GACCTC ACCTCA CCTCAA CTCAAG TCAAGG CAAGGT AAGGTT AGGTTC GGTTCC GTTCCC,AACATGG ACATGGA CATGGAC ATGGACG TGGACGT GGACGTC GACGTCC ACGTCCC CGTCCCC GTCCCCG TCCCCGT CCCCGTC CCCGTCG CCGTCGT CGTCGTC GTCGTCA TCGTCAA CGTCAAG GTCAAGC TCAAGCG CAAGCGC AAGCGCA AGCGCAA GCGCAAG CGCAAGG GCAAGGA CAAGGAC AAGGACT AGGACTA GGACTAC GACTACG ACTACGA CTACGAG TACGAGC ACGAGCT CGAGCTC GAGCTCG AGCTCGT GCTCGTC CTCGTCG TCGTCGA CGTCGAC GTCGACA TCGACAT CGACATT GACATTG ACATTGA CATTGAC ATTGACT TTGACTC TGACTCG GACTCGG ACTCGGA CTCGGAC TCGGACG CGGACGA GGACGAA GACGAAT ACGAATT CGAATTC GAATTCG AATTCGT ATTCGTT TTCGTTT TCGTTTC CGTTTCG GTTTCGC TTTCGCT TTCGCTG TCGCTGA CGCTGAT GCTGATG CTGATGA TGATGAA GATGAAC ATGAACG TGAACGA GAACGAT AACGATG ACGATGA CGATGAC GATGACG ATGACGG TGACGGT GACGGTG ACGGTGA CGGTGAG GGTGAGA GTGAGAT TGAGATC GAGATCC AGATCCG GATCCGC ATCCGCA TCCGCAA CCGCAAC CGCAACG GCAACGA CAACGAC AACGACC ACGACCT CGACCTC GACCTCA ACCTCAA CCTCAAG CTCAAGG TCAAGGT CAAGGTT AAGGTTC AGGTTCC GGTTCCC,"ID   IF5A_SPOEX              Reviewed;         160 AA.
AC   P62924; Q9TVJ8;
DT   31-AUG-2004, integrated into UniProtKB/Swiss-Prot.
DT   31-AUG-2004, sequence version 1.
DT   05-FEB-2025, entry version 67.
DE   RecName: Full=Eukaryotic translation initiation factor 5A;
DE            Short=eIF-5A;
GN   Name=eIF-5A; Synonyms=eIF5A;
OS   Spodoptera exigua (Beet armyworm) (Noctua fulgens).
OC   Eukaryota; Metazoa; Ecdysozoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC   Neoptera; Endopterygota; Lepidoptera; Glossata; Ditrysia; Noctuoidea;
OC   Noctuidae; Amphipyrinae; Spodoptera.
OX   NCBI_TaxID=7107;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Midgut, and Ovary;
RX   PubMed=10620048; DOI=10.1046/j.1365-2583.1999.00148.x;
RA   van Oers M.M., van Marwijk M., Kwa M.S.G., Vlak J.M., Thomas A.A.M.;
RT   ""Cloning and analysis of cDNAs encoding the hypusine-containing protein
RT   eIF5A of two lepidopteran insect species."";
RL   Insect Mol. Biol. 8:531-538(1999).
CC   -!- FUNCTION: Translation factor that promotes translation elongation and
CC       termination, particularly upon ribosome stalling at specific amino acid
CC       sequence contexts. Binds between the exit (E) and peptidyl (P) site of
CC       the ribosome and promotes rescue of stalled ribosome: specifically
CC       required for efficient translation of polyproline-containing peptides
CC       as well as other motifs that stall the ribosome. Acts as a ribosome
CC       quality control (RQC) cofactor by joining the RQC complex to facilitate
CC       peptidyl transfer during CAT tailing step.
CC       {ECO:0000250|UniProtKB:P23301}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:P23301}.
CC   -!- PTM: Lys-52 undergoes hypusination, a unique post-translational
CC       modification that consists in the addition of a butylamino group from
CC       spermidine to lysine side chain, leading to the formation of the
CC       unusual amino acid hypusine. eIF-5As are the only known proteins to
CC       undergo this modification, which is essential for their function.
CC       {ECO:0000250|UniProtKB:P63241}.
CC   -!- SIMILARITY: Belongs to the eIF-5A family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF109730; AAF13315.1; -; mRNA.
DR   AlphaFoldDB; P62924; -.
DR   SMR; P62924; -.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0043022; F:ribosome binding; IEA:InterPro.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003746; F:translation elongation factor activity; IEA:UniProtKB-KW.
DR   GO; GO:0045901; P:positive regulation of translational elongation; IEA:InterPro.
DR   GO; GO:0045905; P:positive regulation of translational termination; IEA:InterPro.
DR   CDD; cd04468; S1_eIF5A; 1.
DR   FunFam; 2.30.30.30:FF:000007; Eukaryotic translation initiation factor 5A; 1.
DR   FunFam; 2.40.50.140:FF:000034; Eukaryotic translation initiation factor 5A; 1.
DR   Gene3D; 2.30.30.30; -; 1.
DR   Gene3D; 2.40.50.140; Nucleic acid-binding proteins; 1.
DR   InterPro; IPR001884; IF5A-like.
DR   InterPro; IPR048670; IF5A-like_N.
DR   InterPro; IPR012340; NA-bd_OB-fold.
DR   InterPro; IPR014722; Rib_uL2_dom2.
DR   InterPro; IPR019769; Trans_elong_IF5A_hypusine_site.
DR   InterPro; IPR020189; Transl_elong_IF5A_C.
DR   InterPro; IPR008991; Translation_prot_SH3-like_sf.
DR   NCBIfam; TIGR00037; eIF_5A; 1.
DR   PANTHER; PTHR11673; TRANSLATION INITIATION FACTOR 5A FAMILY MEMBER; 1.
DR   Pfam; PF01287; eIF-5a; 1.
DR   Pfam; PF21485; IF5A-like_N; 1.
DR   PIRSF; PIRSF003025; eIF5A; 1.
DR   SMART; SM01376; eIF-5a; 1.
DR   SUPFAM; SSF50249; Nucleic acid-binding proteins; 1.
DR   SUPFAM; SSF50104; Translation proteins SH3-like domain; 1.
DR   PROSITE; PS00302; IF5A_HYPUSINE; 1.
PE   2: Evidence at transcript level;
KW   Cytoplasm; Elongation factor; Hypusine; Protein biosynthesis; RNA-binding.
FT   CHAIN           1..160
FT                   /note=""Eukaryotic translation initiation factor 5A""
FT                   /id=""PRO_0000142461""
FT   MOD_RES         52
FT                   /note=""Hypusine""
FT                   /evidence=""ECO:0000250|UniProtKB:P63241""
SQ   SEQUENCE   160 AA;  17525 MW;  D3CE1E65CEA21732 CRC64;
     MADIEDTHFE TGDSGASATF PMQCSALRKN GFVMLKGRPC KIVEMSTSKT GKHGHAKVHL
     VGIDIFNGKK YEDICPSTHN MDVPHVKRED YQLTDISDDG YLTLMADNGD LREDLKIPDG
     DLGTQLRSDF DSGKELLCTV LKSCGEECVI AVKANTALDK
//
",39139
CGTAAG GTAAGA TAAGAG AAGAGT AGAGTG GAGTGA AGTGAT GTGATG TGATGG GATGGA ATGGAG TGGAGC GGAGCT GAGCTG AGCTGG GCTGGT CTGGTA TGGTAG GGTAGT GTAGTA TAGTAT AGTATG GTATGT TATGTA ATGTAT TGTATA GTATAC TATACT ATACTG TACTGA ACTGAA CTGAAC TGAACT GAACTG AACTGG ACTGGA CTGGAG TGGAGG GGAGGC GAGGCA AGGCAA GGCAAA GCAAAT CAAATT AAATTG AATTGT ATTGTA TTGTAG TGTAGG GTAGGT TAGGTT AGGTTT GGTTTG GTTTGT TTTGTG TTGTGA TGTGAC GTGACA TGACAA GACAAA ACAAAC CAAACA AAACAG AACAGA ACAGAC CAGACC AGACCG GACCGA ACCGAA CCGAAT CGAATG GAATGG AATGGG ATGGGA TGGGAC GGGACT GGACTA GACTAA ACTAAA CTAAAG TAAAGT AAAGTG AAGTGA AGTGAG GTGAGG TGAGGA GAGGAG AGGAGT GGAGTT GAGTTT AGTTTG GTTTGT TTTGTA TTGTAC TGTACT GTACTT TACTTG ACTTGA CTTGAT TTGATT TGATTA GATTAA ATTAAA TTAAAG TAAAGG AAAGGA AAGGAT AGGATT GGATTA GATTAA ATTAAA TTAAAC TAAACA AAACAG AACAGG ACAGGC CAGGCT AGGCTA GGCTAA GCTAAA CTAAAT TAAATA AAATAG AATAGA ATAGAG TAGAGA AGAGAC GAGACA AGACAT GACATG ACATGG CATGGC ATGGCA TGGCAC GGCACT GCACTT CACTTG ACTTGT CTTGTG TTGTGA TGTGAG GTGAGT TGAGTT GAGTTT AGTTTA,0,145,CGTA GTAA TAAG AAGA AGAG GAGT AGTG GTGA TGAT GATG ATGG TGGA GGAG GAGC AGCT GCTG CTGG TGGT GGTA GTAG TAGT AGTA GTAT TATG ATGT TGTA GTAT TATA ATAC TACT ACTG CTGA TGAA GAAC AACT ACTG CTGG TGGA GGAG GAGG AGGC GGCA GCAA CAAA AAAT AATT ATTG TTGT TGTA GTAG TAGG AGGT GGTT GTTT TTTG TTGT TGTG GTGA TGAC GACA ACAA CAAA AAAC AACA ACAG CAGA AGAC GACC ACCG CCGA CGAA GAAT AATG ATGG TGGG GGGA GGAC GACT ACTA CTAA TAAA AAAG AAGT AGTG GTGA TGAG GAGG AGGA GGAG GAGT AGTT GTTT TTTG TTGT TGTA GTAC TACT ACTT CTTG TTGA TGAT GATT ATTA TTAA TAAA AAAG AAGG AGGA GGAT GATT ATTA TTAA TAAA AAAC AACA ACAG CAGG AGGC GGCT GCTA CTAA TAAA AAAT AATA ATAG TAGA AGAG GAGA AGAC GACA ACAT CATG ATGG TGGC GGCA GCAC CACT ACTT CTTG TTGT TGTG GTGA TGAG GAGT AGTT GTTT TTTA,CGTAA GTAAG TAAGA AAGAG AGAGT GAGTG AGTGA GTGAT TGATG GATGG ATGGA TGGAG GGAGC GAGCT AGCTG GCTGG CTGGT TGGTA GGTAG GTAGT TAGTA AGTAT GTATG TATGT ATGTA TGTAT GTATA TATAC ATACT TACTG ACTGA CTGAA TGAAC GAACT AACTG ACTGG CTGGA TGGAG GGAGG GAGGC AGGCA GGCAA GCAAA CAAAT AAATT AATTG ATTGT TTGTA TGTAG GTAGG TAGGT AGGTT GGTTT GTTTG TTTGT TTGTG TGTGA GTGAC TGACA GACAA ACAAA CAAAC AAACA AACAG ACAGA CAGAC AGACC GACCG ACCGA CCGAA CGAAT GAATG AATGG ATGGG TGGGA GGGAC GGACT GACTA ACTAA CTAAA TAAAG AAAGT AAGTG AGTGA GTGAG TGAGG GAGGA AGGAG GGAGT GAGTT AGTTT GTTTG TTTGT TTGTA TGTAC GTACT TACTT ACTTG CTTGA TTGAT TGATT GATTA ATTAA TTAAA TAAAG AAAGG AAGGA AGGAT GGATT GATTA ATTAA TTAAA TAAAC AAACA AACAG ACAGG CAGGC AGGCT GGCTA GCTAA CTAAA TAAAT AAATA AATAG ATAGA TAGAG AGAGA GAGAC AGACA GACAT ACATG CATGG ATGGC TGGCA GGCAC GCACT CACTT ACTTG CTTGT TTGTG TGTGA GTGAG TGAGT GAGTT AGTTT GTTTA,CGTAAG GTAAGA TAAGAG AAGAGT AGAGTG GAGTGA AGTGAT GTGATG TGATGG GATGGA ATGGAG TGGAGC GGAGCT GAGCTG AGCTGG GCTGGT CTGGTA TGGTAG GGTAGT GTAGTA TAGTAT AGTATG GTATGT TATGTA ATGTAT TGTATA GTATAC TATACT ATACTG TACTGA ACTGAA CTGAAC TGAACT GAACTG AACTGG ACTGGA CTGGAG TGGAGG GGAGGC GAGGCA AGGCAA GGCAAA GCAAAT CAAATT AAATTG AATTGT ATTGTA TTGTAG TGTAGG GTAGGT TAGGTT AGGTTT GGTTTG GTTTGT TTTGTG TTGTGA TGTGAC GTGACA TGACAA GACAAA ACAAAC CAAACA AAACAG AACAGA ACAGAC CAGACC AGACCG GACCGA ACCGAA CCGAAT CGAATG GAATGG AATGGG ATGGGA TGGGAC GGGACT GGACTA GACTAA ACTAAA CTAAAG TAAAGT AAAGTG AAGTGA AGTGAG GTGAGG TGAGGA GAGGAG AGGAGT GGAGTT GAGTTT AGTTTG GTTTGT TTTGTA TTGTAC TGTACT GTACTT TACTTG ACTTGA CTTGAT TTGATT TGATTA GATTAA ATTAAA TTAAAG TAAAGG AAAGGA AAGGAT AGGATT GGATTA GATTAA ATTAAA TTAAAC TAAACA AAACAG AACAGG ACAGGC CAGGCT AGGCTA GGCTAA GCTAAA CTAAAT TAAATA AAATAG AATAGA ATAGAG TAGAGA AGAGAC GAGACA AGACAT GACATG ACATGG CATGGC ATGGCA TGGCAC GGCACT GCACTT CACTTG ACTTGT CTTGTG TTGTGA TGTGAG GTGAGT TGAGTT GAGTTT AGTTTA,CGTAAGA GTAAGAG TAAGAGT AAGAGTG AGAGTGA GAGTGAT AGTGATG GTGATGG TGATGGA GATGGAG ATGGAGC TGGAGCT GGAGCTG GAGCTGG AGCTGGT GCTGGTA CTGGTAG TGGTAGT GGTAGTA GTAGTAT TAGTATG AGTATGT GTATGTA TATGTAT ATGTATA TGTATAC GTATACT TATACTG ATACTGA TACTGAA ACTGAAC CTGAACT TGAACTG GAACTGG AACTGGA ACTGGAG CTGGAGG TGGAGGC GGAGGCA GAGGCAA AGGCAAA GGCAAAT GCAAATT CAAATTG AAATTGT AATTGTA ATTGTAG TTGTAGG TGTAGGT GTAGGTT TAGGTTT AGGTTTG GGTTTGT GTTTGTG TTTGTGA TTGTGAC TGTGACA GTGACAA TGACAAA GACAAAC ACAAACA CAAACAG AAACAGA AACAGAC ACAGACC CAGACCG AGACCGA GACCGAA ACCGAAT CCGAATG CGAATGG GAATGGG AATGGGA ATGGGAC TGGGACT GGGACTA GGACTAA GACTAAA ACTAAAG CTAAAGT TAAAGTG AAAGTGA AAGTGAG AGTGAGG GTGAGGA TGAGGAG GAGGAGT AGGAGTT GGAGTTT GAGTTTG AGTTTGT GTTTGTA TTTGTAC TTGTACT TGTACTT GTACTTG TACTTGA ACTTGAT CTTGATT TTGATTA TGATTAA GATTAAA ATTAAAG TTAAAGG TAAAGGA AAAGGAT AAGGATT AGGATTA GGATTAA GATTAAA ATTAAAC TTAAACA TAAACAG AAACAGG AACAGGC ACAGGCT CAGGCTA AGGCTAA GGCTAAA GCTAAAT CTAAATA TAAATAG AAATAGA AATAGAG ATAGAGA TAGAGAC AGAGACA GAGACAT AGACATG GACATGG ACATGGC CATGGCA ATGGCAC TGGCACT GGCACTT GCACTTG CACTTGT ACTTGTG CTTGTGA TTGTGAG TGTGAGT GTGAGTT TGAGTTT GAGTTTA,"ID   R1A_BCHK3               Reviewed;        4376 AA.
AC   P0C6F8; Q3LZX2;
DT   10-JUN-2008, integrated into UniProtKB/Swiss-Prot.
DT   10-JUN-2008, sequence version 1.
DT   05-FEB-2025, entry version 94.
DE   RecName: Full=Replicase polyprotein 1a;
DE            Short=pp1a;
DE   AltName: Full=ORF1a polyprotein;
DE   Contains:
DE     RecName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE     AltName: Full=Leader protein;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3;
DE              Short=PL-PRO;
DE              EC=3.4.19.12;
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69;
DE     AltName: Full=nsp5;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=RNA-capping enzyme subunit nsp9;
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE              EC=2.7.7.50;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=Non-structural protein 11;
DE              Short=nsp11;
GN   ORFNames=1a;
OS   Bat coronavirus HKU3 (BtCoV) (SARS-like coronavirus HKU3).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=442736;
OH   NCBI_TaxID=89399; Rhinolophus sinicus (Chinese rufous horseshoe bat).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HKU3-1;
RX   PubMed=16169905; DOI=10.1073/pnas.0506735102;
RA   Lau S.K.P., Woo P.C.Y., Li K.S.M., Huang Y., Tsoi H.-W., Wong B.H.L.,
RA   Wong S.S.Y., Leung S.-Y., Chan K.-H., Yuen K.-Y.;
RT   ""Severe acute respiratory syndrome coronavirus-like virus in Chinese
RT   horseshoe bats."";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:14040-14045(2005).
CC   -!- FUNCTION: The papain-like proteinase (PL-PRO) is responsible for the
CC       cleavages located at the N-terminus of replicase polyprotein. In
CC       addition, PL-PRO possesses a deubiquitinating/deISGylating activity and
CC       processes both 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from
CC       cellular substrates. Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF-3 (By similarity). {ECO:0000250}.
CC   -!- FUNCTION: [3C-like proteinase nsp5]: Responsible for the majority of
CC       cleavages as it cleaves the C-terminus of replicase polyprotein at 11
CC       sites. Recognizes substrates containing the core sequence [ILMVF]-Q-|-
CC       [SGACN]. Inhibited by the substrate-analog Cbz-Val-Asn-Ser-Thr-Leu-Gln-
CC       CMK. Also contains an ADP-ribose-1''-phosphate (ADRP)-binding function
CC       (By similarity). {ECO:0000255|PROSITE-ProRule:PRU00772}.
CC   -!- FUNCTION: Nsp7-nsp8 hexadecamer may possibly confer processivity to the
CC       polymerase, maybe by binding to dsRNA or by producing primers utilized
CC       by the latter. {ECO:0000250}.
CC   -!- FUNCTION: [RNA-capping enzyme subunit nsp9]: Catalytic subunit of viral
CC       RNA capping enzyme which catalyzes the RNA guanylyltransferase reaction
CC       for genomic and sub-genomic RNAs. The kinase-like NiRAN domain of NSP12
CC       transfers RNA to the amino terminus of NSP9, forming a covalent RNA-
CC       protein intermediate. Subsequently, the NiRAN domain transfers RNA to
CC       GDP, forming the core cap structure GpppA-RNA. The NSP14 and NSP16
CC       methyltransferases then add methyl groups to form functional cap
CC       structures. {ECO:0000250|UniProtKB:P0DTC1}.
CC   -!- FUNCTION: [Non-structural protein 1]: Binds to the 40S ribosomal
CC       subunit and inhibits host translation. The nsp1-40S ribosome complex
CC       further induces an endonucleolytic cleavage near the 5'UTR of host
CC       mRNAs, targeting them for degradation. By suppressing host gene
CC       expression, nsp1 facilitates efficient viral gene expression in
CC       infected cells and evasion from host immune response (By similarity).
CC       {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: [Papain-like protease nsp3]:
CC       Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide
CC         and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-
CC         residue protein attached to proteins as an intracellular targeting
CC         signal).; EC=3.4.19.12; Evidence={ECO:0000250|UniProtKB:P0DTC1};
CC   -!- CATALYTIC ACTIVITY: [3C-like proteinase nsp5]:
CC       Reaction=TSAVLQ-|-SGFRK-NH2 and SGVTFQ-|-GKFKK the two peptides
CC         corresponding to the two self-cleavage sites of the SARS 3C-like
CC         proteinase are the two most reactive peptide substrates. The enzyme
CC         exhibits a strong preference for substrates containing Gln at P1
CC         position and Leu at P2 position.; EC=3.4.22.69;
CC         Evidence={ECO:0000250|UniProtKB:P0DTC1};
CC   -!- CATALYTIC ACTIVITY: [RNA-capping enzyme subunit nsp9]:
CC       Reaction=a 5'-end diphospho-ribonucleoside in mRNA + GTP + H(+) = a 5'-
CC         end (5'-triphosphoguanosine)-ribonucleoside in mRNA + diphosphate;
CC         Xref=Rhea:RHEA:67012, Rhea:RHEA-COMP:17165, Rhea:RHEA-COMP:17166,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:33019, ChEBI:CHEBI:37565,
CC         ChEBI:CHEBI:167616, ChEBI:CHEBI:167617; EC=2.7.7.50;
CC         Evidence={ECO:0000250|UniProtKB:P0DTC1};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:67014;
CC         Evidence={ECO:0000250|UniProtKB:P0DTC1};
CC   -!- SUBUNIT: 3CL-PRO exists as monomer and homodimer. Eight copies of nsp7
CC       and eight copies of nsp8 assemble to form a heterohexadecamer. Nsp9 is
CC       a dimer. Nsp10 forms a dodecamer (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Papain-like protease nsp3]: Host membrane
CC       {ECO:0000305}; Multi-pass membrane protein {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 4]: Host membrane
CC       {ECO:0000305}; Multi-pass membrane protein {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 6]: Host membrane
CC       {ECO:0000305}; Multi-pass membrane protein {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 7]: Host cytoplasm, host
CC       perinuclear region {ECO:0000250}. Note=nsp7, nsp8, nsp9 and nsp10 are
CC       localized in cytoplasmic foci, largely perinuclear. Late in infection,
CC       they merge into confluent complexes (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 8]: Host cytoplasm, host
CC       perinuclear region {ECO:0000250}. Note=nsp7, nsp8, nsp9 and nsp10 are
CC       localized in cytoplasmic foci, largely perinuclear. Late in infection,
CC       they merge into confluent complexes (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [RNA-capping enzyme subunit nsp9]: Host
CC       cytoplasm, host perinuclear region {ECO:0000250}. Note=nsp7, nsp8, nsp9
CC       and nsp10 are localized in cytoplasmic foci, largely perinuclear. Late
CC       in infection, they merge into confluent complexes (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 10]: Host cytoplasm, host
CC       perinuclear region {ECO:0000250}. Note=nsp7, nsp8, nsp9 and nsp10 are
CC       localized in cytoplasmic foci, largely perinuclear. Late in infection,
CC       they merge into confluent complexes (By similarity). {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Ribosomal frameshifting; Named isoforms=2;
CC       Name=Replicase polyprotein 1a; Synonyms=pp1a, ORF1a polyprotein;
CC         IsoId=P0C6F8-1; Sequence=Displayed;
CC       Name=Replicase polyprotein 1ab; Synonyms=pp1ab;
CC         IsoId=P0C6W2-1; Sequence=External;
CC   -!- DOMAIN: The hydrophobic domains (HD) could mediate the membrane
CC       association of the replication complex and thereby alter the
CC       architecture of the host cell membrane. {ECO:0000250}.
CC   -!- PTM: Specific enzymatic cleavages in vivo by its own proteases yield
CC       mature proteins. 3CL-PRO and PL-PRO proteinases are autocatalytically
CC       processed (By similarity). {ECO:0000250}.
CC   -!- MISCELLANEOUS: Bat coronavirus HKU3 is highly similar to SARS-CoV
CC       (SARS-like).
CC   -!- MISCELLANEOUS: [Isoform Replicase polyprotein 1a]: Produced by
CC       conventional translation.
CC   -!- SIMILARITY: Belongs to the coronaviruses polyprotein 1ab family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; DQ022305; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   BMRB; P0C6F8; -.
DR   SMR; P0C6F8; -.
DR   Proteomes; UP000007450; Segment.
DR   GO; GO:0033644; C:host cell membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-KW.
DR   GO; GO:0004843; F:cysteine-type deubiquitinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0004519; F:endonuclease activity; IEA:UniProtKB-KW.
DR   GO; GO:0002151; F:G-quadruplex RNA binding; IEA:InterPro.
DR   GO; GO:0008168; F:methyltransferase activity; IEA:UniProtKB-KW.
DR   GO; GO:0008242; F:omega peptidase activity; IEA:InterPro.
DR   GO; GO:0003727; F:single-stranded RNA binding; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0039520; P:induction by virus of host autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0032259; P:methylation; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:UniProtKB-KW.
DR   GO; GO:0039595; P:symbiont-mediated degradation of host mRNA; IEA:UniProtKB-KW.
DR   GO; GO:0039648; P:symbiont-mediated perturbation of host ubiquitin-like protein modification; IEA:UniProtKB-KW.
DR   GO; GO:0039548; P:symbiont-mediated suppression of host cytoplasmic pattern recognition receptor signaling pathway via inhibition of IRF3 activity; IEA:UniProtKB-KW.
DR   GO; GO:0039657; P:symbiont-mediated suppression of host gene expression; IEA:UniProtKB-KW.
DR   GO; GO:0039579; P:symbiont-mediated suppression of host ISG15-protein conjugation; IEA:UniProtKB-KW.
DR   GO; GO:0039502; P:symbiont-mediated suppression of host type I interferon-mediated signaling pathway; IEA:UniProtKB-KW.
DR   GO; GO:0019079; P:viral genome replication; IEA:InterPro.
DR   GO; GO:0019082; P:viral protein processing; IEA:InterPro.
DR   GO; GO:0075523; P:viral translational frameshifting; IEA:UniProtKB-KW.
DR   GO; GO:0019049; P:virus-mediated perturbation of host defense response; IEA:UniProtKB-KW.
DR   CDD; cd21560; betaCoV-Nsp6; 1.
DR   CDD; cd21516; betaCoV_Nsp2_SARS-like; 1.
DR   CDD; cd21666; betaCoV_Nsp5_Mpro; 1.
DR   CDD; cd21827; betaCoV_Nsp7; 1.
DR   CDD; cd21831; betaCoV_Nsp8; 1.
DR   CDD; cd21898; betaCoV_Nsp9; 1.
DR   CDD; cd21732; betaCoV_PLPro; 1.
DR   CDD; cd21872; CoV_Nsp10; 1.
DR   CDD; cd21473; cv_Nsp4_TM; 1.
DR   CDD; cd21563; Macro_cv_SUD-M_Nsp3-like; 1.
DR   CDD; cd21562; Macro_cv_SUD-N_Nsp3-like; 1.
DR   CDD; cd21557; Macro_X_Nsp3-like; 1.
DR   CDD; cd22662; SARS-CoV-like_Nsp1_C; 1.
DR   CDD; cd21796; SARS-CoV-like_Nsp1_N; 1.
DR   CDD; cd21814; SARS-CoV-like_Nsp3_betaSM; 1.
DR   CDD; cd21822; SARS-CoV-like_Nsp3_NAB; 1.
DR   CDD; cd21525; SUD_C_SARS-CoV_Nsp3; 1.
DR   CDD; cd21717; TM_Y_SARS-CoV-like_Nsp3_C; 1.
DR   CDD; cd21467; Ubl1_cv_Nsp3_N-like; 1.
DR   FunFam; 1.10.8.370:FF:000001; Orf1a polyprotein; 1.
DR   FunFam; 2.40.10.250:FF:000001; Orf1a polyprotein; 1.
DR   FunFam; 3.40.220.30:FF:000001; Orf1a polyprotein; 1.
DR   FunFam; 1.10.150.420:FF:000001; Replicase polyprotein; 1.
DR   FunFam; 1.10.1840.10:FF:000001; Replicase polyprotein 1a; 1.
DR   FunFam; 1.10.8.1190:FF:000001; Replicase polyprotein 1a; 1.
DR   FunFam; 2.40.10.10:FF:000033; Replicase polyprotein 1a; 1.
DR   Gene3D; 1.10.8.1190; -; 1.
DR   Gene3D; 2.60.120.1680; -; 1.
DR   Gene3D; 3.10.20.350; -; 1.
DR   Gene3D; 3.10.20.540; -; 1.
DR   Gene3D; 6.10.140.2090; -; 1.
DR   Gene3D; 1.10.150.420; Coronavirus nonstructural protein 4 C-terminus; 1.
DR   Gene3D; 3.40.30.150; Coronavirus polyprotein cleavage domain; 1.
DR   Gene3D; 3.40.220.10; Leucine Aminopeptidase, subunit E, domain 1; 1.
DR   Gene3D; 1.10.1840.10; main proteinase (3clpro) structure, domain 3; 1.
DR   Gene3D; 3.40.220.20; Nsp3, SUD-M subdomain; 1.
DR   Gene3D; 3.40.220.30; Nsp3, SUD-N subdomain; 1.
DR   Gene3D; 1.10.8.370; nsp7 replicase; 1.
DR   Gene3D; 3.30.70.3540; Nsp8 replicase, head domain; 1.
DR   Gene3D; 2.40.10.250; Replicase NSP9; 1.
DR   Gene3D; 3.40.50.11020; Replicase polyprotein, nucleic acid-binding domain; 1.
DR   Gene3D; 2.40.10.10; Trypsin-like serine proteases; 2.
DR   InterPro; IPR046443; a/bCoV_NSP1_glob.
DR   InterPro; IPR046442; bCoV_NSP1_C.
DR   InterPro; IPR043613; CoV_NSP2_C.
DR   InterPro; IPR047573; CoV_NSP2_M.
DR   InterPro; IPR049894; COV_NSP3_3ECTO.
DR   InterPro; IPR043611; CoV_NSP3_C.
DR   InterPro; IPR047566; CoV_NSP3_Y.
DR   InterPro; IPR032505; CoV_NSP4_C.
DR   InterPro; IPR043612; CoV_NSP4_N.
DR   InterPro; IPR022733; DPUP_SUD_C_bCoV.
DR   InterPro; IPR002589; Macro_dom.
DR   InterPro; IPR043472; Macro_dom-like.
DR   InterPro; IPR044371; Macro_X_NSP3-like.
DR   InterPro; IPR036333; NSP10_sf_CoV.
DR   InterPro; IPR021590; NSP1_glob_bCoV.
DR   InterPro; IPR038030; NSP1_glob_sf_bCoV.
DR   InterPro; IPR043615; NSP2_N_CoV.
DR   InterPro; IPR044389; NSP2_SARS-CoV-like.
DR   InterPro; IPR024375; NSP3_bCoV.
DR   InterPro; IPR047567; NSP3_G2M_bCoV.
DR   InterPro; IPR024358; NSP3_N_bCoV.
DR   InterPro; IPR032592; NSP3_NAB_bCoV.
DR   InterPro; IPR042570; NSP3_NAB_bCoV_sf.
DR   InterPro; IPR038166; NSP3_PL2pro_sf_bCoV.
DR   InterPro; IPR038400; NSP3_SUD-M_sf_bCoV.
DR   InterPro; IPR044864; NSP3_SUD-N_bCoV.
DR   InterPro; IPR044374; NSP3_SUD-N_SARS-CoV.
DR   InterPro; IPR043478; NSP3_SUD-N_sf_bCoV.
DR   InterPro; IPR044357; NSP3_Ubl1_dom_CoV.
DR   InterPro; IPR044353; Nsp3_Ubl2_dom_CoV.
DR   InterPro; IPR038083; NSP3A-like.
DR   InterPro; IPR038123; NSP4_C_sf_CoV.
DR   InterPro; IPR044367; NSP6_betaCoV.
DR   InterPro; IPR043610; NSP6_CoV.
DR   InterPro; IPR014828; NSP7_CoV.
DR   InterPro; IPR037204; NSP7_sf_CoV.
DR   InterPro; IPR014829; NSP8_CoV.
DR   InterPro; IPR037230; NSP8_sf_CoV.
DR   InterPro; IPR014822; NSP9_CoV.
DR   InterPro; IPR036499; NSP9_sf_CoV.
DR   InterPro; IPR013016; Peptidase_C16_CoV.
DR   InterPro; IPR008740; Peptidase_C30_CoV.
DR   InterPro; IPR043477; Peptidase_C30_dom3_CoV.
DR   InterPro; IPR009003; Peptidase_S1_PA.
DR   InterPro; IPR043504; Peptidase_S1_PA_chymotrypsin.
DR   InterPro; IPR043177; PLpro_N_sf_CoV.
DR   InterPro; IPR043503; PLpro_palm_finger_dom_CoV.
DR   InterPro; IPR043178; PLpro_thumb_sf_CoV.
DR   InterPro; IPR018995; RNA_synth_NSP10_CoV.
DR   Pfam; PF16251; bCoV_NAB; 1.
DR   Pfam; PF11501; bCoV_NSP1; 1.
DR   Pfam; PF12379; bCoV_NSP3_N; 1.
DR   Pfam; PF12124; bCoV_SUD_C; 1.
DR   Pfam; PF11633; bCoV_SUD_M; 1.
DR   Pfam; PF09401; CoV_NSP10; 1.
DR   Pfam; PF19212; CoV_NSP2_C; 1.
DR   Pfam; PF19211; CoV_NSP2_N; 1.
DR   Pfam; PF19218; CoV_NSP3_C; 1.
DR   Pfam; PF16348; CoV_NSP4_C; 1.
DR   Pfam; PF19217; CoV_NSP4_N; 1.
DR   Pfam; PF19213; CoV_NSP6; 1.
DR   Pfam; PF08716; CoV_NSP7; 1.
DR   Pfam; PF08717; CoV_NSP8; 1.
DR   Pfam; PF08710; CoV_NSP9; 1.
DR   Pfam; PF08715; CoV_peptidase; 1.
DR   Pfam; PF01661; Macro; 1.
DR   Pfam; PF05409; Peptidase_C30; 1.
DR   SMART; SM00506; A1pp; 1.
DR   SUPFAM; SSF144246; Coronavirus NSP10-like; 1.
DR   SUPFAM; SSF140367; Coronavirus NSP7-like; 1.
DR   SUPFAM; SSF143076; Coronavirus NSP8-like; 1.
DR   SUPFAM; SSF52949; Macro domain-like; 1.
DR   SUPFAM; SSF159936; NSP3A-like; 1.
DR   SUPFAM; SSF101816; Replicase NSP9; 1.
DR   SUPFAM; SSF160099; SARS Nsp1-like; 1.
DR   SUPFAM; SSF50494; Trypsin-like serine proteases; 1.
DR   PROSITE; PS51963; BCOV_NSP1_C; 1.
DR   PROSITE; PS51942; BCOV_NSP3C_C; 1.
DR   PROSITE; PS51941; BCOV_NSP3C_M; 1.
DR   PROSITE; PS51994; BCOV_NSP3E_G2M; 1.
DR   PROSITE; PS51945; BCOV_NSP3E_NAB; 1.
DR   PROSITE; PS51993; COV_3ECTO; 1.
DR   PROSITE; PS51952; COV_EXON_MTASE_COACT; 1.
DR   PROSITE; PS51962; COV_NSP1; 1.
DR   PROSITE; PS51991; COV_NSP2_C; 1.
DR   PROSITE; PS51990; COV_NSP2_M; 1.
DR   PROSITE; PS51989; COV_NSP2_N; 1.
DR   PROSITE; PS51992; COV_NSP3_Y; 1.
DR   PROSITE; PS51943; COV_NSP3A_UBL; 1.
DR   PROSITE; PS51944; COV_NSP3D_UBL; 1.
DR   PROSITE; PS51946; COV_NSP4C; 1.
DR   PROSITE; PS51949; COV_NSP7; 1.
DR   PROSITE; PS51950; COV_NSP8; 1.
DR   PROSITE; PS51951; COV_NSP9_SSRNA_BD; 1.
DR   PROSITE; PS51442; M_PRO; 1.
DR   PROSITE; PS51154; MACRO; 1.
DR   PROSITE; PS51124; PEPTIDASE_C16; 1.
DR   PROSITE; PS51940; SARS_NSP3C_N; 1.
PE   3: Inferred from homology;
KW   Activation of host autophagy by virus; Decay of host mRNAs by virus;
KW   Disulfide bond; Endonuclease;
KW   Eukaryotic host gene expression shutoff by virus;
KW   Eukaryotic host translation shutoff by virus; Host cytoplasm;
KW   Host gene expression shutoff by virus; Host membrane;
KW   Host mRNA suppression by virus; Host-virus interaction; Hydrolase;
KW   Inhibition of host innate immune response by virus;
KW   Inhibition of host interferon signaling pathway by virus;
KW   Inhibition of host IRF3 by virus; Inhibition of host ISG15 by virus;
KW   Inhibition of host RLR pathway by virus;
KW   Interferon antiviral system evasion; Membrane; Metal-binding;
KW   Methyltransferase;
KW   Modulation of host ubiquitin pathway by viral deubiquitinase;
KW   Modulation of host ubiquitin pathway by virus; Nuclease; Protease; Repeat;
KW   Ribosomal frameshifting; RNA-binding; Thiol protease; Transferase;
KW   Transmembrane; Transmembrane helix; Ubl conjugation pathway;
KW   Viral immunoevasion; Zinc; Zinc-finger.
FT   CHAIN           1..4376
FT                   /note=""Replicase polyprotein 1a""
FT                   /id=""PRO_0000338074""
FT   CHAIN           1..179
FT                   /note=""Non-structural protein 1""
FT                   /evidence=""ECO:0000250""
FT                   /id=""PRO_0000338075""
FT   CHAIN           180..818
FT                   /note=""Non-structural protein 2""
FT                   /evidence=""ECO:0000250""
FT                   /id=""PRO_0000338076""
FT   CHAIN           819..2734
FT                   /note=""Papain-like protease nsp3""
FT                   /evidence=""ECO:0000250""
FT                   /id=""PRO_0000338077""
FT   CHAIN           2735..3234
FT                   /note=""Non-structural protein 4""
FT                   /evidence=""ECO:0000250""
FT                   /id=""PRO_0000338078""
FT   CHAIN           3235..3540
FT                   /note=""3C-like proteinase nsp5""
FT                   /evidence=""ECO:0000250""
FT                   /id=""PRO_0000338079""
FT   CHAIN           3541..3830
FT                   /note=""Non-structural protein 6""
FT                   /evidence=""ECO:0000250""
FT                   /id=""PRO_0000338080""
FT   CHAIN           3831..3913
FT                   /note=""Non-structural protein 7""
FT                   /evidence=""ECO:0000250""
FT                   /id=""PRO_0000338081""
FT   CHAIN           3914..4111
FT                   /note=""Non-structural protein 8""
FT                   /evidence=""ECO:0000250""
FT                   /id=""PRO_0000338082""
FT   CHAIN           4112..4224
FT                   /note=""RNA-capping enzyme subunit nsp9""
FT                   /evidence=""ECO:0000250""
FT                   /id=""PRO_0000338083""
FT   CHAIN           4225..4363
FT                   /note=""Non-structural protein 10""
FT                   /evidence=""ECO:0000250""
FT                   /id=""PRO_0000338084""
FT   CHAIN           4364..4376
FT                   /note=""Non-structural protein 11""
FT                   /evidence=""ECO:0000255""
FT                   /id=""PRO_0000338085""
FT   TRANSMEM        2197..2217
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        2298..2318
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        2345..2365
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        2744..2764
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        2986..3006
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        3016..3036
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        3048..3068
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        3071..3091
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        3099..3119
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        3136..3156
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        3558..3578
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        3580..3600
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        3606..3626
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        3652..3672
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        3679..3698
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        3722..3742
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        3750..3770
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   DOMAIN          12..127
FT                   /note=""CoV Nsp1 globular""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01307""
FT   DOMAIN          148..179
FT                   /note=""BetaCoV Nsp1 C-terminal""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01308""
FT   DOMAIN          183..456
FT                   /note=""CoV Nsp2 N-terminal""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01333""
FT   DOMAIN          458..688
FT                   /note=""CoV Nsp2 middle""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01334""
FT   DOMAIN          690..818
FT                   /note=""CoV Nsp2 C-terminal""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01335""
FT   DOMAIN          822..930
FT                   /note=""Ubiquitin-like 1""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00214""
FT   DOMAIN          998..1164
FT                   /note=""Macro 1""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00490""
FT   DOMAIN          1201..1329
FT                   /note=""Macro 2""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00490""
FT   DOMAIN          1337..1464
FT                   /note=""Macro 3""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00490""
FT   DOMAIN          1466..1532
FT                   /note=""DPUP""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01289""
FT   DOMAIN          1536..1591
FT                   /note=""Ubiquitin-like 2""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00214""
FT   DOMAIN          1605..1869
FT                   /note=""Peptidase C16""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00444""
FT   DOMAIN          1882..1992
FT                   /note=""Nucleic acid-binding""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01290""
FT   DOMAIN          2017..2126
FT                   /note=""G2M""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01338""
FT   DOMAIN          2218..2288
FT                   /note=""3Ecto""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01337""
FT   DOMAIN          2366..2734
FT                   /note=""CoV Nsp3 Y""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01336""
FT   DOMAIN          3136..3234
FT                   /note=""Nsp4C""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01291""
FT   DOMAIN          3235..3540
FT                   /note=""Peptidase C30""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00772""
FT   DOMAIN          3831..3913
FT                   /note=""RdRp Nsp7 cofactor""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01294""
FT   DOMAIN          3914..4111
FT                   /note=""RdRp Nsp8 cofactor""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01295""
FT   DOMAIN          4112..4224
FT                   /note=""Nsp9 ssRNA-binding""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01296""
FT   DOMAIN          4225..4363
FT                   /note=""ExoN/MTase coactivator""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01297""
FT   ZN_FING         1723..1760
FT                   /note=""C4-type""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00444""
FT   ZN_FING         4298..4314
FT                   /evidence=""ECO:0000250""
FT   ZN_FING         4341..4354
FT                   /evidence=""ECO:0000250""
FT   REGION          200..236
FT                   /note=""C2H2""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01333""
FT   REGION          323..344
FT                   /note=""C4""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01333""
FT   REGION          370..416
FT                   /note=""C2HC""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01333""
FT   REGION          2086..2365
FT                   /note=""HD1""
FT                   /evidence=""ECO:0000250""
FT   REGION          2366..2456
FT                   /note=""Y1""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01336""
FT   REGION          2370..2383
FT                   /note=""ZF1""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01336""
FT   REGION          2416..2426
FT                   /note=""ZF2""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01336""
FT   REGION          2457..2734
FT                   /note=""CoV-Y""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01336""
FT   REGION          2457..2551
FT                   /note=""Y2""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01336""
FT   REGION          2552..2633
FT                   /note=""Y3""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01336""
FT   REGION          2634..2734
FT                   /note=""Y4""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01336""
FT   REGION          2749..3156
FT                   /note=""HD2""
FT                   /evidence=""ECO:0000250""
FT   REGION          3558..3770
FT                   /note=""HD3""
FT                   /evidence=""ECO:0000250""
FT   ACT_SITE        1645
FT                   /note=""For PL-PRO activity""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00444""
FT   ACT_SITE        1806
FT                   /note=""For PL-PRO activity""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00444""
FT   ACT_SITE        1820
FT                   /note=""For PL-PRO activity""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00444""
FT   ACT_SITE        3275
FT                   /note=""For 3CL-PRO activity""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00772""
FT   ACT_SITE        3379
FT                   /note=""For 3CL-PRO activity""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00772""
FT   BINDING         200
FT                   /ligand=""Zn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29105""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01333""
FT   BINDING         231
FT                   /ligand=""Zn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29105""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01333""
FT   BINDING         234
FT                   /ligand=""Zn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29105""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01333""
FT   BINDING         236
FT                   /ligand=""Zn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29105""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01333""
FT   BINDING         323
FT                   /ligand=""Zn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29105""
FT                   /ligand_label=""2""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01333""
FT   BINDING         326
FT                   /ligand=""Zn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29105""
FT                   /ligand_label=""2""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01333""
FT   BINDING         341
FT                   /ligand=""Zn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29105""
FT                   /ligand_label=""2""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01333""
FT   BINDING         344
FT                   /ligand=""Zn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29105""
FT                   /ligand_label=""2""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01333""
FT   BINDING         370
FT                   /ligand=""Zn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29105""
FT                   /ligand_label=""3""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01333""
FT   BINDING         373
FT                   /ligand=""Zn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29105""
FT                   /ligand_label=""3""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01333""
FT   BINDING         382
FT                   /ligand=""Zn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29105""
FT                   /ligand_label=""3""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01333""
FT   BINDING         416
FT                   /ligand=""Zn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29105""
FT                   /ligand_label=""3""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01333""
FT   BINDING         1723
FT                   /ligand=""Zn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29105""
FT                   /ligand_label=""4""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00444""
FT   BINDING         1726
FT                   /ligand=""Zn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29105""
FT                   /ligand_label=""4""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00444""
FT   BINDING         1758
FT                   /ligand=""Zn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29105""
FT                   /ligand_label=""4""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00444""
FT   BINDING         1760
FT                   /ligand=""Zn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29105""
FT                   /ligand_label=""4""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00444""
FT   BINDING         2370
FT                   /ligand=""Zn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29105""
FT                   /ligand_label=""5""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01336""
FT   BINDING         2375
FT                   /ligand=""Zn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29105""
FT                   /ligand_label=""5""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01336""
FT   BINDING         2380
FT                   /ligand=""Zn(2+)""
FT                   /ligand_id=""ChEBI:C",37526
TACAGT ACAGTC CAGTCA AGTCAT GTCATG TCATGT CATGTA ATGTAG TGTAGT GTAGTT TAGTTG AGTTGC GTTGCC TTGCCT TGCCTT GCCTTT CCTTTA CTTTAA TTTAAT TTAATA TAATAC AATACT ATACTT TACTTT ACTTTA CTTTAC TTTACT TTACTT TACTTT ACTTTT CTTTTC TTTTCT TTTCTT TTCTTT TCTTTA CTTTAT TTTATG TTATGT TATGTC ATGTCA TGTCAT GTCATC TCATCC CATCCA ATCCAT TCCATT CCATTG CATTGT ATTGTC TTGTCC TGTCCT GTCCTC TCCTCT CCTCTG CTCTGT TCTGTT CTGTTT TGTTTA GTTTAA TTTAAC TTAACA TAACAC AACACC ACACCA CACCAG ACCAGT CCAGTT CAGTTT AGTTTA GTTTAT TTTATT TTATTC TATTCA ATTCAT TTCATT TCATTC CATTCT ATTCTT TTCTTA TCTTAC CTTACC TTACCT TACCTC ACCTCT CCTCTG CTCTGT TCTGTC CTGTCT TGTCTC GTCTCT TCTCTT CTCTTA TCTTAT CTTATA TTATAC TATACC ATACCC TACCCT ACCCTT CCCTTC CCTTCT CTTCTC TTCTCC TCTCCG CTCCGA TCCGAG CCGAGC CGAGCC GAGCCA AGCCAC GCCACC CCACCG CACCGA ACCGAG CCGAGA CGAGAC GAGACG AGACGG GACGGA ACGGAC CGGACT GGACTC GACTCC ACTCCT CTCCTA TCCTAT CCTATT CTATTT TATTTC ATTTCT TTTCTT TTCTTA TCTTAT CTTATG TTATGC TATGCC ATGCCG TGCCGT GCCGTT CCGTTT CGTTTT GTTTTC,0,142,TACA ACAG CAGT AGTC GTCA TCAT CATG ATGT TGTA GTAG TAGT AGTT GTTG TTGC TGCC GCCT CCTT CTTT TTTA TTAA TAAT AATA ATAC TACT ACTT CTTT TTTA TTAC TACT ACTT CTTT TTTT TTTC TTCT TCTT CTTT TTTA TTAT TATG ATGT TGTC GTCA TCAT CATC ATCC TCCA CCAT CATT ATTG TTGT TGTC GTCC TCCT CCTC CTCT TCTG CTGT TGTT GTTT TTTA TTAA TAAC AACA ACAC CACC ACCA CCAG CAGT AGTT GTTT TTTA TTAT TATT ATTC TTCA TCAT CATT ATTC TTCT TCTT CTTA TTAC TACC ACCT CCTC CTCT TCTG CTGT TGTC GTCT TCTC CTCT TCTT CTTA TTAT TATA ATAC TACC ACCC CCCT CCTT CTTC TTCT TCTC CTCC TCCG CCGA CGAG GAGC AGCC GCCA CCAC CACC ACCG CCGA CGAG GAGA AGAC GACG ACGG CGGA GGAC GACT ACTC CTCC TCCT CCTA CTAT TATT ATTT TTTC TTCT TCTT CTTA TTAT TATG ATGC TGCC GCCG CCGT CGTT GTTT TTTT TTTC,TACAG ACAGT CAGTC AGTCA GTCAT TCATG CATGT ATGTA TGTAG GTAGT TAGTT AGTTG GTTGC TTGCC TGCCT GCCTT CCTTT CTTTA TTTAA TTAAT TAATA AATAC ATACT TACTT ACTTT CTTTA TTTAC TTACT TACTT ACTTT CTTTT TTTTC TTTCT TTCTT TCTTT CTTTA TTTAT TTATG TATGT ATGTC TGTCA GTCAT TCATC CATCC ATCCA TCCAT CCATT CATTG ATTGT TTGTC TGTCC GTCCT TCCTC CCTCT CTCTG TCTGT CTGTT TGTTT GTTTA TTTAA TTAAC TAACA AACAC ACACC CACCA ACCAG CCAGT CAGTT AGTTT GTTTA TTTAT TTATT TATTC ATTCA TTCAT TCATT CATTC ATTCT TTCTT TCTTA CTTAC TTACC TACCT ACCTC CCTCT CTCTG TCTGT CTGTC TGTCT GTCTC TCTCT CTCTT TCTTA CTTAT TTATA TATAC ATACC TACCC ACCCT CCCTT CCTTC CTTCT TTCTC TCTCC CTCCG TCCGA CCGAG CGAGC GAGCC AGCCA GCCAC CCACC CACCG ACCGA CCGAG CGAGA GAGAC AGACG GACGG ACGGA CGGAC GGACT GACTC ACTCC CTCCT TCCTA CCTAT CTATT TATTT ATTTC TTTCT TTCTT TCTTA CTTAT TTATG TATGC ATGCC TGCCG GCCGT CCGTT CGTTT GTTTT TTTTC,TACAGT ACAGTC CAGTCA AGTCAT GTCATG TCATGT CATGTA ATGTAG TGTAGT GTAGTT TAGTTG AGTTGC GTTGCC TTGCCT TGCCTT GCCTTT CCTTTA CTTTAA TTTAAT TTAATA TAATAC AATACT ATACTT TACTTT ACTTTA CTTTAC TTTACT TTACTT TACTTT ACTTTT CTTTTC TTTTCT TTTCTT TTCTTT TCTTTA CTTTAT TTTATG TTATGT TATGTC ATGTCA TGTCAT GTCATC TCATCC CATCCA ATCCAT TCCATT CCATTG CATTGT ATTGTC TTGTCC TGTCCT GTCCTC TCCTCT CCTCTG CTCTGT TCTGTT CTGTTT TGTTTA GTTTAA TTTAAC TTAACA TAACAC AACACC ACACCA CACCAG ACCAGT CCAGTT CAGTTT AGTTTA GTTTAT TTTATT TTATTC TATTCA ATTCAT TTCATT TCATTC CATTCT ATTCTT TTCTTA TCTTAC CTTACC TTACCT TACCTC ACCTCT CCTCTG CTCTGT TCTGTC CTGTCT TGTCTC GTCTCT TCTCTT CTCTTA TCTTAT CTTATA TTATAC TATACC ATACCC TACCCT ACCCTT CCCTTC CCTTCT CTTCTC TTCTCC TCTCCG CTCCGA TCCGAG CCGAGC CGAGCC GAGCCA AGCCAC GCCACC CCACCG CACCGA ACCGAG CCGAGA CGAGAC GAGACG AGACGG GACGGA ACGGAC CGGACT GGACTC GACTCC ACTCCT CTCCTA TCCTAT CCTATT CTATTT TATTTC ATTTCT TTTCTT TTCTTA TCTTAT CTTATG TTATGC TATGCC ATGCCG TGCCGT GCCGTT CCGTTT CGTTTT GTTTTC,TACAGTC ACAGTCA CAGTCAT AGTCATG GTCATGT TCATGTA CATGTAG ATGTAGT TGTAGTT GTAGTTG TAGTTGC AGTTGCC GTTGCCT TTGCCTT TGCCTTT GCCTTTA CCTTTAA CTTTAAT TTTAATA TTAATAC TAATACT AATACTT ATACTTT TACTTTA ACTTTAC CTTTACT TTTACTT TTACTTT TACTTTT ACTTTTC CTTTTCT TTTTCTT TTTCTTT TTCTTTA TCTTTAT CTTTATG TTTATGT TTATGTC TATGTCA ATGTCAT TGTCATC GTCATCC TCATCCA CATCCAT ATCCATT TCCATTG CCATTGT CATTGTC ATTGTCC TTGTCCT TGTCCTC GTCCTCT TCCTCTG CCTCTGT CTCTGTT TCTGTTT CTGTTTA TGTTTAA GTTTAAC TTTAACA TTAACAC TAACACC AACACCA ACACCAG CACCAGT ACCAGTT CCAGTTT CAGTTTA AGTTTAT GTTTATT TTTATTC TTATTCA TATTCAT ATTCATT TTCATTC TCATTCT CATTCTT ATTCTTA TTCTTAC TCTTACC CTTACCT TTACCTC TACCTCT ACCTCTG CCTCTGT CTCTGTC TCTGTCT CTGTCTC TGTCTCT GTCTCTT TCTCTTA CTCTTAT TCTTATA CTTATAC TTATACC TATACCC ATACCCT TACCCTT ACCCTTC CCCTTCT CCTTCTC CTTCTCC TTCTCCG TCTCCGA CTCCGAG TCCGAGC CCGAGCC CGAGCCA GAGCCAC AGCCACC GCCACCG CCACCGA CACCGAG ACCGAGA CCGAGAC CGAGACG GAGACGG AGACGGA GACGGAC ACGGACT CGGACTC GGACTCC GACTCCT ACTCCTA CTCCTAT TCCTATT CCTATTT CTATTTC TATTTCT ATTTCTT TTTCTTA TTCTTAT TCTTATG CTTATGC TTATGCC TATGCCG ATGCCGT TGCCGTT GCCGTTT CCGTTTT CGTTTTC,"ID   R1A_SARS2               Reviewed;        4405 AA.
AC   P0DTC1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1a;
DE            Short=pp1a;
DE   AltName: Full=ORF1a polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69;
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=RNA-capping enzyme subunit nsp9;
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=Non-structural protein 11;
DE              Short=nsp11;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [5]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [6]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [7]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (NON-STRUCTURAL PROTEIN 10),
RP   MUTAGENESIS OF ASN-4141 AND ASN-4142, AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [8]
RP   REVIEW, SUBUNIT (NON-STRUCTURAL PROTEIN 7), AND SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [9]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [10]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [11]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN
RP   COMPLEX WITH ALPHA-KETOAMIDE INHIBITORS, SUBUNIT (3C-LIKE PROTEINASE NSP5),
RP   ACTIVE SITE, AND ACTIVITY REGULATION.
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE APOENZYME AND
RP   IN COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5), AND CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7 AND NON-STRUCTURAL PROTEIN 8, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 7), AND
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [16]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7 AND NON-STRUCTURAL PROTEIN 8, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 7), AND
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [18]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7 AND NON-STRUCTURAL PROTEIN 8, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 7), AND
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION OF NON-STRUCTURAL PROTEIN 3.
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [20]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7 AND NON-STRUCTURAL PROTEIN 8 IN COMPLEX WITH ZINC ION, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), AND FUNCTION (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), CATALYTIC ACTIVITY (NON-STRUCTURAL
RP   PROTEIN 3), ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 3), AND MUTAGENESIS
RP   OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [22]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [23]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [24]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   AND INTERACTION WITH HOST TBK1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [25]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), AND SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [26]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [27]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [28]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9 AND NON-STRUCTURAL
RP   PROTEIN 10, AND SUBUNIT (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [29]
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
CC   -!- FUNCTION: [Replicase polyprotein 1a]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by nsp3 and nsp4, while nsp6 zippers
CC       ER membranes and connects to lipid droplets (PubMed:35551511).
CC       {ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [3C-like proteinase nsp5]: Cleaves the C-terminus of
CC       replicase polyprotein at 11 sites (PubMed:32321856). Recognizes
CC       substrates containing the core sequence [ILMVF]-Q-|-[SGACN]
CC       (PubMed:32198291, PubMed:32272481). May cleave human NLRP1 in lung
CC       epithelial cells, thereby activating the NLRP1 inflammasome pathway
CC       (PubMed:35594856). May cleave human GSDMD, triggering alternative
CC       GSDME-mediated epithelial cell death upon activation of the NLRP1
CC       inflammasome, which may enhance the release interleukins 1B, 6, 16 and
CC       18 (PubMed:35594856). Also able to bind an ADP-ribose-1''-phosphate
CC       (ADRP) (PubMed:32198291, PubMed:32272481).
CC       {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481,
CC       ECO:0000269|PubMed:32321856, ECO:0000269|PubMed:32680882,
CC       ECO:0000269|PubMed:35594856}.
CC   -!- FUNCTION: [Non-structural protein 6]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by nsp3 and nsp4, while nsp6 zippers
CC       ER membranes and connects to lipid droplets (LDs) (PubMed:35551511).
CC       LDs are consumed during DMV formation (PubMed:35551511). Binds to host
CC       TBK1 without affecting TBK1 phosphorylation; the interaction with TBK1
CC       decreases IRF3 phosphorylation, which leads to reduced IFN-beta
CC       production (PubMed:32979938). {ECO:0000269|PubMed:32979938,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 7]: Plays a role in viral RNA
CC       synthesis (PubMed:32277040, PubMed:32358203, PubMed:32438371,
CC       PubMed:32526208). Forms a hexadecamer with nsp8 (8 subunits of each)
CC       that may participate in viral replication by acting as a primase.
CC       Alternatively, may synthesize substantially longer products than
CC       oligonucleotide primers (By similarity). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32277040, ECO:0000269|PubMed:32358203,
CC       ECO:0000269|PubMed:32438371, ECO:0000269|PubMed:32526208}.
CC   -!- FUNCTION: [Non-structural protein 8]: Plays a role in viral RNA
CC       synthesis (PubMed:32277040, PubMed:32358203, PubMed:32438371,
CC       PubMed:32526208). Forms a hexadecamer with nsp7 (8 subunits of each)
CC       that may participate in viral replication by acting as a primase.
CC       Alternatively, may synthesize substantially longer products than
CC       oligonucleotide primers (By similarity). Interacts with ribosome signal
CC       recognition particle RNA (SRP) (PubMed:33080218). Together with NSP9,
CC       suppress protein integration into the cell membrane, thereby disrupting
CC       host immune defenses (PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32277040, ECO:0000269|PubMed:32358203,
CC       ECO:0000269|PubMed:32438371, ECO:0000269|PubMed:32526208,
CC       ECO:0000269|PubMed:33080218}.
CC   -!- FUNCTION: [RNA-capping enzyme subunit nsp9]: Catalytic subunit of viral
CC       RNA capping enzyme which catalyzes the RNA guanylyltransferase reaction
CC       for genomic and sub-genomic RNAs (PubMed:35944563). The kinase-like
CC       NiRAN domain of NSP12 transfers RNA to the amino terminus of NSP9,
CC       forming a covalent RNA-protein intermediate (PubMed:35944563).
CC       Subsequently, the NiRAN domain transfers RNA to GDP, forming the core
CC       cap structure GpppA-RNA (PubMed:35944563). The NSP14 and NSP16
CC       methyltransferases then add methyl groups to form functional cap
CC       structures (PubMed:35944563). Interacts with ribosome signal
CC       recognition particle RNA (SRP) (PubMed:33080218). Together with NSP8,
CC       suppress protein integration into the cell membrane, thereby disrupting
CC       host immune defenses (PubMed:33080218). {ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:35944563}.
CC   -!- FUNCTION: [Non-structural protein 10]: Plays a pivotal role in viral
CC       transcription by stimulating both nsp14 3'-5' exoribonuclease (By
CC       similarity) and nsp16 2'-O-methyltransferase activities
CC       (PubMed:35944563). Therefore plays an essential role in viral mRNAs cap
CC       methylation. {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:35944563}.
CC   -!- CATALYTIC ACTIVITY: [Papain-like protease nsp3]:
CC       Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide
CC         and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-
CC         residue protein attached to proteins as an intracellular targeting
CC         signal).; EC=3.4.19.12; Evidence={ECO:0000269|PubMed:32726803};
CC   -!- CATALYTIC ACTIVITY: [3C-like proteinase nsp5]:
CC       Reaction=TSAVLQ-|-SGFRK-NH2 and SGVTFQ-|-GKFKK the two peptides
CC         corresponding to the two self-cleavage sites of the SARS 3C-like
CC         proteinase are the two most reactive peptide substrates. The enzyme
CC         exhibits a strong preference for substrates containing Gln at P1
CC         position and Leu at P2 position.; EC=3.4.22.69;
CC         Evidence={ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481,
CC         ECO:0000269|PubMed:32321856};
CC   -!- CATALYTIC ACTIVITY: [RNA-capping enzyme subunit nsp9]:
CC       Reaction=a 5'-end diphospho-ribonucleoside in mRNA + GTP + H(+) = a 5'-
CC         end (5'-triphosphoguanosine)-ribonucleoside in mRNA + diphosphate;
CC         Xref=Rhea:RHEA:67012, Rhea:RHEA-COMP:17165, Rhea:RHEA-COMP:17166,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:33019, ChEBI:CHEBI:37565,
CC         ChEBI:CHEBI:167616, ChEBI:CHEBI:167617; EC=2.7.7.50;
CC         Evidence={ECO:0000269|PubMed:35944563};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:67014;
CC         Evidence={ECO:0000269|PubMed:35944563};
CC   -!- ACTIVITY REGULATION: [Non-structural protein 6]: Inhibited ex vivo by
CC       K22. It may shift NSP6 zippering activity towards the nuclear envelope,
CC       thereby impairing formation of the NSP6-compartment necessary for viral
CC       transcription/replication. {ECO:0000269|PubMed:35551511}.
CC   -!- ACTIVITY REGULATION: [Papain-like protease nsp3]: Inhibited in vitro by
CC       GRL-0617. {ECO:0000269|PubMed:32726803}.
CC   -!- ACTIVITY REGULATION: [3C-like proteinase nsp5]: Inhibited by pyridone-
CC       containing alpha-ketoamides compounds 13a and 13b. In turn, alpha-
CC       ketoamide 13b (tert-butyl (1-((S)-1-(((S)-4-(benzylamino)-3,4-dioxo-1-
CC       ((S)-2-oxopyrrolidin-3-yl)butan-2-yl)amino)-3-cyclopropyl-1-oxopropan-
CC       2-yl)-2-oxo-1,2-dihydropyridin-3-yl)carbamate) inhibits SARS-CoV-2
CC       replication in human lung cells (PubMed:32198291). Inhibited ex vivo by
CC       michael acceptor inhibitor N3 (PubMed:32272481). Inhibited ex vivo by
CC       compound 11a and 11b (PubMed:32321856). {ECO:0000269|PubM",3294
CGCCGG GCCGGC CCGGCC CGGCCC GGCCCG GCCCGA CCCGAG CCGAGC CGAGCA GAGCAG AGCAGG GCAGGG CAGGGC AGGGCT GGGCTC GGCTCC GCTCCC CTCCCC TCCCCC CCCCCA CCCCAC CCCACC CCACCG CACCGT ACCGTT CCGTTC CGTTCC GTTCCC TTCCCC TCCCCC CCCCCC CCCCCG CCCCGC CCCGCC CCGCCG CGCCGG GCCGGA CCGGAA CGGAAC GGAACC GAACCG AACCGC ACCGCC CCGCCG CGCCGA GCCGAC CCGACT CGACTC GACTCC ACTCCT CTCCTT TCCTTC CCTTCG CTTCGC TTCGCG TCGCGC CGCGCG GCGCGC CGCGCG GCGCGC CGCGCT GCGCTG CGCTGG GCTGGG CTGGGA TGGGAT GGGATC GGATCA GATCAA ATCAAG TCAAGA CAAGAG AAGAGT AGAGTG GAGTGA AGTGAG GTGAGC TGAGCG GAGCGC AGCGCG GCGCGT CGCGTG GCGTGA CGTGAA GTGAAC TGAACA GAACAA AACAAG ACAAGG CAAGGT AAGGTG AGGTGC GGTGCT GTGCTC TGCTCG GCTCGA CTCGAA TCGAAG CGAAGG GAAGGC AAGGCC AGGCCG GGCCGC GCCGCC CCGCCC CGCCCC GCCCCG CCCCGA CCCGAC CCGACA CGACAT GACATC ACATCG CATCGT ATCGTC TCGTCG CGTCGA GTCGAC TCGACC CGACCG GACCGG ACCGGC CCGGCT CGGCTT GGCTTC GCTTCG CTTCGC TTCGCA TCGCAA CGCAAC GCAACG CAACGG AACGGC ACGGCG CGGCGA GGCGAG GCGAGA CGAGAT GAGATT AGATTG GATTGC ATTGCG,0,142,CGCC GCCG CCGG CGGC GGCC GCCC CCCG CCGA CGAG GAGC AGCA GCAG CAGG AGGG GGGC GGCT GCTC CTCC TCCC CCCC CCCC CCCA CCAC CACC ACCG CCGT CGTT GTTC TTCC TCCC CCCC CCCC CCCC CCCG CCGC CGCC GCCG CCGG CGGA GGAA GAAC AACC ACCG CCGC CGCC GCCG CCGA CGAC GACT ACTC CTCC TCCT CCTT CTTC TTCG TCGC CGCG GCGC CGCG GCGC CGCG GCGC CGCT GCTG CTGG TGGG GGGA GGAT GATC ATCA TCAA CAAG AAGA AGAG GAGT AGTG GTGA TGAG GAGC AGCG GCGC CGCG GCGT CGTG GTGA TGAA GAAC AACA ACAA CAAG AAGG AGGT GGTG GTGC TGCT GCTC CTCG TCGA CGAA GAAG AAGG AGGC GGCC GCCG CCGC CGCC GCCC CCCC CCCG CCGA CGAC GACA ACAT CATC ATCG TCGT CGTC GTCG TCGA CGAC GACC ACCG CCGG CGGC GGCT GCTT CTTC TTCG TCGC CGCA GCAA CAAC AACG ACGG CGGC GGCG GCGA CGAG GAGA AGAT GATT ATTG TTGC TGCG,CGCCG GCCGG CCGGC CGGCC GGCCC GCCCG CCCGA CCGAG CGAGC GAGCA AGCAG GCAGG CAGGG AGGGC GGGCT GGCTC GCTCC CTCCC TCCCC CCCCC CCCCA CCCAC CCACC CACCG ACCGT CCGTT CGTTC GTTCC TTCCC TCCCC CCCCC CCCCC CCCCG CCCGC CCGCC CGCCG GCCGG CCGGA CGGAA GGAAC GAACC AACCG ACCGC CCGCC CGCCG GCCGA CCGAC CGACT GACTC ACTCC CTCCT TCCTT CCTTC CTTCG TTCGC TCGCG CGCGC GCGCG CGCGC GCGCG CGCGC GCGCT CGCTG GCTGG CTGGG TGGGA GGGAT GGATC GATCA ATCAA TCAAG CAAGA AAGAG AGAGT GAGTG AGTGA GTGAG TGAGC GAGCG AGCGC GCGCG CGCGT GCGTG CGTGA GTGAA TGAAC GAACA AACAA ACAAG CAAGG AAGGT AGGTG GGTGC GTGCT TGCTC GCTCG CTCGA TCGAA CGAAG GAAGG AAGGC AGGCC GGCCG GCCGC CCGCC CGCCC GCCCC CCCCG CCCGA CCGAC CGACA GACAT ACATC CATCG ATCGT TCGTC CGTCG GTCGA TCGAC CGACC GACCG ACCGG CCGGC CGGCT GGCTT GCTTC CTTCG TTCGC TCGCA CGCAA GCAAC CAACG AACGG ACGGC CGGCG GGCGA GCGAG CGAGA GAGAT AGATT GATTG ATTGC TTGCG,CGCCGG GCCGGC CCGGCC CGGCCC GGCCCG GCCCGA CCCGAG CCGAGC CGAGCA GAGCAG AGCAGG GCAGGG CAGGGC AGGGCT GGGCTC GGCTCC GCTCCC CTCCCC TCCCCC CCCCCA CCCCAC CCCACC CCACCG CACCGT ACCGTT CCGTTC CGTTCC GTTCCC TTCCCC TCCCCC CCCCCC CCCCCG CCCCGC CCCGCC CCGCCG CGCCGG GCCGGA CCGGAA CGGAAC GGAACC GAACCG AACCGC ACCGCC CCGCCG CGCCGA GCCGAC CCGACT CGACTC GACTCC ACTCCT CTCCTT TCCTTC CCTTCG CTTCGC TTCGCG TCGCGC CGCGCG GCGCGC CGCGCG GCGCGC CGCGCT GCGCTG CGCTGG GCTGGG CTGGGA TGGGAT GGGATC GGATCA GATCAA ATCAAG TCAAGA CAAGAG AAGAGT AGAGTG GAGTGA AGTGAG GTGAGC TGAGCG GAGCGC AGCGCG GCGCGT CGCGTG GCGTGA CGTGAA GTGAAC TGAACA GAACAA AACAAG ACAAGG CAAGGT AAGGTG AGGTGC GGTGCT GTGCTC TGCTCG GCTCGA CTCGAA TCGAAG CGAAGG GAAGGC AAGGCC AGGCCG GGCCGC GCCGCC CCGCCC CGCCCC GCCCCG CCCCGA CCCGAC CCGACA CGACAT GACATC ACATCG CATCGT ATCGTC TCGTCG CGTCGA GTCGAC TCGACC CGACCG GACCGG ACCGGC CCGGCT CGGCTT GGCTTC GCTTCG CTTCGC TTCGCA TCGCAA CGCAAC GCAACG CAACGG AACGGC ACGGCG CGGCGA GGCGAG GCGAGA CGAGAT GAGATT AGATTG GATTGC ATTGCG,CGCCGGC GCCGGCC CCGGCCC CGGCCCG GGCCCGA GCCCGAG CCCGAGC CCGAGCA CGAGCAG GAGCAGG AGCAGGG GCAGGGC CAGGGCT AGGGCTC GGGCTCC GGCTCCC GCTCCCC CTCCCCC TCCCCCA CCCCCAC CCCCACC CCCACCG CCACCGT CACCGTT ACCGTTC CCGTTCC CGTTCCC GTTCCCC TTCCCCC TCCCCCC CCCCCCG CCCCCGC CCCCGCC CCCGCCG CCGCCGG CGCCGGA GCCGGAA CCGGAAC CGGAACC GGAACCG GAACCGC AACCGCC ACCGCCG CCGCCGA CGCCGAC GCCGACT CCGACTC CGACTCC GACTCCT ACTCCTT CTCCTTC TCCTTCG CCTTCGC CTTCGCG TTCGCGC TCGCGCG CGCGCGC GCGCGCG CGCGCGC GCGCGCT CGCGCTG GCGCTGG CGCTGGG GCTGGGA CTGGGAT TGGGATC GGGATCA GGATCAA GATCAAG ATCAAGA TCAAGAG CAAGAGT AAGAGTG AGAGTGA GAGTGAG AGTGAGC GTGAGCG TGAGCGC GAGCGCG AGCGCGT GCGCGTG CGCGTGA GCGTGAA CGTGAAC GTGAACA TGAACAA GAACAAG AACAAGG ACAAGGT CAAGGTG AAGGTGC AGGTGCT GGTGCTC GTGCTCG TGCTCGA GCTCGAA CTCGAAG TCGAAGG CGAAGGC GAAGGCC AAGGCCG AGGCCGC GGCCGCC GCCGCCC CCGCCCC CGCCCCG GCCCCGA CCCCGAC CCCGACA CCGACAT CGACATC GACATCG ACATCGT CATCGTC ATCGTCG TCGTCGA CGTCGAC GTCGACC TCGACCG CGACCGG GACCGGC ACCGGCT CCGGCTT CGGCTTC GGCTTCG GCTTCGC CTTCGCA TTCGCAA TCGCAAC CGCAACG GCAACGG CAACGGC AACGGCG ACGGCGA CGGCGAG GGCGAGA GCGAGAT CGAGATT GAGATTG AGATTGC GATTGCG,"ID   CARB_PSEPK              Reviewed;        1073 AA.
AC   Q88DU6;
DT   31-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   31-OCT-2003, sequence version 2.
DT   05-FEB-2025, entry version 134.
DE   RecName: Full=Carbamoyl phosphate synthase large chain {ECO:0000255|HAMAP-Rule:MF_01210};
DE            EC=6.3.4.16 {ECO:0000255|HAMAP-Rule:MF_01210};
DE            EC=6.3.5.5 {ECO:0000255|HAMAP-Rule:MF_01210};
DE   AltName: Full=Carbamoyl phosphate synthetase ammonia chain {ECO:0000255|HAMAP-Rule:MF_01210};
GN   Name=carB {ECO:0000255|HAMAP-Rule:MF_01210};
GN   OrderedLocusNames=PP_4723;
OS   Pseudomonas putida (strain ATCC 47054 / DSM 6125 / CFBP 8728 / NCIMB 11950
OS   / KT2440).
OC   Bacteria; Pseudomonadota; Gammaproteobacteria; Pseudomonadales;
OC   Pseudomonadaceae; Pseudomonas.
OX   NCBI_TaxID=160488;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 47054 / DSM 6125 / CFBP 8728 / NCIMB 11950 / KT2440;
RX   PubMed=12534463; DOI=10.1046/j.1462-2920.2002.00366.x;
RA   Nelson K.E., Weinel C., Paulsen I.T., Dodson R.J., Hilbert H.,
RA   Martins dos Santos V.A.P., Fouts D.E., Gill S.R., Pop M., Holmes M.,
RA   Brinkac L.M., Beanan M.J., DeBoy R.T., Daugherty S.C., Kolonay J.F.,
RA   Madupu R., Nelson W.C., White O., Peterson J.D., Khouri H.M., Hance I.,
RA   Chris Lee P., Holtzapple E.K., Scanlan D., Tran K., Moazzez A.,
RA   Utterback T.R., Rizzo M., Lee K., Kosack D., Moestl D., Wedler H.,
RA   Lauber J., Stjepandic D., Hoheisel J., Straetz M., Heim S., Kiewitz C.,
RA   Eisen J.A., Timmis K.N., Duesterhoeft A., Tuemmler B., Fraser C.M.;
RT   ""Complete genome sequence and comparative analysis of the metabolically
RT   versatile Pseudomonas putida KT2440."";
RL   Environ. Microbiol. 4:799-808(2002).
CC   -!- FUNCTION: Large subunit of the glutamine-dependent carbamoyl phosphate
CC       synthetase (CPSase). CPSase catalyzes the formation of carbamoyl
CC       phosphate from the ammonia moiety of glutamine, carbonate, and
CC       phosphate donated by ATP, constituting the first step of 2 biosynthetic
CC       pathways, one leading to arginine and/or urea and the other to
CC       pyrimidine nucleotides. The large subunit (synthetase) binds the
CC       substrates ammonia (free or transferred from glutamine from the small
CC       subunit), hydrogencarbonate and ATP and carries out an ATP-coupled
CC       ligase reaction, activating hydrogencarbonate by forming carboxy
CC       phosphate which reacts with ammonia to form carbamoyl phosphate.
CC       {ECO:0000255|HAMAP-Rule:MF_01210}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=hydrogencarbonate + L-glutamine + 2 ATP + H2O = carbamoyl
CC         phosphate + L-glutamate + 2 ADP + phosphate + 2 H(+);
CC         Xref=Rhea:RHEA:18633, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:17544, ChEBI:CHEBI:29985, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:58228, ChEBI:CHEBI:58359,
CC         ChEBI:CHEBI:456216; EC=6.3.5.5; Evidence={ECO:0000255|HAMAP-
CC         Rule:MF_01210};
CC   -!- CATALYTIC ACTIVITY: [Carbamoyl phosphate synthase large chain]:
CC       Reaction=hydrogencarbonate + NH4(+) + 2 ATP = carbamoyl phosphate + 2
CC         ADP + phosphate + 2 H(+); Xref=Rhea:RHEA:18029, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:17544, ChEBI:CHEBI:28938, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:58228, ChEBI:CHEBI:456216;
CC         EC=6.3.4.16; Evidence={ECO:0000255|HAMAP-Rule:MF_01210};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000255|HAMAP-
CC         Rule:MF_01210};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000255|HAMAP-
CC         Rule:MF_01210};
CC       Note=Binds 4 Mg(2+) or Mn(2+) ions per subunit. {ECO:0000255|HAMAP-
CC       Rule:MF_01210};
CC   -!- PATHWAY: Amino-acid biosynthesis; L-arginine biosynthesis; carbamoyl
CC       phosphate from bicarbonate: step 1/1. {ECO:0000255|HAMAP-
CC       Rule:MF_01210}.
CC   -!- PATHWAY: Pyrimidine metabolism; UMP biosynthesis via de novo pathway;
CC       (S)-dihydroorotate from bicarbonate: step 1/3. {ECO:0000255|HAMAP-
CC       Rule:MF_01210}.
CC   -!- SUBUNIT: Composed of two chains; the small (or glutamine) chain
CC       promotes the hydrolysis of glutamine to ammonia, which is used by the
CC       large (or ammonia) chain to synthesize carbamoyl phosphate. Tetramer of
CC       heterodimers (alpha,beta)4. {ECO:0000255|HAMAP-Rule:MF_01210}.
CC   -!- DOMAIN: The large subunit is composed of 2 ATP-grasp domains that are
CC       involved in binding the 2 ATP molecules needed for carbamoyl phosphate
CC       synthesis. The N-terminal ATP-grasp domain (referred to as the
CC       carboxyphosphate synthetic component) catalyzes the ATP-dependent
CC       phosphorylation of hydrogencarbonate to carboxyphosphate and the
CC       subsequent nucleophilic attack by ammonia to form a carbamate
CC       intermediate. The C-terminal ATP-grasp domain (referred to as the
CC       carbamoyl phosphate synthetic component) then catalyzes the
CC       phosphorylation of carbamate with the second ATP to form the end
CC       product carbamoyl phosphate. The reactive and unstable enzyme
CC       intermediates are sequentially channeled from one active site to the
CC       next through the interior of the protein over a distance of at least 96
CC       A. {ECO:0000255|HAMAP-Rule:MF_01210}.
CC   -!- SIMILARITY: Belongs to the CarB family. {ECO:0000255|HAMAP-
CC       Rule:MF_01210}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAN70295.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AE015451; AAN70295.1; ALT_INIT; Genomic_DNA.
DR   RefSeq; NP_746831.3; NC_002947.4.
DR   RefSeq; WP_010955363.1; NC_002947.4.
DR   AlphaFoldDB; Q88DU6; -.
DR   SMR; Q88DU6; -.
DR   STRING; 160488.PP_4723; -.
DR   PaxDb; 160488-PP_4723; -.
DR   GeneID; 83682440; -.
DR   KEGG; ppu:PP_4723; -.
DR   PATRIC; fig|160488.4.peg.5034; -.
DR   eggNOG; COG0458; Bacteria.
DR   HOGENOM; CLU_000513_1_2_6; -.
DR   OrthoDB; 9804197at2; -.
DR   PhylomeDB; Q88DU6; -.
DR   UniPathway; UPA00068; UER00171.
DR   UniPathway; UPA00070; UER00115.
DR   Proteomes; UP000000556; Chromosome.
DR   GO; GO:0005737; C:cytoplasm; IEA:TreeGrafter.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0004087; F:carbamoyl-phosphate synthase (ammonia) activity; IEA:RHEA.
DR   GO; GO:0004088; F:carbamoyl-phosphate synthase (glutamine-hydrolyzing) activity; IEA:UniProtKB-UniRule.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0044205; P:'de novo' UMP biosynthetic process; IEA:UniProtKB-UniRule.
DR   GO; GO:0006541; P:glutamine metabolic process; IEA:TreeGrafter.
DR   GO; GO:0006526; P:L-arginine biosynthetic process; IEA:UniProtKB-UniRule.
DR   CDD; cd01424; MGS_CPS_II; 1.
DR   FunFam; 1.10.1030.10:FF:000002; Carbamoyl-phosphate synthase large chain; 1.
DR   FunFam; 3.30.1490.20:FF:000001; Carbamoyl-phosphate synthase large chain; 1.
DR   FunFam; 3.30.470.20:FF:000007; Carbamoyl-phosphate synthase large chain; 1.
DR   FunFam; 3.30.470.20:FF:000013; Carbamoyl-phosphate synthase large chain; 1.
DR   FunFam; 3.40.50.1380:FF:000004; Carbamoyl-phosphate synthase large chain; 1.
DR   FunFam; 3.40.50.20:FF:000001; Carbamoyl-phosphate synthase large chain; 1.
DR   FunFam; 3.40.50.20:FF:000003; Carbamoyl-phosphate synthase large chain; 1.
DR   Gene3D; 3.40.50.20; -; 2.
DR   Gene3D; 3.30.470.20; ATP-grasp fold, B domain; 2.
DR   Gene3D; 1.10.1030.10; Carbamoyl-phosphate synthetase, large subunit oligomerisation domain; 1.
DR   Gene3D; 3.40.50.1380; Methylglyoxal synthase-like domain; 1.
DR   HAMAP; MF_01210_A; CPSase_L_chain_A; 1.
DR   HAMAP; MF_01210_B; CPSase_L_chain_B; 1.
DR   InterPro; IPR011761; ATP-grasp.
DR   InterPro; IPR006275; CarbamoylP_synth_lsu.
DR   InterPro; IPR005480; CarbamoylP_synth_lsu_oligo.
DR   InterPro; IPR036897; CarbamoylP_synth_lsu_oligo_sf.
DR   InterPro; IPR005479; CbamoylP_synth_lsu-like_ATP-bd.
DR   InterPro; IPR005483; CbamoylP_synth_lsu_CPSase_dom.
DR   InterPro; IPR011607; MGS-like_dom.
DR   InterPro; IPR036914; MGS-like_dom_sf.
DR   InterPro; IPR033937; MGS_CPS_CarB.
DR   InterPro; IPR016185; PreATP-grasp_dom_sf.
DR   NCBIfam; TIGR01369; CPSaseII_lrg; 1.
DR   PANTHER; PTHR11405:SF53; CARBAMOYL-PHOSPHATE SYNTHASE [AMMONIA], MITOCHONDRIAL; 1.
DR   PANTHER; PTHR11405; CARBAMOYLTRANSFERASE FAMILY MEMBER; 1.
DR   Pfam; PF02786; CPSase_L_D2; 2.
DR   Pfam; PF02787; CPSase_L_D3; 1.
DR   Pfam; PF02142; MGS; 1.
DR   PRINTS; PR00098; CPSASE.
DR   SMART; SM01096; CPSase_L_D3; 1.
DR   SMART; SM00851; MGS; 1.
DR   SUPFAM; SSF48108; Carbamoyl phosphate synthetase, large subunit connection domain; 1.
DR   SUPFAM; SSF56059; Glutathione synthetase ATP-binding domain-like; 2.
DR   SUPFAM; SSF52335; Methylglyoxal synthase-like; 1.
DR   SUPFAM; SSF52440; PreATP-grasp domain; 2.
DR   PROSITE; PS50975; ATP_GRASP; 2.
DR   PROSITE; PS00866; CPSASE_1; 2.
DR   PROSITE; PS00867; CPSASE_2; 2.
DR   PROSITE; PS51855; MGS; 1.
PE   3: Inferred from homology;
KW   Amino-acid biosynthesis; Arginine biosynthesis; ATP-binding; Ligase;
KW   Magnesium; Manganese; Metal-binding; Nucleotide-binding;
KW   Pyrimidine biosynthesis; Reference proteome; Repeat.
FT   CHAIN           1..1073
FT                   /note=""Carbamoyl phosphate synthase large chain""
FT                   /id=""PRO_0000145029""
FT   DOMAIN          133..328
FT                   /note=""ATP-grasp 1""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   DOMAIN          678..869
FT                   /note=""ATP-grasp 2""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   DOMAIN          936..1073
FT                   /note=""MGS-like""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   REGION          1..403
FT                   /note=""Carboxyphosphate synthetic domain""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   REGION          404..553
FT                   /note=""Oligomerization domain""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   REGION          554..935
FT                   /note=""Carbamoyl phosphate synthetic domain""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   REGION          936..1073
FT                   /note=""Allosteric domain""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         129
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         169
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         175
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         176
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         208
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         210
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         215
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         241
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         242
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         243
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         285
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         285
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         285
FT                   /ligand=""Mn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29035""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         299
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         299
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         299
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /ligand_label=""2""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         299
FT                   /ligand=""Mn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29035""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         299
FT                   /ligand=""Mn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29035""
FT                   /ligand_label=""2""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         301
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /ligand_label=""2""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         301
FT                   /ligand=""Mn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29035""
FT                   /ligand_label=""2""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         714
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /ligand_label=""2""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         753
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /ligand_label=""2""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         755
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /ligand_label=""2""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         760
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /ligand_label=""2""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         785
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /ligand_label=""2""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         786
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /ligand_label=""2""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         787
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /ligand_label=""2""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         788
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /ligand_label=""2""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         828
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /ligand_label=""2""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         828
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /ligand_label=""3""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         828
FT                   /ligand=""Mn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29035""
FT                   /ligand_label=""3""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         840
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /ligand_label=""2""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         840
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /ligand_label=""3""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         840
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /ligand_label=""4""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         840
FT                   /ligand=""Mn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29035""
FT                   /ligand_label=""3""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         840
FT                   /ligand=""Mn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29035""
FT                   /ligand_label=""4""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         842
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /ligand_label=""4""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
FT   BINDING         842
FT                   /ligand=""Mn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29035""
FT                   /ligand_label=""4""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01210""
SQ   SEQUENCE   1073 AA;  117397 MW;  0A0343DA2D212FAD CRC64;
     MPKRTDIKSI LILGAGPIVI GQACEFDYSG AQACKALREE GFRVILVNSN PATIMTDPAM
     ADATYIEPIK WQSVAKIIEK ERPDAVLPTM GGQTALNCAL DLERHGVLEK FGVEMIGANA
     DTIDKAEDRS RFDKAMKDIG LECPRSGIAH SMEEANAVLE KLGFPCIIRP SFTMGGTGGG
     IAYNREEFEE ICTRGLDLSP TKELLIDESL IGWKEYEMEV VRDKKDNCII VCSIENFDPM
     GVHTGDSITV APAQTLTDKE YQIMRNASLA VLREIGVETG GSNVQFGICP NTGRMVVIEM
     NPRVSRSSAL ASKATGFPIA KIAAKLAIGY TLDELQNDIT GGRTPASFEP SIDYVVTKLP
     RFAFEKFPKA DARLTTQMKS VGEVMAIGRT FQESLQKALR GLEVGACGLD PKVDLASPEA
     ASILKRELTV PGAERIWYVA DAMRSGMTCE EIFNLTGIDM WFLVQMEDLI KEEEKVKTLA
     LSAIDKDYML RLKRKGFSDQ RLAVLLGITD KNLRRHRHKL EVFPVYKRVD TCAAEFATDT
     AYLYSTYEEE CEANPSTRDK IMILGGGPNR IGQGIEFDYC CVHAALALRE DGYETIMVNC
     NPETVSTDYD TSDRLYFEPL TLEDVLEVCR VEKPKGVIVH YGGQTPLKLA RALEEAGVPI
     IGTSPDAIDR AEDRERFQQM VQRLSLLQPP NATVRSEEEA IRAAGSIGYP LVVRPSYVLG
     GRAMEIVYEL DELKRYLREA VQVSNDSPVL LDHFLNCAIE MDVDAVCDGT DVVIGAIMQH
     IEQAGVHSGD SACSLPPYSL SKEVQDEVRV QVKKMALELG VVGLMNVQLA LQGDKIYVIE
     VNPRASRTVP FVSKCIGTSL AMIAARVMAG KTLKELGFTQ EIIPNFYSVK EAVFPFAKFP
     GVDPILGPEM KSTGEVMGVG DSFGEAFAKA QMGASEVLPT GGTAFISVRD DDKPQVAGVA
     RDLIALGFEV VATAGTAKVI EAAGLKVRRV NKVTEGRPHV VDMIKNDEVS LIINTTEGRQ
     SIADSYSIRR NALQHKIYCT TTIAAGEAIC EALKFGPEKT VRRLQDLHAG LKA
//
",1324
CTCGCC TCGCCG CGCCGC GCCGCC CCGCCG CGCCGG GCCGGC CCGGCG CGGCGA GGCGAA GCGAAA CGAAAA GAAAAT AAAATC AAATCA AATCAC ATCACT TCACTA CACTAC ACTACA CTACAC TACACG ACACGC CACGCG ACGCGT CGCGTT GCGTTT CGTTTT GTTTTG TTTTGA TTTGAA TTGAAT TGAATT GAATTC AATTCA ATTCAA TTCAAC TCAACC CAACCG AACCGC ACCGCG CCGCGC CGCGCA GCGCAA CGCAAT GCAATC CAATCG AATCGA ATCGAG TCGAGG CGAGGA GAGGAC AGGACG GGACGG GACGGC ACGGCG CGGCGC GGCGCG GCGCGA CGCGAT GCGATC CGATCA GATCAC ATCACC TCACCA CACCAT ACCATT CCATTC CATTCT ATTCTG TTCTGC TCTGCA CTGCAG TGCAGC GCAGCC CAGCCC AGCCCG GCCCGA CCCGAC CCGACC CGACCT GACCTC ACCTCT CCTCTC CTCTCC TCTCCA CTCCAA TCCAAA CCAAAA CAAAAC AAAACC AAACCG AACCGG ACCGGC CCGGCG CGGCGG GGCGGC GCGGCA CGGCAT GGCATC GCATCA CATCAC ATCACC TCACCG CACCGA ACCGAA CCGAAG CGAAGC GAAGCG AAGCGC AGCGCT GCGCTG CGCTGC GCTGCG CTGCGC TGCGCG GCGCGT CGCGTC GCGTCG CGTCGC GTCGCC TCGCCG CGCCGC GCCGCC CCGCCA CGCCAT GCCATG CCATGG CATGGC ATGGCC TGGCCT GGCCTC GCCTCG CCTCGG CTCGGC TCGGCT CGGCTT GGCTTA GCTTAC CTTACA TTACAA TACAAA ACAAAC CAAACT AAACTG,0,145,CTCG TCGC CGCC GCCG CCGC CGCC GCCG CCGG CGGC GGCG GCGA CGAA GAAA AAAA AAAT AATC ATCA TCAC CACT ACTA CTAC TACA ACAC CACG ACGC CGCG GCGT CGTT GTTT TTTT TTTG TTGA TGAA GAAT AATT ATTC TTCA TCAA CAAC AACC ACCG CCGC CGCG GCGC CGCA GCAA CAAT AATC ATCG TCGA CGAG GAGG AGGA GGAC GACG ACGG CGGC GGCG GCGC CGCG GCGA CGAT GATC ATCA TCAC CACC ACCA CCAT CATT ATTC TTCT TCTG CTGC TGCA GCAG CAGC AGCC GCCC CCCG CCGA CGAC GACC ACCT CCTC CTCT TCTC CTCC TCCA CCAA CAAA AAAA AAAC AACC ACCG CCGG CGGC GGCG GCGG CGGC GGCA GCAT CATC ATCA TCAC CACC ACCG CCGA CGAA GAAG AAGC AGCG GCGC CGCT GCTG CTGC TGCG GCGC CGCG GCGT CGTC GTCG TCGC CGCC GCCG CCGC CGCC GCCA CCAT CATG ATGG TGGC GGCC GCCT CCTC CTCG TCGG CGGC GGCT GCTT CTTA TTAC TACA ACAA CAAA AAAC AACT ACTG,CTCGC TCGCC CGCCG GCCGC CCGCC CGCCG GCCGG CCGGC CGGCG GGCGA GCGAA CGAAA GAAAA AAAAT AAATC AATCA ATCAC TCACT CACTA ACTAC CTACA TACAC ACACG CACGC ACGCG CGCGT GCGTT CGTTT GTTTT TTTTG TTTGA TTGAA TGAAT GAATT AATTC ATTCA TTCAA TCAAC CAACC AACCG ACCGC CCGCG CGCGC GCGCA CGCAA GCAAT CAATC AATCG ATCGA TCGAG CGAGG GAGGA AGGAC GGACG GACGG ACGGC CGGCG GGCGC GCGCG CGCGA GCGAT CGATC GATCA ATCAC TCACC CACCA ACCAT CCATT CATTC ATTCT TTCTG TCTGC CTGCA TGCAG GCAGC CAGCC AGCCC GCCCG CCCGA CCGAC CGACC GACCT ACCTC CCTCT CTCTC TCTCC CTCCA TCCAA CCAAA CAAAA AAAAC AAACC AACCG ACCGG CCGGC CGGCG GGCGG GCGGC CGGCA GGCAT GCATC CATCA ATCAC TCACC CACCG ACCGA CCGAA CGAAG GAAGC AAGCG AGCGC GCGCT CGCTG GCTGC CTGCG TGCGC GCGCG CGCGT GCGTC CGTCG GTCGC TCGCC CGCCG GCCGC CCGCC CGCCA GCCAT CCATG CATGG ATGGC TGGCC GGCCT GCCTC CCTCG CTCGG TCGGC CGGCT GGCTT GCTTA CTTAC TTACA TACAA ACAAA CAAAC AAACT AACTG,CTCGCC TCGCCG CGCCGC GCCGCC CCGCCG CGCCGG GCCGGC CCGGCG CGGCGA GGCGAA GCGAAA CGAAAA GAAAAT AAAATC AAATCA AATCAC ATCACT TCACTA CACTAC ACTACA CTACAC TACACG ACACGC CACGCG ACGCGT CGCGTT GCGTTT CGTTTT GTTTTG TTTTGA TTTGAA TTGAAT TGAATT GAATTC AATTCA ATTCAA TTCAAC TCAACC CAACCG AACCGC ACCGCG CCGCGC CGCGCA GCGCAA CGCAAT GCAATC CAATCG AATCGA ATCGAG TCGAGG CGAGGA GAGGAC AGGACG GGACGG GACGGC ACGGCG CGGCGC GGCGCG GCGCGA CGCGAT GCGATC CGATCA GATCAC ATCACC TCACCA CACCAT ACCATT CCATTC CATTCT ATTCTG TTCTGC TCTGCA CTGCAG TGCAGC GCAGCC CAGCCC AGCCCG GCCCGA CCCGAC CCGACC CGACCT GACCTC ACCTCT CCTCTC CTCTCC TCTCCA CTCCAA TCCAAA CCAAAA CAAAAC AAAACC AAACCG AACCGG ACCGGC CCGGCG CGGCGG GGCGGC GCGGCA CGGCAT GGCATC GCATCA CATCAC ATCACC TCACCG CACCGA ACCGAA CCGAAG CGAAGC GAAGCG AAGCGC AGCGCT GCGCTG CGCTGC GCTGCG CTGCGC TGCGCG GCGCGT CGCGTC GCGTCG CGTCGC GTCGCC TCGCCG CGCCGC GCCGCC CCGCCA CGCCAT GCCATG CCATGG CATGGC ATGGCC TGGCCT GGCCTC GCCTCG CCTCGG CTCGGC TCGGCT CGGCTT GGCTTA GCTTAC CTTACA TTACAA TACAAA ACAAAC CAAACT AAACTG,CTCGCCG TCGCCGC CGCCGCC GCCGCCG CCGCCGG CGCCGGC GCCGGCG CCGGCGA CGGCGAA GGCGAAA GCGAAAA CGAAAAT GAAAATC AAAATCA AAATCAC AATCACT ATCACTA TCACTAC CACTACA ACTACAC CTACACG TACACGC ACACGCG CACGCGT ACGCGTT CGCGTTT GCGTTTT CGTTTTG GTTTTGA TTTTGAA TTTGAAT TTGAATT TGAATTC GAATTCA AATTCAA ATTCAAC TTCAACC TCAACCG CAACCGC AACCGCG ACCGCGC CCGCGCA CGCGCAA GCGCAAT CGCAATC GCAATCG CAATCGA AATCGAG ATCGAGG TCGAGGA CGAGGAC GAGGACG AGGACGG GGACGGC GACGGCG ACGGCGC CGGCGCG GGCGCGA GCGCGAT CGCGATC GCGATCA CGATCAC GATCACC ATCACCA TCACCAT CACCATT ACCATTC CCATTCT CATTCTG ATTCTGC TTCTGCA TCTGCAG CTGCAGC TGCAGCC GCAGCCC CAGCCCG AGCCCGA GCCCGAC CCCGACC CCGACCT CGACCTC GACCTCT ACCTCTC CCTCTCC CTCTCCA TCTCCAA CTCCAAA TCCAAAA CCAAAAC CAAAACC AAAACCG AAACCGG AACCGGC ACCGGCG CCGGCGG CGGCGGC GGCGGCA GCGGCAT CGGCATC GGCATCA GCATCAC CATCACC ATCACCG TCACCGA CACCGAA ACCGAAG CCGAAGC CGAAGCG GAAGCGC AAGCGCT AGCGCTG GCGCTGC CGCTGCG GCTGCGC CTGCGCG TGCGCGT GCGCGTC CGCGTCG GCGTCGC CGTCGCC GTCGCCG TCGCCGC CGCCGCC GCCGCCA CCGCCAT CGCCATG GCCATGG CCATGGC CATGGCC ATGGCCT TGGCCTC GGCCTCG GCCTCGG CCTCGGC CTCGGCT TCGGCTT CGGCTTA GGCTTAC GCTTACA CTTACAA TTACAAA TACAAAC ACAAACT CAAACTG,"ID   DGOD_RALPJ              Reviewed;         382 AA.
AC   B2UCA8;
DT   14-APR-2009, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-2008, sequence version 1.
DT   27-NOV-2024, entry version 104.
DE   RecName: Full=D-galactonate dehydratase {ECO:0000255|HAMAP-Rule:MF_01289};
DE            Short=GalD {ECO:0000255|HAMAP-Rule:MF_01289};
DE            EC=4.2.1.6 {ECO:0000255|HAMAP-Rule:MF_01289};
GN   Name=dgoD {ECO:0000255|HAMAP-Rule:MF_01289};
GN   OrderedLocusNames=Rpic_2990;
OS   Ralstonia pickettii (strain 12J).
OC   Bacteria; Pseudomonadota; Betaproteobacteria; Burkholderiales;
OC   Burkholderiaceae; Ralstonia.
OX   NCBI_TaxID=402626;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=12J;
RA   Lucas S., Copeland A., Lapidus A., Glavina del Rio T., Dalin E., Tice H.,
RA   Bruce D., Goodwin L., Pitluck S., Meincke L., Brettin T., Detter J.C.,
RA   Han C., Kuske C.R., Schmutz J., Larimer F., Land M., Hauser L.,
RA   Kyrpides N., Mikhailova N., Marsh T., Richardson P.;
RT   ""Complete sequence of chromosome 1 of Ralstonia pickettii 12J."";
RL   Submitted (MAY-2008) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Catalyzes the dehydration of D-galactonate to 2-keto-3-deoxy-
CC       D-galactonate. {ECO:0000255|HAMAP-Rule:MF_01289}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=D-galactonate = 2-dehydro-3-deoxy-D-galactonate + H2O;
CC         Xref=Rhea:RHEA:18649, ChEBI:CHEBI:12931, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:57989; EC=4.2.1.6; Evidence={ECO:0000255|HAMAP-
CC         Rule:MF_01289};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000255|HAMAP-
CC         Rule:MF_01289};
CC       Note=Binds 1 Mg(2+) ion per subunit. {ECO:0000255|HAMAP-Rule:MF_01289};
CC   -!- PATHWAY: Carbohydrate acid metabolism; D-galactonate degradation; D-
CC       glyceraldehyde 3-phosphate and pyruvate from D-galactonate: step 1/3.
CC       {ECO:0000255|HAMAP-Rule:MF_01289}.
CC   -!- MISCELLANEOUS: Reaction proceeds via an anti dehydration.
CC       {ECO:0000255|HAMAP-Rule:MF_01289}.
CC   -!- SIMILARITY: Belongs to the mandelate racemase/muconate lactonizing
CC       enzyme family. GalD subfamily. {ECO:0000255|HAMAP-Rule:MF_01289}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CP001068; ACD28113.1; -; Genomic_DNA.
DR   PDB; 3RR1; X-ray; 1.95 A; A/B=2-382.
DR   PDB; 3RRA; X-ray; 2.30 A; A/B=2-382.
DR   PDBsum; 3RR1; -.
DR   PDBsum; 3RRA; -.
DR   AlphaFoldDB; B2UCA8; -.
DR   SMR; B2UCA8; -.
DR   STRING; 402626.Rpic_2990; -.
DR   KEGG; rpi:Rpic_2990; -.
DR   PATRIC; fig|402626.5.peg.4126; -.
DR   eggNOG; COG4948; Bacteria.
DR   HOGENOM; CLU_030273_3_2_4; -.
DR   UniPathway; UPA00081; UER00518.
DR   EvolutionaryTrace; B2UCA8; -.
DR   GO; GO:0008869; F:galactonate dehydratase activity; IEA:UniProtKB-UniRule.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0009063; P:amino acid catabolic process; IEA:InterPro.
DR   GO; GO:0034194; P:D-galactonate catabolic process; IEA:UniProtKB-UniRule.
DR   CDD; cd03325; D-galactonate_dehydratase; 1.
DR   FunFam; 3.30.390.10:FF:000003; D-galactonate dehydratase; 1.
DR   Gene3D; 3.20.20.120; Enolase-like C-terminal domain; 1.
DR   Gene3D; 3.30.390.10; Enolase-like, N-terminal domain; 1.
DR   HAMAP; MF_01289; Galacton_dehydrat; 1.
DR   InterPro; IPR034593; DgoD-like.
DR   InterPro; IPR036849; Enolase-like_C_sf.
DR   InterPro; IPR029017; Enolase-like_N.
DR   InterPro; IPR029065; Enolase_C-like.
DR   InterPro; IPR023592; Galactonate_deHydtase.
DR   InterPro; IPR018110; Mandel_Rmase/mucon_lact_enz_CS.
DR   InterPro; IPR013342; Mandelate_racemase_C.
DR   InterPro; IPR013341; Mandelate_racemase_N_dom.
DR   PANTHER; PTHR48080:SF2; D-GALACTONATE DEHYDRATASE; 1.
DR   PANTHER; PTHR48080; D-GALACTONATE DEHYDRATASE-RELATED; 1.
DR   Pfam; PF13378; MR_MLE_C; 1.
DR   Pfam; PF02746; MR_MLE_N; 1.
DR   SFLD; SFLDF00003; D-galactonate_dehydratase; 1.
DR   SFLD; SFLDG00179; mandelate_racemase; 1.
DR   SMART; SM00922; MR_MLE; 1.
DR   SUPFAM; SSF51604; Enolase C-terminal domain-like; 1.
DR   SUPFAM; SSF54826; Enolase N-terminal domain-like; 1.
DR   PROSITE; PS00908; MR_MLE_1; 1.
DR   PROSITE; PS00909; MR_MLE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Lyase; Magnesium; Metal-binding.
FT   CHAIN           1..382
FT                   /note=""D-galactonate dehydratase""
FT                   /id=""PRO_1000140385""
FT   ACT_SITE        185
FT                   /note=""Proton donor""
FT                   /evidence=""ECO:0000250""
FT   ACT_SITE        285
FT                   /note=""Proton acceptor""
FT                   /evidence=""ECO:0000250""
FT   BINDING         183
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01289""
FT   BINDING         209
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01289""
FT   BINDING         235
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01289""
FT   SITE            258
FT                   /note=""Increases basicity of active site His""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01289""
FT   SITE            310
FT                   /note=""Transition state stabilizer""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01289""
FT   STRAND          3..11
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   TURN            12..14
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          15..22
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          27..30
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           38..48
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           49..51
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   TURN            52..54
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           60..69
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          71..73
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           77..98
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           102..105
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          114..119
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           125..137
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          142..147
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          150..152
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           157..172
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           175..177
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          178..183
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           190..200
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           201..203
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           218..224
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          231..233
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           240..249
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          253..255
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   TURN            259..263
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           264..276
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   TURN            277..279
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           290..302
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          309..311
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           323..326
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           330..333
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          345..347
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           354..362
FT                   /evidence=""ECO:0007829|PDB:3RR1""
SQ   SEQUENCE   382 AA;  42098 MW;  198F1A16BC5819F0 CRC64;
     MKITRLTTYR LPPRWMFLKV ETDEGVTGWG EPVIEGRART VEAAVHELSD YLIGQDPSRI
     NDLWQTMYRA GFYRGGPILM SAIAGIDQAL WDIKGKVLGV PVYELLGGLV RDKMRTYSWV
     GGDRPADVIA GMKALQAGGF DHFKLNGCEE MGIIDTSRAV DAAVARVAEI RSAFGNTVEF
     GLDFHGRVSA PMAKVLIKEL EPYRPLFIEE PVLAEQAETY ARLAAHTHLP IAAGERMFSR
     FDFKRVLEAG GVSILQPDLS HAGGITECVK IAAMAEAYDV ALAPHCPLGP IALAACLHVD
     FVSWNATLQE QSMGIHYNKG AELLDYVRNK ADFALEGGYI RPPRLPGLGV DIDEALVIER
     SKEAPDWRNP VWRHADGSVA EW
//
",260
TTAACA TAACAT AACATT ACATTA CATTAG ATTAGC TTAGCT TAGCTG AGCTGT GCTGTA CTGTAC TGTACC GTACCC TACCCT ACCCTA CCCTAT CCTATA CTATAA TATAAT ATAATA TAATAT AATATG ATATGA TATGAG ATGAGA TGAGAG GAGAGT AGAGTT GAGTTA AGTTAT GTTATA TTATAC TATACA ATACAT TACATT ACATTT CATTTT ATTTTG TTTTGG TTTGGT TTGGTG TGGTGC GGTGCT GTGCTG TGCTGG GCTGGT CTGGTT TGGTTC GGTTCT GTTCTG TTCTGA TCTGAT CTGATA TGATAA GATAAA ATAAAG TAAAGG AAAGGA AAGGAG AGGAGT GGAGTT GAGTTG AGTTGC GTTGCA TTGCAC TGCACC GCACCA CACCAG ACCAGG CCAGGT CAGGTA AGGTAC GGTACA GTACAG TACAGC ACAGCT CAGCTG AGCTGT GCTGTT CTGTTT TGTTTT GTTTTA TTTTAA TTTAAG TTAAGA TAAGAC AAGACA AGACAG GACAGT ACAGTG CAGTGG AGTGGT GTGGTT TGGTTC GGTTCT GTTCTG TTCTGT TCTGTC CTGTCT TGTCTC GTCTCT TCTCTT CTCTTA TCTTAT CTTATA TTATAC TATACA ATACAC TACACA ACACAT CACATT ACATTC CATTCC ATTCCG TTCCGA TCCGAG CCGAGC CGAGCC GAGCCC AGCCCA GCCCAC CCCACG CCACGA CACGAG ACGAGA CGAGAC GAGACT AGACTC GACTCC ACTCCT CTCCTG TCCTGA CCTGAG CTGAGC TGAGCA GAGCAT AGCATC GCATCT CATCTC ATCTCG TCTCGT CTCGTA,0,142,TTAA TAAC AACA ACAT CATT ATTA TTAG TAGC AGCT GCTG CTGT TGTA GTAC TACC ACCC CCCT CCTA CTAT TATA ATAA TAAT AATA ATAT TATG ATGA TGAG GAGA AGAG GAGT AGTT GTTA TTAT TATA ATAC TACA ACAT CATT ATTT TTTT TTTG TTGG TGGT GGTG GTGC TGCT GCTG CTGG TGGT GGTT GTTC TTCT TCTG CTGA TGAT GATA ATAA TAAA AAAG AAGG AGGA GGAG GAGT AGTT GTTG TTGC TGCA GCAC CACC ACCA CCAG CAGG AGGT GGTA GTAC TACA ACAG CAGC AGCT GCTG CTGT TGTT GTTT TTTT TTTA TTAA TAAG AAGA AGAC GACA ACAG CAGT AGTG GTGG TGGT GGTT GTTC TTCT TCTG CTGT TGTC GTCT TCTC CTCT TCTT CTTA TTAT TATA ATAC TACA ACAC CACA ACAT CATT ATTC TTCC TCCG CCGA CGAG GAGC AGCC GCCC CCCA CCAC CACG ACGA CGAG GAGA AGAC GACT ACTC CTCC TCCT CCTG CTGA TGAG GAGC AGCA GCAT CATC ATCT TCTC CTCG TCGT CGTA,TTAAC TAACA AACAT ACATT CATTA ATTAG TTAGC TAGCT AGCTG GCTGT CTGTA TGTAC GTACC TACCC ACCCT CCCTA CCTAT CTATA TATAA ATAAT TAATA AATAT ATATG TATGA ATGAG TGAGA GAGAG AGAGT GAGTT AGTTA GTTAT TTATA TATAC ATACA TACAT ACATT CATTT ATTTT TTTTG TTTGG TTGGT TGGTG GGTGC GTGCT TGCTG GCTGG CTGGT TGGTT GGTTC GTTCT TTCTG TCTGA CTGAT TGATA GATAA ATAAA TAAAG AAAGG AAGGA AGGAG GGAGT GAGTT AGTTG GTTGC TTGCA TGCAC GCACC CACCA ACCAG CCAGG CAGGT AGGTA GGTAC GTACA TACAG ACAGC CAGCT AGCTG GCTGT CTGTT TGTTT GTTTT TTTTA TTTAA TTAAG TAAGA AAGAC AGACA GACAG ACAGT CAGTG AGTGG GTGGT TGGTT GGTTC GTTCT TTCTG TCTGT CTGTC TGTCT GTCTC TCTCT CTCTT TCTTA CTTAT TTATA TATAC ATACA TACAC ACACA CACAT ACATT CATTC ATTCC TTCCG TCCGA CCGAG CGAGC GAGCC AGCCC GCCCA CCCAC CCACG CACGA ACGAG CGAGA GAGAC AGACT GACTC ACTCC CTCCT TCCTG CCTGA CTGAG TGAGC GAGCA AGCAT GCATC CATCT ATCTC TCTCG CTCGT TCGTA,TTAACA TAACAT AACATT ACATTA CATTAG ATTAGC TTAGCT TAGCTG AGCTGT GCTGTA CTGTAC TGTACC GTACCC TACCCT ACCCTA CCCTAT CCTATA CTATAA TATAAT ATAATA TAATAT AATATG ATATGA TATGAG ATGAGA TGAGAG GAGAGT AGAGTT GAGTTA AGTTAT GTTATA TTATAC TATACA ATACAT TACATT ACATTT CATTTT ATTTTG TTTTGG TTTGGT TTGGTG TGGTGC GGTGCT GTGCTG TGCTGG GCTGGT CTGGTT TGGTTC GGTTCT GTTCTG TTCTGA TCTGAT CTGATA TGATAA GATAAA ATAAAG TAAAGG AAAGGA AAGGAG AGGAGT GGAGTT GAGTTG AGTTGC GTTGCA TTGCAC TGCACC GCACCA CACCAG ACCAGG CCAGGT CAGGTA AGGTAC GGTACA GTACAG TACAGC ACAGCT CAGCTG AGCTGT GCTGTT CTGTTT TGTTTT GTTTTA TTTTAA TTTAAG TTAAGA TAAGAC AAGACA AGACAG GACAGT ACAGTG CAGTGG AGTGGT GTGGTT TGGTTC GGTTCT GTTCTG TTCTGT TCTGTC CTGTCT TGTCTC GTCTCT TCTCTT CTCTTA TCTTAT CTTATA TTATAC TATACA ATACAC TACACA ACACAT CACATT ACATTC CATTCC ATTCCG TTCCGA TCCGAG CCGAGC CGAGCC GAGCCC AGCCCA GCCCAC CCCACG CCACGA CACGAG ACGAGA CGAGAC GAGACT AGACTC GACTCC ACTCCT CTCCTG TCCTGA CCTGAG CTGAGC TGAGCA GAGCAT AGCATC GCATCT CATCTC ATCTCG TCTCGT CTCGTA,TTAACAT TAACATT AACATTA ACATTAG CATTAGC ATTAGCT TTAGCTG TAGCTGT AGCTGTA GCTGTAC CTGTACC TGTACCC GTACCCT TACCCTA ACCCTAT CCCTATA CCTATAA CTATAAT TATAATA ATAATAT TAATATG AATATGA ATATGAG TATGAGA ATGAGAG TGAGAGT GAGAGTT AGAGTTA GAGTTAT AGTTATA GTTATAC TTATACA TATACAT ATACATT TACATTT ACATTTT CATTTTG ATTTTGG TTTTGGT TTTGGTG TTGGTGC TGGTGCT GGTGCTG GTGCTGG TGCTGGT GCTGGTT CTGGTTC TGGTTCT GGTTCTG GTTCTGA TTCTGAT TCTGATA CTGATAA TGATAAA GATAAAG ATAAAGG TAAAGGA AAAGGAG AAGGAGT AGGAGTT GGAGTTG GAGTTGC AGTTGCA GTTGCAC TTGCACC TGCACCA GCACCAG CACCAGG ACCAGGT CCAGGTA CAGGTAC AGGTACA GGTACAG GTACAGC TACAGCT ACAGCTG CAGCTGT AGCTGTT GCTGTTT CTGTTTT TGTTTTA GTTTTAA TTTTAAG TTTAAGA TTAAGAC TAAGACA AAGACAG AGACAGT GACAGTG ACAGTGG CAGTGGT AGTGGTT GTGGTTC TGGTTCT GGTTCTG GTTCTGT TTCTGTC TCTGTCT CTGTCTC TGTCTCT GTCTCTT TCTCTTA CTCTTAT TCTTATA CTTATAC TTATACA TATACAC ATACACA TACACAT ACACATT CACATTC ACATTCC CATTCCG ATTCCGA TTCCGAG TCCGAGC CCGAGCC CGAGCCC GAGCCCA AGCCCAC GCCCACG CCCACGA CCACGAG CACGAGA ACGAGAC CGAGACT GAGACTC AGACTCC GACTCCT ACTCCTG CTCCTGA TCCTGAG CCTGAGC CTGAGCA TGAGCAT GAGCATC AGCATCT GCATCTC CATCTCG ATCTCGT TCTCGTA,"ID   R1AB_BCHK3              Reviewed;        7067 AA.
AC   P0C6W2; Q3LZX2;
DT   10-JUN-2008, integrated into UniProtKB/Swiss-Prot.
DT   10-JUN-2008, sequence version 1.
DT   05-FEB-2025, entry version 109.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE              Short=nsp1;
DE     AltName: Full=Leader protein;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like proteinase nsp3;
DE              Short=PL-PRO;
DE              EC=3.4.19.12;
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.-;
DE     AltName: Full=nsp5;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9;
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE     AltName: Full=p12;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50;
DE     AltName: Full=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              Short=ExoN;
DE              EC=2.1.1.56;
DE              EC=3.1.13.-;
DE     AltName: Full=nsp14;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.-;
DE     AltName: Full=NendoU;
DE     AltName: Full=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Bat coronavirus HKU3 (BtCoV) (SARS-like coronavirus HKU3).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=442736;
OH   NCBI_TaxID=89399; Rhinolophus sinicus (Chinese rufous horseshoe bat).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HKU3-1;
RX   PubMed=16169905; DOI=10.1073/pnas.0506735102;
RA   Lau S.K.P., Woo P.C.Y., Li K.S.M., Huang Y., Tsoi H.-W., Wong B.H.L.,
RA   Wong S.S.Y., Leung S.-Y., Chan K.-H., Yuen K.-Y.;
RT   ""Severe acute respiratory syndrome coronavirus-like virus in Chinese
RT   horseshoe bats."";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:14040-14045(2005).
CC   -!- FUNCTION: The replicase polyprotein of coronaviruses is a
CC       multifunctional protein: it contains the activities necessary for the
CC       transcription of negative stranded RNA, leader RNA, subgenomic mRNAs
CC       and progeny virion RNA as well as proteinases responsible for the
CC       cleavage of the polyprotein into functional products.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by interacting with the 40S ribosomal subunit. The nsp1-40S ribosome
CC       complex further induces an endonucleolytic cleavage near the 5'UTR of
CC       host mRNAs, targeting them for degradation. Viral mRNAs are not
CC       susceptible to nsp1-mediated endonucleolytic RNA cleavage thanks to the
CC       presence of a 5'-end leader sequence and are therefore protected from
CC       degradation. By suppressing host gene expression, nsp1 facilitates
CC       efficient viral gene expression in infected cells and evasion from host
CC       immune response. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Non-structural protein 2]: May play a role in the modulation
CC       of host cell survival signaling pathway by interacting with host PHB
CC       and PHB2. Indeed, these two proteins play a role in maintaining the
CC       functional integrity of the mitochondria and protecting cells from
CC       various stresses. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Papain-like proteinase nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. In addition,
CC       PL-PRO possesses a deubiquitinating/deISGylating activity and processes
CC       both 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates. Participates together with nsp4 in the assembly of virally-
CC       induced cytoplasmic double-membrane vesicles necessary for viral
CC       replication. Antagonizes innate immune induction of type I interferon
CC       by blocking the phosphorylation, dimerization and subsequent nuclear
CC       translocation of host IRF3. Prevents also host NF-kappa-B signaling.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Non-structural protein 4]: Participates in the assembly of
CC       virally-induced cytoplasmic double-membrane vesicles necessary for
CC       viral replication. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [3C-like proteinase nsp5]: Cleaves the C-terminus of
CC       replicase polyprotein at 11 sites. Recognizes substrates containing the
CC       core sequence [ILMVF]-Q-|-[SGACN]. Also able to bind an ADP-ribose-1''-
CC       phosphate (ADRP). {ECO:0000250|UniProtKB:P0C6X7, ECO:0000255|PROSITE-
CC       ProRule:PRU00772}.
CC   -!- FUNCTION: [Non-structural protein 6]: Plays a role in the initial
CC       induction of autophagosomes from host endoplasmic reticulum. Later,
CC       limits the expansion of these phagosomes that are no longer able to
CC       deliver viral components to lysosomes. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Non-structural protein 7]: Forms a hexadecamer with nsp8 (8
CC       subunits of each) that may participate in viral replication by acting
CC       as a primase. Alternatively, may synthesize substantially longer
CC       products than oligonucleotide primers. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Non-structural protein 8]: Forms a hexadecamer with nsp7 (8
CC       subunits of each) that may participate in viral replication by acting
CC       as a primase. Alternatively, may synthesize substantially longer
CC       products than oligonucleotide primers. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Viral protein genome-linked nsp9]: Forms a primer, NSP9-pU,
CC       which is utilized by the polymerase for the initiation of RNA chains.
CC       Interacts with ribosome signal recognition particle RNA (SRP). Together
CC       with NSP8, suppress protein integration into the cell membrane, thereby
CC       disrupting host immune defenses. {ECO:0000250|UniProtKB:P0DTD1}.
CC   -!- FUNCTION: [Non-structural protein 10]: Plays a pivotal role in viral
CC       transcription by stimulating both nsp14 3'-5' exoribonuclease and nsp16
CC       2'-O-methyltransferase activities. Therefore plays an essential role in
CC       viral mRNAs cap methylation. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [RNA-directed RNA polymerase nsp12]: RNA-directed RNA
CC       polymerase that catalyzes the transcription of viral genomic and
CC       subgenomic RNAs. Acts in complex with nsp7 and nsp8 to transcribe both
CC       the minus and positive strands of genomic RNA. The kinase-like NiRAN
CC       domain of NSP12 attaches one or more nucleotides to the amino terminus
CC       of NSP9, forming a covalent RNA-protein intermediate that serves as
CC       transcription/replication primer. Subgenomic RNAs (sgRNAs) are formed
CC       by discontinuous transcription: The polymerase has the ability to pause
CC       at transcription-regulating sequences (TRS) and jump to the leader TRS,
CC       resulting in a major deletion. This creates a series of subgenomic RNAs
CC       that are replicated, transcribed and translated. In addition, Nsp12 is
CC       a subunit of the viral RNA capping enzyme that catalyzes the RNA
CC       guanylyltransferase reaction for genomic and sub-genomic RNAs.
CC       Subsequently, the NiRAN domain transfers RNA to GDP, and forms the core
CC       cap structure GpppA-RNA. {ECO:0000250|UniProtKB:P0DTD1}.
CC   -!- FUNCTION: [Helicase nsp13]: Multi-functional protein with a zinc-
CC       binding domain in N-terminus displaying RNA and DNA duplex-unwinding
CC       activities with 5' to 3' polarity. Activity of helicase is dependent on
CC       magnesium. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Guanine-N7 methyltransferase nsp14]: Plays a role in viral
CC       RNA synthesis through two distinct activities. The N7-guanine
CC       methyltransferase activity plays a role in the formation of the cap
CC       structure GpppA-RNA. The proofreading exoribonuclease reduces the
CC       sensitivity of the virus to RNA mutagens during replication. This
CC       activity acts on both ssRNA and dsRNA in a 3'-5' direction.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Uridylate-specific endoribonuclease nsp15]: Plays a role in
CC       viral transcription/replication and prevents the simultaneous
CC       activation of host cell dsRNA sensors, such as MDA5/IFIH1, OAS, and PKR
CC       (By similarity). Acts by degrading the 5'-polyuridines generated during
CC       replication of the poly(A) region of viral genomic and subgenomic RNAs.
CC       Catalyzes a two-step reaction in which a 2'3'-cyclic phosphate (2'3'-
CC       cP) is first generated by 2'-O transesterification, which is then
CC       hydrolyzed to a 3'-phosphate (3'-P) (By similarity). If not degraded,
CC       poly(U) RNA would hybridize with poly(A) RNA tails and activate host
CC       dsRNA sensors (By similarity). {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [2'-O-methyltransferase nsp16]: Methyltransferase that
CC       mediates mRNA cap 2'-O-ribose methylation to the 5'-cap structure of
CC       viral mRNAs. N7-methyl guanosine cap is a prerequisite for binding of
CC       nsp16. Therefore plays an essential role in viral mRNAs cap methylation
CC       which is essential to evade immune system.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- CATALYTIC ACTIVITY: [RNA-directed RNA polymerase nsp12]:
CC       Reaction=RNA(n) + a ribonucleoside 5'-triphosphate = RNA(n+1) +
CC         diphosphate; Xref=Rhea:RHEA:21248, Rhea:RHEA-COMP:14527, Rhea:RHEA-
CC         COMP:17342, ChEBI:CHEBI:33019, ChEBI:CHEBI:61557, ChEBI:CHEBI:140395;
CC         EC=2.7.7.48; Evidence={ECO:0000255|PROSITE-ProRule:PRU00539};
CC   -!- CATALYTIC ACTIVITY: [Helicase nsp13]:
CC       Reaction=ATP + H2O = ADP + phosphate + H(+); Xref=Rhea:RHEA:13065,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; EC=3.6.4.12;
CC   -!- CATALYTIC ACTIVITY: [Helicase nsp13]:
CC       Reaction=ATP + H2O = ADP + phosphate + H(+); Xref=Rhea:RHEA:13065,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; EC=3.6.4.13;
CC   -!- CATALYTIC ACTIVITY: [Papain-like proteinase nsp3]:
CC       Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide
CC         and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-
CC         residue protein attached to proteins as an intracellular targeting
CC         signal).; EC=3.4.19.12;
CC   -!- CATALYTIC ACTIVITY: [2'-O-methyltransferase nsp16]:
CC       Reaction=a 5'-end (N(7)-methyl 5'-triphosphoguanosine)-ribonucleoside
CC         in mRNA + S-adenosyl-L-methionine = a 5'-end (N(7)-methyl 5'-
CC         triphosphoguanosine)-(2'-O-methyl-ribonucleoside) in mRNA + S-
CC         adenosyl-L-homocysteine + H(+); Xref=Rhea:RHEA:67020, Rhea:RHEA-
CC         COMP:17167, Rhea:RHEA-COMP:17168, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:57856, ChEBI:CHEBI:59789, ChEBI:CHEBI:156461,
CC         ChEBI:CHEBI:167609; EC=2.1.1.57;
CC         Evidence={ECO:0000250|UniProtKB:P0C6X7};
CC   -!- CATALYTIC ACTIVITY: [Uridylate-specific endoribonuclease nsp15]:
CC       Reaction=uridylyl-uridylyl-ribonucleotide-RNA = a 3'-end uridylyl-
CC         2',3'-cyclophospho-uridine-RNA + a 5'-end dephospho-ribonucleoside-
CC         RNA; Xref=Rhea:RHEA:67732, Rhea:RHEA-COMP:13936, Rhea:RHEA-
CC         COMP:17334, Rhea:RHEA-COMP:17335, ChEBI:CHEBI:138284,
CC         ChEBI:CHEBI:173079, ChEBI:CHEBI:173080;
CC         Evidence={ECO:0000250|UniProtKB:P0C6X7};
CC   -!- CATALYTIC ACTIVITY: [RNA-directed RNA polymerase nsp12]:
CC       Reaction=a 5'-end diphospho-ribonucleoside in mRNA + GTP + H(+) = a 5'-
CC         end (5'-triphosphoguanosine)-ribonucleoside in mRNA + diphosphate;
CC         Xref=Rhea:RHEA:67012, Rhea:RHEA-COMP:17165, Rhea:RHEA-COMP:17166,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:33019, ChEBI:CHEBI:37565,
CC         ChEBI:CHEBI:167616, ChEBI:CHEBI:167617; EC=2.7.7.50;
CC         Evidence={ECO:0000250|UniProtKB:P0DTD1};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:67013;
CC         Evidence={ECO:0000250|UniProtKB:P0DTD1};
CC   -!- CATALYTIC ACTIVITY: [Guanine-N7 methyltransferase nsp14]:
CC       Reaction=a 5'-end (5'-triphosphoguanosine)-ribonucleoside in mRNA + S-
CC         adenosyl-L-methionine = a 5'-end (N(7)-methyl 5'-
CC         triphosphoguanosine)-ribonucleoside in mRNA + S-adenosyl-L-
CC         homocysteine; Xref=Rhea:RHEA:67008, Rhea:RHEA-COMP:17166, Rhea:RHEA-
CC         COMP:17167, ChEBI:CHEBI:57856, ChEBI:CHEBI:59789, ChEBI:CHEBI:156461,
CC         ChEBI:CHEBI:167617; EC=2.1.1.56;
CC         Evidence={ECO:0000250|UniProtKB:P0C6X7};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:67009;
CC         Evidence={ECO:0000250|UniProtKB:P0C6X7};
CC   -!- COFACTOR: [Uridylate-specific endoribonuclease nsp15]:
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000250|UniProtKB:P0C6X7};
CC       Note=Likely affects Nsp15 binding to RNA.
CC       {ECO:0000250|UniProtKB:P0C6X7};
CC   -!- COFACTOR: [RNA-directed RNA polymerase nsp12]:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000250|UniProtKB:P0DTD1};
CC   -!- SUBUNIT: [Non-structural protein 2]: Interacts with host PHB and PHB2.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBUNIT: [Non-structural protein 4]: Interacts with papain-like
CC       protease nsp3 and non-structural protein 6.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBUNIT: [3C-like proteinase nsp5]: Monomer. Homodimer. Only the
CC       homodimer shows catalytic activity. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBUNIT: [Non-structural protein 7]: Interacts with nsp8 and nsp12 to
CC       form the replication-transcription complex (RTC): nsp12, nsp7, two
CC       subunits of nsp8, and up to two subunits of nsp13.
CC       {ECO:0000250|UniProtKB:P0DTD1}.
CC   -!- SUBUNIT: [Non-structural protein 8]: Interacts with nsp7, nsp13 and
CC       nsp12 to form the replication-transcription complex (RTC): nsp12, nsp7,
CC       two subunits of nsp8, and up to two subunits of nsp13.
CC       {ECO:0000250|UniProtKB:P0DTD1}.
CC   -!- SUBUNIT: [Viral protein genome-linked nsp9]: Interacts with nsp12.
CC       {ECO:0000250|UniProtKB:P0DTD1}.
CC   -!- SUBUNIT: [Non-structural protein 10]: Interacts with proofreading
CC       exoribonuclease nsp14 and 2'-O-methyltransferase nsp16; these
CC       interactions enhance nsp14 and nsp16 enzymatic activities.
CC       {ECO:0000250|UniProtKB:P0DTD1}.
CC   -!- SUBUNIT: [RNA-directed RNA polymerase nsp12]: Interacts with nsp7 and
CC       nsp8 to form the replication-transcription complex (RTC): nsp12, nsp7,
CC       two subunits of nsp8, and up to two subunits of nsp13. Interacts with
CC       nsp9. {ECO:0000250|UniProtKB:P0DTD1}.
CC   -!- SUBUNIT: [Helicase nsp13]: Interacts with nsp8 to form the replication-
CC       transcription complex (RTC): nsp12, nsp7, two subunits of nsp8, and up
CC       to two subunits of nsp13. {ECO:0000250|UniProtKB:P0DTD1}.
CC   -!- SUBCELLULAR LOCATION: [Papain-like proteinase nsp3]: Host membrane;
CC       Multi-pass membrane protein. Host cytoplasm
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 4]: Host membrane; Multi-
CC       pass membrane protein. Host cytoplasm. Note=Localizes in virally-
CC       induced cytoplasmic double-membrane vesicles.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 6]: Host membrane
CC       {ECO:0000305}; Multi-pass membrane protein {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 7]: Host cytoplasm, host
CC       perinuclear region {ECO:0000250}. Note=nsp7, nsp8, nsp9 and nsp10 are
CC       localized in cytoplasmic foci, largely perinuclear. Late in infection,
CC       they merge into confluent complexes (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 8]: Host cytoplasm, host
CC       perinuclear region {ECO:0000250}. Note=nsp7, nsp8, nsp9 and nsp10 are
CC       localized in cytoplasmic foci, largely perinuclear. Late in infection,
CC       they merge into confluent complexes (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Viral protein genome-linked nsp9]: Host
CC       cytoplasm, host perinuclear region {ECO:0000250}. Note=nsp7, nsp8, nsp9
CC       and nsp10 are localized in cytoplasmic foci, largely perinuclear. Late
CC       in infection, they merge into confluent complexes (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 10]: Host cytoplasm, host
CC       perinuclear region {ECO:0000250}. Note=nsp7, nsp8, nsp9 and nsp10 are
CC       localized in cytoplasmic foci, largely perinuclear. Late in infection,
CC       they merge into confluent complexes (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Helicase nsp13]: Host endoplasmic reticulum-
CC       Golgi intermediate compartment {ECO:0000305}. Note=The helicase
CC       interacts with the N protein in membranous complexes and colocalizes
CC       with sites of synthesis of new viral RNA. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Uridylate-specific endoribonuclease nsp15]: Host
CC       cytoplasm, host perinuclear region {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Ribosomal frameshifting; Named isoforms=2;
CC       Name=Replicase polyprotein 1ab; Synonyms=pp1ab;
CC         IsoId=P0C6W2-1; Sequence=Displayed;
CC       Name=Replicase polyprotein 1a; Synonyms=pp1a, ORF1a polyprotein;
CC         IsoId=P0C6F8-1; Sequence=External;
CC   -!- DOMAIN: The hydrophobic domains (HD) could mediate the membrane
CC       association of the replication complex and thereby alter the
CC       architecture of the host cell membrane. {ECO:0000250}.
CC   -!- PTM: Specific enzymatic cleavages in vivo by its own proteases yield
CC       mature proteins. 3CL-PRO and PL-PRO proteinases are autocatalytically
CC       processed (By similarity). {ECO:0000250}.
CC   -!- MISCELLANEOUS: Bat coronavirus HKU3 is highly similar to SARS-CoV
CC       (SARS-like).
CC   -!- MISCELLANEOUS: [Isoform Replicase polyprotein 1ab]: Produced by -1
CC       ribosomal frameshifting at the 1a-1b genes boundary.
CC   -!- SIMILARITY: Belongs to the coronaviruses polyprotein 1ab family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; DQ022305; AAY88865.2; -; Genomic_RNA.
DR   BMRB; P0C6W2; -.
DR   SMR; P0C6W2; -.
DR   MEROPS; C16.009; -.
DR   MEROPS; C30.005; -.
DR   Proteomes; UP000007450; Segment.
DR   GO; GO:0044172; C:host cell endoplasmic reticulum-Golgi intermediate compartment; IEA:UniProtKB-SubCell.
DR   GO; GO:0033644; C:host cell membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-KW.
DR   GO; GO:0000175; F:3'-5'-RNA exonuclease activity; IEA:InterPro.
DR   GO; GO:0043139; F:5'-3' DNA helicase activity; IEA:TreeGrafter.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IEA:RHEA.
DR   GO; GO:0140849; F:ATP-dependent H2AZ histone chaperone activity; IEA:RHEA.
DR   GO; GO:0140665; F:ATP-dependent H3-H4 histone complex chaperone activity; IEA:RHEA.
DR   GO; GO:0140584; F:chromatin extrusion motor activity; IEA:RHEA.
DR   GO; GO:0061775; F:cohesin loader activity; IEA:RHEA.
DR   GO; GO:0004843; F:cysteine-type deubiquitinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0003689; F:DNA clamp loader activity; IEA:RHEA.
DR   GO; GO:0036121; F:double-stranded DNA helicase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004519; F:endonuclease activity; IEA:UniProtKB-KW.
DR   GO; GO:0061749; F:forked DNA-dependent helicase activity; IEA:UniProtKB-EC.
DR   GO; GO:0009378; F:four-way junction helicase activity; IEA:UniProtKB-EC.
DR   GO; GO:0002151; F:G-quadruplex RNA binding; IEA:InterPro.
DR   GO; GO:0016829; F:lyase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004483; F:mRNA (nucleoside-2'-O-)-methyltransferase activity; IEA:InterPro.
DR   GO; GO:0004482; F:mRNA 5'-cap (guanine-N7-)-methyltransferase activity; IEA:InterPro.
DR   GO; GO:0008242; F:omega peptidase activity; IEA:InterPro.
DR   GO; GO:0003724; F:RNA helicase activity; IEA:UniProtKB-EC.
DR   GO; GO:0003968; F:RNA-dependent RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:1990518; F:single-stranded 3'-5' DNA helicase activity; IEA:UniProtKB-EC.
DR   GO; GO:0003727; F:single-stranded RNA binding; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0006351; P:DNA-templated transcription; IEA:InterPro.
DR   GO; GO:0039520; P:induction by virus of host autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:UniProtKB-KW.
DR   GO; GO:0039595; P:symbiont-mediated degradation of host mRNA; IEA:UniProtKB-KW.
DR   GO; GO:0039648; P:symbiont-mediated perturbation of host ubiquitin-like protein modification; IEA:UniProtKB-KW.
DR   GO; GO:0039657; P:symbiont-mediated suppression of host gene expression; IEA:UniProtKB-KW.
DR   GO; GO:0039579; P:symbiont-mediated suppression of host ISG15-protein conjugation; IEA:UniProtKB-KW.
DR   GO; GO:0085034; P:symbiont-mediated suppression of host NF-kappaB cascade; IEA:UniProtKB-KW.
DR   GO; GO:0039502; P:symbiont-mediated suppression of host type I interferon-mediated signaling pathway; IEA:UniProtKB-KW.
DR   GO; GO:0019082; P:viral protein processing; IEA:InterPro.
DR   GO; GO:0039694; P:viral RNA genome replication; IEA:InterPro.
DR   GO; GO:0075523; P:viral translational frameshifting; IEA:UniProtKB-KW.
DR   GO; GO:0019049; P:virus-mediated perturbation of host defense response; IEA:UniProtKB-KW.
DR   CDD; cd21409; 1B_cv_Nsp13-like; 1.
DR   CDD; cd21560; betaCoV-Nsp6; 1.
DR   CDD; cd21722; betaCoV_Nsp13-helicase; 1.
DR   CDD; cd21659; betaCoV_Nsp14; 1.
DR   CDD; cd21516; betaCoV_Nsp2_SARS-like; 1.
DR   CDD; cd21666; betaCoV_Nsp5_Mpro; 1.
DR   CDD; cd21827; betaCoV_Nsp7; 1.
DR   CDD; cd21831; betaCoV_Nsp8; 1.
DR   CDD; cd21898; betaCoV_Nsp9; 1.
DR   CDD; cd21732; betaCoV_PLPro; 1.
DR   CDD; cd20762; capping_2-OMTase_Nidovirales; 1.
DR   CDD; cd21872; CoV_Nsp10; 1.
DR   CDD; cd21473; cv_Nsp4_TM; 1.
DR   CDD; cd21167; M_alpha_beta_cv_Nsp15-like; 1.
DR   CDD; cd21563; Macro_cv_SUD-M_Nsp3-like; 1.
DR   CDD; cd21562; Macro_cv_SUD-N_Nsp3-like; 1.
DR   CDD; cd21557; Macro_X_Nsp3-like; 1.
DR   CDD; cd21161; NendoU_cv_Nsp15-like; 1.
DR   CDD; cd21171; NTD_alpha_betaCoV_Nsp15-like; 1.
DR   CDD; cd22662; SARS-CoV-like_Nsp1_C; 1.
DR   CDD; cd21796; SARS-CoV-like_Nsp1_N; 1.
DR   CDD; cd21814; SARS-CoV-like_Nsp3_betaSM; 1.
DR   CDD; cd21822; SARS-CoV-like_Nsp3_NAB; 1.
DR   CDD; cd21591; SARS-CoV-like_RdRp; 1.
DR   CDD; cd21689; stalk_CoV_Nsp13-like; 1.
DR   CDD; cd21525; SUD_C_SARS-CoV_Nsp3; 1.
DR   CDD; cd21717; TM_Y_SARS-CoV-like_Nsp3_C; 1.
DR   CDD; cd21467; Ubl1_cv_Nsp3_N-like; 1.
DR   CDD; cd21401; ZBD_cv_Nsp13-like; 1.
DR   FunFam; 1.10.8.370:FF:000001; Orf1a polyprotein; 1.
DR   FunFam; 2.40.10.250:FF:000001; Orf1a polyprotein; 1.
DR   FunFam; 3.40.220.30:FF:000001; Orf1a polyprotein; 1.
DR   FunFam; 3.30.160.820:FF:000001; Orf1ab polyprotein; 1.
DR   FunFam; 3.40.50.150:FF:000162; Orf1ab polyprotein; 1.
DR   FunFam; 3.40.50.300:FF:001105; Orf1ab polyprotein; 1.
DR   FunFam; 3.40.50.300:FF:001139; Orf1ab polyprotein; 1.
DR   FunFam; 1.10.150.420:FF:000001; Replicase polyprotein; 1.
DR   FunFam; 1.10.1840.10:FF:000001; Replicase polyprotein 1a; 1.
DR   FunFam; 1.10.8.1190:FF:000001; Replicase polyprotein 1a; 1.
DR   FunFam; 2.40.10.10:FF:000033; Replicase polyprotein 1a; 1.
DR   FunFam; 3.40.50.11580:FF:000001; Replicase polyprotein 1ab; 1.
DR   Gene3D; 1.10.8.1190; -; 1.
DR   Gene3D; 2.60.120.1680; -; 1.
DR   Gene3D; 3.10.20.350; -; 1.
DR   Gene3D; 3.10.20.540; -; 1.
DR   Gene3D; 3.40.50.11580; -; 1.
DR   Gene3D; 6.10.140.2090; -; 1.
DR   Gene3D; 1.10.150.420; Coronavirus nonstructural protein 4 C-terminus; 1.
DR   Gene3D; 3.40.30.150; Coronavirus polyprotein cleavage domain; 1.
DR   Gene3D; 3.40.220.10; Leucine Aminopeptidase, subunit E, domain 1; 1.
DR   Gene3D; 1.10.1840.10; main proteinase (3clpro) structure, domain 3; 1.
DR   Gene3D; 3.30.160.820; Nsp15 N-terminal domain-like; 1.
DR   Gene3D; 3.40.220.20; Nsp3, SUD-M subdomain; 1.
DR   Gene3D; 3.40.220.30; Nsp3, SUD-N subdomain; 1.
DR   Gene3D; 1.10.8.370; nsp7 replicase; 1.
DR   Gene3D; 3.30.70.3540; Nsp8 replicase, head domain; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 2.
DR   Gene3D; 2.40.10.250; Replicase NSP9; 1.
DR   Gene3D; 3.40.50.11020; Replicase polyprotein, nucleic acid-binding domain; 1.
DR   Gene3D; 2.40.10.10; Trypsin-like serine proteases; 2.
DR   Gene3D; 3.40.50.150; Vaccinia Virus protein VP39; 1.
DR   InterPro; IPR027351; (+)RNA_virus_helicase_core_dom.
DR   InterPro; IPR046443; a/bCoV_NSP1_glob.
DR   InterPro; IPR046440; AV_NSP11N_COV_NSP15M.
DR   InterPro; IPR046442; bCoV_NSP1_C.
DR   InterPro; IPR050534; Coronavir_polyprotein_1ab.
DR   InterPro; IPR043608; CoV_NSP15_M.
DR   InterPro; IPR043606; CoV_NSP15_N.
DR   InterPro; IPR043613; CoV_NSP2_C.
DR   InterPro; IPR047573; CoV_NSP2_M.
DR   InterPro; IPR049894; COV_NSP3_3ECTO.
DR   InterPro; IPR043611; CoV_NSP3_C.
DR   InterPro; IPR047566; CoV_NSP3_Y.
DR   InterPro; IPR032505; CoV_NSP4_C.
DR   InterPro; IPR043612; CoV_NSP4_N.
DR   InterPro; IPR043502; DNA/RNA_pol_sf.
DR   InterPro; IPR041679; DNA2/NAM7-like_C.
DR   InterPro; IPR022733; DPUP_SUD_C_bCoV.
DR   InterPro; IPR037227; EndoU-like.
DR   InterPro; IPR002589; Macro_dom.
DR   InterPro; IPR043472; Macro_dom-like.
DR   InterPro; IPR044371; Macro_X_NSP3-like.
DR   InterPro; IPR046435; N7_MTase_CoV.
DR   InterPro; IPR043609; NendoU_nidovirus.
DR   InterPro; IPR044863; NIRAN.
DR   InterPro; IPR046438; NIV_2_O_MTASE.
DR   InterPro; IPR046436; NIV_EXON.
DR   InterPro; IPR036333; NSP10_sf_CoV.
DR   InterPro; IPR047570; NSP12_IF_CoV.
DR   InterPro; IPR044343; NSP13_1B_dom_CoV.
DR   InterPro; IPR048673; NSP13_stalk_CoV.
DR   InterPro; IPR048672; NSP13_ZBD_CoV.
DR   InterPro; IPR027352; NSP13_ZBD_CoV-like.
DR   InterPro; IPR044315; NSP14_betaCoV.
DR   InterPro; IPR009466; NSP14_CoV.
DR   InterPro; IPR044330; NSP15_alpha_betaCoV_N.
DR   InterPro; IPR044322; NSP15_M_alpha_beta_CoV.
DR   InterPro; IPR043174; NSP15_middle_sf.
DR   InterPro; IPR042515; NSP15_N_CoV.
DR   InterPro; IPR044401; NSP15_NendoU_CoV.
DR   InterPro; IPR009461; NSP16_CoV-like.
DR   InterPro; IPR021590; NSP1_glob_bCoV.
DR   InterPro; IPR038030; NSP1_glob_sf_bCoV.
DR   InterPro; IPR043615; NSP2_N_CoV.
DR   InterPro; IPR044389; NSP2_SARS-CoV-like.
DR   InterPro; IPR024375; NSP3_bCoV.
DR   InterPro; IPR047567; NSP3_G2M_bCoV.
DR   InterPro; IPR024358; NSP3_N_bCoV.
DR   InterPro; IPR032592; NSP3_NAB_bCoV.
DR   InterPro; IPR042570; NSP3_NAB_bCoV_sf.
DR   InterPro; IPR038166; NSP3_PL2pro_sf_bCoV.
DR   InterPro; IPR038400; NSP3_SUD-M_sf_bCoV.
DR   InterPro; IPR044864; NSP3_SUD-N_bCoV.
DR   InterPro; IPR044374; NSP3_SUD-N_SARS-CoV.
DR   InterPro; IPR043478; NSP3_SUD-N_sf_bCoV.
DR   InterPro; IPR044357; NSP3_Ubl1_dom_CoV.
DR   InterPro; IPR044353; Nsp3_Ubl2_dom_CoV.
DR   InterPro; IPR038083; NSP3A-like.
DR   InterPro; IPR038123; NSP4_C_sf_CoV.
DR   InterPro; IPR044367; NSP6_betaCoV.
DR   InterPro; IPR043610; NSP6_CoV.
DR   InterPro; IPR014828; NSP7_CoV.
DR   InterPro; IPR037204; NSP7_sf_CoV.
DR   InterPro; IPR014829; NSP8_CoV.
DR   InterPro; IPR037230; NSP8_sf_CoV.
DR   InterPro; IPR014822; NSP9_CoV.
DR   InterPro; IPR036499; NSP9_sf_CoV.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR013016; Peptidase_C16_CoV.
DR   InterPro; IPR008740; Peptidase_C30_CoV.
DR   InterPro; IPR043477; Peptidase_C30_dom3_CoV.
DR   InterPro; IPR009003; Peptidase_S1_PA.
DR   InterPro; IPR043504; Peptidase_S1_PA_chymotrypsin.
DR   InterPro; IPR043177; PLpro_N_sf_CoV.
DR   InterPro; IPR043503; PLpro_palm_finger_dom_CoV.
DR   InterPro; IPR043178; PLpro_thumb_sf_CoV.
DR   InterPro; IPR046441; RdRp_CoV.
DR   InterPro; IPR009469; RdRp_N_CoV.
DR   InterPro; IPR044351; RdRp_SARS-CoV-like.
DR   InterPro; IPR001205; RNA-dir_pol_C.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR018995; RNA_synth_NSP10_CoV.
DR   InterPro; IPR029063; SAM-dependent_MTases_sf.
DR   PANTHER; PTHR43788; DNA2/NAM7 HELICASE FAMILY MEMBER; 1.
DR   PANTHER; PTHR43788:SF16; HELICASE WITH ZINC FINGER 2; 1.
DR   Pfam; PF13087; AAA_12; 1.
DR   Pfam; PF16251; bCoV_NAB; 1.
DR   Pfam; PF11501; bCoV_NSP1; 1.
DR   Pfam; PF12379; bCoV_NSP3_N; 1.
DR   Pfam; PF12124; bCoV_SUD_C; 1.
DR   Pfam; PF11633; bCoV_SUD_M; 1.
DR   Pfam; PF06471; CoV_ExoN; 1.
DR   Pfam; PF06460; CoV_Methyltr_2; 1.
DR   Pfam; PF09401; CoV_NSP10; 1.
DR   Pfam; PF20631; CoV_NSP13_1B; 1.
DR   Pfam; PF20633; CoV_NSP13_stalk; 1.
DR   Pfam; PF20632; CoV_NSP13_ZBD; 1.
DR   Pfam; PF19215; CoV_NSP15_C; 1.
DR   Pfam; PF19216; CoV_NSP15_M; 1.
DR   Pfam; PF19219; CoV_NSP15_N; 1.
DR   Pfam; PF19212; CoV_NSP2_C; 1.
DR   Pfam; PF19211; CoV_NSP2_N; 1.
DR   Pfam; PF19218; CoV_NSP3_C; 1.
DR   Pfam; PF16348; CoV_NSP4_C; 1.
DR   Pfam; PF19217; CoV_NSP4_N; 1.
DR   Pfam; PF19213; CoV_NSP6; 1.
DR   Pfam; PF08716; CoV_NSP7; 1.
DR   Pfam; PF08717; CoV_NSP8; 1.
DR   Pfam; PF08710; CoV_NSP9; 1.
DR   Pfam; PF08715; CoV_peptidase; 1.
DR   Pfam; PF06478; CoV_RPol_N; 1.
DR   Pfam; PF01661; Macro; 1.
DR   Pfam; PF05409; Peptidase_C30; 1.
DR   Pfam; PF00680; RdRP_1; 1.
DR   SMART; SM00506; A1pp; 1.
DR   SUPFAM; SSF144246; Coronavirus NSP10-like; 1.
DR   SUPFAM; SSF140367; Coronavirus NSP7-like; 1.
DR   SUPFAM; SSF143076; Coronavirus NSP8-like; 1.
DR   SUPFAM; SSF56672; DNA/RNA polymerases; 1.
DR   SUPFAM; SSF142877; EndoU-like; 1.
DR   SUPFAM; SSF52949; Macro domain-like; 1.
DR   SUPFAM; SSF159936; NSP3A-like; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   SUPFAM; SSF101816; Replicase NSP9; 1.
DR   SUPFAM; SSF53335; S-adenosyl-L-methionine-dependent methyltransferases; 1.
DR   SUPFAM; SSF160099; SARS Nsp1-like; 1.
DR   SUPFAM; SSF50494; Trypsin-like serine proteases; 1.
DR   PROSITE; PS51961; AV_NSP11N_COV_NSP15M; 1.
DR   PROSITE; PS51963; BCOV_NSP1_C; 1.
DR   PROSITE; PS51942; BCOV_NSP3C_C; 1.
DR   PROSITE; PS51941; BCOV_NSP3C_M; 1.
DR   PROSITE; PS51994; BCOV_NSP3E_G2M; 1.
DR   PROSITE; PS51945; BCOV_NSP3E_NAB; 1.
DR   PROSITE; PS51993; COV_3ECTO; 1.
DR   PROSITE; PS51952; COV_EXON_MTASE_COACT; 1.
DR   PROSITE; PS51954; COV_N7_MTASE; 1.
DR   PROSITE; PS51962; COV_NSP1; 1.
DR   PROSITE; PS52000; COV_NSP12_IF; 1.
DR   PROSITE; PS51948; COV_NSP12_RDRP; 1.
DR   PROSITE; PS51960; COV_NSP15_NTD; 1.
DR   PROSITE; PS51991; COV_NSP2_C; 1.
DR   PROSITE; PS51990; COV_NSP2_M; 1.
DR   PROSITE; PS51989; COV_NSP2_N; 1.
DR   P",52909
TTAACA TAACAT AACATT ACATTA CATTAG ATTAGC TTAGCT TAGCTG AGCTGT GCTGTA CTGTAC TGTACC GTACCC TACCCT ACCCTA CCCTAT CCTATA CTATAA TATAAT ATAATA TAATAT AATATG ATATGA TATGAG ATGAGA TGAGAG GAGAGT AGAGTT GAGTTA AGTTAT GTTATA TTATAC TATACA ATACAT TACATT ACATTT CATTTT ATTTTG TTTTGG TTTGGT TTGGTG TGGTGC GGTGCT GTGCTG TGCTGG GCTGGT CTGGTT TGGTTC GGTTCT GTTCTG TTCTGA TCTGAT CTGATA TGATAA GATAAA ATAAAG TAAAGG AAAGGA AAGGAG AGGAGT GGAGTT GAGTTG AGTTGC GTTGCA TTGCAC TGCACC GCACCA CACCAG ACCAGG CCAGGT CAGGTA AGGTAC GGTACA GTACAG TACAGC ACAGCT CAGCTG AGCTGT GCTGTT CTGTTT TGTTTT GTTTTA TTTTAA TTTAAG TTAAGA TAAGAC AAGACA AGACAG GACAGT ACAGTG CAGTGG AGTGGT GTGGTT TGGTTC GGTTCT GTTCTG TTCTGT TCTGTC CTGTCT TGTCTC GTCTCT TCTCTT CTCTTA TCTTAT CTTATA TTATAC TATACA ATACAC TACACA ACACAT CACATT ACATTC CATTCC ATTCCG TTCCGA TCCGAG CCGAGC CGAGCC GAGCCC AGCCCA GCCCAC CCCACG CCACGA CACGAG ACGAGA CGAGAC GAGACT AGACTC GACTCC ACTCCT CTCCTG TCCTGA CCTGAG CTGAGC TGAGCA GAGCAT AGCATC GCATCT CATCTC ATCTCG TCTCGT CTCGTA,0,142,TTAA TAAC AACA ACAT CATT ATTA TTAG TAGC AGCT GCTG CTGT TGTA GTAC TACC ACCC CCCT CCTA CTAT TATA ATAA TAAT AATA ATAT TATG ATGA TGAG GAGA AGAG GAGT AGTT GTTA TTAT TATA ATAC TACA ACAT CATT ATTT TTTT TTTG TTGG TGGT GGTG GTGC TGCT GCTG CTGG TGGT GGTT GTTC TTCT TCTG CTGA TGAT GATA ATAA TAAA AAAG AAGG AGGA GGAG GAGT AGTT GTTG TTGC TGCA GCAC CACC ACCA CCAG CAGG AGGT GGTA GTAC TACA ACAG CAGC AGCT GCTG CTGT TGTT GTTT TTTT TTTA TTAA TAAG AAGA AGAC GACA ACAG CAGT AGTG GTGG TGGT GGTT GTTC TTCT TCTG CTGT TGTC GTCT TCTC CTCT TCTT CTTA TTAT TATA ATAC TACA ACAC CACA ACAT CATT ATTC TTCC TCCG CCGA CGAG GAGC AGCC GCCC CCCA CCAC CACG ACGA CGAG GAGA AGAC GACT ACTC CTCC TCCT CCTG CTGA TGAG GAGC AGCA GCAT CATC ATCT TCTC CTCG TCGT CGTA,TTAAC TAACA AACAT ACATT CATTA ATTAG TTAGC TAGCT AGCTG GCTGT CTGTA TGTAC GTACC TACCC ACCCT CCCTA CCTAT CTATA TATAA ATAAT TAATA AATAT ATATG TATGA ATGAG TGAGA GAGAG AGAGT GAGTT AGTTA GTTAT TTATA TATAC ATACA TACAT ACATT CATTT ATTTT TTTTG TTTGG TTGGT TGGTG GGTGC GTGCT TGCTG GCTGG CTGGT TGGTT GGTTC GTTCT TTCTG TCTGA CTGAT TGATA GATAA ATAAA TAAAG AAAGG AAGGA AGGAG GGAGT GAGTT AGTTG GTTGC TTGCA TGCAC GCACC CACCA ACCAG CCAGG CAGGT AGGTA GGTAC GTACA TACAG ACAGC CAGCT AGCTG GCTGT CTGTT TGTTT GTTTT TTTTA TTTAA TTAAG TAAGA AAGAC AGACA GACAG ACAGT CAGTG AGTGG GTGGT TGGTT GGTTC GTTCT TTCTG TCTGT CTGTC TGTCT GTCTC TCTCT CTCTT TCTTA CTTAT TTATA TATAC ATACA TACAC ACACA CACAT ACATT CATTC ATTCC TTCCG TCCGA CCGAG CGAGC GAGCC AGCCC GCCCA CCCAC CCACG CACGA ACGAG CGAGA GAGAC AGACT GACTC ACTCC CTCCT TCCTG CCTGA CTGAG TGAGC GAGCA AGCAT GCATC CATCT ATCTC TCTCG CTCGT TCGTA,TTAACA TAACAT AACATT ACATTA CATTAG ATTAGC TTAGCT TAGCTG AGCTGT GCTGTA CTGTAC TGTACC GTACCC TACCCT ACCCTA CCCTAT CCTATA CTATAA TATAAT ATAATA TAATAT AATATG ATATGA TATGAG ATGAGA TGAGAG GAGAGT AGAGTT GAGTTA AGTTAT GTTATA TTATAC TATACA ATACAT TACATT ACATTT CATTTT ATTTTG TTTTGG TTTGGT TTGGTG TGGTGC GGTGCT GTGCTG TGCTGG GCTGGT CTGGTT TGGTTC GGTTCT GTTCTG TTCTGA TCTGAT CTGATA TGATAA GATAAA ATAAAG TAAAGG AAAGGA AAGGAG AGGAGT GGAGTT GAGTTG AGTTGC GTTGCA TTGCAC TGCACC GCACCA CACCAG ACCAGG CCAGGT CAGGTA AGGTAC GGTACA GTACAG TACAGC ACAGCT CAGCTG AGCTGT GCTGTT CTGTTT TGTTTT GTTTTA TTTTAA TTTAAG TTAAGA TAAGAC AAGACA AGACAG GACAGT ACAGTG CAGTGG AGTGGT GTGGTT TGGTTC GGTTCT GTTCTG TTCTGT TCTGTC CTGTCT TGTCTC GTCTCT TCTCTT CTCTTA TCTTAT CTTATA TTATAC TATACA ATACAC TACACA ACACAT CACATT ACATTC CATTCC ATTCCG TTCCGA TCCGAG CCGAGC CGAGCC GAGCCC AGCCCA GCCCAC CCCACG CCACGA CACGAG ACGAGA CGAGAC GAGACT AGACTC GACTCC ACTCCT CTCCTG TCCTGA CCTGAG CTGAGC TGAGCA GAGCAT AGCATC GCATCT CATCTC ATCTCG TCTCGT CTCGTA,TTAACAT TAACATT AACATTA ACATTAG CATTAGC ATTAGCT TTAGCTG TAGCTGT AGCTGTA GCTGTAC CTGTACC TGTACCC GTACCCT TACCCTA ACCCTAT CCCTATA CCTATAA CTATAAT TATAATA ATAATAT TAATATG AATATGA ATATGAG TATGAGA ATGAGAG TGAGAGT GAGAGTT AGAGTTA GAGTTAT AGTTATA GTTATAC TTATACA TATACAT ATACATT TACATTT ACATTTT CATTTTG ATTTTGG TTTTGGT TTTGGTG TTGGTGC TGGTGCT GGTGCTG GTGCTGG TGCTGGT GCTGGTT CTGGTTC TGGTTCT GGTTCTG GTTCTGA TTCTGAT TCTGATA CTGATAA TGATAAA GATAAAG ATAAAGG TAAAGGA AAAGGAG AAGGAGT AGGAGTT GGAGTTG GAGTTGC AGTTGCA GTTGCAC TTGCACC TGCACCA GCACCAG CACCAGG ACCAGGT CCAGGTA CAGGTAC AGGTACA GGTACAG GTACAGC TACAGCT ACAGCTG CAGCTGT AGCTGTT GCTGTTT CTGTTTT TGTTTTA GTTTTAA TTTTAAG TTTAAGA TTAAGAC TAAGACA AAGACAG AGACAGT GACAGTG ACAGTGG CAGTGGT AGTGGTT GTGGTTC TGGTTCT GGTTCTG GTTCTGT TTCTGTC TCTGTCT CTGTCTC TGTCTCT GTCTCTT TCTCTTA CTCTTAT TCTTATA CTTATAC TTATACA TATACAC ATACACA TACACAT ACACATT CACATTC ACATTCC CATTCCG ATTCCGA TTCCGAG TCCGAGC CCGAGCC CGAGCCC GAGCCCA AGCCCAC GCCCACG CCCACGA CCACGAG CACGAGA ACGAGAC CGAGACT GAGACTC AGACTCC GACTCCT ACTCCTG CTCCTGA TCCTGAG CCTGAGC CTGAGCA TGAGCAT GAGCATC AGCATCT GCATCTC CATCTCG ATCTCGT TCTCGTA,"ID   R1AB_BCHK3              Reviewed;        7067 AA.
AC   P0C6W2; Q3LZX2;
DT   10-JUN-2008, integrated into UniProtKB/Swiss-Prot.
DT   10-JUN-2008, sequence version 1.
DT   05-FEB-2025, entry version 109.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE              Short=nsp1;
DE     AltName: Full=Leader protein;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like proteinase nsp3;
DE              Short=PL-PRO;
DE              EC=3.4.19.12;
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.-;
DE     AltName: Full=nsp5;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9;
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE     AltName: Full=p12;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50;
DE     AltName: Full=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              Short=ExoN;
DE              EC=2.1.1.56;
DE              EC=3.1.13.-;
DE     AltName: Full=nsp14;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.-;
DE     AltName: Full=NendoU;
DE     AltName: Full=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Bat coronavirus HKU3 (BtCoV) (SARS-like coronavirus HKU3).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=442736;
OH   NCBI_TaxID=89399; Rhinolophus sinicus (Chinese rufous horseshoe bat).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HKU3-1;
RX   PubMed=16169905; DOI=10.1073/pnas.0506735102;
RA   Lau S.K.P., Woo P.C.Y., Li K.S.M., Huang Y., Tsoi H.-W., Wong B.H.L.,
RA   Wong S.S.Y., Leung S.-Y., Chan K.-H., Yuen K.-Y.;
RT   ""Severe acute respiratory syndrome coronavirus-like virus in Chinese
RT   horseshoe bats."";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:14040-14045(2005).
CC   -!- FUNCTION: The replicase polyprotein of coronaviruses is a
CC       multifunctional protein: it contains the activities necessary for the
CC       transcription of negative stranded RNA, leader RNA, subgenomic mRNAs
CC       and progeny virion RNA as well as proteinases responsible for the
CC       cleavage of the polyprotein into functional products.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by interacting with the 40S ribosomal subunit. The nsp1-40S ribosome
CC       complex further induces an endonucleolytic cleavage near the 5'UTR of
CC       host mRNAs, targeting them for degradation. Viral mRNAs are not
CC       susceptible to nsp1-mediated endonucleolytic RNA cleavage thanks to the
CC       presence of a 5'-end leader sequence and are therefore protected from
CC       degradation. By suppressing host gene expression, nsp1 facilitates
CC       efficient viral gene expression in infected cells and evasion from host
CC       immune response. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Non-structural protein 2]: May play a role in the modulation
CC       of host cell survival signaling pathway by interacting with host PHB
CC       and PHB2. Indeed, these two proteins play a role in maintaining the
CC       functional integrity of the mitochondria and protecting cells from
CC       various stresses. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Papain-like proteinase nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. In addition,
CC       PL-PRO possesses a deubiquitinating/deISGylating activity and processes
CC       both 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates. Participates together with nsp4 in the assembly of virally-
CC       induced cytoplasmic double-membrane vesicles necessary for viral
CC       replication. Antagonizes innate immune induction of type I interferon
CC       by blocking the phosphorylation, dimerization and subsequent nuclear
CC       translocation of host IRF3. Prevents also host NF-kappa-B signaling.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Non-structural protein 4]: Participates in the assembly of
CC       virally-induced cytoplasmic double-membrane vesicles necessary for
CC       viral replication. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [3C-like proteinase nsp5]: Cleaves the C-terminus of
CC       replicase polyprotein at 11 sites. Recognizes substrates containing the
CC       core sequence [ILMVF]-Q-|-[SGACN]. Also able to bind an ADP-ribose-1''-
CC       phosphate (ADRP). {ECO:0000250|UniProtKB:P0C6X7, ECO:0000255|PROSITE-
CC       ProRule:PRU00772}.
CC   -!- FUNCTION: [Non-structural protein 6]: Plays a role in the initial
CC       induction of autophagosomes from host endoplasmic reticulum. Later,
CC       limits the expansion of these phagosomes that are no longer able to
CC       deliver viral components to lysosomes. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Non-structural protein 7]: Forms a hexadecamer with nsp8 (8
CC       subunits of each) that may participate in viral replication by acting
CC       as a primase. Alternatively, may synthesize substantially longer
CC       products than oligonucleotide primers. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Non-structural protein 8]: Forms a hexadecamer with nsp7 (8
CC       subunits of each) that may participate in viral replication by acting
CC       as a primase. Alternatively, may synthesize substantially longer
CC       products than oligonucleotide primers. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Viral protein genome-linked nsp9]: Forms a primer, NSP9-pU,
CC       which is utilized by the polymerase for the initiation of RNA chains.
CC       Interacts with ribosome signal recognition particle RNA (SRP). Together
CC       with NSP8, suppress protein integration into the cell membrane, thereby
CC       disrupting host immune defenses. {ECO:0000250|UniProtKB:P0DTD1}.
CC   -!- FUNCTION: [Non-structural protein 10]: Plays a pivotal role in viral
CC       transcription by stimulating both nsp14 3'-5' exoribonuclease and nsp16
CC       2'-O-methyltransferase activities. Therefore plays an essential role in
CC       viral mRNAs cap methylation. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [RNA-directed RNA polymerase nsp12]: RNA-directed RNA
CC       polymerase that catalyzes the transcription of viral genomic and
CC       subgenomic RNAs. Acts in complex with nsp7 and nsp8 to transcribe both
CC       the minus and positive strands of genomic RNA. The kinase-like NiRAN
CC       domain of NSP12 attaches one or more nucleotides to the amino terminus
CC       of NSP9, forming a covalent RNA-protein intermediate that serves as
CC       transcription/replication primer. Subgenomic RNAs (sgRNAs) are formed
CC       by discontinuous transcription: The polymerase has the ability to pause
CC       at transcription-regulating sequences (TRS) and jump to the leader TRS,
CC       resulting in a major deletion. This creates a series of subgenomic RNAs
CC       that are replicated, transcribed and translated. In addition, Nsp12 is
CC       a subunit of the viral RNA capping enzyme that catalyzes the RNA
CC       guanylyltransferase reaction for genomic and sub-genomic RNAs.
CC       Subsequently, the NiRAN domain transfers RNA to GDP, and forms the core
CC       cap structure GpppA-RNA. {ECO:0000250|UniProtKB:P0DTD1}.
CC   -!- FUNCTION: [Helicase nsp13]: Multi-functional protein with a zinc-
CC       binding domain in N-terminus displaying RNA and DNA duplex-unwinding
CC       activities with 5' to 3' polarity. Activity of helicase is dependent on
CC       magnesium. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Guanine-N7 methyltransferase nsp14]: Plays a role in viral
CC       RNA synthesis through two distinct activities. The N7-guanine
CC       methyltransferase activity plays a role in the formation of the cap
CC       structure GpppA-RNA. The proofreading exoribonuclease reduces the
CC       sensitivity of the virus to RNA mutagens during replication. This
CC       activity acts on both ssRNA and dsRNA in a 3'-5' direction.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Uridylate-specific endoribonuclease nsp15]: Plays a role in
CC       viral transcription/replication and prevents the simultaneous
CC       activation of host cell dsRNA sensors, such as MDA5/IFIH1, OAS, and PKR
CC       (By similarity). Acts by degrading the 5'-polyuridines generated during
CC       replication of the poly(A) region of viral genomic and subgenomic RNAs.
CC       Catalyzes a two-step reaction in which a 2'3'-cyclic phosphate (2'3'-
CC       cP) is first generated by 2'-O transesterification, which is then
CC       hydrolyzed to a 3'-phosphate (3'-P) (By similarity). If not degraded,
CC       poly(U) RNA would hybridize with poly(A) RNA tails and activate host
CC       dsRNA sensors (By similarity). {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [2'-O-methyltransferase nsp16]: Methyltransferase that
CC       mediates mRNA cap 2'-O-ribose methylation to the 5'-cap structure of
CC       viral mRNAs. N7-methyl guanosine cap is a prerequisite for binding of
CC       nsp16. Therefore plays an essential role in viral mRNAs cap methylation
CC       which is essential to evade immune system.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- CATALYTIC ACTIVITY: [RNA-directed RNA polymerase nsp12]:
CC       Reaction=RNA(n) + a ribonucleoside 5'-triphosphate = RNA(n+1) +
CC         diphosphate; Xref=Rhea:RHEA:21248, Rhea:RHEA-COMP:14527, Rhea:RHEA-
CC         COMP:17342, ChEBI:CHEBI:33019, ChEBI:CHEBI:61557, ChEBI:CHEBI:140395;
CC         EC=2.7.7.48; Evidence={ECO:0000255|PROSITE-ProRule:PRU00539};
CC   -!- CATALYTIC ACTIVITY: [Helicase nsp13]:
CC       Reaction=ATP + H2O = ADP + phosphate + H(+); Xref=Rhea:RHEA:13065,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; EC=3.6.4.12;
CC   -!- CATALYTIC ACTIVITY: [Helicase nsp13]:
CC       Reaction=ATP + H2O = ADP + phosphate + H(+); Xref=Rhea:RHEA:13065,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; EC=3.6.4.13;
CC   -!- CATALYTIC ACTIVITY: [Papain-like proteinase nsp3]:
CC       Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide
CC         and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-
CC         residue protein attached to proteins as an intracellular targeting
CC         signal).; EC=3.4.19.12;
CC   -!- CATALYTIC ACTIVITY: [2'-O-methyltransferase nsp16]:
CC       Reaction=a 5'-end (N(7)-methyl 5'-triphosphoguanosine)-ribonucleoside
CC         in mRNA + S-adenosyl-L-methionine = a 5'-end (N(7)-methyl 5'-
CC         triphosphoguanosine)-(2'-O-methyl-ribonucleoside) in mRNA + S-
CC         adenosyl-L-homocysteine + H(+); Xref=Rhea:RHEA:67020, Rhea:RHEA-
CC         COMP:17167, Rhea:RHEA-COMP:17168, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:57856, ChEBI:CHEBI:59789, ChEBI:CHEBI:156461,
CC         ChEBI:CHEBI:167609; EC=2.1.1.57;
CC         Evidence={ECO:0000250|UniProtKB:P0C6X7};
CC   -!- CATALYTIC ACTIVITY: [Uridylate-specific endoribonuclease nsp15]:
CC       Reaction=uridylyl-uridylyl-ribonucleotide-RNA = a 3'-end uridylyl-
CC         2',3'-cyclophospho-uridine-RNA + a 5'-end dephospho-ribonucleoside-
CC         RNA; Xref=Rhea:RHEA:67732, Rhea:RHEA-COMP:13936, Rhea:RHEA-
CC         COMP:17334, Rhea:RHEA-COMP:17335, ChEBI:CHEBI:138284,
CC         ChEBI:CHEBI:173079, ChEBI:CHEBI:173080;
CC         Evidence={ECO:0000250|UniProtKB:P0C6X7};
CC   -!- CATALYTIC ACTIVITY: [RNA-directed RNA polymerase nsp12]:
CC       Reaction=a 5'-end diphospho-ribonucleoside in mRNA + GTP + H(+) = a 5'-
CC         end (5'-triphosphoguanosine)-ribonucleoside in mRNA + diphosphate;
CC         Xref=Rhea:RHEA:67012, Rhea:RHEA-COMP:17165, Rhea:RHEA-COMP:17166,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:33019, ChEBI:CHEBI:37565,
CC         ChEBI:CHEBI:167616, ChEBI:CHEBI:167617; EC=2.7.7.50;
CC         Evidence={ECO:0000250|UniProtKB:P0DTD1};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:67013;
CC         Evidence={ECO:0000250|UniProtKB:P0DTD1};
CC   -!- CATALYTIC ACTIVITY: [Guanine-N7 methyltransferase nsp14]:
CC       Reaction=a 5'-end (5'-triphosphoguanosine)-ribonucleoside in mRNA + S-
CC         adenosyl-L-methionine = a 5'-end (N(7)-methyl 5'-
CC         triphosphoguanosine)-ribonucleoside in mRNA + S-adenosyl-L-
CC         homocysteine; Xref=Rhea:RHEA:67008, Rhea:RHEA-COMP:17166, Rhea:RHEA-
CC         COMP:17167, ChEBI:CHEBI:57856, ChEBI:CHEBI:59789, ChEBI:CHEBI:156461,
CC         ChEBI:CHEBI:167617; EC=2.1.1.56;
CC         Evidence={ECO:0000250|UniProtKB:P0C6X7};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:67009;
CC         Evidence={ECO:0000250|UniProtKB:P0C6X7};
CC   -!- COFACTOR: [Uridylate-specific endoribonuclease nsp15]:
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000250|UniProtKB:P0C6X7};
CC       Note=Likely affects Nsp15 binding to RNA.
CC       {ECO:0000250|UniProtKB:P0C6X7};
CC   -!- COFACTOR: [RNA-directed RNA polymerase nsp12]:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000250|UniProtKB:P0DTD1};
CC   -!- SUBUNIT: [Non-structural protein 2]: Interacts with host PHB and PHB2.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBUNIT: [Non-structural protein 4]: Interacts with papain-like
CC       protease nsp3 and non-structural protein 6.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBUNIT: [3C-like proteinase nsp5]: Monomer. Homodimer. Only the
CC       homodimer shows catalytic activity. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBUNIT: [Non-structural protein 7]: Interacts with nsp8 and nsp12 to
CC       form the replication-transcription complex (RTC): nsp12, nsp7, two
CC       subunits of nsp8, and up to two subunits of nsp13.
CC       {ECO:0000250|UniProtKB:P0DTD1}.
CC   -!- SUBUNIT: [Non-structural protein 8]: Interacts with nsp7, nsp13 and
CC       nsp12 to form the replication-transcription complex (RTC): nsp12, nsp7,
CC       two subunits of nsp8, and up to two subunits of nsp13.
CC       {ECO:0000250|UniProtKB:P0DTD1}.
CC   -!- SUBUNIT: [Viral protein genome-linked nsp9]: Interacts with nsp12.
CC       {ECO:0000250|UniProtKB:P0DTD1}.
CC   -!- SUBUNIT: [Non-structural protein 10]: Interacts with proofreading
CC       exoribonuclease nsp14 and 2'-O-methyltransferase nsp16; these
CC       interactions enhance nsp14 and nsp16 enzymatic activities.
CC       {ECO:0000250|UniProtKB:P0DTD1}.
CC   -!- SUBUNIT: [RNA-directed RNA polymerase nsp12]: Interacts with nsp7 and
CC       nsp8 to form the replication-transcription complex (RTC): nsp12, nsp7,
CC       two subunits of nsp8, and up to two subunits of nsp13. Interacts with
CC       nsp9. {ECO:0000250|UniProtKB:P0DTD1}.
CC   -!- SUBUNIT: [Helicase nsp13]: Interacts with nsp8 to form the replication-
CC       transcription complex (RTC): nsp12, nsp7, two subunits of nsp8, and up
CC       to two subunits of nsp13. {ECO:0000250|UniProtKB:P0DTD1}.
CC   -!- SUBCELLULAR LOCATION: [Papain-like proteinase nsp3]: Host membrane;
CC       Multi-pass membrane protein. Host cytoplasm
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 4]: Host membrane; Multi-
CC       pass membrane protein. Host cytoplasm. Note=Localizes in virally-
CC       induced cytoplasmic double-membrane vesicles.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 6]: Host membrane
CC       {ECO:0000305}; Multi-pass membrane protein {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 7]: Host cytoplasm, host
CC       perinuclear region {ECO:0000250}. Note=nsp7, nsp8, nsp9 and nsp10 are
CC       localized in cytoplasmic foci, largely perinuclear. Late in infection,
CC       they merge into confluent complexes (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 8]: Host cytoplasm, host
CC       perinuclear region {ECO:0000250}. Note=nsp7, nsp8, nsp9 and nsp10 are
CC       localized in cytoplasmic foci, largely perinuclear. Late in infection,
CC       they merge into confluent complexes (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Viral protein genome-linked nsp9]: Host
CC       cytoplasm, host perinuclear region {ECO:0000250}. Note=nsp7, nsp8, nsp9
CC       and nsp10 are localized in cytoplasmic foci, largely perinuclear. Late
CC       in infection, they merge into confluent complexes (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 10]: Host cytoplasm, host
CC       perinuclear region {ECO:0000250}. Note=nsp7, nsp8, nsp9 and nsp10 are
CC       localized in cytoplasmic foci, largely perinuclear. Late in infection,
CC       they merge into confluent complexes (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Helicase nsp13]: Host endoplasmic reticulum-
CC       Golgi intermediate compartment {ECO:0000305}. Note=The helicase
CC       interacts with the N protein in membranous complexes and colocalizes
CC       with sites of synthesis of new viral RNA. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Uridylate-specific endoribonuclease nsp15]: Host
CC       cytoplasm, host perinuclear region {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Ribosomal frameshifting; Named isoforms=2;
CC       Name=Replicase polyprotein 1ab; Synonyms=pp1ab;
CC         IsoId=P0C6W2-1; Sequence=Displayed;
CC       Name=Replicase polyprotein 1a; Synonyms=pp1a, ORF1a polyprotein;
CC         IsoId=P0C6F8-1; Sequence=External;
CC   -!- DOMAIN: The hydrophobic domains (HD) could mediate the membrane
CC       association of the replication complex and thereby alter the
CC       architecture of the host cell membrane. {ECO:0000250}.
CC   -!- PTM: Specific enzymatic cleavages in vivo by its own proteases yield
CC       mature proteins. 3CL-PRO and PL-PRO proteinases are autocatalytically
CC       processed (By similarity). {ECO:0000250}.
CC   -!- MISCELLANEOUS: Bat coronavirus HKU3 is highly similar to SARS-CoV
CC       (SARS-like).
CC   -!- MISCELLANEOUS: [Isoform Replicase polyprotein 1ab]: Produced by -1
CC       ribosomal frameshifting at the 1a-1b genes boundary.
CC   -!- SIMILARITY: Belongs to the coronaviruses polyprotein 1ab family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; DQ022305; AAY88865.2; -; Genomic_RNA.
DR   BMRB; P0C6W2; -.
DR   SMR; P0C6W2; -.
DR   MEROPS; C16.009; -.
DR   MEROPS; C30.005; -.
DR   Proteomes; UP000007450; Segment.
DR   GO; GO:0044172; C:host cell endoplasmic reticulum-Golgi intermediate compartment; IEA:UniProtKB-SubCell.
DR   GO; GO:0033644; C:host cell membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-KW.
DR   GO; GO:0000175; F:3'-5'-RNA exonuclease activity; IEA:InterPro.
DR   GO; GO:0043139; F:5'-3' DNA helicase activity; IEA:TreeGrafter.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IEA:RHEA.
DR   GO; GO:0140849; F:ATP-dependent H2AZ histone chaperone activity; IEA:RHEA.
DR   GO; GO:0140665; F:ATP-dependent H3-H4 histone complex chaperone activity; IEA:RHEA.
DR   GO; GO:0140584; F:chromatin extrusion motor activity; IEA:RHEA.
DR   GO; GO:0061775; F:cohesin loader activity; IEA:RHEA.
DR   GO; GO:0004843; F:cysteine-type deubiquitinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0003689; F:DNA clamp loader activity; IEA:RHEA.
DR   GO; GO:0036121; F:double-stranded DNA helicase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004519; F:endonuclease activity; IEA:UniProtKB-KW.
DR   GO; GO:0061749; F:forked DNA-dependent helicase activity; IEA:UniProtKB-EC.
DR   GO; GO:0009378; F:four-way junction helicase activity; IEA:UniProtKB-EC.
DR   GO; GO:0002151; F:G-quadruplex RNA binding; IEA:InterPro.
DR   GO; GO:0016829; F:lyase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004483; F:mRNA (nucleoside-2'-O-)-methyltransferase activity; IEA:InterPro.
DR   GO; GO:0004482; F:mRNA 5'-cap (guanine-N7-)-methyltransferase activity; IEA:InterPro.
DR   GO; GO:0008242; F:omega peptidase activity; IEA:InterPro.
DR   GO; GO:0003724; F:RNA helicase activity; IEA:UniProtKB-EC.
DR   GO; GO:0003968; F:RNA-dependent RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:1990518; F:single-stranded 3'-5' DNA helicase activity; IEA:UniProtKB-EC.
DR   GO; GO:0003727; F:single-stranded RNA binding; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0006351; P:DNA-templated transcription; IEA:InterPro.
DR   GO; GO:0039520; P:induction by virus of host autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:UniProtKB-KW.
DR   GO; GO:0039595; P:symbiont-mediated degradation of host mRNA; IEA:UniProtKB-KW.
DR   GO; GO:0039648; P:symbiont-mediated perturbation of host ubiquitin-like protein modification; IEA:UniProtKB-KW.
DR   GO; GO:0039657; P:symbiont-mediated suppression of host gene expression; IEA:UniProtKB-KW.
DR   GO; GO:0039579; P:symbiont-mediated suppression of host ISG15-protein conjugation; IEA:UniProtKB-KW.
DR   GO; GO:0085034; P:symbiont-mediated suppression of host NF-kappaB cascade; IEA:UniProtKB-KW.
DR   GO; GO:0039502; P:symbiont-mediated suppression of host type I interferon-mediated signaling pathway; IEA:UniProtKB-KW.
DR   GO; GO:0019082; P:viral protein processing; IEA:InterPro.
DR   GO; GO:0039694; P:viral RNA genome replication; IEA:InterPro.
DR   GO; GO:0075523; P:viral translational frameshifting; IEA:UniProtKB-KW.
DR   GO; GO:0019049; P:virus-mediated perturbation of host defense response; IEA:UniProtKB-KW.
DR   CDD; cd21409; 1B_cv_Nsp13-like; 1.
DR   CDD; cd21560; betaCoV-Nsp6; 1.
DR   CDD; cd21722; betaCoV_Nsp13-helicase; 1.
DR   CDD; cd21659; betaCoV_Nsp14; 1.
DR   CDD; cd21516; betaCoV_Nsp2_SARS-like; 1.
DR   CDD; cd21666; betaCoV_Nsp5_Mpro; 1.
DR   CDD; cd21827; betaCoV_Nsp7; 1.
DR   CDD; cd21831; betaCoV_Nsp8; 1.
DR   CDD; cd21898; betaCoV_Nsp9; 1.
DR   CDD; cd21732; betaCoV_PLPro; 1.
DR   CDD; cd20762; capping_2-OMTase_Nidovirales; 1.
DR   CDD; cd21872; CoV_Nsp10; 1.
DR   CDD; cd21473; cv_Nsp4_TM; 1.
DR   CDD; cd21167; M_alpha_beta_cv_Nsp15-like; 1.
DR   CDD; cd21563; Macro_cv_SUD-M_Nsp3-like; 1.
DR   CDD; cd21562; Macro_cv_SUD-N_Nsp3-like; 1.
DR   CDD; cd21557; Macro_X_Nsp3-like; 1.
DR   CDD; cd21161; NendoU_cv_Nsp15-like; 1.
DR   CDD; cd21171; NTD_alpha_betaCoV_Nsp15-like; 1.
DR   CDD; cd22662; SARS-CoV-like_Nsp1_C; 1.
DR   CDD; cd21796; SARS-CoV-like_Nsp1_N; 1.
DR   CDD; cd21814; SARS-CoV-like_Nsp3_betaSM; 1.
DR   CDD; cd21822; SARS-CoV-like_Nsp3_NAB; 1.
DR   CDD; cd21591; SARS-CoV-like_RdRp; 1.
DR   CDD; cd21689; stalk_CoV_Nsp13-like; 1.
DR   CDD; cd21525; SUD_C_SARS-CoV_Nsp3; 1.
DR   CDD; cd21717; TM_Y_SARS-CoV-like_Nsp3_C; 1.
DR   CDD; cd21467; Ubl1_cv_Nsp3_N-like; 1.
DR   CDD; cd21401; ZBD_cv_Nsp13-like; 1.
DR   FunFam; 1.10.8.370:FF:000001; Orf1a polyprotein; 1.
DR   FunFam; 2.40.10.250:FF:000001; Orf1a polyprotein; 1.
DR   FunFam; 3.40.220.30:FF:000001; Orf1a polyprotein; 1.
DR   FunFam; 3.30.160.820:FF:000001; Orf1ab polyprotein; 1.
DR   FunFam; 3.40.50.150:FF:000162; Orf1ab polyprotein; 1.
DR   FunFam; 3.40.50.300:FF:001105; Orf1ab polyprotein; 1.
DR   FunFam; 3.40.50.300:FF:001139; Orf1ab polyprotein; 1.
DR   FunFam; 1.10.150.420:FF:000001; Replicase polyprotein; 1.
DR   FunFam; 1.10.1840.10:FF:000001; Replicase polyprotein 1a; 1.
DR   FunFam; 1.10.8.1190:FF:000001; Replicase polyprotein 1a; 1.
DR   FunFam; 2.40.10.10:FF:000033; Replicase polyprotein 1a; 1.
DR   FunFam; 3.40.50.11580:FF:000001; Replicase polyprotein 1ab; 1.
DR   Gene3D; 1.10.8.1190; -; 1.
DR   Gene3D; 2.60.120.1680; -; 1.
DR   Gene3D; 3.10.20.350; -; 1.
DR   Gene3D; 3.10.20.540; -; 1.
DR   Gene3D; 3.40.50.11580; -; 1.
DR   Gene3D; 6.10.140.2090; -; 1.
DR   Gene3D; 1.10.150.420; Coronavirus nonstructural protein 4 C-terminus; 1.
DR   Gene3D; 3.40.30.150; Coronavirus polyprotein cleavage domain; 1.
DR   Gene3D; 3.40.220.10; Leucine Aminopeptidase, subunit E, domain 1; 1.
DR   Gene3D; 1.10.1840.10; main proteinase (3clpro) structure, domain 3; 1.
DR   Gene3D; 3.30.160.820; Nsp15 N-terminal domain-like; 1.
DR   Gene3D; 3.40.220.20; Nsp3, SUD-M subdomain; 1.
DR   Gene3D; 3.40.220.30; Nsp3, SUD-N subdomain; 1.
DR   Gene3D; 1.10.8.370; nsp7 replicase; 1.
DR   Gene3D; 3.30.70.3540; Nsp8 replicase, head domain; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 2.
DR   Gene3D; 2.40.10.250; Replicase NSP9; 1.
DR   Gene3D; 3.40.50.11020; Replicase polyprotein, nucleic acid-binding domain; 1.
DR   Gene3D; 2.40.10.10; Trypsin-like serine proteases; 2.
DR   Gene3D; 3.40.50.150; Vaccinia Virus protein VP39; 1.
DR   InterPro; IPR027351; (+)RNA_virus_helicase_core_dom.
DR   InterPro; IPR046443; a/bCoV_NSP1_glob.
DR   InterPro; IPR046440; AV_NSP11N_COV_NSP15M.
DR   InterPro; IPR046442; bCoV_NSP1_C.
DR   InterPro; IPR050534; Coronavir_polyprotein_1ab.
DR   InterPro; IPR043608; CoV_NSP15_M.
DR   InterPro; IPR043606; CoV_NSP15_N.
DR   InterPro; IPR043613; CoV_NSP2_C.
DR   InterPro; IPR047573; CoV_NSP2_M.
DR   InterPro; IPR049894; COV_NSP3_3ECTO.
DR   InterPro; IPR043611; CoV_NSP3_C.
DR   InterPro; IPR047566; CoV_NSP3_Y.
DR   InterPro; IPR032505; CoV_NSP4_C.
DR   InterPro; IPR043612; CoV_NSP4_N.
DR   InterPro; IPR043502; DNA/RNA_pol_sf.
DR   InterPro; IPR041679; DNA2/NAM7-like_C.
DR   InterPro; IPR022733; DPUP_SUD_C_bCoV.
DR   InterPro; IPR037227; EndoU-like.
DR   InterPro; IPR002589; Macro_dom.
DR   InterPro; IPR043472; Macro_dom-like.
DR   InterPro; IPR044371; Macro_X_NSP3-like.
DR   InterPro; IPR046435; N7_MTase_CoV.
DR   InterPro; IPR043609; NendoU_nidovirus.
DR   InterPro; IPR044863; NIRAN.
DR   InterPro; IPR046438; NIV_2_O_MTASE.
DR   InterPro; IPR046436; NIV_EXON.
DR   InterPro; IPR036333; NSP10_sf_CoV.
DR   InterPro; IPR047570; NSP12_IF_CoV.
DR   InterPro; IPR044343; NSP13_1B_dom_CoV.
DR   InterPro; IPR048673; NSP13_stalk_CoV.
DR   InterPro; IPR048672; NSP13_ZBD_CoV.
DR   InterPro; IPR027352; NSP13_ZBD_CoV-like.
DR   InterPro; IPR044315; NSP14_betaCoV.
DR   InterPro; IPR009466; NSP14_CoV.
DR   InterPro; IPR044330; NSP15_alpha_betaCoV_N.
DR   InterPro; IPR044322; NSP15_M_alpha_beta_CoV.
DR   InterPro; IPR043174; NSP15_middle_sf.
DR   InterPro; IPR042515; NSP15_N_CoV.
DR   InterPro; IPR044401; NSP15_NendoU_CoV.
DR   InterPro; IPR009461; NSP16_CoV-like.
DR   InterPro; IPR021590; NSP1_glob_bCoV.
DR   InterPro; IPR038030; NSP1_glob_sf_bCoV.
DR   InterPro; IPR043615; NSP2_N_CoV.
DR   InterPro; IPR044389; NSP2_SARS-CoV-like.
DR   InterPro; IPR024375; NSP3_bCoV.
DR   InterPro; IPR047567; NSP3_G2M_bCoV.
DR   InterPro; IPR024358; NSP3_N_bCoV.
DR   InterPro; IPR032592; NSP3_NAB_bCoV.
DR   InterPro; IPR042570; NSP3_NAB_bCoV_sf.
DR   InterPro; IPR038166; NSP3_PL2pro_sf_bCoV.
DR   InterPro; IPR038400; NSP3_SUD-M_sf_bCoV.
DR   InterPro; IPR044864; NSP3_SUD-N_bCoV.
DR   InterPro; IPR044374; NSP3_SUD-N_SARS-CoV.
DR   InterPro; IPR043478; NSP3_SUD-N_sf_bCoV.
DR   InterPro; IPR044357; NSP3_Ubl1_dom_CoV.
DR   InterPro; IPR044353; Nsp3_Ubl2_dom_CoV.
DR   InterPro; IPR038083; NSP3A-like.
DR   InterPro; IPR038123; NSP4_C_sf_CoV.
DR   InterPro; IPR044367; NSP6_betaCoV.
DR   InterPro; IPR043610; NSP6_CoV.
DR   InterPro; IPR014828; NSP7_CoV.
DR   InterPro; IPR037204; NSP7_sf_CoV.
DR   InterPro; IPR014829; NSP8_CoV.
DR   InterPro; IPR037230; NSP8_sf_CoV.
DR   InterPro; IPR014822; NSP9_CoV.
DR   InterPro; IPR036499; NSP9_sf_CoV.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR013016; Peptidase_C16_CoV.
DR   InterPro; IPR008740; Peptidase_C30_CoV.
DR   InterPro; IPR043477; Peptidase_C30_dom3_CoV.
DR   InterPro; IPR009003; Peptidase_S1_PA.
DR   InterPro; IPR043504; Peptidase_S1_PA_chymotrypsin.
DR   InterPro; IPR043177; PLpro_N_sf_CoV.
DR   InterPro; IPR043503; PLpro_palm_finger_dom_CoV.
DR   InterPro; IPR043178; PLpro_thumb_sf_CoV.
DR   InterPro; IPR046441; RdRp_CoV.
DR   InterPro; IPR009469; RdRp_N_CoV.
DR   InterPro; IPR044351; RdRp_SARS-CoV-like.
DR   InterPro; IPR001205; RNA-dir_pol_C.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR018995; RNA_synth_NSP10_CoV.
DR   InterPro; IPR029063; SAM-dependent_MTases_sf.
DR   PANTHER; PTHR43788; DNA2/NAM7 HELICASE FAMILY MEMBER; 1.
DR   PANTHER; PTHR43788:SF16; HELICASE WITH ZINC FINGER 2; 1.
DR   Pfam; PF13087; AAA_12; 1.
DR   Pfam; PF16251; bCoV_NAB; 1.
DR   Pfam; PF11501; bCoV_NSP1; 1.
DR   Pfam; PF12379; bCoV_NSP3_N; 1.
DR   Pfam; PF12124; bCoV_SUD_C; 1.
DR   Pfam; PF11633; bCoV_SUD_M; 1.
DR   Pfam; PF06471; CoV_ExoN; 1.
DR   Pfam; PF06460; CoV_Methyltr_2; 1.
DR   Pfam; PF09401; CoV_NSP10; 1.
DR   Pfam; PF20631; CoV_NSP13_1B; 1.
DR   Pfam; PF20633; CoV_NSP13_stalk; 1.
DR   Pfam; PF20632; CoV_NSP13_ZBD; 1.
DR   Pfam; PF19215; CoV_NSP15_C; 1.
DR   Pfam; PF19216; CoV_NSP15_M; 1.
DR   Pfam; PF19219; CoV_NSP15_N; 1.
DR   Pfam; PF19212; CoV_NSP2_C; 1.
DR   Pfam; PF19211; CoV_NSP2_N; 1.
DR   Pfam; PF19218; CoV_NSP3_C; 1.
DR   Pfam; PF16348; CoV_NSP4_C; 1.
DR   Pfam; PF19217; CoV_NSP4_N; 1.
DR   Pfam; PF19213; CoV_NSP6; 1.
DR   Pfam; PF08716; CoV_NSP7; 1.
DR   Pfam; PF08717; CoV_NSP8; 1.
DR   Pfam; PF08710; CoV_NSP9; 1.
DR   Pfam; PF08715; CoV_peptidase; 1.
DR   Pfam; PF06478; CoV_RPol_N; 1.
DR   Pfam; PF01661; Macro; 1.
DR   Pfam; PF05409; Peptidase_C30; 1.
DR   Pfam; PF00680; RdRP_1; 1.
DR   SMART; SM00506; A1pp; 1.
DR   SUPFAM; SSF144246; Coronavirus NSP10-like; 1.
DR   SUPFAM; SSF140367; Coronavirus NSP7-like; 1.
DR   SUPFAM; SSF143076; Coronavirus NSP8-like; 1.
DR   SUPFAM; SSF56672; DNA/RNA polymerases; 1.
DR   SUPFAM; SSF142877; EndoU-like; 1.
DR   SUPFAM; SSF52949; Macro domain-like; 1.
DR   SUPFAM; SSF159936; NSP3A-like; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   SUPFAM; SSF101816; Replicase NSP9; 1.
DR   SUPFAM; SSF53335; S-adenosyl-L-methionine-dependent methyltransferases; 1.
DR   SUPFAM; SSF160099; SARS Nsp1-like; 1.
DR   SUPFAM; SSF50494; Trypsin-like serine proteases; 1.
DR   PROSITE; PS51961; AV_NSP11N_COV_NSP15M; 1.
DR   PROSITE; PS51963; BCOV_NSP1_C; 1.
DR   PROSITE; PS51942; BCOV_NSP3C_C; 1.
DR   PROSITE; PS51941; BCOV_NSP3C_M; 1.
DR   PROSITE; PS51994; BCOV_NSP3E_G2M; 1.
DR   PROSITE; PS51945; BCOV_NSP3E_NAB; 1.
DR   PROSITE; PS51993; COV_3ECTO; 1.
DR   PROSITE; PS51952; COV_EXON_MTASE_COACT; 1.
DR   PROSITE; PS51954; COV_N7_MTASE; 1.
DR   PROSITE; PS51962; COV_NSP1; 1.
DR   PROSITE; PS52000; COV_NSP12_IF; 1.
DR   PROSITE; PS51948; COV_NSP12_RDRP; 1.
DR   PROSITE; PS51960; COV_NSP15_NTD; 1.
DR   PROSITE; PS51991; COV_NSP2_C; 1.
DR   PROSITE; PS51990; COV_NSP2_M; 1.
DR   PROSITE; PS51989; COV_NSP2_N; 1.
DR   P",52909
GCTTCT CTTCTT TTCTTT TCTTTC CTTTCA TTTCAG TTCAGA TCAGAC CAGACT AGACTG GACTGT ACTGTT CTGTTT TGTTTG GTTTGC TTTGCG TTGCGC TGCGCG GCGCGT CGCGTA GCGTAC CGTACG GTACGC TACGCG ACGCGT CGCGTT GCGTTC CGTTCC GTTCCA TTCCAT TCCATG CCATGT CATGTG ATGTGG TGTGGT GTGGTC TGGTCA GGTCAT GTCATT TCATTT CATTTA ATTTAA TTTAAT TTAATC TAATCC AATCCA ATCCAG TCCAGA CCAGAA CAGAAA AGAAAC GAAACT AAACTA AACTAA ACTAAC CTAACA TAACAT AACATT ACATTC CATTCT ATTCTT TTCTTC TCTTCT CTTCTC TTCTCA TCTCAA CTCAAC TCAACG CAACGT AACGTG ACGTGC CGTGCC GTGCCA TGCCAC GCCACT CCACTC CACTCC ACTCCA CTCCAT TCCATG CCATGG CATGGC ATGGCA TGGCAC GGCACT GCACTA CACTAT ACTATT CTATTC TATTCT ATTCTG TTCTGA TCTGAC CTGACC TGACCA GACCAG ACCAGA CCAGAC CAGACC AGACCG GACCGC ACCGCT CCGCTT CGCTTC GCTTCT CTTCTA TTCTAG TCTAGA CTAGAA TAGAAA AGAAAG GAAAGT AAAGTG AAGTGA AGTGAA GTGAAC TGAACT GAACTC AACTCG ACTCGT CTCGTA TCGTAA CGTAAT GTAATC TAATCG AATCGG ATCGGA TCGGAG CGGAGC GGAGCT GAGCTG AGCTGT GCTGTG CTGTGA TGTGAT GTGATC TGATCC GATCCT ATCCTT TCCTTC CCTTCG CTTCGT TTCGTG TCGTGG CGTGGA,1,145,GCTCTTTT T C CTCTTTTCTC  TTC CTCTGC T T TCTCTCTTTT T C CTTTTTT T T TTTTTGTCTTCACTCTGTTCTGCCA  TCT C GAG CCG CAGAGAGA A A AGAGAGACAC AAT GAGACACTCT  ACACTCTGTG  CTCTGTGTGT T TGCTTGTGTTTT T G GTGTTTTTTT T T TTTTT CATG  AA TTTGCC T TGCG GCGCG CAA GCGCGTTCTTC CGCGCGCGCATG G GCGCGCGTT C CGCGTGTATA A G GTTACC T TATACACGCG G AACGCGCGC C CCGCGCGG G GCCTGCGTGT T C CGA AGTTTT T G GTGTTTTCTC C T TTTTCTCCCC C T TCTCCCCAA C CCCCACATAT T C CAAACTG G A ATATGTGTGT T T TGTGTGTGTG G GC AGTGTGGG T TGTCCGGTGT T GGGTCGCTC C G GTGTCTCA TCCA CATAT T C CACATCT T A ATATTTTTTT T T TTTTTTTATA A T TTTAAAA A T TATAAAATAT T A AAAATATCTC C A ATTCCCC C T TCTCCCCACA A C CCCCACAGAG C TCATCAGAGAGA A A AGAGAAA A G GAGAAAAAAA T T AAAAAAACAC  TG AAAACACTCT GC  ACACTTA A C CTTAAACCA T TATAA CAAC AACACAA A ACCATAT T CCATATTTT T A ATATTTC G CGG T CTCTCT T T TCTCTCTTTT T C CTCTTTTCTC  TTC TTCTCT T TTCATCTCTCCT C C CTCTCTCACA A T TCTCACAAA CTTGGG AACTGGC AACGAAC AGG A ACACCCGTGT  CGCGTGTGTG G G GTGTGAC T AC T TGTGCGCCCC C G GCGCCCA A C CCCCACACAC C C CACACTTCCT T A ACACTCTCTC  CTTCCCC GA  TCTGGCCACA A C CCCCACATAT T C CA CAA GTG G A AT ACTGGG GG T TGG TGGCGC  GGGGCGCA TCA G GC TCAC C C CATGCACTTC T AGTAACTCTATA A C CTCTAC GAT T T TATATATTTT T ATA TTCTC C T GATCTCT T T TCTCTCTGTG  CTGCGTGAGA CAGC ATGAGACAC C GTTCGAC AACC C A ACACCCCACA A C CCCCACAGG C CACAGCT CGT AGAGAGACAC C G GAGACACCCC  GT ACCG G C CCCCGCGCGC C C CGGC GCTCT T G GCGCTCTTTT T CCTTTC TC C T TTTTCTCTCT A ACACTCTCTATA A C CTCTAT CAG G T TATAGAGAGA A ACG AGAAA  CC GAGAAAA A A AAAAAAAGG AAAGAGTGT T A AGAGTTG  GTGTGTGAA T TGTGAAC AA TAGAG GAAAACGAAC AG TAACACTGA T A ACACTCTCTC A T CTTGATCGTCAG T TCTCGCGTGT TTCCGTCTCATTA G GTAA C CTAAC GAT T AAATATCTC C A ATTCGCG G T TCTCGCGGGG G C CGGGAGA ATG GGGGAGAGAG G G GAGAGCACGC C AGTGAGCGCTATTT G TGCTGG CG C CTTGGTGTGT T TTGTGTGTG  GTGTGTGAC TA TGCAATGGATAT  TT GAGATTC C A ATATCTCCCC C T TCTCCCCTCT T CA GCCTCTTTT A G CTCTTTTCTC C T TTTTCTCGCG TGG TCTCGCGTGT A T CGGTGTG G G GTGTGGG G T TGGGA,GCTCTT GCTC  CTTTCTCTCT  TTACTTCTCTTTT  CT TCTCTCTTTTTTT C GCTTTTTTTCTC TT  TTTTTTTCTCACA A T TTTTCTCACAGAG G T TCTCACAGAGAGA A C CACAGAGAGACAC C ATC AGAGACACTCT T G GAGACACTCTGTG G A ACACTGCGTGTGT T CCTGTGTGTTT TT T TGTGTGTTTTTTT T G GTTTTTTGTG G TACTTTGTGCGC AACGCGCG G T TGA TTTCCGCGC C G GCGCGCGCGCGCG A T CGCGCGCGGATGT T G GCTGCCGTGTATA A C CGCGTGTATGCCATTAC GTTACACGCG G TTTTTACACGCGTTC C A ACCGCGCGG C CGCGCGCGA AGT T GACCGCGCGTGTTTT  CGCGTTTCTC C G GTGTTTTCAG CC C T TTTTCTG CCACA G CAC TCCCCACAT TGT CTGTCCACATATGG C CAATGTGTGT ATGC GC CTG G T TGTTCGTGTGGG G GTGTGTGGGT T TTGGGGTGTCGC C GCAAGTCTCACA A G GTGTCTCAAC AT GCG TCTCACATATT CA CTTCCTT T A ATATTTTTTTATA A T TT TATTAAA A TA CTTATAATTCAT T T TATAAAATATCTC C A AATGAATCCC C AA AATCTCCCCAGTGA T TCTCCCCACAGTCCG C CCCAGAGAGA A CAGACAGAC GCTA AA AAGATAAAAATC A G GAACTGAAAACAC C A AAAAAACTCT T A AAAACACTCTA AGA A ACACTCTATTCAA  CTCTAAACAC ATC TAC TACACA  ATCT AACACACATAT T A ACACACATATTTT T C CAAC ATTTTCTC T A AT CTCT TTCTCT TCC TT T TCTCTCTTTTCTC ATG CTCTTTTCT CT T TTTGTTCTCTC CAC T TCTCTCTCTCACA T T CTATCCAAAA CA  TCAACCATC CT TGGTAACACGCG  AAT ACG CGTGT AACA CCGTTG G C CGCGTGTGTGCGC T C GTGTGGCCCC C TTGCGCCCCACA A G GCGCCCCACACGAAC C CCCACACTCT T C CACACACTCTCTC C A ACACTCC C C CTTCCCCACA A TACCTCCCCAAT T C CCCCAATGTG G C CACATATGTGGG A ATGTGTGGGGCGC T C TGTGGGGCCA A G GGGGCCACAC C GAATCACACTCT  CATGATTCCTATA CGTAAACTATATTCAT CTT CTATATATTTT T TTATATTTTCCTTC A ATATTTTCTCT AAT T TTTTCTCTCTGTCCG TCTTGA CTGTGAGA  CTCTGTGAGACAC C T TGTGAGACACCCC  CC GAGACACCCCACA A A ACCCAAG G CCCACAGGA A CGACTGTC A AGAGA GCAT C GGACCCGCG G A ACACCCCGCGCGC C C CCCCGCGCGCTCT T C CGCGCGCTCTT GCGCTTAA AGC C CTCTT TTA GCT T T TTTTCTCTCTACC  TCTCTCTATAGAG G C CTTAG AG TATAGAGAGAAAA A TTA AGAGAAAAAAA TCT GAGAAAAAAAGAG CAC AAAAAAAGAGTGT C ACTCAAGAGTGTGTG G AAGTGTGTGAGA  GTGTGTGAGAAAA A T TGG AGAA TCC G GAGAAAACACTCT GTA AAAACACTCTCTC CCA AC TTCTCTCGACGG C CTCTCTCG TGGT T TTCGCGTGTATA A C CGCGTT ATAAAA A G GTGTATAAAATAT T T TATAAAATTC C A AAAATATCTCG GGG A ATATCTCGCGGAGCG T TCTCGCGGGGAGA  AC CGCGGGGAGAGAG G GCG GGAAGCGC C G GAGAGAGCGCTCT T A AGGG GCTTG G G GCAA CTGTGTT CTTCCTGAC TG G TCGTTGTGTGTCTA G GTC GTGAGATAT T TAATCGTATCTC C G GAGATATCTCCCC C A ATC TTTTCCTCT T T TCTCCCCTCTTTT C T CCCCTTC TTCTC C C CTCTTTTCTCGCG G T TTTTCTCGCGCGT AA  TCTCGCGTGTGG C CGGTGTGGGG  GTGTGTGGGGA,GCTCTTTTCTCTCGCT CCTTTTCCAGCTTTT T T TTTTCTCTTTA CG TCATCCTTTTTTTCTC  CTTTTTTCCA A T TTGTTTCACAGAG G T TTAGTCAGAGAGA A T TCTCATCCAGAGACATCCAGAGAG CACTCT T ACGTAGATT ACTTGTTG  AA GA GCACTTGTTTCT ATGTACTCT TGTGTTCAT CTCTGTGTGTTTTTGAC TGGTTTTTTTGTG G G GTGTTTTTTTGTGC TTG TTTGTGCGCGCG G T TTTTGTGCGCGCGCGC C T TGGCGCGCGCGG GGACTCGCGCAGACGTGT T C CGGCGCGTGTATA A GC AGCGCGTGTATACAC TGATTTCGTGTATACACGGCAG G GTGTATACACG ACCG C T ACTACACGCGCG ACG CGC ACACGG AGCGCGTGT T C CGTGACGTTCTTT T G GCGCGCGTTTTTTCTC C C CGTAAGTTTTCTCCCC C G GTTTCTCCCCACA A T TTTTCTCCCCACATT T TCTCCCCACATATGTG  CCCCACATGT T C CACATATGTGTTG GCT ATATGTGTGTGTGGGG G T TGTGTGTGTGGGGTGT T G GTGTGTGGGGTGTCTC C T TGTGGGGTTCACA A G GGGGTGTCTCATT AT T GACTGTCTCACATATTTCAT T TCCGGAC TTTTT T C CACATATTTTTTTATA A A ATGAATTTTAAAA A T TTCTGTTATAAAATAT T T TTCTTAATATCTC  TATAATCCCC CCAAATCG G CCCACA G G ATATCTCCCCACAGAG  TCTCCCCACAGAGAGA  CCCCACAGCTCGAAAA A C CATGATGAGAAAAAA AGCGGAAAAAAACAC C G GAGAACTTAACACTCT T A AAAACACTCTATA A A AAAACACTCTATAAAA AA ACTCTGTAACTAAC C CT AAACTAA CTCA A T TA AACGCACACATAT T A AAAACACACATATTTT T A ACACACATATTGT TC C CTCACATTTCTCTCT  ATATTTTCCTTTT T T TTTCTA ATTCTC C T TCTCTCTTTTCTCTT C CTCTTTTCTTCTGATC C T TTTCTCTCTT A TA TTCTAG TCACA AA A C CTCTCTCACAAAACAC C T TCTCACAAAACCG G C CACAAAACACGCGTGT TAACTCACGCGTGTG GAGCG AGACG AGGAGGC C C CGGACGTGTGCGCCCC C G GTGTG ACCCACA C T TGTGCGCCCCACACAC  GCGACCCACACACTCTGT C CCCCACACACTCTCTC C C CACTCCC C ACTT GT ATTCCCCACA A C CTCTCTCCCCACATAT  TCTCCCCACATATGTG G C CCCCACATATGTGGGG GAC CACATATGGGCCTC GC ATATGGGCGCACA A T TGTGGGGCGA CACATTC G GGGGCGCACACACTCT T G GCGC CACACTCTATA A CCACACTCTATATAT T ATTTACTCTATATATTTGAT C CTCTATATATTTTCTC C T TAATTTTCCT T A ATATTTTCTCT ACGATTTT TTTTCTCTCTGTAGGA A TTA CTGAC C CGGACTGTGAAT ACCAA C TGCCACCCA A GCT GACACCG GCAGCTCG A TAACCCCACAGGG GA A C CCCCACAGAGACGTAC C C CACAGAGAGACACCCC C ACGGAGAGACACCCCGCG G G GAGACACCCCGCGCGC C A ACACCCCGCT  CACT T C CCCCGCGCGCTCTTTT T C CGCGCGCTAAATC C G GCGCTCTTTTCTCTCT T C CTCTTTTCTCTCTATA A TTTCTCTCTATAGAG G T TCTCTCTATAGAGAGA CTATAGGAAAA  TATGAAGAGAAAA A A AGATCGAAAAAAAGAG A A GAG AAAAAAGAGTGT T A AAAAAAAGAGTGTGTG G A AAAAGAGTGTGGCA AGTTCGTGTGAGAAA AA G GTGTGTGAATTTTCAC C T TGCT GAAAACACT GAT G GAGAAAACACTTC C A AAACTCTCAC CG G AGCCACTAACCGTGT T C CTCTCTCGCGTGTAGAA TCGCGCGTGTATAAAA A C CGCGTGTATAAAATAT T G GTGTATAAAATATCTC C TTAAAATATCTCGCG AATTCGCGGTGGG A ATATCTCGAACGGAGA A T TCCGGGGAGAGAG G C CGTCA CTTGCAGCGC C G GGGGAGAGAGCGCTTGAT G GAGAGAGCCTGTG G A AGAGCGCTCTATGTGT T GGCTCTGTGTGTGG C CTCTGTGTGTGGC  TC TGTGTGTG TAGATT GTATGTGGATC CTC C T TGTT GATAGATCCCC C GTG TG ATCTCCCCTCT AACATCTCCCCTCTTTT T T TCTCCCCTCTTTTCTC C C CCCCTCTTTTCTCGATCG C CTTT TCGCGTT T TTTTCTCGCGTGTGTG  TCTCGCGTGTGTGGAGATCCGGACGTGTGTGG,CTTGACTCTCTTTT TCCCTTTTCTCTC GATGTT CTT TTTTCCGCC CTTTTTCTC C TTCTTTTTTCCCACA A C CTCTTTTTTTCAG G T TTTTTTTCTCATCTAGAA T TTTTCTCACAGAGAGACC T TCGGTCAGAGATTCGTGAA T C CAT CAGAGACACTACGTG G A AGAGAACTTGTGT  GAGACACTCTGTGTGTTTT T A ACACTCTGTGTTT TTTT C CTCTGTGTGTTGTTTTGTG G T TGTGTGTTTTTTTGCG GC C G GTGTTTTT CCTGCGCGCG TTTTTGTGCGCGCGCGC C T TTTTGT GCGCGCGGCG TGTGCGCGCGCGCGCGTGT  GCGCGCGCGAAGTATA A CGGACGCGCGTACAC C G GCGCGCGTGTAAACCTGCG G CGGACGTGTAGCGACGCGCGC C G GTGTATACGACCGCGCGTGCG TTACCG CGCCGTTG GT  ATACGCGCGCGCGTTTTTT T C CGCGCGCGCGTGTTTTCC G GCGCGCGTTCTTTCTCCCC  CGCGTGTTCT TCCCA A GCGTCTTTTCTCCCCACATAT T T TTTCCCCACATATGTG G T TCGTGTCACATATGTGT AGT C CC ACTCAATGTGTGTGTG G C CACATTTTTGTGTGTGGGG G A ATTGTGTGTGGGT T T TGTGTGTGTGGGGTGTCTC C GACTAGATCACTCTCACA A T TGTGGGGTGTCTCACATAT  GGTCGGTCTCACATATTGTTT G GTGTCC CCGTATTTTTT T TCTCACAAATTTTTTTATA A C CAG GT CTTTTTAAA A A ATATTTTTTTATAAAATAT T T AATTAAATG TTC  TTTTATAAAATATCTCCTGGC T TATAAAATATCTCCCCACA A AATGAATATCTCCCCACAGAG G A ATATC CTCCACAG GTA TTCCC CCAGAGAGAAAA A CTTGCCACGCAGAAAACT CTC CACAGAGATTCAACAC C AGT AGAGAAAAAAACCT  GAGAAAACACT CCTA A AGTGAAAAACACTCTAAA  AATACACTGTGTT AACAC C A ACACTCTATAAAACACACA A C CTCTATAAAACACACATAT T TTAAAACACACATATTAACT AAACACACATATTTTCTC C A ACACAGAAATTTTCTCTCT T C CACATATTCACTCTCTTTT T A ATTG TTCTCTCTTTTCC T TTTTCTCTCCATTCTCTTGAT T TCGTTTTCTCTC C CTCTTGAAGTTCT TCACA A T TTTTCTCTA CTCACAAAA  TCTCTCTCAC C C CTCTCCATAACACGCG G T TCTCACAATT ACGCGTGT  CACAAACGCGTTTTTG G A AAAACACGCGTGTGTGCGC C A ACACGGT TGCGCCCC TAA CGCGTGTCTGCGCCCCACA A GGTGTGCGCCCCACACAC C T TGTGCGCCCCACACACTCT T G GCGCCCCATTCACTCTCC C CCCCACACACTTG TCCTCA CACACCTCTCCCCACA A A ACCTCTCCCCACATT CAG CTCTCCCCATAGATGTG A C TCTCC AATGGGG G CTCCCCATAGATGGGCGC C C CACATATGCC GGCGCACA A AT AATGTGGGGCGCACACAC GCTTGGGGCGCACACACTCT T G TTGGCGAACACACTCTATA A G GCGCACACACTCTATAT CACACACTCTATATATTTT CTTACTCTATATATTTTCTC GAACTATATATTTTCTCTTCG TATATGGATCTCTGTG G A ATATTTCTCTGTGAATT GGTTCTCTCTGTGAGACAC C T TCTCTAC TGAGACACCCC  CTCTGGA CAGACCCCACA A T TGACCCCACAGG G GAGACACCCCACAGGA A A ACACCCCACAGAGAGACAC C C CCCCACAGAGAGACACCCC CTT CACAGAGAACCCCGCG T GAGAA CACCCCGCGCGC C G GAGACACCCCGCGCC TCT T ACCAACCCCGCAGGCTTAAA T CCCCGTCTC TCTTTTCTC C C CGCGCCTTTTCTCTCTCT G GCGCTCTTTCCTCTCTATA A C CTT ATTCCTAAG ATC TTTTCTCTCTACATTGGGA A T TCTCTCTATAGAGAAA G T CTCTATAGAGAGAAAAAAA A T TAAGAGAAAAAAAGAG G A AGAGAAAAAAGAGTGT  AG GAGAAAAAAGTGTGATTG A AATCGAAGAGTGTGTGATGAA A AAAAGAGTGTGTGA CTAA A A AGAGTGTGTGACGTAACCTGCTT GTGTGAC CAACT T T TGTGACATAACACTCTCTC C GATCAACACT TGCG  AAAACACTCTCCGTG CT AACTGAATCGCGTGTATA GAC CTTCGGCTGTATAAAA AAA TCCTGCGTGTATAAAATT C CGTGTGTATAAAATATCTC C G GTGTATAAAATATCATCCG G T TATCGATCTCGCGGGG  AAAATATCT TCGGATTGA A A ATATCTCGCGGGGA CTG T TCTCGCGG CGGAGAGCGC C C CGCGG CGGAGAGCCATCT TGC GGGGAGAGAGCGCTCTGCTCCATGAGAGCGCTCTGATCGT  AGGCTCTGTGTGTGTG G GTCAGCTTGTGTGGAAGA A C CTCTGTGTGTGTGAT TTTCTGTCTATGAGATCGTTC C GAGA GAACGGATATCCTACC C T TGTGAGATTCGTCCCCTGCTTCCGATGAATCCCTTTT T A ATATCTCCCCTT TTTCTC C T TC TGCCTCTTTTCA TCG GT  CCCCTCTTTTCTAACGTGTGCAG CTCTTTTCTCGCGTTGAG T TTTTCTCGCGTGTGGG G T TCTCGGTGTGGGGA,"ID   VME1_SARS2              Reviewed;         222 AA.
AC   P0DTC5;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Membrane protein {ECO:0000255|HAMAP-Rule:MF_04202};
DE            Short=M;
DE   AltName: Full=E1 glycoprotein {ECO:0000255|HAMAP-Rule:MF_04202};
DE   AltName: Full=Matrix glycoprotein {ECO:0000255|HAMAP-Rule:MF_04202};
DE   AltName: Full=Membrane glycoprotein {ECO:0000255|HAMAP-Rule:MF_04202};
GN   ORFNames=M;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   SUBCELLULAR LOCATION.
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [3]
RP   INTERACTION WITH S PROTEIN, AND FUNCTION.
RX   PubMed=33229438; DOI=10.1074/jbc.ra120.016175;
RA   Boson B., Legros V., Zhou B., Siret E., Mathieu C., Cosset F.L.,
RA   Lavillette D., Denolly S.;
RT   ""The SARS-CoV-2 Envelope and Membrane proteins modulate maturation and
RT   retention of the Spike protein, allowing assembly of virus-like
RT   particles."";
RL   J. Biol. Chem. 296:100111-100111(2020).
RN   [4]
RP   GLYCOSYLATION AT ASN-5, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=38666819; DOI=10.3390/biology13040207;
RA   Schwarze M., Volke D., Rojas Echeverri J.C., Schick R., Lakowa N.,
RA   Gruenewald T., Wolf J., Borte S., Scholz M., Krizsan A., Hoffmann R.;
RT   ""Influence of Mutations and N-Glycosylation Sites in the Receptor-Binding
RT   Domain (RBD) and the Membrane Protein of SARS-CoV-2 Variants of Concern on
RT   Antibody Binding in ELISA."";
RL   Biology 13:1-21(2024).
RN   [5] {ECO:0007744|PDB:8CTK}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.52 ANGSTROMS), TOPOLOGY, AND
RP   GLYCOSYLATION AT ASN-5.
RX   PubMed=36264056; DOI=10.7554/elife.81702;
RA   Dolan K.A., Dutta M., Kern D.M., Kotecha A., Voth G.A., Brohawn S.G.;
RT   ""Structure of SARS-CoV-2 M protein in lipid nanodiscs."";
RL   Elife 11:1-16(2022).
RN   [6] {ECO:0007744|PDB:7VGR, ECO:0007744|PDB:7VGS}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.70 ANGSTROMS), SUBUNIT, MUTAGENESIS OF
RP   42-ARG--ARG-44, AND GLYCOSYLATION AT ASN-5.
RX   PubMed=35931673; DOI=10.1038/s41467-022-32019-3;
RA   Zhang Z., Nomura N., Muramoto Y., Ekimoto T., Uemura T., Liu K., Yui M.,
RA   Kono N., Aoki J., Ikeguchi M., Noda T., Iwata S., Ohto U., Shimizu T.;
RT   ""Structure of SARS-CoV-2 membrane protein essential for virus assembly."";
RL   Nat. Commun. 13:1-12(2022).
CC   -!- FUNCTION: Component of the viral envelope that plays a central role in
CC       virus morphogenesis and assembly via its interactions with other viral
CC       proteins (By similarity). Regulates the localization of S protein at
CC       cis-Golgi, the place of virus budding (PubMed:33229438). May act by
CC       binding cytoplasmic c-terminus of S (PubMed:33229438).
CC       {ECO:0000255|HAMAP-Rule:MF_04202, ECO:0000255|PROSITE-ProRule:PRU01275,
CC       ECO:0000269|PubMed:33229438}.
CC   -!- SUBUNIT: Homomultimer (PubMed:35931673). Interacts with envelope E
CC       protein in the budding compartment of the host cell, which is located
CC       between endoplasmic reticulum and the Golgi complex (By similarity).
CC       Forms a complex with S proteins (PubMed:33229438). Interacts with
CC       nucleocapsid N protein. This interaction probably participates in RNA
CC       packaging into the virus (PubMed:35931673). Interacts with the
CC       accessory proteins 3a and 7a (By similarity).
CC       {ECO:0000250|UniProtKB:P59596, ECO:0000255|HAMAP-Rule:MF_04202,
CC       ECO:0000269|PubMed:33229438, ECO:0000269|PubMed:35931673}.
CC   -!- INTERACTION:
CC       P0DTC5; P0DTD8: 7b; NbExp=4; IntAct=EBI-25475853, EBI-25475914;
CC       P0DTC5; P0DTC4: E; NbExp=5; IntAct=EBI-25475853, EBI-25475850;
CC       P0DTC5; P0DTC5: M; NbExp=4; IntAct=EBI-25475853, EBI-25475853;
CC       P0DTC5; P0DTC9: N; NbExp=6; IntAct=EBI-25475853, EBI-25475856;
CC       P0DTC5; Q9BYX4: IFIH1; Xeno; NbExp=3; IntAct=EBI-25475853, EBI-6115771;
CC       P0DTC5; Q7Z434: MAVS; Xeno; NbExp=11; IntAct=EBI-25475853, EBI-995373;
CC       P0DTC5; O00487: PSMD14; Xeno; NbExp=2; IntAct=EBI-25475853, EBI-722193;
CC       P0DTC5; Q9UHD2: TBK1; Xeno; NbExp=10; IntAct=EBI-25475853, EBI-356402;
CC   -!- SUBCELLULAR LOCATION: Virion membrane {ECO:0000255|HAMAP-
CC       Rule:MF_04202}; Multi-pass membrane protein {ECO:0000255|HAMAP-
CC       Rule:MF_04202}. Host Golgi apparatus membrane {ECO:0000255|HAMAP-
CC       Rule:MF_04202, ECO:0000269|PubMed:33060197}; Multi-pass membrane
CC       protein {ECO:0000255|HAMAP-Rule:MF_04202}. Host membrane
CC       {ECO:0000269|PubMed:33060197}; Multi-pass membrane protein.
CC       Note=Largely embedded in the lipid bilayer. {ECO:0000255|HAMAP-
CC       Rule:MF_04202}.
CC   -!- PTM: Glycosylated at N-terminus by host. {ECO:0000269|PubMed:35931673,
CC       ECO:0000269|PubMed:36264056, ECO:0000269|PubMed:38666819}.
CC   -!- POLYMORPHISM: Variant Delta/B.1.617.2 belongs to a lineage first
CC       isolated in India (October 2020) and is also called G/478K.V1. It has
CC       an estimated 97% increase of transmissibility. {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/BA.1 and BA.2 belong to a lineage first
CC       isolated in South Africa (November 2021). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/BQ.1.1 belongs to a lineage first
CC       isolated in Nigeria (November 2022). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/XBB.1.5 belongs to a lineage first
CC       isolated in United States (November 2022). It is the result of
CC       recombination between omicron BJ.1 and BM.1.1. Moreover XBB.1.5 do not
CC       express ORF8. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the betacoronaviruses M protein family.
CC       {ECO:0000255|HAMAP-Rule:MF_04202}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43419.1; -; Genomic_RNA.
DR   PDB; 7VGR; EM; 2.70 A; A/B=1-222.
DR   PDB; 7VGS; EM; 2.80 A; A/B=1-222.
DR   PDB; 8CME; X-ray; 2.26 A; C/F/I=176-190.
DR   PDB; 8CTK; EM; 3.52 A; A/B=1-222.
DR   PDBsum; 7VGR; -.
DR   PDBsum; 7VGS; -.
DR   PDBsum; 8CME; -.
DR   PDBsum; 8CTK; -.
DR   EMDB; EMD-26993; -.
DR   EMDB; EMD-31977; -.
DR   EMDB; EMD-31978; -.
DR   SMR; P0DTC5; -.
DR   BioGRID; 4383846; 2055.
DR   IntAct; P0DTC5; 270.
DR   MINT; P0DTC5; -.
DR   TCDB; 1.A.117.1.2; the coronavirus membrane matrix-protein (m-protein) family.
DR   GlyGen; P0DTC5; 1 site.
DR   iPTMnet; P0DTC5; -.
DR   ABCD; P0DTC5; 10 sequenced antibodies.
DR   DNASU; 43740571; -.
DR   KEGG; vg:43740571; -.
DR   AGR; RefSeq:YP_009724393; -.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-HSA-918233; TRAF3-dependent IRF activation pathway.
DR   Reactome; R-HSA-9694322; Virion Assembly and Release.
DR   Reactome; R-HSA-9694594; Maturation of protein M.
DR   Reactome; R-HSA-9694614; Attachment and Entry.
DR   Reactome; R-HSA-9694635; Translation of Structural Proteins.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   Reactome; R-HSA-9733458; Induction of Cell-Cell Fusion.
DR   Reactome; R-HSA-9754560; SARS-CoV-2 modulates autophagy.
DR   Reactome; R-HSA-9755779; SARS-CoV-2 targets host intracellular signalling and regulatory pathways.
DR   SIGNOR; P0DTC5; -.
DR   PRO; PR:P0DTC5; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0005793; C:endoplasmic reticulum-Golgi intermediate compartment; ISS:UniProt.
DR   GO; GO:0044178; C:host cell Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-UniRule.
DR   GO; GO:0055036; C:virion membrane; TAS:Reactome.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0140311; F:protein sequestering activity; IDA:UniProt.
DR   GO; GO:0039660; F:structural constituent of virion; IDA:UniProt.
DR   GO; GO:0039709; P:cytoplasmic capsid assembly; IDA:UniProt.
DR   GO; GO:0039545; P:symbiont-mediated suppression of host cytoplasmic pattern recognition receptor signaling pathway via inhibition of MAVS activity; IDA:UniProt.
DR   GO; GO:0019049; P:virus-mediated perturbation of host defense response; IEA:UniProtKB-KW.
DR   CDD; cd21569; SARS-like-CoV_M; 1.
DR   HAMAP; MF_04202; BETA_CORONA_M; 1.
DR   InterPro; IPR002574; M_CoV.
DR   InterPro; IPR044361; M_SARS-like-CoV.
DR   Pfam; PF01635; CoV_M; 1.
DR   PROSITE; PS51927; COV_M; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Glycoprotein; Host Golgi apparatus; Host membrane;
KW   Host-virus interaction; Membrane; Reference proteome; Transmembrane;
KW   Transmembrane helix; Viral envelope protein; Viral immunoevasion;
KW   Viral matrix protein; Virion.
FT   CHAIN           1..222
FT                   /note=""Membrane protein""
FT                   /id=""PRO_0000449652""
FT   TOPO_DOM        2..16
FT                   /note=""Virion surface""
FT                   /evidence=""ECO:0000269|PubMed:36264056""
FT   TRANSMEM        17..36
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:36264056""
FT   TOPO_DOM        37..44
FT                   /note=""Intravirion""
FT                   /evidence=""ECO:0000269|PubMed:36264056""
FT   TRANSMEM        45..70
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:36264056""
FT   TOPO_DOM        71..75
FT                   /note=""Virion surface""
FT                   /evidence=""ECO:0000269|PubMed:36264056""
FT   TRANSMEM        76..105
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:36264056""
FT   TOPO_DOM        106..222
FT                   /note=""Intravirion""
FT                   /evidence=""ECO:0000269|PubMed:36264056""
FT   CARBOHYD        5
FT                   /note=""N-linked (GlcNAc...) asparagine; by host""
FT                   /evidence=""ECO:0000269|PubMed:35931673,
FT                   ECO:0000269|PubMed:36264056, ECO:0000269|PubMed:38666819""
FT   VARIANT         3
FT                   /note=""D -> G (in strain: Omicron/BA.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         3
FT                   /note=""D -> N (in strain: Omicron/BA.5, Omicron/BQ.1.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         19
FT                   /note=""Q -> E (in strain: Omicron/BA.1, Omicron/BA.2,
FT                   Omicron/BA.2.12.1, Omicron/BA.2.75, Omicron/BA.4,
FT                   Omicron/BA.5, Omicron/BQ.1.1, Omicron/XBB.1.5,
FT                   Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         63
FT                   /note=""A -> T (in strain: Omicron/BA.1, Omicron/BA.2,
FT                   Omicron/BA.2.12.1, Omicron/BA.2.75, Omicron/BA.4,
FT                   Omicron/BA.5, Omicron/BQ.1.1, Omicron/XBB.1.5,
FT                   Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         82
FT                   /note=""I -> T (in strain: Eta/B.1.525 and Delta/B.1.617.2)""
FT                   /evidence=""ECO:0000305""
FT   MUTAGEN         42..44
FT                   /note=""RNR->ANA: Partial loss of N-RNA binding.""
FT                   /evidence=""ECO:0000269|PubMed:35931673""
FT   HELIX           11..36
FT                   /evidence=""ECO:0007829|PDB:7VGR""
FT   TURN            40..42
FT                   /evidence=""ECO:0007829|PDB:7VGR""
FT   HELIX           44..70
FT                   /evidence=""ECO:0007829|PDB:7VGR""
FT   HELIX           77..105
FT                   /evidence=""ECO:0007829|PDB:7VGR""
FT   HELIX           109..112
FT                   /evidence=""ECO:0007829|PDB:7VGR""
FT   STRAND          117..135
FT                   /evidence=""ECO:0007829|PDB:7VGR""
FT   STRAND          138..140
FT                   /evidence=""ECO:0007829|PDB:7VGR""
FT   TURN            145..147
FT                   /evidence=""ECO:0007829|PDB:7VGR""
FT   STRAND          149..151
FT                   /evidence=""ECO:0007829|PDB:7VGR""
FT   STRAND          154..157
FT                   /evidence=""ECO:0007829|PDB:7VGR""
FT   STRAND          167..170
FT                   /evidence=""ECO:0007829|PDB:7VGR""
FT   STRAND          172..174
FT                   /evidence=""ECO:0007829|PDB:7VGR""
FT   STRAND          177..182
FT                   /evidence=""ECO:0007829|PDB:7VGR""
FT   STRAND          188..190
FT                   /evidence=""ECO:0007829|PDB:7VGR""
FT   STRAND          195..200
FT                   /evidence=""ECO:0007829|PDB:7VGR""
SQ   SEQUENCE   222 AA;  25147 MW;  ED44D84C3BB9A6DB CRC64;
     MADSNGTITV EELKKLLEQW NLVIGFLFLT WICLLQFAYA NRNRFLYIIK LIFLWLLWPV
     TLACFVLAAV YRINWITGGI AIAMACLVGL MWLSYFIASF RLFARTRSMW SFNPETNILL
     NVPLHGTILT RPLLESELVI GAVILRGHLR IAGHHLGRCD IKDLPKEITV ATSRTLSYYK
     LGASQRVAGD SGFAAYSRYR IGNYKLNTDH SSSSDNIALL VQ
//
",17889
ATGTTT TGTTTG GTTTGT TTTGTA TTGTAC TGTACG GTACGC TACGCG ACGCGT CGCGTA GCGTAA CGTAAG GTAAGA TAAGAT AAGATC AGATCG GATCGT ATCGTC TCGTCG CGTCGG GTCGGC TCGGCA CGGCAG GGCAGC GCAGCG CAGCGT AGCGTC GCGTCA CGTCAG GTCAGA TCAGAT CAGATG AGATGA GATGAG ATGAGT TGAGTA GAGTAT AGTATA GTATAA TATAAG ATAAGA TAAGAG AAGAGA AGAGAG GAGAGA AGAGAG GAGAGG AGAGGC GAGGCT AGGCTG GGCTGA GCTGAA CTGAAT TGAATG GAATGT AATGTA ATGTAC TGTACA GTACAA TACAAT ACAATT CAATTT AATTTT ATTTTT TTTTTA TTTTAA TTTAAA TTAAAG TAAAGA AAAGAT AAGATG AGATGG GATGGT ATGGTT TGGTTC GGTTCA GTTCAG TTCAGA TCAGAT CAGATA AGATAG GATAGG ATAGGC TAGGCC AGGCCA GGCCAG GCCAGT CCAGTA CAGTAC AGTACC GTACCA TACCAT ACCATA CCATAT CATATT ATATTG TATTGT ATTGTT TTGTTA TGTTAT GTTATG TTATGA TATGAT ATGATA TGATAC GATACC ATACCA TACCAA ACCAAT CCAATG CAATGT AATGTA ATGTAC TGTACT GTACTA TACTAG ACTAGA CTAGAA,0,118,ATGT TGTT GTTT TTTG TTGT TGTA GTAC TACG ACGC CGCG GCGT CGTA GTAA TAAG AAGA AGAT GATC ATCG TCGT CGTC GTCG TCGG CGGC GGCA GCAG CAGC AGCG GCGT CGTC GTCA TCAG CAGA AGAT GATG ATGA TGAG GAGT AGTA GTAT TATA ATAA TAAG AAGA AGAG GAGA AGAG GAGA AGAG GAGG AGGC GGCT GCTG CTGA TGAA GAAT AATG ATGT TGTA GTAC TACA ACAA CAAT AATT ATTT TTTT TTTT TTTA TTAA TAAA AAAG AAGA AGAT GATG ATGG TGGT GGTT GTTC TTCA TCAG CAGA AGAT GATA ATAG TAGG AGGC GGCC GCCA CCAG CAGT AGTA GTAC TACC ACCA CCAT CATA ATAT TATT ATTG TTGT TGTT GTTA TTAT TATG ATGA TGAT GATA ATAC TACC ACCA CCAA CAAT AATG ATGT TGTA GTAC TACT ACTA CTAG TAGA AGAA,ATGTT TGTTT GTTTG TTTGT TTGTA TGTAC GTACG TACGC ACGCG CGCGT GCGTA CGTAA GTAAG TAAGA AAGAT AGATC GATCG ATCGT TCGTC CGTCG GTCGG TCGGC CGGCA GGCAG GCAGC CAGCG AGCGT GCGTC CGTCA GTCAG TCAGA CAGAT AGATG GATGA ATGAG TGAGT GAGTA AGTAT GTATA TATAA ATAAG TAAGA AAGAG AGAGA GAGAG AGAGA GAGAG AGAGG GAGGC AGGCT GGCTG GCTGA CTGAA TGAAT GAATG AATGT ATGTA TGTAC GTACA TACAA ACAAT CAATT AATTT ATTTT TTTTT TTTTA TTTAA TTAAA TAAAG AAAGA AAGAT AGATG GATGG ATGGT TGGTT GGTTC GTTCA TTCAG TCAGA CAGAT AGATA GATAG ATAGG TAGGC AGGCC GGCCA GCCAG CCAGT CAGTA AGTAC GTACC TACCA ACCAT CCATA CATAT ATATT TATTG ATTGT TTGTT TGTTA GTTAT TTATG TATGA ATGAT TGATA GATAC ATACC TACCA ACCAA CCAAT CAATG AATGT ATGTA TGTAC GTACT TACTA ACTAG CTAGA TAGAA,ATGTTT TGTTTG GTTTGT TTTGTA TTGTAC TGTACG GTACGC TACGCG ACGCGT CGCGTA GCGTAA CGTAAG GTAAGA TAAGAT AAGATC AGATCG GATCGT ATCGTC TCGTCG CGTCGG GTCGGC TCGGCA CGGCAG GGCAGC GCAGCG CAGCGT AGCGTC GCGTCA CGTCAG GTCAGA TCAGAT CAGATG AGATGA GATGAG ATGAGT TGAGTA GAGTAT AGTATA GTATAA TATAAG ATAAGA TAAGAG AAGAGA AGAGAG GAGAGA AGAGAG GAGAGG AGAGGC GAGGCT AGGCTG GGCTGA GCTGAA CTGAAT TGAATG GAATGT AATGTA ATGTAC TGTACA GTACAA TACAAT ACAATT CAATTT AATTTT ATTTTT TTTTTA TTTTAA TTTAAA TTAAAG TAAAGA AAAGAT AAGATG AGATGG GATGGT ATGGTT TGGTTC GGTTCA GTTCAG TTCAGA TCAGAT CAGATA AGATAG GATAGG ATAGGC TAGGCC AGGCCA GGCCAG GCCAGT CCAGTA CAGTAC AGTACC GTACCA TACCAT ACCATA CCATAT CATATT ATATTG TATTGT ATTGTT TTGTTA TGTTAT GTTATG TTATGA TATGAT ATGATA TGATAC GATACC ATACCA TACCAA ACCAAT CCAATG CAATGT AATGTA ATGTAC TGTACT GTACTA TACTAG ACTAGA CTAGAA,ATGTTTG TGTTTGT GTTTGTA TTTGTAC TTGTACG TGTACGC GTACGCG TACGCGT ACGCGTA CGCGTAA GCGTAAG CGTAAGA GTAAGAT TAAGATC AAGATCG AGATCGT GATCGTC ATCGTCG TCGTCGG CGTCGGC GTCGGCA TCGGCAG CGGCAGC GGCAGCG GCAGCGT CAGCGTC AGCGTCA GCGTCAG CGTCAGA GTCAGAT TCAGATG CAGATGA AGATGAG GATGAGT ATGAGTA TGAGTAT GAGTATA AGTATAA GTATAAG TATAAGA ATAAGAG TAAGAGA AAGAGAG AGAGAGA GAGAGAG AGAGAGG GAGAGGC AGAGGCT GAGGCTG AGGCTGA GGCTGAA GCTGAAT CTGAATG TGAATGT GAATGTA AATGTAC ATGTACA TGTACAA GTACAAT TACAATT ACAATTT CAATTTT AATTTTT ATTTTTA TTTTTAA TTTTAAA TTTAAAG TTAAAGA TAAAGAT AAAGATG AAGATGG AGATGGT GATGGTT ATGGTTC TGGTTCA GGTTCAG GTTCAGA TTCAGAT TCAGATA CAGATAG AGATAGG GATAGGC ATAGGCC TAGGCCA AGGCCAG GGCCAGT GCCAGTA CCAGTAC CAGTACC AGTACCA GTACCAT TACCATA ACCATAT CCATATT CATATTG ATATTGT TATTGTT ATTGTTA TTGTTAT TGTTATG GTTATGA TTATGAT TATGATA ATGATAC TGATACC GATACCA ATACCAA TACCAAT ACCAATG CCAATGT CAATGTA AATGTAC ATGTACT TGTACTA GTACTAG TACTAGA ACTAGAA,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",62930
GCCACC CCACCA CACCAC ACCACC CCACCA CACCAC ACCACC CCACCG CACCGA ACCGAC CCGACA CGACAC GACACG ACACGT CACGTT ACGTTC CGTTCG GTTCGA TTCGAG TCGAGG CGAGGC GAGGCC AGGCCG GGCCGA GCCGAC CCGACG CGACGT GACGTC ACGTCG CGTCGC GTCGCC TCGCCA CGCCAT GCCATA CCATAT CATATC ATATCA TATCAG ATCAGG TCAGGC CAGGCG AGGCGA GGCGAG GCGAGA CGAGAC GAGACC AGACCA GACCAT ACCATC CCATCG CATCGC ATCGCG TCGCGG CGCGGC GCGGCG CGGCGA GGCGAT GCGATC CGATCG GATCGG ATCGGC TCGGCC CGGCCA GGCCAC GCCACG CCACGG CACGGG ACGGGC CGGGCT GGGCTG GGCTGG GCTGGG CTGGGG TGGGGC GGGGCC GGGCCT GGCCTG GCCTGC CCTGCG CTGCGA TGCGAA GCGAAG CGAAGC GAAGCG AAGCGC AGCGCG GCGCGA CGCGAG GCGAGA CGAGAT GAGATC AGATCG GATCGA ATCGAC TCGACG CGACGC GACGCG ACGCGC CGCGCG GCGCGC CGCGCG GCGCGG CGCGGC GCGGCA CGGCAA GGCAAA GCAAAT CAAATA AAATAT AATATG ATATGT TATGTG ATGTGC TGTGCT GTGCTG TGCTGC GCTGCC CTGCCC TGCCCG GCCCGG CCCGGC CCGGCG CGGCGG GGCGGC GCGGCG CGGCGT GGCGTC GCGTCG CGTCGA GTCGAC TCGACA CGACAG GACAGC ACAGCC CAGCCA AGCCAT GCCATT CCATTG CATTGC ATTGCC TTGCCA TGCCAT,3,142,GCCA CCAC CACC ACCA CCAC CACC ACCA CCAC CACC ACCG CCGA CGAC GACA ACAC CACG ACGT CGTT GTTC TTCG TCGA CGAG GAGG AGGC GGCC GCCG CCGA CGAC GACG ACGT CGTC GTCG TCGC CGCC GCCA CCAT CATA ATAT TATC ATCA TCAG CAGG AGGC GGCG GCGA CGAG GAGA AGAC GACC ACCA CCAT CATC ATCG TCGC CGCG GCGG CGGC GGCG GCGA CGAT GATC ATCG TCGG CGGC GGCC GCCA CCAC CACG ACGG CGGG GGGC GGCT GCTG CTGG TGGG GGGG GGGC GGCC GCCT CCTG CTGC TGCG GCGA CGAA GAAG AAGC AGCG GCGC CGCG GCGA CGAG GAGA AGAT GATC ATCG TCGA CGAC GACG ACGC CGCG GCGC CGCG GCGC CGCG GCGG CGGC GGCA GCAA CAAA AAAT AATA ATAT TATG ATGT TGTG GTGC TGCT GCTG CTGC TGCC GCCC CCCG CCGG CGGC GGCG GCGG CGGC GGCG GCGT CGTC GTCG TCGA CGAC GACA ACAG CAGC AGCC GCCA CCAT CATT ATTG TTGC TGCC GCCA CCAT,GCCAC CCACC CACCA ACCAC CCACC CACCA ACCAC CCACC CACCG ACCGA CCGAC CGACA GACAC ACACG CACGT ACGTT CGTTC GTTCG TTCGA TCGAG CGAGG GAGGC AGGCC GGCCG GCCGA CCGAC CGACG GACGT ACGTC CGTCG GTCGC TCGCC CGCCA GCCAT CCATA CATAT ATATC TATCA ATCAG TCAGG CAGGC AGGCG GGCGA GCGAG CGAGA GAGAC AGACC GACCA ACCAT CCATC CATCG ATCGC TCGCG CGCGG GCGGC CGGCG GGCGA GCGAT CGATC GATCG ATCGG TCGGC CGGCC GGCCA GCCAC CCACG CACGG ACGGG CGGGC GGGCT GGCTG GCTGG CTGGG TGGGG GGGGC GGGCC GGCCT GCCTG CCTGC CTGCG TGCGA GCGAA CGAAG GAAGC AAGCG AGCGC GCGCG CGCGA GCGAG CGAGA GAGAT AGATC GATCG ATCGA TCGAC CGACG GACGC ACGCG CGCGC GCGCG CGCGC GCGCG CGCGG GCGGC CGGCA GGCAA GCAAA CAAAT AAATA AATAT ATATG TATGT ATGTG TGTGC GTGCT TGCTG GCTGC CTGCC TGCCC GCCCG CCCGG CCGGC CGGCG GGCGG GCGGC CGGCG GGCGT GCGTC CGTCG GTCGA TCGAC CGACA GACAG ACAGC CAGCC AGCCA GCCAT CCATT CATTG ATTGC TTGCC TGCCA GCCAT,GCCACC CCACCA CACCAC ACCACC CCACCA CACCAC ACCACC CCACCG CACCGA ACCGAC CCGACA CGACAC GACACG ACACGT CACGTT ACGTTC CGTTCG GTTCGA TTCGAG TCGAGG CGAGGC GAGGCC AGGCCG GGCCGA GCCGAC CCGACG CGACGT GACGTC ACGTCG CGTCGC GTCGCC TCGCCA CGCCAT GCCATA CCATAT CATATC ATATCA TATCAG ATCAGG TCAGGC CAGGCG AGGCGA GGCGAG GCGAGA CGAGAC GAGACC AGACCA GACCAT ACCATC CCATCG CATCGC ATCGCG TCGCGG CGCGGC GCGGCG CGGCGA GGCGAT GCGATC CGATCG GATCGG ATCGGC TCGGCC CGGCCA GGCCAC GCCACG CCACGG CACGGG ACGGGC CGGGCT GGGCTG GGCTGG GCTGGG CTGGGG TGGGGC GGGGCC GGGCCT GGCCTG GCCTGC CCTGCG CTGCGA TGCGAA GCGAAG CGAAGC GAAGCG AAGCGC AGCGCG GCGCGA CGCGAG GCGAGA CGAGAT GAGATC AGATCG GATCGA ATCGAC TCGACG CGACGC GACGCG ACGCGC CGCGCG GCGCGC CGCGCG GCGCGG CGCGGC GCGGCA CGGCAA GGCAAA GCAAAT CAAATA AAATAT AATATG ATATGT TATGTG ATGTGC TGTGCT GTGCTG TGCTGC GCTGCC CTGCCC TGCCCG GCCCGG CCCGGC CCGGCG CGGCGG GGCGGC GCGGCG CGGCGT GGCGTC GCGTCG CGTCGA GTCGAC TCGACA CGACAG GACAGC ACAGCC CAGCCA AGCCAT GCCATT CCATTG CATTGC ATTGCC TTGCCA TGCCAT,GCCACCA CCACCAC CACCACC ACCACCA CCACCAC CACCACC ACCACCG CCACCGA CACCGAC ACCGACA CCGACAC CGACACG GACACGT ACACGTT CACGTTC ACGTTCG CGTTCGA GTTCGAG TTCGAGG TCGAGGC CGAGGCC GAGGCCG AGGCCGA GGCCGAC GCCGACG CCGACGT CGACGTC GACGTCG ACGTCGC CGTCGCC GTCGCCA TCGCCAT CGCCATA GCCATAT CCATATC CATATCA ATATCAG TATCAGG ATCAGGC TCAGGCG CAGGCGA AGGCGAG GGCGAGA GCGAGAC CGAGACC GAGACCA AGACCAT GACCATC ACCATCG CCATCGC CATCGCG ATCGCGG TCGCGGC CGCGGCG GCGGCGA CGGCGAT GGCGATC GCGATCG CGATCGG GATCGGC ATCGGCC TCGGCCA CGGCCAC GGCCACG GCCACGG CCACGGG CACGGGC ACGGGCT CGGGCTG GGGCTGG GGCTGGG GCTGGGG CTGGGGC TGGGGCC GGGGCCT GGGCCTG GGCCTGC GCCTGCG CCTGCGA CTGCGAA TGCGAAG GCGAAGC CGAAGCG GAAGCGC AAGCGCG AGCGCGA GCGCGAG CGCGAGA GCGAGAT CGAGATC GAGATCG AGATCGA GATCGAC ATCGACG TCGACGC CGACGCG GACGCGC ACGCGCG CGCGCGC GCGCGCG CGCGCGG GCGCGGC CGCGGCA GCGGCAA CGGCAAA GGCAAAT GCAAATA CAAATAT AAATATG AATATGT ATATGTG TATGTGC ATGTGCT TGTGCTG GTGCTGC TGCTGCC GCTGCCC CTGCCCG TGCCCGG GCCCGGC CCCGGCG CCGGCGG CGGCGGC GGCGGCG GCGGCGT CGGCGTC GGCGTCG GCGTCGA CGTCGAC GTCGACA TCGACAG CGACAGC GACAGCC ACAGCCA CAGCCAT AGCCATT GCCATTG CCATTGC CATTGCC ATTGCCA TTGCCAT,"ID   NDED_ALCXX              Reviewed;         488 AA.
AC   P94211;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1997, sequence version 1.
DT   05-FEB-2025, entry version 110.
DE   RecName: Full=N-acyl-D-glutamate deacylase {ECO:0000305};
DE            EC=3.5.1.82 {ECO:0000269|PubMed:8537313};
DE   AltName: Full=D-AGase {ECO:0000303|PubMed:8537313};
DE   AltName: Full=N-acyl-D-glutamate amidohydrolase {ECO:0000303|PubMed:8537313};
GN   Name=dag {ECO:0000303|PubMed:8537313};
OS   Alcaligenes xylosoxydans xylosoxydans (Achromobacter xylosoxidans).
OC   Bacteria; Pseudomonadota; Betaproteobacteria; Burkholderiales;
OC   Alcaligenaceae; Achromobacter.
OX   NCBI_TaxID=85698;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], PROTEIN SEQUENCE OF 1-20, CATALYTIC
RP   ACTIVITY, ACTIVITY REGULATION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RC   STRAIN=A-6;
RX   PubMed=8537313; DOI=10.1093/oxfordjournals.jbchem.a124879;
RA   Wakayama M., Ashika T., Miyamoto Y., Yoshikawa T., Sonoda Y., Sakai K.,
RA   Moriguchi M.;
RT   ""Primary structure of N-acyl-D-glutamate amidohydrolase from Alcaligenes
RT   xylosoxydans subsp. xylosoxydans A-6."";
RL   J. Biochem. 118:204-209(1995).
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=an N-acyl-D-glutamate + H2O = D-glutamate + a carboxylate;
CC         Xref=Rhea:RHEA:12833, ChEBI:CHEBI:15377, ChEBI:CHEBI:17503,
CC         ChEBI:CHEBI:29067, ChEBI:CHEBI:29986; EC=3.5.1.82;
CC         Evidence={ECO:0000269|PubMed:8537313};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC   -!- ACTIVITY REGULATION: Inhibited by cobalt, copper and EDTA.
CC       {ECO:0000269|PubMed:8537313}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Optimum pH is 7.5. {ECO:0000269|PubMed:8537313};
CC       Temperature dependence:
CC         Optimum temperature is 55 degrees Celsius.
CC         {ECO:0000269|PubMed:8537313};
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the metallo-dependent hydrolases superfamily. N-
CC       acyl-D-amino-acid deacylase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D50061; BAA08778.1; -; Genomic_DNA.
DR   PIR; JC4165; JC4165.
DR   RefSeq; WP_006384305.1; NZ_LN890476.1.
DR   AlphaFoldDB; P94211; -.
DR   SMR; P94211; -.
DR   PATRIC; fig|85698.22.peg.5897; -.
DR   eggNOG; COG3653; Bacteria.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0047421; F:N-acyl-D-glutamate deacylase activity; IEA:UniProtKB-EC.
DR   CDD; cd01297; D-aminoacylase; 1.
DR   Gene3D; 3.30.1490.130; D-aminoacylase. Domain 3; 1.
DR   Gene3D; 3.20.20.140; Metal-dependent hydrolases; 1.
DR   Gene3D; 2.30.40.10; Urease, subunit C, domain 1; 1.
DR   InterPro; IPR013108; Amidohydro_3.
DR   InterPro; IPR023100; D-aminoacylase_insert_dom_sf.
DR   InterPro; IPR011059; Metal-dep_hydrolase_composite.
DR   InterPro; IPR032466; Metal_Hydrolase.
DR   InterPro; IPR050378; Metallo-dep_Hydrolases_sf.
DR   PANTHER; PTHR11647:SF1; COLLAPSIN RESPONSE MEDIATOR PROTEIN; 1.
DR   PANTHER; PTHR11647; HYDRANTOINASE/DIHYDROPYRIMIDINASE FAMILY MEMBER; 1.
DR   Pfam; PF07969; Amidohydro_3; 2.
DR   SUPFAM; SSF51338; Composite domain of metallo-dependent hydrolases; 1.
DR   SUPFAM; SSF51556; Metallo-dependent hydrolases; 1.
PE   1: Evidence at protein level;
KW   Cytoplasm; Direct protein sequencing; Hydrolase; Zinc.
FT   CHAIN           1..488
FT                   /note=""N-acyl-D-glutamate deacylase""
FT                   /id=""PRO_0000182705""
SQ   SEQUENCE   488 AA;  51493 MW;  F5A1B8315BEA167F CRC64;
     MQEKLDLVIE GGWVIDGLGG PRRRADVGIR GERIAAIGDL SAAPADRRLD AGGRIVAPGF
     IDTHGHDDLM FVEKPGLEWK TSQGITSVVV GNCGISGAPA PLPGNTAAAL ALLGDSPLFA
     DMAMYFGALE AQRPMINVAA LVGHANLRLA AMRDPAAQPS AKEQRAMERM LADALEAGAV
     GFSTGLAYQP GGVAEQAELD GLARVAAARG ALHTSHIRNE GDAVEAAVDE VLAVGRRTGC
     ATVLSHHKCM MPANWGKSAA TLANIDRARA AGVDVALDIY PYPGSSTILI PERADQIDDI
     RITWSTPHPE CGGQSLAEIA ARWGCDAVTA ARRLCPAGAI YFAMDENEVR RIFQHECCMV
     GSDGLPNDAH PHPRLWGSFT RVLGRYVREA ELLTLEAAVA KMTALPARVF GLADRGRLAV
     GAWADVVVFD ADTVCDRATW DAPTLASAGI EHVLVNGCAV FPQAPPSHRP GRILRRDASI
     AGAPEFSR
//
",41338
TCTCCT CTCCTA TCCTAC CCTACT CTACTA TACTAA ACTAAA CTAAAT TAAATT AAATTA AATTAA ATTAAA TTAAAT TAAATG AAATGA AATGAT ATGATC TGATCT GATCTC ATCTCT TCTCTG CTCTGC TCTGCT CTGCTT TGCTTT GCTTTA CTTTAC TTTACT TTACTA TACTAA ACTAAT CTAATG TAATGT AATGTC ATGTCT TGTCTA GTCTAT TCTATG CTATGC TATGCA ATGCAG TGCAGA GCAGAT CAGATT AGATTC GATTCA ATTCAT TTCATT TCATTT CATTTG ATTTGT TTTGTA TTGTAA TGTAAT GTAATT TAATTA AATTAG ATTAGA TTAGAG TAGAGG AGAGGT,1,61,TCTCTCTC C CA GTCCC T TCTCCCCTCT T C CCCCTCTAAA A C CTCTATACAC C T TAACTCT TGC ACACTCTAA C CTTT TAAAA A T TA TGAAATA A A AAAAAAATAT TAA AAAATATTTT A G ATATTTTAA T TTTTATAAAA  TAAC AAATTAA A AATGCAATAT T A AAAATG A ATATGTGAGA A T TGTGAGATAT T G GAATCGC C A ATTGC TACT T T TCTCTCTCTT CTCTCTT TGG TCTCTGTG G CAGACTGT AGC C TTAA GAGCTCTAT GGCTTT T CCTTTTTCTAT T TTTTTAA TA A T TTTTATAC GCC TTCTACTCT T A ACGA CTATA A C CTA TTAAAA A T TATAAAT T A AAAATATGTG G AAGGATGTGTGT T T TGA CTC C G GTCT T T TCTCTCT TA TGT CTCTATATAT T TC TTATATGTG G AATTATGTGCTC C TATTGCACA CTCT AGCACAGAG CAGACTA A AG CTGATA TT G GAGAT ATTT T A ATATTGGTTC  TTTTCTCACA A T TCTCACATAT T C CACATATTTT T A AT TGCTA CTT T TTTTTTTGTG G TGA TTGTGTT T TGTGTGTATA T A GTAGATAAAA  TATAAAATAT T A AAAATATTTT T A ATTTATA  TTTTATAGAG G T TATAGGTA TT AGAGAAG G GAAAGAG AT TCG A AGAGGTTC,T CCTCTCCCC C C CTCTCTT CCTTG T T TCTCC CTCTATA  TGCCTCTATACCT  CTCTACTTACTT AT T TATACACTCTAA A ACACTTAAAA A CAATCTATAAAAAAA TGT TATAAAAAA TAT  AAAAA TTATTTT T A AAAATATTTTATTCA ACATATTTTATAAAA A T TTTTATAAAAAAA  TATAAAATAT T A AAAAAAATATG AACCTATGTGAGA A A ATATGTGAT TA TT T TGTGATTAATCTC C G GAGATATCTCTCT T A ATATCTCTCTCTC C T TCTCTCTCTCTCT T C CTCTCTCTCTGTG G T TCTCTAATTGCGC C C CTCTGTGCGCTCT ATTA CTGCGCTATGA G GCGCTCTTTTTTT TCT CTCTTTTTTTAAATAT TTTTTATACAC C T TTTTATACACTCT T T TATACACTCTATA A A ACCTATAAAA A C CTCTATAAAATAT T TTAAAATTACTG G A AAAATGAGCTGGT T A ATT GTGTGTCTC C T TGTCAGTCTCT CCT G GTGTCGATCTATA A T CACTATATAT T C CTCTATAGATGTG G T TATATATGTGCC A ATATGATTGCAA T TGTGCGCACAGG G GCGCACAGAGAGA A C CACAGAGAGATAT T A AGAGAGATGATTT ATG GAATTGATTA TC C ATATATTTTCTCACA A T TTTTCTGTCATAT T T TCTCA ATATT ATTCTCATATTTTTTT CT  ATTTTTTGTG G T TTTTTTTGTGTGT T TTGTGTATA  TCGTATAAAA T G GTGTATAAAATAT T T TA AGAATATTTGTT A AAAATATTTCTTA  ATTGCTCCAG G T TTTTATAGAGAGA A T TATAGAGAAG G ATAAAGAGAGAGGGG G G GAATGAGGGGT,GT TCTTCC TAAGAT C CTCTCCCTTA A TTTTTCCCCTCTA ATAAT CCCCTAT TACACTCT T CCTATACACTCTATA A T TAGTCACTCTA CAAA GAT ACACTCTATAAAAAAA A C CTCTATAAAAAAATAT TAAAAAAATATTTT AAAAATATTTTATA A A AAC CATTTTATAAAA A A ATATTTTATAAGC AA A T TTTTAAAAAATAT GATCCTTAAAAAAATATGTG G A AAAAAAATATGTGAGA A A AAAATTACTGAGATAT T ATACTTTTGATT ATCATGC T TGTGAGATA ATCTCT T G GAA AATCTCTCTCTC C AATCATCCTCTCTCT T T TCCTCTCTCTGTG  CTTAACTGTGCAAAC T TCTCTCTGTCTGCTCT TGT CTCTGGCTTT CTCTGCGCTCTTTTT GCGCTCTTTTTTTAA C CTCTTTTTTTAAC C TTTATACACTCT T T TTTTATC ACTT TTA A T TATACACT TGTAAA A ACACTCA AATCTAT C CTCTATAAAATATGTG G T TATAAAATATGTGTT A AAAATATGTGTTACTC C A ATATGTGTGTCCT T T TGTGTGTCTCTTCTTA A G GTGTCTCTTTCTATAT  TCTCTTATATGAATG CTA CTATATATGTGCGC C TTATTGCGCATAAA AATGTGCATTCAGAG G T TGTGCGCACAGAGAGA A G GCGCACAGT CTTCAT GA TAAAGAGATATTTT T A AGAGAATTTC C GGATTTGCTATCACA  ATATTGAT AACATAT T TTTCATGCATATTTT T T TCTCACATATTTTTTT T C CA TCTTGTG G A ATATTTCAATTTGTGT T T TTTTTTTGTGTAGA CTA TTTGTGTGTATAAAA A TCTAAA GTATAATG AT T G GTGTATAAAGGATTTT T T TATAAAATATTTTATA A AAATATTTAGAG G A ATATTTTATAGCT A T TTTTATAGAGAGAGAG G T TATAGAGAGAGAATGG G AAC GAGAGGGGT,TCTCTCTCCCTATA A C CTCTCTCCCCTCTATAC TCTCCCCTCTTGAGCT TC  CCCCTCTATACACTCTATA TGT CTCTAAAAACTTAAAA  TATACACTCTAATCAAAAA A A ACACTCTATAAAAAAATATGT C CTCTATAAAAAAATATTTT T TTAAATTAATCTGTTAATTA A AAGATAATATTTTATAAAA A A AAAATATTTTATAAAAAAA  ATATTTTATAAAAAAATAT T T TTTTATAAAAAAATATGTG  TA TATAAAAAAATTCACA A AAAAAATATGTGAGATAT T AATTATGAGGCTAC A AT GCTGAGATATCG TCT T T TGAGAGATATCTCTCTCTC C G GAGATATCTCTCTCTCTCT  ATTCTCTCTCTCTGTG G T TCTCTCTTTCTCTGTGCGC C C CTCTCTCTATTTGCGCT TGGAT TCTCTCTGGCTTACTT TGA CTCTGAATGCTCTCAATTT T T TGTGCCTTTTTTTATA A GATGGCTCTTAC TTATAC AAC CCTTTACACTCT T T TTTTTTTAACTCTATA A TTTAAG CTATAAAA A T TATACACTCTATAATTA ACCTAAATATGTG G C CTTGCTAAATGTGTGT T T TATAAAATATGGTC AATTTTGTATTCT  ATATGTGTGTCTGCTC A TT TTGTGTCTCTCTATATAT T GTCTCTAG CTG TCT TCTCTCTATAT ATCTAGC C C CTCTATATATGTGCGCATA A T TATATATGTCTGCACAGAG G A ATATGTGCGCACAGTAAGA CT TGCGCACAGTGAT TAT T G GCGCACAGAGAGATAATTT T C CACAGAGAATTTTCTC C A AGTACATTTTCTCACA A GGATGATATTTTCTCACATAT T A ATATTAG TCACATTT  TG TTTTCATGCATTA TTTTT T T TCTCACATATTTTTTTGTG TAT CACATTTTTTGAT T A ATATTTTTTTGTGTGTAT CA T TTTTTTTGTGTGTATAAA T TTTTGTGTGTAAATAATAT  TGTGTGTATAATAAGTCTT  GTTAAAATATTTTATA A T TATAATGCATTTAGTTCG AAC AATATTTTATAGAGAGA A AA C GAA ATAGAGAGAGTACG T TTAT TAGAGAGAGGG G TTAGAGAACTAGGGGT,"ID   SPIKE_SARS2             Reviewed;        1273 AA.
AC   P0DTC2;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Spike glycoprotein {ECO:0000255|HAMAP-Rule:MF_04099};
DE            Short=S glycoprotein {ECO:0000255|HAMAP-Rule:MF_04099};
DE   AltName: Full=E2 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   AltName: Full=Peplomer protein {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S1 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S2 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S2' {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Flags: Precursor;
GN   Name=S {ECO:0000255|HAMAP-Rule:MF_04099}; ORFNames=2;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   FUNCTION (SPIKE PROTEIN S1), AND CLEAVAGE BETWEEN S2 AND S2' BY HOST
RP   TMPRSS2.
RX   PubMed=32142651; DOI=10.1016/j.cell.2020.02.052;
RA   Hoffmann M., Kleine-Weber H., Schroeder S., Krueger N., Herrler T.,
RA   Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A.,
RA   Mueller M.A., Drosten C., Poehlmann S.;
RT   ""SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a
RT   clinically proven protease inhibitor."";
RL   Cell 181:1-10(2020).
RN   [3]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, FUNCTION, AND MUTAGENESIS OF
RP   681-PRO--ALA-684.
RX   PubMed=32362314; DOI=10.1016/j.molcel.2020.04.022;
RA   Hoffmann M., Kleine-Weber H., Poehlmann S.;
RT   ""A multibasic cleavage site in the Spike protein of SARS-CoV-2 is essential
RT   for infection of human lung cells."";
RL   Mol. Cell 78:779-784(2020).
RN   [4]
RP   GLYCOSYLATION AT ASN-17; ASN-61; ASN-74; ASN-122; ASN-149; ASN-165;
RP   ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098; ASN-1134; ASN-1158; ASN-1173 AND
RP   ASN-1194, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=32366695; DOI=10.1126/science.abb9983;
RA   Watanabe Y., Allen J.D., Wrapp D., McLellan J.S., Crispin M.;
RT   ""Site-specific glycan analysis of the SARS-CoV-2 spike."";
RL   Science 369:330-333(2020).
RN   [5]
RP   GLYCOSYLATION AT ASN-61; ASN-74; ASN-122; ASN-149; ASN-165; ASN-234;
RP   ASN-282; THR-323; SER-325; ASN-331; ASN-343; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098 AND ASN-1194, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=32363391; DOI=10.1093/glycob/cwaa042;
RA   Shajahan A., Supekar N.T., Gleinich A.S., Azadi P.;
RT   ""Deducing the N- and O- glycosylation profile of the spike protein of novel
RT   coronavirus SARS-CoV-2."";
RL   Glycobiology 30:981-988(2020).
RN   [6]
RP   VARIANT GLY-614.
RX   PubMed=32820179; DOI=10.1038/s41598-020-70827-z;
RA   Isabel S., Grana-Miraglia L., Gutierrez J.M., Bundalovic-Torma C.,
RA   Groves H.E., Isabel M.R., Eshaghi A., Patel S.N., Gubbay J.B., Poutanen T.,
RA   Guttman D.S., Poutanen S.M.;
RT   ""Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein
RT   mutation now documented worldwide."";
RL   Sci. Rep. 10:14031-14031(2020).
RN   [7]
RP   VARIANT GLY-614, AND MUTAGENESIS OF ASP-614.
RX   PubMed=32697968; DOI=10.1016/j.cell.2020.06.043;
RG   Sheffield COVID-19 Genomics Group;
RA   Korber B., Fischer W.M., Gnanakaran S., Yoon H., Theiler J., Abfalterer W.,
RA   Hengartner N., Giorgi E.E., Bhattacharya T., Foley B., Hastie K.M.,
RA   Parker M.D., Partridge D.G., Evans C.M., Freeman T.M., de Silva T.I.,
RA   McDanal C., Perez L.G., Tang H., Moon-Walker A., Whelan S.P.,
RA   LaBranche C.C., Saphire E.O., Montefiori D.C.;
RT   ""Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases
RT   Infectivity of the COVID-19 Virus."";
RL   Cell 182:812-827(2020).
RN   [8]
RP   FUNCTION.
RX   PubMed=32817270; DOI=10.1126/science.abd5223;
RA   Turonova B., Sikora M., Schuermann C., Hagen W.J.H., Welsch S.,
RA   Blanc F.E.C., von Buelow S., Gecht M., Bagola K., Hoerner C.,
RA   van Zandbergen G., Landry J., de Azevedo N.T.D., Mosalaganti S.,
RA   Schwarz A., Covino R., Muehlebach M.D., Hummer G., Krijnse Locker J.,
RA   Beck M.;
RT   ""In situ structural analysis of SARS-CoV-2 spike reveals flexibility
RT   mediated by three hinges."";
RL   Science 370:203-208(2020).
RN   [9]
RP   GLYCOSYLATION.
RX   PubMed=32929138; DOI=10.1038/s41598-020-71748-7;
RA   Grant O.C., Montgomery D., Ito K., Woods R.J.;
RT   ""Analysis of the SARS-CoV-2 spike protein glycan shield reveals
RT   implications for immune recognition."";
RL   Sci. Rep. 10:14991-14991(2020).
RN   [10]
RP   GLYCOSYLATION AT ASN-17; ASN-61; ASN-74; ASN-122; ASN-149; ASN-165;
RP   ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098; ASN-1134; ASN-1158; ASN-1173 AND
RP   ASN-1194, IDENTIFICATION BY MASS SPECTROMETRY, SUBCELLULAR LOCATION, AND
RP   SUBUNIT.
RX   PubMed=32979942; DOI=10.1016/j.cell.2020.09.018;
RA   Yao H., Song Y., Chen Y., Wu N., Xu J., Sun C., Zhang J., Weng T.,
RA   Zhang Z., Wu Z., Cheng L., Shi D., Lu X., Lei J., Crispin M., Shi Y.,
RA   Li L., Li S.;
RT   ""Molecular Architecture of the SARS-CoV-2 Virus."";
RL   Cell 183:730-738(2020).
RN   [11]
RP   VARIANT GLY-614, AND MUTAGENESIS OF ASP-614.
RX   PubMed=33106671; DOI=10.1038/s41586-020-2895-3;
RA   Plante J.A., Liu Y., Liu J., Xia H., Johnson B.A., Lokugamage K.G.,
RA   Zhang X., Muruato A.E., Zou J., Fontes-Garfias C.R., Mirchandani D.,
RA   Scharton D., Bilello J.P., Ku Z., An Z., Kalveram B., Freiberg A.N.,
RA   Menachery V.D., Xie X., Plante K.S., Weaver S.C., Shi P.Y.;
RT   ""Spike mutation D614G alters SARS-CoV-2 fitness."";
RL   Nature 592:116-121(2020).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH HUMAN NRP1 AND NRP2.
RC   STRAIN=SARS-CoV-2/human/Liverpool/REMRQ001/2020;
RX   PubMed=33082294; DOI=10.1126/science.abd3072;
RA   Daly J.L., Simonetti B., Klein K., Chen K.E., Williamson M.K.,
RA   Anton-Plagaro C., Shoemark D.K., Simon-Gracia L., Bauer M., Hollandi R.,
RA   Greber U.F., Horvath P., Sessions R.B., Helenius A., Hiscox J.A.,
RA   Teesalu T., Matthews D.A., Davidson A.D., Collins B.M., Cullen P.J.,
RA   Yamauchi Y.;
RT   ""Neuropilin-1 is a host factor for SARS-CoV-2 infection."";
RL   Science 370:861-865(2020).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH HUMAN NRP1 AND NRP2.
RC   STRAIN=SARS-CoV-2/human/Finland/1/2020;
RX   PubMed=33082293; DOI=10.1126/science.abd2985;
RA   Cantuti-Castelvetri L., Ojha R., Pedro L.D., Djannatian M., Franz J.,
RA   Kuivanen S., van der Meer F., Kallio K., Kaya T., Anastasina M., Smura T.,
RA   Levanov L., Szirovicza L., Tobi A., Kallio-Kokko H., Oesterlund P.,
RA   Joensuu M., Meunier F.A., Butcher S.J., Winkler M.S., Mollenhauer B.,
RA   Helenius A., Gokce O., Teesalu T., Hepojoki J., Vapalahti O.,
RA   Stadelmann C., Balistreri G., Simons M.;
RT   ""Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity."";
RL   Science 370:856-860(2020).
RN   [14]
RP   INTERACTION WITH HUMAN ITGA5 AND ITGB1.
RX   PubMed=33102950; DOI=10.1016/j.jacbts.2020.10.003;
RA   Beddingfield B.J., Iwanaga N., Chapagain P.P., Zheng W., Roy C.J., Hu T.Y.,
RA   Kolls J.K., Bix G.J.;
RT   ""The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2
RT   Infection."";
RL   JACC Basic Transl. Sci. 6:1-8(2021).
RN   [15]
RP   VARIANT GLY-614.
RX   PubMed=33184236; DOI=10.1126/science.abe8499;
RA   Hou Y.J., Chiba S., Halfmann P., Ehre C., Kuroda M., Dinnon K.H. III,
RA   Leist S.R., Schaefer A., Nakajima N., Takahashi K., Lee R.E.,
RA   Mascenik T.M., Graham R., Edwards C.E., Tse L.V., Okuda K., Markmann A.J.,
RA   Bartelt L., de Silva A., Margolis D.M., Boucher R.C., Randell S.H.,
RA   Suzuki T., Gralinski L.E., Kawaoka Y., Baric R.S.;
RT   ""SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and
RT   transmission in vivo."";
RL   Science 370:1464-1468(2020).
RN   [16]
RP   VARIANT GLY-614.
RX   PubMed=33417835; DOI=10.1016/j.celrep.2020.108630;
RA   Gobeil S.M., Janowska K., McDowell S., Mansouri K., Parks R., Manne K.,
RA   Stalls V., Kopp M.F., Henderson R., Edwards R.J., Haynes B.F., Acharya P.;
RT   ""D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease
RT   Cleavage at the S1/S2 Junction."";
RL   Cell Rep. 34:108630-108630(2021).
RN   [17]
RP   VARIANTS 69-VAL--PHE-70 DEL; LYS-144 DEL; TYR-501; ASP-570; GLY-614;
RP   HIS-681; ILE-716; ALA-982 AND HIS-1118.
RC   STRAIN=20I/501Y.V1, Alpha, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [18]
RP   VARIANT TYR-501.
RX   PubMed=32732280; DOI=10.1126/science.abc4730;
RA   Gu H., Chen Q., Yang G., He L., Fan H., Deng Y.Q., Wang Y., Teng Y.,
RA   Zhao Z., Cui Y., Li Y., Li X.F., Li J., Zhang N.N., Yang X., Chen S.,
RA   Guo Y., Zhao G., Wang X., Luo D.Y., Wang H., Yang X., Li Y., Han G., He Y.,
RA   Zhou X., Geng S., Sheng X., Jiang S., Sun S., Qin C.F., Zhou Y.;
RT   ""Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy."";
RL   Science 369:1603-1607(2020).
RN   [19]
RP   VARIANT GLY-614, AND MUTAGENESIS OF GLY-614.
RX   PubMed=33636719; DOI=10.1038/s41586-021-03361-1;
RA   Zhou B., Thi Nhu Thao T., Hoffmann D., Taddeo A., Ebert N., Labroussaa F.,
RA   Pohlmann A., King J., Steiner S., Kelly J.N., Portmann J., Halwe N.J.,
RA   Ulrich L., Trueeb B.S., Fan X., Hoffmann B., Wang L., Thomann L., Lin X.,
RA   Stalder H., Pozzi B., de Brot S., Jiang N., Cui D., Hossain J., Wilson M.,
RA   Keller M., Stark T.J., Barnes J.R., Dijkman R., Jores J., Benarafa C.,
RA   Wentworth D.E., Thiel V., Beer M.;
RT   ""SARS-CoV-2 spike D614G change enhances replication and transmission."";
RL   Nature 5920:122-127(2021).
RN   [20]
RP   MUTAGENESIS OF ASN-165; ASN-234; ASN-331; ASN-343; LEU-452; ALA-475;
RP   VAL-483; PHE-490 AND HIS-519.
RX   PubMed=32730807; DOI=10.1016/j.cell.2020.07.012;
RA   Li Q., Wu J., Nie J., Zhang L., Hao H., Liu S., Zhao C., Zhang Q., Liu H.,
RA   Nie L., Qin H., Wang M., Lu Q., Li X., Sun Q., Liu J., Zhang L., Li X.,
RA   Huang W., Wang Y.;
RT   ""The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and
RT   Antigenicity."";
RL   Cell 182:1284-1294(2020).
RN   [21]
RP   FUNCTION, CLEAVAGE BETWEEN S1 AND S2 BY HOST CTSL, AND INTERACTION WITH
RP   HUMAN ACE2.
RX   PubMed=32221306; DOI=10.1038/s41467-020-15562-9;
RA   Ou X., Liu Y., Lei X., Li P., Mi D., Ren L., Guo L., Guo R., Chen T.,
RA   Hu J., Xiang Z., Mu Z., Chen X., Chen J., Hu K., Jin Q., Wang J., Qian Z.;
RT   ""Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and
RT   its immune cross-reactivity with SARS-CoV."";
RL   Nat. Commun. 11:1620-1620(2020).
RN   [22]
RP   INTERACTION WITH HUMAN ACE2.
RX   PubMed=33607086; DOI=10.1016/j.bpj.2021.02.007;
RA   Cao W., Dong C., Kim S., Hou D., Tai W., Du L., Im W., Zhang X.F.;
RT   ""Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2
RT   protein-protein interaction."";
RL   Biophys. J. 120:1011-1019(2021).
RN   [23]
RP   FUNCTION, AND CLEAVAGE BETWEEN S1 AND S2 BY HOST TMPRSS2.
RX   PubMed=33465165; DOI=10.1371/journal.ppat.1009212;
RA   Ou T., Mou H., Zhang L., Ojha A., Choe H., Farzan M.;
RT   ""Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated
RT   by TMPRSS2."";
RL   PLoS Pathog. 17:e1009212-e1009212(2021).
RN   [24]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH S PROTEIN.
RX   PubMed=33229438; DOI=10.1074/jbc.ra120.016175;
RA   Boson B., Legros V., Zhou B., Siret E., Mathieu C., Cosset F.L.,
RA   Lavillette D., Denolly S.;
RT   ""The SARS-CoV-2 Envelope and Membrane proteins modulate maturation and
RT   retention of the Spike protein, allowing assembly of virus-like
RT   particles."";
RL   J. Biol. Chem. 296:100111-100111(2020).
RN   [25]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, CLEAVAGE BETWEEN S2 AND S2' BY
RP   HOST TMPRSS2, MUTAGENESIS OF ALA-684, AND FUNCTION (SPIKE PROTEIN S2').
RX   PubMed=32703818; DOI=10.26508/lsa.202000786;
RA   Bestle D., Heindl M.R., Limburg H., Van Lam van T., Pilgram O., Moulton H.,
RA   Stein D.A., Hardes K., Eickmann M., Dolnik O., Rohde C., Klenk H.D.,
RA   Garten W., Steinmetzer T., Boettcher-Friebertshaeuser E.;
RT   ""TMPRSS2 and furin are both essential for proteolytic activation of SARS-
RT   CoV-2 in human airway cells."";
RL   Life. Sci Alliance 3:1-14(2020).
RN   [26]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, CLEAVAGE BETWEEN S2 AND S2' BY
RP   HOST TMPRSS2, CLEAVAGE BETWEEN S2 AND S2' BY HOST CSTL, AND FUNCTION (SPIKE
RP   PROTEIN S2').
RX   PubMed=34159616; DOI=10.15252/embj.2021107821;
RA   Koch J., Uckeley Z.M., Doldan P., Stanifer M., Boulant S., Lozach P.Y.;
RT   ""TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect
RT   host cells."";
RL   EMBO J. 40:1-20(2021).
RN   [27]
RP   VARIANTS PHE-18; ALA-80; GLY-215; ASN-417; LYS-484; TYR-501; GLY-614 AND
RP   VAL-701.
RC   STRAIN=20H/501Y.V2, B.1.351, and Beta;
RX   PubMed=33690265; DOI=10.1038/s41586-021-03402-9;
RA   Tegally H., Wilkinson E., Giovanetti M., Iranzadeh A., Fonseca V.,
RA   Giandhari J., Doolabh D., Pillay S., San E.J., Msomi N., Mlisana K.,
RA   von Gottberg A., Walaza S., Allam M., Ismail A., Mohale T., Glass A.J.,
RA   Engelbrecht S., Van Zyl G., Preiser W., Petruccione F., Sigal A.,
RA   Hardie D., Marais G., Hsiao M., Korsman S., Davies M.A., Tyers L.,
RA   Mudau I., York D., Maslo C., Goedhals D., Abrahams S., Laguda-Akingba O.,
RA   Alisoltani-Dehkordi A., Godzik A., Wibmer C.K., Sewell B.T., Lourenco J.,
RA   Alcantara L.C.J., Kosakovsky Pond S.L., Weaver S., Martin D.,
RA   Lessells R.J., Bhiman J.N., Williamson C., de Oliveira T.;
RT   ""Emergence of a SARS-CoV-2 variant of concern with mutations in spike
RT   glycoprotein."";
RL   Nature 592:438-443(2021).
RN   [28]
RP   POLYMORPHISM.
RX   PubMed=34142653; DOI=10.2807/1560-7917.es.2021.26.24.2100509;
RA   Campbell F., Archer B., Laurenson-Schafer H., Jinnai Y., Konings F.,
RA   Batra N., Pavlin B., Vandemaele K., Van Kerkhove M.D., Jombart T.,
RA   Morgan O., le Polain de Waroux O.;
RT   ""Increased transmissibility and global spread of SARS-CoV-2 variants of
RT   concern as at June 2021."";
RL   Eurosurveillance 26:0-0(2021).
RN   [29]
RP   VARIANTS ARG-452 AND PHE-453, AND MUTAGENESIS OF LEU-452; TYR-453 AND
RP   ASN-501.
RX   PubMed=34171266; DOI=10.1016/j.chom.2021.06.006;
RG   Genotype to Phenotype Japan (G2P-Japan) Consortium;
RA   Motozono C., Toyoda M., Zahradnik J., Saito A., Nasser H., Tan T.S.,
RA   Ngare I., Kimura I., Uriu K., Kosugi Y., Yue Y., Shimizu R., Ito J.,
RA   Torii S., Yonekawa A., Shimono N., Nagasaki Y., Minami R., Toya T.,
RA   Sekiya N., Fukuhara T., Matsuura Y., Schreiber G., Ikeda T., Nakagawa S.,
RA   Ueno T., Sato K.;
RT   ""SARS-CoV-2 spike L452R variant evades cellular immunity and increases
RT   infectivity."";
RL   Cell Host Microbe 0:0-0(2021).
RN   [30]
RP   VARIANT 69-VAL--PHE-70 DEL, AND MUTAGENESIS OF 69-HIS-VAL-70.
RX   PubMed=34166617; DOI=10.1016/j.celrep.2021.109292;
RG   COVID-19 Genomics UK (COG-UK) Consortium;
RA   Meng B., Kemp S.A., Papa G., Datir R., Ferreira I.A.T.M., Marelli S.,
RA   Harvey W.T., Lytras S., Mohamed A., Gallo G., Thakur N., Collier D.A.,
RA   Mlcochova P., Duncan L.M., Carabelli A.M., Kenyon J.C., Lever A.M.,
RA   De Marco A., Saliba C., Culap K., Cameroni E., Matheson N.J., Piccoli L.,
RA   Corti D., James L.C., Robertson D.L., Bailey D., Gupta R.K.;
RT   ""Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in
RT   the Alpha variant B.1.1.7."";
RL   Cell Rep. 35:109292-109292(2021).
RN   [31]
RP   VARIANTS ILE-13 AND CYS-152, POLYMORPHISM, AND MASS SPECTROMETRY (SIGNAL).
RX   PubMed=34210893; DOI=10.1126/science.abi7994;
RA   McCallum M., Bassi J., De Marco A., Chen A., Walls A.C., Di Iulio J.,
RA   Tortorici M.A., Navarro M.J., Silacci-Fregni C., Saliba C., Sprouse K.R.,
RA   Agostini M., Pinto D., Culap K., Bianchi S., Jaconi S., Cameroni E.,
RA   Bowen J.E., Tilles S.W., Pizzuto M.S., Guastalla S.B., Bona G.,
RA   Pellanda A.F., Garzoni C., Van Voorhis W.C., Rosen L.E., Snell G.,
RA   Telenti A., Virgin H.W., Piccoli L., Corti D., Veesler D.;
RT   ""SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern."";
RL   Science 373:648-654(2021).
RN   [32]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-1269 AND HIS-1271.
RX   PubMed=34504087; DOI=10.1038/s41467-021-25589-1;
RA   Cattin-Ortola J., Welch L.G., Maslen S.L., Papa G., James L.C., Munro S.;
RT   ""Sequences in the cytoplasmic tail of SARS-CoV-2 Spike facilitate
RT   expression at the cell surface and syncytia formation."";
RL   Nat. Commun. 12:5333-5333(2021).
RN   [33]
RP   PALMITOYLATION AT CYS-1235; CYS-1236; CYS-1240; CYS-1241; CYS-1243;
RP   CYS-1247; CYS-1248; CYS-1250; CYS-1253 AND CYS-1254.
RX   PubMed=34599882; DOI=10.1016/j.devcel.2021.09.016;
RA   Mesquita F.S., Abrami L., Sergeeva O., Turelli P., Qing E., Kunz B.,
RA   Raclot C., Paz Montoya J., Abriata L.A., Gallagher T., Dal Peraro M.,
RA   Trono D., D'Angelo G., van der Goot F.G.;
RT   ""S-acylation controls SARS-CoV-2 membrane lipid organization and enhances
RT   infectivity."";
RL   Dev. Cell 56:1-18(2021).
RN   [34] {ECO:0007744|PDB:6M17}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.90 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), DOMAIN, AND INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN S1).
RX   PubMed=32132184; DOI=10.1126/science.abb2762;
RA   Yan R., Zhang Y., Li Y., Xia L., Guo Y., Zhou Q.;
RT   ""Structural basis for the recognition of the SARS-CoV-2 by full-length
RT   human ACE2."";
RL   Science 367:1444-1448(2020).
RN   [35]
RP   SUPERANTIGEN, AND DOMAIN.
RX   PubMed=32989130; DOI=10.1073/pnas.2010722117;
RA   Cheng M.H., Zhang S., Porritt R.A., Noval Rivas M., Paschold L.,
RA   Willscher E., Binder M., Arditi M., Bahar I.;
RT   ""Superantigenic character of an insert unique to SARS-CoV-2 spike supported
RT   by skewed TCR repertoire in patients with hyperinflammation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 117:25254-25262(2020).
RN   [36]
RP   INTERACTION WITH HUMAN BILIRUBIN, INTERACTION WITH HUMAN BILIVERDIN, AND
RP   MUTAGENESIS OF ASN-121 AND ARG-190.
RX   PubMed=33888467; DOI=10.1126/sciadv.abg7607;
RA   Rosa A., Pye V.E., Graham C., Muir L., Seow J., Ng K.W., Cook N.J.,
RA   Rees-Spear C., Parker E., Dos Santos M.S., Rosadas C., Susana A., Rhys H.,
RA   Nans A., Masino L., Roustan C., Christodoulou E., Ulferts R., Wrobel A.G.,
RA   Short C.E., Fertleman M., Sanders R.W., Heaney J., Spyer M., Kjaer S.,
RA   Riddell A., Malim M.H., Beale R., MacRae J.I., Taylor G.P., Nastouli E.,
RA   van Gils M.J., Rosenthal P.B., Pizzato M., McClure M.O., Tedder R.S.,
RA   Kassiotis G., McCoy L.E., Doores K.J., Cherepanov P.;
RT   ""SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity."";
RL   Sci. Adv. 7:0-0(2021).
RN   [37]
RP   BIOTECHNOLOGY, AND MUTAGENESIS OF 682-ARG--ARG-685 AND 986-LYS-VAL-987.
RX   PubMed=34322129; DOI=10.3389/fimmu.2021.701501;
RA   Martinez-Flores D., Zepeda-Cervantes J., Cruz-Resendiz A.,
RA   Aguirre-Sampieri S., Sampieri A., Vaca L.;
RT   ""SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of
RT   New Viral Variants."";
RL   Front. Immunol. 12:701501-701501(2021).
RN   [38]
RP   GLYCOSYLATION AT THR-676 AND THR-678 BY HOST GALNT1, AND MUTAGENESIS OF
RP   SER-673; THR-676; THR-678; SER-680 AND PRO-681.
RX   PubMed=34732583; DOI=10.1073/pnas.2109905118;
RA   Zhang L., Mann M., Syed Z.A., Reynolds H.M., Tian E., Samara N.L.,
RA   Zeldin D.C., Tabak L.A., Ten Hagen K.G.;
RT   ""Furin cleavage of the SARS-CoV-2 spike is modulated by O-glycosylation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [39]
RP   REVIEW, PROTEOLITIC PROCESSING, FUNCTION (SPIKE PROTEIN S2), AND FUNCTION
RP   (SPIKE PROTEIN S2').
RX   PubMed=34561887; DOI=10.1111/1348-0421.12945;
RA   Takeda M.;
RT   ""Proteolytic activation of SARS-CoV-2 spike protein."";
RL   Microbiol. Immunol. 66:15-23(2022).
RN   [40]
RP   INTERACTION WITH HOST MBL2.
RX   PubMed=35102342; DOI=10.1038/s41590-021-01114-w;
RA   Stravalaci M., Pagani I., Paraboschi E.M., Pedotti M., Doni A.,
RA   Scavello F., Mapelli S.N., Sironi M., Perucchini C., Varani L.,
RA   Matkovic M., Cavalli A., Cesana D., Gallina P., Pedemonte N., Capurro V.,
RA   Clementi N., Mancini N., Invernizzi P., Bayarri-Olmos R., Garred P.,
RA   Rappuoli R., Duga S., Bottazzi B., Uguccioni M., Asselta R., Vicenzi E.,
RA   Mantovani A., Garlanda C.;
RT   ""Recognition and inhibition of SARS-CoV-2 by humoral innate immunity
RT   pattern recognition molecules."";
RL   Nat. Immunol. 23:275-286(2022).
RN   [41]
RP   FUNCTION (SPIKE PROTEIN S1), AND INTERACTION WITH HOST INTEGRIN (SPIKE
RP   PROTEIN S1).
RX   PubMed=35150743; DOI=10.1016/j.jbc.2022.101710;
RA   Liu J., Lu F., Chen Y., Plow E., Qin J.;
RT   ""Integrin mediates cell entry of the SARS-CoV-2 virus independent of
RT   cellular receptor ACE2."";
RL   J. Biol. Chem. 1:101710-101710(2022).
RN   [42]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [43]
RP   SUBUNIT.
RX   PubMed=36735681; DOI=10.1371/journal.pbio.3001959;
RA   Shilts J., Crozier T.W.M., Teixeira-Silva A., Gabaev I., Gerber P.P.,
RA   Greenwood E.J.D., Watson S.J., Ortmann B.M., Gawden-Bone C.M., Pauzaite T.,
RA   Hoffmann M., Nathan J.A., Poehlmann S., Matheson N.J., Lehner P.J.,
RA   Wright G.J.;
RT   ""LRRC15 mediates an accessory interaction with the SARS-CoV-2 spike
RT   protein."";
RL   PLoS Biol. 21:e3001959-e3001959(2023).
RN   [44]
RP   VARIANT ASN-405.
RX   PubMed=36851546; DOI=10.3390/v15020332;
RA   Bugatti A., Filippini F., Messali S., Giovanetti M., Ravelli C., Zani A.,
RA   Ciccozzi M., Caruso A., Caccuri F.;
RT   ""The D405N Mutation in the Spike Protein of SARS-CoV-2 Omicron BA.5
RT   Inhibits Spike/Integrins Interaction and Viral Infection of Human Lung
RT   Microvascular Endothelial Cells."";
RL   Viruses 15:0-0(2023).
RN   [45]
RP   MUTAGENESIS OF GLU-484.
RX   PubMed=37421949; DOI=10.1016/j.cell.2023.06.005;
RA   Baggen J., Jacquemyn M., Persoons L., Vanstreels E., Pye V.E., Wrobel A.G.,
RA   Calvaresi V., Martin S.R., Roustan C., Cronin N.B., Reading E.,
RA   Thibaut H.J., Vercruysse T., Maes P., De Smet F., Yee A., Nivitchanyong T.,
RA   Roell M., Franco-Hernandez N., Rhinn H., Mamchak A.A., Ah Young-Chapon M.,
RA   Brown E., Cherepanov P., Daelemans D.;
RT   ""TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry."";
RL   Cell 186:1-16(2023).
RN   [46] {ECO:0007744|PDB:6VSB}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.46 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN S1), SUBUNIT, AND
RP   GLYCOSYLATION.
RX   PubMed=32075877; DOI=10.1126/science.abb2507;
RA   Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.L., Abiona O.,
RA   Graham B.S., McLellan J.S.;
RT   ""Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation."";
RL   Science 367:1260-1263(2020).
RN   [47] {ECO:0007744|PDB:6VXX, ECO:0007744|PDB:6VYB}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.80 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), SUBUNIT (SPIKE PROTEIN S1), INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN
RP   S1), MUTAGENESIS OF 679-GLN--ALA-684, GLYCOSYLATION AT ASN-61; ASN-122;
RP   ASN-61; ASN-165; ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616;
RP   ASN-657; ASN-709; ASN-717; ASN-801; ASN-1074; ASN-1098 AND ASN-1134, AND
RP   DISULFIDE BOND.
RX   PubMed=32155444; DOI=10.1016/j.cell.2020.02.058;
RA   Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., Veesler D.;
RT   ""Structure, function, and antigenicity of the SARS-CoV-2 spike
RT   glycoprotein."";
RL   Cell 180:1-12(2020).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HOST ACE2.
RX   PubMed=32225176; DOI=10.1038/s41586-020-2180-5;
RA   Lan J., Ge J., Yu J., Shan S., Zhou H., Fan S., Zhang Q., Shi X., Wang Q.,
RA   Zhang L., Wang X.;
RT   ""Structure of the SARS-CoV-2 spike receptor-binding domain bound to the
RT   ACE2 receptor."";
RL   Nature 581:215-220(2020).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.68 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HOST ACE2, INTERACTION WITH HOST ACE2, AND MUTAGENESIS OF GLN-493 AND
RP   ASN-501.
RX   PubMed=32225175; DOI=10.1038/s41586-020-2179-y;
RA   Shang J., Ye G., Shi K., Wan Y., Luo C., Aihara H., Geng Q., Auerbach A.,
RA   Li F.;
RT   ""Structural basis of receptor recognition by SARS-CoV-2."";
RL   Nature 581:221-224(2020).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (3.08 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HUMAN ANTIBODY CR3022, AND DISULFIDE BOND.
RX   PubMed=32245784; DOI=10.1126/science.abb7269;
RA   Yuan M., Wu N.C., Zhu X., Lee C.D., So R.T.Y., Lv H., Mok C.K.P.,
RA   Wilson I.A.;
RT   ""A highly conserved cryptic epitope in the receptor-binding domains of
RT   SARS-CoV-2 and SARS-CoV."";
RL   Science 368:630-633(2020).
CC   -!- FUNCTION: [Spike protein S1]: Attaches the virion to the cell membrane
CC       by interacting with host receptor, initiating the infection. The major
CC       receptor is host ACE2 (PubMed:32142651, PubMed:32155444,
CC       PubMed:33607086). When S2/S2' has been cleaved, binding to the receptor
CC       triggers direct fusion at the cell membrane (PubMed:34561887). When
CC       S2/S2' has not been cleaved, binding to the receptor results in
CC       internalization of the virus by endocytosis leading to fusion of the
CC       virion membrane with the host endosomal membrane (PubMed:32075877,
CC       PubMed:32221306). Alternatively, may use NRP1/NRP2 (PubMed:33082294,
CC       PubMed:33082293) and integrin as entry receptors (PubMed:35150743). The
CC       use of NRP1/NRP2 receptors may explain the tropism of the virus in
CC       human olfactory epithelial cells, which express these molecules at high
CC       levels but ACE2 at low levels (PubMed:33082293). The stalk domain of S
CC       contains three hinges, giving the head unexpected orientational freedom
CC       (PubMed:32817270). {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:32075877, ECO:0000269|PubMed:32142651,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32221306,
CC       ECO:0000269|PubMed:32817270, ECO:0000269|PubMed:33082293,
CC       ECO:0000269|PubMed:33082294, ECO:0000269|PubMed:35150743,
CC       ECO:0000303|PubMed:33082293, ECO:0000305|PubMed:34561887}.
CC   -!- FUNCTION: [Spike protein S2]: Precursor of the fusion protein processed
CC       in the biosynthesis of the S protein and the formation of virus
CC       particle. Mediates fusion of the virion and cellular membranes by
CC       functioning as a class I viral fusion protein. Contains two viral
CC       fusion peptides that are unmasked after cleavage. The S2/S2' cleavage
CC       occurs during virus entry at the cell membrane by host TMPRSS2
CC       (PubMed:32142651) or during endocytosis by host CSTL (PubMed:32703818,
CC       PubMed:34159616). In either case, this triggers an extensive and
CC       irreversible conformational change leading to fusion of the viral
CC       envelope with the cellular cytoplasmic membrane, releasing viral
CC       genomic RNA into the host cell cytoplasm (PubMed:34561887). Under the
CC       current model, the protein has at least three conformational states:
CC       pre-fusion native state, pre-hairpin intermediate state, and post-
CC       fusion hairpin state. During fusion of the viral and target cell
CC       membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-
CC       hairpins structure and position the fusion peptide in close proximity
CC       to the C-terminal region of the ectodomain. Formation of this structure
CC       appears to promote apposition and subsequent fusion of viral and target
CC       cell membranes. {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:32703818, ECO:0000269|PubMed:34159616,
CC       ECO:0000305|PubMed:34561887}.
CC   -!- FUNCTION: [Spike protein S2']: Subunit of the fusion protein that is
CC       processed upon entry into the host cell. Mediates fusion of the virion
CC       and cellular membranes by functioning as a class I viral fusion
CC       protein. Contains a viral fusion peptide that is unmasked after S2
CC       cleavage. This cleavage can occur at the cell membrane by host TMPRSS2
CC       or during endocytosis by host CSTL (PubMed:32703818, PubMed:34159616).
CC       In either case, this triggers an extensive and irreversible
CC       conformational change that leads to fusion of the viral envelope with
CC       the cellular cytoplasmic membrane, releasing viral genomic RNA into the
CC       host cell cytoplasm (PubMed:34561887). Under the current model, the
CC       protein has at least three conformational states: pre-fusion native
CC       state, pre-hairpin intermediate state, and post-fusion hairpin state.
CC       During fusion of the viral and target cell membranes, the coiled coil
CC       regions (heptad repeats) adopt a trimer-of-hairpins structure and
CC       position the fusion peptide in close proximity to the C-terminal region
CC       of the ectodomain. Formation of this structure appears to promote
CC       apposition and subsequent fusion of viral and target cell membranes.
CC       {ECO:0000255|HAMAP-Rule:MF_04099, ECO:0000269|PubMed:32703818,
CC       ECO:0000269|PubMed:34159616, ECO:0000305|PubMed:34561887}.
CC   -!- SUBUNIT: [Spike glycoprotein]: Homotrimer; each monomer consists of a
CC       S1 and a S2 subunit (PubMed:32075877, PubMed:32155444,
CC       PubMed:32245784). The resulting peplomers protrude from the virus
CC       surface as spikes (PubMed:32979942). Interacts with ORF3a protein and
CC       ORF7a protein (By similarity) (PubMed:32075877, PubMed:32155444,
CC       PubMed:32245784, PubMed:32979942). There are an average of 26 +/-15
CC       spike trimers at the surface of virion particles (PubMed:32979942).
CC       Binds to host MBL2 (PubMed:35102342). This binding occurs via glycans
CC       and inhibits viral infectivity. Inhibition is effective against alpha,
CC       beta, gamma, and delta variants (PubMed:35102342). {ECO:0000255|HAMAP-
CC       Rule:MF_04099, ECO:0000269|PubMed:32075877,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32245784,
CC       ECO:0000269|PubMed:32979942, ECO:0000269|PubMed:35102342}.
CC   -!- SUBUNIT: [Spike protein S1]: Binds to host ACE2 (PubMed:32075877,
CC       PubMed:32132184, PubMed:32155444, PubMed:32221306, PubMed:32225175,
CC       PubMed:32225176, PubMed:33607086). RBD also interacts with the N-linked
CC       glycan on 'Asn-90' of ACE2 (PubMed:33607086). Cleavage of S generates a
CC       polybasic C-terminal sequence on S1 that binds to host Neuropilin-1
CC       (NRP1) and Neuropilin-2 (NRP2) receptors (PubMed:33082293,
CC       PubMed:33082294). Interacts with host integrin alpha-5/beta-1
CC       (ITGA5:ITGB1) and with ACE2 in complex with integrin alpha-5/beta-1
CC       (ITGA5:ITGB1) (PubMed:33102950). May interact via cytoplasmic c-
CC       terminus with M protein (PubMed:33229438). May interact (via N-
CC       terminus) with host bilirubin and biliverdin, thereby preventing
CC       antibody binding to the SARS-CoV-2 spike NTD via an allosteric
CC       mechanism (PubMed:33888467). May interact with host LRRC15, thereby
CC       allowing attachment to host cells (PubMed:36735681).
CC       {ECO:0000269|PubMed:32075877, ECO:0000269|PubMed:32132184,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32221306,
CC       ECO:0000269|PubMed:32225",13777
CTAGGA TAGGAA AGGAAC GGAACT GAACTG AACTGC ACTGCC CTGCCC TGCCCC GCCCCA CCCCAG CCCAGA CCAGAA CAGAAG AGAAGC GAAGCT AAGCTG AGCTGG GCTGGA CTGGAC TGGACT GGACTT GACTTC ACTTCC CTTCCC TTCCCT TCCCTA CCCTAC CCTACC CTACCG TACCGC ACCGCG CCGCGC CGCGCT GCGCTA CGCTAA GCTAAC CTAACA TAACAA AACAAA ACAAAG CAAAGA AAAGAC AAGACG AGACGG GACGGC ACGGCA CGGCAT GGCATC GCATCA CATCAT ATCATA TCATAC CATACG ATACGC TACGCG ACGCGT CGCGTC GCGTCG CGTCGC GTCGCA TCGCAC CGCACC GCACCT CACCTG ACCTGC CCTGCG CTGCGC TGCGCG GCGCGA CGCGAG GCGAGC CGAGCC GAGCCT AGCCTC GCCTCG CCTCGA CTCGAA TCGAAT CGAATA GAATAC AATACA ATACAC TACACC ACACCA CACCAA ACCAAA CCAAAC CAAACG AAACGA AACGAT ACGATC CGATCA GATCAC ATCACA TCACAT CACATT ACATTG CATTGG ATTGGC TTGGCA TGGCAC GGCACC GCACCC CACCCG ACCCGC CCCGCA CCGCAA CGCAAT GCAATC CAATCC AATCCT ATCCTG TCCTGC CCTGCT CTGCTA TGCTAC GCTACC CTACCA TACCAA ACCAAT CCAATG CAATGC AATGCT ATGCTG TGCTGC GCTGCA CTGCAA TGCAAT GCAATC CAATCG AATCGC ATCGCG TCGCGC CGCGCC GCGCCA CGCCAC GCCACA CCACAA CACAAC ACAACT CAACTT,1,142,CTAG TAGG AGGA GGAA GAAC AACT ACTG CTGC TGCC GCCC CCCC CCCA CCAG CAGA AGAA GAAG AAGC AGCT GCTG CTGG TGGA GGAC GACT ACTT CTTC TTCC TCCC CCCT CCTA CTAC TACC ACCG CCGC CGCG GCGC CGCT GCTA CTAA TAAC AACA ACAA CAAA AAAG AAGA AGAC GACG ACGG CGGC GGCA GCAT CATC ATCA TCAT CATA ATAC TACG ACGC CGCG GCGT CGTC GTCG TCGC CGCA GCAC CACC ACCT CCTG CTGC TGCG GCGC CGCG GCGA CGAG GAGC AGCC GCCT CCTC CTCG TCGA CGAA GAAT AATA ATAC TACA ACAC CACC ACCA CCAA CAAA AAAC AACG ACGA CGAT GATC ATCA TCAC CACA ACAT CATT ATTG TTGG TGGC GGCA GCAC CACC ACCC CCCG CCGC CGCA GCAA CAAT AATC ATCC TCCT CCTG CTGC TGCT GCTA CTAC TACC ACCA CCAA CAAT AATG ATGC TGCT GCTG CTGC TGCA GCAA CAAT AATC ATCG TCGC CGCG GCGC CGCC GCCA CCAC CACA ACAA CAAC AACT ACTT,CTAGG TAGGA AGGAA GGAAC GAACT AACTG ACTGC CTGCC TGCCC GCCCC CCCCA CCCAG CCAGA CAGAA AGAAG GAAGC AAGCT AGCTG GCTGG CTGGA TGGAC GGACT GACTT ACTTC CTTCC TTCCC TCCCT CCCTA CCTAC CTACC TACCG ACCGC CCGCG CGCGC GCGCT CGCTA GCTAA CTAAC TAACA AACAA ACAAA CAAAG AAAGA AAGAC AGACG GACGG ACGGC CGGCA GGCAT GCATC CATCA ATCAT TCATA CATAC ATACG TACGC ACGCG CGCGT GCGTC CGTCG GTCGC TCGCA CGCAC GCACC CACCT ACCTG CCTGC CTGCG TGCGC GCGCG CGCGA GCGAG CGAGC GAGCC AGCCT GCCTC CCTCG CTCGA TCGAA CGAAT GAATA AATAC ATACA TACAC ACACC CACCA ACCAA CCAAA CAAAC AAACG AACGA ACGAT CGATC GATCA ATCAC TCACA CACAT ACATT CATTG ATTGG TTGGC TGGCA GGCAC GCACC CACCC ACCCG CCCGC CCGCA CGCAA GCAAT CAATC AATCC ATCCT TCCTG CCTGC CTGCT TGCTA GCTAC CTACC TACCA ACCAA CCAAT CAATG AATGC ATGCT TGCTG GCTGC CTGCA TGCAA GCAAT CAATC AATCG ATCGC TCGCG CGCGC GCGCC CGCCA GCCAC CCACA CACAA ACAAC CAACT AACTT,CTAGGA TAGGAA AGGAAC GGAACT GAACTG AACTGC ACTGCC CTGCCC TGCCCC GCCCCA CCCCAG CCCAGA CCAGAA CAGAAG AGAAGC GAAGCT AAGCTG AGCTGG GCTGGA CTGGAC TGGACT GGACTT GACTTC ACTTCC CTTCCC TTCCCT TCCCTA CCCTAC CCTACC CTACCG TACCGC ACCGCG CCGCGC CGCGCT GCGCTA CGCTAA GCTAAC CTAACA TAACAA AACAAA ACAAAG CAAAGA AAAGAC AAGACG AGACGG GACGGC ACGGCA CGGCAT GGCATC GCATCA CATCAT ATCATA TCATAC CATACG ATACGC TACGCG ACGCGT CGCGTC GCGTCG CGTCGC GTCGCA TCGCAC CGCACC GCACCT CACCTG ACCTGC CCTGCG CTGCGC TGCGCG GCGCGA CGCGAG GCGAGC CGAGCC GAGCCT AGCCTC GCCTCG CCTCGA CTCGAA TCGAAT CGAATA GAATAC AATACA ATACAC TACACC ACACCA CACCAA ACCAAA CCAAAC CAAACG AAACGA AACGAT ACGATC CGATCA GATCAC ATCACA TCACAT CACATT ACATTG CATTGG ATTGGC TTGGCA TGGCAC GGCACC GCACCC CACCCG ACCCGC CCCGCA CCGCAA CGCAAT GCAATC CAATCC AATCCT ATCCTG TCCTGC CCTGCT CTGCTA TGCTAC GCTACC CTACCA TACCAA ACCAAT CCAATG CAATGC AATGCT ATGCTG TGCTGC GCTGCA CTGCAA TGCAAT GCAATC CAATCG AATCGC ATCGCG TCGCGC CGCGCC GCGCCA CGCCAC GCCACA CCACAA CACAAC ACAACT CAACTT,CTAGGAA TAGGAAC AGGAACT GGAACTG GAACTGC AACTGCC ACTGCCC CTGCCCC TGCCCCA GCCCCAG CCCCAGA CCCAGAA CCAGAAG CAGAAGC AGAAGCT GAAGCTG AAGCTGG AGCTGGA GCTGGAC CTGGACT TGGACTT GGACTTC GACTTCC ACTTCCC CTTCCCT TTCCCTA TCCCTAC CCCTACC CCTACCG CTACCGC TACCGCG ACCGCGC CCGCGCT CGCGCTA GCGCTAA CGCTAAC GCTAACA CTAACAA TAACAAA AACAAAG ACAAAGA CAAAGAC AAAGACG AAGACGG AGACGGC GACGGCA ACGGCAT CGGCATC GGCATCA GCATCAT CATCATA ATCATAC TCATACG CATACGC ATACGCG TACGCGT ACGCGTC CGCGTCG GCGTCGC CGTCGCA GTCGCAC TCGCACC CGCACCT GCACCTG CACCTGC ACCTGCG CCTGCGC CTGCGCG TGCGCGA GCGCGAG CGCGAGC GCGAGCC CGAGCCT GAGCCTC AGCCTCG GCCTCGA CCTCGAA CTCGAAT TCGAATA CGAATAC GAATACA AATACAC ATACACC TACACCA ACACCAA CACCAAA ACCAAAC CCAAACG CAAACGA AAACGAT AACGATC ACGATCA CGATCAC GATCACA ATCACAT TCACATT CACATTG ACATTGG CATTGGC ATTGGCA TTGGCAC TGGCACC GGCACCC GCACCCG CACCCGC ACCCGCA CCCGCAA CCGCAAT CGCAATC GCAATCC CAATCCT AATCCTG ATCCTGC TCCTGCT CCTGCTA CTGCTAC TGCTACC GCTACCA CTACCAA TACCAAT ACCAATG CCAATGC CAATGCT AATGCTG ATGCTGC TGCTGCA GCTGCAA CTGCAAT TGCAATC GCAATCG CAATCGC AATCGCG ATCGCGC TCGCGCC CGCGCCA GCGCCAC CGCCACA GCCACAA CCACAAC CACAACT ACAACTT,"ID   NCAP_SARS2              Reviewed;         419 AA.
AC   P0DTC9;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Nucleoprotein {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=N;
DE   AltName: Full=Nucleocapsid protein {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=NC {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=Protein N {ECO:0000255|HAMAP-Rule:MF_04096};
GN   Name=N {ECO:0000255|HAMAP-Rule:MF_04096};
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   SUBCELLULAR LOCATION.
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [3] {ECO:0007744|PDB:6WZO, ECO:0007744|PDB:6WZQ}
RP   X-RAY CRYSTALLOGRAPHY (1.42 ANGSTROMS) OF 247-364, AND SUBUNIT.
RX   PubMed=32654247; DOI=10.1002/pro.3909;
RA   Ye Q., West A.M.V., Silletti S., Corbett K.D.;
RT   ""Architecture and self-assembly of the SARS-CoV-2 nucleocapsid protein."";
RL   Protein Sci. 29:1890-1901(2020).
RN   [4]
RP   REVIEW.
RX   PubMed=32974389; DOI=10.3389/fmolb.2020.00219;
RA   Nikolakaki E., Giannakouros T.;
RT   ""SR/RS Motifs as Critical Determinants of Coronavirus Life Cycle."";
RL   Front. Mol. Biosci. 7:219-219(2020).
RN   [5]
RP   VARIANTS LEU-3 AND PHE-235.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [6]
RP   FUNCTION, INTERACTION WITH HOST NLRP3, AND SUBCELLULAR LOCATION.
RX   PubMed=34341353; DOI=10.1038/s41467-021-25015-6;
RA   Pan P., Shen M., Yu Z., Ge W., Chen K., Tian M., Xiao F., Wang Z., Wang J.,
RA   Jia Y., Wang W., Wan P., Zhang J., Chen W., Lei Z., Chen X., Luo Z.,
RA   Zhang Q., Xu M., Li G., Li Y., Wu J.;
RT   ""SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce
RT   hyperinflammation."";
RL   Nat. Commun. 12:4664-4664(2021).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 41-174, AND MUTAGENESIS OF
RP   TYR-109.
RX   PubMed=32363136; DOI=10.1016/j.apsb.2020.04.009;
RA   Kang S., Yang M., Hong Z., Zhang L., Huang Z., Chen X., He S., Zhou Z.,
RA   Zhou Z., Chen Q., Yan Y., Zhang C., Shan H., Chen S.;
RT   ""Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain
RT   reveals potential unique drug targeting sites."";
RL   Acta Pharmacol. Sin. 10:1228-1238(2020).
RN   [8] {ECO:0007744|PDB:6YI3, ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT}
RP   STRUCTURE BY NMR OF 44-180, FUNCTION, AND MUTAGENESIS OF ARG-68; ARG-92;
RP   ILE-94; ARG-107; GLN-163; TYR-172 AND GLU-174.
RX   PubMed=33264373; DOI=10.1371/journal.ppat.1009100;
RA   Dinesh D.C., Chalupska D., Silhan J., Koutna E., Nencka R., Veverka V.,
RA   Boura E.;
RT   ""Structural basis of RNA recognition by the SARS-CoV-2 nucleocapsid
RT   phosphoprotein."";
RL   PLoS Pathog. 16:1-16(2020).
RN   [9]
RP   MUTAGENESIS OF SER-188 AND SER-206, AND PHOSPHORYLATION AT SER-206.
RX   PubMed=34593624; DOI=10.1073/pnas.2113401118;
RA   Liu X., Verma A., Garcia G. Jr., Ramage H., Lucas A., Myers R.L.,
RA   Michaelson J.J., Coryell W., Kumar A., Charney A.W., Kazanietz M.G.,
RA   Rader D.J., Ritchie M.D., Berrettini W.H., Schultz D.C., Cherry S.,
RA   Damoiseaux R., Arumugaswami V., Klein P.S.;
RT   ""Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:1-9(2021).
RN   [10]
RP   CLEAVAGE.
RX   PubMed=35922005; DOI=10.1038/s41586-022-05148-4;
RA   Chu H., Hou Y., Yang D., Wen L., Shuai H., Yoon C., Shi J., Chai Y.,
RA   Yuen T.T., Hu B., Li C., Zhao X., Wang Y., Huang X., Lee K.S., Luo C.,
RA   Cai J.P., Poon V.K., Chan C.C., Zhang A.J., Yuan S., Sit K.Y., Foo D.C.,
RA   Au W.K., Wong K.K., Zhou J., Kok K.H., Jin D.Y., Chan J.F., Yuen K.Y.;
RT   ""Coronaviruses exploit a host cysteine-aspartic protease for replication."";
RL   Nature 0:0-0(2022).
RN   [11]
RP   MUTAGENESIS OF 203-ARG-GLY-204 AND ARG-203, AND PHOSPHORYLATION.
RX   PubMed=35728038; DOI=10.1371/journal.ppat.1010627;
RA   Johnson B.A., Zhou Y., Lokugamage K.G., Vu M.N., Bopp N.,
RA   Crocquet-Valdes P.A., Kalveram B., Schindewolf C., Liu Y., Scharton D.,
RA   Plante J.A., Xie X., Aguilar P., Weaver S.C., Shi P.Y., Walker D.H.,
RA   Routh A.L., Plante K.S., Menachery V.D.;
RT   ""Nucleocapsid mutations in SARS-CoV-2 augment replication and
RT   pathogenesis."";
RL   PLoS Pathog. 18:e1010627-e1010627(2022).
RN   [12]
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=35921414; DOI=10.1126/sciadv.abp9770;
RA   Lopez-Munoz A.D., Kosik I., Holly J., Yewdell J.W.;
RT   ""Cell surface SARS-CoV-2 nucleocapsid protein modulates innate and adaptive
RT   immunity."";
RL   Sci. Adv. 8:eabp9770-eabp9770(2022).
RN   [13]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=34901782; DOI=10.1016/j.isci.2021.103562;
RA   Nabeel-Shah S., Lee H., Ahmed N., Burke G.L., Farhangmehr S., Ashraf K.,
RA   Pu S., Braunschweig U., Zhong G., Wei H., Tang H., Yang J., Marcon E.,
RA   Blencowe B.J., Zhang Z., Greenblatt J.F.;
RT   ""SARS-CoV-2 nucleocapsid protein binds host mRNAs and attenuates stress
RT   granules to impair host stress response."";
RL   IScience 25:103562-103562(2022).
RN   [14]
RP   FUNCTION.
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [15] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 191-263, AND INTERACTION WITH NSP3.
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
CC   -!- FUNCTION: Packages the positive strand viral genome RNA into a helical
CC       ribonucleocapsid (RNP) and plays a fundamental role during virion
CC       assembly through its interactions with the viral genome and membrane
CC       protein M (PubMed:33264373). Plays an important role in enhancing the
CC       efficiency of subgenomic viral RNA transcription as well as viral
CC       replication. Attenuates the stress granules formation by reducing host
CC       G3BP1 access to host mRNAs under stress conditions (PubMed:34901782,
CC       PubMed:36534661). {ECO:0000269|PubMed:32974389,
CC       ECO:0000269|PubMed:33264373, ECO:0000269|PubMed:34901782,
CC       ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: May block host chemokine function in vivo, facilitating viral
CC       replication and transmission (PubMed:35921414). Acts by being secreted
CC       into the extracellular space where it competes to host chemokines for
CC       binding to host glycosaminoglycans (GAG) (PubMed:35921414).
CC       {ECO:0000269|PubMed:35921414}.
CC   -!- FUNCTION: May induce inflammasome responses in cultured cells and mice.
CC       Acts by interacting with host NLRP3 to facilitate inflammasome
CC       assembly, which induces cytokine release that may play a role in COVID
CC       lung injury. {ECO:0000269|PubMed:34341353}.
CC   -!- SUBUNIT: Homodimer, homotetramer, homooligomer with RNA
CC       (PubMed:32654247). Both monomeric and oligomeric forms interact with
CC       RNA. Interacts with protein M (By similarity). Interacts with protein E
CC       (By similarity). Interacts with NSP3; this interaction serves to tether
CC       the genome to the newly translated replicase-transcriptase complex at a
CC       very early stage of infection (PubMed:35044811). May interact with host
CC       NLRP3 (PubMed:34341353). {ECO:0000250|UniProtKB:P59595,
CC       ECO:0000255|HAMAP-Rule:MF_04096, ECO:0000269|PubMed:32654247,
CC       ECO:0000269|PubMed:34341353, ECO:0000269|PubMed:35044811}.
CC   -!- INTERACTION:
CC       P0DTC9; P0DTC4: E; NbExp=3; IntAct=EBI-25475856, EBI-25475850;
CC       P0DTC9; P0DTC5: M; NbExp=6; IntAct=EBI-25475856, EBI-25475853;
CC       P0DTC9; P0DTC9: N; NbExp=105; IntAct=EBI-25475856, EBI-25475856;
CC       P0DTC9; PRO_0000449621 [P0DTD1]: rep; NbExp=15; IntAct=EBI-25475856, EBI-25492388;
CC       P0DTC9; P78563: ADARB1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-2967304;
CC       P0DTC9; O15145: ARPC3; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-351829;
CC       P0DTC9; Q13895: BYSL; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-358049;
CC       P0DTC9; Q16543: CDC37; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-295634;
CC       P0DTC9; Q92793: CREBBP; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-81215;
CC       P0DTC9; Q92499: DDX1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-358474;
CC       P0DTC9; Q9NR30: DDX21; Xeno; NbExp=12; IntAct=EBI-25475856, EBI-357942;
CC       P0DTC9; P26196: DDX6; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-351257;
CC       P0DTC9; Q08426: EHHADH; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-2339219;
CC       P0DTC9; P19525: EIF2AK2; Xeno; NbExp=8; IntAct=EBI-25475856, EBI-640775;
CC       P0DTC9; Q14241: ELOA; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-742350;
CC       P0DTC9; Q13283: G3BP1; Xeno; NbExp=71; IntAct=EBI-25475856, EBI-1047359;
CC       P0DTC9; Q9UN86: G3BP2; Xeno; NbExp=37; IntAct=EBI-25475856, EBI-1044298;
CC       P0DTC9; P57764: GSDMD; Xeno; NbExp=13; IntAct=EBI-25475856, EBI-2798865;
CC       P0DTC9; P49841: GSK3B; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-373586;
CC       P0DTC9; P10412: H1-4; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-358163;
CC       P0DTC9; O14920: IKBKB; Xeno; NbExp=7; IntAct=EBI-25475856, EBI-81266;
CC       P0DTC9; Q92830: KAT2A; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-477622;
CC       P0DTC9; Q92831: KAT2B; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-477430;
CC       P0DTC9; Q07866: KLC1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-721019;
CC       P0DTC9; Q9H0B6: KLC2; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-726994;
CC       P0DTC9; Q9NSK0: KLC4; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-949319;
CC       P0DTC9; Q9NX58: LYAR; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-713507;
CC       P0DTC9; O43318: MAP3K7; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-358684;
CC       P0DTC9; Q9UBU8: MORF4L1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-399246;
CC       P0DTC9; Q15014: MORF4L2; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-399257;
CC       P0DTC9; Q9HCE1: MOV10; Xeno; NbExp=11; IntAct=EBI-25475856, EBI-1055820;
CC       P0DTC9; Q9HC36: MRM3; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-1045440;
CC       P0DTC9; O15226: NKRF; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-766011;
CC       P0DTC9; Q96P20: NLRP3; Xeno; NbExp=18; IntAct=EBI-25475856, EBI-6253230;
CC       P0DTC9; O15118: NPC1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-2368710;
CC       P0DTC9; Q96HA8: NTAQ1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-741158;
CC       P0DTC9; P11940: PABPC1; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-81531;
CC       P0DTC9; P62937: PPIA; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-437708;
CC       P0DTC9; O75569: PRKRA; Xeno; NbExp=8; IntAct=EBI-25475856, EBI-713955;
CC       P0DTC9; Q99873: PRMT1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-78738;
CC       P0DTC9; P61289: PSME3; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-355546;
CC       P0DTC9; P26022: PTX3; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-11574553;
CC       P0DTC9; P54727: RAD23B; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-954531;
CC       P0DTC9; O95786: RIGI; Xeno; NbExp=15; IntAct=EBI-25475856, EBI-995350;
CC       P0DTC9; P62899: RPL31; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-1053664;
CC       P0DTC9; P62753: RPS6; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-356625;
CC       P0DTC9; P37840: SNCA; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-985879;
CC       P0DTC9; Q96SB4: SRPK1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-539478;
CC       P0DTC9; P78362: SRPK2; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-593303;
CC       P0DTC9; P42224: STAT1; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-1057697;
CC       P0DTC9; P52630: STAT2; Xeno; NbExp=7; IntAct=EBI-25475856, EBI-1546963;
CC       P0DTC9; Q15633: TARBP2; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-978581;
CC       P0DTC9; Q14258: TRIM25; Xeno; NbExp=13; IntAct=EBI-25475856, EBI-2341129;
CC       P0DTC9; O60763: USO1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-356164;
CC       P0DTC9; Q93008: USP9X; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-302524;
CC   -!- SUBCELLULAR LOCATION: Virion {ECO:0000255|HAMAP-Rule:MF_04096}. Host
CC       cytoplasm {ECO:0000269|PubMed:33060197, ECO:0000269|PubMed:34341353}.
CC       Secreted {ECO:0000269|PubMed:35921414}. Host extracellular space
CC       {ECO:0000269|PubMed:35921414}. Note=Probably associates with ER-derived
CC       membranes where it participates in viral RNA synthesis and virus
CC       budding. When located inside the virion, complexed with the viral RNA.
CC       Can be secreted by unconventional protein secretion (UPS)
CC       (PubMed:35921414). When secreted, can bind to host glycosaminoglycans
CC       on infected and non infected cells (PubMed:35921414). Found in host
CC       cytoplasmic stress granules (PubMed:34901782). {ECO:0000255|HAMAP-
CC       Rule:MF_04096, ECO:0000269|PubMed:34901782,
CC       ECO:0000269|PubMed:35921414}.
CC   -!- PTM: ADP-ribosylated. The ADP-ribosylation is retained in the virion
CC       during infection. {ECO:0000255|HAMAP-Rule:MF_04096}.
CC   -!- PTM: Phosphorylated on serine residues by host GSK3A and GSK3B
CC       (PubMed:34593624, PubMed:35728038). This promotes the solubility of
CC       homodimers that would otherwise aggregate (PubMed:32974389). Host
CC       phosphatase would dephosphorylate the protein during assembly at M
CC       bound membranes (PubMed:32974389). {ECO:0000269|PubMed:34593624,
CC       ECO:0000269|PubMed:35728038, ECO:0000305|PubMed:32974389}.
CC   -!- PTM: Proteolytically cleaved by host CASP6. The cleavage leads to two
CC       fragments and facilitates viral replication by inhibiting host IFN
CC       signaling. The two fragments may interact with IRF3 inhibiting its
CC       nuclear translocation after activation and reduce the expression of
CC       IFNB and IFN-stimulated genes. {ECO:0000269|PubMed:35922005}.
CC   -!- POLYMORPHISM: Variant Alpha/B.1.1.7 belongs to a lineage isolated first
CC       in United Kingdom (December 2020). It is also called Variant of Concern
CC       (VOC) 202012/01, Variant Under Investigation (VUI) 202012/01, 501Y.V1
CC       or 20B/501Y.V1. {ECO:0000305|PubMed:33413740}.
CC   -!- POLYMORPHISM: Variant Omicron/BA.1 and BA.2 belong to a lineage first
CC       isolated in South Africa (November 2021). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/BQ.1.1 belongs to a lineage first
CC       isolated in Nigeria (November 2022). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/XBB.1.5 belongs to a lineage first
CC       isolated in United States (November 2022). It is the result of
CC       recombination between omicron BJ.1 and BM.1.1. Moreover XBB.1.5 do not
CC       express ORF8. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the betacoronavirus nucleocapsid protein family.
CC       {ECO:0000255|HAMAP-Rule:MF_04096}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43423.2; -; Genomic_RNA.
DR   PDB; 6M3M; X-ray; 2.70 A; A/B/C/D=41-174.
DR   PDB; 6VYO; X-ray; 1.70 A; A/B/C/D=47-173.
DR   PDB; 6WJI; X-ray; 2.05 A; A/B/C/D/E/F=257-364.
DR   PDB; 6WKP; X-ray; 2.67 A; A/B/C/D=47-173.
DR   PDB; 6WZO; X-ray; 1.42 A; A/B/C/D=247-364.
DR   PDB; 6WZQ; X-ray; 1.45 A; A/B/C/D=247-364.
DR   PDB; 6YI3; NMR; -; A=44-180.
DR   PDB; 6YUN; X-ray; 1.44 A; A/B=249-364.
DR   PDB; 6ZCO; X-ray; 1.36 A; A=247-364.
DR   PDB; 7ACS; NMR; -; A=44-180.
DR   PDB; 7ACT; NMR; -; A=44-180.
DR   PDB; 7C22; X-ray; 2.00 A; A/B/C/D=248-364.
DR   PDB; 7CDZ; X-ray; 1.80 A; A/B/C/D=44-174.
DR   PDB; 7CE0; X-ray; 1.50 A; A/B/C/D=255-364.
DR   PDB; 7CR5; X-ray; 2.08 A; A=41-174.
DR   PDB; 7DE1; X-ray; 2.00 A; A/B=250-364.
DR   PDB; 7F2B; X-ray; 2.00 A; A/B=257-362.
DR   PDB; 7F2E; X-ray; 3.10 A; A/B/C/D/E/F/G/H/I/J/K/L=255-362.
DR   PDB; 7KGO; X-ray; 2.15 A; C=351-359.
DR   PDB; 7KGP; X-ray; 1.40 A; C=316-324.
DR   PDB; 7KGQ; X-ray; 1.34 A; C=222-230.
DR   PDB; 7KGR; X-ray; 1.55 A; C=159-167.
DR   PDB; 7KGS; X-ray; 1.58 A; C=138-146.
DR   PDB; 7KGT; X-ray; 1.90 A; C=226-234.
DR   PDB; 7LGD; X-ray; 2.88 A; E/F=105-113.
DR   PDB; 7LTU; X-ray; 1.12 A; A/B=217-222.
DR   PDB; 7LUX; X-ray; 1.30 A; A=217-222.
DR   PDB; 7LUZ; X-ray; 1.10 A; A=243-248.
DR   PDB; 7LV2; X-ray; 1.30 A; A=179-184.
DR   PDB; 7N0I; X-ray; 2.20 A; A/B/C/D/E/F/G/H=269-364.
DR   PDB; 7N0R; X-ray; 1.42 A; A/B=49-174.
DR   PDB; 7N3C; X-ray; 1.82 A; C=47-173.
DR   PDB; 7N3D; X-ray; 1.53 A; C=47-173.
DR   PDB; 7O05; X-ray; 1.94 A; A/B/C/D=247-364.
DR   PDB; 7O35; X-ray; 1.80 A; A/B/C/D=247-364.
DR   PDB; 7O36; X-ray; 2.00 A; A/B/C/D=247-364.
DR   PDB; 7PKU; NMR; -; B=191-263.
DR   PDB; 7QIK; X-ray; 2.01 A; E/F=193-200.
DR   PDB; 7QIP; X-ray; 2.65 A; C/D=201-210.
DR   PDB; 7R98; X-ray; 2.51 A; A/B/C=49-174.
DR   PDB; 7SD4; NMR; -; A=40-174.
DR   PDB; 7STR; X-ray; 1.50 A; C=47-173.
DR   PDB; 7STS; X-ray; 2.16 A; C/D=47-173.
DR   PDB; 7SUE; X-ray; 2.90 A; C/D/J/K=47-173.
DR   PDB; 7SUO; X-ray; 2.35 A; C/D=12-22.
DR   PDB; 7UW3; X-ray; 1.70 A; A/B/C/D=40-174.
DR   PDB; 7UXX; X-ray; 1.85 A; AAA/BBB/CCC/DDD/EEE/FFF=251-364.
DR   PDB; 7UXZ; X-ray; 1.73 A; AAA/BBB/CCC/DDD/EEE/FFF=251-364.
DR   PDB; 7VBD; X-ray; 1.94 A; A/B/C/D=48-174.
DR   PDB; 7VBE; X-ray; 1.59 A; A/B=257-364.
DR   PDB; 7VBF; X-ray; 1.30 A; A/B=255-364.
DR   PDB; 7VNU; X-ray; 1.95 A; A/B/C/D=47-174.
DR   PDB; 7WKJ; X-ray; 1.50 A; C=361-369.
DR   PDB; 7WZO; X-ray; 2.64 A; A=47-174.
DR   PDB; 7XWX; X-ray; 3.00 A; A/B/C/D/E/F/G/H=269-367.
DR   PDB; 7XWZ; X-ray; 2.25 A; A/B=48-172.
DR   PDB; 7XX1; X-ray; 1.90 A; A/B/C/D=49-173.
DR   PDB; 7XXK; X-ray; 2.00 A; A/B/C/D/E/F=248-364.
DR   PDB; 7YLB; X-ray; 2.41 A; A/B/C/D/G/H/J/K=247-364.
DR   PDB; 7YLD; X-ray; 2.80 A; A/B/C/D=47-174.
DR   PDB; 7ZIT; X-ray; 1.79 A; C/D=194-200.
DR   PDB; 8DNT; X-ray; 3.18 A; D/J/Q/X=222-230.
DR   PDB; 8FD5; EM; 4.57 A; A=1-419.
DR   PDB; 8FG2; EM; 6.00 A; A/B=1-419.
DR   PDB; 8IQJ; X-ray; 2.30 A; A/B/C/D=41-174.
DR   PDB; 8IV3; X-ray; 1.90 A; A/B/C/D=41-174.
DR   PDB; 8J6X; X-ray; 2.70 A; A/B/C/D=41-174.
DR   PDB; 8TH1; X-ray; 1.80 A; E/F/G/H=1-25.
DR   PDB; 8TH5; X-ray; 2.62 A; K/L/M/N/O/P/Q=1-25.
DR   PDB; 8X1H; X-ray; 2.00 A; A/B/C/D=44-175.
DR   PDBsum; 6M3M; -.
DR   PDBsum; 6VYO; -.
DR   PDBsum; 6WJI; -.
DR   PDBsum; 6WKP; -.
DR   PDBsum; 6WZO; -.
DR   PDBsum; 6WZQ; -.
DR   PDBsum; 6YI3; -.
DR   PDBsum; 6YUN; -.
DR   PDBsum; 6ZCO; -.
DR   PDBsum; 7ACS; -.
DR   PDBsum; 7ACT; -.
DR   PDBsum; 7C22; -.
DR   PDBsum; 7CDZ; -.
DR   PDBsum; 7CE0; -.
DR   PDBsum; 7CR5; -.
DR   PDBsum; 7DE1; -.
DR   PDBsum; 7F2B; -.
DR   PDBsum; 7F2E; -.
DR   PDBsum; 7KGO; -.
DR   PDBsum; 7KGP; -.
DR   PDBsum; 7KGQ; -.
DR   PDBsum; 7KGR; -.
DR   PDBsum; 7KGS; -.
DR   PDBsum; 7KGT; -.
DR   PDBsum; 7LGD; -.
DR   PDBsum; 7LTU; -.
DR   PDBsum; 7LUX; -.
DR   PDBsum; 7LUZ; -.
DR   PDBsum; 7LV2; -.
DR   PDBsum; 7N0I; -.
DR   PDBsum; 7N0R; -.
DR   PDBsum; 7N3C; -.
DR   PDBsum; 7N3D; -.
DR   PDBsum; 7O05; -.
DR   PDBsum; 7O35; -.
DR   PDBsum; 7O36; -.
DR   PDBsum; 7PKU; -.
DR   PDBsum; 7QIK; -.
DR   PDBsum; 7QIP; -.
DR   PDBsum; 7R98; -.
DR   PDBsum; 7SD4; -.
DR   PDBsum; 7STR; -.
DR   PDBsum; 7STS; -.
DR   PDBsum; 7SUE; -.
DR   PDBsum; 7SUO; -.
DR   PDBsum; 7UW3; -.
DR   PDBsum; 7UXX; -.
DR   PDBsum; 7UXZ; -.
DR   PDBsum; 7VBD; -.
DR   PDBsum; 7VBE; -.
DR   PDBsum; 7VBF; -.
DR   PDBsum; 7VNU; -.
DR   PDBsum; 7WKJ; -.
DR   PDBsum; 7WZO; -.
DR   PDBsum; 7XWX; -.
DR   PDBsum; 7XWZ; -.
DR   PDBsum; 7XX1; -.
DR   PDBsum; 7XXK; -.
DR   PDBsum; 7YLB; -.
DR   PDBsum; 7YLD; -.
DR   PDBsum; 7ZIT; -.
DR   PDBsum; 8DNT; -.
DR   PDBsum; 8FD5; -.
DR   PDBsum; 8FG2; -.
DR   PDBsum; 8IQJ; -.
DR   PDBsum; 8IV3; -.
DR   PDBsum; 8J6X; -.
DR   PDBsum; 8TH1; -.
DR   PDBsum; 8TH5; -.
DR   PDBsum; 8X1H; -.
DR   BMRB; P0DTC9; -.
DR   EMDB; EMD-29002; -.
DR   EMDB; EMD-29072; -.
DR   SASBDB; P0DTC9; -.
DR   SMR; P0DTC9; -.
DR   BioGRID; 4383847; 1532.
DR   ComplexPortal; CPX-5686; SARS-CoV-2 nucleocapsid complex.
DR   IntAct; P0DTC9; 608.
DR   MINT; P0DTC9; -.
DR   ChEMBL; CHEMBL5169223; -.
DR   iPTMnet; P0DTC9; -.
DR   ABCD; P0DTC9; 27 sequenced antibodies.
DR   DNASU; 43740575; -.
DR   KEGG; vg:43740575; -.
DR   AGR; RefSeq:YP_009724397; -.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-HSA-168928; DDX58/IFIH1-mediated induction of interferon-alpha/beta.
DR   Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-HSA-445989; TAK1-dependent IKK and NF-kappa-B activation.
DR   Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-HSA-9020702; Interleukin-1 signaling.
DR   Reactome; R-HSA-909733; Interferon alpha/beta signaling.
DR   Reactome; R-HSA-9694322; Virion Assembly and Release.
DR   Reactome; R-HSA-9694614; Attachment and Entry.
DR   Reactome; R-HSA-9694631; Maturation of nucleoprotein.
DR   Reactome; R-HSA-9694635; Translation of Structural Proteins.
DR   Reactome; R-HSA-9694786; Transcription of SARS-CoV-2 sgRNAs.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   Reactome; R-HSA-9733458; Induction of Cell-Cell Fusion.
DR   Reactome; R-HSA-9755779; SARS-CoV-2 targets host intracellular signalling and regulatory pathways.
DR   SIGNOR; P0DTC9; -.
DR   PRO; PR:P0DTC9; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProt.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0044172; C:host cell endoplasmic reticulum-Golgi intermediate compartment; ISS:UniProtKB.
DR   GO; GO:0044177; C:host cell Golgi apparatus; ISS:UniProtKB.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; ISS:UniProtKB.
DR   GO; GO:0043655; C:host extracellular space; IEA:UniProtKB-SubCell.
DR   GO; GO:0043232; C:intracellular non-membrane-bounded organelle; IDA:DisProt.
DR   GO; GO:0042612; C:MHC class I protein complex; EXP:DisProt.
DR   GO; GO:1990904; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IPI:ComplexPortal.
DR   GO; GO:0019013; C:viral nucleocapsid; ISS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0042288; F:MHC class I protein binding; EXP:DisProt.
DR   GO; GO:0140693; F:molecular condensate scaffold activity; IDA:DisProt.
DR   GO; GO:0008266; F:poly(U) RNA binding; IMP:DisProt.
DR   GO; GO:0042803; F:protein homodimerization activity; EXP:DisProt.
DR   GO; GO:0140311; F:protein sequestering activity; IDA:UniProt.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProt.
DR   GO; GO:0035613; F:RNA stem-loop binding; IDA:DisProt.
DR   GO; GO:0039709; P:cytoplasmic capsid assembly; IDA:UniProt.
DR   GO; GO:0032688; P:negative regulation of interferon-beta production; IDA:ComplexPortal.
DR   GO; GO:1900227; P:positive regulation of NLRP3 inflammasome complex assembly; IDA:UniProtKB.
DR   GO; GO:0052572; P:response to host immune response; IDA:DisProt.
DR   GO; GO:0019074; P:viral RNA genome packaging; NAS:ComplexPortal.
DR   CDD; cd21595; CoV_N-CTD; 1.
DR   CDD; cd21554; CoV_N-NTD; 1.
DR   HAMAP; MF_04096; BETA_CORONA_NCAP; 1.
DR   InterPro; IPR044344; N_prot_C_CoV.
DR   InterPro; IPR044345; N_prot_N_CoV.
DR   InterPro; IPR043505; NCAP_bCoV.
DR   InterPro; IPR001218; Nucleocap_CoV.
DR   InterPro; IPR037179; Nucleocapsid_C.
DR   InterPro; IPR037195; Nucleocapsid_N.
DR   Pfam; PF00937; CoV_nucleocap; 1.
DR   PIRSF; PIRSF003888; Corona_nucleocap; 1.
DR   SUPFAM; SSF110304; Coronavirus RNA-binding domain; 1.
DR   SUPFAM; SSF103068; Nucleocapsid protein dimerization domain; 1.
DR   PROSITE; PS51929; COV_N_CTD; 1.
DR   PROSITE; PS51928; COV_N_NTD; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ADP-ribosylation; Host cytoplasm; Phosphoprotein;
KW   Reference proteome; Ribonucleoprotein; RNA-binding; Secreted;
KW   Transcription; Transcription regulation; Viral nucleoprotein; Virion.
FT   CHAIN           1..419
FT                   /note=""Nucleoprotein""
FT                   /id=""PRO_0000449656""
FT   DOMAIN          48..174
FT                   /note=""CoV N NTD""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01276,
FT                   ECO:0000269|PubMed:32363136""
FT   DOMAIN          247..364
FT                   /note=""CoV N CTD""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01277""
FT   REGION          1..51
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          41..186
FT                   /note=""RNA-binding""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   REGION          63..83
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          168..212
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          176..206
FT                   /note=""SR region""
FT                   /evidence=""ECO:0000305|PubMed:32974389""
FT   REGION          233..266
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          258..361
FT                   /note=""Dimerization""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   REGION          260..340
FT                   /note=""Putative NLRP3 binding""
FT                   /evidence=""ECO:0000269|PubMed:34341353""
FT   REGION          361..391
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          400..419
FT                   /note=""Tetramerization""
FT                   /evidence=""ECO:0000269|PubMed:32654247""
FT   MOTIF           256..264
FT                   /note=""Nuclear localization signal""
FT                   /evidence=""ECO:0000250|UniProtKB:P59595""
FT   COMPBIAS        1..11
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        21..31
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        367..378
FT                   /note=""Basic and acidic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   BINDING         92
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   BINDING         107
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   BINDING         149
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   SITE            399..402
FT                   /note=""Cleavage (by host CASP6)""
FT                   /evidence=""ECO:0000250|UniProtKB:P59595""
FT   MOD_RES         176
FT                   /note=""Phosphoserine; by host""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   MOD_RES         206
FT                   /note=""Phosphoserine; by host GSK3-alpha and GSK3-beta""
FT                   /evidence=""ECO:0000269|PubMed:34593624""
FT   VARIANT         2..3
FT                   /note=""SD -> Y (in strain: Eta/B.1.525)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         3
FT                   /note=""D -> L (in strain: Alpha/B.1.1.7)""
FT                   /evidence=""ECO:0000305|PubMed:33413740""
FT   VARIANT         12
FT                   /note=""A -> G (in strain: Eta/B.1.525)""
FT   VARIANT         13
FT                   /note=""P -> L (in strain: Lambda/C.37, Omicron/BA.1,
FT                   Omicron/BA.2, Omicron/BA.2.12.1, Omicron/BA.2.75,
FT                   Omicron/BA.4, Omicron/BA.5, Omicron/BQ.1.1,
FT                   Omicron/XBB.1.5, Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         31..33
FT                   /note=""Missing (in strain: Omicron/BA.1, Omicron/BA.2,
FT                   Omicron/BA.2.12.1, Omicron/BA.2.75, Omicron/BA.4,
FT                   Omicron/BA.5, Omicron/BQ.1.1, Omicron/XBB.1.5,
FT                   Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         63
FT                   /note=""D -> G (in strain: Delta/B.1.617.2)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT  ",50430
ACTGAT CTGATC TGATCC GATCCT ATCCTT TCCTTA CCTTAT CTTATG TTATGA TATGAA ATGAAG TGAAGA GAAGAT AAGATT AGATTT GATTTT ATTTTC TTTTCA TTTCAA TTCAAG TCAAGA CAAGAA AAGAAA AGAAAA GAAAAC AAAACT AAACTG AACTGG ACTGGA CTGGAA TGGAAC GGAACA GAACAC AACACT ACACTA CACTAA ACTAAA CTAAAC TAAACA AAACAT AACATA ACATAG CATAGC ATAGCA TAGCAG AGCAGT GCAGTG CAGTGG AGTGGT GTGGTG TGGTGT GGTGTT GTGTTA TGTTAC GTTACC TTACCC TACCCG ACCCGT CCCGTG CCGTGA CGTGAA GTGAAC TGAACT GAACTC AACTCA ACTCAT CTCATG TCATGC CATGCG ATGCGT TGCGTG GCGTGA CGTGAG GTGAGC TGAGCT GAGCTT AGCTTA GCTTAA CTTAAC,0,79,ACTG CTGA TGAT GATC ATCC TCCT CCTT CTTA TTAT TATG ATGA TGAA GAAG AAGA AGAT GATT ATTT TTTT TTTC TTCA TCAA CAAG AAGA AGAA GAAA AAAA AAAC AACT ACTG CTGG TGGA GGAA GAAC AACA ACAC CACT ACTA CTAA TAAA AAAC AACA ACAT CATA ATAG TAGC AGCA GCAG CAGT AGTG GTGG TGGT GGTG GTGT TGTT GTTA TTAC TACC ACCC CCCG CCGT CGTG GTGA TGAA GAAC AACT ACTC CTCA TCAT CATG ATGC TGCG GCGT CGTG GTGA TGAG GAGC AGCT GCTT CTTA TTAA TAAC,ACTGA CTGAT TGATC GATCC ATCCT TCCTT CCTTA CTTAT TTATG TATGA ATGAA TGAAG GAAGA AAGAT AGATT GATTT ATTTT TTTTC TTTCA TTCAA TCAAG CAAGA AAGAA AGAAA GAAAA AAAAC AAACT AACTG ACTGG CTGGA TGGAA GGAAC GAACA AACAC ACACT CACTA ACTAA CTAAA TAAAC AAACA AACAT ACATA CATAG ATAGC TAGCA AGCAG GCAGT CAGTG AGTGG GTGGT TGGTG GGTGT GTGTT TGTTA GTTAC TTACC TACCC ACCCG CCCGT CCGTG CGTGA GTGAA TGAAC GAACT AACTC ACTCA CTCAT TCATG CATGC ATGCG TGCGT GCGTG CGTGA GTGAG TGAGC GAGCT AGCTT GCTTA CTTAA TTAAC,ACTGAT CTGATC TGATCC GATCCT ATCCTT TCCTTA CCTTAT CTTATG TTATGA TATGAA ATGAAG TGAAGA GAAGAT AAGATT AGATTT GATTTT ATTTTC TTTTCA TTTCAA TTCAAG TCAAGA CAAGAA AAGAAA AGAAAA GAAAAC AAAACT AAACTG AACTGG ACTGGA CTGGAA TGGAAC GGAACA GAACAC AACACT ACACTA CACTAA ACTAAA CTAAAC TAAACA AAACAT AACATA ACATAG CATAGC ATAGCA TAGCAG AGCAGT GCAGTG CAGTGG AGTGGT GTGGTG TGGTGT GGTGTT GTGTTA TGTTAC GTTACC TTACCC TACCCG ACCCGT CCCGTG CCGTGA CGTGAA GTGAAC TGAACT GAACTC AACTCA ACTCAT CTCATG TCATGC CATGCG ATGCGT TGCGTG GCGTGA CGTGAG GTGAGC TGAGCT GAGCTT AGCTTA GCTTAA CTTAAC,ACTGATC CTGATCC TGATCCT GATCCTT ATCCTTA TCCTTAT CCTTATG CTTATGA TTATGAA TATGAAG ATGAAGA TGAAGAT GAAGATT AAGATTT AGATTTT GATTTTC ATTTTCA TTTTCAA TTTCAAG TTCAAGA TCAAGAA CAAGAAA AAGAAAA AGAAAAC GAAAACT AAAACTG AAACTGG AACTGGA ACTGGAA CTGGAAC TGGAACA GGAACAC GAACACT AACACTA ACACTAA CACTAAA ACTAAAC CTAAACA TAAACAT AAACATA AACATAG ACATAGC CATAGCA ATAGCAG TAGCAGT AGCAGTG GCAGTGG CAGTGGT AGTGGTG GTGGTGT TGGTGTT GGTGTTA GTGTTAC TGTTACC GTTACCC TTACCCG TACCCGT ACCCGTG CCCGTGA CCGTGAA CGTGAAC GTGAACT TGAACTC GAACTCA AACTCAT ACTCATG CTCATGC TCATGCG CATGCGT ATGCGTG TGCGTGA GCGTGAG CGTGAGC GTGAGCT TGAGCTT GAGCTTA AGCTTAA GCTTAAC,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",495
GTGGTG TGGTGA GGTGAA GTGAAG TGAAGC GAAGCT AAGCTC AGCTCA GCTCAC CTCACC TCACCG CACCGA ACCGAT CCGATT CGATTA GATTAC ATTACG TTACGA TACGAG ACGAGA CGAGAA GAGAAT AGAATC GAATCC AATCCG ATCCGC TCCGCG CCGCGC CGCGCA GCGCAC CGCACC GCACCG CACCGA ACCGAC CCGACA CGACAC GACACG ACACGA CACGAT ACGATC CGATCT GATCTA ATCTAC TCTACG CTACGA TACGAG ACGAGG CGAGGA GAGGAC AGGACA GGACAG GACAGT ACAGTC CAGTCT AGTCTC GTCTCA TCTCAT CTCATC TCATCA CATCAT ATCATG TCATGA CATGAA ATGAAA TGAAAC GAAACT AAACTG AACTGT ACTGTT CTGTTC TGTTCG GTTCGT TTCGTG TCGTGT CGTGTT GTGTTT TGTTTC GTTTCA TTTCAG TTCAGT TCAGTT CAGTTT AGTTTG GTTTGT TTTGTC TTGTCA TGTCAA GTCAAC TCAACT CAACTC AACTCG ACTCGT CTCGTA TCGTAC CGTACG GTACGC TACGCC ACGCCT CGCCTC GCCTCG CCTCGT CTCGTT TCGTTC CGTTCT GTTCTT TTCTTT TCTTTT CTTTTT TTTTTC TTTTCT TTTCTT TTCTTG TCTTGG CTTGGC TTGGCG TGGCGT GGCGTT GCGTTC CGTTCA GTTCAT TTCATT,2,121,GTGGG G T ATTGGGGTGT T G GGGGTGTGCAGATG GTTGAGA A T TGTGAGAAAA A G GAGAAAAGGTTG A AAAAGCCGC A AGAGC TTCT T G GCGCTCTCTC  GCG GCTCTCACA A T TCTCAC CAC GT  TCTTCACCCC C A ACG CCG GA TT CGAGA  CGCGAGATAT T G GAGATATTAA  TGATTTTATA A T TTTTATACAC C T TATACACGCG G A ACACGAT GA A C CGCT GAGAG  GAGAGAGTGA  GA AGAGAAA A G GAGAAAT T A AAAATATCTC C AC AA CC CCC C T TCTCCA TGCGCCG CCCCGCGCGC CACACCCGCCG  CT GCCGCGC C C CGGCAA G GCT GCACTCTTCA CACAC TGCC C G AC CGCCGCG G C CCCCGCGA GTTCGCGAGACAC C G GAGACACA CCA A ACCACAC C C CACACACGG A ACACGCGAGA A C CGCGAGATCGAT G GAGATATCTC C A ATATCTCTCT TT  TCTCTTA A C CTCTATACAC C T TATACACGCG  AA ACACGCGAGA A C CGCGAGAGAG G G GAAGGGG  AGAGGGGAGA A GCATGGCAC C GA AGACGTCA A ACAC TG G C CACAGTTTT A AGAGACA TC TTCG CG GTCTG TT T TC CTCTCTC C CAT CTCTCACA  TCTCACATAT T C CACATATCTC C A ATATCTCAA T TCTCAGGATCTT C CACATATGTG G A ATGTCTGAGA A T TGAA CATAAATCTA AG AAAAACAC A AAAACACTCA  ACACTCTGTG G C CTCTGTGTT TACCGTTTT T G GTGTTTTCCTCC CTTTTCGCG G TTCGTT T C CGCGTGTGTG G G GTGTGTGTGT T T TGTGTTT GCA GTGTTTTTTT T T TTTTTTTCTC C TTTGTTCTCACA TG TCACAGAG G C CACAGAGTGT T A AGAGTAACTT T G GTGTTTTTT T TTTTTTTGTG CT  TTTTGGT T T TGTGTGTCTC  GTCA A T TCC TCAAA C CACAAAG AC  AT AAAACACTCGAT A ACACTC TTC C C CTCTC CGCG G T TCTCGCGTA GT C CGCGTGTATA  GTGTATACC TTACACG ACACGCGCTCCCGTCGCGCCCC C AC CGCCCCTCT T C CCCCTCTCTC C C CTCTCTCGCG G T TCTCGCGT CGCGTGTTT TT G GTGTTCACTC C TGCTTTCCT T T TCCTTTT T C CTCTTCT TT T T TTTTTTTTTT T T TTTTTTTTT AT T TTTTCTC TCA TTTTCTCTCT T T TCGT CTTTT T C CTCTTTTGGC G T TTTGGGG G TGGCGC C G GGGACGCGCG G G GCCG  CGGT  CGCGTGTTTT T G GTGTTTTCTC  TTC GTCACA A T TCTCACATAT T C CAATT,GTGTGGGGTTC T T TGTGGGGTGTGG G GGGTGTGATCTA G GTGTGTGAT TA T TGTGACT AAGAG G G GAGAAAAGGC C AC TAAGAGCGCTGAA AGAGCGCTCTCTC C G GCGCTCTCTCACA A C CTCTCTCACACC TGAGTCACACACCCC C C CACACACCCG G A ACC AG ACGAGA A C CCGAGCGAGATT C CGCGAGATATTT G GAGATATTAC TA  GT ATATTTGTTACAC C T TTTTATAC CTCG G T TATACCGAGCCA AACGCGAGAGAG G C CGCGAGAGAGAGA  GACCGAGAGAAAA A A AGAGAGAA ATT G GAGAACGTATCTC C A AAAAT GTTCGCC C A ATATCTCCCCGCG G T TCTCCCCGCGCGC TTT CCCGCGCGCG TCACGCGCGCGCGC C GCTTGCGGCACA A C CGCTCGCACACC G GCGCACACACCCC C CACGCACACCCCGCG G A ACACCCCGGATGA A C CCCCGCGAGACAC  GA CGCGAGACACACA A GCTGGACACACTTAC C A ACACACACACGCG G C CAACGTTG ACACGGATAT T C CGCGAGATATCTC C G GACGAAT TCTCT TTTAT CCGTCTCTATA A T TCCAGTACAC C C CTCTATACACGCG T G TATACACGCGAGA A A ACACGCGAGAGCC  CGCGACTAAGGGG G G GA TCAGGGGAGA T T AGAGGGGAG GAC  TT GGGGAGACACACA A GT A GTACAGAGAG CCG ACAGTGT T C CACAGAGTGTCTC C A AGAGTGTCTCTCT  GTGTCTCTCGCTC  AA TCTCTGTTTCACA A C CTCTCTCACATAT T T TCTCACATATCC CCGT TCTCACA A ATTGATCTCACATT TT CCATATGTG G CCATATGACTA A ATATGTGAGAAAA A T TGTGAGAAAAAAA GAAGAAAAAAACAC C A AAAAAAACACTCT T A AAAACT G GAG A ACACTTGTT CGACCTGCGCGTTTT  TT TGTTATTCTC C GA AGTTTTCTCGCG G TC GTTCTCGGT T T TCTCGAATGTGTG G C CAGTGTGTGT T G GTGTGTGTGTTTT T TGT TGTGTTTC TT T G GTGTTTTTTTCTC C T TTTTTTTCCA A TG CTTCCAG TCTCACAGAGTGT T CGTACAGAGTGTTTT ATC AGAGTGTTTTTTT ACTATCTTTTTGTG TGA TTC CGA TGTGT T T TTTTGTGTGTCTC C T TGTGTGTCCA A G CATACTCACAAG CA T TCTCACAAAACC C CACAAAACACTCT T A AAAACACTCTCTC  ACG TCTCTCGCG AA  CTG CTCGCGT TGT T TCTCGCGTGTATA A C CGCGTGTATACAC C G CAGTCACGCG G T TATACACGCGCGC  ACACGTGTTT AG C CTGGCAGCT T G GCGCCCTCTTTC C CCCCTCTCCG G CATTCTCTCGCGTGT  TCTCCGTTTT T C CGCGTGTTTTCTC C G GTGTTTTCTCTCT T TTTCTCTT TATCTCTCACATCT C CTCTTTTTTTTTT T TTTTTTTTTTTT  TTTTTTTTTTCTC C T TTTTTTTCTCTCT  CG TTTTCTCTCTTGA AA  TCTCTCTT ATTG  TT CT GCTTG CGGG G T TTTTGTGGGGCGC C T TGTGGGGCGCGCG GAC GGGCGCGTG T GCGCGT TGTTTT  TC CGCGTGTTTTCTC C GTTCTCACA A TT TTTCG CAT T T TCTCACAT,TGGAGTGTGCATTACTGGGGTGTGGCGGA  AG GGGGTGTGTGAGAAAA A G GTGTGGAAAG G T TGTGAGAAAAGC G GAGAAAAGAGCGC  CC AAAAGAGCGCTCAATC C AT TAGCGCTCTCTCACA GAGT TCTTAGATCACACAC  CTCTCACCCC C T TCTCACACACCT TCG G CCA ACCCCGCGAGA A A ACCCGCGAG T CCGAGGAAGATATTTT T C CGCGAGATATTTTAA G GAGATATTTTA TAAC C A ATCGATTATACACGTCGTTA GCACGATTGA GTC TATACACGCGACCGG A ACACGCGAGAGAGAGA TG CGAGAGCTCGAAAA A G GAGCGGAAAATTTGT A AGGAAAATATC GAGAAAATATCTCCCC C A AAAATATCAT CCGCG G A ATATCTCCCCGACAGC TTGGCGTCCCCGCGCAGACG G C CCCCGCGCTC CGCGCTC CCGCGCGCGCT A CAA G GCGCGCGCGCACACTCTC C CGCGCGCACACACCCC ACG GCGCACACCG GAA CAACCCCGCGAGA A ATCGACCCCGCGAAC C C CCCCGCGAGACACACA A C CGCGACAACACAC C G GAGACACAACGCG GT TCGACGCGAGA A C CACACACGCGAGATTCCT A ACCGTCGAGATATCTC C CATCGATATCTCTCA T G GAGATATCTCTCTATA A A ATATCTCTCTATACAC TTT TCTCTTACTGTCG G C CTCTATACC GCGAGA  TATACACGCGAGAGAG G A ACCGAGAGAGGGG G C CGCGAGAGAGGGGAGA A G GAA G GCGGAGACC A AGAGGGGAGACCA A GATCGGAGACACAATGAG  GAGACACACAGTCTACAT A ACC TCAGAGTAGTTTCC C CACAGAGTTCT AGAGTGTCTCTCTCAA C GGTCAC CTCTCACT A T TCCATCTCTCACATAT T C CTCTCTGTCATATCTC C T TCTCACAT CGTCACA A C CAT ATCGTCACATAT T A ATTGT TCCATATGTG TC TCAATGTGAGA A C CATCTAA A A ATATGTGAGAAAAAAA A T TGTGAG CAAACAGGTTC G GACGAAAAAACACT AC AAAAAAACACTTG G A AAAACCTGTGTGT GCAACTCTGTGTGTTTCAT C CTCTG GGGTTTTCTC C T TGACGGTTTTCTCGCG G G GTGTTTTCTCGCGTGT TAC TTTTCTCGCGTGTGTG T C TCTCGCGTGTGTT GT T C CGCGTGTGTGTGTTTT T G GTGTGTGTGTTTTTTT GC TGTGTTTTTAACTC C G GTGTTTTTTTCTCACA A T TTTTTTTCTCACAGACAG T TTTTCTCACAGGTCGT CCG TCTCATTCGTTTT T C CACAGAGTGTTTTTT A AGGGTGTTTTTTTG CGG G GTGTTC TTTGTTTGT T T TTTTTTACTGTA TTTCC T TTTTGTGTGTCTCAGTAA T TGGTCTCACAATC A G GTCACGACAACAC C T TCTCG CTAACACTCT T C CA TTAACACTTC C A AAAACACTTCGCG G A ACACTCTCTCGCGTGT T CCTCCTCCG CGTTA A T TCCGTACGGTATACAC C C CGCGTGTATACACGCG CA ACGCGCGC ACA TGTACACGCGCGCCCC C A ACACGCGCGCCCCTCT G TCGCGCCCCTCTCTC C GGCCCTCGTCCG G CT ACCTCTCTTCCGTT C CTCTCTCGCGTGTTTT T TTCAGTTGATTC  CGCGTGTTTC CT T G GTGTTTTCAGT TTTTCTTTT T TCTCTCTTTTTTTTT C CTGCTTTTTTTTTTTT A GCAATGGTTTTTTTTCTC C T TTTTTTTTATCTCTCT T T TTTTCTCTCTTT T TTTTCTCTCTTC TTG G T TCTCTCTTTTGTGGGG G C CTCTTTTGTGGGGC TGC T TTTTGTGGGGCGCGCG  TGTTTGGCGCGCGTGAAT GGGC TCCGTAC TT T G GCTGACGTACGTTCC C CGCGTGTTTTCCA A G GTGTTTTCTCA CGAT T T TTTTCTCACATATT,GTGTGGGGTGTGTGAGA A T TGTGGGGTGTGTGAGAAAA GAA GGGGTGTGGTATTAAAGAG GCG GTGTGTGAGAAAAGAGCGC C T TGTC GCTCT T GCGCGAAAAGAGCTC AGTGT C AAGCGCTCTCTCACA A ACCGAGCGCTCTCTCACACAC TTC GCGCTCTCTCACC C C CTCTCTCACACACCCCGCG ACG TCTC CACACCCGAA CTCAACCCCGCGACAGAT T A ACACCCCGGATATTTT TCA CCCCGCGAGGAATTTTATA A C CGCGATT  TCTACAC C G GAGATATTGAACG GAC ATATTTTATACACGCGAGA  GATTATACCACCGAGAGAG G T TATACACGCGAGAGAGGA AG TCGAGAGAGAGAA CGGAGAGAGAAAT T GTACTGAA CGAAAATTC C A AGAGAGAAACGATCTCCCC C G GACTTAATATCTCCCCGCG G A AAAATATCTCCT TCGCGC C A ATTCCCCGAT CG G T TCTCCCCGCGCGCGCGCGC C C CCCATCGCGCGACGGCACA  CGCGCGCGCGCGCACGAAC C G GCGCG GAGCACACACCC C CGCGCCACCTCCCGCG G G AAGCACACACCCCGCGAGA A CCACACCCCGCGAGACAC C A ACACCCCGCGAGACCTCTTT CCCCGCGAGACACAAAGAC C C CGCGAG AACACACAGGCG G GC AGACACACACACGGGCA A ACTCTAATACGCGATGTAT T C CAACGCGAGATATCTC C AACGCGAGATATCTC CT T C ACGATGATATCTCTCTATA A G GAGATATCTCTCTAAC  ATTACCG G T TCTCTCTATACACGCGAA C CTTACACGAT GCGAG G TTTGTACCGAGAGAGAGG G A ACCGAAGGGGAGA A CCTCTTGGAGACGGATAC C G GAGAGAGGTTCGACACACA A A AGAGGGGAGACACACAGAG ACG GGTCT TCACACAGAGTTCTT G GAGACACACAGAGTGTCTTCGTT ACACACAGAGTGTCGGACT T C CACAGAGTGTCCTCCTG AGCTCGTCTCTACATCACA A G GTTCTACCCATCACT TTCTCTCTCACATATCTC C CTCACATATCTCACA TTT TCA CCATATCTCAT GT CTTCCATATCTCATTCTG G A ATATCT CCATATGTGAGA A T TCTCACATATGTGAGAAAA A C CACATATGTGAGAAAAAAA A A ATGAGGAAAAAAACAC C T TGGAAAAAACTCT T G GAGAAAAAAACTAC CATG  GCAAAAACACTTTCTGTGT T A AAAACACTCTGTGT CGGTTT A ACT TCTGTGTGTTTTCTC C CGC CTGTGTGTTTTCTCGCG CTT TGTGTCGTTTCCCTCGTGT T G AGTT TTCATCCGTGTGTG G TTCTTTCTCGCGTGTGTGTGT ACT TCTCGCGTTGTGTTT C CGCGTGTGTGTGTTTTTTT CGA GTGTGTGTGTTTTTTTCC T TGTGTGTTTTTTTCA TCA A G GTGTTTTTATGTCACAGAG G T TTTTCCAGCGTGT T T TTTTCTCACAGAGTGTT CAT T TCTCAGATAGTGTTTTTTT AGTTACCAGT CGTTTTTTTGTG G A AGAGTGTTTTT TATTGGT T G GTGTTTTGTGTGTCGCGC TTTTTTGTGTGTCTCACA A T TTTTGTGTGTCCAAAA A T TGGTCTCACAAAACGTTGGA GTGTCCAAAACACTCT T T TCGCCCAAACTCTCTCTC CCGACAAAACT TCTCTCGCG G A AAAACACTCTCTCGCGTGT T A ACACTTCGTGATA TCA CTCGTGTAC TGA TCGCGTGTATACACGCG G C CGAC GTA CACGC CTC G GTGTAACTACGCGCTCACC  TAACGCGCGCCCCTCT T ATACACGCGCGCCTCGCTCTC C C CGCGCGCCCTCTCGCG  GCCCTCTCTCGCGTT C CCTCGTC GTTTT T C CTCTCTCGCGTC ATTCTC CACTCGCGTGTTCTGACACT T C CGCGTGTTTCATCTCTTTT T G GTGTTTTCTCTCTTTTTTT  GTTTCTCTCTTTTTTTTTT ACTATT TTCTTTTTTTTTTTTT T C CTCTTTTTTTTTTTCGTC T TTTTTTTTTTT CACT T T TTCA TTTTTCTCTG TTT T T TTTTTC GTCTTTGTG G TTTCGCTCTTTGGGG G TGACTCTCTTCGATGGGC C CA GTGTGGCGCGCG G T TTTTGTGGGGCGCGCGTGT T T TGTGGTCAGAGAGTTT T G GGGGCGCGCGTGTTC GTC C G GCG GCGTGTTTTCTCACA A C CGCGTGTTTTCTCACATAT T G GTTTCGGCCCGACG,"ID   ANO6_MOUSE              Reviewed;         911 AA.
AC   Q6P9J9; Q8C242;
DT   13-SEP-2005, integrated into UniProtKB/Swiss-Prot.
DT   05-JUL-2004, sequence version 1.
DT   05-FEB-2025, entry version 152.
DE   RecName: Full=Anoctamin-6;
DE   AltName: Full=Small-conductance calcium-activated nonselective cation channel;
DE            Short=SCAN channel;
DE   AltName: Full=Transmembrane protein 16F;
GN   Name=Ano6;
GN   Synonyms=Tmem16f {ECO:0000303|PubMed:21107324,
GN   ECO:0000303|PubMed:30785399};
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   STRAIN=C57BL/6J; TISSUE=Dendritic cell;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., Davis M.J.,
RA   Wilming L.G., Aidinis V., Allen J.E., Ambesi-Impiombato A., Apweiler R.,
RA   Aturaliya R.N., Bailey T.L., Bansal M., Baxter L., Beisel K.W., Bersano T.,
RA   Bono H., Chalk A.M., Chiu K.P., Choudhary V., Christoffels A.,
RA   Clutterbuck D.R., Crowe M.L., Dalla E., Dalrymple B.P., de Bono B.,
RA   Della Gatta G., di Bernardo D., Down T., Engstrom P., Fagiolini M.,
RA   Faulkner G., Fletcher C.F., Fukushima T., Furuno M., Futaki S.,
RA   Gariboldi M., Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N., Hill D.,
RA   Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T., Jakt M.,
RA   Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H., Kitano H.,
RA   Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K., Kurochkin I.V.,
RA   Lareau L.F., Lazarevic D., Lipovich L., Liu J., Liuni S., McWilliam S.,
RA   Madan Babu M., Madera M., Marchionni L., Matsuda H., Matsuzawa S., Miki H.,
RA   Mignone F., Miyake S., Morris K., Mottagui-Tabar S., Mulder N., Nakano N.,
RA   Nakauchi H., Ng P., Nilsson R., Nishiguchi S., Nishikawa S., Nori F.,
RA   Ohara O., Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G.,
RA   Pesole G., Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z.,
RA   Ringwald M., Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B., Sperling S.,
RA   Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K., Tammoja K.,
RA   Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A., Ueda H.R.,
RA   van Nimwegen E., Verardo R., Wei C.L., Yagi K., Yamanishi H.,
RA   Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C., Grimmond S.M.,
RA   Teasdale R.D., Liu E.T., Brusic V., Quackenbush J., Wahlestedt C.,
RA   Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y., Fukuda S.,
RA   Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T., Iida J., Imamura K.,
RA   Itoh M., Kato T., Kawaji H., Kawagashira N., Kawashima T., Kojima M.,
RA   Kondo S., Konno H., Nakano K., Ninomiya N., Nishio T., Okada M., Plessy C.,
RA   Shibata K., Shiraki T., Suzuki S., Tagami M., Waki K., Watahiki A.,
RA   Okamura-Oho Y., Suzuki H., Kawai J., Hayashizaki Y.;
RT   ""The transcriptional landscape of the mammalian genome."";
RL   Science 309:1559-1563(2005).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   STRAIN=C57BL/6J; TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   ""The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC)."";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   DEVELOPMENTAL STAGE.
RX   PubMed=18729231; DOI=10.1002/dvdy.21676;
RA   Rock J.R., Harfe B.D.;
RT   ""Expression of TMEM16 paralogs during murine embryogenesis."";
RL   Dev. Dyn. 237:2566-2574(2008).
RN   [4]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-494; ASN-785 AND ASN-803.
RC   TISSUE=Myoblast;
RX   PubMed=19656770; DOI=10.1074/mcp.m900195-mcp200;
RA   Gundry R.L., Raginski K., Tarasova Y., Tchernyshyov I., Bausch-Fluck D.,
RA   Elliott S.T., Boheler K.R., Van Eyk J.E., Wollscheid B.;
RT   ""The mouse C2C12 myoblast cell surface N-linked glycoproteome:
RT   identification, glycosite occupancy, and membrane orientation."";
RL   Mol. Cell. Proteomics 8:2555-2569(2009).
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brown adipose tissue, Kidney, Lung, Pancreas, and Spleen;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   ""A tissue-specific atlas of mouse protein phosphorylation and expression."";
RL   Cell 143:1174-1189(2010).
RN   [6]
RP   TISSUE SPECIFICITY.
RX   PubMed=20056604; DOI=10.1074/jbc.m109.065367;
RA   Schreiber R., Uliyakina I., Kongsuphol P., Warth R., Mirza M.,
RA   Martins J.R., Kunzelmann K.;
RT   ""Expression and function of epithelial anoctamins."";
RL   J. Biol. Chem. 285:7838-7845(2010).
RN   [7]
RP   FUNCTION.
RX   PubMed=21107324; DOI=10.1038/nature09583;
RA   Suzuki J., Umeda M., Sims P.J., Nagata S.;
RT   ""Calcium-dependent phospholipid scrambling by TMEM16F."";
RL   Nature 468:834-838(2010).
RN   [8]
RP   ABSENCE OF CALCIUM-ACTIVATED CHLORIDE CHANNEL ACTIVITY.
RX   PubMed=22075693; DOI=10.1152/ajpcell.00140.2011;
RA   Duran C., Qu Z., Osunkoya A.O., Cui Y., Hartzell H.C.;
RT   ""ANOs 3-7 in the anoctamin/Tmem16 Cl- channel family are intracellular
RT   proteins."";
RL   Am. J. Physiol. 302:C482-C493(2012).
RN   [9]
RP   FUNCTION, DISRUPTION PHENOTYPE, ACTIVITY REGULATION, AND MUTAGENESIS OF
RP   ASP-409; GLN-559 AND GLU-667.
RX   PubMed=23021219; DOI=10.1016/j.cell.2012.07.036;
RA   Yang H., Kim A., David T., Palmer D., Jin T., Tien J., Huang F., Cheng T.,
RA   Coughlin S.R., Jan Y.N., Jan L.Y.;
RT   ""TMEM16F forms a Ca(2+)-activated cation channel required for lipid
RT   scrambling in platelets during blood coagulation."";
RL   Cell 151:111-122(2012).
RN   [10]
RP   REVIEW.
RX   PubMed=22302790; DOI=10.1113/expphysiol.2011.058214;
RA   Winpenny J.P., Gray M.A.;
RT   ""The anoctamin (TMEM16) gene family: calcium-activated chloride channels
RT   come of age."";
RL   Exp. Physiol. 97:175-176(2012).
RN   [11]
RP   REVIEW, AND FUNCTION.
RX   PubMed=21908539; DOI=10.1113/expphysiol.2011.058206;
RA   Kunzelmann K., Schreiber R., Kmit A., Jantarajit W., Martins J.R.,
RA   Faria D., Kongsuphol P., Ousingsawat J., Tian Y.;
RT   ""Expression and function of epithelial anoctamins."";
RL   Exp. Physiol. 97:184-192(2012).
RN   [12]
RP   FUNCTION, AND TRANSPORTER ACTIVITY.
RX   PubMed=23532839; DOI=10.1074/jbc.m113.457937;
RA   Suzuki J., Fujii T., Imao T., Ishihara K., Kuba H., Nagata S.;
RT   ""Calcium-dependent phospholipid scramblase activity of TMEM16 protein
RT   family members."";
RL   J. Biol. Chem. 288:13305-13316(2013).
RN   [13]
RP   FUNCTION, DISRUPTION PHENOTYPE, AND TISSUE SPECIFICITY.
RX   PubMed=22936354; DOI=10.1002/jbmr.1751;
RA   Ehlen H.W., Chinenkova M., Moser M., Munter H.M., Krause Y., Gross S.,
RA   Brachvogel B., Wuelling M., Kornak U., Vortkamp A.;
RT   ""Inactivation of Anoctamin-6/Tmem16f, a regulator of phosphatidylserine
RT   scrambling in osteoblasts, leads to decreased mineral deposition in
RT   skeletal tissues."";
RL   J. Bone Miner. Res. 28:246-259(2013).
RN   [14]
RP   FUNCTION, TRANSPORTER ACTIVITY, AND MUTAGENESIS OF ASP-409; PHE-518;
RP   TYR-563; ILE-612 AND ASP-703.
RX   PubMed=31015464; DOI=10.1038/s41467-019-09778-7;
RA   Le T., Jia Z., Le S.C., Zhang Y., Chen J., Yang H.;
RT   ""An inner activation gate controls TMEM16F phospholipid scrambling."";
RL   Nat. Commun. 10:1846-1846(2019).
RN   [15] {ECO:0007744|PDB:6QP6, ECO:0007744|PDB:6QPB, ECO:0007744|PDB:6QPC, ECO:0007744|PDB:6QPI}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.20 ANGSTROMS), FUNCTION, SUBUNIT,
RP   SUBCELLULAR LOCATION, TOPOLOGY, DISULFIDE BONDS, AND MUTAGENESIS OF
RP   ARG-478; GLY-615; GLU-624 AND GLU-667.
RX   PubMed=30785399; DOI=10.7554/elife.44365;
RA   Alvadia C., Lim N.K., Clerico Mosina V., Oostergetel G.T., Dutzler R.,
RA   Paulino C.;
RT   ""Cryo-EM structures and functional characterization of the murine lipid
RT   scramblase TMEM16F."";
RL   Elife 8:0-0(2019).
CC   -!- FUNCTION: Small-conductance calcium-activated nonselective cation
CC       (SCAN) channel which acts as a regulator of phospholipid scrambling in
CC       platelets, osteoblasts and fetal thymocytes. Phospholipid scrambling
CC       results in surface exposure of phosphatidylserine which in platelets is
CC       essential to trigger the clotting system whereas in osteoblasts is
CC       essential for the deposition of hydroxyapatite during bone
CC       mineralization. Has calcium-dependent phospholipid scramblase activity;
CC       scrambles phosphatidylserine, phosphatidylcholine and
CC       galactosylceramide. Can generate outwardly rectifying chloride channel
CC       currents in airway epithelial cells and Jurkat T lymphocytes.
CC       {ECO:0000269|PubMed:21107324, ECO:0000269|PubMed:21908539,
CC       ECO:0000269|PubMed:22936354, ECO:0000269|PubMed:23021219,
CC       ECO:0000269|PubMed:23532839, ECO:0000269|PubMed:30785399,
CC       ECO:0000269|PubMed:31015464}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phospho-L-serine(in) = a 1,2-diacyl-
CC         sn-glycero-3-phospho-L-serine(out); Xref=Rhea:RHEA:38663,
CC         ChEBI:CHEBI:57262; Evidence={ECO:0000269|PubMed:23532839,
CC         ECO:0000269|PubMed:31015464};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:38664;
CC         Evidence={ECO:0000305|PubMed:23532839};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a beta-D-galactosyl-(1<->1')-N-acylsphing-4-enine(out) = a
CC         beta-D-galactosyl-(1<->1')-N-acylsphing-4-enine(in);
CC         Xref=Rhea:RHEA:38899, ChEBI:CHEBI:18390;
CC         Evidence={ECO:0000269|PubMed:23532839};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:38900;
CC         Evidence={ECO:0000305|PubMed:23532839};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phosphocholine(in) = a 1,2-diacyl-
CC         sn-glycero-3-phosphocholine(out); Xref=Rhea:RHEA:38571,
CC         ChEBI:CHEBI:57643; Evidence={ECO:0000269|PubMed:23532839};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:38573;
CC         Evidence={ECO:0000305|PubMed:23532839};
CC   -!- ACTIVITY REGULATION: Exhibits synergistic gating by Ca(2+) and voltage.
CC       Inhibited by some non-specific cation channel blockers such as:
CC       ruthenium red, 2-aminoethyl diphenylborinate (2APB), gadolinium and
CC       cadmium ions. {ECO:0000269|PubMed:23021219}.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:30785399}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:30785399};
CC       Multi-pass membrane protein {ECO:0000269|PubMed:30785399}. Note=Shows
CC       an intracellular localization. {ECO:0000250|UniProtKB:Q4KMQ2}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q6P9J9-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q6P9J9-2; Sequence=VSP_015654, VSP_015655;
CC   -!- TISSUE SPECIFICITY: Predominant expression seen in epithelial tissues.
CC       Also found in skeletal system where it is primarily expressed in
CC       osteoblasts. {ECO:0000269|PubMed:20056604,
CC       ECO:0000269|PubMed:22936354}.
CC   -!- DEVELOPMENTAL STAGE: At 14.5 dpc, expressed in lung epithelium and
CC       mesenchyme. At 16.5 dpc, expressed in esophageal epithelium and
CC       mesenchyme. In the caudal digestive tract, detected in small intestine
CC       epithelium at 14.5 dpc. Also detected at 14.5 dpc in epithelium and
CC       mesenchyme of trachea, ovary, kidney and stomach. In the developing
CC       skeleton, expressed in developing rib perichondria at 14.5 dpc. Also
CC       expressed in the neural tube and dorsal root ganglia at 14.5 dpc. In
CC       developing skin, expression is restricted to basal layers of the
CC       epidermis at 16.5 dpc. {ECO:0000269|PubMed:18729231}.
CC   -!- DISRUPTION PHENOTYPE: Mice are viable and fertile, and display no major
CC       morphological defects. They exhibit deficiencies in Ca(2+)-dependent
CC       phospholipid scramblase activity in platelets and defects in blood
CC       coagulation (PubMed:23021219). They also show reduced skeleton size and
CC       skeletal deformities. {ECO:0000269|PubMed:22936354,
CC       ECO:0000269|PubMed:23021219}.
CC   -!- MISCELLANEOUS: The term 'anoctamin' was coined because these channels
CC       are anion selective and are predicted to have eight (OCT) transmembrane
CC       segments. There is some dissatisfaction in the field with the Ano
CC       nomenclature because it is not certain that all the members of this
CC       family are anion channels or have the 8-transmembrane topology.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the anoctamin family. {ECO:0000305}.
CC   -!- CAUTION: Contains ten transmembrane regions, not eight as predicted.
CC       {ECO:0000269|PubMed:30785399}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK089300; BAC40833.1; -; mRNA.
DR   EMBL; BC060732; AAH60732.1; -; mRNA.
DR   CCDS; CCDS37184.1; -. [Q6P9J9-1]
DR   RefSeq; NP_001240742.1; NM_001253813.1.
DR   RefSeq; NP_780553.2; NM_175344.4. [Q6P9J9-1]
DR   PDB; 6P46; EM; 3.50 A; A/B=1-911.
DR   PDB; 6P47; EM; 3.90 A; A/B=1-911.
DR   PDB; 6P48; EM; 3.20 A; A/B=1-911.
DR   PDB; 6P49; EM; 3.30 A; A/B=1-911.
DR   PDB; 6QP6; EM; 3.20 A; A/B=1-911.
DR   PDB; 6QPB; EM; 3.60 A; A/B=1-911.
DR   PDB; 6QPC; EM; 3.50 A; A/B=1-911.
DR   PDB; 6QPI; EM; 3.30 A; A/B=1-911.
DR   PDB; 8B8G; EM; 3.39 A; A/B=1-911.
DR   PDB; 8B8J; EM; 2.96 A; A/B=1-911.
DR   PDB; 8B8K; EM; 3.01 A; A/B=1-911.
DR   PDB; 8B8M; EM; 3.49 A; A/B=1-911.
DR   PDB; 8B8Q; EM; 2.94 A; A/B=1-911.
DR   PDB; 8BC0; EM; 3.09 A; A/B=1-911.
DR   PDB; 8BC1; EM; 2.93 A; A/B=1-911.
DR   PDB; 8SUN; EM; 3.12 A; A/B=52-871.
DR   PDB; 8SUR; EM; 3.10 A; A/B=52-871.
DR   PDB; 8TAG; EM; 3.20 A; A/B=52-871.
DR   PDB; 8TAI; EM; 3.10 A; A/B=52-871.
DR   PDB; 8TAL; EM; 3.20 A; A/B=52-871.
DR   PDBsum; 6P46; -.
DR   PDBsum; 6P47; -.
DR   PDBsum; 6P48; -.
DR   PDBsum; 6P49; -.
DR   PDBsum; 6QP6; -.
DR   PDBsum; 6QPB; -.
DR   PDBsum; 6QPC; -.
DR   PDBsum; 6QPI; -.
DR   PDBsum; 8B8G; -.
DR   PDBsum; 8B8J; -.
DR   PDBsum; 8B8K; -.
DR   PDBsum; 8B8M; -.
DR   PDBsum; 8B8Q; -.
DR   PDBsum; 8BC0; -.
DR   PDBsum; 8BC1; -.
DR   PDBsum; 8SUN; -.
DR   PDBsum; 8SUR; -.
DR   PDBsum; 8TAG; -.
DR   PDBsum; 8TAI; -.
DR   PDBsum; 8TAL; -.
DR   AlphaFoldDB; Q6P9J9; -.
DR   EMDB; EMD-15913; -.
DR   EMDB; EMD-15914; -.
DR   EMDB; EMD-15916; -.
DR   EMDB; EMD-15917; -.
DR   EMDB; EMD-15919; -.
DR   EMDB; EMD-15958; -.
DR   EMDB; EMD-20244; -.
DR   EMDB; EMD-20245; -.
DR   EMDB; EMD-20246; -.
DR   EMDB; EMD-20247; -.
DR   EMDB; EMD-40768; -.
DR   EMDB; EMD-40776; -.
DR   EMDB; EMD-41134; -.
DR   EMDB; EMD-41136; -.
DR   EMDB; EMD-41137; -.
DR   EMDB; EMD-4611; -.
DR   EMDB; EMD-4612; -.
DR   EMDB; EMD-4613; -.
DR   EMDB; EMD-4614; -.
DR   SMR; Q6P9J9; -.
DR   BioGRID; 222904; 1.
DR   STRING; 10090.ENSMUSP00000071770; -.
DR   SwissLipids; SLP:000000373; -.
DR   MoonProt; Q6P9J9; -.
DR   GlyCosmos; Q6P9J9; 6 sites, No reported glycans.
DR   GlyGen; Q6P9J9; 7 sites, 3 N-linked glycans (3 sites), 1 O-linked glycan (1 site).
DR   iPTMnet; Q6P9J9; -.
DR   PhosphoSitePlus; Q6P9J9; -.
DR   SwissPalm; Q6P9J9; -.
DR   jPOST; Q6P9J9; -.
DR   PaxDb; 10090-ENSMUSP00000071770; -.
DR   PeptideAtlas; Q6P9J9; -.
DR   ProteomicsDB; 281994; -. [Q6P9J9-1]
DR   ProteomicsDB; 281995; -. [Q6P9J9-2]
DR   Pumba; Q6P9J9; -.
DR   ABCD; Q6P9J9; 1 sequenced antibody.
DR   Antibodypedia; 42608; 154 antibodies from 22 providers.
DR   Ensembl; ENSMUST00000071874.8; ENSMUSP00000071770.7; ENSMUSG00000064210.8. [Q6P9J9-1]
DR   GeneID; 105722; -.
DR   KEGG; mmu:105722; -.
DR   UCSC; uc007xju.2; mouse. [Q6P9J9-1]
DR   AGR; MGI:2145890; -.
DR   CTD; 196527; -.
DR   MGI; MGI:2145890; Ano6.
DR   VEuPathDB; HostDB:ENSMUSG00000064210; -.
DR   eggNOG; KOG2514; Eukaryota.
DR   GeneTree; ENSGT00940000158969; -.
DR   HOGENOM; CLU_006685_1_3_1; -.
DR   InParanoid; Q6P9J9; -.
DR   OMA; PYAVREQ; -.
DR   OrthoDB; 296386at2759; -.
DR   PhylomeDB; Q6P9J9; -.
DR   TreeFam; TF314265; -.
DR   Reactome; R-MMU-2672351; Stimuli-sensing channels.
DR   Reactome; R-MMU-6798695; Neutrophil degranulation.
DR   BioGRID-ORCS; 105722; 3 hits in 78 CRISPR screens.
DR   ChiTaRS; Ano6; mouse.
DR   PRO; PR:Q6P9J9; -.
DR   Proteomes; UP000000589; Chromosome 15.
DR   RNAct; Q6P9J9; protein.
DR   Bgee; ENSMUSG00000064210; Expressed in otolith organ and 256 other cell types or tissues.
DR   ExpressionAtlas; Q6P9J9; baseline and differential.
DR   GO; GO:0034707; C:chloride channel complex; IEA:UniProtKB-KW.
DR   GO; GO:0098981; C:cholinergic synapse; IDA:SynGO.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0097060; C:synaptic membrane; IDA:SynGO.
DR   GO; GO:0005227; F:calcium-activated cation channel activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:MGI.
DR   GO; GO:0005229; F:intracellularly calcium-gated chloride channel activity; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0017128; F:phospholipid scramblase activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0005244; F:voltage-gated monoatomic ion channel activity; IDA:UniProtKB.
DR   GO; GO:0032060; P:bleb assembly; IMP:UniProtKB.
DR   GO; GO:0007596; P:blood coagulation; IMP:UniProtKB.
DR   GO; GO:0035630; P:bone mineralization involved in bone maturation; IMP:MGI.
DR   GO; GO:0061591; P:calcium activated galactosylceramide scrambling; IDA:MGI.
DR   GO; GO:0061590; P:calcium activated phosphatidylcholine scrambling; IDA:MGI.
DR   GO; GO:0061589; P:calcium activated phosphatidylserine scrambling; IDA:MGI.
DR   GO; GO:0061588; P:calcium activated phospholipid scrambling; IMP:MGI.
DR   GO; GO:0070588; P:calcium ion transmembrane transport; IGI:UniProtKB.
DR   GO; GO:1902476; P:chloride transmembrane transport; IDA:UniProtKB.
DR   GO; GO:0006821; P:chloride transport; IDA:MGI.
DR   GO; GO:0002407; P:dendritic cell chemotaxis; IMP:MGI.
DR   GO; GO:0051649; P:establishment of localization in cell; IDA:MGI.
DR   GO; GO:0045794; P:negative regulation of cell volume; IMP:UniProtKB.
DR   GO; GO:0045332; P:phospholipid translocation; IDA:UniProtKB.
DR   GO; GO:0017121; P:plasma membrane phospholipid scrambling; IMP:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; IMP:UniProtKB.
DR   GO; GO:0034767; P:positive regulation of monoatomic ion transmembrane transport; IMP:UniProtKB.
DR   GO; GO:0090026; P:positive regulation of monocyte chemotaxis; IMP:UniProtKB.
DR   GO; GO:0060100; P:positive regulation of phagocytosis, engulfment; IMP:UniProtKB.
DR   GO; GO:1903766; P:positive regulation of potassium ion export across plasma membrane; ISS:BHF-UCL.
DR   GO; GO:0035590; P:purinergic nucleotide receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0060078; P:regulation of postsynaptic membrane potential; IDA:SynGO.
DR   InterPro; IPR032394; Anoct_dimer.
DR   InterPro; IPR007632; Anoctamin.
DR   InterPro; IPR049452; Anoctamin_TM.
DR   PANTHER; PTHR12308; ANOCTAMIN; 1.
DR   PANTHER; PTHR12308:SF21; ANOCTAMIN-6; 1.
DR   Pfam; PF16178; Anoct_dimer; 1.
DR   Pfam; PF04547; Anoctamin; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Cell membrane; Chloride;
KW   Chloride channel; Disulfide bond; Glycoprotein; Ion channel; Ion transport;
KW   Lipid transport; Membrane; Metal-binding; Reference proteome;
KW   Transmembrane; Transmembrane helix; Transport; Voltage-gated channel.
FT   CHAIN           1..911
FT                   /note=""Anoctamin-6""
FT                   /id=""PRO_0000191758""
FT   TOPO_DOM        1..301
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TRANSMEM        302..322
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TOPO_DOM        323..376
FT                   /note=""Extracellular""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TRANSMEM        377..397
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TOPO_DOM        398..456
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TRANSMEM        457..477
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TOPO_DOM        478..510
FT                   /note=""Extracellular""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TRANSMEM        511..531
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TOPO_DOM        532..552
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TRANSMEM        553..573
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TOPO_DOM        574..602
FT                   /note=""Extracellular""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TRANSMEM        603..622
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TOPO_DOM        623..664
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TRANSMEM        665..685
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TRANSMEM        686..706
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TOPO_DOM        707..723
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TRANSMEM        724..744
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TOPO_DOM        745..837
FT                   /note=""Extracellular""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TRANSMEM        838..858
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TOPO_DOM        859..911
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   BINDING         624
FT                   /ligand=""Ca(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29108""
FT                   /evidence=""ECO:0000305|PubMed:30785399""
FT   BINDING         667
FT                   /ligand=""Ca(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29108""
FT                   /evidence=""ECO:0000305|PubMed:30785399""
FT   BINDING         670
FT                   /ligand=""Ca(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29108""
FT                   /evidence=""ECO:0000305|PubMed:30785399""
FT   CARBOHYD        330
FT                   /note=""N-linked (GlcNAc...) asparagine""
FT                   /evidence=""ECO:0000255""
FT   CARBOHYD        362
FT                   /note=""N-linked (GlcNAc...) asparagine""
FT                   /evidence=""ECO:0000255""
FT   CARBOHYD        494
FT                   /note=""N-linked (GlcNAc...) asparagine""
FT                   /evidence=""ECO:0000269|PubMed:19656770""
FT   CARBOHYD        778
FT                   /note=""N-linked (GlcNAc...) asparagine""
FT                   /evidence=""ECO:0000255""
FT   CARBOHYD        785
FT                   /note=""N-linked (GlcNAc...) asparagine""
FT                   /evidence=""ECO:0000269|PubMed:19656770""
FT   CARBOHYD        803
FT                   /note=""N-linked (GlcNAc...) asparagine""
FT                   /evidence=""ECO:0000269|PubMed:19656770""
FT   DISULFID        331..372
FT                   /evidence=""ECO:0000269|PubMed:30785399,
FT                   ECO:0007744|PDB:6QP6, ECO:0007744|PDB:6QPC""
FT   DISULFID        338..365
FT                   /evidence=""ECO:0000269|PubMed:30785399,
FT                   ECO:0007744|PDB:6QP6, ECO:0007744|PDB:6QPB,
FT                   ECO:0007744|PDB:6QPC""
FT   DISULFID        349..807
FT                   /evidence=""ECO:0000269|PubMed:30785399,
FT                   ECO:0007744|PDB:6QP6, ECO:0007744|PDB:6QPB,
FT                   ECO:0007744|PDB:6QPC""
FT   DISULFID        352..356
FT                   /evidence=""ECO:0000269|PubMed:30785399,
FT                   ECO:0007744|PDB:6QPC""
FT   DISULFID        596..601
FT                   /evidence=""ECO:0000269|PubMed:30785399,
FT                   ECO:0007744|PDB:6QP6, ECO:0007744|PDB:6QPB,
FT                   ECO:0007744|PDB:6QPC""
FT   VAR_SEQ         1..427
FT                   /note=""Missing (in isoform 2)""
FT                   /evidence=""ECO:0000303|PubMed:16141072""
FT                   /id=""VSP_015654""
FT   VAR_SEQ         428..436
FT                   /note=""NHVVINEIT -> MALMAESLC (in isoform 2)""
FT                   /evidence=""ECO:0000303|PubMed:16141072""
FT                   /id=""VSP_015655""
FT   MUTAGEN         370
FT                   /note=""K->A: No effect on lipid scramblase activity.""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   MUTAGEN         409
FT                   /note=""D->G: Increased speed of phospholipid scrambling.""
FT                   /evidence=""ECO:0000269|PubMed:31015464""
FT   MUTAGEN         409
FT                   /note=""D->G: Reduced channel activity and sensitivity to
FT                   Ca(2+).""
FT                   /evidence=""ECO:0000269|PubMed:23021219""
FT   MUTAGEN         478
FT                   /note=""R->A: Decreased lipid scramblase and ion channel
FT                   activity. Requires lower calcium levels for activation of
FT                   ion channel activity.""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   MUTAGEN         518
FT                   /note=""F->A: Increased speed of phospholipid scrambling.
FT                   Constitutive scramblase activity at basal cytosolic calcium
FT                   levels; when associated with A-563 and A-612.""
FT                   /evidence=""ECO:0000269|PubMed:31015464""
FT   MUTAGEN         518
FT                   /note=""F->E,K,Q: Constitutive lipid scramblase activity at
FT                   basal cytosolic calcium levels.""
FT                   /evidence=""ECO:0000269|PubMed:31015464""
FT   MUTAGEN         518
FT                   /note=""F->L: Decreased lipid scramblase activity.""
FT                   /evidence=""ECO:0000269|PubMed:31015464""
FT   MUTAGEN         518
FT                   /note=""F->W: Slightly increased lipid scramblase activity.""
FT                   /evidence=""ECO:0000269|PubMed:31015464""
FT   MUTAGEN         559
FT                   /note=""Q->K: Moderately decreased sensitivity to activation
FT                   by calcium.""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   MUTAGEN         559
FT                   /note=""Q->K: Slower channel activation. Increased
FT                   permeability to chloride ions.""
FT                   /evidence=""ECO:0000269|PubMed:23021219""
FT   MUTAGEN         563
FT                   /note=""Y->A: Increased speed of phospholipid scrambling.
FT                   Requires lower calcium levels for activation of scramblase
FT                   and ion channel activity. Constitutive scramblase activity
FT                   at basal cytosolic calcium levels; when associated with
FT                   A-518 and A-612.""
FT                   /evidence=""ECO:0000269|PubMed:31015464""
FT   MUTAGEN         563
FT                   /note=""Y->K,Q: Constitutive lipid scramblase activity at
FT                   basal cytosolic calcium levels.""
FT                   /evidence=""ECO:0000269|PubMed:31015464""
FT   MUTAGEN         563
FT                   /note=""Y->S: No effect on lipid scramblase activity.""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   MUTAGEN         563
FT                   /note=""Y->W: Loss of lipid scramblase activity.""
FT                   /evidence=""ECO:0000269|PubMed:31015464""
FT   MUTAGEN         612
FT                   /note=""I->A: Increased speed of phospholipid scrambling.
FT                   Constitutive scramblase activity at basal cytosolic calcium
FT                   levels; when associated with A-518 and A-563.""
FT                   /evidence=""ECO:0000269|PubMed:31015464""
FT   MUTAGEN         612
FT                   /note=""I->E,K: Constitutive lipid scramblase activity at
FT                   basal cytosolic calcium levels.""
FT                   /evidence=""ECO:0000269|PubMed:31015464""
FT   MUTAGEN         612
FT                   /note=""I->W: Decreased lipid scramblase activity.""
FT                   /evidence=""ECO:0000269|PubMed:31015464""
FT   MUTAGEN         615
FT                   /note=""G->A: Requires lower calcium levels for activation
FT                   of scramblase and ion channel activity.""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   MUTAGEN         623
FT                   /note=""Q->F: No effect on lipid scramblase activity.""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   MUTAGEN         624
FT                   /note=""E->Q: Expected to disrupt calcium binding. Loss of
FT                   scramblase and ion channel activity.""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   MUTAGEN         667
FT                   /note=""E->Q: Requires much higher calcium levels for the
FT                   activation of scramblase and ion channel activity.""
FT                   /evidence=""ECO:0000269|PubMed:23021219,
FT                   ECO:0000269|PubMed:30785399""
FT   MUTAGEN         703
FT                   /note=""D->R: Expected to disrupt calcium binding. Loss of
FT                   scramblase activity.""
FT                   /evidence=""ECO:0000269|PubMed:31015464""
FT   STRAND          45..47
FT                   /evidence=""ECO:0007829|PDB:6QP6""
FT   STRAND          67..70
FT                   /evidence=""ECO:0007829|PDB:6QP6""
FT   STRAND          73..76
FT                   /evidence=""ECO:0007829|PDB:6P48""
FT   HELIX           91..103
FT                   /evidence=""ECO:0007829|PDB:6P48""
FT   STRAND          111..116
FT                   /evidence=""ECO:0007829|PDB:6QP6""
FT   STRAND          121..129
FT                   /evidence=""ECO:0007829|PDB:6QP6""
FT   TURN            137..141
FT                   /evidence=""ECO:0007829|PDB:6P48""
FT   STRAND          146..148
FT                   /evidence=""ECO:0007829|PDB:6QP6""
FT   STRAND          188..192
FT                   /evidence=""ECO:0007829|PDB:6QP6""
FT   HELIX           206..219
FT                   /evidence=""ECO:0007829|PDB:6P48""
FT   HELIX           234..238
FT                   /evidence=""ECO:0007829|PDB:6P48""
FT   STRAND          243..247
FT                   /evidence=""ECO:0007829|PDB:6P48""
FT   STRAND          253..255
FT                   /evidence=""ECO:0007829|PDB:6QP6""
FT   STRAND          260..262
FT                   /evidence=""ECO:0007829|PDB:6QP6""
FT   HELIX           268..271
FT                   /evidence=""ECO:0007829|PDB:6P48""
FT   TURN            272..274
FT                   /evidence=""ECO:0007829|PDB:6P48""
FT   HELIX           276..278
FT                   /evidence=""ECO:0007829|PDB:6QP6""
FT   STRAND          279..281
FT                   /evidence=""ECO:0007829|PDB:6QP6""
FT   HELIX           286..289
FT                   /evidence=""ECO:0007829|PDB:6P48""
FT   TURN            290..296
FT                   /evidence=""ECO:0007829|PDB:6P48""
FT   HELIX           297..309
FT                   /evidence=""ECO:0007829|PDB:6P48""
FT   HELIX           312..325
FT                   /evidence=""ECO:0007829|PDB:6P48""
FT   STRAND          327..329
FT                   /evidence=""ECO:0007829|PDB:6P46""
FT   STRAND          330..335
FT                   /evidence=""ECO:0007829|PDB:6P48""
FT   TURN            336..338
FT                   /evidence=""ECO:0007829|PDB:6P48""
FT   TURN       ",44137
GCATGC CATGCT ATGCTA TGCTAT GCTATC CTATCA TATCAT ATCATC TCATCA CATCAT ATCATA TCATAT CATATC ATATCA TATCAA ATCAAG TCAAGA CAAGAA AAGAAA AGAAAG GAAAGA AAAGAG AAGAGA AGAGAA GAGAAT AGAATA GAATAT AATATC ATATCG TATCGG ATCGGT TCGGTC CGGTCT GGTCTT GTCTTA TCTTAT CTTATC TTATCG TATCGA ATCGAA TCGAAG CGAAGT GAAGTT AAGTTA AGTTAT GTTATG TTATGG TATGGG ATGGGA TGGGAC GGGACT GGACTC GACTCG ACTCGC CTCGCT TCGCTG CGCTGT GCTGTT CTGTTC TGTTCT GTTCTT TTCTTC TCTTCC CTTCCG TTCCGG TCCGGC CCGGCA CGGCAC GGCACG GCACGT CACGTC ACGTCT CGTCTG GTCTGA TCTGAA CTGAAA TGAAAG GAAAGA AAAGAA AAGAAG AGAAGA GAAGAG AAGAGC AGAGCT GAGCTG AGCTGG GCTGGA CTGGAG TGGAGC GGAGCT GAGCTT AGCTTC GCTTCT CTTCTT TTCTTG TCTTGA CTTGAA TTGAAG TGAAGA GAAGAA AAGAAT AGAATA GAATAC AATACA ATACAT TACATT ACATTT CATTTT ATTTTA TTTTAA TTTAAG TTAAGC TAAGCG AAGCGG AGCGGC GCGGCA CGGCAG GGCAGG GCAGGG CAGGGA AGGGAC GGGACA GGACAT GACATC ACATCG CATCGC ATCGCT TCGCTT CGCTTC GCTTCC CTTCCA TTCCAA TCCAAT CCAATG CAATGA AATGAG ATGAGA TGAGAA GAGAAA AGAAAA GAAAAT AAAATC AAATCG AATCGA ATCGAG,3,145,TAACATAT T CT ACATTGAG A ATATGTGCGC  TGTGCGCTCT T GGACTA  CTCTATATAT T T TATATATCTC C AATCTCACA A T TCTCACATAT T C CAAT ATCTC C AGC ATCTCACA A T TCTCACATCATT C CAC TATATA A AA AATATATC GT T TATATTACTC C A ATATCTCACA  TCTCACAATTACGATTCCAACA A GG A AAAAGAGAGA A A AGAGAGAA AAAG  TTGAAA GAA A A CG CTG A AAAAGAGAGA A AGAGAG G G GAAGAGA A ACTTAGAGAAAA A G GAGAA GAAT T A AAAATATATA A A ATATAAT T T TATATGT C A ATATCTCGCG  AATCGCGGGG G C CGCGGGGTGT T G GGGGTGTCTC  GTGTCTCTCT T T TCCTTTT T C CTCTTTTA GA TTTATC TT T TATATATCTC C A ATATCTCGCG G T TCTCGCGAGA A C CGA CGAAA G GAGAAAAGAG G A AAAAGAGTGT T A AGAGTCG TT AA TA A T TTTTATATAT T T TATATCA G A ATCG TGGGG G T TGTGGGGGGG G G GGGGGGGAGA A GGGAGACTC C G GAGACACTCT T A ACCTCTC C C CTCTCTCGGTTA G TCCGCGC C C CGCGCGCTCT T G GCGCTCTGTG G C CT CAGAGT T TGAAGGTTT GGTTTTCC T TTTTCTTGAAGT T TCTCT AGTT T CCTT TTTTCTCCC T TCGAGCG G CCCGCGGAAAA G CGCGGGGCGC C G GGGGCCTGA G GCGCAAC T G CACACACGCG G AACGCGTGT T C CGCGTGTCC G GT TTTCTCT  TCCTGTG G CAAGCTGTG GA G C TGTGAGAAAA  GAATTAA C A TCAAAAAGAG G A AAAAGGA A A AGAGAGAAAA AAA GAAAGAG G AGA TGTAGAGA  AT AGTATGAGTCG TG GAGAGAGCC A AGAGCCT C CGCTCTGTG G CGG TTTTGGTT G T TGTGGGA GGACCGG GA TGAGAGCGC C AA GAGCGCTCT T G GCGCTCTTTT T C CTGGC CTTC C T GACTGTCTT T TCCTTTT T C CTCTT ATTG G T TTTGAGA A TG GGAAA G GAGAAAAGAG  AAAAGAGAAA A AA GGAAAA AGA GAGAAAATAT T A AAAATATAA AATAATCAC C T TATACACACA A AAT ACACAT ACT C CACATAAATT T A ATATTGCAT T TTCGCTTTTT T TTTTTTATA A TA ATTAGCAAA A T TATAACT AG G A AAAAGAGCTTGA A AGAGCGCGCG G G GCGCG CTA GTCGCGGCTTGC  GGGCACA A G GCGCACAGAG G C CACAGAGGTCCG A AGAGGGGGGG G G GGGGGGGAGA G T GGGGAGCTAC C GAATGACACAAAGA A ACACACATAT T C CACATATCTC C AATCG T TCCGCGC C C CGGCTT G GCCTTTT T CTTCCTTTC AT  TTTTCTCCCC CAT TCTCCCCAATGA CTT CCACAAAA A CG ACAAAATAT  CA AAAATATGTG  ATATGTGAGA A T TGTGAGAGAG G G GAAA AGAGA  TT AGAGAGAAAA A T GAGAAAAAA A AAAAAAAAGAG AAAAAAATT A AAAATATCTC  ATATCTCGCG GAG TCTCGCGAGA A C CGCGAG T,GCACATTG G C CACGGGAAGC C A ATATG AAGCTCT T T TGTGCGCTCTATA A G GCCA CTATCGAT T CG CTATATCTC C TATCTCACA A A ATG TA GCATAT T T TCTCACATAGAC CGAGCATATCCA  CTATCC TCATAT T T TCCATATATA A C CAAT  ATATATATATCTC GAA TATATATCTCAGCTA A GAATCTCACAAAA A T TCTCAAAGAG  CT CACAAAGAGA A A AAAAGAGAA AAA A A AGAGAG GAAAA G GA GCAAGATT AAAAAAAGAGAGA A A AAAAGGAGGGCG A AGAGA CAAGAGA A GGAGAGAGAAAA A A AGAGAGAAAT T GATAGAAAATG CTA A A AAAATATAG TAT T A AT GATATTATTCA TATATATC AACG G A ATGAATCGCGGGG AAGGAATCGCGGGGTGT T CACACGGAGCGTCC G GGGGTGTC CTCT T G GTGTCTCTCTTT T TCTCTCTTTA A CAATTTATATAT T T TTGC GA TC C T TA AGATCTCGCG ATCTCGCGAA TG ACGAAA A C CGATTGAAAG G G GAGAACATAGTGT T A AAAAGC GGTTTT T ATCGTTATA A G GTGTTTTAGGCAT T T TTTATATGTTCGGG TATATATGTGGGG G A ATA GAAAGG  TGTGGGGGGGAGA A GTTCGGAGACAC C G GGGGAACTT G GAGACACTCTCC ACTCTCGCG GGA CTCTCGTTCGCTCA TCTATCGCGCTCT T C CGCGCGCTCTGTG GAAGAAGCTCTGGT  CTCTGTGT GCTT T T TGG TGTTTTCTC C G GTGTTTTCTCTCT TGG TTTTCTCTCTTTT  TCTCTCTTTTCTC C C CTCTTTG TCCG AC T TTTTCTCCCCGCG G TTCCCCGCGGGG G CCACCCGCGGGC C C CGCATAG CA GAA GGGGCGCACACC GGTTGCA CCACGCG G C CACACACGCGTGT T A ACACGCGTGTCTC C C CGCGTGTCTCTCT T G GTTCTCTGTG GAG TCC TCTGTGAGA TTC CTCTGGAAAA A TTC TGAGAAAAAAA ATG GATCTT TAAGAG G ATGCAAGAGAA A AAAAGAGA TCAA A A AGAA GAAAAGAG G GCGAGAATA AGAGA A A AAAAGAGAGAGAG G A AGAGAG TAGCTAT GAGAGATCGCTGC GCGAGCGCTCTGTG  GCCTGTGG AT ATCTG GAGGAGA CTT TGG CTGAAG G G GGGGAATGAGCGC C GGAGGGTGCTT ATC AGCGCTCTTTT T G GCGCTCTTA CTC C C CTCTTTTCTCTCT T T TTTTCGG CTTTT T T ACTCTCTTTTGTG G C CTCTTTTGG TATCTTGTGAGAAAA A T TGTGAA GAG G G TAGAAAT AGAGA A AAGAAAGAGAGAAAA A A AGAGAGAAAATAT TTAGAAAATATATA TGG AAAATATATAC AAC A ATATATACACAA TGAGTACACACATTCCT A ACACACATCGATT  CACATATTTTTTT T A ATAG TTTTGATT T T TTTTTCA TGAAAGA T TTTTTTAAAA A T TTTTTTAAAAGAG TTA TATAAAAGAGCGC C AAC AAGAGAGCGCG G A AGAGC AGCGGGG G G GCGCGCGGTATT AC C CGCGGGGCGCACA A G GGGGCGCACAGAG G G GCGCACAGAGGTCT CAAGGGGGCC  AGAGGTGTGGAGA TCA GGGGGGGAGACAGTTCGGAGGACACACA A G GAGAC CGCATAT T A TCACACATATCTC C C CAG TATCTCGCG G A ATATCCGCGC C TTCGCGCGCTCT T C CGCGCGCTCTTTT T G GCGCTCTTGGGTC  CTCTTTTCAAGCC C T TTTCCCCATTTA T TCTCCCCACAAAA A C CCCCACAATCTAT T C CACAAAATATGTG TC  AAAATATGTGAA A ATATGTTAGAGAG  TGTGAGAG AAGA A G GAGGAAGAGAAAA A A AGAAAA GAAAAAAAGAA A AAAAAAATAT T A AAAAAAATAATC AATCTCGCG  TC ATAGCTCG GAGA A T TCCGAGAG,CTACATATGTGCGC C C CACATATGTGCGGCCT T A ATATGTGCGCTTA A T TGT GAAAGCATATC CT GGAGGCTCTGATCAG C CTTTCTATATATCTCACA G TTATATCTCAAT T AATCTC C TAT CATATCAAAC ACATATCTCACATAT T A ATATCTCACATATATA AATTCACATATATATTTAT CCATATATATATCTC  TC ATATATATATCTCACA A T TACTTATCTCACAAAA A A ATATCTCACAAC AG T TCTCACAAA TAGAGA A C CACAAAAGAGAGAATC AAGAGATGT GCA A AGAGAGAAAAATA AG G G GAAAGGAAGA A AA TGTTAAGGAGAG G A AA ATGAGGAGAGAGA ACA AGTTTGAGAGAG TAA A GGAGAGAGAA TCCT GGG AGAGAATATA A GTTCA CATATATAT T A AAAATATATATATCTC C A ATATATATATCTCGCG G T TATATATCA TCGGC AG A ATATCTCGCGGGT  TCT GGGTCTTAGAC C GAGAATCTGGAT G GGGGTGTCTCTCTTTT T G GTGTCTCTCTTAAATA A T TCTCTCTTAAATATAT T C CTC GTTATATATCA AC TTTAATCGCACG GAA TAATCTCGAAGGA A A ATATCTCGACAAA  TCTCGCGAGAACG G CCGCCGAGAAAAGAGTGT T G GAGAAAAGAGTGTTTT T A AAAAGAGTGTTTTATA AAA AGAGTGTTTTATATAT  CT GTGTTTTATATATGTG G TTTATATATGTGGGG G T TATATATGTGGGGGTCGG AATGTGGGGAGG  TGTCGGGGCGGGACAC TGG GGGA GGAGACACTCTCT G GGGGAGACACTTGCC G GAGACACTCTCTCGCG G A ACGAGCTCCGCGC AT  CTCTCTCGCGCGCTCT T TTCGCGCAT TG G CGAACGCGCTCTGAAAT GAA GCTTATTGTGTTTT T C CTCTGTGTTTATTCTCGC TTTTTGTGTTTTCTCTTTC GTGTTTTCTCTTT T T TT GATCTCTTTTCTC C T TCTCTCTTTTCTCCCC C C CTCTTTTCTCCCCGCG G T TTTCCCCGACT TAG T TCCCGCGGGGCGC C C CCCCGGGAGCTAT A C CGCGGGGCGCACAC GACTT GGGGCGCAACGAG G G GCGCACACACGCGTGT  CACACACGCGTGTCTC C A ACACGCGTGTCTCTCT T C CGGTCTCTACAG G GTGTCTCTCTGTGAGA AAG TCTCTCTGTGAGAAAA A C CTCTGTGAGAAAAAAA A T TGTGAGAAAT AAGAG G GAC AGAAAAAAGAGAGA  AAAAAAAGAGAATAAA A AAAGAGAGAAAAGG A AGAGAAAGTC GA A G GA CGAAGAGAGAGAG G A AAAGAACAAGCC A AGAGAGAGAGCGCTCT CTT GAAGAAGCCTGATCG A AGAGCGCTCTGTGGGG  GCGCTTGAC GGGAGA A C CTCTGTGGGGAGAGAG  TATGGGGAGAGAGCGC C G AACG GAGAGCGCTCT T G GAGAGAGCGCTCTTTT T A AGAGCGTCTTCTC GAGCAG ACTCTCT T CCTTTTCTCTTATTT T T TTT GTCTCTTTG G T TCTCTCTTTTGGA A C CTTTGTGAGAAAA  TTTTGCTGGAAAAGAG TGAGAAAAGAGAGA  CGGAAAAGAGAGAAAA A A AAAAGAGAGAAAATGCT AGAGAGAAAATATAG CA G GAAATATATACAC C A AAAATATAAGACA A AAAGTACA ACATTCGT T AGTACACACATATTTT T AGCTTCCCATTTTTT T CGCGCATATTTTTTT T ACTTATT CTTTTTTAAAT TTAGATTTTTATAAAA A T TTTTTTTATAAAAGG T TTTTATAACGAAGCGC C TGG TAAG GAGC CACG G A AAAAGAGCGCGCGGGG G A TAAGCGCGCGGGGCGC C GA CGCGCGGGGCGCACA  GC CGCGGGGCGCACAGAG G G GGGGCGCACAGAGGGG G G GCGCACAGAGGGGGGG G C CA GCAGGGGGGGAA A AGGGGGGAGACAC C G GGCGCGGAGACACACA A GGGATG CATAT CGG GACGACATTG TC AAT AAACACATTCGCG  CAATCTGGCGCGC C A ATATCTCGGGGGCTCT T T TCTC  CGGCTCTTTT T C CGCGCGCTCTTTTCC G GCGCTAT TTCTCCCC C CT GCTTTTCTCCCCACA  TTTTCTCCCCACAAAA A TTCCCCACAAAATAAGT C CCCAACCAAATATGTG AAG CACAAAATATGTGAGA T TA A TCTGAAG G A ATATGGAGAGAGA A T TGTGA GCAGAGAAAA A G GAC GAGAGAAAAAAA A A AGAGAGAAAAAA AAA A G GAGAAAAAAAAAATAT T AAAAGCTAATATCTC GG  AAAAAAATATCTCGCT G A GGATCTCGCGAAATA A ATATCTCGGAG,CATATGTGCTCTCT CATATGTGCGCTCTATA AT  ATATGTGCGCTTATAT T TA AGCTG GTATATCTC  GCAGACTAATCTCAA C CTCTAGAAATCCATAT T T TATATATC GGCATATCTC C AATCTCACATGAATCACA A T TCTCACATAT TCACATAAGT CAGCCATATCTCACATATATA A AATCAAGCATATATATAT T T TCTCACATATATATCGGTATC C CACATGCTTATATC AATTCA A AT CTCGTATCTCACTTAA A T TATATATCTCACAAAAGAG G A ATATCCAAAGAGA A T TCTCACAAAAG GAGAAAA ATG CACAAAAGAGAAAAAA A AAAGAGAGAAAAAAAGG A TCAGAGAAAAGAGAGA  GAGAGGAAAAAAAGCTCGAGAG G A AAAAAAAGAGAGA A A AAAAGAGA TCGAAAA TAT AGAGAGAGAGAGAACTGA AT G GA CGCTC GAATAA A AGCGCAATATACAAAT T GAAT TCAATATAGAAATCTC C A AAAATATATATAGCTCGCG G A ATTATATCTCGCGGG T TATAT GACGGGT T A ATATCTCGAAAGGTGTCTC C TAGATCGGGTGTCTCTCT T C CGCGGGGTTCTCTTTT T G GG CGCTTTA A G GTGTCTCTCTTTTACTG TTT T TCTCTCTTTTATATATCAT T ACTTTTATATATCTCGGA GAATA TATATCTCGCT CG A T TATATATCTCGCGAG CCATA ACGAATCTCG ATAAGAG G T TCTCGCGAGAAAGTCT T C CGCGAGAAAAGAGTGTTTT T G GAGAAAGTGTTTTATTAA A AAAGTG ATATC CT AAGTC ATTATATATGTG  GAGTTTTA GCGACTGGG T TTTTATATATGTGGGGG AAG T TATATATGAGAGGGGGAGA A A ATATGGCTGGGGGCGACAC C T TGTGGGGGGGAGACACTCGAT G GGGGGGGAGACACTGAATC C GAA GACACTCTCTCGCG  GAGACACTA GTCGCGCGC C A ACACTCTT AACGCC CCT CTCTCGCGCCTGAT TG G T AATCGATCGCTTATTGTGT  CGCGCGAGCTGTGTGTTTT TCTTATGCTGCTGTTTTCTC C C CTAATTGTGTTTTCTCTCT  TGTGTGTTTTCTCTCTTTT T G GTGTTTTCCTTTC CTGTTCTCTCTTTTCTCCCC C T TCTCTCTTTTCTCCCCGCG G C CTCTTCA CCGATCGG G T TTTTCTCCCCGCGGGGCGC C T TCTCCCCGCATGGCATAA CTATGGCAC C C CGCGGAT GCAAAACG G GGGAGCACACACGTATGT  GCGCAACGCGTGTCGCT CACACACGCGTGTCTCTCT ACA ACACGCGTGTCCACCTGTG TATGCTCGTGTCTCTCTGTGAA GGTCTCTCTGTGAGAAAA ATC TCC CCTGTGAGAAA CATA GAGAAAAAAAGGACG T TGTGAGAAAAAAAGAGAA GGCTGAAAAAAGAGAAAA A AAAAAAGAGAAAGTTA AAG TAGAAAGAGAGA A A AGAGAGAATCAAGAGAGAG CTA GAGAAAAGAGAGACAGCGC C A AAG TAGC CGCT T A AGAGAGAGAGCGCTCTGTG G GTCGGAG CAGCTTGGGG G AAGCGCT CTTGGGGAGA A G GCATACTGGGAGAGAG G C CTCTGTGGGGAGCTAGCGC C T TGTGGGGAGAGATCGCTTGAT GT GGGAGAGAGCGCTCTTTT T GAGAGAGAGCCTTTTCTC C A AGAGCGCTCTTTTCTCTCT GCTCTTTTCTCTCTTTT T C CTCTTTTCTCTT GTTGTG G T TTTTCCTTCTTTTGA GGA A TTCTCTTTTGTGAGAAA C CTCTTCTCTGAGAAAAGAG GAG TTTTGGAAAAGAGAGA A T TGTGAGAAAGA CCAA TGA GAGAA GGAGAGAAGGAT ATCAAT AGAGAAAATA A AGAGAGAAC AAC C G GAGAAAAGATATACACACA A ATCGAATATATACCATATCGACAGCTACACACATATTTT  AG TATACACAATTTTTTT T A ACACACGGATTTTTTTTTT T C CAATTTTTTTATA  ATTTTTTTTTATAACTGA T TTTTTTTTTTAAAGAG AAG TTTTTTTATAAAA AATGC TGATTATAAAAGAGCGCGCG  TATAAAAGAGCCGGGG G AGG AAGAGCGCGCGGGGCGC GTT AGAGCGCGCGGGGCGCA GCGCGCGGGGCGCACAGAG G CGAGCGGGCACAGAGGGG G GTGGGGCATC ATAGGGGGGG G G GCGCACAGAGGGGGGGCGA A C CAAGGGGGGGAATGAC TCG AGAGGGGGGGAGAGACACA A GTCAGGGGGAGACACACATAT T G GGGGAAG CATATCTC C G GACAGACACATATCTCGCG G A ACACAAA A TC ACGCA TTCT CACATTCGATGGCTCT T A ATATCTCGCGCGCTCTTTT T T AGCGCGCTTTGTTCTC C CGGTCGCGCTCTTTTCTCCCC C G GCGCTCTTTTCTCCCCACA A C CTA ATTCTCCCCACAAAA A T TTTCCCCACAAATAAT T T TCTCCCCACAAAATA CTG G C CCAATATGTGAGA TGG CACAAAATCGC TTGAGAG G A AAAATATGTGAGAGAGAGA A A ATGAAGT GAGAGAGAAAAGGC  TGTGAGAGAGAGAAAAAAA A GG GGAGAGATCTAA A A AGA CGAAAAAAAAAATAT T G GAGAAAAAAATTC GCA AAAAAAAAAATTCGCG G AG TAAAAATATCTCGCGAGA  TG AAAATATCTCGCGAGAG,"ID   GALT1_STRPN             Reviewed;         491 AA.
AC   Q97P15;
DT   26-JUL-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2001, sequence version 1.
DT   05-FEB-2025, entry version 117.
DE   RecName: Full=Galactose-1-phosphate uridylyltransferase 1;
DE            Short=Gal-1-P uridylyltransferase 1;
DE            EC=2.7.7.12;
DE   AltName: Full=UDP-glucose--hexose-1-phosphate uridylyltransferase 1;
GN   Name=galT1; OrderedLocusNames=SP_1829;
OS   Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4).
OC   Bacteria; Bacillati; Bacillota; Bacilli; Lactobacillales; Streptococcaceae;
OC   Streptococcus.
OX   NCBI_TaxID=170187;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC BAA-334 / TIGR4;
RX   PubMed=11463916; DOI=10.1126/science.1061217;
RA   Tettelin H., Nelson K.E., Paulsen I.T., Eisen J.A., Read T.D.,
RA   Peterson S.N., Heidelberg J.F., DeBoy R.T., Haft D.H., Dodson R.J.,
RA   Durkin A.S., Gwinn M.L., Kolonay J.F., Nelson W.C., Peterson J.D.,
RA   Umayam L.A., White O., Salzberg S.L., Lewis M.R., Radune D.,
RA   Holtzapple E.K., Khouri H.M., Wolf A.M., Utterback T.R., Hansen C.L.,
RA   McDonald L.A., Feldblyum T.V., Angiuoli S.V., Dickinson T., Hickey E.K.,
RA   Holt I.E., Loftus B.J., Yang F., Smith H.O., Venter J.C., Dougherty B.A.,
RA   Morrison D.A., Hollingshead S.K., Fraser C.M.;
RT   ""Complete genome sequence of a virulent isolate of Streptococcus
RT   pneumoniae."";
RL   Science 293:498-506(2001).
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=alpha-D-galactose 1-phosphate + UDP-alpha-D-glucose = alpha-D-
CC         glucose 1-phosphate + UDP-alpha-D-galactose; Xref=Rhea:RHEA:13989,
CC         ChEBI:CHEBI:58336, ChEBI:CHEBI:58601, ChEBI:CHEBI:58885,
CC         ChEBI:CHEBI:66914; EC=2.7.7.12;
CC   -!- PATHWAY: Carbohydrate metabolism; galactose metabolism.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the galactose-1-phosphate uridylyltransferase
CC       type 2 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AE005672; AAK75902.1; -; Genomic_DNA.
DR   PIR; E95213; E95213.
DR   RefSeq; WP_000848795.1; NZ_CP155539.1.
DR   AlphaFoldDB; Q97P15; -.
DR   PaxDb; 170187-SP_1829; -.
DR   EnsemblBacteria; AAK75902; AAK75902; SP_1829.
DR   KEGG; spn:SP_1829; -.
DR   eggNOG; COG4468; Bacteria.
DR   PhylomeDB; Q97P15; -.
DR   BioCyc; SPNE170187:G1FZB-1859-MONOMER; -.
DR   UniPathway; UPA00214; -.
DR   Proteomes; UP000000585; Chromosome.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0008108; F:UDP-glucose:hexose-1-phosphate uridylyltransferase activity; IEA:UniProtKB-UniRule.
DR   GO; GO:0006012; P:galactose metabolic process; IEA:UniProtKB-UniRule.
DR   HAMAP; MF_00571; GalP_UDP_trans; 1.
DR   InterPro; IPR000766; GalP_uridyl_Trfase_II.
DR   InterPro; IPR023425; GalP_uridyl_Trfase_II_CS.
DR   InterPro; IPR005850; GalP_Utransf_C.
DR   InterPro; IPR005849; GalP_Utransf_N.
DR   NCBIfam; TIGR01239; galT_2; 1.
DR   PANTHER; PTHR39191:SF1; DUF4922 DOMAIN-CONTAINING PROTEIN; 1.
DR   PANTHER; PTHR39191; GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE; 1.
DR   Pfam; PF02744; GalP_UDP_tr_C; 1.
DR   Pfam; PF01087; GalP_UDP_transf; 1.
DR   PIRSF; PIRSF006005; GalT_BS; 1.
DR   PROSITE; PS01163; GAL_P_UDP_TRANSF_II; 1.
PE   3: Inferred from homology;
KW   Carbohydrate metabolism; Cytoplasm; Galactose metabolism;
KW   Nucleotidyltransferase; Reference proteome; Transferase.
FT   CHAIN           1..491
FT                   /note=""Galactose-1-phosphate uridylyltransferase 1""
FT                   /id=""PRO_0000169914""
SQ   SEQUENCE   491 AA;  56381 MW;  A11F78D61F4D4B09 CRC64;
     MKTIIDNFVD RVIEYGMYNE IDKIYVKNRV LALIGEEGID RISDENDLKQ IKDYLVEIAL
     KNGKIKDLIE EKECLGAELM NFIVPLPSRL NDIFWSSYDI SPQEAVEEFY KLSKDSDYIK
     TSAIAKNIEF RASTKYGELE ITINLSKPEK DPKTIAAEKL VKATNYPKCL LCMENEGYQG
     RINYPARSNH RIIRLKLGDE VWGFQYSPYS YFNEHAIFLN SQHVPMAITS KTFEQLLEIV
     DILPGYFAGS NSDLPISGGS ILSHNHYQGG KHIFPMEKAK FESEFCFKDF EDVNAGIVKW
     PMSVIRLQSE NKNRLLDLAT KILNKWREYS DLEVDIIAMT EDVPHHTVTP IARKVDGRYE
     LDIVLRDNHT TEQYPDGVFH PHQDVQHIKK ENIGLIEVMG LAILPPRLKP ELEEVGKYLL
     GEDNAIADYH LEWADQLKEK YPRINKEEVN SVVQHEAGQV FARVLEDAGV YKNTPSGHEA
     FMRFVKSVGI N
//
",31458
TCCGGC CCGGCG CGGCGC GGCGCG GCGCGG CGCGGG GCGGGT CGGGTA GGGTAA GGTAAA GTAAAA TAAAAG AAAAGC AAAGCA AAGCAC AGCACC GCACCC CACCCT ACCCTG CCCTGT CCTGTT CTGTTG TGTTGC GTTGCG TTGCGG TGCGGC GCGGCT CGGCTA GGCTAA GCTAAT CTAATC TAATCA AATCAA ATCAAT TCAATC CAATCG AATCGC ATCGCC TCGCCT CGCCTT GCCTTG CCTTGA CTTGAA TTGAAG TGAAGA GAAGAG AAGAGC AGAGCC GAGCCT AGCCTT GCCTTC CCTTCT CTTCTG TTCTGG TCTGGC CTGGCG TGGCGG GGCGGA GCGGAC CGGACG GGACGA GACGAA ACGAAT CGAATT GAATTA AATTAT ATTATC TTATCG TATCGT ATCGTC TCGTCG CGTCGA GTCGAC TCGACG CGACGG GACGGC ACGGCG CGGCGT GGCGTA GCGTAG CGTAGA GTAGAC TAGACG AGACGT GACGTC ACGTCA CGTCAC GTCACT TCACTG CACTGC ACTGCC CTGCCC TGCCCT GCCCTT CCCTTA CCTTAA CTTAAC TTAACT TAACTC AACTCC ACTCCG CTCCGA TCCGAG CCGAGG CGAGGG GAGGGT AGGGTT GGGTTT GGTTTA GTTTAC TTTACG TTACGC TACGCC ACGCCA CGCCAG GCCAGT CCAGTT CAGTTT AGTTTC GTTTCG TTTCGC TTCGCC TCGCCA CGCCAG GCCAGC CCAGCA CAGCAA AGCAAG GCAAGC CAAGCG AAGCGG AGCGGG GCGGGA CGGGAA GGGAAT GGAATG GAATGA AATGAT ATGATC TGATCT GATCTT ATCTTC,2,142,TCCG CCGG CGGC GGCG GCGC CGCG GCGG CGGG GGGT GGTA GTAA TAAA AAAA AAAG AAGC AGCA GCAC CACC ACCC CCCT CCTG CTGT TGTT GTTG TTGC TGCG GCGG CGGC GGCT GCTA CTAA TAAT AATC ATCA TCAA CAAT AATC ATCG TCGC CGCC GCCT CCTT CTTG TTGA TGAA GAAG AAGA AGAG GAGC AGCC GCCT CCTT CTTC TTCT TCTG CTGG TGGC GGCG GCGG CGGA GGAC GACG ACGA CGAA GAAT AATT ATTA TTAT TATC ATCG TCGT CGTC GTCG TCGA CGAC GACG ACGG CGGC GGCG GCGT CGTA GTAG TAGA AGAC GACG ACGT CGTC GTCA TCAC CACT ACTG CTGC TGCC GCCC CCCT CCTT CTTA TTAA TAAC AACT ACTC CTCC TCCG CCGA CGAG GAGG AGGG GGGT GGTT GTTT TTTA TTAC TACG ACGC CGCC GCCA CCAG CAGT AGTT GTTT TTTC TTCG TCGC CGCC GCCA CCAG CAGC AGCA GCAA CAAG AAGC AGCG GCGG CGGG GGGA GGAA GAAT AATG ATGA TGAT GATC ATCT TCTT CTTC,TCCGG CCGGC CGGCG GGCGC GCGCG CGCGG GCGGG CGGGT GGGTA GGTAA GTAAA TAAAA AAAAG AAAGC AAGCA AGCAC GCACC CACCC ACCCT CCCTG CCTGT CTGTT TGTTG GTTGC TTGCG TGCGG GCGGC CGGCT GGCTA GCTAA CTAAT TAATC AATCA ATCAA TCAAT CAATC AATCG ATCGC TCGCC CGCCT GCCTT CCTTG CTTGA TTGAA TGAAG GAAGA AAGAG AGAGC GAGCC AGCCT GCCTT CCTTC CTTCT TTCTG TCTGG CTGGC TGGCG GGCGG GCGGA CGGAC GGACG GACGA ACGAA CGAAT GAATT AATTA ATTAT TTATC TATCG ATCGT TCGTC CGTCG GTCGA TCGAC CGACG GACGG ACGGC CGGCG GGCGT GCGTA CGTAG GTAGA TAGAC AGACG GACGT ACGTC CGTCA GTCAC TCACT CACTG ACTGC CTGCC TGCCC GCCCT CCCTT CCTTA CTTAA TTAAC TAACT AACTC ACTCC CTCCG TCCGA CCGAG CGAGG GAGGG AGGGT GGGTT GGTTT GTTTA TTTAC TTACG TACGC ACGCC CGCCA GCCAG CCAGT CAGTT AGTTT GTTTC TTTCG TTCGC TCGCC CGCCA GCCAG CCAGC CAGCA AGCAA GCAAG CAAGC AAGCG AGCGG GCGGG CGGGA GGGAA GGAAT GAATG AATGA ATGAT TGATC GATCT ATCTT TCTTC,TCCGGC CCGGCG CGGCGC GGCGCG GCGCGG CGCGGG GCGGGT CGGGTA GGGTAA GGTAAA GTAAAA TAAAAG AAAAGC AAAGCA AAGCAC AGCACC GCACCC CACCCT ACCCTG CCCTGT CCTGTT CTGTTG TGTTGC GTTGCG TTGCGG TGCGGC GCGGCT CGGCTA GGCTAA GCTAAT CTAATC TAATCA AATCAA ATCAAT TCAATC CAATCG AATCGC ATCGCC TCGCCT CGCCTT GCCTTG CCTTGA CTTGAA TTGAAG TGAAGA GAAGAG AAGAGC AGAGCC GAGCCT AGCCTT GCCTTC CCTTCT CTTCTG TTCTGG TCTGGC CTGGCG TGGCGG GGCGGA GCGGAC CGGACG GGACGA GACGAA ACGAAT CGAATT GAATTA AATTAT ATTATC TTATCG TATCGT ATCGTC TCGTCG CGTCGA GTCGAC TCGACG CGACGG GACGGC ACGGCG CGGCGT GGCGTA GCGTAG CGTAGA GTAGAC TAGACG AGACGT GACGTC ACGTCA CGTCAC GTCACT TCACTG CACTGC ACTGCC CTGCCC TGCCCT GCCCTT CCCTTA CCTTAA CTTAAC TTAACT TAACTC AACTCC ACTCCG CTCCGA TCCGAG CCGAGG CGAGGG GAGGGT AGGGTT GGGTTT GGTTTA GTTTAC TTTACG TTACGC TACGCC ACGCCA CGCCAG GCCAGT CCAGTT CAGTTT AGTTTC GTTTCG TTTCGC TTCGCC TCGCCA CGCCAG GCCAGC CCAGCA CAGCAA AGCAAG GCAAGC CAAGCG AAGCGG AGCGGG GCGGGA CGGGAA GGGAAT GGAATG GAATGA AATGAT ATGATC TGATCT GATCTT ATCTTC,TCCGGCG CCGGCGC CGGCGCG GGCGCGG GCGCGGG CGCGGGT GCGGGTA CGGGTAA GGGTAAA GGTAAAA GTAAAAG TAAAAGC AAAAGCA AAAGCAC AAGCACC AGCACCC GCACCCT CACCCTG ACCCTGT CCCTGTT CCTGTTG CTGTTGC TGTTGCG GTTGCGG TTGCGGC TGCGGCT GCGGCTA CGGCTAA GGCTAAT GCTAATC CTAATCA TAATCAA AATCAAT ATCAATC TCAATCG CAATCGC AATCGCC ATCGCCT TCGCCTT CGCCTTG GCCTTGA CCTTGAA CTTGAAG TTGAAGA TGAAGAG GAAGAGC AAGAGCC AGAGCCT GAGCCTT AGCCTTC GCCTTCT CCTTCTG CTTCTGG TTCTGGC TCTGGCG CTGGCGG TGGCGGA GGCGGAC GCGGACG CGGACGA GGACGAA GACGAAT ACGAATT CGAATTA GAATTAT AATTATC ATTATCG TTATCGT TATCGTC ATCGTCG TCGTCGA CGTCGAC GTCGACG TCGACGG CGACGGC GACGGCG ACGGCGT CGGCGTA GGCGTAG GCGTAGA CGTAGAC GTAGACG TAGACGT AGACGTC GACGTCA ACGTCAC CGTCACT GTCACTG TCACTGC CACTGCC ACTGCCC CTGCCCT TGCCCTT GCCCTTA CCCTTAA CCTTAAC CTTAACT TTAACTC TAACTCC AACTCCG ACTCCGA CTCCGAG TCCGAGG CCGAGGG CGAGGGT GAGGGTT AGGGTTT GGGTTTA GGTTTAC GTTTACG TTTACGC TTACGCC TACGCCA ACGCCAG CGCCAGT GCCAGTT CCAGTTT CAGTTTC AGTTTCG GTTTCGC TTTCGCC TTCGCCA TCGCCAG CGCCAGC GCCAGCA CCAGCAA CAGCAAG AGCAAGC GCAAGCG CAAGCGG AAGCGGG AGCGGGA GCGGGAA CGGGAAT GGGAATG GGAATGA GAATGAT AATGATC ATGATCT TGATCTT GATCTTC,"ID   METN1_PSEPF             Reviewed;         335 AA.
AC   Q3KK97;
DT   09-JAN-2007, integrated into UniProtKB/Swiss-Prot.
DT   08-NOV-2005, sequence version 1.
DT   05-FEB-2025, entry version 129.
DE   RecName: Full=Methionine import ATP-binding protein MetN 1 {ECO:0000255|HAMAP-Rule:MF_01719};
DE            EC=7.4.2.11 {ECO:0000255|HAMAP-Rule:MF_01719};
GN   Name=metN1 {ECO:0000255|HAMAP-Rule:MF_01719};
GN   OrderedLocusNames=Pfl01_0065;
OS   Pseudomonas fluorescens (strain Pf0-1).
OC   Bacteria; Pseudomonadota; Gammaproteobacteria; Pseudomonadales;
OC   Pseudomonadaceae; Pseudomonas.
OX   NCBI_TaxID=205922;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Pf0-1;
RX   PubMed=19432983; DOI=10.1186/gb-2009-10-5-r51;
RA   Silby M.W., Cerdeno-Tarraga A.M., Vernikos G.S., Giddens S.R.,
RA   Jackson R.W., Preston G.M., Zhang X.-X., Moon C.D., Gehrig S.M.,
RA   Godfrey S.A.C., Knight C.G., Malone J.G., Robinson Z., Spiers A.J.,
RA   Harris S., Challis G.L., Yaxley A.M., Harris D., Seeger K., Murphy L.,
RA   Rutter S., Squares R., Quail M.A., Saunders E., Mavromatis K.,
RA   Brettin T.S., Bentley S.D., Hothersall J., Stephens E., Thomas C.M.,
RA   Parkhill J., Levy S.B., Rainey P.B., Thomson N.R.;
RT   ""Genomic and genetic analyses of diversity and plant interactions of
RT   Pseudomonas fluorescens."";
RL   Genome Biol. 10:R51.1-R51.16(2009).
CC   -!- FUNCTION: Part of the ABC transporter complex MetNIQ involved in
CC       methionine import. Responsible for energy coupling to the transport
CC       system. {ECO:0000255|HAMAP-Rule:MF_01719}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-methionine(out) + ATP + H2O = L-methionine(in) + ADP +
CC         phosphate + H(+); Xref=Rhea:RHEA:29779, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:57844, ChEBI:CHEBI:456216; EC=7.4.2.11;
CC         Evidence={ECO:0000255|HAMAP-Rule:MF_01719};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=D-methionine(out) + ATP + H2O = D-methionine(in) + ADP +
CC         phosphate + H(+); Xref=Rhea:RHEA:29767, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:57932, ChEBI:CHEBI:456216; EC=7.4.2.11;
CC         Evidence={ECO:0000255|HAMAP-Rule:MF_01719};
CC   -!- SUBUNIT: The complex is composed of two ATP-binding proteins (MetN),
CC       two transmembrane proteins (MetI) and a solute-binding protein (MetQ).
CC       {ECO:0000255|HAMAP-Rule:MF_01719}.
CC   -!- SUBCELLULAR LOCATION: Cell inner membrane {ECO:0000255|HAMAP-
CC       Rule:MF_01719}; Peripheral membrane protein {ECO:0000255|HAMAP-
CC       Rule:MF_01719}.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. Methionine
CC       importer (TC 3.A.1.24) family. {ECO:0000255|HAMAP-Rule:MF_01719}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CP000094; ABA71809.1; -; Genomic_DNA.
DR   RefSeq; WP_011331788.1; NC_007492.2.
DR   AlphaFoldDB; Q3KK97; -.
DR   SMR; Q3KK97; -.
DR   KEGG; pfo:Pfl01_0065; -.
DR   eggNOG; COG1135; Bacteria.
DR   HOGENOM; CLU_000604_1_3_6; -.
DR   Proteomes; UP000002704; Chromosome.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0033232; F:ABC-type D-methionine transporter activity; IEA:UniProtKB-EC.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IEA:InterPro.
DR   CDD; cd03258; ABC_MetN_methionine_transporter; 1.
DR   FunFam; 3.40.50.300:FF:000056; Cell division ATP-binding protein FtsE; 1.
DR   FunFam; 3.30.70.260:FF:000038; Methionine import ATP-binding protein MetN; 1.
DR   Gene3D; 3.30.70.260; -; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR003439; ABC_transporter-like_ATP-bd.
DR   InterPro; IPR017871; ABC_transporter-like_CS.
DR   InterPro; IPR045865; ACT-like_dom_sf.
DR   InterPro; IPR041701; MetN_ABC.
DR   InterPro; IPR050086; MetN_ABC_transporter-like.
DR   InterPro; IPR018449; NIL_domain.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   PANTHER; PTHR43166; AMINO ACID IMPORT ATP-BINDING PROTEIN; 1.
DR   PANTHER; PTHR43166:SF30; METHIONINE IMPORT ATP-BINDING PROTEIN METN; 1.
DR   Pfam; PF00005; ABC_tran; 1.
DR   Pfam; PF09383; NIL; 1.
DR   SMART; SM00382; AAA; 1.
DR   SMART; SM00930; NIL; 1.
DR   SUPFAM; SSF55021; ACT-like; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 1.
DR   PROSITE; PS51264; METN; 1.
PE   3: Inferred from homology;
KW   Amino-acid transport; ATP-binding; Cell inner membrane; Cell membrane;
KW   Membrane; Nucleotide-binding; Translocase; Transport.
FT   CHAIN           1..335
FT                   /note=""Methionine import ATP-binding protein MetN 1""
FT                   /id=""PRO_0000270350""
FT   DOMAIN          2..242
FT                   /note=""ABC transporter""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01719""
FT   BINDING         38..45
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01719""
SQ   SEQUENCE   335 AA;  36568 MW;  74D455552A5788EA CRC64;
     MIEFQNVHKT YRVAGKDITA LHPTSFSIEN GQVFGLIGHS GAGKSTLLRL INRLEQSSGG
     KIIVDGEEVT ALDANGLRRF RQQVGMIFQH FNLLASKTVA DNVALPLTLA GELSRAEIDQ
     RVAELLARVG LSDHAKKYPA QLSGGQKQRV GIARALATKP KILLCDEATS ALDPQTTASV
     LQLLAEINRE LKLTIVLITH EMDVIRRVCD QVGVMDAGVI VEQGSVADVF LHPKHPTTKR
     FVQESEQIDE SEQRDDFAHV PGRIVRLTFQ GEATYAPLLG TVARETGVDY SILAGRIDRI
     KDIPYGQLTL AVTGGDMDAA FARFTAADVH MEVLR
//
",13325
CTGGAC TGGACC GGACCT GACCTG ACCTGG CCTGGT CTGGTG TGGTGG GGTGGC GTGGCC TGGCCA GGCCAA GCCAAG CCAAGC CAAGCG AAGCGC AGCGCC GCGCCA CGCCAC GCCACC CCACCC CACCCG ACCCGG CCCGGG CCGGGC CGGGCG GGGCGT GGCGTG GCGTGA CGTGAT GTGATC TGATCC GATCCT ATCCTG TCCTGA CCTGAA CTGAAG TGAAGT GAAGTT AAGTTT AGTTTG GTTTGG TTTGGC TTGGCG TGGCGG GGCGGC GCGGCC CGGCCA GGCCAC GCCACG CCACGC CACGCC ACGCCA CGCCAT GCCATG CCATGG CATGGC ATGGCG TGGCGG GGCGGC GCGGCG CGGCGG GGCGGG GCGGGT CGGGTT GGGTTG GGTTGC GTTGCA TTGCAC TGCACC GCACCG CACCGT ACCGTG CCGTGG CGTGGC GTGGCC TGGCCG GGCCGA GCCGAG CCGAGG CGAGGA GAGGAA AGGAAT GGAATC GAATCG AATCGT ATCGTT TCGTTC CGTTCG GTTCGA TTCGAT TCGATG CGATGT GATGTG ATGTGT TGTGTT GTGTTC TGTTCG GTTCGA TTCGAG TCGAGC CGAGCA GAGCAG AGCAGG GCAGGC CAGGCG AGGCGT GGCGTT GCGTTT CGTTTG GTTTGC TTTGCC TTGCCC TGCCCA GCCCAG CCCAGG CCAGGT CAGGTC AGGTCG GGTCGC GTCGCG TCGCGC CGCGCA GCGCAG CGCAGG GCAGGA CAGGAA AGGAAT GGAATG GAATGG AATGGC ATGGCT TGGCTG GGCTGG GCTGGA CTGGAC TGGACG GGACGC GACGCC ACGCCG CGCCGC GCCGCC,3,142,CTGG TGGA GGAC GACC ACCT CCTG CTGG TGGT GGTG GTGG TGGC GGCC GCCA CCAA CAAG AAGC AGCG GCGC CGCC GCCA CCAC CACC ACCC CCCG CCGG CGGG GGGC GGCG GCGT CGTG GTGA TGAT GATC ATCC TCCT CCTG CTGA TGAA GAAG AAGT AGTT GTTT TTTG TTGG TGGC GGCG GCGG CGGC GGCC GCCA CCAC CACG ACGC CGCC GCCA CCAT CATG ATGG TGGC GGCG GCGG CGGC GGCG GCGG CGGG GGGT GGTT GTTG TTGC TGCA GCAC CACC ACCG CCGT CGTG GTGG TGGC GGCC GCCG CCGA CGAG GAGG AGGA GGAA GAAT AATC ATCG TCGT CGTT GTTC TTCG TCGA CGAT GATG ATGT TGTG GTGT TGTT GTTC TTCG TCGA CGAG GAGC AGCA GCAG CAGG AGGC GGCG GCGT CGTT GTTT TTTG TTGC TGCC GCCC CCCA CCAG CAGG AGGT GGTC GTCG TCGC CGCG GCGC CGCA GCAG CAGG AGGA GGAA GAAT AATG ATGG TGGC GGCT GCTG CTGG TGGA GGAC GACG ACGC CGCC GCCG CCGC CGCC,CTGGA TGGAC GGACC GACCT ACCTG CCTGG CTGGT TGGTG GGTGG GTGGC TGGCC GGCCA GCCAA CCAAG CAAGC AAGCG AGCGC GCGCC CGCCA GCCAC CCACC CACCC ACCCG CCCGG CCGGG CGGGC GGGCG GGCGT GCGTG CGTGA GTGAT TGATC GATCC ATCCT TCCTG CCTGA CTGAA TGAAG GAAGT AAGTT AGTTT GTTTG TTTGG TTGGC TGGCG GGCGG GCGGC CGGCC GGCCA GCCAC CCACG CACGC ACGCC CGCCA GCCAT CCATG CATGG ATGGC TGGCG GGCGG GCGGC CGGCG GGCGG GCGGG CGGGT GGGTT GGTTG GTTGC TTGCA TGCAC GCACC CACCG ACCGT CCGTG CGTGG GTGGC TGGCC GGCCG GCCGA CCGAG CGAGG GAGGA AGGAA GGAAT GAATC AATCG ATCGT TCGTT CGTTC GTTCG TTCGA TCGAT CGATG GATGT ATGTG TGTGT GTGTT TGTTC GTTCG TTCGA TCGAG CGAGC GAGCA AGCAG GCAGG CAGGC AGGCG GGCGT GCGTT CGTTT GTTTG TTTGC TTGCC TGCCC GCCCA CCCAG CCAGG CAGGT AGGTC GGTCG GTCGC TCGCG CGCGC GCGCA CGCAG GCAGG CAGGA AGGAA GGAAT GAATG AATGG ATGGC TGGCT GGCTG GCTGG CTGGA TGGAC GGACG GACGC ACGCC CGCCG GCCGC CCGCC,CTGGAC TGGACC GGACCT GACCTG ACCTGG CCTGGT CTGGTG TGGTGG GGTGGC GTGGCC TGGCCA GGCCAA GCCAAG CCAAGC CAAGCG AAGCGC AGCGCC GCGCCA CGCCAC GCCACC CCACCC CACCCG ACCCGG CCCGGG CCGGGC CGGGCG GGGCGT GGCGTG GCGTGA CGTGAT GTGATC TGATCC GATCCT ATCCTG TCCTGA CCTGAA CTGAAG TGAAGT GAAGTT AAGTTT AGTTTG GTTTGG TTTGGC TTGGCG TGGCGG GGCGGC GCGGCC CGGCCA GGCCAC GCCACG CCACGC CACGCC ACGCCA CGCCAT GCCATG CCATGG CATGGC ATGGCG TGGCGG GGCGGC GCGGCG CGGCGG GGCGGG GCGGGT CGGGTT GGGTTG GGTTGC GTTGCA TTGCAC TGCACC GCACCG CACCGT ACCGTG CCGTGG CGTGGC GTGGCC TGGCCG GGCCGA GCCGAG CCGAGG CGAGGA GAGGAA AGGAAT GGAATC GAATCG AATCGT ATCGTT TCGTTC CGTTCG GTTCGA TTCGAT TCGATG CGATGT GATGTG ATGTGT TGTGTT GTGTTC TGTTCG GTTCGA TTCGAG TCGAGC CGAGCA GAGCAG AGCAGG GCAGGC CAGGCG AGGCGT GGCGTT GCGTTT CGTTTG GTTTGC TTTGCC TTGCCC TGCCCA GCCCAG CCCAGG CCAGGT CAGGTC AGGTCG GGTCGC GTCGCG TCGCGC CGCGCA GCGCAG CGCAGG GCAGGA CAGGAA AGGAAT GGAATG GAATGG AATGGC ATGGCT TGGCTG GGCTGG GCTGGA CTGGAC TGGACG GGACGC GACGCC ACGCCG CGCCGC GCCGCC,CTGGACC TGGACCT GGACCTG GACCTGG ACCTGGT CCTGGTG CTGGTGG TGGTGGC GGTGGCC GTGGCCA TGGCCAA GGCCAAG GCCAAGC CCAAGCG CAAGCGC AAGCGCC AGCGCCA GCGCCAC CGCCACC GCCACCC CCACCCG CACCCGG ACCCGGG CCCGGGC CCGGGCG CGGGCGT GGGCGTG GGCGTGA GCGTGAT CGTGATC GTGATCC TGATCCT GATCCTG ATCCTGA TCCTGAA CCTGAAG CTGAAGT TGAAGTT GAAGTTT AAGTTTG AGTTTGG GTTTGGC TTTGGCG TTGGCGG TGGCGGC GGCGGCC GCGGCCA CGGCCAC GGCCACG GCCACGC CCACGCC CACGCCA ACGCCAT CGCCATG GCCATGG CCATGGC CATGGCG ATGGCGG TGGCGGC GGCGGCG GCGGCGG CGGCGGG GGCGGGT GCGGGTT CGGGTTG GGGTTGC GGTTGCA GTTGCAC TTGCACC TGCACCG GCACCGT CACCGTG ACCGTGG CCGTGGC CGTGGCC GTGGCCG TGGCCGA GGCCGAG GCCGAGG CCGAGGA CGAGGAA GAGGAAT AGGAATC GGAATCG GAATCGT AATCGTT ATCGTTC TCGTTCG CGTTCGA GTTCGAT TTCGATG TCGATGT CGATGTG GATGTGT ATGTGTT TGTGTTC GTGTTCG TGTTCGA GTTCGAG TTCGAGC TCGAGCA CGAGCAG GAGCAGG AGCAGGC GCAGGCG CAGGCGT AGGCGTT GGCGTTT GCGTTTG CGTTTGC GTTTGCC TTTGCCC TTGCCCA TGCCCAG GCCCAGG CCCAGGT CCAGGTC CAGGTCG AGGTCGC GGTCGCG GTCGCGC TCGCGCA CGCGCAG GCGCAGG CGCAGGA GCAGGAA CAGGAAT AGGAATG GGAATGG GAATGGC AATGGCT ATGGCTG TGGCTGG GGCTGGA GCTGGAC CTGGACG TGGACGC GGACGCC GACGCCG ACGCCGC CGCCGCC,"ID   RECJ_DICD3              Reviewed;         576 AA.
AC   P39693; E0SLQ7; Q47007;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   30-NOV-2010, sequence version 3.
DT   05-FEB-2025, entry version 96.
DE   RecName: Full=Single-stranded-DNA-specific exonuclease RecJ;
DE            EC=3.1.-.-;
GN   Name=recJ; OrderedLocusNames=Dda3937_02294;
OS   Dickeya dadantii (strain 3937) (Erwinia chrysanthemi (strain 3937)).
OC   Bacteria; Pseudomonadota; Gammaproteobacteria; Enterobacterales;
OC   Pectobacteriaceae; Dickeya.
OX   NCBI_TaxID=198628;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Lovett S.T., Tzoneva M., Sutera V.A.;
RL   Submitted (JUN-1996) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=3937;
RX   PubMed=21217001; DOI=10.1128/jb.01513-10;
RA   Glasner J.D., Yang C.H., Reverchon S., Hugouvieux-Cotte-Pattat N.,
RA   Condemine G., Bohin J.P., Van Gijsegem F., Yang S., Franza T., Expert D.,
RA   Plunkett G. III, San Francisco M.J., Charkowski A.O., Py B., Bell K.,
RA   Rauscher L., Rodriguez-Palenzuela P., Toussaint A., Holeva M.C., He S.Y.,
RA   Douet V., Boccara M., Blanco C., Toth I., Anderson B.D., Biehl B.S.,
RA   Mau B., Flynn S.M., Barras F., Lindeberg M., Birch P.R., Tsuyumu S.,
RA   Shi X., Hibbing M., Yap M.N., Carpentier M., Dassa E., Umehara M.,
RA   Kim J.F., Rusch M., Soni P., Mayhew G.F., Fouts D.E., Gill S.R.,
RA   Blattner F.R., Keen N.T., Perna N.T.;
RT   ""Genome sequence of the plant-pathogenic bacterium Dickeya dadantii 3937."";
RL   J. Bacteriol. 193:2076-2077(2011).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-100.
RX   PubMed=8168497; DOI=10.1002/j.1460-2075.1994.tb06470.x;
RA   Shevchik V.E., Condemine G., Robert-Baudouy J.;
RT   ""Characterization of DsbC, a periplasmic protein of Erwinia chrysanthemi
RT   and Escherichia coli with disulfide isomerase activity."";
RL   EMBO J. 13:2007-2012(1994).
CC   -!- FUNCTION: Single-stranded-DNA-specific exonuclease. Required for many
CC       types of recombinational events, although the stringency of the
CC       requirement for RecJ appears to vary with the type of recombinational
CC       event monitored and the other recombination gene products which are
CC       available (By similarity). {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the RecJ family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U57963; AAB02261.1; -; Genomic_DNA.
DR   EMBL; CP002038; ADM96891.1; -; Genomic_DNA.
DR   EMBL; X76687; CAA54109.1; -; Genomic_DNA.
DR   RefSeq; WP_013316368.1; NC_014500.1.
DR   AlphaFoldDB; P39693; -.
DR   SMR; P39693; -.
DR   STRING; 198628.Dda3937_02294; -.
DR   KEGG; ddd:Dda3937_02294; -.
DR   PATRIC; fig|198628.6.peg.694; -.
DR   eggNOG; COG0608; Bacteria.
DR   HOGENOM; CLU_009736_5_1_6; -.
DR   OrthoDB; 9809852at2; -.
DR   Proteomes; UP000006859; Chromosome.
DR   GO; GO:0008409; F:5'-3' exonuclease activity; IEA:InterPro.
DR   GO; GO:0003676; F:nucleic acid binding; IEA:InterPro.
DR   GO; GO:0006310; P:DNA recombination; IEA:InterPro.
DR   GO; GO:0006281; P:DNA repair; IEA:InterPro.
DR   FunFam; 3.90.1640.30:FF:000001; Single-stranded-DNA-specific exonuclease RecJ; 1.
DR   FunFam; 3.10.310.30:FF:000001; Single-stranded-DNA-specific exonuclease recJ; 1.
DR   Gene3D; 3.10.310.30; -; 1.
DR   Gene3D; 3.90.1640.30; -; 1.
DR   InterPro; IPR001667; DDH_dom.
DR   InterPro; IPR038763; DHH_sf.
DR   InterPro; IPR003156; DHHA1_dom.
DR   InterPro; IPR004610; RecJ.
DR   InterPro; IPR041122; RecJ_OB.
DR   InterPro; IPR051673; SSDNA_exonuclease_RecJ.
DR   NCBIfam; TIGR00644; recJ; 1.
DR   PANTHER; PTHR30255; SINGLE-STRANDED-DNA-SPECIFIC EXONUCLEASE RECJ; 1.
DR   PANTHER; PTHR30255:SF2; SINGLE-STRANDED-DNA-SPECIFIC EXONUCLEASE RECJ; 1.
DR   Pfam; PF01368; DHH; 1.
DR   Pfam; PF02272; DHHA1; 1.
DR   Pfam; PF17768; RecJ_OB; 1.
DR   SUPFAM; SSF64182; DHH phosphoesterases; 1.
PE   3: Inferred from homology;
KW   Exonuclease; Hydrolase; Nuclease; Reference proteome.
FT   CHAIN           1..576
FT                   /note=""Single-stranded-DNA-specific exonuclease RecJ""
FT                   /id=""PRO_0000097229""
FT   CONFLICT        1..6
FT                   /note=""MNVVTQ -> MLLPN (in Ref. 3; CAA54109)""
FT                   /evidence=""ECO:0000305""
FT   CONFLICT        83
FT                   /note=""G -> R (in Ref. 1; AAB02261)""
FT                   /evidence=""ECO:0000305""
FT   CONFLICT        98..99
FT                   /note=""GG -> AA (in Ref. 1; AAB02261)""
FT                   /evidence=""ECO:0000305""
FT   CONFLICT        100
FT                   /note=""R -> H (in Ref. 3; CAA54109)""
FT                   /evidence=""ECO:0000305""
FT   CONFLICT        125
FT                   /note=""A -> P (in Ref. 1; AAB02261)""
FT                   /evidence=""ECO:0000305""
FT   CONFLICT        309..310
FT                   /note=""ND -> KH (in Ref. 1; AAB02261)""
FT                   /evidence=""ECO:0000305""
FT   CONFLICT        349
FT                   /note=""S -> T (in Ref. 1; AAB02261)""
FT                   /evidence=""ECO:0000305""
FT   CONFLICT        408..409
FT                   /note=""RD -> H (in Ref. 1; AAB02261)""
FT                   /evidence=""ECO:0000305""
FT   CONFLICT        475..476
FT                   /note=""EL -> DV (in Ref. 1; AAB02261)""
FT                   /evidence=""ECO:0000305""
SQ   SEQUENCE   576 AA;  62883 MW;  91F4DC0A11EB3E63 CRC64;
     MNVVTQLRRR PTAETELPDS LPALLRRLYA QRGVRQMQEL ERSLRGLLDY RLLGGITQAV
     EVLRQALADN RRIVIVGDFD ADGATSTALT VLALRSMGGR EVQYLVPNRF EDGYGLSPEV
     VAQAAAKGAE LIVTVDNGIS SHAGVDDAHR RGIAVVVTDH HLPGETLPAA EAMINPNLSD
     CAFPSKALAG VGVAFYLMMA LRANLRECGW FAERGLAEPN LAELLDLVAL GTVADVVPLD
     ANNRILISQG LSRIRAGKCR PGIRALLEVS NRDAAQLVAS DLGFALGPRL NAAGRLDDMS
     VGVELLLCND IVQARMLASD LDALNQSRRE IEAGMQVEAL HLCEQLERSR DTLPLGLAMY
     HPQWHQGVVG ILASRIKERF HRPVIAFAPA GDGILKGSGR SIAGLHLRDA LERLDTCHPG
     LMLKFGGHAM AAGLSLVEDR FDEFRQRFAD LVGEWLDASQ LEGVVWSDGE LASPELTLGT
     AEMLREAGPW GQAFPEPTFD GRFRLLQQRL VGERHLKVMV EPLGGGPLLD GIAFNVDTLL
     WPDSSVREVE LAYKLDVNEF RGKRSVQLLI EHLWPL
//
",27096
TCTCCT CTCCTG TCCTGC CCTGCT CTGCTA TGCTAG GCTAGA CTAGAA TAGAAT AGAATG GAATGG AATGGC ATGGCT TGGCTG GGCTGG GCTGGC CTGGCA TGGCAA GGCAAT GCAATG CAATGG AATGGC ATGGCG TGGCGG GGCGGT GCGGTG CGGTGA GGTGAT GTGATG TGATGC GATGCT ATGCTG TGCTGC GCTGCT CTGCTC TGCTCT GCTCTT CTCTTC TCTTCT CTTCTT TTCTTT TCTTTT CTTTTG TTTTGC TTTGCT TTGCTG TGCTGG GCTGGT CTGGTG TGGTGC GGTGCT GTGCTT TGCTTG GCTTGA CTTGAC TTGACA TGACAG GACAGA ACAGAA CAGAAT AGAATG GAATGA AATGAA ATGAAC TGAACC GAACCA AACCAG ACCAGC CCAGCT CAGCTT AGCTTG GCTTGG CTTGGG TTGGGA TGGGAG GGGAGG GGAGGA GAGGAA AGGAAA GGAAAA GAAAAT AAAATG AAATGT AATGTC ATGTCT TGTCTG GTCTGG TCTGGG CTGGGA TGGGAA GGGAAA GGAAAG GAAAGG AAAGGC AAGGCC AGGCCC GGCCCA GCCCAC CCCACA CCACAA CACAAC ACAACA CAACAA AACAAC ACAACA CAACAA AACAAG ACAAGG CAAGGC AAGGCC AGGCCA GGCCAA GCCAAA CCAAAC CAAACT AAACTG AACTGT ACTGTC CTGTCA TGTCAC GTCACT TCACTA CACTAA ACTAAG CTAAGA TAAGAA AAGAAA AGAAAT GAAATA AAATAT AATATG ATATGC TATGCT ATGCTG TGCTGC GCTGCC CTGCCG TGCCGA GCCGAG CCGAGG CGAGGC GAGGCC AGGCCT GGCCTT GCCTTT,1,145,TCTC CTCC TCCT CCTG CTGC TGCT GCTA CTAG TAGA AGAA GAAT AATG ATGG TGGC GGCT GCTG CTGG TGGC GGCA GCAA CAAT AATG ATGG TGGC GGCG GCGG CGGT GGTG GTGA TGAT GATG ATGC TGCT GCTG CTGC TGCT GCTC CTCT TCTT CTTC TTCT TCTT CTTT TTTT TTTG TTGC TGCT GCTG CTGG TGGT GGTG GTGC TGCT GCTT CTTG TTGA TGAC GACA ACAG CAGA AGAA GAAT AATG ATGA TGAA GAAC AACC ACCA CCAG CAGC AGCT GCTT CTTG TTGG TGGG GGGA GGAG GAGG AGGA GGAA GAAA AAAA AAAT AATG ATGT TGTC GTCT TCTG CTGG TGGG GGGA GGAA GAAA AAAG AAGG AGGC GGCC GCCC CCCA CCAC CACA ACAA CAAC AACA ACAA CAAC AACA ACAA CAAG AAGG AGGC GGCC GCCA CCAA CAAA AAAC AACT ACTG CTGT TGTC GTCA TCAC CACT ACTA CTAA TAAG AAGA AGAA GAAA AAAT AATA ATAT TATG ATGC TGCT GCTG CTGC TGCC GCCG CCGA CGAG GAGG AGGC GGCC GCCT CCTT CTTT,TCTCC CTCCT TCCTG CCTGC CTGCT TGCTA GCTAG CTAGA TAGAA AGAAT GAATG AATGG ATGGC TGGCT GGCTG GCTGG CTGGC TGGCA GGCAA GCAAT CAATG AATGG ATGGC TGGCG GGCGG GCGGT CGGTG GGTGA GTGAT TGATG GATGC ATGCT TGCTG GCTGC CTGCT TGCTC GCTCT CTCTT TCTTC CTTCT TTCTT TCTTT CTTTT TTTTG TTTGC TTGCT TGCTG GCTGG CTGGT TGGTG GGTGC GTGCT TGCTT GCTTG CTTGA TTGAC TGACA GACAG ACAGA CAGAA AGAAT GAATG AATGA ATGAA TGAAC GAACC AACCA ACCAG CCAGC CAGCT AGCTT GCTTG CTTGG TTGGG TGGGA GGGAG GGAGG GAGGA AGGAA GGAAA GAAAA AAAAT AAATG AATGT ATGTC TGTCT GTCTG TCTGG CTGGG TGGGA GGGAA GGAAA GAAAG AAAGG AAGGC AGGCC GGCCC GCCCA CCCAC CCACA CACAA ACAAC CAACA AACAA ACAAC CAACA AACAA ACAAG CAAGG AAGGC AGGCC GGCCA GCCAA CCAAA CAAAC AAACT AACTG ACTGT CTGTC TGTCA GTCAC TCACT CACTA ACTAA CTAAG TAAGA AAGAA AGAAA GAAAT AAATA AATAT ATATG TATGC ATGCT TGCTG GCTGC CTGCC TGCCG GCCGA CCGAG CGAGG GAGGC AGGCC GGCCT GCCTT CCTTT,TCTCCT CTCCTG TCCTGC CCTGCT CTGCTA TGCTAG GCTAGA CTAGAA TAGAAT AGAATG GAATGG AATGGC ATGGCT TGGCTG GGCTGG GCTGGC CTGGCA TGGCAA GGCAAT GCAATG CAATGG AATGGC ATGGCG TGGCGG GGCGGT GCGGTG CGGTGA GGTGAT GTGATG TGATGC GATGCT ATGCTG TGCTGC GCTGCT CTGCTC TGCTCT GCTCTT CTCTTC TCTTCT CTTCTT TTCTTT TCTTTT CTTTTG TTTTGC TTTGCT TTGCTG TGCTGG GCTGGT CTGGTG TGGTGC GGTGCT GTGCTT TGCTTG GCTTGA CTTGAC TTGACA TGACAG GACAGA ACAGAA CAGAAT AGAATG GAATGA AATGAA ATGAAC TGAACC GAACCA AACCAG ACCAGC CCAGCT CAGCTT AGCTTG GCTTGG CTTGGG TTGGGA TGGGAG GGGAGG GGAGGA GAGGAA AGGAAA GGAAAA GAAAAT AAAATG AAATGT AATGTC ATGTCT TGTCTG GTCTGG TCTGGG CTGGGA TGGGAA GGGAAA GGAAAG GAAAGG AAAGGC AAGGCC AGGCCC GGCCCA GCCCAC CCCACA CCACAA CACAAC ACAACA CAACAA AACAAC ACAACA CAACAA AACAAG ACAAGG CAAGGC AAGGCC AGGCCA GGCCAA GCCAAA CCAAAC CAAACT AAACTG AACTGT ACTGTC CTGTCA TGTCAC GTCACT TCACTA CACTAA ACTAAG CTAAGA TAAGAA AAGAAA AGAAAT GAAATA AAATAT AATATG ATATGC TATGCT ATGCTG TGCTGC GCTGCC CTGCCG TGCCGA GCCGAG CCGAGG CGAGGC GAGGCC AGGCCT GGCCTT GCCTTT,TCTCCTG CTCCTGC TCCTGCT CCTGCTA CTGCTAG TGCTAGA GCTAGAA CTAGAAT TAGAATG AGAATGG GAATGGC AATGGCT ATGGCTG TGGCTGG GGCTGGC GCTGGCA CTGGCAA TGGCAAT GGCAATG GCAATGG CAATGGC AATGGCG ATGGCGG TGGCGGT GGCGGTG GCGGTGA CGGTGAT GGTGATG GTGATGC TGATGCT GATGCTG ATGCTGC TGCTGCT GCTGCTC CTGCTCT TGCTCTT GCTCTTC CTCTTCT TCTTCTT CTTCTTT TTCTTTT TCTTTTG CTTTTGC TTTTGCT TTTGCTG TTGCTGG TGCTGGT GCTGGTG CTGGTGC TGGTGCT GGTGCTT GTGCTTG TGCTTGA GCTTGAC CTTGACA TTGACAG TGACAGA GACAGAA ACAGAAT CAGAATG AGAATGA GAATGAA AATGAAC ATGAACC TGAACCA GAACCAG AACCAGC ACCAGCT CCAGCTT CAGCTTG AGCTTGG GCTTGGG CTTGGGA TTGGGAG TGGGAGG GGGAGGA GGAGGAA GAGGAAA AGGAAAA GGAAAAT GAAAATG AAAATGT AAATGTC AATGTCT ATGTCTG TGTCTGG GTCTGGG TCTGGGA CTGGGAA TGGGAAA GGGAAAG GGAAAGG GAAAGGC AAAGGCC AAGGCCC AGGCCCA GGCCCAC GCCCACA CCCACAA CCACAAC CACAACA ACAACAA CAACAAC AACAACA ACAACAA CAACAAG AACAAGG ACAAGGC CAAGGCC AAGGCCA AGGCCAA GGCCAAA GCCAAAC CCAAACT CAAACTG AAACTGT AACTGTC ACTGTCA CTGTCAC TGTCACT GTCACTA TCACTAA CACTAAG ACTAAGA CTAAGAA TAAGAAA AAGAAAT AGAAATA GAAATAT AAATATG AATATGC ATATGCT TATGCTG ATGCTGC TGCTGCC GCTGCCG CTGCCGA TGCCGAG GCCGAGG CCGAGGC CGAGGCC GAGGCCT AGGCCTT GGCCTTT,"ID   NCAP_SARS2              Reviewed;         419 AA.
AC   P0DTC9;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Nucleoprotein {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=N;
DE   AltName: Full=Nucleocapsid protein {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=NC {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=Protein N {ECO:0000255|HAMAP-Rule:MF_04096};
GN   Name=N {ECO:0000255|HAMAP-Rule:MF_04096};
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   SUBCELLULAR LOCATION.
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [3] {ECO:0007744|PDB:6WZO, ECO:0007744|PDB:6WZQ}
RP   X-RAY CRYSTALLOGRAPHY (1.42 ANGSTROMS) OF 247-364, AND SUBUNIT.
RX   PubMed=32654247; DOI=10.1002/pro.3909;
RA   Ye Q., West A.M.V., Silletti S., Corbett K.D.;
RT   ""Architecture and self-assembly of the SARS-CoV-2 nucleocapsid protein."";
RL   Protein Sci. 29:1890-1901(2020).
RN   [4]
RP   REVIEW.
RX   PubMed=32974389; DOI=10.3389/fmolb.2020.00219;
RA   Nikolakaki E., Giannakouros T.;
RT   ""SR/RS Motifs as Critical Determinants of Coronavirus Life Cycle."";
RL   Front. Mol. Biosci. 7:219-219(2020).
RN   [5]
RP   VARIANTS LEU-3 AND PHE-235.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [6]
RP   FUNCTION, INTERACTION WITH HOST NLRP3, AND SUBCELLULAR LOCATION.
RX   PubMed=34341353; DOI=10.1038/s41467-021-25015-6;
RA   Pan P., Shen M., Yu Z., Ge W., Chen K., Tian M., Xiao F., Wang Z., Wang J.,
RA   Jia Y., Wang W., Wan P., Zhang J., Chen W., Lei Z., Chen X., Luo Z.,
RA   Zhang Q., Xu M., Li G., Li Y., Wu J.;
RT   ""SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce
RT   hyperinflammation."";
RL   Nat. Commun. 12:4664-4664(2021).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 41-174, AND MUTAGENESIS OF
RP   TYR-109.
RX   PubMed=32363136; DOI=10.1016/j.apsb.2020.04.009;
RA   Kang S., Yang M., Hong Z., Zhang L., Huang Z., Chen X., He S., Zhou Z.,
RA   Zhou Z., Chen Q., Yan Y., Zhang C., Shan H., Chen S.;
RT   ""Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain
RT   reveals potential unique drug targeting sites."";
RL   Acta Pharmacol. Sin. 10:1228-1238(2020).
RN   [8] {ECO:0007744|PDB:6YI3, ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT}
RP   STRUCTURE BY NMR OF 44-180, FUNCTION, AND MUTAGENESIS OF ARG-68; ARG-92;
RP   ILE-94; ARG-107; GLN-163; TYR-172 AND GLU-174.
RX   PubMed=33264373; DOI=10.1371/journal.ppat.1009100;
RA   Dinesh D.C., Chalupska D., Silhan J., Koutna E., Nencka R., Veverka V.,
RA   Boura E.;
RT   ""Structural basis of RNA recognition by the SARS-CoV-2 nucleocapsid
RT   phosphoprotein."";
RL   PLoS Pathog. 16:1-16(2020).
RN   [9]
RP   MUTAGENESIS OF SER-188 AND SER-206, AND PHOSPHORYLATION AT SER-206.
RX   PubMed=34593624; DOI=10.1073/pnas.2113401118;
RA   Liu X., Verma A., Garcia G. Jr., Ramage H., Lucas A., Myers R.L.,
RA   Michaelson J.J., Coryell W., Kumar A., Charney A.W., Kazanietz M.G.,
RA   Rader D.J., Ritchie M.D., Berrettini W.H., Schultz D.C., Cherry S.,
RA   Damoiseaux R., Arumugaswami V., Klein P.S.;
RT   ""Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:1-9(2021).
RN   [10]
RP   CLEAVAGE.
RX   PubMed=35922005; DOI=10.1038/s41586-022-05148-4;
RA   Chu H., Hou Y., Yang D., Wen L., Shuai H., Yoon C., Shi J., Chai Y.,
RA   Yuen T.T., Hu B., Li C., Zhao X., Wang Y., Huang X., Lee K.S., Luo C.,
RA   Cai J.P., Poon V.K., Chan C.C., Zhang A.J., Yuan S., Sit K.Y., Foo D.C.,
RA   Au W.K., Wong K.K., Zhou J., Kok K.H., Jin D.Y., Chan J.F., Yuen K.Y.;
RT   ""Coronaviruses exploit a host cysteine-aspartic protease for replication."";
RL   Nature 0:0-0(2022).
RN   [11]
RP   MUTAGENESIS OF 203-ARG-GLY-204 AND ARG-203, AND PHOSPHORYLATION.
RX   PubMed=35728038; DOI=10.1371/journal.ppat.1010627;
RA   Johnson B.A., Zhou Y., Lokugamage K.G., Vu M.N., Bopp N.,
RA   Crocquet-Valdes P.A., Kalveram B., Schindewolf C., Liu Y., Scharton D.,
RA   Plante J.A., Xie X., Aguilar P., Weaver S.C., Shi P.Y., Walker D.H.,
RA   Routh A.L., Plante K.S., Menachery V.D.;
RT   ""Nucleocapsid mutations in SARS-CoV-2 augment replication and
RT   pathogenesis."";
RL   PLoS Pathog. 18:e1010627-e1010627(2022).
RN   [12]
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=35921414; DOI=10.1126/sciadv.abp9770;
RA   Lopez-Munoz A.D., Kosik I., Holly J., Yewdell J.W.;
RT   ""Cell surface SARS-CoV-2 nucleocapsid protein modulates innate and adaptive
RT   immunity."";
RL   Sci. Adv. 8:eabp9770-eabp9770(2022).
RN   [13]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=34901782; DOI=10.1016/j.isci.2021.103562;
RA   Nabeel-Shah S., Lee H., Ahmed N., Burke G.L., Farhangmehr S., Ashraf K.,
RA   Pu S., Braunschweig U., Zhong G., Wei H., Tang H., Yang J., Marcon E.,
RA   Blencowe B.J., Zhang Z., Greenblatt J.F.;
RT   ""SARS-CoV-2 nucleocapsid protein binds host mRNAs and attenuates stress
RT   granules to impair host stress response."";
RL   IScience 25:103562-103562(2022).
RN   [14]
RP   FUNCTION.
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [15] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 191-263, AND INTERACTION WITH NSP3.
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
CC   -!- FUNCTION: Packages the positive strand viral genome RNA into a helical
CC       ribonucleocapsid (RNP) and plays a fundamental role during virion
CC       assembly through its interactions with the viral genome and membrane
CC       protein M (PubMed:33264373). Plays an important role in enhancing the
CC       efficiency of subgenomic viral RNA transcription as well as viral
CC       replication. Attenuates the stress granules formation by reducing host
CC       G3BP1 access to host mRNAs under stress conditions (PubMed:34901782,
CC       PubMed:36534661). {ECO:0000269|PubMed:32974389,
CC       ECO:0000269|PubMed:33264373, ECO:0000269|PubMed:34901782,
CC       ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: May block host chemokine function in vivo, facilitating viral
CC       replication and transmission (PubMed:35921414). Acts by being secreted
CC       into the extracellular space where it competes to host chemokines for
CC       binding to host glycosaminoglycans (GAG) (PubMed:35921414).
CC       {ECO:0000269|PubMed:35921414}.
CC   -!- FUNCTION: May induce inflammasome responses in cultured cells and mice.
CC       Acts by interacting with host NLRP3 to facilitate inflammasome
CC       assembly, which induces cytokine release that may play a role in COVID
CC       lung injury. {ECO:0000269|PubMed:34341353}.
CC   -!- SUBUNIT: Homodimer, homotetramer, homooligomer with RNA
CC       (PubMed:32654247). Both monomeric and oligomeric forms interact with
CC       RNA. Interacts with protein M (By similarity). Interacts with protein E
CC       (By similarity). Interacts with NSP3; this interaction serves to tether
CC       the genome to the newly translated replicase-transcriptase complex at a
CC       very early stage of infection (PubMed:35044811). May interact with host
CC       NLRP3 (PubMed:34341353). {ECO:0000250|UniProtKB:P59595,
CC       ECO:0000255|HAMAP-Rule:MF_04096, ECO:0000269|PubMed:32654247,
CC       ECO:0000269|PubMed:34341353, ECO:0000269|PubMed:35044811}.
CC   -!- INTERACTION:
CC       P0DTC9; P0DTC4: E; NbExp=3; IntAct=EBI-25475856, EBI-25475850;
CC       P0DTC9; P0DTC5: M; NbExp=6; IntAct=EBI-25475856, EBI-25475853;
CC       P0DTC9; P0DTC9: N; NbExp=105; IntAct=EBI-25475856, EBI-25475856;
CC       P0DTC9; PRO_0000449621 [P0DTD1]: rep; NbExp=15; IntAct=EBI-25475856, EBI-25492388;
CC       P0DTC9; P78563: ADARB1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-2967304;
CC       P0DTC9; O15145: ARPC3; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-351829;
CC       P0DTC9; Q13895: BYSL; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-358049;
CC       P0DTC9; Q16543: CDC37; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-295634;
CC       P0DTC9; Q92793: CREBBP; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-81215;
CC       P0DTC9; Q92499: DDX1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-358474;
CC       P0DTC9; Q9NR30: DDX21; Xeno; NbExp=12; IntAct=EBI-25475856, EBI-357942;
CC       P0DTC9; P26196: DDX6; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-351257;
CC       P0DTC9; Q08426: EHHADH; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-2339219;
CC       P0DTC9; P19525: EIF2AK2; Xeno; NbExp=8; IntAct=EBI-25475856, EBI-640775;
CC       P0DTC9; Q14241: ELOA; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-742350;
CC       P0DTC9; Q13283: G3BP1; Xeno; NbExp=71; IntAct=EBI-25475856, EBI-1047359;
CC       P0DTC9; Q9UN86: G3BP2; Xeno; NbExp=37; IntAct=EBI-25475856, EBI-1044298;
CC       P0DTC9; P57764: GSDMD; Xeno; NbExp=13; IntAct=EBI-25475856, EBI-2798865;
CC       P0DTC9; P49841: GSK3B; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-373586;
CC       P0DTC9; P10412: H1-4; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-358163;
CC       P0DTC9; O14920: IKBKB; Xeno; NbExp=7; IntAct=EBI-25475856, EBI-81266;
CC       P0DTC9; Q92830: KAT2A; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-477622;
CC       P0DTC9; Q92831: KAT2B; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-477430;
CC       P0DTC9; Q07866: KLC1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-721019;
CC       P0DTC9; Q9H0B6: KLC2; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-726994;
CC       P0DTC9; Q9NSK0: KLC4; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-949319;
CC       P0DTC9; Q9NX58: LYAR; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-713507;
CC       P0DTC9; O43318: MAP3K7; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-358684;
CC       P0DTC9; Q9UBU8: MORF4L1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-399246;
CC       P0DTC9; Q15014: MORF4L2; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-399257;
CC       P0DTC9; Q9HCE1: MOV10; Xeno; NbExp=11; IntAct=EBI-25475856, EBI-1055820;
CC       P0DTC9; Q9HC36: MRM3; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-1045440;
CC       P0DTC9; O15226: NKRF; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-766011;
CC       P0DTC9; Q96P20: NLRP3; Xeno; NbExp=18; IntAct=EBI-25475856, EBI-6253230;
CC       P0DTC9; O15118: NPC1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-2368710;
CC       P0DTC9; Q96HA8: NTAQ1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-741158;
CC       P0DTC9; P11940: PABPC1; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-81531;
CC       P0DTC9; P62937: PPIA; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-437708;
CC       P0DTC9; O75569: PRKRA; Xeno; NbExp=8; IntAct=EBI-25475856, EBI-713955;
CC       P0DTC9; Q99873: PRMT1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-78738;
CC       P0DTC9; P61289: PSME3; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-355546;
CC       P0DTC9; P26022: PTX3; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-11574553;
CC       P0DTC9; P54727: RAD23B; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-954531;
CC       P0DTC9; O95786: RIGI; Xeno; NbExp=15; IntAct=EBI-25475856, EBI-995350;
CC       P0DTC9; P62899: RPL31; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-1053664;
CC       P0DTC9; P62753: RPS6; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-356625;
CC       P0DTC9; P37840: SNCA; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-985879;
CC       P0DTC9; Q96SB4: SRPK1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-539478;
CC       P0DTC9; P78362: SRPK2; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-593303;
CC       P0DTC9; P42224: STAT1; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-1057697;
CC       P0DTC9; P52630: STAT2; Xeno; NbExp=7; IntAct=EBI-25475856, EBI-1546963;
CC       P0DTC9; Q15633: TARBP2; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-978581;
CC       P0DTC9; Q14258: TRIM25; Xeno; NbExp=13; IntAct=EBI-25475856, EBI-2341129;
CC       P0DTC9; O60763: USO1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-356164;
CC       P0DTC9; Q93008: USP9X; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-302524;
CC   -!- SUBCELLULAR LOCATION: Virion {ECO:0000255|HAMAP-Rule:MF_04096}. Host
CC       cytoplasm {ECO:0000269|PubMed:33060197, ECO:0000269|PubMed:34341353}.
CC       Secreted {ECO:0000269|PubMed:35921414}. Host extracellular space
CC       {ECO:0000269|PubMed:35921414}. Note=Probably associates with ER-derived
CC       membranes where it participates in viral RNA synthesis and virus
CC       budding. When located inside the virion, complexed with the viral RNA.
CC       Can be secreted by unconventional protein secretion (UPS)
CC       (PubMed:35921414). When secreted, can bind to host glycosaminoglycans
CC       on infected and non infected cells (PubMed:35921414). Found in host
CC       cytoplasmic stress granules (PubMed:34901782). {ECO:0000255|HAMAP-
CC       Rule:MF_04096, ECO:0000269|PubMed:34901782,
CC       ECO:0000269|PubMed:35921414}.
CC   -!- PTM: ADP-ribosylated. The ADP-ribosylation is retained in the virion
CC       during infection. {ECO:0000255|HAMAP-Rule:MF_04096}.
CC   -!- PTM: Phosphorylated on serine residues by host GSK3A and GSK3B
CC       (PubMed:34593624, PubMed:35728038). This promotes the solubility of
CC       homodimers that would otherwise aggregate (PubMed:32974389). Host
CC       phosphatase would dephosphorylate the protein during assembly at M
CC       bound membranes (PubMed:32974389). {ECO:0000269|PubMed:34593624,
CC       ECO:0000269|PubMed:35728038, ECO:0000305|PubMed:32974389}.
CC   -!- PTM: Proteolytically cleaved by host CASP6. The cleavage leads to two
CC       fragments and facilitates viral replication by inhibiting host IFN
CC       signaling. The two fragments may interact with IRF3 inhibiting its
CC       nuclear translocation after activation and reduce the expression of
CC       IFNB and IFN-stimulated genes. {ECO:0000269|PubMed:35922005}.
CC   -!- POLYMORPHISM: Variant Alpha/B.1.1.7 belongs to a lineage isolated first
CC       in United Kingdom (December 2020). It is also called Variant of Concern
CC       (VOC) 202012/01, Variant Under Investigation (VUI) 202012/01, 501Y.V1
CC       or 20B/501Y.V1. {ECO:0000305|PubMed:33413740}.
CC   -!- POLYMORPHISM: Variant Omicron/BA.1 and BA.2 belong to a lineage first
CC       isolated in South Africa (November 2021). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/BQ.1.1 belongs to a lineage first
CC       isolated in Nigeria (November 2022). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/XBB.1.5 belongs to a lineage first
CC       isolated in United States (November 2022). It is the result of
CC       recombination between omicron BJ.1 and BM.1.1. Moreover XBB.1.5 do not
CC       express ORF8. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the betacoronavirus nucleocapsid protein family.
CC       {ECO:0000255|HAMAP-Rule:MF_04096}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43423.2; -; Genomic_RNA.
DR   PDB; 6M3M; X-ray; 2.70 A; A/B/C/D=41-174.
DR   PDB; 6VYO; X-ray; 1.70 A; A/B/C/D=47-173.
DR   PDB; 6WJI; X-ray; 2.05 A; A/B/C/D/E/F=257-364.
DR   PDB; 6WKP; X-ray; 2.67 A; A/B/C/D=47-173.
DR   PDB; 6WZO; X-ray; 1.42 A; A/B/C/D=247-364.
DR   PDB; 6WZQ; X-ray; 1.45 A; A/B/C/D=247-364.
DR   PDB; 6YI3; NMR; -; A=44-180.
DR   PDB; 6YUN; X-ray; 1.44 A; A/B=249-364.
DR   PDB; 6ZCO; X-ray; 1.36 A; A=247-364.
DR   PDB; 7ACS; NMR; -; A=44-180.
DR   PDB; 7ACT; NMR; -; A=44-180.
DR   PDB; 7C22; X-ray; 2.00 A; A/B/C/D=248-364.
DR   PDB; 7CDZ; X-ray; 1.80 A; A/B/C/D=44-174.
DR   PDB; 7CE0; X-ray; 1.50 A; A/B/C/D=255-364.
DR   PDB; 7CR5; X-ray; 2.08 A; A=41-174.
DR   PDB; 7DE1; X-ray; 2.00 A; A/B=250-364.
DR   PDB; 7F2B; X-ray; 2.00 A; A/B=257-362.
DR   PDB; 7F2E; X-ray; 3.10 A; A/B/C/D/E/F/G/H/I/J/K/L=255-362.
DR   PDB; 7KGO; X-ray; 2.15 A; C=351-359.
DR   PDB; 7KGP; X-ray; 1.40 A; C=316-324.
DR   PDB; 7KGQ; X-ray; 1.34 A; C=222-230.
DR   PDB; 7KGR; X-ray; 1.55 A; C=159-167.
DR   PDB; 7KGS; X-ray; 1.58 A; C=138-146.
DR   PDB; 7KGT; X-ray; 1.90 A; C=226-234.
DR   PDB; 7LGD; X-ray; 2.88 A; E/F=105-113.
DR   PDB; 7LTU; X-ray; 1.12 A; A/B=217-222.
DR   PDB; 7LUX; X-ray; 1.30 A; A=217-222.
DR   PDB; 7LUZ; X-ray; 1.10 A; A=243-248.
DR   PDB; 7LV2; X-ray; 1.30 A; A=179-184.
DR   PDB; 7N0I; X-ray; 2.20 A; A/B/C/D/E/F/G/H=269-364.
DR   PDB; 7N0R; X-ray; 1.42 A; A/B=49-174.
DR   PDB; 7N3C; X-ray; 1.82 A; C=47-173.
DR   PDB; 7N3D; X-ray; 1.53 A; C=47-173.
DR   PDB; 7O05; X-ray; 1.94 A; A/B/C/D=247-364.
DR   PDB; 7O35; X-ray; 1.80 A; A/B/C/D=247-364.
DR   PDB; 7O36; X-ray; 2.00 A; A/B/C/D=247-364.
DR   PDB; 7PKU; NMR; -; B=191-263.
DR   PDB; 7QIK; X-ray; 2.01 A; E/F=193-200.
DR   PDB; 7QIP; X-ray; 2.65 A; C/D=201-210.
DR   PDB; 7R98; X-ray; 2.51 A; A/B/C=49-174.
DR   PDB; 7SD4; NMR; -; A=40-174.
DR   PDB; 7STR; X-ray; 1.50 A; C=47-173.
DR   PDB; 7STS; X-ray; 2.16 A; C/D=47-173.
DR   PDB; 7SUE; X-ray; 2.90 A; C/D/J/K=47-173.
DR   PDB; 7SUO; X-ray; 2.35 A; C/D=12-22.
DR   PDB; 7UW3; X-ray; 1.70 A; A/B/C/D=40-174.
DR   PDB; 7UXX; X-ray; 1.85 A; AAA/BBB/CCC/DDD/EEE/FFF=251-364.
DR   PDB; 7UXZ; X-ray; 1.73 A; AAA/BBB/CCC/DDD/EEE/FFF=251-364.
DR   PDB; 7VBD; X-ray; 1.94 A; A/B/C/D=48-174.
DR   PDB; 7VBE; X-ray; 1.59 A; A/B=257-364.
DR   PDB; 7VBF; X-ray; 1.30 A; A/B=255-364.
DR   PDB; 7VNU; X-ray; 1.95 A; A/B/C/D=47-174.
DR   PDB; 7WKJ; X-ray; 1.50 A; C=361-369.
DR   PDB; 7WZO; X-ray; 2.64 A; A=47-174.
DR   PDB; 7XWX; X-ray; 3.00 A; A/B/C/D/E/F/G/H=269-367.
DR   PDB; 7XWZ; X-ray; 2.25 A; A/B=48-172.
DR   PDB; 7XX1; X-ray; 1.90 A; A/B/C/D=49-173.
DR   PDB; 7XXK; X-ray; 2.00 A; A/B/C/D/E/F=248-364.
DR   PDB; 7YLB; X-ray; 2.41 A; A/B/C/D/G/H/J/K=247-364.
DR   PDB; 7YLD; X-ray; 2.80 A; A/B/C/D=47-174.
DR   PDB; 7ZIT; X-ray; 1.79 A; C/D=194-200.
DR   PDB; 8DNT; X-ray; 3.18 A; D/J/Q/X=222-230.
DR   PDB; 8FD5; EM; 4.57 A; A=1-419.
DR   PDB; 8FG2; EM; 6.00 A; A/B=1-419.
DR   PDB; 8IQJ; X-ray; 2.30 A; A/B/C/D=41-174.
DR   PDB; 8IV3; X-ray; 1.90 A; A/B/C/D=41-174.
DR   PDB; 8J6X; X-ray; 2.70 A; A/B/C/D=41-174.
DR   PDB; 8TH1; X-ray; 1.80 A; E/F/G/H=1-25.
DR   PDB; 8TH5; X-ray; 2.62 A; K/L/M/N/O/P/Q=1-25.
DR   PDB; 8X1H; X-ray; 2.00 A; A/B/C/D=44-175.
DR   PDBsum; 6M3M; -.
DR   PDBsum; 6VYO; -.
DR   PDBsum; 6WJI; -.
DR   PDBsum; 6WKP; -.
DR   PDBsum; 6WZO; -.
DR   PDBsum; 6WZQ; -.
DR   PDBsum; 6YI3; -.
DR   PDBsum; 6YUN; -.
DR   PDBsum; 6ZCO; -.
DR   PDBsum; 7ACS; -.
DR   PDBsum; 7ACT; -.
DR   PDBsum; 7C22; -.
DR   PDBsum; 7CDZ; -.
DR   PDBsum; 7CE0; -.
DR   PDBsum; 7CR5; -.
DR   PDBsum; 7DE1; -.
DR   PDBsum; 7F2B; -.
DR   PDBsum; 7F2E; -.
DR   PDBsum; 7KGO; -.
DR   PDBsum; 7KGP; -.
DR   PDBsum; 7KGQ; -.
DR   PDBsum; 7KGR; -.
DR   PDBsum; 7KGS; -.
DR   PDBsum; 7KGT; -.
DR   PDBsum; 7LGD; -.
DR   PDBsum; 7LTU; -.
DR   PDBsum; 7LUX; -.
DR   PDBsum; 7LUZ; -.
DR   PDBsum; 7LV2; -.
DR   PDBsum; 7N0I; -.
DR   PDBsum; 7N0R; -.
DR   PDBsum; 7N3C; -.
DR   PDBsum; 7N3D; -.
DR   PDBsum; 7O05; -.
DR   PDBsum; 7O35; -.
DR   PDBsum; 7O36; -.
DR   PDBsum; 7PKU; -.
DR   PDBsum; 7QIK; -.
DR   PDBsum; 7QIP; -.
DR   PDBsum; 7R98; -.
DR   PDBsum; 7SD4; -.
DR   PDBsum; 7STR; -.
DR   PDBsum; 7STS; -.
DR   PDBsum; 7SUE; -.
DR   PDBsum; 7SUO; -.
DR   PDBsum; 7UW3; -.
DR   PDBsum; 7UXX; -.
DR   PDBsum; 7UXZ; -.
DR   PDBsum; 7VBD; -.
DR   PDBsum; 7VBE; -.
DR   PDBsum; 7VBF; -.
DR   PDBsum; 7VNU; -.
DR   PDBsum; 7WKJ; -.
DR   PDBsum; 7WZO; -.
DR   PDBsum; 7XWX; -.
DR   PDBsum; 7XWZ; -.
DR   PDBsum; 7XX1; -.
DR   PDBsum; 7XXK; -.
DR   PDBsum; 7YLB; -.
DR   PDBsum; 7YLD; -.
DR   PDBsum; 7ZIT; -.
DR   PDBsum; 8DNT; -.
DR   PDBsum; 8FD5; -.
DR   PDBsum; 8FG2; -.
DR   PDBsum; 8IQJ; -.
DR   PDBsum; 8IV3; -.
DR   PDBsum; 8J6X; -.
DR   PDBsum; 8TH1; -.
DR   PDBsum; 8TH5; -.
DR   PDBsum; 8X1H; -.
DR   BMRB; P0DTC9; -.
DR   EMDB; EMD-29002; -.
DR   EMDB; EMD-29072; -.
DR   SASBDB; P0DTC9; -.
DR   SMR; P0DTC9; -.
DR   BioGRID; 4383847; 1532.
DR   ComplexPortal; CPX-5686; SARS-CoV-2 nucleocapsid complex.
DR   IntAct; P0DTC9; 608.
DR   MINT; P0DTC9; -.
DR   ChEMBL; CHEMBL5169223; -.
DR   iPTMnet; P0DTC9; -.
DR   ABCD; P0DTC9; 27 sequenced antibodies.
DR   DNASU; 43740575; -.
DR   KEGG; vg:43740575; -.
DR   AGR; RefSeq:YP_009724397; -.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-HSA-168928; DDX58/IFIH1-mediated induction of interferon-alpha/beta.
DR   Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-HSA-445989; TAK1-dependent IKK and NF-kappa-B activation.
DR   Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-HSA-9020702; Interleukin-1 signaling.
DR   Reactome; R-HSA-909733; Interferon alpha/beta signaling.
DR   Reactome; R-HSA-9694322; Virion Assembly and Release.
DR   Reactome; R-HSA-9694614; Attachment and Entry.
DR   Reactome; R-HSA-9694631; Maturation of nucleoprotein.
DR   Reactome; R-HSA-9694635; Translation of Structural Proteins.
DR   Reactome; R-HSA-9694786; Transcription of SARS-CoV-2 sgRNAs.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   Reactome; R-HSA-9733458; Induction of Cell-Cell Fusion.
DR   Reactome; R-HSA-9755779; SARS-CoV-2 targets host intracellular signalling and regulatory pathways.
DR   SIGNOR; P0DTC9; -.
DR   PRO; PR:P0DTC9; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProt.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0044172; C:host cell endoplasmic reticulum-Golgi intermediate compartment; ISS:UniProtKB.
DR   GO; GO:0044177; C:host cell Golgi apparatus; ISS:UniProtKB.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; ISS:UniProtKB.
DR   GO; GO:0043655; C:host extracellular space; IEA:UniProtKB-SubCell.
DR   GO; GO:0043232; C:intracellular non-membrane-bounded organelle; IDA:DisProt.
DR   GO; GO:0042612; C:MHC class I protein complex; EXP:DisProt.
DR   GO; GO:1990904; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IPI:ComplexPortal.
DR   GO; GO:0019013; C:viral nucleocapsid; ISS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0042288; F:MHC class I protein binding; EXP:DisProt.
DR   GO; GO:0140693; F:molecular condensate scaffold activity; IDA:DisProt.
DR   GO; GO:0008266; F:poly(U) RNA binding; IMP:DisProt.
DR   GO; GO:0042803; F:protein homodimerization activity; EXP:DisProt.
DR   GO; GO:0140311; F:protein sequestering activity; IDA:UniProt.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProt.
DR   GO; GO:0035613; F:RNA stem-loop binding; IDA:DisProt.
DR   GO; GO:0039709; P:cytoplasmic capsid assembly; IDA:UniProt.
DR   GO; GO:0032688; P:negative regulation of interferon-beta production; IDA:ComplexPortal.
DR   GO; GO:1900227; P:positive regulation of NLRP3 inflammasome complex assembly; IDA:UniProtKB.
DR   GO; GO:0052572; P:response to host immune response; IDA:DisProt.
DR   GO; GO:0019074; P:viral RNA genome packaging; NAS:ComplexPortal.
DR   CDD; cd21595; CoV_N-CTD; 1.
DR   CDD; cd21554; CoV_N-NTD; 1.
DR   HAMAP; MF_04096; BETA_CORONA_NCAP; 1.
DR   InterPro; IPR044344; N_prot_C_CoV.
DR   InterPro; IPR044345; N_prot_N_CoV.
DR   InterPro; IPR043505; NCAP_bCoV.
DR   InterPro; IPR001218; Nucleocap_CoV.
DR   InterPro; IPR037179; Nucleocapsid_C.
DR   InterPro; IPR037195; Nucleocapsid_N.
DR   Pfam; PF00937; CoV_nucleocap; 1.
DR   PIRSF; PIRSF003888; Corona_nucleocap; 1.
DR   SUPFAM; SSF110304; Coronavirus RNA-binding domain; 1.
DR   SUPFAM; SSF103068; Nucleocapsid protein dimerization domain; 1.
DR   PROSITE; PS51929; COV_N_CTD; 1.
DR   PROSITE; PS51928; COV_N_NTD; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ADP-ribosylation; Host cytoplasm; Phosphoprotein;
KW   Reference proteome; Ribonucleoprotein; RNA-binding; Secreted;
KW   Transcription; Transcription regulation; Viral nucleoprotein; Virion.
FT   CHAIN           1..419
FT                   /note=""Nucleoprotein""
FT                   /id=""PRO_0000449656""
FT   DOMAIN          48..174
FT                   /note=""CoV N NTD""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01276,
FT                   ECO:0000269|PubMed:32363136""
FT   DOMAIN          247..364
FT                   /note=""CoV N CTD""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01277""
FT   REGION          1..51
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          41..186
FT                   /note=""RNA-binding""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   REGION          63..83
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          168..212
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          176..206
FT                   /note=""SR region""
FT                   /evidence=""ECO:0000305|PubMed:32974389""
FT   REGION          233..266
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          258..361
FT                   /note=""Dimerization""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   REGION          260..340
FT                   /note=""Putative NLRP3 binding""
FT                   /evidence=""ECO:0000269|PubMed:34341353""
FT   REGION          361..391
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          400..419
FT                   /note=""Tetramerization""
FT                   /evidence=""ECO:0000269|PubMed:32654247""
FT   MOTIF           256..264
FT                   /note=""Nuclear localization signal""
FT                   /evidence=""ECO:0000250|UniProtKB:P59595""
FT   COMPBIAS        1..11
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        21..31
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        367..378
FT                   /note=""Basic and acidic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   BINDING         92
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   BINDING         107
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   BINDING         149
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   SITE            399..402
FT                   /note=""Cleavage (by host CASP6)""
FT                   /evidence=""ECO:0000250|UniProtKB:P59595""
FT   MOD_RES         176
FT                   /note=""Phosphoserine; by host""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   MOD_RES         206
FT                   /note=""Phosphoserine; by host GSK3-alpha and GSK3-beta""
FT                   /evidence=""ECO:0000269|PubMed:34593624""
FT   VARIANT         2..3
FT                   /note=""SD -> Y (in strain: Eta/B.1.525)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         3
FT                   /note=""D -> L (in strain: Alpha/B.1.1.7)""
FT                   /evidence=""ECO:0000305|PubMed:33413740""
FT   VARIANT         12
FT                   /note=""A -> G (in strain: Eta/B.1.525)""
FT   VARIANT         13
FT                   /note=""P -> L (in strain: Lambda/C.37, Omicron/BA.1,
FT                   Omicron/BA.2, Omicron/BA.2.12.1, Omicron/BA.2.75,
FT                   Omicron/BA.4, Omicron/BA.5, Omicron/BQ.1.1,
FT                   Omicron/XBB.1.5, Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         31..33
FT                   /note=""Missing (in strain: Omicron/BA.1, Omicron/BA.2,
FT                   Omicron/BA.2.12.1, Omicron/BA.2.75, Omicron/BA.4,
FT                   Omicron/BA.5, Omicron/BQ.1.1, Omicron/XBB.1.5,
FT                   Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         63
FT                   /note=""D -> G (in strain: Delta/B.1.617.2)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT  ",40005
ATCACT TCACTA CACTAG ACTAGG CTAGGT TAGGTT AGGTTT GGTTTC GTTTCA TTTCAA TTCAAA TCAAAC CAAACT AAACTT AACTTT ACTTTA CTTTAC TTTACT TTACTT TACTTG ACTTGC CTTGCT TTGCTT TGCTTT GCTTTA CTTTAC TTTACA TTACAT TACATA ACATAG CATAGA ATAGAA TAGAAG AGAAGT GAAGTT AAGTTA AGTTAT GTTATT TTATTT TATTTG ATTTGA TTTGAC TTGACT TGACTC GACTCC ACTCCT CTCCTG TCCTGG CCTGGT CTGGTG TGGTGA GGTGAT GTGATT TGATTC GATTCT ATTCTT TTCTTC TCTTCT CTTCTT TTCTTC TCTTCA CTTCAG TTCAGG TCAGGT CAGGTT AGGTTG GGTTGG GTTGGA TTGGAC TGGACA GGACAG GACAGC ACAGCT CAGCTG AGCTGG GCTGGT CTGGTG TGGTGC GGTGCT GTGCTG TGCTGC GCTGCA CTGCAG TGCAGC GCAGCT CAGCTT AGCTTA GCTTAT CTTATT TTATTA TATTAT ATTATG TTATGT TATGTG ATGTGG TGTGGG GTGGGT TGGGTT GGGTTA GGTTAT GTTATC TTATCT TATCTT ATCTTC TCTTCA CTTCAA TTCAAC TCAACC CAACCT AACCTA ACCTAG CCTAGG CTAGGA TAGGAC AGGACT GGACTT GACTTT ACTTTT CTTTTC TTTTCT TTTCTA TTCTAT TCTATT CTATTA TATTAA ATTAAA TTAAAA TAAAAT AAAATA AAATAT AATATA ATATAA TATAAT ATAATG TAATGA AATGAA ATGAAA TGAAAA GAAAAT AAAATG AAATGG AATGGA ATGGAA TGGAAC GGAACC,1,145,ATCA TCAC CACT ACTA CTAG TAGG AGGT GGTT GTTT TTTC TTCA TCAA CAAA AAAC AACT ACTT CTTT TTTA TTAC TACT ACTT CTTG TTGC TGCT GCTT CTTT TTTA TTAC TACA ACAT CATA ATAG TAGA AGAA GAAG AAGT AGTT GTTA TTAT TATT ATTT TTTG TTGA TGAC GACT ACTC CTCC TCCT CCTG CTGG TGGT GGTG GTGA TGAT GATT ATTC TTCT TCTT CTTC TTCT TCTT CTTC TTCA TCAG CAGG AGGT GGTT GTTG TTGG TGGA GGAC GACA ACAG CAGC AGCT GCTG CTGG TGGT GGTG GTGC TGCT GCTG CTGC TGCA GCAG CAGC AGCT GCTT CTTA TTAT TATT ATTA TTAT TATG ATGT TGTG GTGG TGGG GGGT GGTT GTTA TTAT TATC ATCT TCTT CTTC TTCA TCAA CAAC AACC ACCT CCTA CTAG TAGG AGGA GGAC GACT ACTT CTTT TTTT TTTC TTCT TCTA CTAT TATT ATTA TTAA TAAA AAAA AAAT AATA ATAT TATA ATAA TAAT AATG ATGA TGAA GAAA AAAA AAAT AATG ATGG TGGA GGAA GAAC AACC,ATCAC TCACT CACTA ACTAG CTAGG TAGGT AGGTT GGTTT GTTTC TTTCA TTCAA TCAAA CAAAC AAACT AACTT ACTTT CTTTA TTTAC TTACT TACTT ACTTG CTTGC TTGCT TGCTT GCTTT CTTTA TTTAC TTACA TACAT ACATA CATAG ATAGA TAGAA AGAAG GAAGT AAGTT AGTTA GTTAT TTATT TATTT ATTTG TTTGA TTGAC TGACT GACTC ACTCC CTCCT TCCTG CCTGG CTGGT TGGTG GGTGA GTGAT TGATT GATTC ATTCT TTCTT TCTTC CTTCT TTCTT TCTTC CTTCA TTCAG TCAGG CAGGT AGGTT GGTTG GTTGG TTGGA TGGAC GGACA GACAG ACAGC CAGCT AGCTG GCTGG CTGGT TGGTG GGTGC GTGCT TGCTG GCTGC CTGCA TGCAG GCAGC CAGCT AGCTT GCTTA CTTAT TTATT TATTA ATTAT TTATG TATGT ATGTG TGTGG GTGGG TGGGT GGGTT GGTTA GTTAT TTATC TATCT ATCTT TCTTC CTTCA TTCAA TCAAC CAACC AACCT ACCTA CCTAG CTAGG TAGGA AGGAC GGACT GACTT ACTTT CTTTT TTTTC TTTCT TTCTA TCTAT CTATT TATTA ATTAA TTAAA TAAAA AAAAT AAATA AATAT ATATA TATAA ATAAT TAATG AATGA ATGAA TGAAA GAAAA AAAAT AAATG AATGG ATGGA TGGAA GGAAC GAACC,ATCACT TCACTA CACTAG ACTAGG CTAGGT TAGGTT AGGTTT GGTTTC GTTTCA TTTCAA TTCAAA TCAAAC CAAACT AAACTT AACTTT ACTTTA CTTTAC TTTACT TTACTT TACTTG ACTTGC CTTGCT TTGCTT TGCTTT GCTTTA CTTTAC TTTACA TTACAT TACATA ACATAG CATAGA ATAGAA TAGAAG AGAAGT GAAGTT AAGTTA AGTTAT GTTATT TTATTT TATTTG ATTTGA TTTGAC TTGACT TGACTC GACTCC ACTCCT CTCCTG TCCTGG CCTGGT CTGGTG TGGTGA GGTGAT GTGATT TGATTC GATTCT ATTCTT TTCTTC TCTTCT CTTCTT TTCTTC TCTTCA CTTCAG TTCAGG TCAGGT CAGGTT AGGTTG GGTTGG GTTGGA TTGGAC TGGACA GGACAG GACAGC ACAGCT CAGCTG AGCTGG GCTGGT CTGGTG TGGTGC GGTGCT GTGCTG TGCTGC GCTGCA CTGCAG TGCAGC GCAGCT CAGCTT AGCTTA GCTTAT CTTATT TTATTA TATTAT ATTATG TTATGT TATGTG ATGTGG TGTGGG GTGGGT TGGGTT GGGTTA GGTTAT GTTATC TTATCT TATCTT ATCTTC TCTTCA CTTCAA TTCAAC TCAACC CAACCT AACCTA ACCTAG CCTAGG CTAGGA TAGGAC AGGACT GGACTT GACTTT ACTTTT CTTTTC TTTTCT TTTCTA TTCTAT TCTATT CTATTA TATTAA ATTAAA TTAAAA TAAAAT AAAATA AAATAT AATATA ATATAA TATAAT ATAATG TAATGA AATGAA ATGAAA TGAAAA GAAAAT AAAATG AAATGG AATGGA ATGGAA TGGAAC GGAACC,ATCACTA TCACTAG CACTAGG ACTAGGT CTAGGTT TAGGTTT AGGTTTC GGTTTCA GTTTCAA TTTCAAA TTCAAAC TCAAACT CAAACTT AAACTTT AACTTTA ACTTTAC CTTTACT TTTACTT TTACTTG TACTTGC ACTTGCT CTTGCTT TTGCTTT TGCTTTA GCTTTAC CTTTACA TTTACAT TTACATA TACATAG ACATAGA CATAGAA ATAGAAG TAGAAGT AGAAGTT GAAGTTA AAGTTAT AGTTATT GTTATTT TTATTTG TATTTGA ATTTGAC TTTGACT TTGACTC TGACTCC GACTCCT ACTCCTG CTCCTGG TCCTGGT CCTGGTG CTGGTGA TGGTGAT GGTGATT GTGATTC TGATTCT GATTCTT ATTCTTC TTCTTCT TCTTCTT CTTCTTC TTCTTCA TCTTCAG CTTCAGG TTCAGGT TCAGGTT CAGGTTG AGGTTGG GGTTGGA GTTGGAC TTGGACA TGGACAG GGACAGC GACAGCT ACAGCTG CAGCTGG AGCTGGT GCTGGTG CTGGTGC TGGTGCT GGTGCTG GTGCTGC TGCTGCA GCTGCAG CTGCAGC TGCAGCT GCAGCTT CAGCTTA AGCTTAT GCTTATT CTTATTA TTATTAT TATTATG ATTATGT TTATGTG TATGTGG ATGTGGG TGTGGGT GTGGGTT TGGGTTA GGGTTAT GGTTATC GTTATCT TTATCTT TATCTTC ATCTTCA TCTTCAA CTTCAAC TTCAACC TCAACCT CAACCTA AACCTAG ACCTAGG CCTAGGA CTAGGAC TAGGACT AGGACTT GGACTTT GACTTTT ACTTTTC CTTTTCT TTTTCTA TTTCTAT TTCTATT TCTATTA CTATTAA TATTAAA ATTAAAA TTAAAAT TAAAATA AAAATAT AAATATA AATATAA ATATAAT TATAATG ATAATGA TAATGAA AATGAAA ATGAAAA TGAAAAT GAAAATG AAAATGG AAATGGA AATGGAA ATGGAAC TGGAACC,"ID   SPIKE_SARS2             Reviewed;        1273 AA.
AC   P0DTC2;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Spike glycoprotein {ECO:0000255|HAMAP-Rule:MF_04099};
DE            Short=S glycoprotein {ECO:0000255|HAMAP-Rule:MF_04099};
DE   AltName: Full=E2 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   AltName: Full=Peplomer protein {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S1 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S2 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S2' {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Flags: Precursor;
GN   Name=S {ECO:0000255|HAMAP-Rule:MF_04099}; ORFNames=2;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   FUNCTION (SPIKE PROTEIN S1), AND CLEAVAGE BETWEEN S2 AND S2' BY HOST
RP   TMPRSS2.
RX   PubMed=32142651; DOI=10.1016/j.cell.2020.02.052;
RA   Hoffmann M., Kleine-Weber H., Schroeder S., Krueger N., Herrler T.,
RA   Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A.,
RA   Mueller M.A., Drosten C., Poehlmann S.;
RT   ""SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a
RT   clinically proven protease inhibitor."";
RL   Cell 181:1-10(2020).
RN   [3]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, FUNCTION, AND MUTAGENESIS OF
RP   681-PRO--ALA-684.
RX   PubMed=32362314; DOI=10.1016/j.molcel.2020.04.022;
RA   Hoffmann M., Kleine-Weber H., Poehlmann S.;
RT   ""A multibasic cleavage site in the Spike protein of SARS-CoV-2 is essential
RT   for infection of human lung cells."";
RL   Mol. Cell 78:779-784(2020).
RN   [4]
RP   GLYCOSYLATION AT ASN-17; ASN-61; ASN-74; ASN-122; ASN-149; ASN-165;
RP   ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098; ASN-1134; ASN-1158; ASN-1173 AND
RP   ASN-1194, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=32366695; DOI=10.1126/science.abb9983;
RA   Watanabe Y., Allen J.D., Wrapp D., McLellan J.S., Crispin M.;
RT   ""Site-specific glycan analysis of the SARS-CoV-2 spike."";
RL   Science 369:330-333(2020).
RN   [5]
RP   GLYCOSYLATION AT ASN-61; ASN-74; ASN-122; ASN-149; ASN-165; ASN-234;
RP   ASN-282; THR-323; SER-325; ASN-331; ASN-343; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098 AND ASN-1194, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=32363391; DOI=10.1093/glycob/cwaa042;
RA   Shajahan A., Supekar N.T., Gleinich A.S., Azadi P.;
RT   ""Deducing the N- and O- glycosylation profile of the spike protein of novel
RT   coronavirus SARS-CoV-2."";
RL   Glycobiology 30:981-988(2020).
RN   [6]
RP   VARIANT GLY-614.
RX   PubMed=32820179; DOI=10.1038/s41598-020-70827-z;
RA   Isabel S., Grana-Miraglia L., Gutierrez J.M., Bundalovic-Torma C.,
RA   Groves H.E., Isabel M.R., Eshaghi A., Patel S.N., Gubbay J.B., Poutanen T.,
RA   Guttman D.S., Poutanen S.M.;
RT   ""Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein
RT   mutation now documented worldwide."";
RL   Sci. Rep. 10:14031-14031(2020).
RN   [7]
RP   VARIANT GLY-614, AND MUTAGENESIS OF ASP-614.
RX   PubMed=32697968; DOI=10.1016/j.cell.2020.06.043;
RG   Sheffield COVID-19 Genomics Group;
RA   Korber B., Fischer W.M., Gnanakaran S., Yoon H., Theiler J., Abfalterer W.,
RA   Hengartner N., Giorgi E.E., Bhattacharya T., Foley B., Hastie K.M.,
RA   Parker M.D., Partridge D.G., Evans C.M., Freeman T.M., de Silva T.I.,
RA   McDanal C., Perez L.G., Tang H., Moon-Walker A., Whelan S.P.,
RA   LaBranche C.C., Saphire E.O., Montefiori D.C.;
RT   ""Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases
RT   Infectivity of the COVID-19 Virus."";
RL   Cell 182:812-827(2020).
RN   [8]
RP   FUNCTION.
RX   PubMed=32817270; DOI=10.1126/science.abd5223;
RA   Turonova B., Sikora M., Schuermann C., Hagen W.J.H., Welsch S.,
RA   Blanc F.E.C., von Buelow S., Gecht M., Bagola K., Hoerner C.,
RA   van Zandbergen G., Landry J., de Azevedo N.T.D., Mosalaganti S.,
RA   Schwarz A., Covino R., Muehlebach M.D., Hummer G., Krijnse Locker J.,
RA   Beck M.;
RT   ""In situ structural analysis of SARS-CoV-2 spike reveals flexibility
RT   mediated by three hinges."";
RL   Science 370:203-208(2020).
RN   [9]
RP   GLYCOSYLATION.
RX   PubMed=32929138; DOI=10.1038/s41598-020-71748-7;
RA   Grant O.C., Montgomery D., Ito K., Woods R.J.;
RT   ""Analysis of the SARS-CoV-2 spike protein glycan shield reveals
RT   implications for immune recognition."";
RL   Sci. Rep. 10:14991-14991(2020).
RN   [10]
RP   GLYCOSYLATION AT ASN-17; ASN-61; ASN-74; ASN-122; ASN-149; ASN-165;
RP   ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098; ASN-1134; ASN-1158; ASN-1173 AND
RP   ASN-1194, IDENTIFICATION BY MASS SPECTROMETRY, SUBCELLULAR LOCATION, AND
RP   SUBUNIT.
RX   PubMed=32979942; DOI=10.1016/j.cell.2020.09.018;
RA   Yao H., Song Y., Chen Y., Wu N., Xu J., Sun C., Zhang J., Weng T.,
RA   Zhang Z., Wu Z., Cheng L., Shi D., Lu X., Lei J., Crispin M., Shi Y.,
RA   Li L., Li S.;
RT   ""Molecular Architecture of the SARS-CoV-2 Virus."";
RL   Cell 183:730-738(2020).
RN   [11]
RP   VARIANT GLY-614, AND MUTAGENESIS OF ASP-614.
RX   PubMed=33106671; DOI=10.1038/s41586-020-2895-3;
RA   Plante J.A., Liu Y., Liu J., Xia H., Johnson B.A., Lokugamage K.G.,
RA   Zhang X., Muruato A.E., Zou J., Fontes-Garfias C.R., Mirchandani D.,
RA   Scharton D., Bilello J.P., Ku Z., An Z., Kalveram B., Freiberg A.N.,
RA   Menachery V.D., Xie X., Plante K.S., Weaver S.C., Shi P.Y.;
RT   ""Spike mutation D614G alters SARS-CoV-2 fitness."";
RL   Nature 592:116-121(2020).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH HUMAN NRP1 AND NRP2.
RC   STRAIN=SARS-CoV-2/human/Liverpool/REMRQ001/2020;
RX   PubMed=33082294; DOI=10.1126/science.abd3072;
RA   Daly J.L., Simonetti B., Klein K., Chen K.E., Williamson M.K.,
RA   Anton-Plagaro C., Shoemark D.K., Simon-Gracia L., Bauer M., Hollandi R.,
RA   Greber U.F., Horvath P., Sessions R.B., Helenius A., Hiscox J.A.,
RA   Teesalu T., Matthews D.A., Davidson A.D., Collins B.M., Cullen P.J.,
RA   Yamauchi Y.;
RT   ""Neuropilin-1 is a host factor for SARS-CoV-2 infection."";
RL   Science 370:861-865(2020).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH HUMAN NRP1 AND NRP2.
RC   STRAIN=SARS-CoV-2/human/Finland/1/2020;
RX   PubMed=33082293; DOI=10.1126/science.abd2985;
RA   Cantuti-Castelvetri L., Ojha R., Pedro L.D., Djannatian M., Franz J.,
RA   Kuivanen S., van der Meer F., Kallio K., Kaya T., Anastasina M., Smura T.,
RA   Levanov L., Szirovicza L., Tobi A., Kallio-Kokko H., Oesterlund P.,
RA   Joensuu M., Meunier F.A., Butcher S.J., Winkler M.S., Mollenhauer B.,
RA   Helenius A., Gokce O., Teesalu T., Hepojoki J., Vapalahti O.,
RA   Stadelmann C., Balistreri G., Simons M.;
RT   ""Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity."";
RL   Science 370:856-860(2020).
RN   [14]
RP   INTERACTION WITH HUMAN ITGA5 AND ITGB1.
RX   PubMed=33102950; DOI=10.1016/j.jacbts.2020.10.003;
RA   Beddingfield B.J., Iwanaga N., Chapagain P.P., Zheng W., Roy C.J., Hu T.Y.,
RA   Kolls J.K., Bix G.J.;
RT   ""The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2
RT   Infection."";
RL   JACC Basic Transl. Sci. 6:1-8(2021).
RN   [15]
RP   VARIANT GLY-614.
RX   PubMed=33184236; DOI=10.1126/science.abe8499;
RA   Hou Y.J., Chiba S., Halfmann P., Ehre C., Kuroda M., Dinnon K.H. III,
RA   Leist S.R., Schaefer A., Nakajima N., Takahashi K., Lee R.E.,
RA   Mascenik T.M., Graham R., Edwards C.E., Tse L.V., Okuda K., Markmann A.J.,
RA   Bartelt L., de Silva A., Margolis D.M., Boucher R.C., Randell S.H.,
RA   Suzuki T., Gralinski L.E., Kawaoka Y., Baric R.S.;
RT   ""SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and
RT   transmission in vivo."";
RL   Science 370:1464-1468(2020).
RN   [16]
RP   VARIANT GLY-614.
RX   PubMed=33417835; DOI=10.1016/j.celrep.2020.108630;
RA   Gobeil S.M., Janowska K., McDowell S., Mansouri K., Parks R., Manne K.,
RA   Stalls V., Kopp M.F., Henderson R., Edwards R.J., Haynes B.F., Acharya P.;
RT   ""D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease
RT   Cleavage at the S1/S2 Junction."";
RL   Cell Rep. 34:108630-108630(2021).
RN   [17]
RP   VARIANTS 69-VAL--PHE-70 DEL; LYS-144 DEL; TYR-501; ASP-570; GLY-614;
RP   HIS-681; ILE-716; ALA-982 AND HIS-1118.
RC   STRAIN=20I/501Y.V1, Alpha, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [18]
RP   VARIANT TYR-501.
RX   PubMed=32732280; DOI=10.1126/science.abc4730;
RA   Gu H., Chen Q., Yang G., He L., Fan H., Deng Y.Q., Wang Y., Teng Y.,
RA   Zhao Z., Cui Y., Li Y., Li X.F., Li J., Zhang N.N., Yang X., Chen S.,
RA   Guo Y., Zhao G., Wang X., Luo D.Y., Wang H., Yang X., Li Y., Han G., He Y.,
RA   Zhou X., Geng S., Sheng X., Jiang S., Sun S., Qin C.F., Zhou Y.;
RT   ""Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy."";
RL   Science 369:1603-1607(2020).
RN   [19]
RP   VARIANT GLY-614, AND MUTAGENESIS OF GLY-614.
RX   PubMed=33636719; DOI=10.1038/s41586-021-03361-1;
RA   Zhou B., Thi Nhu Thao T., Hoffmann D., Taddeo A., Ebert N., Labroussaa F.,
RA   Pohlmann A., King J., Steiner S., Kelly J.N., Portmann J., Halwe N.J.,
RA   Ulrich L., Trueeb B.S., Fan X., Hoffmann B., Wang L., Thomann L., Lin X.,
RA   Stalder H., Pozzi B., de Brot S., Jiang N., Cui D., Hossain J., Wilson M.,
RA   Keller M., Stark T.J., Barnes J.R., Dijkman R., Jores J., Benarafa C.,
RA   Wentworth D.E., Thiel V., Beer M.;
RT   ""SARS-CoV-2 spike D614G change enhances replication and transmission."";
RL   Nature 5920:122-127(2021).
RN   [20]
RP   MUTAGENESIS OF ASN-165; ASN-234; ASN-331; ASN-343; LEU-452; ALA-475;
RP   VAL-483; PHE-490 AND HIS-519.
RX   PubMed=32730807; DOI=10.1016/j.cell.2020.07.012;
RA   Li Q., Wu J., Nie J., Zhang L., Hao H., Liu S., Zhao C., Zhang Q., Liu H.,
RA   Nie L., Qin H., Wang M., Lu Q., Li X., Sun Q., Liu J., Zhang L., Li X.,
RA   Huang W., Wang Y.;
RT   ""The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and
RT   Antigenicity."";
RL   Cell 182:1284-1294(2020).
RN   [21]
RP   FUNCTION, CLEAVAGE BETWEEN S1 AND S2 BY HOST CTSL, AND INTERACTION WITH
RP   HUMAN ACE2.
RX   PubMed=32221306; DOI=10.1038/s41467-020-15562-9;
RA   Ou X., Liu Y., Lei X., Li P., Mi D., Ren L., Guo L., Guo R., Chen T.,
RA   Hu J., Xiang Z., Mu Z., Chen X., Chen J., Hu K., Jin Q., Wang J., Qian Z.;
RT   ""Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and
RT   its immune cross-reactivity with SARS-CoV."";
RL   Nat. Commun. 11:1620-1620(2020).
RN   [22]
RP   INTERACTION WITH HUMAN ACE2.
RX   PubMed=33607086; DOI=10.1016/j.bpj.2021.02.007;
RA   Cao W., Dong C., Kim S., Hou D., Tai W., Du L., Im W., Zhang X.F.;
RT   ""Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2
RT   protein-protein interaction."";
RL   Biophys. J. 120:1011-1019(2021).
RN   [23]
RP   FUNCTION, AND CLEAVAGE BETWEEN S1 AND S2 BY HOST TMPRSS2.
RX   PubMed=33465165; DOI=10.1371/journal.ppat.1009212;
RA   Ou T., Mou H., Zhang L., Ojha A., Choe H., Farzan M.;
RT   ""Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated
RT   by TMPRSS2."";
RL   PLoS Pathog. 17:e1009212-e1009212(2021).
RN   [24]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH S PROTEIN.
RX   PubMed=33229438; DOI=10.1074/jbc.ra120.016175;
RA   Boson B., Legros V., Zhou B., Siret E., Mathieu C., Cosset F.L.,
RA   Lavillette D., Denolly S.;
RT   ""The SARS-CoV-2 Envelope and Membrane proteins modulate maturation and
RT   retention of the Spike protein, allowing assembly of virus-like
RT   particles."";
RL   J. Biol. Chem. 296:100111-100111(2020).
RN   [25]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, CLEAVAGE BETWEEN S2 AND S2' BY
RP   HOST TMPRSS2, MUTAGENESIS OF ALA-684, AND FUNCTION (SPIKE PROTEIN S2').
RX   PubMed=32703818; DOI=10.26508/lsa.202000786;
RA   Bestle D., Heindl M.R., Limburg H., Van Lam van T., Pilgram O., Moulton H.,
RA   Stein D.A., Hardes K., Eickmann M., Dolnik O., Rohde C., Klenk H.D.,
RA   Garten W., Steinmetzer T., Boettcher-Friebertshaeuser E.;
RT   ""TMPRSS2 and furin are both essential for proteolytic activation of SARS-
RT   CoV-2 in human airway cells."";
RL   Life. Sci Alliance 3:1-14(2020).
RN   [26]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, CLEAVAGE BETWEEN S2 AND S2' BY
RP   HOST TMPRSS2, CLEAVAGE BETWEEN S2 AND S2' BY HOST CSTL, AND FUNCTION (SPIKE
RP   PROTEIN S2').
RX   PubMed=34159616; DOI=10.15252/embj.2021107821;
RA   Koch J., Uckeley Z.M., Doldan P., Stanifer M., Boulant S., Lozach P.Y.;
RT   ""TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect
RT   host cells."";
RL   EMBO J. 40:1-20(2021).
RN   [27]
RP   VARIANTS PHE-18; ALA-80; GLY-215; ASN-417; LYS-484; TYR-501; GLY-614 AND
RP   VAL-701.
RC   STRAIN=20H/501Y.V2, B.1.351, and Beta;
RX   PubMed=33690265; DOI=10.1038/s41586-021-03402-9;
RA   Tegally H., Wilkinson E., Giovanetti M., Iranzadeh A., Fonseca V.,
RA   Giandhari J., Doolabh D., Pillay S., San E.J., Msomi N., Mlisana K.,
RA   von Gottberg A., Walaza S., Allam M., Ismail A., Mohale T., Glass A.J.,
RA   Engelbrecht S., Van Zyl G., Preiser W., Petruccione F., Sigal A.,
RA   Hardie D., Marais G., Hsiao M., Korsman S., Davies M.A., Tyers L.,
RA   Mudau I., York D., Maslo C., Goedhals D., Abrahams S., Laguda-Akingba O.,
RA   Alisoltani-Dehkordi A., Godzik A., Wibmer C.K., Sewell B.T., Lourenco J.,
RA   Alcantara L.C.J., Kosakovsky Pond S.L., Weaver S., Martin D.,
RA   Lessells R.J., Bhiman J.N., Williamson C., de Oliveira T.;
RT   ""Emergence of a SARS-CoV-2 variant of concern with mutations in spike
RT   glycoprotein."";
RL   Nature 592:438-443(2021).
RN   [28]
RP   POLYMORPHISM.
RX   PubMed=34142653; DOI=10.2807/1560-7917.es.2021.26.24.2100509;
RA   Campbell F., Archer B., Laurenson-Schafer H., Jinnai Y., Konings F.,
RA   Batra N., Pavlin B., Vandemaele K., Van Kerkhove M.D., Jombart T.,
RA   Morgan O., le Polain de Waroux O.;
RT   ""Increased transmissibility and global spread of SARS-CoV-2 variants of
RT   concern as at June 2021."";
RL   Eurosurveillance 26:0-0(2021).
RN   [29]
RP   VARIANTS ARG-452 AND PHE-453, AND MUTAGENESIS OF LEU-452; TYR-453 AND
RP   ASN-501.
RX   PubMed=34171266; DOI=10.1016/j.chom.2021.06.006;
RG   Genotype to Phenotype Japan (G2P-Japan) Consortium;
RA   Motozono C., Toyoda M., Zahradnik J., Saito A., Nasser H., Tan T.S.,
RA   Ngare I., Kimura I., Uriu K., Kosugi Y., Yue Y., Shimizu R., Ito J.,
RA   Torii S., Yonekawa A., Shimono N., Nagasaki Y., Minami R., Toya T.,
RA   Sekiya N., Fukuhara T., Matsuura Y., Schreiber G., Ikeda T., Nakagawa S.,
RA   Ueno T., Sato K.;
RT   ""SARS-CoV-2 spike L452R variant evades cellular immunity and increases
RT   infectivity."";
RL   Cell Host Microbe 0:0-0(2021).
RN   [30]
RP   VARIANT 69-VAL--PHE-70 DEL, AND MUTAGENESIS OF 69-HIS-VAL-70.
RX   PubMed=34166617; DOI=10.1016/j.celrep.2021.109292;
RG   COVID-19 Genomics UK (COG-UK) Consortium;
RA   Meng B., Kemp S.A., Papa G., Datir R., Ferreira I.A.T.M., Marelli S.,
RA   Harvey W.T., Lytras S., Mohamed A., Gallo G., Thakur N., Collier D.A.,
RA   Mlcochova P., Duncan L.M., Carabelli A.M., Kenyon J.C., Lever A.M.,
RA   De Marco A., Saliba C., Culap K., Cameroni E., Matheson N.J., Piccoli L.,
RA   Corti D., James L.C., Robertson D.L., Bailey D., Gupta R.K.;
RT   ""Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in
RT   the Alpha variant B.1.1.7."";
RL   Cell Rep. 35:109292-109292(2021).
RN   [31]
RP   VARIANTS ILE-13 AND CYS-152, POLYMORPHISM, AND MASS SPECTROMETRY (SIGNAL).
RX   PubMed=34210893; DOI=10.1126/science.abi7994;
RA   McCallum M., Bassi J., De Marco A., Chen A., Walls A.C., Di Iulio J.,
RA   Tortorici M.A., Navarro M.J., Silacci-Fregni C., Saliba C., Sprouse K.R.,
RA   Agostini M., Pinto D., Culap K., Bianchi S., Jaconi S., Cameroni E.,
RA   Bowen J.E., Tilles S.W., Pizzuto M.S., Guastalla S.B., Bona G.,
RA   Pellanda A.F., Garzoni C., Van Voorhis W.C., Rosen L.E., Snell G.,
RA   Telenti A., Virgin H.W., Piccoli L., Corti D., Veesler D.;
RT   ""SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern."";
RL   Science 373:648-654(2021).
RN   [32]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-1269 AND HIS-1271.
RX   PubMed=34504087; DOI=10.1038/s41467-021-25589-1;
RA   Cattin-Ortola J., Welch L.G., Maslen S.L., Papa G., James L.C., Munro S.;
RT   ""Sequences in the cytoplasmic tail of SARS-CoV-2 Spike facilitate
RT   expression at the cell surface and syncytia formation."";
RL   Nat. Commun. 12:5333-5333(2021).
RN   [33]
RP   PALMITOYLATION AT CYS-1235; CYS-1236; CYS-1240; CYS-1241; CYS-1243;
RP   CYS-1247; CYS-1248; CYS-1250; CYS-1253 AND CYS-1254.
RX   PubMed=34599882; DOI=10.1016/j.devcel.2021.09.016;
RA   Mesquita F.S., Abrami L., Sergeeva O., Turelli P., Qing E., Kunz B.,
RA   Raclot C., Paz Montoya J., Abriata L.A., Gallagher T., Dal Peraro M.,
RA   Trono D., D'Angelo G., van der Goot F.G.;
RT   ""S-acylation controls SARS-CoV-2 membrane lipid organization and enhances
RT   infectivity."";
RL   Dev. Cell 56:1-18(2021).
RN   [34] {ECO:0007744|PDB:6M17}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.90 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), DOMAIN, AND INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN S1).
RX   PubMed=32132184; DOI=10.1126/science.abb2762;
RA   Yan R., Zhang Y., Li Y., Xia L., Guo Y., Zhou Q.;
RT   ""Structural basis for the recognition of the SARS-CoV-2 by full-length
RT   human ACE2."";
RL   Science 367:1444-1448(2020).
RN   [35]
RP   SUPERANTIGEN, AND DOMAIN.
RX   PubMed=32989130; DOI=10.1073/pnas.2010722117;
RA   Cheng M.H., Zhang S., Porritt R.A., Noval Rivas M., Paschold L.,
RA   Willscher E., Binder M., Arditi M., Bahar I.;
RT   ""Superantigenic character of an insert unique to SARS-CoV-2 spike supported
RT   by skewed TCR repertoire in patients with hyperinflammation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 117:25254-25262(2020).
RN   [36]
RP   INTERACTION WITH HUMAN BILIRUBIN, INTERACTION WITH HUMAN BILIVERDIN, AND
RP   MUTAGENESIS OF ASN-121 AND ARG-190.
RX   PubMed=33888467; DOI=10.1126/sciadv.abg7607;
RA   Rosa A., Pye V.E., Graham C., Muir L., Seow J., Ng K.W., Cook N.J.,
RA   Rees-Spear C., Parker E., Dos Santos M.S., Rosadas C., Susana A., Rhys H.,
RA   Nans A., Masino L., Roustan C., Christodoulou E., Ulferts R., Wrobel A.G.,
RA   Short C.E., Fertleman M., Sanders R.W., Heaney J., Spyer M., Kjaer S.,
RA   Riddell A., Malim M.H., Beale R., MacRae J.I., Taylor G.P., Nastouli E.,
RA   van Gils M.J., Rosenthal P.B., Pizzato M., McClure M.O., Tedder R.S.,
RA   Kassiotis G., McCoy L.E., Doores K.J., Cherepanov P.;
RT   ""SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity."";
RL   Sci. Adv. 7:0-0(2021).
RN   [37]
RP   BIOTECHNOLOGY, AND MUTAGENESIS OF 682-ARG--ARG-685 AND 986-LYS-VAL-987.
RX   PubMed=34322129; DOI=10.3389/fimmu.2021.701501;
RA   Martinez-Flores D., Zepeda-Cervantes J., Cruz-Resendiz A.,
RA   Aguirre-Sampieri S., Sampieri A., Vaca L.;
RT   ""SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of
RT   New Viral Variants."";
RL   Front. Immunol. 12:701501-701501(2021).
RN   [38]
RP   GLYCOSYLATION AT THR-676 AND THR-678 BY HOST GALNT1, AND MUTAGENESIS OF
RP   SER-673; THR-676; THR-678; SER-680 AND PRO-681.
RX   PubMed=34732583; DOI=10.1073/pnas.2109905118;
RA   Zhang L., Mann M., Syed Z.A., Reynolds H.M., Tian E., Samara N.L.,
RA   Zeldin D.C., Tabak L.A., Ten Hagen K.G.;
RT   ""Furin cleavage of the SARS-CoV-2 spike is modulated by O-glycosylation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [39]
RP   REVIEW, PROTEOLITIC PROCESSING, FUNCTION (SPIKE PROTEIN S2), AND FUNCTION
RP   (SPIKE PROTEIN S2').
RX   PubMed=34561887; DOI=10.1111/1348-0421.12945;
RA   Takeda M.;
RT   ""Proteolytic activation of SARS-CoV-2 spike protein."";
RL   Microbiol. Immunol. 66:15-23(2022).
RN   [40]
RP   INTERACTION WITH HOST MBL2.
RX   PubMed=35102342; DOI=10.1038/s41590-021-01114-w;
RA   Stravalaci M., Pagani I., Paraboschi E.M., Pedotti M., Doni A.,
RA   Scavello F., Mapelli S.N., Sironi M., Perucchini C., Varani L.,
RA   Matkovic M., Cavalli A., Cesana D., Gallina P., Pedemonte N., Capurro V.,
RA   Clementi N., Mancini N., Invernizzi P., Bayarri-Olmos R., Garred P.,
RA   Rappuoli R., Duga S., Bottazzi B., Uguccioni M., Asselta R., Vicenzi E.,
RA   Mantovani A., Garlanda C.;
RT   ""Recognition and inhibition of SARS-CoV-2 by humoral innate immunity
RT   pattern recognition molecules."";
RL   Nat. Immunol. 23:275-286(2022).
RN   [41]
RP   FUNCTION (SPIKE PROTEIN S1), AND INTERACTION WITH HOST INTEGRIN (SPIKE
RP   PROTEIN S1).
RX   PubMed=35150743; DOI=10.1016/j.jbc.2022.101710;
RA   Liu J., Lu F., Chen Y., Plow E., Qin J.;
RT   ""Integrin mediates cell entry of the SARS-CoV-2 virus independent of
RT   cellular receptor ACE2."";
RL   J. Biol. Chem. 1:101710-101710(2022).
RN   [42]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [43]
RP   SUBUNIT.
RX   PubMed=36735681; DOI=10.1371/journal.pbio.3001959;
RA   Shilts J., Crozier T.W.M., Teixeira-Silva A., Gabaev I., Gerber P.P.,
RA   Greenwood E.J.D., Watson S.J., Ortmann B.M., Gawden-Bone C.M., Pauzaite T.,
RA   Hoffmann M., Nathan J.A., Poehlmann S., Matheson N.J., Lehner P.J.,
RA   Wright G.J.;
RT   ""LRRC15 mediates an accessory interaction with the SARS-CoV-2 spike
RT   protein."";
RL   PLoS Biol. 21:e3001959-e3001959(2023).
RN   [44]
RP   VARIANT ASN-405.
RX   PubMed=36851546; DOI=10.3390/v15020332;
RA   Bugatti A., Filippini F., Messali S., Giovanetti M., Ravelli C., Zani A.,
RA   Ciccozzi M., Caruso A., Caccuri F.;
RT   ""The D405N Mutation in the Spike Protein of SARS-CoV-2 Omicron BA.5
RT   Inhibits Spike/Integrins Interaction and Viral Infection of Human Lung
RT   Microvascular Endothelial Cells."";
RL   Viruses 15:0-0(2023).
RN   [45]
RP   MUTAGENESIS OF GLU-484.
RX   PubMed=37421949; DOI=10.1016/j.cell.2023.06.005;
RA   Baggen J., Jacquemyn M., Persoons L., Vanstreels E., Pye V.E., Wrobel A.G.,
RA   Calvaresi V., Martin S.R., Roustan C., Cronin N.B., Reading E.,
RA   Thibaut H.J., Vercruysse T., Maes P., De Smet F., Yee A., Nivitchanyong T.,
RA   Roell M., Franco-Hernandez N., Rhinn H., Mamchak A.A., Ah Young-Chapon M.,
RA   Brown E., Cherepanov P., Daelemans D.;
RT   ""TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry."";
RL   Cell 186:1-16(2023).
RN   [46] {ECO:0007744|PDB:6VSB}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.46 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN S1), SUBUNIT, AND
RP   GLYCOSYLATION.
RX   PubMed=32075877; DOI=10.1126/science.abb2507;
RA   Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.L., Abiona O.,
RA   Graham B.S., McLellan J.S.;
RT   ""Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation."";
RL   Science 367:1260-1263(2020).
RN   [47] {ECO:0007744|PDB:6VXX, ECO:0007744|PDB:6VYB}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.80 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), SUBUNIT (SPIKE PROTEIN S1), INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN
RP   S1), MUTAGENESIS OF 679-GLN--ALA-684, GLYCOSYLATION AT ASN-61; ASN-122;
RP   ASN-61; ASN-165; ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616;
RP   ASN-657; ASN-709; ASN-717; ASN-801; ASN-1074; ASN-1098 AND ASN-1134, AND
RP   DISULFIDE BOND.
RX   PubMed=32155444; DOI=10.1016/j.cell.2020.02.058;
RA   Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., Veesler D.;
RT   ""Structure, function, and antigenicity of the SARS-CoV-2 spike
RT   glycoprotein."";
RL   Cell 180:1-12(2020).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HOST ACE2.
RX   PubMed=32225176; DOI=10.1038/s41586-020-2180-5;
RA   Lan J., Ge J., Yu J., Shan S., Zhou H., Fan S., Zhang Q., Shi X., Wang Q.,
RA   Zhang L., Wang X.;
RT   ""Structure of the SARS-CoV-2 spike receptor-binding domain bound to the
RT   ACE2 receptor."";
RL   Nature 581:215-220(2020).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.68 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HOST ACE2, INTERACTION WITH HOST ACE2, AND MUTAGENESIS OF GLN-493 AND
RP   ASN-501.
RX   PubMed=32225175; DOI=10.1038/s41586-020-2179-y;
RA   Shang J., Ye G., Shi K., Wan Y., Luo C., Aihara H., Geng Q., Auerbach A.,
RA   Li F.;
RT   ""Structural basis of receptor recognition by SARS-CoV-2."";
RL   Nature 581:221-224(2020).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (3.08 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HUMAN ANTIBODY CR3022, AND DISULFIDE BOND.
RX   PubMed=32245784; DOI=10.1126/science.abb7269;
RA   Yuan M., Wu N.C., Zhu X., Lee C.D., So R.T.Y., Lv H., Mok C.K.P.,
RA   Wilson I.A.;
RT   ""A highly conserved cryptic epitope in the receptor-binding domains of
RT   SARS-CoV-2 and SARS-CoV."";
RL   Science 368:630-633(2020).
CC   -!- FUNCTION: [Spike protein S1]: Attaches the virion to the cell membrane
CC       by interacting with host receptor, initiating the infection. The major
CC       receptor is host ACE2 (PubMed:32142651, PubMed:32155444,
CC       PubMed:33607086). When S2/S2' has been cleaved, binding to the receptor
CC       triggers direct fusion at the cell membrane (PubMed:34561887). When
CC       S2/S2' has not been cleaved, binding to the receptor results in
CC       internalization of the virus by endocytosis leading to fusion of the
CC       virion membrane with the host endosomal membrane (PubMed:32075877,
CC       PubMed:32221306). Alternatively, may use NRP1/NRP2 (PubMed:33082294,
CC       PubMed:33082293) and integrin as entry receptors (PubMed:35150743). The
CC       use of NRP1/NRP2 receptors may explain the tropism of the virus in
CC       human olfactory epithelial cells, which express these molecules at high
CC       levels but ACE2 at low levels (PubMed:33082293). The stalk domain of S
CC       contains three hinges, giving the head unexpected orientational freedom
CC       (PubMed:32817270). {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:32075877, ECO:0000269|PubMed:32142651,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32221306,
CC       ECO:0000269|PubMed:32817270, ECO:0000269|PubMed:33082293,
CC       ECO:0000269|PubMed:33082294, ECO:0000269|PubMed:35150743,
CC       ECO:0000303|PubMed:33082293, ECO:0000305|PubMed:34561887}.
CC   -!- FUNCTION: [Spike protein S2]: Precursor of the fusion protein processed
CC       in the biosynthesis of the S protein and the formation of virus
CC       particle. Mediates fusion of the virion and cellular membranes by
CC       functioning as a class I viral fusion protein. Contains two viral
CC       fusion peptides that are unmasked after cleavage. The S2/S2' cleavage
CC       occurs during virus entry at the cell membrane by host TMPRSS2
CC       (PubMed:32142651) or during endocytosis by host CSTL (PubMed:32703818,
CC       PubMed:34159616). In either case, this triggers an extensive and
CC       irreversible conformational change leading to fusion of the viral
CC       envelope with the cellular cytoplasmic membrane, releasing viral
CC       genomic RNA into the host cell cytoplasm (PubMed:34561887). Under the
CC       current model, the protein has at least three conformational states:
CC       pre-fusion native state, pre-hairpin intermediate state, and post-
CC       fusion hairpin state. During fusion of the viral and target cell
CC       membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-
CC       hairpins structure and position the fusion peptide in close proximity
CC       to the C-terminal region of the ectodomain. Formation of this structure
CC       appears to promote apposition and subsequent fusion of viral and target
CC       cell membranes. {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:32703818, ECO:0000269|PubMed:34159616,
CC       ECO:0000305|PubMed:34561887}.
CC   -!- FUNCTION: [Spike protein S2']: Subunit of the fusion protein that is
CC       processed upon entry into the host cell. Mediates fusion of the virion
CC       and cellular membranes by functioning as a class I viral fusion
CC       protein. Contains a viral fusion peptide that is unmasked after S2
CC       cleavage. This cleavage can occur at the cell membrane by host TMPRSS2
CC       or during endocytosis by host CSTL (PubMed:32703818, PubMed:34159616).
CC       In either case, this triggers an extensive and irreversible
CC       conformational change that leads to fusion of the viral envelope with
CC       the cellular cytoplasmic membrane, releasing viral genomic RNA into the
CC       host cell cytoplasm (PubMed:34561887). Under the current model, the
CC       protein has at least three conformational states: pre-fusion native
CC       state, pre-hairpin intermediate state, and post-fusion hairpin state.
CC       During fusion of the viral and target cell membranes, the coiled coil
CC       regions (heptad repeats) adopt a trimer-of-hairpins structure and
CC       position the fusion peptide in close proximity to the C-terminal region
CC       of the ectodomain. Formation of this structure appears to promote
CC       apposition and subsequent fusion of viral and target cell membranes.
CC       {ECO:0000255|HAMAP-Rule:MF_04099, ECO:0000269|PubMed:32703818,
CC       ECO:0000269|PubMed:34159616, ECO:0000305|PubMed:34561887}.
CC   -!- SUBUNIT: [Spike glycoprotein]: Homotrimer; each monomer consists of a
CC       S1 and a S2 subunit (PubMed:32075877, PubMed:32155444,
CC       PubMed:32245784). The resulting peplomers protrude from the virus
CC       surface as spikes (PubMed:32979942). Interacts with ORF3a protein and
CC       ORF7a protein (By similarity) (PubMed:32075877, PubMed:32155444,
CC       PubMed:32245784, PubMed:32979942). There are an average of 26 +/-15
CC       spike trimers at the surface of virion particles (PubMed:32979942).
CC       Binds to host MBL2 (PubMed:35102342). This binding occurs via glycans
CC       and inhibits viral infectivity. Inhibition is effective against alpha,
CC       beta, gamma, and delta variants (PubMed:35102342). {ECO:0000255|HAMAP-
CC       Rule:MF_04099, ECO:0000269|PubMed:32075877,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32245784,
CC       ECO:0000269|PubMed:32979942, ECO:0000269|PubMed:35102342}.
CC   -!- SUBUNIT: [Spike protein S1]: Binds to host ACE2 (PubMed:32075877,
CC       PubMed:32132184, PubMed:32155444, PubMed:32221306, PubMed:32225175,
CC       PubMed:32225176, PubMed:33607086). RBD also interacts with the N-linked
CC       glycan on 'Asn-90' of ACE2 (PubMed:33607086). Cleavage of S generates a
CC       polybasic C-terminal sequence on S1 that binds to host Neuropilin-1
CC       (NRP1) and Neuropilin-2 (NRP2) receptors (PubMed:33082293,
CC       PubMed:33082294). Interacts with host integrin alpha-5/beta-1
CC       (ITGA5:ITGB1) and with ACE2 in complex with integrin alpha-5/beta-1
CC       (ITGA5:ITGB1) (PubMed:33102950). May interact via cytoplasmic c-
CC       terminus with M protein (PubMed:33229438). May interact (via N-
CC       terminus) with host bilirubin and biliverdin, thereby preventing
CC       antibody binding to the SARS-CoV-2 spike NTD via an allosteric
CC       mechanism (PubMed:33888467). May interact with host LRRC15, thereby
CC       allowing attachment to host cells (PubMed:36735681).
CC       {ECO:0000269|PubMed:32075877, ECO:0000269|PubMed:32132184,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32221306,
CC       ECO:0000269|PubMed:32225",53124
GATATG ATATGC TATGCA ATGCAC TGCACT GCACTC CACTCC ACTCCG CTCCGC TCCGCA CCGCAT CGCATT GCATTA CATTAC ATTACG TTACGC TACGCT ACGCTC CGCTCG GCTCGG CTCGGT TCGGTG CGGTGG GGTGGA GTGGAT TGGATC GGATCC GATCCT ATCCTC TCCTCA CCTCAG CTCAGA TCAGAT CAGATC AGATCC GATCCA ATCCAA TCCAAC CCAACT CAACTG AACTGG ACTGGC CTGGCA TGGCAG GGCAGT GCAGTA CAGTAA AGTAAC GTAACC TAACCC AACCCG ACCCGA CCCGAT CCGATT CGATTG GATTGG ATTGGT TTGGTG TGGTGG GGTGGG GTGGGG TGGGGC GGGGCG GGGCGC GGCGCG GCGCGT CGCGTA GCGTAC CGTACA GTACAA TACAAA ACAAAA CAAAAC AAAACA AAACAA AACAAC ACAACG CAACGA AACGAC ACGACG CGACGG GACGGC ACGGCC CGGCCC GGCCCC GCCCCA CCCCAC CCCACG CCACGG CACGGG ACGGGT CGGGTT GGGTTA GGTTAC GTTACC TTACCC TACCCA ACCCAC CCCACT CCACTA CACTAA ACTAAT CTAATA TAATAA AATAAC ATAACG TAACGC AACGCG ACGCGA CGCGAC GCGACT CGACTT GACTTG ACTTGG CTTGGT TTGGTT TGGTTC GGTTCA GTTCAC TTCACG TCACGG CACGGC ACGGCT CGGCTC GGCTCT GCTCTC CTCTCA TCTCAC CTCACT TCACTC CACTCA ACTCAA CTCAAC TCAACA CAACAT AACATG ACATGG CATGGC ATGGCA TGGCAA GGCAAG GCAAGG,3,142,GATA ATAT TATG ATGC TGCA GCAC CACT ACTC CTCC TCCG CCGC CGCA GCAT CATT ATTA TTAC TACG ACGC CGCT GCTC CTCG TCGG CGGT GGTG GTGG TGGA GGAT GATC ATCC TCCT CCTC CTCA TCAG CAGA AGAT GATC ATCC TCCA CCAA CAAC AACT ACTG CTGG TGGC GGCA GCAG CAGT AGTA GTAA TAAC AACC ACCC CCCG CCGA CGAT GATT ATTG TTGG TGGT GGTG GTGG TGGG GGGG GGGC GGCG GCGC CGCG GCGT CGTA GTAC TACA ACAA CAAA AAAA AAAC AACA ACAA CAAC AACG ACGA CGAC GACG ACGG CGGC GGCC GCCC CCCC CCCA CCAC CACG ACGG CGGG GGGT GGTT GTTA TTAC TACC ACCC CCCA CCAC CACT ACTA CTAA TAAT AATA ATAA TAAC AACG ACGC CGCG GCGA CGAC GACT ACTT CTTG TTGG TGGT GGTT GTTC TTCA TCAC CACG ACGG CGGC GGCT GCTC CTCT TCTC CTCA TCAC CACT ACTC CTCA TCAA CAAC AACA ACAT CATG ATGG TGGC GGCA GCAA CAAG AAGG,GATAT ATATG TATGC ATGCA TGCAC GCACT CACTC ACTCC CTCCG TCCGC CCGCA CGCAT GCATT CATTA ATTAC TTACG TACGC ACGCT CGCTC GCTCG CTCGG TCGGT CGGTG GGTGG GTGGA TGGAT GGATC GATCC ATCCT TCCTC CCTCA CTCAG TCAGA CAGAT AGATC GATCC ATCCA TCCAA CCAAC CAACT AACTG ACTGG CTGGC TGGCA GGCAG GCAGT CAGTA AGTAA GTAAC TAACC AACCC ACCCG CCCGA CCGAT CGATT GATTG ATTGG TTGGT TGGTG GGTGG GTGGG TGGGG GGGGC GGGCG GGCGC GCGCG CGCGT GCGTA CGTAC GTACA TACAA ACAAA CAAAA AAAAC AAACA AACAA ACAAC CAACG AACGA ACGAC CGACG GACGG ACGGC CGGCC GGCCC GCCCC CCCCA CCCAC CCACG CACGG ACGGG CGGGT GGGTT GGTTA GTTAC TTACC TACCC ACCCA CCCAC CCACT CACTA ACTAA CTAAT TAATA AATAA ATAAC TAACG AACGC ACGCG CGCGA GCGAC CGACT GACTT ACTTG CTTGG TTGGT TGGTT GGTTC GTTCA TTCAC TCACG CACGG ACGGC CGGCT GGCTC GCTCT CTCTC TCTCA CTCAC TCACT CACTC ACTCA CTCAA TCAAC CAACA AACAT ACATG CATGG ATGGC TGGCA GGCAA GCAAG CAAGG,GATATG ATATGC TATGCA ATGCAC TGCACT GCACTC CACTCC ACTCCG CTCCGC TCCGCA CCGCAT CGCATT GCATTA CATTAC ATTACG TTACGC TACGCT ACGCTC CGCTCG GCTCGG CTCGGT TCGGTG CGGTGG GGTGGA GTGGAT TGGATC GGATCC GATCCT ATCCTC TCCTCA CCTCAG CTCAGA TCAGAT CAGATC AGATCC GATCCA ATCCAA TCCAAC CCAACT CAACTG AACTGG ACTGGC CTGGCA TGGCAG GGCAGT GCAGTA CAGTAA AGTAAC GTAACC TAACCC AACCCG ACCCGA CCCGAT CCGATT CGATTG GATTGG ATTGGT TTGGTG TGGTGG GGTGGG GTGGGG TGGGGC GGGGCG GGGCGC GGCGCG GCGCGT CGCGTA GCGTAC CGTACA GTACAA TACAAA ACAAAA CAAAAC AAAACA AAACAA AACAAC ACAACG CAACGA AACGAC ACGACG CGACGG GACGGC ACGGCC CGGCCC GGCCCC GCCCCA CCCCAC CCCACG CCACGG CACGGG ACGGGT CGGGTT GGGTTA GGTTAC GTTACC TTACCC TACCCA ACCCAC CCCACT CCACTA CACTAA ACTAAT CTAATA TAATAA AATAAC ATAACG TAACGC AACGCG ACGCGA CGCGAC GCGACT CGACTT GACTTG ACTTGG CTTGGT TTGGTT TGGTTC GGTTCA GTTCAC TTCACG TCACGG CACGGC ACGGCT CGGCTC GGCTCT GCTCTC CTCTCA TCTCAC CTCACT TCACTC CACTCA ACTCAA CTCAAC TCAACA CAACAT AACATG ACATGG CATGGC ATGGCA TGGCAA GGCAAG GCAAGG,GATATGC ATATGCA TATGCAC ATGCACT TGCACTC GCACTCC CACTCCG ACTCCGC CTCCGCA TCCGCAT CCGCATT CGCATTA GCATTAC CATTACG ATTACGC TTACGCT TACGCTC ACGCTCG CGCTCGG GCTCGGT CTCGGTG TCGGTGG CGGTGGA GGTGGAT GTGGATC TGGATCC GGATCCT GATCCTC ATCCTCA TCCTCAG CCTCAGA CTCAGAT TCAGATC CAGATCC AGATCCA GATCCAA ATCCAAC TCCAACT CCAACTG CAACTGG AACTGGC ACTGGCA CTGGCAG TGGCAGT GGCAGTA GCAGTAA CAGTAAC AGTAACC GTAACCC TAACCCG AACCCGA ACCCGAT CCCGATT CCGATTG CGATTGG GATTGGT ATTGGTG TTGGTGG TGGTGGG GGTGGGG GTGGGGC TGGGGCG GGGGCGC GGGCGCG GGCGCGT GCGCGTA CGCGTAC GCGTACA CGTACAA GTACAAA TACAAAA ACAAAAC CAAAACA AAAACAA AAACAAC AACAACG ACAACGA CAACGAC AACGACG ACGACGG CGACGGC GACGGCC ACGGCCC CGGCCCC GGCCCCA GCCCCAC CCCCACG CCCACGG CCACGGG CACGGGT ACGGGTT CGGGTTA GGGTTAC GGTTACC GTTACCC TTACCCA TACCCAC ACCCACT CCCACTA CCACTAA CACTAAT ACTAATA CTAATAA TAATAAC AATAACG ATAACGC TAACGCG AACGCGA ACGCGAC CGCGACT GCGACTT CGACTTG GACTTGG ACTTGGT CTTGGTT TTGGTTC TGGTTCA GGTTCAC GTTCACG TTCACGG TCACGGC CACGGCT ACGGCTC CGGCTCT GGCTCTC GCTCTCA CTCTCAC TCTCACT CTCACTC TCACTCA CACTCAA ACTCAAC CTCAACA TCAACAT CAACATG AACATGG ACATGGC CATGGCA ATGGCAA TGGCAAG GGCAAGG,"ID   ORF9B_BCHK3             Reviewed;          97 AA.
AC   Q3LZX3;
DT   12-JUN-2007, integrated into UniProtKB/Swiss-Prot.
DT   25-OCT-2005, sequence version 1.
DT   02-OCT-2024, entry version 58.
DE   RecName: Full=Protein 9b;
DE   AltName: Full=Accessory protein 9b;
DE   AltName: Full=ORF-9b;
GN   ORFNames=9b;
OS   Bat coronavirus HKU3 (BtCoV) (SARS-like coronavirus HKU3).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=442736;
OH   NCBI_TaxID=89399; Rhinolophus sinicus (Chinese rufous horseshoe bat).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HKU3-1;
RX   PubMed=16169905; DOI=10.1073/pnas.0506735102;
RA   Lau S.K.P., Woo P.C.Y., Li K.S.M., Huang Y., Tsoi H.-W., Wong B.H.L.,
RA   Wong S.S.Y., Leung S.-Y., Chan K.-H., Yuen K.-Y.;
RT   ""Severe acute respiratory syndrome coronavirus-like virus in Chinese
RT   horseshoe bats."";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:14040-14045(2005).
CC   -!- SUBUNIT: Homodimer. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Host cytoplasmic vesicle membrane; Peripheral
CC       membrane protein. Host cytoplasm. Note=Binds non-covalently to
CC       intracellular lipid bilayers. {ECO:0000250}.
CC   -!- MISCELLANEOUS: The gene encoding this protein is included within the N
CC       gene (alternative ORF).
CC   -!- MISCELLANEOUS: Bat coronavirus HKU3 is highly similar to SARS-CoV
CC       (SARS-like).
CC   -!- SIMILARITY: Belongs to the coronavirus group 2 protein 9b family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; DQ022305; AAY88875.1; -; Genomic_RNA.
DR   SMR; Q3LZX3; -.
DR   Proteomes; UP000007450; Segment.
DR   GO; GO:0044162; C:host cell cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-KW.
DR   CDD; cd21955; SARS-CoV_ORF9b; 1.
DR   InterPro; IPR018542; Protein_9b_Betacoronavirus.
DR   InterPro; IPR037223; Protein_9b_SARS.
DR   Pfam; PF09399; bCoV_lipid_BD; 1.
DR   SUPFAM; SSF141666; SARS ORF9b-like; 1.
DR   PROSITE; PS51920; SARS_9B; 1.
PE   3: Inferred from homology;
KW   Host cytoplasm; Host cytoplasmic vesicle; Host membrane; Membrane.
FT   CHAIN           1..97
FT                   /note=""Protein 9b""
FT                   /id=""PRO_0000291325""
FT   DOMAIN          8..97
FT                   /note=""9b""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01268""
SQ   SEQUENCE   97 AA;  10723 MW;  1CAD2AFC3882E232 CRC64;
     MDPKVNVVPP ALHLVDPQIQ MTITRMEDAV VHDQNNAGPK VYPIILRLGS QLSLSMAKRN
     LDSLEARAFQ STPIVVKMTK LATTEELPDE FVVVTAK
//
",42289
CTCCCA TCCCAT CCCATC CCATCT CATCTC ATCTCG TCTCGT CTCGTT TCGTTA CGTTAC GTTACG TTACGC TACGCC ACGCCA CGCCAT GCCATT CCATTC CATTCA ATTCAT TTCATG TCATGC CATGCA ATGCAG TGCAGG GCAGGT CAGGTC AGGTCG GGTCGG GTCGGT TCGGTA CGGTAT GGTATT GTATTT TATTTA ATTTAA TTTAAC TTAACC TAACCG AACCGA ACCGAC CCGACA CGACAA GACAAG ACAAGG CAAGGA AAGGAA AGGAAT GGAATT GAATTT AATTTC ATTTCG TTTCGC TTCGCT TCGCTA CGCTAC GCTACC CTACCT TACCTT ACCTTA CCTTAG CTTAGG TTAGGA TAGGAC AGGACC GGACCG GACCGT ACCGTT CCGTTA CGTTAT GTTATT TTATTG TATTGT ATTGTT,3,73,CTCTCCCC C T TCTCCGA CC C C CCCCCTT TC  CCCCACATAT  GT CACATCA T T ATATC TAT TG TTCTCTCCC C C CTCTCG TATTG TTC TCGCGTGT T C CGCGTGTTTT T GT CGTT TCTA A TTTATACAC C TTACACGGA G A ACACGCGCGC C C CGGCTGCCG CC G GCGCCCCACA A CCCAAT T CCGACATTCATT  ATATTTC C T TTTTCATTA T TC TTAT  CAGGATATG A ATATGTGCGC  TGTGCGCAA G GCGCAGT AG  CACAGAGGGG G A AGGAAGGTGT T G GGGGTGTCTC C G GTGTCTCGC G TCTTATCGTTT CAG C CGTAGT G GGTTTGTATA A GC GGTATATCGG TATATATTTT T A ATATTTTATT T T TTGGTTTATA A T TTTTATAAAA A TCT TAAAACAC C A AAAACACCC AACCCCGCG  TC CCCCGGG CCCA C CGCGAGACAC  GT GAGACCCGCA A A ACACACAAAA A C CACAAAG G AAAGAGGGG G A AGAGGGGAGA A GGAAAA A G GAAGGAATAT T A AAAATCG TT T A ATATTG CTCG TTAT TTCC T TTTTCT TCG G TTCGCGCGC C C CGCGCCGCT G GCGCTCTAA C CTCTAATCAC C T TATACACCCC C A ACACCCCTCT TTA CCCCTCTTTT  CTCTTTTATA  TTTTTTAGAG TT  TAGGTAGGGG G A AGAGGCATCG A G GGGGAGACAC CG  GAGACACCCC C A ACACCCCGCG TTT CCACACGTT C CGCGTGTTTCGT G GTGTTTTATA A T TTT CAT  TATG ATTCCAT A ATATTTTGTG G TCATTTGTGTC A TGGTT,CTC ACCCCCC G C TCTCCCCCCCACA A C CCCCCCCACATGGT CCCCACATTC C C CACATATCTCTCT T A ATATCTCTCTCACC TCTCTCTCTCGCG G CTTATCGGT TCGCGTGTTTT T C CGCGTGTTTTATA A GA GGTTTACAC C T TTCTCTACACGCG G T TATACACG TACGTC A ACACGCGCGCCAAC CGCGCGCCCCACA A G GC GGC AT AAT AA  CCAT TT TT  CAATTTC ACC ATATTTCACA A T TTTTCTCACATAT T T TCTCACATATGTG C TTAACATATGTGCGC C A ATCAATGCGCACA  GG TGTGCGCACAGAG G G GCGCAATTAGGGG G C CACAGAGGT CGT T A AGAGGGGTGTCTC C GG AGGTGTCTCGCG CTT CTCCGCGGGG  TCTCG AAGGTCTAT C CGCGGGGTGTATA A GGGTTATAT T G GTGTATATATTTT  TATATATTTTTT CT ACAAATTTTTTTAA T TTTTTTTA GAAA A T TTTTATAAC CAC C T TATAAAACTC CCAAACCCGCG  ACACCCCGCGAGA A C CCTCGCGAGACAC C C CGCGAGACACA TAA GGAC ATACAT CA AACAATGCTTCGGG CCGTCAAAAGAGGG A AAAAGAGGGGAAAGA A AG TTGGAGAAAA  GT GGTTAGAAAATAT  GAGAAAATCAGTT T AAG AATATTTTTTT CATATTTTTTTCTC C T TTTTTTTCTCGCG G T TTTTCAGGCGCGC C T TCTCGCGCGCTCT T C CGCGCGCTCTATA A G GCCTATACAC C CGTCGT TACCC C TCA TACACCCCTCT ATT ACACCCCTGA TT T CCCTCTTTA TA A C CTG GGGATAGAG G T TTTTATAGAGGGG G T TATAGAGGGGAC TA A AGAGGGGAGACAC C GGCCGGAACCTGTC G CAGACACCCG G ATCCCCGGT T C CCCCGGC GTTTT T C CGCGTGTTTTATTAA GGTTTTATATCATT TTCGTTATT T TCGCTATTTGTG A T ATT ATTGGT GCT TTTTGTGTGTT,CTCCCCCCAG AA T TCTCCGGTCCACATAT  CCCCCATTATTATCTC C CG GCCACATATCTTACT T C CACATC CTCTCTCTTTC A AT ATTCTCTCTCGCG  TCTCTCTCTCGCGT TTT C CTCTCTCGGTTC TT TG TTCGCGTTCATTATA  CGCGTGTTTTATACAC C GGTTTTAACGCG G T TTGGTTACACGCGCGC  TATACAGGCGCCC C A ACC CGCCACACA GTC CGCGCGCCCCAGGAAT TTT GCGCCCATCATCCAATTTTCTC ACG CACCAATTTTCTAGCA TGC ATATTTTCTCACATAT GTCGT  CCTCACATATGTG G TTATGTTCATATGTGCGC C C CACATAATTGCGCACA A AATCATGA AGCACAG TC TGGAAGCACAGAGGGG  GCGCACAGAGGGGTGT T CTAGCAGAGGGGTCG TC C A AGAGGGGTT TTCGCG G GGCCCCCGTCTCGCGG AAG GCCTGTCTCGGGTT T TCTCGCGGTTAGTATA CGC CGCGGGGTGTATATAT T G GGGGTGTATATATTT G GTGTACCATTTTT T T TATATATTTC TTATA  ATATTTTTTTATAAA T TTTTTAGGAACAACTT  TTTTATAAAACACC TATAAC AACCCCGA CG A AAAC ACCCGACCGA A ACACCCGTGACAC C C CCCCGCGAGACACACA A C CGCGAGACCCACAAAA A G GAGACCAAAAGAG CA  ACACACAAACGGG G C CACAAAAGAGGCATGA A A AAAAGAGGGGATGCAA  AGAGGGGAGAAAT  GGGGAGAAAATCATTT  GAGAAAATATTT GTT T AGG ATGATTTTTTTCTC C A ATTTTTTCCG G T TTTTTTTCTCG GGCTAC T TTTTCTCGGCTCT T T TCTCGCGCGCTCTATA A C CGGACCTATACAGGC G GCGCTCTATACAACCC ATC CTGC TACACCGTTCT T T TATACACCCCTCTTTT T A ACACC GTCTTTTATA A C CCCCTTTA CAAG  CTCTTTTATAGTTAGG G T TTTTATAGAGGTAAGA A T TATCAAGGGGAGACAC ACC AGAC GGAGACACCCC C G GGGGACGCACCTTACG G G GAACCCCGCGTGT T A ACGA CGTGTTTT T C CCCGTCCTTCTTA A C CGA CGTTTTA TCAT T G GTGTT GTTATATTTT T TTTATATATTTTGTG G T TATATATTTTGTGTGT T A ATATTTTGTGTGTT,CTCTCCCGTCCACATAT T T TCGCTCCCCGACATATCTC C C CCCCCCCACATATCTCTCT A A CCCCGC TATC CACTCC C CATATC TCTCTCGCG G A ATATCTCTTA GT T T TCTCTCTCTCGCGTGTTTT T C CTCTCTCGCGTGTTTTATA A T TCTCGCCCGTTTTATACAC C C CGCGTTATTTATACACG GTGTTGGATACACGCGCTAC TTTTAACGCGCGCCCC C T TATACGTTCGAGCCCATCA ACGCGCC CCCACATAT T C CGCGCGCCCCACATATTTT T GGAAGCCCCAAT ATTTTCTC C C CCC TCATATTTTCTCACA A CTCTCATATTTTCCATAT T A ATATTCGGGCTCATATGGACG T TTTTCTCACATGC TAC TCTCACATATGTGCGCACG A C CACCAATGTGCGCACAGG A ATATGTGCGCACAGACCGG G T GATGCCAGAGGGGTGT AAG GCCAGAGGATTGTCTC TCG CACAGAGGGGAGTCTCGCG AAC AGAGGGGTGTCTAACGGGG G G GGGTCC CCGGGGTAGGTCGTCGCGGGGTGTAA T TC GTGAAGGTTATCATT C CGCGGGTAATCATTTT T G GGGGTGTATATT ATTTTT T G GTGTATATATTTTTTTATA A T TAACGATTTTTTTATAAAA A A ATATTTTTTTAAACAC TCT TTTCGG AT CCC CCA TTTTATAAAACACCCCACG G T TATAAAACACCCCGAC TCG AAAACACCCCGCCGCGAC A ACACCCCGCGAGACACACA A CCCGCGAATTACACAAAA A CATTCGCGACACACAAAAGAG G G GAGACACACTTAGGGG  ACACACAAAAGAGGGGAGA A C CACAAAAGAGGG GTTCAA A A AAAAGAGGGGAGAAAATAT T A AGAGGGGA GCATTTT T GCATGAAAATATTTT T G TGGAAAAT CGTTCTC AATATT TATCGCG G A ATATTTTTTTCTCGGC C T TTTTCTCGCGCGCTCT T T TTTTCTCGCGCCTATA A T TCGA CGCGCTCTATACAC  CGCGCGCTCTATACACCCC C G GCTCACTATACACCAT CT T C CTCTAC TCCTCG TT T TTTTACCCCTT GTTATA A A ACACCCCTTTATAGAG G C CCCGCCTTTTAAGGGG  CTCTTTTATAGAGGGGAGA A T TTTTATAGAGGGTTGACAC C TTAGAGGGACACCTTAC A AGAGGGGAGACACCGCAG G GGGGAGT CCGCGTGT T G GAGACACCCGTTTATT GGT ACACCCCATTGGTTCC TA A CCCGCGTGTTTTATATCCTT C CGCGTTTATTATATATTTT T G GTGTTGTTTATATTTTGTG G T TTTTATATGT  TATATTG CGTTGTGTT,"ID   YCX91_PHAAO             Reviewed;          91 AA.
AC   Q3BAI2;
DT   25-JUL-2006, integrated into UniProtKB/Swiss-Prot.
DT   22-NOV-2005, sequence version 1.
DT   05-FEB-2025, entry version 27.
DE   RecName: Full=Uncharacterized protein ORF91;
OS   Phalaenopsis aphrodite subsp. formosana (Moth orchid).
OG   Plastid; Chloroplast.
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliopsida; Liliopsida; Asparagales; Orchidaceae;
OC   Epidendroideae; Vandeae; Aeridinae; Phalaenopsis.
OX   NCBI_TaxID=308872;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=cv. Taisugar TS-97;
RX   PubMed=16207935; DOI=10.1093/molbev/msj029;
RA   Chang C.-C., Lin H.-C., Lin I.-P., Chow T.-Y., Chen H.-H., Chen W.-H.,
RA   Cheng C.-H., Lin C.-Y., Liu S.-M., Chang C.-C., Chaw S.-M.;
RT   ""The chloroplast genome of Phalaenopsis aphrodite (Orchidaceae):
RT   comparative analysis of evolutionary rate with that of grasses and its
RT   phylogenetic implications."";
RL   Mol. Biol. Evol. 23:279-291(2006).
CC   -!- SUBCELLULAR LOCATION: Plastid, chloroplast.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY916449; AAW82572.1; -; Genomic_DNA.
DR   RefSeq; YP_358636.1; NC_007499.1.
DR   AlphaFoldDB; Q3BAI2; -.
DR   GeneID; 3741793; -.
DR   GO; GO:0009507; C:chloroplast; IEA:UniProtKB-SubCell.
DR   AntiFam; ANF00025; Antisense to 23S rRNA.
PE   4: Predicted;
KW   Chloroplast; Plastid.
FT   CHAIN           1..91
FT                   /note=""Uncharacterized protein ORF91""
FT                   /id=""PRO_0000246135""
SQ   SEQUENCE   91 AA;  10596 MW;  C770491A1FF96EE8 CRC64;
     MQVVRIFTDM SISPSLSPRQ CPDRYAFRAG RNLPDKEFRY LRTVLVTAAV HRGFGRRLPC
     HQVTNFLDLP ALGRRQPPYM VLRLCGDLCF W
//
",21062
GTGTAT TGTATG GTATGA TATGAT ATGATG TGATGA GATGAT ATGATG TGATGG GATGGT ATGGTG TGGTGC GGTGCT GTGCTA TGCTAG GCTAGG CTAGGA TAGGAG AGGAGA GGAGAG GAGAGT AGAGTG GAGTGT AGTGTG GTGTGG TGTGGA GTGGAC TGGACA GGACAC GACACT ACACTT CACTTA ACTTAT CTTATG TTATGA TATGAA ATGAAT TGAATG GAATGT AATGTC ATGTCT TGTCTT GTCTTG TCTTGA CTTGAC TTGACA TGACAC GACACT ACACTC CACTCG ACTCGT CTCGTT TCGTTT CGTTTA GTTTAT TTTATA TTATAA TATAAA ATAAAG TAAAGT AAAGTT AAGTTT AGTTTA GTTTAT TTTATT TTATTA TATTAT,0,67,GTGT TGTA GTAT TATG ATGA TGAT GATG ATGA TGAT GATG ATGG TGGT GGTG GTGC TGCT GCTA CTAG TAGG AGGA GGAG GAGA AGAG GAGT AGTG GTGT TGTG GTGG TGGA GGAC GACA ACAC CACT ACTT CTTA TTAT TATG ATGA TGAA GAAT AATG ATGT TGTC GTCT TCTT CTTG TTGA TGAC GACA ACAC CACT ACTC CTCG TCGT CGTT GTTT TTTA TTAT TATA ATAA TAAA AAAG AAGT AGTT GTTT TTTA TTAT TATT ATTA TTAT,GTGTA TGTAT GTATG TATGA ATGAT TGATG GATGA ATGAT TGATG GATGG ATGGT TGGTG GGTGC GTGCT TGCTA GCTAG CTAGG TAGGA AGGAG GGAGA GAGAG AGAGT GAGTG AGTGT GTGTG TGTGG GTGGA TGGAC GGACA GACAC ACACT CACTT ACTTA CTTAT TTATG TATGA ATGAA TGAAT GAATG AATGT ATGTC TGTCT GTCTT TCTTG CTTGA TTGAC TGACA GACAC ACACT CACTC ACTCG CTCGT TCGTT CGTTT GTTTA TTTAT TTATA TATAA ATAAA TAAAG AAAGT AAGTT AGTTT GTTTA TTTAT TTATT TATTA ATTAT,GTGTAT TGTATG GTATGA TATGAT ATGATG TGATGA GATGAT ATGATG TGATGG GATGGT ATGGTG TGGTGC GGTGCT GTGCTA TGCTAG GCTAGG CTAGGA TAGGAG AGGAGA GGAGAG GAGAGT AGAGTG GAGTGT AGTGTG GTGTGG TGTGGA GTGGAC TGGACA GGACAC GACACT ACACTT CACTTA ACTTAT CTTATG TTATGA TATGAA ATGAAT TGAATG GAATGT AATGTC ATGTCT TGTCTT GTCTTG TCTTGA CTTGAC TTGACA TGACAC GACACT ACACTC CACTCG ACTCGT CTCGTT TCGTTT CGTTTA GTTTAT TTTATA TTATAA TATAAA ATAAAG TAAAGT AAAGTT AAGTTT AGTTTA GTTTAT TTTATT TTATTA TATTAT,GTGTATG TGTATGA GTATGAT TATGATG ATGATGA TGATGAT GATGATG ATGATGG TGATGGT GATGGTG ATGGTGC TGGTGCT GGTGCTA GTGCTAG TGCTAGG GCTAGGA CTAGGAG TAGGAGA AGGAGAG GGAGAGT GAGAGTG AGAGTGT GAGTGTG AGTGTGG GTGTGGA TGTGGAC GTGGACA TGGACAC GGACACT GACACTT ACACTTA CACTTAT ACTTATG CTTATGA TTATGAA TATGAAT ATGAATG TGAATGT GAATGTC AATGTCT ATGTCTT TGTCTTG GTCTTGA TCTTGAC CTTGACA TTGACAC TGACACT GACACTC ACACTCG CACTCGT ACTCGTT CTCGTTT TCGTTTA CGTTTAT GTTTATA TTTATAA TTATAAA TATAAAG ATAAAGT TAAAGTT AAAGTTT AAGTTTA AGTTTAT GTTTATT TTTATTA TTATTAT,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",29566
TATATT ATATTA TATTAG ATTAGA TTAGAG TAGAGT AGAGTA GAGTAG AGTAGG GTAGGA TAGGAG AGGAGC GGAGCT GAGCTA AGCTAG GCTAGA CTAGAA TAGAAA AGAAAA GAAAAT AAAATC AAATCA AATCAG ATCAGC TCAGCA CAGCAC AGCACC GCACCT CACCTT ACCTTT CCTTTA CTTTAA TTTAAT TTAATT TAATTG AATTGA ATTGAA TTGAAT TGAATT GAATTG AATTGT ATTGTG TTGTGC TGTGCG GTGCGT TGCGTG GCGTGG CGTGGA GTGGAT TGGATG GGATGA GATGAG ATGAGG TGAGGC GAGGCT AGGCTG GGCTGG GCTGGT CTGGTT TGGTTC GGTTCT GTTCTA TTCTAA TCTAAA CTAAAT TAAATC AAATCA AATCAC ATCACC TCACCC CACCCA ACCCAT CCCATT CCATTC CATTCA ATTCAG TTCAGT TCAGTA CAGTAC AGTACA GTACAT TACATC ACATCG CATCGA ATCGAT TCGATA CGATAT GATATC ATATCG TATCGG ATCGGT TCGGTA CGGTAA GGTAAT,1,94,TATATATA A AGGT CCTATAT  TC TATATTT T A ATATTTA A T TTTTATAGAG G T TATAGAGAGA  AGAGAGAGAG G G GAGAGAGTGT T A AGAGTGTATA  TAT GGTATAGAG G T TATAGAGGGG AC  AGAGGGGAGA A G GGGGAGAGAG G G GAA A GAGC C A AGAGCGCTCT T G GCGCTCTATA A C CTCTATAGAG T TTAGAGAAGA AGA AGAAAA A GGAAAAAAA A A AAAAAAAAAA TTT AAG AAATAT T AAATATCTC AG  ATATCTCACA A TTCACC TCTG C CAAGCGC C A AGAGCGCACA  GCCACAC C C CAACCCAGC A ACACCCCTCT T C CCCCTCTTC TT C CTCTTA ATT TT GATTTTTTATA  TTTTATAAAA A TC CAATAT T A AAAATATTAAAT AC ACTATTGTG G T TTTTGTGAGA A T TGTGAT TAA A G GAGAAAATA T TT AAAATATT TAT A AT CATTGG TCACTTGTGTGT  TGTGTGTGTG G GCGGTGCGC TT  TGTGCGCGCG G G GCGCGCGTCATT C CGCGTA GTG TC  GTGTGTGGCATG T TGTGGGGAACCATTAAAGGAGATAT T G GAGATATGG AGG ATGTGAGA TG  TGTGAGAGAG G GTCGGG  GG AGAGGGGCGC  GGGGCGCTCT  GCGCTCTGTG  CTCTGGG  TGTGGGGTGT GAG GGGTTTT T G GTGTTTTCTC TTCT ATTC ATCT T T TCTCTATTA C CTCTATAAAA A T TATAATT AA  AAAAAAATAT T G AAAATATCTC ATT ATATCCA A T TCTCATAAGTGCACACCCC C A ACGA CCCCC C C CCCCACA A CATACCACATAT  CA ATATTTT T A ATATTC TTC C T TTTTCTCACA A G TCTCACAGG C CACAGAGTGT T A AGAGTTA AT  GTGTATACAC TAA TATACACACA A A ACACACATT C CAGA ATCC A ATG T TCTCGCGAGT  CGCGA TTAT T AAGCGATATAGAGCCCATAAT GAA TATATATCTC C A ATATCTCGCG G TT T GACGGGG  CG GTGGTGT  GT GG ATGTATA A G GTGTATAAAA A TA GC TAAT,TC ATATATTTGGTG ATTATAATTT AGA TATATATTGGATA A ATAAATTTTATAGAG G T ATTTATAGAGAAATA T TAC GAGAGAGG A AGAGAGAGAGTGT T G GATTCTTGATCTA A AAGTGTATAGG G GTGTATAGAGGGG G T TATAGTGTGGAGA A A AGAGGGGAGAGAG G G GGGGAGAGAGCGC C G GAGAGAGCGCTCT T ATA GCTCTAA G GCGCTCTAA GG C CTTAGAGAGA A T TAAGAAGGAA  AGT TGAAAAAAA A GAAAAAAAA A A AAAAAAAAG GCA T A AAAAAAATATCC A AAAAT GACA CTG ATATCTCACAGAG G T TCTCACAGAGCGAAC C CACAGAGCGCACA A A AGCAGT GGTGAC TAG GCGCAGTACC C C CACACACCCCTCT ACCCCTCTTTGGT C CCCCTAGCTTTTT T CTC CTTTTTTTATA A T TTTTTTTATAAAA A T TTTTATAAAATAGGT T TATAAGA ATTTT T ACTGAAAATTAGTTG G A ATATTTTGGA A TCATAT TGAGC AA A T TGTGAGAATG AT GCAATCGAAACCATTTT T A AAGTTATTTTGG AGAGATTTTGAGGGT T T TTTGTGTGTG G T TGTGTGTGTGCGC C G GTGTGTGCGCGCG G T TGTGCGC TTCCA T T GCGCGCGTAATTG G C CGCGTATCTGGGG G G GTT AA CGGA TGTGGGATAT T G GGAGCGATATGTG G GGATATGTGAGA A A ATATGTGAGAGG T TG ATAT GG ATTGAGAGGC A AGGAAGGCGCTCT T G GGGGCGCTA AAATGCT AATGGGG CCA CTCTGTGGT CGT T G TGTGGGGTTT T GCCCGGTAATGAGA TC G GTGTTTTCTCTCT T T TTTTCTCTCTATA  TCTCTCTATAAAA A C CTTAAAAAAA A T TATAAG TAATAT  AAAATAATATCTC C A AACACATCCA A A ATATCTCACACC T TCTCACACACCCC C C CACACACCCC C A ACCCCG CCA  CC GGCATAT GGT CCCCACATTT T C CAATTTTCTC C A ATATTTTCTCAGT A T TTCGTTCAAG AAT TCTCACAGAGTGT T C CACAGAGTGTAA A AGAGTGTATACAC C G GTGTATACACA TAACACATAT  ACACA TTGTG CTGGT CACATATCTCGCG TCG ATATCTCGGA A T TCG ACGAGATAT TAT CGCGAGATATATA TAG GAGATATATATAT T A ATT CTATC T TATATCACTCGCG G A TTATCTCGCGGGG G T TCTCGCGGGGTGT T C CGCGGTC GTATA  GGGGTGTAAA A G GTGTA ATAAT,TATATATATATTT AG TATATATATTTTATA A T TAATTTTATAGG A AT GAG TTAGAGAGA A T TTTTATAGAGAGAGAG G T TATAG GTGAGAGTGT T AAGAGAGTT GTATA A G GAGAGGTAAG G A AGAGTGTATAGAGGGG G G GTGTACTTAGGGA A TCG TAGAGGGGAAATAG G A AGTT GAGAGCTAGC G GGGGAGAGAGCGCTCT T GCATAGCTA CTATA A A AGAGCGCTCTAGGTAG  GT GCGCTCTATAGAGAGA A C ATTAGGAAAA A T TAAGAGAACCAAA A A AGGTAGAAAAAAAATAGA G GAGAAAAAAAAAATAT T A AAAAAAGTAAT CAC A AAAAAAATATCTCACA A A AAATCTCACAGAG G A ATATCTCACAGAGCTG C T CTTCACAGTG GCACA A C CACAGAGCGCACACAC  AGAGCGCACACACCCC C G GCGCACACACCCT  CACACACCCCTCTT ATT A ACACCCCTCTTTTTTT T CCCTATACGTTTAA C CTCTTTTTTTATAAAA A T TTTTTTAAAATT TATCTTGTAAAATATTGGATGGTAAGAGATTATGACCG A AAAATATTTTGTGAGA ACC ATTTAGAAT ATTG TTTTGTGAGAAAATAT AATAC TGAATTTT T G GAGAAAATATTA TTG G A AAAATATTTTGTGTGT AA  ATATTTTGTGTGTGTG ATC TTTTGA AGTGTGCGC C TCAGTGTGTGTGCGCG TAG GAGAGTGTGAGCGTTTGT T TGTTTGCGCGCGTGTGGC G G GCTATCGTGTGGG G C CGCGTATATGGGGAGA A G GTGTGTGGGTTAT  TGTGGGGAGATATGTG G G GAGGAGATATGTGCGA A G GAGATATGTGAGAGAG G A ATTTGGAGAGGGG G T AATGAGAGAGGGGCGC C GGG GAGAGGGGCGCTCT T A AGAGG GGGCTCTGTG G G GGGGCGCTTGG GAG GTT GCTCTGTGGGGTGT T C TCT TTGGGGTGGATCTT T TG TAGGTGTTTTCTC C GGGCGGTTTCTCTCT  GTGTTTTC AACTATA A T TTTTCTCTCTATAAAA A T TCTT CTATAAAAAAA A C CTGTAAT AAATATAT CTG TATAAAAAAATC ATC TCTAAAAATATCTCACA A A TGAATATCTCACAC TGC A ATT CTCACACAGC GGC T TCTCACACCCCCC C C CACACACCCCCCCACA TGTACCCCCCCA GGAT T C CCCCCCCACATATTTT  CCAAACATTTCC CATTTCACA A A ATATTTTCTCACAGAG G T TTTTCTCAAGTGT T T TCTCACAGAGTCTATA A CATCAGTAGATACAC C A AGAGTGTATACACACA A GG GGTAACAACACATAT  TATACTACCATATCTC C A ACACACATATCTCGCG G C CACAT TTCGAGA A AAGT ATTCGCGAAT T T TCTCGCGAGATATATA A C CGCGAGATTTCTAAATTGATATATATATCTC C A CTAATTATATCTCGCG TTA TAAATATCTCGCGGGTAG A ATATCTCGCGGAA GT T T TCTCGCGGGGTGTAGCTA C CGGGTCTAAA A GCC GGTGTAAAT,TATATATATAGCTA A A ATATATATATTTTATAGAG  AA TATATATTTTATAGAGAGA A A ATATTTTATAGTATGAG TCTAA GATTATAGAGAGAGAGTGT  TATAGAGAGAGAGTTA A A AGAGAGAGAGTGTATAGAG G G GAC CAGTGTATAGAGGCTGG A AGAGTCC TAGAGGGGAGA A G GTGTATAGAGGGAGCGTG T TATAGAGGGGACA ATTGC TTC AGAGGGGAGAGAGCGCTACAT G GGGGAGCTCTATA A G TTGAGCT GCTTAGAG G A AGAGCGCT AGTAGCGTGA A GTATGCTCTATAGAGATCAAA A CCTA TCGAAAAAAA TAGAGAGAAAAAAAAAA A A AGCATGAAAAAAAAAATAT T G GAGAAA CAATATCCGG AT AAGGCAAAATCTCACA A A AAAAAAATATCTCACGAAG G A AAAATATCTCACAGAGCC AC AATCTCACA CGAGCACAGA TTCAAGCGCACACAC  CACAGAGCGCAACCGTAC ACTAAGCGCACACACCCCTT G GCGCACACACCCCTGGCG TT C CAA ATG ATCCTTTTTTT AGA ACACCCCTCTTTTTTTA TGA C CCGAATTTT GAA AAA CTCTTTTTTTATAAAT ATC TTTTTTTATAAAATATTTT T TTTATAAAATTTGTG G T TATC CCCGTGTTGTGAGA TTC AAAATATTTGAGAAAA CAC ATATTGAAAT T T TTTTGACCT AC TTTCT T TGG GGAAAATATTTTGTG G G GACTTAATATTTTGGT AATTT AATATTTTGTGTTG G AATTTTGTGTTGCGC C T TTTTG GTGTGTGCCG G TTA TGTGTGTGCGCGAG  GTGTGTGCGCGGTGTG G T TGTGCGCGATTTGGGG  GCGCGAGAGTGTGGGA A C CGCGTGTGTGGGGAAT T G GTGTGTGGGGAGTA TTACCCGG TGTGGGGA CTATGTGAGA TGA GGGGAGATATGA GGAGAG TGA GAGATATGTGAGAGAGGGG G A ATAATTGAGAGGGCGC ATT TGTGAGAGAGGGGCGCTCT TATGAGAGGAAAGCTCTGTG G A AGAGGGGCGCTCTGGG TCA GGAATGCTGG TGGGGTGT T G GCGCTCTGTGGGGTGTTTT T CGATA ATGGGGTGTTCTGTC  TGTGGGGTGTTATTTCTCT TTC GGGGTGTTTT TCTCTATA  GTGTTTTCTCTTAAAA A T TTTAATCTCTATAAAAAAA A T TCCTAAAAAATAT TCG CTTAAAAAAATATCTC C T TATTCCTAATGATCTCACA A A AAAAATTGATCGAACACAC C A AAAATT TCACACCCC C A ATATCTCAACCCCCCC C TAG TCAACCCCCCCACA A C CACACACCCCACATAT T A ACTGAAATCCACATATTTT T CCCCCCACATATTTTCTC C CTTCCCACATATTC ATCACA A C CAT AATTATAG GAG G A ATATTTCAAGTT T TT CCTCAAGTGTATA A T TCTCACAGAGTTACAC GAG CAGTATACCT GAGA A AGAGTGTAGGAACACATAT T GTGTGTATACACACATGGTTAAC T TAACAC TTCGCG G A ACACACATCCTT CCGAGA A C CACATATCTCGTC GATAT T A ATATCTCGCAGGATATATA G GAGATCGCGAATATATATCT C CGAGCGATATA GCATCTC C G GAGATATAATCTCGCG G A ATTTCT GTCGCGGGG G T TAAGAATCTCGGGTGT T A ATATCTCGCGAGGTGTATA  TCTCGGGTGTATAAAA CAGG TAT GTAAAT,"ID   NS8_SARS2               Reviewed;         121 AA.
AC   P0DTC8;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 24.
DE   RecName: Full=ORF8 protein;
DE            Short=ORF8;
DE   AltName: Full=Non-structural protein 8;
DE            Short=ns8;
DE   Flags: Precursor;
GN   ORFNames=8;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=isolate 2019-nCoV_HKU-SZ-002a_2020;
RX   PubMed=31986261; DOI=10.1016/s0140-6736(20)30154-9;
RA   Chan J.F., Yuan S., Kok K.H., To K.K., Chu H., Yang J., Xing F., Liu J.,
RA   Yip C.C., Poon R.W., Tsoi H.W., Lo S.K., Chan K.H., Poon V.K., Chan W.M.,
RA   Ip J.D., Cai J.P., Cheng V.C., Chen H., Hui C.K., Yuen K.Y.;
RT   ""A familial cluster of pneumonia associated with the 2019 novel coronavirus
RT   indicating person-to-person transmission: a study of a family cluster."";
RL   Lancet 395:514-523(2020).
RN   [3]
RP   MISCELLANEOUS.
RX   PubMed=32854725; DOI=10.1186/s12985-020-01402-1;
RA   Michel C.J., Mayer C., Poch O., Thompson J.D.;
RT   ""Characterization of accessory genes in coronavirus genomes."";
RL   Virol. J. 17:131-131(2020).
RN   [4]
RP   MISCELLANEOUS.
RX   PubMed=32807944; DOI=10.1038/s41590-020-0773-7;
RA   Hachim A., Kavian N., Cohen C.A., Chin A.W.H., Chu D.K.W., Mok C.K.P.,
RA   Tsang O.T.Y., Yeung Y.C., Perera R.A.P.M., Poon L.L.M., Peiris J.S.M.,
RA   Valkenburg S.A.;
RT   ""ORF8 and ORF3b antibodies are accurate serological markers of early and
RT   late SARS-CoV-2 infection."";
RL   Nat. Immunol. 21:1293-1301(2020).
RN   [5]
RP   INTERACTION WITH HUMAN IL17RA, AND SUBCELLULAR LOCATION.
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [6]
RP   INTERACTION WITH HUMAN IL17RA, AND FUNCTION.
RX   PubMed=33723527; DOI=10.1016/j.isci.2021.102293;
RA   Lin X., Fu B., Yin S., Li Z., Liu H., Zhang H., Xing N., Wang Y., Xue W.,
RA   Xiong Y., Zhang S., Zhao Q., Xu S., Zhang J., Wang P., Nian W., Wang X.,
RA   Wu H.;
RT   ""Title: ORF8 contributes to cytokine storm during SARS-CoV-2 infection by
RT   activating IL-17 pathway."";
RL   IScience 1:102293-102293(2021).
RN   [7]
RP   VARIANT SER-84.
RX   PubMed=32615316; DOI=10.1016/j.meegid.2020.104445;
RA   Laha S., Chakraborty J., Das S., Manna S.K., Biswas S., Chatterjee R.;
RT   ""Characterizations of SARS-CoV-2 mutational profile, spike protein
RT   stability and viral transmission."";
RL   Infect. Genet. Evol. 85:104445-104445(2020).
RN   [8]
RP   VARIANT 28-HIS--ILE-121 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [9]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=34177923; DOI=10.3389/fimmu.2021.679482;
RA   Geng H., Subramanian S., Wu L., Bu H.F., Wang X., Du C., De Plaen I.G.,
RA   Tan X.D.;
RT   ""SARS-CoV-2 ORF8 Forms Intracellular Aggregates and Inhibits IFNgamma-
RT   Induced Antiviral Gene Expression in Human Lung Epithelial Cells."";
RL   Front. Immunol. 12:679482-679482(2021).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH HOST MHC-I.
RX   PubMed=34021074; DOI=10.1073/pnas.2024202118;
RA   Zhang Y., Chen Y., Li Y., Huang F., Luo B., Yuan Y., Xia B., Ma X.,
RA   Yang T., Yu F., Liu J., Liu B., Song Z., Chen J., Yan S., Wu L., Pan T.,
RA   Zhang X., Li R., Huang W., He X., Xiao F., Zhang J., Zhang H.;
RT   ""The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-
RT   regulating MHC-Iota."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:1-12(2021).
RN   [11]
RP   FUNCTION, SUBCELLULAR LOCATION, HOMODIMERIZATION, MUTAGENESIS OF CYS-20 AND
RP   ASN-78, DISULFIDE BOND, AND GLYCOSYLATION AT ASN-78.
RX   PubMed=35157849; DOI=10.1016/j.jbc.2022.101724;
RA   Matsuoka K., Imahashi N., Ohno M., Ode H., Nakata Y., Kubota M.,
RA   Sugimoto A., Imahashi M., Yokomaku Y., Iwatani Y.;
RT   ""SARS-CoV-2 accessory protein ORF8 is secreted extracellularly as a
RT   glycoprotein homodimer."";
RL   J. Biol. Chem. 1:101724-101724(2022).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH HUMAN IL17RA, AND
RP   MUTAGENESIS OF SER-24; TYR-42; VAL-62; ILE-71; ILE-76; LEU-84 AND GLU-106.
RX   PubMed=35343786; DOI=10.1128/mbio.00402-22;
RA   Wu X., Xia T., Shin W.J., Yu K.M., Jung W., Herrmann A., Foo S.S., Chen W.,
RA   Zhang P., Lee J.S., Poo H., Comhair S.A.A., Jehi L., Choi Y.K., Ensser A.,
RA   Jung J.U.;
RT   ""Viral Mimicry of Interleukin-17A by SARS-CoV-2 ORF8."";
RL   MBio 1:e0040222-e0040222(2022).
RN   [13]
RP   FUNCTION, MUTAGENESIS OF 1-MET--PHE-16 AND ASN-78, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=36689483; DOI=10.1371/journal.ppat.1011128;
RA   Lin X., Fu B., Xiong Y., Xing N., Xue W., Guo D., Zaky M., Pavani K.,
RA   Kunec D., Trimpert J., Wu H.;
RT   ""Unconventional secretion of unglycosylated ORF8 is critical for the
RT   cytokine storm during SARS-CoV-2 infection."";
RL   PLoS Pathog. 19:e1011128-e1011128(2023).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.61 ANGSTROMS) OF 18-121, AND DISULFIDE BOND.
RA   Nelson C.A., Hall P.D., Fremont D.H.;
RT   ""Crystal Structure of the SARS-CoV-2 ORF8 Protein."";
RL   Submitted (AUG-2020) to the PDB data bank.
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.04 ANGSTROMS) OF 18-121, DISULFIDE BOND, AND
RP   HOMODIMERIZATION.
RX   PubMed=33361333; DOI=10.1073/pnas.2021785118;
RA   Flower T.G., Buffalo C.Z., Hooy R.M., Allaire M., Ren X., Hurley J.H.;
RT   ""Structure of SARS-CoV-2 ORF8, a rapidly evolving immune evasion protein."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
CC   -!- FUNCTION: Plays a role in modulating the host immune response
CC       (PubMed:31986261, PubMed:35343786, PubMed:36689483). May act as a
CC       secreted virokine by mimicking interleukin-17A (IL17A), and thereby
CC       binding to the IL17RA receptor, leading to activation of the IL17
CC       pathway and increased secretion of pro-inflammatory factors
CC       (PubMed:35343786, PubMed:36689483). Contributes to the cytokine storm
CC       during SARS-CoV-2 infection when secreted by unconventional pathway
CC       (PubMed:33723527, PubMed:36689483). May act by down-regulating major
CC       histocompability complex class I (MHC-I) at cell surface
CC       (PubMed:34021074, PubMed:35157849). May inhibit expression of some
CC       members of the IFN-stimulated gene (ISG) family including hosts
CC       IGF2BP1/ZBP1, MX1 and MX2, and DHX58 (PubMed:34177923).
CC       {ECO:0000269|PubMed:33723527, ECO:0000269|PubMed:34021074,
CC       ECO:0000269|PubMed:34177923, ECO:0000269|PubMed:35157849,
CC       ECO:0000269|PubMed:35343786, ECO:0000269|PubMed:36689483,
CC       ECO:0000303|PubMed:31986261}.
CC   -!- SUBUNIT: Homodimer (PubMed:33361333, PubMed:35157849). Interacts with
CC       host IL17RA (PubMed:33060197, PubMed:35343786). Interacts with host
CC       IL17RC (PubMed:35343786). Interacts with host MHC-I (PubMed:34021074).
CC       {ECO:0000269|PubMed:33060197, ECO:0000269|PubMed:33361333,
CC       ECO:0000269|PubMed:33723527, ECO:0000269|PubMed:35157849,
CC       ECO:0000269|PubMed:35343786}.
CC   -!- INTERACTION:
CC       P0DTC8; P0DTC8: 8; NbExp=3; IntAct=EBI-25475900, EBI-25475900;
CC       P0DTC8; Q9UHI8: ADAMTS1; Xeno; NbExp=3; IntAct=EBI-25475900, EBI-2511802;
CC       P0DTC8; Q8N766: EMC1; Xeno; NbExp=3; IntAct=EBI-25475900, EBI-1044442;
CC       P0DTC8; P01892: HLA-A; Xeno; NbExp=5; IntAct=EBI-25475900, EBI-2839473;
CC       P0DTC8; Q96F46: IL17RA; Xeno; NbExp=3; IntAct=EBI-25475900, EBI-5591258;
CC       PRO_0000449655; PRO_0000449655 [P0DTC8]: 8; NbExp=2; IntAct=EBI-28965865, EBI-28965865;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:35157849,
CC       ECO:0000269|PubMed:35343786}. Note=Is secreted during a normal viral
CC       infection by unconventional pathway (PubMed:35157849, PubMed:36689483).
CC       Its mRNA is expressed in cytoplasm and not spliced during a viral
CC       infection, but is spliced when expressed from cDNA in nucleus
CC       (PubMed:35157849). Splicing changes localization to host endosome
CC       and/or cytoplasm (PubMed:33060197, PubMed:34177923). May also localize
CC       in nucleus when fused with GFP (PubMed:34177923).
CC       {ECO:0000269|PubMed:33060197, ECO:0000269|PubMed:34177923,
CC       ECO:0000269|PubMed:35157849}.
CC   -!- PTM: Glycosylated by the host when secreted via the conventional
CC       pathway. The glycosylated form cannot bind IL17A and would not
CC       participate in the cytokine storm. {ECO:0000269|PubMed:36689483}.
CC   -!- POLYMORPHISM: Variant B.1.1.7 is also called Variant Of Concern (VOC)
CC       202012/01, Variant Under Investigation (VUI) 202012/01, or 20B/501Y.V1.
CC       {ECO:0000305|PubMed:33413740}.
CC   -!- POLYMORPHISM: Variant Omicron/BA.1 and BA.2 belong to a lineage first
CC       isolated in South Africa (November 2021). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/BQ.1.1 belongs to a lineage first
CC       isolated in Nigeria (November 2022). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/XBB.1.5 belongs to a lineage first
CC       isolated in United States (November 2022). It is the result of
CC       recombination between omicron BJ.1 and BM.1.1. Moreover XBB.1.5 do not
CC       express ORF8. {ECO:0000305}.
CC   -!- MISCELLANEOUS: Similar to some Bat coronavirus ns8 genes, but is
CC       entirely different from SARS ns8a or Ns8b (Probable). Elicits strong
CC       specific antibody response (PubMed:32807944).
CC       {ECO:0000269|PubMed:32807944, ECO:0000305|PubMed:32854725}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43422.1; -; Genomic_RNA.
DR   EMBL; MN938384; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   PDB; 7F5F; X-ray; 1.62 A; A=18-121.
DR   PDB; 7JTL; X-ray; 2.04 A; A/B=18-121.
DR   PDB; 7JX6; X-ray; 1.61 A; A/B=18-121.
DR   PDB; 7MX9; X-ray; 2.60 A; A=15-121.
DR   PDB; 7XMN; X-ray; 2.30 A; B=16-121.
DR   PDBsum; 7F5F; -.
DR   PDBsum; 7JTL; -.
DR   PDBsum; 7JX6; -.
DR   PDBsum; 7MX9; -.
DR   PDBsum; 7XMN; -.
DR   SMR; P0DTC8; -.
DR   BioGRID; 4383873; 1317.
DR   ComplexPortal; CPX-6147; SARS-CoV-2 ORF8 complex.
DR   IntAct; P0DTC8; 152.
DR   MINT; P0DTC8; -.
DR   GlyGen; P0DTC8; 1 site.
DR   iPTMnet; P0DTC8; -.
DR   KEGG; vg:43740577; -.
DR   AGR; RefSeq:YP_009724396; -.
DR   Reactome; R-HSA-448424; Interleukin-17 signaling.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   Reactome; R-HSA-9727281; Translation of Accessory Proteins.
DR   Reactome; R-HSA-983170; Antigen Presentation: Folding, assembly and peptide loading of class I MHC.
DR   PRO; PR:P0DTC8; -.
DR   Proteomes; UP000464024; Genome.
DR   Proteomes; UP000464747; Genome.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:ComplexPortal.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProt.
DR   GO; GO:0005764; C:lysosome; IDA:ComplexPortal.
DR   GO; GO:0005125; F:cytokine activity; IDA:UniProt.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0032688; P:negative regulation of interferon-beta production; IDA:ComplexPortal.
DR   GO; GO:0002891; P:positive regulation of immunoglobulin mediated immune response; IDA:ComplexPortal.
DR   GO; GO:0046776; P:symbiont-mediated suppression of host antigen processing and presentation of peptide antigen via MHC class I; IDA:ComplexPortal.
DR   GO; GO:0019049; P:virus-mediated perturbation of host defense response; IDA:UniProt.
DR   CDD; cd21641; ORF8-Ig_SARS-CoV-2-like; 1.
DR   InterPro; IPR022722; ORF8_betacoronavirus.
DR   InterPro; IPR044391; ORF8_SARS-CoV-2-like.
DR   InterPro; IPR046444; SARS_ORF8_IG.
DR   Pfam; PF12093; bCoV_NS8; 1.
DR   PROSITE; PS51964; SARS_ORF8_IG; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Disulfide bond;
KW   Evasion of host immunity by viral interleukin-like protein; Glycoprotein;
KW   Host-virus interaction; Reference proteome; Secreted; Signal;
KW   Viral immunoevasion.
FT   SIGNAL          1..15
FT                   /evidence=""ECO:0000255""
FT   CHAIN           16..121
FT                   /note=""ORF8 protein""
FT                   /id=""PRO_0000449655""
FT   DOMAIN          19..121
FT                   /note=""SARS ORF8 Ig-like""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01309""
FT   CARBOHYD        78
FT                   /note=""N-linked (GlcNAc...) (complex) asparagine; by host""
FT                   /evidence=""ECO:0000269|PubMed:35157849,
FT                   ECO:0000269|PubMed:36689483""
FT   DISULFID        20
FT                   /note=""Interchain""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01309,
FT                   ECO:0000269|PubMed:33361333, ECO:0000269|PubMed:35157849""
FT   DISULFID        25..90
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01309,
FT                   ECO:0000269|PubMed:33361333, ECO:0000269|Ref.14""
FT   DISULFID        37..102
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01309,
FT                   ECO:0000269|PubMed:33361333, ECO:0000269|Ref.14""
FT   DISULFID        61..83
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01309,
FT                   ECO:0000269|PubMed:33361333, ECO:0000269|Ref.14""
FT   VARIANT         2
FT                   /note=""K -> Q (in strain: Theta/P.3)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         8..121
FT                   /note=""Missing (in strain: Omicron/XBB.1.5,
FT                   Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         11
FT                   /note=""T -> I (in strain: Iota/B.1.526)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         11
FT                   /note=""T -> K (in strain: Mu/B.1.621)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         28..121
FT                   /note=""Missing (in strain: B.1.1.7)""
FT                   /evidence=""ECO:0000305|PubMed:33413740""
FT   VARIANT         38
FT                   /note=""P -> S (in strain: Mu/B.1.621)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         84
FT                   /note=""L -> S""
FT                   /evidence=""ECO:0000305, ECO:0000305|PubMed:32615316""
FT   VARIANT         92
FT                   /note=""E -> K (in strain: Gamma/P.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         119
FT                   /note=""D -> I (in strain: Delta/B.1.617.2)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         120..121
FT                   /note=""Missing (in strain: Delta/B.1.617.2)""
FT                   /evidence=""ECO:0000305""
FT   MUTAGEN         1..16
FT                   /note=""Missing: Partial loss of secretion.""
FT                   /evidence=""ECO:0000269|PubMed:36689483""
FT   MUTAGEN         20
FT                   /note=""C->A: Complete loss of dimerization.""
FT                   /evidence=""ECO:0000269|PubMed:35157849""
FT   MUTAGEN         24
FT                   /note=""S->L: Partial loss of hIL-17RC binding.""
FT                   /evidence=""ECO:0000269|PubMed:35343786""
FT   MUTAGEN         42
FT                   /note=""Y->H: Complete loss of hIL-17RA binding.""
FT                   /evidence=""ECO:0000269|PubMed:35343786""
FT   MUTAGEN         62
FT                   /note=""V->L: Partial loss of hIL-17RC binding.""
FT                   /evidence=""ECO:0000269|PubMed:35343786""
FT   MUTAGEN         71
FT                   /note=""I->D: Complete loss of hIL-17RC binding.""
FT                   /evidence=""ECO:0000269|PubMed:35343786""
FT   MUTAGEN         76
FT                   /note=""I->D: Complete loss of hIL-17RC binding.""
FT                   /evidence=""ECO:0000269|PubMed:35343786""
FT   MUTAGEN         78
FT                   /note=""N->D: Complete loss of N-glycosylation and of
FT                   secretion.""
FT                   /evidence=""ECO:0000269|PubMed:35157849""
FT   MUTAGEN         78
FT                   /note=""N->Q: Complete loss of glycosylation when secreted
FT                   by conventional route. Increases cytokine storm effects.""
FT                   /evidence=""ECO:0000269|PubMed:36689483""
FT   MUTAGEN         84
FT                   /note=""L->S: Complete loss of IL17RA binding.""
FT                   /evidence=""ECO:0000269|PubMed:35343786""
FT   MUTAGEN         106
FT                   /note=""E->P: Complete loss of hIL-17RA binding.""
FT                   /evidence=""ECO:0000269|PubMed:35343786""
FT   STRAND          19..25
FT                   /evidence=""ECO:0007829|PDB:7JX6""
FT   STRAND          29..32
FT                   /evidence=""ECO:0007829|PDB:7JX6""
FT   STRAND          41..49
FT                   /evidence=""ECO:0007829|PDB:7JX6""
FT   STRAND          57..70
FT                   /evidence=""ECO:0007829|PDB:7JX6""
FT   TURN            74..78
FT                   /evidence=""ECO:0007829|PDB:7F5F""
FT   STRAND          80..82
FT                   /evidence=""ECO:0007829|PDB:7JX6""
FT   TURN            83..86
FT                   /evidence=""ECO:0007829|PDB:7JX6""
FT   STRAND          87..91
FT                   /evidence=""ECO:0007829|PDB:7JX6""
FT   STRAND          96..105
FT                   /evidence=""ECO:0007829|PDB:7JX6""
FT   STRAND          112..120
FT                   /evidence=""ECO:0007829|PDB:7JX6""
SQ   SEQUENCE   121 AA;  13831 MW;  912AD9E147A64907 CRC64;
     MKFLVFLGII TTVAAFHQEC SLQSCTQHQP YVVDDPCPIH FYSKWYIRVG ARKSAPLIEL
     CVDEAGSKSP IQYIDIGNYT VSCLPFTINC QEPKLGSLVV RCSFYEDFLE YHDVRVVLDF
     I
//
",3586
CGCGAA GCGAAG CGAAGA GAAGAA AAGAAG AGAAGC GAAGCT AAGCTA AGCTAT GCTATA CTATAA TATAAG ATAAGA TAAGAC AAGACA AGACAT GACATG ACATGT CATGTA ATGTAC TGTACG GTACGT TACGTG ACGTGC CGTGCA GTGCAT TGCATG GCATGG CATGGA ATGGAT TGGATT GGATTG GATTGG ATTGGC TTGGCT TGGCTT GGCTTC GCTTCG CTTCGA TTCGAT TCGATG CGATGT GATGTC ATGTCG TGTCGA GTCGAG TCGAGG CGAGGG GAGGGG AGGGGT GGGGTG GGGTGT GGTGTC GTGTCA TGTCAT GTCATG TCATGC CATGCT ATGCTA TGCTAC GCTACT CTACTA TACTAG ACTAGA CTAGAG TAGAGA AGAGAA GAGAAG AGAAGC GAAGCT AAGCTG AGCTGT GCTGTT CTGTTG TGTTGG GTTGGT TTGGTA TGGTAC GGTACC GTACCA TACCAA ACCAAT CCAATT CAATTT AATTTA ATTTAC TTTACC TTACCT TACCTT ACCTTT CCTTTA CTTTAC TTTACA TTACAG TACAGC ACAGCT CAGCTA AGCTAG GCTAGG CTAGGT TAGGTT AGGTTT GGTTTT GTTTTT TTTTTC TTTTCT TTTCTA TTCTAC TCTACA CTACAG TACAGG ACAGGT CAGGTG AGGTGT GGTGTT GTGTTA TGTTAA GTTAAC TTAACC TAACCT AACCTA ACCTAG CCTAGT CTAGTT TAGTTG AGTTGC GTTGCT TTGCTG TGCTGT GCTGTA CTGTAC TGTACC GTACCT TACCTA ACCTAC CCTACA CTACAG TACAGG ACAGGT CAGGTT AGGTTA GGTTAT,0,142,CGCG GCGA CGAA GAAG AAGA AGAA GAAG AAGC AGCT GCTA CTAT TATA ATAA TAAG AAGA AGAC GACA ACAT CATG ATGT TGTA GTAC TACG ACGT CGTG GTGC TGCA GCAT CATG ATGG TGGA GGAT GATT ATTG TTGG TGGC GGCT GCTT CTTC TTCG TCGA CGAT GATG ATGT TGTC GTCG TCGA CGAG GAGG AGGG GGGG GGGT GGTG GTGT TGTC GTCA TCAT CATG ATGC TGCT GCTA CTAC TACT ACTA CTAG TAGA AGAG GAGA AGAA GAAG AAGC AGCT GCTG CTGT TGTT GTTG TTGG TGGT GGTA GTAC TACC ACCA CCAA CAAT AATT ATTT TTTA TTAC TACC ACCT CCTT CTTT TTTA TTAC TACA ACAG CAGC AGCT GCTA CTAG TAGG AGGT GGTT GTTT TTTT TTTT TTTC TTCT TCTA CTAC TACA ACAG CAGG AGGT GGTG GTGT TGTT GTTA TTAA TAAC AACC ACCT CCTA CTAG TAGT AGTT GTTG TTGC TGCT GCTG CTGT TGTA GTAC TACC ACCT CCTA CTAC TACA ACAG CAGG AGGT GGTT GTTA TTAT,CGCGA GCGAA CGAAG GAAGA AAGAA AGAAG GAAGC AAGCT AGCTA GCTAT CTATA TATAA ATAAG TAAGA AAGAC AGACA GACAT ACATG CATGT ATGTA TGTAC GTACG TACGT ACGTG CGTGC GTGCA TGCAT GCATG CATGG ATGGA TGGAT GGATT GATTG ATTGG TTGGC TGGCT GGCTT GCTTC CTTCG TTCGA TCGAT CGATG GATGT ATGTC TGTCG GTCGA TCGAG CGAGG GAGGG AGGGG GGGGT GGGTG GGTGT GTGTC TGTCA GTCAT TCATG CATGC ATGCT TGCTA GCTAC CTACT TACTA ACTAG CTAGA TAGAG AGAGA GAGAA AGAAG GAAGC AAGCT AGCTG GCTGT CTGTT TGTTG GTTGG TTGGT TGGTA GGTAC GTACC TACCA ACCAA CCAAT CAATT AATTT ATTTA TTTAC TTACC TACCT ACCTT CCTTT CTTTA TTTAC TTACA TACAG ACAGC CAGCT AGCTA GCTAG CTAGG TAGGT AGGTT GGTTT GTTTT TTTTT TTTTC TTTCT TTCTA TCTAC CTACA TACAG ACAGG CAGGT AGGTG GGTGT GTGTT TGTTA GTTAA TTAAC TAACC AACCT ACCTA CCTAG CTAGT TAGTT AGTTG GTTGC TTGCT TGCTG GCTGT CTGTA TGTAC GTACC TACCT ACCTA CCTAC CTACA TACAG ACAGG CAGGT AGGTT GGTTA GTTAT,CGCGAA GCGAAG CGAAGA GAAGAA AAGAAG AGAAGC GAAGCT AAGCTA AGCTAT GCTATA CTATAA TATAAG ATAAGA TAAGAC AAGACA AGACAT GACATG ACATGT CATGTA ATGTAC TGTACG GTACGT TACGTG ACGTGC CGTGCA GTGCAT TGCATG GCATGG CATGGA ATGGAT TGGATT GGATTG GATTGG ATTGGC TTGGCT TGGCTT GGCTTC GCTTCG CTTCGA TTCGAT TCGATG CGATGT GATGTC ATGTCG TGTCGA GTCGAG TCGAGG CGAGGG GAGGGG AGGGGT GGGGTG GGGTGT GGTGTC GTGTCA TGTCAT GTCATG TCATGC CATGCT ATGCTA TGCTAC GCTACT CTACTA TACTAG ACTAGA CTAGAG TAGAGA AGAGAA GAGAAG AGAAGC GAAGCT AAGCTG AGCTGT GCTGTT CTGTTG TGTTGG GTTGGT TTGGTA TGGTAC GGTACC GTACCA TACCAA ACCAAT CCAATT CAATTT AATTTA ATTTAC TTTACC TTACCT TACCTT ACCTTT CCTTTA CTTTAC TTTACA TTACAG TACAGC ACAGCT CAGCTA AGCTAG GCTAGG CTAGGT TAGGTT AGGTTT GGTTTT GTTTTT TTTTTC TTTTCT TTTCTA TTCTAC TCTACA CTACAG TACAGG ACAGGT CAGGTG AGGTGT GGTGTT GTGTTA TGTTAA GTTAAC TTAACC TAACCT AACCTA ACCTAG CCTAGT CTAGTT TAGTTG AGTTGC GTTGCT TTGCTG TGCTGT GCTGTA CTGTAC TGTACC GTACCT TACCTA ACCTAC CCTACA CTACAG TACAGG ACAGGT CAGGTT AGGTTA GGTTAT,CGCGAAG GCGAAGA CGAAGAA GAAGAAG AAGAAGC AGAAGCT GAAGCTA AAGCTAT AGCTATA GCTATAA CTATAAG TATAAGA ATAAGAC TAAGACA AAGACAT AGACATG GACATGT ACATGTA CATGTAC ATGTACG TGTACGT GTACGTG TACGTGC ACGTGCA CGTGCAT GTGCATG TGCATGG GCATGGA CATGGAT ATGGATT TGGATTG GGATTGG GATTGGC ATTGGCT TTGGCTT TGGCTTC GGCTTCG GCTTCGA CTTCGAT TTCGATG TCGATGT CGATGTC GATGTCG ATGTCGA TGTCGAG GTCGAGG TCGAGGG CGAGGGG GAGGGGT AGGGGTG GGGGTGT GGGTGTC GGTGTCA GTGTCAT TGTCATG GTCATGC TCATGCT CATGCTA ATGCTAC TGCTACT GCTACTA CTACTAG TACTAGA ACTAGAG CTAGAGA TAGAGAA AGAGAAG GAGAAGC AGAAGCT GAAGCTG AAGCTGT AGCTGTT GCTGTTG CTGTTGG TGTTGGT GTTGGTA TTGGTAC TGGTACC GGTACCA GTACCAA TACCAAT ACCAATT CCAATTT CAATTTA AATTTAC ATTTACC TTTACCT TTACCTT TACCTTT ACCTTTA CCTTTAC CTTTACA TTTACAG TTACAGC TACAGCT ACAGCTA CAGCTAG AGCTAGG GCTAGGT CTAGGTT TAGGTTT AGGTTTT GGTTTTT GTTTTTC TTTTTCT TTTTCTA TTTCTAC TTCTACA TCTACAG CTACAGG TACAGGT ACAGGTG CAGGTGT AGGTGTT GGTGTTA GTGTTAA TGTTAAC GTTAACC TTAACCT TAACCTA AACCTAG ACCTAGT CCTAGTT CTAGTTG TAGTTGC AGTTGCT GTTGCTG TTGCTGT TGCTGTA GCTGTAC CTGTACC TGTACCT GTACCTA TACCTAC ACCTACA CCTACAG CTACAGG TACAGGT ACAGGTT CAGGTTA AGGTTAT,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",26355
AGTGTA GTGTAA TGTAAC GTAACT TAACTT AACTTC ACTTCT CTTCTT TTCTTC TCTTCA CTTCAA TTCAAT TCAATT CAATTG AATTGT ATTGTC TTGTCA TGTCAT GTCATT TCATTA CATTAC ATTACT TTACTT TACTTC ACTTCA CTTCAG TTCAGG TCAGGT CAGGTG AGGTGA GGTGAT GTGATG TGATGG GATGGC ATGGCA TGGCAC GGCACA GCACAA CACAAC ACAACA CAACAA AACAAG ACAAGT CAAGTC AAGTCC AGTCCT GTCCTA TCCTAT CCTATT CTATTT TATTTC ATTTCT TTTCTG TTCTGA TCTGAA CTGAAC TGAACA GAACAT AACATG ACATGA CATGAC ATGACT TGACTA GACTAC,1,64,AGTG GTGT TGTA GTAA TAAC AACT ACTT CTTC TTCT TCTT CTTC TTCA TCAA CAAT AATT ATTG TTGT TGTC GTCA TCAT CATT ATTA TTAC TACT ACTT CTTC TTCA TCAG CAGG AGGT GGTG GTGA TGAT GATG ATGG TGGC GGCA GCAC CACA ACAA CAAC AACA ACAA CAAG AAGT AGTC GTCC TCCT CCTA CTAT TATT ATTT TTTC TTCT TCTG CTGA TGAA GAAC AACA ACAT CATG ATGA TGAC GACT ACTA CTAC,AGTGT GTGTA TGTAA GTAAC TAACT AACTT ACTTC CTTCT TTCTT TCTTC CTTCA TTCAA TCAAT CAATT AATTG ATTGT TTGTC TGTCA GTCAT TCATT CATTA ATTAC TTACT TACTT ACTTC CTTCA TTCAG TCAGG CAGGT AGGTG GGTGA GTGAT TGATG GATGG ATGGC TGGCA GGCAC GCACA CACAA ACAAC CAACA AACAA ACAAG CAAGT AAGTC AGTCC GTCCT TCCTA CCTAT CTATT TATTT ATTTC TTTCT TTCTG TCTGA CTGAA TGAAC GAACA AACAT ACATG CATGA ATGAC TGACT GACTA ACTAC,AGTGTA GTGTAA TGTAAC GTAACT TAACTT AACTTC ACTTCT CTTCTT TTCTTC TCTTCA CTTCAA TTCAAT TCAATT CAATTG AATTGT ATTGTC TTGTCA TGTCAT GTCATT TCATTA CATTAC ATTACT TTACTT TACTTC ACTTCA CTTCAG TTCAGG TCAGGT CAGGTG AGGTGA GGTGAT GTGATG TGATGG GATGGC ATGGCA TGGCAC GGCACA GCACAA CACAAC ACAACA CAACAA AACAAG ACAAGT CAAGTC AAGTCC AGTCCT GTCCTA TCCTAT CCTATT CTATTT TATTTC ATTTCT TTTCTG TTCTGA TCTGAA CTGAAC TGAACA GAACAT AACATG ACATGA CATGAC ATGACT TGACTA GACTAC,AGTGTAA GTGTAAC TGTAACT GTAACTT TAACTTC AACTTCT ACTTCTT CTTCTTC TTCTTCA TCTTCAA CTTCAAT TTCAATT TCAATTG CAATTGT AATTGTC ATTGTCA TTGTCAT TGTCATT GTCATTA TCATTAC CATTACT ATTACTT TTACTTC TACTTCA ACTTCAG CTTCAGG TTCAGGT TCAGGTG CAGGTGA AGGTGAT GGTGATG GTGATGG TGATGGC GATGGCA ATGGCAC TGGCACA GGCACAA GCACAAC CACAACA ACAACAA CAACAAG AACAAGT ACAAGTC CAAGTCC AAGTCCT AGTCCTA GTCCTAT TCCTATT CCTATTT CTATTTC TATTTCT ATTTCTG TTTCTGA TTCTGAA TCTGAAC CTGAACA TGAACAT GAACATG AACATGA ACATGAC CATGACT ATGACTA TGACTAC,"ID   AP3A_SARS2              Reviewed;         275 AA.
AC   P0DTC3;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 25.
DE   RecName: Full=ORF3a protein;
DE            Short=ORF3a;
DE   AltName: Full=Accessory protein 3a;
DE   AltName: Full=Protein 3a;
DE   AltName: Full=Protein U274;
DE   AltName: Full=Protein X1;
GN   ORFNames=3a;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   SUBCELLULAR LOCATION.
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [3]
RP   FUNCTION.
RX   PubMed=33157038; DOI=10.1016/j.cell.2020.10.039;
RA   Ghosh S., Dellibovi-Ragheb T.A., Kerviel A., Pak E., Qiu Q., Fisher M.,
RA   Takvorian P.M., Bleck C., Hsu V.W., Fehr A.R., Perlman S., Achar S.R.,
RA   Straus M.R., Whittaker G.R., de Haan C.A.M., Kehrl J., Altan-Bonnet G.,
RA   Altan-Bonnet N.;
RT   ""beta-Coronaviruses Use Lysosomes for Egress Instead of the Biosynthetic
RT   Secretory Pathway."";
RL   Cell 183:1520-1535(2020).
RN   [4]
RP   FUNCTION, INTERACTION WITH HOST VPS39, AND SUBCELLULAR LOCATION.
RX   PubMed=33422265; DOI=10.1016/j.devcel.2020.12.010;
RA   Miao G., Zhao H., Li Y., Ji M., Chen Y., Shi Y., Bi Y., Wang P., Zhang H.;
RT   ""ORF3a of the COVID-19 virus SARS-CoV-2 blocks HOPS complex-mediated
RT   assembly of the SNARE complex required for autolysosome formation."";
RL   Dev. Cell 56:427-442(2020).
RN   [5]
RP   FUNCTION, INTERACTION WITH HOST HMGB1 AND HOST HMOX1, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=35239449; DOI=10.1080/15548627.2022.2039992;
RA   Zhang X., Yang Z., Pan T., Long X., Sun Q., Wang P.H., Li X., Kuang E.;
RT   ""SARS-CoV-2 ORF3a induces RETREG1/FAM134B-dependent reticulophagy and
RT   triggers sequential ER stress and inflammatory responses during SARS-CoV-2
RT   infection."";
RL   Autophagy 0:0-0(2022).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.1 ANGSTROMS), FUNCTION, SUBUNIT,
RP   MUTAGENESIS OF 1-MET--LEU-41; 57-GLN-SER-58; GLN-57 AND GLN-116, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=34158638; DOI=10.1038/s41594-021-00619-0;
RA   Kern D.M., Sorum B., Mali S.S., Hoel C.M., Sridharan S., Remis J.P.,
RA   Toso D.B., Kotecha A., Bautista D.M., Brohawn S.G.;
RT   ""Cryo-EM structure of SARS-CoV-2 ORF3a in lipid nanodiscs."";
RL   Nat. Struct. Mol. Biol. 28:573-582(2021).
CC   -!- FUNCTION: Plays a role in viral egress via lysosomal trafficking
CC       (PubMed:33157038, PubMed:33422265). Forms homotetrameric ion channels
CC       (viroporins) localized at endosomes and lysosomes, that may induce
CC       deacidification of lysosomes, allowing safe egress of virions via
CC       lysosomal trafficking (PubMed:33157038, PubMed:33422265,
CC       PubMed:34158638). Also blocks autolysosome formation by binding and
CC       sequestering the host component VPS39 for homotypic fusion and protein
CC       sorting (HOPS) on late endosomes (PubMed:33422265). This prevents
CC       fusion of autophagosomes with lysosomes, disrupting autophagy and
CC       facilitating virus egress (PubMed:33422265). Induces host
CC       RETREG1/FAM134B-dependent reticulophagy by interacting with host HMGB1
CC       and enhancing the association between HMGB1 and host BECN1
CC       (PubMed:35239449). This induces endoplasmic reticulum stress and
CC       inflammatory responses and facilitates viral infection
CC       (PubMed:35239449). {ECO:0000269|PubMed:33157038,
CC       ECO:0000269|PubMed:33422265, ECO:0000269|PubMed:34158638,
CC       ECO:0000269|PubMed:35239449}.
CC   -!- SUBUNIT: Homodimer (PubMed:34158638), a subset forms homotetramer of
CC       two homodimers linked non covalently (PubMed:34158638). Interacts with
CC       M, S and E proteins. Also interacts with the accessory protein 7a (By
CC       similarity). Interacts with host VPS39, sequestering it on late
CC       endosomes (PubMed:33422265). Interacts with host HMGB1; the interaction
CC       enhances the association between HMGB1 and host BECN1, promoting
CC       reticulophagy (PubMed:35239449). Interacts with HMOX1; the interaction
CC       promotes ORF3A-induced autophagy but is unlikely to be involved in
CC       ORF3A-mediated induction of reticulophagy (PubMed:35239449).
CC       {ECO:0000250|UniProtKB:P59632, ECO:0000269|PubMed:33422265,
CC       ECO:0000269|PubMed:34158638, ECO:0000269|PubMed:35239449}.
CC   -!- INTERACTION:
CC       P0DTC3; P0DTC3: 3a; NbExp=4; IntAct=EBI-25475894, EBI-25475894;
CC       P0DTC3; P0DTD8: 7b; NbExp=3; IntAct=EBI-25475894, EBI-25475914;
CC       P0DTC3; Q9Y673: ALG5; Xeno; NbExp=4; IntAct=EBI-25475894, EBI-11725055;
CC       P0DTC3; Q01518: CAP1; Xeno; NbExp=3; IntAct=EBI-25475894, EBI-2808398;
CC       P0DTC3; P09601: HMOX1; Xeno; NbExp=4; IntAct=EBI-25475894, EBI-2806151;
CC       P0DTC3; Q12846: STX4; Xeno; NbExp=4; IntAct=EBI-25475894, EBI-744942;
CC       P0DTC3; Q8NBJ7: SUMF2; Xeno; NbExp=3; IntAct=EBI-25475894, EBI-723091;
CC       P0DTC3; Q9UH99: SUN2; Xeno; NbExp=3; IntAct=EBI-25475894, EBI-1044964;
CC       P0DTC3; Q9P2Y5: UVRAG; Xeno; NbExp=6; IntAct=EBI-25475894, EBI-2952704;
CC       P0DTC3; P51809: VAMP7; Xeno; NbExp=4; IntAct=EBI-25475894, EBI-1052205;
CC       P0DTC3; Q96JC1: VPS39; Xeno; NbExp=19; IntAct=EBI-25475894, EBI-1050197;
CC       P0DTC3; P49754: VPS41; Xeno; NbExp=4; IntAct=EBI-25475894, EBI-2130459;
CC       P0DTC3; Q8NAF0: ZNF579; Xeno; NbExp=2; IntAct=EBI-25475894, EBI-6164383;
CC   -!- SUBCELLULAR LOCATION: Virion {ECO:0000250|UniProtKB:P59632}. Host cell
CC       membrane {ECO:0000250|UniProtKB:P59632, ECO:0000269|PubMed:33060197,
CC       ECO:0000269|PubMed:34158638}; Multi-pass membrane protein
CC       {ECO:0000250|UniProtKB:P59632, ECO:0000269|PubMed:34158638}. Host
CC       endoplasmic reticulum membrane {ECO:0000269|PubMed:35239449}; Multi-
CC       pass membrane protein {ECO:0000269|PubMed:34158638}. Secreted
CC       {ECO:0000250|UniProtKB:P59632}. Host cytoplasm
CC       {ECO:0000250|UniProtKB:P59632, ECO:0000269|PubMed:33060197}. Host
CC       endosome {ECO:0000269|PubMed:33060197, ECO:0000269|PubMed:33422265}.
CC       Host lysosome {ECO:0000269|PubMed:33422265}. Note=The cell surface
CC       expressed protein can undergo endocytosis. The protein is secreted in
CC       association with membranous structures. {ECO:0000250|UniProtKB:P59632}.
CC   -!- DOMAIN: The second or the third transmembrane region are responsible
CC       for Golgi localization. {ECO:0000250|UniProtKB:P59632}.
CC   -!- PTM: Exists in both O-glycosylated and non-glycosylated forms. The
CC       glycosylated form is associated with the virion.
CC       {ECO:0000250|UniProtKB:P59632}.
CC   -!- POLYMORPHISM: Variant Omicron/BA.1 and BA.2 belong to a lineage first
CC       isolated in South Africa (November 2021). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/BQ.1.1 belongs to a lineage first
CC       isolated in Nigeria (November 2022). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/XBB.1.5 belongs to a lineage first
CC       isolated in United States (November 2022). It is the result of
CC       recombination between omicron BJ.1 and BM.1.1. Moreover XBB.1.5 do not
CC       express ORF8. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43417.1; -; Genomic_RNA.
DR   PDB; 6XDC; EM; 2.90 A; A/B=1-275.
DR   PDB; 7KJR; EM; 2.08 A; A/B=1-275.
DR   PDB; 8EQJ; EM; 3.00 A; A/B=1-275.
DR   PDB; 8EQT; EM; 3.40 A; A/B=1-275.
DR   PDB; 8EQU; EM; 2.80 A; A/B=1-275.
DR   PDB; 8T5P; X-ray; 2.50 A; G/H/I=36-40.
DR   PDB; 8T5Q; X-ray; 1.90 A; G/H/I=36-40.
DR   PDBsum; 6XDC; -.
DR   PDBsum; 7KJR; -.
DR   PDBsum; 8EQJ; -.
DR   PDBsum; 8EQT; -.
DR   PDBsum; 8EQU; -.
DR   PDBsum; 8T5P; -.
DR   PDBsum; 8T5Q; -.
DR   EMDB; EMD-22136; -.
DR   EMDB; EMD-22898; -.
DR   EMDB; EMD-28538; -.
DR   EMDB; EMD-28545; -.
DR   EMDB; EMD-28546; -.
DR   SMR; P0DTC3; -.
DR   BioGRID; 4383868; 1267.
DR   ComplexPortal; CPX-6098; SARS-CoV-2 3a complex.
DR   IntAct; P0DTC3; 468.
DR   MINT; P0DTC3; -.
DR   TCDB; 1.A.57.1.5; the human sars coronavirus viroporin (sars-vp) family.
DR   GlyGen; P0DTC3; 2 sites.
DR   iPTMnet; P0DTC3; -.
DR   DNASU; 43740569; -.
DR   KEGG; vg:43740569; -.
DR   AGR; RefSeq:YP_009724391; -.
DR   Reactome; R-HSA-9694322; Virion Assembly and Release.
DR   Reactome; R-HSA-9694614; Attachment and Entry.
DR   Reactome; R-HSA-9694635; Translation of Structural Proteins.
DR   Reactome; R-HSA-9694719; Maturation of protein 3a.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   Reactome; R-HSA-9733458; Induction of Cell-Cell Fusion.
DR   Reactome; R-HSA-9754560; SARS-CoV-2 modulates autophagy.
DR   Reactome; R-HSA-9755779; SARS-CoV-2 targets host intracellular signalling and regulatory pathways.
DR   PRO; PR:P0DTC3; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:DisProt.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0044165; C:host cell endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044174; C:host cell endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0044187; C:host cell lysosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:ComplexPortal.
DR   GO; GO:0055036; C:virion membrane; TAS:Reactome.
DR   GO; GO:0005891; C:voltage-gated calcium channel complex; IPI:ComplexPortal.
DR   GO; GO:0008076; C:voltage-gated potassium channel complex; IPI:ComplexPortal.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0140677; F:molecular function activator activity; IMP:DisProt.
DR   GO; GO:0005216; F:monoatomic ion channel activity; IEA:InterPro.
DR   GO; GO:0039520; P:induction by virus of host autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0140883; P:induction by virus of host reticulophagy; IDA:UniProtKB.
DR   GO; GO:0098662; P:inorganic cation transmembrane transport; IDA:ComplexPortal.
DR   CDD; cd21648; SARS-CoV-like_ORF3a; 1.
DR   DisProt; DP03003; -.
DR   InterPro; IPR046446; a/bCoV_VIROPORIN_3A-like_CD.
DR   InterPro; IPR046445; a/bCoV_VIROPORIN_3A-like_TM.
DR   InterPro; IPR024407; Protein_3a_bCoV.
DR   Pfam; PF11289; bCoV_viroporin; 1.
DR   PROSITE; PS51967; COV_VIROPORIN_3A_CD; 1.
DR   PROSITE; PS51966; COV_VIROPORIN_3A_TM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activation of host autophagy by virus; Glycoprotein;
KW   Host cell membrane; Host cytoplasm; Host endoplasmic reticulum;
KW   Host endosome; Host lysosome; Host membrane; Host-virus interaction;
KW   Ion channel; Ion transport; Membrane; Reference proteome; Secreted;
KW   Transmembrane; Transmembrane helix; Transport; Viral ion channel; Virion.
FT   CHAIN           1..275
FT                   /note=""ORF3a protein""
FT                   /id=""PRO_0000449650""
FT   TOPO_DOM        1..42
FT                   /note=""Extracellular""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   TRANSMEM        43..61
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   TOPO_DOM        62..67
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   TRANSMEM        68..93
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   TOPO_DOM        94..101
FT                   /note=""Extracellular""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   TRANSMEM        102..126
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   TOPO_DOM        127..275
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   DOMAIN          33..141
FT                   /note=""CoV 3a-like viroporin TM""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01311""
FT   DOMAIN          145..237
FT                   /note=""CoV 3a-like viroporin CD""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01312""
FT   REGION          1..39
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000305|PubMed:35108439""
FT   REGION          239..275
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000305|PubMed:35108439""
FT   SITE            133
FT                   /note=""Involved in polymerization""
FT                   /evidence=""ECO:0000250|UniProtKB:P59632""
FT   CARBOHYD        32
FT                   /note=""O-linked (GalNAc...) threonine; by host""
FT                   /evidence=""ECO:0000250|UniProtKB:P59632""
FT   CARBOHYD        34
FT                   /note=""O-linked (GalNAc...) threonine; by host""
FT                   /evidence=""ECO:0000255""
FT   VARIANT         26
FT                   /note=""S -> L (in strain: Delta/B.1.617.2 and
FT                   Kappa/B.1.617.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         42
FT                   /note=""P -> L (in strain: Iota/B.1.526)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         57
FT                   /note=""Q -> H (in strain: Beta/B.1.351, Epsilon/B.1.429,
FT                   Iota/B.1.526 and Mu/B.1.621)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         171
FT                   /note=""S -> L (in strain: Beta/B.1.351)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         223
FT                   /note=""T -> I (in strain: Omicron/BA.2, Omicron/BA.2.12.1,
FT                   Omicron/BA.2.75, Omicron/BA.4, Omicron/BA.5,
FT                   Omicron/BQ.1.1, Omicron/XBB.1.5, Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         253
FT                   /note=""S -> P (in strain: Gamma/P.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         257
FT                   /note=""Missing (in strain: Mu/B.1.621)""
FT                   /evidence=""ECO:0000305""
FT   MUTAGEN         1..41
FT                   /note=""Missing: Partial loss of Ca(2+) and NMDG(+)
FT                   permeability. Increased localization at host plasma
FT                   membrane.""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   MUTAGEN         57..58
FT                   /note=""QS->EL: Partial loss of Ca(2+) and NMDG(+)
FT                   permeability.""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   MUTAGEN         57
FT                   /note=""Q->H: No effect on ion permeability.""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   MUTAGEN         116
FT                   /note=""Q->L: Partial loss of Ca(2+) and NMDG(+)
FT                   permeability.""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   HELIX           44..60
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   HELIX           68..99
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   HELIX           103..105
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   HELIX           106..133
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   HELIX           137..140
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   STRAND          144..150
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   STRAND          155..160
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   STRAND          165..172
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   STRAND          183..186
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   STRAND          189..192
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   STRAND          199..204
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   STRAND          209..218
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   HELIX           220..223
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   STRAND          228..235
FT                   /evidence=""ECO:0007829|PDB:7KJR""
SQ   SEQUENCE   275 AA;  31123 MW;  4688E6D477E031C4 CRC64;
     MDLFMRIFTI GTVTLKQGEI KDATPSDFVR ATATIPIQAS LPFGWLIVGV ALLAVFQSAS
     KIITLKKRWQ LALSKGVHFV CNLLLLFVTV YSHLLLVAAG LEAPFLYLYA LVYFLQSINF
     VRIIMRLWLC WKCRSKNPLL YDANYFLCWH TNCYDYCIPY NSVTSSIVIT SGDGTTSPIS
     EHDYQIGGYT EKWESGVKDC VVLHSYFTSD YYQLYSTQLS TDTGVEHVTF FIYNKIVDEP
     EEHVQIHTID GSSGVVNPVM EPIYDEPTTT TSVPL
//
",53651
GGTCTG GTCTGC TCTGCT CTGCTG TGCTGG GCTGGG CTGGGC TGGGCA GGGCAC GGCACG GCACGG CACGGT ACGGTG CGGTGG GGTGGT GTGGTG TGGTGG GGTGGG GTGGGC TGGGCG GGGCGT GGCGTG GCGTGA CGTGAT GTGATG TGATGA GATGAT ATGATC TGATCA GATCAC ATCACC TCACCT CACCTT ACCTTC CCTTCG CTTCGC TTCGCG TCGCGG CGCGGC GCGGCC CGGCCA GGCCAT GCCATC CCATCG CATCGC ATCGCG TCGCGG CGCGGC GCGGCG CGGCGG GGCGGC GCGGCG CGGCGG GGCGGG GCGGGC CGGGCG GGGCGA GGCGAT GCGATG CGATGT GATGTG ATGTGA TGTGAA GTGAAC TGAACG GAACGT AACGTC ACGTCA CGTCAA GTCAAT TCAATG CAATGC AATGCC ATGCCA TGCCAT GCCATC CCATCG CATCGC ATCGCC TCGCCC CGCCCC GCCCCG CCCCGG CCCGGG CCGGGT CGGGTA GGGTAT GGTATT GTATTG TATTGC ATTGCC TTGCCG TGCCGC GCCGCC CCGCCG CGCCGC GCCGCG CCGCGC CGCGCT GCGCTG CGCTGC GCTGCT CTGCTG TGCTGG GCTGGC CTGGCC TGGCCA GGCCAC GCCACC CCACCG CACCGT ACCGTG CCGTGG CGTGGC GTGGCC TGGCCG GGCCGG GCCGGC CCGGCC CGGCCT GGCCTG GCCTGG CCTGGG CTGGGC TGGGCG GGGCGT GGCGTC GCGTCG CGTCGC GTCGCG TCGCGA CGCGAT GCGATC CGATCC GATCCC ATCCCG TCCCGG CCCGGC CCGGCG CGGCGC GGCGCT GCGCTG CGCTGT GCTGTT CTGTTT,2,145,GGTC GTCT TCTG CTGC TGCT GCTG CTGG TGGG GGGC GGCA GCAC CACG ACGG CGGT GGTG GTGG TGGT GGTG GTGG TGGG GGGC GGCG GCGT CGTG GTGA TGAT GATG ATGA TGAT GATC ATCA TCAC CACC ACCT CCTT CTTC TTCG TCGC CGCG GCGG CGGC GGCC GCCA CCAT CATC ATCG TCGC CGCG GCGG CGGC GGCG GCGG CGGC GGCG GCGG CGGG GGGC GGCG GCGA CGAT GATG ATGT TGTG GTGA TGAA GAAC AACG ACGT CGTC GTCA TCAA CAAT AATG ATGC TGCC GCCA CCAT CATC ATCG TCGC CGCC GCCC CCCC CCCG CCGG CGGG GGGT GGTA GTAT TATT ATTG TTGC TGCC GCCG CCGC CGCC GCCG CCGC CGCG GCGC CGCT GCTG CTGC TGCT GCTG CTGG TGGC GGCC GCCA CCAC CACC ACCG CCGT CGTG GTGG TGGC GGCC GCCG CCGG CGGC GGCC GCCT CCTG CTGG TGGG GGGC GGCG GCGT CGTC GTCG TCGC CGCG GCGA CGAT GATC ATCC TCCC CCCG CCGG CGGC GGCG GCGC CGCT GCTG CTGT TGTT GTTT,GGTCT GTCTG TCTGC CTGCT TGCTG GCTGG CTGGG TGGGC GGGCA GGCAC GCACG CACGG ACGGT CGGTG GGTGG GTGGT TGGTG GGTGG GTGGG TGGGC GGGCG GGCGT GCGTG CGTGA GTGAT TGATG GATGA ATGAT TGATC GATCA ATCAC TCACC CACCT ACCTT CCTTC CTTCG TTCGC TCGCG CGCGG GCGGC CGGCC GGCCA GCCAT CCATC CATCG ATCGC TCGCG CGCGG GCGGC CGGCG GGCGG GCGGC CGGCG GGCGG GCGGG CGGGC GGGCG GGCGA GCGAT CGATG GATGT ATGTG TGTGA GTGAA TGAAC GAACG AACGT ACGTC CGTCA GTCAA TCAAT CAATG AATGC ATGCC TGCCA GCCAT CCATC CATCG ATCGC TCGCC CGCCC GCCCC CCCCG CCCGG CCGGG CGGGT GGGTA GGTAT GTATT TATTG ATTGC TTGCC TGCCG GCCGC CCGCC CGCCG GCCGC CCGCG CGCGC GCGCT CGCTG GCTGC CTGCT TGCTG GCTGG CTGGC TGGCC GGCCA GCCAC CCACC CACCG ACCGT CCGTG CGTGG GTGGC TGGCC GGCCG GCCGG CCGGC CGGCC GGCCT GCCTG CCTGG CTGGG TGGGC GGGCG GGCGT GCGTC CGTCG GTCGC TCGCG CGCGA GCGAT CGATC GATCC ATCCC TCCCG CCCGG CCGGC CGGCG GGCGC GCGCT CGCTG GCTGT CTGTT TGTTT,GGTCTG GTCTGC TCTGCT CTGCTG TGCTGG GCTGGG CTGGGC TGGGCA GGGCAC GGCACG GCACGG CACGGT ACGGTG CGGTGG GGTGGT GTGGTG TGGTGG GGTGGG GTGGGC TGGGCG GGGCGT GGCGTG GCGTGA CGTGAT GTGATG TGATGA GATGAT ATGATC TGATCA GATCAC ATCACC TCACCT CACCTT ACCTTC CCTTCG CTTCGC TTCGCG TCGCGG CGCGGC GCGGCC CGGCCA GGCCAT GCCATC CCATCG CATCGC ATCGCG TCGCGG CGCGGC GCGGCG CGGCGG GGCGGC GCGGCG CGGCGG GGCGGG GCGGGC CGGGCG GGGCGA GGCGAT GCGATG CGATGT GATGTG ATGTGA TGTGAA GTGAAC TGAACG GAACGT AACGTC ACGTCA CGTCAA GTCAAT TCAATG CAATGC AATGCC ATGCCA TGCCAT GCCATC CCATCG CATCGC ATCGCC TCGCCC CGCCCC GCCCCG CCCCGG CCCGGG CCGGGT CGGGTA GGGTAT GGTATT GTATTG TATTGC ATTGCC TTGCCG TGCCGC GCCGCC CCGCCG CGCCGC GCCGCG CCGCGC CGCGCT GCGCTG CGCTGC GCTGCT CTGCTG TGCTGG GCTGGC CTGGCC TGGCCA GGCCAC GCCACC CCACCG CACCGT ACCGTG CCGTGG CGTGGC GTGGCC TGGCCG GGCCGG GCCGGC CCGGCC CGGCCT GGCCTG GCCTGG CCTGGG CTGGGC TGGGCG GGGCGT GGCGTC GCGTCG CGTCGC GTCGCG TCGCGA CGCGAT GCGATC CGATCC GATCCC ATCCCG TCCCGG CCCGGC CCGGCG CGGCGC GGCGCT GCGCTG CGCTGT GCTGTT CTGTTT,GGTCTGC GTCTGCT TCTGCTG CTGCTGG TGCTGGG GCTGGGC CTGGGCA TGGGCAC GGGCACG GGCACGG GCACGGT CACGGTG ACGGTGG CGGTGGT GGTGGTG GTGGTGG TGGTGGG GGTGGGC GTGGGCG TGGGCGT GGGCGTG GGCGTGA GCGTGAT CGTGATG GTGATGA TGATGAT GATGATC ATGATCA TGATCAC GATCACC ATCACCT TCACCTT CACCTTC ACCTTCG CCTTCGC CTTCGCG TTCGCGG TCGCGGC CGCGGCC GCGGCCA CGGCCAT GGCCATC GCCATCG CCATCGC CATCGCG ATCGCGG TCGCGGC CGCGGCG GCGGCGG CGGCGGC GGCGGCG GCGGCGG CGGCGGG GGCGGGC GCGGGCG CGGGCGA GGGCGAT GGCGATG GCGATGT CGATGTG GATGTGA ATGTGAA TGTGAAC GTGAACG TGAACGT GAACGTC AACGTCA ACGTCAA CGTCAAT GTCAATG TCAATGC CAATGCC AATGCCA ATGCCAT TGCCATC GCCATCG CCATCGC CATCGCC ATCGCCC TCGCCCC CGCCCCG GCCCCGG CCCCGGG CCCGGGT CCGGGTA CGGGTAT GGGTATT GGTATTG GTATTGC TATTGCC ATTGCCG TTGCCGC TGCCGCC GCCGCCG CCGCCGC CGCCGCG GCCGCGC CCGCGCT CGCGCTG GCGCTGC CGCTGCT GCTGCTG CTGCTGG TGCTGGC GCTGGCC CTGGCCA TGGCCAC GGCCACC GCCACCG CCACCGT CACCGTG ACCGTGG CCGTGGC CGTGGCC GTGGCCG TGGCCGG GGCCGGC GCCGGCC CCGGCCT CGGCCTG GGCCTGG GCCTGGG CCTGGGC CTGGGCG TGGGCGT GGGCGTC GGCGTCG GCGTCGC CGTCGCG GTCGCGA TCGCGAT CGCGATC GCGATCC CGATCCC GATCCCG ATCCCGG TCCCGGC CCCGGCG CCGGCGC CGGCGCT GGCGCTG GCGCTGT CGCTGTT GCTGTTT,"ID   EXBB_ECO57              Reviewed;         244 AA.
AC   P0ABU8; P18783;
DT   25-OCT-2005, integrated into UniProtKB/Swiss-Prot.
DT   25-OCT-2005, sequence version 1.
DT   05-FEB-2025, entry version 105.
DE   RecName: Full=Biopolymer transport protein ExbB;
GN   Name=exbB; OrderedLocusNames=Z4359, ECs3890;
OS   Escherichia coli O157:H7.
OC   Bacteria; Pseudomonadota; Gammaproteobacteria; Enterobacterales;
OC   Enterobacteriaceae; Escherichia.
OX   NCBI_TaxID=83334;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=O157:H7 / EDL933 / ATCC 700927 / EHEC;
RX   PubMed=11206551; DOI=10.1038/35054089;
RA   Perna N.T., Plunkett G. III, Burland V., Mau B., Glasner J.D., Rose D.J.,
RA   Mayhew G.F., Evans P.S., Gregor J., Kirkpatrick H.A., Posfai G.,
RA   Hackett J., Klink S., Boutin A., Shao Y., Miller L., Grotbeck E.J.,
RA   Davis N.W., Lim A., Dimalanta E.T., Potamousis K., Apodaca J.,
RA   Anantharaman T.S., Lin J., Yen G., Schwartz D.C., Welch R.A.,
RA   Blattner F.R.;
RT   ""Genome sequence of enterohaemorrhagic Escherichia coli O157:H7."";
RL   Nature 409:529-533(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=O157:H7 / Sakai / RIMD 0509952 / EHEC;
RX   PubMed=11258796; DOI=10.1093/dnares/8.1.11;
RA   Hayashi T., Makino K., Ohnishi M., Kurokawa K., Ishii K., Yokoyama K.,
RA   Han C.-G., Ohtsubo E., Nakayama K., Murata T., Tanaka M., Tobe T., Iida T.,
RA   Takami H., Honda T., Sasakawa C., Ogasawara N., Yasunaga T., Kuhara S.,
RA   Shiba T., Hattori M., Shinagawa H.;
RT   ""Complete genome sequence of enterohemorrhagic Escherichia coli O157:H7 and
RT   genomic comparison with a laboratory strain K-12."";
RL   DNA Res. 8:11-22(2001).
CC   -!- FUNCTION: Involved in the TonB-dependent energy-dependent transport of
CC       various receptor-bound substrates. Protects ExbD from proteolytic
CC       degradation and functionally stabilizes TonB (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBUNIT: The accessory proteins ExbB and ExbD seem to form a complex
CC       with TonB. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Cell inner membrane {ECO:0000250}; Multi-pass
CC       membrane protein {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the ExbB/TolQ family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AE005174; AAG58142.1; -; Genomic_DNA.
DR   EMBL; BA000007; BAB37313.1; -; Genomic_DNA.
DR   PIR; B85960; B85960.
DR   PIR; B91115; B91115.
DR   RefSeq; NP_311917.1; NC_002695.1.
DR   RefSeq; WP_000527844.1; NZ_VOAI01000009.1.
DR   AlphaFoldDB; P0ABU8; -.
DR   SMR; P0ABU8; -.
DR   STRING; 155864.Z4359; -.
DR   GeneID; 916284; -.
DR   GeneID; 93778981; -.
DR   KEGG; ece:Z4359; -.
DR   KEGG; ecs:ECs_3890; -.
DR   PATRIC; fig|386585.9.peg.4058; -.
DR   eggNOG; COG0811; Bacteria.
DR   HOGENOM; CLU_053325_0_2_6; -.
DR   OMA; PHMVKVG; -.
DR   Proteomes; UP000000558; Chromosome.
DR   Proteomes; UP000002519; Chromosome.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0022857; F:transmembrane transporter activity; IEA:InterPro.
DR   GO; GO:0043213; P:bacteriocin transport; IEA:UniProtKB-KW.
DR   GO; GO:0017038; P:protein import; IEA:TreeGrafter.
DR   InterPro; IPR050790; ExbB/TolQ_transport.
DR   InterPro; IPR002898; MotA_ExbB_proton_chnl.
DR   InterPro; IPR014164; TonB_ExbB_1.
DR   NCBIfam; TIGR02797; exbB; 1.
DR   PANTHER; PTHR30625:SF16; BIOPOLYMER TRANSPORT PROTEIN EXBB; 1.
DR   PANTHER; PTHR30625; PROTEIN TOLQ; 1.
DR   Pfam; PF01618; MotA_ExbB; 1.
PE   3: Inferred from homology;
KW   Bacteriocin transport; Cell inner membrane; Cell membrane; Membrane;
KW   Protein transport; Reference proteome; Transmembrane; Transmembrane helix;
KW   Transport.
FT   CHAIN           1..244
FT                   /note=""Biopolymer transport protein ExbB""
FT                   /id=""PRO_0000145800""
FT   TOPO_DOM        1..15
FT                   /note=""Periplasmic""
FT                   /evidence=""ECO:0000305""
FT   TRANSMEM        16..39
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000305""
FT   TOPO_DOM        40..127
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000305""
FT   TRANSMEM        128..155
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000305""
FT   TOPO_DOM        156..161
FT                   /note=""Periplasmic""
FT                   /evidence=""ECO:0000305""
FT   TRANSMEM        162..194
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000305""
FT   TOPO_DOM        195..244
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000305""
SQ   SEQUENCE   244 AA;  26287 MW;  CEB63893A80BA71F CRC64;
     MGNNLMQTDL SVWGMYQHAD IVVKCVMIGL ILASVVTWAI FFSKSVEFFN QKRRLKREQQ
     LLAEARSLNQ ANDIAADFGS KSLSLHLLNE AQNELELSEG SDDNEGIKER TSFRLERRVA
     AVGRQMGRGN GYLATIGAIS PFVGLFGTVW GIMNSFIGIA QTQTTNLAVV APGIAEALLA
     TAIGLVAAIP AVVIYNVFAR QIGGFKAMLG DVAAQVLLLQ SRDLDLEASA AAHPVRVAQK
     LRAG
//
",3911
AGTGGA GTGGAG TGGAGA GGAGAA GAGAAG AGAAGC GAAGCC AAGCCT AGCCTT GCCTTA CCTTAA CTTAAT TTAATG TAATGG AATGGG ATGGGT TGGGTG GGGTGA GGTGAT GTGATT TGATTT GATTTA ATTTAC TTTACA TTACAA TACAAT ACAATA CAATAT AATATG ATATGG TATGGA ATGGAA TGGAAT GGAATA GAATAG AATAGA ATAGAC TAGACC AGACCC GACCCA ACCCAA CCCAAA CCAAAT CAAATC AAATCG AATCGA ATCGAT TCGATT CGATTA GATTAG ATTAGC TTAGCT TAGCTG AGCTGA GCTGAA CTGAAT TGAATA GAATAT AATATG ATATGC TATGCT ATGCTG TGCTGA GCTGAT CTGATG TGATGA GATGAA ATGAAA TGAAAT GAAATT AAATTA AATTAA ATTAAG,3,73,AGTG GTGG TGGA GGAG GAGA AGAA GAAG AAGC AGCC GCCT CCTT CTTA TTAA TAAT AATG ATGG TGGG GGGT GGTG GTGA TGAT GATT ATTT TTTA TTAC TACA ACAA CAAT AATA ATAT TATG ATGG TGGA GGAA GAAT AATA ATAG TAGA AGAC GACC ACCC CCCA CCAA CAAA AAAT AATC ATCG TCGA CGAT GATT ATTA TTAG TAGC AGCT GCTG CTGA TGAA GAAT AATA ATAT TATG ATGC TGCT GCTG CTGA TGAT GATG ATGA TGAA GAAA AAAT AATT ATTA TTAA TAAG,AGTGG GTGGA TGGAG GGAGA GAGAA AGAAG GAAGC AAGCC AGCCT GCCTT CCTTA CTTAA TTAAT TAATG AATGG ATGGG TGGGT GGGTG GGTGA GTGAT TGATT GATTT ATTTA TTTAC TTACA TACAA ACAAT CAATA AATAT ATATG TATGG ATGGA TGGAA GGAAT GAATA AATAG ATAGA TAGAC AGACC GACCC ACCCA CCCAA CCAAA CAAAT AAATC AATCG ATCGA TCGAT CGATT GATTA ATTAG TTAGC TAGCT AGCTG GCTGA CTGAA TGAAT GAATA AATAT ATATG TATGC ATGCT TGCTG GCTGA CTGAT TGATG GATGA ATGAA TGAAA GAAAT AAATT AATTA ATTAA TTAAG,AGTGGA GTGGAG TGGAGA GGAGAA GAGAAG AGAAGC GAAGCC AAGCCT AGCCTT GCCTTA CCTTAA CTTAAT TTAATG TAATGG AATGGG ATGGGT TGGGTG GGGTGA GGTGAT GTGATT TGATTT GATTTA ATTTAC TTTACA TTACAA TACAAT ACAATA CAATAT AATATG ATATGG TATGGA ATGGAA TGGAAT GGAATA GAATAG AATAGA ATAGAC TAGACC AGACCC GACCCA ACCCAA CCCAAA CCAAAT CAAATC AAATCG AATCGA ATCGAT TCGATT CGATTA GATTAG ATTAGC TTAGCT TAGCTG AGCTGA GCTGAA CTGAAT TGAATA GAATAT AATATG ATATGC TATGCT ATGCTG TGCTGA GCTGAT CTGATG TGATGA GATGAA ATGAAA TGAAAT GAAATT AAATTA AATTAA ATTAAG,AGTGGAG GTGGAGA TGGAGAA GGAGAAG GAGAAGC AGAAGCC GAAGCCT AAGCCTT AGCCTTA GCCTTAA CCTTAAT CTTAATG TTAATGG TAATGGG AATGGGT ATGGGTG TGGGTGA GGGTGAT GGTGATT GTGATTT TGATTTA GATTTAC ATTTACA TTTACAA TTACAAT TACAATA ACAATAT CAATATG AATATGG ATATGGA TATGGAA ATGGAAT TGGAATA GGAATAG GAATAGA AATAGAC ATAGACC TAGACCC AGACCCA GACCCAA ACCCAAA CCCAAAT CCAAATC CAAATCG AAATCGA AATCGAT ATCGATT TCGATTA CGATTAG GATTAGC ATTAGCT TTAGCTG TAGCTGA AGCTGAA GCTGAAT CTGAATA TGAATAT GAATATG AATATGC ATATGCT TATGCTG ATGCTGA TGCTGAT GCTGATG CTGATGA TGATGAA GATGAAA ATGAAAT TGAAATT GAAATTA AAATTAA AATTAAG,"ID   PYRH_FLAPJ              Reviewed;         235 AA.
AC   A6GWS3;
DT   18-MAR-2008, integrated into UniProtKB/Swiss-Prot.
DT   24-JUL-2007, sequence version 1.
DT   05-FEB-2025, entry version 95.
DE   RecName: Full=Uridylate kinase {ECO:0000255|HAMAP-Rule:MF_01220};
DE            Short=UK {ECO:0000255|HAMAP-Rule:MF_01220};
DE            EC=2.7.4.22 {ECO:0000255|HAMAP-Rule:MF_01220};
DE   AltName: Full=Uridine monophosphate kinase {ECO:0000255|HAMAP-Rule:MF_01220};
DE            Short=UMP kinase {ECO:0000255|HAMAP-Rule:MF_01220};
DE            Short=UMPK {ECO:0000255|HAMAP-Rule:MF_01220};
GN   Name=pyrH {ECO:0000255|HAMAP-Rule:MF_01220}; OrderedLocusNames=FP0435;
OS   Flavobacterium psychrophilum (strain ATCC 49511 / DSM 21280 / CIP 103535 /
OS   JIP02/86).
OC   Bacteria; Bacteroidota; Flavobacteriia; Flavobacteriales;
OC   Flavobacteriaceae; Flavobacterium.
OX   NCBI_TaxID=402612;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 49511 / DSM 21280 / CIP 103535 / JIP02/86;
RX   PubMed=17592475; DOI=10.1038/nbt1313;
RA   Duchaud E., Boussaha M., Loux V., Bernardet J.-F., Michel C., Kerouault B.,
RA   Mondot S., Nicolas P., Bossy R., Caron C., Bessieres P., Gibrat J.-F.,
RA   Claverol S., Dumetz F., Le Henaff M., Benmansour A.;
RT   ""Complete genome sequence of the fish pathogen Flavobacterium
RT   psychrophilum."";
RL   Nat. Biotechnol. 25:763-769(2007).
CC   -!- FUNCTION: Catalyzes the reversible phosphorylation of UMP to UDP.
CC       {ECO:0000255|HAMAP-Rule:MF_01220}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=UMP + ATP = UDP + ADP; Xref=Rhea:RHEA:24400,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:57865, ChEBI:CHEBI:58223,
CC         ChEBI:CHEBI:456216; EC=2.7.4.22; Evidence={ECO:0000255|HAMAP-
CC         Rule:MF_01220};
CC   -!- ACTIVITY REGULATION: Inhibited by UTP. {ECO:0000255|HAMAP-
CC       Rule:MF_01220}.
CC   -!- PATHWAY: Pyrimidine metabolism; CTP biosynthesis via de novo pathway;
CC       UDP from UMP (UMPK route): step 1/1. {ECO:0000255|HAMAP-Rule:MF_01220}.
CC   -!- SUBUNIT: Homohexamer. {ECO:0000255|HAMAP-Rule:MF_01220}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000255|HAMAP-Rule:MF_01220}.
CC   -!- SIMILARITY: Belongs to the UMP kinase family. {ECO:0000255|HAMAP-
CC       Rule:MF_01220}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AM398681; CAL42546.1; -; Genomic_DNA.
DR   RefSeq; WP_011962604.1; NC_009613.3.
DR   RefSeq; YP_001295364.1; NC_009613.3.
DR   AlphaFoldDB; A6GWS3; -.
DR   SMR; A6GWS3; -.
DR   STRING; 402612.FP0435; -.
DR   EnsemblBacteria; CAL42546; CAL42546; FP0435.
DR   GeneID; 66551572; -.
DR   KEGG; fps:FP0435; -.
DR   PATRIC; fig|402612.5.peg.449; -.
DR   eggNOG; COG0528; Bacteria.
DR   HOGENOM; CLU_033861_0_0_10; -.
DR   OrthoDB; 9807458at2; -.
DR   UniPathway; UPA00159; UER00275.
DR   Proteomes; UP000006394; Chromosome.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0033862; F:UMP kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0044210; P:'de novo' CTP biosynthetic process; IEA:UniProtKB-UniRule.
DR   GO; GO:0006225; P:UDP biosynthetic process; IEA:TreeGrafter.
DR   CDD; cd04254; AAK_UMPK-PyrH-Ec; 1.
DR   FunFam; 3.40.1160.10:FF:000001; Uridylate kinase; 1.
DR   Gene3D; 3.40.1160.10; Acetylglutamate kinase-like; 1.
DR   HAMAP; MF_01220_B; PyrH_B; 1.
DR   InterPro; IPR036393; AceGlu_kinase-like_sf.
DR   InterPro; IPR001048; Asp/Glu/Uridylate_kinase.
DR   InterPro; IPR011817; Uridylate_kinase.
DR   InterPro; IPR015963; Uridylate_kinase_bac.
DR   NCBIfam; TIGR02075; pyrH_bact; 1.
DR   PANTHER; PTHR42833; URIDYLATE KINASE; 1.
DR   PANTHER; PTHR42833:SF4; URIDYLATE KINASE PUMPKIN, CHLOROPLASTIC; 1.
DR   Pfam; PF00696; AA_kinase; 1.
DR   PIRSF; PIRSF005650; Uridylate_kin; 1.
DR   SUPFAM; SSF53633; Carbamate kinase-like; 1.
PE   3: Inferred from homology;
KW   ATP-binding; Cytoplasm; Kinase; Nucleotide-binding;
KW   Pyrimidine biosynthesis; Reference proteome; Transferase.
FT   CHAIN           1..235
FT                   /note=""Uridylate kinase""
FT                   /id=""PRO_0000323847""
FT   BINDING         9..12
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01220""
FT   BINDING         51
FT                   /ligand=""UMP""
FT                   /ligand_id=""ChEBI:CHEBI:57865""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01220""
FT   BINDING         52
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01220""
FT   BINDING         56
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01220""
FT   BINDING         71
FT                   /ligand=""UMP""
FT                   /ligand_id=""ChEBI:CHEBI:57865""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01220""
FT   BINDING         132..139
FT                   /ligand=""UMP""
FT                   /ligand_id=""ChEBI:CHEBI:57865""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01220""
FT   BINDING         159
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01220""
FT   BINDING         165
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01220""
FT   BINDING         168
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01220""
SQ   SEQUENCE   235 AA;  25789 MW;  2FA389132E403B4C CRC64;
     MKYKRILLKL SGEALMGDRQ YGIDPKRLAE YADEIKQIHD LGVQIAIVIG GGNIFRGIAG
     ASNGMDRVQG DYMGMLATVI NGMALQGALE EKGMLTRLQT ALKIEAIAEP YIKRRAVRHL
     EKNRIVIFGA GTGNPYFTTD TAAVLRGVEV DADVILKGTR VDGIYNVDPE KNKDAVKFDN
     ISFEDVLKKG LNVMDTTAFT LSQENKLPII VFDMNKEGNL LKICKGENIG TVVNI
//
",25758
GATACT ATACTT TACTTG ACTTGT CTTGTT TTGTTT TGTTTT GTTTTG TTTTGC TTTGCT TTGCTA TGCTAA GCTAAC CTAACA TAACAA AACAAA ACAAAC CAAACA AAACAT AACATG ACATGC CATGCT ATGCTG TGCTGA GCTGAT CTGATT TGATTT GATTTT ATTTTG TTTTGA TTTGAC TTGACA TGACAC GACACA ACACAT CACATG ACATGG CATGGT ATGGTT TGGTTT GGTTTA GTTTAG TTTAGC TTAGCC TAGCCA AGCCAG GCCAGC CCAGCG CAGCGT AGCGTG GCGTGG CGTGGT GTGGTG TGGTGG GGTGGT GTGGTA TGGTAG GGTAGT GTAGTT TAGTTA AGTTAT,0,61,GATA ATAC TACT ACTT CTTG TTGT TGTT GTTT TTTT TTTG TTGC TGCT GCTA CTAA TAAC AACA ACAA CAAA AAAC AACA ACAT CATG ATGC TGCT GCTG CTGA TGAT GATT ATTT TTTT TTTG TTGA TGAC GACA ACAC CACA ACAT CATG ATGG TGGT GGTT GTTT TTTA TTAG TAGC AGCC GCCA CCAG CAGC AGCG GCGT CGTG GTGG TGGT GGTG GTGG TGGT GGTA GTAG TAGT AGTT GTTA TTAT,GATAC ATACT TACTT ACTTG CTTGT TTGTT TGTTT GTTTT TTTTG TTTGC TTGCT TGCTA GCTAA CTAAC TAACA AACAA ACAAA CAAAC AAACA AACAT ACATG CATGC ATGCT TGCTG GCTGA CTGAT TGATT GATTT ATTTT TTTTG TTTGA TTGAC TGACA GACAC ACACA CACAT ACATG CATGG ATGGT TGGTT GGTTT GTTTA TTTAG TTAGC TAGCC AGCCA GCCAG CCAGC CAGCG AGCGT GCGTG CGTGG GTGGT TGGTG GGTGG GTGGT TGGTA GGTAG GTAGT TAGTT AGTTA GTTAT,GATACT ATACTT TACTTG ACTTGT CTTGTT TTGTTT TGTTTT GTTTTG TTTTGC TTTGCT TTGCTA TGCTAA GCTAAC CTAACA TAACAA AACAAA ACAAAC CAAACA AAACAT AACATG ACATGC CATGCT ATGCTG TGCTGA GCTGAT CTGATT TGATTT GATTTT ATTTTG TTTTGA TTTGAC TTGACA TGACAC GACACA ACACAT CACATG ACATGG CATGGT ATGGTT TGGTTT GGTTTA GTTTAG TTTAGC TTAGCC TAGCCA AGCCAG GCCAGC CCAGCG CAGCGT AGCGTG GCGTGG CGTGGT GTGGTG TGGTGG GGTGGT GTGGTA TGGTAG GGTAGT GTAGTT TAGTTA AGTTAT,GATACTT ATACTTG TACTTGT ACTTGTT CTTGTTT TTGTTTT TGTTTTG GTTTTGC TTTTGCT TTTGCTA TTGCTAA TGCTAAC GCTAACA CTAACAA TAACAAA AACAAAC ACAAACA CAAACAT AAACATG AACATGC ACATGCT CATGCTG ATGCTGA TGCTGAT GCTGATT CTGATTT TGATTTT GATTTTG ATTTTGA TTTTGAC TTTGACA TTGACAC TGACACA GACACAT ACACATG CACATGG ACATGGT CATGGTT ATGGTTT TGGTTTA GGTTTAG GTTTAGC TTTAGCC TTAGCCA TAGCCAG AGCCAGC GCCAGCG CCAGCGT CAGCGTG AGCGTGG GCGTGGT CGTGGTG GTGGTGG TGGTGGT GGTGGTA GTGGTAG TGGTAGT GGTAGTT GTAGTTA TAGTTAT,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",54670
TATATA ATATAA TATAAA ATAAAA TAAAAT AAAATG AAATGG AATGGC ATGGCC TGGCCA GGCCAT GCCATG CCATGG CATGGT ATGGTA TGGTAC GGTACA GTACAT TACATT ACATTT CATTTG ATTTGG TTTGGC TTGGCT TGGCTA GGCTAG GCTAGG CTAGGT TAGGTT AGGTTT GGTTTT GTTTTA TTTTAT TTTATA TTATAG TATAGC ATAGCT TAGCTG AGCTGG GCTGGC CTGGCT TGGCTT GGCTTG GCTTGA CTTGAT TTGATT TGATTG GATTGC ATTGCC TTGCCA TGCCAT GCCATA CCATAG CATAGT ATAGTA TAGTAA AGTAAT GTAATG TAATGG AATGGT ATGGTG TGGTGA GGTGAC GTGACA TGACAA GACAAT ACAATT CAATTA AATTAT ATTATG,1,70,TATA ATAT TATA ATAA TAAA AAAA AAAT AATG ATGG TGGC GGCC GCCA CCAT CATG ATGG TGGT GGTA GTAC TACA ACAT CATT ATTT TTTG TTGG TGGC GGCT GCTA CTAG TAGG AGGT GGTT GTTT TTTT TTTA TTAT TATA ATAG TAGC AGCT GCTG CTGG TGGC GGCT GCTT CTTG TTGA TGAT GATT ATTG TTGC TGCC GCCA CCAT CATA ATAG TAGT AGTA GTAA TAAT AATG ATGG TGGT GGTG GTGA TGAC GACA ACAA CAAT AATT ATTA TTAT TATG,TATAT ATATA TATAA ATAAA TAAAA AAAAT AAATG AATGG ATGGC TGGCC GGCCA GCCAT CCATG CATGG ATGGT TGGTA GGTAC GTACA TACAT ACATT CATTT ATTTG TTTGG TTGGC TGGCT GGCTA GCTAG CTAGG TAGGT AGGTT GGTTT GTTTT TTTTA TTTAT TTATA TATAG ATAGC TAGCT AGCTG GCTGG CTGGC TGGCT GGCTT GCTTG CTTGA TTGAT TGATT GATTG ATTGC TTGCC TGCCA GCCAT CCATA CATAG ATAGT TAGTA AGTAA GTAAT TAATG AATGG ATGGT TGGTG GGTGA GTGAC TGACA GACAA ACAAT CAATT AATTA ATTAT TTATG,TATATA ATATAA TATAAA ATAAAA TAAAAT AAAATG AAATGG AATGGC ATGGCC TGGCCA GGCCAT GCCATG CCATGG CATGGT ATGGTA TGGTAC GGTACA GTACAT TACATT ACATTT CATTTG ATTTGG TTTGGC TTGGCT TGGCTA GGCTAG GCTAGG CTAGGT TAGGTT AGGTTT GGTTTT GTTTTA TTTTAT TTTATA TTATAG TATAGC ATAGCT TAGCTG AGCTGG GCTGGC CTGGCT TGGCTT GGCTTG GCTTGA CTTGAT TTGATT TGATTG GATTGC ATTGCC TTGCCA TGCCAT GCCATA CCATAG CATAGT ATAGTA TAGTAA AGTAAT GTAATG TAATGG AATGGT ATGGTG TGGTGA GGTGAC GTGACA TGACAA GACAAT ACAATT CAATTA AATTAT ATTATG,TATATAA ATATAAA TATAAAA ATAAAAT TAAAATG AAAATGG AAATGGC AATGGCC ATGGCCA TGGCCAT GGCCATG GCCATGG CCATGGT CATGGTA ATGGTAC TGGTACA GGTACAT GTACATT TACATTT ACATTTG CATTTGG ATTTGGC TTTGGCT TTGGCTA TGGCTAG GGCTAGG GCTAGGT CTAGGTT TAGGTTT AGGTTTT GGTTTTA GTTTTAT TTTTATA TTTATAG TTATAGC TATAGCT ATAGCTG TAGCTGG AGCTGGC GCTGGCT CTGGCTT TGGCTTG GGCTTGA GCTTGAT CTTGATT TTGATTG TGATTGC GATTGCC ATTGCCA TTGCCAT TGCCATA GCCATAG CCATAGT CATAGTA ATAGTAA TAGTAAT AGTAATG GTAATGG TAATGGT AATGGTG ATGGTGA TGGTGAC GGTGACA GTGACAA TGACAAT GACAATT ACAATTA CAATTAT AATTATG,"ID   SPIKE_SARS2             Reviewed;        1273 AA.
AC   P0DTC2;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Spike glycoprotein {ECO:0000255|HAMAP-Rule:MF_04099};
DE            Short=S glycoprotein {ECO:0000255|HAMAP-Rule:MF_04099};
DE   AltName: Full=E2 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   AltName: Full=Peplomer protein {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S1 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S2 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S2' {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Flags: Precursor;
GN   Name=S {ECO:0000255|HAMAP-Rule:MF_04099}; ORFNames=2;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   FUNCTION (SPIKE PROTEIN S1), AND CLEAVAGE BETWEEN S2 AND S2' BY HOST
RP   TMPRSS2.
RX   PubMed=32142651; DOI=10.1016/j.cell.2020.02.052;
RA   Hoffmann M., Kleine-Weber H., Schroeder S., Krueger N., Herrler T.,
RA   Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A.,
RA   Mueller M.A., Drosten C., Poehlmann S.;
RT   ""SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a
RT   clinically proven protease inhibitor."";
RL   Cell 181:1-10(2020).
RN   [3]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, FUNCTION, AND MUTAGENESIS OF
RP   681-PRO--ALA-684.
RX   PubMed=32362314; DOI=10.1016/j.molcel.2020.04.022;
RA   Hoffmann M., Kleine-Weber H., Poehlmann S.;
RT   ""A multibasic cleavage site in the Spike protein of SARS-CoV-2 is essential
RT   for infection of human lung cells."";
RL   Mol. Cell 78:779-784(2020).
RN   [4]
RP   GLYCOSYLATION AT ASN-17; ASN-61; ASN-74; ASN-122; ASN-149; ASN-165;
RP   ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098; ASN-1134; ASN-1158; ASN-1173 AND
RP   ASN-1194, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=32366695; DOI=10.1126/science.abb9983;
RA   Watanabe Y., Allen J.D., Wrapp D., McLellan J.S., Crispin M.;
RT   ""Site-specific glycan analysis of the SARS-CoV-2 spike."";
RL   Science 369:330-333(2020).
RN   [5]
RP   GLYCOSYLATION AT ASN-61; ASN-74; ASN-122; ASN-149; ASN-165; ASN-234;
RP   ASN-282; THR-323; SER-325; ASN-331; ASN-343; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098 AND ASN-1194, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=32363391; DOI=10.1093/glycob/cwaa042;
RA   Shajahan A., Supekar N.T., Gleinich A.S., Azadi P.;
RT   ""Deducing the N- and O- glycosylation profile of the spike protein of novel
RT   coronavirus SARS-CoV-2."";
RL   Glycobiology 30:981-988(2020).
RN   [6]
RP   VARIANT GLY-614.
RX   PubMed=32820179; DOI=10.1038/s41598-020-70827-z;
RA   Isabel S., Grana-Miraglia L., Gutierrez J.M., Bundalovic-Torma C.,
RA   Groves H.E., Isabel M.R., Eshaghi A., Patel S.N., Gubbay J.B., Poutanen T.,
RA   Guttman D.S., Poutanen S.M.;
RT   ""Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein
RT   mutation now documented worldwide."";
RL   Sci. Rep. 10:14031-14031(2020).
RN   [7]
RP   VARIANT GLY-614, AND MUTAGENESIS OF ASP-614.
RX   PubMed=32697968; DOI=10.1016/j.cell.2020.06.043;
RG   Sheffield COVID-19 Genomics Group;
RA   Korber B., Fischer W.M., Gnanakaran S., Yoon H., Theiler J., Abfalterer W.,
RA   Hengartner N., Giorgi E.E., Bhattacharya T., Foley B., Hastie K.M.,
RA   Parker M.D., Partridge D.G., Evans C.M., Freeman T.M., de Silva T.I.,
RA   McDanal C., Perez L.G., Tang H., Moon-Walker A., Whelan S.P.,
RA   LaBranche C.C., Saphire E.O., Montefiori D.C.;
RT   ""Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases
RT   Infectivity of the COVID-19 Virus."";
RL   Cell 182:812-827(2020).
RN   [8]
RP   FUNCTION.
RX   PubMed=32817270; DOI=10.1126/science.abd5223;
RA   Turonova B., Sikora M., Schuermann C., Hagen W.J.H., Welsch S.,
RA   Blanc F.E.C., von Buelow S., Gecht M., Bagola K., Hoerner C.,
RA   van Zandbergen G., Landry J., de Azevedo N.T.D., Mosalaganti S.,
RA   Schwarz A., Covino R., Muehlebach M.D., Hummer G., Krijnse Locker J.,
RA   Beck M.;
RT   ""In situ structural analysis of SARS-CoV-2 spike reveals flexibility
RT   mediated by three hinges."";
RL   Science 370:203-208(2020).
RN   [9]
RP   GLYCOSYLATION.
RX   PubMed=32929138; DOI=10.1038/s41598-020-71748-7;
RA   Grant O.C., Montgomery D., Ito K., Woods R.J.;
RT   ""Analysis of the SARS-CoV-2 spike protein glycan shield reveals
RT   implications for immune recognition."";
RL   Sci. Rep. 10:14991-14991(2020).
RN   [10]
RP   GLYCOSYLATION AT ASN-17; ASN-61; ASN-74; ASN-122; ASN-149; ASN-165;
RP   ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098; ASN-1134; ASN-1158; ASN-1173 AND
RP   ASN-1194, IDENTIFICATION BY MASS SPECTROMETRY, SUBCELLULAR LOCATION, AND
RP   SUBUNIT.
RX   PubMed=32979942; DOI=10.1016/j.cell.2020.09.018;
RA   Yao H., Song Y., Chen Y., Wu N., Xu J., Sun C., Zhang J., Weng T.,
RA   Zhang Z., Wu Z., Cheng L., Shi D., Lu X., Lei J., Crispin M., Shi Y.,
RA   Li L., Li S.;
RT   ""Molecular Architecture of the SARS-CoV-2 Virus."";
RL   Cell 183:730-738(2020).
RN   [11]
RP   VARIANT GLY-614, AND MUTAGENESIS OF ASP-614.
RX   PubMed=33106671; DOI=10.1038/s41586-020-2895-3;
RA   Plante J.A., Liu Y., Liu J., Xia H., Johnson B.A., Lokugamage K.G.,
RA   Zhang X., Muruato A.E., Zou J., Fontes-Garfias C.R., Mirchandani D.,
RA   Scharton D., Bilello J.P., Ku Z., An Z., Kalveram B., Freiberg A.N.,
RA   Menachery V.D., Xie X., Plante K.S., Weaver S.C., Shi P.Y.;
RT   ""Spike mutation D614G alters SARS-CoV-2 fitness."";
RL   Nature 592:116-121(2020).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH HUMAN NRP1 AND NRP2.
RC   STRAIN=SARS-CoV-2/human/Liverpool/REMRQ001/2020;
RX   PubMed=33082294; DOI=10.1126/science.abd3072;
RA   Daly J.L., Simonetti B., Klein K., Chen K.E., Williamson M.K.,
RA   Anton-Plagaro C., Shoemark D.K., Simon-Gracia L., Bauer M., Hollandi R.,
RA   Greber U.F., Horvath P., Sessions R.B., Helenius A., Hiscox J.A.,
RA   Teesalu T., Matthews D.A., Davidson A.D., Collins B.M., Cullen P.J.,
RA   Yamauchi Y.;
RT   ""Neuropilin-1 is a host factor for SARS-CoV-2 infection."";
RL   Science 370:861-865(2020).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH HUMAN NRP1 AND NRP2.
RC   STRAIN=SARS-CoV-2/human/Finland/1/2020;
RX   PubMed=33082293; DOI=10.1126/science.abd2985;
RA   Cantuti-Castelvetri L., Ojha R., Pedro L.D., Djannatian M., Franz J.,
RA   Kuivanen S., van der Meer F., Kallio K., Kaya T., Anastasina M., Smura T.,
RA   Levanov L., Szirovicza L., Tobi A., Kallio-Kokko H., Oesterlund P.,
RA   Joensuu M., Meunier F.A., Butcher S.J., Winkler M.S., Mollenhauer B.,
RA   Helenius A., Gokce O., Teesalu T., Hepojoki J., Vapalahti O.,
RA   Stadelmann C., Balistreri G., Simons M.;
RT   ""Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity."";
RL   Science 370:856-860(2020).
RN   [14]
RP   INTERACTION WITH HUMAN ITGA5 AND ITGB1.
RX   PubMed=33102950; DOI=10.1016/j.jacbts.2020.10.003;
RA   Beddingfield B.J., Iwanaga N., Chapagain P.P., Zheng W., Roy C.J., Hu T.Y.,
RA   Kolls J.K., Bix G.J.;
RT   ""The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2
RT   Infection."";
RL   JACC Basic Transl. Sci. 6:1-8(2021).
RN   [15]
RP   VARIANT GLY-614.
RX   PubMed=33184236; DOI=10.1126/science.abe8499;
RA   Hou Y.J., Chiba S., Halfmann P., Ehre C., Kuroda M., Dinnon K.H. III,
RA   Leist S.R., Schaefer A., Nakajima N., Takahashi K., Lee R.E.,
RA   Mascenik T.M., Graham R., Edwards C.E., Tse L.V., Okuda K., Markmann A.J.,
RA   Bartelt L., de Silva A., Margolis D.M., Boucher R.C., Randell S.H.,
RA   Suzuki T., Gralinski L.E., Kawaoka Y., Baric R.S.;
RT   ""SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and
RT   transmission in vivo."";
RL   Science 370:1464-1468(2020).
RN   [16]
RP   VARIANT GLY-614.
RX   PubMed=33417835; DOI=10.1016/j.celrep.2020.108630;
RA   Gobeil S.M., Janowska K., McDowell S., Mansouri K., Parks R., Manne K.,
RA   Stalls V., Kopp M.F., Henderson R., Edwards R.J., Haynes B.F., Acharya P.;
RT   ""D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease
RT   Cleavage at the S1/S2 Junction."";
RL   Cell Rep. 34:108630-108630(2021).
RN   [17]
RP   VARIANTS 69-VAL--PHE-70 DEL; LYS-144 DEL; TYR-501; ASP-570; GLY-614;
RP   HIS-681; ILE-716; ALA-982 AND HIS-1118.
RC   STRAIN=20I/501Y.V1, Alpha, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [18]
RP   VARIANT TYR-501.
RX   PubMed=32732280; DOI=10.1126/science.abc4730;
RA   Gu H., Chen Q., Yang G., He L., Fan H., Deng Y.Q., Wang Y., Teng Y.,
RA   Zhao Z., Cui Y., Li Y., Li X.F., Li J., Zhang N.N., Yang X., Chen S.,
RA   Guo Y., Zhao G., Wang X., Luo D.Y., Wang H., Yang X., Li Y., Han G., He Y.,
RA   Zhou X., Geng S., Sheng X., Jiang S., Sun S., Qin C.F., Zhou Y.;
RT   ""Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy."";
RL   Science 369:1603-1607(2020).
RN   [19]
RP   VARIANT GLY-614, AND MUTAGENESIS OF GLY-614.
RX   PubMed=33636719; DOI=10.1038/s41586-021-03361-1;
RA   Zhou B., Thi Nhu Thao T., Hoffmann D., Taddeo A., Ebert N., Labroussaa F.,
RA   Pohlmann A., King J., Steiner S., Kelly J.N., Portmann J., Halwe N.J.,
RA   Ulrich L., Trueeb B.S., Fan X., Hoffmann B., Wang L., Thomann L., Lin X.,
RA   Stalder H., Pozzi B., de Brot S., Jiang N., Cui D., Hossain J., Wilson M.,
RA   Keller M., Stark T.J., Barnes J.R., Dijkman R., Jores J., Benarafa C.,
RA   Wentworth D.E., Thiel V., Beer M.;
RT   ""SARS-CoV-2 spike D614G change enhances replication and transmission."";
RL   Nature 5920:122-127(2021).
RN   [20]
RP   MUTAGENESIS OF ASN-165; ASN-234; ASN-331; ASN-343; LEU-452; ALA-475;
RP   VAL-483; PHE-490 AND HIS-519.
RX   PubMed=32730807; DOI=10.1016/j.cell.2020.07.012;
RA   Li Q., Wu J., Nie J., Zhang L., Hao H., Liu S., Zhao C., Zhang Q., Liu H.,
RA   Nie L., Qin H., Wang M., Lu Q., Li X., Sun Q., Liu J., Zhang L., Li X.,
RA   Huang W., Wang Y.;
RT   ""The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and
RT   Antigenicity."";
RL   Cell 182:1284-1294(2020).
RN   [21]
RP   FUNCTION, CLEAVAGE BETWEEN S1 AND S2 BY HOST CTSL, AND INTERACTION WITH
RP   HUMAN ACE2.
RX   PubMed=32221306; DOI=10.1038/s41467-020-15562-9;
RA   Ou X., Liu Y., Lei X., Li P., Mi D., Ren L., Guo L., Guo R., Chen T.,
RA   Hu J., Xiang Z., Mu Z., Chen X., Chen J., Hu K., Jin Q., Wang J., Qian Z.;
RT   ""Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and
RT   its immune cross-reactivity with SARS-CoV."";
RL   Nat. Commun. 11:1620-1620(2020).
RN   [22]
RP   INTERACTION WITH HUMAN ACE2.
RX   PubMed=33607086; DOI=10.1016/j.bpj.2021.02.007;
RA   Cao W., Dong C., Kim S., Hou D., Tai W., Du L., Im W., Zhang X.F.;
RT   ""Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2
RT   protein-protein interaction."";
RL   Biophys. J. 120:1011-1019(2021).
RN   [23]
RP   FUNCTION, AND CLEAVAGE BETWEEN S1 AND S2 BY HOST TMPRSS2.
RX   PubMed=33465165; DOI=10.1371/journal.ppat.1009212;
RA   Ou T., Mou H., Zhang L., Ojha A., Choe H., Farzan M.;
RT   ""Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated
RT   by TMPRSS2."";
RL   PLoS Pathog. 17:e1009212-e1009212(2021).
RN   [24]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH S PROTEIN.
RX   PubMed=33229438; DOI=10.1074/jbc.ra120.016175;
RA   Boson B., Legros V., Zhou B., Siret E., Mathieu C., Cosset F.L.,
RA   Lavillette D., Denolly S.;
RT   ""The SARS-CoV-2 Envelope and Membrane proteins modulate maturation and
RT   retention of the Spike protein, allowing assembly of virus-like
RT   particles."";
RL   J. Biol. Chem. 296:100111-100111(2020).
RN   [25]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, CLEAVAGE BETWEEN S2 AND S2' BY
RP   HOST TMPRSS2, MUTAGENESIS OF ALA-684, AND FUNCTION (SPIKE PROTEIN S2').
RX   PubMed=32703818; DOI=10.26508/lsa.202000786;
RA   Bestle D., Heindl M.R., Limburg H., Van Lam van T., Pilgram O., Moulton H.,
RA   Stein D.A., Hardes K., Eickmann M., Dolnik O., Rohde C., Klenk H.D.,
RA   Garten W., Steinmetzer T., Boettcher-Friebertshaeuser E.;
RT   ""TMPRSS2 and furin are both essential for proteolytic activation of SARS-
RT   CoV-2 in human airway cells."";
RL   Life. Sci Alliance 3:1-14(2020).
RN   [26]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, CLEAVAGE BETWEEN S2 AND S2' BY
RP   HOST TMPRSS2, CLEAVAGE BETWEEN S2 AND S2' BY HOST CSTL, AND FUNCTION (SPIKE
RP   PROTEIN S2').
RX   PubMed=34159616; DOI=10.15252/embj.2021107821;
RA   Koch J., Uckeley Z.M., Doldan P., Stanifer M., Boulant S., Lozach P.Y.;
RT   ""TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect
RT   host cells."";
RL   EMBO J. 40:1-20(2021).
RN   [27]
RP   VARIANTS PHE-18; ALA-80; GLY-215; ASN-417; LYS-484; TYR-501; GLY-614 AND
RP   VAL-701.
RC   STRAIN=20H/501Y.V2, B.1.351, and Beta;
RX   PubMed=33690265; DOI=10.1038/s41586-021-03402-9;
RA   Tegally H., Wilkinson E., Giovanetti M., Iranzadeh A., Fonseca V.,
RA   Giandhari J., Doolabh D., Pillay S., San E.J., Msomi N., Mlisana K.,
RA   von Gottberg A., Walaza S., Allam M., Ismail A., Mohale T., Glass A.J.,
RA   Engelbrecht S., Van Zyl G., Preiser W., Petruccione F., Sigal A.,
RA   Hardie D., Marais G., Hsiao M., Korsman S., Davies M.A., Tyers L.,
RA   Mudau I., York D., Maslo C., Goedhals D., Abrahams S., Laguda-Akingba O.,
RA   Alisoltani-Dehkordi A., Godzik A., Wibmer C.K., Sewell B.T., Lourenco J.,
RA   Alcantara L.C.J., Kosakovsky Pond S.L., Weaver S., Martin D.,
RA   Lessells R.J., Bhiman J.N., Williamson C., de Oliveira T.;
RT   ""Emergence of a SARS-CoV-2 variant of concern with mutations in spike
RT   glycoprotein."";
RL   Nature 592:438-443(2021).
RN   [28]
RP   POLYMORPHISM.
RX   PubMed=34142653; DOI=10.2807/1560-7917.es.2021.26.24.2100509;
RA   Campbell F., Archer B., Laurenson-Schafer H., Jinnai Y., Konings F.,
RA   Batra N., Pavlin B., Vandemaele K., Van Kerkhove M.D., Jombart T.,
RA   Morgan O., le Polain de Waroux O.;
RT   ""Increased transmissibility and global spread of SARS-CoV-2 variants of
RT   concern as at June 2021."";
RL   Eurosurveillance 26:0-0(2021).
RN   [29]
RP   VARIANTS ARG-452 AND PHE-453, AND MUTAGENESIS OF LEU-452; TYR-453 AND
RP   ASN-501.
RX   PubMed=34171266; DOI=10.1016/j.chom.2021.06.006;
RG   Genotype to Phenotype Japan (G2P-Japan) Consortium;
RA   Motozono C., Toyoda M., Zahradnik J., Saito A., Nasser H., Tan T.S.,
RA   Ngare I., Kimura I., Uriu K., Kosugi Y., Yue Y., Shimizu R., Ito J.,
RA   Torii S., Yonekawa A., Shimono N., Nagasaki Y., Minami R., Toya T.,
RA   Sekiya N., Fukuhara T., Matsuura Y., Schreiber G., Ikeda T., Nakagawa S.,
RA   Ueno T., Sato K.;
RT   ""SARS-CoV-2 spike L452R variant evades cellular immunity and increases
RT   infectivity."";
RL   Cell Host Microbe 0:0-0(2021).
RN   [30]
RP   VARIANT 69-VAL--PHE-70 DEL, AND MUTAGENESIS OF 69-HIS-VAL-70.
RX   PubMed=34166617; DOI=10.1016/j.celrep.2021.109292;
RG   COVID-19 Genomics UK (COG-UK) Consortium;
RA   Meng B., Kemp S.A., Papa G., Datir R., Ferreira I.A.T.M., Marelli S.,
RA   Harvey W.T., Lytras S., Mohamed A., Gallo G., Thakur N., Collier D.A.,
RA   Mlcochova P., Duncan L.M., Carabelli A.M., Kenyon J.C., Lever A.M.,
RA   De Marco A., Saliba C., Culap K., Cameroni E., Matheson N.J., Piccoli L.,
RA   Corti D., James L.C., Robertson D.L., Bailey D., Gupta R.K.;
RT   ""Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in
RT   the Alpha variant B.1.1.7."";
RL   Cell Rep. 35:109292-109292(2021).
RN   [31]
RP   VARIANTS ILE-13 AND CYS-152, POLYMORPHISM, AND MASS SPECTROMETRY (SIGNAL).
RX   PubMed=34210893; DOI=10.1126/science.abi7994;
RA   McCallum M., Bassi J., De Marco A., Chen A., Walls A.C., Di Iulio J.,
RA   Tortorici M.A., Navarro M.J., Silacci-Fregni C., Saliba C., Sprouse K.R.,
RA   Agostini M., Pinto D., Culap K., Bianchi S., Jaconi S., Cameroni E.,
RA   Bowen J.E., Tilles S.W., Pizzuto M.S., Guastalla S.B., Bona G.,
RA   Pellanda A.F., Garzoni C., Van Voorhis W.C., Rosen L.E., Snell G.,
RA   Telenti A., Virgin H.W., Piccoli L., Corti D., Veesler D.;
RT   ""SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern."";
RL   Science 373:648-654(2021).
RN   [32]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-1269 AND HIS-1271.
RX   PubMed=34504087; DOI=10.1038/s41467-021-25589-1;
RA   Cattin-Ortola J., Welch L.G., Maslen S.L., Papa G., James L.C., Munro S.;
RT   ""Sequences in the cytoplasmic tail of SARS-CoV-2 Spike facilitate
RT   expression at the cell surface and syncytia formation."";
RL   Nat. Commun. 12:5333-5333(2021).
RN   [33]
RP   PALMITOYLATION AT CYS-1235; CYS-1236; CYS-1240; CYS-1241; CYS-1243;
RP   CYS-1247; CYS-1248; CYS-1250; CYS-1253 AND CYS-1254.
RX   PubMed=34599882; DOI=10.1016/j.devcel.2021.09.016;
RA   Mesquita F.S., Abrami L., Sergeeva O., Turelli P., Qing E., Kunz B.,
RA   Raclot C., Paz Montoya J., Abriata L.A., Gallagher T., Dal Peraro M.,
RA   Trono D., D'Angelo G., van der Goot F.G.;
RT   ""S-acylation controls SARS-CoV-2 membrane lipid organization and enhances
RT   infectivity."";
RL   Dev. Cell 56:1-18(2021).
RN   [34] {ECO:0007744|PDB:6M17}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.90 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), DOMAIN, AND INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN S1).
RX   PubMed=32132184; DOI=10.1126/science.abb2762;
RA   Yan R., Zhang Y., Li Y., Xia L., Guo Y., Zhou Q.;
RT   ""Structural basis for the recognition of the SARS-CoV-2 by full-length
RT   human ACE2."";
RL   Science 367:1444-1448(2020).
RN   [35]
RP   SUPERANTIGEN, AND DOMAIN.
RX   PubMed=32989130; DOI=10.1073/pnas.2010722117;
RA   Cheng M.H., Zhang S., Porritt R.A., Noval Rivas M., Paschold L.,
RA   Willscher E., Binder M., Arditi M., Bahar I.;
RT   ""Superantigenic character of an insert unique to SARS-CoV-2 spike supported
RT   by skewed TCR repertoire in patients with hyperinflammation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 117:25254-25262(2020).
RN   [36]
RP   INTERACTION WITH HUMAN BILIRUBIN, INTERACTION WITH HUMAN BILIVERDIN, AND
RP   MUTAGENESIS OF ASN-121 AND ARG-190.
RX   PubMed=33888467; DOI=10.1126/sciadv.abg7607;
RA   Rosa A., Pye V.E., Graham C., Muir L., Seow J., Ng K.W., Cook N.J.,
RA   Rees-Spear C., Parker E., Dos Santos M.S., Rosadas C., Susana A., Rhys H.,
RA   Nans A., Masino L., Roustan C., Christodoulou E., Ulferts R., Wrobel A.G.,
RA   Short C.E., Fertleman M., Sanders R.W., Heaney J., Spyer M., Kjaer S.,
RA   Riddell A., Malim M.H., Beale R., MacRae J.I., Taylor G.P., Nastouli E.,
RA   van Gils M.J., Rosenthal P.B., Pizzato M., McClure M.O., Tedder R.S.,
RA   Kassiotis G., McCoy L.E., Doores K.J., Cherepanov P.;
RT   ""SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity."";
RL   Sci. Adv. 7:0-0(2021).
RN   [37]
RP   BIOTECHNOLOGY, AND MUTAGENESIS OF 682-ARG--ARG-685 AND 986-LYS-VAL-987.
RX   PubMed=34322129; DOI=10.3389/fimmu.2021.701501;
RA   Martinez-Flores D., Zepeda-Cervantes J., Cruz-Resendiz A.,
RA   Aguirre-Sampieri S., Sampieri A., Vaca L.;
RT   ""SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of
RT   New Viral Variants."";
RL   Front. Immunol. 12:701501-701501(2021).
RN   [38]
RP   GLYCOSYLATION AT THR-676 AND THR-678 BY HOST GALNT1, AND MUTAGENESIS OF
RP   SER-673; THR-676; THR-678; SER-680 AND PRO-681.
RX   PubMed=34732583; DOI=10.1073/pnas.2109905118;
RA   Zhang L., Mann M., Syed Z.A., Reynolds H.M., Tian E., Samara N.L.,
RA   Zeldin D.C., Tabak L.A., Ten Hagen K.G.;
RT   ""Furin cleavage of the SARS-CoV-2 spike is modulated by O-glycosylation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [39]
RP   REVIEW, PROTEOLITIC PROCESSING, FUNCTION (SPIKE PROTEIN S2), AND FUNCTION
RP   (SPIKE PROTEIN S2').
RX   PubMed=34561887; DOI=10.1111/1348-0421.12945;
RA   Takeda M.;
RT   ""Proteolytic activation of SARS-CoV-2 spike protein."";
RL   Microbiol. Immunol. 66:15-23(2022).
RN   [40]
RP   INTERACTION WITH HOST MBL2.
RX   PubMed=35102342; DOI=10.1038/s41590-021-01114-w;
RA   Stravalaci M., Pagani I., Paraboschi E.M., Pedotti M., Doni A.,
RA   Scavello F., Mapelli S.N., Sironi M., Perucchini C., Varani L.,
RA   Matkovic M., Cavalli A., Cesana D., Gallina P., Pedemonte N., Capurro V.,
RA   Clementi N., Mancini N., Invernizzi P., Bayarri-Olmos R., Garred P.,
RA   Rappuoli R., Duga S., Bottazzi B., Uguccioni M., Asselta R., Vicenzi E.,
RA   Mantovani A., Garlanda C.;
RT   ""Recognition and inhibition of SARS-CoV-2 by humoral innate immunity
RT   pattern recognition molecules."";
RL   Nat. Immunol. 23:275-286(2022).
RN   [41]
RP   FUNCTION (SPIKE PROTEIN S1), AND INTERACTION WITH HOST INTEGRIN (SPIKE
RP   PROTEIN S1).
RX   PubMed=35150743; DOI=10.1016/j.jbc.2022.101710;
RA   Liu J., Lu F., Chen Y., Plow E., Qin J.;
RT   ""Integrin mediates cell entry of the SARS-CoV-2 virus independent of
RT   cellular receptor ACE2."";
RL   J. Biol. Chem. 1:101710-101710(2022).
RN   [42]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [43]
RP   SUBUNIT.
RX   PubMed=36735681; DOI=10.1371/journal.pbio.3001959;
RA   Shilts J., Crozier T.W.M., Teixeira-Silva A., Gabaev I., Gerber P.P.,
RA   Greenwood E.J.D., Watson S.J., Ortmann B.M., Gawden-Bone C.M., Pauzaite T.,
RA   Hoffmann M., Nathan J.A., Poehlmann S., Matheson N.J., Lehner P.J.,
RA   Wright G.J.;
RT   ""LRRC15 mediates an accessory interaction with the SARS-CoV-2 spike
RT   protein."";
RL   PLoS Biol. 21:e3001959-e3001959(2023).
RN   [44]
RP   VARIANT ASN-405.
RX   PubMed=36851546; DOI=10.3390/v15020332;
RA   Bugatti A., Filippini F., Messali S., Giovanetti M., Ravelli C., Zani A.,
RA   Ciccozzi M., Caruso A., Caccuri F.;
RT   ""The D405N Mutation in the Spike Protein of SARS-CoV-2 Omicron BA.5
RT   Inhibits Spike/Integrins Interaction and Viral Infection of Human Lung
RT   Microvascular Endothelial Cells."";
RL   Viruses 15:0-0(2023).
RN   [45]
RP   MUTAGENESIS OF GLU-484.
RX   PubMed=37421949; DOI=10.1016/j.cell.2023.06.005;
RA   Baggen J., Jacquemyn M., Persoons L., Vanstreels E., Pye V.E., Wrobel A.G.,
RA   Calvaresi V., Martin S.R., Roustan C., Cronin N.B., Reading E.,
RA   Thibaut H.J., Vercruysse T., Maes P., De Smet F., Yee A., Nivitchanyong T.,
RA   Roell M., Franco-Hernandez N., Rhinn H., Mamchak A.A., Ah Young-Chapon M.,
RA   Brown E., Cherepanov P., Daelemans D.;
RT   ""TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry."";
RL   Cell 186:1-16(2023).
RN   [46] {ECO:0007744|PDB:6VSB}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.46 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN S1), SUBUNIT, AND
RP   GLYCOSYLATION.
RX   PubMed=32075877; DOI=10.1126/science.abb2507;
RA   Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.L., Abiona O.,
RA   Graham B.S., McLellan J.S.;
RT   ""Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation."";
RL   Science 367:1260-1263(2020).
RN   [47] {ECO:0007744|PDB:6VXX, ECO:0007744|PDB:6VYB}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.80 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), SUBUNIT (SPIKE PROTEIN S1), INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN
RP   S1), MUTAGENESIS OF 679-GLN--ALA-684, GLYCOSYLATION AT ASN-61; ASN-122;
RP   ASN-61; ASN-165; ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616;
RP   ASN-657; ASN-709; ASN-717; ASN-801; ASN-1074; ASN-1098 AND ASN-1134, AND
RP   DISULFIDE BOND.
RX   PubMed=32155444; DOI=10.1016/j.cell.2020.02.058;
RA   Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., Veesler D.;
RT   ""Structure, function, and antigenicity of the SARS-CoV-2 spike
RT   glycoprotein."";
RL   Cell 180:1-12(2020).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HOST ACE2.
RX   PubMed=32225176; DOI=10.1038/s41586-020-2180-5;
RA   Lan J., Ge J., Yu J., Shan S., Zhou H., Fan S., Zhang Q., Shi X., Wang Q.,
RA   Zhang L., Wang X.;
RT   ""Structure of the SARS-CoV-2 spike receptor-binding domain bound to the
RT   ACE2 receptor."";
RL   Nature 581:215-220(2020).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.68 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HOST ACE2, INTERACTION WITH HOST ACE2, AND MUTAGENESIS OF GLN-493 AND
RP   ASN-501.
RX   PubMed=32225175; DOI=10.1038/s41586-020-2179-y;
RA   Shang J., Ye G., Shi K., Wan Y., Luo C., Aihara H., Geng Q., Auerbach A.,
RA   Li F.;
RT   ""Structural basis of receptor recognition by SARS-CoV-2."";
RL   Nature 581:221-224(2020).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (3.08 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HUMAN ANTIBODY CR3022, AND DISULFIDE BOND.
RX   PubMed=32245784; DOI=10.1126/science.abb7269;
RA   Yuan M., Wu N.C., Zhu X., Lee C.D., So R.T.Y., Lv H., Mok C.K.P.,
RA   Wilson I.A.;
RT   ""A highly conserved cryptic epitope in the receptor-binding domains of
RT   SARS-CoV-2 and SARS-CoV."";
RL   Science 368:630-633(2020).
CC   -!- FUNCTION: [Spike protein S1]: Attaches the virion to the cell membrane
CC       by interacting with host receptor, initiating the infection. The major
CC       receptor is host ACE2 (PubMed:32142651, PubMed:32155444,
CC       PubMed:33607086). When S2/S2' has been cleaved, binding to the receptor
CC       triggers direct fusion at the cell membrane (PubMed:34561887). When
CC       S2/S2' has not been cleaved, binding to the receptor results in
CC       internalization of the virus by endocytosis leading to fusion of the
CC       virion membrane with the host endosomal membrane (PubMed:32075877,
CC       PubMed:32221306). Alternatively, may use NRP1/NRP2 (PubMed:33082294,
CC       PubMed:33082293) and integrin as entry receptors (PubMed:35150743). The
CC       use of NRP1/NRP2 receptors may explain the tropism of the virus in
CC       human olfactory epithelial cells, which express these molecules at high
CC       levels but ACE2 at low levels (PubMed:33082293). The stalk domain of S
CC       contains three hinges, giving the head unexpected orientational freedom
CC       (PubMed:32817270). {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:32075877, ECO:0000269|PubMed:32142651,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32221306,
CC       ECO:0000269|PubMed:32817270, ECO:0000269|PubMed:33082293,
CC       ECO:0000269|PubMed:33082294, ECO:0000269|PubMed:35150743,
CC       ECO:0000303|PubMed:33082293, ECO:0000305|PubMed:34561887}.
CC   -!- FUNCTION: [Spike protein S2]: Precursor of the fusion protein processed
CC       in the biosynthesis of the S protein and the formation of virus
CC       particle. Mediates fusion of the virion and cellular membranes by
CC       functioning as a class I viral fusion protein. Contains two viral
CC       fusion peptides that are unmasked after cleavage. The S2/S2' cleavage
CC       occurs during virus entry at the cell membrane by host TMPRSS2
CC       (PubMed:32142651) or during endocytosis by host CSTL (PubMed:32703818,
CC       PubMed:34159616). In either case, this triggers an extensive and
CC       irreversible conformational change leading to fusion of the viral
CC       envelope with the cellular cytoplasmic membrane, releasing viral
CC       genomic RNA into the host cell cytoplasm (PubMed:34561887). Under the
CC       current model, the protein has at least three conformational states:
CC       pre-fusion native state, pre-hairpin intermediate state, and post-
CC       fusion hairpin state. During fusion of the viral and target cell
CC       membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-
CC       hairpins structure and position the fusion peptide in close proximity
CC       to the C-terminal region of the ectodomain. Formation of this structure
CC       appears to promote apposition and subsequent fusion of viral and target
CC       cell membranes. {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:32703818, ECO:0000269|PubMed:34159616,
CC       ECO:0000305|PubMed:34561887}.
CC   -!- FUNCTION: [Spike protein S2']: Subunit of the fusion protein that is
CC       processed upon entry into the host cell. Mediates fusion of the virion
CC       and cellular membranes by functioning as a class I viral fusion
CC       protein. Contains a viral fusion peptide that is unmasked after S2
CC       cleavage. This cleavage can occur at the cell membrane by host TMPRSS2
CC       or during endocytosis by host CSTL (PubMed:32703818, PubMed:34159616).
CC       In either case, this triggers an extensive and irreversible
CC       conformational change that leads to fusion of the viral envelope with
CC       the cellular cytoplasmic membrane, releasing viral genomic RNA into the
CC       host cell cytoplasm (PubMed:34561887). Under the current model, the
CC       protein has at least three conformational states: pre-fusion native
CC       state, pre-hairpin intermediate state, and post-fusion hairpin state.
CC       During fusion of the viral and target cell membranes, the coiled coil
CC       regions (heptad repeats) adopt a trimer-of-hairpins structure and
CC       position the fusion peptide in close proximity to the C-terminal region
CC       of the ectodomain. Formation of this structure appears to promote
CC       apposition and subsequent fusion of viral and target cell membranes.
CC       {ECO:0000255|HAMAP-Rule:MF_04099, ECO:0000269|PubMed:32703818,
CC       ECO:0000269|PubMed:34159616, ECO:0000305|PubMed:34561887}.
CC   -!- SUBUNIT: [Spike glycoprotein]: Homotrimer; each monomer consists of a
CC       S1 and a S2 subunit (PubMed:32075877, PubMed:32155444,
CC       PubMed:32245784). The resulting peplomers protrude from the virus
CC       surface as spikes (PubMed:32979942). Interacts with ORF3a protein and
CC       ORF7a protein (By similarity) (PubMed:32075877, PubMed:32155444,
CC       PubMed:32245784, PubMed:32979942). There are an average of 26 +/-15
CC       spike trimers at the surface of virion particles (PubMed:32979942).
CC       Binds to host MBL2 (PubMed:35102342). This binding occurs via glycans
CC       and inhibits viral infectivity. Inhibition is effective against alpha,
CC       beta, gamma, and delta variants (PubMed:35102342). {ECO:0000255|HAMAP-
CC       Rule:MF_04099, ECO:0000269|PubMed:32075877,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32245784,
CC       ECO:0000269|PubMed:32979942, ECO:0000269|PubMed:35102342}.
CC   -!- SUBUNIT: [Spike protein S1]: Binds to host ACE2 (PubMed:32075877,
CC       PubMed:32132184, PubMed:32155444, PubMed:32221306, PubMed:32225175,
CC       PubMed:32225176, PubMed:33607086). RBD also interacts with the N-linked
CC       glycan on 'Asn-90' of ACE2 (PubMed:33607086). Cleavage of S generates a
CC       polybasic C-terminal sequence on S1 that binds to host Neuropilin-1
CC       (NRP1) and Neuropilin-2 (NRP2) receptors (PubMed:33082293,
CC       PubMed:33082294). Interacts with host integrin alpha-5/beta-1
CC       (ITGA5:ITGB1) and with ACE2 in complex with integrin alpha-5/beta-1
CC       (ITGA5:ITGB1) (PubMed:33102950). May interact via cytoplasmic c-
CC       terminus with M protein (PubMed:33229438). May interact (via N-
CC       terminus) with host bilirubin and biliverdin, thereby preventing
CC       antibody binding to the SARS-CoV-2 spike NTD via an allosteric
CC       mechanism (PubMed:33888467). May interact with host LRRC15, thereby
CC       allowing attachment to host cells (PubMed:36735681).
CC       {ECO:0000269|PubMed:32075877, ECO:0000269|PubMed:32132184,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32221306,
CC       ECO:0000269|PubMed:32225",62251
CCCACC CCACCC CACCCC ACCCCG CCCCGC CCCGCC CCGCCC CGCCCC GCCCCA CCCCAG CCCAGT CCAGTC CAGTCG AGTCGT GTCGTG TCGTGG CGTGGG GTGGGC TGGGCC GGGCCG GGCCGA GCCGAC CCGACC CGACCT GACCTG ACCTGC CCTGCT CTGCTC TGCTCA GCTCAA CTCAAG TCAAGC CAAGCC AAGCCC AGCCCG GCCCGA CCCGAG CCGAGT CGAGTT GAGTTC AGTTCA GTTCAA TTCAAG TCAAGG CAAGGG AAGGGC AGGGCG GGGCGA GGCGAG GCGAGG CGAGGT GAGGTG AGGTGC GGTGCA GTGCAG TGCAGA GCAGAT CAGATG AGATGG GATGGC ATGGCC TGGCCA GGCCAA GCCAAC CCAACC CAACCC AACCCC ACCCCG CCCCGC CCCGCA CCGCAT CGCATC GCATCG CATCGA ATCGAG TCGAGC CGAGCG GAGCGG AGCGGC GCGGCA CGGCAC GGCACC GCACCG CACCGC ACCGCC CCGCCT CGCCTA GCCTAC CCTACA CTACAC TACACC ACACCA CACCAT ACCATG CCATGA CATGAT ATGATC TGATCG GATCGC ATCGCC TCGCCA CGCCAC GCCACG CCACGC CACGCT ACGCTG CGCTGG GCTGGT CTGGTG TGGTGC GGTGCA GTGCAG TGCAGA GCAGAT CAGATC AGATCA GATCAT ATCATG TCATGG CATGGG ATGGGC TGGGCG GGGCGA GGCGAG GCGAGG CGAGGA GAGGAA AGGAAA GGAAAA GAAAAA AAAAAG AAAAGC AAAGCG AAGCGT AGCGTT GCGTTC CGTTCG GTTCGA TTCGAG TCGAGT CGAGTA GAGTAC AGTACC GTACCT TACCTC,2,145,CCCA CCAC CACC ACCC CCCC CCCG CCGC CGCC GCCC CCCC CCCA CCAG CAGT AGTC GTCG TCGT CGTG GTGG TGGG GGGC GGCC GCCG CCGA CGAC GACC ACCT CCTG CTGC TGCT GCTC CTCA TCAA CAAG AAGC AGCC GCCC CCCG CCGA CGAG GAGT AGTT GTTC TTCA TCAA CAAG AAGG AGGG GGGC GGCG GCGA CGAG GAGG AGGT GGTG GTGC TGCA GCAG CAGA AGAT GATG ATGG TGGC GGCC GCCA CCAA CAAC AACC ACCC CCCC CCCG CCGC CGCA GCAT CATC ATCG TCGA CGAG GAGC AGCG GCGG CGGC GGCA GCAC CACC ACCG CCGC CGCC GCCT CCTA CTAC TACA ACAC CACC ACCA CCAT CATG ATGA TGAT GATC ATCG TCGC CGCC GCCA CCAC CACG ACGC CGCT GCTG CTGG TGGT GGTG GTGC TGCA GCAG CAGA AGAT GATC ATCA TCAT CATG ATGG TGGG GGGC GGCG GCGA CGAG GAGG AGGA GGAA GAAA AAAA AAAA AAAG AAGC AGCG GCGT CGTT GTTC TTCG TCGA CGAG GAGT AGTA GTAC TACC ACCT CCTC,CCCAC CCACC CACCC ACCCC CCCCG CCCGC CCGCC CGCCC GCCCC CCCCA CCCAG CCAGT CAGTC AGTCG GTCGT TCGTG CGTGG GTGGG TGGGC GGGCC GGCCG GCCGA CCGAC CGACC GACCT ACCTG CCTGC CTGCT TGCTC GCTCA CTCAA TCAAG CAAGC AAGCC AGCCC GCCCG CCCGA CCGAG CGAGT GAGTT AGTTC GTTCA TTCAA TCAAG CAAGG AAGGG AGGGC GGGCG GGCGA GCGAG CGAGG GAGGT AGGTG GGTGC GTGCA TGCAG GCAGA CAGAT AGATG GATGG ATGGC TGGCC GGCCA GCCAA CCAAC CAACC AACCC ACCCC CCCCG CCCGC CCGCA CGCAT GCATC CATCG ATCGA TCGAG CGAGC GAGCG AGCGG GCGGC CGGCA GGCAC GCACC CACCG ACCGC CCGCC CGCCT GCCTA CCTAC CTACA TACAC ACACC CACCA ACCAT CCATG CATGA ATGAT TGATC GATCG ATCGC TCGCC CGCCA GCCAC CCACG CACGC ACGCT CGCTG GCTGG CTGGT TGGTG GGTGC GTGCA TGCAG GCAGA CAGAT AGATC GATCA ATCAT TCATG CATGG ATGGG TGGGC GGGCG GGCGA GCGAG CGAGG GAGGA AGGAA GGAAA GAAAA AAAAA AAAAG AAAGC AAGCG AGCGT GCGTT CGTTC GTTCG TTCGA TCGAG CGAGT GAGTA AGTAC GTACC TACCT ACCTC,CCCACC CCACCC CACCCC ACCCCG CCCCGC CCCGCC CCGCCC CGCCCC GCCCCA CCCCAG CCCAGT CCAGTC CAGTCG AGTCGT GTCGTG TCGTGG CGTGGG GTGGGC TGGGCC GGGCCG GGCCGA GCCGAC CCGACC CGACCT GACCTG ACCTGC CCTGCT CTGCTC TGCTCA GCTCAA CTCAAG TCAAGC CAAGCC AAGCCC AGCCCG GCCCGA CCCGAG CCGAGT CGAGTT GAGTTC AGTTCA GTTCAA TTCAAG TCAAGG CAAGGG AAGGGC AGGGCG GGGCGA GGCGAG GCGAGG CGAGGT GAGGTG AGGTGC GGTGCA GTGCAG TGCAGA GCAGAT CAGATG AGATGG GATGGC ATGGCC TGGCCA GGCCAA GCCAAC CCAACC CAACCC AACCCC ACCCCG CCCCGC CCCGCA CCGCAT CGCATC GCATCG CATCGA ATCGAG TCGAGC CGAGCG GAGCGG AGCGGC GCGGCA CGGCAC GGCACC GCACCG CACCGC ACCGCC CCGCCT CGCCTA GCCTAC CCTACA CTACAC TACACC ACACCA CACCAT ACCATG CCATGA CATGAT ATGATC TGATCG GATCGC ATCGCC TCGCCA CGCCAC GCCACG CCACGC CACGCT ACGCTG CGCTGG GCTGGT CTGGTG TGGTGC GGTGCA GTGCAG TGCAGA GCAGAT CAGATC AGATCA GATCAT ATCATG TCATGG CATGGG ATGGGC TGGGCG GGGCGA GGCGAG GCGAGG CGAGGA GAGGAA AGGAAA GGAAAA GAAAAA AAAAAG AAAAGC AAAGCG AAGCGT AGCGTT GCGTTC CGTTCG GTTCGA TTCGAG TCGAGT CGAGTA GAGTAC AGTACC GTACCT TACCTC,CCCACCC CCACCCC CACCCCG ACCCCGC CCCCGCC CCCGCCC CCGCCCC CGCCCCA GCCCCAG CCCCAGT CCCAGTC CCAGTCG CAGTCGT AGTCGTG GTCGTGG TCGTGGG CGTGGGC GTGGGCC TGGGCCG GGGCCGA GGCCGAC GCCGACC CCGACCT CGACCTG GACCTGC ACCTGCT CCTGCTC CTGCTCA TGCTCAA GCTCAAG CTCAAGC TCAAGCC CAAGCCC AAGCCCG AGCCCGA GCCCGAG CCCGAGT CCGAGTT CGAGTTC GAGTTCA AGTTCAA GTTCAAG TTCAAGG TCAAGGG CAAGGGC AAGGGCG AGGGCGA GGGCGAG GGCGAGG GCGAGGT CGAGGTG GAGGTGC AGGTGCA GGTGCAG GTGCAGA TGCAGAT GCAGATG CAGATGG AGATGGC GATGGCC ATGGCCA TGGCCAA GGCCAAC GCCAACC CCAACCC CAACCCC AACCCCG ACCCCGC CCCCGCA CCCGCAT CCGCATC CGCATCG GCATCGA CATCGAG ATCGAGC TCGAGCG CGAGCGG GAGCGGC AGCGGCA GCGGCAC CGGCACC GGCACCG GCACCGC CACCGCC ACCGCCT CCGCCTA CGCCTAC GCCTACA CCTACAC CTACACC TACACCA ACACCAT CACCATG ACCATGA CCATGAT CATGATC ATGATCG TGATCGC GATCGCC ATCGCCA TCGCCAC CGCCACG GCCACGC CCACGCT CACGCTG ACGCTGG CGCTGGT GCTGGTG CTGGTGC TGGTGCA GGTGCAG GTGCAGA TGCAGAT GCAGATC CAGATCA AGATCAT GATCATG ATCATGG TCATGGG CATGGGC ATGGGCG TGGGCGA GGGCGAG GGCGAGG GCGAGGA CGAGGAA GAGGAAA AGGAAAA GGAAAAA GAAAAAG AAAAAGC AAAAGCG AAAGCGT AAGCGTT AGCGTTC GCGTTCG CGTTCGA GTTCGAG TTCGAGT TCGAGTA CGAGTAC GAGTACC AGTACCT GTACCTC,"ID   Y131_HAEIN              Reviewed;         346 AA.
AC   P43951;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   02-OCT-2024, entry version 110.
DE   RecName: Full=Uncharacterized protein HI_0131;
DE   Flags: Precursor;
GN   OrderedLocusNames=HI_0131;
OS   Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd).
OC   Bacteria; Pseudomonadota; Gammaproteobacteria; Pasteurellales;
OC   Pasteurellaceae; Haemophilus.
OX   NCBI_TaxID=71421;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 51907 / DSM 11121 / KW20 / Rd;
RX   PubMed=7542800; DOI=10.1126/science.7542800;
RA   Fleischmann R.D., Adams M.D., White O., Clayton R.A., Kirkness E.F.,
RA   Kerlavage A.R., Bult C.J., Tomb J.-F., Dougherty B.A., Merrick J.M.,
RA   McKenney K., Sutton G.G., FitzHugh W., Fields C.A., Gocayne J.D.,
RA   Scott J.D., Shirley R., Liu L.-I., Glodek A., Kelley J.M., Weidman J.F.,
RA   Phillips C.A., Spriggs T., Hedblom E., Cotton M.D., Utterback T.R.,
RA   Hanna M.C., Nguyen D.T., Saudek D.M., Brandon R.C., Fine L.D.,
RA   Fritchman J.L., Fuhrmann J.L., Geoghagen N.S.M., Gnehm C.L., McDonald L.A.,
RA   Small K.V., Fraser C.M., Smith H.O., Venter J.C.;
RT   ""Whole-genome random sequencing and assembly of Haemophilus influenzae
RT   Rd."";
RL   Science 269:496-512(1995).
RN   [2]
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   STRAIN=ATCC 51907 / DSM 11121 / KW20 / Rd;
RX   PubMed=10675023;
RX   DOI=10.1002/(sici)1522-2683(20000101)21:2<411::aid-elps411>3.0.co;2-4;
RA   Langen H., Takacs B., Evers S., Berndt P., Lahm H.W., Wipf B., Gray C.,
RA   Fountoulakis M.;
RT   ""Two-dimensional map of the proteome of Haemophilus influenzae."";
RL   Electrophoresis 21:411-429(2000).
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L42023; AAC21803.1; -; Genomic_DNA.
DR   PIR; D64002; D64002.
DR   PIR; E64002; E64002.
DR   RefSeq; NP_438300.1; NC_000907.1.
DR   AlphaFoldDB; P43951; -.
DR   SMR; P43951; -.
DR   STRING; 71421.HI_0131; -.
DR   EnsemblBacteria; AAC21803; AAC21803; HI_0131.
DR   KEGG; hin:HI_0131; -.
DR   PATRIC; fig|71421.8.peg.133; -.
DR   eggNOG; COG1840; Bacteria.
DR   HOGENOM; CLU_026974_0_1_6; -.
DR   OrthoDB; 305758at2; -.
DR   PhylomeDB; P43951; -.
DR   BioCyc; HINF71421:G1GJ1-141-MONOMER; -.
DR   Proteomes; UP000000579; Chromosome.
DR   GO; GO:0030288; C:outer membrane-bounded periplasmic space; IBA:GO_Central.
DR   GO; GO:0030975; F:thiamine binding; IBA:GO_Central.
DR   GO; GO:0030976; F:thiamine pyrophosphate binding; IBA:GO_Central.
DR   GO; GO:0015888; P:thiamine transport; IBA:GO_Central.
DR   CDD; cd13544; PBP2_Fbp_like_1; 1.
DR   Gene3D; 3.40.190.10; Periplasmic binding protein-like II; 2.
DR   InterPro; IPR026045; Ferric-bd.
DR   PANTHER; PTHR30006:SF2; ABC TRANSPORTER SUBSTRATE-BINDING PROTEIN; 1.
DR   PANTHER; PTHR30006; THIAMINE-BINDING PERIPLASMIC PROTEIN-RELATED; 1.
DR   Pfam; PF13343; SBP_bac_6; 1.
DR   PIRSF; PIRSF002825; CfbpA; 1.
DR   SUPFAM; SSF53850; Periplasmic binding protein-like II; 1.
PE   1: Evidence at protein level;
KW   Reference proteome; Signal.
FT   SIGNAL          1..27
FT                   /evidence=""ECO:0000255""
FT   CHAIN           28..346
FT                   /note=""Uncharacterized protein HI_0131""
FT                   /id=""PRO_0000013951""
SQ   SEQUENCE   346 AA;  37898 MW;  233AD90C54E10710 CRC64;
     MKFNKISLSV STALLAAGLA VSGSANAKGR LVVYCSATNI LCETTTKAFG EKYDVKTSFI
     RNGSGSTFAK VEAEKNNPQA DVWFGGTFDP QAQAAELGLI EPYKSKHIDE IVERFREPAK
     TKGHYVSSIY MGILGFGVNT ERLAKLGIKE VPKCWKDLTD PRLKGEVQIA DPQSAGTAYT
     ALATFVQLWG EKEAFDFLKE LHPNVSQYTK SGITPSRNSA RGEATIGVGF LHDYALEKRN
     GAPLELVVPC EGTGYELGGV SILKGARNID NAKLFVDWAL SKEGQELAWK QGDSLQILTN
     TTAEQSPTAF DPNKLKLINY DFEKYGATEQ RKALIEKWVQ EVKLAK
//
",61935
CCAGCT CAGCTG AGCTGT GCTGTT CTGTTG TGTTGC GTTGCT TTGCTA TGCTAA GCTAAA CTAAAC TAAACA AAACAT AACATG ACATGA CATGAC ATGACT TGACTT GACTTC ACTTCT CTTCTT TTCTTT TCTTTA CTTTAA TTTAAG TTAAGT TAAGTT AAGTTT AGTTTA GTTTAG TTTAGA TTAGAA TAGAAT AGAATA GAATAG AATAGA ATAGAC TAGACG AGACGG GACGGT ACGGTG CGGTGA GGTGAC GTGACA TGACAT GACATG ACATGG CATGGT ATGGTA TGGTAC GGTACC GTACCA TACCAC ACCACA CCACAT CACATA ACATAT CATATA ATATAT TATATC ATATCA TATCAC ATCACG TCACGT CACGTC ACGTCA CGTCAA GTCAAC TCAACG CAACGT AACGTC ACGTCT CGTCTT GTCTTA TCTTAC CTTACT,0,76,CCAG CAGC AGCT GCTG CTGT TGTT GTTG TTGC TGCT GCTA CTAA TAAA AAAC AACA ACAT CATG ATGA TGAC GACT ACTT CTTC TTCT TCTT CTTT TTTA TTAA TAAG AAGT AGTT GTTT TTTA TTAG TAGA AGAA GAAT AATA ATAG TAGA AGAC GACG ACGG CGGT GGTG GTGA TGAC GACA ACAT CATG ATGG TGGT GGTA GTAC TACC ACCA CCAC CACA ACAT CATA ATAT TATA ATAT TATC ATCA TCAC CACG ACGT CGTC GTCA TCAA CAAC AACG ACGT CGTC GTCT TCTT CTTA TTAC TACT,CCAGC CAGCT AGCTG GCTGT CTGTT TGTTG GTTGC TTGCT TGCTA GCTAA CTAAA TAAAC AAACA AACAT ACATG CATGA ATGAC TGACT GACTT ACTTC CTTCT TTCTT TCTTT CTTTA TTTAA TTAAG TAAGT AAGTT AGTTT GTTTA TTTAG TTAGA TAGAA AGAAT GAATA AATAG ATAGA TAGAC AGACG GACGG ACGGT CGGTG GGTGA GTGAC TGACA GACAT ACATG CATGG ATGGT TGGTA GGTAC GTACC TACCA ACCAC CCACA CACAT ACATA CATAT ATATA TATAT ATATC TATCA ATCAC TCACG CACGT ACGTC CGTCA GTCAA TCAAC CAACG AACGT ACGTC CGTCT GTCTT TCTTA CTTAC TTACT,CCAGCT CAGCTG AGCTGT GCTGTT CTGTTG TGTTGC GTTGCT TTGCTA TGCTAA GCTAAA CTAAAC TAAACA AAACAT AACATG ACATGA CATGAC ATGACT TGACTT GACTTC ACTTCT CTTCTT TTCTTT TCTTTA CTTTAA TTTAAG TTAAGT TAAGTT AAGTTT AGTTTA GTTTAG TTTAGA TTAGAA TAGAAT AGAATA GAATAG AATAGA ATAGAC TAGACG AGACGG GACGGT ACGGTG CGGTGA GGTGAC GTGACA TGACAT GACATG ACATGG CATGGT ATGGTA TGGTAC GGTACC GTACCA TACCAC ACCACA CCACAT CACATA ACATAT CATATA ATATAT TATATC ATATCA TATCAC ATCACG TCACGT CACGTC ACGTCA CGTCAA GTCAAC TCAACG CAACGT AACGTC ACGTCT CGTCTT GTCTTA TCTTAC CTTACT,CCAGCTG CAGCTGT AGCTGTT GCTGTTG CTGTTGC TGTTGCT GTTGCTA TTGCTAA TGCTAAA GCTAAAC CTAAACA TAAACAT AAACATG AACATGA ACATGAC CATGACT ATGACTT TGACTTC GACTTCT ACTTCTT CTTCTTT TTCTTTA TCTTTAA CTTTAAG TTTAAGT TTAAGTT TAAGTTT AAGTTTA AGTTTAG GTTTAGA TTTAGAA TTAGAAT TAGAATA AGAATAG GAATAGA AATAGAC ATAGACG TAGACGG AGACGGT GACGGTG ACGGTGA CGGTGAC GGTGACA GTGACAT TGACATG GACATGG ACATGGT CATGGTA ATGGTAC TGGTACC GGTACCA GTACCAC TACCACA ACCACAT CCACATA CACATAT ACATATA CATATAT ATATATC TATATCA ATATCAC TATCACG ATCACGT TCACGTC CACGTCA ACGTCAA CGTCAAC GTCAACG TCAACGT CAACGTC AACGTCT ACGTCTT CGTCTTA GTCTTAC TCTTACT,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",53431
GCCGAA CCGAAG CGAAGG GAAGGC AAGGCC AGGCCG GGCCGC GCCGCG CCGCGT CGCGTC GCGTCA CGTCAG GTCAGC TCAGCA CAGCAG AGCAGC GCAGCG CAGCGC AGCGCG GCGCGC CGCGCA GCGCAG CGCAGC GCAGCG CAGCGC AGCGCG GCGCGA CGCGAG GCGAGC CGAGCA GAGCAC AGCACG GCACGC CACGCG ACGCGC CGCGCG GCGCGC CGCGCA GCGCAG CGCAGC GCAGCC CAGCCT AGCCTG GCCTGC CCTGCT CTGCTG TGCTGG GCTGGC CTGGCC TGGCCG GGCCGC GCCGCC CCGCCG CGCCGT GCCGTG CCGTGG CGTGGG GTGGGC TGGGCC GGGCCT GGCCTG GCCTGG CCTGGC CTGGCG TGGCGC GGCGCA GCGCAG CGCAGG GCAGGC CAGGCC AGGCCA GGCCAT GCCATG CCATGG CATGGA ATGGAC TGGACA GGACAA GACAAG ACAAGC CAAGCG AAGCGT AGCGTC GCGTCC CGTCCG GTCCGG TCCGGG CCGGGG CGGGGG GGGGGA GGGGAG GGGAGC GGAGCT GAGCTG AGCTGT GCTGTC CTGTCG TGTCGG GTCGGG TCGGGC CGGGCG GGGCGG GGCGGC GCGGCA CGGCAT GGCATG GCATGC CATGCA ATGCAG TGCAGC GCAGCA CAGCAG AGCAGC GCAGCG CAGCGT AGCGTG GCGTGT CGTGTG GTGTGG TGTGGC GTGGCC TGGCCA GGCCAT GCCATT CCATTG CATTGC ATTGCC TTGCCC TGCCCG GCCCGC CCCGCG CCGCGC CGCGCA GCGCAC CGCACT GCACTG CACTGG ACTGGT CTGGTG TGGTGA GGTGAT GTGATG TGATGA GATGAA ATGAAC,2,145,GCCG CCGA CGAA GAAG AAGG AGGC GGCC GCCG CCGC CGCG GCGT CGTC GTCA TCAG CAGC AGCA GCAG CAGC AGCG GCGC CGCG GCGC CGCA GCAG CAGC AGCG GCGC CGCG GCGA CGAG GAGC AGCA GCAC CACG ACGC CGCG GCGC CGCG GCGC CGCA GCAG CAGC AGCC GCCT CCTG CTGC TGCT GCTG CTGG TGGC GGCC GCCG CCGC CGCC GCCG CCGT CGTG GTGG TGGG GGGC GGCC GCCT CCTG CTGG TGGC GGCG GCGC CGCA GCAG CAGG AGGC GGCC GCCA CCAT CATG ATGG TGGA GGAC GACA ACAA CAAG AAGC AGCG GCGT CGTC GTCC TCCG CCGG CGGG GGGG GGGG GGGA GGAG GAGC AGCT GCTG CTGT TGTC GTCG TCGG CGGG GGGC GGCG GCGG CGGC GGCA GCAT CATG ATGC TGCA GCAG CAGC AGCA GCAG CAGC AGCG GCGT CGTG GTGT TGTG GTGG TGGC GGCC GCCA CCAT CATT ATTG TTGC TGCC GCCC CCCG CCGC CGCG GCGC CGCA GCAC CACT ACTG CTGG TGGT GGTG GTGA TGAT GATG ATGA TGAA GAAC,GCCGA CCGAA CGAAG GAAGG AAGGC AGGCC GGCCG GCCGC CCGCG CGCGT GCGTC CGTCA GTCAG TCAGC CAGCA AGCAG GCAGC CAGCG AGCGC GCGCG CGCGC GCGCA CGCAG GCAGC CAGCG AGCGC GCGCG CGCGA GCGAG CGAGC GAGCA AGCAC GCACG CACGC ACGCG CGCGC GCGCG CGCGC GCGCA CGCAG GCAGC CAGCC AGCCT GCCTG CCTGC CTGCT TGCTG GCTGG CTGGC TGGCC GGCCG GCCGC CCGCC CGCCG GCCGT CCGTG CGTGG GTGGG TGGGC GGGCC GGCCT GCCTG CCTGG CTGGC TGGCG GGCGC GCGCA CGCAG GCAGG CAGGC AGGCC GGCCA GCCAT CCATG CATGG ATGGA TGGAC GGACA GACAA ACAAG CAAGC AAGCG AGCGT GCGTC CGTCC GTCCG TCCGG CCGGG CGGGG GGGGG GGGGA GGGAG GGAGC GAGCT AGCTG GCTGT CTGTC TGTCG GTCGG TCGGG CGGGC GGGCG GGCGG GCGGC CGGCA GGCAT GCATG CATGC ATGCA TGCAG GCAGC CAGCA AGCAG GCAGC CAGCG AGCGT GCGTG CGTGT GTGTG TGTGG GTGGC TGGCC GGCCA GCCAT CCATT CATTG ATTGC TTGCC TGCCC GCCCG CCCGC CCGCG CGCGC GCGCA CGCAC GCACT CACTG ACTGG CTGGT TGGTG GGTGA GTGAT TGATG GATGA ATGAA TGAAC,GCCGAA CCGAAG CGAAGG GAAGGC AAGGCC AGGCCG GGCCGC GCCGCG CCGCGT CGCGTC GCGTCA CGTCAG GTCAGC TCAGCA CAGCAG AGCAGC GCAGCG CAGCGC AGCGCG GCGCGC CGCGCA GCGCAG CGCAGC GCAGCG CAGCGC AGCGCG GCGCGA CGCGAG GCGAGC CGAGCA GAGCAC AGCACG GCACGC CACGCG ACGCGC CGCGCG GCGCGC CGCGCA GCGCAG CGCAGC GCAGCC CAGCCT AGCCTG GCCTGC CCTGCT CTGCTG TGCTGG GCTGGC CTGGCC TGGCCG GGCCGC GCCGCC CCGCCG CGCCGT GCCGTG CCGTGG CGTGGG GTGGGC TGGGCC GGGCCT GGCCTG GCCTGG CCTGGC CTGGCG TGGCGC GGCGCA GCGCAG CGCAGG GCAGGC CAGGCC AGGCCA GGCCAT GCCATG CCATGG CATGGA ATGGAC TGGACA GGACAA GACAAG ACAAGC CAAGCG AAGCGT AGCGTC GCGTCC CGTCCG GTCCGG TCCGGG CCGGGG CGGGGG GGGGGA GGGGAG GGGAGC GGAGCT GAGCTG AGCTGT GCTGTC CTGTCG TGTCGG GTCGGG TCGGGC CGGGCG GGGCGG GGCGGC GCGGCA CGGCAT GGCATG GCATGC CATGCA ATGCAG TGCAGC GCAGCA CAGCAG AGCAGC GCAGCG CAGCGT AGCGTG GCGTGT CGTGTG GTGTGG TGTGGC GTGGCC TGGCCA GGCCAT GCCATT CCATTG CATTGC ATTGCC TTGCCC TGCCCG GCCCGC CCCGCG CCGCGC CGCGCA GCGCAC CGCACT GCACTG CACTGG ACTGGT CTGGTG TGGTGA GGTGAT GTGATG TGATGA GATGAA ATGAAC,GCCGAAG CCGAAGG CGAAGGC GAAGGCC AAGGCCG AGGCCGC GGCCGCG GCCGCGT CCGCGTC CGCGTCA GCGTCAG CGTCAGC GTCAGCA TCAGCAG CAGCAGC AGCAGCG GCAGCGC CAGCGCG AGCGCGC GCGCGCA CGCGCAG GCGCAGC CGCAGCG GCAGCGC CAGCGCG AGCGCGA GCGCGAG CGCGAGC GCGAGCA CGAGCAC GAGCACG AGCACGC GCACGCG CACGCGC ACGCGCG CGCGCGC GCGCGCA CGCGCAG GCGCAGC CGCAGCC GCAGCCT CAGCCTG AGCCTGC GCCTGCT CCTGCTG CTGCTGG TGCTGGC GCTGGCC CTGGCCG TGGCCGC GGCCGCC GCCGCCG CCGCCGT CGCCGTG GCCGTGG CCGTGGG CGTGGGC GTGGGCC TGGGCCT GGGCCTG GGCCTGG GCCTGGC CCTGGCG CTGGCGC TGGCGCA GGCGCAG GCGCAGG CGCAGGC GCAGGCC CAGGCCA AGGCCAT GGCCATG GCCATGG CCATGGA CATGGAC ATGGACA TGGACAA GGACAAG GACAAGC ACAAGCG CAAGCGT AAGCGTC AGCGTCC GCGTCCG CGTCCGG GTCCGGG TCCGGGG CCGGGGG CGGGGGA GGGGGAG GGGGAGC GGGAGCT GGAGCTG GAGCTGT AGCTGTC GCTGTCG CTGTCGG TGTCGGG GTCGGGC TCGGGCG CGGGCGG GGGCGGC GGCGGCA GCGGCAT CGGCATG GGCATGC GCATGCA CATGCAG ATGCAGC TGCAGCA GCAGCAG CAGCAGC AGCAGCG GCAGCGT CAGCGTG AGCGTGT GCGTGTG CGTGTGG GTGTGGC TGTGGCC GTGGCCA TGGCCAT GGCCATT GCCATTG CCATTGC CATTGCC ATTGCCC TTGCCCG TGCCCGC GCCCGCG CCCGCGC CCGCGCA CGCGCAC GCGCACT CGCACTG GCACTGG CACTGGT ACTGGTG CTGGTGA TGGTGAT GGTGATG GTGATGA TGATGAA GATGAAC,"ID   MACB_MANSM              Reviewed;         643 AA.
AC   Q65TH4;
DT   09-JAN-2007, integrated into UniProtKB/Swiss-Prot.
DT   25-OCT-2004, sequence version 1.
DT   05-FEB-2025, entry version 129.
DE   RecName: Full=Macrolide export ATP-binding/permease protein MacB {ECO:0000255|HAMAP-Rule:MF_01720};
DE            EC=7.6.2.- {ECO:0000255|HAMAP-Rule:MF_01720};
GN   Name=macB {ECO:0000255|HAMAP-Rule:MF_01720}; OrderedLocusNames=MS1129;
OS   Mannheimia succiniciproducens (strain KCTC 0769BP / MBEL55E).
OC   Bacteria; Pseudomonadota; Gammaproteobacteria; Pasteurellales;
OC   Pasteurellaceae; Basfia.
OX   NCBI_TaxID=221988;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=KCTC 0769BP / MBEL55E;
RX   PubMed=15378067; DOI=10.1038/nbt1010;
RA   Hong S.H., Kim J.S., Lee S.Y., In Y.H., Choi S.S., Rih J.-K., Kim C.H.,
RA   Jeong H., Hur C.G., Kim J.J.;
RT   ""The genome sequence of the capnophilic rumen bacterium Mannheimia
RT   succiniciproducens."";
RL   Nat. Biotechnol. 22:1275-1281(2004).
CC   -!- FUNCTION: Part of the tripartite efflux system MacAB-TolC. MacB is a
CC       non-canonical ABC transporter that contains transmembrane domains
CC       (TMD), which form a pore in the inner membrane, and an ATP-binding
CC       domain (NBD), which is responsible for energy generation. Confers
CC       resistance against macrolides. {ECO:0000255|HAMAP-Rule:MF_01720}.
CC   -!- SUBUNIT: Homodimer. Part of the tripartite efflux system MacAB-TolC,
CC       which is composed of an inner membrane transporter, MacB, a periplasmic
CC       membrane fusion protein, MacA, and an outer membrane component, TolC.
CC       The complex forms a large protein conduit and can translocate molecules
CC       across both the inner and outer membranes. Interacts with MacA.
CC       {ECO:0000255|HAMAP-Rule:MF_01720}.
CC   -!- SUBCELLULAR LOCATION: Cell inner membrane {ECO:0000255|HAMAP-
CC       Rule:MF_01720}; Multi-pass membrane protein {ECO:0000255|HAMAP-
CC       Rule:MF_01720}.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. Macrolide
CC       exporter (TC 3.A.1.122) family. {ECO:0000255|HAMAP-Rule:MF_01720}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AE016827; AAU37736.1; -; Genomic_DNA.
DR   RefSeq; WP_011200304.1; NC_006300.1.
DR   AlphaFoldDB; Q65TH4; -.
DR   SMR; Q65TH4; -.
DR   STRING; 221988.MS1129; -.
DR   KEGG; msu:MS1129; -.
DR   eggNOG; COG0577; Bacteria.
DR   eggNOG; COG1136; Bacteria.
DR   HOGENOM; CLU_000604_78_2_6; -.
DR   OrthoDB; 9770036at2; -.
DR   Proteomes; UP000000607; Chromosome.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IEA:InterPro.
DR   GO; GO:0022857; F:transmembrane transporter activity; IEA:TreeGrafter.
DR   GO; GO:0046677; P:response to antibiotic; IEA:UniProtKB-KW.
DR   CDD; cd03255; ABC_MJ0796_LolCDE_FtsE; 1.
DR   FunFam; 3.40.50.300:FF:000032; Export ABC transporter ATP-binding protein; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR003838; ABC3_permease_C.
DR   InterPro; IPR003439; ABC_transporter-like_ATP-bd.
DR   InterPro; IPR017871; ABC_transporter-like_CS.
DR   InterPro; IPR017911; MacB-like_ATP-bd.
DR   InterPro; IPR025857; MacB_PCD.
DR   InterPro; IPR050250; Macrolide_Exporter_MacB.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   PANTHER; PTHR30572:SF14; MACROLIDE EXPORT ATP-BINDING_PERMEASE PROTEIN MACB; 1.
DR   PANTHER; PTHR30572; MEMBRANE COMPONENT OF TRANSPORTER-RELATED; 1.
DR   Pfam; PF00005; ABC_tran; 1.
DR   Pfam; PF02687; FtsX; 1.
DR   Pfam; PF12704; MacB_PCD; 1.
DR   SMART; SM00382; AAA; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 1.
DR   PROSITE; PS51267; MACB; 1.
PE   3: Inferred from homology;
KW   Antibiotic resistance; ATP-binding; Cell inner membrane; Cell membrane;
KW   Membrane; Nucleotide-binding; Translocase; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN           1..643
FT                   /note=""Macrolide export ATP-binding/permease protein MacB""
FT                   /id=""PRO_0000269946""
FT   TRANSMEM        269..289
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01720""
FT   TRANSMEM        523..543
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01720""
FT   TRANSMEM        572..592
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01720""
FT   TRANSMEM        603..623
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01720""
FT   DOMAIN          4..242
FT                   /note=""ABC transporter""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01720""
FT   BINDING         40..47
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01720""
SQ   SEQUENCE   643 AA;  69529 MW;  7A9AF8C63DB0DFA3 CRC64;
     MNIIEIKELN RYFGEGENTV HVLKNISVNI EKGDFVAIIG QSGSGKSTLM NIIGCLDTAT
     SGSYKIDGKE TNELTSDQLS DLRSQKFGFI FQRYNLLSAL TAAENVALPA IYAGKSQSER
     LARAEELLKK LGLDGKEKNK PSELSGGQQQ RVSIARALMN GGEIILADEP TGALDSHSGE
     NVLEILRQLH SEGHTIIMVT HDKNIAASAN RIIEIKDGEI IDDTQKHPVQ NTVNNQSKAK
     SRFGFSKDQL MEAFQMSVSA IIAHKMRSLL TMLGIIIGIT SVVSVVALGN GSQQKILSNI
     SGLGTNTMTI FNGTGFGDRR AEQMQNLTVN DANALAKQSY VQNVTPNSSS SGLLIYGNQS
     FTSTNLKGIG EQYFDVEGMT LKQGRSITAQ EVRDNAQVAL LDESSKKSIF PNDNPIDKIV
     MFAKRPFRII GVVADRQMGA ASSSLNIYAP YTTVMNKVTG GTKIDSITVK IADNVNTAVA
     EKSLTEYLTV RHGKKDFFIM NSDTIKQTIE STTGTMKLLI SSIAFISLIV GGIGVMNIML
     VSVTERTKEI GVRMAIGARK SNILQQFLIE AILICMIGGI SGIMLSLIIG GIFNVFMTDF
     TMVFSTFSIV AAVLCSTLIG VIFGYMPAKN AAQLDPITAL ARE
//
",29843
GCTAGA CTAGAA TAGAAT AGAATG GAATGG AATGGC ATGGCT TGGCTG GGCTGG GCTGGC CTGGCA TGGCAA GGCAAT GCAATG CAATGG AATGGC ATGGCG TGGCGG GGCGGT GCGGTG CGGTGA GGTGAT GTGATG TGATGC GATGCT ATGCTG TGCTGC GCTGCT CTGCTC TGCTCT GCTCTT CTCTTG TCTTGC CTTGCT TTGCTT TGCTTT GCTTTT CTTTTC TTTTCT TTTCTG TTCTGC TCTGCG CTGCGG TGCGGC GCGGCT CGGCTT GGCTTG GCTTGA CTTGAC TTGACA TGACAG GACAGA ACAGAC CAGACT AGACTG GACTGA ACTGAA CTGAAC TGAACC GAACCA AACCAG ACCAGC CCAGCT CAGCTT AGCTTG GCTTGA CTTGAC TTGACA TGACAG GACAGC ACAGCA CAGCAA AGCAAA GCAAAA CAAAAT AAAATT AAATTT AATTTC ATTTCT TTTCTG TTCTGG TCTGGT CTGGTA TGGTAA GGTAAA GTAAAG TAAAGG AAAGGT AAGGTC AGGTCA GGTCAA GTCAAC TCAACA CAACAA AACAAA ACAAAA CAAAAA AAAAAC AAAACA AAACAA AACAAG ACAAGG CAAGGC AAGGCC AGGCCA GGCCAA GCCAAA CCAAAA CAAAAT AAAATG AAATGG AATGGC ATGGCA TGGCAC GGCACT GCACTA CACTAA ACTAAG CTAAGA TAAGAA AAGAAA AGAAAT GAAATC AAATCT AATCTG ATCTGC TCTGCT CTGCTG TGCTGC GCTGCC CTGCCG TGCCGA GCCGAG CCGAGG CGAGGA GAGGAT AGGATT GGATTT GATTTT ATTTTA TTTTAA TTTAAA TTAAAA TAAAAA AAAAAA,1,145,GCTA CTAG TAGA AGAA GAAT AATG ATGG TGGC GGCT GCTG CTGG TGGC GGCA GCAA CAAT AATG ATGG TGGC GGCG GCGG CGGT GGTG GTGA TGAT GATG ATGC TGCT GCTG CTGC TGCT GCTC CTCT TCTT CTTG TTGC TGCT GCTT CTTT TTTT TTTC TTCT TCTG CTGC TGCG GCGG CGGC GGCT GCTT CTTG TTGA TGAC GACA ACAG CAGA AGAC GACT ACTG CTGA TGAA GAAC AACC ACCA CCAG CAGC AGCT GCTT CTTG TTGA TGAC GACA ACAG CAGC AGCA GCAA CAAA AAAA AAAT AATT ATTT TTTC TTCT TCTG CTGG TGGT GGTA GTAA TAAA AAAG AAGG AGGT GGTC GTCA TCAA CAAC AACA ACAA CAAA AAAA AAAA AAAC AACA ACAA CAAG AAGG AGGC GGCC GCCA CCAA CAAA AAAA AAAT AATG ATGG TGGC GGCA GCAC CACT ACTA CTAA TAAG AAGA AGAA GAAA AAAT AATC ATCT TCTG CTGC TGCT GCTG CTGC TGCC GCCG CCGA CGAG GAGG AGGA GGAT GATT ATTT TTTT TTTA TTAA TAAA AAAA AAAA AAAA,GCTAG CTAGA TAGAA AGAAT GAATG AATGG ATGGC TGGCT GGCTG GCTGG CTGGC TGGCA GGCAA GCAAT CAATG AATGG ATGGC TGGCG GGCGG GCGGT CGGTG GGTGA GTGAT TGATG GATGC ATGCT TGCTG GCTGC CTGCT TGCTC GCTCT CTCTT TCTTG CTTGC TTGCT TGCTT GCTTT CTTTT TTTTC TTTCT TTCTG TCTGC CTGCG TGCGG GCGGC CGGCT GGCTT GCTTG CTTGA TTGAC TGACA GACAG ACAGA CAGAC AGACT GACTG ACTGA CTGAA TGAAC GAACC AACCA ACCAG CCAGC CAGCT AGCTT GCTTG CTTGA TTGAC TGACA GACAG ACAGC CAGCA AGCAA GCAAA CAAAA AAAAT AAATT AATTT ATTTC TTTCT TTCTG TCTGG CTGGT TGGTA GGTAA GTAAA TAAAG AAAGG AAGGT AGGTC GGTCA GTCAA TCAAC CAACA AACAA ACAAA CAAAA AAAAA AAAAC AAACA AACAA ACAAG CAAGG AAGGC AGGCC GGCCA GCCAA CCAAA CAAAA AAAAT AAATG AATGG ATGGC TGGCA GGCAC GCACT CACTA ACTAA CTAAG TAAGA AAGAA AGAAA GAAAT AAATC AATCT ATCTG TCTGC CTGCT TGCTG GCTGC CTGCC TGCCG GCCGA CCGAG CGAGG GAGGA AGGAT GGATT GATTT ATTTT TTTTA TTTAA TTAAA TAAAA AAAAA AAAAA,GCTAGA CTAGAA TAGAAT AGAATG GAATGG AATGGC ATGGCT TGGCTG GGCTGG GCTGGC CTGGCA TGGCAA GGCAAT GCAATG CAATGG AATGGC ATGGCG TGGCGG GGCGGT GCGGTG CGGTGA GGTGAT GTGATG TGATGC GATGCT ATGCTG TGCTGC GCTGCT CTGCTC TGCTCT GCTCTT CTCTTG TCTTGC CTTGCT TTGCTT TGCTTT GCTTTT CTTTTC TTTTCT TTTCTG TTCTGC TCTGCG CTGCGG TGCGGC GCGGCT CGGCTT GGCTTG GCTTGA CTTGAC TTGACA TGACAG GACAGA ACAGAC CAGACT AGACTG GACTGA ACTGAA CTGAAC TGAACC GAACCA AACCAG ACCAGC CCAGCT CAGCTT AGCTTG GCTTGA CTTGAC TTGACA TGACAG GACAGC ACAGCA CAGCAA AGCAAA GCAAAA CAAAAT AAAATT AAATTT AATTTC ATTTCT TTTCTG TTCTGG TCTGGT CTGGTA TGGTAA GGTAAA GTAAAG TAAAGG AAAGGT AAGGTC AGGTCA GGTCAA GTCAAC TCAACA CAACAA AACAAA ACAAAA CAAAAA AAAAAC AAAACA AAACAA AACAAG ACAAGG CAAGGC AAGGCC AGGCCA GGCCAA GCCAAA CCAAAA CAAAAT AAAATG AAATGG AATGGC ATGGCA TGGCAC GGCACT GCACTA CACTAA ACTAAG CTAAGA TAAGAA AAGAAA AGAAAT GAAATC AAATCT AATCTG ATCTGC TCTGCT CTGCTG TGCTGC GCTGCC CTGCCG TGCCGA GCCGAG CCGAGG CGAGGA GAGGAT AGGATT GGATTT GATTTT ATTTTA TTTTAA TTTAAA TTAAAA TAAAAA AAAAAA,GCTAGAA CTAGAAT TAGAATG AGAATGG GAATGGC AATGGCT ATGGCTG TGGCTGG GGCTGGC GCTGGCA CTGGCAA TGGCAAT GGCAATG GCAATGG CAATGGC AATGGCG ATGGCGG TGGCGGT GGCGGTG GCGGTGA CGGTGAT GGTGATG GTGATGC TGATGCT GATGCTG ATGCTGC TGCTGCT GCTGCTC CTGCTCT TGCTCTT GCTCTTG CTCTTGC TCTTGCT CTTGCTT TTGCTTT TGCTTTT GCTTTTC CTTTTCT TTTTCTG TTTCTGC TTCTGCG TCTGCGG CTGCGGC TGCGGCT GCGGCTT CGGCTTG GGCTTGA GCTTGAC CTTGACA TTGACAG TGACAGA GACAGAC ACAGACT CAGACTG AGACTGA GACTGAA ACTGAAC CTGAACC TGAACCA GAACCAG AACCAGC ACCAGCT CCAGCTT CAGCTTG AGCTTGA GCTTGAC CTTGACA TTGACAG TGACAGC GACAGCA ACAGCAA CAGCAAA AGCAAAA GCAAAAT CAAAATT AAAATTT AAATTTC AATTTCT ATTTCTG TTTCTGG TTCTGGT TCTGGTA CTGGTAA TGGTAAA GGTAAAG GTAAAGG TAAAGGT AAAGGTC AAGGTCA AGGTCAA GGTCAAC GTCAACA TCAACAA CAACAAA AACAAAA ACAAAAA CAAAAAC AAAAACA AAAACAA AAACAAG AACAAGG ACAAGGC CAAGGCC AAGGCCA AGGCCAA GGCCAAA GCCAAAA CCAAAAT CAAAATG AAAATGG AAATGGC AATGGCA ATGGCAC TGGCACT GGCACTA GCACTAA CACTAAG ACTAAGA CTAAGAA TAAGAAA AAGAAAT AGAAATC GAAATCT AAATCTG AATCTGC ATCTGCT TCTGCTG CTGCTGC TGCTGCC GCTGCCG CTGCCGA TGCCGAG GCCGAGG CCGAGGA CGAGGAT GAGGATT AGGATTT GGATTTT GATTTTA ATTTTAA TTTTAAA TTTAAAA TTAAAAA TAAAAAA,"ID   NCAP_SARS2              Reviewed;         419 AA.
AC   P0DTC9;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Nucleoprotein {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=N;
DE   AltName: Full=Nucleocapsid protein {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=NC {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=Protein N {ECO:0000255|HAMAP-Rule:MF_04096};
GN   Name=N {ECO:0000255|HAMAP-Rule:MF_04096};
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   SUBCELLULAR LOCATION.
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [3] {ECO:0007744|PDB:6WZO, ECO:0007744|PDB:6WZQ}
RP   X-RAY CRYSTALLOGRAPHY (1.42 ANGSTROMS) OF 247-364, AND SUBUNIT.
RX   PubMed=32654247; DOI=10.1002/pro.3909;
RA   Ye Q., West A.M.V., Silletti S., Corbett K.D.;
RT   ""Architecture and self-assembly of the SARS-CoV-2 nucleocapsid protein."";
RL   Protein Sci. 29:1890-1901(2020).
RN   [4]
RP   REVIEW.
RX   PubMed=32974389; DOI=10.3389/fmolb.2020.00219;
RA   Nikolakaki E., Giannakouros T.;
RT   ""SR/RS Motifs as Critical Determinants of Coronavirus Life Cycle."";
RL   Front. Mol. Biosci. 7:219-219(2020).
RN   [5]
RP   VARIANTS LEU-3 AND PHE-235.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [6]
RP   FUNCTION, INTERACTION WITH HOST NLRP3, AND SUBCELLULAR LOCATION.
RX   PubMed=34341353; DOI=10.1038/s41467-021-25015-6;
RA   Pan P., Shen M., Yu Z., Ge W., Chen K., Tian M., Xiao F., Wang Z., Wang J.,
RA   Jia Y., Wang W., Wan P., Zhang J., Chen W., Lei Z., Chen X., Luo Z.,
RA   Zhang Q., Xu M., Li G., Li Y., Wu J.;
RT   ""SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce
RT   hyperinflammation."";
RL   Nat. Commun. 12:4664-4664(2021).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 41-174, AND MUTAGENESIS OF
RP   TYR-109.
RX   PubMed=32363136; DOI=10.1016/j.apsb.2020.04.009;
RA   Kang S., Yang M., Hong Z., Zhang L., Huang Z., Chen X., He S., Zhou Z.,
RA   Zhou Z., Chen Q., Yan Y., Zhang C., Shan H., Chen S.;
RT   ""Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain
RT   reveals potential unique drug targeting sites."";
RL   Acta Pharmacol. Sin. 10:1228-1238(2020).
RN   [8] {ECO:0007744|PDB:6YI3, ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT}
RP   STRUCTURE BY NMR OF 44-180, FUNCTION, AND MUTAGENESIS OF ARG-68; ARG-92;
RP   ILE-94; ARG-107; GLN-163; TYR-172 AND GLU-174.
RX   PubMed=33264373; DOI=10.1371/journal.ppat.1009100;
RA   Dinesh D.C., Chalupska D., Silhan J., Koutna E., Nencka R., Veverka V.,
RA   Boura E.;
RT   ""Structural basis of RNA recognition by the SARS-CoV-2 nucleocapsid
RT   phosphoprotein."";
RL   PLoS Pathog. 16:1-16(2020).
RN   [9]
RP   MUTAGENESIS OF SER-188 AND SER-206, AND PHOSPHORYLATION AT SER-206.
RX   PubMed=34593624; DOI=10.1073/pnas.2113401118;
RA   Liu X., Verma A., Garcia G. Jr., Ramage H., Lucas A., Myers R.L.,
RA   Michaelson J.J., Coryell W., Kumar A., Charney A.W., Kazanietz M.G.,
RA   Rader D.J., Ritchie M.D., Berrettini W.H., Schultz D.C., Cherry S.,
RA   Damoiseaux R., Arumugaswami V., Klein P.S.;
RT   ""Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:1-9(2021).
RN   [10]
RP   CLEAVAGE.
RX   PubMed=35922005; DOI=10.1038/s41586-022-05148-4;
RA   Chu H., Hou Y., Yang D., Wen L., Shuai H., Yoon C., Shi J., Chai Y.,
RA   Yuen T.T., Hu B., Li C., Zhao X., Wang Y., Huang X., Lee K.S., Luo C.,
RA   Cai J.P., Poon V.K., Chan C.C., Zhang A.J., Yuan S., Sit K.Y., Foo D.C.,
RA   Au W.K., Wong K.K., Zhou J., Kok K.H., Jin D.Y., Chan J.F., Yuen K.Y.;
RT   ""Coronaviruses exploit a host cysteine-aspartic protease for replication."";
RL   Nature 0:0-0(2022).
RN   [11]
RP   MUTAGENESIS OF 203-ARG-GLY-204 AND ARG-203, AND PHOSPHORYLATION.
RX   PubMed=35728038; DOI=10.1371/journal.ppat.1010627;
RA   Johnson B.A., Zhou Y., Lokugamage K.G., Vu M.N., Bopp N.,
RA   Crocquet-Valdes P.A., Kalveram B., Schindewolf C., Liu Y., Scharton D.,
RA   Plante J.A., Xie X., Aguilar P., Weaver S.C., Shi P.Y., Walker D.H.,
RA   Routh A.L., Plante K.S., Menachery V.D.;
RT   ""Nucleocapsid mutations in SARS-CoV-2 augment replication and
RT   pathogenesis."";
RL   PLoS Pathog. 18:e1010627-e1010627(2022).
RN   [12]
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=35921414; DOI=10.1126/sciadv.abp9770;
RA   Lopez-Munoz A.D., Kosik I., Holly J., Yewdell J.W.;
RT   ""Cell surface SARS-CoV-2 nucleocapsid protein modulates innate and adaptive
RT   immunity."";
RL   Sci. Adv. 8:eabp9770-eabp9770(2022).
RN   [13]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=34901782; DOI=10.1016/j.isci.2021.103562;
RA   Nabeel-Shah S., Lee H., Ahmed N., Burke G.L., Farhangmehr S., Ashraf K.,
RA   Pu S., Braunschweig U., Zhong G., Wei H., Tang H., Yang J., Marcon E.,
RA   Blencowe B.J., Zhang Z., Greenblatt J.F.;
RT   ""SARS-CoV-2 nucleocapsid protein binds host mRNAs and attenuates stress
RT   granules to impair host stress response."";
RL   IScience 25:103562-103562(2022).
RN   [14]
RP   FUNCTION.
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [15] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 191-263, AND INTERACTION WITH NSP3.
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
CC   -!- FUNCTION: Packages the positive strand viral genome RNA into a helical
CC       ribonucleocapsid (RNP) and plays a fundamental role during virion
CC       assembly through its interactions with the viral genome and membrane
CC       protein M (PubMed:33264373). Plays an important role in enhancing the
CC       efficiency of subgenomic viral RNA transcription as well as viral
CC       replication. Attenuates the stress granules formation by reducing host
CC       G3BP1 access to host mRNAs under stress conditions (PubMed:34901782,
CC       PubMed:36534661). {ECO:0000269|PubMed:32974389,
CC       ECO:0000269|PubMed:33264373, ECO:0000269|PubMed:34901782,
CC       ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: May block host chemokine function in vivo, facilitating viral
CC       replication and transmission (PubMed:35921414). Acts by being secreted
CC       into the extracellular space where it competes to host chemokines for
CC       binding to host glycosaminoglycans (GAG) (PubMed:35921414).
CC       {ECO:0000269|PubMed:35921414}.
CC   -!- FUNCTION: May induce inflammasome responses in cultured cells and mice.
CC       Acts by interacting with host NLRP3 to facilitate inflammasome
CC       assembly, which induces cytokine release that may play a role in COVID
CC       lung injury. {ECO:0000269|PubMed:34341353}.
CC   -!- SUBUNIT: Homodimer, homotetramer, homooligomer with RNA
CC       (PubMed:32654247). Both monomeric and oligomeric forms interact with
CC       RNA. Interacts with protein M (By similarity). Interacts with protein E
CC       (By similarity). Interacts with NSP3; this interaction serves to tether
CC       the genome to the newly translated replicase-transcriptase complex at a
CC       very early stage of infection (PubMed:35044811). May interact with host
CC       NLRP3 (PubMed:34341353). {ECO:0000250|UniProtKB:P59595,
CC       ECO:0000255|HAMAP-Rule:MF_04096, ECO:0000269|PubMed:32654247,
CC       ECO:0000269|PubMed:34341353, ECO:0000269|PubMed:35044811}.
CC   -!- INTERACTION:
CC       P0DTC9; P0DTC4: E; NbExp=3; IntAct=EBI-25475856, EBI-25475850;
CC       P0DTC9; P0DTC5: M; NbExp=6; IntAct=EBI-25475856, EBI-25475853;
CC       P0DTC9; P0DTC9: N; NbExp=105; IntAct=EBI-25475856, EBI-25475856;
CC       P0DTC9; PRO_0000449621 [P0DTD1]: rep; NbExp=15; IntAct=EBI-25475856, EBI-25492388;
CC       P0DTC9; P78563: ADARB1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-2967304;
CC       P0DTC9; O15145: ARPC3; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-351829;
CC       P0DTC9; Q13895: BYSL; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-358049;
CC       P0DTC9; Q16543: CDC37; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-295634;
CC       P0DTC9; Q92793: CREBBP; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-81215;
CC       P0DTC9; Q92499: DDX1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-358474;
CC       P0DTC9; Q9NR30: DDX21; Xeno; NbExp=12; IntAct=EBI-25475856, EBI-357942;
CC       P0DTC9; P26196: DDX6; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-351257;
CC       P0DTC9; Q08426: EHHADH; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-2339219;
CC       P0DTC9; P19525: EIF2AK2; Xeno; NbExp=8; IntAct=EBI-25475856, EBI-640775;
CC       P0DTC9; Q14241: ELOA; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-742350;
CC       P0DTC9; Q13283: G3BP1; Xeno; NbExp=71; IntAct=EBI-25475856, EBI-1047359;
CC       P0DTC9; Q9UN86: G3BP2; Xeno; NbExp=37; IntAct=EBI-25475856, EBI-1044298;
CC       P0DTC9; P57764: GSDMD; Xeno; NbExp=13; IntAct=EBI-25475856, EBI-2798865;
CC       P0DTC9; P49841: GSK3B; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-373586;
CC       P0DTC9; P10412: H1-4; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-358163;
CC       P0DTC9; O14920: IKBKB; Xeno; NbExp=7; IntAct=EBI-25475856, EBI-81266;
CC       P0DTC9; Q92830: KAT2A; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-477622;
CC       P0DTC9; Q92831: KAT2B; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-477430;
CC       P0DTC9; Q07866: KLC1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-721019;
CC       P0DTC9; Q9H0B6: KLC2; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-726994;
CC       P0DTC9; Q9NSK0: KLC4; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-949319;
CC       P0DTC9; Q9NX58: LYAR; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-713507;
CC       P0DTC9; O43318: MAP3K7; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-358684;
CC       P0DTC9; Q9UBU8: MORF4L1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-399246;
CC       P0DTC9; Q15014: MORF4L2; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-399257;
CC       P0DTC9; Q9HCE1: MOV10; Xeno; NbExp=11; IntAct=EBI-25475856, EBI-1055820;
CC       P0DTC9; Q9HC36: MRM3; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-1045440;
CC       P0DTC9; O15226: NKRF; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-766011;
CC       P0DTC9; Q96P20: NLRP3; Xeno; NbExp=18; IntAct=EBI-25475856, EBI-6253230;
CC       P0DTC9; O15118: NPC1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-2368710;
CC       P0DTC9; Q96HA8: NTAQ1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-741158;
CC       P0DTC9; P11940: PABPC1; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-81531;
CC       P0DTC9; P62937: PPIA; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-437708;
CC       P0DTC9; O75569: PRKRA; Xeno; NbExp=8; IntAct=EBI-25475856, EBI-713955;
CC       P0DTC9; Q99873: PRMT1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-78738;
CC       P0DTC9; P61289: PSME3; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-355546;
CC       P0DTC9; P26022: PTX3; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-11574553;
CC       P0DTC9; P54727: RAD23B; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-954531;
CC       P0DTC9; O95786: RIGI; Xeno; NbExp=15; IntAct=EBI-25475856, EBI-995350;
CC       P0DTC9; P62899: RPL31; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-1053664;
CC       P0DTC9; P62753: RPS6; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-356625;
CC       P0DTC9; P37840: SNCA; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-985879;
CC       P0DTC9; Q96SB4: SRPK1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-539478;
CC       P0DTC9; P78362: SRPK2; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-593303;
CC       P0DTC9; P42224: STAT1; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-1057697;
CC       P0DTC9; P52630: STAT2; Xeno; NbExp=7; IntAct=EBI-25475856, EBI-1546963;
CC       P0DTC9; Q15633: TARBP2; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-978581;
CC       P0DTC9; Q14258: TRIM25; Xeno; NbExp=13; IntAct=EBI-25475856, EBI-2341129;
CC       P0DTC9; O60763: USO1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-356164;
CC       P0DTC9; Q93008: USP9X; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-302524;
CC   -!- SUBCELLULAR LOCATION: Virion {ECO:0000255|HAMAP-Rule:MF_04096}. Host
CC       cytoplasm {ECO:0000269|PubMed:33060197, ECO:0000269|PubMed:34341353}.
CC       Secreted {ECO:0000269|PubMed:35921414}. Host extracellular space
CC       {ECO:0000269|PubMed:35921414}. Note=Probably associates with ER-derived
CC       membranes where it participates in viral RNA synthesis and virus
CC       budding. When located inside the virion, complexed with the viral RNA.
CC       Can be secreted by unconventional protein secretion (UPS)
CC       (PubMed:35921414). When secreted, can bind to host glycosaminoglycans
CC       on infected and non infected cells (PubMed:35921414). Found in host
CC       cytoplasmic stress granules (PubMed:34901782). {ECO:0000255|HAMAP-
CC       Rule:MF_04096, ECO:0000269|PubMed:34901782,
CC       ECO:0000269|PubMed:35921414}.
CC   -!- PTM: ADP-ribosylated. The ADP-ribosylation is retained in the virion
CC       during infection. {ECO:0000255|HAMAP-Rule:MF_04096}.
CC   -!- PTM: Phosphorylated on serine residues by host GSK3A and GSK3B
CC       (PubMed:34593624, PubMed:35728038). This promotes the solubility of
CC       homodimers that would otherwise aggregate (PubMed:32974389). Host
CC       phosphatase would dephosphorylate the protein during assembly at M
CC       bound membranes (PubMed:32974389). {ECO:0000269|PubMed:34593624,
CC       ECO:0000269|PubMed:35728038, ECO:0000305|PubMed:32974389}.
CC   -!- PTM: Proteolytically cleaved by host CASP6. The cleavage leads to two
CC       fragments and facilitates viral replication by inhibiting host IFN
CC       signaling. The two fragments may interact with IRF3 inhibiting its
CC       nuclear translocation after activation and reduce the expression of
CC       IFNB and IFN-stimulated genes. {ECO:0000269|PubMed:35922005}.
CC   -!- POLYMORPHISM: Variant Alpha/B.1.1.7 belongs to a lineage isolated first
CC       in United Kingdom (December 2020). It is also called Variant of Concern
CC       (VOC) 202012/01, Variant Under Investigation (VUI) 202012/01, 501Y.V1
CC       or 20B/501Y.V1. {ECO:0000305|PubMed:33413740}.
CC   -!- POLYMORPHISM: Variant Omicron/BA.1 and BA.2 belong to a lineage first
CC       isolated in South Africa (November 2021). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/BQ.1.1 belongs to a lineage first
CC       isolated in Nigeria (November 2022). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/XBB.1.5 belongs to a lineage first
CC       isolated in United States (November 2022). It is the result of
CC       recombination between omicron BJ.1 and BM.1.1. Moreover XBB.1.5 do not
CC       express ORF8. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the betacoronavirus nucleocapsid protein family.
CC       {ECO:0000255|HAMAP-Rule:MF_04096}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43423.2; -; Genomic_RNA.
DR   PDB; 6M3M; X-ray; 2.70 A; A/B/C/D=41-174.
DR   PDB; 6VYO; X-ray; 1.70 A; A/B/C/D=47-173.
DR   PDB; 6WJI; X-ray; 2.05 A; A/B/C/D/E/F=257-364.
DR   PDB; 6WKP; X-ray; 2.67 A; A/B/C/D=47-173.
DR   PDB; 6WZO; X-ray; 1.42 A; A/B/C/D=247-364.
DR   PDB; 6WZQ; X-ray; 1.45 A; A/B/C/D=247-364.
DR   PDB; 6YI3; NMR; -; A=44-180.
DR   PDB; 6YUN; X-ray; 1.44 A; A/B=249-364.
DR   PDB; 6ZCO; X-ray; 1.36 A; A=247-364.
DR   PDB; 7ACS; NMR; -; A=44-180.
DR   PDB; 7ACT; NMR; -; A=44-180.
DR   PDB; 7C22; X-ray; 2.00 A; A/B/C/D=248-364.
DR   PDB; 7CDZ; X-ray; 1.80 A; A/B/C/D=44-174.
DR   PDB; 7CE0; X-ray; 1.50 A; A/B/C/D=255-364.
DR   PDB; 7CR5; X-ray; 2.08 A; A=41-174.
DR   PDB; 7DE1; X-ray; 2.00 A; A/B=250-364.
DR   PDB; 7F2B; X-ray; 2.00 A; A/B=257-362.
DR   PDB; 7F2E; X-ray; 3.10 A; A/B/C/D/E/F/G/H/I/J/K/L=255-362.
DR   PDB; 7KGO; X-ray; 2.15 A; C=351-359.
DR   PDB; 7KGP; X-ray; 1.40 A; C=316-324.
DR   PDB; 7KGQ; X-ray; 1.34 A; C=222-230.
DR   PDB; 7KGR; X-ray; 1.55 A; C=159-167.
DR   PDB; 7KGS; X-ray; 1.58 A; C=138-146.
DR   PDB; 7KGT; X-ray; 1.90 A; C=226-234.
DR   PDB; 7LGD; X-ray; 2.88 A; E/F=105-113.
DR   PDB; 7LTU; X-ray; 1.12 A; A/B=217-222.
DR   PDB; 7LUX; X-ray; 1.30 A; A=217-222.
DR   PDB; 7LUZ; X-ray; 1.10 A; A=243-248.
DR   PDB; 7LV2; X-ray; 1.30 A; A=179-184.
DR   PDB; 7N0I; X-ray; 2.20 A; A/B/C/D/E/F/G/H=269-364.
DR   PDB; 7N0R; X-ray; 1.42 A; A/B=49-174.
DR   PDB; 7N3C; X-ray; 1.82 A; C=47-173.
DR   PDB; 7N3D; X-ray; 1.53 A; C=47-173.
DR   PDB; 7O05; X-ray; 1.94 A; A/B/C/D=247-364.
DR   PDB; 7O35; X-ray; 1.80 A; A/B/C/D=247-364.
DR   PDB; 7O36; X-ray; 2.00 A; A/B/C/D=247-364.
DR   PDB; 7PKU; NMR; -; B=191-263.
DR   PDB; 7QIK; X-ray; 2.01 A; E/F=193-200.
DR   PDB; 7QIP; X-ray; 2.65 A; C/D=201-210.
DR   PDB; 7R98; X-ray; 2.51 A; A/B/C=49-174.
DR   PDB; 7SD4; NMR; -; A=40-174.
DR   PDB; 7STR; X-ray; 1.50 A; C=47-173.
DR   PDB; 7STS; X-ray; 2.16 A; C/D=47-173.
DR   PDB; 7SUE; X-ray; 2.90 A; C/D/J/K=47-173.
DR   PDB; 7SUO; X-ray; 2.35 A; C/D=12-22.
DR   PDB; 7UW3; X-ray; 1.70 A; A/B/C/D=40-174.
DR   PDB; 7UXX; X-ray; 1.85 A; AAA/BBB/CCC/DDD/EEE/FFF=251-364.
DR   PDB; 7UXZ; X-ray; 1.73 A; AAA/BBB/CCC/DDD/EEE/FFF=251-364.
DR   PDB; 7VBD; X-ray; 1.94 A; A/B/C/D=48-174.
DR   PDB; 7VBE; X-ray; 1.59 A; A/B=257-364.
DR   PDB; 7VBF; X-ray; 1.30 A; A/B=255-364.
DR   PDB; 7VNU; X-ray; 1.95 A; A/B/C/D=47-174.
DR   PDB; 7WKJ; X-ray; 1.50 A; C=361-369.
DR   PDB; 7WZO; X-ray; 2.64 A; A=47-174.
DR   PDB; 7XWX; X-ray; 3.00 A; A/B/C/D/E/F/G/H=269-367.
DR   PDB; 7XWZ; X-ray; 2.25 A; A/B=48-172.
DR   PDB; 7XX1; X-ray; 1.90 A; A/B/C/D=49-173.
DR   PDB; 7XXK; X-ray; 2.00 A; A/B/C/D/E/F=248-364.
DR   PDB; 7YLB; X-ray; 2.41 A; A/B/C/D/G/H/J/K=247-364.
DR   PDB; 7YLD; X-ray; 2.80 A; A/B/C/D=47-174.
DR   PDB; 7ZIT; X-ray; 1.79 A; C/D=194-200.
DR   PDB; 8DNT; X-ray; 3.18 A; D/J/Q/X=222-230.
DR   PDB; 8FD5; EM; 4.57 A; A=1-419.
DR   PDB; 8FG2; EM; 6.00 A; A/B=1-419.
DR   PDB; 8IQJ; X-ray; 2.30 A; A/B/C/D=41-174.
DR   PDB; 8IV3; X-ray; 1.90 A; A/B/C/D=41-174.
DR   PDB; 8J6X; X-ray; 2.70 A; A/B/C/D=41-174.
DR   PDB; 8TH1; X-ray; 1.80 A; E/F/G/H=1-25.
DR   PDB; 8TH5; X-ray; 2.62 A; K/L/M/N/O/P/Q=1-25.
DR   PDB; 8X1H; X-ray; 2.00 A; A/B/C/D=44-175.
DR   PDBsum; 6M3M; -.
DR   PDBsum; 6VYO; -.
DR   PDBsum; 6WJI; -.
DR   PDBsum; 6WKP; -.
DR   PDBsum; 6WZO; -.
DR   PDBsum; 6WZQ; -.
DR   PDBsum; 6YI3; -.
DR   PDBsum; 6YUN; -.
DR   PDBsum; 6ZCO; -.
DR   PDBsum; 7ACS; -.
DR   PDBsum; 7ACT; -.
DR   PDBsum; 7C22; -.
DR   PDBsum; 7CDZ; -.
DR   PDBsum; 7CE0; -.
DR   PDBsum; 7CR5; -.
DR   PDBsum; 7DE1; -.
DR   PDBsum; 7F2B; -.
DR   PDBsum; 7F2E; -.
DR   PDBsum; 7KGO; -.
DR   PDBsum; 7KGP; -.
DR   PDBsum; 7KGQ; -.
DR   PDBsum; 7KGR; -.
DR   PDBsum; 7KGS; -.
DR   PDBsum; 7KGT; -.
DR   PDBsum; 7LGD; -.
DR   PDBsum; 7LTU; -.
DR   PDBsum; 7LUX; -.
DR   PDBsum; 7LUZ; -.
DR   PDBsum; 7LV2; -.
DR   PDBsum; 7N0I; -.
DR   PDBsum; 7N0R; -.
DR   PDBsum; 7N3C; -.
DR   PDBsum; 7N3D; -.
DR   PDBsum; 7O05; -.
DR   PDBsum; 7O35; -.
DR   PDBsum; 7O36; -.
DR   PDBsum; 7PKU; -.
DR   PDBsum; 7QIK; -.
DR   PDBsum; 7QIP; -.
DR   PDBsum; 7R98; -.
DR   PDBsum; 7SD4; -.
DR   PDBsum; 7STR; -.
DR   PDBsum; 7STS; -.
DR   PDBsum; 7SUE; -.
DR   PDBsum; 7SUO; -.
DR   PDBsum; 7UW3; -.
DR   PDBsum; 7UXX; -.
DR   PDBsum; 7UXZ; -.
DR   PDBsum; 7VBD; -.
DR   PDBsum; 7VBE; -.
DR   PDBsum; 7VBF; -.
DR   PDBsum; 7VNU; -.
DR   PDBsum; 7WKJ; -.
DR   PDBsum; 7WZO; -.
DR   PDBsum; 7XWX; -.
DR   PDBsum; 7XWZ; -.
DR   PDBsum; 7XX1; -.
DR   PDBsum; 7XXK; -.
DR   PDBsum; 7YLB; -.
DR   PDBsum; 7YLD; -.
DR   PDBsum; 7ZIT; -.
DR   PDBsum; 8DNT; -.
DR   PDBsum; 8FD5; -.
DR   PDBsum; 8FG2; -.
DR   PDBsum; 8IQJ; -.
DR   PDBsum; 8IV3; -.
DR   PDBsum; 8J6X; -.
DR   PDBsum; 8TH1; -.
DR   PDBsum; 8TH5; -.
DR   PDBsum; 8X1H; -.
DR   BMRB; P0DTC9; -.
DR   EMDB; EMD-29002; -.
DR   EMDB; EMD-29072; -.
DR   SASBDB; P0DTC9; -.
DR   SMR; P0DTC9; -.
DR   BioGRID; 4383847; 1532.
DR   ComplexPortal; CPX-5686; SARS-CoV-2 nucleocapsid complex.
DR   IntAct; P0DTC9; 608.
DR   MINT; P0DTC9; -.
DR   ChEMBL; CHEMBL5169223; -.
DR   iPTMnet; P0DTC9; -.
DR   ABCD; P0DTC9; 27 sequenced antibodies.
DR   DNASU; 43740575; -.
DR   KEGG; vg:43740575; -.
DR   AGR; RefSeq:YP_009724397; -.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-HSA-168928; DDX58/IFIH1-mediated induction of interferon-alpha/beta.
DR   Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-HSA-445989; TAK1-dependent IKK and NF-kappa-B activation.
DR   Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-HSA-9020702; Interleukin-1 signaling.
DR   Reactome; R-HSA-909733; Interferon alpha/beta signaling.
DR   Reactome; R-HSA-9694322; Virion Assembly and Release.
DR   Reactome; R-HSA-9694614; Attachment and Entry.
DR   Reactome; R-HSA-9694631; Maturation of nucleoprotein.
DR   Reactome; R-HSA-9694635; Translation of Structural Proteins.
DR   Reactome; R-HSA-9694786; Transcription of SARS-CoV-2 sgRNAs.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   Reactome; R-HSA-9733458; Induction of Cell-Cell Fusion.
DR   Reactome; R-HSA-9755779; SARS-CoV-2 targets host intracellular signalling and regulatory pathways.
DR   SIGNOR; P0DTC9; -.
DR   PRO; PR:P0DTC9; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProt.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0044172; C:host cell endoplasmic reticulum-Golgi intermediate compartment; ISS:UniProtKB.
DR   GO; GO:0044177; C:host cell Golgi apparatus; ISS:UniProtKB.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; ISS:UniProtKB.
DR   GO; GO:0043655; C:host extracellular space; IEA:UniProtKB-SubCell.
DR   GO; GO:0043232; C:intracellular non-membrane-bounded organelle; IDA:DisProt.
DR   GO; GO:0042612; C:MHC class I protein complex; EXP:DisProt.
DR   GO; GO:1990904; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IPI:ComplexPortal.
DR   GO; GO:0019013; C:viral nucleocapsid; ISS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0042288; F:MHC class I protein binding; EXP:DisProt.
DR   GO; GO:0140693; F:molecular condensate scaffold activity; IDA:DisProt.
DR   GO; GO:0008266; F:poly(U) RNA binding; IMP:DisProt.
DR   GO; GO:0042803; F:protein homodimerization activity; EXP:DisProt.
DR   GO; GO:0140311; F:protein sequestering activity; IDA:UniProt.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProt.
DR   GO; GO:0035613; F:RNA stem-loop binding; IDA:DisProt.
DR   GO; GO:0039709; P:cytoplasmic capsid assembly; IDA:UniProt.
DR   GO; GO:0032688; P:negative regulation of interferon-beta production; IDA:ComplexPortal.
DR   GO; GO:1900227; P:positive regulation of NLRP3 inflammasome complex assembly; IDA:UniProtKB.
DR   GO; GO:0052572; P:response to host immune response; IDA:DisProt.
DR   GO; GO:0019074; P:viral RNA genome packaging; NAS:ComplexPortal.
DR   CDD; cd21595; CoV_N-CTD; 1.
DR   CDD; cd21554; CoV_N-NTD; 1.
DR   HAMAP; MF_04096; BETA_CORONA_NCAP; 1.
DR   InterPro; IPR044344; N_prot_C_CoV.
DR   InterPro; IPR044345; N_prot_N_CoV.
DR   InterPro; IPR043505; NCAP_bCoV.
DR   InterPro; IPR001218; Nucleocap_CoV.
DR   InterPro; IPR037179; Nucleocapsid_C.
DR   InterPro; IPR037195; Nucleocapsid_N.
DR   Pfam; PF00937; CoV_nucleocap; 1.
DR   PIRSF; PIRSF003888; Corona_nucleocap; 1.
DR   SUPFAM; SSF110304; Coronavirus RNA-binding domain; 1.
DR   SUPFAM; SSF103068; Nucleocapsid protein dimerization domain; 1.
DR   PROSITE; PS51929; COV_N_CTD; 1.
DR   PROSITE; PS51928; COV_N_NTD; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ADP-ribosylation; Host cytoplasm; Phosphoprotein;
KW   Reference proteome; Ribonucleoprotein; RNA-binding; Secreted;
KW   Transcription; Transcription regulation; Viral nucleoprotein; Virion.
FT   CHAIN           1..419
FT                   /note=""Nucleoprotein""
FT                   /id=""PRO_0000449656""
FT   DOMAIN          48..174
FT                   /note=""CoV N NTD""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01276,
FT                   ECO:0000269|PubMed:32363136""
FT   DOMAIN          247..364
FT                   /note=""CoV N CTD""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01277""
FT   REGION          1..51
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          41..186
FT                   /note=""RNA-binding""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   REGION          63..83
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          168..212
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          176..206
FT                   /note=""SR region""
FT                   /evidence=""ECO:0000305|PubMed:32974389""
FT   REGION          233..266
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          258..361
FT                   /note=""Dimerization""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   REGION          260..340
FT                   /note=""Putative NLRP3 binding""
FT                   /evidence=""ECO:0000269|PubMed:34341353""
FT   REGION          361..391
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          400..419
FT                   /note=""Tetramerization""
FT                   /evidence=""ECO:0000269|PubMed:32654247""
FT   MOTIF           256..264
FT                   /note=""Nuclear localization signal""
FT                   /evidence=""ECO:0000250|UniProtKB:P59595""
FT   COMPBIAS        1..11
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        21..31
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        367..378
FT                   /note=""Basic and acidic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   BINDING         92
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   BINDING         107
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   BINDING         149
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   SITE            399..402
FT                   /note=""Cleavage (by host CASP6)""
FT                   /evidence=""ECO:0000250|UniProtKB:P59595""
FT   MOD_RES         176
FT                   /note=""Phosphoserine; by host""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   MOD_RES         206
FT                   /note=""Phosphoserine; by host GSK3-alpha and GSK3-beta""
FT                   /evidence=""ECO:0000269|PubMed:34593624""
FT   VARIANT         2..3
FT                   /note=""SD -> Y (in strain: Eta/B.1.525)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         3
FT                   /note=""D -> L (in strain: Alpha/B.1.1.7)""
FT                   /evidence=""ECO:0000305|PubMed:33413740""
FT   VARIANT         12
FT                   /note=""A -> G (in strain: Eta/B.1.525)""
FT   VARIANT         13
FT                   /note=""P -> L (in strain: Lambda/C.37, Omicron/BA.1,
FT                   Omicron/BA.2, Omicron/BA.2.12.1, Omicron/BA.2.75,
FT                   Omicron/BA.4, Omicron/BA.5, Omicron/BQ.1.1,
FT                   Omicron/XBB.1.5, Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         31..33
FT                   /note=""Missing (in strain: Omicron/BA.1, Omicron/BA.2,
FT                   Omicron/BA.2.12.1, Omicron/BA.2.75, Omicron/BA.4,
FT                   Omicron/BA.5, Omicron/BQ.1.1, Omicron/XBB.1.5,
FT                   Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         63
FT                   /note=""D -> G (in strain: Delta/B.1.617.2)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT  ",19249
GTCTTC TCTTCC CTTCCA TTCCAG TCCAGT CCAGTT CAGTTC AGTTCC GTTCCA TTCCAC TCCACC CCACCA CACCAC ACCACC CCACCT CACCTG ACCTGC CCTGCT CTGCTG TGCTGC GCTGCC CTGCCC TGCCCG GCCCGC CCCGCG CCGCGT CGCGTT GCGTTC CGTTCT GTTCTC TTCTCG TCTCGG CTCGGC TCGGCG CGGCGC GGCGCT GCGCTG CGCTGG GCTGGA CTGGAA TGGAAA GGAAAA GAAAAC AAAACG AAACGT AACGTG ACGTGA CGTGAC GTGACG TGACGC GACGCT ACGCTT CGCTTC GCTTCC CTTCCG TTCCGG TCCGGC CCGGCC CGGCCC GGCCCT GCCCTC CCCTCA CCTCAT CTCATG TCATGG CATGGC ATGGCC TGGCCG GGCCGA GCCGAA CCGAAG CGAAGG GAAGGC AAGGCC AGGCCG GGCCGC GCCGCG CCGCGT CGCGTC GCGTCA CGTCAG GTCAGC TCAGCA CAGCAG AGCAGC GCAGCG CAGCGC AGCGCG GCGCGC CGCGCA GCGCAG CGCAGC GCAGCG CAGCGC AGCGCG GCGCGA CGCGAG GCGAGC CGAGCA GAGCAC AGCACG GCACGC CACGCG ACGCGC CGCGCG GCGCGC CGCGCA GCGCAG CGCAGC GCAGCC CAGCCT AGCCTG GCCTGC CCTGCT CTGCTG TGCTGG GCTGGC CTGGCC TGGCCG GGCCGC GCCGCC CCGCCG CGCCGT GCCGTG CCGTGG CGTGGG GTGGGC TGGGCC GGGCCT GGCCTG GCCTGG CCTGGC CTGGCG TGGCGC GGCGCA GCGCAG CGCAGG GCAGGC CAGGCC AGGCCA GGCCAT GCCATG,2,142,GTCT TCTT CTTC TTCC TCCA CCAG CAGT AGTT GTTC TTCC TCCA CCAC CACC ACCA CCAC CACC ACCT CCTG CTGC TGCT GCTG CTGC TGCC GCCC CCCG CCGC CGCG GCGT CGTT GTTC TTCT TCTC CTCG TCGG CGGC GGCG GCGC CGCT GCTG CTGG TGGA GGAA GAAA AAAA AAAC AACG ACGT CGTG GTGA TGAC GACG ACGC CGCT GCTT CTTC TTCC TCCG CCGG CGGC GGCC GCCC CCCT CCTC CTCA TCAT CATG ATGG TGGC GGCC GCCG CCGA CGAA GAAG AAGG AGGC GGCC GCCG CCGC CGCG GCGT CGTC GTCA TCAG CAGC AGCA GCAG CAGC AGCG GCGC CGCG GCGC CGCA GCAG CAGC AGCG GCGC CGCG GCGA CGAG GAGC AGCA GCAC CACG ACGC CGCG GCGC CGCG GCGC CGCA GCAG CAGC AGCC GCCT CCTG CTGC TGCT GCTG CTGG TGGC GGCC GCCG CCGC CGCC GCCG CCGT CGTG GTGG TGGG GGGC GGCC GCCT CCTG CTGG TGGC GGCG GCGC CGCA GCAG CAGG AGGC GGCC GCCA CCAT CATG,GTCTT TCTTC CTTCC TTCCA TCCAG CCAGT CAGTT AGTTC GTTCC TTCCA TCCAC CCACC CACCA ACCAC CCACC CACCT ACCTG CCTGC CTGCT TGCTG GCTGC CTGCC TGCCC GCCCG CCCGC CCGCG CGCGT GCGTT CGTTC GTTCT TTCTC TCTCG CTCGG TCGGC CGGCG GGCGC GCGCT CGCTG GCTGG CTGGA TGGAA GGAAA GAAAA AAAAC AAACG AACGT ACGTG CGTGA GTGAC TGACG GACGC ACGCT CGCTT GCTTC CTTCC TTCCG TCCGG CCGGC CGGCC GGCCC GCCCT CCCTC CCTCA CTCAT TCATG CATGG ATGGC TGGCC GGCCG GCCGA CCGAA CGAAG GAAGG AAGGC AGGCC GGCCG GCCGC CCGCG CGCGT GCGTC CGTCA GTCAG TCAGC CAGCA AGCAG GCAGC CAGCG AGCGC GCGCG CGCGC GCGCA CGCAG GCAGC CAGCG AGCGC GCGCG CGCGA GCGAG CGAGC GAGCA AGCAC GCACG CACGC ACGCG CGCGC GCGCG CGCGC GCGCA CGCAG GCAGC CAGCC AGCCT GCCTG CCTGC CTGCT TGCTG GCTGG CTGGC TGGCC GGCCG GCCGC CCGCC CGCCG GCCGT CCGTG CGTGG GTGGG TGGGC GGGCC GGCCT GCCTG CCTGG CTGGC TGGCG GGCGC GCGCA CGCAG GCAGG CAGGC AGGCC GGCCA GCCAT CCATG,GTCTTC TCTTCC CTTCCA TTCCAG TCCAGT CCAGTT CAGTTC AGTTCC GTTCCA TTCCAC TCCACC CCACCA CACCAC ACCACC CCACCT CACCTG ACCTGC CCTGCT CTGCTG TGCTGC GCTGCC CTGCCC TGCCCG GCCCGC CCCGCG CCGCGT CGCGTT GCGTTC CGTTCT GTTCTC TTCTCG TCTCGG CTCGGC TCGGCG CGGCGC GGCGCT GCGCTG CGCTGG GCTGGA CTGGAA TGGAAA GGAAAA GAAAAC AAAACG AAACGT AACGTG ACGTGA CGTGAC GTGACG TGACGC GACGCT ACGCTT CGCTTC GCTTCC CTTCCG TTCCGG TCCGGC CCGGCC CGGCCC GGCCCT GCCCTC CCCTCA CCTCAT CTCATG TCATGG CATGGC ATGGCC TGGCCG GGCCGA GCCGAA CCGAAG CGAAGG GAAGGC AAGGCC AGGCCG GGCCGC GCCGCG CCGCGT CGCGTC GCGTCA CGTCAG GTCAGC TCAGCA CAGCAG AGCAGC GCAGCG CAGCGC AGCGCG GCGCGC CGCGCA GCGCAG CGCAGC GCAGCG CAGCGC AGCGCG GCGCGA CGCGAG GCGAGC CGAGCA GAGCAC AGCACG GCACGC CACGCG ACGCGC CGCGCG GCGCGC CGCGCA GCGCAG CGCAGC GCAGCC CAGCCT AGCCTG GCCTGC CCTGCT CTGCTG TGCTGG GCTGGC CTGGCC TGGCCG GGCCGC GCCGCC CCGCCG CGCCGT GCCGTG CCGTGG CGTGGG GTGGGC TGGGCC GGGCCT GGCCTG GCCTGG CCTGGC CTGGCG TGGCGC GGCGCA GCGCAG CGCAGG GCAGGC CAGGCC AGGCCA GGCCAT GCCATG,GTCTTCC TCTTCCA CTTCCAG TTCCAGT TCCAGTT CCAGTTC CAGTTCC AGTTCCA GTTCCAC TTCCACC TCCACCA CCACCAC CACCACC ACCACCT CCACCTG CACCTGC ACCTGCT CCTGCTG CTGCTGC TGCTGCC GCTGCCC CTGCCCG TGCCCGC GCCCGCG CCCGCGT CCGCGTT CGCGTTC GCGTTCT CGTTCTC GTTCTCG TTCTCGG TCTCGGC CTCGGCG TCGGCGC CGGCGCT GGCGCTG GCGCTGG CGCTGGA GCTGGAA CTGGAAA TGGAAAA GGAAAAC GAAAACG AAAACGT AAACGTG AACGTGA ACGTGAC CGTGACG GTGACGC TGACGCT GACGCTT ACGCTTC CGCTTCC GCTTCCG CTTCCGG TTCCGGC TCCGGCC CCGGCCC CGGCCCT GGCCCTC GCCCTCA CCCTCAT CCTCATG CTCATGG TCATGGC CATGGCC ATGGCCG TGGCCGA GGCCGAA GCCGAAG CCGAAGG CGAAGGC GAAGGCC AAGGCCG AGGCCGC GGCCGCG GCCGCGT CCGCGTC CGCGTCA GCGTCAG CGTCAGC GTCAGCA TCAGCAG CAGCAGC AGCAGCG GCAGCGC CAGCGCG AGCGCGC GCGCGCA CGCGCAG GCGCAGC CGCAGCG GCAGCGC CAGCGCG AGCGCGA GCGCGAG CGCGAGC GCGAGCA CGAGCAC GAGCACG AGCACGC GCACGCG CACGCGC ACGCGCG CGCGCGC GCGCGCA CGCGCAG GCGCAGC CGCAGCC GCAGCCT CAGCCTG AGCCTGC GCCTGCT CCTGCTG CTGCTGG TGCTGGC GCTGGCC CTGGCCG TGGCCGC GGCCGCC GCCGCCG CCGCCGT CGCCGTG GCCGTGG CCGTGGG CGTGGGC GTGGGCC TGGGCCT GGGCCTG GGCCTGG GCCTGGC CCTGGCG CTGGCGC TGGCGCA GGCGCAG GCGCAGG CGCAGGC GCAGGCC CAGGCCA AGGCCAT GGCCATG,"ID   LOLD2_RHORT             Reviewed;         231 AA.
AC   Q2RQQ0;
DT   23-JAN-2007, integrated into UniProtKB/Swiss-Prot.
DT   24-JAN-2006, sequence version 1.
DT   05-FEB-2025, entry version 106.
DE   RecName: Full=Lipoprotein-releasing system ATP-binding protein LolD 2 {ECO:0000255|HAMAP-Rule:MF_01708};
DE            EC=7.6.2.- {ECO:0000255|HAMAP-Rule:MF_01708};
GN   Name=lolD2 {ECO:0000255|HAMAP-Rule:MF_01708};
GN   OrderedLocusNames=Rru_A2748;
OS   Rhodospirillum rubrum (strain ATCC 11170 / ATH 1.1.1 / DSM 467 / LMG 4362 /
OS   NCIMB 8255 / S1).
OC   Bacteria; Pseudomonadota; Alphaproteobacteria; Rhodospirillales;
OC   Rhodospirillaceae; Rhodospirillum.
OX   NCBI_TaxID=269796;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 11170 / ATH 1.1.1 / DSM 467 / LMG 4362 / NCIMB 8255 / S1;
RX   PubMed=21886856; DOI=10.4056/sigs.1804360;
RA   Munk A.C., Copeland A., Lucas S., Lapidus A., Del Rio T.G., Barry K.,
RA   Detter J.C., Hammon N., Israni S., Pitluck S., Brettin T., Bruce D.,
RA   Han C., Tapia R., Gilna P., Schmutz J., Larimer F., Land M., Kyrpides N.C.,
RA   Mavromatis K., Richardson P., Rohde M., Goeker M., Klenk H.P., Zhang Y.,
RA   Roberts G.P., Reslewic S., Schwartz D.C.;
RT   ""Complete genome sequence of Rhodospirillum rubrum type strain (S1)."";
RL   Stand. Genomic Sci. 4:293-302(2011).
CC   -!- FUNCTION: Part of the ABC transporter complex LolCDE involved in the
CC       translocation of mature outer membrane-directed lipoproteins, from the
CC       inner membrane to the periplasmic chaperone, LolA. Responsible for the
CC       formation of the LolA-lipoprotein complex in an ATP-dependent manner.
CC       {ECO:0000255|HAMAP-Rule:MF_01708}.
CC   -!- SUBUNIT: The complex is composed of two ATP-binding proteins (LolD) and
CC       two transmembrane proteins (LolC and LolE). {ECO:0000255|HAMAP-
CC       Rule:MF_01708}.
CC   -!- SUBCELLULAR LOCATION: Cell inner membrane {ECO:0000255|HAMAP-
CC       Rule:MF_01708}; Peripheral membrane protein {ECO:0000255|HAMAP-
CC       Rule:MF_01708}.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. Lipoprotein
CC       translocase (TC 3.A.1.125) family. {ECO:0000255|HAMAP-Rule:MF_01708}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CP000230; ABC23545.1; -; Genomic_DNA.
DR   RefSeq; WP_011390558.1; NC_007643.1.
DR   RefSeq; YP_427832.1; NC_007643.1.
DR   AlphaFoldDB; Q2RQQ0; -.
DR   SMR; Q2RQQ0; -.
DR   STRING; 269796.Rru_A2748; -.
DR   EnsemblBacteria; ABC23545; ABC23545; Rru_A2748.
DR   KEGG; rru:Rru_A2748; -.
DR   PATRIC; fig|269796.9.peg.2856; -.
DR   eggNOG; COG1136; Bacteria.
DR   HOGENOM; CLU_000604_1_22_5; -.
DR   PhylomeDB; Q2RQQ0; -.
DR   Proteomes; UP000001929; Chromosome.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IEA:InterPro.
DR   GO; GO:0022857; F:transmembrane transporter activity; IEA:TreeGrafter.
DR   CDD; cd03255; ABC_MJ0796_LolCDE_FtsE; 1.
DR   FunFam; 3.40.50.300:FF:000032; Export ABC transporter ATP-binding protein; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR003439; ABC_transporter-like_ATP-bd.
DR   InterPro; IPR017871; ABC_transporter-like_CS.
DR   InterPro; IPR015854; ABC_transpr_LolD-like.
DR   InterPro; IPR017911; MacB-like_ATP-bd.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   PANTHER; PTHR24220; IMPORT ATP-BINDING PROTEIN; 1.
DR   PANTHER; PTHR24220:SF689; LIPOPROTEIN-RELEASING SYSTEM ATP-BINDING PROTEIN LOLD; 1.
DR   Pfam; PF00005; ABC_tran; 1.
DR   SMART; SM00382; AAA; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 1.
DR   PROSITE; PS51244; LOLD; 1.
PE   3: Inferred from homology;
KW   ATP-binding; Cell inner membrane; Cell membrane; Membrane;
KW   Nucleotide-binding; Reference proteome; Translocase; Transport.
FT   CHAIN           1..231
FT                   /note=""Lipoprotein-releasing system ATP-binding protein
FT                   LolD 2""
FT                   /id=""PRO_0000272143""
FT   DOMAIN          6..230
FT                   /note=""ABC transporter""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01708""
FT   BINDING         42..49
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01708""
SQ   SEQUENCE   231 AA;  24778 MW;  6BA9F719DB4FBEDC CRC64;
     MTLPLVEARS LSKSFGEGEL ASQVLKRLSF DINAGERVAL VGPSGSGKST LLAVLGTLLG
     ATSGDLRILG QPMIGLPEAE LARFRNRNLG FVFQFHHLLP DFTALENVLF PAAAGKGRET
     RLMRERARAL LVRVGLEDRV DYGARKLSGG QKQRVALARA LINRPALVLA DEPTGNLDSG
     PAEQVMNLLG EINAEDGTTF LISTHDAAVA ARCTRRMELL DGRLVGQDPA D
//
",29338
ACTAAA CTAAAG TAAAGA AAAGAA AAGAAG AGAAGG GAAGGT AAGGTG AGGTGC GGTGCC GTGCCA TGCCAC GCCACT CCACTA CACTAC ACTACT CTACTT TACTTG ACTTGT CTTGTG TTGTGG TGTGGT GTGGTT TGGTTA GGTTAC GTTACT TTACTT TACTTA ACTTAC CTTACC TTACCC TACCCC ACCCCA CCCCAA CCCAAA CCAAAA CAAAAT AAAATG AAATGC AATGCT ATGCTG TGCTGT GCTGTT CTGTTG TGTTGT GTTGTT TTGTTA TGTTAA GTTAAA TTAAAA TAAAAT AAAATT AAATTT AATTTA ATTTAT TTTATT TTATTG TATTGT ATTGTC TTGTCC TGTCCA GTCCAG TCCAGC CCAGCA CAGCAT AGCATG GCATGT CATGTC ATGTCA TGTCAC GTCACA TCACAA CACAAT ACAATT CAATTC AATTCA ATTCAG TTCAGA TCAGAA CAGAAG AGAAGT GAAGTA AAGTAG AGTAGG GTAGGA TAGGAC AGGACC GGACCT GACCTG ACCTGA CCTGAG CTGAGC TGAGCA GAGCAT AGCATA GCATAG CATAGT ATAGTC TAGTCT AGTCTT GTCTTG TCTTGC CTTGCC TTGCCG TGCCGA GCCGAA CCGAAT CGAATA GAATAC AATACC ATACCA TACCAT ACCATA CCATAA CATAAT ATAATG TAATGA AATGAA ATGAAT TGAATC GAATCT AATCTG ATCTGG TCTGGC CTGGCT TGGCTT GGCTTG GCTTGA CTTGAA TTGAAA TGAAAA GAAAAC AAAACC AAACCA AACCAT ACCATT,0,136,ACTA CTAA TAAA AAAG AAGA AGAA GAAG AAGG AGGT GGTG GTGC TGCC GCCA CCAC CACT ACTA CTAC TACT ACTT CTTG TTGT TGTG GTGG TGGT GGTT GTTA TTAC TACT ACTT CTTA TTAC TACC ACCC CCCC CCCA CCAA CAAA AAAA AAAT AATG ATGC TGCT GCTG CTGT TGTT GTTG TTGT TGTT GTTA TTAA TAAA AAAA AAAT AATT ATTT TTTA TTAT TATT ATTG TTGT TGTC GTCC TCCA CCAG CAGC AGCA GCAT CATG ATGT TGTC GTCA TCAC CACA ACAA CAAT AATT ATTC TTCA TCAG CAGA AGAA GAAG AAGT AGTA GTAG TAGG AGGA GGAC GACC ACCT CCTG CTGA TGAG GAGC AGCA GCAT CATA ATAG TAGT AGTC GTCT TCTT CTTG TTGC TGCC GCCG CCGA CGAA GAAT AATA ATAC TACC ACCA CCAT CATA ATAA TAAT AATG ATGA TGAA GAAT AATC ATCT TCTG CTGG TGGC GGCT GCTT CTTG TTGA TGAA GAAA AAAA AAAC AACC ACCA CCAT CATT,ACTAA CTAAA TAAAG AAAGA AAGAA AGAAG GAAGG AAGGT AGGTG GGTGC GTGCC TGCCA GCCAC CCACT CACTA ACTAC CTACT TACTT ACTTG CTTGT TTGTG TGTGG GTGGT TGGTT GGTTA GTTAC TTACT TACTT ACTTA CTTAC TTACC TACCC ACCCC CCCCA CCCAA CCAAA CAAAA AAAAT AAATG AATGC ATGCT TGCTG GCTGT CTGTT TGTTG GTTGT TTGTT TGTTA GTTAA TTAAA TAAAA AAAAT AAATT AATTT ATTTA TTTAT TTATT TATTG ATTGT TTGTC TGTCC GTCCA TCCAG CCAGC CAGCA AGCAT GCATG CATGT ATGTC TGTCA GTCAC TCACA CACAA ACAAT CAATT AATTC ATTCA TTCAG TCAGA CAGAA AGAAG GAAGT AAGTA AGTAG GTAGG TAGGA AGGAC GGACC GACCT ACCTG CCTGA CTGAG TGAGC GAGCA AGCAT GCATA CATAG ATAGT TAGTC AGTCT GTCTT TCTTG CTTGC TTGCC TGCCG GCCGA CCGAA CGAAT GAATA AATAC ATACC TACCA ACCAT CCATA CATAA ATAAT TAATG AATGA ATGAA TGAAT GAATC AATCT ATCTG TCTGG CTGGC TGGCT GGCTT GCTTG CTTGA TTGAA TGAAA GAAAA AAAAC AAACC AACCA ACCAT CCATT,ACTAAA CTAAAG TAAAGA AAAGAA AAGAAG AGAAGG GAAGGT AAGGTG AGGTGC GGTGCC GTGCCA TGCCAC GCCACT CCACTA CACTAC ACTACT CTACTT TACTTG ACTTGT CTTGTG TTGTGG TGTGGT GTGGTT TGGTTA GGTTAC GTTACT TTACTT TACTTA ACTTAC CTTACC TTACCC TACCCC ACCCCA CCCCAA CCCAAA CCAAAA CAAAAT AAAATG AAATGC AATGCT ATGCTG TGCTGT GCTGTT CTGTTG TGTTGT GTTGTT TTGTTA TGTTAA GTTAAA TTAAAA TAAAAT AAAATT AAATTT AATTTA ATTTAT TTTATT TTATTG TATTGT ATTGTC TTGTCC TGTCCA GTCCAG TCCAGC CCAGCA CAGCAT AGCATG GCATGT CATGTC ATGTCA TGTCAC GTCACA TCACAA CACAAT ACAATT CAATTC AATTCA ATTCAG TTCAGA TCAGAA CAGAAG AGAAGT GAAGTA AAGTAG AGTAGG GTAGGA TAGGAC AGGACC GGACCT GACCTG ACCTGA CCTGAG CTGAGC TGAGCA GAGCAT AGCATA GCATAG CATAGT ATAGTC TAGTCT AGTCTT GTCTTG TCTTGC CTTGCC TTGCCG TGCCGA GCCGAA CCGAAT CGAATA GAATAC AATACC ATACCA TACCAT ACCATA CCATAA CATAAT ATAATG TAATGA AATGAA ATGAAT TGAATC GAATCT AATCTG ATCTGG TCTGGC CTGGCT TGGCTT GGCTTG GCTTGA CTTGAA TTGAAA TGAAAA GAAAAC AAAACC AAACCA AACCAT ACCATT,ACTAAAG CTAAAGA TAAAGAA AAAGAAG AAGAAGG AGAAGGT GAAGGTG AAGGTGC AGGTGCC GGTGCCA GTGCCAC TGCCACT GCCACTA CCACTAC CACTACT ACTACTT CTACTTG TACTTGT ACTTGTG CTTGTGG TTGTGGT TGTGGTT GTGGTTA TGGTTAC GGTTACT GTTACTT TTACTTA TACTTAC ACTTACC CTTACCC TTACCCC TACCCCA ACCCCAA CCCCAAA CCCAAAA CCAAAAT CAAAATG AAAATGC AAATGCT AATGCTG ATGCTGT TGCTGTT GCTGTTG CTGTTGT TGTTGTT GTTGTTA TTGTTAA TGTTAAA GTTAAAA TTAAAAT TAAAATT AAAATTT AAATTTA AATTTAT ATTTATT TTTATTG TTATTGT TATTGTC ATTGTCC TTGTCCA TGTCCAG GTCCAGC TCCAGCA CCAGCAT CAGCATG AGCATGT GCATGTC CATGTCA ATGTCAC TGTCACA GTCACAA TCACAAT CACAATT ACAATTC CAATTCA AATTCAG ATTCAGA TTCAGAA TCAGAAG CAGAAGT AGAAGTA GAAGTAG AAGTAGG AGTAGGA GTAGGAC TAGGACC AGGACCT GGACCTG GACCTGA ACCTGAG CCTGAGC CTGAGCA TGAGCAT GAGCATA AGCATAG GCATAGT CATAGTC ATAGTCT TAGTCTT AGTCTTG GTCTTGC TCTTGCC CTTGCCG TTGCCGA TGCCGAA GCCGAAT CCGAATA CGAATAC GAATACC AATACCA ATACCAT TACCATA ACCATAA CCATAAT CATAATG ATAATGA TAATGAA AATGAAT ATGAATC TGAATCT GAATCTG AATCTGG ATCTGGC TCTGGCT CTGGCTT TGGCTTG GGCTTGA GCTTGAA CTTGAAA TTGAAAA TGAAAAC GAAAACC AAAACCA AAACCAT AACCATT,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",606
CGAGTA GAGTAC AGTACG GTACGC TACGCG ACGCGC CGCGCC GCGCCG CGCCGA GCCGAC CCGACG CGACGA GACGAC ACGACC CGACCG GACCGG ACCGGC CCGGCT CGGCTG GGCTGT GCTGTC CTGTCC TGTCCG GTCCGG TCCGGC CCGGCG CGGCGC GGCGCC GCGCCG CGCCGA GCCGAA CCGAAG CGAAGT GAAGTG AAGTGC AGTGCT GTGCTG TGCTGC GCTGCT CTGCTG TGCTGC GCTGCG CTGCGC TGCGCT GCGCTG CGCTGG GCTGGC CTGGCA TGGCAC GGCACC GCACCA CACCAC ACCACC CCACCC CACCCG ACCCGC CCCGCG CCGCGG CGCGGC GCGGCG CGGCGC GGCGCG GCGCGG CGCGGT GCGGTC CGGTCT GGTCTG GTCTGG TCTGGT CTGGTG TGGTGT GGTGTT GTGTTG TGTTGC GTTGCC TTGCCC TGCCCG GCCCGG CCCGGC CCGGCG CGGCGA GGCGAG GCGAGT CGAGTT GAGTTC AGTTCA GTTCAT TTCATC TCATCG CATCGC ATCGCG TCGCGC CGCGCT GCGCTG CGCTGG GCTGGC CTGGCC TGGCCG GGCCGA GCCGAG CCGAGC CGAGCA GAGCAG AGCAGA GCAGAC CAGACC AGACCG GACCGG ACCGGA CCGGAC CGGACT GGACTG GACTGA ACTGAT CTGATC TGATCC GATCCT ATCCTG TCCTGG CCTGGC CTGGCG TGGCGC GGCGCT GCGCTC CGCTCG GCTCGG CTCGGG TCGGGC CGGGCG GGGCGC GGCGCT GCGCTG CGCTGG GCTGGG CTGGGT TGGGTG GGGTGC GGTGCT GTGCTC TGCTCA GCTCAG CTCAGG TCAGGA CAGGAC AGGACG,2,145,CGAG GAGT AGTA GTAC TACG ACGC CGCG GCGC CGCC GCCG CCGA CGAC GACG ACGA CGAC GACC ACCG CCGG CGGC GGCT GCTG CTGT TGTC GTCC TCCG CCGG CGGC GGCG GCGC CGCC GCCG CCGA CGAA GAAG AAGT AGTG GTGC TGCT GCTG CTGC TGCT GCTG CTGC TGCG GCGC CGCT GCTG CTGG TGGC GGCA GCAC CACC ACCA CCAC CACC ACCC CCCG CCGC CGCG GCGG CGGC GGCG GCGC CGCG GCGG CGGT GGTC GTCT TCTG CTGG TGGT GGTG GTGT TGTT GTTG TTGC TGCC GCCC CCCG CCGG CGGC GGCG GCGA CGAG GAGT AGTT GTTC TTCA TCAT CATC ATCG TCGC CGCG GCGC CGCT GCTG CTGG TGGC GGCC GCCG CCGA CGAG GAGC AGCA GCAG CAGA AGAC GACC ACCG CCGG CGGA GGAC GACT ACTG CTGA TGAT GATC ATCC TCCT CCTG CTGG TGGC GGCG GCGC CGCT GCTC CTCG TCGG CGGG GGGC GGCG GCGC CGCT GCTG CTGG TGGG GGGT GGTG GTGC TGCT GCTC CTCA TCAG CAGG AGGA GGAC GACG,CGAGT GAGTA AGTAC GTACG TACGC ACGCG CGCGC GCGCC CGCCG GCCGA CCGAC CGACG GACGA ACGAC CGACC GACCG ACCGG CCGGC CGGCT GGCTG GCTGT CTGTC TGTCC GTCCG TCCGG CCGGC CGGCG GGCGC GCGCC CGCCG GCCGA CCGAA CGAAG GAAGT AAGTG AGTGC GTGCT TGCTG GCTGC CTGCT TGCTG GCTGC CTGCG TGCGC GCGCT CGCTG GCTGG CTGGC TGGCA GGCAC GCACC CACCA ACCAC CCACC CACCC ACCCG CCCGC CCGCG CGCGG GCGGC CGGCG GGCGC GCGCG CGCGG GCGGT CGGTC GGTCT GTCTG TCTGG CTGGT TGGTG GGTGT GTGTT TGTTG GTTGC TTGCC TGCCC GCCCG CCCGG CCGGC CGGCG GGCGA GCGAG CGAGT GAGTT AGTTC GTTCA TTCAT TCATC CATCG ATCGC TCGCG CGCGC GCGCT CGCTG GCTGG CTGGC TGGCC GGCCG GCCGA CCGAG CGAGC GAGCA AGCAG GCAGA CAGAC AGACC GACCG ACCGG CCGGA CGGAC GGACT GACTG ACTGA CTGAT TGATC GATCC ATCCT TCCTG CCTGG CTGGC TGGCG GGCGC GCGCT CGCTC GCTCG CTCGG TCGGG CGGGC GGGCG GGCGC GCGCT CGCTG GCTGG CTGGG TGGGT GGGTG GGTGC GTGCT TGCTC GCTCA CTCAG TCAGG CAGGA AGGAC GGACG,CGAGTA GAGTAC AGTACG GTACGC TACGCG ACGCGC CGCGCC GCGCCG CGCCGA GCCGAC CCGACG CGACGA GACGAC ACGACC CGACCG GACCGG ACCGGC CCGGCT CGGCTG GGCTGT GCTGTC CTGTCC TGTCCG GTCCGG TCCGGC CCGGCG CGGCGC GGCGCC GCGCCG CGCCGA GCCGAA CCGAAG CGAAGT GAAGTG AAGTGC AGTGCT GTGCTG TGCTGC GCTGCT CTGCTG TGCTGC GCTGCG CTGCGC TGCGCT GCGCTG CGCTGG GCTGGC CTGGCA TGGCAC GGCACC GCACCA CACCAC ACCACC CCACCC CACCCG ACCCGC CCCGCG CCGCGG CGCGGC GCGGCG CGGCGC GGCGCG GCGCGG CGCGGT GCGGTC CGGTCT GGTCTG GTCTGG TCTGGT CTGGTG TGGTGT GGTGTT GTGTTG TGTTGC GTTGCC TTGCCC TGCCCG GCCCGG CCCGGC CCGGCG CGGCGA GGCGAG GCGAGT CGAGTT GAGTTC AGTTCA GTTCAT TTCATC TCATCG CATCGC ATCGCG TCGCGC CGCGCT GCGCTG CGCTGG GCTGGC CTGGCC TGGCCG GGCCGA GCCGAG CCGAGC CGAGCA GAGCAG AGCAGA GCAGAC CAGACC AGACCG GACCGG ACCGGA CCGGAC CGGACT GGACTG GACTGA ACTGAT CTGATC TGATCC GATCCT ATCCTG TCCTGG CCTGGC CTGGCG TGGCGC GGCGCT GCGCTC CGCTCG GCTCGG CTCGGG TCGGGC CGGGCG GGGCGC GGCGCT GCGCTG CGCTGG GCTGGG CTGGGT TGGGTG GGGTGC GGTGCT GTGCTC TGCTCA GCTCAG CTCAGG TCAGGA CAGGAC AGGACG,CGAGTAC GAGTACG AGTACGC GTACGCG TACGCGC ACGCGCC CGCGCCG GCGCCGA CGCCGAC GCCGACG CCGACGA CGACGAC GACGACC ACGACCG CGACCGG GACCGGC ACCGGCT CCGGCTG CGGCTGT GGCTGTC GCTGTCC CTGTCCG TGTCCGG GTCCGGC TCCGGCG CCGGCGC CGGCGCC GGCGCCG GCGCCGA CGCCGAA GCCGAAG CCGAAGT CGAAGTG GAAGTGC AAGTGCT AGTGCTG GTGCTGC TGCTGCT GCTGCTG CTGCTGC TGCTGCG GCTGCGC CTGCGCT TGCGCTG GCGCTGG CGCTGGC GCTGGCA CTGGCAC TGGCACC GGCACCA GCACCAC CACCACC ACCACCC CCACCCG CACCCGC ACCCGCG CCCGCGG CCGCGGC CGCGGCG GCGGCGC CGGCGCG GGCGCGG GCGCGGT CGCGGTC GCGGTCT CGGTCTG GGTCTGG GTCTGGT TCTGGTG CTGGTGT TGGTGTT GGTGTTG GTGTTGC TGTTGCC GTTGCCC TTGCCCG TGCCCGG GCCCGGC CCCGGCG CCGGCGA CGGCGAG GGCGAGT GCGAGTT CGAGTTC GAGTTCA AGTTCAT GTTCATC TTCATCG TCATCGC CATCGCG ATCGCGC TCGCGCT CGCGCTG GCGCTGG CGCTGGC GCTGGCC CTGGCCG TGGCCGA GGCCGAG GCCGAGC CCGAGCA CGAGCAG GAGCAGA AGCAGAC GCAGACC CAGACCG AGACCGG GACCGGA ACCGGAC CCGGACT CGGACTG GGACTGA GACTGAT ACTGATC CTGATCC TGATCCT GATCCTG ATCCTGG TCCTGGC CCTGGCG CTGGCGC TGGCGCT GGCGCTC GCGCTCG CGCTCGG GCTCGGG CTCGGGC TCGGGCG CGGGCGC GGGCGCT GGCGCTG GCGCTGG CGCTGGG GCTGGGT CTGGGTG TGGGTGC GGGTGCT GGTGCTC GTGCTCA TGCTCAG GCTCAGG CTCAGGA TCAGGAC CAGGACG,"ID   MODB_AZOVI              Reviewed;         226 AA.
AC   P37731;
DT   01-OCT-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1994, sequence version 1.
DT   27-NOV-2024, entry version 95.
DE   RecName: Full=Molybdenum transport system permease protein ModB;
GN   Name=modB; Synonyms=modC;
OS   Azotobacter vinelandii.
OC   Bacteria; Pseudomonadota; Gammaproteobacteria; Pseudomonadales;
OC   Pseudomonadaceae; Azotobacter.
OX   NCBI_TaxID=354;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=DJ35;
RX   PubMed=8384683; DOI=10.1111/j.1365-2958.1993.tb01136.x;
RA   Luque F., Mitchenall L.A., Chapman M., Christine R., Pau R.N.;
RT   ""Characterization of genes involved in molybdenum transport in Azotobacter
RT   vinelandii."";
RL   Mol. Microbiol. 7:447-459(1993).
RN   [2]
RP   GENE NAME.
RX   PubMed=7665518; DOI=10.1128/jb.177.18.5294-5302.1995;
RA   Mouncey N.J., Mitchenall L.A., Pau R.N.;
RT   ""Mutational analysis of genes of the mod locus involved in molybdenum
RT   transport, homeostasis, and processing in Azotobacter vinelandii."";
RL   J. Bacteriol. 177:5294-5302(1995).
CC   -!- FUNCTION: Part of the binding-protein-dependent transport system for
CC       molybdenum; probably responsible for the translocation of the substrate
CC       across the membrane.
CC   -!- SUBCELLULAR LOCATION: Cell inner membrane {ECO:0000250}; Multi-pass
CC       membrane protein {ECO:0000255|PROSITE-ProRule:PRU00441}.
CC   -!- SIMILARITY: Belongs to the binding-protein-dependent transport system
CC       permease family. CysTW subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X69077; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   PIR; S31046; S31046.
DR   RefSeq; WP_012703507.1; NZ_FPKM01000015.1.
DR   AlphaFoldDB; P37731; -.
DR   SMR; P37731; -.
DR   GeneID; 88187901; -.
DR   OMA; GPWDTFF; -.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0015098; F:molybdate ion transmembrane transporter activity; IEA:InterPro.
DR   CDD; cd06261; TM_PBP2; 1.
DR   FunFam; 1.10.3720.10:FF:000054; Molybdenum transport system permease; 1.
DR   Gene3D; 1.10.3720.10; MetI-like; 1.
DR   InterPro; IPR000515; MetI-like.
DR   InterPro; IPR035906; MetI-like_sf.
DR   InterPro; IPR011867; ModB_ABC.
DR   NCBIfam; TIGR02141; modB_ABC; 1.
DR   PANTHER; PTHR30183:SF8; MOLYBDENUM TRANSPORT SYSTEM PERMEASE; 1.
DR   PANTHER; PTHR30183; MOLYBDENUM TRANSPORT SYSTEM PERMEASE PROTEIN MODB; 1.
DR   Pfam; PF00528; BPD_transp_1; 1.
DR   SUPFAM; SSF161098; MetI-like; 1.
DR   PROSITE; PS50928; ABC_TM1; 1.
PE   3: Inferred from homology;
KW   Cell inner membrane; Cell membrane; Membrane; Molybdenum; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN           1..226
FT                   /note=""Molybdenum transport system permease protein ModB""
FT                   /id=""PRO_0000060110""
FT   TRANSMEM        17..37
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00441""
FT   TRANSMEM        47..67
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00441""
FT   TRANSMEM        88..108
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00441""
FT   TRANSMEM        150..170
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00441""
FT   TRANSMEM        197..217
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00441""
FT   DOMAIN          11..217
FT                   /note=""ABC transmembrane type-1""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00441""
SQ   SEQUENCE   226 AA;  24302 MW;  1024EC9E63BB8B24 CRC64;
     MPLSEHDLAA IRLTLELASL TTVLLLVVGT PIAWWLARTR SRLKGAIGAV VALPLVLPPT
     VLGFYLLVTM GPHGPIGQLT QFLGLGTLPF TFAGLVVASV FYSLPFVVQP LQNAFEAIGE
     RPLEVASTLR AGPWDTFFTV VVPLARPGFI TAAILGFAHT VGEFGVVLMI GGNIPEKTRT
     VAVQIFDHVE AMEYAQAHWL AGGMVLFSFL VLFALYSSRR FKAGLS
//
",30427
ACCGAC CCGACA CGACAA GACAAT ACAATT CAATTA AATTAT ATTATA TTATAG TATAGA ATAGAT TAGATC AGATCC GATCCC ATCCCA TCCCAT CCCATT CCATTC CATTCC ATTCCC TTCCCC TCCCCG CCCCGG CCCGGG CCGGGT CGGGTC GGGTCA GGTCAT GTCATG TCATGG CATGGT ATGGTT TGGTTT GGTTTG GTTTGA TTTGAA TTGAAT TGAATG GAATGG AATGGT ATGGTT TGGTTG GGTTGC GTTGCA TTGCAC TGCACT GCACTG CACTGT ACTGTA CTGTAA TGTAAA GTAAAG TAAAGG AAAGGA AAGGAG AGGAGG GGAGGC GAGGCA AGGCAA GGCAAA GCAAAG CAAAGA AAAGAC AAGACA AGACAG GACAGT ACAGTG CAGTGC AGTGCT GTGCTC TGCTCA GCTCAA CTCAAC TCAACA CAACAA AACAAG ACAAGT CAAGTG AAGTGT AGTGTA GTGTAA TGTAAA GTAAAA TAAAAG AAAAGT AAAGTG AAGTGG AGTGGT GTGGTT TGGTTT GGTTTT GTTTTT TTTTTA TTTTAC TTTACT TTACTT TACTTT ACTTTC CTTTCT TTTCTT TTCTTC TCTTCC CTTCCA TTCCAT TCCATC CCATCT CATCTA ATCTAT TCTATT CTATTA TATTAA ATTAAC TTAACC TAACCC AACCCT ACCCTA CCCTAA CCTAAT CTAATG TAATGA AATGAG ATGAGA TGAGAA GAGAAG AGAAGC GAAGCA AAGCAA AGCAAG GCAAGC CAAGCA AAGCAA AGCAAT GCAATT CAATTC AATTCT ATTCTT TTCTTG TCTTGG CTTGGA TTGGAA TGGAAT GGAATA GAATAA AATAAT ATAATA,0,145,ACCG CCGA CGAC GACA ACAA CAAT AATT ATTA TTAT TATA ATAG TAGA AGAT GATC ATCC TCCC CCCA CCAT CATT ATTC TTCC TCCC CCCC CCCG CCGG CGGG GGGT GGTC GTCA TCAT CATG ATGG TGGT GGTT GTTT TTTG TTGA TGAA GAAT AATG ATGG TGGT GGTT GTTG TTGC TGCA GCAC CACT ACTG CTGT TGTA GTAA TAAA AAAG AAGG AGGA GGAG GAGG AGGC GGCA GCAA CAAA AAAG AAGA AGAC GACA ACAG CAGT AGTG GTGC TGCT GCTC CTCA TCAA CAAC AACA ACAA CAAG AAGT AGTG GTGT TGTA GTAA TAAA AAAA AAAG AAGT AGTG GTGG TGGT GGTT GTTT TTTT TTTT TTTA TTAC TACT ACTT CTTT TTTC TTCT TCTT CTTC TTCC TCCA CCAT CATC ATCT TCTA CTAT TATT ATTA TTAA TAAC AACC ACCC CCCT CCTA CTAA TAAT AATG ATGA TGAG GAGA AGAA GAAG AAGC AGCA GCAA CAAG AAGC AGCA GCAA CAAT AATT ATTC TTCT TCTT CTTG TTGG TGGA GGAA GAAT AATA ATAA TAAT AATA,ACCGA CCGAC CGACA GACAA ACAAT CAATT AATTA ATTAT TTATA TATAG ATAGA TAGAT AGATC GATCC ATCCC TCCCA CCCAT CCATT CATTC ATTCC TTCCC TCCCC CCCCG CCCGG CCGGG CGGGT GGGTC GGTCA GTCAT TCATG CATGG ATGGT TGGTT GGTTT GTTTG TTTGA TTGAA TGAAT GAATG AATGG ATGGT TGGTT GGTTG GTTGC TTGCA TGCAC GCACT CACTG ACTGT CTGTA TGTAA GTAAA TAAAG AAAGG AAGGA AGGAG GGAGG GAGGC AGGCA GGCAA GCAAA CAAAG AAAGA AAGAC AGACA GACAG ACAGT CAGTG AGTGC GTGCT TGCTC GCTCA CTCAA TCAAC CAACA AACAA ACAAG CAAGT AAGTG AGTGT GTGTA TGTAA GTAAA TAAAA AAAAG AAAGT AAGTG AGTGG GTGGT TGGTT GGTTT GTTTT TTTTT TTTTA TTTAC TTACT TACTT ACTTT CTTTC TTTCT TTCTT TCTTC CTTCC TTCCA TCCAT CCATC CATCT ATCTA TCTAT CTATT TATTA ATTAA TTAAC TAACC AACCC ACCCT CCCTA CCTAA CTAAT TAATG AATGA ATGAG TGAGA GAGAA AGAAG GAAGC AAGCA AGCAA GCAAG CAAGC AAGCA AGCAA GCAAT CAATT AATTC ATTCT TTCTT TCTTG CTTGG TTGGA TGGAA GGAAT GAATA AATAA ATAAT TAATA,ACCGAC CCGACA CGACAA GACAAT ACAATT CAATTA AATTAT ATTATA TTATAG TATAGA ATAGAT TAGATC AGATCC GATCCC ATCCCA TCCCAT CCCATT CCATTC CATTCC ATTCCC TTCCCC TCCCCG CCCCGG CCCGGG CCGGGT CGGGTC GGGTCA GGTCAT GTCATG TCATGG CATGGT ATGGTT TGGTTT GGTTTG GTTTGA TTTGAA TTGAAT TGAATG GAATGG AATGGT ATGGTT TGGTTG GGTTGC GTTGCA TTGCAC TGCACT GCACTG CACTGT ACTGTA CTGTAA TGTAAA GTAAAG TAAAGG AAAGGA AAGGAG AGGAGG GGAGGC GAGGCA AGGCAA GGCAAA GCAAAG CAAAGA AAAGAC AAGACA AGACAG GACAGT ACAGTG CAGTGC AGTGCT GTGCTC TGCTCA GCTCAA CTCAAC TCAACA CAACAA AACAAG ACAAGT CAAGTG AAGTGT AGTGTA GTGTAA TGTAAA GTAAAA TAAAAG AAAAGT AAAGTG AAGTGG AGTGGT GTGGTT TGGTTT GGTTTT GTTTTT TTTTTA TTTTAC TTTACT TTACTT TACTTT ACTTTC CTTTCT TTTCTT TTCTTC TCTTCC CTTCCA TTCCAT TCCATC CCATCT CATCTA ATCTAT TCTATT CTATTA TATTAA ATTAAC TTAACC TAACCC AACCCT ACCCTA CCCTAA CCTAAT CTAATG TAATGA AATGAG ATGAGA TGAGAA GAGAAG AGAAGC GAAGCA AAGCAA AGCAAG GCAAGC CAAGCA AAGCAA AGCAAT GCAATT CAATTC AATTCT ATTCTT TTCTTG TCTTGG CTTGGA TTGGAA TGGAAT GGAATA GAATAA AATAAT ATAATA,ACCGACA CCGACAA CGACAAT GACAATT ACAATTA CAATTAT AATTATA ATTATAG TTATAGA TATAGAT ATAGATC TAGATCC AGATCCC GATCCCA ATCCCAT TCCCATT CCCATTC CCATTCC CATTCCC ATTCCCC TTCCCCG TCCCCGG CCCCGGG CCCGGGT CCGGGTC CGGGTCA GGGTCAT GGTCATG GTCATGG TCATGGT CATGGTT ATGGTTT TGGTTTG GGTTTGA GTTTGAA TTTGAAT TTGAATG TGAATGG GAATGGT AATGGTT ATGGTTG TGGTTGC GGTTGCA GTTGCAC TTGCACT TGCACTG GCACTGT CACTGTA ACTGTAA CTGTAAA TGTAAAG GTAAAGG TAAAGGA AAAGGAG AAGGAGG AGGAGGC GGAGGCA GAGGCAA AGGCAAA GGCAAAG GCAAAGA CAAAGAC AAAGACA AAGACAG AGACAGT GACAGTG ACAGTGC CAGTGCT AGTGCTC GTGCTCA TGCTCAA GCTCAAC CTCAACA TCAACAA CAACAAG AACAAGT ACAAGTG CAAGTGT AAGTGTA AGTGTAA GTGTAAA TGTAAAA GTAAAAG TAAAAGT AAAAGTG AAAGTGG AAGTGGT AGTGGTT GTGGTTT TGGTTTT GGTTTTT GTTTTTA TTTTTAC TTTTACT TTTACTT TTACTTT TACTTTC ACTTTCT CTTTCTT TTTCTTC TTCTTCC TCTTCCA CTTCCAT TTCCATC TCCATCT CCATCTA CATCTAT ATCTATT TCTATTA CTATTAA TATTAAC ATTAACC TTAACCC TAACCCT AACCCTA ACCCTAA CCCTAAT CCTAATG CTAATGA TAATGAG AATGAGA ATGAGAA TGAGAAG GAGAAGC AGAAGCA GAAGCAA AAGCAAG AGCAAGC GCAAGCA CAAGCAA AAGCAAT AGCAATT GCAATTC CAATTCT AATTCTT ATTCTTG TTCTTGG TCTTGGA CTTGGAA TTGGAAT TGGAATA GGAATAA GAATAAT AATAATA,"ID   R1A_SARS2               Reviewed;        4405 AA.
AC   P0DTC1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1a;
DE            Short=pp1a;
DE   AltName: Full=ORF1a polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69;
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=RNA-capping enzyme subunit nsp9;
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=Non-structural protein 11;
DE              Short=nsp11;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [5]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [6]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [7]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (NON-STRUCTURAL PROTEIN 10),
RP   MUTAGENESIS OF ASN-4141 AND ASN-4142, AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [8]
RP   REVIEW, SUBUNIT (NON-STRUCTURAL PROTEIN 7), AND SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [9]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [10]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [11]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN
RP   COMPLEX WITH ALPHA-KETOAMIDE INHIBITORS, SUBUNIT (3C-LIKE PROTEINASE NSP5),
RP   ACTIVE SITE, AND ACTIVITY REGULATION.
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE APOENZYME AND
RP   IN COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5), AND CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7 AND NON-STRUCTURAL PROTEIN 8, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 7), AND
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [16]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7 AND NON-STRUCTURAL PROTEIN 8, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 7), AND
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [18]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7 AND NON-STRUCTURAL PROTEIN 8, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 7), AND
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION OF NON-STRUCTURAL PROTEIN 3.
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [20]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7 AND NON-STRUCTURAL PROTEIN 8 IN COMPLEX WITH ZINC ION, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), AND FUNCTION (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), CATALYTIC ACTIVITY (NON-STRUCTURAL
RP   PROTEIN 3), ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 3), AND MUTAGENESIS
RP   OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [22]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [23]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [24]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   AND INTERACTION WITH HOST TBK1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [25]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), AND SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [26]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [27]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [28]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9 AND NON-STRUCTURAL
RP   PROTEIN 10, AND SUBUNIT (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [29]
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
CC   -!- FUNCTION: [Replicase polyprotein 1a]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by nsp3 and nsp4, while nsp6 zippers
CC       ER membranes and connects to lipid droplets (PubMed:35551511).
CC       {ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [3C-like proteinase nsp5]: Cleaves the C-terminus of
CC       replicase polyprotein at 11 sites (PubMed:32321856). Recognizes
CC       substrates containing the core sequence [ILMVF]-Q-|-[SGACN]
CC       (PubMed:32198291, PubMed:32272481). May cleave human NLRP1 in lung
CC       epithelial cells, thereby activating the NLRP1 inflammasome pathway
CC       (PubMed:35594856). May cleave human GSDMD, triggering alternative
CC       GSDME-mediated epithelial cell death upon activation of the NLRP1
CC       inflammasome, which may enhance the release interleukins 1B, 6, 16 and
CC       18 (PubMed:35594856). Also able to bind an ADP-ribose-1''-phosphate
CC       (ADRP) (PubMed:32198291, PubMed:32272481).
CC       {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481,
CC       ECO:0000269|PubMed:32321856, ECO:0000269|PubMed:32680882,
CC       ECO:0000269|PubMed:35594856}.
CC   -!- FUNCTION: [Non-structural protein 6]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by nsp3 and nsp4, while nsp6 zippers
CC       ER membranes and connects to lipid droplets (LDs) (PubMed:35551511).
CC       LDs are consumed during DMV formation (PubMed:35551511). Binds to host
CC       TBK1 without affecting TBK1 phosphorylation; the interaction with TBK1
CC       decreases IRF3 phosphorylation, which leads to reduced IFN-beta
CC       production (PubMed:32979938). {ECO:0000269|PubMed:32979938,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 7]: Plays a role in viral RNA
CC       synthesis (PubMed:32277040, PubMed:32358203, PubMed:32438371,
CC       PubMed:32526208). Forms a hexadecamer with nsp8 (8 subunits of each)
CC       that may participate in viral replication by acting as a primase.
CC       Alternatively, may synthesize substantially longer products than
CC       oligonucleotide primers (By similarity). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32277040, ECO:0000269|PubMed:32358203,
CC       ECO:0000269|PubMed:32438371, ECO:0000269|PubMed:32526208}.
CC   -!- FUNCTION: [Non-structural protein 8]: Plays a role in viral RNA
CC       synthesis (PubMed:32277040, PubMed:32358203, PubMed:32438371,
CC       PubMed:32526208). Forms a hexadecamer with nsp7 (8 subunits of each)
CC       that may participate in viral replication by acting as a primase.
CC       Alternatively, may synthesize substantially longer products than
CC       oligonucleotide primers (By similarity). Interacts with ribosome signal
CC       recognition particle RNA (SRP) (PubMed:33080218). Together with NSP9,
CC       suppress protein integration into the cell membrane, thereby disrupting
CC       host immune defenses (PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32277040, ECO:0000269|PubMed:32358203,
CC       ECO:0000269|PubMed:32438371, ECO:0000269|PubMed:32526208,
CC       ECO:0000269|PubMed:33080218}.
CC   -!- FUNCTION: [RNA-capping enzyme subunit nsp9]: Catalytic subunit of viral
CC       RNA capping enzyme which catalyzes the RNA guanylyltransferase reaction
CC       for genomic and sub-genomic RNAs (PubMed:35944563). The kinase-like
CC       NiRAN domain of NSP12 transfers RNA to the amino terminus of NSP9,
CC       forming a covalent RNA-protein intermediate (PubMed:35944563).
CC       Subsequently, the NiRAN domain transfers RNA to GDP, forming the core
CC       cap structure GpppA-RNA (PubMed:35944563). The NSP14 and NSP16
CC       methyltransferases then add methyl groups to form functional cap
CC       structures (PubMed:35944563). Interacts with ribosome signal
CC       recognition particle RNA (SRP) (PubMed:33080218). Together with NSP8,
CC       suppress protein integration into the cell membrane, thereby disrupting
CC       host immune defenses (PubMed:33080218). {ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:35944563}.
CC   -!- FUNCTION: [Non-structural protein 10]: Plays a pivotal role in viral
CC       transcription by stimulating both nsp14 3'-5' exoribonuclease (By
CC       similarity) and nsp16 2'-O-methyltransferase activities
CC       (PubMed:35944563). Therefore plays an essential role in viral mRNAs cap
CC       methylation. {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:35944563}.
CC   -!- CATALYTIC ACTIVITY: [Papain-like protease nsp3]:
CC       Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide
CC         and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-
CC         residue protein attached to proteins as an intracellular targeting
CC         signal).; EC=3.4.19.12; Evidence={ECO:0000269|PubMed:32726803};
CC   -!- CATALYTIC ACTIVITY: [3C-like proteinase nsp5]:
CC       Reaction=TSAVLQ-|-SGFRK-NH2 and SGVTFQ-|-GKFKK the two peptides
CC         corresponding to the two self-cleavage sites of the SARS 3C-like
CC         proteinase are the two most reactive peptide substrates. The enzyme
CC         exhibits a strong preference for substrates containing Gln at P1
CC         position and Leu at P2 position.; EC=3.4.22.69;
CC         Evidence={ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481,
CC         ECO:0000269|PubMed:32321856};
CC   -!- CATALYTIC ACTIVITY: [RNA-capping enzyme subunit nsp9]:
CC       Reaction=a 5'-end diphospho-ribonucleoside in mRNA + GTP + H(+) = a 5'-
CC         end (5'-triphosphoguanosine)-ribonucleoside in mRNA + diphosphate;
CC         Xref=Rhea:RHEA:67012, Rhea:RHEA-COMP:17165, Rhea:RHEA-COMP:17166,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:33019, ChEBI:CHEBI:37565,
CC         ChEBI:CHEBI:167616, ChEBI:CHEBI:167617; EC=2.7.7.50;
CC         Evidence={ECO:0000269|PubMed:35944563};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:67014;
CC         Evidence={ECO:0000269|PubMed:35944563};
CC   -!- ACTIVITY REGULATION: [Non-structural protein 6]: Inhibited ex vivo by
CC       K22. It may shift NSP6 zippering activity towards the nuclear envelope,
CC       thereby impairing formation of the NSP6-compartment necessary for viral
CC       transcription/replication. {ECO:0000269|PubMed:35551511}.
CC   -!- ACTIVITY REGULATION: [Papain-like protease nsp3]: Inhibited in vitro by
CC       GRL-0617. {ECO:0000269|PubMed:32726803}.
CC   -!- ACTIVITY REGULATION: [3C-like proteinase nsp5]: Inhibited by pyridone-
CC       containing alpha-ketoamides compounds 13a and 13b. In turn, alpha-
CC       ketoamide 13b (tert-butyl (1-((S)-1-(((S)-4-(benzylamino)-3,4-dioxo-1-
CC       ((S)-2-oxopyrrolidin-3-yl)butan-2-yl)amino)-3-cyclopropyl-1-oxopropan-
CC       2-yl)-2-oxo-1,2-dihydropyridin-3-yl)carbamate) inhibits SARS-CoV-2
CC       replication in human lung cells (PubMed:32198291). Inhibited ex vivo by
CC       michael acceptor inhibitor N3 (PubMed:32272481). Inhibited ex vivo by
CC       compound 11a and 11b (PubMed:32321856). {ECO:0000269|PubM",46821
ACCGGC CCGGCA CGGCAT GGCATG GCATGT CATGTA ATGTAC TGTACG GTACGC TACGCC ACGCCC CGCCCG GCCCGC CCCGCC CCGCCT CGCCTG GCCTGG CCTGGC CTGGCC TGGCCG GGCCGC GCCGCC CCGCCA CGCCAC GCCACG CCACGC CACGCT ACGCTG CGCTGC GCTGCA CTGCAC TGCACG GCACGG CACGGG ACGGGC CGGGCT GGGCTG GGCTGA GCTGAC CTGACC TGACCG GACCGG ACCGGC CCGGCA CGGCAC GGCACC GCACCG CACCGA ACCGAA CCGAAG CGAAGC GAAGCG AAGCGC AGCGCT GCGCTG CGCTGC GCTGCG CTGCGC TGCGCC GCGCCA CGCCAT GCCATG CCATGC CATGCC ATGCCG TGCCGT GCCGTC CCGTCG CGTCGC GTCGCG TCGCGC CGCGCC GCGCCG CGCCGC GCCGCA CCGCAG CGCAGG GCAGGA CAGGAC AGGACC GGACCC GACCCC ACCCCT CCCCTA CCCTAC CCTACC CTACCG TACCGC ACCGCA CCGCAC CGCACG GCACGC CACGCC ACGCCC CGCCCG GCCCGA CCCGAG CCGAGG CGAGGA GAGGAG AGGAGC GGAGCT GAGCTG AGCTGC GCTGCT CTGCTG TGCTGG GCTGGC CTGGCC TGGCCG GGCCGA GCCGAC CCGACC CGACCT GACCTG ACCTGC CCTGCG CTGCGC TGCGCA GCGCAC CGCACC GCACCA CACCAT ACCATC CCATCG CATCGA ATCGAG TCGAGG CGAGGC GAGGCC AGGCCT GGCCTC GCCTCG CCTCGC CTCGCT TCGCTG CGCTGA GCTGAA CTGAAG TGAAGA GAAGAG AAGAGC AGAGCC GAGCCA AGCCAC,3,145,ACCG CCGG CGGC GGCA GCAT CATG ATGT TGTA GTAC TACG ACGC CGCC GCCC CCCG CCGC CGCC GCCT CCTG CTGG TGGC GGCC GCCG CCGC CGCC GCCA CCAC CACG ACGC CGCT GCTG CTGC TGCA GCAC CACG ACGG CGGG GGGC GGCT GCTG CTGA TGAC GACC ACCG CCGG CGGC GGCA GCAC CACC ACCG CCGA CGAA GAAG AAGC AGCG GCGC CGCT GCTG CTGC TGCG GCGC CGCC GCCA CCAT CATG ATGC TGCC GCCG CCGT CGTC GTCG TCGC CGCG GCGC CGCC GCCG CCGC CGCA GCAG CAGG AGGA GGAC GACC ACCC CCCC CCCT CCTA CTAC TACC ACCG CCGC CGCA GCAC CACG ACGC CGCC GCCC CCCG CCGA CGAG GAGG AGGA GGAG GAGC AGCT GCTG CTGC TGCT GCTG CTGG TGGC GGCC GCCG CCGA CGAC GACC ACCT CCTG CTGC TGCG GCGC CGCA GCAC CACC ACCA CCAT CATC ATCG TCGA CGAG GAGG AGGC GGCC GCCT CCTC CTCG TCGC CGCT GCTG CTGA TGAA GAAG AAGA AGAG GAGC AGCC GCCA CCAC,ACCGG CCGGC CGGCA GGCAT GCATG CATGT ATGTA TGTAC GTACG TACGC ACGCC CGCCC GCCCG CCCGC CCGCC CGCCT GCCTG CCTGG CTGGC TGGCC GGCCG GCCGC CCGCC CGCCA GCCAC CCACG CACGC ACGCT CGCTG GCTGC CTGCA TGCAC GCACG CACGG ACGGG CGGGC GGGCT GGCTG GCTGA CTGAC TGACC GACCG ACCGG CCGGC CGGCA GGCAC GCACC CACCG ACCGA CCGAA CGAAG GAAGC AAGCG AGCGC GCGCT CGCTG GCTGC CTGCG TGCGC GCGCC CGCCA GCCAT CCATG CATGC ATGCC TGCCG GCCGT CCGTC CGTCG GTCGC TCGCG CGCGC GCGCC CGCCG GCCGC CCGCA CGCAG GCAGG CAGGA AGGAC GGACC GACCC ACCCC CCCCT CCCTA CCTAC CTACC TACCG ACCGC CCGCA CGCAC GCACG CACGC ACGCC CGCCC GCCCG CCCGA CCGAG CGAGG GAGGA AGGAG GGAGC GAGCT AGCTG GCTGC CTGCT TGCTG GCTGG CTGGC TGGCC GGCCG GCCGA CCGAC CGACC GACCT ACCTG CCTGC CTGCG TGCGC GCGCA CGCAC GCACC CACCA ACCAT CCATC CATCG ATCGA TCGAG CGAGG GAGGC AGGCC GGCCT GCCTC CCTCG CTCGC TCGCT CGCTG GCTGA CTGAA TGAAG GAAGA AAGAG AGAGC GAGCC AGCCA GCCAC,ACCGGC CCGGCA CGGCAT GGCATG GCATGT CATGTA ATGTAC TGTACG GTACGC TACGCC ACGCCC CGCCCG GCCCGC CCCGCC CCGCCT CGCCTG GCCTGG CCTGGC CTGGCC TGGCCG GGCCGC GCCGCC CCGCCA CGCCAC GCCACG CCACGC CACGCT ACGCTG CGCTGC GCTGCA CTGCAC TGCACG GCACGG CACGGG ACGGGC CGGGCT GGGCTG GGCTGA GCTGAC CTGACC TGACCG GACCGG ACCGGC CCGGCA CGGCAC GGCACC GCACCG CACCGA ACCGAA CCGAAG CGAAGC GAAGCG AAGCGC AGCGCT GCGCTG CGCTGC GCTGCG CTGCGC TGCGCC GCGCCA CGCCAT GCCATG CCATGC CATGCC ATGCCG TGCCGT GCCGTC CCGTCG CGTCGC GTCGCG TCGCGC CGCGCC GCGCCG CGCCGC GCCGCA CCGCAG CGCAGG GCAGGA CAGGAC AGGACC GGACCC GACCCC ACCCCT CCCCTA CCCTAC CCTACC CTACCG TACCGC ACCGCA CCGCAC CGCACG GCACGC CACGCC ACGCCC CGCCCG GCCCGA CCCGAG CCGAGG CGAGGA GAGGAG AGGAGC GGAGCT GAGCTG AGCTGC GCTGCT CTGCTG TGCTGG GCTGGC CTGGCC TGGCCG GGCCGA GCCGAC CCGACC CGACCT GACCTG ACCTGC CCTGCG CTGCGC TGCGCA GCGCAC CGCACC GCACCA CACCAT ACCATC CCATCG CATCGA ATCGAG TCGAGG CGAGGC GAGGCC AGGCCT GGCCTC GCCTCG CCTCGC CTCGCT TCGCTG CGCTGA GCTGAA CTGAAG TGAAGA GAAGAG AAGAGC AGAGCC GAGCCA AGCCAC,ACCGGCA CCGGCAT CGGCATG GGCATGT GCATGTA CATGTAC ATGTACG TGTACGC GTACGCC TACGCCC ACGCCCG CGCCCGC GCCCGCC CCCGCCT CCGCCTG CGCCTGG GCCTGGC CCTGGCC CTGGCCG TGGCCGC GGCCGCC GCCGCCA CCGCCAC CGCCACG GCCACGC CCACGCT CACGCTG ACGCTGC CGCTGCA GCTGCAC CTGCACG TGCACGG GCACGGG CACGGGC ACGGGCT CGGGCTG GGGCTGA GGCTGAC GCTGACC CTGACCG TGACCGG GACCGGC ACCGGCA CCGGCAC CGGCACC GGCACCG GCACCGA CACCGAA ACCGAAG CCGAAGC CGAAGCG GAAGCGC AAGCGCT AGCGCTG GCGCTGC CGCTGCG GCTGCGC CTGCGCC TGCGCCA GCGCCAT CGCCATG GCCATGC CCATGCC CATGCCG ATGCCGT TGCCGTC GCCGTCG CCGTCGC CGTCGCG GTCGCGC TCGCGCC CGCGCCG GCGCCGC CGCCGCA GCCGCAG CCGCAGG CGCAGGA GCAGGAC CAGGACC AGGACCC GGACCCC GACCCCT ACCCCTA CCCCTAC CCCTACC CCTACCG CTACCGC TACCGCA ACCGCAC CCGCACG CGCACGC GCACGCC CACGCCC ACGCCCG CGCCCGA GCCCGAG CCCGAGG CCGAGGA CGAGGAG GAGGAGC AGGAGCT GGAGCTG GAGCTGC AGCTGCT GCTGCTG CTGCTGG TGCTGGC GCTGGCC CTGGCCG TGGCCGA GGCCGAC GCCGACC CCGACCT CGACCTG GACCTGC ACCTGCG CCTGCGC CTGCGCA TGCGCAC GCGCACC CGCACCA GCACCAT CACCATC ACCATCG CCATCGA CATCGAG ATCGAGG TCGAGGC CGAGGCC GAGGCCT AGGCCTC GGCCTCG GCCTCGC CCTCGCT CTCGCTG TCGCTGA CGCTGAA GCTGAAG CTGAAGA TGAAGAG GAAGAGC AAGAGCC AGAGCCA GAGCCAC,"ID   CAPP_VEREI              Reviewed;         930 AA.
AC   A1WGR0;
DT   15-JAN-2008, integrated into UniProtKB/Swiss-Prot.
DT   06-FEB-2007, sequence version 1.
DT   05-FEB-2025, entry version 88.
DE   RecName: Full=Phosphoenolpyruvate carboxylase {ECO:0000255|HAMAP-Rule:MF_00595};
DE            Short=PEPC {ECO:0000255|HAMAP-Rule:MF_00595};
DE            Short=PEPCase {ECO:0000255|HAMAP-Rule:MF_00595};
DE            EC=4.1.1.31 {ECO:0000255|HAMAP-Rule:MF_00595};
GN   Name=ppc {ECO:0000255|HAMAP-Rule:MF_00595};
GN   OrderedLocusNames=Veis_1041;
OS   Verminephrobacter eiseniae (strain EF01-2).
OC   Bacteria; Pseudomonadota; Betaproteobacteria; Burkholderiales;
OC   Comamonadaceae; Verminephrobacter.
OX   NCBI_TaxID=391735;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=EF01-2;
RA   Copeland A., Lucas S., Lapidus A., Barry K., Detter J.C.,
RA   Glavina del Rio T., Dalin E., Tice H., Pitluck S., Chertkov O., Brettin T.,
RA   Bruce D., Han C., Tapia R., Gilna P., Schmutz J., Larimer F., Land M.,
RA   Hauser L., Kyrpides N., Kim E., Stahl D., Richardson P.;
RT   ""Complete sequence of chromosome 1 of Verminephrobacter eiseniae EF01-2."";
RL   Submitted (DEC-2006) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Forms oxaloacetate, a four-carbon dicarboxylic acid source
CC       for the tricarboxylic acid cycle. {ECO:0000255|HAMAP-Rule:MF_00595}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=oxaloacetate + phosphate = phosphoenolpyruvate +
CC         hydrogencarbonate; Xref=Rhea:RHEA:28370, ChEBI:CHEBI:16452,
CC         ChEBI:CHEBI:17544, ChEBI:CHEBI:43474, ChEBI:CHEBI:58702; EC=4.1.1.31;
CC         Evidence={ECO:0000255|HAMAP-Rule:MF_00595};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000255|HAMAP-
CC         Rule:MF_00595};
CC   -!- SIMILARITY: Belongs to the PEPCase type 1 family. {ECO:0000255|HAMAP-
CC       Rule:MF_00595}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CP000542; ABM56817.1; -; Genomic_DNA.
DR   RefSeq; WP_011808829.1; NC_008786.1.
DR   AlphaFoldDB; A1WGR0; -.
DR   SMR; A1WGR0; -.
DR   STRING; 391735.Veis_1041; -.
DR   GeneID; 76459715; -.
DR   KEGG; vei:Veis_1041; -.
DR   eggNOG; COG2352; Bacteria.
DR   HOGENOM; CLU_006557_2_0_4; -.
DR   OrthoDB; 9768133at2; -.
DR   Proteomes; UP000000374; Chromosome.
DR   GO; GO:0005829; C:cytosol; IEA:TreeGrafter.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0008964; F:phosphoenolpyruvate carboxylase activity; IEA:UniProtKB-UniRule.
DR   GO; GO:0015977; P:carbon fixation; IEA:UniProtKB-UniRule.
DR   GO; GO:0006107; P:oxaloacetate metabolic process; IEA:UniProtKB-UniRule.
DR   GO; GO:0006099; P:tricarboxylic acid cycle; IEA:InterPro.
DR   Gene3D; 1.20.1440.90; Phosphoenolpyruvate/pyruvate domain; 1.
DR   HAMAP; MF_00595; PEPcase_type1; 1.
DR   InterPro; IPR021135; PEP_COase.
DR   InterPro; IPR022805; PEP_COase_bac/pln-type.
DR   InterPro; IPR018129; PEP_COase_Lys_AS.
DR   InterPro; IPR033129; PEPCASE_His_AS.
DR   InterPro; IPR015813; Pyrv/PenolPyrv_kinase-like_dom.
DR   PANTHER; PTHR30523; PHOSPHOENOLPYRUVATE CARBOXYLASE; 1.
DR   PANTHER; PTHR30523:SF6; PHOSPHOENOLPYRUVATE CARBOXYLASE; 1.
DR   Pfam; PF00311; PEPcase; 1.
DR   PRINTS; PR00150; PEPCARBXLASE.
DR   SUPFAM; SSF51621; Phosphoenolpyruvate/pyruvate domain; 1.
DR   PROSITE; PS00781; PEPCASE_1; 1.
DR   PROSITE; PS00393; PEPCASE_2; 1.
PE   3: Inferred from homology;
KW   Carbon dioxide fixation; Lyase; Magnesium; Reference proteome.
FT   CHAIN           1..930
FT                   /note=""Phosphoenolpyruvate carboxylase""
FT                   /id=""PRO_1000025600""
FT   ACT_SITE        144
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00595""
FT   ACT_SITE        586
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00595""
SQ   SEQUENCE   930 AA;  102615 MW;  6C229CB95AE88753 CRC64;
     MQPADKDLPL MDDIRLLGRI LGDVIREQEG PRVYALVEQV RKLSVSFRRD ADQEADRALK
     KLLESLSTGQ TVGVIRAFTY FSHLANLAED RHRIRRRAVH ERAGDTQEGS IELALARLRA
     AGIAPQTIAQ TLAGSHVAPV LTAHPTEVQR KSILDAERSI AQLLAERDDI QARARLYDGA
     NDALTPRALA ANEALLRARV TQLWQTRLLR YSKLTVADEI ENALSYYEAT FLREIPEIYA
     ALENALGQHP VHSFLRMGQW IGGDRDGNPN ATAQTLQYAL GRQAEVALRH YLTEVHYLGG
     ELSLSTRLVQ VSAPMQALAL RSPDRNEHRQ DEPYRLALTG IYARLAATLK ALTGGEAARH
     AVAPQNAYAS AQEFLADLRV IEDSLTAHHG AALAAGRLHP LIRAVQVFGF HLATVDLRQS
     SDKHELVVAE LLATARVQER YADLPEAGKR ALLIRLLNDA RPLRVVGARY SAHAQGELAI
     FETARALRER FGAEAIRHYI ISHTETMSDL LEVLLLHKEV GLMSGTLDDA AARNQLIVVP
     LFETIADLRN AAPIMREFYA LPGVAALVQR SGGEQDIMLG YSDSNKDGGI FTSNWELYRA
     EIALVQLFDE LAASHGIQLR MFHGRGGTVG RGGGPSYQAI LAQPPGTVRG QIRLTEQGEV
     IASKYANPEI GRRNLEILVA ATLEATLLQP TKPAPKTFLA AAGQLSQASM AAYRALVYET
     PGFTEYFFNA TPIREIAELN IGSRPAARKA SQKIEDLRAI PWGFSWGQCR LTLPGWYGFG
     AAVAAFVNLQ GKTPGAQLAL LQRMYRQWPF FRTLLSNMDM VLAKSDLALA GRYSELVSDA
     RLRKKVFAAI EAEWHSTADA LSRITGDQQR LAHNSALARS IKHRFAYIDP LHHLQVELVR
     RWRAGQDDER VQTGIHISIN GIAAGLRNTG
//
",23643
CAATAT AATATG ATATGA TATGAG ATGAGT TGAGTA GAGTAT AGTATG GTATGG TATGGT ATGGTA TGGTAC GGTACT GTACTG TACTGA ACTGAA CTGAAG TGAAGA GAAGAT AAGATG AGATGA GATGAT ATGATT TGATTA GATTAC ATTACC TTACCA TACCAA ACCAAG CCAAGG CAAGGT AAGGTA AGGTAA GGTAAA GTAAAC TAAACC AAACCT AACCTT ACCTTT CCTTTG CTTTGG TTTGGA TTGGAA TGGAAT GGAATT GAATTT AATTTG ATTTGG TTTGGT TTGGTG TGGTGC GGTGCC GTGCCA TGCCAC GCCACT CCACTT CACTTC ACTTCT CTTCTG TTCTGC TCTGCT CTGCTG TGCTGC GCTGCT CTGCTC TGCTCT GCTCTT CTCTTC TCTTCA CTTCAA TTCAAC TCAACC CAACCT AACCTG ACCTGA CCTGAA CTGAAG TGAAGA GAAGAA AAGAAG AGAAGA GAAGAG AAGAGC AGAGCA GAGCAA AGCAAG GCAAGA CAAGAA AAGAAG AGAAGA GAAGAA AAGAAG AGAAGA GAAGAT AAGATT AGATTG GATTGG ATTGGT TTGGTT TGGTTA GGTTAG GTTAGA TTAGAT TAGATG AGATGA GATGAT ATGATG TGATGA GATGAT ATGATA TGATAG GATAGT ATAGTC TAGTCC AGTCCT GTCCTG TCCTGT CCTGTC CTGTCT TGTCTC GTCTCT TCTCTT CTCTTA TCTTAT CTTATA TTATAC TATACA ATACAC TACACA ACACAT CACATT ACATTC CATTCC ATTCCG TTCCGA TCCGAG CCGAGC CGAGCC GAGCCC AGCCCA GCCCAC CCCACG CCACGA CACGAG ACGAGA,0,145,CAAT AATA ATAT TATG ATGA TGAG GAGT AGTA GTAT TATG ATGG TGGT GGTA GTAC TACT ACTG CTGA TGAA GAAG AAGA AGAT GATG ATGA TGAT GATT ATTA TTAC TACC ACCA CCAA CAAG AAGG AGGT GGTA GTAA TAAA AAAC AACC ACCT CCTT CTTT TTTG TTGG TGGA GGAA GAAT AATT ATTT TTTG TTGG TGGT GGTG GTGC TGCC GCCA CCAC CACT ACTT CTTC TTCT TCTG CTGC TGCT GCTG CTGC TGCT GCTC CTCT TCTT CTTC TTCA TCAA CAAC AACC ACCT CCTG CTGA TGAA GAAG AAGA AGAA GAAG AAGA AGAG GAGC AGCA GCAA CAAG AAGA AGAA GAAG AAGA AGAA GAAG AAGA AGAT GATT ATTG TTGG TGGT GGTT GTTA TTAG TAGA AGAT GATG ATGA TGAT GATG ATGA TGAT GATA ATAG TAGT AGTC GTCC TCCT CCTG CTGT TGTC GTCT TCTC CTCT TCTT CTTA TTAT TATA ATAC TACA ACAC CACA ACAT CATT ATTC TTCC TCCG CCGA CGAG GAGC AGCC GCCC CCCA CCAC CACG ACGA CGAG GAGA,CAATA AATAT ATATG TATGA ATGAG TGAGT GAGTA AGTAT GTATG TATGG ATGGT TGGTA GGTAC GTACT TACTG ACTGA CTGAA TGAAG GAAGA AAGAT AGATG GATGA ATGAT TGATT GATTA ATTAC TTACC TACCA ACCAA CCAAG CAAGG AAGGT AGGTA GGTAA GTAAA TAAAC AAACC AACCT ACCTT CCTTT CTTTG TTTGG TTGGA TGGAA GGAAT GAATT AATTT ATTTG TTTGG TTGGT TGGTG GGTGC GTGCC TGCCA GCCAC CCACT CACTT ACTTC CTTCT TTCTG TCTGC CTGCT TGCTG GCTGC CTGCT TGCTC GCTCT CTCTT TCTTC CTTCA TTCAA TCAAC CAACC AACCT ACCTG CCTGA CTGAA TGAAG GAAGA AAGAA AGAAG GAAGA AAGAG AGAGC GAGCA AGCAA GCAAG CAAGA AAGAA AGAAG GAAGA AAGAA AGAAG GAAGA AAGAT AGATT GATTG ATTGG TTGGT TGGTT GGTTA GTTAG TTAGA TAGAT AGATG GATGA ATGAT TGATG GATGA ATGAT TGATA GATAG ATAGT TAGTC AGTCC GTCCT TCCTG CCTGT CTGTC TGTCT GTCTC TCTCT CTCTT TCTTA CTTAT TTATA TATAC ATACA TACAC ACACA CACAT ACATT CATTC ATTCC TTCCG TCCGA CCGAG CGAGC GAGCC AGCCC GCCCA CCCAC CCACG CACGA ACGAG CGAGA,CAATAT AATATG ATATGA TATGAG ATGAGT TGAGTA GAGTAT AGTATG GTATGG TATGGT ATGGTA TGGTAC GGTACT GTACTG TACTGA ACTGAA CTGAAG TGAAGA GAAGAT AAGATG AGATGA GATGAT ATGATT TGATTA GATTAC ATTACC TTACCA TACCAA ACCAAG CCAAGG CAAGGT AAGGTA AGGTAA GGTAAA GTAAAC TAAACC AAACCT AACCTT ACCTTT CCTTTG CTTTGG TTTGGA TTGGAA TGGAAT GGAATT GAATTT AATTTG ATTTGG TTTGGT TTGGTG TGGTGC GGTGCC GTGCCA TGCCAC GCCACT CCACTT CACTTC ACTTCT CTTCTG TTCTGC TCTGCT CTGCTG TGCTGC GCTGCT CTGCTC TGCTCT GCTCTT CTCTTC TCTTCA CTTCAA TTCAAC TCAACC CAACCT AACCTG ACCTGA CCTGAA CTGAAG TGAAGA GAAGAA AAGAAG AGAAGA GAAGAG AAGAGC AGAGCA GAGCAA AGCAAG GCAAGA CAAGAA AAGAAG AGAAGA GAAGAA AAGAAG AGAAGA GAAGAT AAGATT AGATTG GATTGG ATTGGT TTGGTT TGGTTA GGTTAG GTTAGA TTAGAT TAGATG AGATGA GATGAT ATGATG TGATGA GATGAT ATGATA TGATAG GATAGT ATAGTC TAGTCC AGTCCT GTCCTG TCCTGT CCTGTC CTGTCT TGTCTC GTCTCT TCTCTT CTCTTA TCTTAT CTTATA TTATAC TATACA ATACAC TACACA ACACAT CACATT ACATTC CATTCC ATTCCG TTCCGA TCCGAG CCGAGC CGAGCC GAGCCC AGCCCA GCCCAC CCCACG CCACGA CACGAG ACGAGA,CAATATG AATATGA ATATGAG TATGAGT ATGAGTA TGAGTAT GAGTATG AGTATGG GTATGGT TATGGTA ATGGTAC TGGTACT GGTACTG GTACTGA TACTGAA ACTGAAG CTGAAGA TGAAGAT GAAGATG AAGATGA AGATGAT GATGATT ATGATTA TGATTAC GATTACC ATTACCA TTACCAA TACCAAG ACCAAGG CCAAGGT CAAGGTA AAGGTAA AGGTAAA GGTAAAC GTAAACC TAAACCT AAACCTT AACCTTT ACCTTTG CCTTTGG CTTTGGA TTTGGAA TTGGAAT TGGAATT GGAATTT GAATTTG AATTTGG ATTTGGT TTTGGTG TTGGTGC TGGTGCC GGTGCCA GTGCCAC TGCCACT GCCACTT CCACTTC CACTTCT ACTTCTG CTTCTGC TTCTGCT TCTGCTG CTGCTGC TGCTGCT GCTGCTC CTGCTCT TGCTCTT GCTCTTC CTCTTCA TCTTCAA CTTCAAC TTCAACC TCAACCT CAACCTG AACCTGA ACCTGAA CCTGAAG CTGAAGA TGAAGAA GAAGAAG AAGAAGA AGAAGAG GAAGAGC AAGAGCA AGAGCAA GAGCAAG AGCAAGA GCAAGAA CAAGAAG AAGAAGA AGAAGAA GAAGAAG AAGAAGA AGAAGAT GAAGATT AAGATTG AGATTGG GATTGGT ATTGGTT TTGGTTA TGGTTAG GGTTAGA GTTAGAT TTAGATG TAGATGA AGATGAT GATGATG ATGATGA TGATGAT GATGATA ATGATAG TGATAGT GATAGTC ATAGTCC TAGTCCT AGTCCTG GTCCTGT TCCTGTC CCTGTCT CTGTCTC TGTCTCT GTCTCTT TCTCTTA CTCTTAT TCTTATA CTTATAC TTATACA TATACAC ATACACA TACACAT ACACATT CACATTC ACATTCC CATTCCG ATTCCGA TTCCGAG TCCGAGC CCGAGCC CGAGCCC GAGCCCA AGCCCAC GCCCACG CCCACGA CCACGAG CACGAGA,"ID   R1A_SARS                Reviewed;        4382 AA.
AC   P0C6U8; P59641;
DT   10-JUN-2008, integrated into UniProtKB/Swiss-Prot.
DT   10-JUN-2008, sequence version 1.
DT   05-FEB-2025, entry version 124.
DE   RecName: Full=Replicase polyprotein 1a;
DE            Short=pp1a;
DE   AltName: Full=ORF1a polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3;
DE              Short=PL-PRO;
DE              EC=3.4.19.12 {ECO:0000269|PubMed:17692280};
DE              EC=3.4.22.- {ECO:0000269|PubMed:12917450, ECO:0000269|PubMed:16306590, ECO:0000269|PubMed:17692280};
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:12917450};
DE     AltName: Full=Main protease;
DE              Short=Mpro;
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=RNA-capping enzyme subunit nsp9;
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE              EC=2.7.7.50;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=Non-structural protein 11;
DE              Short=nsp11;
GN   ORFNames=1a;
OS   Severe acute respiratory syndrome coronavirus (SARS-CoV).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=694009;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
OH   NCBI_TaxID=9675; Paguma larvata (Masked palm civet).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Urbani;
RX   PubMed=12730500; DOI=10.1126/science.1085952;
RA   Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R.,
RA   Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.-H., Tong S.,
RA   Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D.,
RA   Peret T.C.T., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S.,
RA   Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R.,
RA   Guenther S., Osterhaus A.D.M.E., Drosten C., Pallansch M.A., Anderson L.J.,
RA   Bellini W.J.;
RT   ""Characterization of a novel coronavirus associated with severe acute
RT   respiratory syndrome."";
RL   Science 300:1394-1399(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Tor2;
RX   PubMed=12730501; DOI=10.1126/science.1085953;
RA   Marra M.A., Jones S.J.M., Astell C.R., Holt R.A., Brooks-Wilson A.,
RA   Butterfield Y.S.N., Khattra J., Asano J.K., Barber S.A., Chan S.Y.,
RA   Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffith O.L., Leach S.R.,
RA   Mayo M., McDonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S.,
RA   Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.M.,
RA   Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K.,
RA   Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R.,
RA   Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A.,
RA   Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S.,
RA   Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M.,
RA   Skowronski D.M., Upton C., Roper R.L.;
RT   ""The genome sequence of the SARS-associated coronavirus."";
RL   Science 300:1399-1404(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate CUHK-Su10, and Isolate CUHK-W1;
RX   PubMed=12853594; DOI=10.1056/nejm200307103490216;
RA   Tsui S.K.W., Chim S.S.C., Lo Y.M.D.;
RT   ""Coronavirus genomic-sequence variations and the epidemiology of the severe
RT   acute respiratory syndrome."";
RL   N. Engl. J. Med. 349:187-188(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate GZ50, Isolate SZ16, and Isolate SZ3;
RX   PubMed=12958366; DOI=10.1126/science.1087139;
RA   Guan Y., Zheng B.J., He Y.Q., Liu X.L., Zhuang Z.X., Cheung C.L., Luo S.W.,
RA   Li P.H., Zhang L.J., Guan Y.J., Butt K.M., Wong K.L., Chan K.W., Lim W.,
RA   Shortridge K.F., Yuen K.Y., Peiris J.S.M., Poon L.L.M.;
RT   ""Isolation and characterization of viruses related to the SARS coronavirus
RT   from animals in southern China."";
RL   Science 302:276-278(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HKU-39849;
RX   PubMed=12876307; DOI=10.1177/15353702-0322807-13;
RA   Zeng F.Y., Chan C.W., Chan M.N., Chen J.D., Chow K.Y.C., Hon C.C.C.,
RA   Hui R.K.H., Li J., Li V.Y.Y., Wang C.Y., Wang P.Y., Guan Y., Zheng B.,
RA   Poon L.L.M., Chan K.H., Yuen K.Y., Peiris J.S.M., Leung F.C.;
RT   ""The complete genome sequence of severe acute respiratory syndrome
RT   coronavirus strain HKU-39849 (HK-39)."";
RL   Exp. Biol. Med. 228:866-873(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Sin2500, Isolate Sin2677, Isolate Sin2679, Isolate
RC   Sin2748, and Isolate sin2774;
RX   PubMed=12781537; DOI=10.1016/s0140-6736(03)13414-9;
RA   Ruan Y., Wei C.L., Ling A.E., Vega V.B., Thoreau H., Se Thoe S.Y.,
RA   Chia J.-M., Ng P., Chiu K.P., Lim L., Zhang T., Chan K.P., Oon L.E.L.,
RA   Ng M.L., Leo S.Y., Ng L.F.P., Ren E.C., Stanton L.W., Long P.M., Liu E.T.;
RT   ""Comparative full-length genome sequence analysis of 14 SARS coronavirus
RT   isolates and common mutations associated with putative origins of
RT   infection."";
RL   Lancet 361:1779-1785(2003).
RN   [7]
RP   ERRATUM OF PUBMED:12781537.
RA   Ruan Y., Wei C.L., Ling A.E., Vega V.B., Thoreau H., Se Thoe S.Y.,
RA   Chia J.-M., Ng P., Chiu K.P., Lim L., Zhang T., Chan K.P., Oon L.E.L.,
RA   Ng M.L., Leo S.Y., Ng L.F.P., Ren E.C., Stanton L.W., Long P.M., Liu E.T.;
RL   Lancet 361:1832-1832(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate ZJ01;
RX   PubMed=14527350;
RA   Li L., Wang Z., Lu Y., Bao Q., Chen S., Wu N., Cheng S., Weng J., Zhang Y.,
RA   Yan J., Mei L., Wang X., Zhu H., Yu Y., Zhang M., Li M., Yao J., Lu Q.,
RA   Yao P., Bo X., Wo J., Wang S., Hu S.;
RT   ""Severe acute respiratory syndrome-associated coronavirus genotype and its
RT   characterization."";
RL   Chin. Med. J. 116:1288-1292(2003).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate BJ01, Isolate BJ02, Isolate BJ03, Isolate BJ04, and
RC   Isolate GD01;
RA   Qin E., Zhu Q., Yu M., Fan B., Chang G., Si B., Yang B., Peng W., Jiang T.,
RA   Liu B., Deng Y., Liu H., Zhang Y., Wang C., Li Y., Gan Y., Li X., Lu F.,
RA   Tan G., Yang R., Cao W.S., Wang J., Chen W., Cong L., Deng Y., Dong W.,
RA   Han Y., Hu W., Lei M., Li C., Li G., Li G., Li H., Li S., Li S., Li W.,
RA   Li W., Lin W., Liu J., Liu Z., Lu H., Ni P., Qi Q., Sun Y., Tang L.,
RA   Tong Z., Wang J., Wang X., Wu Q., Xi Y., Xu Z., Yang L., Ye C., Ye J.,
RA   Zhang B., Zhang F., Zhang J., Zhang X., Zhou J., Yang H.;
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TW1;
RA   Yeh S.-H., Kao C.-L., Tsai C.-Y., Liu C.-J., Chen D.-S., Chen P.-J.;
RT   ""The complete genome of SARS coronavirus clone TW1."";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate FRA;
RX   PubMed=14645828; DOI=10.1126/science.302.5650.1504b;
RA   Eickmann M., Becker S., Klenk H.-D., Doerr H.W., Stadler K., Censini S.,
RA   Guidotti S., Masignani V., Scarselli M., Mora M., Donati C., Han J.H.,
RA   Song H.C., Abrignani S., Covacci A., Rappuoli R.;
RT   ""Phylogeny of the SARS coronavirus."";
RL   Science 302:1504-1505(2003).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Frankfurt-1;
RA   Thiel V., Hertzig T., Putics A., Ivanov K.A., Schelle B., Bayer S.,
RA   Scheiner B., Weinand H., Weissbrich B., Ziebuhr J.;
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWC;
RA   Yang J.-Y., Lin J.-H., Chiu S.-C., Wang S.-F., Lee S.C., Lin Y.-C.,
RA   Hsu C.-K., Chen H.-Y., Chang J.G., Chen P.-J., Su I.-J.;
RT   ""Genomic sequence of SARS isolate from the first fatal case in Taiwan."";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Shanghai QXC1;
RA   Yuan Z., Zhang X., Hu Y., Lan S., Wang H., Zhou Z., Wen Y.;
RT   ""Analysis of SARS coronavirus genome in Shanghai isolates."";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HSR 1;
RA   Canducci F., Clementi M., Poli G., Vicenzi E.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [16]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Taiwan TC1, Isolate Taiwan TC2, and Isolate Taiwan TC3;
RA   Chang J.-G.C., Lin T.-H., Chen C.-M., Lin C.-S., Chan W.-L., Shih M.-C.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [17]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWH, Isolate TWJ, Isolate TWK, Isolate TWS, and Isolate
RC   TWY;
RA   Shu H.Y., Wu K.M., Tsai S.F.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [18]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate AS;
RA   Balotta C., Corvasce S., Violin M., Galli M., Moroni M., Vigevani G.M.,
RA   Ruan Y.J., Salemi M.;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [19]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate ZJ01;
RA   Wang Z., Cheng S., Zhang Y.;
RL   Submitted (NOV-2003) to the EMBL/GenBank/DDBJ databases.
RN   [20]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA] OF 1-507 AND 1655-4382.
RC   STRAIN=Isolate Shanghai LY;
RA   Yuan Z., Zhang X., Hu Y., Lan S., Wang H., Zhou Z., Wen Y.;
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [21]
RP   PROTEOLYTIC CLEAVAGE (ISOFORM REPLICASE POLYPROTEIN 1A), CATALYTIC ACTIVITY
RP   (3C-LIKE PROTEINASE NSP5), AND CATALYTIC ACTIVITY (PAPAIN-LIKE PROTEASE
RP   NSP3).
RX   PubMed=12917450; DOI=10.1099/vir.0.19424-0;
RA   Thiel V., Ivanov K.A., Putics A., Hertzig T., Schelle B., Bayer S.,
RA   Weissbrich B., Snijder E.J., Rabenau H., Doerr H.W., Gorbalenya A.E.,
RA   Ziebuhr J.;
RT   ""Mechanisms and enzymes involved in SARS coronavirus genome expression."";
RL   J. Gen. Virol. 84:2305-2315(2003).
RN   [22]
RP   PROTEOLYTIC CLEAVAGE (ISOFORM REPLICASE POLYPROTEIN 1A).
RX   PubMed=15331731; DOI=10.1128/jvi.78.18.9977-9986.2004;
RA   Prentice E., McAuliffe J., Lu X., Subbarao K., Denison M.R.;
RT   ""Identification and characterization of severe acute respiratory syndrome
RT   coronavirus replicase proteins."";
RL   J. Virol. 78:9977-9986(2004).
RN   [23]
RP   PROTEOLYTIC CLEAVAGE (ISOFORM REPLICASE POLYPROTEIN 1A).
RC   STRAIN=Isolate Urbani;
RX   PubMed=15564471; DOI=10.1128/jvi.78.24.13600-13612.2004;
RA   Harcourt B.H., Jukneliene D., Kanjanahaluethai A., Bechill J.,
RA   Severson K.M., Smith C.M., Rota P.A., Baker S.C.;
RT   ""Identification of severe acute respiratory syndrome coronavirus replicase
RT   products and characterization of papain-like protease activity."";
RL   J. Virol. 78:13600-13612(2004).
RN   [24]
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), AND BIOPHYSICOCHEMICAL PROPERTIES (3C-LIKE PROTEINASE NSP5).
RX   PubMed=14561748; DOI=10.1074/jbc.m310875200;
RA   Fan K., Wei P., Feng Q., Chen S., Huang C., Ma L., Lai B., Pei J., Liu Y.,
RA   Chen J., Lai L.;
RT   ""Biosynthesis, purification, and substrate specificity of severe acute
RT   respiratory syndrome coronavirus 3C-like proteinase."";
RL   J. Biol. Chem. 279:1637-1642(2004).
RN   [25]
RP   CATALYTIC ACTIVITY (PAPAIN-LIKE PROTEASE NSP3), FUNCTION (PAPAIN-LIKE
RP   PROTEASE NSP3), PROTEOLYTIC CLEAVAGE (ISOFORM REPLICASE POLYPROTEIN 1A),
RP   COFACTOR (PAPAIN-LIKE PROTEASE NSP3), MUTAGENESIS OF CYS-1651; CYS-1688;
RP   CYS-1729; CYS-1732; CYS-1764; CYS-1766 AND ASP-1826, AND ACTIVE SITE
RP   (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=16306590; DOI=10.1128/jvi.79.24.15189-15198.2005;
RA   Barretto N., Jukneliene D., Ratia K., Chen Z., Mesecar A.D., Baker S.C.;
RT   ""The papain-like protease of severe acute respiratory syndrome coronavirus
RT   has deubiquitinating activity."";
RL   J. Virol. 79:15189-15198(2005).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=16226257; DOI=10.1016/j.febslet.2005.09.075;
RA   Lin C.W., Tsai F.J., Wan L., Lai C.C., Lin K.H., Hsieh T.H., Shiu S.Y.,
RA   Li J.Y.;
RT   ""Binding interaction of SARS coronavirus 3CL(pro) protease with vacuolar-H+
RT   ATPase G1 subunit."";
RL   FEBS Lett. 579:6089-6094(2005).
RN   [27]
RP   SUBUNIT (3C-LIKE PROTEINASE NSP5).
RX   PubMed=15507456; DOI=10.1074/jbc.m408211200;
RA   Chen S., Chen L., Tan J., Chen J., Du L., Sun T., Shen J., Chen K.,
RA   Jiang H., Shen X.;
RT   ""Severe acute respiratory syndrome coronavirus 3C-like proteinase N
RT   terminus is indispensable for proteolytic activity but not for enzyme
RT   dimerization. Biochemical and thermodynamic investigation in conjunction
RT   with molecular dynamics simulations."";
RL   J. Biol. Chem. 280:164-173(2005).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=17024178; DOI=10.1038/sj.emboj.7601368;
RA   Imbert I., Guillemot J.-C., Bourhis J.-M., Bussetta C., Coutard B.,
RA   Egloff M.-P., Ferron F., Gorbalenya A.E., Canard B.;
RT   ""A second, non-canonical RNA-dependent RNA polymerase in SARS
RT   coronavirus."";
RL   EMBO J. 25:4933-4942(2006).
RN   [29]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3).
RX   PubMed=17692280; DOI=10.1016/j.abb.2007.07.006;
RA   Lindner H.A., Lytvyn V., Qi H., Lachance P., Ziomek E., Menard R.;
RT   ""Selectivity in ISG15 and ubiquitin recognition by the SARS coronavirus
RT   papain-like protease."";
RL   Arch. Biochem. Biophys. 466:8-14(2007).
RN   [30]
RP   INTERACTION WITH ORF6 PROTEIN (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=17532020; DOI=10.1016/j.virol.2007.04.029;
RA   Kumar P., Gunalan V., Liu B., Chow V.T., Druce J., Birch C., Catton M.,
RA   Fielding B.C., Tan Y.J., Lal S.K.;
RT   ""The nonstructural protein 8 (nsp8) of the SARS coronavirus interacts with
RT   its ORF6 accessory protein."";
RL   Virology 366:293-303(2007).
RN   [31]
RP   TOPOLOGY (PAPAIN-LIKE PROTEASE NSP3), TOPOLOGY (NON-STRUCTURAL PROTEIN 4),
RP   AND TOPOLOGY (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=18842706; DOI=10.1128/jvi.01219-08;
RA   Oostra M., Hagemeijer M.C., van Gent M., Bekker C.P., te Lintelo E.G.,
RA   Rottier P.J., de Haan C.A.;
RT   ""Topology and membrane anchoring of the coronavirus replication complex:
RT   not all hydrophobic domains of nsp3 and nsp6 are membrane spanning."";
RL   J. Virol. 82:12392-12405(2008).
RN   [32]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=19369340; DOI=10.1128/jvi.02220-08;
RA   Frieman M., Ratia K., Johnston R.E., Mesecar A.D., Baric R.S.;
RT   ""Severe acute respiratory syndrome coronavirus papain-like protease
RT   ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and
RT   NF-kappaB signaling."";
RL   J. Virol. 83:6689-6705(2009).
RN   [33]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), AND INTERACTION WITH HOST PHB AND PHB2
RP   (NON-STRUCTURAL PROTEIN 2).
RX   PubMed=19640993; DOI=10.1128/jvi.00842-09;
RA   Cornillez-Ty C.T., Liao L., Yates J.R., Kuhn P., Buchmeier M.J.;
RT   ""Severe acute respiratory syndrome coronavirus nonstructural protein 2
RT   interacts with a host protein complex involved in mitochondrial biogenesis
RT   and intracellular signaling."";
RL   J. Virol. 83:10314-10318(2009).
RN   [34]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=19153232; DOI=10.1128/jvi.01505-08;
RA   Miknis Z.J., Donaldson E.F., Umland T.C., Rimmer R.A., Baric R.S.,
RA   Schultz L.W.;
RT   ""Severe acute respiratory syndrome coronavirus nsp9 dimerization is
RT   essential for efficient viral growth."";
RL   J. Virol. 83:3007-3018(2009).
RN   [35]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=22174690; DOI=10.1371/journal.ppat.1002433;
RA   Huang C., Lokugamage K.G., Rozovics J.M., Narayanan K., Semler B.L.,
RA   Makino S.;
RT   ""SARS coronavirus nsp1 protein induces template-dependent endonucleolytic
RT   cleavage of mRNAs: viral mRNAs are resistant to nsp1-induced RNA
RT   cleavage."";
RL   PLoS Pathog. 7:E1002433-E1002433(2011).
RN   [36]
RP   INTERACTION WITH PAPAIN-LIKE PROTEASE NSP3 (NON-STRUCTURAL PROTEIN 4),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 4), AND INTERACTION WITH
RP   NON-STRUCTURAL PROTEIN 6 (NON-STRUCTURAL PROTEIN 4).
RX   PubMed=21345958; DOI=10.1128/jvi.00042-11;
RA   Hagemeijer M.C., Ulasli M., Vonk A.M., Reggiori F., Rottier P.J.,
RA   de Haan C.A.;
RT   ""Mobility and interactions of coronavirus nonstructural protein 4."";
RL   J. Virol. 85:4572-4577(2011).
RN   [37]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=23035226; DOI=10.1128/jvi.01958-12;
RA   Lokugamage K.G., Narayanan K., Huang C., Makino S.;
RT   ""Severe acute respiratory syndrome coronavirus protein nsp1 is a novel
RT   eukaryotic translation inhibitor that represses multiple steps of
RT   translation initiation."";
RL   J. Virol. 86:13598-13608(2012).
RN   [38]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 7), AND FUNCTION (NON-STRUCTURAL PROTEIN
RP   8).
RX   PubMed=22039154; DOI=10.1093/nar/gkr893;
RA   te Velthuis A.J., van den Worm S.H., Snijder E.J.;
RT   ""The SARS-coronavirus nsp7+nsp8 complex is a unique multimeric RNA
RT   polymerase capable of both de novo initiation and primer extension."";
RL   Nucleic Acids Res. 40:1737-1747(2012).
RN   [39]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 10), AND INTERACTION WITH PROOFREADING
RP   EXORIBONUCLEASE NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=22635272; DOI=10.1073/pnas.1201130109;
RA   Bouvet M., Imbert I., Subissi L., Gluais L., Canard B., Decroly E.;
RT   ""RNA 3'-end mismatch excision by the severe acute respiratory syndrome
RT   coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complex."";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:9372-9377(2012).
RN   [40]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 4), FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND FUNCTION
RP   (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=23943763; DOI=10.1128/mbio.00524-13;
RA   Angelini M.M., Akhlaghpour M., Neuman B.W., Buchmeier M.J.;
RT   ""Severe acute respiratory syndrome coronavirus nonstructural proteins 3, 4,
RT   and 6 induce double-membrane vesicles."";
RL   MBio 4:0-0(2013).
RN   [41]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=24991833; DOI=10.4161/auto.29309;
RA   Cottam E.M., Whelband M.C., Wileman T.;
RT   ""Coronavirus NSP6 restricts autophagosome expansion."";
RL   Autophagy 10:1426-1441(2014).
RN   [42]
RP   REVIEW.
RX   PubMed=24410069; DOI=10.1089/dna.2013.2304;
RA   Angelini M.M., Neuman B.W., Buchmeier M.J.;
RT   ""Untangling membrane rearrangement in the nidovirales."";
RL   DNA Cell Biol. 33:122-127(2014).
RN   [43]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=24622840; DOI=10.1007/s13238-014-0026-3;
RA   Chen X., Yang X., Zheng Y., Yang Y., Xing Y., Chen Z.;
RT   ""SARS coronavirus papain-like protease inhibits the type I interferon
RT   signaling pathway through interaction with the STING-TRAF3-TBK1 complex."";
RL   Protein Cell 5:369-381(2014).
RN   [44]
RP   INTERACTION WITH NUP93 (HOST TRANSLATION INHIBITOR NSP1), AND FUNCTION
RP   (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=30943371; DOI=10.1139/bcb-2018-0394;
RA   Gomez G.N., Abrar F., Dodhia M.P., Gonzalez F.G., Nag A.;
RT   ""SARS coronavirus protein nsp1 disrupts localization of Nup93 from the
RT   nuclear pore complex."";
RL   Biochem. Cell Biol. 97:758-766(2019).
RN   [45]
RP   PROTEOLYTIC CLEAVAGE (ISOFORM REPLICASE POLYPROTEIN 1A), MASS SPECTROMETRY
RP   (NON-STRUCTURAL PROTEIN 8), MASS SPECTROMETRY (NON-STRUCTURAL PROTEIN 9),
RP   AND MASS SPECTROMETRY (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=32083638; DOI=10.1042/bcj20200029;
RA   Krichel B., Falke S., Hilgenfeld R., Redecke L., Uetrecht C.;
RT   ""Processing of the SARS-CoV pp1a/ab nsp7-10 region."";
RL   Biochem. J. 477:1009-1019(2020).
RN   [46]
RP   3D-STRUCTURE MODELING OF 3241-3540, AND CHARACTERIZATION (3C-LIKE
RP   PROTEINASE NSP5).
RX   PubMed=12746549; DOI=10.1126/science.1085658;
RA   Anand K., Ziebuhr J., Wadhwani P., Mesters J.R., Hilgenfeld R.;
RT   ""Coronavirus main proteinase (3CLpro) structure: basis for design of anti-
RT   SARS drugs."";
RL   Science 300:1763-1767(2003).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 4118-4230 (NON-STRUCTURAL PROTEIN
RP   9).
RC   STRAIN=Isolate Frankfurt-1;
RX   PubMed=12925794; DOI=10.1107/s0907444903016779;
RA   Campanacci V., Egloff M.-P., Longhi S., Ferron F., Rancurel C.,
RA   Salomoni A., Durousseau C., Tocque F., Bremond N., Dobbe J.C.,
RA   Snijder E.J., Canard B., Cambillau C.;
RT   ""Structural genomics of the SARS coronavirus: cloning, expression,
RT   crystallization and preliminary crystallographic study of the Nsp9
RT   protein."";
RL   Acta Crystallogr. D 59:1628-1631(2003).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 4118-4230.
RX   PubMed=15007178; DOI=10.1073/pnas.0307877101;
RA   Egloff M.-P., Ferron F., Campanacci V., Longhi S., Rancurel C.,
RA   Dutartre H., Snijder E.J., Gorbalenya A.E., Cambillau C., Canard B.;
RT   ""The severe acute respiratory syndrome-coronavirus replicative protein nsp9
RT   is a single-stranded RNA-binding subunit unique in the RNA virus world."";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:3792-3796(2004).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 4107-4230.
RX   PubMed=14962394; DOI=10.1016/j.str.2004.01.016;
RA   Sutton G., Fry E., Carter L., Sainsbury S., Walter T., Nettleship J.,
RA   Berrow N., Owens R., Gilbert R., Davidson A., Siddell S., Poon L.L.M.,
RA   Diprose J., Alderton D., Walsh M., Grimes J.M., Stuart D.I.;
RT   ""The nsp9 replicase protein of SARS-coronavirus, structure and functional
RT   insights."";
RL   Structure 12:341-353(2004).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 3837-4117 AND 3920-4117,
RP   INTERACTION WITH NON-STRUCTURAL PROTEIN 7 (NON-STRUCTURAL PROTEIN 8), AND
RP   INTERACTION WITH NON-STRUCTURAL PROTEIN 8 (NON-STRUCTURAL PROTEIN 7).
RX   PubMed=16228002; DOI=10.1038/nsmb999;
RA   Zhai Y., Sun F., Li X., Pang H., Xu X., Bartlam M., Rao Z.;
RT   ""Insights into SARS-CoV transcription and replication from the structure of
RT   the nsp7-nsp8 hexadecamer."";
RL   Nat. Struct. Mol. Biol. 12:980-986(2005).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 1002-1176.
RX   PubMed=16271890; DOI=10.1016/j.str.2005.07.022;
RA   Saikatendu K.S., Joseph J.S., Subramanian V., Clayton T., Griffith M.,
RA   Moy K., Velasquez J., Neuman B.W., Buchmeier M.J., Stevens R.C., Kuhn P.;
RT   ""Structural basis of severe acute respiratory syndrome coronavirus ADP-
RT   ribose-1''-phosphate dephosphorylation by a conserved domain of nsP3."";
RL   Structure 13:1665-1675(2005).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 1541-1854.
RX   PubMed=16581910; DOI=10.1073/pnas.0510851103;
RA   Ratia K., Saikatendu K.S., Santarsiero B.D., Barretto N., Baker S.C.,
RA   Stevens R.C., Mesecar A.D.;
RT   ""Severe acute respiratory syndrome coronavirus papain-like protease:
RT   structure of a viral deubiquitinating enzyme."";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:5717-5722(2006).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 4240-4362.
RC   STRAIN=Isolate Tor2;
RX   PubMed=16873246; DOI=10.1128/jvi.00467-06;
RA   Joseph J.S., Saikatendu K.S., Subramanian V., Neuman B.W., Brooun A.,
RA   Griffith M., Moy K., Yadav M.K., Velasquez J., Buchmeier M.J.,
RA   Stevens R.C., Kuhn P.;
RT   ""Crystal structure of nonstructural protein 10 from the severe acute
RT   respiratory syndrome coronavirus reveals a novel fold with two zinc-binding
RT   motifs."";
RL   J. Virol. 80:7894-7901(2006).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 4231-4378.
RX   PubMed=16873247; DOI=10.1128/jvi.00483-06;
RA   Su D., Lou Z., Sun F., Zhai Y., Yang H., Zhang R., Joachimiak A.,
RA   Zhang X.C., Bartlam M., Rao Z.;
RT   ""Dodecamer structure of severe acute respiratory syndrome coronavirus
RT   nonstructural protein nsp10."";
RL   J. Virol. 80:7902-7908(2006).
RN   [55]
RP   STRUCTURE BY NMR OF 13-127.
RX   PubMed=17202208; DOI=10.1128/jvi.01939-06;
RA   Almeida M.S., Johnson M.A., Herrmann T., Geralt M., Wuthrich K.;
RT   ""Novel beta-barrel fold in the nuclear magnetic resonance structure of the
RT   replicase nonstructural protein 1 from the severe acute respiratory
RT   syndrome coronavirus."";
RL   J. Virol. 81:3151-3161(2007).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3241-3546.
RG   RIKEN structural genomics initiative (RSGI);
RT   ""Crystal structure of Sars coronavirus main proteinase(3CLPRO)."";
RL   Submitted (JUL-2007) to the PDB data bank.
CC   -!- FUNCTION: [Isoform Replicase polyprotein 1a]: Multifunctional protein
CC       involved in the transcription and replication of viral RNAs. Contains
CC       the proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000305}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by interacting with the 40S ribosomal subunit. The nsp1-40S ribosome
CC       complex further induces an endonucleolytic cleavage near the 5'UTR of
CC       host mRNAs, targeting them for degradation. Viral mRNAs are not
CC       susceptible to nsp1-mediated endonucleolytic RNA cleavage thanks to the
CC       presence of a 5'-end leader sequence and are therefore protected from
CC       degradation. By suppressing host gene expression, nsp1 facilitates
CC       efficient viral gene expression in infected cells and evasion from host
CC       immune response (PubMed:23035226). May disrupt nuclear pore function by
CC       binding and displacing host NUP93 (PubMed:30943371).
CC       {ECO:0000269|PubMed:23035226, ECO:0000269|PubMed:30943371}.
CC   -!- FUNCTION: [Non-structural protein 2]: May play a role in the modulation
CC       of host cell survival signaling pathway by interacting with host PHB
CC       and PHB2 (PubMed:19640993). Indeed, these two proteins play a role in
CC       maintaining the functional integrity of the mitochondria and protecting
CC       cells from various stresses (PubMed:19640993).
CC       {ECO:0000269|PubMed:19640993}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. In addition,
CC       PL-PRO possesses a deubiquitinating/deISGylating activity and processes
CC       both 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:17692280). Plays a role in host membrane
CC       rearrangement that leads to creation of cytoplasmic double-membrane
CC       vesicles (DMV) necessary for viral replication (PubMed:23943763). Nsp3,
CC       nsp4 and nsp6 together are sufficient to form DMV (PubMed:23943763,
CC       PubMed:24410069). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:19369340, PubMed:24622840).
CC       Prevents also host NF-kappa-B signaling (PubMed:19369340,
CC       PubMed:24622840). {ECO:0000269|PubMed:16271890,
CC       ECO:0000269|PubMed:17692280, ECO:0000269|PubMed:19369340,
CC       ECO:0000269|PubMed:23943763, ECO:0000269|PubMed:24622840,
CC       ECO:0000303|PubMed:24410069}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in host membrane
CC       rearrangement that leads to creation of cytoplasmic double-membrane
CC       vesicles (DMV) necessary for viral replication (PubMed:23943763,
CC       PubMed:24410069). Alone appears incapable to induce membrane curvature,
CC       but together with nsp3 is able to induce paired membranes
CC       (PubMed:23943763). Nsp3, nsp4 and nsp6 together are sufficient to form
CC       DMV (PubMed:23943763, PubMed:24410069). {ECO:0000269|PubMed:23943763,
CC       ECO:0000303|PubMed:24410069}.
CC   -!- FUNCTION: [3C-like proteinase nsp5]: Cleaves the C-terminus of
CC       replicase polyprotein at 11 sites. Recognizes substrates containing the
CC       core sequence [ILMVF]-Q-|-[SGACN]. Also able to bind an ADP-ribose-1''-
CC       phosphate (ADRP). May cleave host ATP6V1G1 thereby modifying host
CC       vacuoles intracellular pH. {ECO:0000255|PROSITE-ProRule:PRU00772,
CC       ECO:0000269|PubMed:16226257}.
CC   -!- FUNCTION: [Non-structural protein 6]: Plays a role in host membrane
CC       rearrangement that leads to creation of cytoplasmic double-membrane
CC       vesicles (DMV) necessary for viral replication (PubMed:23943763). Nsp3,
CC       nsp4 and nsp6 together are sufficient to form DMV (PubMed:23943763,
CC       PubMed:24410069). Plays a role in the initial induction of
CC       autophagosomes from host endoplasmic reticulum. Later, limits the
CC       expansion of these phagosomes that are no longer able to deliver viral
CC       components to lysosomes (PubMed:24991833).
CC       {ECO:0000269|PubMed:23943763, ECO:0000269|PubMed:24991833,
CC       ECO:0000303|PubMed:24410069}.
CC   -!- FUNCTION: [Non-structural protein 7]: Forms a hexadecamer with nsp8 (8
CC       subunits of each) that may participate in viral replication by acting
CC       as a primase. Alternatively, may synthesize substantially longer
CC       products than oligonucleotide primers. {ECO:0000269|PubMed:22039154}.
CC   -!- FUNCTION: [Non-structural protein 8]: Forms a hexadecamer with nsp7 (8
CC       subunits of each) that may participate in viral replication by acting
CC       as a primase. Alternatively, may synthesize substantially longer
CC       products than oligonucleotide primers. {ECO:0000269|PubMed:22039154}.
CC   -!- FUNCTION: [RNA-capping enzyme subunit nsp9]: Catalytic subunit of viral
CC       RNA capping enzyme which catalyzes the RNA guanylyltransferase reaction
CC       for genomic and sub-genomic RNAs. The kinase-like NiRAN domain of NSP12
CC       transfers RNA to the amino terminus of NSP9, forming a covalent RNA-
CC       protein intermediate. Subsequently, the NiRAN domain transfers RNA to
CC       GDP, forming the core cap structure GpppA-RNA. The NSP14 and NSP16
CC       methyltransferases then add methyl groups to form functional cap
CC       structures. {ECO:0000250|UniProtKB:P0DTC1,
CC       ECO:0000269|PubMed:19153232}.
CC   -!- FUNCTION: [Non-structural protein 10]: Plays a pivotal role in viral
CC       transcription by stimulating both nsp14 3'-5' exoribonuclease and nsp16
CC       2'-O-methyltransferase activities. Therefore plays an essential role in
CC       viral mRNAs cap methylation. {ECO:0000269|PubMed:22635272}.
CC   -!- CATALYTIC ACTIVITY: [3C-like proteinase nsp5]:
CC       Reaction=TSAVLQ-|-SGFRK-NH2 and SGVTFQ-|-GKFKK the two peptides
CC         corresponding to the two self-cleavage sites of the SARS 3C-like
CC         proteinase are the two most reactive peptide substrates. The enzyme
CC         exhibits a strong preference for substrates containing Gln at P1
CC         position and Leu at P2 position.; EC=3.4.22.69;
CC         Evidence={ECO:0000269|PubMed:12917450, ECO:0000269|PubMed:14561748};
CC   -!- CATALYTIC ACTIVITY: [Papain-like protease nsp3]:
CC       Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide
CC         and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-
CC         residue protein attached to proteins as an intracellular targeting
CC         signal).; EC=3.4.19.12; Evidence={ECO:0000269|PubMed:12917450,
CC         ECO:0000269|PubMed:17692280};
CC   -!- CATALYTIC ACTIVITY: [RNA-capping enzyme subunit nsp9]:
CC       Reaction=a 5'-end diphospho-ribonuc",52854
CTCTGG TCTGGG CTGGGT TGGGTG GGGTGG GGTGGA GTGGAA TGGAAC GGAACA GAACAC AACACT ACACTG CACTGC ACTGCG CTGCGA TGCGAC GCGACT CGACTG GACTGG ACTGGA CTGGAT TGGATG GGATGT GATGTC ATGTCA TGTCAG GTCAGC TCAGCC CAGCCG AGCCGT GCCGTG CCGTGC CGTGCT GTGCTG TGCTGA GCTGAC CTGACC TGACCG GACCGG ACCGGC CCGGCA CGGCAC GGCACC GCACCA CACCAC ACCACG CCACGC CACGCA ACGCAC CGCACC GCACCC CACCCG ACCCGA CCCGAC CCGACG CGACGC GACGCA ACGCAA CGCAAT GCAATT CAATTG AATTGC ATTGCG TTGCGC TGCGCA GCGCAT CGCATG GCATGG CATGGG ATGGGG TGGGGC GGGGCG GGGCGC GGCGCT GCGCTG CGCTGT GCTGTG CTGTGC TGTGCC GTGCCA TGCCAC GCCACC CCACCG CACCGG ACCGGG CCGGGC CGGGCA GGGCAC GGCACA GCACAA CACAAG ACAAGT CAAGTT AAGTTG AGTTGA GTTGAT TTGATG TGATGT GATGTG ATGTGG TGTGGC GTGGCA TGGCAT GGCATG GCATGC CATGCC,3,106,CTCT TCTG CTGG TGGG GGGT GGTG GTGG TGGA GGAA GAAC AACA ACAC CACT ACTG CTGC TGCG GCGA CGAC GACT ACTG CTGG TGGA GGAT GATG ATGT TGTC GTCA TCAG CAGC AGCC GCCG CCGT CGTG GTGC TGCT GCTG CTGA TGAC GACC ACCG CCGG CGGC GGCA GCAC CACC ACCA CCAC CACG ACGC CGCA GCAC CACC ACCC CCCG CCGA CGAC GACG ACGC CGCA GCAA CAAT AATT ATTG TTGC TGCG GCGC CGCA GCAT CATG ATGG TGGG GGGG GGGC GGCG GCGC CGCT GCTG CTGT TGTG GTGC TGCC GCCA CCAC CACC ACCG CCGG CGGG GGGC GGCA GCAC CACA ACAA CAAG AAGT AGTT GTTG TTGA TGAT GATG ATGT TGTG GTGG TGGC GGCA GCAT CATG ATGC TGCC,CTCTG TCTGG CTGGG TGGGT GGGTG GGTGG GTGGA TGGAA GGAAC GAACA AACAC ACACT CACTG ACTGC CTGCG TGCGA GCGAC CGACT GACTG ACTGG CTGGA TGGAT GGATG GATGT ATGTC TGTCA GTCAG TCAGC CAGCC AGCCG GCCGT CCGTG CGTGC GTGCT TGCTG GCTGA CTGAC TGACC GACCG ACCGG CCGGC CGGCA GGCAC GCACC CACCA ACCAC CCACG CACGC ACGCA CGCAC GCACC CACCC ACCCG CCCGA CCGAC CGACG GACGC ACGCA CGCAA GCAAT CAATT AATTG ATTGC TTGCG TGCGC GCGCA CGCAT GCATG CATGG ATGGG TGGGG GGGGC GGGCG GGCGC GCGCT CGCTG GCTGT CTGTG TGTGC GTGCC TGCCA GCCAC CCACC CACCG ACCGG CCGGG CGGGC GGGCA GGCAC GCACA CACAA ACAAG CAAGT AAGTT AGTTG GTTGA TTGAT TGATG GATGT ATGTG TGTGG GTGGC TGGCA GGCAT GCATG CATGC ATGCC,CTCTGG TCTGGG CTGGGT TGGGTG GGGTGG GGTGGA GTGGAA TGGAAC GGAACA GAACAC AACACT ACACTG CACTGC ACTGCG CTGCGA TGCGAC GCGACT CGACTG GACTGG ACTGGA CTGGAT TGGATG GGATGT GATGTC ATGTCA TGTCAG GTCAGC TCAGCC CAGCCG AGCCGT GCCGTG CCGTGC CGTGCT GTGCTG TGCTGA GCTGAC CTGACC TGACCG GACCGG ACCGGC CCGGCA CGGCAC GGCACC GCACCA CACCAC ACCACG CCACGC CACGCA ACGCAC CGCACC GCACCC CACCCG ACCCGA CCCGAC CCGACG CGACGC GACGCA ACGCAA CGCAAT GCAATT CAATTG AATTGC ATTGCG TTGCGC TGCGCA GCGCAT CGCATG GCATGG CATGGG ATGGGG TGGGGC GGGGCG GGGCGC GGCGCT GCGCTG CGCTGT GCTGTG CTGTGC TGTGCC GTGCCA TGCCAC GCCACC CCACCG CACCGG ACCGGG CCGGGC CGGGCA GGGCAC GGCACA GCACAA CACAAG ACAAGT CAAGTT AAGTTG AGTTGA GTTGAT TTGATG TGATGT GATGTG ATGTGG TGTGGC GTGGCA TGGCAT GGCATG GCATGC CATGCC,CTCTGGG TCTGGGT CTGGGTG TGGGTGG GGGTGGA GGTGGAA GTGGAAC TGGAACA GGAACAC GAACACT AACACTG ACACTGC CACTGCG ACTGCGA CTGCGAC TGCGACT GCGACTG CGACTGG GACTGGA ACTGGAT CTGGATG TGGATGT GGATGTC GATGTCA ATGTCAG TGTCAGC GTCAGCC TCAGCCG CAGCCGT AGCCGTG GCCGTGC CCGTGCT CGTGCTG GTGCTGA TGCTGAC GCTGACC CTGACCG TGACCGG GACCGGC ACCGGCA CCGGCAC CGGCACC GGCACCA GCACCAC CACCACG ACCACGC CCACGCA CACGCAC ACGCACC CGCACCC GCACCCG CACCCGA ACCCGAC CCCGACG CCGACGC CGACGCA GACGCAA ACGCAAT CGCAATT GCAATTG CAATTGC AATTGCG ATTGCGC TTGCGCA TGCGCAT GCGCATG CGCATGG GCATGGG CATGGGG ATGGGGC TGGGGCG GGGGCGC GGGCGCT GGCGCTG GCGCTGT CGCTGTG GCTGTGC CTGTGCC TGTGCCA GTGCCAC TGCCACC GCCACCG CCACCGG CACCGGG ACCGGGC CCGGGCA CGGGCAC GGGCACA GGCACAA GCACAAG CACAAGT ACAAGTT CAAGTTG AAGTTGA AGTTGAT GTTGATG TTGATGT TGATGTG GATGTGG ATGTGGC TGTGGCA GTGGCAT TGGCATG GGCATGC GCATGCC,"ID   ARAB_SALEP              Reviewed;         569 AA.
AC   B5R1U0;
DT   14-APR-2009, integrated into UniProtKB/Swiss-Prot.
DT   04-NOV-2008, sequence version 1.
DT   27-NOV-2024, entry version 79.
DE   RecName: Full=Ribulokinase {ECO:0000255|HAMAP-Rule:MF_00520};
DE            EC=2.7.1.16 {ECO:0000255|HAMAP-Rule:MF_00520};
GN   Name=araB {ECO:0000255|HAMAP-Rule:MF_00520};
GN   OrderedLocusNames=SEN0104;
OS   Salmonella enteritidis PT4 (strain P125109).
OC   Bacteria; Pseudomonadota; Gammaproteobacteria; Enterobacterales;
OC   Enterobacteriaceae; Salmonella.
OX   NCBI_TaxID=550537;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=P125109;
RX   PubMed=18583645; DOI=10.1101/gr.077404.108;
RA   Thomson N.R., Clayton D.J., Windhorst D., Vernikos G., Davidson S.,
RA   Churcher C., Quail M.A., Stevens M., Jones M.A., Watson M., Barron A.,
RA   Layton A., Pickard D., Kingsley R.A., Bignell A., Clark L., Harris B.,
RA   Ormond D., Abdellah Z., Brooks K., Cherevach I., Chillingworth T.,
RA   Woodward J., Norberczak H., Lord A., Arrowsmith C., Jagels K., Moule S.,
RA   Mungall K., Saunders M., Whitehead S., Chabalgoity J.A., Maskell D.,
RA   Humphreys T., Roberts M., Barrow P.A., Dougan G., Parkhill J.;
RT   ""Comparative genome analysis of Salmonella enteritidis PT4 and Salmonella
RT   gallinarum 287/91 provides insights into evolutionary and host adaptation
RT   pathways."";
RL   Genome Res. 18:1624-1637(2008).
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=D-ribulose + ATP = D-ribulose 5-phosphate + ADP + H(+);
CC         Xref=Rhea:RHEA:17601, ChEBI:CHEBI:15378, ChEBI:CHEBI:17173,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:58121, ChEBI:CHEBI:456216;
CC         EC=2.7.1.16; Evidence={ECO:0000255|HAMAP-Rule:MF_00520};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-ribulose + ATP = L-ribulose 5-phosphate + ADP + H(+);
CC         Xref=Rhea:RHEA:22072, ChEBI:CHEBI:15378, ChEBI:CHEBI:16880,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:58226, ChEBI:CHEBI:456216;
CC         EC=2.7.1.16; Evidence={ECO:0000255|HAMAP-Rule:MF_00520};
CC   -!- PATHWAY: Carbohydrate degradation; L-arabinose degradation via L-
CC       ribulose; D-xylulose 5-phosphate from L-arabinose (bacterial route):
CC       step 2/3. {ECO:0000255|HAMAP-Rule:MF_00520}.
CC   -!- SIMILARITY: Belongs to the ribulokinase family. {ECO:0000255|HAMAP-
CC       Rule:MF_00520}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AM933172; CAR31691.1; -; Genomic_DNA.
DR   RefSeq; WP_000951810.1; NC_011294.1.
DR   AlphaFoldDB; B5R1U0; -.
DR   SMR; B5R1U0; -.
DR   KEGG; set:SEN0104; -.
DR   HOGENOM; CLU_009281_9_1_6; -.
DR   UniPathway; UPA00145; UER00566.
DR   Proteomes; UP000000613; Chromosome.
DR   GO; GO:0005737; C:cytoplasm; IEA:TreeGrafter.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019150; F:D-ribulokinase activity; IEA:RHEA.
DR   GO; GO:0008741; F:ribulokinase activity; IEA:UniProtKB-UniRule.
DR   GO; GO:0019569; P:L-arabinose catabolic process to xylulose 5-phosphate; IEA:UniProtKB-UniRule.
DR   CDD; cd07781; FGGY_RBK; 1.
DR   Gene3D; 1.20.58.2240; -; 1.
DR   Gene3D; 3.30.420.40; -; 1.
DR   HAMAP; MF_00520; Ribulokinase; 1.
DR   InterPro; IPR043129; ATPase_NBD.
DR   InterPro; IPR018485; FGGY_C.
DR   InterPro; IPR005929; Ribulokinase.
DR   NCBIfam; TIGR01234; L-ribulokinase; 1.
DR   PANTHER; PTHR43435:SF4; FGGY CARBOHYDRATE KINASE DOMAIN-CONTAINING PROTEIN; 1.
DR   PANTHER; PTHR43435; RIBULOKINASE; 1.
DR   Pfam; PF02782; FGGY_C; 1.
DR   SUPFAM; SSF53067; Actin-like ATPase domain; 2.
PE   3: Inferred from homology;
KW   Arabinose catabolism; ATP-binding; Carbohydrate metabolism; Kinase;
KW   Nucleotide-binding; Transferase.
FT   CHAIN           1..569
FT                   /note=""Ribulokinase""
FT                   /id=""PRO_1000127638""
SQ   SEQUENCE   569 AA;  61730 MW;  AE92815A1F5A0040 CRC64;
     MAIAIGLDFG SDSVRALAVD CATGDEIATS VEWYPRWQEG RYCDGPNNQF RHHPRDYMES
     MEAALKAVLA QLSAAQRANV VGIGVDSTGS TPAPIDADGN VLALRPEFAE NPNAMFVLWK
     DHTAVEEADE ITRLCHKPGK VDYSRYIGGI YSSEWFWAKI LHVTRQDSAV AQAAVSWIEL
     CDWVPALLSG TTRPQDIRRG RCSAGHKTLW HASWGGLPPA SFFDELDPCI NRHLHYPLFS
     ETFTADLPVG TLCAEWAQRL DLPESVVISG GAFDCHMGAV GAGAQSNTLV KVIGTSTCDI
     LIADKQSVGD RAVKGICGQV DGSVVPNFIG LEAGQSAFGD IYAWFSRVLS WPLEQLAAQH
     PELKTQINAS QKQLLPALTD AWAKNPSLDH LPVVLDWFNG RRTPNANQRL KGVITDLNLA
     TDAPALFGGL VASTAFGARA IQECFTEQGI AVNNVMALGG IARKNQVIMQ VCCDVLNRPL
     QIVASDQCCA LGAAIFAAVA AKVHADIPAA QQSMASAVER TLRPRPEQAQ RFERLYRRYQ
     QWALSAEQHY LPTAAPAPTT PANQAILTH
//
",60685
CTAAAT TAAATA AAATAG AATAGA ATAGAG TAGAGG AGAGGT GAGGTA AGGTAT GGTATG GTATGG TATGGT ATGGTA TGGTAC GGTACT GTACTT TACTTG ACTTGG CTTGGT TTGGTA TGGTAG GGTAGT GTAGTT TAGTTT AGTTTA GTTTAG TTTAGC TTAGCT TAGCTG AGCTGC GCTGCC CTGCCA TGCCAC GCCACA CCACAG CACAGT ACAGTA CAGTAC AGTACG GTACGT TACGTC ACGTCT CGTCTA GTCTAC TCTACA CTACAA TACAAG ACAAGC CAAGCT AAGCTG AGCTGG GCTGGT CTGGTA TGGTAA GGTAAT GTAATG TAATGC AATGCA ATGCAA TGCAAC GCAACA CAACAG AACAGA ACAGAA CAGAAG AGAAGT GAAGTG AAGTGC AGTGCC GTGCCT TGCCTG GCCTGC CCTGCC CTGCCA TGCCAA GCCAAT CCAATT CAATTC AATTCA ATTCAA TTCAAC TCAACT CAACTG AACTGT ACTGTA CTGTAT TGTATT GTATTA TATTAT ATTATC TTATCT TATCTT ATCTTT TCTTTC CTTTCT TTTCTG TTCTGT TCTGTG CTGTGC TGTGCT GTGCTT TGCTTT GCTTTT CTTTTG TTTTGC TTTGCT TTGCTG TGCTGT GCTGTA CTGTAG TGTAGA GTAGAT TAGATG AGATGC GATGCT ATGCTG TGCTGC GCTGCT CTGCTA TGCTAA GCTAAA CTAAAG TAAAGC AAAGCT AAGCTT AGCTTA GCTTAC CTTACA TTACAA TACAAA ACAAAG CAAAGA AAAGAT AAGATT AGATTA GATTAT ATTATC TTATCT TATCTA ATCTAG TCTAGC CTAGCT TAGCTA AGCTAG GCTAGT,0,145,CTAA TAAA AAAT AATA ATAG TAGA AGAG GAGG AGGT GGTA GTAT TATG ATGG TGGT GGTA GTAC TACT ACTT CTTG TTGG TGGT GGTA GTAG TAGT AGTT GTTT TTTA TTAG TAGC AGCT GCTG CTGC TGCC GCCA CCAC CACA ACAG CAGT AGTA GTAC TACG ACGT CGTC GTCT TCTA CTAC TACA ACAA CAAG AAGC AGCT GCTG CTGG TGGT GGTA GTAA TAAT AATG ATGC TGCA GCAA CAAC AACA ACAG CAGA AGAA GAAG AAGT AGTG GTGC TGCC GCCT CCTG CTGC TGCC GCCA CCAA CAAT AATT ATTC TTCA TCAA CAAC AACT ACTG CTGT TGTA GTAT TATT ATTA TTAT TATC ATCT TCTT CTTT TTTC TTCT TCTG CTGT TGTG GTGC TGCT GCTT CTTT TTTT TTTG TTGC TGCT GCTG CTGT TGTA GTAG TAGA AGAT GATG ATGC TGCT GCTG CTGC TGCT GCTA CTAA TAAA AAAG AAGC AGCT GCTT CTTA TTAC TACA ACAA CAAA AAAG AAGA AGAT GATT ATTA TTAT TATC ATCT TCTA CTAG TAGC AGCT GCTA CTAG TAGT,CTAAA TAAAT AAATA AATAG ATAGA TAGAG AGAGG GAGGT AGGTA GGTAT GTATG TATGG ATGGT TGGTA GGTAC GTACT TACTT ACTTG CTTGG TTGGT TGGTA GGTAG GTAGT TAGTT AGTTT GTTTA TTTAG TTAGC TAGCT AGCTG GCTGC CTGCC TGCCA GCCAC CCACA CACAG ACAGT CAGTA AGTAC GTACG TACGT ACGTC CGTCT GTCTA TCTAC CTACA TACAA ACAAG CAAGC AAGCT AGCTG GCTGG CTGGT TGGTA GGTAA GTAAT TAATG AATGC ATGCA TGCAA GCAAC CAACA AACAG ACAGA CAGAA AGAAG GAAGT AAGTG AGTGC GTGCC TGCCT GCCTG CCTGC CTGCC TGCCA GCCAA CCAAT CAATT AATTC ATTCA TTCAA TCAAC CAACT AACTG ACTGT CTGTA TGTAT GTATT TATTA ATTAT TTATC TATCT ATCTT TCTTT CTTTC TTTCT TTCTG TCTGT CTGTG TGTGC GTGCT TGCTT GCTTT CTTTT TTTTG TTTGC TTGCT TGCTG GCTGT CTGTA TGTAG GTAGA TAGAT AGATG GATGC ATGCT TGCTG GCTGC CTGCT TGCTA GCTAA CTAAA TAAAG AAAGC AAGCT AGCTT GCTTA CTTAC TTACA TACAA ACAAA CAAAG AAAGA AAGAT AGATT GATTA ATTAT TTATC TATCT ATCTA TCTAG CTAGC TAGCT AGCTA GCTAG CTAGT,CTAAAT TAAATA AAATAG AATAGA ATAGAG TAGAGG AGAGGT GAGGTA AGGTAT GGTATG GTATGG TATGGT ATGGTA TGGTAC GGTACT GTACTT TACTTG ACTTGG CTTGGT TTGGTA TGGTAG GGTAGT GTAGTT TAGTTT AGTTTA GTTTAG TTTAGC TTAGCT TAGCTG AGCTGC GCTGCC CTGCCA TGCCAC GCCACA CCACAG CACAGT ACAGTA CAGTAC AGTACG GTACGT TACGTC ACGTCT CGTCTA GTCTAC TCTACA CTACAA TACAAG ACAAGC CAAGCT AAGCTG AGCTGG GCTGGT CTGGTA TGGTAA GGTAAT GTAATG TAATGC AATGCA ATGCAA TGCAAC GCAACA CAACAG AACAGA ACAGAA CAGAAG AGAAGT GAAGTG AAGTGC AGTGCC GTGCCT TGCCTG GCCTGC CCTGCC CTGCCA TGCCAA GCCAAT CCAATT CAATTC AATTCA ATTCAA TTCAAC TCAACT CAACTG AACTGT ACTGTA CTGTAT TGTATT GTATTA TATTAT ATTATC TTATCT TATCTT ATCTTT TCTTTC CTTTCT TTTCTG TTCTGT TCTGTG CTGTGC TGTGCT GTGCTT TGCTTT GCTTTT CTTTTG TTTTGC TTTGCT TTGCTG TGCTGT GCTGTA CTGTAG TGTAGA GTAGAT TAGATG AGATGC GATGCT ATGCTG TGCTGC GCTGCT CTGCTA TGCTAA GCTAAA CTAAAG TAAAGC AAAGCT AAGCTT AGCTTA GCTTAC CTTACA TTACAA TACAAA ACAAAG CAAAGA AAAGAT AAGATT AGATTA GATTAT ATTATC TTATCT TATCTA ATCTAG TCTAGC CTAGCT TAGCTA AGCTAG GCTAGT,CTAAATA TAAATAG AAATAGA AATAGAG ATAGAGG TAGAGGT AGAGGTA GAGGTAT AGGTATG GGTATGG GTATGGT TATGGTA ATGGTAC TGGTACT GGTACTT GTACTTG TACTTGG ACTTGGT CTTGGTA TTGGTAG TGGTAGT GGTAGTT GTAGTTT TAGTTTA AGTTTAG GTTTAGC TTTAGCT TTAGCTG TAGCTGC AGCTGCC GCTGCCA CTGCCAC TGCCACA GCCACAG CCACAGT CACAGTA ACAGTAC CAGTACG AGTACGT GTACGTC TACGTCT ACGTCTA CGTCTAC GTCTACA TCTACAA CTACAAG TACAAGC ACAAGCT CAAGCTG AAGCTGG AGCTGGT GCTGGTA CTGGTAA TGGTAAT GGTAATG GTAATGC TAATGCA AATGCAA ATGCAAC TGCAACA GCAACAG CAACAGA AACAGAA ACAGAAG CAGAAGT AGAAGTG GAAGTGC AAGTGCC AGTGCCT GTGCCTG TGCCTGC GCCTGCC CCTGCCA CTGCCAA TGCCAAT GCCAATT CCAATTC CAATTCA AATTCAA ATTCAAC TTCAACT TCAACTG CAACTGT AACTGTA ACTGTAT CTGTATT TGTATTA GTATTAT TATTATC ATTATCT TTATCTT TATCTTT ATCTTTC TCTTTCT CTTTCTG TTTCTGT TTCTGTG TCTGTGC CTGTGCT TGTGCTT GTGCTTT TGCTTTT GCTTTTG CTTTTGC TTTTGCT TTTGCTG TTGCTGT TGCTGTA GCTGTAG CTGTAGA TGTAGAT GTAGATG TAGATGC AGATGCT GATGCTG ATGCTGC TGCTGCT GCTGCTA CTGCTAA TGCTAAA GCTAAAG CTAAAGC TAAAGCT AAAGCTT AAGCTTA AGCTTAC GCTTACA CTTACAA TTACAAA TACAAAG ACAAAGA CAAAGAT AAAGATT AAGATTA AGATTAT GATTATC ATTATCT TTATCTA TATCTAG ATCTAGC TCTAGCT CTAGCTA TAGCTAG AGCTAGT,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",439
TTTGGC TTGGCC TGGCCT GGCCTG GCCTGT CCTGTT CTGTTG TGTTGA GTTGAT TTGATG TGATGG GATGGT ATGGTG TGGTGC GGTGCT GTGCTG TGCTGA GCTGAC CTGACC TGACCA GACCAT ACCATG CCATGA CATGAT ATGATG TGATGC GATGCC ATGCCG TGCCGC GCCGCT CCGCTG CGCTGG GCTGGA CTGGAG TGGAGA GGAGAT GAGATG AGATGC GATGCT ATGCTC TGCTCT GCTCTC CTCTCA TCTCAG CTCAGG TCAGGC CAGGCG AGGCGG GGCGGC GCGGCG CGGCGT GGCGTG GCGTGA CGTGAC GTGACC TGACCC GACCCC ACCCCG CCCCGC CCCGCG CCGCGC CGCGCG GCGCGA CGCGAG GCGAGA CGAGAG GAGAGC AGAGCA GAGCAT AGCATG GCATGC CATGCC ATGCCG TGCCGC GCCGCT CCGCTG CGCTGT GCTGTG CTGTGG TGTGGG GTGGGT TGGGTG GGGTGC GGTGCA GTGCAG TGCAGT GCAGTA CAGTAC AGTACG GTACGT TACGTG ACGTGA CGTGAT GTGATG TGATGT GATGTC ATGTCT TGTCTC GTCTCT TCTCTG CTCTGG TCTGGC CTGGCC TGGCCC GGCCCC GCCCCC CCCCCA CCCCAC CCCACC CCACCA CACCAC ACCACG CCACGC CACGCA ACGCAT CGCATT GCATTT CATTTC ATTTCA TTTCAC TTCACC TCACCG CACCGA ACCGAG CCGAGC CGAGCT GAGCTG AGCTGT GCTGTC CTGTCT TGTCTC GTCTCA TCTCAG CTCAGG TCAGGC CAGGCC AGGCCA GGCCAT GCCATC CCATCC CATCCT ATCCTG TCCTGT CCTGTA CTGTAC,2,145,TTTG TTGG TGGC GGCC GCCT CCTG CTGT TGTT GTTG TTGA TGAT GATG ATGG TGGT GGTG GTGC TGCT GCTG CTGA TGAC GACC ACCA CCAT CATG ATGA TGAT GATG ATGC TGCC GCCG CCGC CGCT GCTG CTGG TGGA GGAG GAGA AGAT GATG ATGC TGCT GCTC CTCT TCTC CTCA TCAG CAGG AGGC GGCG GCGG CGGC GGCG GCGT CGTG GTGA TGAC GACC ACCC CCCC CCCG CCGC CGCG GCGC CGCG GCGA CGAG GAGA AGAG GAGC AGCA GCAT CATG ATGC TGCC GCCG CCGC CGCT GCTG CTGT TGTG GTGG TGGG GGGT GGTG GTGC TGCA GCAG CAGT AGTA GTAC TACG ACGT CGTG GTGA TGAT GATG ATGT TGTC GTCT TCTC CTCT TCTG CTGG TGGC GGCC GCCC CCCC CCCC CCCA CCAC CACC ACCA CCAC CACG ACGC CGCA GCAT CATT ATTT TTTC TTCA TCAC CACC ACCG CCGA CGAG GAGC AGCT GCTG CTGT TGTC GTCT TCTC CTCA TCAG CAGG AGGC GGCC GCCA CCAT CATC ATCC TCCT CCTG CTGT TGTA GTAC,TTTGG TTGGC TGGCC GGCCT GCCTG CCTGT CTGTT TGTTG GTTGA TTGAT TGATG GATGG ATGGT TGGTG GGTGC GTGCT TGCTG GCTGA CTGAC TGACC GACCA ACCAT CCATG CATGA ATGAT TGATG GATGC ATGCC TGCCG GCCGC CCGCT CGCTG GCTGG CTGGA TGGAG GGAGA GAGAT AGATG GATGC ATGCT TGCTC GCTCT CTCTC TCTCA CTCAG TCAGG CAGGC AGGCG GGCGG GCGGC CGGCG GGCGT GCGTG CGTGA GTGAC TGACC GACCC ACCCC CCCCG CCCGC CCGCG CGCGC GCGCG CGCGA GCGAG CGAGA GAGAG AGAGC GAGCA AGCAT GCATG CATGC ATGCC TGCCG GCCGC CCGCT CGCTG GCTGT CTGTG TGTGG GTGGG TGGGT GGGTG GGTGC GTGCA TGCAG GCAGT CAGTA AGTAC GTACG TACGT ACGTG CGTGA GTGAT TGATG GATGT ATGTC TGTCT GTCTC TCTCT CTCTG TCTGG CTGGC TGGCC GGCCC GCCCC CCCCC CCCCA CCCAC CCACC CACCA ACCAC CCACG CACGC ACGCA CGCAT GCATT CATTT ATTTC TTTCA TTCAC TCACC CACCG ACCGA CCGAG CGAGC GAGCT AGCTG GCTGT CTGTC TGTCT GTCTC TCTCA CTCAG TCAGG CAGGC AGGCC GGCCA GCCAT CCATC CATCC ATCCT TCCTG CCTGT CTGTA TGTAC,TTTGGC TTGGCC TGGCCT GGCCTG GCCTGT CCTGTT CTGTTG TGTTGA GTTGAT TTGATG TGATGG GATGGT ATGGTG TGGTGC GGTGCT GTGCTG TGCTGA GCTGAC CTGACC TGACCA GACCAT ACCATG CCATGA CATGAT ATGATG TGATGC GATGCC ATGCCG TGCCGC GCCGCT CCGCTG CGCTGG GCTGGA CTGGAG TGGAGA GGAGAT GAGATG AGATGC GATGCT ATGCTC TGCTCT GCTCTC CTCTCA TCTCAG CTCAGG TCAGGC CAGGCG AGGCGG GGCGGC GCGGCG CGGCGT GGCGTG GCGTGA CGTGAC GTGACC TGACCC GACCCC ACCCCG CCCCGC CCCGCG CCGCGC CGCGCG GCGCGA CGCGAG GCGAGA CGAGAG GAGAGC AGAGCA GAGCAT AGCATG GCATGC CATGCC ATGCCG TGCCGC GCCGCT CCGCTG CGCTGT GCTGTG CTGTGG TGTGGG GTGGGT TGGGTG GGGTGC GGTGCA GTGCAG TGCAGT GCAGTA CAGTAC AGTACG GTACGT TACGTG ACGTGA CGTGAT GTGATG TGATGT GATGTC ATGTCT TGTCTC GTCTCT TCTCTG CTCTGG TCTGGC CTGGCC TGGCCC GGCCCC GCCCCC CCCCCA CCCCAC CCCACC CCACCA CACCAC ACCACG CCACGC CACGCA ACGCAT CGCATT GCATTT CATTTC ATTTCA TTTCAC TTCACC TCACCG CACCGA ACCGAG CCGAGC CGAGCT GAGCTG AGCTGT GCTGTC CTGTCT TGTCTC GTCTCA TCTCAG CTCAGG TCAGGC CAGGCC AGGCCA GGCCAT GCCATC CCATCC CATCCT ATCCTG TCCTGT CCTGTA CTGTAC,TTTGGCC TTGGCCT TGGCCTG GGCCTGT GCCTGTT CCTGTTG CTGTTGA TGTTGAT GTTGATG TTGATGG TGATGGT GATGGTG ATGGTGC TGGTGCT GGTGCTG GTGCTGA TGCTGAC GCTGACC CTGACCA TGACCAT GACCATG ACCATGA CCATGAT CATGATG ATGATGC TGATGCC GATGCCG ATGCCGC TGCCGCT GCCGCTG CCGCTGG CGCTGGA GCTGGAG CTGGAGA TGGAGAT GGAGATG GAGATGC AGATGCT GATGCTC ATGCTCT TGCTCTC GCTCTCA CTCTCAG TCTCAGG CTCAGGC TCAGGCG CAGGCGG AGGCGGC GGCGGCG GCGGCGT CGGCGTG GGCGTGA GCGTGAC CGTGACC GTGACCC TGACCCC GACCCCG ACCCCGC CCCCGCG CCCGCGC CCGCGCG CGCGCGA GCGCGAG CGCGAGA GCGAGAG CGAGAGC GAGAGCA AGAGCAT GAGCATG AGCATGC GCATGCC CATGCCG ATGCCGC TGCCGCT GCCGCTG CCGCTGT CGCTGTG GCTGTGG CTGTGGG TGTGGGT GTGGGTG TGGGTGC GGGTGCA GGTGCAG GTGCAGT TGCAGTA GCAGTAC CAGTACG AGTACGT GTACGTG TACGTGA ACGTGAT CGTGATG GTGATGT TGATGTC GATGTCT ATGTCTC TGTCTCT GTCTCTG TCTCTGG CTCTGGC TCTGGCC CTGGCCC TGGCCCC GGCCCCC GCCCCCA CCCCCAC CCCCACC CCCACCA CCACCAC CACCACG ACCACGC CCACGCA CACGCAT ACGCATT CGCATTT GCATTTC CATTTCA ATTTCAC TTTCACC TTCACCG TCACCGA CACCGAG ACCGAGC CCGAGCT CGAGCTG GAGCTGT AGCTGTC GCTGTCT CTGTCTC TGTCTCA GTCTCAG TCTCAGG CTCAGGC TCAGGCC CAGGCCA AGGCCAT GGCCATC GCCATCC CCATCCT CATCCTG ATCCTGT TCCTGTA CCTGTAC,"ID   YHHJ_ECOLI              Reviewed;         374 AA.
AC   P0AGH1; P31993; P76703; Q2M7E8;
DT   20-DEC-2005, integrated into UniProtKB/Swiss-Prot.
DT   24-NOV-2009, sequence version 3.
DT   27-NOV-2024, entry version 118.
DE   RecName: Full=Inner membrane transport permease YhhJ;
GN   Name=yhhJ; OrderedLocusNames=b3485, JW5677;
OS   Escherichia coli (strain K12).
OC   Bacteria; Pseudomonadota; Gammaproteobacteria; Enterobacterales;
OC   Enterobacteriaceae; Escherichia.
OX   NCBI_TaxID=83333;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   PubMed=8041620; DOI=10.1093/nar/22.13.2576;
RA   Sofia H.J., Burland V., Daniels D.L., Plunkett G. III, Blattner F.R.;
RT   ""Analysis of the Escherichia coli genome. V. DNA sequence of the region
RT   from 76.0 to 81.5 minutes."";
RL   Nucleic Acids Res. 22:2576-2586(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   PubMed=9278503; DOI=10.1126/science.277.5331.1453;
RA   Blattner F.R., Plunkett G. III, Bloch C.A., Perna N.T., Burland V.,
RA   Riley M., Collado-Vides J., Glasner J.D., Rode C.K., Mayhew G.F.,
RA   Gregor J., Davis N.W., Kirkpatrick H.A., Goeden M.A., Rose D.J., Mau B.,
RA   Shao Y.;
RT   ""The complete genome sequence of Escherichia coli K-12."";
RL   Science 277:1453-1462(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RX   PubMed=16738553; DOI=10.1038/msb4100049;
RA   Hayashi K., Morooka N., Yamamoto Y., Fujita K., Isono K., Choi S.,
RA   Ohtsubo E., Baba T., Wanner B.L., Mori H., Horiuchi T.;
RT   ""Highly accurate genome sequences of Escherichia coli K-12 strains MG1655
RT   and W3110."";
RL   Mol. Syst. Biol. 2:E1-E5(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 225-374.
RC   STRAIN=K12;
RX   PubMed=8387990; DOI=10.1128/jb.175.10.2799-2808.1993;
RA   Zhao S., Sandt C.H., Feulner G., Vlazny D.A., Gray J.A., Hill C.W.;
RT   ""Rhs elements of Escherichia coli K-12: complex composites of shared and
RT   unique components that have different evolutionary histories."";
RL   J. Bacteriol. 175:2799-2808(1993).
RN   [5]
RP   TOPOLOGY [LARGE SCALE ANALYSIS].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   PubMed=15919996; DOI=10.1126/science.1109730;
RA   Daley D.O., Rapp M., Granseth E., Melen K., Drew D., von Heijne G.;
RT   ""Global topology analysis of the Escherichia coli inner membrane
RT   proteome."";
RL   Science 308:1321-1323(2005).
CC   -!- SUBCELLULAR LOCATION: Cell inner membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the ABC-2 integral membrane protein family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB18460.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U00039; AAB18460.1; ALT_INIT; Genomic_DNA.
DR   EMBL; U00096; AAC76510.4; -; Genomic_DNA.
DR   EMBL; AP009048; BAE77808.1; -; Genomic_DNA.
DR   EMBL; L02370; AAC61886.1; -; Genomic_DNA.
DR   RefSeq; NP_417942.6; NC_000913.3.
DR   RefSeq; WP_001216257.1; NZ_SSZK01000042.1.
DR   AlphaFoldDB; P0AGH1; -.
DR   SMR; P0AGH1; -.
DR   BioGRID; 4262513; 11.
DR   STRING; 511145.b3485; -.
DR   TCDB; 3.A.1.105.16; the atp-binding cassette (abc) superfamily.
DR   PaxDb; 511145-b3485; -.
DR   EnsemblBacteria; AAC76510; AAC76510; b3485.
DR   GeneID; 947991; -.
DR   KEGG; ecj:JW5677; -.
DR   KEGG; eco:b3485; -.
DR   KEGG; ecoc:C3026_18875; -.
DR   PATRIC; fig|511145.12.peg.3584; -.
DR   EchoBASE; EB1717; -.
DR   eggNOG; COG0842; Bacteria.
DR   HOGENOM; CLU_039483_8_1_6; -.
DR   InParanoid; P0AGH1; -.
DR   OMA; AVRMRFN; -.
DR   OrthoDB; 9808686at2; -.
DR   PhylomeDB; P0AGH1; -.
DR   BioCyc; EcoCyc:YHHJ-MONOMER; -.
DR   PRO; PR:P0AGH1; -.
DR   Proteomes; UP000000318; Chromosome.
DR   Proteomes; UP000000625; Chromosome.
DR   GO; GO:0005886; C:plasma membrane; IDA:EcoCyc.
DR   GO; GO:0140359; F:ABC-type transporter activity; IEA:InterPro.
DR   FunFam; 3.40.1710.10:FF:000003; ABC transporter permease; 1.
DR   Gene3D; 3.40.1710.10; abc type-2 transporter like domain; 1.
DR   InterPro; IPR051449; ABC-2_transporter_component.
DR   InterPro; IPR013525; ABC2_TM.
DR   InterPro; IPR047817; ABC2_TM_bact-type.
DR   PANTHER; PTHR30294:SF47; INNER MEMBRANE TRANSPORT PERMEASE YHHJ; 1.
DR   PANTHER; PTHR30294; MEMBRANE COMPONENT OF ABC TRANSPORTER YHHJ-RELATED; 1.
DR   Pfam; PF12698; ABC2_membrane_3; 1.
DR   PROSITE; PS51012; ABC_TM2; 1.
PE   1: Evidence at protein level;
KW   Cell inner membrane; Cell membrane; Membrane; Reference proteome;
KW   Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..374
FT                   /note=""Inner membrane transport permease YhhJ""
FT                   /id=""PRO_0000183008""
FT   TOPO_DOM        1..22
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        23..43
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TOPO_DOM        44..172
FT                   /note=""Periplasmic""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        173..193
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TOPO_DOM        194..229
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        230..250
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TOPO_DOM        251..255
FT                   /note=""Periplasmic""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        256..276
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TOPO_DOM        277..283
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        284..304
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TOPO_DOM        305..342
FT                   /note=""Periplasmic""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        343..363
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TOPO_DOM        364..374
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000255""
FT   DOMAIN          133..369
FT                   /note=""ABC transmembrane type-2""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00442""
SQ   SEQUENCE   374 AA;  41062 MW;  02895FB13F493391 CRC64;
     MRHLRNIFNL GIKELRSLLG DKAMLTLIVF SFTVSVYSSA TVTPGSLNLA PIAIADMDQS
     QLSNRIVNSF YRPWFLPPEM ITADEMDAGL DAGRYTFAIN IPPNFQRDVL AGRQPDIQVN
     VDATRMSQAF TGNGYIQNII NGEVNSFVAR YRDNSEPLVS LETRMRFNPN LDPAWFGGVM
     AIINNITMLA IVLTGSALIR EREHGTVEHL LVMPITPFEI MMAKIWSMGL VVLVVSGLSL
     VLMVKGVLGV PIEGSIPLFM LGVALSLFAT TSIGIFMGTI ARSMPQLGLL VILVLLPLQM
     LSGGSTPRES MPQMVQDIML TMPTTHFVSL AQAILYRGAG FEIVWPQFLT LMAIGGAFFT
     IALLRFRKTI GTMA
//
",31759
CAATAT AATATG ATATGA TATGAG ATGAGT TGAGTA GAGTAT AGTATG GTATGG TATGGT ATGGTA TGGTAC GGTACT GTACTG TACTGA ACTGAA CTGAAG TGAAGA GAAGAT AAGATG AGATGA GATGAT ATGATT TGATTA GATTAC ATTACC TTACCA TACCAA ACCAAG CCAAGG CAAGGT AAGGTA AGGTAA GGTAAA GTAAAC TAAACC AAACCT AACCTT ACCTTT CCTTTG CTTTGG TTTGGA TTGGAA TGGAAT GGAATT GAATTT AATTTG ATTTGG TTTGGT TTGGTG TGGTGC GGTGCC GTGCCA TGCCAC GCCACT CCACTT CACTTC ACTTCT CTTCTG TTCTGC TCTGCT CTGCTG TGCTGC GCTGCT CTGCTC TGCTCT GCTCTT CTCTTC TCTTCA CTTCAA TTCAAC TCAACC CAACCT AACCTG ACCTGA CCTGAA CTGAAG TGAAGA GAAGAA AAGAAG AGAAGA GAAGAG AAGAGC AGAGCA GAGCAA AGCAAG GCAAGA CAAGAA AAGAAG AGAAGA GAAGAA AAGAAG AGAAGA GAAGAT AAGATT AGATTG GATTGG ATTGGT TTGGTT TGGTTA GGTTAG GTTAGA TTAGAT TAGATG AGATGA GATGAT ATGATG TGATGA GATGAT ATGATA TGATAG GATAGT ATAGTC TAGTCC AGTCCT GTCCTG TCCTGT CCTGTC CTGTCT TGTCTC GTCTCT TCTCTT CTCTTA TCTTAT CTTATA TTATAC TATACA ATACAC TACACA ACACAT CACATT ACATTC CATTCC ATTCCG TTCCGA TCCGAG CCGAGC CGAGCC GAGCCC AGCCCA GCCCAC CCCACG CCACGA CACGAG ACGAGA,0,145,CAAT AATA ATAT TATG ATGA TGAG GAGT AGTA GTAT TATG ATGG TGGT GGTA GTAC TACT ACTG CTGA TGAA GAAG AAGA AGAT GATG ATGA TGAT GATT ATTA TTAC TACC ACCA CCAA CAAG AAGG AGGT GGTA GTAA TAAA AAAC AACC ACCT CCTT CTTT TTTG TTGG TGGA GGAA GAAT AATT ATTT TTTG TTGG TGGT GGTG GTGC TGCC GCCA CCAC CACT ACTT CTTC TTCT TCTG CTGC TGCT GCTG CTGC TGCT GCTC CTCT TCTT CTTC TTCA TCAA CAAC AACC ACCT CCTG CTGA TGAA GAAG AAGA AGAA GAAG AAGA AGAG GAGC AGCA GCAA CAAG AAGA AGAA GAAG AAGA AGAA GAAG AAGA AGAT GATT ATTG TTGG TGGT GGTT GTTA TTAG TAGA AGAT GATG ATGA TGAT GATG ATGA TGAT GATA ATAG TAGT AGTC GTCC TCCT CCTG CTGT TGTC GTCT TCTC CTCT TCTT CTTA TTAT TATA ATAC TACA ACAC CACA ACAT CATT ATTC TTCC TCCG CCGA CGAG GAGC AGCC GCCC CCCA CCAC CACG ACGA CGAG GAGA,CAATA AATAT ATATG TATGA ATGAG TGAGT GAGTA AGTAT GTATG TATGG ATGGT TGGTA GGTAC GTACT TACTG ACTGA CTGAA TGAAG GAAGA AAGAT AGATG GATGA ATGAT TGATT GATTA ATTAC TTACC TACCA ACCAA CCAAG CAAGG AAGGT AGGTA GGTAA GTAAA TAAAC AAACC AACCT ACCTT CCTTT CTTTG TTTGG TTGGA TGGAA GGAAT GAATT AATTT ATTTG TTTGG TTGGT TGGTG GGTGC GTGCC TGCCA GCCAC CCACT CACTT ACTTC CTTCT TTCTG TCTGC CTGCT TGCTG GCTGC CTGCT TGCTC GCTCT CTCTT TCTTC CTTCA TTCAA TCAAC CAACC AACCT ACCTG CCTGA CTGAA TGAAG GAAGA AAGAA AGAAG GAAGA AAGAG AGAGC GAGCA AGCAA GCAAG CAAGA AAGAA AGAAG GAAGA AAGAA AGAAG GAAGA AAGAT AGATT GATTG ATTGG TTGGT TGGTT GGTTA GTTAG TTAGA TAGAT AGATG GATGA ATGAT TGATG GATGA ATGAT TGATA GATAG ATAGT TAGTC AGTCC GTCCT TCCTG CCTGT CTGTC TGTCT GTCTC TCTCT CTCTT TCTTA CTTAT TTATA TATAC ATACA TACAC ACACA CACAT ACATT CATTC ATTCC TTCCG TCCGA CCGAG CGAGC GAGCC AGCCC GCCCA CCCAC CCACG CACGA ACGAG CGAGA,CAATAT AATATG ATATGA TATGAG ATGAGT TGAGTA GAGTAT AGTATG GTATGG TATGGT ATGGTA TGGTAC GGTACT GTACTG TACTGA ACTGAA CTGAAG TGAAGA GAAGAT AAGATG AGATGA GATGAT ATGATT TGATTA GATTAC ATTACC TTACCA TACCAA ACCAAG CCAAGG CAAGGT AAGGTA AGGTAA GGTAAA GTAAAC TAAACC AAACCT AACCTT ACCTTT CCTTTG CTTTGG TTTGGA TTGGAA TGGAAT GGAATT GAATTT AATTTG ATTTGG TTTGGT TTGGTG TGGTGC GGTGCC GTGCCA TGCCAC GCCACT CCACTT CACTTC ACTTCT CTTCTG TTCTGC TCTGCT CTGCTG TGCTGC GCTGCT CTGCTC TGCTCT GCTCTT CTCTTC TCTTCA CTTCAA TTCAAC TCAACC CAACCT AACCTG ACCTGA CCTGAA CTGAAG TGAAGA GAAGAA AAGAAG AGAAGA GAAGAG AAGAGC AGAGCA GAGCAA AGCAAG GCAAGA CAAGAA AAGAAG AGAAGA GAAGAA AAGAAG AGAAGA GAAGAT AAGATT AGATTG GATTGG ATTGGT TTGGTT TGGTTA GGTTAG GTTAGA TTAGAT TAGATG AGATGA GATGAT ATGATG TGATGA GATGAT ATGATA TGATAG GATAGT ATAGTC TAGTCC AGTCCT GTCCTG TCCTGT CCTGTC CTGTCT TGTCTC GTCTCT TCTCTT CTCTTA TCTTAT CTTATA TTATAC TATACA ATACAC TACACA ACACAT CACATT ACATTC CATTCC ATTCCG TTCCGA TCCGAG CCGAGC CGAGCC GAGCCC AGCCCA GCCCAC CCCACG CCACGA CACGAG ACGAGA,CAATATG AATATGA ATATGAG TATGAGT ATGAGTA TGAGTAT GAGTATG AGTATGG GTATGGT TATGGTA ATGGTAC TGGTACT GGTACTG GTACTGA TACTGAA ACTGAAG CTGAAGA TGAAGAT GAAGATG AAGATGA AGATGAT GATGATT ATGATTA TGATTAC GATTACC ATTACCA TTACCAA TACCAAG ACCAAGG CCAAGGT CAAGGTA AAGGTAA AGGTAAA GGTAAAC GTAAACC TAAACCT AAACCTT AACCTTT ACCTTTG CCTTTGG CTTTGGA TTTGGAA TTGGAAT TGGAATT GGAATTT GAATTTG AATTTGG ATTTGGT TTTGGTG TTGGTGC TGGTGCC GGTGCCA GTGCCAC TGCCACT GCCACTT CCACTTC CACTTCT ACTTCTG CTTCTGC TTCTGCT TCTGCTG CTGCTGC TGCTGCT GCTGCTC CTGCTCT TGCTCTT GCTCTTC CTCTTCA TCTTCAA CTTCAAC TTCAACC TCAACCT CAACCTG AACCTGA ACCTGAA CCTGAAG CTGAAGA TGAAGAA GAAGAAG AAGAAGA AGAAGAG GAAGAGC AAGAGCA AGAGCAA GAGCAAG AGCAAGA GCAAGAA CAAGAAG AAGAAGA AGAAGAA GAAGAAG AAGAAGA AGAAGAT GAAGATT AAGATTG AGATTGG GATTGGT ATTGGTT TTGGTTA TGGTTAG GGTTAGA GTTAGAT TTAGATG TAGATGA AGATGAT GATGATG ATGATGA TGATGAT GATGATA ATGATAG TGATAGT GATAGTC ATAGTCC TAGTCCT AGTCCTG GTCCTGT TCCTGTC CCTGTCT CTGTCTC TGTCTCT GTCTCTT TCTCTTA CTCTTAT TCTTATA CTTATAC TTATACA TATACAC ATACACA TACACAT ACACATT CACATTC ACATTCC CATTCCG ATTCCGA TTCCGAG TCCGAGC CCGAGCC CGAGCCC GAGCCCA AGCCCAC GCCCACG CCCACGA CCACGAG CACGAGA,"ID   R1A_SARS                Reviewed;        4382 AA.
AC   P0C6U8; P59641;
DT   10-JUN-2008, integrated into UniProtKB/Swiss-Prot.
DT   10-JUN-2008, sequence version 1.
DT   05-FEB-2025, entry version 124.
DE   RecName: Full=Replicase polyprotein 1a;
DE            Short=pp1a;
DE   AltName: Full=ORF1a polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3;
DE              Short=PL-PRO;
DE              EC=3.4.19.12 {ECO:0000269|PubMed:17692280};
DE              EC=3.4.22.- {ECO:0000269|PubMed:12917450, ECO:0000269|PubMed:16306590, ECO:0000269|PubMed:17692280};
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:12917450};
DE     AltName: Full=Main protease;
DE              Short=Mpro;
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=RNA-capping enzyme subunit nsp9;
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE              EC=2.7.7.50;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=Non-structural protein 11;
DE              Short=nsp11;
GN   ORFNames=1a;
OS   Severe acute respiratory syndrome coronavirus (SARS-CoV).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=694009;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
OH   NCBI_TaxID=9675; Paguma larvata (Masked palm civet).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Urbani;
RX   PubMed=12730500; DOI=10.1126/science.1085952;
RA   Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R.,
RA   Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.-H., Tong S.,
RA   Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D.,
RA   Peret T.C.T., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S.,
RA   Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R.,
RA   Guenther S., Osterhaus A.D.M.E., Drosten C., Pallansch M.A., Anderson L.J.,
RA   Bellini W.J.;
RT   ""Characterization of a novel coronavirus associated with severe acute
RT   respiratory syndrome."";
RL   Science 300:1394-1399(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Tor2;
RX   PubMed=12730501; DOI=10.1126/science.1085953;
RA   Marra M.A., Jones S.J.M., Astell C.R., Holt R.A., Brooks-Wilson A.,
RA   Butterfield Y.S.N., Khattra J., Asano J.K., Barber S.A., Chan S.Y.,
RA   Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffith O.L., Leach S.R.,
RA   Mayo M., McDonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S.,
RA   Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.M.,
RA   Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K.,
RA   Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R.,
RA   Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A.,
RA   Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S.,
RA   Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M.,
RA   Skowronski D.M., Upton C., Roper R.L.;
RT   ""The genome sequence of the SARS-associated coronavirus."";
RL   Science 300:1399-1404(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate CUHK-Su10, and Isolate CUHK-W1;
RX   PubMed=12853594; DOI=10.1056/nejm200307103490216;
RA   Tsui S.K.W., Chim S.S.C., Lo Y.M.D.;
RT   ""Coronavirus genomic-sequence variations and the epidemiology of the severe
RT   acute respiratory syndrome."";
RL   N. Engl. J. Med. 349:187-188(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate GZ50, Isolate SZ16, and Isolate SZ3;
RX   PubMed=12958366; DOI=10.1126/science.1087139;
RA   Guan Y., Zheng B.J., He Y.Q., Liu X.L., Zhuang Z.X., Cheung C.L., Luo S.W.,
RA   Li P.H., Zhang L.J., Guan Y.J., Butt K.M., Wong K.L., Chan K.W., Lim W.,
RA   Shortridge K.F., Yuen K.Y., Peiris J.S.M., Poon L.L.M.;
RT   ""Isolation and characterization of viruses related to the SARS coronavirus
RT   from animals in southern China."";
RL   Science 302:276-278(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HKU-39849;
RX   PubMed=12876307; DOI=10.1177/15353702-0322807-13;
RA   Zeng F.Y., Chan C.W., Chan M.N., Chen J.D., Chow K.Y.C., Hon C.C.C.,
RA   Hui R.K.H., Li J., Li V.Y.Y., Wang C.Y., Wang P.Y., Guan Y., Zheng B.,
RA   Poon L.L.M., Chan K.H., Yuen K.Y., Peiris J.S.M., Leung F.C.;
RT   ""The complete genome sequence of severe acute respiratory syndrome
RT   coronavirus strain HKU-39849 (HK-39)."";
RL   Exp. Biol. Med. 228:866-873(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Sin2500, Isolate Sin2677, Isolate Sin2679, Isolate
RC   Sin2748, and Isolate sin2774;
RX   PubMed=12781537; DOI=10.1016/s0140-6736(03)13414-9;
RA   Ruan Y., Wei C.L., Ling A.E., Vega V.B., Thoreau H., Se Thoe S.Y.,
RA   Chia J.-M., Ng P., Chiu K.P., Lim L., Zhang T., Chan K.P., Oon L.E.L.,
RA   Ng M.L., Leo S.Y., Ng L.F.P., Ren E.C., Stanton L.W., Long P.M., Liu E.T.;
RT   ""Comparative full-length genome sequence analysis of 14 SARS coronavirus
RT   isolates and common mutations associated with putative origins of
RT   infection."";
RL   Lancet 361:1779-1785(2003).
RN   [7]
RP   ERRATUM OF PUBMED:12781537.
RA   Ruan Y., Wei C.L., Ling A.E., Vega V.B., Thoreau H., Se Thoe S.Y.,
RA   Chia J.-M., Ng P., Chiu K.P., Lim L., Zhang T., Chan K.P., Oon L.E.L.,
RA   Ng M.L., Leo S.Y., Ng L.F.P., Ren E.C., Stanton L.W., Long P.M., Liu E.T.;
RL   Lancet 361:1832-1832(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate ZJ01;
RX   PubMed=14527350;
RA   Li L., Wang Z., Lu Y., Bao Q., Chen S., Wu N., Cheng S., Weng J., Zhang Y.,
RA   Yan J., Mei L., Wang X., Zhu H., Yu Y., Zhang M., Li M., Yao J., Lu Q.,
RA   Yao P., Bo X., Wo J., Wang S., Hu S.;
RT   ""Severe acute respiratory syndrome-associated coronavirus genotype and its
RT   characterization."";
RL   Chin. Med. J. 116:1288-1292(2003).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate BJ01, Isolate BJ02, Isolate BJ03, Isolate BJ04, and
RC   Isolate GD01;
RA   Qin E., Zhu Q., Yu M., Fan B., Chang G., Si B., Yang B., Peng W., Jiang T.,
RA   Liu B., Deng Y., Liu H., Zhang Y., Wang C., Li Y., Gan Y., Li X., Lu F.,
RA   Tan G., Yang R., Cao W.S., Wang J., Chen W., Cong L., Deng Y., Dong W.,
RA   Han Y., Hu W., Lei M., Li C., Li G., Li G., Li H., Li S., Li S., Li W.,
RA   Li W., Lin W., Liu J., Liu Z., Lu H., Ni P., Qi Q., Sun Y., Tang L.,
RA   Tong Z., Wang J., Wang X., Wu Q., Xi Y., Xu Z., Yang L., Ye C., Ye J.,
RA   Zhang B., Zhang F., Zhang J., Zhang X., Zhou J., Yang H.;
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TW1;
RA   Yeh S.-H., Kao C.-L., Tsai C.-Y., Liu C.-J., Chen D.-S., Chen P.-J.;
RT   ""The complete genome of SARS coronavirus clone TW1."";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate FRA;
RX   PubMed=14645828; DOI=10.1126/science.302.5650.1504b;
RA   Eickmann M., Becker S., Klenk H.-D., Doerr H.W., Stadler K., Censini S.,
RA   Guidotti S., Masignani V., Scarselli M., Mora M., Donati C., Han J.H.,
RA   Song H.C., Abrignani S., Covacci A., Rappuoli R.;
RT   ""Phylogeny of the SARS coronavirus."";
RL   Science 302:1504-1505(2003).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Frankfurt-1;
RA   Thiel V., Hertzig T., Putics A., Ivanov K.A., Schelle B., Bayer S.,
RA   Scheiner B., Weinand H., Weissbrich B., Ziebuhr J.;
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWC;
RA   Yang J.-Y., Lin J.-H., Chiu S.-C., Wang S.-F., Lee S.C., Lin Y.-C.,
RA   Hsu C.-K., Chen H.-Y., Chang J.G., Chen P.-J., Su I.-J.;
RT   ""Genomic sequence of SARS isolate from the first fatal case in Taiwan."";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Shanghai QXC1;
RA   Yuan Z., Zhang X., Hu Y., Lan S., Wang H., Zhou Z., Wen Y.;
RT   ""Analysis of SARS coronavirus genome in Shanghai isolates."";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HSR 1;
RA   Canducci F., Clementi M., Poli G., Vicenzi E.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [16]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Taiwan TC1, Isolate Taiwan TC2, and Isolate Taiwan TC3;
RA   Chang J.-G.C., Lin T.-H., Chen C.-M., Lin C.-S., Chan W.-L., Shih M.-C.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [17]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWH, Isolate TWJ, Isolate TWK, Isolate TWS, and Isolate
RC   TWY;
RA   Shu H.Y., Wu K.M., Tsai S.F.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [18]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate AS;
RA   Balotta C., Corvasce S., Violin M., Galli M., Moroni M., Vigevani G.M.,
RA   Ruan Y.J., Salemi M.;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [19]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate ZJ01;
RA   Wang Z., Cheng S., Zhang Y.;
RL   Submitted (NOV-2003) to the EMBL/GenBank/DDBJ databases.
RN   [20]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA] OF 1-507 AND 1655-4382.
RC   STRAIN=Isolate Shanghai LY;
RA   Yuan Z., Zhang X., Hu Y., Lan S., Wang H., Zhou Z., Wen Y.;
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [21]
RP   PROTEOLYTIC CLEAVAGE (ISOFORM REPLICASE POLYPROTEIN 1A), CATALYTIC ACTIVITY
RP   (3C-LIKE PROTEINASE NSP5), AND CATALYTIC ACTIVITY (PAPAIN-LIKE PROTEASE
RP   NSP3).
RX   PubMed=12917450; DOI=10.1099/vir.0.19424-0;
RA   Thiel V., Ivanov K.A., Putics A., Hertzig T., Schelle B., Bayer S.,
RA   Weissbrich B., Snijder E.J., Rabenau H., Doerr H.W., Gorbalenya A.E.,
RA   Ziebuhr J.;
RT   ""Mechanisms and enzymes involved in SARS coronavirus genome expression."";
RL   J. Gen. Virol. 84:2305-2315(2003).
RN   [22]
RP   PROTEOLYTIC CLEAVAGE (ISOFORM REPLICASE POLYPROTEIN 1A).
RX   PubMed=15331731; DOI=10.1128/jvi.78.18.9977-9986.2004;
RA   Prentice E., McAuliffe J., Lu X., Subbarao K., Denison M.R.;
RT   ""Identification and characterization of severe acute respiratory syndrome
RT   coronavirus replicase proteins."";
RL   J. Virol. 78:9977-9986(2004).
RN   [23]
RP   PROTEOLYTIC CLEAVAGE (ISOFORM REPLICASE POLYPROTEIN 1A).
RC   STRAIN=Isolate Urbani;
RX   PubMed=15564471; DOI=10.1128/jvi.78.24.13600-13612.2004;
RA   Harcourt B.H., Jukneliene D., Kanjanahaluethai A., Bechill J.,
RA   Severson K.M., Smith C.M., Rota P.A., Baker S.C.;
RT   ""Identification of severe acute respiratory syndrome coronavirus replicase
RT   products and characterization of papain-like protease activity."";
RL   J. Virol. 78:13600-13612(2004).
RN   [24]
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), AND BIOPHYSICOCHEMICAL PROPERTIES (3C-LIKE PROTEINASE NSP5).
RX   PubMed=14561748; DOI=10.1074/jbc.m310875200;
RA   Fan K., Wei P., Feng Q., Chen S., Huang C., Ma L., Lai B., Pei J., Liu Y.,
RA   Chen J., Lai L.;
RT   ""Biosynthesis, purification, and substrate specificity of severe acute
RT   respiratory syndrome coronavirus 3C-like proteinase."";
RL   J. Biol. Chem. 279:1637-1642(2004).
RN   [25]
RP   CATALYTIC ACTIVITY (PAPAIN-LIKE PROTEASE NSP3), FUNCTION (PAPAIN-LIKE
RP   PROTEASE NSP3), PROTEOLYTIC CLEAVAGE (ISOFORM REPLICASE POLYPROTEIN 1A),
RP   COFACTOR (PAPAIN-LIKE PROTEASE NSP3), MUTAGENESIS OF CYS-1651; CYS-1688;
RP   CYS-1729; CYS-1732; CYS-1764; CYS-1766 AND ASP-1826, AND ACTIVE SITE
RP   (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=16306590; DOI=10.1128/jvi.79.24.15189-15198.2005;
RA   Barretto N., Jukneliene D., Ratia K., Chen Z., Mesecar A.D., Baker S.C.;
RT   ""The papain-like protease of severe acute respiratory syndrome coronavirus
RT   has deubiquitinating activity."";
RL   J. Virol. 79:15189-15198(2005).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=16226257; DOI=10.1016/j.febslet.2005.09.075;
RA   Lin C.W., Tsai F.J., Wan L., Lai C.C., Lin K.H., Hsieh T.H., Shiu S.Y.,
RA   Li J.Y.;
RT   ""Binding interaction of SARS coronavirus 3CL(pro) protease with vacuolar-H+
RT   ATPase G1 subunit."";
RL   FEBS Lett. 579:6089-6094(2005).
RN   [27]
RP   SUBUNIT (3C-LIKE PROTEINASE NSP5).
RX   PubMed=15507456; DOI=10.1074/jbc.m408211200;
RA   Chen S., Chen L., Tan J., Chen J., Du L., Sun T., Shen J., Chen K.,
RA   Jiang H., Shen X.;
RT   ""Severe acute respiratory syndrome coronavirus 3C-like proteinase N
RT   terminus is indispensable for proteolytic activity but not for enzyme
RT   dimerization. Biochemical and thermodynamic investigation in conjunction
RT   with molecular dynamics simulations."";
RL   J. Biol. Chem. 280:164-173(2005).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=17024178; DOI=10.1038/sj.emboj.7601368;
RA   Imbert I., Guillemot J.-C., Bourhis J.-M., Bussetta C., Coutard B.,
RA   Egloff M.-P., Ferron F., Gorbalenya A.E., Canard B.;
RT   ""A second, non-canonical RNA-dependent RNA polymerase in SARS
RT   coronavirus."";
RL   EMBO J. 25:4933-4942(2006).
RN   [29]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3).
RX   PubMed=17692280; DOI=10.1016/j.abb.2007.07.006;
RA   Lindner H.A., Lytvyn V., Qi H., Lachance P., Ziomek E., Menard R.;
RT   ""Selectivity in ISG15 and ubiquitin recognition by the SARS coronavirus
RT   papain-like protease."";
RL   Arch. Biochem. Biophys. 466:8-14(2007).
RN   [30]
RP   INTERACTION WITH ORF6 PROTEIN (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=17532020; DOI=10.1016/j.virol.2007.04.029;
RA   Kumar P., Gunalan V., Liu B., Chow V.T., Druce J., Birch C., Catton M.,
RA   Fielding B.C., Tan Y.J., Lal S.K.;
RT   ""The nonstructural protein 8 (nsp8) of the SARS coronavirus interacts with
RT   its ORF6 accessory protein."";
RL   Virology 366:293-303(2007).
RN   [31]
RP   TOPOLOGY (PAPAIN-LIKE PROTEASE NSP3), TOPOLOGY (NON-STRUCTURAL PROTEIN 4),
RP   AND TOPOLOGY (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=18842706; DOI=10.1128/jvi.01219-08;
RA   Oostra M., Hagemeijer M.C., van Gent M., Bekker C.P., te Lintelo E.G.,
RA   Rottier P.J., de Haan C.A.;
RT   ""Topology and membrane anchoring of the coronavirus replication complex:
RT   not all hydrophobic domains of nsp3 and nsp6 are membrane spanning."";
RL   J. Virol. 82:12392-12405(2008).
RN   [32]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=19369340; DOI=10.1128/jvi.02220-08;
RA   Frieman M., Ratia K., Johnston R.E., Mesecar A.D., Baric R.S.;
RT   ""Severe acute respiratory syndrome coronavirus papain-like protease
RT   ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and
RT   NF-kappaB signaling."";
RL   J. Virol. 83:6689-6705(2009).
RN   [33]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), AND INTERACTION WITH HOST PHB AND PHB2
RP   (NON-STRUCTURAL PROTEIN 2).
RX   PubMed=19640993; DOI=10.1128/jvi.00842-09;
RA   Cornillez-Ty C.T., Liao L., Yates J.R., Kuhn P., Buchmeier M.J.;
RT   ""Severe acute respiratory syndrome coronavirus nonstructural protein 2
RT   interacts with a host protein complex involved in mitochondrial biogenesis
RT   and intracellular signaling."";
RL   J. Virol. 83:10314-10318(2009).
RN   [34]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=19153232; DOI=10.1128/jvi.01505-08;
RA   Miknis Z.J., Donaldson E.F., Umland T.C., Rimmer R.A., Baric R.S.,
RA   Schultz L.W.;
RT   ""Severe acute respiratory syndrome coronavirus nsp9 dimerization is
RT   essential for efficient viral growth."";
RL   J. Virol. 83:3007-3018(2009).
RN   [35]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=22174690; DOI=10.1371/journal.ppat.1002433;
RA   Huang C., Lokugamage K.G., Rozovics J.M., Narayanan K., Semler B.L.,
RA   Makino S.;
RT   ""SARS coronavirus nsp1 protein induces template-dependent endonucleolytic
RT   cleavage of mRNAs: viral mRNAs are resistant to nsp1-induced RNA
RT   cleavage."";
RL   PLoS Pathog. 7:E1002433-E1002433(2011).
RN   [36]
RP   INTERACTION WITH PAPAIN-LIKE PROTEASE NSP3 (NON-STRUCTURAL PROTEIN 4),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 4), AND INTERACTION WITH
RP   NON-STRUCTURAL PROTEIN 6 (NON-STRUCTURAL PROTEIN 4).
RX   PubMed=21345958; DOI=10.1128/jvi.00042-11;
RA   Hagemeijer M.C., Ulasli M., Vonk A.M., Reggiori F., Rottier P.J.,
RA   de Haan C.A.;
RT   ""Mobility and interactions of coronavirus nonstructural protein 4."";
RL   J. Virol. 85:4572-4577(2011).
RN   [37]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=23035226; DOI=10.1128/jvi.01958-12;
RA   Lokugamage K.G., Narayanan K., Huang C., Makino S.;
RT   ""Severe acute respiratory syndrome coronavirus protein nsp1 is a novel
RT   eukaryotic translation inhibitor that represses multiple steps of
RT   translation initiation."";
RL   J. Virol. 86:13598-13608(2012).
RN   [38]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 7), AND FUNCTION (NON-STRUCTURAL PROTEIN
RP   8).
RX   PubMed=22039154; DOI=10.1093/nar/gkr893;
RA   te Velthuis A.J., van den Worm S.H., Snijder E.J.;
RT   ""The SARS-coronavirus nsp7+nsp8 complex is a unique multimeric RNA
RT   polymerase capable of both de novo initiation and primer extension."";
RL   Nucleic Acids Res. 40:1737-1747(2012).
RN   [39]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 10), AND INTERACTION WITH PROOFREADING
RP   EXORIBONUCLEASE NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=22635272; DOI=10.1073/pnas.1201130109;
RA   Bouvet M., Imbert I., Subissi L., Gluais L., Canard B., Decroly E.;
RT   ""RNA 3'-end mismatch excision by the severe acute respiratory syndrome
RT   coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complex."";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:9372-9377(2012).
RN   [40]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 4), FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND FUNCTION
RP   (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=23943763; DOI=10.1128/mbio.00524-13;
RA   Angelini M.M., Akhlaghpour M., Neuman B.W., Buchmeier M.J.;
RT   ""Severe acute respiratory syndrome coronavirus nonstructural proteins 3, 4,
RT   and 6 induce double-membrane vesicles."";
RL   MBio 4:0-0(2013).
RN   [41]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=24991833; DOI=10.4161/auto.29309;
RA   Cottam E.M., Whelband M.C., Wileman T.;
RT   ""Coronavirus NSP6 restricts autophagosome expansion."";
RL   Autophagy 10:1426-1441(2014).
RN   [42]
RP   REVIEW.
RX   PubMed=24410069; DOI=10.1089/dna.2013.2304;
RA   Angelini M.M., Neuman B.W., Buchmeier M.J.;
RT   ""Untangling membrane rearrangement in the nidovirales."";
RL   DNA Cell Biol. 33:122-127(2014).
RN   [43]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=24622840; DOI=10.1007/s13238-014-0026-3;
RA   Chen X., Yang X., Zheng Y., Yang Y., Xing Y., Chen Z.;
RT   ""SARS coronavirus papain-like protease inhibits the type I interferon
RT   signaling pathway through interaction with the STING-TRAF3-TBK1 complex."";
RL   Protein Cell 5:369-381(2014).
RN   [44]
RP   INTERACTION WITH NUP93 (HOST TRANSLATION INHIBITOR NSP1), AND FUNCTION
RP   (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=30943371; DOI=10.1139/bcb-2018-0394;
RA   Gomez G.N., Abrar F., Dodhia M.P., Gonzalez F.G., Nag A.;
RT   ""SARS coronavirus protein nsp1 disrupts localization of Nup93 from the
RT   nuclear pore complex."";
RL   Biochem. Cell Biol. 97:758-766(2019).
RN   [45]
RP   PROTEOLYTIC CLEAVAGE (ISOFORM REPLICASE POLYPROTEIN 1A), MASS SPECTROMETRY
RP   (NON-STRUCTURAL PROTEIN 8), MASS SPECTROMETRY (NON-STRUCTURAL PROTEIN 9),
RP   AND MASS SPECTROMETRY (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=32083638; DOI=10.1042/bcj20200029;
RA   Krichel B., Falke S., Hilgenfeld R., Redecke L., Uetrecht C.;
RT   ""Processing of the SARS-CoV pp1a/ab nsp7-10 region."";
RL   Biochem. J. 477:1009-1019(2020).
RN   [46]
RP   3D-STRUCTURE MODELING OF 3241-3540, AND CHARACTERIZATION (3C-LIKE
RP   PROTEINASE NSP5).
RX   PubMed=12746549; DOI=10.1126/science.1085658;
RA   Anand K., Ziebuhr J., Wadhwani P., Mesters J.R., Hilgenfeld R.;
RT   ""Coronavirus main proteinase (3CLpro) structure: basis for design of anti-
RT   SARS drugs."";
RL   Science 300:1763-1767(2003).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 4118-4230 (NON-STRUCTURAL PROTEIN
RP   9).
RC   STRAIN=Isolate Frankfurt-1;
RX   PubMed=12925794; DOI=10.1107/s0907444903016779;
RA   Campanacci V., Egloff M.-P., Longhi S., Ferron F., Rancurel C.,
RA   Salomoni A., Durousseau C., Tocque F., Bremond N., Dobbe J.C.,
RA   Snijder E.J., Canard B., Cambillau C.;
RT   ""Structural genomics of the SARS coronavirus: cloning, expression,
RT   crystallization and preliminary crystallographic study of the Nsp9
RT   protein."";
RL   Acta Crystallogr. D 59:1628-1631(2003).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 4118-4230.
RX   PubMed=15007178; DOI=10.1073/pnas.0307877101;
RA   Egloff M.-P., Ferron F., Campanacci V., Longhi S., Rancurel C.,
RA   Dutartre H., Snijder E.J., Gorbalenya A.E., Cambillau C., Canard B.;
RT   ""The severe acute respiratory syndrome-coronavirus replicative protein nsp9
RT   is a single-stranded RNA-binding subunit unique in the RNA virus world."";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:3792-3796(2004).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 4107-4230.
RX   PubMed=14962394; DOI=10.1016/j.str.2004.01.016;
RA   Sutton G., Fry E., Carter L., Sainsbury S., Walter T., Nettleship J.,
RA   Berrow N., Owens R., Gilbert R., Davidson A., Siddell S., Poon L.L.M.,
RA   Diprose J., Alderton D., Walsh M., Grimes J.M., Stuart D.I.;
RT   ""The nsp9 replicase protein of SARS-coronavirus, structure and functional
RT   insights."";
RL   Structure 12:341-353(2004).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 3837-4117 AND 3920-4117,
RP   INTERACTION WITH NON-STRUCTURAL PROTEIN 7 (NON-STRUCTURAL PROTEIN 8), AND
RP   INTERACTION WITH NON-STRUCTURAL PROTEIN 8 (NON-STRUCTURAL PROTEIN 7).
RX   PubMed=16228002; DOI=10.1038/nsmb999;
RA   Zhai Y., Sun F., Li X., Pang H., Xu X., Bartlam M., Rao Z.;
RT   ""Insights into SARS-CoV transcription and replication from the structure of
RT   the nsp7-nsp8 hexadecamer."";
RL   Nat. Struct. Mol. Biol. 12:980-986(2005).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 1002-1176.
RX   PubMed=16271890; DOI=10.1016/j.str.2005.07.022;
RA   Saikatendu K.S., Joseph J.S., Subramanian V., Clayton T., Griffith M.,
RA   Moy K., Velasquez J., Neuman B.W., Buchmeier M.J., Stevens R.C., Kuhn P.;
RT   ""Structural basis of severe acute respiratory syndrome coronavirus ADP-
RT   ribose-1''-phosphate dephosphorylation by a conserved domain of nsP3."";
RL   Structure 13:1665-1675(2005).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 1541-1854.
RX   PubMed=16581910; DOI=10.1073/pnas.0510851103;
RA   Ratia K., Saikatendu K.S., Santarsiero B.D., Barretto N., Baker S.C.,
RA   Stevens R.C., Mesecar A.D.;
RT   ""Severe acute respiratory syndrome coronavirus papain-like protease:
RT   structure of a viral deubiquitinating enzyme."";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:5717-5722(2006).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 4240-4362.
RC   STRAIN=Isolate Tor2;
RX   PubMed=16873246; DOI=10.1128/jvi.00467-06;
RA   Joseph J.S., Saikatendu K.S., Subramanian V., Neuman B.W., Brooun A.,
RA   Griffith M., Moy K., Yadav M.K., Velasquez J., Buchmeier M.J.,
RA   Stevens R.C., Kuhn P.;
RT   ""Crystal structure of nonstructural protein 10 from the severe acute
RT   respiratory syndrome coronavirus reveals a novel fold with two zinc-binding
RT   motifs."";
RL   J. Virol. 80:7894-7901(2006).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 4231-4378.
RX   PubMed=16873247; DOI=10.1128/jvi.00483-06;
RA   Su D., Lou Z., Sun F., Zhai Y., Yang H., Zhang R., Joachimiak A.,
RA   Zhang X.C., Bartlam M., Rao Z.;
RT   ""Dodecamer structure of severe acute respiratory syndrome coronavirus
RT   nonstructural protein nsp10."";
RL   J. Virol. 80:7902-7908(2006).
RN   [55]
RP   STRUCTURE BY NMR OF 13-127.
RX   PubMed=17202208; DOI=10.1128/jvi.01939-06;
RA   Almeida M.S., Johnson M.A., Herrmann T., Geralt M., Wuthrich K.;
RT   ""Novel beta-barrel fold in the nuclear magnetic resonance structure of the
RT   replicase nonstructural protein 1 from the severe acute respiratory
RT   syndrome coronavirus."";
RL   J. Virol. 81:3151-3161(2007).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3241-3546.
RG   RIKEN structural genomics initiative (RSGI);
RT   ""Crystal structure of Sars coronavirus main proteinase(3CLPRO)."";
RL   Submitted (JUL-2007) to the PDB data bank.
CC   -!- FUNCTION: [Isoform Replicase polyprotein 1a]: Multifunctional protein
CC       involved in the transcription and replication of viral RNAs. Contains
CC       the proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000305}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by interacting with the 40S ribosomal subunit. The nsp1-40S ribosome
CC       complex further induces an endonucleolytic cleavage near the 5'UTR of
CC       host mRNAs, targeting them for degradation. Viral mRNAs are not
CC       susceptible to nsp1-mediated endonucleolytic RNA cleavage thanks to the
CC       presence of a 5'-end leader sequence and are therefore protected from
CC       degradation. By suppressing host gene expression, nsp1 facilitates
CC       efficient viral gene expression in infected cells and evasion from host
CC       immune response (PubMed:23035226). May disrupt nuclear pore function by
CC       binding and displacing host NUP93 (PubMed:30943371).
CC       {ECO:0000269|PubMed:23035226, ECO:0000269|PubMed:30943371}.
CC   -!- FUNCTION: [Non-structural protein 2]: May play a role in the modulation
CC       of host cell survival signaling pathway by interacting with host PHB
CC       and PHB2 (PubMed:19640993). Indeed, these two proteins play a role in
CC       maintaining the functional integrity of the mitochondria and protecting
CC       cells from various stresses (PubMed:19640993).
CC       {ECO:0000269|PubMed:19640993}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. In addition,
CC       PL-PRO possesses a deubiquitinating/deISGylating activity and processes
CC       both 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:17692280). Plays a role in host membrane
CC       rearrangement that leads to creation of cytoplasmic double-membrane
CC       vesicles (DMV) necessary for viral replication (PubMed:23943763). Nsp3,
CC       nsp4 and nsp6 together are sufficient to form DMV (PubMed:23943763,
CC       PubMed:24410069). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:19369340, PubMed:24622840).
CC       Prevents also host NF-kappa-B signaling (PubMed:19369340,
CC       PubMed:24622840). {ECO:0000269|PubMed:16271890,
CC       ECO:0000269|PubMed:17692280, ECO:0000269|PubMed:19369340,
CC       ECO:0000269|PubMed:23943763, ECO:0000269|PubMed:24622840,
CC       ECO:0000303|PubMed:24410069}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in host membrane
CC       rearrangement that leads to creation of cytoplasmic double-membrane
CC       vesicles (DMV) necessary for viral replication (PubMed:23943763,
CC       PubMed:24410069). Alone appears incapable to induce membrane curvature,
CC       but together with nsp3 is able to induce paired membranes
CC       (PubMed:23943763). Nsp3, nsp4 and nsp6 together are sufficient to form
CC       DMV (PubMed:23943763, PubMed:24410069). {ECO:0000269|PubMed:23943763,
CC       ECO:0000303|PubMed:24410069}.
CC   -!- FUNCTION: [3C-like proteinase nsp5]: Cleaves the C-terminus of
CC       replicase polyprotein at 11 sites. Recognizes substrates containing the
CC       core sequence [ILMVF]-Q-|-[SGACN]. Also able to bind an ADP-ribose-1''-
CC       phosphate (ADRP). May cleave host ATP6V1G1 thereby modifying host
CC       vacuoles intracellular pH. {ECO:0000255|PROSITE-ProRule:PRU00772,
CC       ECO:0000269|PubMed:16226257}.
CC   -!- FUNCTION: [Non-structural protein 6]: Plays a role in host membrane
CC       rearrangement that leads to creation of cytoplasmic double-membrane
CC       vesicles (DMV) necessary for viral replication (PubMed:23943763). Nsp3,
CC       nsp4 and nsp6 together are sufficient to form DMV (PubMed:23943763,
CC       PubMed:24410069). Plays a role in the initial induction of
CC       autophagosomes from host endoplasmic reticulum. Later, limits the
CC       expansion of these phagosomes that are no longer able to deliver viral
CC       components to lysosomes (PubMed:24991833).
CC       {ECO:0000269|PubMed:23943763, ECO:0000269|PubMed:24991833,
CC       ECO:0000303|PubMed:24410069}.
CC   -!- FUNCTION: [Non-structural protein 7]: Forms a hexadecamer with nsp8 (8
CC       subunits of each) that may participate in viral replication by acting
CC       as a primase. Alternatively, may synthesize substantially longer
CC       products than oligonucleotide primers. {ECO:0000269|PubMed:22039154}.
CC   -!- FUNCTION: [Non-structural protein 8]: Forms a hexadecamer with nsp7 (8
CC       subunits of each) that may participate in viral replication by acting
CC       as a primase. Alternatively, may synthesize substantially longer
CC       products than oligonucleotide primers. {ECO:0000269|PubMed:22039154}.
CC   -!- FUNCTION: [RNA-capping enzyme subunit nsp9]: Catalytic subunit of viral
CC       RNA capping enzyme which catalyzes the RNA guanylyltransferase reaction
CC       for genomic and sub-genomic RNAs. The kinase-like NiRAN domain of NSP12
CC       transfers RNA to the amino terminus of NSP9, forming a covalent RNA-
CC       protein intermediate. Subsequently, the NiRAN domain transfers RNA to
CC       GDP, forming the core cap structure GpppA-RNA. The NSP14 and NSP16
CC       methyltransferases then add methyl groups to form functional cap
CC       structures. {ECO:0000250|UniProtKB:P0DTC1,
CC       ECO:0000269|PubMed:19153232}.
CC   -!- FUNCTION: [Non-structural protein 10]: Plays a pivotal role in viral
CC       transcription by stimulating both nsp14 3'-5' exoribonuclease and nsp16
CC       2'-O-methyltransferase activities. Therefore plays an essential role in
CC       viral mRNAs cap methylation. {ECO:0000269|PubMed:22635272}.
CC   -!- CATALYTIC ACTIVITY: [3C-like proteinase nsp5]:
CC       Reaction=TSAVLQ-|-SGFRK-NH2 and SGVTFQ-|-GKFKK the two peptides
CC         corresponding to the two self-cleavage sites of the SARS 3C-like
CC         proteinase are the two most reactive peptide substrates. The enzyme
CC         exhibits a strong preference for substrates containing Gln at P1
CC         position and Leu at P2 position.; EC=3.4.22.69;
CC         Evidence={ECO:0000269|PubMed:12917450, ECO:0000269|PubMed:14561748};
CC   -!- CATALYTIC ACTIVITY: [Papain-like protease nsp3]:
CC       Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide
CC         and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-
CC         residue protein attached to proteins as an intracellular targeting
CC         signal).; EC=3.4.19.12; Evidence={ECO:0000269|PubMed:12917450,
CC         ECO:0000269|PubMed:17692280};
CC   -!- CATALYTIC ACTIVITY: [RNA-capping enzyme subunit nsp9]:
CC       Reaction=a 5'-end diphospho-ribonuc",52854
ATGGAG TGGAGA GGAGAG GAGAGC AGAGCC GAGCCT AGCCTT GCCTTG CCTTGT CTTGTC TTGTCC TGTCCC GTCCCT TCCCTG CCCTGG CCTGGT CTGGTT TGGTTT GGTTTC GTTTCA TTTCAA TTCAAC TCAACG CAACGA AACGAG ACGAGA CGAGAA GAGAAA AGAAAA GAAAAC AAAACA AAACAC AACACA ACACAC CACACG ACACGT CACGTC ACGTCC CGTCCA GTCCAA TCCAAC CCAACT CAACTC AACTCA ACTCAG CTCAGT TCAGTT CAGTTT AGTTTG GTTTGC TTTGCC TTGCCT TGCCTG GCCTGT CCTGTT CTGTTT TGTTTT GTTTTA TTTTAC TTTACA TTACAG TACAGG ACAGGT CAGGTT AGGTTC GGTTCG GTTCGC TTCGCG TCGCGA CGCGAC GCGACG CGACGT GACGTG ACGTGC CGTGCT GTGCTC TGCTCG GCTCGT CTCGTA,0,79,ATGG TGGA GGAG GAGA AGAG GAGC AGCC GCCT CCTT CTTG TTGT TGTC GTCC TCCC CCCT CCTG CTGG TGGT GGTT GTTT TTTC TTCA TCAA CAAC AACG ACGA CGAG GAGA AGAA GAAA AAAA AAAC AACA ACAC CACA ACAC CACG ACGT CGTC GTCC TCCA CCAA CAAC AACT ACTC CTCA TCAG CAGT AGTT GTTT TTTG TTGC TGCC GCCT CCTG CTGT TGTT GTTT TTTT TTTA TTAC TACA ACAG CAGG AGGT GGTT GTTC TTCG TCGC CGCG GCGA CGAC GACG ACGT CGTG GTGC TGCT GCTC CTCG TCGT CGTA,ATGGA TGGAG GGAGA GAGAG AGAGC GAGCC AGCCT GCCTT CCTTG CTTGT TTGTC TGTCC GTCCC TCCCT CCCTG CCTGG CTGGT TGGTT GGTTT GTTTC TTTCA TTCAA TCAAC CAACG AACGA ACGAG CGAGA GAGAA AGAAA GAAAA AAAAC AAACA AACAC ACACA CACAC ACACG CACGT ACGTC CGTCC GTCCA TCCAA CCAAC CAACT AACTC ACTCA CTCAG TCAGT CAGTT AGTTT GTTTG TTTGC TTGCC TGCCT GCCTG CCTGT CTGTT TGTTT GTTTT TTTTA TTTAC TTACA TACAG ACAGG CAGGT AGGTT GGTTC GTTCG TTCGC TCGCG CGCGA GCGAC CGACG GACGT ACGTG CGTGC GTGCT TGCTC GCTCG CTCGT TCGTA,ATGGAG TGGAGA GGAGAG GAGAGC AGAGCC GAGCCT AGCCTT GCCTTG CCTTGT CTTGTC TTGTCC TGTCCC GTCCCT TCCCTG CCCTGG CCTGGT CTGGTT TGGTTT GGTTTC GTTTCA TTTCAA TTCAAC TCAACG CAACGA AACGAG ACGAGA CGAGAA GAGAAA AGAAAA GAAAAC AAAACA AAACAC AACACA ACACAC CACACG ACACGT CACGTC ACGTCC CGTCCA GTCCAA TCCAAC CCAACT CAACTC AACTCA ACTCAG CTCAGT TCAGTT CAGTTT AGTTTG GTTTGC TTTGCC TTGCCT TGCCTG GCCTGT CCTGTT CTGTTT TGTTTT GTTTTA TTTTAC TTTACA TTACAG TACAGG ACAGGT CAGGTT AGGTTC GGTTCG GTTCGC TTCGCG TCGCGA CGCGAC GCGACG CGACGT GACGTG ACGTGC CGTGCT GTGCTC TGCTCG GCTCGT CTCGTA,ATGGAGA TGGAGAG GGAGAGC GAGAGCC AGAGCCT GAGCCTT AGCCTTG GCCTTGT CCTTGTC CTTGTCC TTGTCCC TGTCCCT GTCCCTG TCCCTGG CCCTGGT CCTGGTT CTGGTTT TGGTTTC GGTTTCA GTTTCAA TTTCAAC TTCAACG TCAACGA CAACGAG AACGAGA ACGAGAA CGAGAAA GAGAAAA AGAAAAC GAAAACA AAAACAC AAACACA AACACAC ACACACG CACACGT ACACGTC CACGTCC ACGTCCA CGTCCAA GTCCAAC TCCAACT CCAACTC CAACTCA AACTCAG ACTCAGT CTCAGTT TCAGTTT CAGTTTG AGTTTGC GTTTGCC TTTGCCT TTGCCTG TGCCTGT GCCTGTT CCTGTTT CTGTTTT TGTTTTA GTTTTAC TTTTACA TTTACAG TTACAGG TACAGGT ACAGGTT CAGGTTC AGGTTCG GGTTCGC GTTCGCG TTCGCGA TCGCGAC CGCGACG GCGACGT CGACGTG GACGTGC ACGTGCT CGTGCTC GTGCTCG TGCTCGT GCTCGTA,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",52808
ATTGAA TTGAAT TGAATT GAATTG AATTGT ATTGTG TTGTGC TGTGCG GTGCGT TGCGTG GCGTGG CGTGGA GTGGAT TGGATG GGATGA GATGAG ATGAGG TGAGGC GAGGCT AGGCTG GGCTGG GCTGGT CTGGTT TGGTTC GGTTCT GTTCTA TTCTAA TCTAAA CTAAAT TAAATC AAATCA AATCAC ATCACC TCACCC CACCCA ACCCAT CCCATT CCATTC CATTCA ATTCAG TTCAGT TCAGTA CAGTAC AGTACA GTACAT TACATC ACATCG CATCGA ATCGAT TCGATA CGATAT GATATC ATATCG TATCGG ATCGGT TCGGTA CGGTAA GGTAAT GTAATT TAATTA AATTAT ATTATA TTATAC TATACA ATACAG TACAGT ACAGTT CAGTTT AGTTTC GTTTCC TTTCCT TTCCTG TCCTGT CCTGTT CTGTTT TGTTTA,1,76,ATTTTGCTGAC  TT CGTGAGA A T TGTA GAAAA A GGTTAATAT T AAATATTTT  ATATTTTGTG G T TTTTGTGTC AT T TGAAATG G G GTGTGATCGC C T TGTTTA TG G GCGCG TTGT T CCGTGTGTG G G GTGTG CATC G T TGTGGGGACGTA G GGGGAAT T G GAGATATGTG  ATATGTGA AGTTCTGAGAGAG G GGTTGAGAGGGG G AGA AGGGGCGC C G GGGGCGCTCT T G GCGCTCTGTG  GT CTCTATGGTTTG T TGTGGGGTGT T G GGGGTGTTTT GTTTTCTC C T TTTTCTCTCT T TTCTTG TA A C CTCTATAACG  TATAAGTGAA TT  AAAAATT AT T AG TAATATCTC C A ATATCGG A AA T TCG TC CTGGCACCC GT  ACACCCCC GTC C CCCCCCCACA A C CCCATAT T C CACATCA TT T A ATATTTC C T TT TGTCAATTA T TCTCACAGG C CACAGAGTT A AGAGTGTAA GA G GTGTAAC C T TATACACAA A ACCATAT T C CACATTGCTC C A ATATCTCGAA G T TCT A AAGA A C CGCGAGATAT T G GAGATATATA  ATATATATAT T T TATATGA TC C A ATATCTCGCG  AA TCTCGCGGGG G CTTGGGTGT T G GGAATGTATA  GTGTATAAAA A T TATAAAT  ATAATATTTACTCG ATATTTGAA TATCTTATATAT T T TATATATAA A AATT AC C T TAACACA CA  ACACACAGAG G C CATCCAGTGT T A AGAGTGTTAATT G GT GATTTA AT TTTTC T TTTTCTCCCC C TT CCAGCCTCT  TC CCCCTCTGTG G C CTCTGTGTGT  TGTGT GATT T GG CGTTTGCTT  TTTCATTA,ATTTTGTGAGA A T TTTTGT AGAATCAA T TGTGAAATTCG GAGAAAATATTTT TGA AAATTTTGTG G A ATATTTTGGT T T TTTTGTGTGTGTG G T TGGTGTGCGC TAC GTGTGTGCGCGCG G T TGTGCGCGGT TTA GCGCGGTGTG  CGCGTGTGGG G GGTGTGGGGAGA A T TGTGGGGAGATTT T GTCAGGAGATATGTG GA  GAGATG GA A ATTAATGAGAGAG G TCTGTGAAGGGG G GA TGAGAGGGGCGC C A AGAGGGGCGCTT G TAGGCCTGTG G G GCGCT TGTGGT C CTCTGTGGGGTGT T T TGTGGGGTGTTTT T G GGGGTGTTTTCTC  GTGTTTTCCT T T TTTTCTCTCTATA T C TCTCTCTATA AA A C CTAATTAAAAAAA A T GGTAATCGAATAT T A AAAAAT CATCTC C AG TAATATCAA CA A A ATATCTCACGACT C T TCCACACCCC C C CAAG AATCCCC AGA C GCCCCCACA A C CCCCCCCAAT T C CCCCACATTATTT A T CACATATTTTCG CC A ATTTCCA GG  TTTTCTCACAGAG G T TCTCACAGAGTGT T C CA ATAGTGTATA A A AGAGTGTAAC ACCATAGTATCTC GA T TAACAACAT GAT  ACACACATTC C C CACATTCGCG G A ATATCTCGCGA ACA TTCGTA CGAGATAT T GATGGGTGATATA TCA G GAGAT GTTATAT T ACAGATATATATCTC C T TATATATCG A ATATCAAACGGGG  AA TCCGTCGGCACGT T C CGCGGGGTGTATA A GCAGGGTTGTAA A G GTTAAAT T TCTAATTT A AA CAATTTTATA A A ATATTTTATATAT T T TTTTATATATA CGA T TAATTATATACCATC A ATATATACACACA  GA TATACACA GGCACG A ACACACAGAGTGT AATCTGAGTGTTAT T AAGTGTTTTTTT ACC GTGTTTTTTTCTC C T TTTTCTCCCC C T TTTTCTCCCCTT T TCTCCCCTCAGTG TC  CCCCTCTGTGTGT T C CTCTGTGTGTTTT T T TGTAAGTTTTTTT T G GTGTTTTTT G,TAATTGTTGGAAA TTTGTGAGAAAATAT T T TGTGAGAAAATATTC CT G GAGAAAATATTTGATG G AGCTAATATT AATGT TGA C ATATTTTGTGTGTGTG G TTGTGTGGA GCGC T TGTGTTGTTGCGCGCG G G GTGTGTGCTT CGTGT GGTTGCGCGCGTGTGGC GCG GCCGTACCTGGGG G C CGCGTGTGTGGGGAA G GTGTGTGGGGAGATAT  GG TGTGGGGAGATATGTG G GGGAGATATGTGCA G GAGATATGTGAGAGAG G A ATATGTGATG AGGGG G T TGTGAGAGAGGGGCTATC G GAGAGAGGGGCCT  AGAGGGGCGCTCTGTG G G ATGGCGCTCTGCACGG G G GC AACTGTGGGGTGT  CTCTGGGTGTTTT T T TGGGTGTTTTCC AC G GGGGTGTTTTCTCTCT T G GT GTTTCTCTCTATA A T TTCGATCTCTATAAAA A TTGTTCTCTATAAAATCTATAAAATAT T T TATAAAATATCTC C A AAAAAAAAATCTCACA A ATTGATCTCAAT C ACCTATCCACACCCC C T TCTCACACACCATTCC C C CAG TGTGCCCTTAA A ACACCCCCCCACATAT T C CCT TCCACATCCCT AT C CC GTCATATTTTC TT CACATT TTTCTCACA A A ATATTTTCTCACAGG TTC TTCTCACAGGT T T TCTCA GGAGTGTAT A CAAGTATCTACAC C A AGAGTGTATACACAA GGTAC AACACATAT ATT TATACACACATATCTC TGA ACGG CATGTATCGG CCATATCTCGGA A A ATATCTTCGATT AT T TCTCGCGAGATATATA A C CGCGAGATATATATT G GAATAATCTC TAC ATATATATTCGCG G T TATATATCTCGCGGG ATCGCGGGGTGT CCC TCTCG TGGTAAGTA C CGCGGGTATAAAA A GT TGGTGTAATTAATAC T G GTGTATAAAATATTTT T T TAAATATTCCATA A A AAAATATTTTATATAT T AATTTTAGAGATATA A T TTTTATATATATACAC C T TAAA TATTACACACA A A GGATATACACACAGAG TGG TAACACAGAGTGT TT  ACACAT CAGTGTTTT CAG CACAGAGTGTTTTTGC AT AGTGTTTTTTTCTC C GCCAGTTTTTTTCTCCC T TTTTTTTCTCCCCTCT T T TTTTCTCC ATCTGTG G TTCCCCTCTGGT T C CCCCTCTGTGTGTTTT T CTTT TCGTTTTTTT T TGTGTAT,ATTATACCCGAAAATAT T T TTTTGTGAGAAAATATTTT T T TGTGAGAAATTTTGTG ATG GAGAAAATATTTTGTGTGT  AAAATTTGTGTGTGTG TTC ATATTTTGTCTGTGTGCCAGC TT ATTGGTGGGTGCGCG G T TGTGTGTGTGCGCGCGTAT T G GTTCATGCGCGCGTCATTG G T TGA CGCGCGTTGGGG  GCG GGCGCGTGTATGGA CGA C A CGGAGTGGGGAGATATGT G GTGTGTGGGGAATGTT G T TGGGAGATAT TGAGA A G GGGGAGATTCATGAGAGAG G G GATAAATGTGACACAGGGG GGT ATG GTGAGAGAGGGGCCGA TGTGATAC AACT T GATTGAGAGGGGCCTGTG  AGAGGGGCGCTTGGGG G G GGGGCGCTGGTTCCT G GCGCTCTGTGGGGTGTTTT T C CTAAAAA TTCTCTC T TGTGGCCAGTTTTCTCTCT T GACAGTTTTCTCTCTATA A G GTGTTTTCTCTG TCCA TTTTCTC CTATAAAAT TCTGTCTATAAAAAAATAT T CCTATAAAAAAATATCTC C T TATAACATAATATCTCACA A A AAAAAATCTCACACC A AATTCATCTCACGTACCCC GGAATCTCAACCCCCCC C T TCTCAACCCCCCA A CCTGCACACCCCCCCACATAT  ACACCTGATA CATATTTT T C CCCCCG ACATATTTTCTC C CCCACATATTTTCATGCA A C CACATATTTTCTCACAGG A ATATTAATTCAGC AGTGT T T TTTTCTCAAGTGTAAA A TAC GTGCAGAGTGTATAC TCC C CAAGTGTATAC TCCA A A AGAGTGTATACACAGGTAT T G GTGTATACATTCAT ACTC C T TATACACACATATCTCGCG G AATCACACATATCTCGCGAGA TGCTACATCTCGGATAT T A ATATCTCGCGAGATATATA A T TCTCGCGAGATATAGT T C CGCGAGATATATATATCTC C G GAGATATATATATCTCGCG G A ATTTGTATATCTCGCGGGG G TCTGTATATCTCGCGGGGTGT T AAT TCGCGGGGTGTATA A TACATCGCGGGTAAA A CC TCGGGGTGTGTAAAATATTT G GGGGTGTATAAAATATTTT T G GTGTAGATAATATCTTATA A T TAAATATTTTATATAT T AGGCAATACAATACAGA A AT GATTAATAGAGAC C T TTTTATATATATACACACA A T TATATATATACACACAGAG G A AT CA GGCAGAGTGTGT T TATACACACAGAGTT A ACACACAGGTTTTTTT T C CATGTAGTAG TTTTTCTC C A AGATTGTTTTTTTCGCTCC C GGTTTTTG ACT T T TTTTTTTCTCCCTGCTGTG  TTTTCCTGCCTCCTGT T T TCCCT TATGTGTTTT T C CCCCTTGTTTTTG AC CTGTGTGTTTTTTTA,"ID   NS8_SARS2               Reviewed;         121 AA.
AC   P0DTC8;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 24.
DE   RecName: Full=ORF8 protein;
DE            Short=ORF8;
DE   AltName: Full=Non-structural protein 8;
DE            Short=ns8;
DE   Flags: Precursor;
GN   ORFNames=8;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=isolate 2019-nCoV_HKU-SZ-002a_2020;
RX   PubMed=31986261; DOI=10.1016/s0140-6736(20)30154-9;
RA   Chan J.F., Yuan S., Kok K.H., To K.K., Chu H., Yang J., Xing F., Liu J.,
RA   Yip C.C., Poon R.W., Tsoi H.W., Lo S.K., Chan K.H., Poon V.K., Chan W.M.,
RA   Ip J.D., Cai J.P., Cheng V.C., Chen H., Hui C.K., Yuen K.Y.;
RT   ""A familial cluster of pneumonia associated with the 2019 novel coronavirus
RT   indicating person-to-person transmission: a study of a family cluster."";
RL   Lancet 395:514-523(2020).
RN   [3]
RP   MISCELLANEOUS.
RX   PubMed=32854725; DOI=10.1186/s12985-020-01402-1;
RA   Michel C.J., Mayer C., Poch O., Thompson J.D.;
RT   ""Characterization of accessory genes in coronavirus genomes."";
RL   Virol. J. 17:131-131(2020).
RN   [4]
RP   MISCELLANEOUS.
RX   PubMed=32807944; DOI=10.1038/s41590-020-0773-7;
RA   Hachim A., Kavian N., Cohen C.A., Chin A.W.H., Chu D.K.W., Mok C.K.P.,
RA   Tsang O.T.Y., Yeung Y.C., Perera R.A.P.M., Poon L.L.M., Peiris J.S.M.,
RA   Valkenburg S.A.;
RT   ""ORF8 and ORF3b antibodies are accurate serological markers of early and
RT   late SARS-CoV-2 infection."";
RL   Nat. Immunol. 21:1293-1301(2020).
RN   [5]
RP   INTERACTION WITH HUMAN IL17RA, AND SUBCELLULAR LOCATION.
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [6]
RP   INTERACTION WITH HUMAN IL17RA, AND FUNCTION.
RX   PubMed=33723527; DOI=10.1016/j.isci.2021.102293;
RA   Lin X., Fu B., Yin S., Li Z., Liu H., Zhang H., Xing N., Wang Y., Xue W.,
RA   Xiong Y., Zhang S., Zhao Q., Xu S., Zhang J., Wang P., Nian W., Wang X.,
RA   Wu H.;
RT   ""Title: ORF8 contributes to cytokine storm during SARS-CoV-2 infection by
RT   activating IL-17 pathway."";
RL   IScience 1:102293-102293(2021).
RN   [7]
RP   VARIANT SER-84.
RX   PubMed=32615316; DOI=10.1016/j.meegid.2020.104445;
RA   Laha S., Chakraborty J., Das S., Manna S.K., Biswas S., Chatterjee R.;
RT   ""Characterizations of SARS-CoV-2 mutational profile, spike protein
RT   stability and viral transmission."";
RL   Infect. Genet. Evol. 85:104445-104445(2020).
RN   [8]
RP   VARIANT 28-HIS--ILE-121 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [9]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=34177923; DOI=10.3389/fimmu.2021.679482;
RA   Geng H., Subramanian S., Wu L., Bu H.F., Wang X., Du C., De Plaen I.G.,
RA   Tan X.D.;
RT   ""SARS-CoV-2 ORF8 Forms Intracellular Aggregates and Inhibits IFNgamma-
RT   Induced Antiviral Gene Expression in Human Lung Epithelial Cells."";
RL   Front. Immunol. 12:679482-679482(2021).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH HOST MHC-I.
RX   PubMed=34021074; DOI=10.1073/pnas.2024202118;
RA   Zhang Y., Chen Y., Li Y., Huang F., Luo B., Yuan Y., Xia B., Ma X.,
RA   Yang T., Yu F., Liu J., Liu B., Song Z., Chen J., Yan S., Wu L., Pan T.,
RA   Zhang X., Li R., Huang W., He X., Xiao F., Zhang J., Zhang H.;
RT   ""The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-
RT   regulating MHC-Iota."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:1-12(2021).
RN   [11]
RP   FUNCTION, SUBCELLULAR LOCATION, HOMODIMERIZATION, MUTAGENESIS OF CYS-20 AND
RP   ASN-78, DISULFIDE BOND, AND GLYCOSYLATION AT ASN-78.
RX   PubMed=35157849; DOI=10.1016/j.jbc.2022.101724;
RA   Matsuoka K., Imahashi N., Ohno M., Ode H., Nakata Y., Kubota M.,
RA   Sugimoto A., Imahashi M., Yokomaku Y., Iwatani Y.;
RT   ""SARS-CoV-2 accessory protein ORF8 is secreted extracellularly as a
RT   glycoprotein homodimer."";
RL   J. Biol. Chem. 1:101724-101724(2022).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH HUMAN IL17RA, AND
RP   MUTAGENESIS OF SER-24; TYR-42; VAL-62; ILE-71; ILE-76; LEU-84 AND GLU-106.
RX   PubMed=35343786; DOI=10.1128/mbio.00402-22;
RA   Wu X., Xia T., Shin W.J., Yu K.M., Jung W., Herrmann A., Foo S.S., Chen W.,
RA   Zhang P., Lee J.S., Poo H., Comhair S.A.A., Jehi L., Choi Y.K., Ensser A.,
RA   Jung J.U.;
RT   ""Viral Mimicry of Interleukin-17A by SARS-CoV-2 ORF8."";
RL   MBio 1:e0040222-e0040222(2022).
RN   [13]
RP   FUNCTION, MUTAGENESIS OF 1-MET--PHE-16 AND ASN-78, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=36689483; DOI=10.1371/journal.ppat.1011128;
RA   Lin X., Fu B., Xiong Y., Xing N., Xue W., Guo D., Zaky M., Pavani K.,
RA   Kunec D., Trimpert J., Wu H.;
RT   ""Unconventional secretion of unglycosylated ORF8 is critical for the
RT   cytokine storm during SARS-CoV-2 infection."";
RL   PLoS Pathog. 19:e1011128-e1011128(2023).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.61 ANGSTROMS) OF 18-121, AND DISULFIDE BOND.
RA   Nelson C.A., Hall P.D., Fremont D.H.;
RT   ""Crystal Structure of the SARS-CoV-2 ORF8 Protein."";
RL   Submitted (AUG-2020) to the PDB data bank.
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.04 ANGSTROMS) OF 18-121, DISULFIDE BOND, AND
RP   HOMODIMERIZATION.
RX   PubMed=33361333; DOI=10.1073/pnas.2021785118;
RA   Flower T.G., Buffalo C.Z., Hooy R.M., Allaire M., Ren X., Hurley J.H.;
RT   ""Structure of SARS-CoV-2 ORF8, a rapidly evolving immune evasion protein."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
CC   -!- FUNCTION: Plays a role in modulating the host immune response
CC       (PubMed:31986261, PubMed:35343786, PubMed:36689483). May act as a
CC       secreted virokine by mimicking interleukin-17A (IL17A), and thereby
CC       binding to the IL17RA receptor, leading to activation of the IL17
CC       pathway and increased secretion of pro-inflammatory factors
CC       (PubMed:35343786, PubMed:36689483). Contributes to the cytokine storm
CC       during SARS-CoV-2 infection when secreted by unconventional pathway
CC       (PubMed:33723527, PubMed:36689483). May act by down-regulating major
CC       histocompability complex class I (MHC-I) at cell surface
CC       (PubMed:34021074, PubMed:35157849). May inhibit expression of some
CC       members of the IFN-stimulated gene (ISG) family including hosts
CC       IGF2BP1/ZBP1, MX1 and MX2, and DHX58 (PubMed:34177923).
CC       {ECO:0000269|PubMed:33723527, ECO:0000269|PubMed:34021074,
CC       ECO:0000269|PubMed:34177923, ECO:0000269|PubMed:35157849,
CC       ECO:0000269|PubMed:35343786, ECO:0000269|PubMed:36689483,
CC       ECO:0000303|PubMed:31986261}.
CC   -!- SUBUNIT: Homodimer (PubMed:33361333, PubMed:35157849). Interacts with
CC       host IL17RA (PubMed:33060197, PubMed:35343786). Interacts with host
CC       IL17RC (PubMed:35343786). Interacts with host MHC-I (PubMed:34021074).
CC       {ECO:0000269|PubMed:33060197, ECO:0000269|PubMed:33361333,
CC       ECO:0000269|PubMed:33723527, ECO:0000269|PubMed:35157849,
CC       ECO:0000269|PubMed:35343786}.
CC   -!- INTERACTION:
CC       P0DTC8; P0DTC8: 8; NbExp=3; IntAct=EBI-25475900, EBI-25475900;
CC       P0DTC8; Q9UHI8: ADAMTS1; Xeno; NbExp=3; IntAct=EBI-25475900, EBI-2511802;
CC       P0DTC8; Q8N766: EMC1; Xeno; NbExp=3; IntAct=EBI-25475900, EBI-1044442;
CC       P0DTC8; P01892: HLA-A; Xeno; NbExp=5; IntAct=EBI-25475900, EBI-2839473;
CC       P0DTC8; Q96F46: IL17RA; Xeno; NbExp=3; IntAct=EBI-25475900, EBI-5591258;
CC       PRO_0000449655; PRO_0000449655 [P0DTC8]: 8; NbExp=2; IntAct=EBI-28965865, EBI-28965865;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:35157849,
CC       ECO:0000269|PubMed:35343786}. Note=Is secreted during a normal viral
CC       infection by unconventional pathway (PubMed:35157849, PubMed:36689483).
CC       Its mRNA is expressed in cytoplasm and not spliced during a viral
CC       infection, but is spliced when expressed from cDNA in nucleus
CC       (PubMed:35157849). Splicing changes localization to host endosome
CC       and/or cytoplasm (PubMed:33060197, PubMed:34177923). May also localize
CC       in nucleus when fused with GFP (PubMed:34177923).
CC       {ECO:0000269|PubMed:33060197, ECO:0000269|PubMed:34177923,
CC       ECO:0000269|PubMed:35157849}.
CC   -!- PTM: Glycosylated by the host when secreted via the conventional
CC       pathway. The glycosylated form cannot bind IL17A and would not
CC       participate in the cytokine storm. {ECO:0000269|PubMed:36689483}.
CC   -!- POLYMORPHISM: Variant B.1.1.7 is also called Variant Of Concern (VOC)
CC       202012/01, Variant Under Investigation (VUI) 202012/01, or 20B/501Y.V1.
CC       {ECO:0000305|PubMed:33413740}.
CC   -!- POLYMORPHISM: Variant Omicron/BA.1 and BA.2 belong to a lineage first
CC       isolated in South Africa (November 2021). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/BQ.1.1 belongs to a lineage first
CC       isolated in Nigeria (November 2022). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/XBB.1.5 belongs to a lineage first
CC       isolated in United States (November 2022). It is the result of
CC       recombination between omicron BJ.1 and BM.1.1. Moreover XBB.1.5 do not
CC       express ORF8. {ECO:0000305}.
CC   -!- MISCELLANEOUS: Similar to some Bat coronavirus ns8 genes, but is
CC       entirely different from SARS ns8a or Ns8b (Probable). Elicits strong
CC       specific antibody response (PubMed:32807944).
CC       {ECO:0000269|PubMed:32807944, ECO:0000305|PubMed:32854725}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43422.1; -; Genomic_RNA.
DR   EMBL; MN938384; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   PDB; 7F5F; X-ray; 1.62 A; A=18-121.
DR   PDB; 7JTL; X-ray; 2.04 A; A/B=18-121.
DR   PDB; 7JX6; X-ray; 1.61 A; A/B=18-121.
DR   PDB; 7MX9; X-ray; 2.60 A; A=15-121.
DR   PDB; 7XMN; X-ray; 2.30 A; B=16-121.
DR   PDBsum; 7F5F; -.
DR   PDBsum; 7JTL; -.
DR   PDBsum; 7JX6; -.
DR   PDBsum; 7MX9; -.
DR   PDBsum; 7XMN; -.
DR   SMR; P0DTC8; -.
DR   BioGRID; 4383873; 1317.
DR   ComplexPortal; CPX-6147; SARS-CoV-2 ORF8 complex.
DR   IntAct; P0DTC8; 152.
DR   MINT; P0DTC8; -.
DR   GlyGen; P0DTC8; 1 site.
DR   iPTMnet; P0DTC8; -.
DR   KEGG; vg:43740577; -.
DR   AGR; RefSeq:YP_009724396; -.
DR   Reactome; R-HSA-448424; Interleukin-17 signaling.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   Reactome; R-HSA-9727281; Translation of Accessory Proteins.
DR   Reactome; R-HSA-983170; Antigen Presentation: Folding, assembly and peptide loading of class I MHC.
DR   PRO; PR:P0DTC8; -.
DR   Proteomes; UP000464024; Genome.
DR   Proteomes; UP000464747; Genome.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:ComplexPortal.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProt.
DR   GO; GO:0005764; C:lysosome; IDA:ComplexPortal.
DR   GO; GO:0005125; F:cytokine activity; IDA:UniProt.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0032688; P:negative regulation of interferon-beta production; IDA:ComplexPortal.
DR   GO; GO:0002891; P:positive regulation of immunoglobulin mediated immune response; IDA:ComplexPortal.
DR   GO; GO:0046776; P:symbiont-mediated suppression of host antigen processing and presentation of peptide antigen via MHC class I; IDA:ComplexPortal.
DR   GO; GO:0019049; P:virus-mediated perturbation of host defense response; IDA:UniProt.
DR   CDD; cd21641; ORF8-Ig_SARS-CoV-2-like; 1.
DR   InterPro; IPR022722; ORF8_betacoronavirus.
DR   InterPro; IPR044391; ORF8_SARS-CoV-2-like.
DR   InterPro; IPR046444; SARS_ORF8_IG.
DR   Pfam; PF12093; bCoV_NS8; 1.
DR   PROSITE; PS51964; SARS_ORF8_IG; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Disulfide bond;
KW   Evasion of host immunity by viral interleukin-like protein; Glycoprotein;
KW   Host-virus interaction; Reference proteome; Secreted; Signal;
KW   Viral immunoevasion.
FT   SIGNAL          1..15
FT                   /evidence=""ECO:0000255""
FT   CHAIN           16..121
FT                   /note=""ORF8 protein""
FT                   /id=""PRO_0000449655""
FT   DOMAIN          19..121
FT                   /note=""SARS ORF8 Ig-like""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01309""
FT   CARBOHYD        78
FT                   /note=""N-linked (GlcNAc...) (complex) asparagine; by host""
FT                   /evidence=""ECO:0000269|PubMed:35157849,
FT                   ECO:0000269|PubMed:36689483""
FT   DISULFID        20
FT                   /note=""Interchain""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01309,
FT                   ECO:0000269|PubMed:33361333, ECO:0000269|PubMed:35157849""
FT   DISULFID        25..90
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01309,
FT                   ECO:0000269|PubMed:33361333, ECO:0000269|Ref.14""
FT   DISULFID        37..102
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01309,
FT                   ECO:0000269|PubMed:33361333, ECO:0000269|Ref.14""
FT   DISULFID        61..83
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01309,
FT                   ECO:0000269|PubMed:33361333, ECO:0000269|Ref.14""
FT   VARIANT         2
FT                   /note=""K -> Q (in strain: Theta/P.3)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         8..121
FT                   /note=""Missing (in strain: Omicron/XBB.1.5,
FT                   Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         11
FT                   /note=""T -> I (in strain: Iota/B.1.526)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         11
FT                   /note=""T -> K (in strain: Mu/B.1.621)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         28..121
FT                   /note=""Missing (in strain: B.1.1.7)""
FT                   /evidence=""ECO:0000305|PubMed:33413740""
FT   VARIANT         38
FT                   /note=""P -> S (in strain: Mu/B.1.621)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         84
FT                   /note=""L -> S""
FT                   /evidence=""ECO:0000305, ECO:0000305|PubMed:32615316""
FT   VARIANT         92
FT                   /note=""E -> K (in strain: Gamma/P.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         119
FT                   /note=""D -> I (in strain: Delta/B.1.617.2)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         120..121
FT                   /note=""Missing (in strain: Delta/B.1.617.2)""
FT                   /evidence=""ECO:0000305""
FT   MUTAGEN         1..16
FT                   /note=""Missing: Partial loss of secretion.""
FT                   /evidence=""ECO:0000269|PubMed:36689483""
FT   MUTAGEN         20
FT                   /note=""C->A: Complete loss of dimerization.""
FT                   /evidence=""ECO:0000269|PubMed:35157849""
FT   MUTAGEN         24
FT                   /note=""S->L: Partial loss of hIL-17RC binding.""
FT                   /evidence=""ECO:0000269|PubMed:35343786""
FT   MUTAGEN         42
FT                   /note=""Y->H: Complete loss of hIL-17RA binding.""
FT                   /evidence=""ECO:0000269|PubMed:35343786""
FT   MUTAGEN         62
FT                   /note=""V->L: Partial loss of hIL-17RC binding.""
FT                   /evidence=""ECO:0000269|PubMed:35343786""
FT   MUTAGEN         71
FT                   /note=""I->D: Complete loss of hIL-17RC binding.""
FT                   /evidence=""ECO:0000269|PubMed:35343786""
FT   MUTAGEN         76
FT                   /note=""I->D: Complete loss of hIL-17RC binding.""
FT                   /evidence=""ECO:0000269|PubMed:35343786""
FT   MUTAGEN         78
FT                   /note=""N->D: Complete loss of N-glycosylation and of
FT                   secretion.""
FT                   /evidence=""ECO:0000269|PubMed:35157849""
FT   MUTAGEN         78
FT                   /note=""N->Q: Complete loss of glycosylation when secreted
FT                   by conventional route. Increases cytokine storm effects.""
FT                   /evidence=""ECO:0000269|PubMed:36689483""
FT   MUTAGEN         84
FT                   /note=""L->S: Complete loss of IL17RA binding.""
FT                   /evidence=""ECO:0000269|PubMed:35343786""
FT   MUTAGEN         106
FT                   /note=""E->P: Complete loss of hIL-17RA binding.""
FT                   /evidence=""ECO:0000269|PubMed:35343786""
FT   STRAND          19..25
FT                   /evidence=""ECO:0007829|PDB:7JX6""
FT   STRAND          29..32
FT                   /evidence=""ECO:0007829|PDB:7JX6""
FT   STRAND          41..49
FT                   /evidence=""ECO:0007829|PDB:7JX6""
FT   STRAND          57..70
FT                   /evidence=""ECO:0007829|PDB:7JX6""
FT   TURN            74..78
FT                   /evidence=""ECO:0007829|PDB:7F5F""
FT   STRAND          80..82
FT                   /evidence=""ECO:0007829|PDB:7JX6""
FT   TURN            83..86
FT                   /evidence=""ECO:0007829|PDB:7JX6""
FT   STRAND          87..91
FT                   /evidence=""ECO:0007829|PDB:7JX6""
FT   STRAND          96..105
FT                   /evidence=""ECO:0007829|PDB:7JX6""
FT   STRAND          112..120
FT                   /evidence=""ECO:0007829|PDB:7JX6""
SQ   SEQUENCE   121 AA;  13831 MW;  912AD9E147A64907 CRC64;
     MKFLVFLGII TTVAAFHQEC SLQSCTQHQP YVVDDPCPIH FYSKWYIRVG ARKSAPLIEL
     CVDEAGSKSP IQYIDIGNYT VSCLPFTINC QEPKLGSLVV RCSFYEDFLE YHDVRVVLDF
     I
//
",34310
AAAGTT AAGTTG AGTTGA GTTGAT TTGATG TGATGG GATGGT ATGGTG TGGTGT GGTGTT GTGTTG TGTTGA GTTGAG TTGAGG TGAGGT GAGGTA AGGTAG GGTAGA GTAGAA TAGAAT AGAATG GAATGG AATGGT ATGGTT TGGTTG GGTTGG GTTGGA TTGGAA TGGAAA GGAAAA GAAAAT AAAATA AAATAA AATAAA ATAAAA TAAAAC AAAACA AAACAA AACAAC ACAACA CAACAT AACATC ACATCA CATCAC ATCACC TCACCT CACCTG ACCTGT CCTGTT CTGTTA TGTTAA GTTAAT TTAATG TAATGC AATGCA ATGCAG TGCAGC GCAGCA CAGCAT AGCATT GCATTT CATTTG ATTTGA TTTGAG TTGAGC TGAGCT GAGCTT AGCTTT GCTTTG CTTTGG TTTGGG TTGGGC TGGGCT GGGCTA GGCTAA GCTAAG CTAAGC TAAGCG AAGCGC AGCGCA GCGCAA CGCAAC GCAACA CAACAT AACATT ACATTA CATTAA ATTAAA TTAAAC TAAACC AAACCA AACCAG ACCAGT CCAGTA CAGTAC AGTACC GTACCA TACCAG ACCAGA CCAGAG CAGAGG AGAGGT GAGGTG AGGTGA GGTGAA GTGAAA TGAAAA GAAAAT AAAATA AAATAC AATACT ATACTC TACTCA ACTCAA CTCAAT TCAATA CAATAA AATAAT ATAATT TAATTT AATTTG ATTTGG TTTGGG TTGGGT TGGGTG GGGTGT GGTGTG GTGTGG TGTGGA GTGGAC TGGACA GGACAG GACAGT ACAGTG CAGTGC AGTGCT GTGCTG TGCTGC GCTGCT CTGCTA TGCTAA GCTAAT CTAATA TAATAC AATACT,0,145,AAAG AAGT AGTT GTTG TTGA TGAT GATG ATGG TGGT GGTG GTGT TGTT GTTG TTGA TGAG GAGG AGGT GGTA GTAG TAGA AGAA GAAT AATG ATGG TGGT GGTT GTTG TTGG TGGA GGAA GAAA AAAA AAAT AATA ATAA TAAA AAAA AAAC AACA ACAA CAAC AACA ACAT CATC ATCA TCAC CACC ACCT CCTG CTGT TGTT GTTA TTAA TAAT AATG ATGC TGCA GCAG CAGC AGCA GCAT CATT ATTT TTTG TTGA TGAG GAGC AGCT GCTT CTTT TTTG TTGG TGGG GGGC GGCT GCTA CTAA TAAG AAGC AGCG GCGC CGCA GCAA CAAC AACA ACAT CATT ATTA TTAA TAAA AAAC AACC ACCA CCAG CAGT AGTA GTAC TACC ACCA CCAG CAGA AGAG GAGG AGGT GGTG GTGA TGAA GAAA AAAA AAAT AATA ATAC TACT ACTC CTCA TCAA CAAT AATA ATAA TAAT AATT ATTT TTTG TTGG TGGG GGGT GGTG GTGT TGTG GTGG TGGA GGAC GACA ACAG CAGT AGTG GTGC TGCT GCTG CTGC TGCT GCTA CTAA TAAT AATA ATAC TACT,AAAGT AAGTT AGTTG GTTGA TTGAT TGATG GATGG ATGGT TGGTG GGTGT GTGTT TGTTG GTTGA TTGAG TGAGG GAGGT AGGTA GGTAG GTAGA TAGAA AGAAT GAATG AATGG ATGGT TGGTT GGTTG GTTGG TTGGA TGGAA GGAAA GAAAA AAAAT AAATA AATAA ATAAA TAAAA AAAAC AAACA AACAA ACAAC CAACA AACAT ACATC CATCA ATCAC TCACC CACCT ACCTG CCTGT CTGTT TGTTA GTTAA TTAAT TAATG AATGC ATGCA TGCAG GCAGC CAGCA AGCAT GCATT CATTT ATTTG TTTGA TTGAG TGAGC GAGCT AGCTT GCTTT CTTTG TTTGG TTGGG TGGGC GGGCT GGCTA GCTAA CTAAG TAAGC AAGCG AGCGC GCGCA CGCAA GCAAC CAACA AACAT ACATT CATTA ATTAA TTAAA TAAAC AAACC AACCA ACCAG CCAGT CAGTA AGTAC GTACC TACCA ACCAG CCAGA CAGAG AGAGG GAGGT AGGTG GGTGA GTGAA TGAAA GAAAA AAAAT AAATA AATAC ATACT TACTC ACTCA CTCAA TCAAT CAATA AATAA ATAAT TAATT AATTT ATTTG TTTGG TTGGG TGGGT GGGTG GGTGT GTGTG TGTGG GTGGA TGGAC GGACA GACAG ACAGT CAGTG AGTGC GTGCT TGCTG GCTGC CTGCT TGCTA GCTAA CTAAT TAATA AATAC ATACT,AAAGTT AAGTTG AGTTGA GTTGAT TTGATG TGATGG GATGGT ATGGTG TGGTGT GGTGTT GTGTTG TGTTGA GTTGAG TTGAGG TGAGGT GAGGTA AGGTAG GGTAGA GTAGAA TAGAAT AGAATG GAATGG AATGGT ATGGTT TGGTTG GGTTGG GTTGGA TTGGAA TGGAAA GGAAAA GAAAAT AAAATA AAATAA AATAAA ATAAAA TAAAAC AAAACA AAACAA AACAAC ACAACA CAACAT AACATC ACATCA CATCAC ATCACC TCACCT CACCTG ACCTGT CCTGTT CTGTTA TGTTAA GTTAAT TTAATG TAATGC AATGCA ATGCAG TGCAGC GCAGCA CAGCAT AGCATT GCATTT CATTTG ATTTGA TTTGAG TTGAGC TGAGCT GAGCTT AGCTTT GCTTTG CTTTGG TTTGGG TTGGGC TGGGCT GGGCTA GGCTAA GCTAAG CTAAGC TAAGCG AAGCGC AGCGCA GCGCAA CGCAAC GCAACA CAACAT AACATT ACATTA CATTAA ATTAAA TTAAAC TAAACC AAACCA AACCAG ACCAGT CCAGTA CAGTAC AGTACC GTACCA TACCAG ACCAGA CCAGAG CAGAGG AGAGGT GAGGTG AGGTGA GGTGAA GTGAAA TGAAAA GAAAAT AAAATA AAATAC AATACT ATACTC TACTCA ACTCAA CTCAAT TCAATA CAATAA AATAAT ATAATT TAATTT AATTTG ATTTGG TTTGGG TTGGGT TGGGTG GGGTGT GGTGTG GTGTGG TGTGGA GTGGAC TGGACA GGACAG GACAGT ACAGTG CAGTGC AGTGCT GTGCTG TGCTGC GCTGCT CTGCTA TGCTAA GCTAAT CTAATA TAATAC AATACT,AAAGTTG AAGTTGA AGTTGAT GTTGATG TTGATGG TGATGGT GATGGTG ATGGTGT TGGTGTT GGTGTTG GTGTTGA TGTTGAG GTTGAGG TTGAGGT TGAGGTA GAGGTAG AGGTAGA GGTAGAA GTAGAAT TAGAATG AGAATGG GAATGGT AATGGTT ATGGTTG TGGTTGG GGTTGGA GTTGGAA TTGGAAA TGGAAAA GGAAAAT GAAAATA AAAATAA AAATAAA AATAAAA ATAAAAC TAAAACA AAAACAA AAACAAC AACAACA ACAACAT CAACATC AACATCA ACATCAC CATCACC ATCACCT TCACCTG CACCTGT ACCTGTT CCTGTTA CTGTTAA TGTTAAT GTTAATG TTAATGC TAATGCA AATGCAG ATGCAGC TGCAGCA GCAGCAT CAGCATT AGCATTT GCATTTG CATTTGA ATTTGAG TTTGAGC TTGAGCT TGAGCTT GAGCTTT AGCTTTG GCTTTGG CTTTGGG TTTGGGC TTGGGCT TGGGCTA GGGCTAA GGCTAAG GCTAAGC CTAAGCG TAAGCGC AAGCGCA AGCGCAA GCGCAAC CGCAACA GCAACAT CAACATT AACATTA ACATTAA CATTAAA ATTAAAC TTAAACC TAAACCA AAACCAG AACCAGT ACCAGTA CCAGTAC CAGTACC AGTACCA GTACCAG TACCAGA ACCAGAG CCAGAGG CAGAGGT AGAGGTG GAGGTGA AGGTGAA GGTGAAA GTGAAAA TGAAAAT GAAAATA AAAATAC AAATACT AATACTC ATACTCA TACTCAA ACTCAAT CTCAATA TCAATAA CAATAAT AATAATT ATAATTT TAATTTG AATTTGG ATTTGGG TTTGGGT TTGGGTG TGGGTGT GGGTGTG GGTGTGG GTGTGGA TGTGGAC GTGGACA TGGACAG GGACAGT GACAGTG ACAGTGC CAGTGCT AGTGCTG GTGCTGC TGCTGCT GCTGCTA CTGCTAA TGCTAAT GCTAATA CTAATAC TAATACT,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",8351
GGTGCG GTGCGT TGCGTT GCGTTG CGTTGC GTTGCT TTGCTG TGCTGG GCTGGA CTGGAT TGGATC GGATCC GATCCC ATCCCC TCCCCC CCCCCG CCCCGA CCCGAC CCGACC CGACCG GACCGA ACCGAG CCGAGG CGAGGA GAGGAC AGGACG GGACGT GACGTC ACGTCA CGTCAC GTCACC TCACCG CACCGC ACCGCG CCGCGC CGCGCG GCGCGC CGCGCT GCGCTG CGCTGC GCTGCA CTGCAT TGCATC GCATCT CATCTC ATCTCG TCTCGA CTCGAT TCGATG CGATGC GATGCT ATGCTG TGCTGG GCTGGC CTGGCC TGGCCC GGCCCA GCCCAG CCCAGC CCAGCT CAGCTC AGCTCG GCTCGG CTCGGC TCGGCG CGGCGA GGCGAG GCGAGA CGAGAC GAGACC AGACCG GACCGC ACCGCC CCGCCG CGCCGA GCCGAA CCGAAA CGAAAC GAAACG AAACGA AACGAG ACGAGC CGAGCA GAGCAA AGCAAA GCAAAG CAAAGC AAAGCG AAGCGG AGCGGC GCGGCG CGGCGG GGCGGC GCGGCG CGGCGG GGCGGG GCGGGC CGGGCG GGGCGG GGCGGG GCGGGA CGGGAT GGGATC GGATCG GATCGG ATCGGC TCGGCT CGGCTA GGCTAT GCTATT CTATTT TATTTG ATTTGC TTTGCG TTGCGC TGCGCC GCGCCG CGCCGC GCCGCA CCGCAC CGCACC GCACCC CACCCA ACCCAG CCCAGC CCAGCT CAGCTT AGCTTG GCTTGC CTTGCG TTGCGG TGCGGA GCGGAG CGGAGG GGAGGG GAGGGC AGGGCT GGGCTC GGCTCG GCTCGT CTCGTG TCGTGG,3,142,GGTG GTGC TGCG GCGT CGTT GTTG TTGC TGCT GCTG CTGG TGGA GGAT GATC ATCC TCCC CCCC CCCC CCCG CCGA CGAC GACC ACCG CCGA CGAG GAGG AGGA GGAC GACG ACGT CGTC GTCA TCAC CACC ACCG CCGC CGCG GCGC CGCG GCGC CGCT GCTG CTGC TGCA GCAT CATC ATCT TCTC CTCG TCGA CGAT GATG ATGC TGCT GCTG CTGG TGGC GGCC GCCC CCCA CCAG CAGC AGCT GCTC CTCG TCGG CGGC GGCG GCGA CGAG GAGA AGAC GACC ACCG CCGC CGCC GCCG CCGA CGAA GAAA AAAC AACG ACGA CGAG GAGC AGCA GCAA CAAA AAAG AAGC AGCG GCGG CGGC GGCG GCGG CGGC GGCG GCGG CGGG GGGC GGCG GCGG CGGG GGGA GGAT GATC ATCG TCGG CGGC GGCT GCTA CTAT TATT ATTT TTTG TTGC TGCG GCGC CGCC GCCG CCGC CGCA GCAC CACC ACCC CCCA CCAG CAGC AGCT GCTT CTTG TTGC TGCG GCGG CGGA GGAG GAGG AGGG GGGC GGCT GCTC CTCG TCGT CGTG GTGG,GGTGC GTGCG TGCGT GCGTT CGTTG GTTGC TTGCT TGCTG GCTGG CTGGA TGGAT GGATC GATCC ATCCC TCCCC CCCCC CCCCG CCCGA CCGAC CGACC GACCG ACCGA CCGAG CGAGG GAGGA AGGAC GGACG GACGT ACGTC CGTCA GTCAC TCACC CACCG ACCGC CCGCG CGCGC GCGCG CGCGC GCGCT CGCTG GCTGC CTGCA TGCAT GCATC CATCT ATCTC TCTCG CTCGA TCGAT CGATG GATGC ATGCT TGCTG GCTGG CTGGC TGGCC GGCCC GCCCA CCCAG CCAGC CAGCT AGCTC GCTCG CTCGG TCGGC CGGCG GGCGA GCGAG CGAGA GAGAC AGACC GACCG ACCGC CCGCC CGCCG GCCGA CCGAA CGAAA GAAAC AAACG AACGA ACGAG CGAGC GAGCA AGCAA GCAAA CAAAG AAAGC AAGCG AGCGG GCGGC CGGCG GGCGG GCGGC CGGCG GGCGG GCGGG CGGGC GGGCG GGCGG GCGGG CGGGA GGGAT GGATC GATCG ATCGG TCGGC CGGCT GGCTA GCTAT CTATT TATTT ATTTG TTTGC TTGCG TGCGC GCGCC CGCCG GCCGC CCGCA CGCAC GCACC CACCC ACCCA CCCAG CCAGC CAGCT AGCTT GCTTG CTTGC TTGCG TGCGG GCGGA CGGAG GGAGG GAGGG AGGGC GGGCT GGCTC GCTCG CTCGT TCGTG CGTGG,GGTGCG GTGCGT TGCGTT GCGTTG CGTTGC GTTGCT TTGCTG TGCTGG GCTGGA CTGGAT TGGATC GGATCC GATCCC ATCCCC TCCCCC CCCCCG CCCCGA CCCGAC CCGACC CGACCG GACCGA ACCGAG CCGAGG CGAGGA GAGGAC AGGACG GGACGT GACGTC ACGTCA CGTCAC GTCACC TCACCG CACCGC ACCGCG CCGCGC CGCGCG GCGCGC CGCGCT GCGCTG CGCTGC GCTGCA CTGCAT TGCATC GCATCT CATCTC ATCTCG TCTCGA CTCGAT TCGATG CGATGC GATGCT ATGCTG TGCTGG GCTGGC CTGGCC TGGCCC GGCCCA GCCCAG CCCAGC CCAGCT CAGCTC AGCTCG GCTCGG CTCGGC TCGGCG CGGCGA GGCGAG GCGAGA CGAGAC GAGACC AGACCG GACCGC ACCGCC CCGCCG CGCCGA GCCGAA CCGAAA CGAAAC GAAACG AAACGA AACGAG ACGAGC CGAGCA GAGCAA AGCAAA GCAAAG CAAAGC AAAGCG AAGCGG AGCGGC GCGGCG CGGCGG GGCGGC GCGGCG CGGCGG GGCGGG GCGGGC CGGGCG GGGCGG GGCGGG GCGGGA CGGGAT GGGATC GGATCG GATCGG ATCGGC TCGGCT CGGCTA GGCTAT GCTATT CTATTT TATTTG ATTTGC TTTGCG TTGCGC TGCGCC GCGCCG CGCCGC GCCGCA CCGCAC CGCACC GCACCC CACCCA ACCCAG CCCAGC CCAGCT CAGCTT AGCTTG GCTTGC CTTGCG TTGCGG TGCGGA GCGGAG CGGAGG GGAGGG GAGGGC AGGGCT GGGCTC GGCTCG GCTCGT CTCGTG TCGTGG,GGTGCGT GTGCGTT TGCGTTG GCGTTGC CGTTGCT GTTGCTG TTGCTGG TGCTGGA GCTGGAT CTGGATC TGGATCC GGATCCC GATCCCC ATCCCCC TCCCCCG CCCCCGA CCCCGAC CCCGACC CCGACCG CGACCGA GACCGAG ACCGAGG CCGAGGA CGAGGAC GAGGACG AGGACGT GGACGTC GACGTCA ACGTCAC CGTCACC GTCACCG TCACCGC CACCGCG ACCGCGC CCGCGCG CGCGCGC GCGCGCT CGCGCTG GCGCTGC CGCTGCA GCTGCAT CTGCATC TGCATCT GCATCTC CATCTCG ATCTCGA TCTCGAT CTCGATG TCGATGC CGATGCT GATGCTG ATGCTGG TGCTGGC GCTGGCC CTGGCCC TGGCCCA GGCCCAG GCCCAGC CCCAGCT CCAGCTC CAGCTCG AGCTCGG GCTCGGC CTCGGCG TCGGCGA CGGCGAG GGCGAGA GCGAGAC CGAGACC GAGACCG AGACCGC GACCGCC ACCGCCG CCGCCGA CGCCGAA GCCGAAA CCGAAAC CGAAACG GAAACGA AAACGAG AACGAGC ACGAGCA CGAGCAA GAGCAAA AGCAAAG GCAAAGC CAAAGCG AAAGCGG AAGCGGC AGCGGCG GCGGCGG CGGCGGC GGCGGCG GCGGCGG CGGCGGG GGCGGGC GCGGGCG CGGGCGG GGGCGGG GGCGGGA GCGGGAT CGGGATC GGGATCG GGATCGG GATCGGC ATCGGCT TCGGCTA CGGCTAT GGCTATT GCTATTT CTATTTG TATTTGC ATTTGCG TTTGCGC TTGCGCC TGCGCCG GCGCCGC CGCCGCA GCCGCAC CCGCACC CGCACCC GCACCCA CACCCAG ACCCAGC CCCAGCT CCAGCTT CAGCTTG AGCTTGC GCTTGCG CTTGCGG TTGCGGA TGCGGAG GCGGAGG CGGAGGG GGAGGGC GAGGGCT AGGGCTC GGGCTCG GGCTCGT GCTCGTG CTCGTGG,"ID   SQHC_SINFN              Reviewed;         647 AA.
AC   P55348;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 1.
DT   05-FEB-2025, entry version 140.
DE   RecName: Full=Probable squalene--hopene cyclase;
DE            EC=4.2.1.129;
DE            EC=5.4.99.17;
DE   AltName: Full=Squalene--hopanol cyclase;
GN   Name=shc; OrderedLocusNames=NGR_a00460; ORFNames=y4aA;
OS   Sinorhizobium fredii (strain NBRC 101917 / NGR234).
OG   Plasmid sym pNGR234a.
OC   Bacteria; Pseudomonadota; Alphaproteobacteria; Hyphomicrobiales;
OC   Rhizobiaceae; Sinorhizobium/Ensifer group; Sinorhizobium.
OX   NCBI_TaxID=394;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=NBRC 101917 / NGR234;
RX   PubMed=9163424; DOI=10.1038/387394a0;
RA   Freiberg C.A., Fellay R., Bairoch A., Broughton W.J., Rosenthal A.,
RA   Perret X.;
RT   ""Molecular basis of symbiosis between Rhizobium and legumes."";
RL   Nature 387:394-401(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=NBRC 101917 / NGR234;
RX   PubMed=19376903; DOI=10.1128/aem.00515-09;
RA   Schmeisser C., Liesegang H., Krysciak D., Bakkou N., Le Quere A.,
RA   Wollherr A., Heinemeyer I., Morgenstern B., Pommerening-Roeser A.,
RA   Flores M., Palacios R., Brenner S., Gottschalk G., Schmitz R.A.,
RA   Broughton W.J., Perret X., Strittmatter A.W., Streit W.R.;
RT   ""Rhizobium sp. strain NGR234 possesses a remarkable number of secretion
RT   systems."";
RL   Appl. Environ. Microbiol. 75:4035-4045(2009).
CC   -!- FUNCTION: Catalyzes the cyclization of squalene into hopene. Probably
CC       part of an operon y4aABCD involved in the synthesis of an isoprenoid
CC       compound.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=squalene = hop-22(29)-ene; Xref=Rhea:RHEA:17637,
CC         ChEBI:CHEBI:4648, ChEBI:CHEBI:15440; EC=5.4.99.17;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=squalene + H2O = hopan-22-ol; Xref=Rhea:RHEA:16561,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15440, ChEBI:CHEBI:36484;
CC         EC=4.2.1.129;
CC   -!- PATHWAY: Secondary metabolite biosynthesis; hopanoid biosynthesis.
CC   -!- SIMILARITY: Belongs to the terpene cyclase/mutase family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U00090; AAB91964.1; -; Genomic_DNA.
DR   RefSeq; NP_443761.1; NC_000914.2.
DR   AlphaFoldDB; P55348; -.
DR   SMR; P55348; -.
DR   KEGG; rhi:NGR_a00460; -.
DR   PATRIC; fig|394.7.peg.43; -.
DR   eggNOG; COG1657; Bacteria.
DR   HOGENOM; CLU_019345_0_0_5; -.
DR   OrthoDB; 9758578at2; -.
DR   UniPathway; UPA00337; -.
DR   Proteomes; UP000001054; Plasmid pNGR234a.
DR   GO; GO:0005811; C:lipid droplet; IEA:InterPro.
DR   GO; GO:0016829; F:lyase activity; IEA:UniProtKB-KW.
DR   GO; GO:0051007; F:squalene-hopene cyclase activity; IEA:UniProtKB-EC.
DR   GO; GO:0016104; P:triterpenoid biosynthetic process; IEA:InterPro.
DR   CDD; cd02892; SQCY_1; 1.
DR   Gene3D; 1.50.10.20; -; 2.
DR   InterPro; IPR006400; Hopene-cyclase.
DR   InterPro; IPR032696; SQ_cyclase_C.
DR   InterPro; IPR032697; SQ_cyclase_N.
DR   InterPro; IPR018333; Squalene_cyclase.
DR   InterPro; IPR002365; Terpene_synthase_CS.
DR   InterPro; IPR008930; Terpenoid_cyclase/PrenylTrfase.
DR   NCBIfam; TIGR01507; hopene_cyclase; 1.
DR   NCBIfam; TIGR01787; squalene_cyclas; 1.
DR   PANTHER; PTHR11764:SF20; LANOSTEROL SYNTHASE; 1.
DR   PANTHER; PTHR11764; TERPENE CYCLASE/MUTASE FAMILY MEMBER; 1.
DR   Pfam; PF13243; SQHop_cyclase_C; 1.
DR   Pfam; PF13249; SQHop_cyclase_N; 1.
DR   SFLD; SFLDG01016; Prenyltransferase_Like_2; 1.
DR   SUPFAM; SSF48239; Terpenoid cyclases/Protein prenyltransferases; 2.
DR   PROSITE; PS01074; TERPENE_SYNTHASES; 1.
PE   3: Inferred from homology;
KW   Isomerase; Lyase; Plasmid; Reference proteome; Repeat.
FT   CHAIN           1..647
FT                   /note=""Probable squalene--hopene cyclase""
FT                   /id=""PRO_0000072652""
FT   REPEAT          67..108
FT                   /note=""PFTB 1""
FT   REPEAT          413..454
FT                   /note=""PFTB 2""
FT   REPEAT          530..577
FT                   /note=""PFTB 3""
FT   ACT_SITE        388
FT                   /note=""Proton donor""
FT                   /evidence=""ECO:0000250|UniProtKB:P48449""
SQ   SEQUENCE   647 AA;  72130 MW;  BD0C336905D1ECAE CRC64;
     MNKHSGNRTA IDPAALEMSI ASATEALLAY RHADGHWAFE LEADSTIPSE YILLRHYLAE
     PIDVVLEAKI GNYLRRTQGA HGGWPLVHDG PFDMSASVKS YFALKMIGDS VDAAHMVKAR
     EAIRARGGAA NSNVLTRFLL ALYGVVSWRA VPVLPIEIVL LPIWSPFHLY KISYWARTTI
     VPLMVLAVLK PRAKNPKGVG IEELFLQDTK SVGMNPKAPH QSWGWFLLFR GIDGILRVIE
     PHLPKKLRER AIASALAFTE ERLNGEDGMG AIYPSMANIV MMYDALGKDD HFPPRAIARR
     AIDKLLVIGE EEAYCQPCLS PVWDTALTCH ALQEVGGANA VAKAKQGLDW LKPRQVLDVK
     GDWAVKAPNI RPGGWPFQYN NAHYPDLDDT AVVVMAMDRA QRHAGSKEYA TAIARGREWI
     EGMQSRDGGW AAFDVNNLEY YLNNLPFADH GALLDPPTED VTARCVSMLA QVGEFTQRSK
     AVAEGIAYLR RTQHAEGSWY GRWGLNYIYG TWSVLCALNA AGIDHQDPMI RKAVEWLVSI
     QSWDGGWGED AISYRLDYSG YEQAPSTSSQ TAWALLGLMA AGEVEHPAVA RGVNYLKNAQ
     TENGLWDEQR YTATGFPRVF YLRYHGYSKF FPLWALARYR NLRSTNV
//
",18234
CTGTTA TGTTAT GTTATC TTATCC TATCCG ATCCGA TCCGAT CCGATT CGATTT GATTTA ATTTAC TTTACA TTACAG TACAGG ACAGGA CAGGAT AGGATT GGATTT GATTTG ATTTGA TTTGAA TTGAAA TGAAAT GAAATG AAATGG AATGGG ATGGGC TGGGCT GGGCTA GGCTAG GCTAGA CTAGAT TAGATT AGATTC GATTCC ATTCCC TTCCCT TCCCTA CCCTAA CCTAAG CTAAGA TAAGAG AAGAGT AGAGTG GAGTGA AGTGAT GTGATG TGATGG GATGGA ATGGAA TGGAAC GGAACT GAACTG AACTGG ACTGGT CTGGTA TGGTAC GGTACT GTACTA TACTAT ACTATT CTATTT TATTTA ATTTAT,0,64,CTGT TGTT GTTA TTAT TATC ATCC TCCG CCGA CGAT GATT ATTT TTTA TTAC TACA ACAG CAGG AGGA GGAT GATT ATTT TTTG TTGA TGAA GAAA AAAT AATG ATGG TGGG GGGC GGCT GCTA CTAG TAGA AGAT GATT ATTC TTCC TCCC CCCT CCTA CTAA TAAG AAGA AGAG GAGT AGTG GTGA TGAT GATG ATGG TGGA GGAA GAAC AACT ACTG CTGG TGGT GGTA GTAC TACT ACTA CTAT TATT ATTT TTTA TTAT,CTGTT TGTTA GTTAT TTATC TATCC ATCCG TCCGA CCGAT CGATT GATTT ATTTA TTTAC TTACA TACAG ACAGG CAGGA AGGAT GGATT GATTT ATTTG TTTGA TTGAA TGAAA GAAAT AAATG AATGG ATGGG TGGGC GGGCT GGCTA GCTAG CTAGA TAGAT AGATT GATTC ATTCC TTCCC TCCCT CCCTA CCTAA CTAAG TAAGA AAGAG AGAGT GAGTG AGTGA GTGAT TGATG GATGG ATGGA TGGAA GGAAC GAACT AACTG ACTGG CTGGT TGGTA GGTAC GTACT TACTA ACTAT CTATT TATTT ATTTA TTTAT,CTGTTA TGTTAT GTTATC TTATCC TATCCG ATCCGA TCCGAT CCGATT CGATTT GATTTA ATTTAC TTTACA TTACAG TACAGG ACAGGA CAGGAT AGGATT GGATTT GATTTG ATTTGA TTTGAA TTGAAA TGAAAT GAAATG AAATGG AATGGG ATGGGC TGGGCT GGGCTA GGCTAG GCTAGA CTAGAT TAGATT AGATTC GATTCC ATTCCC TTCCCT TCCCTA CCCTAA CCTAAG CTAAGA TAAGAG AAGAGT AGAGTG GAGTGA AGTGAT GTGATG TGATGG GATGGA ATGGAA TGGAAC GGAACT GAACTG AACTGG ACTGGT CTGGTA TGGTAC GGTACT GTACTA TACTAT ACTATT CTATTT TATTTA ATTTAT,CTGTTAT TGTTATC GTTATCC TTATCCG TATCCGA ATCCGAT TCCGATT CCGATTT CGATTTA GATTTAC ATTTACA TTTACAG TTACAGG TACAGGA ACAGGAT CAGGATT AGGATTT GGATTTG GATTTGA ATTTGAA TTTGAAA TTGAAAT TGAAATG GAAATGG AAATGGG AATGGGC ATGGGCT TGGGCTA GGGCTAG GGCTAGA GCTAGAT CTAGATT TAGATTC AGATTCC GATTCCC ATTCCCT TTCCCTA TCCCTAA CCCTAAG CCTAAGA CTAAGAG TAAGAGT AAGAGTG AGAGTGA GAGTGAT AGTGATG GTGATGG TGATGGA GATGGAA ATGGAAC TGGAACT GGAACTG GAACTGG AACTGGT ACTGGTA CTGGTAC TGGTACT GGTACTA GTACTAT TACTATT ACTATTT CTATTTA TATTTAT,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",32288
ATGTCT TGTCTG GTCTGA TCTGAT CTGATA TGATAA GATAAA ATAAAG TAAAGG AAAGGA AAGGAC AGGACC GGACCC GACCCC ACCCCA CCCCAA CCCAAA CCAAAA CAAAAA AAAAAC AAAACA AAACAG AACAGC ACAGCG CAGCGA AGCGAA GCGAAA CGAAAG GAAAGG AAAGGC AAGGCA AGGCAC GGCACT GCACTG CACTGC ACTGCG CTGCGG TGCGGA GCGGAT CGGATT GGATTG GATTGC ATTGCA TTGCAT TGCATT GCATTT CATTTG ATTTGG TTTGGG TTGGGG TGGGGG GGGGGA GGGGAC GGGACC GGACCC GACCCT ACCCTC CCCTCA CCTCAA CTCAAA TCAAAT CAAATT AAATTC AATTCA ATTCAG TTCAGC TCAGCT CAGCTG AGCTGG GCTGGC CTGGCA TGGCAG GGCAGT GCAGTA CAGTAG AGTAGC GTAGCC TAGCCT AGCCTG GCCTGA CCTGAA CTGAAT TGAATG GAATGA AATGAT ATGATG TGATGG GATGGG ATGGGG TGGGGC GGGGCG GGGCGC GGCGCG GCGCGA CGCGAT GCGATC CGATCA GATCAA ATCAAA TCAAAT CAAATG AAATGA AATGAA ATGAAC TGAACG GAACGT AACGTC ACGTCG CGTCGG GTCGGC TCGGCC CGGCCC,1,112,ATGT TGTC GTCT TCTG CTGA TGAT GATA ATAA TAAA AAAG AAGG AGGA GGAC GACC ACCC CCCC CCCA CCAA CAAA AAAA AAAA AAAC AACA ACAG CAGC AGCG GCGA CGAA GAAA AAAG AAGG AGGC GGCA GCAC CACT ACTG CTGC TGCG GCGG CGGA GGAT GATT ATTG TTGC TGCA GCAT CATT ATTT TTTG TTGG TGGG GGGG GGGG GGGA GGAC GACC ACCC CCCT CCTC CTCA TCAA CAAA AAAT AATT ATTC TTCA TCAG CAGC AGCT GCTG CTGG TGGC GGCA GCAG CAGT AGTA GTAG TAGC AGCC GCCT CCTG CTGA TGAA GAAT AATG ATGA TGAT GATG ATGG TGGG GGGG GGGC GGCG GCGC CGCG GCGA CGAT GATC ATCA TCAA CAAA AAAT AATG ATGA TGAA GAAC AACG ACGT CGTC GTCG TCGG CGGC GGCC GCCC,ATGTC TGTCT GTCTG TCTGA CTGAT TGATA GATAA ATAAA TAAAG AAAGG AAGGA AGGAC GGACC GACCC ACCCC CCCCA CCCAA CCAAA CAAAA AAAAA AAAAC AAACA AACAG ACAGC CAGCG AGCGA GCGAA CGAAA GAAAG AAAGG AAGGC AGGCA GGCAC GCACT CACTG ACTGC CTGCG TGCGG GCGGA CGGAT GGATT GATTG ATTGC TTGCA TGCAT GCATT CATTT ATTTG TTTGG TTGGG TGGGG GGGGG GGGGA GGGAC GGACC GACCC ACCCT CCCTC CCTCA CTCAA TCAAA CAAAT AAATT AATTC ATTCA TTCAG TCAGC CAGCT AGCTG GCTGG CTGGC TGGCA GGCAG GCAGT CAGTA AGTAG GTAGC TAGCC AGCCT GCCTG CCTGA CTGAA TGAAT GAATG AATGA ATGAT TGATG GATGG ATGGG TGGGG GGGGC GGGCG GGCGC GCGCG CGCGA GCGAT CGATC GATCA ATCAA TCAAA CAAAT AAATG AATGA ATGAA TGAAC GAACG AACGT ACGTC CGTCG GTCGG TCGGC CGGCC GGCCC,ATGTCT TGTCTG GTCTGA TCTGAT CTGATA TGATAA GATAAA ATAAAG TAAAGG AAAGGA AAGGAC AGGACC GGACCC GACCCC ACCCCA CCCCAA CCCAAA CCAAAA CAAAAA AAAAAC AAAACA AAACAG AACAGC ACAGCG CAGCGA AGCGAA GCGAAA CGAAAG GAAAGG AAAGGC AAGGCA AGGCAC GGCACT GCACTG CACTGC ACTGCG CTGCGG TGCGGA GCGGAT CGGATT GGATTG GATTGC ATTGCA TTGCAT TGCATT GCATTT CATTTG ATTTGG TTTGGG TTGGGG TGGGGG GGGGGA GGGGAC GGGACC GGACCC GACCCT ACCCTC CCCTCA CCTCAA CTCAAA TCAAAT CAAATT AAATTC AATTCA ATTCAG TTCAGC TCAGCT CAGCTG AGCTGG GCTGGC CTGGCA TGGCAG GGCAGT GCAGTA CAGTAG AGTAGC GTAGCC TAGCCT AGCCTG GCCTGA CCTGAA CTGAAT TGAATG GAATGA AATGAT ATGATG TGATGG GATGGG ATGGGG TGGGGC GGGGCG GGGCGC GGCGCG GCGCGA CGCGAT GCGATC CGATCA GATCAA ATCAAA TCAAAT CAAATG AAATGA AATGAA ATGAAC TGAACG GAACGT AACGTC ACGTCG CGTCGG GTCGGC TCGGCC CGGCCC,ATGTCTG TGTCTGA GTCTGAT TCTGATA CTGATAA TGATAAA GATAAAG ATAAAGG TAAAGGA AAAGGAC AAGGACC AGGACCC GGACCCC GACCCCA ACCCCAA CCCCAAA CCCAAAA CCAAAAA CAAAAAC AAAAACA AAAACAG AAACAGC AACAGCG ACAGCGA CAGCGAA AGCGAAA GCGAAAG CGAAAGG GAAAGGC AAAGGCA AAGGCAC AGGCACT GGCACTG GCACTGC CACTGCG ACTGCGG CTGCGGA TGCGGAT GCGGATT CGGATTG GGATTGC GATTGCA ATTGCAT TTGCATT TGCATTT GCATTTG CATTTGG ATTTGGG TTTGGGG TTGGGGG TGGGGGA GGGGGAC GGGGACC GGGACCC GGACCCT GACCCTC ACCCTCA CCCTCAA CCTCAAA CTCAAAT TCAAATT CAAATTC AAATTCA AATTCAG ATTCAGC TTCAGCT TCAGCTG CAGCTGG AGCTGGC GCTGGCA CTGGCAG TGGCAGT GGCAGTA GCAGTAG CAGTAGC AGTAGCC GTAGCCT TAGCCTG AGCCTGA GCCTGAA CCTGAAT CTGAATG TGAATGA GAATGAT AATGATG ATGATGG TGATGGG GATGGGG ATGGGGC TGGGGCG GGGGCGC GGGCGCG GGCGCGA GCGCGAT CGCGATC GCGATCA CGATCAA GATCAAA ATCAAAT TCAAATG CAAATGA AAATGAA AATGAAC ATGAACG TGAACGT GAACGTC AACGTCG ACGTCGG CGTCGGC GTCGGCC TCGGCCC,"ID   NCAP_SARS2              Reviewed;         419 AA.
AC   P0DTC9;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Nucleoprotein {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=N;
DE   AltName: Full=Nucleocapsid protein {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=NC {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=Protein N {ECO:0000255|HAMAP-Rule:MF_04096};
GN   Name=N {ECO:0000255|HAMAP-Rule:MF_04096};
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   SUBCELLULAR LOCATION.
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [3] {ECO:0007744|PDB:6WZO, ECO:0007744|PDB:6WZQ}
RP   X-RAY CRYSTALLOGRAPHY (1.42 ANGSTROMS) OF 247-364, AND SUBUNIT.
RX   PubMed=32654247; DOI=10.1002/pro.3909;
RA   Ye Q., West A.M.V., Silletti S., Corbett K.D.;
RT   ""Architecture and self-assembly of the SARS-CoV-2 nucleocapsid protein."";
RL   Protein Sci. 29:1890-1901(2020).
RN   [4]
RP   REVIEW.
RX   PubMed=32974389; DOI=10.3389/fmolb.2020.00219;
RA   Nikolakaki E., Giannakouros T.;
RT   ""SR/RS Motifs as Critical Determinants of Coronavirus Life Cycle."";
RL   Front. Mol. Biosci. 7:219-219(2020).
RN   [5]
RP   VARIANTS LEU-3 AND PHE-235.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [6]
RP   FUNCTION, INTERACTION WITH HOST NLRP3, AND SUBCELLULAR LOCATION.
RX   PubMed=34341353; DOI=10.1038/s41467-021-25015-6;
RA   Pan P., Shen M., Yu Z., Ge W., Chen K., Tian M., Xiao F., Wang Z., Wang J.,
RA   Jia Y., Wang W., Wan P., Zhang J., Chen W., Lei Z., Chen X., Luo Z.,
RA   Zhang Q., Xu M., Li G., Li Y., Wu J.;
RT   ""SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce
RT   hyperinflammation."";
RL   Nat. Commun. 12:4664-4664(2021).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 41-174, AND MUTAGENESIS OF
RP   TYR-109.
RX   PubMed=32363136; DOI=10.1016/j.apsb.2020.04.009;
RA   Kang S., Yang M., Hong Z., Zhang L., Huang Z., Chen X., He S., Zhou Z.,
RA   Zhou Z., Chen Q., Yan Y., Zhang C., Shan H., Chen S.;
RT   ""Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain
RT   reveals potential unique drug targeting sites."";
RL   Acta Pharmacol. Sin. 10:1228-1238(2020).
RN   [8] {ECO:0007744|PDB:6YI3, ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT}
RP   STRUCTURE BY NMR OF 44-180, FUNCTION, AND MUTAGENESIS OF ARG-68; ARG-92;
RP   ILE-94; ARG-107; GLN-163; TYR-172 AND GLU-174.
RX   PubMed=33264373; DOI=10.1371/journal.ppat.1009100;
RA   Dinesh D.C., Chalupska D., Silhan J., Koutna E., Nencka R., Veverka V.,
RA   Boura E.;
RT   ""Structural basis of RNA recognition by the SARS-CoV-2 nucleocapsid
RT   phosphoprotein."";
RL   PLoS Pathog. 16:1-16(2020).
RN   [9]
RP   MUTAGENESIS OF SER-188 AND SER-206, AND PHOSPHORYLATION AT SER-206.
RX   PubMed=34593624; DOI=10.1073/pnas.2113401118;
RA   Liu X., Verma A., Garcia G. Jr., Ramage H., Lucas A., Myers R.L.,
RA   Michaelson J.J., Coryell W., Kumar A., Charney A.W., Kazanietz M.G.,
RA   Rader D.J., Ritchie M.D., Berrettini W.H., Schultz D.C., Cherry S.,
RA   Damoiseaux R., Arumugaswami V., Klein P.S.;
RT   ""Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:1-9(2021).
RN   [10]
RP   CLEAVAGE.
RX   PubMed=35922005; DOI=10.1038/s41586-022-05148-4;
RA   Chu H., Hou Y., Yang D., Wen L., Shuai H., Yoon C., Shi J., Chai Y.,
RA   Yuen T.T., Hu B., Li C., Zhao X., Wang Y., Huang X., Lee K.S., Luo C.,
RA   Cai J.P., Poon V.K., Chan C.C., Zhang A.J., Yuan S., Sit K.Y., Foo D.C.,
RA   Au W.K., Wong K.K., Zhou J., Kok K.H., Jin D.Y., Chan J.F., Yuen K.Y.;
RT   ""Coronaviruses exploit a host cysteine-aspartic protease for replication."";
RL   Nature 0:0-0(2022).
RN   [11]
RP   MUTAGENESIS OF 203-ARG-GLY-204 AND ARG-203, AND PHOSPHORYLATION.
RX   PubMed=35728038; DOI=10.1371/journal.ppat.1010627;
RA   Johnson B.A., Zhou Y., Lokugamage K.G., Vu M.N., Bopp N.,
RA   Crocquet-Valdes P.A., Kalveram B., Schindewolf C., Liu Y., Scharton D.,
RA   Plante J.A., Xie X., Aguilar P., Weaver S.C., Shi P.Y., Walker D.H.,
RA   Routh A.L., Plante K.S., Menachery V.D.;
RT   ""Nucleocapsid mutations in SARS-CoV-2 augment replication and
RT   pathogenesis."";
RL   PLoS Pathog. 18:e1010627-e1010627(2022).
RN   [12]
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=35921414; DOI=10.1126/sciadv.abp9770;
RA   Lopez-Munoz A.D., Kosik I., Holly J., Yewdell J.W.;
RT   ""Cell surface SARS-CoV-2 nucleocapsid protein modulates innate and adaptive
RT   immunity."";
RL   Sci. Adv. 8:eabp9770-eabp9770(2022).
RN   [13]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=34901782; DOI=10.1016/j.isci.2021.103562;
RA   Nabeel-Shah S., Lee H., Ahmed N., Burke G.L., Farhangmehr S., Ashraf K.,
RA   Pu S., Braunschweig U., Zhong G., Wei H., Tang H., Yang J., Marcon E.,
RA   Blencowe B.J., Zhang Z., Greenblatt J.F.;
RT   ""SARS-CoV-2 nucleocapsid protein binds host mRNAs and attenuates stress
RT   granules to impair host stress response."";
RL   IScience 25:103562-103562(2022).
RN   [14]
RP   FUNCTION.
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [15] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 191-263, AND INTERACTION WITH NSP3.
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
CC   -!- FUNCTION: Packages the positive strand viral genome RNA into a helical
CC       ribonucleocapsid (RNP) and plays a fundamental role during virion
CC       assembly through its interactions with the viral genome and membrane
CC       protein M (PubMed:33264373). Plays an important role in enhancing the
CC       efficiency of subgenomic viral RNA transcription as well as viral
CC       replication. Attenuates the stress granules formation by reducing host
CC       G3BP1 access to host mRNAs under stress conditions (PubMed:34901782,
CC       PubMed:36534661). {ECO:0000269|PubMed:32974389,
CC       ECO:0000269|PubMed:33264373, ECO:0000269|PubMed:34901782,
CC       ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: May block host chemokine function in vivo, facilitating viral
CC       replication and transmission (PubMed:35921414). Acts by being secreted
CC       into the extracellular space where it competes to host chemokines for
CC       binding to host glycosaminoglycans (GAG) (PubMed:35921414).
CC       {ECO:0000269|PubMed:35921414}.
CC   -!- FUNCTION: May induce inflammasome responses in cultured cells and mice.
CC       Acts by interacting with host NLRP3 to facilitate inflammasome
CC       assembly, which induces cytokine release that may play a role in COVID
CC       lung injury. {ECO:0000269|PubMed:34341353}.
CC   -!- SUBUNIT: Homodimer, homotetramer, homooligomer with RNA
CC       (PubMed:32654247). Both monomeric and oligomeric forms interact with
CC       RNA. Interacts with protein M (By similarity). Interacts with protein E
CC       (By similarity). Interacts with NSP3; this interaction serves to tether
CC       the genome to the newly translated replicase-transcriptase complex at a
CC       very early stage of infection (PubMed:35044811). May interact with host
CC       NLRP3 (PubMed:34341353). {ECO:0000250|UniProtKB:P59595,
CC       ECO:0000255|HAMAP-Rule:MF_04096, ECO:0000269|PubMed:32654247,
CC       ECO:0000269|PubMed:34341353, ECO:0000269|PubMed:35044811}.
CC   -!- INTERACTION:
CC       P0DTC9; P0DTC4: E; NbExp=3; IntAct=EBI-25475856, EBI-25475850;
CC       P0DTC9; P0DTC5: M; NbExp=6; IntAct=EBI-25475856, EBI-25475853;
CC       P0DTC9; P0DTC9: N; NbExp=105; IntAct=EBI-25475856, EBI-25475856;
CC       P0DTC9; PRO_0000449621 [P0DTD1]: rep; NbExp=15; IntAct=EBI-25475856, EBI-25492388;
CC       P0DTC9; P78563: ADARB1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-2967304;
CC       P0DTC9; O15145: ARPC3; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-351829;
CC       P0DTC9; Q13895: BYSL; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-358049;
CC       P0DTC9; Q16543: CDC37; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-295634;
CC       P0DTC9; Q92793: CREBBP; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-81215;
CC       P0DTC9; Q92499: DDX1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-358474;
CC       P0DTC9; Q9NR30: DDX21; Xeno; NbExp=12; IntAct=EBI-25475856, EBI-357942;
CC       P0DTC9; P26196: DDX6; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-351257;
CC       P0DTC9; Q08426: EHHADH; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-2339219;
CC       P0DTC9; P19525: EIF2AK2; Xeno; NbExp=8; IntAct=EBI-25475856, EBI-640775;
CC       P0DTC9; Q14241: ELOA; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-742350;
CC       P0DTC9; Q13283: G3BP1; Xeno; NbExp=71; IntAct=EBI-25475856, EBI-1047359;
CC       P0DTC9; Q9UN86: G3BP2; Xeno; NbExp=37; IntAct=EBI-25475856, EBI-1044298;
CC       P0DTC9; P57764: GSDMD; Xeno; NbExp=13; IntAct=EBI-25475856, EBI-2798865;
CC       P0DTC9; P49841: GSK3B; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-373586;
CC       P0DTC9; P10412: H1-4; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-358163;
CC       P0DTC9; O14920: IKBKB; Xeno; NbExp=7; IntAct=EBI-25475856, EBI-81266;
CC       P0DTC9; Q92830: KAT2A; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-477622;
CC       P0DTC9; Q92831: KAT2B; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-477430;
CC       P0DTC9; Q07866: KLC1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-721019;
CC       P0DTC9; Q9H0B6: KLC2; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-726994;
CC       P0DTC9; Q9NSK0: KLC4; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-949319;
CC       P0DTC9; Q9NX58: LYAR; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-713507;
CC       P0DTC9; O43318: MAP3K7; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-358684;
CC       P0DTC9; Q9UBU8: MORF4L1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-399246;
CC       P0DTC9; Q15014: MORF4L2; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-399257;
CC       P0DTC9; Q9HCE1: MOV10; Xeno; NbExp=11; IntAct=EBI-25475856, EBI-1055820;
CC       P0DTC9; Q9HC36: MRM3; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-1045440;
CC       P0DTC9; O15226: NKRF; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-766011;
CC       P0DTC9; Q96P20: NLRP3; Xeno; NbExp=18; IntAct=EBI-25475856, EBI-6253230;
CC       P0DTC9; O15118: NPC1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-2368710;
CC       P0DTC9; Q96HA8: NTAQ1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-741158;
CC       P0DTC9; P11940: PABPC1; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-81531;
CC       P0DTC9; P62937: PPIA; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-437708;
CC       P0DTC9; O75569: PRKRA; Xeno; NbExp=8; IntAct=EBI-25475856, EBI-713955;
CC       P0DTC9; Q99873: PRMT1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-78738;
CC       P0DTC9; P61289: PSME3; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-355546;
CC       P0DTC9; P26022: PTX3; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-11574553;
CC       P0DTC9; P54727: RAD23B; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-954531;
CC       P0DTC9; O95786: RIGI; Xeno; NbExp=15; IntAct=EBI-25475856, EBI-995350;
CC       P0DTC9; P62899: RPL31; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-1053664;
CC       P0DTC9; P62753: RPS6; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-356625;
CC       P0DTC9; P37840: SNCA; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-985879;
CC       P0DTC9; Q96SB4: SRPK1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-539478;
CC       P0DTC9; P78362: SRPK2; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-593303;
CC       P0DTC9; P42224: STAT1; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-1057697;
CC       P0DTC9; P52630: STAT2; Xeno; NbExp=7; IntAct=EBI-25475856, EBI-1546963;
CC       P0DTC9; Q15633: TARBP2; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-978581;
CC       P0DTC9; Q14258: TRIM25; Xeno; NbExp=13; IntAct=EBI-25475856, EBI-2341129;
CC       P0DTC9; O60763: USO1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-356164;
CC       P0DTC9; Q93008: USP9X; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-302524;
CC   -!- SUBCELLULAR LOCATION: Virion {ECO:0000255|HAMAP-Rule:MF_04096}. Host
CC       cytoplasm {ECO:0000269|PubMed:33060197, ECO:0000269|PubMed:34341353}.
CC       Secreted {ECO:0000269|PubMed:35921414}. Host extracellular space
CC       {ECO:0000269|PubMed:35921414}. Note=Probably associates with ER-derived
CC       membranes where it participates in viral RNA synthesis and virus
CC       budding. When located inside the virion, complexed with the viral RNA.
CC       Can be secreted by unconventional protein secretion (UPS)
CC       (PubMed:35921414). When secreted, can bind to host glycosaminoglycans
CC       on infected and non infected cells (PubMed:35921414). Found in host
CC       cytoplasmic stress granules (PubMed:34901782). {ECO:0000255|HAMAP-
CC       Rule:MF_04096, ECO:0000269|PubMed:34901782,
CC       ECO:0000269|PubMed:35921414}.
CC   -!- PTM: ADP-ribosylated. The ADP-ribosylation is retained in the virion
CC       during infection. {ECO:0000255|HAMAP-Rule:MF_04096}.
CC   -!- PTM: Phosphorylated on serine residues by host GSK3A and GSK3B
CC       (PubMed:34593624, PubMed:35728038). This promotes the solubility of
CC       homodimers that would otherwise aggregate (PubMed:32974389). Host
CC       phosphatase would dephosphorylate the protein during assembly at M
CC       bound membranes (PubMed:32974389). {ECO:0000269|PubMed:34593624,
CC       ECO:0000269|PubMed:35728038, ECO:0000305|PubMed:32974389}.
CC   -!- PTM: Proteolytically cleaved by host CASP6. The cleavage leads to two
CC       fragments and facilitates viral replication by inhibiting host IFN
CC       signaling. The two fragments may interact with IRF3 inhibiting its
CC       nuclear translocation after activation and reduce the expression of
CC       IFNB and IFN-stimulated genes. {ECO:0000269|PubMed:35922005}.
CC   -!- POLYMORPHISM: Variant Alpha/B.1.1.7 belongs to a lineage isolated first
CC       in United Kingdom (December 2020). It is also called Variant of Concern
CC       (VOC) 202012/01, Variant Under Investigation (VUI) 202012/01, 501Y.V1
CC       or 20B/501Y.V1. {ECO:0000305|PubMed:33413740}.
CC   -!- POLYMORPHISM: Variant Omicron/BA.1 and BA.2 belong to a lineage first
CC       isolated in South Africa (November 2021). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/BQ.1.1 belongs to a lineage first
CC       isolated in Nigeria (November 2022). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/XBB.1.5 belongs to a lineage first
CC       isolated in United States (November 2022). It is the result of
CC       recombination between omicron BJ.1 and BM.1.1. Moreover XBB.1.5 do not
CC       express ORF8. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the betacoronavirus nucleocapsid protein family.
CC       {ECO:0000255|HAMAP-Rule:MF_04096}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43423.2; -; Genomic_RNA.
DR   PDB; 6M3M; X-ray; 2.70 A; A/B/C/D=41-174.
DR   PDB; 6VYO; X-ray; 1.70 A; A/B/C/D=47-173.
DR   PDB; 6WJI; X-ray; 2.05 A; A/B/C/D/E/F=257-364.
DR   PDB; 6WKP; X-ray; 2.67 A; A/B/C/D=47-173.
DR   PDB; 6WZO; X-ray; 1.42 A; A/B/C/D=247-364.
DR   PDB; 6WZQ; X-ray; 1.45 A; A/B/C/D=247-364.
DR   PDB; 6YI3; NMR; -; A=44-180.
DR   PDB; 6YUN; X-ray; 1.44 A; A/B=249-364.
DR   PDB; 6ZCO; X-ray; 1.36 A; A=247-364.
DR   PDB; 7ACS; NMR; -; A=44-180.
DR   PDB; 7ACT; NMR; -; A=44-180.
DR   PDB; 7C22; X-ray; 2.00 A; A/B/C/D=248-364.
DR   PDB; 7CDZ; X-ray; 1.80 A; A/B/C/D=44-174.
DR   PDB; 7CE0; X-ray; 1.50 A; A/B/C/D=255-364.
DR   PDB; 7CR5; X-ray; 2.08 A; A=41-174.
DR   PDB; 7DE1; X-ray; 2.00 A; A/B=250-364.
DR   PDB; 7F2B; X-ray; 2.00 A; A/B=257-362.
DR   PDB; 7F2E; X-ray; 3.10 A; A/B/C/D/E/F/G/H/I/J/K/L=255-362.
DR   PDB; 7KGO; X-ray; 2.15 A; C=351-359.
DR   PDB; 7KGP; X-ray; 1.40 A; C=316-324.
DR   PDB; 7KGQ; X-ray; 1.34 A; C=222-230.
DR   PDB; 7KGR; X-ray; 1.55 A; C=159-167.
DR   PDB; 7KGS; X-ray; 1.58 A; C=138-146.
DR   PDB; 7KGT; X-ray; 1.90 A; C=226-234.
DR   PDB; 7LGD; X-ray; 2.88 A; E/F=105-113.
DR   PDB; 7LTU; X-ray; 1.12 A; A/B=217-222.
DR   PDB; 7LUX; X-ray; 1.30 A; A=217-222.
DR   PDB; 7LUZ; X-ray; 1.10 A; A=243-248.
DR   PDB; 7LV2; X-ray; 1.30 A; A=179-184.
DR   PDB; 7N0I; X-ray; 2.20 A; A/B/C/D/E/F/G/H=269-364.
DR   PDB; 7N0R; X-ray; 1.42 A; A/B=49-174.
DR   PDB; 7N3C; X-ray; 1.82 A; C=47-173.
DR   PDB; 7N3D; X-ray; 1.53 A; C=47-173.
DR   PDB; 7O05; X-ray; 1.94 A; A/B/C/D=247-364.
DR   PDB; 7O35; X-ray; 1.80 A; A/B/C/D=247-364.
DR   PDB; 7O36; X-ray; 2.00 A; A/B/C/D=247-364.
DR   PDB; 7PKU; NMR; -; B=191-263.
DR   PDB; 7QIK; X-ray; 2.01 A; E/F=193-200.
DR   PDB; 7QIP; X-ray; 2.65 A; C/D=201-210.
DR   PDB; 7R98; X-ray; 2.51 A; A/B/C=49-174.
DR   PDB; 7SD4; NMR; -; A=40-174.
DR   PDB; 7STR; X-ray; 1.50 A; C=47-173.
DR   PDB; 7STS; X-ray; 2.16 A; C/D=47-173.
DR   PDB; 7SUE; X-ray; 2.90 A; C/D/J/K=47-173.
DR   PDB; 7SUO; X-ray; 2.35 A; C/D=12-22.
DR   PDB; 7UW3; X-ray; 1.70 A; A/B/C/D=40-174.
DR   PDB; 7UXX; X-ray; 1.85 A; AAA/BBB/CCC/DDD/EEE/FFF=251-364.
DR   PDB; 7UXZ; X-ray; 1.73 A; AAA/BBB/CCC/DDD/EEE/FFF=251-364.
DR   PDB; 7VBD; X-ray; 1.94 A; A/B/C/D=48-174.
DR   PDB; 7VBE; X-ray; 1.59 A; A/B=257-364.
DR   PDB; 7VBF; X-ray; 1.30 A; A/B=255-364.
DR   PDB; 7VNU; X-ray; 1.95 A; A/B/C/D=47-174.
DR   PDB; 7WKJ; X-ray; 1.50 A; C=361-369.
DR   PDB; 7WZO; X-ray; 2.64 A; A=47-174.
DR   PDB; 7XWX; X-ray; 3.00 A; A/B/C/D/E/F/G/H=269-367.
DR   PDB; 7XWZ; X-ray; 2.25 A; A/B=48-172.
DR   PDB; 7XX1; X-ray; 1.90 A; A/B/C/D=49-173.
DR   PDB; 7XXK; X-ray; 2.00 A; A/B/C/D/E/F=248-364.
DR   PDB; 7YLB; X-ray; 2.41 A; A/B/C/D/G/H/J/K=247-364.
DR   PDB; 7YLD; X-ray; 2.80 A; A/B/C/D=47-174.
DR   PDB; 7ZIT; X-ray; 1.79 A; C/D=194-200.
DR   PDB; 8DNT; X-ray; 3.18 A; D/J/Q/X=222-230.
DR   PDB; 8FD5; EM; 4.57 A; A=1-419.
DR   PDB; 8FG2; EM; 6.00 A; A/B=1-419.
DR   PDB; 8IQJ; X-ray; 2.30 A; A/B/C/D=41-174.
DR   PDB; 8IV3; X-ray; 1.90 A; A/B/C/D=41-174.
DR   PDB; 8J6X; X-ray; 2.70 A; A/B/C/D=41-174.
DR   PDB; 8TH1; X-ray; 1.80 A; E/F/G/H=1-25.
DR   PDB; 8TH5; X-ray; 2.62 A; K/L/M/N/O/P/Q=1-25.
DR   PDB; 8X1H; X-ray; 2.00 A; A/B/C/D=44-175.
DR   PDBsum; 6M3M; -.
DR   PDBsum; 6VYO; -.
DR   PDBsum; 6WJI; -.
DR   PDBsum; 6WKP; -.
DR   PDBsum; 6WZO; -.
DR   PDBsum; 6WZQ; -.
DR   PDBsum; 6YI3; -.
DR   PDBsum; 6YUN; -.
DR   PDBsum; 6ZCO; -.
DR   PDBsum; 7ACS; -.
DR   PDBsum; 7ACT; -.
DR   PDBsum; 7C22; -.
DR   PDBsum; 7CDZ; -.
DR   PDBsum; 7CE0; -.
DR   PDBsum; 7CR5; -.
DR   PDBsum; 7DE1; -.
DR   PDBsum; 7F2B; -.
DR   PDBsum; 7F2E; -.
DR   PDBsum; 7KGO; -.
DR   PDBsum; 7KGP; -.
DR   PDBsum; 7KGQ; -.
DR   PDBsum; 7KGR; -.
DR   PDBsum; 7KGS; -.
DR   PDBsum; 7KGT; -.
DR   PDBsum; 7LGD; -.
DR   PDBsum; 7LTU; -.
DR   PDBsum; 7LUX; -.
DR   PDBsum; 7LUZ; -.
DR   PDBsum; 7LV2; -.
DR   PDBsum; 7N0I; -.
DR   PDBsum; 7N0R; -.
DR   PDBsum; 7N3C; -.
DR   PDBsum; 7N3D; -.
DR   PDBsum; 7O05; -.
DR   PDBsum; 7O35; -.
DR   PDBsum; 7O36; -.
DR   PDBsum; 7PKU; -.
DR   PDBsum; 7QIK; -.
DR   PDBsum; 7QIP; -.
DR   PDBsum; 7R98; -.
DR   PDBsum; 7SD4; -.
DR   PDBsum; 7STR; -.
DR   PDBsum; 7STS; -.
DR   PDBsum; 7SUE; -.
DR   PDBsum; 7SUO; -.
DR   PDBsum; 7UW3; -.
DR   PDBsum; 7UXX; -.
DR   PDBsum; 7UXZ; -.
DR   PDBsum; 7VBD; -.
DR   PDBsum; 7VBE; -.
DR   PDBsum; 7VBF; -.
DR   PDBsum; 7VNU; -.
DR   PDBsum; 7WKJ; -.
DR   PDBsum; 7WZO; -.
DR   PDBsum; 7XWX; -.
DR   PDBsum; 7XWZ; -.
DR   PDBsum; 7XX1; -.
DR   PDBsum; 7XXK; -.
DR   PDBsum; 7YLB; -.
DR   PDBsum; 7YLD; -.
DR   PDBsum; 7ZIT; -.
DR   PDBsum; 8DNT; -.
DR   PDBsum; 8FD5; -.
DR   PDBsum; 8FG2; -.
DR   PDBsum; 8IQJ; -.
DR   PDBsum; 8IV3; -.
DR   PDBsum; 8J6X; -.
DR   PDBsum; 8TH1; -.
DR   PDBsum; 8TH5; -.
DR   PDBsum; 8X1H; -.
DR   BMRB; P0DTC9; -.
DR   EMDB; EMD-29002; -.
DR   EMDB; EMD-29072; -.
DR   SASBDB; P0DTC9; -.
DR   SMR; P0DTC9; -.
DR   BioGRID; 4383847; 1532.
DR   ComplexPortal; CPX-5686; SARS-CoV-2 nucleocapsid complex.
DR   IntAct; P0DTC9; 608.
DR   MINT; P0DTC9; -.
DR   ChEMBL; CHEMBL5169223; -.
DR   iPTMnet; P0DTC9; -.
DR   ABCD; P0DTC9; 27 sequenced antibodies.
DR   DNASU; 43740575; -.
DR   KEGG; vg:43740575; -.
DR   AGR; RefSeq:YP_009724397; -.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-HSA-168928; DDX58/IFIH1-mediated induction of interferon-alpha/beta.
DR   Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-HSA-445989; TAK1-dependent IKK and NF-kappa-B activation.
DR   Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-HSA-9020702; Interleukin-1 signaling.
DR   Reactome; R-HSA-909733; Interferon alpha/beta signaling.
DR   Reactome; R-HSA-9694322; Virion Assembly and Release.
DR   Reactome; R-HSA-9694614; Attachment and Entry.
DR   Reactome; R-HSA-9694631; Maturation of nucleoprotein.
DR   Reactome; R-HSA-9694635; Translation of Structural Proteins.
DR   Reactome; R-HSA-9694786; Transcription of SARS-CoV-2 sgRNAs.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   Reactome; R-HSA-9733458; Induction of Cell-Cell Fusion.
DR   Reactome; R-HSA-9755779; SARS-CoV-2 targets host intracellular signalling and regulatory pathways.
DR   SIGNOR; P0DTC9; -.
DR   PRO; PR:P0DTC9; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProt.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0044172; C:host cell endoplasmic reticulum-Golgi intermediate compartment; ISS:UniProtKB.
DR   GO; GO:0044177; C:host cell Golgi apparatus; ISS:UniProtKB.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; ISS:UniProtKB.
DR   GO; GO:0043655; C:host extracellular space; IEA:UniProtKB-SubCell.
DR   GO; GO:0043232; C:intracellular non-membrane-bounded organelle; IDA:DisProt.
DR   GO; GO:0042612; C:MHC class I protein complex; EXP:DisProt.
DR   GO; GO:1990904; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IPI:ComplexPortal.
DR   GO; GO:0019013; C:viral nucleocapsid; ISS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0042288; F:MHC class I protein binding; EXP:DisProt.
DR   GO; GO:0140693; F:molecular condensate scaffold activity; IDA:DisProt.
DR   GO; GO:0008266; F:poly(U) RNA binding; IMP:DisProt.
DR   GO; GO:0042803; F:protein homodimerization activity; EXP:DisProt.
DR   GO; GO:0140311; F:protein sequestering activity; IDA:UniProt.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProt.
DR   GO; GO:0035613; F:RNA stem-loop binding; IDA:DisProt.
DR   GO; GO:0039709; P:cytoplasmic capsid assembly; IDA:UniProt.
DR   GO; GO:0032688; P:negative regulation of interferon-beta production; IDA:ComplexPortal.
DR   GO; GO:1900227; P:positive regulation of NLRP3 inflammasome complex assembly; IDA:UniProtKB.
DR   GO; GO:0052572; P:response to host immune response; IDA:DisProt.
DR   GO; GO:0019074; P:viral RNA genome packaging; NAS:ComplexPortal.
DR   CDD; cd21595; CoV_N-CTD; 1.
DR   CDD; cd21554; CoV_N-NTD; 1.
DR   HAMAP; MF_04096; BETA_CORONA_NCAP; 1.
DR   InterPro; IPR044344; N_prot_C_CoV.
DR   InterPro; IPR044345; N_prot_N_CoV.
DR   InterPro; IPR043505; NCAP_bCoV.
DR   InterPro; IPR001218; Nucleocap_CoV.
DR   InterPro; IPR037179; Nucleocapsid_C.
DR   InterPro; IPR037195; Nucleocapsid_N.
DR   Pfam; PF00937; CoV_nucleocap; 1.
DR   PIRSF; PIRSF003888; Corona_nucleocap; 1.
DR   SUPFAM; SSF110304; Coronavirus RNA-binding domain; 1.
DR   SUPFAM; SSF103068; Nucleocapsid protein dimerization domain; 1.
DR   PROSITE; PS51929; COV_N_CTD; 1.
DR   PROSITE; PS51928; COV_N_NTD; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ADP-ribosylation; Host cytoplasm; Phosphoprotein;
KW   Reference proteome; Ribonucleoprotein; RNA-binding; Secreted;
KW   Transcription; Transcription regulation; Viral nucleoprotein; Virion.
FT   CHAIN           1..419
FT                   /note=""Nucleoprotein""
FT                   /id=""PRO_0000449656""
FT   DOMAIN          48..174
FT                   /note=""CoV N NTD""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01276,
FT                   ECO:0000269|PubMed:32363136""
FT   DOMAIN          247..364
FT                   /note=""CoV N CTD""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01277""
FT   REGION          1..51
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          41..186
FT                   /note=""RNA-binding""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   REGION          63..83
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          168..212
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          176..206
FT                   /note=""SR region""
FT                   /evidence=""ECO:0000305|PubMed:32974389""
FT   REGION          233..266
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          258..361
FT                   /note=""Dimerization""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   REGION          260..340
FT                   /note=""Putative NLRP3 binding""
FT                   /evidence=""ECO:0000269|PubMed:34341353""
FT   REGION          361..391
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          400..419
FT                   /note=""Tetramerization""
FT                   /evidence=""ECO:0000269|PubMed:32654247""
FT   MOTIF           256..264
FT                   /note=""Nuclear localization signal""
FT                   /evidence=""ECO:0000250|UniProtKB:P59595""
FT   COMPBIAS        1..11
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        21..31
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        367..378
FT                   /note=""Basic and acidic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   BINDING         92
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   BINDING         107
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   BINDING         149
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   SITE            399..402
FT                   /note=""Cleavage (by host CASP6)""
FT                   /evidence=""ECO:0000250|UniProtKB:P59595""
FT   MOD_RES         176
FT                   /note=""Phosphoserine; by host""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   MOD_RES         206
FT                   /note=""Phosphoserine; by host GSK3-alpha and GSK3-beta""
FT                   /evidence=""ECO:0000269|PubMed:34593624""
FT   VARIANT         2..3
FT                   /note=""SD -> Y (in strain: Eta/B.1.525)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         3
FT                   /note=""D -> L (in strain: Alpha/B.1.1.7)""
FT                   /evidence=""ECO:0000305|PubMed:33413740""
FT   VARIANT         12
FT                   /note=""A -> G (in strain: Eta/B.1.525)""
FT   VARIANT         13
FT                   /note=""P -> L (in strain: Lambda/C.37, Omicron/BA.1,
FT                   Omicron/BA.2, Omicron/BA.2.12.1, Omicron/BA.2.75,
FT                   Omicron/BA.4, Omicron/BA.5, Omicron/BQ.1.1,
FT                   Omicron/XBB.1.5, Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         31..33
FT                   /note=""Missing (in strain: Omicron/BA.1, Omicron/BA.2,
FT                   Omicron/BA.2.12.1, Omicron/BA.2.75, Omicron/BA.4,
FT                   Omicron/BA.5, Omicron/BQ.1.1, Omicron/XBB.1.5,
FT                   Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         63
FT                   /note=""D -> G (in strain: Delta/B.1.617.2)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT  ",45206
ACTACA CTACAA TACAAT ACAATT CAATTT AATTTC ATTTCA TTTCAC TTCACT TCACTG CACTGG ACTGGA CTGGAT TGGATC GGATCC GATCCC ATCCCT TCCCTG CCCTGG CCTGGT CTGGTT TGGTTG GGTTGA GTTGAG TTGAGA TGAGAC GAGACA AGACAG GACAGC ACAGCT CAGCTC AGCTCC GCTCCC CTCCCA TCCCAT CCCATC CCATCT CATCTC ATCTCG TCTCGT CTCGTT TCGTTA CGTTAC GTTACG TTACGC TACGCC ACGCCA CGCCAT GCCATT CCATTC CATTCA ATTCAT TTCATG TCATGC CATGCA ATGCAG TGCAGG GCAGGT CAGGTC AGGTCG GGTCGG GTCGGT TCGGTA CGGTAT GGTATT GTATTT TATTTA ATTTAA TTTAAC TTAACC TAACCG AACCGA ACCGAC CCGACA CGACAA GACAAG ACAAGG CAAGGA AAGGAA AGGAAT GGAATT GAATTT AATTTC ATTTCG TTTCGC TTCGCT TCGCTA CGCTAC GCTACC CTACCT TACCTT ACCTTA CCTTAG CTTAGG TTAGGA TAGGAC AGGACC GGACCG GACCGT ACCGTT CCGTTA CGTTAT GTTATT TTATTG TATTGT ATTGTT TTGTTA TGTTAC GTTACG TTACGG TACGGC ACGGCC CGGCCG GGCCGC GCCGCC CCGCCG CGCCGT GCCGTT CCGTTT CGTTTA GTTTAC TTTACT TTACTC TACTCG ACTCGG CTCGGG TCGGGC CGGGCT GGGCTT GGCTTC GCTTCA CTTCAA TTCAAT TCAATC CAATCA AATCAA ATCAAA TCAAAT CAAATG AAATGC AATGCT ATGCTT,3,142,ACTA CTAC TACA ACAA CAAT AATT ATTT TTTC TTCA TCAC CACT ACTG CTGG TGGA GGAT GATC ATCC TCCC CCCT CCTG CTGG TGGT GGTT GTTG TTGA TGAG GAGA AGAC GACA ACAG CAGC AGCT GCTC CTCC TCCC CCCA CCAT CATC ATCT TCTC CTCG TCGT CGTT GTTA TTAC TACG ACGC CGCC GCCA CCAT CATT ATTC TTCA TCAT CATG ATGC TGCA GCAG CAGG AGGT GGTC GTCG TCGG CGGT GGTA GTAT TATT ATTT TTTA TTAA TAAC AACC ACCG CCGA CGAC GACA ACAA CAAG AAGG AGGA GGAA GAAT AATT ATTT TTTC TTCG TCGC CGCT GCTA CTAC TACC ACCT CCTT CTTA TTAG TAGG AGGA GGAC GACC ACCG CCGT CGTT GTTA TTAT TATT ATTG TTGT TGTT GTTA TTAC TACG ACGG CGGC GGCC GCCG CCGC CGCC GCCG CCGT CGTT GTTT TTTA TTAC TACT ACTC CTCG TCGG CGGG GGGC GGCT GCTT CTTC TTCA TCAA CAAT AATC ATCA TCAA CAAA AAAT AATG ATGC TGCT GCTT,ACTAC CTACA TACAA ACAAT CAATT AATTT ATTTC TTTCA TTCAC TCACT CACTG ACTGG CTGGA TGGAT GGATC GATCC ATCCC TCCCT CCCTG CCTGG CTGGT TGGTT GGTTG GTTGA TTGAG TGAGA GAGAC AGACA GACAG ACAGC CAGCT AGCTC GCTCC CTCCC TCCCA CCCAT CCATC CATCT ATCTC TCTCG CTCGT TCGTT CGTTA GTTAC TTACG TACGC ACGCC CGCCA GCCAT CCATT CATTC ATTCA TTCAT TCATG CATGC ATGCA TGCAG GCAGG CAGGT AGGTC GGTCG GTCGG TCGGT CGGTA GGTAT GTATT TATTT ATTTA TTTAA TTAAC TAACC AACCG ACCGA CCGAC CGACA GACAA ACAAG CAAGG AAGGA AGGAA GGAAT GAATT AATTT ATTTC TTTCG TTCGC TCGCT CGCTA GCTAC CTACC TACCT ACCTT CCTTA CTTAG TTAGG TAGGA AGGAC GGACC GACCG ACCGT CCGTT CGTTA GTTAT TTATT TATTG ATTGT TTGTT TGTTA GTTAC TTACG TACGG ACGGC CGGCC GGCCG GCCGC CCGCC CGCCG GCCGT CCGTT CGTTT GTTTA TTTAC TTACT TACTC ACTCG CTCGG TCGGG CGGGC GGGCT GGCTT GCTTC CTTCA TTCAA TCAAT CAATC AATCA ATCAA TCAAA CAAAT AAATG AATGC ATGCT TGCTT,ACTACA CTACAA TACAAT ACAATT CAATTT AATTTC ATTTCA TTTCAC TTCACT TCACTG CACTGG ACTGGA CTGGAT TGGATC GGATCC GATCCC ATCCCT TCCCTG CCCTGG CCTGGT CTGGTT TGGTTG GGTTGA GTTGAG TTGAGA TGAGAC GAGACA AGACAG GACAGC ACAGCT CAGCTC AGCTCC GCTCCC CTCCCA TCCCAT CCCATC CCATCT CATCTC ATCTCG TCTCGT CTCGTT TCGTTA CGTTAC GTTACG TTACGC TACGCC ACGCCA CGCCAT GCCATT CCATTC CATTCA ATTCAT TTCATG TCATGC CATGCA ATGCAG TGCAGG GCAGGT CAGGTC AGGTCG GGTCGG GTCGGT TCGGTA CGGTAT GGTATT GTATTT TATTTA ATTTAA TTTAAC TTAACC TAACCG AACCGA ACCGAC CCGACA CGACAA GACAAG ACAAGG CAAGGA AAGGAA AGGAAT GGAATT GAATTT AATTTC ATTTCG TTTCGC TTCGCT TCGCTA CGCTAC GCTACC CTACCT TACCTT ACCTTA CCTTAG CTTAGG TTAGGA TAGGAC AGGACC GGACCG GACCGT ACCGTT CCGTTA CGTTAT GTTATT TTATTG TATTGT ATTGTT TTGTTA TGTTAC GTTACG TTACGG TACGGC ACGGCC CGGCCG GGCCGC GCCGCC CCGCCG CGCCGT GCCGTT CCGTTT CGTTTA GTTTAC TTTACT TTACTC TACTCG ACTCGG CTCGGG TCGGGC CGGGCT GGGCTT GGCTTC GCTTCA CTTCAA TTCAAT TCAATC CAATCA AATCAA ATCAAA TCAAAT CAAATG AAATGC AATGCT ATGCTT,ACTACAA CTACAAT TACAATT ACAATTT CAATTTC AATTTCA ATTTCAC TTTCACT TTCACTG TCACTGG CACTGGA ACTGGAT CTGGATC TGGATCC GGATCCC GATCCCT ATCCCTG TCCCTGG CCCTGGT CCTGGTT CTGGTTG TGGTTGA GGTTGAG GTTGAGA TTGAGAC TGAGACA GAGACAG AGACAGC GACAGCT ACAGCTC CAGCTCC AGCTCCC GCTCCCA CTCCCAT TCCCATC CCCATCT CCATCTC CATCTCG ATCTCGT TCTCGTT CTCGTTA TCGTTAC CGTTACG GTTACGC TTACGCC TACGCCA ACGCCAT CGCCATT GCCATTC CCATTCA CATTCAT ATTCATG TTCATGC TCATGCA CATGCAG ATGCAGG TGCAGGT GCAGGTC CAGGTCG AGGTCGG GGTCGGT GTCGGTA TCGGTAT CGGTATT GGTATTT GTATTTA TATTTAA ATTTAAC TTTAACC TTAACCG TAACCGA AACCGAC ACCGACA CCGACAA CGACAAG GACAAGG ACAAGGA CAAGGAA AAGGAAT AGGAATT GGAATTT GAATTTC AATTTCG ATTTCGC TTTCGCT TTCGCTA TCGCTAC CGCTACC GCTACCT CTACCTT TACCTTA ACCTTAG CCTTAGG CTTAGGA TTAGGAC TAGGACC AGGACCG GGACCGT GACCGTT ACCGTTA CCGTTAT CGTTATT GTTATTG TTATTGT TATTGTT ATTGTTA TTGTTAC TGTTACG GTTACGG TTACGGC TACGGCC ACGGCCG CGGCCGC GGCCGCC GCCGCCG CCGCCGT CGCCGTT GCCGTTT CCGTTTA CGTTTAC GTTTACT TTTACTC TTACTCG TACTCGG ACTCGGG CTCGGGC TCGGGCT CGGGCTT GGGCTTC GGCTTCA GCTTCAA CTTCAAT TTCAATC TCAATCA CAATCAA AATCAAA ATCAAAT TCAAATG CAAATGC AAATGCT AATGCTT,"ID   YCX91_PHAAO             Reviewed;          91 AA.
AC   Q3BAI2;
DT   25-JUL-2006, integrated into UniProtKB/Swiss-Prot.
DT   22-NOV-2005, sequence version 1.
DT   05-FEB-2025, entry version 27.
DE   RecName: Full=Uncharacterized protein ORF91;
OS   Phalaenopsis aphrodite subsp. formosana (Moth orchid).
OG   Plastid; Chloroplast.
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliopsida; Liliopsida; Asparagales; Orchidaceae;
OC   Epidendroideae; Vandeae; Aeridinae; Phalaenopsis.
OX   NCBI_TaxID=308872;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=cv. Taisugar TS-97;
RX   PubMed=16207935; DOI=10.1093/molbev/msj029;
RA   Chang C.-C., Lin H.-C., Lin I.-P., Chow T.-Y., Chen H.-H., Chen W.-H.,
RA   Cheng C.-H., Lin C.-Y., Liu S.-M., Chang C.-C., Chaw S.-M.;
RT   ""The chloroplast genome of Phalaenopsis aphrodite (Orchidaceae):
RT   comparative analysis of evolutionary rate with that of grasses and its
RT   phylogenetic implications."";
RL   Mol. Biol. Evol. 23:279-291(2006).
CC   -!- SUBCELLULAR LOCATION: Plastid, chloroplast.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY916449; AAW82572.1; -; Genomic_DNA.
DR   RefSeq; YP_358636.1; NC_007499.1.
DR   AlphaFoldDB; Q3BAI2; -.
DR   GeneID; 3741793; -.
DR   GO; GO:0009507; C:chloroplast; IEA:UniProtKB-SubCell.
DR   AntiFam; ANF00025; Antisense to 23S rRNA.
PE   4: Predicted;
KW   Chloroplast; Plastid.
FT   CHAIN           1..91
FT                   /note=""Uncharacterized protein ORF91""
FT                   /id=""PRO_0000246135""
SQ   SEQUENCE   91 AA;  10596 MW;  C770491A1FF96EE8 CRC64;
     MQVVRIFTDM SISPSLSPRQ CPDRYAFRAG RNLPDKEFRY LRTVLVTAAV HRGFGRRLPC
     HQVTNFLDLP ALGRRQPPYM VLRLCGDLCF W
//
",54523
TTGGAT TGGATC GGATCG GATCGT ATCGTA TCGTAT CGTATT GTATTT TATTTG ATTTGT TTTGTA TTGTAC TGTACG GTACGC TACGCA ACGCAC CGCACA GCACAT CACATT ACATTT CATTTT ATTTTA TTTTAG TTTAGC TTAGCT TAGCTT AGCTTT GCTTTC CTTTCG TTTCGA TTCGAA TCGAAG CGAAGG GAAGGC AAGGCG AGGCGA GGCGAT GCGATT CGATTC GATTCA ATTCAG TTCAGA TCAGAA CAGAAG AGAAGT GAAGTG AAGTGT AGTGTA GTGTAT TGTATT GTATTT TATTTT ATTTTT TTTTTT TTTTTC TTTTCG TTTCGA TTCGAA TCGAAG CGAAGG GAAGGA AAGGAA AGGAAG GGAAGT GAAGTT AAGTTT AGTTTC GTTTCT TTTCTC TTCTCT TCTCTG CTCTGA TCTGAT CTGATT TGATTA GATTAT ATTATG TTATGA TATGAA ATGAAG TGAAGA GAAGAA AAGAAA AGAAAA GAAAAC AAAACA AAACAA AACAAA ACAAAA CAAAAA AAAAAG AAAAGA AAAGAA AAGAAA AGAAAC GAAACG AAACGT AACGTT ACGTTT CGTTTA GTTTAG TTTAGG TTAGGT TAGGTG AGGTGG GGTGGC GTGGCG TGGCGA GGCGAT GCGATT CGATTT GATTTG ATTTGA TTTGAC TTGACT TGACTC GACTCC ACTCCA CTCCAA TCCAAA CCAAAA CAAAAC AAAACG AAACGT AACGTT ACGTTT CGTTTG GTTTGA TTTGAA TTGAAA TGAAAT GAAATA AAATAC AATACA ATACAG TACAGA ACAGAA CAGAAA AGAAAA GAAAAT AAAATT AAATTG AATTGA ATTGAT TTGATT,2,145,TTGG TGGA GGAT GATC ATCG TCGT CGTA GTAT TATT ATTT TTTG TTGT TGTA GTAC TACG ACGC CGCA GCAC CACA ACAT CATT ATTT TTTT TTTA TTAG TAGC AGCT GCTT CTTT TTTC TTCG TCGA CGAA GAAG AAGG AGGC GGCG GCGA CGAT GATT ATTC TTCA TCAG CAGA AGAA GAAG AAGT AGTG GTGT TGTA GTAT TATT ATTT TTTT TTTT TTTT TTTC TTCG TCGA CGAA GAAG AAGG AGGA GGAA GAAG AAGT AGTT GTTT TTTC TTCT TCTC CTCT TCTG CTGA TGAT GATT ATTA TTAT TATG ATGA TGAA GAAG AAGA AGAA GAAA AAAA AAAC AACA ACAA CAAA AAAA AAAA AAAG AAGA AGAA GAAA AAAC AACG ACGT CGTT GTTT TTTA TTAG TAGG AGGT GGTG GTGG TGGC GGCG GCGA CGAT GATT ATTT TTTG TTGA TGAC GACT ACTC CTCC TCCA CCAA CAAA AAAA AAAC AACG ACGT CGTT GTTT TTTG TTGA TGAA GAAA AAAT AATA ATAC TACA ACAG CAGA AGAA GAAA AAAA AAAT AATT ATTG TTGA TGAT GATT,TTGGA TGGAT GGATC GATCG ATCGT TCGTA CGTAT GTATT TATTT ATTTG TTTGT TTGTA TGTAC GTACG TACGC ACGCA CGCAC GCACA CACAT ACATT CATTT ATTTT TTTTA TTTAG TTAGC TAGCT AGCTT GCTTT CTTTC TTTCG TTCGA TCGAA CGAAG GAAGG AAGGC AGGCG GGCGA GCGAT CGATT GATTC ATTCA TTCAG TCAGA CAGAA AGAAG GAAGT AAGTG AGTGT GTGTA TGTAT GTATT TATTT ATTTT TTTTT TTTTT TTTTC TTTCG TTCGA TCGAA CGAAG GAAGG AAGGA AGGAA GGAAG GAAGT AAGTT AGTTT GTTTC TTTCT TTCTC TCTCT CTCTG TCTGA CTGAT TGATT GATTA ATTAT TTATG TATGA ATGAA TGAAG GAAGA AAGAA AGAAA GAAAA AAAAC AAACA AACAA ACAAA CAAAA AAAAA AAAAG AAAGA AAGAA AGAAA GAAAC AAACG AACGT ACGTT CGTTT GTTTA TTTAG TTAGG TAGGT AGGTG GGTGG GTGGC TGGCG GGCGA GCGAT CGATT GATTT ATTTG TTTGA TTGAC TGACT GACTC ACTCC CTCCA TCCAA CCAAA CAAAA AAAAC AAACG AACGT ACGTT CGTTT GTTTG TTTGA TTGAA TGAAA GAAAT AAATA AATAC ATACA TACAG ACAGA CAGAA AGAAA GAAAA AAAAT AAATT AATTG ATTGA TTGAT TGATT,TTGGAT TGGATC GGATCG GATCGT ATCGTA TCGTAT CGTATT GTATTT TATTTG ATTTGT TTTGTA TTGTAC TGTACG GTACGC TACGCA ACGCAC CGCACA GCACAT CACATT ACATTT CATTTT ATTTTA TTTTAG TTTAGC TTAGCT TAGCTT AGCTTT GCTTTC CTTTCG TTTCGA TTCGAA TCGAAG CGAAGG GAAGGC AAGGCG AGGCGA GGCGAT GCGATT CGATTC GATTCA ATTCAG TTCAGA TCAGAA CAGAAG AGAAGT GAAGTG AAGTGT AGTGTA GTGTAT TGTATT GTATTT TATTTT ATTTTT TTTTTT TTTTTC TTTTCG TTTCGA TTCGAA TCGAAG CGAAGG GAAGGA AAGGAA AGGAAG GGAAGT GAAGTT AAGTTT AGTTTC GTTTCT TTTCTC TTCTCT TCTCTG CTCTGA TCTGAT CTGATT TGATTA GATTAT ATTATG TTATGA TATGAA ATGAAG TGAAGA GAAGAA AAGAAA AGAAAA GAAAAC AAAACA AAACAA AACAAA ACAAAA CAAAAA AAAAAG AAAAGA AAAGAA AAGAAA AGAAAC GAAACG AAACGT AACGTT ACGTTT CGTTTA GTTTAG TTTAGG TTAGGT TAGGTG AGGTGG GGTGGC GTGGCG TGGCGA GGCGAT GCGATT CGATTT GATTTG ATTTGA TTTGAC TTGACT TGACTC GACTCC ACTCCA CTCCAA TCCAAA CCAAAA CAAAAC AAAACG AAACGT AACGTT ACGTTT CGTTTG GTTTGA TTTGAA TTGAAA TGAAAT GAAATA AAATAC AATACA ATACAG TACAGA ACAGAA CAGAAA AGAAAA GAAAAT AAAATT AAATTG AATTGA ATTGAT TTGATT,TTGGATC TGGATCG GGATCGT GATCGTA ATCGTAT TCGTATT CGTATTT GTATTTG TATTTGT ATTTGTA TTTGTAC TTGTACG TGTACGC GTACGCA TACGCAC ACGCACA CGCACAT GCACATT CACATTT ACATTTT CATTTTA ATTTTAG TTTTAGC TTTAGCT TTAGCTT TAGCTTT AGCTTTC GCTTTCG CTTTCGA TTTCGAA TTCGAAG TCGAAGG CGAAGGC GAAGGCG AAGGCGA AGGCGAT GGCGATT GCGATTC CGATTCA GATTCAG ATTCAGA TTCAGAA TCAGAAG CAGAAGT AGAAGTG GAAGTGT AAGTGTA AGTGTAT GTGTATT TGTATTT GTATTTT TATTTTT ATTTTTT TTTTTTC TTTTTCG TTTTCGA TTTCGAA TTCGAAG TCGAAGG CGAAGGA GAAGGAA AAGGAAG AGGAAGT GGAAGTT GAAGTTT AAGTTTC AGTTTCT GTTTCTC TTTCTCT TTCTCTG TCTCTGA CTCTGAT TCTGATT CTGATTA TGATTAT GATTATG ATTATGA TTATGAA TATGAAG ATGAAGA TGAAGAA GAAGAAA AAGAAAA AGAAAAC GAAAACA AAAACAA AAACAAA AACAAAA ACAAAAA CAAAAAG AAAAAGA AAAAGAA AAAGAAA AAGAAAC AGAAACG GAAACGT AAACGTT AACGTTT ACGTTTA CGTTTAG GTTTAGG TTTAGGT TTAGGTG TAGGTGG AGGTGGC GGTGGCG GTGGCGA TGGCGAT GGCGATT GCGATTT CGATTTG GATTTGA ATTTGAC TTTGACT TTGACTC TGACTCC GACTCCA ACTCCAA CTCCAAA TCCAAAA CCAAAAC CAAAACG AAAACGT AAACGTT AACGTTT ACGTTTG CGTTTGA GTTTGAA TTTGAAA TTGAAAT TGAAATA GAAATAC AAATACA AATACAG ATACAGA TACAGAA ACAGAAA CAGAAAA AGAAAAT GAAAATT AAAATTG AAATTGA AATTGAT ATTGATT,"ID   ETTA_MYCTO              Reviewed;         558 AA.
AC   P9WQK2; L0T9X4; O53204; Q7D727;
DT   16-APR-2014, integrated into UniProtKB/Swiss-Prot.
DT   16-APR-2014, sequence version 1.
DT   05-FEB-2025, entry version 49.
DE   RecName: Full=Energy-dependent translational throttle protein EttA {ECO:0000255|HAMAP-Rule:MF_00847};
DE            EC=3.6.1.- {ECO:0000255|HAMAP-Rule:MF_00847};
DE   AltName: Full=Translational regulatory factor EttA {ECO:0000255|HAMAP-Rule:MF_00847};
GN   Name=ettA {ECO:0000255|HAMAP-Rule:MF_00847}; OrderedLocusNames=MT2552;
OS   Mycobacterium tuberculosis (strain CDC 1551 / Oshkosh).
OC   Bacteria; Bacillati; Actinomycetota; Actinomycetes; Mycobacteriales;
OC   Mycobacteriaceae; Mycobacterium; Mycobacterium tuberculosis complex.
OX   NCBI_TaxID=83331;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=CDC 1551 / Oshkosh;
RX   PubMed=12218036; DOI=10.1128/jb.184.19.5479-5490.2002;
RA   Fleischmann R.D., Alland D., Eisen J.A., Carpenter L., White O.,
RA   Peterson J.D., DeBoy R.T., Dodson R.J., Gwinn M.L., Haft D.H., Hickey E.K.,
RA   Kolonay J.F., Nelson W.C., Umayam L.A., Ermolaeva M.D., Salzberg S.L.,
RA   Delcher A., Utterback T.R., Weidman J.F., Khouri H.M., Gill J., Mikula A.,
RA   Bishai W., Jacobs W.R. Jr., Venter J.C., Fraser C.M.;
RT   ""Whole-genome comparison of Mycobacterium tuberculosis clinical and
RT   laboratory strains."";
RL   J. Bacteriol. 184:5479-5490(2002).
CC   -!- FUNCTION: A translation factor that gates the progression of the 70S
CC       ribosomal initiation complex (IC, containing tRNA(fMet) in the P-site)
CC       into the translation elongation cycle by using a mechanism sensitive to
CC       the ATP/ADP ratio. Binds to the 70S ribosome E-site where it modulates
CC       the state of the translating ribosome during subunit translocation. ATP
CC       hydrolysis probably frees it from the ribosome, which can enter the
CC       elongation phase. {ECO:0000255|HAMAP-Rule:MF_00847}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + H2O = ADP + phosphate + H(+); Xref=Rhea:RHEA:13065,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; Evidence={ECO:0000255|HAMAP-
CC         Rule:MF_00847};
CC   -!- SUBUNIT: Monomer. Probably contacts ribosomal proteins L1, L5, L33 and
CC       S7, the 16S and 23S rRNA and the P-site containing tRNA(fMet).
CC       {ECO:0000255|HAMAP-Rule:MF_00847}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000255|HAMAP-Rule:MF_00847}.
CC       Note=Associates with ribosomes and polysomes. {ECO:0000255|HAMAP-
CC       Rule:MF_00847}.
CC   -!- DOMAIN: The arm domain is inserted in the first ABC transporter domain.
CC       Probably contacts ribosomal protein L1. {ECO:0000255|HAMAP-
CC       Rule:MF_00847}.
CC   -!- DOMAIN: The P-site tRNA interaction motif (PtIM domain) probably
CC       interacts with the P-site tRNA(fMet) as well as the 23S rRNA.
CC       {ECO:0000255|HAMAP-Rule:MF_00847}.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCF family.
CC       Translational throttle EttA subfamily. {ECO:0000255|HAMAP-
CC       Rule:MF_00847, ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AE000516; AAK46854.1; -; Genomic_DNA.
DR   PIR; D70867; D70867.
DR   RefSeq; WP_003412708.1; NZ_KK341227.1.
DR   AlphaFoldDB; P9WQK2; -.
DR   SMR; P9WQK2; -.
DR   GeneID; 45426470; -.
DR   KEGG; mtc:MT2552; -.
DR   PATRIC; fig|83331.31.peg.2754; -.
DR   HOGENOM; CLU_000604_36_0_11; -.
DR   Proteomes; UP000001020; Chromosome.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IEA:UniProtKB-UniRule.
DR   GO; GO:0140849; F:ATP-dependent H2AZ histone chaperone activity; IEA:RHEA.
DR   GO; GO:0140665; F:ATP-dependent H3-H4 histone complex chaperone activity; IEA:RHEA.
DR   GO; GO:0140584; F:chromatin extrusion motor activity; IEA:RHEA.
DR   GO; GO:0061775; F:cohesin loader activity; IEA:RHEA.
DR   GO; GO:0003689; F:DNA clamp loader activity; IEA:RHEA.
DR   GO; GO:0043022; F:ribosome binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0019843; F:rRNA binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0000049; F:tRNA binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0045900; P:negative regulation of translational elongation; IEA:UniProtKB-UniRule.
DR   GO; GO:0006412; P:translation; IEA:UniProtKB-KW.
DR   CDD; cd03221; ABCF_EF-3; 2.
DR   FunFam; 3.40.50.300:FF:000183; ABC transporter ATP-binding protein yjjK; 1.
DR   FunFam; 3.40.50.300:FF:000011; Putative ABC transporter ATP-binding component; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 2.
DR   HAMAP; MF_00847; EttA; 1.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR032781; ABC_tran_Xtn.
DR   InterPro; IPR003439; ABC_transporter-like_ATP-bd.
DR   InterPro; IPR017871; ABC_transporter-like_CS.
DR   InterPro; IPR022374; EttA.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   NCBIfam; TIGR03719; ABC_ABC_ChvD; 1.
DR   PANTHER; PTHR43858:SF1; ABC TRANSPORTER-RELATED PROTEIN; 1.
DR   PANTHER; PTHR43858; ENERGY-DEPENDENT TRANSLATIONAL THROTTLE PROTEIN ETTA; 1.
DR   Pfam; PF00005; ABC_tran; 2.
DR   Pfam; PF12848; ABC_tran_Xtn; 1.
DR   SMART; SM00382; AAA; 2.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 2.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 2.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 2.
PE   3: Inferred from homology;
KW   ATP-binding; Cytoplasm; Hydrolase; Nucleotide-binding;
KW   Protein biosynthesis; Reference proteome; Repeat; RNA-binding;
KW   rRNA-binding; Translation regulation; tRNA-binding.
FT   CHAIN           1..558
FT                   /note=""Energy-dependent translational throttle protein
FT                   EttA""
FT                   /id=""PRO_0000426761""
FT   DOMAIN          6..256
FT                   /note=""ABC transporter 1""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00847""
FT   DOMAIN          322..552
FT                   /note=""ABC transporter 2""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00847""
FT   REGION          94..136
FT                   /note=""Arm""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00847""
FT   REGION          239..320
FT                   /note=""PtIM""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00847""
FT   BINDING         38..45
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00847""
FT   BINDING         354..361
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /ligand_label=""2""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00847""
SQ   SEQUENCE   558 AA;  61893 MW;  1B2E6E600C4FDD8A CRC64;
     MAEFIYTMKK VRKAHGDKVI LDDVTLSFYP GAKIGVVGPN GAGKSSVLRI MAGLDKPNNG
     DAFLATGATV GILQQEPPLN EDKTVRGNVE EGMGDIKIKL DRFNEVAELM ATDYTDELME
     EMGRLQEELD HADAWDLDAQ LEQAMDALRC PPADEPVTNL SGGERRRVAL CKLLLSKPDL
     LLLDEPTNHL DAESVQWLEQ HLASYPGAIL AVTHDRYFLD NVAEWILELD RGRAYPYEGN
     YSTYLEKKAE RLAVQGRKDA KLQKRLTEEL AWVRSGAKAR QAKSKARLQR YEEMAAEAEK
     TRKLDFEEIQ IPVGPRLGNV VVEVDHLDKG YDGRALIKDL SFSLPRNGIV GVIGPNGVGK
     TTLFKTIVGL ETPDSGSVKV GETVKLSYVD QARAGIDPRK TVWEVVSDGL DYIQVGQTEV
     PSRAYVSAFG FKGPDQQKPA GVLSGGERNR LNLALTLKQG GNLILLDEPT NDLDVETLGS
     LENALLNFPG CAVVISHDRW FLDRTCTHIL AWEGDDDNEA KWFWFEGNFG AYEENKVERL
     GVDAARPHRV THRKLTRG
//
",23395
GCCCTC CCCTCC CCTCCC CTCCCT TCCCTA CCCTAT CCTATT CTATTC TATTCT ATTCTT TTCTTC TCTTCC CTTCCT TTCCTT TCCTTT CCTTTA CTTTAA TTTAAG TTAAGA TAAGAA AAGAAA AGAAAT GAAATA AAATAC AATACC ATACCG TACCGT ACCGTA CCGTAT CGTATT GTATTG TATTGC ATTGCT TTGCTT TGCTTC GCTTCC CTTCCC TTCCCG TCCCGG CCCGGA CCGGAG CGGAGT GGAGTA GAGTAG AGTAGT GTAGTG TAGTGC AGTGCT GTGCTG TGCTGC GCTGCC CTGCCG TGCCGA GCCGAT CCGATT CGATTA GATTAC ATTACG TTACGG TACGGT ACGGTA CGGTAG GGTAGG GTAGGA TAGGAA AGGAAG GGAAGG GAAGGG AAGGGA AGGGAT GGGATA GGATAA GATAAA ATAAAA TAAAAG AAAAGC AAAGCA AAGCAT AGCATC GCATCA CATCAA ATCAAG TCAAGG CAAGGC AAGGCG AGGCGG GGCGGT GCGGTG CGGTGA GGTGAA GTGAAC TGAACG GAACGA AACGAC ACGACG CGACGC GACGCT ACGCTT CGCTTA GCTTAT CTTATA TTATAA TATAAA ATAAAA TAAAAA AAAAAC AAAACG AAACGA AACGAT ACGATA CGATAA GATAAA ATAAAC TAAACT AAACTG AACTGG ACTGGT CTGGTA TGGTAG GGTAGG GTAGGG TAGGGG AGGGGT GGGGTG GGGTGC GGTGCT GTGCTG TGCTGG GCTGGC CTGGCC TGGCCC GGCCCA GCCCAG CCCAGA CCAGAA CAGAAA AGAAAG GAAAGA AAAGAT AAGATG AGATGT GATGTG,3,142,GCCC CCCT CCTC CTCC TCCC CCCT CCTA CTAT TATT ATTC TTCT TCTT CTTC TTCC TCCT CCTT CTTT TTTA TTAA TAAG AAGA AGAA GAAA AAAT AATA ATAC TACC ACCG CCGT CGTA GTAT TATT ATTG TTGC TGCT GCTT CTTC TTCC TCCC CCCG CCGG CGGA GGAG GAGT AGTA GTAG TAGT AGTG GTGC TGCT GCTG CTGC TGCC GCCG CCGA CGAT GATT ATTA TTAC TACG ACGG CGGT GGTA GTAG TAGG AGGA GGAA GAAG AAGG AGGG GGGA GGAT GATA ATAA TAAA AAAA AAAG AAGC AGCA GCAT CATC ATCA TCAA CAAG AAGG AGGC GGCG GCGG CGGT GGTG GTGA TGAA GAAC AACG ACGA CGAC GACG ACGC CGCT GCTT CTTA TTAT TATA ATAA TAAA AAAA AAAA AAAC AACG ACGA CGAT GATA ATAA TAAA AAAC AACT ACTG CTGG TGGT GGTA GTAG TAGG AGGG GGGG GGGT GGTG GTGC TGCT GCTG CTGG TGGC GGCC GCCC CCCA CCAG CAGA AGAA GAAA AAAG AAGA AGAT GATG ATGT TGTG,GCCCT CCCTC CCTCC CTCCC TCCCT CCCTA CCTAT CTATT TATTC ATTCT TTCTT TCTTC CTTCC TTCCT TCCTT CCTTT CTTTA TTTAA TTAAG TAAGA AAGAA AGAAA GAAAT AAATA AATAC ATACC TACCG ACCGT CCGTA CGTAT GTATT TATTG ATTGC TTGCT TGCTT GCTTC CTTCC TTCCC TCCCG CCCGG CCGGA CGGAG GGAGT GAGTA AGTAG GTAGT TAGTG AGTGC GTGCT TGCTG GCTGC CTGCC TGCCG GCCGA CCGAT CGATT GATTA ATTAC TTACG TACGG ACGGT CGGTA GGTAG GTAGG TAGGA AGGAA GGAAG GAAGG AAGGG AGGGA GGGAT GGATA GATAA ATAAA TAAAA AAAAG AAAGC AAGCA AGCAT GCATC CATCA ATCAA TCAAG CAAGG AAGGC AGGCG GGCGG GCGGT CGGTG GGTGA GTGAA TGAAC GAACG AACGA ACGAC CGACG GACGC ACGCT CGCTT GCTTA CTTAT TTATA TATAA ATAAA TAAAA AAAAA AAAAC AAACG AACGA ACGAT CGATA GATAA ATAAA TAAAC AAACT AACTG ACTGG CTGGT TGGTA GGTAG GTAGG TAGGG AGGGG GGGGT GGGTG GGTGC GTGCT TGCTG GCTGG CTGGC TGGCC GGCCC GCCCA CCCAG CCAGA CAGAA AGAAA GAAAG AAAGA AAGAT AGATG GATGT ATGTG,GCCCTC CCCTCC CCTCCC CTCCCT TCCCTA CCCTAT CCTATT CTATTC TATTCT ATTCTT TTCTTC TCTTCC CTTCCT TTCCTT TCCTTT CCTTTA CTTTAA TTTAAG TTAAGA TAAGAA AAGAAA AGAAAT GAAATA AAATAC AATACC ATACCG TACCGT ACCGTA CCGTAT CGTATT GTATTG TATTGC ATTGCT TTGCTT TGCTTC GCTTCC CTTCCC TTCCCG TCCCGG CCCGGA CCGGAG CGGAGT GGAGTA GAGTAG AGTAGT GTAGTG TAGTGC AGTGCT GTGCTG TGCTGC GCTGCC CTGCCG TGCCGA GCCGAT CCGATT CGATTA GATTAC ATTACG TTACGG TACGGT ACGGTA CGGTAG GGTAGG GTAGGA TAGGAA AGGAAG GGAAGG GAAGGG AAGGGA AGGGAT GGGATA GGATAA GATAAA ATAAAA TAAAAG AAAAGC AAAGCA AAGCAT AGCATC GCATCA CATCAA ATCAAG TCAAGG CAAGGC AAGGCG AGGCGG GGCGGT GCGGTG CGGTGA GGTGAA GTGAAC TGAACG GAACGA AACGAC ACGACG CGACGC GACGCT ACGCTT CGCTTA GCTTAT CTTATA TTATAA TATAAA ATAAAA TAAAAA AAAAAC AAAACG AAACGA AACGAT ACGATA CGATAA GATAAA ATAAAC TAAACT AAACTG AACTGG ACTGGT CTGGTA TGGTAG GGTAGG GTAGGG TAGGGG AGGGGT GGGGTG GGGTGC GGTGCT GTGCTG TGCTGG GCTGGC CTGGCC TGGCCC GGCCCA GCCCAG CCCAGA CCAGAA CAGAAA AGAAAG GAAAGA AAAGAT AAGATG AGATGT GATGTG,GCCCTCC CCCTCCC CCTCCCT CTCCCTA TCCCTAT CCCTATT CCTATTC CTATTCT TATTCTT ATTCTTC TTCTTCC TCTTCCT CTTCCTT TTCCTTT TCCTTTA CCTTTAA CTTTAAG TTTAAGA TTAAGAA TAAGAAA AAGAAAT AGAAATA GAAATAC AAATACC AATACCG ATACCGT TACCGTA ACCGTAT CCGTATT CGTATTG GTATTGC TATTGCT ATTGCTT TTGCTTC TGCTTCC GCTTCCC CTTCCCG TTCCCGG TCCCGGA CCCGGAG CCGGAGT CGGAGTA GGAGTAG GAGTAGT AGTAGTG GTAGTGC TAGTGCT AGTGCTG GTGCTGC TGCTGCC GCTGCCG CTGCCGA TGCCGAT GCCGATT CCGATTA CGATTAC GATTACG ATTACGG TTACGGT TACGGTA ACGGTAG CGGTAGG GGTAGGA GTAGGAA TAGGAAG AGGAAGG GGAAGGG GAAGGGA AAGGGAT AGGGATA GGGATAA GGATAAA GATAAAA ATAAAAG TAAAAGC AAAAGCA AAAGCAT AAGCATC AGCATCA GCATCAA CATCAAG ATCAAGG TCAAGGC CAAGGCG AAGGCGG AGGCGGT GGCGGTG GCGGTGA CGGTGAA GGTGAAC GTGAACG TGAACGA GAACGAC AACGACG ACGACGC CGACGCT GACGCTT ACGCTTA CGCTTAT GCTTATA CTTATAA TTATAAA TATAAAA ATAAAAA TAAAAAC AAAAACG AAAACGA AAACGAT AACGATA ACGATAA CGATAAA GATAAAC ATAAACT TAAACTG AAACTGG AACTGGT ACTGGTA CTGGTAG TGGTAGG GGTAGGG GTAGGGG TAGGGGT AGGGGTG GGGGTGC GGGTGCT GGTGCTG GTGCTGG TGCTGGC GCTGGCC CTGGCCC TGGCCCA GGCCCAG GCCCAGA CCCAGAA CCAGAAA CAGAAAG AGAAAGA GAAAGAT AAAGATG AAGATGT AGATGTG,"ID   LON_FLAJ1               Reviewed;         817 AA.
AC   A5FG89;
DT   10-AUG-2010, integrated into UniProtKB/Swiss-Prot.
DT   12-JUN-2007, sequence version 1.
DT   05-FEB-2025, entry version 102.
DE   RecName: Full=Lon protease {ECO:0000255|HAMAP-Rule:MF_01973};
DE            EC=3.4.21.53 {ECO:0000255|HAMAP-Rule:MF_01973};
DE   AltName: Full=ATP-dependent protease La {ECO:0000255|HAMAP-Rule:MF_01973};
GN   Name=lon {ECO:0000255|HAMAP-Rule:MF_01973};
GN   OrderedLocusNames=Fjoh_2754;
OS   Flavobacterium johnsoniae (strain ATCC 17061 / DSM 2064 / JCM 8514 / BCRC
OS   14874 / CCUG 350202 / NBRC 14942 / NCIMB 11054 / UW101) (Cytophaga
OS   johnsonae).
OC   Bacteria; Bacteroidota; Flavobacteriia; Flavobacteriales;
OC   Flavobacteriaceae; Flavobacterium.
OX   NCBI_TaxID=376686;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 17061 / DSM 2064 / JCM 8514 / BCRC 14874 / CCUG 350202 /
RC   NBRC 14942 / NCIMB 11054 / UW101;
RX   PubMed=19717629; DOI=10.1128/aem.01495-09;
RA   McBride M.J., Xie G., Martens E.C., Lapidus A., Henrissat B., Rhodes R.G.,
RA   Goltsman E., Wang W., Xu J., Hunnicutt D.W., Staroscik A.M., Hoover T.R.,
RA   Cheng Y.Q., Stein J.L.;
RT   ""Novel features of the polysaccharide-digesting gliding bacterium
RT   Flavobacterium johnsoniae as revealed by genome sequence analysis."";
RL   Appl. Environ. Microbiol. 75:6864-6875(2009).
CC   -!- FUNCTION: ATP-dependent serine protease that mediates the selective
CC       degradation of mutant and abnormal proteins as well as certain short-
CC       lived regulatory proteins. Required for cellular homeostasis and for
CC       survival from DNA damage and developmental changes induced by stress.
CC       Degrades polypeptides processively to yield small peptide fragments
CC       that are 5 to 10 amino acids long. Binds to DNA in a double-stranded,
CC       site-specific manner. {ECO:0000255|HAMAP-Rule:MF_01973}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Hydrolysis of proteins in presence of ATP.; EC=3.4.21.53;
CC         Evidence={ECO:0000255|HAMAP-Rule:MF_01973};
CC   -!- SUBUNIT: Homohexamer. Organized in a ring with a central cavity.
CC       {ECO:0000255|HAMAP-Rule:MF_01973}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000255|HAMAP-Rule:MF_01973}.
CC   -!- INDUCTION: By heat shock. {ECO:0000255|HAMAP-Rule:MF_01973}.
CC   -!- SIMILARITY: Belongs to the peptidase S16 family. {ECO:0000255|HAMAP-
CC       Rule:MF_01973}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CP000685; ABQ05776.1; -; Genomic_DNA.
DR   RefSeq; WP_012024815.1; NZ_MUGZ01000005.1.
DR   AlphaFoldDB; A5FG89; -.
DR   SMR; A5FG89; -.
DR   STRING; 376686.Fjoh_2754; -.
DR   KEGG; fjo:Fjoh_2754; -.
DR   eggNOG; COG0466; Bacteria.
DR   HOGENOM; CLU_004109_4_3_10; -.
DR   OrthoDB; 9803599at2; -.
DR   Proteomes; UP000006694; Chromosome.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IEA:UniProtKB-UniRule.
DR   GO; GO:0004176; F:ATP-dependent peptidase activity; IEA:UniProtKB-UniRule.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; IEA:UniProtKB-UniRule.
DR   GO; GO:0034605; P:cellular response to heat; IEA:UniProtKB-UniRule.
DR   GO; GO:0006515; P:protein quality control for misfolded or incompletely synthesized proteins; IEA:UniProtKB-UniRule.
DR   CDD; cd19500; RecA-like_Lon; 1.
DR   FunFam; 3.40.50.300:FF:000021; Lon protease homolog; 1.
DR   Gene3D; 1.10.8.60; -; 1.
DR   Gene3D; 1.20.5.5270; -; 1.
DR   Gene3D; 1.20.58.1480; -; 1.
DR   Gene3D; 3.30.230.10; -; 1.
DR   Gene3D; 2.30.130.40; LON domain-like; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   HAMAP; MF_01973; lon_bact; 1.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR003959; ATPase_AAA_core.
DR   InterPro; IPR027543; Lon_bac.
DR   InterPro; IPR004815; Lon_bac/euk-typ.
DR   InterPro; IPR054594; Lon_lid.
DR   InterPro; IPR008269; Lon_proteolytic.
DR   InterPro; IPR027065; Lon_Prtase.
DR   InterPro; IPR003111; Lon_prtase_N.
DR   InterPro; IPR046336; Lon_prtase_N_sf.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR008268; Peptidase_S16_AS.
DR   InterPro; IPR015947; PUA-like_sf.
DR   InterPro; IPR020568; Ribosomal_Su5_D2-typ_SF.
DR   InterPro; IPR014721; Ribsml_uS5_D2-typ_fold_subgr.
DR   NCBIfam; TIGR00763; lon; 1.
DR   PANTHER; PTHR10046; ATP DEPENDENT LON PROTEASE FAMILY MEMBER; 1.
DR   Pfam; PF00004; AAA; 1.
DR   Pfam; PF05362; Lon_C; 1.
DR   Pfam; PF22667; Lon_lid; 1.
DR   Pfam; PF02190; LON_substr_bdg; 1.
DR   PIRSF; PIRSF001174; Lon_proteas; 1.
DR   PRINTS; PR00830; ENDOLAPTASE.
DR   SMART; SM00382; AAA; 1.
DR   SMART; SM00464; LON; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   SUPFAM; SSF88697; PUA domain-like; 1.
DR   SUPFAM; SSF54211; Ribosomal protein S5 domain 2-like; 1.
DR   PROSITE; PS51787; LON_N; 1.
DR   PROSITE; PS51786; LON_PROTEOLYTIC; 1.
DR   PROSITE; PS01046; LON_SER; 1.
PE   3: Inferred from homology;
KW   ATP-binding; Cytoplasm; Hydrolase; Nucleotide-binding; Protease;
KW   Serine protease; Stress response.
FT   CHAIN           1..817
FT                   /note=""Lon protease""
FT                   /id=""PRO_0000396565""
FT   DOMAIN          44..239
FT                   /note=""Lon N-terminal""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01123""
FT   DOMAIN          626..807
FT                   /note=""Lon proteolytic""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01122""
FT   ACT_SITE        713
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01973""
FT   ACT_SITE        756
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01973""
FT   BINDING         390..397
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01973""
SQ   SEQUENCE   817 AA;  91375 MW;  F1056EB18ABA1172 CRC64;
     MSNHKILTID NLSLQEFDSE AELIPLLTPE DEEEMNNEEL PVSLPILPLR NTVLFPGVVI
     PISAGRDKSI KLINDANAGG KIIGVVSQIN EEDEDPSKDD IHKIGTVARI LRVLKMPDGN
     VTVILQGKKR FEIDEVVSEE PYMTASIKEV SEERPDENDS EFTAILDSVK ELAIQIIKES
     PNIPSEATFA IKNIESQSFL INFVSSNMNL SVKEKQGLLS INGLKERALE TLRYMNVELQ
     KLELKNDIQS KVRFDLDQQQ REYFLHQQMK TIQEELGGVS QEEEMDEMGQ KAKTKKWDEK
     TQKHFEKELS KMRRMNPQSP DFGIQRNYLE LFLELPWGEY SKDKFDLKHA QKVLDKDHFG
     LDEVKKRMIE HLAVLKLRND MKSPIICLTG PPGVGKTSIG RSVAEALGRE YVRISLGGLR
     DEAEIRGHRK TYIGAMPGRI IQSLKKAGTS NPVFILDEID KLSSGNSGDP SSALLEVLDP
     EQNNAFYDNF LEMGYDLSKV MFIATSNNMA AIQPALRDRM EVIKMSGYTI EEKVEIAKRH
     LFPKQLEAHG LTSKDLTIGK KQLEKIVEGY TRESGVRNLE TKIAQVIRNA AKAVAMEEEY
     NKKVTDEDIV KVLGVPRLER DKYENNDVAG VVTGLAWTSV GGDILFIESL ISEGKGALTI
     TGNLGNVMKE SATIALEYIK ANAKKLGLAI ELFQKYNIHL HVPEGATPKD GPSAGIAMLT
     SLVSLLTQKK VKKSLAMTGE ITLRGKVLPV GGIKEKILAA KRAGIKEIIL CHENKSDIDE
     IKEEYLEGLT FHYVKEMSEV LAIALTDQNV KNAKTLK
//
",46749
TCTGGA CTGGAA TGGAAC GGAACA GAACAT AACATA ACATAC CATACG ATACGA TACGAA ACGAAG CGAAGG GAAGGC AAGGCA AGGCAA GGCAAT GCAATT CAATTC AATTCA ATTCAC TTCACC TCACCA CACCAT ACCATT CCATTT CATTTC ATTTCA TTTCAT TTCATC TCATCC CATCCT ATCCTC TCCTCT CCTCTA CTCTAG TCTAGC CTAGCT TAGCTG AGCTGA GCTGAT CTGATA TGATAA GATAAC ATAACA TAACAA AACAAA ACAAAT CAAATT AAATTT AATTTG ATTTGC TTTGCA TTGCAC TGCACT GCACTG CACTGA ACTGAC CTGACT TGACTT GACTTG ACTTGC CTTGCT TTGCTT TGCTTT GCTTTA CTTTAG TTTAGC TTAGCA TAGCAC AGCACT GCACTC CACTCA ACTCAA CTCAAT TCAATT CAATTT AATTTG ATTTGC TTTGCT TTGCTT TGCTTT GCTTTT CTTTTG TTTTGC TTTGCT TTGCTT TGCTTG GCTTGT CTTGTC TTGTCC TGTCCT GTCCTG TCCTGA CCTGAC,1,94,TCTG CTGG TGGA GGAA GAAC AACA ACAT CATA ATAC TACG ACGA CGAA GAAG AAGG AGGC GGCA GCAA CAAT AATT ATTC TTCA TCAC CACC ACCA CCAT CATT ATTT TTTC TTCA TCAT CATC ATCC TCCT CCTC CTCT TCTA CTAG TAGC AGCT GCTG CTGA TGAT GATA ATAA TAAC AACA ACAA CAAA AAAT AATT ATTT TTTG TTGC TGCA GCAC CACT ACTG CTGA TGAC GACT ACTT CTTG TTGC TGCT GCTT CTTT TTTA TTAG TAGC AGCA GCAC CACT ACTC CTCA TCAA CAAT AATT ATTT TTTG TTGC TGCT GCTT CTTT TTTT TTTG TTGC TGCT GCTT CTTG TTGT TGTC GTCC TCCT CCTG CTGA TGAC,TCTGG CTGGA TGGAA GGAAC GAACA AACAT ACATA CATAC ATACG TACGA ACGAA CGAAG GAAGG AAGGC AGGCA GGCAA GCAAT CAATT AATTC ATTCA TTCAC TCACC CACCA ACCAT CCATT CATTT ATTTC TTTCA TTCAT TCATC CATCC ATCCT TCCTC CCTCT CTCTA TCTAG CTAGC TAGCT AGCTG GCTGA CTGAT TGATA GATAA ATAAC TAACA AACAA ACAAA CAAAT AAATT AATTT ATTTG TTTGC TTGCA TGCAC GCACT CACTG ACTGA CTGAC TGACT GACTT ACTTG CTTGC TTGCT TGCTT GCTTT CTTTA TTTAG TTAGC TAGCA AGCAC GCACT CACTC ACTCA CTCAA TCAAT CAATT AATTT ATTTG TTTGC TTGCT TGCTT GCTTT CTTTT TTTTG TTTGC TTGCT TGCTT GCTTG CTTGT TTGTC TGTCC GTCCT TCCTG CCTGA CTGAC,TCTGGA CTGGAA TGGAAC GGAACA GAACAT AACATA ACATAC CATACG ATACGA TACGAA ACGAAG CGAAGG GAAGGC AAGGCA AGGCAA GGCAAT GCAATT CAATTC AATTCA ATTCAC TTCACC TCACCA CACCAT ACCATT CCATTT CATTTC ATTTCA TTTCAT TTCATC TCATCC CATCCT ATCCTC TCCTCT CCTCTA CTCTAG TCTAGC CTAGCT TAGCTG AGCTGA GCTGAT CTGATA TGATAA GATAAC ATAACA TAACAA AACAAA ACAAAT CAAATT AAATTT AATTTG ATTTGC TTTGCA TTGCAC TGCACT GCACTG CACTGA ACTGAC CTGACT TGACTT GACTTG ACTTGC CTTGCT TTGCTT TGCTTT GCTTTA CTTTAG TTTAGC TTAGCA TAGCAC AGCACT GCACTC CACTCA ACTCAA CTCAAT TCAATT CAATTT AATTTG ATTTGC TTTGCT TTGCTT TGCTTT GCTTTT CTTTTG TTTTGC TTTGCT TTGCTT TGCTTG GCTTGT CTTGTC TTGTCC TGTCCT GTCCTG TCCTGA CCTGAC,TCTGGAA CTGGAAC TGGAACA GGAACAT GAACATA AACATAC ACATACG CATACGA ATACGAA TACGAAG ACGAAGG CGAAGGC GAAGGCA AAGGCAA AGGCAAT GGCAATT GCAATTC CAATTCA AATTCAC ATTCACC TTCACCA TCACCAT CACCATT ACCATTT CCATTTC CATTTCA ATTTCAT TTTCATC TTCATCC TCATCCT CATCCTC ATCCTCT TCCTCTA CCTCTAG CTCTAGC TCTAGCT CTAGCTG TAGCTGA AGCTGAT GCTGATA CTGATAA TGATAAC GATAACA ATAACAA TAACAAA AACAAAT ACAAATT CAAATTT AAATTTG AATTTGC ATTTGCA TTTGCAC TTGCACT TGCACTG GCACTGA CACTGAC ACTGACT CTGACTT TGACTTG GACTTGC ACTTGCT CTTGCTT TTGCTTT TGCTTTA GCTTTAG CTTTAGC TTTAGCA TTAGCAC TAGCACT AGCACTC GCACTCA CACTCAA ACTCAAT CTCAATT TCAATTT CAATTTG AATTTGC ATTTGCT TTTGCTT TTGCTTT TGCTTTT GCTTTTG CTTTTGC TTTTGCT TTTGCTT TTGCTTG TGCTTGT GCTTGTC CTTGTCC TTGTCCT TGTCCTG GTCCTGA TCCTGAC,"ID   NS7A_SARS2              Reviewed;         121 AA.
AC   P0DTC7;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 24.
DE   RecName: Full=ORF7a protein;
DE            Short=ORF7a;
DE   AltName: Full=Accessory protein 7a;
DE   AltName: Full=Protein U122;
DE   AltName: Full=Protein X4;
DE   Flags: Precursor;
GN   ORFNames=7a;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANT ILE-14.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION, UBIQUITINATION AT LYS-119, AND MUTAGENESIS OF LYS-2; LYS-32;
RP   LYS-53; LYS-72; LYS-85; LYS-117 AND LYS-119.
RX   PubMed=33473190; DOI=10.1038/s41423-020-00603-6;
RA   Cao Z., Xia H., Rajsbaum R., Xia X., Wang H., Shi P.Y.;
RT   ""Ubiquitination of SARS-CoV-2 ORF7a promotes antagonism of interferon
RT   response."";
RL   Cell. Mol. Immunol. 18:746-748(2021).
RN   [4]
RP   FUNCTION, INTERACTION WITH HOST BST2, AND SUBCELLULAR LOCATION.
RX   PubMed=33930332; DOI=10.1016/j.molcel.2021.04.008;
RA   Martin-Sancho L., Lewinski M.K., Pache L., Stoneham C.A., Yin X.,
RA   Becker M.E., Pratt D., Churas C., Rosenthal S.B., Liu S., Weston S.,
RA   De Jesus P.D., O'Neill A.M., Gounder A.P., Nguyen C., Pu Y., Curry H.M.,
RA   Oom A.L., Miorin L., Rodriguez-Frandsen A., Zheng F., Wu C., Xiong Y.,
RA   Urbanowski M., Shaw M.L., Chang M.W., Benner C., Hope T.J., Frieman M.B.,
RA   Garcia-Sastre A., Ideker T., Hultquist J.F., Guatelli J., Chanda S.K.;
RT   ""Functional landscape of SARS-CoV-2 cellular restriction."";
RL   Mol. Cell 81:2656-2668.e8(2021).
RN   [5]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [6]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF 117-LYS--LYS-119.
RX   PubMed=36574644; DOI=10.1073/pnas.2208525120;
RA   Arshad N., Laurent-Rolle M., Ahmed W.S., Hsu J.C., Mitchell S.M.,
RA   Pawlak J., Sengupta D., Biswas K.H., Cresswell P.;
RT   ""SARS-CoV-2 accessory proteins ORF7a and ORF3a use distinct mechanisms to
RT   down-regulate MHC-I surface expression."";
RL   Proc. Natl. Acad. Sci. U.S.A. 120:e2208525120-e2208525120(2023).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 16-82, AND DISULFIDE BOND.
RA   Nelson C.A., Minasov G., Shuvalova L., Fremont D.H.;
RT   ""STRUCTURE OF THE SARS-CoV-2 ORF7A ENCODED ACCESSORY PROTEIN."";
RL   Submitted (MAR-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 14-96.
RX   PubMed=33615195; DOI=10.1016/j.isci.2021.102187;
RA   Zhou Z., Huang C., Zhou Z., Huang Z., Su L., Kang S., Chen X., Chen Q.,
RA   He S., Rong X., Xiao F., Chen J., Chen S.;
RT   ""Structural insight reveals SARS-CoV-2 ORF7a as an immunomodulating factor
RT   for human CD14+ monocytes."";
RL   IScience 24:102187-102187(2021).
CC   -!- FUNCTION: Plays a role as antagonist of host tetherin (BST2),
CC       disrupting its antiviral effect (PubMed:33930332). Acts by binding to
CC       BST2 and sequestering it to perinuclear region, thereby preventing its
CC       antiviral function at cell membrane (PubMed:33930332). May specifically
CC       downregulate MHC-I allele HLA-A*02:01 (HLA-A2) (PubMed:36574644).
CC       {ECO:0000269|PubMed:33930332, ECO:0000269|PubMed:36574644}.
CC   -!- SUBUNIT: Interacts with host BST2 (PubMed:33930332). Interacts with the
CC       spike glycoprotein (By similarity). Interacts with M protein (By
CC       similarity). Interacts with E protein (By similarity). Interacts with
CC       the ORF3a protein (By similarity). {ECO:0000250|UniProtKB:P59635,
CC       ECO:0000269|PubMed:33930332}.
CC   -!- INTERACTION:
CC       P0DTC7; P0DTD8: 7b; NbExp=5; IntAct=EBI-25475903, EBI-25475914;
CC       P0DTC7; PRO_0000449625 [P0DTD1]: rep; NbExp=3; IntAct=EBI-25475903, EBI-25475871;
CC   -!- SUBCELLULAR LOCATION: Host cytoplasm, host perinuclear region
CC       {ECO:0000269|PubMed:33930332}. Virion {ECO:0000250|UniProtKB:P59635}.
CC       Host endoplasmic reticulum membrane {ECO:0000269|PubMed:36574644};
CC       Single-pass membrane protein {ECO:0000269|PubMed:36574644}. Host
CC       endoplasmic reticulum-Golgi intermediate compartment membrane
CC       {ECO:0000269|PubMed:36574644}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:36574644}. Host Golgi apparatus membrane
CC       {ECO:0000269|PubMed:36574644}; Single-pass membrane protein
CC       {ECO:0000269|PubMed:36574644}.
CC   -!- DOMAIN: The di-lysine motif confers endoplasmic reticulum localization
CC       for type I membrane proteins. {ECO:0000250|UniProtKB:P59635}.
CC   -!- PTM: Poly-ubiquitinated by host with K63-linked polyubiquitin chains.
CC       {ECO:0000269|PubMed:33473190}.
CC   -!- MISCELLANEOUS: Variant B.1.1.7 is also called Variant Of Concern (VOC)
CC       202012/01, Variant Under Investigation (VUI) 202012/01, or 20B/501Y.V1.
CC       {ECO:0000305|PubMed:33413740}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43421.1; -; Genomic_RNA.
DR   PDB; 6W37; X-ray; 2.90 A; A=16-82.
DR   PDB; 7CI3; X-ray; 2.20 A; A=14-96.
DR   PDBsum; 6W37; -.
DR   PDBsum; 7CI3; -.
DR   SMR; P0DTC7; -.
DR   BioGRID; 4383872; 1267.
DR   IntAct; P0DTC7; 128.
DR   MINT; P0DTC7; -.
DR   iPTMnet; P0DTC7; -.
DR   KEGG; vg:43740573; -.
DR   AGR; RefSeq:YP_009724395; -.
DR   Reactome; R-HSA-9694322; Virion Assembly and Release.
DR   Reactome; R-HSA-9694614; Attachment and Entry.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   Reactome; R-HSA-9727281; Translation of Accessory Proteins.
DR   Reactome; R-HSA-9733458; Induction of Cell-Cell Fusion.
DR   Reactome; R-HSA-9754560; SARS-CoV-2 modulates autophagy.
DR   PRO; PR:P0DTC7; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044173; C:host cell endoplasmic reticulum-Golgi intermediate compartment membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044178; C:host cell Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; TAS:Reactome.
DR   GO; GO:0039587; P:suppression by virus of host tetherin activity; IEA:UniProtKB-KW.
DR   GO; GO:0039646; P:symbiont-mediated perturbation of host cell cycle G0/G1 transition checkpoint; IEA:UniProtKB-KW.
DR   GO; GO:0044071; P:symbiont-mediated perturbation of host cell cycle progression; IEA:UniProtKB-KW.
DR   GO; GO:0046776; P:symbiont-mediated suppression of host antigen processing and presentation of peptide antigen via MHC class I; IEA:UniProtKB-KW.
DR   GO; GO:0052170; P:symbiont-mediated suppression of host innate immune response; IEA:UniProtKB-KW.
DR   CDD; cd21684; ORF7a_SARS-CoV-2-like; 1.
DR   Gene3D; 2.60.40.1550; SARS coronavirus X4; 1.
DR   InterPro; IPR044390; ORF7a_SARS-CoV-2-like.
DR   InterPro; IPR014888; ORF7a_SARS-CoV-like.
DR   InterPro; IPR044871; ORF7a_SARS-CoV-like_X4e.
DR   InterPro; IPR036495; ORF7a_sf_CoV.
DR   Pfam; PF08779; bCoV_NS7A; 1.
DR   SUPFAM; SSF117066; Accessory protein X4 (ORF8, ORF7a); 1.
DR   PROSITE; PS51919; X4E; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Disulfide bond;
KW   G0/G1 host cell cycle checkpoint dysregulation by virus; Host cytoplasm;
KW   Host endoplasmic reticulum; Host Golgi apparatus; Host membrane;
KW   Host-virus interaction;
KW   Inhibition of host adaptive immune response by virus;
KW   Inhibition of host innate immune response by virus;
KW   Inhibition of host MHC class I molecule presentation by virus;
KW   Inhibition of host tetherin by virus; Isopeptide bond; Membrane;
KW   Modulation of host cell cycle by virus; Reference proteome; Signal;
KW   Transmembrane; Transmembrane helix; Ubl conjugation; Viral immunoevasion;
KW   Virion.
FT   SIGNAL          1..15
FT                   /evidence=""ECO:0000255""
FT   CHAIN           16..121
FT                   /note=""ORF7a protein""
FT                   /evidence=""ECO:0000255""
FT                   /id=""PRO_0000449654""
FT   TRANSMEM        96..116
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   DOMAIN          16..81
FT                   /note=""X4e""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01267""
FT   REGION          16..80
FT                   /note=""Ig-like fold""
FT                   /evidence=""ECO:0000305|PubMed:36574644""
FT   REGION          83..95
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000305|PubMed:35108439""
FT   MOTIF           117..119
FT                   /note=""ER-retrieval motif""
FT                   /evidence=""ECO:0000269|PubMed:36574644""
FT   DISULFID        23..58
FT                   /evidence=""ECO:0000269|PubMed:33615195, ECO:0000269|Ref.7""
FT   DISULFID        35..67
FT                   /evidence=""ECO:0000269|PubMed:33615195, ECO:0000269|Ref.7""
FT   CROSSLNK        119
FT                   /note=""Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)""
FT                   /evidence=""ECO:0000269|PubMed:33473190""
FT   VARIANT         14
FT                   /note=""T -> I (in strain: Alpha/B.1.1.7)""
FT                   /evidence=""ECO:0000305|PubMed:33413740""
FT   VARIANT         82
FT                   /note=""V -> A (in strain: Delta/B.1.617.2 and
FT                   Kappa/B.1.617.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         120
FT                   /note=""T -> I (in strain: Delta/B.1.617.2)""
FT                   /evidence=""ECO:0000305""
FT   MUTAGEN         2
FT                   /note=""K->A: No effect on ubiquitination.""
FT                   /evidence=""ECO:0000269|PubMed:33473190""
FT   MUTAGEN         32
FT                   /note=""K->A: No effect on ubiquitination.""
FT                   /evidence=""ECO:0000269|PubMed:33473190""
FT   MUTAGEN         53
FT                   /note=""K->A: No effect on ubiquitination.""
FT                   /evidence=""ECO:0000269|PubMed:33473190""
FT   MUTAGEN         72
FT                   /note=""K->A: No effect on ubiquitination.""
FT                   /evidence=""ECO:0000269|PubMed:33473190""
FT   MUTAGEN         85
FT                   /note=""K->A: No effect on ubiquitination.""
FT                   /evidence=""ECO:0000269|PubMed:33473190""
FT   MUTAGEN         117..119
FT                   /note=""KRK->ARA: Complete loss of MHC-I retention in ER.""
FT                   /evidence=""ECO:0000269|PubMed:36574644""
FT   MUTAGEN         117
FT                   /note=""K->A: No effect on ubiquitination.""
FT                   /evidence=""ECO:0000269|PubMed:33473190""
FT   MUTAGEN         119
FT                   /note=""K->A: Complete loss of ubiquitination. Partial loss
FT                   of interferon pathway inhibition.""
FT                   /evidence=""ECO:0000269|PubMed:33473190""
FT   STRAND          16..24
FT                   /evidence=""ECO:0007829|PDB:7CI3""
FT   STRAND          27..32
FT                   /evidence=""ECO:0007829|PDB:7CI3""
FT   STRAND          34..37
FT                   /evidence=""ECO:0007829|PDB:7CI3""
FT   STRAND          39..44
FT                   /evidence=""ECO:0007829|PDB:7CI3""
FT   STRAND          47..49
FT                   /evidence=""ECO:0007829|PDB:6W37""
FT   HELIX           50..52
FT                   /evidence=""ECO:0007829|PDB:7CI3""
FT   STRAND          53..57
FT                   /evidence=""ECO:0007829|PDB:7CI3""
FT   STRAND          60..66
FT                   /evidence=""ECO:0007829|PDB:7CI3""
FT   STRAND          72..80
FT                   /evidence=""ECO:0007829|PDB:7CI3""
SQ   SEQUENCE   121 AA;  13744 MW;  891E7EAB9E8A5BA9 CRC64;
     MKIILFLALI TLATCELYHY QECVRGTTVL LKEPCSSGTY EGNSPFHPLA DNKFALTCFS
     TQFAFACPDG VKHVYQLRAR SVSPKLFIRQ EEVQELYSPI FLIVAAIVFI TLCFTLKRKT
     E
//
",34794
CGCCGC GCCGCG CCGCGC CGCGCC GCGCCG CGCCGG GCCGGC CCGGCT CGGCTA GGCTAC GCTACC CTACCA TACCAC ACCACG CCACGT CACGTG ACGTGT CGTGTG GTGTGG TGTGGC GTGGCT TGGCTG GGCTGT GCTGTT CTGTTG TGTTGG GTTGGC TTGGCC TGGCCG GGCCGC GCCGCC CCGCCC CGCCCT GCCCTG CCCTGG CCTGGT CTGGTG TGGTGG GGTGGG GTGGGC TGGGCA GGGCAG GGCAGC GCAGCT CAGCTC AGCTCC GCTCCG CTCCGA TCCGAG CCGAGC CGAGCA GAGCAG AGCAGC GCAGCA CAGCAA AGCAAC GCAACC CAACCG AACCGC ACCGCC CCGCCC CGCCCG GCCCGA CCCGAC CCGACC CGACCT GACCTG ACCTGC CCTGCT CTGCTG TGCTGG GCTGGC CTGGCC TGGCCG GGCCGA GCCGAA CCGAAC CGAACT GAACTG AACTGC ACTGCA CTGCAG TGCAGC GCAGCG CAGCGC AGCGCG GCGCGA CGCGAC GCGACC CGACCG GACCGC ACCGCC CCGCCG CGCCGC GCCGCT CCGCTG CGCTGG GCTGGT CTGGTG TGGTGC GGTGCC GTGCCA TGCCAG GCCAGG CCAGGG CAGGGC AGGGCA GGGCAA GGCAAT GCAATC CAATCT AATCTG ATCTGC TCTGCA CTGCAG TGCAGA GCAGAA CAGAAT AGAATG GAATGC AATGCG ATGCGC TGCGCG GCGCGC CGCGCC GCGCCT CGCCTG GCCTGA CCTGAT CTGATG TGATGG GATGGC ATGGCC TGGCCG GGCCGA GCCGAG CCGAGC CGAGCC GAGCCC AGCCCG GCCCGG CCCGGC,3,142,CGCC GCCG CCGC CGCG GCGC CGCC GCCG CCGG CGGC GGCT GCTA CTAC TACC ACCA CCAC CACG ACGT CGTG GTGT TGTG GTGG TGGC GGCT GCTG CTGT TGTT GTTG TTGG TGGC GGCC GCCG CCGC CGCC GCCC CCCT CCTG CTGG TGGT GGTG GTGG TGGG GGGC GGCA GCAG CAGC AGCT GCTC CTCC TCCG CCGA CGAG GAGC AGCA GCAG CAGC AGCA GCAA CAAC AACC ACCG CCGC CGCC GCCC CCCG CCGA CGAC GACC ACCT CCTG CTGC TGCT GCTG CTGG TGGC GGCC GCCG CCGA CGAA GAAC AACT ACTG CTGC TGCA GCAG CAGC AGCG GCGC CGCG GCGA CGAC GACC ACCG CCGC CGCC GCCG CCGC CGCT GCTG CTGG TGGT GGTG GTGC TGCC GCCA CCAG CAGG AGGG GGGC GGCA GCAA CAAT AATC ATCT TCTG CTGC TGCA GCAG CAGA AGAA GAAT AATG ATGC TGCG GCGC CGCG GCGC CGCC GCCT CCTG CTGA TGAT GATG ATGG TGGC GGCC GCCG CCGA CGAG GAGC AGCC GCCC CCCG CCGG CGGC,CGCCG GCCGC CCGCG CGCGC GCGCC CGCCG GCCGG CCGGC CGGCT GGCTA GCTAC CTACC TACCA ACCAC CCACG CACGT ACGTG CGTGT GTGTG TGTGG GTGGC TGGCT GGCTG GCTGT CTGTT TGTTG GTTGG TTGGC TGGCC GGCCG GCCGC CCGCC CGCCC GCCCT CCCTG CCTGG CTGGT TGGTG GGTGG GTGGG TGGGC GGGCA GGCAG GCAGC CAGCT AGCTC GCTCC CTCCG TCCGA CCGAG CGAGC GAGCA AGCAG GCAGC CAGCA AGCAA GCAAC CAACC AACCG ACCGC CCGCC CGCCC GCCCG CCCGA CCGAC CGACC GACCT ACCTG CCTGC CTGCT TGCTG GCTGG CTGGC TGGCC GGCCG GCCGA CCGAA CGAAC GAACT AACTG ACTGC CTGCA TGCAG GCAGC CAGCG AGCGC GCGCG CGCGA GCGAC CGACC GACCG ACCGC CCGCC CGCCG GCCGC CCGCT CGCTG GCTGG CTGGT TGGTG GGTGC GTGCC TGCCA GCCAG CCAGG CAGGG AGGGC GGGCA GGCAA GCAAT CAATC AATCT ATCTG TCTGC CTGCA TGCAG GCAGA CAGAA AGAAT GAATG AATGC ATGCG TGCGC GCGCG CGCGC GCGCC CGCCT GCCTG CCTGA CTGAT TGATG GATGG ATGGC TGGCC GGCCG GCCGA CCGAG CGAGC GAGCC AGCCC GCCCG CCCGG CCGGC,CGCCGC GCCGCG CCGCGC CGCGCC GCGCCG CGCCGG GCCGGC CCGGCT CGGCTA GGCTAC GCTACC CTACCA TACCAC ACCACG CCACGT CACGTG ACGTGT CGTGTG GTGTGG TGTGGC GTGGCT TGGCTG GGCTGT GCTGTT CTGTTG TGTTGG GTTGGC TTGGCC TGGCCG GGCCGC GCCGCC CCGCCC CGCCCT GCCCTG CCCTGG CCTGGT CTGGTG TGGTGG GGTGGG GTGGGC TGGGCA GGGCAG GGCAGC GCAGCT CAGCTC AGCTCC GCTCCG CTCCGA TCCGAG CCGAGC CGAGCA GAGCAG AGCAGC GCAGCA CAGCAA AGCAAC GCAACC CAACCG AACCGC ACCGCC CCGCCC CGCCCG GCCCGA CCCGAC CCGACC CGACCT GACCTG ACCTGC CCTGCT CTGCTG TGCTGG GCTGGC CTGGCC TGGCCG GGCCGA GCCGAA CCGAAC CGAACT GAACTG AACTGC ACTGCA CTGCAG TGCAGC GCAGCG CAGCGC AGCGCG GCGCGA CGCGAC GCGACC CGACCG GACCGC ACCGCC CCGCCG CGCCGC GCCGCT CCGCTG CGCTGG GCTGGT CTGGTG TGGTGC GGTGCC GTGCCA TGCCAG GCCAGG CCAGGG CAGGGC AGGGCA GGGCAA GGCAAT GCAATC CAATCT AATCTG ATCTGC TCTGCA CTGCAG TGCAGA GCAGAA CAGAAT AGAATG GAATGC AATGCG ATGCGC TGCGCG GCGCGC CGCGCC GCGCCT CGCCTG GCCTGA CCTGAT CTGATG TGATGG GATGGC ATGGCC TGGCCG GGCCGA GCCGAG CCGAGC CGAGCC GAGCCC AGCCCG GCCCGG CCCGGC,CGCCGCG GCCGCGC CCGCGCC CGCGCCG GCGCCGG CGCCGGC GCCGGCT CCGGCTA CGGCTAC GGCTACC GCTACCA CTACCAC TACCACG ACCACGT CCACGTG CACGTGT ACGTGTG CGTGTGG GTGTGGC TGTGGCT GTGGCTG TGGCTGT GGCTGTT GCTGTTG CTGTTGG TGTTGGC GTTGGCC TTGGCCG TGGCCGC GGCCGCC GCCGCCC CCGCCCT CGCCCTG GCCCTGG CCCTGGT CCTGGTG CTGGTGG TGGTGGG GGTGGGC GTGGGCA TGGGCAG GGGCAGC GGCAGCT GCAGCTC CAGCTCC AGCTCCG GCTCCGA CTCCGAG TCCGAGC CCGAGCA CGAGCAG GAGCAGC AGCAGCA GCAGCAA CAGCAAC AGCAACC GCAACCG CAACCGC AACCGCC ACCGCCC CCGCCCG CGCCCGA GCCCGAC CCCGACC CCGACCT CGACCTG GACCTGC ACCTGCT CCTGCTG CTGCTGG TGCTGGC GCTGGCC CTGGCCG TGGCCGA GGCCGAA GCCGAAC CCGAACT CGAACTG GAACTGC AACTGCA ACTGCAG CTGCAGC TGCAGCG GCAGCGC CAGCGCG AGCGCGA GCGCGAC CGCGACC GCGACCG CGACCGC GACCGCC ACCGCCG CCGCCGC CGCCGCT GCCGCTG CCGCTGG CGCTGGT GCTGGTG CTGGTGC TGGTGCC GGTGCCA GTGCCAG TGCCAGG GCCAGGG CCAGGGC CAGGGCA AGGGCAA GGGCAAT GGCAATC GCAATCT CAATCTG AATCTGC ATCTGCA TCTGCAG CTGCAGA TGCAGAA GCAGAAT CAGAATG AGAATGC GAATGCG AATGCGC ATGCGCG TGCGCGC GCGCGCC CGCGCCT GCGCCTG CGCCTGA GCCTGAT CCTGATG CTGATGG TGATGGC GATGGCC ATGGCCG TGGCCGA GGCCGAG GCCGAGC CCGAGCC CGAGCCC GAGCCCG AGCCCGG GCCCGGC,"ID   OPGH_PSEPW              Reviewed;         857 AA.
AC   B1J2R4;
DT   14-APR-2009, integrated into UniProtKB/Swiss-Prot.
DT   29-APR-2008, sequence version 1.
DT   05-FEB-2025, entry version 78.
DE   RecName: Full=Glucans biosynthesis glucosyltransferase H {ECO:0000255|HAMAP-Rule:MF_01072};
DE            EC=2.4.1.- {ECO:0000255|HAMAP-Rule:MF_01072};
GN   Name=opgH {ECO:0000255|HAMAP-Rule:MF_01072};
GN   OrderedLocusNames=PputW619_0440;
OS   Pseudomonas putida (strain W619).
OC   Bacteria; Pseudomonadota; Gammaproteobacteria; Pseudomonadales;
OC   Pseudomonadaceae; Pseudomonas.
OX   NCBI_TaxID=390235;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=W619;
RA   Copeland A., Lucas S., Lapidus A., Barry K., Detter J.C.,
RA   Glavina del Rio T., Dalin E., Tice H., Pitluck S., Chain P., Malfatti S.,
RA   Shin M., Vergez L., Schmutz J., Larimer F., Land M., Hauser L.,
RA   Kyrpides N., Kim E., Taghavi S., Vangronsveld D., van der Lelie D.,
RA   Richardson P.;
RT   ""Complete sequence of Pseudomonas putida W619."";
RL   Submitted (FEB-2008) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Involved in the biosynthesis of osmoregulated periplasmic
CC       glucans (OPGs). {ECO:0000255|HAMAP-Rule:MF_01072}.
CC   -!- PATHWAY: Glycan metabolism; osmoregulated periplasmic glucan (OPG)
CC       biosynthesis. {ECO:0000255|HAMAP-Rule:MF_01072}.
CC   -!- SUBCELLULAR LOCATION: Cell inner membrane {ECO:0000255|HAMAP-
CC       Rule:MF_01072}; Multi-pass membrane protein {ECO:0000255|HAMAP-
CC       Rule:MF_01072}.
CC   -!- SIMILARITY: Belongs to the glycosyltransferase 2 family. OpgH
CC       subfamily. {ECO:0000255|HAMAP-Rule:MF_01072}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CP000949; ACA70945.1; -; Genomic_DNA.
DR   AlphaFoldDB; B1J2R4; -.
DR   STRING; 390235.PputW619_0440; -.
DR   CAZy; GT2; Glycosyltransferase Family 2.
DR   KEGG; ppw:PputW619_0440; -.
DR   eggNOG; COG2943; Bacteria.
DR   HOGENOM; CLU_015730_1_0_6; -.
DR   OrthoDB; 9775281at2; -.
DR   UniPathway; UPA00637; -.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016758; F:hexosyltransferase activity; IEA:UniProtKB-UniRule.
DR   GO; GO:0009250; P:glucan biosynthetic process; IEA:UniProtKB-UniRule.
DR   CDD; cd04191; Glucan_BSP_MdoH; 1.
DR   FunFam; 3.90.550.10:FF:000047; Glucans biosynthesis glucosyltransferase H; 1.
DR   Gene3D; 3.90.550.10; Spore Coat Polysaccharide Biosynthesis Protein SpsA, Chain A; 1.
DR   HAMAP; MF_01072; MdoH_OpgH; 1.
DR   InterPro; IPR023725; Glucans_biosynth_gluTrFase_H.
DR   InterPro; IPR001173; Glyco_trans_2-like.
DR   InterPro; IPR050321; Glycosyltr_2/OpgH_subfam.
DR   InterPro; IPR029044; Nucleotide-diphossugar_trans.
DR   PANTHER; PTHR43867; CELLULOSE SYNTHASE CATALYTIC SUBUNIT A [UDP-FORMING]; 1.
DR   PANTHER; PTHR43867:SF5; GLUCANS BIOSYNTHESIS GLUCOSYLTRANSFERASE H; 1.
DR   Pfam; PF00535; Glycos_transf_2; 1.
DR   SUPFAM; SSF53448; Nucleotide-diphospho-sugar transferases; 1.
PE   3: Inferred from homology;
KW   Cell inner membrane; Cell membrane; Glycosyltransferase; Membrane;
KW   Transferase; Transmembrane; Transmembrane helix.
FT   CHAIN           1..857
FT                   /note=""Glucans biosynthesis glucosyltransferase H""
FT                   /id=""PRO_1000136658""
FT   TRANSMEM        142..162
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01072""
FT   TRANSMEM        196..216
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01072""
FT   TRANSMEM        515..535
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01072""
FT   TRANSMEM        572..592
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01072""
FT   TRANSMEM        606..626
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01072""
FT   TRANSMEM        682..702
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01072""
SQ   SEQUENCE   857 AA;  95930 MW;  B80AA0E4A24F4E79 CRC64;
     MSNSSARPES LGEYLAHLPL SDEQRAELAS CTSFSELHQR LAGNATATTT EAVQASVGPR
     LTVGSAAELE DAEMLGVDGS GRLCLKIAPP IKRTRVVPEP WRTNVLIRMW RRMTGRTNAP
     QPPKRELPPA RWRTVGSIRR YILLTLMIGQ TLVAGWYMKG ILPYQGWSFV DLDEVVNQPL
     WDTVVQVWPY ALQTSILILF GILFCWVSAG FWTALMGFLE LLTGRDKYRI SGSSAGSEPI
     APEARTALVM PICNEDVPRV FAGLRATFES VAASGNLDRF DFFVLSDTND TDIAVAEQQA
     WLDVCRETKG FGRIFYRRRR RRVKRKSGNL DDFCRRWGGE YKYMVVLDAD SVMSGECLSS
     LVRLMEANPD AGIIQTAPKA SGMDTLYARM QQFATRVYGP LFTAGLHFWQ LGESHYWGHN
     AIIRMKPFIE HCALAPLPGK GAFAGAILSH DFVEAALMRR AGWGVWIAYD LPGSYEELPP
     NLLDELKRDR RWCHGNLMNF RLFLVKGMHP VHRAVFLTGV MSYLSAPLWF FFLVLSTALL
     ATNTLMEPQY FIEPYQLYPL WPQWHPEKAV ALFSTTIVLL FLPKLLSIIL IWAKGAVEFG
     GRIKVTLSML MEMLFSMLLA PVRMIFHTRF VLAAFLGWAA TWNSPQRDDD STPWSEAVRR
     HGPQTLLGIA WAALVAWLNP SFLWWLAPIV GSLVLSIPVS VISSRTRLGL AAKDEKLFLI
     PEEYATPQEL LATDQYTHEN RWHALHDGFV RAVVDPRQNA LACAMATARH GQAAPIEAMR
     AERLAKAIEV GPKGLDLGTR LALLSDPVAL ARLHAQVWAE HNAAWIDVWR ASINNDPHSP
     LLPLHPANEA QPSLVGA
//
",31582
CTGCAG TGCAGG GCAGGC CAGGCT AGGCTG GGCTGG GCTGGC CTGGCA TGGCAG GGCAGC GCAGCG CAGCGG AGCGGC GCGGCG CGGCGC GGCGCA GCGCAC CGCACC GCACCG CACCGG ACCGGA CCGGAT CGGATA GGATAT GATATG ATATGT TATGTG ATGTGC TGTGCG GTGCGA TGCGAT GCGATA CGATAT GATATC ATATCG TATCGA ATCGAG TCGAGA CGAGAT GAGATC AGATCG GATCGG ATCGGC TCGGCC CGGCCA GGCCAG GCCAGT CCAGTT CAGTTC AGTTCC GTTCCC TTCCCG TCCCGA CCCGAA CCGAAC CGAACT GAACTA AACTAT ACTATG CTATGT TATGTT ATGTTG TGTTGG GTTGGA TTGGAG TGGAGA GGAGAG GAGAGG AGAGGA GAGGAC AGGACT GGACTG GACTGC ACTGCC CTGCCC TGCCCG GCCCGC CCCGCT CCGCTG CGCTGT GCTGTA CTGTAC TGTACG GTACGA TACGAT ACGATA CGATAT GATATG ATATGA TATGAC ATGACA TGACAG GACAGA ACAGAG CAGAGG AGAGGC GAGGCA AGGCAC GGCACT GCACTT CACTTG ACTTGC CTTGCT TTGCTC TGCTCC GCTCCG CTCCGT TCCGTA CCGTAT CGTATG GTATGA TATGAG ATGAGG TGAGGA GAGGAT AGGATT GGATTC GATTCT ATTCTC TTCTCT TCTCTG CTCTGG TCTGGT CTGGTT TGGTTC GGTTCA GTTCAG TTCAGG TCAGGC CAGGCT AGGCTC GGCTCG GCTCGT CTCGTC TCGTCT CGTCTG GTCTGG TCTGGA CTGGAT TGGATG GGATGT GATGTA ATGTAT TGTATA GTATAC,2,145,CTGC TGCA GCAG CAGG AGGC GGCT GCTG CTGG TGGC GGCA GCAG CAGC AGCG GCGG CGGC GGCG GCGC CGCA GCAC CACC ACCG CCGG CGGA GGAT GATA ATAT TATG ATGT TGTG GTGC TGCG GCGA CGAT GATA ATAT TATC ATCG TCGA CGAG GAGA AGAT GATC ATCG TCGG CGGC GGCC GCCA CCAG CAGT AGTT GTTC TTCC TCCC CCCG CCGA CGAA GAAC AACT ACTA CTAT TATG ATGT TGTT GTTG TTGG TGGA GGAG GAGA AGAG GAGG AGGA GGAC GACT ACTG CTGC TGCC GCCC CCCG CCGC CGCT GCTG CTGT TGTA GTAC TACG ACGA CGAT GATA ATAT TATG ATGA TGAC GACA ACAG CAGA AGAG GAGG AGGC GGCA GCAC CACT ACTT CTTG TTGC TGCT GCTC CTCC TCCG CCGT CGTA GTAT TATG ATGA TGAG GAGG AGGA GGAT GATT ATTC TTCT TCTC CTCT TCTG CTGG TGGT GGTT GTTC TTCA TCAG CAGG AGGC GGCT GCTC CTCG TCGT CGTC GTCT TCTG CTGG TGGA GGAT GATG ATGT TGTA GTAT TATA ATAC,CTGCA TGCAG GCAGG CAGGC AGGCT GGCTG GCTGG CTGGC TGGCA GGCAG GCAGC CAGCG AGCGG GCGGC CGGCG GGCGC GCGCA CGCAC GCACC CACCG ACCGG CCGGA CGGAT GGATA GATAT ATATG TATGT ATGTG TGTGC GTGCG TGCGA GCGAT CGATA GATAT ATATC TATCG ATCGA TCGAG CGAGA GAGAT AGATC GATCG ATCGG TCGGC CGGCC GGCCA GCCAG CCAGT CAGTT AGTTC GTTCC TTCCC TCCCG CCCGA CCGAA CGAAC GAACT AACTA ACTAT CTATG TATGT ATGTT TGTTG GTTGG TTGGA TGGAG GGAGA GAGAG AGAGG GAGGA AGGAC GGACT GACTG ACTGC CTGCC TGCCC GCCCG CCCGC CCGCT CGCTG GCTGT CTGTA TGTAC GTACG TACGA ACGAT CGATA GATAT ATATG TATGA ATGAC TGACA GACAG ACAGA CAGAG AGAGG GAGGC AGGCA GGCAC GCACT CACTT ACTTG CTTGC TTGCT TGCTC GCTCC CTCCG TCCGT CCGTA CGTAT GTATG TATGA ATGAG TGAGG GAGGA AGGAT GGATT GATTC ATTCT TTCTC TCTCT CTCTG TCTGG CTGGT TGGTT GGTTC GTTCA TTCAG TCAGG CAGGC AGGCT GGCTC GCTCG CTCGT TCGTC CGTCT GTCTG TCTGG CTGGA TGGAT GGATG GATGT ATGTA TGTAT GTATA TATAC,CTGCAG TGCAGG GCAGGC CAGGCT AGGCTG GGCTGG GCTGGC CTGGCA TGGCAG GGCAGC GCAGCG CAGCGG AGCGGC GCGGCG CGGCGC GGCGCA GCGCAC CGCACC GCACCG CACCGG ACCGGA CCGGAT CGGATA GGATAT GATATG ATATGT TATGTG ATGTGC TGTGCG GTGCGA TGCGAT GCGATA CGATAT GATATC ATATCG TATCGA ATCGAG TCGAGA CGAGAT GAGATC AGATCG GATCGG ATCGGC TCGGCC CGGCCA GGCCAG GCCAGT CCAGTT CAGTTC AGTTCC GTTCCC TTCCCG TCCCGA CCCGAA CCGAAC CGAACT GAACTA AACTAT ACTATG CTATGT TATGTT ATGTTG TGTTGG GTTGGA TTGGAG TGGAGA GGAGAG GAGAGG AGAGGA GAGGAC AGGACT GGACTG GACTGC ACTGCC CTGCCC TGCCCG GCCCGC CCCGCT CCGCTG CGCTGT GCTGTA CTGTAC TGTACG GTACGA TACGAT ACGATA CGATAT GATATG ATATGA TATGAC ATGACA TGACAG GACAGA ACAGAG CAGAGG AGAGGC GAGGCA AGGCAC GGCACT GCACTT CACTTG ACTTGC CTTGCT TTGCTC TGCTCC GCTCCG CTCCGT TCCGTA CCGTAT CGTATG GTATGA TATGAG ATGAGG TGAGGA GAGGAT AGGATT GGATTC GATTCT ATTCTC TTCTCT TCTCTG CTCTGG TCTGGT CTGGTT TGGTTC GGTTCA GTTCAG TTCAGG TCAGGC CAGGCT AGGCTC GGCTCG GCTCGT CTCGTC TCGTCT CGTCTG GTCTGG TCTGGA CTGGAT TGGATG GGATGT GATGTA ATGTAT TGTATA GTATAC,CTGCAGG TGCAGGC GCAGGCT CAGGCTG AGGCTGG GGCTGGC GCTGGCA CTGGCAG TGGCAGC GGCAGCG GCAGCGG CAGCGGC AGCGGCG GCGGCGC CGGCGCA GGCGCAC GCGCACC CGCACCG GCACCGG CACCGGA ACCGGAT CCGGATA CGGATAT GGATATG GATATGT ATATGTG TATGTGC ATGTGCG TGTGCGA GTGCGAT TGCGATA GCGATAT CGATATC GATATCG ATATCGA TATCGAG ATCGAGA TCGAGAT CGAGATC GAGATCG AGATCGG GATCGGC ATCGGCC TCGGCCA CGGCCAG GGCCAGT GCCAGTT CCAGTTC CAGTTCC AGTTCCC GTTCCCG TTCCCGA TCCCGAA CCCGAAC CCGAACT CGAACTA GAACTAT AACTATG ACTATGT CTATGTT TATGTTG ATGTTGG TGTTGGA GTTGGAG TTGGAGA TGGAGAG GGAGAGG GAGAGGA AGAGGAC GAGGACT AGGACTG GGACTGC GACTGCC ACTGCCC CTGCCCG TGCCCGC GCCCGCT CCCGCTG CCGCTGT CGCTGTA GCTGTAC CTGTACG TGTACGA GTACGAT TACGATA ACGATAT CGATATG GATATGA ATATGAC TATGACA ATGACAG TGACAGA GACAGAG ACAGAGG CAGAGGC AGAGGCA GAGGCAC AGGCACT GGCACTT GCACTTG CACTTGC ACTTGCT CTTGCTC TTGCTCC TGCTCCG GCTCCGT CTCCGTA TCCGTAT CCGTATG CGTATGA GTATGAG TATGAGG ATGAGGA TGAGGAT GAGGATT AGGATTC GGATTCT GATTCTC ATTCTCT TTCTCTG TCTCTGG CTCTGGT TCTGGTT CTGGTTC TGGTTCA GGTTCAG GTTCAGG TTCAGGC TCAGGCT CAGGCTC AGGCTCG GGCTCGT GCTCGTC CTCGTCT TCGTCTG CGTCTGG GTCTGGA TCTGGAT CTGGATG TGGATGT GGATGTA GATGTAT ATGTATA TGTATAC,"ID   ARAN_HALH5              Reviewed;         445 AA.
AC   Q9KEE7;
DT   19-SEP-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   05-FEB-2025, entry version 115.
DE   RecName: Full=Arabinooligosaccharide-binding protein {ECO:0000250|UniProtKB:P94528};
DE   Flags: Precursor;
GN   Name=araN; OrderedLocusNames=BH0905;
OS   Halalkalibacterium halodurans (strain ATCC BAA-125 / DSM 18197 / FERM 7344
OS   / JCM 9153 / C-125) (Bacillus halodurans).
OC   Bacteria; Bacillati; Bacillota; Bacilli; Bacillales; Bacillaceae;
OC   Halalkalibacterium (ex Joshi et al. 2022).
OX   NCBI_TaxID=272558;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC BAA-125 / DSM 18197 / FERM 7344 / JCM 9153 / C-125;
RX   PubMed=11058132; DOI=10.1093/nar/28.21.4317;
RA   Takami H., Nakasone K., Takaki Y., Maeno G., Sasaki R., Masui N., Fuji F.,
RA   Hirama C., Nakamura Y., Ogasawara N., Kuhara S., Horikoshi K.;
RT   ""Complete genome sequence of the alkaliphilic bacterium Bacillus halodurans
RT   and genomic sequence comparison with Bacillus subtilis."";
RL   Nucleic Acids Res. 28:4317-4331(2000).
CC   -!- FUNCTION: Part of the ABC transporter complex AraNPQ involved in the
CC       uptake of arabinooligosaccharides (By similarity). AraN captures the
CC       substrate and delivers it to the two transmembrane components (By
CC       similarity). {ECO:0000250|UniProtKB:P94528}.
CC   -!- SUBUNIT: The complex is composed of two ATP-binding proteins (MsmX),
CC       two transmembrane proteins (AraP and AraQ) and a solute-binding protein
CC       (AraN). {ECO:0000250|UniProtKB:P94528}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000255|PROSITE-
CC       ProRule:PRU00303}; Lipid-anchor {ECO:0000255|PROSITE-ProRule:PRU00303}.
CC   -!- SIMILARITY: Belongs to the bacterial solute-binding protein 1 family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; BA000004; BAB04624.1; -; Genomic_DNA.
DR   PIR; A83763; A83763.
DR   RefSeq; WP_010897078.1; NC_002570.2.
DR   AlphaFoldDB; Q9KEE7; -.
DR   SMR; Q9KEE7; -.
DR   STRING; 272558.gene:10726779; -.
DR   KEGG; bha:BH0905; -.
DR   eggNOG; COG1653; Bacteria.
DR   HOGENOM; CLU_031285_2_4_9; -.
DR   OrthoDB; 9768630at2; -.
DR   Proteomes; UP000001258; Chromosome.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   Gene3D; 3.40.190.10; Periplasmic binding protein-like II; 1.
DR   InterPro; IPR050490; Bact_solute-bd_prot1.
DR   InterPro; IPR006059; SBP.
DR   PANTHER; PTHR43649; ARABINOSE-BINDING PROTEIN-RELATED; 1.
DR   PANTHER; PTHR43649:SF33; POLYGALACTURONAN_RHAMNOGALACTURONAN-BINDING PROTEIN YTCQ; 1.
DR   Pfam; PF01547; SBP_bac_1; 1.
DR   SUPFAM; SSF53850; Periplasmic binding protein-like II; 1.
DR   PROSITE; PS51257; PROKAR_LIPOPROTEIN; 1.
PE   3: Inferred from homology;
KW   Cell membrane; Lipoprotein; Membrane; Palmitate; Reference proteome;
KW   Signal; Sugar transport; Transport.
FT   SIGNAL          1..20
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00303""
FT   CHAIN           21..445
FT                   /note=""Arabinooligosaccharide-binding protein""
FT                   /id=""PRO_0000031688""
FT   LIPID           21
FT                   /note=""N-palmitoyl cysteine""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00303""
FT   LIPID           21
FT                   /note=""S-diacylglycerol cysteine""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00303""
SQ   SEQUENCE   445 AA;  50220 MW;  0ED29FDA9C84C52B CRC64;
     MGKNILFFSF VGVMVLVLVA CGGSSSSSSD ADETSVIGDD IEGATELIFW TFAGQHVDLF
     EDAVVSWNEE FPDRPIKLVA ETYPFDQMHN NLLLALQSGS GAPDLADIEV SRFPNFLQGV
     PQLLPMNDHV EPVIDKFVEA RFNLYAKDGE YYGIPTHVGA SVMYYNKEIM DEAGVDIESI
     ETWDDYVEAG KQVVERTGKV MTTVPTDDYL PMFQMVSQRG SDFFDENGNL TLDTQENIEV
     LQFLYDLIYV HEIAELTPGG QPHAEEYYQY MNDGNVASMA MPIWYMGRFL DNMPDLAGKM
     LIQPLPAWEE GGFRSAGMGG TGTVVTNQTD HEELAKDFLA YAKISEKANE KLWTILGFDP
     PRWDVWDNPV FQEDNDFYQF FGENIFEVLL DVRDEINSIN ISQYTPSVAN EFSTNIFNDV
     LRQQTHTPEE ALKKAQETIE ANMQQ
//
",41626
ATAGAC TAGACC AGACCG GACCGG ACCGGG CCGGGA CGGGAA GGGAAG GGAAGA GAAGAG AAGAGC AGAGCG GAGCGG AGCGGC GCGGCC CGGCCG GGCCGG GCCGGA CCGGAC CGGACC GGACCT GACCTG ACCTGG CCTGGA CTGGAT TGGATC GGATCA GATCAT ATCATA TCATAT CATATT ATATTT TATTTA ATTTAT TTTATA TTATAT TATATG ATATGG TATGGA ATGGAT TGGATG GGATGC GATGCT ATGCTG TGCTGT GCTGTT CTGTTC TGTTCA GTTCAG TTCAGG TCAGGC CAGGCT AGGCTA GGCTAT GCTATG CTATGA TATGAC ATGACA TGACAG GACAGG ACAGGA CAGGAA AGGAAG GGAAGC GAAGCG AAGCGG AGCGGG GCGGGG CGGGGG GGGGGG GGGGGT GGGGTG GGGTGG GGTGGC GTGGCC TGGCCG GGCCGT GCCGTT CCGTTG CGTTGA GTTGAA TTGAAT TGAATG GAATGT AATGTT ATGTTT TGTTTT GTTTTC TTTTCC TTTCCT TTCCTT TCCTTA CCTTAC CTTACC TTACCC TACCCC ACCCCC CCCCCG CCCCGA CCCGAA CCGAAG CGAAGG GAAGGG AAGGGA AGGGAA GGGAAG GGAAGC GAAGCC AAGCCT AGCCTT GCCTTT CCTTTT CTTTTT TTTTTA TTTTAC TTTACG TTACGG TACGGC ACGGCG CGGCGG GGCGGC GCGGCA CGGCAC GGCACT GCACTT CACTTA ACTTAT CTTATT TTATTT TATTTT ATTTTC TTTTCC TTTCCT TTCCTC TCCTCC CCTCCT CTCCTG TCCTGA CCTGAG CTGAGC TGAGCG GAGCGG AGCGGG GCGGGC CGGGCA,3,145,ATTAG G T TATAGAGAGA A A AGAGAGACAC C G GAGACGAAC ACTGACCCCGGGCG C CCCCGGG CGT CGCGGGGG GGG GGGGGGAGA A G GGGGAGAA CTA G GAGAAAAGAG  AACTTAGAGA  AGAGAGAGA CG G GAGAGAGCGC  AGGCG GCTGA GCGCGCGG CGCGGGC C GGGCGCCC GGCCGGGCG G C CCCCGCGGGG G C CGCC GGAGA A GGACAC C GAC GACACCCC C A ACACCCCTTTTCT  CCCCTCTGTG G C CTCTGTGGGG G T TGTGGCCGGA A G GGGATAA  GAGATATCTC TTC ATATCTCACA A T TCTCACATAT T C CACATATATA A A ATATATATAT T TCAG TTATTTT T AT T ATTTTTT TCA TTTTTTTATA A TGA  AGAT T T TAATATA A A ATATATAT TTT C TATATATGTG  ATATGTGGGG  TGGGA TT GGTTAGATAT T G GAGATCTGTG  TA ATATGTGCGC C T TGTGCGCTCT T GCG GCT ACTG G CAG CTGTGTGT AGG TGTGTGTTT G GTGTTTTCC T TTTTCT TCA A TTCAG AATTT T CACAGAGGGG G A AGAGGGGCC GG ACT T G GCGCTCTATA A CCTAGCAAT T T TATATATGTG G A ATATGTGAGA GC  TGG CGAC GAC GACACA  ACACATT AG  CT CACAGAGGGG G AGGTAGGGGAGA A G GGGAAAA A G GAGAAAAGAG G A AAAGCGC C AAGCG ACG G GCC GCCCGGGG G C CGCGGGGGCTCG G GGTTTCCGGG G G GGGGGGG G G GGGGGGGGGG G G GGGGGT TTTTT G GG AGTG G G GTGTGTGGG T TGC TC GTT GGCGCCCC C G GCGCCCC CG TCC CCCCGG CGT T T CGCGTGTTTT  GTCCCTTGTG G T TTTTGGA A T TGTGAGAAA G GAGAAAATAT T A AAAATATGTG G ATCCCTTTGTGT G C TGTGTGTTTT T G GT ACCT TT T TC CTTTGT TT  ATAT C GC ATC C T TTTTCTCCCC C T TCTCCCCTCT T C CCCCTCTTTT T C CTCTTTTATA  TTTTATACAC C T TATACACCCC  TT ACACCCCCCC C CCCCCCCCGG TTGTTCC GGA GGGGTCCCCCGCG G C CCCCGCGAGA AG  TACGAGAAAA ATA GAGAAAAGAG GCGA TAAGG A AGAGGGGGGG G G GGGGGGGAGA A G GGGGAACCAA A G GAGAAAAGAG G A AAAAGGC C AAGCGCCCCCC G GCGCGCCT CCAAGTT T C CTCTTTAT GGT TTTTTTTTT T T TTTTTTTTTT  CC TTAG GGATA A T TTTACTCCCG  CGTACACGCG GGCGTTCGGGG G C CGCGGGC C GGGCCG G GTTTGCGGG G C CGCGGGGCGC C G ACGGCGCACA A G GCTATCACAC C C CACACACTT CT A GGACTATGCAGT C CTCTTTTA AATATTTATATAT T T TATATATTTT T A ATTAGTTTTT T TC ATTTGGGTT T TTTTTTCTC C T TTTTCAC CC C T TCTCCCCTCT T C CCCCTGG C CG CCTCG CCC C T TC CTCCTCT T C CCCCTCTGTG G C CTATGG GGA A T TGTGATTTG G GAGAGAGCGC C ATTAAGCGCGCG G G GCGCGGG TGA CGCGGGGGGG G GGGGA TTTT GGGCA,ATATAGG GGA A T TATT AGAGACAC C A AGGACCC CC C G GAACCCCGCG G A ACACCAC C TCCGCGGGGGGG G C CGCGG GAGGATTTA G GGGGGGGAGAAAA A G GGGGAAAGAG  GAGAAAGAA A AAAAGAGAAG G A AGGAGAGCGC  GAGAGAGCGCGTT G A AGAGCGCGCGGGG AGA GCGCGCGGGGCCG C C CGCGGGGCGCCCC C G GGGG GCCCCGCG G G GCGCCCGGGG G CT GCCGG CGGAGA A CACCCGGGGAGACAC C G GGGGAGAC CGCC C G GAACCC GCT T A TAACCGC CTGG CCCT AGTTCGG TT  CTCTGTGGGGAGA A T TGCT GGAGATAT GGAAT AGCTATATCG A GAGATCTTTCAA A ATATC ATCATAT T T TCTCAGCAATA AC CACATATATAT GGT AGGAATAATTTT T T TATATATTTTTG CT A ATATTTTTC G CGA T TTTTTTTATATTA  TC TTTTATATATATA A T TATATATATATAT T A ATATAGATATGTG G T TATATCG TGGG AATGTGGGGAA T TGTGGT GGATAT T G GGGGAGATATGG G GAGATATGGC ATGC ATGCCT T T TGTGCGCTCAG GCCTGTGTGT T C CTGGGTGTGTTT T TGTGTGTTTTCTC C G GTGTTTTCTCACA A T TTTTCTCACAGAG G T TCTCACAGAGGGG CGG CAAGGGGCGC G C AGTGAGGCGCTCT T G GGCT GCTCTAAT A GGCTCTACATAT GCG CTCTATATATGTG G T TATATATGTGAGA A A ATTTTTGAGACCCGC TGC TGAGACCA A GGGGGAC AAAG G A CCACACAGAGGTTTG C CACAGGGAATCA ACTGAGGGGAGAAAA A G GGGGAGAAAAGAG G G GAGAAAAGAGCC A AAAATGCGG A AGAGCGCGCGGT AAGA GCGCGCTGGG G C CGCGGGG G G CTGGGGGGGG G G GG GCGGGGGGGG GGC GGGGGGGGGGTTACT GGAAGGG TAGTGAT G G GGGGTGTGTGGG G GTGTG GCG G CGC T TGTGGGCCCC C G GGGGCGAACCGCACG GGG  CACCGCGTT C CCCCGCGTGTTTT T CCGTGTTTTGTG G G GTGTTTTGTGAGA A T TTTTGGAAAA A T TGTGAAATAT GG  AAAGCG AGAAAATATGTGT ATT AGT ATGTGTGTTTT TGTGTTTTTGC  GTGTTTTTGGCTT  TTTTTTTTTTCTC C T TTTCCC TTGGCCTCT T TTCCCCTCTTTT GAACCTCTTTTATA A CGGGCTTTTATACAC C T TTTTATACACCCC C T TATACACCCCCACCC A ACACCCCCCCCCC  ACCCCCCCCCCTG C C CCCCCCCCCCGCG G C CCCCCCCGCGAGA A C TTCCGCGAGAAAA A C CGCGA ATAAGAG  GAT CAAGAGGGG G A AAAAGAGGGGGGG  AGAGGGGGGC GA A G GGGGGGGAGCCAA GGA GGAAGAG G G GAGAAAAG ATC ACAGAGCGCCCC C A AGGAACCTGGC GCGCCCTTT C CCCTTAGCTT T C CTCTTTT T TTATTTTTTTA TT T TTTTTTTTTTA TTTTTTTAAC GG TTATACACGCG G TGGTTACACGGG G A ACACGCGGGGCC C TGCGGTTTGCGCG G G GGGCGCGGGG G G GCGCGCGGGGCGC C CTA CGGGGCTATCA A GC AGGCGCACACAC C GGCACACACTCT T CGCCCG CTTTT TCCA CACTGA GGGA C CTCTT TC CCCC T TTTAATTTT T T ACTATATTTTTTT  GAGCCATTTTTGGCTAGT T TTTTTTTTTTCTC C T TTTTTTTCTCCC TTTCT ACCTCT T T TCTCCCCTCTCTC C C CCCCTCTCTCCCC C C CTCTCTCCCCTTGGTCCCCTCTGTG G C CCCCTCTGGA A C CTCTGAGGGAGAG G T TGTGAGAGAGCGC C G GAGAGAGCGCGG GC G CGGGAGCGCGGGG G G GCCGGGGGGG G CCGGGGCCCTTTA GGGGGGGCGCA,ATATAGAGA TAACC TATAGAGAACCCC C AAGAGACC T GCCG G G GACCTACCT GCGGGG G A ACACCCCGCGGGGGGG G C CCCCGCGGGGGGGAGA A C CGT TGGAAGCAA  GGGGGGGAGAAAAGCGGG G GGGGAGAAAAG TTGA A G GAGAAAAGAGAAG G AAAGGAGGC C ATTAAGAGAG CGGCGCG G G GAGCGCGGTACG CAGCGCGCGGGGCGC C G GCGCGCGGGGCGCCCC C C CGCGGGGCCCGT AG GAGGGGCGCCCCGCGGG G GCCCGCGGGGAACAA C CCCCGAG AAGGACAC CT  CGCGGAGCGACACCCC  GAGGAGACACCCCTTGAT GGACACCTG G A ACACCCCTAGGTGGGG G C CCCCTCC TGGGGAA C CTCTGTGGGGAGATAT T TTT TGGGGA TCATCTC C G GGGATATCTCACA C T GAGATATCTCACATAT T ACCCATCTCACATATATA GTT TCCC TTCTATAT T CCCCCCCATAATTTT AA CCGATATATATTTTT TGT T TATATATTTTTTTATA A A ATATTTTTTTACGAG AT T TTTTTTTATATATAA T AGTATATATATAT CGG TAATATATATGTG G A ATATATATATGTTTG TTTATATATGTGGGGAGA A AATGTGGGAAGATT TGGCTGGC GGATATGTG  TGTCCGATATGTGCCCTTTT GAGATGCTCT CCG ATAAGGCTCTGTG G TG GTGCTGACTGTGTT G GCGCTCTGTA GTTT C CTCTGTGTGTTGAATC C TT CTGTGTTTTCTCACA A G GTGTTTCACAGAG G T TTGGGTGGCAGAGGGG G TGATTCACAGGGCC C CACAGAGGGGCC CT A AGGTGGGCGCTCTATGTA G TCGGCGGATATAT T G GCGCTCTATATATGTG  AG CTTTTTATATGTGAGA A TATGTGAGACAC C A ATATGTGAGA TTCA T TGTGAGACACACAGG GGACACACAGAGGGG G A ACACAGAAAGGGGAGA A C CACAGGGAGAAAA A A AGAGGGGAGAAAAGG GGAGGGA CTGCTGC C G GAGAAAAGAGCGCGCG AT GCCAAGGCCCGGGG G A GGAGCGCGCGGGGGGG G G CGCGGTTTGGGTTTG C CGGGGGGGTTCGG G G GGGGGGGGGGGGGGGG  GC GGGGGGGGGGTTTGCCGGGGGGGGGTTG G G GGGGGGGTGTGAGGG G GGGGTTGGTGGGGCC G GTGTGTGGGGCGCCCATAGCAAGGCGCCGCG G G GGGCCCCGGT CCCTTCGCCCGTTT T C CCCGTGTTTG G CAGCCGTGTTTTGTGAGA A G GTA TGT TGAGGAAA CTCAGAGT TGACAGAATAT T TTATTGAGAAAATATGTG G G GGGAAATGTGTGT T A AAAATATGTGTGTTTT  ATATGTGTGTTTTTTT  TGTGTGTTGG TTTTT T G GTGTTTTTTTTTTCTC  TTCTA TGTCCCC C T TTT TATATCCCCTCT T T GGCA TCCCCTCTTTT TTT GGTCCCCTCTTTTATA A CCTTTTATACAC C CTGCCTTTTATACACCCC C T TTT TCCCCC C T TATACACC ATCCCCC C A ACACCT GCCCCC C C CCCCCCCCGAGCCGG C CCTTTCCC ATCGAA CTGACATCCTTATTT AA A CCTC AACGAGAAAGCAG GCGCGAGAAAGGGG G G GAGGCAGGGGGGG GGACTGGGGGA A ACAC GGGGGGGAGAAT AA G GGGGGGGATTCAAGG G GGGGAGAAAAGAGCGC C G GA TTAAGAGCGCCCC C A AAAAGAAGGCCGACT A AGAGCGCCCCTGAAT G GCGCCCTTTTTTT  CCCTTTTTTT T C CTCTTTTTTTTGGGTT TAC TTTTTTTTTTTTTATA A TGAATTTCCCCCGAC  CACGGTTTTTATACCG G T TT TAGC ACG TTGG G T TAACGGGCGC  ACCGGGGCGCGCTT CGCG GGCGCGCGGGG G G TTGGCGCGCGGGGCGC C GG GGCGCGGGGCGCACA A C CGCGGGCACACAC GGA GGGGCGCACACACTCT T GGCACACTCCCTTTT T C CAACTCTTTTATA ACTCTTTTATATAT T C CTG CTTA GCATTTT T T TTTTAATTTTTTT GACATTTTTTTTTT T A ATATTTTTTTCTC C T TTTTTGG TTCTCCCTGC T TTTTTTTCTCCCCTCT T T TTTTCTCCGC  CCC T TCACTCCTCTCTCCCC C C CCCCTCTACCTCT T C CTA TTCCCCGCTGTG G T TCTCCCTGTGAGA A C CCCCTCTG CCA GAG G C CTCTGGCTGAGGAATACC T TGCGGGAG TGGCGCG G G GAGAGAGCGCGCGGGG G A AGAGCCGGGGGGG  GCGCGCGGGGGGGCGC C C CGCT GGGGGCGCA,ATATAGAGAGACGCGCC C T TATAGAGAGACACCCCGCG G A AGAGAGACACCCCGCGGGG G GGACACCATGCGGGGGGG  ACACCCCGCGGGGAGA A C CCCCGGGGTGAGAAAA CTG CGCGGGGGATCTCAAAGAG G GGGGCTTGAAAAGTCAGA  GGGAAAAGAGAGAGAG G G GA CTAAGAGAGAGAGCGC C AAGAAAGGAGAGCGCGC GG A TG AAGAATTTGG G G GAGAGCGGGGCGC C A AGT GCGGGGCGCCCGGC G GCTTTCC GGCGCCCCGCG G CCCCCGGGGCGCCGTTCGGTTTG G GGGGCGCCTCCGGAACCA G GCGCCCCGGGAGACAC C C TACAGCGGGGAGACACCCC C C CGCGGGGAGACGA  ACCT T G GGGGAGACACCCCTCTGG G GAGACACCCCTCTGTGGGG T T ACACCCCTCTGTGGGGAGA A C CCCTG AAGATAT T C CTCTGTGGGGAGATGGATC C T TGGAACTGGATATCAGAATAA G GGGATCGGTCATT CCGT GATCTCACATAGCGAGA A ATTCACATATATATAT T TCCTCGACATATATATATTTATT CCATATATATATTTTTTT T ACCTATATATATTTTTC TTA A TTATATTTTTTTATATAT GGC TAATTTTTTTATATATAGAAA T TTACTTTAATATATAT T TTATCA TATGT TG G T TATATATATATATGTTGGG GCT CCATATATCCGGGAGA TTTTATATGA TGGAAT ATGTGGGGAGATATGTG G T TGTGGGGAGATATGA GC G GGGGAGATAT GAAGCTACGT G GAGATGTTTGCG ACTGTG G AT TATGTGCGCTTGTGGACTG ATTGCGCTCTGTGTTT CATT G TTGCTCTGTGTGTTTTCTC C C CTCTGTGTGTTTTCGAACA A T AGTGTGTTTTCTCACAGAG G G GTGCGTTCTCACAGGG G T TTTTCTCACAGAGGGGCGC C T TCTCACAGAGGGGCGCTCT T C CACAGAGGGGCGCTCTATTAA A AGAGGGGCGCTCTATT AT GCG GGGGCCTATATATGTG G GGT GCTCTATATTGA CGA C CTTATATGTGAGACAC  CCTATATGTATGACACACA A A ATATGTGAATTACACAGAG TGG TGTGATTTACACAGAGGGG G G GAGACGGGAGGGGACCTA A ACACACAG ACG CTGCAA GCG CACAGAGGGGAGAAAAGTTAG AGACAGGGGAGAAA CAGCGC C G GGGAAAAGAGCCG CCT GAAAGGCGCGGGG G AGC AAGAGCGCGTTTTATAC G ACTTAGCGCGCGGGGGGG G G GCGCGCGGGGGGGGGGGGG G C CGATCGGGGGGGGGGG G G TAGGGGGGGGGGGGGGT GGGGGGGGACAGGTTG G G GGGGGGGGGGTGTGTGGGG G G GGGGGGTGTGGGGCGC C G GGGGTTGGGGCC G GTGTGTGGGTTTTCCCGCG TGA TGTGGGGCGCCATGCGTGT T GCACGGCGCCCCGCGTGGCTT T G GCGCCCCCCGTTTGTG G C CCCCGCGTGTTTTGTGAGA A CGA CCGTTGGAA AGA GGTTG CTGAGAAAATAT T T TTCTGTGAGAAAATATGTG G T TGG TGAAAATATGTGTGT T G GATGGAATATGTGTTT T AGGAAATT CTGTGTT GGTT T A ATATGTGTCTTTTTTTTTT T TTGTGTTATGTTCTC  GTGTTTTTTTTTTCTCCCC C T TTTTTTTTTTCTCC ATCT T T TTTTTTTCTTTCCTGGGTT T T TTTTCTCCCCT AGTTATA  TCTCCG GCTTTTAGC CCGC CCCTCTTTTAACCC CCTTTGATACACCCCCC T TTTACACCCCCCC  TAAAGACCCCCCCCCCCCC C AACCCCGCCCCCCCCGCG G C CCCCCCCC GCCGAGA A C CCCCCCCCCCGCGAGAAAA A C CCCCCAC CGAGAAAAGAG GGA CCCCGCGAGAAAAGGG G C CGTCAGAAAAGAGGGG  GATA AAGAGGGGGGGAGA A A AAAAGAGGGGGGGAGAAAA A AA TAGGGGGGGAGAATACAG G G GGGGGGGAGAAAAGGC CG  GGGGAGAAAAGAGCGCCCC C G GAGAAAAGAGCGCCCCTCT T A AAAAGAGCGCCCCTCTTTT T ACTGAGCGCCCCTCTTTTTTT T G GCGCCCCTGTTTTTTCCTT T C CCCCTCTTGACTTTGTTTCCAGCCTTTTTTTTTTTTTATA A T TTTTTTTTTTTTTATACC TAGGTTTAG CT CG G T TTGG TTAACGCGGGG G TTTATACACGCGGGGC AAC T ATACGCGGGCGCG G ACCTACGCGGGGCAAGCGGGG G C CGGGCTTTCGGGC C G GGT AGCGCGGGGCGCACA TGC GCCGGGGCGCAGGAGG C CT ACGGGGC GGACTCT T GGGCGCACACACTTTTTT T GGCACACACTGGAA C CAACT TTTTATATTTTT A ACTTTCTTATTTT T C CTTTATAT AGAT TT  AT TTTTAGGGATTTTTTTTTT T T TATATATTACCCGGTTCTC C A ATATTTTTCTTTTCTCCC T TTTTTTTCTCCCCTG GT T TTTTTGCCTCCCCTTC C T TTTTCTCCCTCCGGCC C T TCTCC TCCTCTCCGA ATGCCTCCTA CTG TTG CTCTCTGAGA  TCTCCCCTTGGTTAGAGAG G C CCCCTCTGTGAGAGAGCTACC C CTGGATGAAGCGCG TGTGAGAGAGCGG CT GAGTTAGCGCGGCTTGG G A AGAGCGCGCGGGGGGGCGC C GGCGCGGGGGGGCGCA,"ID   YYAL_BACSU              Reviewed;         689 AA.
AC   P37512;
DT   01-OCT-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1994, sequence version 1.
DT   05-FEB-2025, entry version 142.
DE   RecName: Full=Uncharacterized protein YyaL;
GN   Name=yyaL; OrderedLocusNames=BSU40820;
OS   Bacillus subtilis (strain 168).
OC   Bacteria; Bacillati; Bacillota; Bacilli; Bacillales; Bacillaceae; Bacillus.
OX   NCBI_TaxID=224308;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=168;
RX   PubMed=7584024; DOI=10.1093/dnares/1.1.1;
RA   Ogasawara N., Nakai S., Yoshikawa H.;
RT   ""Systematic sequencing of the 180 kilobase region of the Bacillus subtilis
RT   chromosome containing the replication origin."";
RL   DNA Res. 1:1-14(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=168;
RX   PubMed=9384377; DOI=10.1038/36786;
RA   Kunst F., Ogasawara N., Moszer I., Albertini A.M., Alloni G., Azevedo V.,
RA   Bertero M.G., Bessieres P., Bolotin A., Borchert S., Borriss R.,
RA   Boursier L., Brans A., Braun M., Brignell S.C., Bron S., Brouillet S.,
RA   Bruschi C.V., Caldwell B., Capuano V., Carter N.M., Choi S.-K.,
RA   Codani J.-J., Connerton I.F., Cummings N.J., Daniel R.A., Denizot F.,
RA   Devine K.M., Duesterhoeft A., Ehrlich S.D., Emmerson P.T., Entian K.-D.,
RA   Errington J., Fabret C., Ferrari E., Foulger D., Fritz C., Fujita M.,
RA   Fujita Y., Fuma S., Galizzi A., Galleron N., Ghim S.-Y., Glaser P.,
RA   Goffeau A., Golightly E.J., Grandi G., Guiseppi G., Guy B.J., Haga K.,
RA   Haiech J., Harwood C.R., Henaut A., Hilbert H., Holsappel S., Hosono S.,
RA   Hullo M.-F., Itaya M., Jones L.-M., Joris B., Karamata D., Kasahara Y.,
RA   Klaerr-Blanchard M., Klein C., Kobayashi Y., Koetter P., Koningstein G.,
RA   Krogh S., Kumano M., Kurita K., Lapidus A., Lardinois S., Lauber J.,
RA   Lazarevic V., Lee S.-M., Levine A., Liu H., Masuda S., Mauel C.,
RA   Medigue C., Medina N., Mellado R.P., Mizuno M., Moestl D., Nakai S.,
RA   Noback M., Noone D., O'Reilly M., Ogawa K., Ogiwara A., Oudega B.,
RA   Park S.-H., Parro V., Pohl T.M., Portetelle D., Porwollik S.,
RA   Prescott A.M., Presecan E., Pujic P., Purnelle B., Rapoport G., Rey M.,
RA   Reynolds S., Rieger M., Rivolta C., Rocha E., Roche B., Rose M., Sadaie Y.,
RA   Sato T., Scanlan E., Schleich S., Schroeter R., Scoffone F., Sekiguchi J.,
RA   Sekowska A., Seror S.J., Serror P., Shin B.-S., Soldo B., Sorokin A.,
RA   Tacconi E., Takagi T., Takahashi H., Takemaru K., Takeuchi M.,
RA   Tamakoshi A., Tanaka T., Terpstra P., Tognoni A., Tosato V., Uchiyama S.,
RA   Vandenbol M., Vannier F., Vassarotti A., Viari A., Wambutt R., Wedler E.,
RA   Wedler H., Weitzenegger T., Winters P., Wipat A., Yamamoto H., Yamane K.,
RA   Yasumoto K., Yata K., Yoshida K., Yoshikawa H.-F., Zumstein E.,
RA   Yoshikawa H., Danchin A.;
RT   ""The complete genome sequence of the Gram-positive bacterium Bacillus
RT   subtilis."";
RL   Nature 390:249-256(1997).
CC   -!- SIMILARITY: To C.elegans B0495.5. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D26185; BAA05212.1; -; Genomic_DNA.
DR   EMBL; AL009126; CAB16119.1; -; Genomic_DNA.
DR   PIR; S66006; S66006.
DR   RefSeq; NP_391962.1; NC_000964.3.
DR   RefSeq; WP_009968448.1; NZ_OZ025638.1.
DR   AlphaFoldDB; P37512; -.
DR   SMR; P37512; -.
DR   STRING; 224308.BSU40820; -.
DR   PaxDb; 224308-BSU40820; -.
DR   DNASU; 937904; -.
DR   EnsemblBacteria; CAB16119; CAB16119; BSU_40820.
DR   GeneID; 937904; -.
DR   KEGG; bsu:BSU40820; -.
DR   PATRIC; fig|224308.179.peg.4423; -.
DR   eggNOG; COG1331; Bacteria.
DR   InParanoid; P37512; -.
DR   OrthoDB; 9762614at2; -.
DR   PhylomeDB; P37512; -.
DR   BioCyc; BSUB:BSU40820-MONOMER; -.
DR   Proteomes; UP000001570; Chromosome.
DR   GO; GO:0005975; P:carbohydrate metabolic process; IEA:InterPro.
DR   CDD; cd02955; SSP411; 1.
DR   Gene3D; 1.50.10.10; -; 1.
DR   Gene3D; 1.50.10.20; -; 1.
DR   Gene3D; 3.40.30.10; Glutaredoxin; 1.
DR   InterPro; IPR008928; 6-hairpin_glycosidase_sf.
DR   InterPro; IPR012341; 6hp_glycosidase-like_sf.
DR   InterPro; IPR004879; DUF255.
DR   InterPro; IPR024705; Ssp411.
DR   InterPro; IPR036249; Thioredoxin-like_sf.
DR   PANTHER; PTHR42899; SPERMATOGENESIS-ASSOCIATED PROTEIN 20; 1.
DR   PANTHER; PTHR42899:SF1; SPERMATOGENESIS-ASSOCIATED PROTEIN 20; 1.
DR   Pfam; PF03190; Thioredox_DsbH; 1.
DR   PIRSF; PIRSF006402; UCP006402_thioredoxin; 1.
DR   SUPFAM; SSF48208; Six-hairpin glycosidases; 1.
DR   SUPFAM; SSF52833; Thioredoxin-like; 1.
PE   4: Predicted;
KW   Reference proteome.
FT   CHAIN           1..689
FT                   /note=""Uncharacterized protein YyaL""
FT                   /id=""PRO_0000050054""
SQ   SEQUENCE   689 AA;  78755 MW;  DB4783D97371428F CRC64;
     MPNKSKPNRL INEKSPYLLQ HAHNPVDWFP WGEEAFEKAK RENKPVLVSI GYSTCHWCHV
     MAHESFEDEE IARLLNERFV AIKVDREERP DVDSVYMRIC QLMTGQGGWP LNVFITPDQK
     PFYAGTYFPK TSKFNRPGFV DVLEHLSETF ANDREHVEDI AENAAKHLQT KTAAKTGEGL
     SESAIHRTFQ QLASGFDTIY GGFGQAPKFP MPHMLMYLLR YDHNTGQENA LYNVTKTLDS
     MANGGIYDHI GYGFARYSTD DEWLVPHFEK MLYDNALLLT AYTEAYQVTQ NSRYKEICEQ
     IITFIQREMT HEDGSFFSAL DADTEGEEGK YYVWSKEEIL KTLGDDLGTL YCQVYDITEE
     GNFEGKNIPN LIHTKREQIK EDAGLTEKEL SLKLEDARQQ LLKTREERTY PHVDDKVLTS
     WNALMIAGLA KAAKVYQEPK YLSLAKDAIT FIENKLIIDG RVMVRYRDGE VKNKGFIDDY
     AFLLWAYLDL YEASFDLSYL QKAKKLTDDM ISLFWDEEHG GFYFTGHDAE ALIVREKEVY
     DGAVPSGNSV AAVQLLRLGQ VTGDLSLIEK AETMFSVFKP DIEAYPSGHA FFMQSVLRHL
     MPKKEIVIFG SADDPARKQI IAELQKAFKP NDSILVAEQP EQCKDIAPFA ADYRIIDGKT
     TVYICENFAC QQPTTNIEEA IHTLISSRD
//
",60844
GCCGTG CCGTGG CGTGGC GTGGCT TGGCTG GGCTGT GCTGTC CTGTCG TGTCGT GTCGTC TCGTCG CGTCGG GTCGGT TCGGTG CGGTGC GGTGCG GTGCGG TGCGGT GCGGTG CGGTGC GGTGCT GTGCTG TGCTGC GCTGCC CTGCCG TGCCGG GCCGGG CCGGGT CGGGTG GGGTGA GGTGAT GTGATT TGATTT GATTTC ATTTCA TTTCAA TTCAAG TCAAGA CAAGAT AAGATC AGATCA GATCAA ATCAAG TCAAGC CAAGCC AAGCCC AGCCCG GCCCGC CCCGCC CCGCCA CGCCAA GCCAAG CCAAGC CAAGCT AAGCTG AGCTGC GCTGCG CTGCGT TGCGTG GCGTGG CGTGGT GTGGTG TGGTGT GGTGTC GTGTCG TGTCGA GTCGAG,3,67,GCCG CCGT CGTG GTGG TGGC GGCT GCTG CTGT TGTC GTCG TCGT CGTC GTCG TCGG CGGT GGTG GTGC TGCG GCGG CGGT GGTG GTGC TGCT GCTG CTGC TGCC GCCG CCGG CGGG GGGT GGTG GTGA TGAT GATT ATTT TTTC TTCA TCAA CAAG AAGA AGAT GATC ATCA TCAA CAAG AAGC AGCC GCCC CCCG CCGC CGCC GCCA CCAA CAAG AAGC AGCT GCTG CTGC TGCG GCGT CGTG GTGG TGGT GGTG GTGT TGTC GTCG TCGA CGAG,GCCGT CCGTG CGTGG GTGGC TGGCT GGCTG GCTGT CTGTC TGTCG GTCGT TCGTC CGTCG GTCGG TCGGT CGGTG GGTGC GTGCG TGCGG GCGGT CGGTG GGTGC GTGCT TGCTG GCTGC CTGCC TGCCG GCCGG CCGGG CGGGT GGGTG GGTGA GTGAT TGATT GATTT ATTTC TTTCA TTCAA TCAAG CAAGA AAGAT AGATC GATCA ATCAA TCAAG CAAGC AAGCC AGCCC GCCCG CCCGC CCGCC CGCCA GCCAA CCAAG CAAGC AAGCT AGCTG GCTGC CTGCG TGCGT GCGTG CGTGG GTGGT TGGTG GGTGT GTGTC TGTCG GTCGA TCGAG,GCCGTG CCGTGG CGTGGC GTGGCT TGGCTG GGCTGT GCTGTC CTGTCG TGTCGT GTCGTC TCGTCG CGTCGG GTCGGT TCGGTG CGGTGC GGTGCG GTGCGG TGCGGT GCGGTG CGGTGC GGTGCT GTGCTG TGCTGC GCTGCC CTGCCG TGCCGG GCCGGG CCGGGT CGGGTG GGGTGA GGTGAT GTGATT TGATTT GATTTC ATTTCA TTTCAA TTCAAG TCAAGA CAAGAT AAGATC AGATCA GATCAA ATCAAG TCAAGC CAAGCC AAGCCC AGCCCG GCCCGC CCCGCC CCGCCA CGCCAA GCCAAG CCAAGC CAAGCT AAGCTG AGCTGC GCTGCG CTGCGT TGCGTG GCGTGG CGTGGT GTGGTG TGGTGT GGTGTC GTGTCG TGTCGA GTCGAG,GCCGTGG CCGTGGC CGTGGCT GTGGCTG TGGCTGT GGCTGTC GCTGTCG CTGTCGT TGTCGTC GTCGTCG TCGTCGG CGTCGGT GTCGGTG TCGGTGC CGGTGCG GGTGCGG GTGCGGT TGCGGTG GCGGTGC CGGTGCT GGTGCTG GTGCTGC TGCTGCC GCTGCCG CTGCCGG TGCCGGG GCCGGGT CCGGGTG CGGGTGA GGGTGAT GGTGATT GTGATTT TGATTTC GATTTCA ATTTCAA TTTCAAG TTCAAGA TCAAGAT CAAGATC AAGATCA AGATCAA GATCAAG ATCAAGC TCAAGCC CAAGCCC AAGCCCG AGCCCGC GCCCGCC CCCGCCA CCGCCAA CGCCAAG GCCAAGC CCAAGCT CAAGCTG AAGCTGC AGCTGCG GCTGCGT CTGCGTG TGCGTGG GCGTGGT CGTGGTG GTGGTGT TGGTGTC GGTGTCG GTGTCGA TGTCGAG,"ID   SYFB_COLP3              Reviewed;         807 AA.
AC   Q47ZS5;
DT   04-APR-2006, integrated into UniProtKB/Swiss-Prot.
DT   13-SEP-2005, sequence version 1.
DT   05-FEB-2025, entry version 109.
DE   RecName: Full=Phenylalanine--tRNA ligase beta subunit {ECO:0000255|HAMAP-Rule:MF_00283};
DE            EC=6.1.1.20 {ECO:0000255|HAMAP-Rule:MF_00283};
DE   AltName: Full=Phenylalanyl-tRNA synthetase beta subunit {ECO:0000255|HAMAP-Rule:MF_00283};
DE            Short=PheRS {ECO:0000255|HAMAP-Rule:MF_00283};
GN   Name=pheT {ECO:0000255|HAMAP-Rule:MF_00283};
GN   OrderedLocusNames=CPS_2995;
OS   Colwellia psychrerythraea (strain 34H / ATCC BAA-681) (Vibrio
OS   psychroerythus).
OC   Bacteria; Pseudomonadota; Gammaproteobacteria; Alteromonadales;
OC   Colwelliaceae; Colwellia.
OX   NCBI_TaxID=167879;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=34H / ATCC BAA-681;
RX   PubMed=16043709; DOI=10.1073/pnas.0504766102;
RA   Methe B.A., Nelson K.E., Deming J.W., Momen B., Melamud E., Zhang X.,
RA   Moult J., Madupu R., Nelson W.C., Dodson R.J., Brinkac L.M.,
RA   Daugherty S.C., Durkin A.S., DeBoy R.T., Kolonay J.F., Sullivan S.A.,
RA   Zhou L., Davidsen T.M., Wu M., Huston A.L., Lewis M., Weaver B.,
RA   Weidman J.F., Khouri H., Utterback T.R., Feldblyum T.V., Fraser C.M.;
RT   ""The psychrophilic lifestyle as revealed by the genome sequence of
RT   Colwellia psychrerythraea 34H through genomic and proteomic analyses."";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:10913-10918(2005).
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=tRNA(Phe) + L-phenylalanine + ATP = L-phenylalanyl-tRNA(Phe) +
CC         AMP + diphosphate + H(+); Xref=Rhea:RHEA:19413, Rhea:RHEA-COMP:9668,
CC         Rhea:RHEA-COMP:9699, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:33019, ChEBI:CHEBI:58095, ChEBI:CHEBI:78442,
CC         ChEBI:CHEBI:78531, ChEBI:CHEBI:456215; EC=6.1.1.20;
CC         Evidence={ECO:0000255|HAMAP-Rule:MF_00283};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000255|HAMAP-
CC         Rule:MF_00283};
CC       Note=Binds 2 magnesium ions per tetramer. {ECO:0000255|HAMAP-
CC       Rule:MF_00283};
CC   -!- SUBUNIT: Tetramer of two alpha and two beta subunits.
CC       {ECO:0000255|HAMAP-Rule:MF_00283}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000255|HAMAP-Rule:MF_00283}.
CC   -!- SIMILARITY: Belongs to the phenylalanyl-tRNA synthetase beta subunit
CC       family. Type 1 subfamily. {ECO:0000255|HAMAP-Rule:MF_00283}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CP000083; AAZ26606.1; -; Genomic_DNA.
DR   RefSeq; WP_011043783.1; NC_003910.7.
DR   AlphaFoldDB; Q47ZS5; -.
DR   SMR; Q47ZS5; -.
DR   STRING; 167879.CPS_2995; -.
DR   KEGG; cps:CPS_2995; -.
DR   eggNOG; COG0072; Bacteria.
DR   eggNOG; COG0073; Bacteria.
DR   HOGENOM; CLU_016891_0_0_6; -.
DR   Proteomes; UP000000547; Chromosome.
DR   GO; GO:0009328; C:phenylalanine-tRNA ligase complex; IEA:TreeGrafter.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0004826; F:phenylalanine-tRNA ligase activity; IEA:UniProtKB-UniRule.
DR   GO; GO:0000049; F:tRNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0006432; P:phenylalanyl-tRNA aminoacylation; IEA:UniProtKB-UniRule.
DR   CDD; cd00769; PheRS_beta_core; 1.
DR   CDD; cd02796; tRNA_bind_bactPheRS; 1.
DR   FunFam; 2.40.50.140:FF:000045; Phenylalanine--tRNA ligase beta subunit; 1.
DR   FunFam; 3.30.56.10:FF:000002; Phenylalanine--tRNA ligase beta subunit; 1.
DR   FunFam; 3.30.70.380:FF:000001; Phenylalanine--tRNA ligase beta subunit; 1.
DR   FunFam; 3.30.930.10:FF:000022; Phenylalanine--tRNA ligase beta subunit; 1.
DR   FunFam; 3.50.40.10:FF:000001; Phenylalanine--tRNA ligase beta subunit; 1.
DR   Gene3D; 3.30.56.10; -; 2.
DR   Gene3D; 3.30.930.10; Bira Bifunctional Protein, Domain 2; 1.
DR   Gene3D; 3.30.70.380; Ferrodoxin-fold anticodon-binding domain; 1.
DR   Gene3D; 2.40.50.140; Nucleic acid-binding proteins; 1.
DR   Gene3D; 3.50.40.10; Phenylalanyl-trna Synthetase, Chain B, domain 3; 1.
DR   HAMAP; MF_00283; Phe_tRNA_synth_beta1; 1.
DR   InterPro; IPR045864; aa-tRNA-synth_II/BPL/LPL.
DR   InterPro; IPR005146; B3/B4_tRNA-bd.
DR   InterPro; IPR009061; DNA-bd_dom_put_sf.
DR   InterPro; IPR005121; Fdx_antiC-bd.
DR   InterPro; IPR036690; Fdx_antiC-bd_sf.
DR   InterPro; IPR012340; NA-bd_OB-fold.
DR   InterPro; IPR045060; Phe-tRNA-ligase_IIc_bsu.
DR   InterPro; IPR004532; Phe-tRNA-ligase_IIc_bsu_bact.
DR   InterPro; IPR020825; Phe-tRNA_synthase-like_B3/B4.
DR   InterPro; IPR041616; PheRS_beta_core.
DR   InterPro; IPR002547; tRNA-bd_dom.
DR   InterPro; IPR033714; tRNA_bind_bactPheRS.
DR   InterPro; IPR005147; tRNA_synthase_B5-dom.
DR   NCBIfam; TIGR00472; pheT_bact; 1.
DR   NCBIfam; NF045760; YtpR; 1.
DR   PANTHER; PTHR10947:SF0; PHENYLALANINE--TRNA LIGASE BETA SUBUNIT; 1.
DR   PANTHER; PTHR10947; PHENYLALANYL-TRNA SYNTHETASE BETA CHAIN AND LEUCINE-RICH REPEAT-CONTAINING PROTEIN 47; 1.
DR   Pfam; PF03483; B3_4; 1.
DR   Pfam; PF03484; B5; 1.
DR   Pfam; PF03147; FDX-ACB; 1.
DR   Pfam; PF01588; tRNA_bind; 1.
DR   Pfam; PF17759; tRNA_synthFbeta; 1.
DR   SMART; SM00873; B3_4; 1.
DR   SMART; SM00874; B5; 1.
DR   SMART; SM00896; FDX-ACB; 1.
DR   SUPFAM; SSF54991; Anticodon-binding domain of PheRS; 1.
DR   SUPFAM; SSF55681; Class II aaRS and biotin synthetases; 1.
DR   SUPFAM; SSF50249; Nucleic acid-binding proteins; 1.
DR   SUPFAM; SSF56037; PheT/TilS domain; 1.
DR   SUPFAM; SSF46955; Putative DNA-binding domain; 1.
DR   PROSITE; PS51483; B5; 1.
DR   PROSITE; PS51447; FDX_ACB; 1.
DR   PROSITE; PS50886; TRBD; 1.
PE   3: Inferred from homology;
KW   Aminoacyl-tRNA synthetase; ATP-binding; Cytoplasm; Ligase; Magnesium;
KW   Metal-binding; Nucleotide-binding; Protein biosynthesis; RNA-binding;
KW   tRNA-binding.
FT   CHAIN           1..807
FT                   /note=""Phenylalanine--tRNA ligase beta subunit""
FT                   /id=""PRO_0000232055""
FT   DOMAIN          39..156
FT                   /note=""tRNA-binding""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00283""
FT   DOMAIN          409..488
FT                   /note=""B5""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00283""
FT   DOMAIN          713..806
FT                   /note=""FDX-ACB""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00283""
FT   BINDING         466
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /ligand_note=""shared with alpha subunit""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00283""
FT   BINDING         472
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /ligand_note=""shared with alpha subunit""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00283""
FT   BINDING         475
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /ligand_note=""shared with alpha subunit""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00283""
FT   BINDING         476
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /ligand_note=""shared with alpha subunit""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00283""
SQ   SEQUENCE   807 AA;  88213 MW;  4E296F84F26C41D3 CRC64;
     MKFSESWLRE WVNPALSSDD LAHQITMAGL EVDGVDPVAG EFSGVVIGEV VECGPHPDAD
     KLQVTKISLG DYSSTTVEKG ELVTIVCGAK NCRLGLKVAV ATVGAVLPGD FKIKKAKLRG
     VPSFGMLCSE SEIGLADDSD GIMELASDAP LGQCVREYLD LNDVTIDVDL TANRGDCLGL
     KGLAREVGVL NSLEVSEPTI TAVAPTIDDV ITINIEANEA CPRYLGRVIK GINPNATTPL
     WMVEKLRRCG TRSIDPVVDV TNYILLELGH PMHAFDLAKL DGGINVRFAN KDEKLTLLDE
     NEVTLKEGTL VIADENKALA MAGIFGGLES GVTNNTTDLF LESAFFAPLA ILGKARQYGL
     HTDSSHRYER GIDPTLQHDA IERATELLLS IVGGQAGPVV EAKSDADIPQ TKDVNLRRKM
     LDSRIGHHIE DAQVSEILTR LGFTVTTTGE GEAKVWQVIV PAYRFDIKIE VDLIEEVARI
     FGYNNIPNIA PKATLKMCEQ KEANLSLSNL KQTLVNRDYQ EAITYSFVDP KVQALLHPGQ
     EVMTLPHPIS SEMSVMRLSL WTGLLQSMVY NQNRQQGRIR LFETGLRFVP DESAENGVRQ
     QNMIAGVISG LRVDEHWSME KAATDFYDIK GDVEALLALT CDAQGYEFSK AEVDALHPGQ
     TAQITKNGVF VGCVGTLHPE LERKLGLNGR TLIFELLLSE VLVQKIPEAT DISRFPANRR
     DLAIVVKEDV DAKNVLQLIE KVGGNYLIDL NLFDVYKGQG IDDGFKSLAI ALVLQDTSKT
     LEEKDITDVI DRVVATLKTE LNASLRD
//
",62694
CCCACG CCACGC CACGCA ACGCAG CGCAGG GCAGGT CAGGTG AGGTGC GGTGCT GTGCTG TGCTGG GCTGGT CTGGTG TGGTGC GGTGCT GTGCTG TGCTGG GCTGGC CTGGCA TGGCAG GGCAGG GCAGGC CAGGCG AGGCGG GGCGGG GCGGGC CGGGCA GGGCAG GGCAGG GCAGGA CAGGAC AGGACT GGACTT GACTTT ACTTTT CTTTTT TTTTTC TTTTCT TTTCTC TTCTCC TCTCCA CTCCAA TCCAAC CCAACG CAACGG AACGGC ACGGCA CGGCAT GGCATC GCATCC CATCCA ATCCAC TCCACC CCACCT CACCTG ACCTGC CCTGCA CTGCAT TGCATG GCATGC CATGCC ATGCCG TGCCGT GCCGTT CCGTTG CGTTGA GTTGAA TTGAAG TGAAGC GAAGCC AAGCCG AGCCGC GCCGCA CCGCAC CGCACA GCACAG CACAGC ACAGCG CAGCGC AGCGCG GCGCGT CGCGTG GCGTGG CGTGGC GTGGCA TGGCAG GGCAGG GCAGGC CAGGCG AGGCGA GGCGAC GCGACA CGACAG GACAGT ACAGTG CAGTGC AGTGCA GTGCAG TGCAGC GCAGCG CAGCGG AGCGGA GCGGAC CGGACG GGACGC GACGCC ACGCCT CGCCTC GCCTCC CCTCCT CTCCTG TCCTGG CCTGGC CTGGCG TGGCGC GGCGCA GCGCAA CGCAAC GCAACA CAACAT AACATC ACATCA CATCAA ATCAAC TCAACG CAACGC AACGCC ACGCCA CGCCAT GCCATG CCATGA CATGAA ATGAAC TGAACG GAACGA AACGAT ACGATG CGATGC GATGCC ATGCCA TGCCAC GCCACG,3,142,CCCA CCAC CACG ACGC CGCA GCAG CAGG AGGT GGTG GTGC TGCT GCTG CTGG TGGT GGTG GTGC TGCT GCTG CTGG TGGC GGCA GCAG CAGG AGGC GGCG GCGG CGGG GGGC GGCA GCAG CAGG AGGA GGAC GACT ACTT CTTT TTTT TTTT TTTC TTCT TCTC CTCC TCCA CCAA CAAC AACG ACGG CGGC GGCA GCAT CATC ATCC TCCA CCAC CACC ACCT CCTG CTGC TGCA GCAT CATG ATGC TGCC GCCG CCGT CGTT GTTG TTGA TGAA GAAG AAGC AGCC GCCG CCGC CGCA GCAC CACA ACAG CAGC AGCG GCGC CGCG GCGT CGTG GTGG TGGC GGCA GCAG CAGG AGGC GGCG GCGA CGAC GACA ACAG CAGT AGTG GTGC TGCA GCAG CAGC AGCG GCGG CGGA GGAC GACG ACGC CGCC GCCT CCTC CTCC TCCT CCTG CTGG TGGC GGCG GCGC CGCA GCAA CAAC AACA ACAT CATC ATCA TCAA CAAC AACG ACGC CGCC GCCA CCAT CATG ATGA TGAA GAAC AACG ACGA CGAT GATG ATGC TGCC GCCA CCAC CACG,CCCAC CCACG CACGC ACGCA CGCAG GCAGG CAGGT AGGTG GGTGC GTGCT TGCTG GCTGG CTGGT TGGTG GGTGC GTGCT TGCTG GCTGG CTGGC TGGCA GGCAG GCAGG CAGGC AGGCG GGCGG GCGGG CGGGC GGGCA GGCAG GCAGG CAGGA AGGAC GGACT GACTT ACTTT CTTTT TTTTT TTTTC TTTCT TTCTC TCTCC CTCCA TCCAA CCAAC CAACG AACGG ACGGC CGGCA GGCAT GCATC CATCC ATCCA TCCAC CCACC CACCT ACCTG CCTGC CTGCA TGCAT GCATG CATGC ATGCC TGCCG GCCGT CCGTT CGTTG GTTGA TTGAA TGAAG GAAGC AAGCC AGCCG GCCGC CCGCA CGCAC GCACA CACAG ACAGC CAGCG AGCGC GCGCG CGCGT GCGTG CGTGG GTGGC TGGCA GGCAG GCAGG CAGGC AGGCG GGCGA GCGAC CGACA GACAG ACAGT CAGTG AGTGC GTGCA TGCAG GCAGC CAGCG AGCGG GCGGA CGGAC GGACG GACGC ACGCC CGCCT GCCTC CCTCC CTCCT TCCTG CCTGG CTGGC TGGCG GGCGC GCGCA CGCAA GCAAC CAACA AACAT ACATC CATCA ATCAA TCAAC CAACG AACGC ACGCC CGCCA GCCAT CCATG CATGA ATGAA TGAAC GAACG AACGA ACGAT CGATG GATGC ATGCC TGCCA GCCAC CCACG,CCCACG CCACGC CACGCA ACGCAG CGCAGG GCAGGT CAGGTG AGGTGC GGTGCT GTGCTG TGCTGG GCTGGT CTGGTG TGGTGC GGTGCT GTGCTG TGCTGG GCTGGC CTGGCA TGGCAG GGCAGG GCAGGC CAGGCG AGGCGG GGCGGG GCGGGC CGGGCA GGGCAG GGCAGG GCAGGA CAGGAC AGGACT GGACTT GACTTT ACTTTT CTTTTT TTTTTC TTTTCT TTTCTC TTCTCC TCTCCA CTCCAA TCCAAC CCAACG CAACGG AACGGC ACGGCA CGGCAT GGCATC GCATCC CATCCA ATCCAC TCCACC CCACCT CACCTG ACCTGC CCTGCA CTGCAT TGCATG GCATGC CATGCC ATGCCG TGCCGT GCCGTT CCGTTG CGTTGA GTTGAA TTGAAG TGAAGC GAAGCC AAGCCG AGCCGC GCCGCA CCGCAC CGCACA GCACAG CACAGC ACAGCG CAGCGC AGCGCG GCGCGT CGCGTG GCGTGG CGTGGC GTGGCA TGGCAG GGCAGG GCAGGC CAGGCG AGGCGA GGCGAC GCGACA CGACAG GACAGT ACAGTG CAGTGC AGTGCA GTGCAG TGCAGC GCAGCG CAGCGG AGCGGA GCGGAC CGGACG GGACGC GACGCC ACGCCT CGCCTC GCCTCC CCTCCT CTCCTG TCCTGG CCTGGC CTGGCG TGGCGC GGCGCA GCGCAA CGCAAC GCAACA CAACAT AACATC ACATCA CATCAA ATCAAC TCAACG CAACGC AACGCC ACGCCA CGCCAT GCCATG CCATGA CATGAA ATGAAC TGAACG GAACGA AACGAT ACGATG CGATGC GATGCC ATGCCA TGCCAC GCCACG,CCCACGC CCACGCA CACGCAG ACGCAGG CGCAGGT GCAGGTG CAGGTGC AGGTGCT GGTGCTG GTGCTGG TGCTGGT GCTGGTG CTGGTGC TGGTGCT GGTGCTG GTGCTGG TGCTGGC GCTGGCA CTGGCAG TGGCAGG GGCAGGC GCAGGCG CAGGCGG AGGCGGG GGCGGGC GCGGGCA CGGGCAG GGGCAGG GGCAGGA GCAGGAC CAGGACT AGGACTT GGACTTT GACTTTT ACTTTTT CTTTTTC TTTTTCT TTTTCTC TTTCTCC TTCTCCA TCTCCAA CTCCAAC TCCAACG CCAACGG CAACGGC AACGGCA ACGGCAT CGGCATC GGCATCC GCATCCA CATCCAC ATCCACC TCCACCT CCACCTG CACCTGC ACCTGCA CCTGCAT CTGCATG TGCATGC GCATGCC CATGCCG ATGCCGT TGCCGTT GCCGTTG CCGTTGA CGTTGAA GTTGAAG TTGAAGC TGAAGCC GAAGCCG AAGCCGC AGCCGCA GCCGCAC CCGCACA CGCACAG GCACAGC CACAGCG ACAGCGC CAGCGCG AGCGCGT GCGCGTG CGCGTGG GCGTGGC CGTGGCA GTGGCAG TGGCAGG GGCAGGC GCAGGCG CAGGCGA AGGCGAC GGCGACA GCGACAG CGACAGT GACAGTG ACAGTGC CAGTGCA AGTGCAG GTGCAGC TGCAGCG GCAGCGG CAGCGGA AGCGGAC GCGGACG CGGACGC GGACGCC GACGCCT ACGCCTC CGCCTCC GCCTCCT CCTCCTG CTCCTGG TCCTGGC CCTGGCG CTGGCGC TGGCGCA GGCGCAA GCGCAAC CGCAACA GCAACAT CAACATC AACATCA ACATCAA CATCAAC ATCAACG TCAACGC CAACGCC AACGCCA ACGCCAT CGCCATG GCCATGA CCATGAA CATGAAC ATGAACG TGAACGA GAACGAT AACGATG ACGATGC CGATGCC GATGCCA ATGCCAC TGCCACG,"ID   HOXX_BRADU              Reviewed;         566 AA.
AC   P31907;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   28-FEB-2003, sequence version 2.
DT   05-FEB-2025, entry version 120.
DE   RecName: Full=Hydrogenase maturation factor HoxX;
GN   Name=hoxX; OrderedLocusNames=bll6926;
OS   Bradyrhizobium diazoefficiens (strain JCM 10833 / BCRC 13528 / IAM 13628 /
OS   NBRC 14792 / USDA 110).
OC   Bacteria; Pseudomonadota; Alphaproteobacteria; Hyphomicrobiales;
OC   Nitrobacteraceae; Bradyrhizobium.
OX   NCBI_TaxID=224911;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PRELIMINARY FUNCTION.
RC   STRAIN=CB1809;
RX   PubMed=8510650; DOI=10.1007/bf00281623;
RA   van Soom C., Verreth C., Sampaio M.J., Vanderleyden J.;
RT   ""Identification of a potential transcriptional regulator of hydrogenase
RT   activity in free-living Bradyrhizobium japonicum strains."";
RL   Mol. Gen. Genet. 239:235-240(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=JCM 10833 / BCRC 13528 / IAM 13628 / NBRC 14792 / USDA 110;
RX   PubMed=12597275; DOI=10.1093/dnares/9.6.189;
RA   Kaneko T., Nakamura Y., Sato S., Minamisawa K., Uchiumi T., Sasamoto S.,
RA   Watanabe A., Idesawa K., Iriguchi M., Kawashima K., Kohara M.,
RA   Matsumoto M., Shimpo S., Tsuruoka H., Wada T., Yamada M., Tabata S.;
RT   ""Complete genomic sequence of nitrogen-fixing symbiotic bacterium
RT   Bradyrhizobium japonicum USDA110."";
RL   DNA Res. 9:189-197(2002).
RN   [3]
RP   FUNCTION.
RX   PubMed=9171416; DOI=10.1128/jb.179.11.3676-3682.1997;
RA   Durmowicz M.C., Maier R.J.;
RT   ""Roles of HoxX and HoxA in biosynthesis of hydrogenase in Bradyrhizobium
RT   japonicum."";
RL   J. Bacteriol. 179:3676-3682(1997).
CC   -!- FUNCTION: Involved in the post-translational processing of the
CC       hydrogenase large subunit. {ECO:0000269|PubMed:9171416}.
CC   -!- CAUTION: Was originally thought to be a sensor protein involved in the
CC       regulation of hydrogenase activity. {ECO:0000305|PubMed:8510650}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Z17373; CAA78990.1; -; Genomic_DNA.
DR   EMBL; BA000040; BAC52191.1; -; Genomic_DNA.
DR   PIR; S35231; S35231.
DR   RefSeq; NP_773566.1; NC_004463.1.
DR   RefSeq; WP_011089664.1; NZ_CP011360.1.
DR   AlphaFoldDB; P31907; -.
DR   SMR; P31907; -.
DR   STRING; 224911.AAV28_32220; -.
DR   EnsemblBacteria; BAC52191; BAC52191; BAC52191.
DR   GeneID; 46493892; -.
DR   KEGG; bja:bll6926; -.
DR   PATRIC; fig|224911.44.peg.6960; -.
DR   eggNOG; COG0223; Bacteria.
DR   eggNOG; COG1024; Bacteria.
DR   HOGENOM; CLU_008537_1_0_5; -.
DR   InParanoid; P31907; -.
DR   OrthoDB; 580992at2; -.
DR   Proteomes; UP000002526; Chromosome.
DR   GO; GO:0003824; F:catalytic activity; IEA:InterPro.
DR   GO; GO:0009058; P:biosynthetic process; IEA:InterPro.
DR   CDD; cd06558; crotonase-like; 1.
DR   CDD; cd08701; FMT_C_HypX; 1.
DR   CDD; cd08650; FMT_core_HypX_N; 1.
DR   Gene3D; 3.40.50.12230; -; 1.
DR   Gene3D; 3.90.226.10; 2-enoyl-CoA Hydratase, Chain A, domain 1; 1.
DR   InterPro; IPR029045; ClpP/crotonase-like_dom_sf.
DR   InterPro; IPR001753; Enoyl-CoA_hydra/iso.
DR   InterPro; IPR005793; Formyl_trans_C.
DR   InterPro; IPR002376; Formyl_transf_N.
DR   InterPro; IPR036477; Formyl_transf_N_sf.
DR   InterPro; IPR011034; Formyl_transferase-like_C_sf.
DR   InterPro; IPR047180; HoxX-like.
DR   InterPro; IPR009188; NiFe-hyd_mat_HypX/HoxX.
DR   PANTHER; PTHR43388; HYDROGENASE MATURATION FACTOR HOXX; 1.
DR   PANTHER; PTHR43388:SF1; HYDROGENASE MATURATION FACTOR HOXX; 1.
DR   Pfam; PF00378; ECH_1; 1.
DR   Pfam; PF02911; Formyl_trans_C; 1.
DR   Pfam; PF00551; Formyl_trans_N; 1.
DR   PIRSF; PIRSF006787; Hydrgn_mat_HoxX; 1.
DR   SUPFAM; SSF52096; ClpP/crotonase; 1.
DR   SUPFAM; SSF50486; FMT C-terminal domain-like; 1.
DR   SUPFAM; SSF53328; Formyltransferase; 1.
PE   4: Predicted;
KW   Reference proteome.
FT   CHAIN           1..566
FT                   /note=""Hydrogenase maturation factor HoxX""
FT                   /id=""PRO_0000209510""
FT   CONFLICT        113
FT                   /note=""I -> V (in Ref. 1)""
FT                   /evidence=""ECO:0000305""
FT   CONFLICT        115
FT                   /note=""S -> A (in Ref. 1)""
FT                   /evidence=""ECO:0000305""
FT   CONFLICT        123
FT                   /note=""C -> R (in Ref. 1; CAA78990)""
FT                   /evidence=""ECO:0000305""
FT   CONFLICT        161
FT                   /note=""A -> V (in Ref. 1; CAA78990)""
FT                   /evidence=""ECO:0000305""
FT   CONFLICT        187
FT                   /note=""M -> A (in Ref. 1; CAA78990)""
FT                   /evidence=""ECO:0000305""
FT   CONFLICT        252
FT                   /note=""K -> R (in Ref. 1; CAA78990)""
FT                   /evidence=""ECO:0000305""
FT   CONFLICT        345
FT                   /note=""E -> G (in Ref. 1; CAA78990)""
FT                   /evidence=""ECO:0000305""
FT   CONFLICT        406
FT                   /note=""I -> V (in Ref. 1; CAA78990)""
FT                   /evidence=""ECO:0000305""
FT   CONFLICT        474
FT                   /note=""Q -> R (in Ref. 1; CAA78990)""
FT                   /evidence=""ECO:0000305""
SQ   SEQUENCE   566 AA;  61710 MW;  810E1D0DE8E2E7C8 CRC64;
     MRILLLSHSF NSLTQRLHVE LRERGHEVSV ELDIHADVTR ESVALHRPDL VIAPFLKRAI
     PDDVWRSVRC LVVHPGPPGD RGPAALDWAV LEGVAEWGVT VLQADGEFDA GPIWSFRSFP
     MRCAAKSSIY RNELTSCAVA AVLEAVAAIE AGQAAPQPMQ AGDPRIRVRG PCRQADRTID
     WQHDSTMTVL RKINSADGMP GLVDSLFFQE VRLFDAHEAH DISGVPGTVI AQCEGALARA
     TVDGAVWIGH VKRLAPKSLK LPAAKVFAAE AAYLPHRPGC GYAPIRYREH GEVGELAFSF
     YNGAMATGDC EALLGAYRAA LERPTRVLLL TGGPDYWSNG IHLAEIEAAE SAADESWRNI
     NAIDDLARAI IETTDRLVVS VIRGNAGAGG VFLSLAADEV WASDQIILNP HYKDMGNLYG
     SEYWTYLLPR RAGAANATRI TQCRLPMGVA EARRLAIVDR VLSGEALADA SLVQSGAAMA
     SDAGFAARLA AKQQRRAADE AEKPLQSYRD EELRRMKLNF YGFDPSYHVA RYNFIHKVPK
     SRTPLTIAGH RIRRAPGRPV GMAVSS
//
",30736
ACATAT CATATG ATATGA TATGAT ATGATT TGATTG GATTGT ATTGTT TTGTTT TGTTTT GTTTTC TTTTCG TTTCGT TTCGTC TCGTCA CGTCAA GTCAAA TCAAAT CAAATC AAATCG AATCGT ATCGTT TCGTTG CGTTGC GTTGCC TTGCCT TGCCTC GCCTCC CCTCCG CTCCGA TCCGAA CCGAAG CGAAGG GAAGGC AAGGCC AGGCCT GGCCTT GCCTTT CCTTTT CTTTTC TTTTCA TTTCAA TTCAAG TCAAGG CAAGGG AAGGGT AGGGTC GGGTCT GGTCTC GTCTCT TCTCTA CTCTAT TCTATC CTATCA TATCAT ATCATG TCATGG CATGGT ATGGTA TGGTAT GGTATC GTATCG TATCGA ATCGAA TCGAAG CGAAGC GAAGCA AAGCAC AGCACA GCACAA CACAAT ACAATT CAATTA AATTAT ATTATG TTATGG TATGGC ATGGCG TGGCGT GGCGTA GCGTAA CGTAAC GTAACG TAACGT AACGTT ACGTTG CGTTGT GTTGTC TTGTCT TGTCTG GTCTGG TCTGGA CTGGAA TGGAAC GGAACA GAACAC AACACC ACACCG CACCGT ACCGTC CCGTCT CGTCTA GTCTAC TCTACT CTACTT TACTTT ACTTTG CTTTGG TTTGGT TTGGTA TGGTAT GGTATC GTATCA TATCAT ATCATC,2,115,ACAT CATA ATAT TATG ATGA TGAT GATT ATTG TTGT TGTT GTTT TTTT TTTC TTCG TCGT CGTC GTCA TCAA CAAA AAAT AATC ATCG TCGT CGTT GTTG TTGC TGCC GCCT CCTC CTCC TCCG CCGA CGAA GAAG AAGG AGGC GGCC GCCT CCTT CTTT TTTT TTTC TTCA TCAA CAAG AAGG AGGG GGGT GGTC GTCT TCTC CTCT TCTA CTAT TATC ATCA TCAT CATG ATGG TGGT GGTA GTAT TATC ATCG TCGA CGAA GAAG AAGC AGCA GCAC CACA ACAA CAAT AATT ATTA TTAT TATG ATGG TGGC GGCG GCGT CGTA GTAA TAAC AACG ACGT CGTT GTTG TTGT TGTC GTCT TCTG CTGG TGGA GGAA GAAC AACA ACAC CACC ACCG CCGT CGTC GTCT TCTA CTAC TACT ACTT CTTT TTTG TTGG TGGT GGTA GTAT TATC ATCA TCAT CATC,ACATA CATAT ATATG TATGA ATGAT TGATT GATTG ATTGT TTGTT TGTTT GTTTT TTTTC TTTCG TTCGT TCGTC CGTCA GTCAA TCAAA CAAAT AAATC AATCG ATCGT TCGTT CGTTG GTTGC TTGCC TGCCT GCCTC CCTCC CTCCG TCCGA CCGAA CGAAG GAAGG AAGGC AGGCC GGCCT GCCTT CCTTT CTTTT TTTTC TTTCA TTCAA TCAAG CAAGG AAGGG AGGGT GGGTC GGTCT GTCTC TCTCT CTCTA TCTAT CTATC TATCA ATCAT TCATG CATGG ATGGT TGGTA GGTAT GTATC TATCG ATCGA TCGAA CGAAG GAAGC AAGCA AGCAC GCACA CACAA ACAAT CAATT AATTA ATTAT TTATG TATGG ATGGC TGGCG GGCGT GCGTA CGTAA GTAAC TAACG AACGT ACGTT CGTTG GTTGT TTGTC TGTCT GTCTG TCTGG CTGGA TGGAA GGAAC GAACA AACAC ACACC CACCG ACCGT CCGTC CGTCT GTCTA TCTAC CTACT TACTT ACTTT CTTTG TTTGG TTGGT TGGTA GGTAT GTATC TATCA ATCAT TCATC,ACATAT CATATG ATATGA TATGAT ATGATT TGATTG GATTGT ATTGTT TTGTTT TGTTTT GTTTTC TTTTCG TTTCGT TTCGTC TCGTCA CGTCAA GTCAAA TCAAAT CAAATC AAATCG AATCGT ATCGTT TCGTTG CGTTGC GTTGCC TTGCCT TGCCTC GCCTCC CCTCCG CTCCGA TCCGAA CCGAAG CGAAGG GAAGGC AAGGCC AGGCCT GGCCTT GCCTTT CCTTTT CTTTTC TTTTCA TTTCAA TTCAAG TCAAGG CAAGGG AAGGGT AGGGTC GGGTCT GGTCTC GTCTCT TCTCTA CTCTAT TCTATC CTATCA TATCAT ATCATG TCATGG CATGGT ATGGTA TGGTAT GGTATC GTATCG TATCGA ATCGAA TCGAAG CGAAGC GAAGCA AAGCAC AGCACA GCACAA CACAAT ACAATT CAATTA AATTAT ATTATG TTATGG TATGGC ATGGCG TGGCGT GGCGTA GCGTAA CGTAAC GTAACG TAACGT AACGTT ACGTTG CGTTGT GTTGTC TTGTCT TGTCTG GTCTGG TCTGGA CTGGAA TGGAAC GGAACA GAACAC AACACC ACACCG CACCGT ACCGTC CCGTCT CGTCTA GTCTAC TCTACT CTACTT TACTTT ACTTTG CTTTGG TTTGGT TTGGTA TGGTAT GGTATC GTATCA TATCAT ATCATC,ACATATG CATATGA ATATGAT TATGATT ATGATTG TGATTGT GATTGTT ATTGTTT TTGTTTT TGTTTTC GTTTTCG TTTTCGT TTTCGTC TTCGTCA TCGTCAA CGTCAAA GTCAAAT TCAAATC CAAATCG AAATCGT AATCGTT ATCGTTG TCGTTGC CGTTGCC GTTGCCT TTGCCTC TGCCTCC GCCTCCG CCTCCGA CTCCGAA TCCGAAG CCGAAGG CGAAGGC GAAGGCC AAGGCCT AGGCCTT GGCCTTT GCCTTTT CCTTTTC CTTTTCA TTTTCAA TTTCAAG TTCAAGG TCAAGGG CAAGGGT AAGGGTC AGGGTCT GGGTCTC GGTCTCT GTCTCTA TCTCTAT CTCTATC TCTATCA CTATCAT TATCATG ATCATGG TCATGGT CATGGTA ATGGTAT TGGTATC GGTATCG GTATCGA TATCGAA ATCGAAG TCGAAGC CGAAGCA GAAGCAC AAGCACA AGCACAA GCACAAT CACAATT ACAATTA CAATTAT AATTATG ATTATGG TTATGGC TATGGCG ATGGCGT TGGCGTA GGCGTAA GCGTAAC CGTAACG GTAACGT TAACGTT AACGTTG ACGTTGT CGTTGTC GTTGTCT TTGTCTG TGTCTGG GTCTGGA TCTGGAA CTGGAAC TGGAACA GGAACAC GAACACC AACACCG ACACCGT CACCGTC ACCGTCT CCGTCTA CGTCTAC GTCTACT TCTACTT CTACTTT TACTTTG ACTTTGG CTTTGGT TTTGGTA TTGGTAT TGGTATC GGTATCA GTATCAT TATCATC,"ID   ODC_SCHPO               Reviewed;         298 AA.
AC   Q9P3T7;
DT   13-NOV-2007, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   27-NOV-2024, entry version 128.
DE   RecName: Full=Probable mitochondrial 2-oxodicarboxylate carrier;
GN   ORFNames=SPAC328.09;
OS   Schizosaccharomyces pombe (strain 972 / ATCC 24843) (Fission yeast).
OC   Eukaryota; Fungi; Dikarya; Ascomycota; Taphrinomycotina;
OC   Schizosaccharomycetes; Schizosaccharomycetales; Schizosaccharomycetaceae;
OC   Schizosaccharomyces.
OX   NCBI_TaxID=284812;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=972 / ATCC 24843;
RX   PubMed=11859360; DOI=10.1038/nature724;
RA   Wood V., Gwilliam R., Rajandream M.A., Lyne M.H., Lyne R., Stewart A.,
RA   Sgouros J.G., Peat N., Hayles J., Baker S.G., Basham D., Bowman S.,
RA   Brooks K., Brown D., Brown S., Chillingworth T., Churcher C.M., Collins M.,
RA   Connor R., Cronin A., Davis P., Feltwell T., Fraser A., Gentles S.,
RA   Goble A., Hamlin N., Harris D.E., Hidalgo J., Hodgson G., Holroyd S.,
RA   Hornsby T., Howarth S., Huckle E.J., Hunt S., Jagels K., James K.D.,
RA   Jones L., Jones M., Leather S., McDonald S., McLean J., Mooney P.,
RA   Moule S., Mungall K.L., Murphy L.D., Niblett D., Odell C., Oliver K.,
RA   O'Neil S., Pearson D., Quail M.A., Rabbinowitsch E., Rutherford K.M.,
RA   Rutter S., Saunders D., Seeger K., Sharp S., Skelton J., Simmonds M.N.,
RA   Squares R., Squares S., Stevens K., Taylor K., Taylor R.G., Tivey A.,
RA   Walsh S.V., Warren T., Whitehead S., Woodward J.R., Volckaert G., Aert R.,
RA   Robben J., Grymonprez B., Weltjens I., Vanstreels E., Rieger M.,
RA   Schaefer M., Mueller-Auer S., Gabel C., Fuchs M., Duesterhoeft A.,
RA   Fritzc C., Holzer E., Moestl D., Hilbert H., Borzym K., Langer I., Beck A.,
RA   Lehrach H., Reinhardt R., Pohl T.M., Eger P., Zimmermann W., Wedler H.,
RA   Wambutt R., Purnelle B., Goffeau A., Cadieu E., Dreano S., Gloux S.,
RA   Lelaure V., Mottier S., Galibert F., Aves S.J., Xiang Z., Hunt C.,
RA   Moore K., Hurst S.M., Lucas M., Rochet M., Gaillardin C., Tallada V.A.,
RA   Garzon A., Thode G., Daga R.R., Cruzado L., Jimenez J., Sanchez M.,
RA   del Rey F., Benito J., Dominguez A., Revuelta J.L., Moreno S.,
RA   Armstrong J., Forsburg S.L., Cerutti L., Lowe T., McCombie W.R.,
RA   Paulsen I., Potashkin J., Shpakovski G.V., Ussery D., Barrell B.G.,
RA   Nurse P.;
RT   ""The genome sequence of Schizosaccharomyces pombe."";
RL   Nature 415:871-880(2002).
CC   -!- FUNCTION: Transports C5-C7 oxodicarboxylates across the inner membranes
CC       of mitochondria. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane {ECO:0000305};
CC       Multi-pass membrane protein {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the mitochondrial carrier (TC 2.A.29) family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CU329670; CAB96004.1; -; Genomic_DNA.
DR   RefSeq; NP_594211.1; NM_001019634.2.
DR   AlphaFoldDB; Q9P3T7; -.
DR   SMR; Q9P3T7; -.
DR   iPTMnet; Q9P3T7; -.
DR   PaxDb; 4896-SPAC328.09.1; -.
DR   EnsemblFungi; SPAC328.09.1; SPAC328.09.1:pep; SPAC328.09.
DR   GeneID; 2543171; -.
DR   KEGG; spo:2543171; -.
DR   PomBase; SPAC328.09; -.
DR   VEuPathDB; FungiDB:SPAC328.09; -.
DR   eggNOG; KOG0754; Eukaryota.
DR   HOGENOM; CLU_015166_5_2_1; -.
DR   InParanoid; Q9P3T7; -.
DR   OMA; LPFQYQF; -.
DR   PhylomeDB; Q9P3T7; -.
DR   PRO; PR:Q9P3T7; -.
DR   Proteomes; UP000002485; Chromosome I.
DR   GO; GO:0005743; C:mitochondrial inner membrane; ISS:PomBase.
DR   GO; GO:0015139; F:alpha-ketoglutarate transmembrane transporter activity; ISS:PomBase.
DR   GO; GO:0015183; F:L-aspartate transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0005313; F:L-glutamate transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0015810; P:aspartate transmembrane transport; IBA:GO_Central.
DR   GO; GO:0015813; P:L-glutamate transmembrane transport; IBA:GO_Central.
DR   GO; GO:0043490; P:malate-aspartate shuttle; IBA:GO_Central.
DR   GO; GO:1990551; P:mitochondrial 2-oxoadipate transmembrane transport; ISS:PomBase.
DR   GO; GO:1990550; P:mitochondrial alpha-ketoglutarate transmembrane transport; ISS:PomBase.
DR   Gene3D; 1.50.40.10; Mitochondrial carrier domain; 1.
DR   InterPro; IPR002067; Mit_carrier.
DR   InterPro; IPR051752; Mito_2-oxodicarb_carrier.
DR   InterPro; IPR018108; Mitochondrial_sb/sol_carrier.
DR   InterPro; IPR023395; Mt_carrier_dom_sf.
DR   PANTHER; PTHR46356; MITOCHONDRIAL 2-OXODICARBOXYLATE CARRIER; 1.
DR   PANTHER; PTHR46356:SF1; MITOCHONDRIAL 2-OXODICARBOXYLATE CARRIER; 1.
DR   Pfam; PF00153; Mito_carr; 3.
DR   PRINTS; PR00926; MITOCARRIER.
DR   SUPFAM; SSF103506; Mitochondrial carrier; 1.
DR   PROSITE; PS50920; SOLCAR; 3.
PE   3: Inferred from homology;
KW   Membrane; Mitochondrion; Mitochondrion inner membrane; Reference proteome;
KW   Repeat; Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..298
FT                   /note=""Probable mitochondrial 2-oxodicarboxylate carrier""
FT                   /id=""PRO_0000310803""
FT   TRANSMEM        6..26
FT                   /note=""Helical; Name=1""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        62..81
FT                   /note=""Helical; Name=2""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        105..125
FT                   /note=""Helical; Name=3""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        159..179
FT                   /note=""Helical; Name=4""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        203..223
FT                   /note=""Helical; Name=5""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        267..287
FT                   /note=""Helical; Name=6""
FT                   /evidence=""ECO:0000255""
FT   REPEAT          6..92
FT                   /note=""Solcar 1""
FT   REPEAT          102..188
FT                   /note=""Solcar 2""
FT   REPEAT          197..287
FT                   /note=""Solcar 3""
SQ   SEQUENCE   298 AA;  33100 MW;  D6ADC939BA1F6F9A CRC64;
     MPHDNIPFPV TFAAGAVAGI SEVLTLYPLD VVKTRMQLSV GKSDYNGTFD CLKKIVKNEG
     PHRLYRGILP PILMEAPKRA LKFASNDTYS KLWRKVFKRK DSSPALSILT GSCAGFTETF
     VVVPFELMKI RLQDVKNASK YNGTVDCFTK IVKQERILAL YNGFEATMWR HVVWNAGYFG
     VIQKIRNSLT PASSRIGEIR NNLIAGTIGG IFGTFLSTPF DVIKSRIQTV PRIAGQVPKY
     NWAYPALVTV AREEGFTALY KGFVPKVLRL GPGGGILLVV FNSVIEFYKR CLVHNASA
//
",43111
ACGCCT CGCCTA GCCTAT CCTATT CTATTA TATTAA ATTAAT TTAATT TAATTT AATTTA ATTTAG TTTAGG TTAGGG TAGGGC AGGGCG GGGCGT GGCGTG GCGTGA CGTGAT GTGATC TGATCT GATCTC ATCTCC TCTCCC CTCCCT TCCCTC CCCTCA CCTCAG CTCAGG TCAGGG CAGGGT AGGGTT GGGTTT GGTTTT GTTTTT TTTTTC TTTTCG TTTCGG TTCGGC TCGGCT CGGCTT GGCTTT GCTTTA CTTTAG TTTAGA TTAGAA TAGAAC AGAACC GAACCA AACCAT ACCATT CCATTG CATTGG ATTGGT TTGGTA TGGTAG GGTAGA GTAGAT TAGATT AGATTT GATTTG ATTTGC TTTGCC TTGCCA TGCCAA GCCAAT CCAATA CAATAG AATAGG ATAGGT TAGGTA AGGTAT GGTATT GTATTA TATTAA ATTAAC TTAACA TAACAT AACATC ACATCA CATCAC ATCACT TCACTA CACTAG ACTAGG CTAGGT TAGGTT AGGTTT GGTTTC GTTTCA TTTCAA TTCAAA TCAAAC CAAACT AAACTT AACTTT ACTTTA CTTTAC TTTACT TTACTT TACTTG ACTTGC CTTGCT TTGCTT TGCTTT GCTTTA CTTTAC TTTACA TTACAT TACATA ACATAG CATAGA ATAGAA TAGAAG AGAAGT GAAGTT AAGTTA AGTTAT GTTATT TTATTT TATTTG ATTTGA TTTGAC TTGACT TGACTC GACTCC ACTCCT CTCCTG TCCTGG CCTGGT CTGGTG TGGTGA GGTGAT GTGATT TGATTC GATTCT ATTCTT TTCTTC TCTTCT CTTCTT TTCTTC TCTTCA,1,142,ACGC CGCC GCCT CCTA CTAT TATT ATTA TTAA TAAT AATT ATTT TTTA TTAG TAGG AGGG GGGC GGCG GCGT CGTG GTGA TGAT GATC ATCT TCTC CTCC TCCC CCCT CCTC CTCA TCAG CAGG AGGG GGGT GGTT GTTT TTTT TTTT TTTC TTCG TCGG CGGC GGCT GCTT CTTT TTTA TTAG TAGA AGAA GAAC AACC ACCA CCAT CATT ATTG TTGG TGGT GGTA GTAG TAGA AGAT GATT ATTT TTTG TTGC TGCC GCCA CCAA CAAT AATA ATAG TAGG AGGT GGTA GTAT TATT ATTA TTAA TAAC AACA ACAT CATC ATCA TCAC CACT ACTA CTAG TAGG AGGT GGTT GTTT TTTC TTCA TCAA CAAA AAAC AACT ACTT CTTT TTTA TTAC TACT ACTT CTTG TTGC TGCT GCTT CTTT TTTA TTAC TACA ACAT CATA ATAG TAGA AGAA GAAG AAGT AGTT GTTA TTAT TATT ATTT TTTG TTGA TGAC GACT ACTC CTCC TCCT CCTG CTGG TGGT GGTG GTGA TGAT GATT ATTC TTCT TCTT CTTC TTCT TCTT CTTC TTCA,ACGCC CGCCT GCCTA CCTAT CTATT TATTA ATTAA TTAAT TAATT AATTT ATTTA TTTAG TTAGG TAGGG AGGGC GGGCG GGCGT GCGTG CGTGA GTGAT TGATC GATCT ATCTC TCTCC CTCCC TCCCT CCCTC CCTCA CTCAG TCAGG CAGGG AGGGT GGGTT GGTTT GTTTT TTTTT TTTTC TTTCG TTCGG TCGGC CGGCT GGCTT GCTTT CTTTA TTTAG TTAGA TAGAA AGAAC GAACC AACCA ACCAT CCATT CATTG ATTGG TTGGT TGGTA GGTAG GTAGA TAGAT AGATT GATTT ATTTG TTTGC TTGCC TGCCA GCCAA CCAAT CAATA AATAG ATAGG TAGGT AGGTA GGTAT GTATT TATTA ATTAA TTAAC TAACA AACAT ACATC CATCA ATCAC TCACT CACTA ACTAG CTAGG TAGGT AGGTT GGTTT GTTTC TTTCA TTCAA TCAAA CAAAC AAACT AACTT ACTTT CTTTA TTTAC TTACT TACTT ACTTG CTTGC TTGCT TGCTT GCTTT CTTTA TTTAC TTACA TACAT ACATA CATAG ATAGA TAGAA AGAAG GAAGT AAGTT AGTTA GTTAT TTATT TATTT ATTTG TTTGA TTGAC TGACT GACTC ACTCC CTCCT TCCTG CCTGG CTGGT TGGTG GGTGA GTGAT TGATT GATTC ATTCT TTCTT TCTTC CTTCT TTCTT TCTTC CTTCA,ACGCCT CGCCTA GCCTAT CCTATT CTATTA TATTAA ATTAAT TTAATT TAATTT AATTTA ATTTAG TTTAGG TTAGGG TAGGGC AGGGCG GGGCGT GGCGTG GCGTGA CGTGAT GTGATC TGATCT GATCTC ATCTCC TCTCCC CTCCCT TCCCTC CCCTCA CCTCAG CTCAGG TCAGGG CAGGGT AGGGTT GGGTTT GGTTTT GTTTTT TTTTTC TTTTCG TTTCGG TTCGGC TCGGCT CGGCTT GGCTTT GCTTTA CTTTAG TTTAGA TTAGAA TAGAAC AGAACC GAACCA AACCAT ACCATT CCATTG CATTGG ATTGGT TTGGTA TGGTAG GGTAGA GTAGAT TAGATT AGATTT GATTTG ATTTGC TTTGCC TTGCCA TGCCAA GCCAAT CCAATA CAATAG AATAGG ATAGGT TAGGTA AGGTAT GGTATT GTATTA TATTAA ATTAAC TTAACA TAACAT AACATC ACATCA CATCAC ATCACT TCACTA CACTAG ACTAGG CTAGGT TAGGTT AGGTTT GGTTTC GTTTCA TTTCAA TTCAAA TCAAAC CAAACT AAACTT AACTTT ACTTTA CTTTAC TTTACT TTACTT TACTTG ACTTGC CTTGCT TTGCTT TGCTTT GCTTTA CTTTAC TTTACA TTACAT TACATA ACATAG CATAGA ATAGAA TAGAAG AGAAGT GAAGTT AAGTTA AGTTAT GTTATT TTATTT TATTTG ATTTGA TTTGAC TTGACT TGACTC GACTCC ACTCCT CTCCTG TCCTGG CCTGGT CTGGTG TGGTGA GGTGAT GTGATT TGATTC GATTCT ATTCTT TTCTTC TCTTCT CTTCTT TTCTTC TCTTCA,ACGCCTA CGCCTAT GCCTATT CCTATTA CTATTAA TATTAAT ATTAATT TTAATTT TAATTTA AATTTAG ATTTAGG TTTAGGG TTAGGGC TAGGGCG AGGGCGT GGGCGTG GGCGTGA GCGTGAT CGTGATC GTGATCT TGATCTC GATCTCC ATCTCCC TCTCCCT CTCCCTC TCCCTCA CCCTCAG CCTCAGG CTCAGGG TCAGGGT CAGGGTT AGGGTTT GGGTTTT GGTTTTT GTTTTTC TTTTTCG TTTTCGG TTTCGGC TTCGGCT TCGGCTT CGGCTTT GGCTTTA GCTTTAG CTTTAGA TTTAGAA TTAGAAC TAGAACC AGAACCA GAACCAT AACCATT ACCATTG CCATTGG CATTGGT ATTGGTA TTGGTAG TGGTAGA GGTAGAT GTAGATT TAGATTT AGATTTG GATTTGC ATTTGCC TTTGCCA TTGCCAA TGCCAAT GCCAATA CCAATAG CAATAGG AATAGGT ATAGGTA TAGGTAT AGGTATT GGTATTA GTATTAA TATTAAC ATTAACA TTAACAT TAACATC AACATCA ACATCAC CATCACT ATCACTA TCACTAG CACTAGG ACTAGGT CTAGGTT TAGGTTT AGGTTTC GGTTTCA GTTTCAA TTTCAAA TTCAAAC TCAAACT CAAACTT AAACTTT AACTTTA ACTTTAC CTTTACT TTTACTT TTACTTG TACTTGC ACTTGCT CTTGCTT TTGCTTT TGCTTTA GCTTTAC CTTTACA TTTACAT TTACATA TACATAG ACATAGA CATAGAA ATAGAAG TAGAAGT AGAAGTT GAAGTTA AAGTTAT AGTTATT GTTATTT TTATTTG TATTTGA ATTTGAC TTTGACT TTGACTC TGACTCC GACTCCT ACTCCTG CTCCTGG TCCTGGT CCTGGTG CTGGTGA TGGTGAT GGTGATT GTGATTC TGATTCT GATTCTT ATTCTTC TTCTTCT TCTTCTT CTTCTTC TTCTTCA,"ID   SPIKE_SARS2             Reviewed;        1273 AA.
AC   P0DTC2;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Spike glycoprotein {ECO:0000255|HAMAP-Rule:MF_04099};
DE            Short=S glycoprotein {ECO:0000255|HAMAP-Rule:MF_04099};
DE   AltName: Full=E2 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   AltName: Full=Peplomer protein {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S1 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S2 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S2' {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Flags: Precursor;
GN   Name=S {ECO:0000255|HAMAP-Rule:MF_04099}; ORFNames=2;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   FUNCTION (SPIKE PROTEIN S1), AND CLEAVAGE BETWEEN S2 AND S2' BY HOST
RP   TMPRSS2.
RX   PubMed=32142651; DOI=10.1016/j.cell.2020.02.052;
RA   Hoffmann M., Kleine-Weber H., Schroeder S., Krueger N., Herrler T.,
RA   Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A.,
RA   Mueller M.A., Drosten C., Poehlmann S.;
RT   ""SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a
RT   clinically proven protease inhibitor."";
RL   Cell 181:1-10(2020).
RN   [3]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, FUNCTION, AND MUTAGENESIS OF
RP   681-PRO--ALA-684.
RX   PubMed=32362314; DOI=10.1016/j.molcel.2020.04.022;
RA   Hoffmann M., Kleine-Weber H., Poehlmann S.;
RT   ""A multibasic cleavage site in the Spike protein of SARS-CoV-2 is essential
RT   for infection of human lung cells."";
RL   Mol. Cell 78:779-784(2020).
RN   [4]
RP   GLYCOSYLATION AT ASN-17; ASN-61; ASN-74; ASN-122; ASN-149; ASN-165;
RP   ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098; ASN-1134; ASN-1158; ASN-1173 AND
RP   ASN-1194, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=32366695; DOI=10.1126/science.abb9983;
RA   Watanabe Y., Allen J.D., Wrapp D., McLellan J.S., Crispin M.;
RT   ""Site-specific glycan analysis of the SARS-CoV-2 spike."";
RL   Science 369:330-333(2020).
RN   [5]
RP   GLYCOSYLATION AT ASN-61; ASN-74; ASN-122; ASN-149; ASN-165; ASN-234;
RP   ASN-282; THR-323; SER-325; ASN-331; ASN-343; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098 AND ASN-1194, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=32363391; DOI=10.1093/glycob/cwaa042;
RA   Shajahan A., Supekar N.T., Gleinich A.S., Azadi P.;
RT   ""Deducing the N- and O- glycosylation profile of the spike protein of novel
RT   coronavirus SARS-CoV-2."";
RL   Glycobiology 30:981-988(2020).
RN   [6]
RP   VARIANT GLY-614.
RX   PubMed=32820179; DOI=10.1038/s41598-020-70827-z;
RA   Isabel S., Grana-Miraglia L., Gutierrez J.M., Bundalovic-Torma C.,
RA   Groves H.E., Isabel M.R., Eshaghi A., Patel S.N., Gubbay J.B., Poutanen T.,
RA   Guttman D.S., Poutanen S.M.;
RT   ""Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein
RT   mutation now documented worldwide."";
RL   Sci. Rep. 10:14031-14031(2020).
RN   [7]
RP   VARIANT GLY-614, AND MUTAGENESIS OF ASP-614.
RX   PubMed=32697968; DOI=10.1016/j.cell.2020.06.043;
RG   Sheffield COVID-19 Genomics Group;
RA   Korber B., Fischer W.M., Gnanakaran S., Yoon H., Theiler J., Abfalterer W.,
RA   Hengartner N., Giorgi E.E., Bhattacharya T., Foley B., Hastie K.M.,
RA   Parker M.D., Partridge D.G., Evans C.M., Freeman T.M., de Silva T.I.,
RA   McDanal C., Perez L.G., Tang H., Moon-Walker A., Whelan S.P.,
RA   LaBranche C.C., Saphire E.O., Montefiori D.C.;
RT   ""Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases
RT   Infectivity of the COVID-19 Virus."";
RL   Cell 182:812-827(2020).
RN   [8]
RP   FUNCTION.
RX   PubMed=32817270; DOI=10.1126/science.abd5223;
RA   Turonova B., Sikora M., Schuermann C., Hagen W.J.H., Welsch S.,
RA   Blanc F.E.C., von Buelow S., Gecht M., Bagola K., Hoerner C.,
RA   van Zandbergen G., Landry J., de Azevedo N.T.D., Mosalaganti S.,
RA   Schwarz A., Covino R., Muehlebach M.D., Hummer G., Krijnse Locker J.,
RA   Beck M.;
RT   ""In situ structural analysis of SARS-CoV-2 spike reveals flexibility
RT   mediated by three hinges."";
RL   Science 370:203-208(2020).
RN   [9]
RP   GLYCOSYLATION.
RX   PubMed=32929138; DOI=10.1038/s41598-020-71748-7;
RA   Grant O.C., Montgomery D., Ito K., Woods R.J.;
RT   ""Analysis of the SARS-CoV-2 spike protein glycan shield reveals
RT   implications for immune recognition."";
RL   Sci. Rep. 10:14991-14991(2020).
RN   [10]
RP   GLYCOSYLATION AT ASN-17; ASN-61; ASN-74; ASN-122; ASN-149; ASN-165;
RP   ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098; ASN-1134; ASN-1158; ASN-1173 AND
RP   ASN-1194, IDENTIFICATION BY MASS SPECTROMETRY, SUBCELLULAR LOCATION, AND
RP   SUBUNIT.
RX   PubMed=32979942; DOI=10.1016/j.cell.2020.09.018;
RA   Yao H., Song Y., Chen Y., Wu N., Xu J., Sun C., Zhang J., Weng T.,
RA   Zhang Z., Wu Z., Cheng L., Shi D., Lu X., Lei J., Crispin M., Shi Y.,
RA   Li L., Li S.;
RT   ""Molecular Architecture of the SARS-CoV-2 Virus."";
RL   Cell 183:730-738(2020).
RN   [11]
RP   VARIANT GLY-614, AND MUTAGENESIS OF ASP-614.
RX   PubMed=33106671; DOI=10.1038/s41586-020-2895-3;
RA   Plante J.A., Liu Y., Liu J., Xia H., Johnson B.A., Lokugamage K.G.,
RA   Zhang X., Muruato A.E., Zou J., Fontes-Garfias C.R., Mirchandani D.,
RA   Scharton D., Bilello J.P., Ku Z., An Z., Kalveram B., Freiberg A.N.,
RA   Menachery V.D., Xie X., Plante K.S., Weaver S.C., Shi P.Y.;
RT   ""Spike mutation D614G alters SARS-CoV-2 fitness."";
RL   Nature 592:116-121(2020).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH HUMAN NRP1 AND NRP2.
RC   STRAIN=SARS-CoV-2/human/Liverpool/REMRQ001/2020;
RX   PubMed=33082294; DOI=10.1126/science.abd3072;
RA   Daly J.L., Simonetti B., Klein K., Chen K.E., Williamson M.K.,
RA   Anton-Plagaro C., Shoemark D.K., Simon-Gracia L., Bauer M., Hollandi R.,
RA   Greber U.F., Horvath P., Sessions R.B., Helenius A., Hiscox J.A.,
RA   Teesalu T., Matthews D.A., Davidson A.D., Collins B.M., Cullen P.J.,
RA   Yamauchi Y.;
RT   ""Neuropilin-1 is a host factor for SARS-CoV-2 infection."";
RL   Science 370:861-865(2020).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH HUMAN NRP1 AND NRP2.
RC   STRAIN=SARS-CoV-2/human/Finland/1/2020;
RX   PubMed=33082293; DOI=10.1126/science.abd2985;
RA   Cantuti-Castelvetri L., Ojha R., Pedro L.D., Djannatian M., Franz J.,
RA   Kuivanen S., van der Meer F., Kallio K., Kaya T., Anastasina M., Smura T.,
RA   Levanov L., Szirovicza L., Tobi A., Kallio-Kokko H., Oesterlund P.,
RA   Joensuu M., Meunier F.A., Butcher S.J., Winkler M.S., Mollenhauer B.,
RA   Helenius A., Gokce O., Teesalu T., Hepojoki J., Vapalahti O.,
RA   Stadelmann C., Balistreri G., Simons M.;
RT   ""Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity."";
RL   Science 370:856-860(2020).
RN   [14]
RP   INTERACTION WITH HUMAN ITGA5 AND ITGB1.
RX   PubMed=33102950; DOI=10.1016/j.jacbts.2020.10.003;
RA   Beddingfield B.J., Iwanaga N., Chapagain P.P., Zheng W., Roy C.J., Hu T.Y.,
RA   Kolls J.K., Bix G.J.;
RT   ""The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2
RT   Infection."";
RL   JACC Basic Transl. Sci. 6:1-8(2021).
RN   [15]
RP   VARIANT GLY-614.
RX   PubMed=33184236; DOI=10.1126/science.abe8499;
RA   Hou Y.J., Chiba S., Halfmann P., Ehre C., Kuroda M., Dinnon K.H. III,
RA   Leist S.R., Schaefer A., Nakajima N., Takahashi K., Lee R.E.,
RA   Mascenik T.M., Graham R., Edwards C.E., Tse L.V., Okuda K., Markmann A.J.,
RA   Bartelt L., de Silva A., Margolis D.M., Boucher R.C., Randell S.H.,
RA   Suzuki T., Gralinski L.E., Kawaoka Y., Baric R.S.;
RT   ""SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and
RT   transmission in vivo."";
RL   Science 370:1464-1468(2020).
RN   [16]
RP   VARIANT GLY-614.
RX   PubMed=33417835; DOI=10.1016/j.celrep.2020.108630;
RA   Gobeil S.M., Janowska K., McDowell S., Mansouri K., Parks R., Manne K.,
RA   Stalls V., Kopp M.F., Henderson R., Edwards R.J., Haynes B.F., Acharya P.;
RT   ""D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease
RT   Cleavage at the S1/S2 Junction."";
RL   Cell Rep. 34:108630-108630(2021).
RN   [17]
RP   VARIANTS 69-VAL--PHE-70 DEL; LYS-144 DEL; TYR-501; ASP-570; GLY-614;
RP   HIS-681; ILE-716; ALA-982 AND HIS-1118.
RC   STRAIN=20I/501Y.V1, Alpha, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [18]
RP   VARIANT TYR-501.
RX   PubMed=32732280; DOI=10.1126/science.abc4730;
RA   Gu H., Chen Q., Yang G., He L., Fan H., Deng Y.Q., Wang Y., Teng Y.,
RA   Zhao Z., Cui Y., Li Y., Li X.F., Li J., Zhang N.N., Yang X., Chen S.,
RA   Guo Y., Zhao G., Wang X., Luo D.Y., Wang H., Yang X., Li Y., Han G., He Y.,
RA   Zhou X., Geng S., Sheng X., Jiang S., Sun S., Qin C.F., Zhou Y.;
RT   ""Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy."";
RL   Science 369:1603-1607(2020).
RN   [19]
RP   VARIANT GLY-614, AND MUTAGENESIS OF GLY-614.
RX   PubMed=33636719; DOI=10.1038/s41586-021-03361-1;
RA   Zhou B., Thi Nhu Thao T., Hoffmann D., Taddeo A., Ebert N., Labroussaa F.,
RA   Pohlmann A., King J., Steiner S., Kelly J.N., Portmann J., Halwe N.J.,
RA   Ulrich L., Trueeb B.S., Fan X., Hoffmann B., Wang L., Thomann L., Lin X.,
RA   Stalder H., Pozzi B., de Brot S., Jiang N., Cui D., Hossain J., Wilson M.,
RA   Keller M., Stark T.J., Barnes J.R., Dijkman R., Jores J., Benarafa C.,
RA   Wentworth D.E., Thiel V., Beer M.;
RT   ""SARS-CoV-2 spike D614G change enhances replication and transmission."";
RL   Nature 5920:122-127(2021).
RN   [20]
RP   MUTAGENESIS OF ASN-165; ASN-234; ASN-331; ASN-343; LEU-452; ALA-475;
RP   VAL-483; PHE-490 AND HIS-519.
RX   PubMed=32730807; DOI=10.1016/j.cell.2020.07.012;
RA   Li Q., Wu J., Nie J., Zhang L., Hao H., Liu S., Zhao C., Zhang Q., Liu H.,
RA   Nie L., Qin H., Wang M., Lu Q., Li X., Sun Q., Liu J., Zhang L., Li X.,
RA   Huang W., Wang Y.;
RT   ""The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and
RT   Antigenicity."";
RL   Cell 182:1284-1294(2020).
RN   [21]
RP   FUNCTION, CLEAVAGE BETWEEN S1 AND S2 BY HOST CTSL, AND INTERACTION WITH
RP   HUMAN ACE2.
RX   PubMed=32221306; DOI=10.1038/s41467-020-15562-9;
RA   Ou X., Liu Y., Lei X., Li P., Mi D., Ren L., Guo L., Guo R., Chen T.,
RA   Hu J., Xiang Z., Mu Z., Chen X., Chen J., Hu K., Jin Q., Wang J., Qian Z.;
RT   ""Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and
RT   its immune cross-reactivity with SARS-CoV."";
RL   Nat. Commun. 11:1620-1620(2020).
RN   [22]
RP   INTERACTION WITH HUMAN ACE2.
RX   PubMed=33607086; DOI=10.1016/j.bpj.2021.02.007;
RA   Cao W., Dong C., Kim S., Hou D., Tai W., Du L., Im W., Zhang X.F.;
RT   ""Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2
RT   protein-protein interaction."";
RL   Biophys. J. 120:1011-1019(2021).
RN   [23]
RP   FUNCTION, AND CLEAVAGE BETWEEN S1 AND S2 BY HOST TMPRSS2.
RX   PubMed=33465165; DOI=10.1371/journal.ppat.1009212;
RA   Ou T., Mou H., Zhang L., Ojha A., Choe H., Farzan M.;
RT   ""Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated
RT   by TMPRSS2."";
RL   PLoS Pathog. 17:e1009212-e1009212(2021).
RN   [24]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH S PROTEIN.
RX   PubMed=33229438; DOI=10.1074/jbc.ra120.016175;
RA   Boson B., Legros V., Zhou B., Siret E., Mathieu C., Cosset F.L.,
RA   Lavillette D., Denolly S.;
RT   ""The SARS-CoV-2 Envelope and Membrane proteins modulate maturation and
RT   retention of the Spike protein, allowing assembly of virus-like
RT   particles."";
RL   J. Biol. Chem. 296:100111-100111(2020).
RN   [25]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, CLEAVAGE BETWEEN S2 AND S2' BY
RP   HOST TMPRSS2, MUTAGENESIS OF ALA-684, AND FUNCTION (SPIKE PROTEIN S2').
RX   PubMed=32703818; DOI=10.26508/lsa.202000786;
RA   Bestle D., Heindl M.R., Limburg H., Van Lam van T., Pilgram O., Moulton H.,
RA   Stein D.A., Hardes K., Eickmann M., Dolnik O., Rohde C., Klenk H.D.,
RA   Garten W., Steinmetzer T., Boettcher-Friebertshaeuser E.;
RT   ""TMPRSS2 and furin are both essential for proteolytic activation of SARS-
RT   CoV-2 in human airway cells."";
RL   Life. Sci Alliance 3:1-14(2020).
RN   [26]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, CLEAVAGE BETWEEN S2 AND S2' BY
RP   HOST TMPRSS2, CLEAVAGE BETWEEN S2 AND S2' BY HOST CSTL, AND FUNCTION (SPIKE
RP   PROTEIN S2').
RX   PubMed=34159616; DOI=10.15252/embj.2021107821;
RA   Koch J., Uckeley Z.M., Doldan P., Stanifer M., Boulant S., Lozach P.Y.;
RT   ""TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect
RT   host cells."";
RL   EMBO J. 40:1-20(2021).
RN   [27]
RP   VARIANTS PHE-18; ALA-80; GLY-215; ASN-417; LYS-484; TYR-501; GLY-614 AND
RP   VAL-701.
RC   STRAIN=20H/501Y.V2, B.1.351, and Beta;
RX   PubMed=33690265; DOI=10.1038/s41586-021-03402-9;
RA   Tegally H., Wilkinson E., Giovanetti M., Iranzadeh A., Fonseca V.,
RA   Giandhari J., Doolabh D., Pillay S., San E.J., Msomi N., Mlisana K.,
RA   von Gottberg A., Walaza S., Allam M., Ismail A., Mohale T., Glass A.J.,
RA   Engelbrecht S., Van Zyl G., Preiser W., Petruccione F., Sigal A.,
RA   Hardie D., Marais G., Hsiao M., Korsman S., Davies M.A., Tyers L.,
RA   Mudau I., York D., Maslo C., Goedhals D., Abrahams S., Laguda-Akingba O.,
RA   Alisoltani-Dehkordi A., Godzik A., Wibmer C.K., Sewell B.T., Lourenco J.,
RA   Alcantara L.C.J., Kosakovsky Pond S.L., Weaver S., Martin D.,
RA   Lessells R.J., Bhiman J.N., Williamson C., de Oliveira T.;
RT   ""Emergence of a SARS-CoV-2 variant of concern with mutations in spike
RT   glycoprotein."";
RL   Nature 592:438-443(2021).
RN   [28]
RP   POLYMORPHISM.
RX   PubMed=34142653; DOI=10.2807/1560-7917.es.2021.26.24.2100509;
RA   Campbell F., Archer B., Laurenson-Schafer H., Jinnai Y., Konings F.,
RA   Batra N., Pavlin B., Vandemaele K., Van Kerkhove M.D., Jombart T.,
RA   Morgan O., le Polain de Waroux O.;
RT   ""Increased transmissibility and global spread of SARS-CoV-2 variants of
RT   concern as at June 2021."";
RL   Eurosurveillance 26:0-0(2021).
RN   [29]
RP   VARIANTS ARG-452 AND PHE-453, AND MUTAGENESIS OF LEU-452; TYR-453 AND
RP   ASN-501.
RX   PubMed=34171266; DOI=10.1016/j.chom.2021.06.006;
RG   Genotype to Phenotype Japan (G2P-Japan) Consortium;
RA   Motozono C., Toyoda M., Zahradnik J., Saito A., Nasser H., Tan T.S.,
RA   Ngare I., Kimura I., Uriu K., Kosugi Y., Yue Y., Shimizu R., Ito J.,
RA   Torii S., Yonekawa A., Shimono N., Nagasaki Y., Minami R., Toya T.,
RA   Sekiya N., Fukuhara T., Matsuura Y., Schreiber G., Ikeda T., Nakagawa S.,
RA   Ueno T., Sato K.;
RT   ""SARS-CoV-2 spike L452R variant evades cellular immunity and increases
RT   infectivity."";
RL   Cell Host Microbe 0:0-0(2021).
RN   [30]
RP   VARIANT 69-VAL--PHE-70 DEL, AND MUTAGENESIS OF 69-HIS-VAL-70.
RX   PubMed=34166617; DOI=10.1016/j.celrep.2021.109292;
RG   COVID-19 Genomics UK (COG-UK) Consortium;
RA   Meng B., Kemp S.A., Papa G., Datir R., Ferreira I.A.T.M., Marelli S.,
RA   Harvey W.T., Lytras S., Mohamed A., Gallo G., Thakur N., Collier D.A.,
RA   Mlcochova P., Duncan L.M., Carabelli A.M., Kenyon J.C., Lever A.M.,
RA   De Marco A., Saliba C., Culap K., Cameroni E., Matheson N.J., Piccoli L.,
RA   Corti D., James L.C., Robertson D.L., Bailey D., Gupta R.K.;
RT   ""Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in
RT   the Alpha variant B.1.1.7."";
RL   Cell Rep. 35:109292-109292(2021).
RN   [31]
RP   VARIANTS ILE-13 AND CYS-152, POLYMORPHISM, AND MASS SPECTROMETRY (SIGNAL).
RX   PubMed=34210893; DOI=10.1126/science.abi7994;
RA   McCallum M., Bassi J., De Marco A., Chen A., Walls A.C., Di Iulio J.,
RA   Tortorici M.A., Navarro M.J., Silacci-Fregni C., Saliba C., Sprouse K.R.,
RA   Agostini M., Pinto D., Culap K., Bianchi S., Jaconi S., Cameroni E.,
RA   Bowen J.E., Tilles S.W., Pizzuto M.S., Guastalla S.B., Bona G.,
RA   Pellanda A.F., Garzoni C., Van Voorhis W.C., Rosen L.E., Snell G.,
RA   Telenti A., Virgin H.W., Piccoli L., Corti D., Veesler D.;
RT   ""SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern."";
RL   Science 373:648-654(2021).
RN   [32]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-1269 AND HIS-1271.
RX   PubMed=34504087; DOI=10.1038/s41467-021-25589-1;
RA   Cattin-Ortola J., Welch L.G., Maslen S.L., Papa G., James L.C., Munro S.;
RT   ""Sequences in the cytoplasmic tail of SARS-CoV-2 Spike facilitate
RT   expression at the cell surface and syncytia formation."";
RL   Nat. Commun. 12:5333-5333(2021).
RN   [33]
RP   PALMITOYLATION AT CYS-1235; CYS-1236; CYS-1240; CYS-1241; CYS-1243;
RP   CYS-1247; CYS-1248; CYS-1250; CYS-1253 AND CYS-1254.
RX   PubMed=34599882; DOI=10.1016/j.devcel.2021.09.016;
RA   Mesquita F.S., Abrami L., Sergeeva O., Turelli P., Qing E., Kunz B.,
RA   Raclot C., Paz Montoya J., Abriata L.A., Gallagher T., Dal Peraro M.,
RA   Trono D., D'Angelo G., van der Goot F.G.;
RT   ""S-acylation controls SARS-CoV-2 membrane lipid organization and enhances
RT   infectivity."";
RL   Dev. Cell 56:1-18(2021).
RN   [34] {ECO:0007744|PDB:6M17}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.90 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), DOMAIN, AND INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN S1).
RX   PubMed=32132184; DOI=10.1126/science.abb2762;
RA   Yan R., Zhang Y., Li Y., Xia L., Guo Y., Zhou Q.;
RT   ""Structural basis for the recognition of the SARS-CoV-2 by full-length
RT   human ACE2."";
RL   Science 367:1444-1448(2020).
RN   [35]
RP   SUPERANTIGEN, AND DOMAIN.
RX   PubMed=32989130; DOI=10.1073/pnas.2010722117;
RA   Cheng M.H., Zhang S., Porritt R.A., Noval Rivas M., Paschold L.,
RA   Willscher E., Binder M., Arditi M., Bahar I.;
RT   ""Superantigenic character of an insert unique to SARS-CoV-2 spike supported
RT   by skewed TCR repertoire in patients with hyperinflammation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 117:25254-25262(2020).
RN   [36]
RP   INTERACTION WITH HUMAN BILIRUBIN, INTERACTION WITH HUMAN BILIVERDIN, AND
RP   MUTAGENESIS OF ASN-121 AND ARG-190.
RX   PubMed=33888467; DOI=10.1126/sciadv.abg7607;
RA   Rosa A., Pye V.E., Graham C., Muir L., Seow J., Ng K.W., Cook N.J.,
RA   Rees-Spear C., Parker E., Dos Santos M.S., Rosadas C., Susana A., Rhys H.,
RA   Nans A., Masino L., Roustan C., Christodoulou E., Ulferts R., Wrobel A.G.,
RA   Short C.E., Fertleman M., Sanders R.W., Heaney J., Spyer M., Kjaer S.,
RA   Riddell A., Malim M.H., Beale R., MacRae J.I., Taylor G.P., Nastouli E.,
RA   van Gils M.J., Rosenthal P.B., Pizzato M., McClure M.O., Tedder R.S.,
RA   Kassiotis G., McCoy L.E., Doores K.J., Cherepanov P.;
RT   ""SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity."";
RL   Sci. Adv. 7:0-0(2021).
RN   [37]
RP   BIOTECHNOLOGY, AND MUTAGENESIS OF 682-ARG--ARG-685 AND 986-LYS-VAL-987.
RX   PubMed=34322129; DOI=10.3389/fimmu.2021.701501;
RA   Martinez-Flores D., Zepeda-Cervantes J., Cruz-Resendiz A.,
RA   Aguirre-Sampieri S., Sampieri A., Vaca L.;
RT   ""SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of
RT   New Viral Variants."";
RL   Front. Immunol. 12:701501-701501(2021).
RN   [38]
RP   GLYCOSYLATION AT THR-676 AND THR-678 BY HOST GALNT1, AND MUTAGENESIS OF
RP   SER-673; THR-676; THR-678; SER-680 AND PRO-681.
RX   PubMed=34732583; DOI=10.1073/pnas.2109905118;
RA   Zhang L., Mann M., Syed Z.A., Reynolds H.M., Tian E., Samara N.L.,
RA   Zeldin D.C., Tabak L.A., Ten Hagen K.G.;
RT   ""Furin cleavage of the SARS-CoV-2 spike is modulated by O-glycosylation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [39]
RP   REVIEW, PROTEOLITIC PROCESSING, FUNCTION (SPIKE PROTEIN S2), AND FUNCTION
RP   (SPIKE PROTEIN S2').
RX   PubMed=34561887; DOI=10.1111/1348-0421.12945;
RA   Takeda M.;
RT   ""Proteolytic activation of SARS-CoV-2 spike protein."";
RL   Microbiol. Immunol. 66:15-23(2022).
RN   [40]
RP   INTERACTION WITH HOST MBL2.
RX   PubMed=35102342; DOI=10.1038/s41590-021-01114-w;
RA   Stravalaci M., Pagani I., Paraboschi E.M., Pedotti M., Doni A.,
RA   Scavello F., Mapelli S.N., Sironi M., Perucchini C., Varani L.,
RA   Matkovic M., Cavalli A., Cesana D., Gallina P., Pedemonte N., Capurro V.,
RA   Clementi N., Mancini N., Invernizzi P., Bayarri-Olmos R., Garred P.,
RA   Rappuoli R., Duga S., Bottazzi B., Uguccioni M., Asselta R., Vicenzi E.,
RA   Mantovani A., Garlanda C.;
RT   ""Recognition and inhibition of SARS-CoV-2 by humoral innate immunity
RT   pattern recognition molecules."";
RL   Nat. Immunol. 23:275-286(2022).
RN   [41]
RP   FUNCTION (SPIKE PROTEIN S1), AND INTERACTION WITH HOST INTEGRIN (SPIKE
RP   PROTEIN S1).
RX   PubMed=35150743; DOI=10.1016/j.jbc.2022.101710;
RA   Liu J., Lu F., Chen Y., Plow E., Qin J.;
RT   ""Integrin mediates cell entry of the SARS-CoV-2 virus independent of
RT   cellular receptor ACE2."";
RL   J. Biol. Chem. 1:101710-101710(2022).
RN   [42]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [43]
RP   SUBUNIT.
RX   PubMed=36735681; DOI=10.1371/journal.pbio.3001959;
RA   Shilts J., Crozier T.W.M., Teixeira-Silva A., Gabaev I., Gerber P.P.,
RA   Greenwood E.J.D., Watson S.J., Ortmann B.M., Gawden-Bone C.M., Pauzaite T.,
RA   Hoffmann M., Nathan J.A., Poehlmann S., Matheson N.J., Lehner P.J.,
RA   Wright G.J.;
RT   ""LRRC15 mediates an accessory interaction with the SARS-CoV-2 spike
RT   protein."";
RL   PLoS Biol. 21:e3001959-e3001959(2023).
RN   [44]
RP   VARIANT ASN-405.
RX   PubMed=36851546; DOI=10.3390/v15020332;
RA   Bugatti A., Filippini F., Messali S., Giovanetti M., Ravelli C., Zani A.,
RA   Ciccozzi M., Caruso A., Caccuri F.;
RT   ""The D405N Mutation in the Spike Protein of SARS-CoV-2 Omicron BA.5
RT   Inhibits Spike/Integrins Interaction and Viral Infection of Human Lung
RT   Microvascular Endothelial Cells."";
RL   Viruses 15:0-0(2023).
RN   [45]
RP   MUTAGENESIS OF GLU-484.
RX   PubMed=37421949; DOI=10.1016/j.cell.2023.06.005;
RA   Baggen J., Jacquemyn M., Persoons L., Vanstreels E., Pye V.E., Wrobel A.G.,
RA   Calvaresi V., Martin S.R., Roustan C., Cronin N.B., Reading E.,
RA   Thibaut H.J., Vercruysse T., Maes P., De Smet F., Yee A., Nivitchanyong T.,
RA   Roell M., Franco-Hernandez N., Rhinn H., Mamchak A.A., Ah Young-Chapon M.,
RA   Brown E., Cherepanov P., Daelemans D.;
RT   ""TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry."";
RL   Cell 186:1-16(2023).
RN   [46] {ECO:0007744|PDB:6VSB}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.46 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN S1), SUBUNIT, AND
RP   GLYCOSYLATION.
RX   PubMed=32075877; DOI=10.1126/science.abb2507;
RA   Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.L., Abiona O.,
RA   Graham B.S., McLellan J.S.;
RT   ""Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation."";
RL   Science 367:1260-1263(2020).
RN   [47] {ECO:0007744|PDB:6VXX, ECO:0007744|PDB:6VYB}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.80 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), SUBUNIT (SPIKE PROTEIN S1), INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN
RP   S1), MUTAGENESIS OF 679-GLN--ALA-684, GLYCOSYLATION AT ASN-61; ASN-122;
RP   ASN-61; ASN-165; ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616;
RP   ASN-657; ASN-709; ASN-717; ASN-801; ASN-1074; ASN-1098 AND ASN-1134, AND
RP   DISULFIDE BOND.
RX   PubMed=32155444; DOI=10.1016/j.cell.2020.02.058;
RA   Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., Veesler D.;
RT   ""Structure, function, and antigenicity of the SARS-CoV-2 spike
RT   glycoprotein."";
RL   Cell 180:1-12(2020).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HOST ACE2.
RX   PubMed=32225176; DOI=10.1038/s41586-020-2180-5;
RA   Lan J., Ge J., Yu J., Shan S., Zhou H., Fan S., Zhang Q., Shi X., Wang Q.,
RA   Zhang L., Wang X.;
RT   ""Structure of the SARS-CoV-2 spike receptor-binding domain bound to the
RT   ACE2 receptor."";
RL   Nature 581:215-220(2020).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.68 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HOST ACE2, INTERACTION WITH HOST ACE2, AND MUTAGENESIS OF GLN-493 AND
RP   ASN-501.
RX   PubMed=32225175; DOI=10.1038/s41586-020-2179-y;
RA   Shang J., Ye G., Shi K., Wan Y., Luo C., Aihara H., Geng Q., Auerbach A.,
RA   Li F.;
RT   ""Structural basis of receptor recognition by SARS-CoV-2."";
RL   Nature 581:221-224(2020).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (3.08 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HUMAN ANTIBODY CR3022, AND DISULFIDE BOND.
RX   PubMed=32245784; DOI=10.1126/science.abb7269;
RA   Yuan M., Wu N.C., Zhu X., Lee C.D., So R.T.Y., Lv H., Mok C.K.P.,
RA   Wilson I.A.;
RT   ""A highly conserved cryptic epitope in the receptor-binding domains of
RT   SARS-CoV-2 and SARS-CoV."";
RL   Science 368:630-633(2020).
CC   -!- FUNCTION: [Spike protein S1]: Attaches the virion to the cell membrane
CC       by interacting with host receptor, initiating the infection. The major
CC       receptor is host ACE2 (PubMed:32142651, PubMed:32155444,
CC       PubMed:33607086). When S2/S2' has been cleaved, binding to the receptor
CC       triggers direct fusion at the cell membrane (PubMed:34561887). When
CC       S2/S2' has not been cleaved, binding to the receptor results in
CC       internalization of the virus by endocytosis leading to fusion of the
CC       virion membrane with the host endosomal membrane (PubMed:32075877,
CC       PubMed:32221306). Alternatively, may use NRP1/NRP2 (PubMed:33082294,
CC       PubMed:33082293) and integrin as entry receptors (PubMed:35150743). The
CC       use of NRP1/NRP2 receptors may explain the tropism of the virus in
CC       human olfactory epithelial cells, which express these molecules at high
CC       levels but ACE2 at low levels (PubMed:33082293). The stalk domain of S
CC       contains three hinges, giving the head unexpected orientational freedom
CC       (PubMed:32817270). {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:32075877, ECO:0000269|PubMed:32142651,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32221306,
CC       ECO:0000269|PubMed:32817270, ECO:0000269|PubMed:33082293,
CC       ECO:0000269|PubMed:33082294, ECO:0000269|PubMed:35150743,
CC       ECO:0000303|PubMed:33082293, ECO:0000305|PubMed:34561887}.
CC   -!- FUNCTION: [Spike protein S2]: Precursor of the fusion protein processed
CC       in the biosynthesis of the S protein and the formation of virus
CC       particle. Mediates fusion of the virion and cellular membranes by
CC       functioning as a class I viral fusion protein. Contains two viral
CC       fusion peptides that are unmasked after cleavage. The S2/S2' cleavage
CC       occurs during virus entry at the cell membrane by host TMPRSS2
CC       (PubMed:32142651) or during endocytosis by host CSTL (PubMed:32703818,
CC       PubMed:34159616). In either case, this triggers an extensive and
CC       irreversible conformational change leading to fusion of the viral
CC       envelope with the cellular cytoplasmic membrane, releasing viral
CC       genomic RNA into the host cell cytoplasm (PubMed:34561887). Under the
CC       current model, the protein has at least three conformational states:
CC       pre-fusion native state, pre-hairpin intermediate state, and post-
CC       fusion hairpin state. During fusion of the viral and target cell
CC       membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-
CC       hairpins structure and position the fusion peptide in close proximity
CC       to the C-terminal region of the ectodomain. Formation of this structure
CC       appears to promote apposition and subsequent fusion of viral and target
CC       cell membranes. {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:32703818, ECO:0000269|PubMed:34159616,
CC       ECO:0000305|PubMed:34561887}.
CC   -!- FUNCTION: [Spike protein S2']: Subunit of the fusion protein that is
CC       processed upon entry into the host cell. Mediates fusion of the virion
CC       and cellular membranes by functioning as a class I viral fusion
CC       protein. Contains a viral fusion peptide that is unmasked after S2
CC       cleavage. This cleavage can occur at the cell membrane by host TMPRSS2
CC       or during endocytosis by host CSTL (PubMed:32703818, PubMed:34159616).
CC       In either case, this triggers an extensive and irreversible
CC       conformational change that leads to fusion of the viral envelope with
CC       the cellular cytoplasmic membrane, releasing viral genomic RNA into the
CC       host cell cytoplasm (PubMed:34561887). Under the current model, the
CC       protein has at least three conformational states: pre-fusion native
CC       state, pre-hairpin intermediate state, and post-fusion hairpin state.
CC       During fusion of the viral and target cell membranes, the coiled coil
CC       regions (heptad repeats) adopt a trimer-of-hairpins structure and
CC       position the fusion peptide in close proximity to the C-terminal region
CC       of the ectodomain. Formation of this structure appears to promote
CC       apposition and subsequent fusion of viral and target cell membranes.
CC       {ECO:0000255|HAMAP-Rule:MF_04099, ECO:0000269|PubMed:32703818,
CC       ECO:0000269|PubMed:34159616, ECO:0000305|PubMed:34561887}.
CC   -!- SUBUNIT: [Spike glycoprotein]: Homotrimer; each monomer consists of a
CC       S1 and a S2 subunit (PubMed:32075877, PubMed:32155444,
CC       PubMed:32245784). The resulting peplomers protrude from the virus
CC       surface as spikes (PubMed:32979942). Interacts with ORF3a protein and
CC       ORF7a protein (By similarity) (PubMed:32075877, PubMed:32155444,
CC       PubMed:32245784, PubMed:32979942). There are an average of 26 +/-15
CC       spike trimers at the surface of virion particles (PubMed:32979942).
CC       Binds to host MBL2 (PubMed:35102342). This binding occurs via glycans
CC       and inhibits viral infectivity. Inhibition is effective against alpha,
CC       beta, gamma, and delta variants (PubMed:35102342). {ECO:0000255|HAMAP-
CC       Rule:MF_04099, ECO:0000269|PubMed:32075877,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32245784,
CC       ECO:0000269|PubMed:32979942, ECO:0000269|PubMed:35102342}.
CC   -!- SUBUNIT: [Spike protein S1]: Binds to host ACE2 (PubMed:32075877,
CC       PubMed:32132184, PubMed:32155444, PubMed:32221306, PubMed:32225175,
CC       PubMed:32225176, PubMed:33607086). RBD also interacts with the N-linked
CC       glycan on 'Asn-90' of ACE2 (PubMed:33607086). Cleavage of S generates a
CC       polybasic C-terminal sequence on S1 that binds to host Neuropilin-1
CC       (NRP1) and Neuropilin-2 (NRP2) receptors (PubMed:33082293,
CC       PubMed:33082294). Interacts with host integrin alpha-5/beta-1
CC       (ITGA5:ITGB1) and with ACE2 in complex with integrin alpha-5/beta-1
CC       (ITGA5:ITGB1) (PubMed:33102950). May interact via cytoplasmic c-
CC       terminus with M protein (PubMed:33229438). May interact (via N-
CC       terminus) with host bilirubin and biliverdin, thereby preventing
CC       antibody binding to the SARS-CoV-2 spike NTD via an allosteric
CC       mechanism (PubMed:33888467). May interact with host LRRC15, thereby
CC       allowing attachment to host cells (PubMed:36735681).
CC       {ECO:0000269|PubMed:32075877, ECO:0000269|PubMed:32132184,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32221306,
CC       ECO:0000269|PubMed:32225",26377
TATCAT ATCATG TCATGG CATGGT ATGGTA TGGTAT GGTATC GTATCG TATCGA ATCGAA TCGAAG CGAAGC GAAGCA AAGCAC AGCACA GCACAA CACAAT ACAATT CAATTA AATTAT ATTATG TTATGG TATGGC ATGGCG TGGCGT GGCGTA GCGTAA CGTAAC GTAACG TAACGT AACGTT ACGTTG CGTTGT GTTGTC TTGTCT TGTCTG GTCTGG TCTGGA CTGGAA TGGAAC GGAACA GAACAC AACACC ACACCG CACCGT ACCGTC CCGTCT CGTCTA GTCTAC TCTACT CTACTT TACTTT ACTTTG CTTTGG TTTGGT TTGGTA TGGTAT GGTATC GTATCA TATCAT ATCATC TCATCG CATCGG ATCGGG TCGGGT CGGGTC GGGTCC GGTCCA GTCCAT TCCATT CCATTA CATTAA ATTAAG TTAAGA TAAGAA AAGAAC AGAACA GAACAC AACACC ACACCT CACCTT ACCTTG CCTTGC CTTGCC TTGCCC TGCCCC GCCCCA CCCCAA CCCAAG CCAAGA CAAGAT AAGATG AGATGC GATGCA ATGCAA TGCAAC GCAACC CAACCC AACCCC ACCCCA CCCCAG CCCAGG CCAGGC CAGGCC AGGCCA GGCCAA GCCAAC CCAACA CAACAC AACACC ACACCA CACCAC ACCACT CCACTT CACTTT ACTTTT CTTTTA TTTTAT TTTATT TTATTC TATTCC ATTCCT TTCCTT TCCTTG CCTTGT CTTGTT TTGTTA TGTTAG GTTAGG TTAGGT TAGGTG AGGTGG GGTGGT GTGGTT TGGTTT GGTTTT GTTTTG TTTTGT TTTGTC TTGTCG TGTCGG GTCGGC TCGGCG CGGCGG GGCGGT,2,145,TATC ATCA TCAT CATG ATGG TGGT GGTA GTAT TATC ATCG TCGA CGAA GAAG AAGC AGCA GCAC CACA ACAA CAAT AATT ATTA TTAT TATG ATGG TGGC GGCG GCGT CGTA GTAA TAAC AACG ACGT CGTT GTTG TTGT TGTC GTCT TCTG CTGG TGGA GGAA GAAC AACA ACAC CACC ACCG CCGT CGTC GTCT TCTA CTAC TACT ACTT CTTT TTTG TTGG TGGT GGTA GTAT TATC ATCA TCAT CATC ATCG TCGG CGGG GGGT GGTC GTCC TCCA CCAT CATT ATTA TTAA TAAG AAGA AGAA GAAC AACA ACAC CACC ACCT CCTT CTTG TTGC TGCC GCCC CCCC CCCA CCAA CAAG AAGA AGAT GATG ATGC TGCA GCAA CAAC AACC ACCC CCCC CCCA CCAG CAGG AGGC GGCC GCCA CCAA CAAC AACA ACAC CACC ACCA CCAC CACT ACTT CTTT TTTT TTTA TTAT TATT ATTC TTCC TCCT CCTT CTTG TTGT TGTT GTTA TTAG TAGG AGGT GGTG GTGG TGGT GGTT GTTT TTTT TTTG TTGT TGTC GTCG TCGG CGGC GGCG GCGG CGGT,TATCA ATCAT TCATG CATGG ATGGT TGGTA GGTAT GTATC TATCG ATCGA TCGAA CGAAG GAAGC AAGCA AGCAC GCACA CACAA ACAAT CAATT AATTA ATTAT TTATG TATGG ATGGC TGGCG GGCGT GCGTA CGTAA GTAAC TAACG AACGT ACGTT CGTTG GTTGT TTGTC TGTCT GTCTG TCTGG CTGGA TGGAA GGAAC GAACA AACAC ACACC CACCG ACCGT CCGTC CGTCT GTCTA TCTAC CTACT TACTT ACTTT CTTTG TTTGG TTGGT TGGTA GGTAT GTATC TATCA ATCAT TCATC CATCG ATCGG TCGGG CGGGT GGGTC GGTCC GTCCA TCCAT CCATT CATTA ATTAA TTAAG TAAGA AAGAA AGAAC GAACA AACAC ACACC CACCT ACCTT CCTTG CTTGC TTGCC TGCCC GCCCC CCCCA CCCAA CCAAG CAAGA AAGAT AGATG GATGC ATGCA TGCAA GCAAC CAACC AACCC ACCCC CCCCA CCCAG CCAGG CAGGC AGGCC GGCCA GCCAA CCAAC CAACA AACAC ACACC CACCA ACCAC CCACT CACTT ACTTT CTTTT TTTTA TTTAT TTATT TATTC ATTCC TTCCT TCCTT CCTTG CTTGT TTGTT TGTTA GTTAG TTAGG TAGGT AGGTG GGTGG GTGGT TGGTT GGTTT GTTTT TTTTG TTTGT TTGTC TGTCG GTCGG TCGGC CGGCG GGCGG GCGGT,TATCAT ATCATG TCATGG CATGGT ATGGTA TGGTAT GGTATC GTATCG TATCGA ATCGAA TCGAAG CGAAGC GAAGCA AAGCAC AGCACA GCACAA CACAAT ACAATT CAATTA AATTAT ATTATG TTATGG TATGGC ATGGCG TGGCGT GGCGTA GCGTAA CGTAAC GTAACG TAACGT AACGTT ACGTTG CGTTGT GTTGTC TTGTCT TGTCTG GTCTGG TCTGGA CTGGAA TGGAAC GGAACA GAACAC AACACC ACACCG CACCGT ACCGTC CCGTCT CGTCTA GTCTAC TCTACT CTACTT TACTTT ACTTTG CTTTGG TTTGGT TTGGTA TGGTAT GGTATC GTATCA TATCAT ATCATC TCATCG CATCGG ATCGGG TCGGGT CGGGTC GGGTCC GGTCCA GTCCAT TCCATT CCATTA CATTAA ATTAAG TTAAGA TAAGAA AAGAAC AGAACA GAACAC AACACC ACACCT CACCTT ACCTTG CCTTGC CTTGCC TTGCCC TGCCCC GCCCCA CCCCAA CCCAAG CCAAGA CAAGAT AAGATG AGATGC GATGCA ATGCAA TGCAAC GCAACC CAACCC AACCCC ACCCCA CCCCAG CCCAGG CCAGGC CAGGCC AGGCCA GGCCAA GCCAAC CCAACA CAACAC AACACC ACACCA CACCAC ACCACT CCACTT CACTTT ACTTTT CTTTTA TTTTAT TTTATT TTATTC TATTCC ATTCCT TTCCTT TCCTTG CCTTGT CTTGTT TTGTTA TGTTAG GTTAGG TTAGGT TAGGTG AGGTGG GGTGGT GTGGTT TGGTTT GGTTTT GTTTTG TTTTGT TTTGTC TTGTCG TGTCGG GTCGGC TCGGCG CGGCGG GGCGGT,TATCATG ATCATGG TCATGGT CATGGTA ATGGTAT TGGTATC GGTATCG GTATCGA TATCGAA ATCGAAG TCGAAGC CGAAGCA GAAGCAC AAGCACA AGCACAA GCACAAT CACAATT ACAATTA CAATTAT AATTATG ATTATGG TTATGGC TATGGCG ATGGCGT TGGCGTA GGCGTAA GCGTAAC CGTAACG GTAACGT TAACGTT AACGTTG ACGTTGT CGTTGTC GTTGTCT TTGTCTG TGTCTGG GTCTGGA TCTGGAA CTGGAAC TGGAACA GGAACAC GAACACC AACACCG ACACCGT CACCGTC ACCGTCT CCGTCTA CGTCTAC GTCTACT TCTACTT CTACTTT TACTTTG ACTTTGG CTTTGGT TTTGGTA TTGGTAT TGGTATC GGTATCA GTATCAT TATCATC ATCATCG TCATCGG CATCGGG ATCGGGT TCGGGTC CGGGTCC GGGTCCA GGTCCAT GTCCATT TCCATTA CCATTAA CATTAAG ATTAAGA TTAAGAA TAAGAAC AAGAACA AGAACAC GAACACC AACACCT ACACCTT CACCTTG ACCTTGC CCTTGCC CTTGCCC TTGCCCC TGCCCCA GCCCCAA CCCCAAG CCCAAGA CCAAGAT CAAGATG AAGATGC AGATGCA GATGCAA ATGCAAC TGCAACC GCAACCC CAACCCC AACCCCA ACCCCAG CCCCAGG CCCAGGC CCAGGCC CAGGCCA AGGCCAA GGCCAAC GCCAACA CCAACAC CAACACC AACACCA ACACCAC CACCACT ACCACTT CCACTTT CACTTTT ACTTTTA CTTTTAT TTTTATT TTTATTC TTATTCC TATTCCT ATTCCTT TTCCTTG TCCTTGT CCTTGTT CTTGTTA TTGTTAG TGTTAGG GTTAGGT TTAGGTG TAGGTGG AGGTGGT GGTGGTT GTGGTTT TGGTTTT GGTTTTG GTTTTGT TTTTGTC TTTGTCG TTGTCGG TGTCGGC GTCGGCG TCGGCGG CGGCGGT,"ID   ODC1_YEAST              Reviewed;         310 AA.
AC   Q03028; D6W3N3;
DT   11-FEB-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   05-FEB-2025, entry version 168.
DE   RecName: Full=Mitochondrial 2-oxodicarboxylate carrier 1;
GN   Name=ODC1; OrderedLocusNames=YPL134C; ORFNames=LPI11C;
OS   Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast).
OC   Eukaryota; Fungi; Dikarya; Ascomycota; Saccharomycotina; Saccharomycetes;
OC   Saccharomycetales; Saccharomycetaceae; Saccharomyces.
OX   NCBI_TaxID=559292;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 204508 / S288c;
RX   PubMed=9169875; DOI=10.1038/387s103;
RA   Bussey H., Storms R.K., Ahmed A., Albermann K., Allen E., Ansorge W.,
RA   Araujo R., Aparicio A., Barrell B.G., Badcock K., Benes V., Botstein D.,
RA   Bowman S., Brueckner M., Carpenter J., Cherry J.M., Chung E.,
RA   Churcher C.M., Coster F., Davis K., Davis R.W., Dietrich F.S., Delius H.,
RA   DiPaolo T., Dubois E., Duesterhoeft A., Duncan M., Floeth M., Fortin N.,
RA   Friesen J.D., Fritz C., Goffeau A., Hall J., Hebling U., Heumann K.,
RA   Hilbert H., Hillier L.W., Hunicke-Smith S., Hyman R.W., Johnston M.,
RA   Kalman S., Kleine K., Komp C., Kurdi O., Lashkari D., Lew H., Lin A.,
RA   Lin D., Louis E.J., Marathe R., Messenguy F., Mewes H.-W., Mirtipati S.,
RA   Moestl D., Mueller-Auer S., Namath A., Nentwich U., Oefner P., Pearson D.,
RA   Petel F.X., Pohl T.M., Purnelle B., Rajandream M.A., Rechmann S.,
RA   Rieger M., Riles L., Roberts D., Schaefer M., Scharfe M., Scherens B.,
RA   Schramm S., Schroeder M., Sdicu A.-M., Tettelin H., Urrestarazu L.A.,
RA   Ushinsky S., Vierendeels F., Vissers S., Voss H., Walsh S.V., Wambutt R.,
RA   Wang Y., Wedler E., Wedler H., Winnett E., Zhong W.-W., Zollner A.,
RA   Vo D.H., Hani J.;
RT   ""The nucleotide sequence of Saccharomyces cerevisiae chromosome XVI."";
RL   Nature 387:103-105(1997).
RN   [2]
RP   GENOME REANNOTATION.
RC   STRAIN=ATCC 204508 / S288c;
RX   PubMed=24374639; DOI=10.1534/g3.113.008995;
RA   Engel S.R., Dietrich F.S., Fisk D.G., Binkley G., Balakrishnan R.,
RA   Costanzo M.C., Dwight S.S., Hitz B.C., Karra K., Nash R.S., Weng S.,
RA   Wong E.D., Lloyd P., Skrzypek M.S., Miyasato S.R., Simison M., Cherry J.M.;
RT   ""The reference genome sequence of Saccharomyces cerevisiae: Then and now."";
RL   G3 (Bethesda) 4:389-398(2014).
RN   [3]
RP   CHARACTERIZATION.
RX   PubMed=11013234; DOI=10.1074/jbc.m004332200;
RA   Palmieri L., Agrimi G., Runswick M.J., Fearnley I.M., Palmieri F.,
RA   Walker J.E.;
RT   ""Identification in Saccharomyces cerevisiae of two isoforms of a novel
RT   mitochondrial transporter for 2-oxoadipate and 2-oxoglutarate."";
RL   J. Biol. Chem. 276:1916-1922(2001).
RN   [4]
RP   LEVEL OF PROTEIN EXPRESSION [LARGE SCALE ANALYSIS].
RX   PubMed=14562106; DOI=10.1038/nature02046;
RA   Ghaemmaghami S., Huh W.-K., Bower K., Howson R.W., Belle A., Dephoure N.,
RA   O'Shea E.K., Weissman J.S.;
RT   ""Global analysis of protein expression in yeast."";
RL   Nature 425:737-741(2003).
CC   -!- FUNCTION: Transports C5-C7 oxodicarboxylates across the inner membranes
CC       of mitochondria. Can transport 2-oxoadipate, 2-oxoglutarate, adipate,
CC       glutarate, 2-oxopimelate, oxaloacetate, citrate and malate. The main
CC       physiological role is probably to supply 2-oxoadipate and 2-
CC       oxoglutarate from the mitochondrial matrix to the cytosol where they
CC       are used in the biosynthesis of lysine and glutamate, respectively, and
CC       in lysine catabolism.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane; Multi-pass membrane
CC       protein.
CC   -!- MISCELLANEOUS: Present with 2840 molecules/cell in log phase SD medium.
CC       {ECO:0000269|PubMed:14562106}.
CC   -!- SIMILARITY: Belongs to the mitochondrial carrier (TC 2.A.29) family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U43703; AAB68225.1; -; Genomic_DNA.
DR   EMBL; BK006949; DAA11299.1; -; Genomic_DNA.
DR   PIR; S69050; S69050.
DR   RefSeq; NP_015191.1; NM_001183948.1.
DR   AlphaFoldDB; Q03028; -.
DR   SMR; Q03028; -.
DR   BioGRID; 36047; 82.
DR   DIP; DIP-8776N; -.
DR   IntAct; Q03028; 2.
DR   STRING; 4932.YPL134C; -.
DR   TCDB; 2.A.29.2.8; the mitochondrial carrier (mc) family.
DR   PaxDb; 4932-YPL134C; -.
DR   PeptideAtlas; Q03028; -.
DR   EnsemblFungi; YPL134C_mRNA; YPL134C; YPL134C.
DR   GeneID; 855969; -.
DR   KEGG; sce:YPL134C; -.
DR   AGR; SGD:S000006055; -.
DR   SGD; S000006055; ODC1.
DR   VEuPathDB; FungiDB:YPL134C; -.
DR   eggNOG; KOG0754; Eukaryota.
DR   GeneTree; ENSGT00730000111119; -.
DR   HOGENOM; CLU_015166_5_2_1; -.
DR   InParanoid; Q03028; -.
DR   OMA; LPFQYQF; -.
DR   OrthoDB; 434783at2759; -.
DR   BioCyc; YEAST:G3O-34033-MONOMER; -.
DR   BioGRID-ORCS; 855969; 2 hits in 10 CRISPR screens.
DR   PRO; PR:Q03028; -.
DR   Proteomes; UP000002311; Chromosome XVI.
DR   RNAct; Q03028; protein.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IDA:SGD.
DR   GO; GO:0005739; C:mitochondrion; IDA:SGD.
DR   GO; GO:0005471; F:ATP:ADP antiporter activity; IEA:InterPro.
DR   GO; GO:0005310; F:dicarboxylic acid transmembrane transporter activity; IDA:SGD.
DR   GO; GO:0015183; F:L-aspartate transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0005313; F:L-glutamate transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0015810; P:aspartate transmembrane transport; IBA:GO_Central.
DR   GO; GO:0015813; P:L-glutamate transmembrane transport; IBA:GO_Central.
DR   GO; GO:0043490; P:malate-aspartate shuttle; IBA:GO_Central.
DR   GO; GO:0140021; P:mitochondrial ADP transmembrane transport; IEA:InterPro.
DR   GO; GO:1990544; P:mitochondrial ATP transmembrane transport; IEA:InterPro.
DR   GO; GO:0006839; P:mitochondrial transport; IDA:SGD.
DR   FunFam; 1.50.40.10:FF:000034; Mitochondrial 2-oxodicarboxylate carrier; 1.
DR   Gene3D; 1.50.40.10; Mitochondrial carrier domain; 1.
DR   InterPro; IPR002113; ADT_euk_type.
DR   InterPro; IPR002067; Mit_carrier.
DR   InterPro; IPR051752; Mito_2-oxodicarb_carrier.
DR   InterPro; IPR018108; Mitochondrial_sb/sol_carrier.
DR   InterPro; IPR023395; Mt_carrier_dom_sf.
DR   PANTHER; PTHR46356; MITOCHONDRIAL 2-OXODICARBOXYLATE CARRIER; 1.
DR   PANTHER; PTHR46356:SF1; MITOCHONDRIAL 2-OXODICARBOXYLATE CARRIER; 1.
DR   Pfam; PF00153; Mito_carr; 3.
DR   PRINTS; PR00927; ADPTRNSLCASE.
DR   PRINTS; PR00926; MITOCARRIER.
DR   SUPFAM; SSF103506; Mitochondrial carrier; 1.
DR   PROSITE; PS50920; SOLCAR; 3.
PE   1: Evidence at protein level;
KW   Membrane; Mitochondrion; Mitochondrion inner membrane; Reference proteome;
KW   Repeat; Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..310
FT                   /note=""Mitochondrial 2-oxodicarboxylate carrier 1""
FT                   /id=""PRO_0000090648""
FT   TRANSMEM        9..29
FT                   /note=""Helical; Name=1""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        78..97
FT                   /note=""Helical; Name=2""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        126..146
FT                   /note=""Helical; Name=3""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        179..199
FT                   /note=""Helical; Name=4""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        219..239
FT                   /note=""Helical; Name=5""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        281..301
FT                   /note=""Helical; Name=6""
FT                   /evidence=""ECO:0000255""
FT   REPEAT          9..108
FT                   /note=""Solcar 1""
FT   REPEAT          120..204
FT                   /note=""Solcar 2""
FT   REPEAT          213..300
FT                   /note=""Solcar 3""
SQ   SEQUENCE   310 AA;  34206 MW;  8EB7D6231BC2BCEE CRC64;
     MTSIDNRPLP FIYQFTAGAI AGVSELLVMY PLDVVKTRMQ LQVTTKGHPA VVAAKAAVDH
     YTGVMDCLTK IVKKEGFSHL YKGITSPILM EAPKRAIKFS GNDTFQTFYK KIFPTPNGEM
     TQKIAIYSGA SAGAVEAFVV APFELVKIRL QDVNSQFKTP IEVVKNSVVK GGVLSLFNGL
     EATIWRHVLW NAGYFGIIFQ IRKLLPAAKT STEKTRNDLI AGAIGGTVGC LLNTPFDVVK
     SRIQRSSGPL RKYNWSLPSV LLVYREEGFK ALYKGFAPKV MRLAPGGGLL LVVFTNVMDF
     FREVKYGKKQ
//
",38329
CCCGCA CCGCAA CGCAAT GCAATC CAATCC AATCCT ATCCTG TCCTGC CCTGCT CTGCTA TGCTAA GCTAAC CTAACA TAACAA AACAAT ACAATG CAATGC AATGCT ATGCTG TGCTGC GCTGCA CTGCAA TGCAAT GCAATC CAATCG AATCGT ATCGTG TCGTGC CGTGCT GTGCTA TGCTAC GCTACA CTACAA TACAAC ACAACT CAACTT AACTTC ACTTCC CTTCCT TTCCTC TCCTCA CCTCAA CTCAAG TCAAGG CAAGGA AAGGAA AGGAAC GGAACA GAACAA AACAAC ACAACA CAACAT AACATT ACATTG CATTGC ATTGCC TTGCCA TGCCAA GCCAAA CCAAAA CAAAAG AAAAGG AAAGGC AAGGCT AGGCTT GGCTTC GCTTCT CTTCTA TTCTAC TCTACG CTACGC TACGCA ACGCAG CGCAGA GCAGAA CAGAAG AGAAGG GAAGGG AAGGGA AGGGAG GGGAGC GGAGCA GAGCAG AGCAGA GCAGAG CAGAGG AGAGGC GAGGCG AGGCGG GGCGGC GCGGCA CGGCAG GGCAGT GCAGTC CAGTCA AGTCAA GTCAAG TCAAGC CAAGCC AAGCCT AGCCTC GCCTCT CCTCTT CTCTTC TCTTCT CTTCTC TTCTCG TCTCGT CTCGTT TCGTTC CGTTCC GTTCCT TTCCTC TCCTCA CCTCAT CTCATC TCATCA CATCAC ATCACG TCACGT CACGTA ACGTAG CGTAGT GTAGTC TAGTCG AGTCGC GTCGCA TCGCAA CGCAAC GCAACA CAACAG AACAGT ACAGTT CAGTTC AGTTCA GTTCAA TTCAAG TCAAGA CAAGAA AAGAAA AGAAAT GAAATT AAATTC AATTCA ATTCAA,3,145,CCCG CCGC CGCA GCAA CAAT AATC ATCC TCCT CCTG CTGC TGCT GCTA CTAA TAAC AACA ACAA CAAT AATG ATGC TGCT GCTG CTGC TGCA GCAA CAAT AATC ATCG TCGT CGTG GTGC TGCT GCTA CTAC TACA ACAA CAAC AACT ACTT CTTC TTCC TCCT CCTC CTCA TCAA CAAG AAGG AGGA GGAA GAAC AACA ACAA CAAC AACA ACAT CATT ATTG TTGC TGCC GCCA CCAA CAAA AAAA AAAG AAGG AGGC GGCT GCTT CTTC TTCT TCTA CTAC TACG ACGC CGCA GCAG CAGA AGAA GAAG AAGG AGGG GGGA GGAG GAGC AGCA GCAG CAGA AGAG GAGG AGGC GGCG GCGG CGGC GGCA GCAG CAGT AGTC GTCA TCAA CAAG AAGC AGCC GCCT CCTC CTCT TCTT CTTC TTCT TCTC CTCG TCGT CGTT GTTC TTCC TCCT CCTC CTCA TCAT CATC ATCA TCAC CACG ACGT CGTA GTAG TAGT AGTC GTCG TCGC CGCA GCAA CAAC AACA ACAG CAGT AGTT GTTC TTCA TCAA CAAG AAGA AGAA GAAA AAAT AATT ATTC TTCA TCAA,CCCGC CCGCA CGCAA GCAAT CAATC AATCC ATCCT TCCTG CCTGC CTGCT TGCTA GCTAA CTAAC TAACA AACAA ACAAT CAATG AATGC ATGCT TGCTG GCTGC CTGCA TGCAA GCAAT CAATC AATCG ATCGT TCGTG CGTGC GTGCT TGCTA GCTAC CTACA TACAA ACAAC CAACT AACTT ACTTC CTTCC TTCCT TCCTC CCTCA CTCAA TCAAG CAAGG AAGGA AGGAA GGAAC GAACA AACAA ACAAC CAACA AACAT ACATT CATTG ATTGC TTGCC TGCCA GCCAA CCAAA CAAAA AAAAG AAAGG AAGGC AGGCT GGCTT GCTTC CTTCT TTCTA TCTAC CTACG TACGC ACGCA CGCAG GCAGA CAGAA AGAAG GAAGG AAGGG AGGGA GGGAG GGAGC GAGCA AGCAG GCAGA CAGAG AGAGG GAGGC AGGCG GGCGG GCGGC CGGCA GGCAG GCAGT CAGTC AGTCA GTCAA TCAAG CAAGC AAGCC AGCCT GCCTC CCTCT CTCTT TCTTC CTTCT TTCTC TCTCG CTCGT TCGTT CGTTC GTTCC TTCCT TCCTC CCTCA CTCAT TCATC CATCA ATCAC TCACG CACGT ACGTA CGTAG GTAGT TAGTC AGTCG GTCGC TCGCA CGCAA GCAAC CAACA AACAG ACAGT CAGTT AGTTC GTTCA TTCAA TCAAG CAAGA AAGAA AGAAA GAAAT AAATT AATTC ATTCA TTCAA,CCCGCA CCGCAA CGCAAT GCAATC CAATCC AATCCT ATCCTG TCCTGC CCTGCT CTGCTA TGCTAA GCTAAC CTAACA TAACAA AACAAT ACAATG CAATGC AATGCT ATGCTG TGCTGC GCTGCA CTGCAA TGCAAT GCAATC CAATCG AATCGT ATCGTG TCGTGC CGTGCT GTGCTA TGCTAC GCTACA CTACAA TACAAC ACAACT CAACTT AACTTC ACTTCC CTTCCT TTCCTC TCCTCA CCTCAA CTCAAG TCAAGG CAAGGA AAGGAA AGGAAC GGAACA GAACAA AACAAC ACAACA CAACAT AACATT ACATTG CATTGC ATTGCC TTGCCA TGCCAA GCCAAA CCAAAA CAAAAG AAAAGG AAAGGC AAGGCT AGGCTT GGCTTC GCTTCT CTTCTA TTCTAC TCTACG CTACGC TACGCA ACGCAG CGCAGA GCAGAA CAGAAG AGAAGG GAAGGG AAGGGA AGGGAG GGGAGC GGAGCA GAGCAG AGCAGA GCAGAG CAGAGG AGAGGC GAGGCG AGGCGG GGCGGC GCGGCA CGGCAG GGCAGT GCAGTC CAGTCA AGTCAA GTCAAG TCAAGC CAAGCC AAGCCT AGCCTC GCCTCT CCTCTT CTCTTC TCTTCT CTTCTC TTCTCG TCTCGT CTCGTT TCGTTC CGTTCC GTTCCT TTCCTC TCCTCA CCTCAT CTCATC TCATCA CATCAC ATCACG TCACGT CACGTA ACGTAG CGTAGT GTAGTC TAGTCG AGTCGC GTCGCA TCGCAA CGCAAC GCAACA CAACAG AACAGT ACAGTT CAGTTC AGTTCA GTTCAA TTCAAG TCAAGA CAAGAA AAGAAA AGAAAT GAAATT AAATTC AATTCA ATTCAA,CCCGCAA CCGCAAT CGCAATC GCAATCC CAATCCT AATCCTG ATCCTGC TCCTGCT CCTGCTA CTGCTAA TGCTAAC GCTAACA CTAACAA TAACAAT AACAATG ACAATGC CAATGCT AATGCTG ATGCTGC TGCTGCA GCTGCAA CTGCAAT TGCAATC GCAATCG CAATCGT AATCGTG ATCGTGC TCGTGCT CGTGCTA GTGCTAC TGCTACA GCTACAA CTACAAC TACAACT ACAACTT CAACTTC AACTTCC ACTTCCT CTTCCTC TTCCTCA TCCTCAA CCTCAAG CTCAAGG TCAAGGA CAAGGAA AAGGAAC AGGAACA GGAACAA GAACAAC AACAACA ACAACAT CAACATT AACATTG ACATTGC CATTGCC ATTGCCA TTGCCAA TGCCAAA GCCAAAA CCAAAAG CAAAAGG AAAAGGC AAAGGCT AAGGCTT AGGCTTC GGCTTCT GCTTCTA CTTCTAC TTCTACG TCTACGC CTACGCA TACGCAG ACGCAGA CGCAGAA GCAGAAG CAGAAGG AGAAGGG GAAGGGA AAGGGAG AGGGAGC GGGAGCA GGAGCAG GAGCAGA AGCAGAG GCAGAGG CAGAGGC AGAGGCG GAGGCGG AGGCGGC GGCGGCA GCGGCAG CGGCAGT GGCAGTC GCAGTCA CAGTCAA AGTCAAG GTCAAGC TCAAGCC CAAGCCT AAGCCTC AGCCTCT GCCTCTT CCTCTTC CTCTTCT TCTTCTC CTTCTCG TTCTCGT TCTCGTT CTCGTTC TCGTTCC CGTTCCT GTTCCTC TTCCTCA TCCTCAT CCTCATC CTCATCA TCATCAC CATCACG ATCACGT TCACGTA CACGTAG ACGTAGT CGTAGTC GTAGTCG TAGTCGC AGTCGCA GTCGCAA TCGCAAC CGCAACA GCAACAG CAACAGT AACAGTT ACAGTTC CAGTTCA AGTTCAA GTTCAAG TTCAAGA TCAAGAA CAAGAAA AAGAAAT AGAAATT GAAATTC AAATTCA AATTCAA,"ID   ORF9C_SARS2             Reviewed;          73 AA.
AC   P0DTD3;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   27-NOV-2024, entry version 16.
DE   RecName: Full=Putative ORF9c protein {ECO:0000305|PubMed:32854725};
DE            Short=ORF9c;
DE   AltName: Full=Uncharacterized protein 14;
DE            Short=ORF14;
GN   ORFNames=9c;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   CONCEPTUAL TRANSLATION.
RX   PubMed=32854725; DOI=10.1186/s12985-020-01402-1;
RA   Michel C.J., Mayer C., Poch O., Thompson J.D.;
RT   ""Characterization of accessory genes in coronavirus genomes."";
RL   Virol. J. 17:131-131(2020).
RN   [3]
RP   GENOME REANNOTATION.
RX   PubMed=33976134; DOI=10.1038/s41467-021-22905-7;
RA   Jungreis I., Sealfon R., Kellis M.;
RT   ""SARS-CoV-2 gene content and COVID-19 mutation impact by comparing 44
RT   Sarbecovirus genomes."";
RL   Nat. Commun. 12:2642-2642(2021).
RN   [4]
RP   FUNCTION.
RX   PubMed=35180394; DOI=10.1016/j.stemcr.2022.01.014;
RA   Liu J., Zhang Y., Han L., Guo S., Wu S., Doud E.H., Wang C., Chen H.,
RA   Rubart-von der Lohe M., Wan J., Yang L.;
RT   ""Genome-wide analyses reveal the detrimental impacts of SARS-CoV-2 viral
RT   gene Orf9c on human pluripotent stem cell-derived cardiomyocytes."";
RL   Stem Cell Reports 17:522-537(2022).
CC   -!- FUNCTION: May induce apoptosis in cardiomyocytes when overexpressed ex-
CC       vivo. {ECO:0000269|PubMed:35180394}.
CC   -!- INTERACTION:
CC       P0DTD3; Q9H3K2: GHITM; Xeno; NbExp=3; IntAct=EBI-25475917, EBI-2868909;
CC       P0DTD3; Q86VR2: RETREG3; Xeno; NbExp=3; IntAct=EBI-25475917, EBI-10192441;
CC       P0DTD3; O43765: SGTA; Xeno; NbExp=3; IntAct=EBI-25475917, EBI-347996;
CC       P0DTD3; Q9UMX0: UBQLN1; Xeno; NbExp=3; IntAct=EBI-25475917, EBI-741480;
CC       P0DTD3; Q9UHD9: UBQLN2; Xeno; NbExp=4; IntAct=EBI-25475917, EBI-947187;
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000255}; Single-pass membrane
CC       protein {ECO:0000255}.
CC   -!- CAUTION: Product of a dubious CDS prediction.
CC       {ECO:0000303|PubMed:33976134}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   BioGRID; 4383954; 514.
DR   IntAct; P0DTD3; 126.
DR   MINT; P0DTD3; -.
DR   AGR; RefSeq:P0DTD3; -.
DR   PRO; PR:P0DTD3; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-SubCell.
DR   InterPro; IPR035113; Protein_14_SARS-like.
DR   Pfam; PF17635; bCoV_Orf14; 1.
PE   5: Uncertain;
KW   Membrane; Reference proteome; Transmembrane; Transmembrane helix.
FT   CHAIN           1..73
FT                   /note=""Putative ORF9c protein""
FT                   /id=""PRO_0000449658""
FT   TRANSMEM        47..67
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   VARIANT         49
FT                   /note=""V -> L (in strain: Gamma)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         50
FT                   /note=""G -> N (in strain: Alpha/B.1.1.7, Gamma/P.1,
FT                   Omicron/BA.1, Omicron/BA.2, Omicron/BA.2.12.2,
FT                   Omicron/BA.4, Omicron BA.5)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         50
FT                   /note=""G -> W (in strain: Delta/B.1.617.2)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         52
FT                   /note=""L -> F (in strain: Beta/B.1.351)""
FT                   /evidence=""ECO:0000305""
SQ   SEQUENCE   73 AA;  8050 MW;  8CCDEF1C0EA37D06 CRC64;
     MLQSCYNFLK EQHCQKASTQ KGAEAAVKPL LVPHHVVATV QEIQLQAAVG ELLLLEWLAM
     AVMLLLLCCC LTD
//
",50065
CCCCTG CCCTGC CCTGCC CTGCCA TGCCAG GCCAGC CCAGCG CAGCGC AGCGCG GCGCGG CGCGGA GCGGAT CGGATA GGATAA GATAAT ATAATC TAATCC AATCCG ATCCGC TCCGCA CCGCAC CGCACC GCACCA CACCAC ACCACA CCACAT CACATT ACATTC CATTCA ATTCAT TTCATT TCATTA CATTAC ATTACA TTACAG TACAGA ACAGAC CAGACA AGACAA GACAAA ACAAAT CAAATG AAATGC AATGCG ATGCGC TGCGCG GCGCGT CGCGTT GCGTTT CGTTTT GTTTTG TTTTGG TTTGGA TTGGAG TGGAGC GGAGCT GAGCTT AGCTTT GCTTTC CTTTCG TTTCGC TTCGCC TCGCCA CGCCAC GCCACG CCACGT CACGTT ACGTTT CGTTTA GTTTAC TTTACC TTACCT TACCTC ACCTCT CCTCTT CTCTTA TCTTAC CTTACT TTACTT TACTTT ACTTTT CTTTTG TTTTGG TTTGGT TTGGTT TGGTTC GGTTCA GTTCAT TTCATG TCATGC CATGCT ATGCTG TGCTGC GCTGCC CTGCCC TGCCCG GCCCGA CCCGAG CCGAGA CGAGAG GAGAGG AGAGGA GAGGAT AGGATA GGATAC GATACA ATACAG TACAGA ACAGAA CAGAAT AGAATA GAATAC AATACC ATACCC TACCCC ACCCCC CCCCCA CCCCAT CCCATC CCATCA CATCAG ATCAGG TCAGGT CAGGTC AGGTCA GGTCAG GTCAGC TCAGCG CAGCGT AGCGTG GCGTGG CGTGGC GTGGCG TGGCGG GGCGGA GCGGAT CGGATA GGATAG GATAGT ATAGTC TAGTCA AGTCAC,3,142,CCCCCCCC C C CCCCCCCTT GT C CCCCTCTGTG G C CTGC TC GC TCA TGTGCGCCC G GCGCCCCACA A C CCCC CAGAG  TG CATTCAGCC A AGAGCGCGGATCC  GCCCGCGCGC  CGG GGCGCG G G GCGCGCGTGG G C CGGA A G GGGGAGATAT T G GACG ATAA A ATATATAAAA A T TATAAAT T A AAAC ATCTC  ATATCTCCCC  TCTCCATACG G C CCCCGC C CGCGCGCACA A G GCGCATGCAATC C CACACACCCATC A TTACCCCACA A C CCCACAC C C CACACACCC AA A ACACACATAT A A CACATCA TT T AATTTTCCGTC T TTC GTCACA A TTCACATAT T C CACATATTTT T A ATATTTTAA T TTTTACTTAC C T TAACACA A A ACACACAGG CCAGAGAGA A A AGAGAGGAAC C G GAGACACACA ACACAAAA A C CATCAC TAA T C AAAAAAATAT T A AAAATATGTG  ATGA CACCAGATCTGCGCGG G GCGCGTG  AGC C CGCGCGCGCG G G GCGCG CTA TT C CGCGTGTTTT T G GTGTTTT T T TTTTTTTTTT T T TTTTTTG G T TTTTGTGGGG G T TGTGGGGAGA  GGGGAGAGAG G G GAGAGAGCCG G G ATT G GCGCTCTTTT T C CTAATTTTTT T TCC TTTTTCTGCC TCGGTTCTCGCG G T TCTCGCGCGC  CGCGC CTCCAC G GCCAGCCAA C CCCCACACAC C C CACACCG G AATTACGT CC TGCTGTTCGG GTGTTTTTGAGT T TTTTTTTATA A TGGCTTATACAC GC  TATAC CA TTC A ACACCCT T C CCCCTCTCC C CTCTCTCTCT A G TCTCTCTTTT T C CTCTT ACGT  TTTTATACAC C T TATACACT ACACTGAGTT T CCTTTTTTT T T TTTTTTT  TTA ATG CC TTGTGGGG G TCA TGGGGTGT T G GGGGTGTTTT T G GTGTTA CTC C TTA TTCTCA ACA T TCTCAAT T C ATCATATGCGCG A ATTGCGC C T TGTGCGCTCT CT CG GCTCTGTG G CCGTCGTTGCGC C T TGTGCGCCCC CAG GCGCCCCC CCCCCCCG GCG C CCCGAGA AAA CGCTTAG G G GAAGAATGGAGAG G G GATT AGGTA AG GGAGA A G GGGGAGATAT T G GAGATATAA A ATATATAC TATACA A ACACACAGG C CAGCCAGAGA TTG AGAGAGAAAA GAATACT G AAAATATATA A AA TTACTTC TATACACCCC C A ACACCCCC TTC CTC CCCCCCCC C C CCG TC C CCCCACA A CCCACATAT T C CACATATCCA CGTG CTCACA  AT TCTCACAGAG G CGC AGGGG G A AGAGGGGTGT AT  GGGGTGTC CCC G GTGTCTCACA A T TCCAGAG G C CACAGAGCCTGC A AGAGCGCGCG CGC GCGCGTC GT T C CGGTGTG AGC GTGTGTGGG T TGTGG TTGC C G GGGCG GCGCG TTGG CGGGACGA A G GGGGAGATAT T G GAGATGCGTA A A ATATATAGAG G T TATAGAGTGT T A AGAGTTC C G GTGTCTCA TGA T TCCAACAC,CCCCCCCTGT C CCCCCCCTCTGTG G C CCCCTCT GC C C CTCTGTGCGCCCC TTT TGTGCGCCCCACA A G GCGCCCCACAGAG  CCTT CAGTTGGC C CCAGAGCGCGCG  GT AGAGCGCGCGCGC C GACCGCGGCGCG G C CGCGCAGACGGGG CCA GCGCGCGGGGAGA A C CGCGGGGAGATT GGGAGATATATA A G GAGATATATAAAA A A ATTAAAATT T TATAATACTC C AAATATCTCCCC  ATCAG GGACCCG G T TCTCCCCGCGCGC C C CCGG G TGCA CAA C CGCGCGCACACAC C G GCGCACACACCCC C C CACACACCCCACA A A ACACCCCAAA AC C GCCAACA CACACACACATTACT AACACATATTTT GC  CACATATTTTCTC C A ATATTTTGCA A T TTTTCTCACATAT CGCTCATCACATATTTT T C CACAGCA TTATA A A CGATTTTATAC TTTTATACCATCA A TTACACACAGG A ACACACAGAGAGA TT  CAAATAGAGAC AAC A AGAGAGACACACA A G GATTTACACAAA A ACACACAAAAATCAA C CACAAAAATGCT AA CAAAAATATGTG G A AAAATATGTGCGC C A ATTACTGCGCGCG G T TGAATGCGCGCGC C G GCGCGCGCGCGCG G C CGCGCGCGCGTGT T G GCGCGCGTGTTTT T C CGGTTTTTTT T G GTGTTTTTTTTTT T T TTTTTC TTTGTG G T TTGACAGCTGGGT ATA TTTCAGGAGCGA T TGTGGGGATTAAG G GGGAGAGAGCT CC G GAGAGAGCGCTACC TG AG ACGCTCTTTT T G GCGCTCTTTTTTT T C CTCTTTTTTTCGAGC T TTTTTCACG T TTTCGGC C TTGCTCGT TGCCATGC C CGGCCCCACA  GCGCCGAGCACAC C C CCCG ACGCG G C CACACACGCGTGT T AACGAT CT T C CGCGTGTTTTTTT T G GTGTTTTTTA A T TTTTTTTATACC T TTTTATACCC C TCC CT CT T AAGC GCCCTTTTTC C C CCCCTTAGTCTCT TCA CTCTCTCTAT TT T T TCGTGCTTTTA TTA CG CCTTGAGCCAAC C T TTTTATACACTCCAT T TATACACTCTTA CA A ACCTTTTTTT ACCCTTC CTTTTT T T TTTTTTTGTG TGG TTAGCTTGTGGGG G TTTGCGCGT T T TGTGGGGTGTTGAAT G GGGGTGTTTC C G GTGTTTTCTCAATTTA TTCTCACATT T TCTCACATGAGTG GAACA ACAATGTGCGC C A ATTGCGCTCT T TC ATGCGCTCTGTG CCG GCGTCTGCGC C C CTCTGTGCCC C TCAGTGCGCCCCCCC C C GCGCCCCCGGACG G C CCCCCCCGCGAGA A C CCCCGTC AG  CT CGGAGAGAGA CC  GAATGAGA ACAG G A AGAGAGAGATCAGGG G GAAT GG GGAGA A AGGAGATTTCT G GGGGAGATG TTA A G GAGATATATACAC  TG ATATATACACACCC TAAATACACAGAG G A ACACACAGAGAGA  AA CA TGGA G CAA TC  AGAGAGAACAGGTTT G GATT A CTA A A AAAATATATACAC C A ATATATACACCCC C T TATACCCGA TCC C A ACACTCCCCCCA GC C CCCCCCCCCCCCC C C CCCCCCCCCCACA AAT CCCCCG GCATAT T C CCCCACATATCTC CTC CACATATCTCACA T AC TATC TCCATAG G T TCT CAGGGG G C CACAGAGGGGTGT T A AGAGGGGTGTCA AC G GGGGTGTC TACA A G GTCTGTCAAGGAG G T TCTCATTTGC C CG CCAGAGCGCGCG G A AGAGCGCGCGTGT T G GCGCGCGTGTGTG G C ATCGTTCTTGGGG G GGTGGGCC TT AGGCGCGCG G GCTTGGCGCGCGGGG G G GCGCGCGGG GGA A C CGCGGGATAT  GGGGAA GATAGAT GAGATATATAGAG G A ATATATAGAGTCCGT TCACCTCAGTGTCTC C A AGAGTTCACA A G GTGTCTCA,CCCCCCCTGCTGTG G C CCCCCCCTCTGTGCGC C C CCCCTCTGTGCGCCCC  CTCTGTGCCCACA A T TGGAGGCCCCACAGAG G G GCGCCCCACAGAGCGC C C CCCCACAGGCGG C CACAGAGCGTTAG TTCCTC AGAGCGCGCGCTTT ATG G GCGCGC AGCGCGGGG G C CGCGCGCGCGGCGTGA A G GCGCGCGGA AGATT C CGCGGGGAGATATATA A G GGGGATTCATATAAAA  GAGATATAACGAT  ATATATAAGGTTG TC C T TATAAAATACACC GTC AATGCGC CCGAAT ATATCTCCCCGCGC CGC T TCTCCTCACGCGCAGAGA C CCCCGCGCGCACACCT C C CGCGCGCACACACCCC C G GCGCATACCCACA A C CACACACC CCCACAC C A ACACCCCACACACACA A CCCACACACACATTT  CACACCATTT T A GGCATATTTTCTC ATA CAATTTCAA A ATTCACATAT  TTTTCTCACATATTTT T TTTATCACATTA A C CAT CATTTTATACC A AT CCTTAAG ACACA A T TTTTATACACACAGCCCG T TATACCAGAGAGA GTTATCCAGAGAGACAC C CTC CAGT CGACACACA A A AGAGAGACACACAAA G GAGACACAG ATCC ACCAAAAAAATAT  CACAA AGAAT CGTG G A AATTTG ACCATGCGC CCG AAATGTCAGCGG AATGTGCGCGCG GC C T TGTGCGCGCGCGCGCGCG G GCGCGGCGCGTATCT CATGCGCGCGTGGTT T G GCGCGCGTGTTTTTT CT CGC GCTGTTTTTTTTTT T G GTGTTTTTTTGG T TTTTTTTTGGTTGGGG G TGA TTGA A AGGA  TTTTGAC AG G TC TTGGGAGAGCGC  GGGGAGAGAGCGCTCT T G GAAGCCTTTT T A AGAGCGCTCTTTTTTT T G TAGCTCTTAAACC TC C C CTCTTTTTGATTCGCG G T TTTTTGC TCGCGCGC  TG TTTTCGG GCCCGCCAC TCTACCGCGCC TACA A C CGCGCGCCATGCACC G GCGCCCCACACACGCG G C CCCAC CAGT  CATACACGCGTGCG CGACTAATGTTTTTTT AGATT CGTGTTGCGTTATA A G GTGTTTTTATGTGCTGGAC  TTTTTTTACAGACCCC C T TTTTAACCACCCCTCT  TATACACCCCTCTC CAC A ACACCCCTC ATCTT C CCCCTTCTCTTTT GTT CTTCTCTTTTATA A T TCTCTCTTTTAC TC C CTTACACTCT T T TTTAC ACCTTTT T TTACACTCTTTTTTT T A ACACTTGGTTTTACT C CTCTTTACTTTTTGACAG T TTTTTTTGGGCGG G T TTTTGTGGGAGGT T T TTTTGTGGGGTGTTTT T T TGTCATTGGTTTTCC G GGGGTT CTTCTCACA A G GTGTTTTCTCACATAT T T TTTTCTCACATATGTG G T TCTGGCATATGTGCGC C C CACATTTATGCGCTCT GCCGGTATGATCGCTCCTTG G T TGTTTCGTCTGTGCGC C GGCTCTGTGCGCCCC AC  CTCTGTGCT ACCCG GC T TGGCCAGCCCGCG G G GCACACCCCCGCGAA C CCCCCCCGCGAAG G CTTACGACC AGAGA A C CGCGAC T GCGAGCC  GAGAGAGA ATGG AAAAGAGAGAGGGGAA G GAGAGAGGGGAGATAT  AGAGGGT GATATATA  GGGGAGATATATACCA C G GAGATATATACGCCCA A A ATATATTTACACAGAG G TCCATACACACAGAGAGA GGA ACA ACAGAGAGAAAA C T CACAGAGAGAAAATAT T A AGAGAGAAAATATATA A G GAGAAAATATATT AC C AATTAATC CTACACCC A ATATAGCGACCCCCCC C T TATACACCCCCCC C A ACACCCCCCCCCCCCC C C CCCCCCCCCCCCCAA C CCCCACATAT  AACCCCCACATATCTC CCACCACATATCTCACA  CACATGT TCACAGTTCG AATCTCACAGAGGT C TCTGCAGGAATCAT CACAGAGGGTCTC C AAAAAGGGGTC ACGCCA A G GGGGTTCACAGAG G G GTC CCAGAGCTCCA C TCTCATACAGC GCCG G CCGTCAGAGCTACCGTGGAT A AGAGCCGTTC G G GCGCGGTGCTTGG G CGGAGTGGGCGC GTGGGCGCGCG  TGTGGGCGCGGCGCG GTCAGGCGCGCGGGGAGA A G GCCGGGGAGATAT T C CGCGGGGAGATATATA A G GGGGAGATATATAGAG G G GAGATATATAGGT  ATATATAGAGTGTCTC C TTAGAGTGTCTCACA A AAGTGTCACACAC,CCCCCCCCTCTGGCCCCAC C CCCCCCCTCTGTGCGCCCC C C CCCCTCTGTGCCGCCCACA A CCTGTGCGCCCCAGGAAG G TTGCGCCCCACACCATGC C G GCGCCGC CAGAGCCCTCTCG C CCCCACAGCGCGC C CAATCAGAGCCAACGCGCGCG G A AGCGCGCGCGGGG G GGTGGCGCGCGCGA CGGAGA A C CGGCGCGGGGATTCAT T G GCGCGCGGGGAGATATATA A C CGCGGGGACCAATACGGAA A G GGGGAGATGA TAAAATAT T G GAGATATATAAAATATCTC C AATATAAAATATCTCCATA TA AGAATATCTCCCCGCG G A AACGAATCTCCCCGCGCGC C A ATATCCCGCAAGCACA  TCTCCCCGCGCGCACAGAC C CCCGCGCGCAGTC CATACC C CGCGCGCACACTCACCACA  GC ATT GACCCCACACAGGATGACCCCACACACACA A AACCCCAAGATA TCG CCCCACACACACATATTTT T C CAACACATG TTTCTC GAT ACCATATTTGGTCACA A C CACATATTTCACAT TCTTC ATATTTTCTCACATATTACC TTTTCACCTC TTATA A T TCTGCATTTTATACAC C C CACATATTTTATACACACA A AAGAATTTTATACACACAGAG G T TTTTATACACACAGAGAGA A T TACAGACACAGAGAGACAA C AATACG CAGAGAGC TCAA CATGAGAACACAAAC A ATAA ATACACAAAAAAA A G GAGACACAGCGTTTAATAT T A ACACAAAAAAT CACAAAAAAATATGTGCAC  AAAAAAATATGTGCGCGCG G A AA CAG CTCAGCGCGCGC C AGCATGCGCGCGCGCGCG  TGTGCGCGGCCGCGCGTGT T G GCGCGG ACGTGTTTT T C CGCGCGCGCGTGTTGATTT TTTGTTCGTGTTTTTTTTTT T CAGACGTGTTTTTTTTTTGTG G G GTGTTTTTTTTTTGTGGGG ATTTTTTTGTGGGGAGA A T TTTTTTTGTGGGGACATAG G TACCAATTGGGGAGAGG TGC C T TGTGGGGAGAGAGCGCTGTT GGGGAGAGAGCGCTTTCTT T GTC GAGAGCGCTTTTTT T A AGGCTCTTTT TTCTC  TGGCTCTTTTTTTCCG G C CTCTTTTTTTCTCGCGCC T TTTTTGATTCGCGCGCCCC CTTTCGCGCGCCCCACA A T TCAT GC GCCCCACACAC C C CGGCCCACACGACAT T GCCCACACCGTGT  CCCCACACACGCGTT GTT T C CACACCGGCGTGTTGTGTT T A ACACGCGTGTTTTTTTATA A C CGCGTGCGTTTTTATAC GGC G GTGTTTTATACTTTC T TTTTTACCGCGCCCTTATACACCG TCTCTC GGA TATACACCCCTTCTCGGT A ACACCCCTCTCTCTCTTTT T C CCCTCTCTCTTCATTA A C CTCG TCTCTTTACC TAT TCTCTTTTATACACTCT T C CTCTTTTATACGTCCTTTT T T TTATGTACACTTTTTT T T TACTTACTTTTAGAT A ACACTCTTTTTTTTTG  CTTACTTTAAATTGTGGGG G T TTT GTTGTGGGGTGT  TTTTTTGGGGTGTTTTTG G TTTTG AG TTGTTT A GAATA TGTGGGGTGTTTTCTCACA A G GGCT TTCTCACATGCT GTGTTCGTTCACAT CATG AGC TTTTCTCACATATGCGCC T TCTCATTAATGTGCGCTCT T CCATATGTGCGCTCTGCGTG A ATT GTGCGCTCTGTGCGC C T TGAT CTGTGCGCCCC C G GCGCTCTGTGCGCCT TCC C C CTTGCTGCCCCCCGTA CCT GCTGCCCCCCGCGAGA A GGCCCCCCGAGAGAG G C CCCCCCCGCGAGAGAGAGA A C CCCCGAATGAGAGAGAGAG G C CGGAGGGTGAGAGGGG AGA GAGAGAGAGAGAGGGGAGA  GG AGCCCGAGGGAGATAT  GAGAGGGAGATATACG CCCAC GATTACGAC GGGGAC AACACA A GGATATAACACAGAG GCG ATATATACACACAGA AGA A T TATACACACAGAGAGAAAA A A AC ACCAGG GGAAAATAT T CTAGCAG CGATACATA A AGACAGAAAATATATACAC C G GAGAACCATACCC C A AAACAACC TCCC C AATACC T TCCCCCCCC  TTCCCCCCCCCCC C A ACACCCCCCCCCCACA A C CCCCCAGA ATCCACATAT T C CCCCCCCCCATCATATCGAGC CCCCCGCCATATCTCACA CT CCCGATACCATCTG CAGAG G C CATTGATCTTACAGAGGG A CCGGCTCACGGTTC ATT T AGTCAAGGGGTTC C C CAAGGGGTACTTCACA TT TGGAGGGGTGTCTCACAGAG G GAC GGTGTCCA CAGAGCACAC G GTGTCTCACAGAGCGCGCG G T TCTCACAGAGCCGTGT T C CACAGAGCGCGTG TTTTCA AGGCGGTGTGGGG G G GCCGT GCTGGATCC C CGCGTGTGAGGGGCGCGCG G G GTGTGTGGGGCGCGCAGGG G T TGTGGGGCGCGCGGGGAA GGGCGCGCGGGGAGATAT T G GCGCGTAACAGGATATATA A C CGACGC TACCATATAGAG G GGGAGATC TTAGGT GTT GAGATATATAGGTCTC C A ATATAAGTGTCCA A T TACATCACGTCTCACAC,"ID   SERB_ECO57              Reviewed;         322 AA.
AC   P0AGB1; P06862;
DT   01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1988, sequence version 1.
DT   05-FEB-2025, entry version 122.
DE   RecName: Full=Phosphoserine phosphatase;
DE            Short=PSP;
DE            Short=PSPase;
DE            EC=3.1.3.3;
DE   AltName: Full=O-phosphoserine phosphohydrolase;
GN   Name=serB; OrderedLocusNames=Z5989, ECs5346;
OS   Escherichia coli O157:H7.
OC   Bacteria; Pseudomonadota; Gammaproteobacteria; Enterobacterales;
OC   Enterobacteriaceae; Escherichia.
OX   NCBI_TaxID=83334;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=O157:H7 / EDL933 / ATCC 700927 / EHEC;
RX   PubMed=11206551; DOI=10.1038/35054089;
RA   Perna N.T., Plunkett G. III, Burland V., Mau B., Glasner J.D., Rose D.J.,
RA   Mayhew G.F., Evans P.S., Gregor J., Kirkpatrick H.A., Posfai G.,
RA   Hackett J., Klink S., Boutin A., Shao Y., Miller L., Grotbeck E.J.,
RA   Davis N.W., Lim A., Dimalanta E.T., Potamousis K., Apodaca J.,
RA   Anantharaman T.S., Lin J., Yen G., Schwartz D.C., Welch R.A.,
RA   Blattner F.R.;
RT   ""Genome sequence of enterohaemorrhagic Escherichia coli O157:H7."";
RL   Nature 409:529-533(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=O157:H7 / Sakai / RIMD 0509952 / EHEC;
RX   PubMed=11258796; DOI=10.1093/dnares/8.1.11;
RA   Hayashi T., Makino K., Ohnishi M., Kurokawa K., Ishii K., Yokoyama K.,
RA   Han C.-G., Ohtsubo E., Nakayama K., Murata T., Tanaka M., Tobe T., Iida T.,
RA   Takami H., Honda T., Sasakawa C., Ogasawara N., Yasunaga T., Kuhara S.,
RA   Shiba T., Hattori M., Shinagawa H.;
RT   ""Complete genome sequence of enterohemorrhagic Escherichia coli O157:H7 and
RT   genomic comparison with a laboratory strain K-12."";
RL   DNA Res. 8:11-22(2001).
CC   -!- FUNCTION: Catalyzes the dephosphorylation of phosphoserine (P-Ser).
CC       {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=O-phospho-L-serine + H2O = L-serine + phosphate;
CC         Xref=Rhea:RHEA:21208, ChEBI:CHEBI:15377, ChEBI:CHEBI:33384,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:57524; EC=3.1.3.3;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=O-phospho-D-serine + H2O = D-serine + phosphate;
CC         Xref=Rhea:RHEA:24873, ChEBI:CHEBI:15377, ChEBI:CHEBI:35247,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:58680; EC=3.1.3.3;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Note=Binds 1 Mg(2+) ion per subunit. {ECO:0000250};
CC   -!- PATHWAY: Amino-acid biosynthesis; L-serine biosynthesis; L-serine from
CC       3-phospho-D-glycerate: step 3/3.
CC   -!- SIMILARITY: Belongs to the HAD-like hydrolase superfamily. SerB family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AE005174; AAG59568.1; -; Genomic_DNA.
DR   EMBL; BA000007; BAB38769.1; -; Genomic_DNA.
DR   PIR; B91297; B91297.
DR   RefSeq; NP_313373.1; NC_002695.1.
DR   RefSeq; WP_001132955.1; NZ_VOAI01000002.1.
DR   AlphaFoldDB; P0AGB1; -.
DR   SMR; P0AGB1; -.
DR   STRING; 155864.Z5989; -.
DR   GeneID; 913496; -.
DR   GeneID; 93777457; -.
DR   KEGG; ece:Z5989; -.
DR   KEGG; ecs:ECs_5346; -.
DR   PATRIC; fig|386585.9.peg.5593; -.
DR   eggNOG; COG0560; Bacteria.
DR   HOGENOM; CLU_036368_4_0_6; -.
DR   OMA; LSMFKHA; -.
DR   UniPathway; UPA00135; UER00198.
DR   Proteomes; UP000000558; Chromosome.
DR   Proteomes; UP000002519; Chromosome.
DR   GO; GO:0005737; C:cytoplasm; IEA:TreeGrafter.
DR   GO; GO:0036424; F:L-phosphoserine phosphatase activity; IEA:UniProtKB-EC.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:TreeGrafter.
DR   GO; GO:0006564; P:L-serine biosynthetic process; IEA:UniProtKB-KW.
DR   CDD; cd07500; HAD_PSP; 1.
DR   FunFam; 1.10.150.210:FF:000001; Phosphoserine phosphatase; 1.
DR   FunFam; 3.40.50.1000:FF:000048; Phosphoserine phosphatase; 1.
DR   Gene3D; 3.30.70.2020; -; 1.
DR   Gene3D; 3.40.50.1000; HAD superfamily/HAD-like; 1.
DR   Gene3D; 1.10.150.210; Phosphoserine phosphatase, domain 2; 1.
DR   InterPro; IPR050582; HAD-like_SerB.
DR   InterPro; IPR036412; HAD-like_sf.
DR   InterPro; IPR023214; HAD_sf.
DR   InterPro; IPR004469; PSP.
DR   InterPro; IPR041449; SerB_N.
DR   NCBIfam; TIGR01488; HAD-SF-IB; 1.
DR   NCBIfam; TIGR00338; serB; 1.
DR   PANTHER; PTHR43344; PHOSPHOSERINE PHOSPHATASE; 1.
DR   PANTHER; PTHR43344:SF2; PHOSPHOSERINE PHOSPHATASE; 1.
DR   Pfam; PF18429; DUF5609; 1.
DR   Pfam; PF12710; HAD; 1.
DR   SFLD; SFLDG01136; C1.6:_Phosphoserine_Phosphatas; 1.
DR   SFLD; SFLDF00029; phosphoserine_phosphatase; 1.
DR   SUPFAM; SSF56784; HAD-like; 1.
PE   3: Inferred from homology;
KW   Amino-acid biosynthesis; Hydrolase; Magnesium; Metal-binding;
KW   Reference proteome; Serine biosynthesis.
FT   CHAIN           1..322
FT                   /note=""Phosphoserine phosphatase""
FT                   /id=""PRO_0000156887""
FT   ACT_SITE        116
FT                   /note=""Nucleophile""
FT                   /evidence=""ECO:0000250""
FT   ACT_SITE        118
FT                   /note=""Proton donor""
FT                   /evidence=""ECO:0000250""
FT   BINDING         10..12
FT                   /ligand=""substrate""
FT                   /evidence=""ECO:0000250""
FT   BINDING         12
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /evidence=""ECO:0000250""
FT   BINDING         116
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /evidence=""ECO:0000250""
FT   BINDING         118
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /evidence=""ECO:0000250""
FT   BINDING         125
FT                   /ligand=""substrate""
FT                   /evidence=""ECO:0000250""
FT   BINDING         161
FT                   /ligand=""substrate""
FT                   /evidence=""ECO:0000250""
FT   BINDING         204..205
FT                   /ligand=""substrate""
FT                   /evidence=""ECO:0000250""
FT   BINDING         249
FT                   /ligand=""substrate""
FT                   /evidence=""ECO:0000250""
FT   BINDING         272
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /evidence=""ECO:0000250""
FT   BINDING         275
FT                   /ligand=""substrate""
FT                   /evidence=""ECO:0000250""
SQ   SEQUENCE   322 AA;  35043 MW;  A09A43BD846B7DE6 CRC64;
     MPNITWCDLP EDVSLWPGLP LSLSGDEVMP LDYHAGRSGW LLYGRGLDKQ RLTQYQSKLG
     AAMVIVAAWC VEDYQVIRLA GSLTARATRL AHEAQLDVAP LGKIPHLRTP GLLVMDMDST
     AIQIECIDEI AKLAGTGEMV AEVTERAMRG ELDFTASLRS RVATLKGADA NILQQVRENL
     PLMPGLTQLV LKLETLGWKV AIASGGFTFF AEYLRDKLRL TAVVANELEI MDGKFTGNVI
     GDIVDAQYKA KTLTRLAQEY EIPLAQTVAI GDGANDLPMI KAAGLGIAYH AKPKVNEKAE
     VTIRHADLMG VFCILSGSLN QK
//
",31608
TTTAAT TTAATG TAATGG AATGGT ATGGTG TGGTGT GGTGTT GTGTTT TGTTTC GTTTCC TTTCCT TTCCTT TCCTTT CCTTTA CTTTAG TTTAGT TTAGTA TAGTAC AGTACC GTACCT TACCTT ACCTTT CCTTTG CTTTGA TTTGAA TTGAAG TGAAGA GAAGAA AAGAAG AGAAGC GAAGCT AAGCTG AGCTGC GCTGCG CTGCGC TGCGCT GCGCTG CGCTGT GCTGTG CTGTGC TGTGCA GTGCAC TGCACC GCACCT CACCTT ACCTTT CCTTTT CTTTTT TTTTTG TTTTGT TTTGTT TTGTTA TGTTAA GTTAAA TTAAAT TAAATA AAATAA AATAAA ATAAAG TAAAGA AAAGAA AAGAAA AGAAAT GAAATG AAATGT AATGTA ATGTAT TGTATC GTATCT TATCTA ATCTAA TCTAAA CTAAAG TAAAGT AAAGTT AAGTTG AGTTGC GTTGCG TTGCGT TGCGTA GCGTAG CGTAGT GTAGTG TAGTGA AGTGAT GTGATG TGATGT GATGTG,0,88,TTTA TTAA TAAT AATG ATGG TGGT GGTG GTGT TGTT GTTT TTTC TTCC TCCT CCTT CTTT TTTA TTAG TAGT AGTA GTAC TACC ACCT CCTT CTTT TTTG TTGA TGAA GAAG AAGA AGAA GAAG AAGC AGCT GCTG CTGC TGCG GCGC CGCT GCTG CTGT TGTG GTGC TGCA GCAC CACC ACCT CCTT CTTT TTTT TTTT TTTG TTGT TGTT GTTA TTAA TAAA AAAT AATA ATAA TAAA AAAG AAGA AGAA GAAA AAAT AATG ATGT TGTA GTAT TATC ATCT TCTA CTAA TAAA AAAG AAGT AGTT GTTG TTGC TGCG GCGT CGTA GTAG TAGT AGTG GTGA TGAT GATG ATGT TGTG,TTTAA TTAAT TAATG AATGG ATGGT TGGTG GGTGT GTGTT TGTTT GTTTC TTTCC TTCCT TCCTT CCTTT CTTTA TTTAG TTAGT TAGTA AGTAC GTACC TACCT ACCTT CCTTT CTTTG TTTGA TTGAA TGAAG GAAGA AAGAA AGAAG GAAGC AAGCT AGCTG GCTGC CTGCG TGCGC GCGCT CGCTG GCTGT CTGTG TGTGC GTGCA TGCAC GCACC CACCT ACCTT CCTTT CTTTT TTTTT TTTTG TTTGT TTGTT TGTTA GTTAA TTAAA TAAAT AAATA AATAA ATAAA TAAAG AAAGA AAGAA AGAAA GAAAT AAATG AATGT ATGTA TGTAT GTATC TATCT ATCTA TCTAA CTAAA TAAAG AAAGT AAGTT AGTTG GTTGC TTGCG TGCGT GCGTA CGTAG GTAGT TAGTG AGTGA GTGAT TGATG GATGT ATGTG,TTTAAT TTAATG TAATGG AATGGT ATGGTG TGGTGT GGTGTT GTGTTT TGTTTC GTTTCC TTTCCT TTCCTT TCCTTT CCTTTA CTTTAG TTTAGT TTAGTA TAGTAC AGTACC GTACCT TACCTT ACCTTT CCTTTG CTTTGA TTTGAA TTGAAG TGAAGA GAAGAA AAGAAG AGAAGC GAAGCT AAGCTG AGCTGC GCTGCG CTGCGC TGCGCT GCGCTG CGCTGT GCTGTG CTGTGC TGTGCA GTGCAC TGCACC GCACCT CACCTT ACCTTT CCTTTT CTTTTT TTTTTG TTTTGT TTTGTT TTGTTA TGTTAA GTTAAA TTAAAT TAAATA AAATAA AATAAA ATAAAG TAAAGA AAAGAA AAGAAA AGAAAT GAAATG AAATGT AATGTA ATGTAT TGTATC GTATCT TATCTA ATCTAA TCTAAA CTAAAG TAAAGT AAAGTT AAGTTG AGTTGC GTTGCG TTGCGT TGCGTA GCGTAG CGTAGT GTAGTG TAGTGA AGTGAT GTGATG TGATGT GATGTG,TTTAATG TTAATGG TAATGGT AATGGTG ATGGTGT TGGTGTT GGTGTTT GTGTTTC TGTTTCC GTTTCCT TTTCCTT TTCCTTT TCCTTTA CCTTTAG CTTTAGT TTTAGTA TTAGTAC TAGTACC AGTACCT GTACCTT TACCTTT ACCTTTG CCTTTGA CTTTGAA TTTGAAG TTGAAGA TGAAGAA GAAGAAG AAGAAGC AGAAGCT GAAGCTG AAGCTGC AGCTGCG GCTGCGC CTGCGCT TGCGCTG GCGCTGT CGCTGTG GCTGTGC CTGTGCA TGTGCAC GTGCACC TGCACCT GCACCTT CACCTTT ACCTTTT CCTTTTT CTTTTTG TTTTTGT TTTTGTT TTTGTTA TTGTTAA TGTTAAA GTTAAAT TTAAATA TAAATAA AAATAAA AATAAAG ATAAAGA TAAAGAA AAAGAAA AAGAAAT AGAAATG GAAATGT AAATGTA AATGTAT ATGTATC TGTATCT GTATCTA TATCTAA ATCTAAA TCTAAAG CTAAAGT TAAAGTT AAAGTTG AAGTTGC AGTTGCG GTTGCGT TTGCGTA TGCGTAG GCGTAGT CGTAGTG GTAGTGA TAGTGAT AGTGATG GTGATGT TGATGTG,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",26193
TATGTG ATGTGA TGTGAC GTGACT TGACTC GACTCA ACTCAA CTCAAC TCAACA CAACAA AACAAT ACAATT CAATTA AATTAA ATTAAT TTAATT TAATTA AATTAG ATTAGA TTAGAG TAGAGC AGAGCT GAGCTG AGCTGC GCTGCA CTGCAG TGCAGA GCAGAA CAGAAA AGAAAT GAAATC AAATCA AATCAG ATCAGA TCAGAG CAGAGC AGAGCT GAGCTT AGCTTC GCTTCT CTTCTG TTCTGC TCTGCT CTGCTA TGCTAA GCTAAT CTAATC TAATCT AATCTT ATCTTG TCTTGC CTTGCT TTGCTG TGCTGC GCTGCT CTGCTA TGCTAC GCTACT CTACTA TACTAA ACTAAA CTAAAA TAAAAT AAAATG AAATGT AATGTC ATGTCA TGTCAG GTCAGA TCAGAG CAGAGT AGAGTG GAGTGT AGTGTG GTGTGT TGTGTA GTGTAC TGTACT GTACTT,1,79,TATG ATGT TGTG GTGA TGAC GACT ACTC CTCA TCAA CAAC AACA ACAA CAAT AATT ATTA TTAA TAAT AATT ATTA TTAG TAGA AGAG GAGC AGCT GCTG CTGC TGCA GCAG CAGA AGAA GAAA AAAT AATC ATCA TCAG CAGA AGAG GAGC AGCT GCTT CTTC TTCT TCTG CTGC TGCT GCTA CTAA TAAT AATC ATCT TCTT CTTG TTGC TGCT GCTG CTGC TGCT GCTA CTAC TACT ACTA CTAA TAAA AAAA AAAT AATG ATGT TGTC GTCA TCAG CAGA AGAG GAGT AGTG GTGT TGTG GTGT TGTA GTAC TACT ACTT,TATGT ATGTG TGTGA GTGAC TGACT GACTC ACTCA CTCAA TCAAC CAACA AACAA ACAAT CAATT AATTA ATTAA TTAAT TAATT AATTA ATTAG TTAGA TAGAG AGAGC GAGCT AGCTG GCTGC CTGCA TGCAG GCAGA CAGAA AGAAA GAAAT AAATC AATCA ATCAG TCAGA CAGAG AGAGC GAGCT AGCTT GCTTC CTTCT TTCTG TCTGC CTGCT TGCTA GCTAA CTAAT TAATC AATCT ATCTT TCTTG CTTGC TTGCT TGCTG GCTGC CTGCT TGCTA GCTAC CTACT TACTA ACTAA CTAAA TAAAA AAAAT AAATG AATGT ATGTC TGTCA GTCAG TCAGA CAGAG AGAGT GAGTG AGTGT GTGTG TGTGT GTGTA TGTAC GTACT TACTT,TATGTG ATGTGA TGTGAC GTGACT TGACTC GACTCA ACTCAA CTCAAC TCAACA CAACAA AACAAT ACAATT CAATTA AATTAA ATTAAT TTAATT TAATTA AATTAG ATTAGA TTAGAG TAGAGC AGAGCT GAGCTG AGCTGC GCTGCA CTGCAG TGCAGA GCAGAA CAGAAA AGAAAT GAAATC AAATCA AATCAG ATCAGA TCAGAG CAGAGC AGAGCT GAGCTT AGCTTC GCTTCT CTTCTG TTCTGC TCTGCT CTGCTA TGCTAA GCTAAT CTAATC TAATCT AATCTT ATCTTG TCTTGC CTTGCT TTGCTG TGCTGC GCTGCT CTGCTA TGCTAC GCTACT CTACTA TACTAA ACTAAA CTAAAA TAAAAT AAAATG AAATGT AATGTC ATGTCA TGTCAG GTCAGA TCAGAG CAGAGT AGAGTG GAGTGT AGTGTG GTGTGT TGTGTA GTGTAC TGTACT GTACTT,TATGTGA ATGTGAC TGTGACT GTGACTC TGACTCA GACTCAA ACTCAAC CTCAACA TCAACAA CAACAAT AACAATT ACAATTA CAATTAA AATTAAT ATTAATT TTAATTA TAATTAG AATTAGA ATTAGAG TTAGAGC TAGAGCT AGAGCTG GAGCTGC AGCTGCA GCTGCAG CTGCAGA TGCAGAA GCAGAAA CAGAAAT AGAAATC GAAATCA AAATCAG AATCAGA ATCAGAG TCAGAGC CAGAGCT AGAGCTT GAGCTTC AGCTTCT GCTTCTG CTTCTGC TTCTGCT TCTGCTA CTGCTAA TGCTAAT GCTAATC CTAATCT TAATCTT AATCTTG ATCTTGC TCTTGCT CTTGCTG TTGCTGC TGCTGCT GCTGCTA CTGCTAC TGCTACT GCTACTA CTACTAA TACTAAA ACTAAAA CTAAAAT TAAAATG AAAATGT AAATGTC AATGTCA ATGTCAG TGTCAGA GTCAGAG TCAGAGT CAGAGTG AGAGTGT GAGTGTG AGTGTGT GTGTGTA TGTGTAC GTGTACT TGTACTT,"ID   SPIKE_SARS2             Reviewed;        1273 AA.
AC   P0DTC2;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Spike glycoprotein {ECO:0000255|HAMAP-Rule:MF_04099};
DE            Short=S glycoprotein {ECO:0000255|HAMAP-Rule:MF_04099};
DE   AltName: Full=E2 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   AltName: Full=Peplomer protein {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S1 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S2 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S2' {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Flags: Precursor;
GN   Name=S {ECO:0000255|HAMAP-Rule:MF_04099}; ORFNames=2;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   FUNCTION (SPIKE PROTEIN S1), AND CLEAVAGE BETWEEN S2 AND S2' BY HOST
RP   TMPRSS2.
RX   PubMed=32142651; DOI=10.1016/j.cell.2020.02.052;
RA   Hoffmann M., Kleine-Weber H., Schroeder S., Krueger N., Herrler T.,
RA   Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A.,
RA   Mueller M.A., Drosten C., Poehlmann S.;
RT   ""SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a
RT   clinically proven protease inhibitor."";
RL   Cell 181:1-10(2020).
RN   [3]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, FUNCTION, AND MUTAGENESIS OF
RP   681-PRO--ALA-684.
RX   PubMed=32362314; DOI=10.1016/j.molcel.2020.04.022;
RA   Hoffmann M., Kleine-Weber H., Poehlmann S.;
RT   ""A multibasic cleavage site in the Spike protein of SARS-CoV-2 is essential
RT   for infection of human lung cells."";
RL   Mol. Cell 78:779-784(2020).
RN   [4]
RP   GLYCOSYLATION AT ASN-17; ASN-61; ASN-74; ASN-122; ASN-149; ASN-165;
RP   ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098; ASN-1134; ASN-1158; ASN-1173 AND
RP   ASN-1194, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=32366695; DOI=10.1126/science.abb9983;
RA   Watanabe Y., Allen J.D., Wrapp D., McLellan J.S., Crispin M.;
RT   ""Site-specific glycan analysis of the SARS-CoV-2 spike."";
RL   Science 369:330-333(2020).
RN   [5]
RP   GLYCOSYLATION AT ASN-61; ASN-74; ASN-122; ASN-149; ASN-165; ASN-234;
RP   ASN-282; THR-323; SER-325; ASN-331; ASN-343; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098 AND ASN-1194, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=32363391; DOI=10.1093/glycob/cwaa042;
RA   Shajahan A., Supekar N.T., Gleinich A.S., Azadi P.;
RT   ""Deducing the N- and O- glycosylation profile of the spike protein of novel
RT   coronavirus SARS-CoV-2."";
RL   Glycobiology 30:981-988(2020).
RN   [6]
RP   VARIANT GLY-614.
RX   PubMed=32820179; DOI=10.1038/s41598-020-70827-z;
RA   Isabel S., Grana-Miraglia L., Gutierrez J.M., Bundalovic-Torma C.,
RA   Groves H.E., Isabel M.R., Eshaghi A., Patel S.N., Gubbay J.B., Poutanen T.,
RA   Guttman D.S., Poutanen S.M.;
RT   ""Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein
RT   mutation now documented worldwide."";
RL   Sci. Rep. 10:14031-14031(2020).
RN   [7]
RP   VARIANT GLY-614, AND MUTAGENESIS OF ASP-614.
RX   PubMed=32697968; DOI=10.1016/j.cell.2020.06.043;
RG   Sheffield COVID-19 Genomics Group;
RA   Korber B., Fischer W.M., Gnanakaran S., Yoon H., Theiler J., Abfalterer W.,
RA   Hengartner N., Giorgi E.E., Bhattacharya T., Foley B., Hastie K.M.,
RA   Parker M.D., Partridge D.G., Evans C.M., Freeman T.M., de Silva T.I.,
RA   McDanal C., Perez L.G., Tang H., Moon-Walker A., Whelan S.P.,
RA   LaBranche C.C., Saphire E.O., Montefiori D.C.;
RT   ""Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases
RT   Infectivity of the COVID-19 Virus."";
RL   Cell 182:812-827(2020).
RN   [8]
RP   FUNCTION.
RX   PubMed=32817270; DOI=10.1126/science.abd5223;
RA   Turonova B., Sikora M., Schuermann C., Hagen W.J.H., Welsch S.,
RA   Blanc F.E.C., von Buelow S., Gecht M., Bagola K., Hoerner C.,
RA   van Zandbergen G., Landry J., de Azevedo N.T.D., Mosalaganti S.,
RA   Schwarz A., Covino R., Muehlebach M.D., Hummer G., Krijnse Locker J.,
RA   Beck M.;
RT   ""In situ structural analysis of SARS-CoV-2 spike reveals flexibility
RT   mediated by three hinges."";
RL   Science 370:203-208(2020).
RN   [9]
RP   GLYCOSYLATION.
RX   PubMed=32929138; DOI=10.1038/s41598-020-71748-7;
RA   Grant O.C., Montgomery D., Ito K., Woods R.J.;
RT   ""Analysis of the SARS-CoV-2 spike protein glycan shield reveals
RT   implications for immune recognition."";
RL   Sci. Rep. 10:14991-14991(2020).
RN   [10]
RP   GLYCOSYLATION AT ASN-17; ASN-61; ASN-74; ASN-122; ASN-149; ASN-165;
RP   ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098; ASN-1134; ASN-1158; ASN-1173 AND
RP   ASN-1194, IDENTIFICATION BY MASS SPECTROMETRY, SUBCELLULAR LOCATION, AND
RP   SUBUNIT.
RX   PubMed=32979942; DOI=10.1016/j.cell.2020.09.018;
RA   Yao H., Song Y., Chen Y., Wu N., Xu J., Sun C., Zhang J., Weng T.,
RA   Zhang Z., Wu Z., Cheng L., Shi D., Lu X., Lei J., Crispin M., Shi Y.,
RA   Li L., Li S.;
RT   ""Molecular Architecture of the SARS-CoV-2 Virus."";
RL   Cell 183:730-738(2020).
RN   [11]
RP   VARIANT GLY-614, AND MUTAGENESIS OF ASP-614.
RX   PubMed=33106671; DOI=10.1038/s41586-020-2895-3;
RA   Plante J.A., Liu Y., Liu J., Xia H., Johnson B.A., Lokugamage K.G.,
RA   Zhang X., Muruato A.E., Zou J., Fontes-Garfias C.R., Mirchandani D.,
RA   Scharton D., Bilello J.P., Ku Z., An Z., Kalveram B., Freiberg A.N.,
RA   Menachery V.D., Xie X., Plante K.S., Weaver S.C., Shi P.Y.;
RT   ""Spike mutation D614G alters SARS-CoV-2 fitness."";
RL   Nature 592:116-121(2020).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH HUMAN NRP1 AND NRP2.
RC   STRAIN=SARS-CoV-2/human/Liverpool/REMRQ001/2020;
RX   PubMed=33082294; DOI=10.1126/science.abd3072;
RA   Daly J.L., Simonetti B., Klein K., Chen K.E., Williamson M.K.,
RA   Anton-Plagaro C., Shoemark D.K., Simon-Gracia L., Bauer M., Hollandi R.,
RA   Greber U.F., Horvath P., Sessions R.B., Helenius A., Hiscox J.A.,
RA   Teesalu T., Matthews D.A., Davidson A.D., Collins B.M., Cullen P.J.,
RA   Yamauchi Y.;
RT   ""Neuropilin-1 is a host factor for SARS-CoV-2 infection."";
RL   Science 370:861-865(2020).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH HUMAN NRP1 AND NRP2.
RC   STRAIN=SARS-CoV-2/human/Finland/1/2020;
RX   PubMed=33082293; DOI=10.1126/science.abd2985;
RA   Cantuti-Castelvetri L., Ojha R., Pedro L.D., Djannatian M., Franz J.,
RA   Kuivanen S., van der Meer F., Kallio K., Kaya T., Anastasina M., Smura T.,
RA   Levanov L., Szirovicza L., Tobi A., Kallio-Kokko H., Oesterlund P.,
RA   Joensuu M., Meunier F.A., Butcher S.J., Winkler M.S., Mollenhauer B.,
RA   Helenius A., Gokce O., Teesalu T., Hepojoki J., Vapalahti O.,
RA   Stadelmann C., Balistreri G., Simons M.;
RT   ""Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity."";
RL   Science 370:856-860(2020).
RN   [14]
RP   INTERACTION WITH HUMAN ITGA5 AND ITGB1.
RX   PubMed=33102950; DOI=10.1016/j.jacbts.2020.10.003;
RA   Beddingfield B.J., Iwanaga N., Chapagain P.P., Zheng W., Roy C.J., Hu T.Y.,
RA   Kolls J.K., Bix G.J.;
RT   ""The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2
RT   Infection."";
RL   JACC Basic Transl. Sci. 6:1-8(2021).
RN   [15]
RP   VARIANT GLY-614.
RX   PubMed=33184236; DOI=10.1126/science.abe8499;
RA   Hou Y.J., Chiba S., Halfmann P., Ehre C., Kuroda M., Dinnon K.H. III,
RA   Leist S.R., Schaefer A., Nakajima N., Takahashi K., Lee R.E.,
RA   Mascenik T.M., Graham R., Edwards C.E., Tse L.V., Okuda K., Markmann A.J.,
RA   Bartelt L., de Silva A., Margolis D.M., Boucher R.C., Randell S.H.,
RA   Suzuki T., Gralinski L.E., Kawaoka Y., Baric R.S.;
RT   ""SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and
RT   transmission in vivo."";
RL   Science 370:1464-1468(2020).
RN   [16]
RP   VARIANT GLY-614.
RX   PubMed=33417835; DOI=10.1016/j.celrep.2020.108630;
RA   Gobeil S.M., Janowska K., McDowell S., Mansouri K., Parks R., Manne K.,
RA   Stalls V., Kopp M.F., Henderson R., Edwards R.J., Haynes B.F., Acharya P.;
RT   ""D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease
RT   Cleavage at the S1/S2 Junction."";
RL   Cell Rep. 34:108630-108630(2021).
RN   [17]
RP   VARIANTS 69-VAL--PHE-70 DEL; LYS-144 DEL; TYR-501; ASP-570; GLY-614;
RP   HIS-681; ILE-716; ALA-982 AND HIS-1118.
RC   STRAIN=20I/501Y.V1, Alpha, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [18]
RP   VARIANT TYR-501.
RX   PubMed=32732280; DOI=10.1126/science.abc4730;
RA   Gu H., Chen Q., Yang G., He L., Fan H., Deng Y.Q., Wang Y., Teng Y.,
RA   Zhao Z., Cui Y., Li Y., Li X.F., Li J., Zhang N.N., Yang X., Chen S.,
RA   Guo Y., Zhao G., Wang X., Luo D.Y., Wang H., Yang X., Li Y., Han G., He Y.,
RA   Zhou X., Geng S., Sheng X., Jiang S., Sun S., Qin C.F., Zhou Y.;
RT   ""Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy."";
RL   Science 369:1603-1607(2020).
RN   [19]
RP   VARIANT GLY-614, AND MUTAGENESIS OF GLY-614.
RX   PubMed=33636719; DOI=10.1038/s41586-021-03361-1;
RA   Zhou B., Thi Nhu Thao T., Hoffmann D., Taddeo A., Ebert N., Labroussaa F.,
RA   Pohlmann A., King J., Steiner S., Kelly J.N., Portmann J., Halwe N.J.,
RA   Ulrich L., Trueeb B.S., Fan X., Hoffmann B., Wang L., Thomann L., Lin X.,
RA   Stalder H., Pozzi B., de Brot S., Jiang N., Cui D., Hossain J., Wilson M.,
RA   Keller M., Stark T.J., Barnes J.R., Dijkman R., Jores J., Benarafa C.,
RA   Wentworth D.E., Thiel V., Beer M.;
RT   ""SARS-CoV-2 spike D614G change enhances replication and transmission."";
RL   Nature 5920:122-127(2021).
RN   [20]
RP   MUTAGENESIS OF ASN-165; ASN-234; ASN-331; ASN-343; LEU-452; ALA-475;
RP   VAL-483; PHE-490 AND HIS-519.
RX   PubMed=32730807; DOI=10.1016/j.cell.2020.07.012;
RA   Li Q., Wu J., Nie J., Zhang L., Hao H., Liu S., Zhao C., Zhang Q., Liu H.,
RA   Nie L., Qin H., Wang M., Lu Q., Li X., Sun Q., Liu J., Zhang L., Li X.,
RA   Huang W., Wang Y.;
RT   ""The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and
RT   Antigenicity."";
RL   Cell 182:1284-1294(2020).
RN   [21]
RP   FUNCTION, CLEAVAGE BETWEEN S1 AND S2 BY HOST CTSL, AND INTERACTION WITH
RP   HUMAN ACE2.
RX   PubMed=32221306; DOI=10.1038/s41467-020-15562-9;
RA   Ou X., Liu Y., Lei X., Li P., Mi D., Ren L., Guo L., Guo R., Chen T.,
RA   Hu J., Xiang Z., Mu Z., Chen X., Chen J., Hu K., Jin Q., Wang J., Qian Z.;
RT   ""Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and
RT   its immune cross-reactivity with SARS-CoV."";
RL   Nat. Commun. 11:1620-1620(2020).
RN   [22]
RP   INTERACTION WITH HUMAN ACE2.
RX   PubMed=33607086; DOI=10.1016/j.bpj.2021.02.007;
RA   Cao W., Dong C., Kim S., Hou D., Tai W., Du L., Im W., Zhang X.F.;
RT   ""Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2
RT   protein-protein interaction."";
RL   Biophys. J. 120:1011-1019(2021).
RN   [23]
RP   FUNCTION, AND CLEAVAGE BETWEEN S1 AND S2 BY HOST TMPRSS2.
RX   PubMed=33465165; DOI=10.1371/journal.ppat.1009212;
RA   Ou T., Mou H., Zhang L., Ojha A., Choe H., Farzan M.;
RT   ""Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated
RT   by TMPRSS2."";
RL   PLoS Pathog. 17:e1009212-e1009212(2021).
RN   [24]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH S PROTEIN.
RX   PubMed=33229438; DOI=10.1074/jbc.ra120.016175;
RA   Boson B., Legros V., Zhou B., Siret E., Mathieu C., Cosset F.L.,
RA   Lavillette D., Denolly S.;
RT   ""The SARS-CoV-2 Envelope and Membrane proteins modulate maturation and
RT   retention of the Spike protein, allowing assembly of virus-like
RT   particles."";
RL   J. Biol. Chem. 296:100111-100111(2020).
RN   [25]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, CLEAVAGE BETWEEN S2 AND S2' BY
RP   HOST TMPRSS2, MUTAGENESIS OF ALA-684, AND FUNCTION (SPIKE PROTEIN S2').
RX   PubMed=32703818; DOI=10.26508/lsa.202000786;
RA   Bestle D., Heindl M.R., Limburg H., Van Lam van T., Pilgram O., Moulton H.,
RA   Stein D.A., Hardes K., Eickmann M., Dolnik O., Rohde C., Klenk H.D.,
RA   Garten W., Steinmetzer T., Boettcher-Friebertshaeuser E.;
RT   ""TMPRSS2 and furin are both essential for proteolytic activation of SARS-
RT   CoV-2 in human airway cells."";
RL   Life. Sci Alliance 3:1-14(2020).
RN   [26]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, CLEAVAGE BETWEEN S2 AND S2' BY
RP   HOST TMPRSS2, CLEAVAGE BETWEEN S2 AND S2' BY HOST CSTL, AND FUNCTION (SPIKE
RP   PROTEIN S2').
RX   PubMed=34159616; DOI=10.15252/embj.2021107821;
RA   Koch J., Uckeley Z.M., Doldan P., Stanifer M., Boulant S., Lozach P.Y.;
RT   ""TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect
RT   host cells."";
RL   EMBO J. 40:1-20(2021).
RN   [27]
RP   VARIANTS PHE-18; ALA-80; GLY-215; ASN-417; LYS-484; TYR-501; GLY-614 AND
RP   VAL-701.
RC   STRAIN=20H/501Y.V2, B.1.351, and Beta;
RX   PubMed=33690265; DOI=10.1038/s41586-021-03402-9;
RA   Tegally H., Wilkinson E., Giovanetti M., Iranzadeh A., Fonseca V.,
RA   Giandhari J., Doolabh D., Pillay S., San E.J., Msomi N., Mlisana K.,
RA   von Gottberg A., Walaza S., Allam M., Ismail A., Mohale T., Glass A.J.,
RA   Engelbrecht S., Van Zyl G., Preiser W., Petruccione F., Sigal A.,
RA   Hardie D., Marais G., Hsiao M., Korsman S., Davies M.A., Tyers L.,
RA   Mudau I., York D., Maslo C., Goedhals D., Abrahams S., Laguda-Akingba O.,
RA   Alisoltani-Dehkordi A., Godzik A., Wibmer C.K., Sewell B.T., Lourenco J.,
RA   Alcantara L.C.J., Kosakovsky Pond S.L., Weaver S., Martin D.,
RA   Lessells R.J., Bhiman J.N., Williamson C., de Oliveira T.;
RT   ""Emergence of a SARS-CoV-2 variant of concern with mutations in spike
RT   glycoprotein."";
RL   Nature 592:438-443(2021).
RN   [28]
RP   POLYMORPHISM.
RX   PubMed=34142653; DOI=10.2807/1560-7917.es.2021.26.24.2100509;
RA   Campbell F., Archer B., Laurenson-Schafer H., Jinnai Y., Konings F.,
RA   Batra N., Pavlin B., Vandemaele K., Van Kerkhove M.D., Jombart T.,
RA   Morgan O., le Polain de Waroux O.;
RT   ""Increased transmissibility and global spread of SARS-CoV-2 variants of
RT   concern as at June 2021."";
RL   Eurosurveillance 26:0-0(2021).
RN   [29]
RP   VARIANTS ARG-452 AND PHE-453, AND MUTAGENESIS OF LEU-452; TYR-453 AND
RP   ASN-501.
RX   PubMed=34171266; DOI=10.1016/j.chom.2021.06.006;
RG   Genotype to Phenotype Japan (G2P-Japan) Consortium;
RA   Motozono C., Toyoda M., Zahradnik J., Saito A., Nasser H., Tan T.S.,
RA   Ngare I., Kimura I., Uriu K., Kosugi Y., Yue Y., Shimizu R., Ito J.,
RA   Torii S., Yonekawa A., Shimono N., Nagasaki Y., Minami R., Toya T.,
RA   Sekiya N., Fukuhara T., Matsuura Y., Schreiber G., Ikeda T., Nakagawa S.,
RA   Ueno T., Sato K.;
RT   ""SARS-CoV-2 spike L452R variant evades cellular immunity and increases
RT   infectivity."";
RL   Cell Host Microbe 0:0-0(2021).
RN   [30]
RP   VARIANT 69-VAL--PHE-70 DEL, AND MUTAGENESIS OF 69-HIS-VAL-70.
RX   PubMed=34166617; DOI=10.1016/j.celrep.2021.109292;
RG   COVID-19 Genomics UK (COG-UK) Consortium;
RA   Meng B., Kemp S.A., Papa G., Datir R., Ferreira I.A.T.M., Marelli S.,
RA   Harvey W.T., Lytras S., Mohamed A., Gallo G., Thakur N., Collier D.A.,
RA   Mlcochova P., Duncan L.M., Carabelli A.M., Kenyon J.C., Lever A.M.,
RA   De Marco A., Saliba C., Culap K., Cameroni E., Matheson N.J., Piccoli L.,
RA   Corti D., James L.C., Robertson D.L., Bailey D., Gupta R.K.;
RT   ""Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in
RT   the Alpha variant B.1.1.7."";
RL   Cell Rep. 35:109292-109292(2021).
RN   [31]
RP   VARIANTS ILE-13 AND CYS-152, POLYMORPHISM, AND MASS SPECTROMETRY (SIGNAL).
RX   PubMed=34210893; DOI=10.1126/science.abi7994;
RA   McCallum M., Bassi J., De Marco A., Chen A., Walls A.C., Di Iulio J.,
RA   Tortorici M.A., Navarro M.J., Silacci-Fregni C., Saliba C., Sprouse K.R.,
RA   Agostini M., Pinto D., Culap K., Bianchi S., Jaconi S., Cameroni E.,
RA   Bowen J.E., Tilles S.W., Pizzuto M.S., Guastalla S.B., Bona G.,
RA   Pellanda A.F., Garzoni C., Van Voorhis W.C., Rosen L.E., Snell G.,
RA   Telenti A., Virgin H.W., Piccoli L., Corti D., Veesler D.;
RT   ""SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern."";
RL   Science 373:648-654(2021).
RN   [32]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-1269 AND HIS-1271.
RX   PubMed=34504087; DOI=10.1038/s41467-021-25589-1;
RA   Cattin-Ortola J., Welch L.G., Maslen S.L., Papa G., James L.C., Munro S.;
RT   ""Sequences in the cytoplasmic tail of SARS-CoV-2 Spike facilitate
RT   expression at the cell surface and syncytia formation."";
RL   Nat. Commun. 12:5333-5333(2021).
RN   [33]
RP   PALMITOYLATION AT CYS-1235; CYS-1236; CYS-1240; CYS-1241; CYS-1243;
RP   CYS-1247; CYS-1248; CYS-1250; CYS-1253 AND CYS-1254.
RX   PubMed=34599882; DOI=10.1016/j.devcel.2021.09.016;
RA   Mesquita F.S., Abrami L., Sergeeva O., Turelli P., Qing E., Kunz B.,
RA   Raclot C., Paz Montoya J., Abriata L.A., Gallagher T., Dal Peraro M.,
RA   Trono D., D'Angelo G., van der Goot F.G.;
RT   ""S-acylation controls SARS-CoV-2 membrane lipid organization and enhances
RT   infectivity."";
RL   Dev. Cell 56:1-18(2021).
RN   [34] {ECO:0007744|PDB:6M17}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.90 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), DOMAIN, AND INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN S1).
RX   PubMed=32132184; DOI=10.1126/science.abb2762;
RA   Yan R., Zhang Y., Li Y., Xia L., Guo Y., Zhou Q.;
RT   ""Structural basis for the recognition of the SARS-CoV-2 by full-length
RT   human ACE2."";
RL   Science 367:1444-1448(2020).
RN   [35]
RP   SUPERANTIGEN, AND DOMAIN.
RX   PubMed=32989130; DOI=10.1073/pnas.2010722117;
RA   Cheng M.H., Zhang S., Porritt R.A., Noval Rivas M., Paschold L.,
RA   Willscher E., Binder M., Arditi M., Bahar I.;
RT   ""Superantigenic character of an insert unique to SARS-CoV-2 spike supported
RT   by skewed TCR repertoire in patients with hyperinflammation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 117:25254-25262(2020).
RN   [36]
RP   INTERACTION WITH HUMAN BILIRUBIN, INTERACTION WITH HUMAN BILIVERDIN, AND
RP   MUTAGENESIS OF ASN-121 AND ARG-190.
RX   PubMed=33888467; DOI=10.1126/sciadv.abg7607;
RA   Rosa A., Pye V.E., Graham C., Muir L., Seow J., Ng K.W., Cook N.J.,
RA   Rees-Spear C., Parker E., Dos Santos M.S., Rosadas C., Susana A., Rhys H.,
RA   Nans A., Masino L., Roustan C., Christodoulou E., Ulferts R., Wrobel A.G.,
RA   Short C.E., Fertleman M., Sanders R.W., Heaney J., Spyer M., Kjaer S.,
RA   Riddell A., Malim M.H., Beale R., MacRae J.I., Taylor G.P., Nastouli E.,
RA   van Gils M.J., Rosenthal P.B., Pizzato M., McClure M.O., Tedder R.S.,
RA   Kassiotis G., McCoy L.E., Doores K.J., Cherepanov P.;
RT   ""SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity."";
RL   Sci. Adv. 7:0-0(2021).
RN   [37]
RP   BIOTECHNOLOGY, AND MUTAGENESIS OF 682-ARG--ARG-685 AND 986-LYS-VAL-987.
RX   PubMed=34322129; DOI=10.3389/fimmu.2021.701501;
RA   Martinez-Flores D., Zepeda-Cervantes J., Cruz-Resendiz A.,
RA   Aguirre-Sampieri S., Sampieri A., Vaca L.;
RT   ""SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of
RT   New Viral Variants."";
RL   Front. Immunol. 12:701501-701501(2021).
RN   [38]
RP   GLYCOSYLATION AT THR-676 AND THR-678 BY HOST GALNT1, AND MUTAGENESIS OF
RP   SER-673; THR-676; THR-678; SER-680 AND PRO-681.
RX   PubMed=34732583; DOI=10.1073/pnas.2109905118;
RA   Zhang L., Mann M., Syed Z.A., Reynolds H.M., Tian E., Samara N.L.,
RA   Zeldin D.C., Tabak L.A., Ten Hagen K.G.;
RT   ""Furin cleavage of the SARS-CoV-2 spike is modulated by O-glycosylation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [39]
RP   REVIEW, PROTEOLITIC PROCESSING, FUNCTION (SPIKE PROTEIN S2), AND FUNCTION
RP   (SPIKE PROTEIN S2').
RX   PubMed=34561887; DOI=10.1111/1348-0421.12945;
RA   Takeda M.;
RT   ""Proteolytic activation of SARS-CoV-2 spike protein."";
RL   Microbiol. Immunol. 66:15-23(2022).
RN   [40]
RP   INTERACTION WITH HOST MBL2.
RX   PubMed=35102342; DOI=10.1038/s41590-021-01114-w;
RA   Stravalaci M., Pagani I., Paraboschi E.M., Pedotti M., Doni A.,
RA   Scavello F., Mapelli S.N., Sironi M., Perucchini C., Varani L.,
RA   Matkovic M., Cavalli A., Cesana D., Gallina P., Pedemonte N., Capurro V.,
RA   Clementi N., Mancini N., Invernizzi P., Bayarri-Olmos R., Garred P.,
RA   Rappuoli R., Duga S., Bottazzi B., Uguccioni M., Asselta R., Vicenzi E.,
RA   Mantovani A., Garlanda C.;
RT   ""Recognition and inhibition of SARS-CoV-2 by humoral innate immunity
RT   pattern recognition molecules."";
RL   Nat. Immunol. 23:275-286(2022).
RN   [41]
RP   FUNCTION (SPIKE PROTEIN S1), AND INTERACTION WITH HOST INTEGRIN (SPIKE
RP   PROTEIN S1).
RX   PubMed=35150743; DOI=10.1016/j.jbc.2022.101710;
RA   Liu J., Lu F., Chen Y., Plow E., Qin J.;
RT   ""Integrin mediates cell entry of the SARS-CoV-2 virus independent of
RT   cellular receptor ACE2."";
RL   J. Biol. Chem. 1:101710-101710(2022).
RN   [42]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [43]
RP   SUBUNIT.
RX   PubMed=36735681; DOI=10.1371/journal.pbio.3001959;
RA   Shilts J., Crozier T.W.M., Teixeira-Silva A., Gabaev I., Gerber P.P.,
RA   Greenwood E.J.D., Watson S.J., Ortmann B.M., Gawden-Bone C.M., Pauzaite T.,
RA   Hoffmann M., Nathan J.A., Poehlmann S., Matheson N.J., Lehner P.J.,
RA   Wright G.J.;
RT   ""LRRC15 mediates an accessory interaction with the SARS-CoV-2 spike
RT   protein."";
RL   PLoS Biol. 21:e3001959-e3001959(2023).
RN   [44]
RP   VARIANT ASN-405.
RX   PubMed=36851546; DOI=10.3390/v15020332;
RA   Bugatti A., Filippini F., Messali S., Giovanetti M., Ravelli C., Zani A.,
RA   Ciccozzi M., Caruso A., Caccuri F.;
RT   ""The D405N Mutation in the Spike Protein of SARS-CoV-2 Omicron BA.5
RT   Inhibits Spike/Integrins Interaction and Viral Infection of Human Lung
RT   Microvascular Endothelial Cells."";
RL   Viruses 15:0-0(2023).
RN   [45]
RP   MUTAGENESIS OF GLU-484.
RX   PubMed=37421949; DOI=10.1016/j.cell.2023.06.005;
RA   Baggen J., Jacquemyn M., Persoons L., Vanstreels E., Pye V.E., Wrobel A.G.,
RA   Calvaresi V., Martin S.R., Roustan C., Cronin N.B., Reading E.,
RA   Thibaut H.J., Vercruysse T., Maes P., De Smet F., Yee A., Nivitchanyong T.,
RA   Roell M., Franco-Hernandez N., Rhinn H., Mamchak A.A., Ah Young-Chapon M.,
RA   Brown E., Cherepanov P., Daelemans D.;
RT   ""TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry."";
RL   Cell 186:1-16(2023).
RN   [46] {ECO:0007744|PDB:6VSB}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.46 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN S1), SUBUNIT, AND
RP   GLYCOSYLATION.
RX   PubMed=32075877; DOI=10.1126/science.abb2507;
RA   Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.L., Abiona O.,
RA   Graham B.S., McLellan J.S.;
RT   ""Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation."";
RL   Science 367:1260-1263(2020).
RN   [47] {ECO:0007744|PDB:6VXX, ECO:0007744|PDB:6VYB}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.80 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), SUBUNIT (SPIKE PROTEIN S1), INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN
RP   S1), MUTAGENESIS OF 679-GLN--ALA-684, GLYCOSYLATION AT ASN-61; ASN-122;
RP   ASN-61; ASN-165; ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616;
RP   ASN-657; ASN-709; ASN-717; ASN-801; ASN-1074; ASN-1098 AND ASN-1134, AND
RP   DISULFIDE BOND.
RX   PubMed=32155444; DOI=10.1016/j.cell.2020.02.058;
RA   Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., Veesler D.;
RT   ""Structure, function, and antigenicity of the SARS-CoV-2 spike
RT   glycoprotein."";
RL   Cell 180:1-12(2020).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HOST ACE2.
RX   PubMed=32225176; DOI=10.1038/s41586-020-2180-5;
RA   Lan J., Ge J., Yu J., Shan S., Zhou H., Fan S., Zhang Q., Shi X., Wang Q.,
RA   Zhang L., Wang X.;
RT   ""Structure of the SARS-CoV-2 spike receptor-binding domain bound to the
RT   ACE2 receptor."";
RL   Nature 581:215-220(2020).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.68 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HOST ACE2, INTERACTION WITH HOST ACE2, AND MUTAGENESIS OF GLN-493 AND
RP   ASN-501.
RX   PubMed=32225175; DOI=10.1038/s41586-020-2179-y;
RA   Shang J., Ye G., Shi K., Wan Y., Luo C., Aihara H., Geng Q., Auerbach A.,
RA   Li F.;
RT   ""Structural basis of receptor recognition by SARS-CoV-2."";
RL   Nature 581:221-224(2020).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (3.08 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HUMAN ANTIBODY CR3022, AND DISULFIDE BOND.
RX   PubMed=32245784; DOI=10.1126/science.abb7269;
RA   Yuan M., Wu N.C., Zhu X., Lee C.D., So R.T.Y., Lv H., Mok C.K.P.,
RA   Wilson I.A.;
RT   ""A highly conserved cryptic epitope in the receptor-binding domains of
RT   SARS-CoV-2 and SARS-CoV."";
RL   Science 368:630-633(2020).
CC   -!- FUNCTION: [Spike protein S1]: Attaches the virion to the cell membrane
CC       by interacting with host receptor, initiating the infection. The major
CC       receptor is host ACE2 (PubMed:32142651, PubMed:32155444,
CC       PubMed:33607086). When S2/S2' has been cleaved, binding to the receptor
CC       triggers direct fusion at the cell membrane (PubMed:34561887). When
CC       S2/S2' has not been cleaved, binding to the receptor results in
CC       internalization of the virus by endocytosis leading to fusion of the
CC       virion membrane with the host endosomal membrane (PubMed:32075877,
CC       PubMed:32221306). Alternatively, may use NRP1/NRP2 (PubMed:33082294,
CC       PubMed:33082293) and integrin as entry receptors (PubMed:35150743). The
CC       use of NRP1/NRP2 receptors may explain the tropism of the virus in
CC       human olfactory epithelial cells, which express these molecules at high
CC       levels but ACE2 at low levels (PubMed:33082293). The stalk domain of S
CC       contains three hinges, giving the head unexpected orientational freedom
CC       (PubMed:32817270). {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:32075877, ECO:0000269|PubMed:32142651,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32221306,
CC       ECO:0000269|PubMed:32817270, ECO:0000269|PubMed:33082293,
CC       ECO:0000269|PubMed:33082294, ECO:0000269|PubMed:35150743,
CC       ECO:0000303|PubMed:33082293, ECO:0000305|PubMed:34561887}.
CC   -!- FUNCTION: [Spike protein S2]: Precursor of the fusion protein processed
CC       in the biosynthesis of the S protein and the formation of virus
CC       particle. Mediates fusion of the virion and cellular membranes by
CC       functioning as a class I viral fusion protein. Contains two viral
CC       fusion peptides that are unmasked after cleavage. The S2/S2' cleavage
CC       occurs during virus entry at the cell membrane by host TMPRSS2
CC       (PubMed:32142651) or during endocytosis by host CSTL (PubMed:32703818,
CC       PubMed:34159616). In either case, this triggers an extensive and
CC       irreversible conformational change leading to fusion of the viral
CC       envelope with the cellular cytoplasmic membrane, releasing viral
CC       genomic RNA into the host cell cytoplasm (PubMed:34561887). Under the
CC       current model, the protein has at least three conformational states:
CC       pre-fusion native state, pre-hairpin intermediate state, and post-
CC       fusion hairpin state. During fusion of the viral and target cell
CC       membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-
CC       hairpins structure and position the fusion peptide in close proximity
CC       to the C-terminal region of the ectodomain. Formation of this structure
CC       appears to promote apposition and subsequent fusion of viral and target
CC       cell membranes. {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:32703818, ECO:0000269|PubMed:34159616,
CC       ECO:0000305|PubMed:34561887}.
CC   -!- FUNCTION: [Spike protein S2']: Subunit of the fusion protein that is
CC       processed upon entry into the host cell. Mediates fusion of the virion
CC       and cellular membranes by functioning as a class I viral fusion
CC       protein. Contains a viral fusion peptide that is unmasked after S2
CC       cleavage. This cleavage can occur at the cell membrane by host TMPRSS2
CC       or during endocytosis by host CSTL (PubMed:32703818, PubMed:34159616).
CC       In either case, this triggers an extensive and irreversible
CC       conformational change that leads to fusion of the viral envelope with
CC       the cellular cytoplasmic membrane, releasing viral genomic RNA into the
CC       host cell cytoplasm (PubMed:34561887). Under the current model, the
CC       protein has at least three conformational states: pre-fusion native
CC       state, pre-hairpin intermediate state, and post-fusion hairpin state.
CC       During fusion of the viral and target cell membranes, the coiled coil
CC       regions (heptad repeats) adopt a trimer-of-hairpins structure and
CC       position the fusion peptide in close proximity to the C-terminal region
CC       of the ectodomain. Formation of this structure appears to promote
CC       apposition and subsequent fusion of viral and target cell membranes.
CC       {ECO:0000255|HAMAP-Rule:MF_04099, ECO:0000269|PubMed:32703818,
CC       ECO:0000269|PubMed:34159616, ECO:0000305|PubMed:34561887}.
CC   -!- SUBUNIT: [Spike glycoprotein]: Homotrimer; each monomer consists of a
CC       S1 and a S2 subunit (PubMed:32075877, PubMed:32155444,
CC       PubMed:32245784). The resulting peplomers protrude from the virus
CC       surface as spikes (PubMed:32979942). Interacts with ORF3a protein and
CC       ORF7a protein (By similarity) (PubMed:32075877, PubMed:32155444,
CC       PubMed:32245784, PubMed:32979942). There are an average of 26 +/-15
CC       spike trimers at the surface of virion particles (PubMed:32979942).
CC       Binds to host MBL2 (PubMed:35102342). This binding occurs via glycans
CC       and inhibits viral infectivity. Inhibition is effective against alpha,
CC       beta, gamma, and delta variants (PubMed:35102342). {ECO:0000255|HAMAP-
CC       Rule:MF_04099, ECO:0000269|PubMed:32075877,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32245784,
CC       ECO:0000269|PubMed:32979942, ECO:0000269|PubMed:35102342}.
CC   -!- SUBUNIT: [Spike protein S1]: Binds to host ACE2 (PubMed:32075877,
CC       PubMed:32132184, PubMed:32155444, PubMed:32221306, PubMed:32225175,
CC       PubMed:32225176, PubMed:33607086). RBD also interacts with the N-linked
CC       glycan on 'Asn-90' of ACE2 (PubMed:33607086). Cleavage of S generates a
CC       polybasic C-terminal sequence on S1 that binds to host Neuropilin-1
CC       (NRP1) and Neuropilin-2 (NRP2) receptors (PubMed:33082293,
CC       PubMed:33082294). Interacts with host integrin alpha-5/beta-1
CC       (ITGA5:ITGB1) and with ACE2 in complex with integrin alpha-5/beta-1
CC       (ITGA5:ITGB1) (PubMed:33102950). May interact via cytoplasmic c-
CC       terminus with M protein (PubMed:33229438). May interact (via N-
CC       terminus) with host bilirubin and biliverdin, thereby preventing
CC       antibody binding to the SARS-CoV-2 spike NTD via an allosteric
CC       mechanism (PubMed:33888467). May interact with host LRRC15, thereby
CC       allowing attachment to host cells (PubMed:36735681).
CC       {ECO:0000269|PubMed:32075877, ECO:0000269|PubMed:32132184,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32221306,
CC       ECO:0000269|PubMed:32225",17530
ATGAAA TGAAAA GAAAAT AAAATT AAATTA AATTAT ATTATT TTATTC TATTCT ATTCTT TTCTTT TCTTTT CTTTTC TTTTCT TTTCTT TTCTTG TCTTGG CTTGGC TTGGCA TGGCAC GGCACT GCACTG CACTGA ACTGAT CTGATA TGATAA GATAAC ATAACA TAACAC AACACT ACACTC CACTCG ACTCGC CTCGCT TCGCTA CGCTAC GCTACT CTACTT TACTTG ACTTGT CTTGTG TTGTGA TGTGAG GTGAGC TGAGCT GAGCTT AGCTTT GCTTTA CTTTAT TTTATC TTATCA TATCAC ATCACT TCACTA CACTAC ACTACC CTACCA TACCAA ACCAAG CCAAGA CAAGAG AAGAGT AGAGTG GAGTGT,1,64,ATGA TGAA GAAA AAAA AAAT AATT ATTA TTAT TATT ATTC TTCT TCTT CTTT TTTT TTTC TTCT TCTT CTTG TTGG TGGC GGCA GCAC CACT ACTG CTGA TGAT GATA ATAA TAAC AACA ACAC CACT ACTC CTCG TCGC CGCT GCTA CTAC TACT ACTT CTTG TTGT TGTG GTGA TGAG GAGC AGCT GCTT CTTT TTTA TTAT TATC ATCA TCAC CACT ACTA CTAC TACC ACCA CCAA CAAG AAGA AGAG GAGT AGTG GTGT,ATGAA TGAAA GAAAA AAAAT AAATT AATTA ATTAT TTATT TATTC ATTCT TTCTT TCTTT CTTTT TTTTC TTTCT TTCTT TCTTG CTTGG TTGGC TGGCA GGCAC GCACT CACTG ACTGA CTGAT TGATA GATAA ATAAC TAACA AACAC ACACT CACTC ACTCG CTCGC TCGCT CGCTA GCTAC CTACT TACTT ACTTG CTTGT TTGTG TGTGA GTGAG TGAGC GAGCT AGCTT GCTTT CTTTA TTTAT TTATC TATCA ATCAC TCACT CACTA ACTAC CTACC TACCA ACCAA CCAAG CAAGA AAGAG AGAGT GAGTG AGTGT,ATGAAA TGAAAA GAAAAT AAAATT AAATTA AATTAT ATTATT TTATTC TATTCT ATTCTT TTCTTT TCTTTT CTTTTC TTTTCT TTTCTT TTCTTG TCTTGG CTTGGC TTGGCA TGGCAC GGCACT GCACTG CACTGA ACTGAT CTGATA TGATAA GATAAC ATAACA TAACAC AACACT ACACTC CACTCG ACTCGC CTCGCT TCGCTA CGCTAC GCTACT CTACTT TACTTG ACTTGT CTTGTG TTGTGA TGTGAG GTGAGC TGAGCT GAGCTT AGCTTT GCTTTA CTTTAT TTTATC TTATCA TATCAC ATCACT TCACTA CACTAC ACTACC CTACCA TACCAA ACCAAG CCAAGA CAAGAG AAGAGT AGAGTG GAGTGT,ATGAAAA TGAAAAT GAAAATT AAAATTA AAATTAT AATTATT ATTATTC TTATTCT TATTCTT ATTCTTT TTCTTTT TCTTTTC CTTTTCT TTTTCTT TTTCTTG TTCTTGG TCTTGGC CTTGGCA TTGGCAC TGGCACT GGCACTG GCACTGA CACTGAT ACTGATA CTGATAA TGATAAC GATAACA ATAACAC TAACACT AACACTC ACACTCG CACTCGC ACTCGCT CTCGCTA TCGCTAC CGCTACT GCTACTT CTACTTG TACTTGT ACTTGTG CTTGTGA TTGTGAG TGTGAGC GTGAGCT TGAGCTT GAGCTTT AGCTTTA GCTTTAT CTTTATC TTTATCA TTATCAC TATCACT ATCACTA TCACTAC CACTACC ACTACCA CTACCAA TACCAAG ACCAAGA CCAAGAG CAAGAGT AAGAGTG AGAGTGT,"ID   NS7A_SARS2              Reviewed;         121 AA.
AC   P0DTC7;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 24.
DE   RecName: Full=ORF7a protein;
DE            Short=ORF7a;
DE   AltName: Full=Accessory protein 7a;
DE   AltName: Full=Protein U122;
DE   AltName: Full=Protein X4;
DE   Flags: Precursor;
GN   ORFNames=7a;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANT ILE-14.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION, UBIQUITINATION AT LYS-119, AND MUTAGENESIS OF LYS-2; LYS-32;
RP   LYS-53; LYS-72; LYS-85; LYS-117 AND LYS-119.
RX   PubMed=33473190; DOI=10.1038/s41423-020-00603-6;
RA   Cao Z., Xia H., Rajsbaum R., Xia X., Wang H., Shi P.Y.;
RT   ""Ubiquitination of SARS-CoV-2 ORF7a promotes antagonism of interferon
RT   response."";
RL   Cell. Mol. Immunol. 18:746-748(2021).
RN   [4]
RP   FUNCTION, INTERACTION WITH HOST BST2, AND SUBCELLULAR LOCATION.
RX   PubMed=33930332; DOI=10.1016/j.molcel.2021.04.008;
RA   Martin-Sancho L., Lewinski M.K., Pache L., Stoneham C.A., Yin X.,
RA   Becker M.E., Pratt D., Churas C., Rosenthal S.B., Liu S., Weston S.,
RA   De Jesus P.D., O'Neill A.M., Gounder A.P., Nguyen C., Pu Y., Curry H.M.,
RA   Oom A.L., Miorin L., Rodriguez-Frandsen A., Zheng F., Wu C., Xiong Y.,
RA   Urbanowski M., Shaw M.L., Chang M.W., Benner C., Hope T.J., Frieman M.B.,
RA   Garcia-Sastre A., Ideker T., Hultquist J.F., Guatelli J., Chanda S.K.;
RT   ""Functional landscape of SARS-CoV-2 cellular restriction."";
RL   Mol. Cell 81:2656-2668.e8(2021).
RN   [5]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [6]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF 117-LYS--LYS-119.
RX   PubMed=36574644; DOI=10.1073/pnas.2208525120;
RA   Arshad N., Laurent-Rolle M., Ahmed W.S., Hsu J.C., Mitchell S.M.,
RA   Pawlak J., Sengupta D., Biswas K.H., Cresswell P.;
RT   ""SARS-CoV-2 accessory proteins ORF7a and ORF3a use distinct mechanisms to
RT   down-regulate MHC-I surface expression."";
RL   Proc. Natl. Acad. Sci. U.S.A. 120:e2208525120-e2208525120(2023).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 16-82, AND DISULFIDE BOND.
RA   Nelson C.A., Minasov G., Shuvalova L., Fremont D.H.;
RT   ""STRUCTURE OF THE SARS-CoV-2 ORF7A ENCODED ACCESSORY PROTEIN."";
RL   Submitted (MAR-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 14-96.
RX   PubMed=33615195; DOI=10.1016/j.isci.2021.102187;
RA   Zhou Z., Huang C., Zhou Z., Huang Z., Su L., Kang S., Chen X., Chen Q.,
RA   He S., Rong X., Xiao F., Chen J., Chen S.;
RT   ""Structural insight reveals SARS-CoV-2 ORF7a as an immunomodulating factor
RT   for human CD14+ monocytes."";
RL   IScience 24:102187-102187(2021).
CC   -!- FUNCTION: Plays a role as antagonist of host tetherin (BST2),
CC       disrupting its antiviral effect (PubMed:33930332). Acts by binding to
CC       BST2 and sequestering it to perinuclear region, thereby preventing its
CC       antiviral function at cell membrane (PubMed:33930332). May specifically
CC       downregulate MHC-I allele HLA-A*02:01 (HLA-A2) (PubMed:36574644).
CC       {ECO:0000269|PubMed:33930332, ECO:0000269|PubMed:36574644}.
CC   -!- SUBUNIT: Interacts with host BST2 (PubMed:33930332). Interacts with the
CC       spike glycoprotein (By similarity). Interacts with M protein (By
CC       similarity). Interacts with E protein (By similarity). Interacts with
CC       the ORF3a protein (By similarity). {ECO:0000250|UniProtKB:P59635,
CC       ECO:0000269|PubMed:33930332}.
CC   -!- INTERACTION:
CC       P0DTC7; P0DTD8: 7b; NbExp=5; IntAct=EBI-25475903, EBI-25475914;
CC       P0DTC7; PRO_0000449625 [P0DTD1]: rep; NbExp=3; IntAct=EBI-25475903, EBI-25475871;
CC   -!- SUBCELLULAR LOCATION: Host cytoplasm, host perinuclear region
CC       {ECO:0000269|PubMed:33930332}. Virion {ECO:0000250|UniProtKB:P59635}.
CC       Host endoplasmic reticulum membrane {ECO:0000269|PubMed:36574644};
CC       Single-pass membrane protein {ECO:0000269|PubMed:36574644}. Host
CC       endoplasmic reticulum-Golgi intermediate compartment membrane
CC       {ECO:0000269|PubMed:36574644}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:36574644}. Host Golgi apparatus membrane
CC       {ECO:0000269|PubMed:36574644}; Single-pass membrane protein
CC       {ECO:0000269|PubMed:36574644}.
CC   -!- DOMAIN: The di-lysine motif confers endoplasmic reticulum localization
CC       for type I membrane proteins. {ECO:0000250|UniProtKB:P59635}.
CC   -!- PTM: Poly-ubiquitinated by host with K63-linked polyubiquitin chains.
CC       {ECO:0000269|PubMed:33473190}.
CC   -!- MISCELLANEOUS: Variant B.1.1.7 is also called Variant Of Concern (VOC)
CC       202012/01, Variant Under Investigation (VUI) 202012/01, or 20B/501Y.V1.
CC       {ECO:0000305|PubMed:33413740}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43421.1; -; Genomic_RNA.
DR   PDB; 6W37; X-ray; 2.90 A; A=16-82.
DR   PDB; 7CI3; X-ray; 2.20 A; A=14-96.
DR   PDBsum; 6W37; -.
DR   PDBsum; 7CI3; -.
DR   SMR; P0DTC7; -.
DR   BioGRID; 4383872; 1267.
DR   IntAct; P0DTC7; 128.
DR   MINT; P0DTC7; -.
DR   iPTMnet; P0DTC7; -.
DR   KEGG; vg:43740573; -.
DR   AGR; RefSeq:YP_009724395; -.
DR   Reactome; R-HSA-9694322; Virion Assembly and Release.
DR   Reactome; R-HSA-9694614; Attachment and Entry.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   Reactome; R-HSA-9727281; Translation of Accessory Proteins.
DR   Reactome; R-HSA-9733458; Induction of Cell-Cell Fusion.
DR   Reactome; R-HSA-9754560; SARS-CoV-2 modulates autophagy.
DR   PRO; PR:P0DTC7; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044173; C:host cell endoplasmic reticulum-Golgi intermediate compartment membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044178; C:host cell Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; TAS:Reactome.
DR   GO; GO:0039587; P:suppression by virus of host tetherin activity; IEA:UniProtKB-KW.
DR   GO; GO:0039646; P:symbiont-mediated perturbation of host cell cycle G0/G1 transition checkpoint; IEA:UniProtKB-KW.
DR   GO; GO:0044071; P:symbiont-mediated perturbation of host cell cycle progression; IEA:UniProtKB-KW.
DR   GO; GO:0046776; P:symbiont-mediated suppression of host antigen processing and presentation of peptide antigen via MHC class I; IEA:UniProtKB-KW.
DR   GO; GO:0052170; P:symbiont-mediated suppression of host innate immune response; IEA:UniProtKB-KW.
DR   CDD; cd21684; ORF7a_SARS-CoV-2-like; 1.
DR   Gene3D; 2.60.40.1550; SARS coronavirus X4; 1.
DR   InterPro; IPR044390; ORF7a_SARS-CoV-2-like.
DR   InterPro; IPR014888; ORF7a_SARS-CoV-like.
DR   InterPro; IPR044871; ORF7a_SARS-CoV-like_X4e.
DR   InterPro; IPR036495; ORF7a_sf_CoV.
DR   Pfam; PF08779; bCoV_NS7A; 1.
DR   SUPFAM; SSF117066; Accessory protein X4 (ORF8, ORF7a); 1.
DR   PROSITE; PS51919; X4E; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Disulfide bond;
KW   G0/G1 host cell cycle checkpoint dysregulation by virus; Host cytoplasm;
KW   Host endoplasmic reticulum; Host Golgi apparatus; Host membrane;
KW   Host-virus interaction;
KW   Inhibition of host adaptive immune response by virus;
KW   Inhibition of host innate immune response by virus;
KW   Inhibition of host MHC class I molecule presentation by virus;
KW   Inhibition of host tetherin by virus; Isopeptide bond; Membrane;
KW   Modulation of host cell cycle by virus; Reference proteome; Signal;
KW   Transmembrane; Transmembrane helix; Ubl conjugation; Viral immunoevasion;
KW   Virion.
FT   SIGNAL          1..15
FT                   /evidence=""ECO:0000255""
FT   CHAIN           16..121
FT                   /note=""ORF7a protein""
FT                   /evidence=""ECO:0000255""
FT                   /id=""PRO_0000449654""
FT   TRANSMEM        96..116
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   DOMAIN          16..81
FT                   /note=""X4e""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01267""
FT   REGION          16..80
FT                   /note=""Ig-like fold""
FT                   /evidence=""ECO:0000305|PubMed:36574644""
FT   REGION          83..95
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000305|PubMed:35108439""
FT   MOTIF           117..119
FT                   /note=""ER-retrieval motif""
FT                   /evidence=""ECO:0000269|PubMed:36574644""
FT   DISULFID        23..58
FT                   /evidence=""ECO:0000269|PubMed:33615195, ECO:0000269|Ref.7""
FT   DISULFID        35..67
FT                   /evidence=""ECO:0000269|PubMed:33615195, ECO:0000269|Ref.7""
FT   CROSSLNK        119
FT                   /note=""Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)""
FT                   /evidence=""ECO:0000269|PubMed:33473190""
FT   VARIANT         14
FT                   /note=""T -> I (in strain: Alpha/B.1.1.7)""
FT                   /evidence=""ECO:0000305|PubMed:33413740""
FT   VARIANT         82
FT                   /note=""V -> A (in strain: Delta/B.1.617.2 and
FT                   Kappa/B.1.617.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         120
FT                   /note=""T -> I (in strain: Delta/B.1.617.2)""
FT                   /evidence=""ECO:0000305""
FT   MUTAGEN         2
FT                   /note=""K->A: No effect on ubiquitination.""
FT                   /evidence=""ECO:0000269|PubMed:33473190""
FT   MUTAGEN         32
FT                   /note=""K->A: No effect on ubiquitination.""
FT                   /evidence=""ECO:0000269|PubMed:33473190""
FT   MUTAGEN         53
FT                   /note=""K->A: No effect on ubiquitination.""
FT                   /evidence=""ECO:0000269|PubMed:33473190""
FT   MUTAGEN         72
FT                   /note=""K->A: No effect on ubiquitination.""
FT                   /evidence=""ECO:0000269|PubMed:33473190""
FT   MUTAGEN         85
FT                   /note=""K->A: No effect on ubiquitination.""
FT                   /evidence=""ECO:0000269|PubMed:33473190""
FT   MUTAGEN         117..119
FT                   /note=""KRK->ARA: Complete loss of MHC-I retention in ER.""
FT                   /evidence=""ECO:0000269|PubMed:36574644""
FT   MUTAGEN         117
FT                   /note=""K->A: No effect on ubiquitination.""
FT                   /evidence=""ECO:0000269|PubMed:33473190""
FT   MUTAGEN         119
FT                   /note=""K->A: Complete loss of ubiquitination. Partial loss
FT                   of interferon pathway inhibition.""
FT                   /evidence=""ECO:0000269|PubMed:33473190""
FT   STRAND          16..24
FT                   /evidence=""ECO:0007829|PDB:7CI3""
FT   STRAND          27..32
FT                   /evidence=""ECO:0007829|PDB:7CI3""
FT   STRAND          34..37
FT                   /evidence=""ECO:0007829|PDB:7CI3""
FT   STRAND          39..44
FT                   /evidence=""ECO:0007829|PDB:7CI3""
FT   STRAND          47..49
FT                   /evidence=""ECO:0007829|PDB:6W37""
FT   HELIX           50..52
FT                   /evidence=""ECO:0007829|PDB:7CI3""
FT   STRAND          53..57
FT                   /evidence=""ECO:0007829|PDB:7CI3""
FT   STRAND          60..66
FT                   /evidence=""ECO:0007829|PDB:7CI3""
FT   STRAND          72..80
FT                   /evidence=""ECO:0007829|PDB:7CI3""
SQ   SEQUENCE   121 AA;  13744 MW;  891E7EAB9E8A5BA9 CRC64;
     MKIILFLALI TLATCELYHY QECVRGTTVL LKEPCSSGTY EGNSPFHPLA DNKFALTCFS
     TQFAFACPDG VKHVYQLRAR SVSPKLFIRQ EEVQELYSPI FLIVAAIVFI TLCFTLKRKT
     E
//
",29240
GAGCCC AGCCCA GCCCAG CCCAGC CCAGCC CAGCCA AGCCAC GCCACT CCACTT CACTTC ACTTCT CTTCTG TTCTGG TCTGGG CTGGGG TGGGGC GGGGCC GGGCCG GGCCGC GCCGCC CCGCCC CGCCCA GCCCAT CCCATC CCATCG CATCGG ATCGGC TCGGCC CGGCCA GGCCAC GCCACA CCACAG CACAGC ACAGCG CAGCGC AGCGCC GCGCCC CGCCCA GCCCAT CCCATG CCATGC CATGCC ATGCCC TGCCCT GCCCTA CCCTAC CCTACA CTACAA TACAAC ACAACG CAACGC AACGCA ACGCAT CGCATC GCATCG CATCGG ATCGGC TCGGCC CGGCCT GGCCTC GCCTCG CCTCGG CTCGGG TCGGGT CGGGTG GGGTGG GGTGGC GTGGCT TGGCTC GGCTCC GCTCCA CTCCAA TCCAAT CCAATC CAATCT AATCTG ATCTGG TCTGGG CTGGGC TGGGCC GGGCCC GGCCCC GCCCCA CCCCAC CCCACC CCACCA CACCAA ACCAAC CCAACC CAACCC AACCCG ACCCGG CCCGGC CCGGCG CGGCGC GGCGCT GCGCTA CGCTAG GCTAGC CTAGCC TAGCCG AGCCGA GCCGAA CCGAAG CGAAGC GAAGCG AAGCGG AGCGGT GCGGTC CGGTCA GGTCAA GTCAAA TCAAAG CAAAGC AAAGCC AAGCCC AGCCCG GCCCGC CCCGCA CCGCAT CGCATT GCATTG CATTGA ATTGAA,2,124,GAGC AGCC GCCC CCCA CCAG CAGC AGCC GCCA CCAC CACT ACTT CTTC TTCT TCTG CTGG TGGG GGGG GGGC GGCC GCCG CCGC CGCC GCCC CCCA CCAT CATC ATCG TCGG CGGC GGCC GCCA CCAC CACA ACAG CAGC AGCG GCGC CGCC GCCC CCCA CCAT CATG ATGC TGCC GCCC CCCT CCTA CTAC TACA ACAA CAAC AACG ACGC CGCA GCAT CATC ATCG TCGG CGGC GGCC GCCT CCTC CTCG TCGG CGGG GGGT GGTG GTGG TGGC GGCT GCTC CTCC TCCA CCAA CAAT AATC ATCT TCTG CTGG TGGG GGGC GGCC GCCC CCCC CCCA CCAC CACC ACCA CCAA CAAC AACC ACCC CCCG CCGG CGGC GGCG GCGC CGCT GCTA CTAG TAGC AGCC GCCG CCGA CGAA GAAG AAGC AGCG GCGG CGGT GGTC GTCA TCAA CAAA AAAG AAGC AGCC GCCC CCCG CCGC CGCA GCAT CATT ATTG TTGA TGAA,GAGCC AGCCC GCCCA CCCAG CCAGC CAGCC AGCCA GCCAC CCACT CACTT ACTTC CTTCT TTCTG TCTGG CTGGG TGGGG GGGGC GGGCC GGCCG GCCGC CCGCC CGCCC GCCCA CCCAT CCATC CATCG ATCGG TCGGC CGGCC GGCCA GCCAC CCACA CACAG ACAGC CAGCG AGCGC GCGCC CGCCC GCCCA CCCAT CCATG CATGC ATGCC TGCCC GCCCT CCCTA CCTAC CTACA TACAA ACAAC CAACG AACGC ACGCA CGCAT GCATC CATCG ATCGG TCGGC CGGCC GGCCT GCCTC CCTCG CTCGG TCGGG CGGGT GGGTG GGTGG GTGGC TGGCT GGCTC GCTCC CTCCA TCCAA CCAAT CAATC AATCT ATCTG TCTGG CTGGG TGGGC GGGCC GGCCC GCCCC CCCCA CCCAC CCACC CACCA ACCAA CCAAC CAACC AACCC ACCCG CCCGG CCGGC CGGCG GGCGC GCGCT CGCTA GCTAG CTAGC TAGCC AGCCG GCCGA CCGAA CGAAG GAAGC AAGCG AGCGG GCGGT CGGTC GGTCA GTCAA TCAAA CAAAG AAAGC AAGCC AGCCC GCCCG CCCGC CCGCA CGCAT GCATT CATTG ATTGA TTGAA,GAGCCC AGCCCA GCCCAG CCCAGC CCAGCC CAGCCA AGCCAC GCCACT CCACTT CACTTC ACTTCT CTTCTG TTCTGG TCTGGG CTGGGG TGGGGC GGGGCC GGGCCG GGCCGC GCCGCC CCGCCC CGCCCA GCCCAT CCCATC CCATCG CATCGG ATCGGC TCGGCC CGGCCA GGCCAC GCCACA CCACAG CACAGC ACAGCG CAGCGC AGCGCC GCGCCC CGCCCA GCCCAT CCCATG CCATGC CATGCC ATGCCC TGCCCT GCCCTA CCCTAC CCTACA CTACAA TACAAC ACAACG CAACGC AACGCA ACGCAT CGCATC GCATCG CATCGG ATCGGC TCGGCC CGGCCT GGCCTC GCCTCG CCTCGG CTCGGG TCGGGT CGGGTG GGGTGG GGTGGC GTGGCT TGGCTC GGCTCC GCTCCA CTCCAA TCCAAT CCAATC CAATCT AATCTG ATCTGG TCTGGG CTGGGC TGGGCC GGGCCC GGCCCC GCCCCA CCCCAC CCCACC CCACCA CACCAA ACCAAC CCAACC CAACCC AACCCG ACCCGG CCCGGC CCGGCG CGGCGC GGCGCT GCGCTA CGCTAG GCTAGC CTAGCC TAGCCG AGCCGA GCCGAA CCGAAG CGAAGC GAAGCG AAGCGG AGCGGT GCGGTC CGGTCA GGTCAA GTCAAA TCAAAG CAAAGC AAAGCC AAGCCC AGCCCG GCCCGC CCCGCA CCGCAT CGCATT GCATTG CATTGA ATTGAA,GAGCCCA AGCCCAG GCCCAGC CCCAGCC CCAGCCA CAGCCAC AGCCACT GCCACTT CCACTTC CACTTCT ACTTCTG CTTCTGG TTCTGGG TCTGGGG CTGGGGC TGGGGCC GGGGCCG GGGCCGC GGCCGCC GCCGCCC CCGCCCA CGCCCAT GCCCATC CCCATCG CCATCGG CATCGGC ATCGGCC TCGGCCA CGGCCAC GGCCACA GCCACAG CCACAGC CACAGCG ACAGCGC CAGCGCC AGCGCCC GCGCCCA CGCCCAT GCCCATG CCCATGC CCATGCC CATGCCC ATGCCCT TGCCCTA GCCCTAC CCCTACA CCTACAA CTACAAC TACAACG ACAACGC CAACGCA AACGCAT ACGCATC CGCATCG GCATCGG CATCGGC ATCGGCC TCGGCCT CGGCCTC GGCCTCG GCCTCGG CCTCGGG CTCGGGT TCGGGTG CGGGTGG GGGTGGC GGTGGCT GTGGCTC TGGCTCC GGCTCCA GCTCCAA CTCCAAT TCCAATC CCAATCT CAATCTG AATCTGG ATCTGGG TCTGGGC CTGGGCC TGGGCCC GGGCCCC GGCCCCA GCCCCAC CCCCACC CCCACCA CCACCAA CACCAAC ACCAACC CCAACCC CAACCCG AACCCGG ACCCGGC CCCGGCG CCGGCGC CGGCGCT GGCGCTA GCGCTAG CGCTAGC GCTAGCC CTAGCCG TAGCCGA AGCCGAA GCCGAAG CCGAAGC CGAAGCG GAAGCGG AAGCGGT AGCGGTC GCGGTCA CGGTCAA GGTCAAA GTCAAAG TCAAAGC CAAAGCC AAAGCCC AAGCCCG AGCCCGC GCCCGCA CCCGCAT CCGCATT CGCATTG GCATTGA CATTGAA,"ID   KDPC_VARPS              Reviewed;         193 AA.
AC   C5CPD2;
DT   22-SEP-2009, integrated into UniProtKB/Swiss-Prot.
DT   28-JUL-2009, sequence version 1.
DT   27-MAR-2024, entry version 76.
DE   RecName: Full=Potassium-transporting ATPase KdpC subunit {ECO:0000255|HAMAP-Rule:MF_00276};
DE   AltName: Full=ATP phosphohydrolase [potassium-transporting] C chain {ECO:0000255|HAMAP-Rule:MF_00276};
DE   AltName: Full=Potassium-binding and translocating subunit C {ECO:0000255|HAMAP-Rule:MF_00276};
DE   AltName: Full=Potassium-translocating ATPase C chain {ECO:0000255|HAMAP-Rule:MF_00276};
GN   Name=kdpC {ECO:0000255|HAMAP-Rule:MF_00276};
GN   OrderedLocusNames=Vapar_4993;
OS   Variovorax paradoxus (strain S110).
OC   Bacteria; Pseudomonadota; Betaproteobacteria; Burkholderiales;
OC   Comamonadaceae; Variovorax.
OX   NCBI_TaxID=543728;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=S110;
RX   PubMed=21183664; DOI=10.1128/jb.00925-10;
RA   Han J.I., Choi H.K., Lee S.W., Orwin P.M., Kim J., Laroe S.L., Kim T.G.,
RA   O'Neil J., Leadbetter J.R., Lee S.Y., Hur C.G., Spain J.C.,
RA   Ovchinnikova G., Goodwin L., Han C.;
RT   ""Complete genome sequence of the metabolically versatile plant growth-
RT   promoting endophyte, Variovorax paradoxus S110."";
RL   J. Bacteriol. 193:1183-1190(2011).
CC   -!- FUNCTION: Part of the high-affinity ATP-driven potassium transport (or
CC       Kdp) system, which catalyzes the hydrolysis of ATP coupled with the
CC       electrogenic transport of potassium into the cytoplasm. This subunit
CC       acts as a catalytic chaperone that increases the ATP-binding affinity
CC       of the ATP-hydrolyzing subunit KdpB by the formation of a transient
CC       KdpB/KdpC/ATP ternary complex. {ECO:0000255|HAMAP-Rule:MF_00276}.
CC   -!- SUBUNIT: The system is composed of three essential subunits: KdpA, KdpB
CC       and KdpC. {ECO:0000255|HAMAP-Rule:MF_00276}.
CC   -!- SUBCELLULAR LOCATION: Cell inner membrane {ECO:0000255|HAMAP-
CC       Rule:MF_00276}; Single-pass membrane protein {ECO:0000255|HAMAP-
CC       Rule:MF_00276}.
CC   -!- SIMILARITY: Belongs to the KdpC family. {ECO:0000255|HAMAP-
CC       Rule:MF_00276}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CP001635; ACS21596.1; -; Genomic_DNA.
DR   AlphaFoldDB; C5CPD2; -.
DR   SMR; C5CPD2; -.
DR   STRING; 543728.Vapar_4993; -.
DR   KEGG; vap:Vapar_4993; -.
DR   eggNOG; COG2156; Bacteria.
DR   HOGENOM; CLU_077094_2_0_4; -.
DR   OrthoDB; 9788285at2; -.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0008556; F:P-type potassium transmembrane transporter activity; IEA:InterPro.
DR   HAMAP; MF_00276; KdpC; 1.
DR   InterPro; IPR003820; KdpC.
DR   NCBIfam; TIGR00681; kdpC; 1.
DR   PANTHER; PTHR30042; POTASSIUM-TRANSPORTING ATPASE C CHAIN; 1.
DR   PANTHER; PTHR30042:SF2; POTASSIUM-TRANSPORTING ATPASE KDPC SUBUNIT; 1.
DR   Pfam; PF02669; KdpC; 1.
DR   PIRSF; PIRSF001296; K_ATPase_KdpC; 1.
PE   3: Inferred from homology;
KW   ATP-binding; Cell inner membrane; Cell membrane; Ion transport; Membrane;
KW   Nucleotide-binding; Potassium; Potassium transport; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN           1..193
FT                   /note=""Potassium-transporting ATPase KdpC subunit""
FT                   /id=""PRO_1000204796""
FT   TRANSMEM        7..27
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00276""
SQ   SEQUENCE   193 AA;  19506 MW;  A38E0C3E6A9DCF6B CRC64;
     MNNVIRPALV LFALLSALTG LAYPLAVTGA AKALFPSQAA GSLVVQGGTT VGSSLIGQNF
     GDPKHFWGRP SATAPQPYNA SASGGSNLGP LNPALADAVK QRIEALRAAD PGNAAAVPVD
     LVTASASGLD PDISPAAAHY QAARVARLRG LPPEQVNALV ASHTQAPLWG WLGEPRVNVL
     ALNLALDASA AAR
//
",26853
ATGTAC TGTACA GTACAT TACATG ACATGG CATGGG ATGGGC TGGGCA GGGCAC GGCACA GCACAC CACACT ACACTT CACTTT ACTTTC CTTTCT TTTCTT TTCTTA TCTTAT CTTATG TTATGA TATGAA ATGAAC TGAACA GAACAA AACAAT ACAATT CAATTT AATTTA ATTTAA TTTAAG TTAAGA TAAGAA AAGAAA AGAAAG GAAAGG AAAGGT AAGGTG AGGTGT GGTGTT GTGTTC TGTTCA GTTCAG TTCAGA TCAGAT CAGATA AGATAC GATACC ATACCT TACCTT ACCTTG CCTTGT CTTGTA TTGTAC TGTACG GTACGT TACGTG ACGTGT,0,58,ATGT TGTA GTAC TACA ACAT CATG ATGG TGGG GGGC GGCA GCAC CACA ACAC CACT ACTT CTTT TTTC TTCT TCTT CTTA TTAT TATG ATGA TGAA GAAC AACA ACAA CAAT AATT ATTT TTTA TTAA TAAG AAGA AGAA GAAA AAAG AAGG AGGT GGTG GTGT TGTT GTTC TTCA TCAG CAGA AGAT GATA ATAC TACC ACCT CCTT CTTG TTGT TGTA GTAC TACG ACGT CGTG GTGT,ATGTA TGTAC GTACA TACAT ACATG CATGG ATGGG TGGGC GGGCA GGCAC GCACA CACAC ACACT CACTT ACTTT CTTTC TTTCT TTCTT TCTTA CTTAT TTATG TATGA ATGAA TGAAC GAACA AACAA ACAAT CAATT AATTT ATTTA TTTAA TTAAG TAAGA AAGAA AGAAA GAAAG AAAGG AAGGT AGGTG GGTGT GTGTT TGTTC GTTCA TTCAG TCAGA CAGAT AGATA GATAC ATACC TACCT ACCTT CCTTG CTTGT TTGTA TGTAC GTACG TACGT ACGTG CGTGT,ATGTAC TGTACA GTACAT TACATG ACATGG CATGGG ATGGGC TGGGCA GGGCAC GGCACA GCACAC CACACT ACACTT CACTTT ACTTTC CTTTCT TTTCTT TTCTTA TCTTAT CTTATG TTATGA TATGAA ATGAAC TGAACA GAACAA AACAAT ACAATT CAATTT AATTTA ATTTAA TTTAAG TTAAGA TAAGAA AAGAAA AGAAAG GAAAGG AAAGGT AAGGTG AGGTGT GGTGTT GTGTTC TGTTCA GTTCAG TTCAGA TCAGAT CAGATA AGATAC GATACC ATACCT TACCTT ACCTTG CCTTGT CTTGTA TTGTAC TGTACG GTACGT TACGTG ACGTGT,ATGTACA TGTACAT GTACATG TACATGG ACATGGG CATGGGC ATGGGCA TGGGCAC GGGCACA GGCACAC GCACACT CACACTT ACACTTT CACTTTC ACTTTCT CTTTCTT TTTCTTA TTCTTAT TCTTATG CTTATGA TTATGAA TATGAAC ATGAACA TGAACAA GAACAAT AACAATT ACAATTT CAATTTA AATTTAA ATTTAAG TTTAAGA TTAAGAA TAAGAAA AAGAAAG AGAAAGG GAAAGGT AAAGGTG AAGGTGT AGGTGTT GGTGTTC GTGTTCA TGTTCAG GTTCAGA TTCAGAT TCAGATA CAGATAC AGATACC GATACCT ATACCTT TACCTTG ACCTTGT CCTTGTA CTTGTAC TTGTACG TGTACGT GTACGTG TACGTGT,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",57606
GTTGTA TTGTAA TGTAAT GTAATA TAATAG AATAGG ATAGGA TAGGAA AGGAAT GGAATT GAATTG AATTGT ATTGTC TTGTCA TGTCAA GTCAAC TCAACA CAACAA AACAAC ACAACA CAACAC AACACA ACACAG CACAGT ACAGTT CAGTTT AGTTTA GTTTAT TTTATG TTATGA TATGAT ATGATC TGATCC GATCCT ATCCTT TCCTTT CCTTTG CTTTGC TTTGCA TTGCAA TGCAAC GCAACC CAACCT AACCTG ACCTGA CCTGAA CTGAAT TGAATT GAATTA AATTAG ATTAGA TTAGAT TAGATT AGATTC GATTCA ATTCAT TTCATT TCATTC CATTCA ATTCAA TTCAAG TCAAGG CAAGGA AAGGAG AGGAGG GGAGGA GAGGAG AGGAGT GGAGTT GAGTTA AGTTAG GTTAGA TTAGAT TAGATA AGATAA GATAAA ATAAAT TAAATA AAATAT AATATT ATATTT TATTTT ATTTTA TTTTAA TTTAAG TTAAGA TAAGAA AAGAAT AGAATC GAATCA AATCAT ATCATA TCATAC CATACA ATACAT TACATC ACATCA CATCAC ATCACC TCACCA CACCAG ACCAGA CCAGAT CAGATG AGATGT GATGTT ATGTTG TGTTGA GTTGAT TTGATT TGATTT GATTTA ATTTAG TTTAGG TTAGGT TAGGTG AGGTGA GGTGAC GTGACA TGACAT GACATC ACATCT CATCTC ATCTCT TCTCTG CTCTGG TCTGGC CTGGCA TGGCAT GGCATT GCATTA CATTAA ATTAAT TTAATG TAATGC AATGCT ATGCTT TGCTTC GCTTCA CTTCAG TTCAGT TCAGTT CAGTTG AGTTGT GTTGTA,1,145,GTTG TTGT TGTA GTAA TAAT AATA ATAG TAGG AGGA GGAA GAAT AATT ATTG TTGT TGTC GTCA TCAA CAAC AACA ACAA CAAC AACA ACAC CACA ACAG CAGT AGTT GTTT TTTA TTAT TATG ATGA TGAT GATC ATCC TCCT CCTT CTTT TTTG TTGC TGCA GCAA CAAC AACC ACCT CCTG CTGA TGAA GAAT AATT ATTA TTAG TAGA AGAT GATT ATTC TTCA TCAT CATT ATTC TTCA TCAA CAAG AAGG AGGA GGAG GAGG AGGA GGAG GAGT AGTT GTTA TTAG TAGA AGAT GATA ATAA TAAA AAAT AATA ATAT TATT ATTT TTTT TTTA TTAA TAAG AAGA AGAA GAAT AATC ATCA TCAT CATA ATAC TACA ACAT CATC ATCA TCAC CACC ACCA CCAG CAGA AGAT GATG ATGT TGTT GTTG TTGA TGAT GATT ATTT TTTA TTAG TAGG AGGT GGTG GTGA TGAC GACA ACAT CATC ATCT TCTC CTCT TCTG CTGG TGGC GGCA GCAT CATT ATTA TTAA TAAT AATG ATGC TGCT GCTT CTTC TTCA TCAG CAGT AGTT GTTG TTGT TGTA,GTTGT TTGTA TGTAA GTAAT TAATA AATAG ATAGG TAGGA AGGAA GGAAT GAATT AATTG ATTGT TTGTC TGTCA GTCAA TCAAC CAACA AACAA ACAAC CAACA AACAC ACACA CACAG ACAGT CAGTT AGTTT GTTTA TTTAT TTATG TATGA ATGAT TGATC GATCC ATCCT TCCTT CCTTT CTTTG TTTGC TTGCA TGCAA GCAAC CAACC AACCT ACCTG CCTGA CTGAA TGAAT GAATT AATTA ATTAG TTAGA TAGAT AGATT GATTC ATTCA TTCAT TCATT CATTC ATTCA TTCAA TCAAG CAAGG AAGGA AGGAG GGAGG GAGGA AGGAG GGAGT GAGTT AGTTA GTTAG TTAGA TAGAT AGATA GATAA ATAAA TAAAT AAATA AATAT ATATT TATTT ATTTT TTTTA TTTAA TTAAG TAAGA AAGAA AGAAT GAATC AATCA ATCAT TCATA CATAC ATACA TACAT ACATC CATCA ATCAC TCACC CACCA ACCAG CCAGA CAGAT AGATG GATGT ATGTT TGTTG GTTGA TTGAT TGATT GATTT ATTTA TTTAG TTAGG TAGGT AGGTG GGTGA GTGAC TGACA GACAT ACATC CATCT ATCTC TCTCT CTCTG TCTGG CTGGC TGGCA GGCAT GCATT CATTA ATTAA TTAAT TAATG AATGC ATGCT TGCTT GCTTC CTTCA TTCAG TCAGT CAGTT AGTTG GTTGT TTGTA,GTTGTA TTGTAA TGTAAT GTAATA TAATAG AATAGG ATAGGA TAGGAA AGGAAT GGAATT GAATTG AATTGT ATTGTC TTGTCA TGTCAA GTCAAC TCAACA CAACAA AACAAC ACAACA CAACAC AACACA ACACAG CACAGT ACAGTT CAGTTT AGTTTA GTTTAT TTTATG TTATGA TATGAT ATGATC TGATCC GATCCT ATCCTT TCCTTT CCTTTG CTTTGC TTTGCA TTGCAA TGCAAC GCAACC CAACCT AACCTG ACCTGA CCTGAA CTGAAT TGAATT GAATTA AATTAG ATTAGA TTAGAT TAGATT AGATTC GATTCA ATTCAT TTCATT TCATTC CATTCA ATTCAA TTCAAG TCAAGG CAAGGA AAGGAG AGGAGG GGAGGA GAGGAG AGGAGT GGAGTT GAGTTA AGTTAG GTTAGA TTAGAT TAGATA AGATAA GATAAA ATAAAT TAAATA AAATAT AATATT ATATTT TATTTT ATTTTA TTTTAA TTTAAG TTAAGA TAAGAA AAGAAT AGAATC GAATCA AATCAT ATCATA TCATAC CATACA ATACAT TACATC ACATCA CATCAC ATCACC TCACCA CACCAG ACCAGA CCAGAT CAGATG AGATGT GATGTT ATGTTG TGTTGA GTTGAT TTGATT TGATTT GATTTA ATTTAG TTTAGG TTAGGT TAGGTG AGGTGA GGTGAC GTGACA TGACAT GACATC ACATCT CATCTC ATCTCT TCTCTG CTCTGG TCTGGC CTGGCA TGGCAT GGCATT GCATTA CATTAA ATTAAT TTAATG TAATGC AATGCT ATGCTT TGCTTC GCTTCA CTTCAG TTCAGT TCAGTT CAGTTG AGTTGT GTTGTA,GTTGTAA TTGTAAT TGTAATA GTAATAG TAATAGG AATAGGA ATAGGAA TAGGAAT AGGAATT GGAATTG GAATTGT AATTGTC ATTGTCA TTGTCAA TGTCAAC GTCAACA TCAACAA CAACAAC AACAACA ACAACAC CAACACA AACACAG ACACAGT CACAGTT ACAGTTT CAGTTTA AGTTTAT GTTTATG TTTATGA TTATGAT TATGATC ATGATCC TGATCCT GATCCTT ATCCTTT TCCTTTG CCTTTGC CTTTGCA TTTGCAA TTGCAAC TGCAACC GCAACCT CAACCTG AACCTGA ACCTGAA CCTGAAT CTGAATT TGAATTA GAATTAG AATTAGA ATTAGAT TTAGATT TAGATTC AGATTCA GATTCAT ATTCATT TTCATTC TCATTCA CATTCAA ATTCAAG TTCAAGG TCAAGGA CAAGGAG AAGGAGG AGGAGGA GGAGGAG GAGGAGT AGGAGTT GGAGTTA GAGTTAG AGTTAGA GTTAGAT TTAGATA TAGATAA AGATAAA GATAAAT ATAAATA TAAATAT AAATATT AATATTT ATATTTT TATTTTA ATTTTAA TTTTAAG TTTAAGA TTAAGAA TAAGAAT AAGAATC AGAATCA GAATCAT AATCATA ATCATAC TCATACA CATACAT ATACATC TACATCA ACATCAC CATCACC ATCACCA TCACCAG CACCAGA ACCAGAT CCAGATG CAGATGT AGATGTT GATGTTG ATGTTGA TGTTGAT GTTGATT TTGATTT TGATTTA GATTTAG ATTTAGG TTTAGGT TTAGGTG TAGGTGA AGGTGAC GGTGACA GTGACAT TGACATC GACATCT ACATCTC CATCTCT ATCTCTG TCTCTGG CTCTGGC TCTGGCA CTGGCAT TGGCATT GGCATTA GCATTAA CATTAAT ATTAATG TTAATGC TAATGCT AATGCTT ATGCTTC TGCTTCA GCTTCAG CTTCAGT TTCAGTT TCAGTTG CAGTTGT AGTTGTA,"ID   SPIKE_SARS2             Reviewed;        1273 AA.
AC   P0DTC2;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Spike glycoprotein {ECO:0000255|HAMAP-Rule:MF_04099};
DE            Short=S glycoprotein {ECO:0000255|HAMAP-Rule:MF_04099};
DE   AltName: Full=E2 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   AltName: Full=Peplomer protein {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S1 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S2 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S2' {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Flags: Precursor;
GN   Name=S {ECO:0000255|HAMAP-Rule:MF_04099}; ORFNames=2;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   FUNCTION (SPIKE PROTEIN S1), AND CLEAVAGE BETWEEN S2 AND S2' BY HOST
RP   TMPRSS2.
RX   PubMed=32142651; DOI=10.1016/j.cell.2020.02.052;
RA   Hoffmann M., Kleine-Weber H., Schroeder S., Krueger N., Herrler T.,
RA   Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A.,
RA   Mueller M.A., Drosten C., Poehlmann S.;
RT   ""SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a
RT   clinically proven protease inhibitor."";
RL   Cell 181:1-10(2020).
RN   [3]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, FUNCTION, AND MUTAGENESIS OF
RP   681-PRO--ALA-684.
RX   PubMed=32362314; DOI=10.1016/j.molcel.2020.04.022;
RA   Hoffmann M., Kleine-Weber H., Poehlmann S.;
RT   ""A multibasic cleavage site in the Spike protein of SARS-CoV-2 is essential
RT   for infection of human lung cells."";
RL   Mol. Cell 78:779-784(2020).
RN   [4]
RP   GLYCOSYLATION AT ASN-17; ASN-61; ASN-74; ASN-122; ASN-149; ASN-165;
RP   ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098; ASN-1134; ASN-1158; ASN-1173 AND
RP   ASN-1194, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=32366695; DOI=10.1126/science.abb9983;
RA   Watanabe Y., Allen J.D., Wrapp D., McLellan J.S., Crispin M.;
RT   ""Site-specific glycan analysis of the SARS-CoV-2 spike."";
RL   Science 369:330-333(2020).
RN   [5]
RP   GLYCOSYLATION AT ASN-61; ASN-74; ASN-122; ASN-149; ASN-165; ASN-234;
RP   ASN-282; THR-323; SER-325; ASN-331; ASN-343; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098 AND ASN-1194, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=32363391; DOI=10.1093/glycob/cwaa042;
RA   Shajahan A., Supekar N.T., Gleinich A.S., Azadi P.;
RT   ""Deducing the N- and O- glycosylation profile of the spike protein of novel
RT   coronavirus SARS-CoV-2."";
RL   Glycobiology 30:981-988(2020).
RN   [6]
RP   VARIANT GLY-614.
RX   PubMed=32820179; DOI=10.1038/s41598-020-70827-z;
RA   Isabel S., Grana-Miraglia L., Gutierrez J.M., Bundalovic-Torma C.,
RA   Groves H.E., Isabel M.R., Eshaghi A., Patel S.N., Gubbay J.B., Poutanen T.,
RA   Guttman D.S., Poutanen S.M.;
RT   ""Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein
RT   mutation now documented worldwide."";
RL   Sci. Rep. 10:14031-14031(2020).
RN   [7]
RP   VARIANT GLY-614, AND MUTAGENESIS OF ASP-614.
RX   PubMed=32697968; DOI=10.1016/j.cell.2020.06.043;
RG   Sheffield COVID-19 Genomics Group;
RA   Korber B., Fischer W.M., Gnanakaran S., Yoon H., Theiler J., Abfalterer W.,
RA   Hengartner N., Giorgi E.E., Bhattacharya T., Foley B., Hastie K.M.,
RA   Parker M.D., Partridge D.G., Evans C.M., Freeman T.M., de Silva T.I.,
RA   McDanal C., Perez L.G., Tang H., Moon-Walker A., Whelan S.P.,
RA   LaBranche C.C., Saphire E.O., Montefiori D.C.;
RT   ""Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases
RT   Infectivity of the COVID-19 Virus."";
RL   Cell 182:812-827(2020).
RN   [8]
RP   FUNCTION.
RX   PubMed=32817270; DOI=10.1126/science.abd5223;
RA   Turonova B., Sikora M., Schuermann C., Hagen W.J.H., Welsch S.,
RA   Blanc F.E.C., von Buelow S., Gecht M., Bagola K., Hoerner C.,
RA   van Zandbergen G., Landry J., de Azevedo N.T.D., Mosalaganti S.,
RA   Schwarz A., Covino R., Muehlebach M.D., Hummer G., Krijnse Locker J.,
RA   Beck M.;
RT   ""In situ structural analysis of SARS-CoV-2 spike reveals flexibility
RT   mediated by three hinges."";
RL   Science 370:203-208(2020).
RN   [9]
RP   GLYCOSYLATION.
RX   PubMed=32929138; DOI=10.1038/s41598-020-71748-7;
RA   Grant O.C., Montgomery D., Ito K., Woods R.J.;
RT   ""Analysis of the SARS-CoV-2 spike protein glycan shield reveals
RT   implications for immune recognition."";
RL   Sci. Rep. 10:14991-14991(2020).
RN   [10]
RP   GLYCOSYLATION AT ASN-17; ASN-61; ASN-74; ASN-122; ASN-149; ASN-165;
RP   ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098; ASN-1134; ASN-1158; ASN-1173 AND
RP   ASN-1194, IDENTIFICATION BY MASS SPECTROMETRY, SUBCELLULAR LOCATION, AND
RP   SUBUNIT.
RX   PubMed=32979942; DOI=10.1016/j.cell.2020.09.018;
RA   Yao H., Song Y., Chen Y., Wu N., Xu J., Sun C., Zhang J., Weng T.,
RA   Zhang Z., Wu Z., Cheng L., Shi D., Lu X., Lei J., Crispin M., Shi Y.,
RA   Li L., Li S.;
RT   ""Molecular Architecture of the SARS-CoV-2 Virus."";
RL   Cell 183:730-738(2020).
RN   [11]
RP   VARIANT GLY-614, AND MUTAGENESIS OF ASP-614.
RX   PubMed=33106671; DOI=10.1038/s41586-020-2895-3;
RA   Plante J.A., Liu Y., Liu J., Xia H., Johnson B.A., Lokugamage K.G.,
RA   Zhang X., Muruato A.E., Zou J., Fontes-Garfias C.R., Mirchandani D.,
RA   Scharton D., Bilello J.P., Ku Z., An Z., Kalveram B., Freiberg A.N.,
RA   Menachery V.D., Xie X., Plante K.S., Weaver S.C., Shi P.Y.;
RT   ""Spike mutation D614G alters SARS-CoV-2 fitness."";
RL   Nature 592:116-121(2020).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH HUMAN NRP1 AND NRP2.
RC   STRAIN=SARS-CoV-2/human/Liverpool/REMRQ001/2020;
RX   PubMed=33082294; DOI=10.1126/science.abd3072;
RA   Daly J.L., Simonetti B., Klein K., Chen K.E., Williamson M.K.,
RA   Anton-Plagaro C., Shoemark D.K., Simon-Gracia L., Bauer M., Hollandi R.,
RA   Greber U.F., Horvath P., Sessions R.B., Helenius A., Hiscox J.A.,
RA   Teesalu T., Matthews D.A., Davidson A.D., Collins B.M., Cullen P.J.,
RA   Yamauchi Y.;
RT   ""Neuropilin-1 is a host factor for SARS-CoV-2 infection."";
RL   Science 370:861-865(2020).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH HUMAN NRP1 AND NRP2.
RC   STRAIN=SARS-CoV-2/human/Finland/1/2020;
RX   PubMed=33082293; DOI=10.1126/science.abd2985;
RA   Cantuti-Castelvetri L., Ojha R., Pedro L.D., Djannatian M., Franz J.,
RA   Kuivanen S., van der Meer F., Kallio K., Kaya T., Anastasina M., Smura T.,
RA   Levanov L., Szirovicza L., Tobi A., Kallio-Kokko H., Oesterlund P.,
RA   Joensuu M., Meunier F.A., Butcher S.J., Winkler M.S., Mollenhauer B.,
RA   Helenius A., Gokce O., Teesalu T., Hepojoki J., Vapalahti O.,
RA   Stadelmann C., Balistreri G., Simons M.;
RT   ""Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity."";
RL   Science 370:856-860(2020).
RN   [14]
RP   INTERACTION WITH HUMAN ITGA5 AND ITGB1.
RX   PubMed=33102950; DOI=10.1016/j.jacbts.2020.10.003;
RA   Beddingfield B.J., Iwanaga N., Chapagain P.P., Zheng W., Roy C.J., Hu T.Y.,
RA   Kolls J.K., Bix G.J.;
RT   ""The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2
RT   Infection."";
RL   JACC Basic Transl. Sci. 6:1-8(2021).
RN   [15]
RP   VARIANT GLY-614.
RX   PubMed=33184236; DOI=10.1126/science.abe8499;
RA   Hou Y.J., Chiba S., Halfmann P., Ehre C., Kuroda M., Dinnon K.H. III,
RA   Leist S.R., Schaefer A., Nakajima N., Takahashi K., Lee R.E.,
RA   Mascenik T.M., Graham R., Edwards C.E., Tse L.V., Okuda K., Markmann A.J.,
RA   Bartelt L., de Silva A., Margolis D.M., Boucher R.C., Randell S.H.,
RA   Suzuki T., Gralinski L.E., Kawaoka Y., Baric R.S.;
RT   ""SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and
RT   transmission in vivo."";
RL   Science 370:1464-1468(2020).
RN   [16]
RP   VARIANT GLY-614.
RX   PubMed=33417835; DOI=10.1016/j.celrep.2020.108630;
RA   Gobeil S.M., Janowska K., McDowell S., Mansouri K., Parks R., Manne K.,
RA   Stalls V., Kopp M.F., Henderson R., Edwards R.J., Haynes B.F., Acharya P.;
RT   ""D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease
RT   Cleavage at the S1/S2 Junction."";
RL   Cell Rep. 34:108630-108630(2021).
RN   [17]
RP   VARIANTS 69-VAL--PHE-70 DEL; LYS-144 DEL; TYR-501; ASP-570; GLY-614;
RP   HIS-681; ILE-716; ALA-982 AND HIS-1118.
RC   STRAIN=20I/501Y.V1, Alpha, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [18]
RP   VARIANT TYR-501.
RX   PubMed=32732280; DOI=10.1126/science.abc4730;
RA   Gu H., Chen Q., Yang G., He L., Fan H., Deng Y.Q., Wang Y., Teng Y.,
RA   Zhao Z., Cui Y., Li Y., Li X.F., Li J., Zhang N.N., Yang X., Chen S.,
RA   Guo Y., Zhao G., Wang X., Luo D.Y., Wang H., Yang X., Li Y., Han G., He Y.,
RA   Zhou X., Geng S., Sheng X., Jiang S., Sun S., Qin C.F., Zhou Y.;
RT   ""Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy."";
RL   Science 369:1603-1607(2020).
RN   [19]
RP   VARIANT GLY-614, AND MUTAGENESIS OF GLY-614.
RX   PubMed=33636719; DOI=10.1038/s41586-021-03361-1;
RA   Zhou B., Thi Nhu Thao T., Hoffmann D., Taddeo A., Ebert N., Labroussaa F.,
RA   Pohlmann A., King J., Steiner S., Kelly J.N., Portmann J., Halwe N.J.,
RA   Ulrich L., Trueeb B.S., Fan X., Hoffmann B., Wang L., Thomann L., Lin X.,
RA   Stalder H., Pozzi B., de Brot S., Jiang N., Cui D., Hossain J., Wilson M.,
RA   Keller M., Stark T.J., Barnes J.R., Dijkman R., Jores J., Benarafa C.,
RA   Wentworth D.E., Thiel V., Beer M.;
RT   ""SARS-CoV-2 spike D614G change enhances replication and transmission."";
RL   Nature 5920:122-127(2021).
RN   [20]
RP   MUTAGENESIS OF ASN-165; ASN-234; ASN-331; ASN-343; LEU-452; ALA-475;
RP   VAL-483; PHE-490 AND HIS-519.
RX   PubMed=32730807; DOI=10.1016/j.cell.2020.07.012;
RA   Li Q., Wu J., Nie J., Zhang L., Hao H., Liu S., Zhao C., Zhang Q., Liu H.,
RA   Nie L., Qin H., Wang M., Lu Q., Li X., Sun Q., Liu J., Zhang L., Li X.,
RA   Huang W., Wang Y.;
RT   ""The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and
RT   Antigenicity."";
RL   Cell 182:1284-1294(2020).
RN   [21]
RP   FUNCTION, CLEAVAGE BETWEEN S1 AND S2 BY HOST CTSL, AND INTERACTION WITH
RP   HUMAN ACE2.
RX   PubMed=32221306; DOI=10.1038/s41467-020-15562-9;
RA   Ou X., Liu Y., Lei X., Li P., Mi D., Ren L., Guo L., Guo R., Chen T.,
RA   Hu J., Xiang Z., Mu Z., Chen X., Chen J., Hu K., Jin Q., Wang J., Qian Z.;
RT   ""Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and
RT   its immune cross-reactivity with SARS-CoV."";
RL   Nat. Commun. 11:1620-1620(2020).
RN   [22]
RP   INTERACTION WITH HUMAN ACE2.
RX   PubMed=33607086; DOI=10.1016/j.bpj.2021.02.007;
RA   Cao W., Dong C., Kim S., Hou D., Tai W., Du L., Im W., Zhang X.F.;
RT   ""Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2
RT   protein-protein interaction."";
RL   Biophys. J. 120:1011-1019(2021).
RN   [23]
RP   FUNCTION, AND CLEAVAGE BETWEEN S1 AND S2 BY HOST TMPRSS2.
RX   PubMed=33465165; DOI=10.1371/journal.ppat.1009212;
RA   Ou T., Mou H., Zhang L., Ojha A., Choe H., Farzan M.;
RT   ""Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated
RT   by TMPRSS2."";
RL   PLoS Pathog. 17:e1009212-e1009212(2021).
RN   [24]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH S PROTEIN.
RX   PubMed=33229438; DOI=10.1074/jbc.ra120.016175;
RA   Boson B., Legros V., Zhou B., Siret E., Mathieu C., Cosset F.L.,
RA   Lavillette D., Denolly S.;
RT   ""The SARS-CoV-2 Envelope and Membrane proteins modulate maturation and
RT   retention of the Spike protein, allowing assembly of virus-like
RT   particles."";
RL   J. Biol. Chem. 296:100111-100111(2020).
RN   [25]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, CLEAVAGE BETWEEN S2 AND S2' BY
RP   HOST TMPRSS2, MUTAGENESIS OF ALA-684, AND FUNCTION (SPIKE PROTEIN S2').
RX   PubMed=32703818; DOI=10.26508/lsa.202000786;
RA   Bestle D., Heindl M.R., Limburg H., Van Lam van T., Pilgram O., Moulton H.,
RA   Stein D.A., Hardes K., Eickmann M., Dolnik O., Rohde C., Klenk H.D.,
RA   Garten W., Steinmetzer T., Boettcher-Friebertshaeuser E.;
RT   ""TMPRSS2 and furin are both essential for proteolytic activation of SARS-
RT   CoV-2 in human airway cells."";
RL   Life. Sci Alliance 3:1-14(2020).
RN   [26]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, CLEAVAGE BETWEEN S2 AND S2' BY
RP   HOST TMPRSS2, CLEAVAGE BETWEEN S2 AND S2' BY HOST CSTL, AND FUNCTION (SPIKE
RP   PROTEIN S2').
RX   PubMed=34159616; DOI=10.15252/embj.2021107821;
RA   Koch J., Uckeley Z.M., Doldan P., Stanifer M., Boulant S., Lozach P.Y.;
RT   ""TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect
RT   host cells."";
RL   EMBO J. 40:1-20(2021).
RN   [27]
RP   VARIANTS PHE-18; ALA-80; GLY-215; ASN-417; LYS-484; TYR-501; GLY-614 AND
RP   VAL-701.
RC   STRAIN=20H/501Y.V2, B.1.351, and Beta;
RX   PubMed=33690265; DOI=10.1038/s41586-021-03402-9;
RA   Tegally H., Wilkinson E., Giovanetti M., Iranzadeh A., Fonseca V.,
RA   Giandhari J., Doolabh D., Pillay S., San E.J., Msomi N., Mlisana K.,
RA   von Gottberg A., Walaza S., Allam M., Ismail A., Mohale T., Glass A.J.,
RA   Engelbrecht S., Van Zyl G., Preiser W., Petruccione F., Sigal A.,
RA   Hardie D., Marais G., Hsiao M., Korsman S., Davies M.A., Tyers L.,
RA   Mudau I., York D., Maslo C., Goedhals D., Abrahams S., Laguda-Akingba O.,
RA   Alisoltani-Dehkordi A., Godzik A., Wibmer C.K., Sewell B.T., Lourenco J.,
RA   Alcantara L.C.J., Kosakovsky Pond S.L., Weaver S., Martin D.,
RA   Lessells R.J., Bhiman J.N., Williamson C., de Oliveira T.;
RT   ""Emergence of a SARS-CoV-2 variant of concern with mutations in spike
RT   glycoprotein."";
RL   Nature 592:438-443(2021).
RN   [28]
RP   POLYMORPHISM.
RX   PubMed=34142653; DOI=10.2807/1560-7917.es.2021.26.24.2100509;
RA   Campbell F., Archer B., Laurenson-Schafer H., Jinnai Y., Konings F.,
RA   Batra N., Pavlin B., Vandemaele K., Van Kerkhove M.D., Jombart T.,
RA   Morgan O., le Polain de Waroux O.;
RT   ""Increased transmissibility and global spread of SARS-CoV-2 variants of
RT   concern as at June 2021."";
RL   Eurosurveillance 26:0-0(2021).
RN   [29]
RP   VARIANTS ARG-452 AND PHE-453, AND MUTAGENESIS OF LEU-452; TYR-453 AND
RP   ASN-501.
RX   PubMed=34171266; DOI=10.1016/j.chom.2021.06.006;
RG   Genotype to Phenotype Japan (G2P-Japan) Consortium;
RA   Motozono C., Toyoda M., Zahradnik J., Saito A., Nasser H., Tan T.S.,
RA   Ngare I., Kimura I., Uriu K., Kosugi Y., Yue Y., Shimizu R., Ito J.,
RA   Torii S., Yonekawa A., Shimono N., Nagasaki Y., Minami R., Toya T.,
RA   Sekiya N., Fukuhara T., Matsuura Y., Schreiber G., Ikeda T., Nakagawa S.,
RA   Ueno T., Sato K.;
RT   ""SARS-CoV-2 spike L452R variant evades cellular immunity and increases
RT   infectivity."";
RL   Cell Host Microbe 0:0-0(2021).
RN   [30]
RP   VARIANT 69-VAL--PHE-70 DEL, AND MUTAGENESIS OF 69-HIS-VAL-70.
RX   PubMed=34166617; DOI=10.1016/j.celrep.2021.109292;
RG   COVID-19 Genomics UK (COG-UK) Consortium;
RA   Meng B., Kemp S.A., Papa G., Datir R., Ferreira I.A.T.M., Marelli S.,
RA   Harvey W.T., Lytras S., Mohamed A., Gallo G., Thakur N., Collier D.A.,
RA   Mlcochova P., Duncan L.M., Carabelli A.M., Kenyon J.C., Lever A.M.,
RA   De Marco A., Saliba C., Culap K., Cameroni E., Matheson N.J., Piccoli L.,
RA   Corti D., James L.C., Robertson D.L., Bailey D., Gupta R.K.;
RT   ""Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in
RT   the Alpha variant B.1.1.7."";
RL   Cell Rep. 35:109292-109292(2021).
RN   [31]
RP   VARIANTS ILE-13 AND CYS-152, POLYMORPHISM, AND MASS SPECTROMETRY (SIGNAL).
RX   PubMed=34210893; DOI=10.1126/science.abi7994;
RA   McCallum M., Bassi J., De Marco A., Chen A., Walls A.C., Di Iulio J.,
RA   Tortorici M.A., Navarro M.J., Silacci-Fregni C., Saliba C., Sprouse K.R.,
RA   Agostini M., Pinto D., Culap K., Bianchi S., Jaconi S., Cameroni E.,
RA   Bowen J.E., Tilles S.W., Pizzuto M.S., Guastalla S.B., Bona G.,
RA   Pellanda A.F., Garzoni C., Van Voorhis W.C., Rosen L.E., Snell G.,
RA   Telenti A., Virgin H.W., Piccoli L., Corti D., Veesler D.;
RT   ""SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern."";
RL   Science 373:648-654(2021).
RN   [32]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-1269 AND HIS-1271.
RX   PubMed=34504087; DOI=10.1038/s41467-021-25589-1;
RA   Cattin-Ortola J., Welch L.G., Maslen S.L., Papa G., James L.C., Munro S.;
RT   ""Sequences in the cytoplasmic tail of SARS-CoV-2 Spike facilitate
RT   expression at the cell surface and syncytia formation."";
RL   Nat. Commun. 12:5333-5333(2021).
RN   [33]
RP   PALMITOYLATION AT CYS-1235; CYS-1236; CYS-1240; CYS-1241; CYS-1243;
RP   CYS-1247; CYS-1248; CYS-1250; CYS-1253 AND CYS-1254.
RX   PubMed=34599882; DOI=10.1016/j.devcel.2021.09.016;
RA   Mesquita F.S., Abrami L., Sergeeva O., Turelli P., Qing E., Kunz B.,
RA   Raclot C., Paz Montoya J., Abriata L.A., Gallagher T., Dal Peraro M.,
RA   Trono D., D'Angelo G., van der Goot F.G.;
RT   ""S-acylation controls SARS-CoV-2 membrane lipid organization and enhances
RT   infectivity."";
RL   Dev. Cell 56:1-18(2021).
RN   [34] {ECO:0007744|PDB:6M17}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.90 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), DOMAIN, AND INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN S1).
RX   PubMed=32132184; DOI=10.1126/science.abb2762;
RA   Yan R., Zhang Y., Li Y., Xia L., Guo Y., Zhou Q.;
RT   ""Structural basis for the recognition of the SARS-CoV-2 by full-length
RT   human ACE2."";
RL   Science 367:1444-1448(2020).
RN   [35]
RP   SUPERANTIGEN, AND DOMAIN.
RX   PubMed=32989130; DOI=10.1073/pnas.2010722117;
RA   Cheng M.H., Zhang S., Porritt R.A., Noval Rivas M., Paschold L.,
RA   Willscher E., Binder M., Arditi M., Bahar I.;
RT   ""Superantigenic character of an insert unique to SARS-CoV-2 spike supported
RT   by skewed TCR repertoire in patients with hyperinflammation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 117:25254-25262(2020).
RN   [36]
RP   INTERACTION WITH HUMAN BILIRUBIN, INTERACTION WITH HUMAN BILIVERDIN, AND
RP   MUTAGENESIS OF ASN-121 AND ARG-190.
RX   PubMed=33888467; DOI=10.1126/sciadv.abg7607;
RA   Rosa A., Pye V.E., Graham C., Muir L., Seow J., Ng K.W., Cook N.J.,
RA   Rees-Spear C., Parker E., Dos Santos M.S., Rosadas C., Susana A., Rhys H.,
RA   Nans A., Masino L., Roustan C., Christodoulou E., Ulferts R., Wrobel A.G.,
RA   Short C.E., Fertleman M., Sanders R.W., Heaney J., Spyer M., Kjaer S.,
RA   Riddell A., Malim M.H., Beale R., MacRae J.I., Taylor G.P., Nastouli E.,
RA   van Gils M.J., Rosenthal P.B., Pizzato M., McClure M.O., Tedder R.S.,
RA   Kassiotis G., McCoy L.E., Doores K.J., Cherepanov P.;
RT   ""SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity."";
RL   Sci. Adv. 7:0-0(2021).
RN   [37]
RP   BIOTECHNOLOGY, AND MUTAGENESIS OF 682-ARG--ARG-685 AND 986-LYS-VAL-987.
RX   PubMed=34322129; DOI=10.3389/fimmu.2021.701501;
RA   Martinez-Flores D., Zepeda-Cervantes J., Cruz-Resendiz A.,
RA   Aguirre-Sampieri S., Sampieri A., Vaca L.;
RT   ""SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of
RT   New Viral Variants."";
RL   Front. Immunol. 12:701501-701501(2021).
RN   [38]
RP   GLYCOSYLATION AT THR-676 AND THR-678 BY HOST GALNT1, AND MUTAGENESIS OF
RP   SER-673; THR-676; THR-678; SER-680 AND PRO-681.
RX   PubMed=34732583; DOI=10.1073/pnas.2109905118;
RA   Zhang L., Mann M., Syed Z.A., Reynolds H.M., Tian E., Samara N.L.,
RA   Zeldin D.C., Tabak L.A., Ten Hagen K.G.;
RT   ""Furin cleavage of the SARS-CoV-2 spike is modulated by O-glycosylation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [39]
RP   REVIEW, PROTEOLITIC PROCESSING, FUNCTION (SPIKE PROTEIN S2), AND FUNCTION
RP   (SPIKE PROTEIN S2').
RX   PubMed=34561887; DOI=10.1111/1348-0421.12945;
RA   Takeda M.;
RT   ""Proteolytic activation of SARS-CoV-2 spike protein."";
RL   Microbiol. Immunol. 66:15-23(2022).
RN   [40]
RP   INTERACTION WITH HOST MBL2.
RX   PubMed=35102342; DOI=10.1038/s41590-021-01114-w;
RA   Stravalaci M., Pagani I., Paraboschi E.M., Pedotti M., Doni A.,
RA   Scavello F., Mapelli S.N., Sironi M., Perucchini C., Varani L.,
RA   Matkovic M., Cavalli A., Cesana D., Gallina P., Pedemonte N., Capurro V.,
RA   Clementi N., Mancini N., Invernizzi P., Bayarri-Olmos R., Garred P.,
RA   Rappuoli R., Duga S., Bottazzi B., Uguccioni M., Asselta R., Vicenzi E.,
RA   Mantovani A., Garlanda C.;
RT   ""Recognition and inhibition of SARS-CoV-2 by humoral innate immunity
RT   pattern recognition molecules."";
RL   Nat. Immunol. 23:275-286(2022).
RN   [41]
RP   FUNCTION (SPIKE PROTEIN S1), AND INTERACTION WITH HOST INTEGRIN (SPIKE
RP   PROTEIN S1).
RX   PubMed=35150743; DOI=10.1016/j.jbc.2022.101710;
RA   Liu J., Lu F., Chen Y., Plow E., Qin J.;
RT   ""Integrin mediates cell entry of the SARS-CoV-2 virus independent of
RT   cellular receptor ACE2."";
RL   J. Biol. Chem. 1:101710-101710(2022).
RN   [42]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [43]
RP   SUBUNIT.
RX   PubMed=36735681; DOI=10.1371/journal.pbio.3001959;
RA   Shilts J., Crozier T.W.M., Teixeira-Silva A., Gabaev I., Gerber P.P.,
RA   Greenwood E.J.D., Watson S.J., Ortmann B.M., Gawden-Bone C.M., Pauzaite T.,
RA   Hoffmann M., Nathan J.A., Poehlmann S., Matheson N.J., Lehner P.J.,
RA   Wright G.J.;
RT   ""LRRC15 mediates an accessory interaction with the SARS-CoV-2 spike
RT   protein."";
RL   PLoS Biol. 21:e3001959-e3001959(2023).
RN   [44]
RP   VARIANT ASN-405.
RX   PubMed=36851546; DOI=10.3390/v15020332;
RA   Bugatti A., Filippini F., Messali S., Giovanetti M., Ravelli C., Zani A.,
RA   Ciccozzi M., Caruso A., Caccuri F.;
RT   ""The D405N Mutation in the Spike Protein of SARS-CoV-2 Omicron BA.5
RT   Inhibits Spike/Integrins Interaction and Viral Infection of Human Lung
RT   Microvascular Endothelial Cells."";
RL   Viruses 15:0-0(2023).
RN   [45]
RP   MUTAGENESIS OF GLU-484.
RX   PubMed=37421949; DOI=10.1016/j.cell.2023.06.005;
RA   Baggen J., Jacquemyn M., Persoons L., Vanstreels E., Pye V.E., Wrobel A.G.,
RA   Calvaresi V., Martin S.R., Roustan C., Cronin N.B., Reading E.,
RA   Thibaut H.J., Vercruysse T., Maes P., De Smet F., Yee A., Nivitchanyong T.,
RA   Roell M., Franco-Hernandez N., Rhinn H., Mamchak A.A., Ah Young-Chapon M.,
RA   Brown E., Cherepanov P., Daelemans D.;
RT   ""TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry."";
RL   Cell 186:1-16(2023).
RN   [46] {ECO:0007744|PDB:6VSB}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.46 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN S1), SUBUNIT, AND
RP   GLYCOSYLATION.
RX   PubMed=32075877; DOI=10.1126/science.abb2507;
RA   Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.L., Abiona O.,
RA   Graham B.S., McLellan J.S.;
RT   ""Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation."";
RL   Science 367:1260-1263(2020).
RN   [47] {ECO:0007744|PDB:6VXX, ECO:0007744|PDB:6VYB}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.80 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), SUBUNIT (SPIKE PROTEIN S1), INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN
RP   S1), MUTAGENESIS OF 679-GLN--ALA-684, GLYCOSYLATION AT ASN-61; ASN-122;
RP   ASN-61; ASN-165; ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616;
RP   ASN-657; ASN-709; ASN-717; ASN-801; ASN-1074; ASN-1098 AND ASN-1134, AND
RP   DISULFIDE BOND.
RX   PubMed=32155444; DOI=10.1016/j.cell.2020.02.058;
RA   Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., Veesler D.;
RT   ""Structure, function, and antigenicity of the SARS-CoV-2 spike
RT   glycoprotein."";
RL   Cell 180:1-12(2020).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HOST ACE2.
RX   PubMed=32225176; DOI=10.1038/s41586-020-2180-5;
RA   Lan J., Ge J., Yu J., Shan S., Zhou H., Fan S., Zhang Q., Shi X., Wang Q.,
RA   Zhang L., Wang X.;
RT   ""Structure of the SARS-CoV-2 spike receptor-binding domain bound to the
RT   ACE2 receptor."";
RL   Nature 581:215-220(2020).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.68 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HOST ACE2, INTERACTION WITH HOST ACE2, AND MUTAGENESIS OF GLN-493 AND
RP   ASN-501.
RX   PubMed=32225175; DOI=10.1038/s41586-020-2179-y;
RA   Shang J., Ye G., Shi K., Wan Y., Luo C., Aihara H., Geng Q., Auerbach A.,
RA   Li F.;
RT   ""Structural basis of receptor recognition by SARS-CoV-2."";
RL   Nature 581:221-224(2020).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (3.08 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HUMAN ANTIBODY CR3022, AND DISULFIDE BOND.
RX   PubMed=32245784; DOI=10.1126/science.abb7269;
RA   Yuan M., Wu N.C., Zhu X., Lee C.D., So R.T.Y., Lv H., Mok C.K.P.,
RA   Wilson I.A.;
RT   ""A highly conserved cryptic epitope in the receptor-binding domains of
RT   SARS-CoV-2 and SARS-CoV."";
RL   Science 368:630-633(2020).
CC   -!- FUNCTION: [Spike protein S1]: Attaches the virion to the cell membrane
CC       by interacting with host receptor, initiating the infection. The major
CC       receptor is host ACE2 (PubMed:32142651, PubMed:32155444,
CC       PubMed:33607086). When S2/S2' has been cleaved, binding to the receptor
CC       triggers direct fusion at the cell membrane (PubMed:34561887). When
CC       S2/S2' has not been cleaved, binding to the receptor results in
CC       internalization of the virus by endocytosis leading to fusion of the
CC       virion membrane with the host endosomal membrane (PubMed:32075877,
CC       PubMed:32221306). Alternatively, may use NRP1/NRP2 (PubMed:33082294,
CC       PubMed:33082293) and integrin as entry receptors (PubMed:35150743). The
CC       use of NRP1/NRP2 receptors may explain the tropism of the virus in
CC       human olfactory epithelial cells, which express these molecules at high
CC       levels but ACE2 at low levels (PubMed:33082293). The stalk domain of S
CC       contains three hinges, giving the head unexpected orientational freedom
CC       (PubMed:32817270). {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:32075877, ECO:0000269|PubMed:32142651,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32221306,
CC       ECO:0000269|PubMed:32817270, ECO:0000269|PubMed:33082293,
CC       ECO:0000269|PubMed:33082294, ECO:0000269|PubMed:35150743,
CC       ECO:0000303|PubMed:33082293, ECO:0000305|PubMed:34561887}.
CC   -!- FUNCTION: [Spike protein S2]: Precursor of the fusion protein processed
CC       in the biosynthesis of the S protein and the formation of virus
CC       particle. Mediates fusion of the virion and cellular membranes by
CC       functioning as a class I viral fusion protein. Contains two viral
CC       fusion peptides that are unmasked after cleavage. The S2/S2' cleavage
CC       occurs during virus entry at the cell membrane by host TMPRSS2
CC       (PubMed:32142651) or during endocytosis by host CSTL (PubMed:32703818,
CC       PubMed:34159616). In either case, this triggers an extensive and
CC       irreversible conformational change leading to fusion of the viral
CC       envelope with the cellular cytoplasmic membrane, releasing viral
CC       genomic RNA into the host cell cytoplasm (PubMed:34561887). Under the
CC       current model, the protein has at least three conformational states:
CC       pre-fusion native state, pre-hairpin intermediate state, and post-
CC       fusion hairpin state. During fusion of the viral and target cell
CC       membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-
CC       hairpins structure and position the fusion peptide in close proximity
CC       to the C-terminal region of the ectodomain. Formation of this structure
CC       appears to promote apposition and subsequent fusion of viral and target
CC       cell membranes. {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:32703818, ECO:0000269|PubMed:34159616,
CC       ECO:0000305|PubMed:34561887}.
CC   -!- FUNCTION: [Spike protein S2']: Subunit of the fusion protein that is
CC       processed upon entry into the host cell. Mediates fusion of the virion
CC       and cellular membranes by functioning as a class I viral fusion
CC       protein. Contains a viral fusion peptide that is unmasked after S2
CC       cleavage. This cleavage can occur at the cell membrane by host TMPRSS2
CC       or during endocytosis by host CSTL (PubMed:32703818, PubMed:34159616).
CC       In either case, this triggers an extensive and irreversible
CC       conformational change that leads to fusion of the viral envelope with
CC       the cellular cytoplasmic membrane, releasing viral genomic RNA into the
CC       host cell cytoplasm (PubMed:34561887). Under the current model, the
CC       protein has at least three conformational states: pre-fusion native
CC       state, pre-hairpin intermediate state, and post-fusion hairpin state.
CC       During fusion of the viral and target cell membranes, the coiled coil
CC       regions (heptad repeats) adopt a trimer-of-hairpins structure and
CC       position the fusion peptide in close proximity to the C-terminal region
CC       of the ectodomain. Formation of this structure appears to promote
CC       apposition and subsequent fusion of viral and target cell membranes.
CC       {ECO:0000255|HAMAP-Rule:MF_04099, ECO:0000269|PubMed:32703818,
CC       ECO:0000269|PubMed:34159616, ECO:0000305|PubMed:34561887}.
CC   -!- SUBUNIT: [Spike glycoprotein]: Homotrimer; each monomer consists of a
CC       S1 and a S2 subunit (PubMed:32075877, PubMed:32155444,
CC       PubMed:32245784). The resulting peplomers protrude from the virus
CC       surface as spikes (PubMed:32979942). Interacts with ORF3a protein and
CC       ORF7a protein (By similarity) (PubMed:32075877, PubMed:32155444,
CC       PubMed:32245784, PubMed:32979942). There are an average of 26 +/-15
CC       spike trimers at the surface of virion particles (PubMed:32979942).
CC       Binds to host MBL2 (PubMed:35102342). This binding occurs via glycans
CC       and inhibits viral infectivity. Inhibition is effective against alpha,
CC       beta, gamma, and delta variants (PubMed:35102342). {ECO:0000255|HAMAP-
CC       Rule:MF_04099, ECO:0000269|PubMed:32075877,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32245784,
CC       ECO:0000269|PubMed:32979942, ECO:0000269|PubMed:35102342}.
CC   -!- SUBUNIT: [Spike protein S1]: Binds to host ACE2 (PubMed:32075877,
CC       PubMed:32132184, PubMed:32155444, PubMed:32221306, PubMed:32225175,
CC       PubMed:32225176, PubMed:33607086). RBD also interacts with the N-linked
CC       glycan on 'Asn-90' of ACE2 (PubMed:33607086). Cleavage of S generates a
CC       polybasic C-terminal sequence on S1 that binds to host Neuropilin-1
CC       (NRP1) and Neuropilin-2 (NRP2) receptors (PubMed:33082293,
CC       PubMed:33082294). Interacts with host integrin alpha-5/beta-1
CC       (ITGA5:ITGB1) and with ACE2 in complex with integrin alpha-5/beta-1
CC       (ITGA5:ITGB1) (PubMed:33102950). May interact via cytoplasmic c-
CC       terminus with M protein (PubMed:33229438). May interact (via N-
CC       terminus) with host bilirubin and biliverdin, thereby preventing
CC       antibody binding to the SARS-CoV-2 spike NTD via an allosteric
CC       mechanism (PubMed:33888467). May interact with host LRRC15, thereby
CC       allowing attachment to host cells (PubMed:36735681).
CC       {ECO:0000269|PubMed:32075877, ECO:0000269|PubMed:32132184,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32221306,
CC       ECO:0000269|PubMed:32225",64380
GATAAG ATAAGC TAAGCT AAGCTG AGCTGA GCTGAT CTGATC TGATCA GATCAC ATCACA TCACAG CACAGG ACAGGC CAGGCA AGGCAG GGCAGA GCAGAC CAGACT AGACTT GACTTC ACTTCA CTTCAA TTCAAA TCAAAG CAAAGT AAAGTT AAGTTT AGTTTG GTTTGC TTTGCA TTGCAG TGCAGA GCAGAC CAGACA AGACAT GACATA ACATAT CATATG ATATGG TATGGG ATGGGA TGGGAC GGGACT GGACTC GACTCA ACTCAA CTCAAC TCAACA CAACAG AACAGT ACAGTT CAGTTA AGTTAA GTTAAT TTAATT TAATTA AATTAG ATTAGA TTAGAT TAGATC AGATCT GATCTG ATCTGC TCTGCA CTGCAA TGCAAA GCAAAA CAAAAA AAAAAG AAAAGC AAAGCA AAGCAG AGCAGA GCAGAA CAGAAC AGAACG GAACGT AACGTC ACGTCT CGTCTG GTCTGC TCTGCT CTGCTA TGCTAA GCTAAT CTAATC TAATCT AATCTG ATCTGG TCTGGC CTGGCT TGGCTG GGCTGC GCTGCG CTGCGA TGCGAC GCGACT CGACTA GACTAA ACTAAA CTAAAA TAAAAT AAAATG AAATGG AATGGC ATGGCA TGGCAG GGCAGA GCAGAA CAGAAT AGAATG GAATGT AATGTG ATGTGT TGTGTA GTGTAC TGTACT GTACTT TACTTT ACTTTG CTTTGG TTTGGC TTGGCA TGGCAA GGCAAT GCAATC CAATCA AATCAA ATCAAG TCAAGA CAAGAA AAGAAG AGAAGA GAAGAG AAGAGT AGAGTG GAGTGG AGTGGA GTGGAT TGGATT GGATTT GATTTT,1,142,GATA ATAA TAAG AAGC AGCT GCTG CTGA TGAT GATC ATCA TCAC CACA ACAG CAGG AGGC GGCA GCAG CAGA AGAC GACT ACTT CTTC TTCA TCAA CAAA AAAG AAGT AGTT GTTT TTTG TTGC TGCA GCAG CAGA AGAC GACA ACAT CATA ATAT TATG ATGG TGGG GGGA GGAC GACT ACTC CTCA TCAA CAAC AACA ACAG CAGT AGTT GTTA TTAA TAAT AATT ATTA TTAG TAGA AGAT GATC ATCT TCTG CTGC TGCA GCAA CAAA AAAA AAAA AAAG AAGC AGCA GCAG CAGA AGAA GAAC AACG ACGT CGTC GTCT TCTG CTGC TGCT GCTA CTAA TAAT AATC ATCT TCTG CTGG TGGC GGCT GCTG CTGC TGCG GCGA CGAC GACT ACTA CTAA TAAA AAAA AAAT AATG ATGG TGGC GGCA GCAG CAGA AGAA GAAT AATG ATGT TGTG GTGT TGTA GTAC TACT ACTT CTTT TTTG TTGG TGGC GGCA GCAA CAAT AATC ATCA TCAA CAAG AAGA AGAA GAAG AAGA AGAG GAGT AGTG GTGG TGGA GGAT GATT ATTT TTTT,GATAA ATAAG TAAGC AAGCT AGCTG GCTGA CTGAT TGATC GATCA ATCAC TCACA CACAG ACAGG CAGGC AGGCA GGCAG GCAGA CAGAC AGACT GACTT ACTTC CTTCA TTCAA TCAAA CAAAG AAAGT AAGTT AGTTT GTTTG TTTGC TTGCA TGCAG GCAGA CAGAC AGACA GACAT ACATA CATAT ATATG TATGG ATGGG TGGGA GGGAC GGACT GACTC ACTCA CTCAA TCAAC CAACA AACAG ACAGT CAGTT AGTTA GTTAA TTAAT TAATT AATTA ATTAG TTAGA TAGAT AGATC GATCT ATCTG TCTGC CTGCA TGCAA GCAAA CAAAA AAAAA AAAAG AAAGC AAGCA AGCAG GCAGA CAGAA AGAAC GAACG AACGT ACGTC CGTCT GTCTG TCTGC CTGCT TGCTA GCTAA CTAAT TAATC AATCT ATCTG TCTGG CTGGC TGGCT GGCTG GCTGC CTGCG TGCGA GCGAC CGACT GACTA ACTAA CTAAA TAAAA AAAAT AAATG AATGG ATGGC TGGCA GGCAG GCAGA CAGAA AGAAT GAATG AATGT ATGTG TGTGT GTGTA TGTAC GTACT TACTT ACTTT CTTTG TTTGG TTGGC TGGCA GGCAA GCAAT CAATC AATCA ATCAA TCAAG CAAGA AAGAA AGAAG GAAGA AAGAG AGAGT GAGTG AGTGG GTGGA TGGAT GGATT GATTT ATTTT,GATAAG ATAAGC TAAGCT AAGCTG AGCTGA GCTGAT CTGATC TGATCA GATCAC ATCACA TCACAG CACAGG ACAGGC CAGGCA AGGCAG GGCAGA GCAGAC CAGACT AGACTT GACTTC ACTTCA CTTCAA TTCAAA TCAAAG CAAAGT AAAGTT AAGTTT AGTTTG GTTTGC TTTGCA TTGCAG TGCAGA GCAGAC CAGACA AGACAT GACATA ACATAT CATATG ATATGG TATGGG ATGGGA TGGGAC GGGACT GGACTC GACTCA ACTCAA CTCAAC TCAACA CAACAG AACAGT ACAGTT CAGTTA AGTTAA GTTAAT TTAATT TAATTA AATTAG ATTAGA TTAGAT TAGATC AGATCT GATCTG ATCTGC TCTGCA CTGCAA TGCAAA GCAAAA CAAAAA AAAAAG AAAAGC AAAGCA AAGCAG AGCAGA GCAGAA CAGAAC AGAACG GAACGT AACGTC ACGTCT CGTCTG GTCTGC TCTGCT CTGCTA TGCTAA GCTAAT CTAATC TAATCT AATCTG ATCTGG TCTGGC CTGGCT TGGCTG GGCTGC GCTGCG CTGCGA TGCGAC GCGACT CGACTA GACTAA ACTAAA CTAAAA TAAAAT AAAATG AAATGG AATGGC ATGGCA TGGCAG GGCAGA GCAGAA CAGAAT AGAATG GAATGT AATGTG ATGTGT TGTGTA GTGTAC TGTACT GTACTT TACTTT ACTTTG CTTTGG TTTGGC TTGGCA TGGCAA GGCAAT GCAATC CAATCA AATCAA ATCAAG TCAAGA CAAGAA AAGAAG AGAAGA GAAGAG AAGAGT AGAGTG GAGTGG AGTGGA GTGGAT TGGATT GGATTT GATTTT,GATAAGC ATAAGCT TAAGCTG AAGCTGA AGCTGAT GCTGATC CTGATCA TGATCAC GATCACA ATCACAG TCACAGG CACAGGC ACAGGCA CAGGCAG AGGCAGA GGCAGAC GCAGACT CAGACTT AGACTTC GACTTCA ACTTCAA CTTCAAA TTCAAAG TCAAAGT CAAAGTT AAAGTTT AAGTTTG AGTTTGC GTTTGCA TTTGCAG TTGCAGA TGCAGAC GCAGACA CAGACAT AGACATA GACATAT ACATATG CATATGG ATATGGG TATGGGA ATGGGAC TGGGACT GGGACTC GGACTCA GACTCAA ACTCAAC CTCAACA TCAACAG CAACAGT AACAGTT ACAGTTA CAGTTAA AGTTAAT GTTAATT TTAATTA TAATTAG AATTAGA ATTAGAT TTAGATC TAGATCT AGATCTG GATCTGC ATCTGCA TCTGCAA CTGCAAA TGCAAAA GCAAAAA CAAAAAG AAAAAGC AAAAGCA AAAGCAG AAGCAGA AGCAGAA GCAGAAC CAGAACG AGAACGT GAACGTC AACGTCT ACGTCTG CGTCTGC GTCTGCT TCTGCTA CTGCTAA TGCTAAT GCTAATC CTAATCT TAATCTG AATCTGG ATCTGGC TCTGGCT CTGGCTG TGGCTGC GGCTGCG GCTGCGA CTGCGAC TGCGACT GCGACTA CGACTAA GACTAAA ACTAAAA CTAAAAT TAAAATG AAAATGG AAATGGC AATGGCA ATGGCAG TGGCAGA GGCAGAA GCAGAAT CAGAATG AGAATGT GAATGTG AATGTGT ATGTGTA TGTGTAC GTGTACT TGTACTT GTACTTT TACTTTG ACTTTGG CTTTGGC TTTGGCA TTGGCAA TGGCAAT GGCAATC GCAATCA CAATCAA AATCAAG ATCAAGA TCAAGAA CAAGAAG AAGAAGA AGAAGAG GAAGAGT AAGAGTG AGAGTGG GAGTGGA AGTGGAT GTGGATT TGGATTT GGATTTT,"ID   SPIKE_SARS2             Reviewed;        1273 AA.
AC   P0DTC2;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Spike glycoprotein {ECO:0000255|HAMAP-Rule:MF_04099};
DE            Short=S glycoprotein {ECO:0000255|HAMAP-Rule:MF_04099};
DE   AltName: Full=E2 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   AltName: Full=Peplomer protein {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S1 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S2 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S2' {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Flags: Precursor;
GN   Name=S {ECO:0000255|HAMAP-Rule:MF_04099}; ORFNames=2;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   FUNCTION (SPIKE PROTEIN S1), AND CLEAVAGE BETWEEN S2 AND S2' BY HOST
RP   TMPRSS2.
RX   PubMed=32142651; DOI=10.1016/j.cell.2020.02.052;
RA   Hoffmann M., Kleine-Weber H., Schroeder S., Krueger N., Herrler T.,
RA   Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A.,
RA   Mueller M.A., Drosten C., Poehlmann S.;
RT   ""SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a
RT   clinically proven protease inhibitor."";
RL   Cell 181:1-10(2020).
RN   [3]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, FUNCTION, AND MUTAGENESIS OF
RP   681-PRO--ALA-684.
RX   PubMed=32362314; DOI=10.1016/j.molcel.2020.04.022;
RA   Hoffmann M., Kleine-Weber H., Poehlmann S.;
RT   ""A multibasic cleavage site in the Spike protein of SARS-CoV-2 is essential
RT   for infection of human lung cells."";
RL   Mol. Cell 78:779-784(2020).
RN   [4]
RP   GLYCOSYLATION AT ASN-17; ASN-61; ASN-74; ASN-122; ASN-149; ASN-165;
RP   ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098; ASN-1134; ASN-1158; ASN-1173 AND
RP   ASN-1194, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=32366695; DOI=10.1126/science.abb9983;
RA   Watanabe Y., Allen J.D., Wrapp D., McLellan J.S., Crispin M.;
RT   ""Site-specific glycan analysis of the SARS-CoV-2 spike."";
RL   Science 369:330-333(2020).
RN   [5]
RP   GLYCOSYLATION AT ASN-61; ASN-74; ASN-122; ASN-149; ASN-165; ASN-234;
RP   ASN-282; THR-323; SER-325; ASN-331; ASN-343; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098 AND ASN-1194, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=32363391; DOI=10.1093/glycob/cwaa042;
RA   Shajahan A., Supekar N.T., Gleinich A.S., Azadi P.;
RT   ""Deducing the N- and O- glycosylation profile of the spike protein of novel
RT   coronavirus SARS-CoV-2."";
RL   Glycobiology 30:981-988(2020).
RN   [6]
RP   VARIANT GLY-614.
RX   PubMed=32820179; DOI=10.1038/s41598-020-70827-z;
RA   Isabel S., Grana-Miraglia L., Gutierrez J.M., Bundalovic-Torma C.,
RA   Groves H.E., Isabel M.R., Eshaghi A., Patel S.N., Gubbay J.B., Poutanen T.,
RA   Guttman D.S., Poutanen S.M.;
RT   ""Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein
RT   mutation now documented worldwide."";
RL   Sci. Rep. 10:14031-14031(2020).
RN   [7]
RP   VARIANT GLY-614, AND MUTAGENESIS OF ASP-614.
RX   PubMed=32697968; DOI=10.1016/j.cell.2020.06.043;
RG   Sheffield COVID-19 Genomics Group;
RA   Korber B., Fischer W.M., Gnanakaran S., Yoon H., Theiler J., Abfalterer W.,
RA   Hengartner N., Giorgi E.E., Bhattacharya T., Foley B., Hastie K.M.,
RA   Parker M.D., Partridge D.G., Evans C.M., Freeman T.M., de Silva T.I.,
RA   McDanal C., Perez L.G., Tang H., Moon-Walker A., Whelan S.P.,
RA   LaBranche C.C., Saphire E.O., Montefiori D.C.;
RT   ""Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases
RT   Infectivity of the COVID-19 Virus."";
RL   Cell 182:812-827(2020).
RN   [8]
RP   FUNCTION.
RX   PubMed=32817270; DOI=10.1126/science.abd5223;
RA   Turonova B., Sikora M., Schuermann C., Hagen W.J.H., Welsch S.,
RA   Blanc F.E.C., von Buelow S., Gecht M., Bagola K., Hoerner C.,
RA   van Zandbergen G., Landry J., de Azevedo N.T.D., Mosalaganti S.,
RA   Schwarz A., Covino R., Muehlebach M.D., Hummer G., Krijnse Locker J.,
RA   Beck M.;
RT   ""In situ structural analysis of SARS-CoV-2 spike reveals flexibility
RT   mediated by three hinges."";
RL   Science 370:203-208(2020).
RN   [9]
RP   GLYCOSYLATION.
RX   PubMed=32929138; DOI=10.1038/s41598-020-71748-7;
RA   Grant O.C., Montgomery D., Ito K., Woods R.J.;
RT   ""Analysis of the SARS-CoV-2 spike protein glycan shield reveals
RT   implications for immune recognition."";
RL   Sci. Rep. 10:14991-14991(2020).
RN   [10]
RP   GLYCOSYLATION AT ASN-17; ASN-61; ASN-74; ASN-122; ASN-149; ASN-165;
RP   ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098; ASN-1134; ASN-1158; ASN-1173 AND
RP   ASN-1194, IDENTIFICATION BY MASS SPECTROMETRY, SUBCELLULAR LOCATION, AND
RP   SUBUNIT.
RX   PubMed=32979942; DOI=10.1016/j.cell.2020.09.018;
RA   Yao H., Song Y., Chen Y., Wu N., Xu J., Sun C., Zhang J., Weng T.,
RA   Zhang Z., Wu Z., Cheng L., Shi D., Lu X., Lei J., Crispin M., Shi Y.,
RA   Li L., Li S.;
RT   ""Molecular Architecture of the SARS-CoV-2 Virus."";
RL   Cell 183:730-738(2020).
RN   [11]
RP   VARIANT GLY-614, AND MUTAGENESIS OF ASP-614.
RX   PubMed=33106671; DOI=10.1038/s41586-020-2895-3;
RA   Plante J.A., Liu Y., Liu J., Xia H., Johnson B.A., Lokugamage K.G.,
RA   Zhang X., Muruato A.E., Zou J., Fontes-Garfias C.R., Mirchandani D.,
RA   Scharton D., Bilello J.P., Ku Z., An Z., Kalveram B., Freiberg A.N.,
RA   Menachery V.D., Xie X., Plante K.S., Weaver S.C., Shi P.Y.;
RT   ""Spike mutation D614G alters SARS-CoV-2 fitness."";
RL   Nature 592:116-121(2020).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH HUMAN NRP1 AND NRP2.
RC   STRAIN=SARS-CoV-2/human/Liverpool/REMRQ001/2020;
RX   PubMed=33082294; DOI=10.1126/science.abd3072;
RA   Daly J.L., Simonetti B., Klein K., Chen K.E., Williamson M.K.,
RA   Anton-Plagaro C., Shoemark D.K., Simon-Gracia L., Bauer M., Hollandi R.,
RA   Greber U.F., Horvath P., Sessions R.B., Helenius A., Hiscox J.A.,
RA   Teesalu T., Matthews D.A., Davidson A.D., Collins B.M., Cullen P.J.,
RA   Yamauchi Y.;
RT   ""Neuropilin-1 is a host factor for SARS-CoV-2 infection."";
RL   Science 370:861-865(2020).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH HUMAN NRP1 AND NRP2.
RC   STRAIN=SARS-CoV-2/human/Finland/1/2020;
RX   PubMed=33082293; DOI=10.1126/science.abd2985;
RA   Cantuti-Castelvetri L., Ojha R., Pedro L.D., Djannatian M., Franz J.,
RA   Kuivanen S., van der Meer F., Kallio K., Kaya T., Anastasina M., Smura T.,
RA   Levanov L., Szirovicza L., Tobi A., Kallio-Kokko H., Oesterlund P.,
RA   Joensuu M., Meunier F.A., Butcher S.J., Winkler M.S., Mollenhauer B.,
RA   Helenius A., Gokce O., Teesalu T., Hepojoki J., Vapalahti O.,
RA   Stadelmann C., Balistreri G., Simons M.;
RT   ""Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity."";
RL   Science 370:856-860(2020).
RN   [14]
RP   INTERACTION WITH HUMAN ITGA5 AND ITGB1.
RX   PubMed=33102950; DOI=10.1016/j.jacbts.2020.10.003;
RA   Beddingfield B.J., Iwanaga N., Chapagain P.P., Zheng W., Roy C.J., Hu T.Y.,
RA   Kolls J.K., Bix G.J.;
RT   ""The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2
RT   Infection."";
RL   JACC Basic Transl. Sci. 6:1-8(2021).
RN   [15]
RP   VARIANT GLY-614.
RX   PubMed=33184236; DOI=10.1126/science.abe8499;
RA   Hou Y.J., Chiba S., Halfmann P., Ehre C., Kuroda M., Dinnon K.H. III,
RA   Leist S.R., Schaefer A., Nakajima N., Takahashi K., Lee R.E.,
RA   Mascenik T.M., Graham R., Edwards C.E., Tse L.V., Okuda K., Markmann A.J.,
RA   Bartelt L., de Silva A., Margolis D.M., Boucher R.C., Randell S.H.,
RA   Suzuki T., Gralinski L.E., Kawaoka Y., Baric R.S.;
RT   ""SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and
RT   transmission in vivo."";
RL   Science 370:1464-1468(2020).
RN   [16]
RP   VARIANT GLY-614.
RX   PubMed=33417835; DOI=10.1016/j.celrep.2020.108630;
RA   Gobeil S.M., Janowska K., McDowell S., Mansouri K., Parks R., Manne K.,
RA   Stalls V., Kopp M.F., Henderson R., Edwards R.J., Haynes B.F., Acharya P.;
RT   ""D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease
RT   Cleavage at the S1/S2 Junction."";
RL   Cell Rep. 34:108630-108630(2021).
RN   [17]
RP   VARIANTS 69-VAL--PHE-70 DEL; LYS-144 DEL; TYR-501; ASP-570; GLY-614;
RP   HIS-681; ILE-716; ALA-982 AND HIS-1118.
RC   STRAIN=20I/501Y.V1, Alpha, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [18]
RP   VARIANT TYR-501.
RX   PubMed=32732280; DOI=10.1126/science.abc4730;
RA   Gu H., Chen Q., Yang G., He L., Fan H., Deng Y.Q., Wang Y., Teng Y.,
RA   Zhao Z., Cui Y., Li Y., Li X.F., Li J., Zhang N.N., Yang X., Chen S.,
RA   Guo Y., Zhao G., Wang X., Luo D.Y., Wang H., Yang X., Li Y., Han G., He Y.,
RA   Zhou X., Geng S., Sheng X., Jiang S., Sun S., Qin C.F., Zhou Y.;
RT   ""Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy."";
RL   Science 369:1603-1607(2020).
RN   [19]
RP   VARIANT GLY-614, AND MUTAGENESIS OF GLY-614.
RX   PubMed=33636719; DOI=10.1038/s41586-021-03361-1;
RA   Zhou B., Thi Nhu Thao T., Hoffmann D., Taddeo A., Ebert N., Labroussaa F.,
RA   Pohlmann A., King J., Steiner S., Kelly J.N., Portmann J., Halwe N.J.,
RA   Ulrich L., Trueeb B.S., Fan X., Hoffmann B., Wang L., Thomann L., Lin X.,
RA   Stalder H., Pozzi B., de Brot S., Jiang N., Cui D., Hossain J., Wilson M.,
RA   Keller M., Stark T.J., Barnes J.R., Dijkman R., Jores J., Benarafa C.,
RA   Wentworth D.E., Thiel V., Beer M.;
RT   ""SARS-CoV-2 spike D614G change enhances replication and transmission."";
RL   Nature 5920:122-127(2021).
RN   [20]
RP   MUTAGENESIS OF ASN-165; ASN-234; ASN-331; ASN-343; LEU-452; ALA-475;
RP   VAL-483; PHE-490 AND HIS-519.
RX   PubMed=32730807; DOI=10.1016/j.cell.2020.07.012;
RA   Li Q., Wu J., Nie J., Zhang L., Hao H., Liu S., Zhao C., Zhang Q., Liu H.,
RA   Nie L., Qin H., Wang M., Lu Q., Li X., Sun Q., Liu J., Zhang L., Li X.,
RA   Huang W., Wang Y.;
RT   ""The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and
RT   Antigenicity."";
RL   Cell 182:1284-1294(2020).
RN   [21]
RP   FUNCTION, CLEAVAGE BETWEEN S1 AND S2 BY HOST CTSL, AND INTERACTION WITH
RP   HUMAN ACE2.
RX   PubMed=32221306; DOI=10.1038/s41467-020-15562-9;
RA   Ou X., Liu Y., Lei X., Li P., Mi D., Ren L., Guo L., Guo R., Chen T.,
RA   Hu J., Xiang Z., Mu Z., Chen X., Chen J., Hu K., Jin Q., Wang J., Qian Z.;
RT   ""Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and
RT   its immune cross-reactivity with SARS-CoV."";
RL   Nat. Commun. 11:1620-1620(2020).
RN   [22]
RP   INTERACTION WITH HUMAN ACE2.
RX   PubMed=33607086; DOI=10.1016/j.bpj.2021.02.007;
RA   Cao W., Dong C., Kim S., Hou D., Tai W., Du L., Im W., Zhang X.F.;
RT   ""Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2
RT   protein-protein interaction."";
RL   Biophys. J. 120:1011-1019(2021).
RN   [23]
RP   FUNCTION, AND CLEAVAGE BETWEEN S1 AND S2 BY HOST TMPRSS2.
RX   PubMed=33465165; DOI=10.1371/journal.ppat.1009212;
RA   Ou T., Mou H., Zhang L., Ojha A., Choe H., Farzan M.;
RT   ""Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated
RT   by TMPRSS2."";
RL   PLoS Pathog. 17:e1009212-e1009212(2021).
RN   [24]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH S PROTEIN.
RX   PubMed=33229438; DOI=10.1074/jbc.ra120.016175;
RA   Boson B., Legros V., Zhou B., Siret E., Mathieu C., Cosset F.L.,
RA   Lavillette D., Denolly S.;
RT   ""The SARS-CoV-2 Envelope and Membrane proteins modulate maturation and
RT   retention of the Spike protein, allowing assembly of virus-like
RT   particles."";
RL   J. Biol. Chem. 296:100111-100111(2020).
RN   [25]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, CLEAVAGE BETWEEN S2 AND S2' BY
RP   HOST TMPRSS2, MUTAGENESIS OF ALA-684, AND FUNCTION (SPIKE PROTEIN S2').
RX   PubMed=32703818; DOI=10.26508/lsa.202000786;
RA   Bestle D., Heindl M.R., Limburg H., Van Lam van T., Pilgram O., Moulton H.,
RA   Stein D.A., Hardes K., Eickmann M., Dolnik O., Rohde C., Klenk H.D.,
RA   Garten W., Steinmetzer T., Boettcher-Friebertshaeuser E.;
RT   ""TMPRSS2 and furin are both essential for proteolytic activation of SARS-
RT   CoV-2 in human airway cells."";
RL   Life. Sci Alliance 3:1-14(2020).
RN   [26]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, CLEAVAGE BETWEEN S2 AND S2' BY
RP   HOST TMPRSS2, CLEAVAGE BETWEEN S2 AND S2' BY HOST CSTL, AND FUNCTION (SPIKE
RP   PROTEIN S2').
RX   PubMed=34159616; DOI=10.15252/embj.2021107821;
RA   Koch J., Uckeley Z.M., Doldan P., Stanifer M., Boulant S., Lozach P.Y.;
RT   ""TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect
RT   host cells."";
RL   EMBO J. 40:1-20(2021).
RN   [27]
RP   VARIANTS PHE-18; ALA-80; GLY-215; ASN-417; LYS-484; TYR-501; GLY-614 AND
RP   VAL-701.
RC   STRAIN=20H/501Y.V2, B.1.351, and Beta;
RX   PubMed=33690265; DOI=10.1038/s41586-021-03402-9;
RA   Tegally H., Wilkinson E., Giovanetti M., Iranzadeh A., Fonseca V.,
RA   Giandhari J., Doolabh D., Pillay S., San E.J., Msomi N., Mlisana K.,
RA   von Gottberg A., Walaza S., Allam M., Ismail A., Mohale T., Glass A.J.,
RA   Engelbrecht S., Van Zyl G., Preiser W., Petruccione F., Sigal A.,
RA   Hardie D., Marais G., Hsiao M., Korsman S., Davies M.A., Tyers L.,
RA   Mudau I., York D., Maslo C., Goedhals D., Abrahams S., Laguda-Akingba O.,
RA   Alisoltani-Dehkordi A., Godzik A., Wibmer C.K., Sewell B.T., Lourenco J.,
RA   Alcantara L.C.J., Kosakovsky Pond S.L., Weaver S., Martin D.,
RA   Lessells R.J., Bhiman J.N., Williamson C., de Oliveira T.;
RT   ""Emergence of a SARS-CoV-2 variant of concern with mutations in spike
RT   glycoprotein."";
RL   Nature 592:438-443(2021).
RN   [28]
RP   POLYMORPHISM.
RX   PubMed=34142653; DOI=10.2807/1560-7917.es.2021.26.24.2100509;
RA   Campbell F., Archer B., Laurenson-Schafer H., Jinnai Y., Konings F.,
RA   Batra N., Pavlin B., Vandemaele K., Van Kerkhove M.D., Jombart T.,
RA   Morgan O., le Polain de Waroux O.;
RT   ""Increased transmissibility and global spread of SARS-CoV-2 variants of
RT   concern as at June 2021."";
RL   Eurosurveillance 26:0-0(2021).
RN   [29]
RP   VARIANTS ARG-452 AND PHE-453, AND MUTAGENESIS OF LEU-452; TYR-453 AND
RP   ASN-501.
RX   PubMed=34171266; DOI=10.1016/j.chom.2021.06.006;
RG   Genotype to Phenotype Japan (G2P-Japan) Consortium;
RA   Motozono C., Toyoda M., Zahradnik J., Saito A., Nasser H., Tan T.S.,
RA   Ngare I., Kimura I., Uriu K., Kosugi Y., Yue Y., Shimizu R., Ito J.,
RA   Torii S., Yonekawa A., Shimono N., Nagasaki Y., Minami R., Toya T.,
RA   Sekiya N., Fukuhara T., Matsuura Y., Schreiber G., Ikeda T., Nakagawa S.,
RA   Ueno T., Sato K.;
RT   ""SARS-CoV-2 spike L452R variant evades cellular immunity and increases
RT   infectivity."";
RL   Cell Host Microbe 0:0-0(2021).
RN   [30]
RP   VARIANT 69-VAL--PHE-70 DEL, AND MUTAGENESIS OF 69-HIS-VAL-70.
RX   PubMed=34166617; DOI=10.1016/j.celrep.2021.109292;
RG   COVID-19 Genomics UK (COG-UK) Consortium;
RA   Meng B., Kemp S.A., Papa G., Datir R., Ferreira I.A.T.M., Marelli S.,
RA   Harvey W.T., Lytras S., Mohamed A., Gallo G., Thakur N., Collier D.A.,
RA   Mlcochova P., Duncan L.M., Carabelli A.M., Kenyon J.C., Lever A.M.,
RA   De Marco A., Saliba C., Culap K., Cameroni E., Matheson N.J., Piccoli L.,
RA   Corti D., James L.C., Robertson D.L., Bailey D., Gupta R.K.;
RT   ""Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in
RT   the Alpha variant B.1.1.7."";
RL   Cell Rep. 35:109292-109292(2021).
RN   [31]
RP   VARIANTS ILE-13 AND CYS-152, POLYMORPHISM, AND MASS SPECTROMETRY (SIGNAL).
RX   PubMed=34210893; DOI=10.1126/science.abi7994;
RA   McCallum M., Bassi J., De Marco A., Chen A., Walls A.C., Di Iulio J.,
RA   Tortorici M.A., Navarro M.J., Silacci-Fregni C., Saliba C., Sprouse K.R.,
RA   Agostini M., Pinto D., Culap K., Bianchi S., Jaconi S., Cameroni E.,
RA   Bowen J.E., Tilles S.W., Pizzuto M.S., Guastalla S.B., Bona G.,
RA   Pellanda A.F., Garzoni C., Van Voorhis W.C., Rosen L.E., Snell G.,
RA   Telenti A., Virgin H.W., Piccoli L., Corti D., Veesler D.;
RT   ""SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern."";
RL   Science 373:648-654(2021).
RN   [32]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-1269 AND HIS-1271.
RX   PubMed=34504087; DOI=10.1038/s41467-021-25589-1;
RA   Cattin-Ortola J., Welch L.G., Maslen S.L., Papa G., James L.C., Munro S.;
RT   ""Sequences in the cytoplasmic tail of SARS-CoV-2 Spike facilitate
RT   expression at the cell surface and syncytia formation."";
RL   Nat. Commun. 12:5333-5333(2021).
RN   [33]
RP   PALMITOYLATION AT CYS-1235; CYS-1236; CYS-1240; CYS-1241; CYS-1243;
RP   CYS-1247; CYS-1248; CYS-1250; CYS-1253 AND CYS-1254.
RX   PubMed=34599882; DOI=10.1016/j.devcel.2021.09.016;
RA   Mesquita F.S., Abrami L., Sergeeva O., Turelli P., Qing E., Kunz B.,
RA   Raclot C., Paz Montoya J., Abriata L.A., Gallagher T., Dal Peraro M.,
RA   Trono D., D'Angelo G., van der Goot F.G.;
RT   ""S-acylation controls SARS-CoV-2 membrane lipid organization and enhances
RT   infectivity."";
RL   Dev. Cell 56:1-18(2021).
RN   [34] {ECO:0007744|PDB:6M17}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.90 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), DOMAIN, AND INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN S1).
RX   PubMed=32132184; DOI=10.1126/science.abb2762;
RA   Yan R., Zhang Y., Li Y., Xia L., Guo Y., Zhou Q.;
RT   ""Structural basis for the recognition of the SARS-CoV-2 by full-length
RT   human ACE2."";
RL   Science 367:1444-1448(2020).
RN   [35]
RP   SUPERANTIGEN, AND DOMAIN.
RX   PubMed=32989130; DOI=10.1073/pnas.2010722117;
RA   Cheng M.H., Zhang S., Porritt R.A., Noval Rivas M., Paschold L.,
RA   Willscher E., Binder M., Arditi M., Bahar I.;
RT   ""Superantigenic character of an insert unique to SARS-CoV-2 spike supported
RT   by skewed TCR repertoire in patients with hyperinflammation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 117:25254-25262(2020).
RN   [36]
RP   INTERACTION WITH HUMAN BILIRUBIN, INTERACTION WITH HUMAN BILIVERDIN, AND
RP   MUTAGENESIS OF ASN-121 AND ARG-190.
RX   PubMed=33888467; DOI=10.1126/sciadv.abg7607;
RA   Rosa A., Pye V.E., Graham C., Muir L., Seow J., Ng K.W., Cook N.J.,
RA   Rees-Spear C., Parker E., Dos Santos M.S., Rosadas C., Susana A., Rhys H.,
RA   Nans A., Masino L., Roustan C., Christodoulou E., Ulferts R., Wrobel A.G.,
RA   Short C.E., Fertleman M., Sanders R.W., Heaney J., Spyer M., Kjaer S.,
RA   Riddell A., Malim M.H., Beale R., MacRae J.I., Taylor G.P., Nastouli E.,
RA   van Gils M.J., Rosenthal P.B., Pizzato M., McClure M.O., Tedder R.S.,
RA   Kassiotis G., McCoy L.E., Doores K.J., Cherepanov P.;
RT   ""SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity."";
RL   Sci. Adv. 7:0-0(2021).
RN   [37]
RP   BIOTECHNOLOGY, AND MUTAGENESIS OF 682-ARG--ARG-685 AND 986-LYS-VAL-987.
RX   PubMed=34322129; DOI=10.3389/fimmu.2021.701501;
RA   Martinez-Flores D., Zepeda-Cervantes J., Cruz-Resendiz A.,
RA   Aguirre-Sampieri S., Sampieri A., Vaca L.;
RT   ""SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of
RT   New Viral Variants."";
RL   Front. Immunol. 12:701501-701501(2021).
RN   [38]
RP   GLYCOSYLATION AT THR-676 AND THR-678 BY HOST GALNT1, AND MUTAGENESIS OF
RP   SER-673; THR-676; THR-678; SER-680 AND PRO-681.
RX   PubMed=34732583; DOI=10.1073/pnas.2109905118;
RA   Zhang L., Mann M., Syed Z.A., Reynolds H.M., Tian E., Samara N.L.,
RA   Zeldin D.C., Tabak L.A., Ten Hagen K.G.;
RT   ""Furin cleavage of the SARS-CoV-2 spike is modulated by O-glycosylation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [39]
RP   REVIEW, PROTEOLITIC PROCESSING, FUNCTION (SPIKE PROTEIN S2), AND FUNCTION
RP   (SPIKE PROTEIN S2').
RX   PubMed=34561887; DOI=10.1111/1348-0421.12945;
RA   Takeda M.;
RT   ""Proteolytic activation of SARS-CoV-2 spike protein."";
RL   Microbiol. Immunol. 66:15-23(2022).
RN   [40]
RP   INTERACTION WITH HOST MBL2.
RX   PubMed=35102342; DOI=10.1038/s41590-021-01114-w;
RA   Stravalaci M., Pagani I., Paraboschi E.M., Pedotti M., Doni A.,
RA   Scavello F., Mapelli S.N., Sironi M., Perucchini C., Varani L.,
RA   Matkovic M., Cavalli A., Cesana D., Gallina P., Pedemonte N., Capurro V.,
RA   Clementi N., Mancini N., Invernizzi P., Bayarri-Olmos R., Garred P.,
RA   Rappuoli R., Duga S., Bottazzi B., Uguccioni M., Asselta R., Vicenzi E.,
RA   Mantovani A., Garlanda C.;
RT   ""Recognition and inhibition of SARS-CoV-2 by humoral innate immunity
RT   pattern recognition molecules."";
RL   Nat. Immunol. 23:275-286(2022).
RN   [41]
RP   FUNCTION (SPIKE PROTEIN S1), AND INTERACTION WITH HOST INTEGRIN (SPIKE
RP   PROTEIN S1).
RX   PubMed=35150743; DOI=10.1016/j.jbc.2022.101710;
RA   Liu J., Lu F., Chen Y., Plow E., Qin J.;
RT   ""Integrin mediates cell entry of the SARS-CoV-2 virus independent of
RT   cellular receptor ACE2."";
RL   J. Biol. Chem. 1:101710-101710(2022).
RN   [42]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [43]
RP   SUBUNIT.
RX   PubMed=36735681; DOI=10.1371/journal.pbio.3001959;
RA   Shilts J., Crozier T.W.M., Teixeira-Silva A., Gabaev I., Gerber P.P.,
RA   Greenwood E.J.D., Watson S.J., Ortmann B.M., Gawden-Bone C.M., Pauzaite T.,
RA   Hoffmann M., Nathan J.A., Poehlmann S., Matheson N.J., Lehner P.J.,
RA   Wright G.J.;
RT   ""LRRC15 mediates an accessory interaction with the SARS-CoV-2 spike
RT   protein."";
RL   PLoS Biol. 21:e3001959-e3001959(2023).
RN   [44]
RP   VARIANT ASN-405.
RX   PubMed=36851546; DOI=10.3390/v15020332;
RA   Bugatti A., Filippini F., Messali S., Giovanetti M., Ravelli C., Zani A.,
RA   Ciccozzi M., Caruso A., Caccuri F.;
RT   ""The D405N Mutation in the Spike Protein of SARS-CoV-2 Omicron BA.5
RT   Inhibits Spike/Integrins Interaction and Viral Infection of Human Lung
RT   Microvascular Endothelial Cells."";
RL   Viruses 15:0-0(2023).
RN   [45]
RP   MUTAGENESIS OF GLU-484.
RX   PubMed=37421949; DOI=10.1016/j.cell.2023.06.005;
RA   Baggen J., Jacquemyn M., Persoons L., Vanstreels E., Pye V.E., Wrobel A.G.,
RA   Calvaresi V., Martin S.R., Roustan C., Cronin N.B., Reading E.,
RA   Thibaut H.J., Vercruysse T., Maes P., De Smet F., Yee A., Nivitchanyong T.,
RA   Roell M., Franco-Hernandez N., Rhinn H., Mamchak A.A., Ah Young-Chapon M.,
RA   Brown E., Cherepanov P., Daelemans D.;
RT   ""TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry."";
RL   Cell 186:1-16(2023).
RN   [46] {ECO:0007744|PDB:6VSB}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.46 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN S1), SUBUNIT, AND
RP   GLYCOSYLATION.
RX   PubMed=32075877; DOI=10.1126/science.abb2507;
RA   Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.L., Abiona O.,
RA   Graham B.S., McLellan J.S.;
RT   ""Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation."";
RL   Science 367:1260-1263(2020).
RN   [47] {ECO:0007744|PDB:6VXX, ECO:0007744|PDB:6VYB}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.80 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), SUBUNIT (SPIKE PROTEIN S1), INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN
RP   S1), MUTAGENESIS OF 679-GLN--ALA-684, GLYCOSYLATION AT ASN-61; ASN-122;
RP   ASN-61; ASN-165; ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616;
RP   ASN-657; ASN-709; ASN-717; ASN-801; ASN-1074; ASN-1098 AND ASN-1134, AND
RP   DISULFIDE BOND.
RX   PubMed=32155444; DOI=10.1016/j.cell.2020.02.058;
RA   Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., Veesler D.;
RT   ""Structure, function, and antigenicity of the SARS-CoV-2 spike
RT   glycoprotein."";
RL   Cell 180:1-12(2020).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HOST ACE2.
RX   PubMed=32225176; DOI=10.1038/s41586-020-2180-5;
RA   Lan J., Ge J., Yu J., Shan S., Zhou H., Fan S., Zhang Q., Shi X., Wang Q.,
RA   Zhang L., Wang X.;
RT   ""Structure of the SARS-CoV-2 spike receptor-binding domain bound to the
RT   ACE2 receptor."";
RL   Nature 581:215-220(2020).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.68 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HOST ACE2, INTERACTION WITH HOST ACE2, AND MUTAGENESIS OF GLN-493 AND
RP   ASN-501.
RX   PubMed=32225175; DOI=10.1038/s41586-020-2179-y;
RA   Shang J., Ye G., Shi K., Wan Y., Luo C., Aihara H., Geng Q., Auerbach A.,
RA   Li F.;
RT   ""Structural basis of receptor recognition by SARS-CoV-2."";
RL   Nature 581:221-224(2020).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (3.08 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HUMAN ANTIBODY CR3022, AND DISULFIDE BOND.
RX   PubMed=32245784; DOI=10.1126/science.abb7269;
RA   Yuan M., Wu N.C., Zhu X., Lee C.D., So R.T.Y., Lv H., Mok C.K.P.,
RA   Wilson I.A.;
RT   ""A highly conserved cryptic epitope in the receptor-binding domains of
RT   SARS-CoV-2 and SARS-CoV."";
RL   Science 368:630-633(2020).
CC   -!- FUNCTION: [Spike protein S1]: Attaches the virion to the cell membrane
CC       by interacting with host receptor, initiating the infection. The major
CC       receptor is host ACE2 (PubMed:32142651, PubMed:32155444,
CC       PubMed:33607086). When S2/S2' has been cleaved, binding to the receptor
CC       triggers direct fusion at the cell membrane (PubMed:34561887). When
CC       S2/S2' has not been cleaved, binding to the receptor results in
CC       internalization of the virus by endocytosis leading to fusion of the
CC       virion membrane with the host endosomal membrane (PubMed:32075877,
CC       PubMed:32221306). Alternatively, may use NRP1/NRP2 (PubMed:33082294,
CC       PubMed:33082293) and integrin as entry receptors (PubMed:35150743). The
CC       use of NRP1/NRP2 receptors may explain the tropism of the virus in
CC       human olfactory epithelial cells, which express these molecules at high
CC       levels but ACE2 at low levels (PubMed:33082293). The stalk domain of S
CC       contains three hinges, giving the head unexpected orientational freedom
CC       (PubMed:32817270). {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:32075877, ECO:0000269|PubMed:32142651,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32221306,
CC       ECO:0000269|PubMed:32817270, ECO:0000269|PubMed:33082293,
CC       ECO:0000269|PubMed:33082294, ECO:0000269|PubMed:35150743,
CC       ECO:0000303|PubMed:33082293, ECO:0000305|PubMed:34561887}.
CC   -!- FUNCTION: [Spike protein S2]: Precursor of the fusion protein processed
CC       in the biosynthesis of the S protein and the formation of virus
CC       particle. Mediates fusion of the virion and cellular membranes by
CC       functioning as a class I viral fusion protein. Contains two viral
CC       fusion peptides that are unmasked after cleavage. The S2/S2' cleavage
CC       occurs during virus entry at the cell membrane by host TMPRSS2
CC       (PubMed:32142651) or during endocytosis by host CSTL (PubMed:32703818,
CC       PubMed:34159616). In either case, this triggers an extensive and
CC       irreversible conformational change leading to fusion of the viral
CC       envelope with the cellular cytoplasmic membrane, releasing viral
CC       genomic RNA into the host cell cytoplasm (PubMed:34561887). Under the
CC       current model, the protein has at least three conformational states:
CC       pre-fusion native state, pre-hairpin intermediate state, and post-
CC       fusion hairpin state. During fusion of the viral and target cell
CC       membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-
CC       hairpins structure and position the fusion peptide in close proximity
CC       to the C-terminal region of the ectodomain. Formation of this structure
CC       appears to promote apposition and subsequent fusion of viral and target
CC       cell membranes. {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:32703818, ECO:0000269|PubMed:34159616,
CC       ECO:0000305|PubMed:34561887}.
CC   -!- FUNCTION: [Spike protein S2']: Subunit of the fusion protein that is
CC       processed upon entry into the host cell. Mediates fusion of the virion
CC       and cellular membranes by functioning as a class I viral fusion
CC       protein. Contains a viral fusion peptide that is unmasked after S2
CC       cleavage. This cleavage can occur at the cell membrane by host TMPRSS2
CC       or during endocytosis by host CSTL (PubMed:32703818, PubMed:34159616).
CC       In either case, this triggers an extensive and irreversible
CC       conformational change that leads to fusion of the viral envelope with
CC       the cellular cytoplasmic membrane, releasing viral genomic RNA into the
CC       host cell cytoplasm (PubMed:34561887). Under the current model, the
CC       protein has at least three conformational states: pre-fusion native
CC       state, pre-hairpin intermediate state, and post-fusion hairpin state.
CC       During fusion of the viral and target cell membranes, the coiled coil
CC       regions (heptad repeats) adopt a trimer-of-hairpins structure and
CC       position the fusion peptide in close proximity to the C-terminal region
CC       of the ectodomain. Formation of this structure appears to promote
CC       apposition and subsequent fusion of viral and target cell membranes.
CC       {ECO:0000255|HAMAP-Rule:MF_04099, ECO:0000269|PubMed:32703818,
CC       ECO:0000269|PubMed:34159616, ECO:0000305|PubMed:34561887}.
CC   -!- SUBUNIT: [Spike glycoprotein]: Homotrimer; each monomer consists of a
CC       S1 and a S2 subunit (PubMed:32075877, PubMed:32155444,
CC       PubMed:32245784). The resulting peplomers protrude from the virus
CC       surface as spikes (PubMed:32979942). Interacts with ORF3a protein and
CC       ORF7a protein (By similarity) (PubMed:32075877, PubMed:32155444,
CC       PubMed:32245784, PubMed:32979942). There are an average of 26 +/-15
CC       spike trimers at the surface of virion particles (PubMed:32979942).
CC       Binds to host MBL2 (PubMed:35102342). This binding occurs via glycans
CC       and inhibits viral infectivity. Inhibition is effective against alpha,
CC       beta, gamma, and delta variants (PubMed:35102342). {ECO:0000255|HAMAP-
CC       Rule:MF_04099, ECO:0000269|PubMed:32075877,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32245784,
CC       ECO:0000269|PubMed:32979942, ECO:0000269|PubMed:35102342}.
CC   -!- SUBUNIT: [Spike protein S1]: Binds to host ACE2 (PubMed:32075877,
CC       PubMed:32132184, PubMed:32155444, PubMed:32221306, PubMed:32225175,
CC       PubMed:32225176, PubMed:33607086). RBD also interacts with the N-linked
CC       glycan on 'Asn-90' of ACE2 (PubMed:33607086). Cleavage of S generates a
CC       polybasic C-terminal sequence on S1 that binds to host Neuropilin-1
CC       (NRP1) and Neuropilin-2 (NRP2) receptors (PubMed:33082293,
CC       PubMed:33082294). Interacts with host integrin alpha-5/beta-1
CC       (ITGA5:ITGB1) and with ACE2 in complex with integrin alpha-5/beta-1
CC       (ITGA5:ITGB1) (PubMed:33102950). May interact via cytoplasmic c-
CC       terminus with M protein (PubMed:33229438). May interact (via N-
CC       terminus) with host bilirubin and biliverdin, thereby preventing
CC       antibody binding to the SARS-CoV-2 spike NTD via an allosteric
CC       mechanism (PubMed:33888467). May interact with host LRRC15, thereby
CC       allowing attachment to host cells (PubMed:36735681).
CC       {ECO:0000269|PubMed:32075877, ECO:0000269|PubMed:32132184,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32221306,
CC       ECO:0000269|PubMed:32225",47815
ATGGAC TGGACT GGACTT GACTTA ACTTAG CTTAGC TTAGCT TAGCTC AGCTCC GCTCCT CTCCTT TCCTTT CCTTTA CTTTAT TTTATT TTATTT TATTTG ATTTGA TTTGAT TTGATG TGATGG GATGGA ATGGAA TGGAAA GGAAAA GAAAAC AAAACC AAACCA AACCAT ACCATT CCATTT CATTTG ATTTGC TTTGCC TTGCCA TGCCAT GCCATT CCATTA CATTAT ATTATT TTATTG TATTGG ATTGGC TTGGCA TGGCAA GGCAAT GCAATT CAATTT AATTTT ATTTTC TTTTCC TTTCCT TTCCTT TCCTTA CCTTAT CTTATA TTATAA TATAAT ATAATA TAATAT AATATT ATATTT TATTTC ATTTCG TTTCGA TTCGAG TCGAGT CGAGTC GAGTCA AGTCAA GTCAAA TCAAAT CAAATT AAATTT AATTTT ATTTTT TTTTTT TTTTTT TTTTTC TTTTCC TTTCCG TTCCGC TCCGCG CCGCGT CGCGTA GCGTAC CGTACT GTACTC TACTCG ACTCGA CTCGAA TCGAAA CGAAAA GAAAAT AAAATC AAATCG AATCGC ATCGCG TCGCGA CGCGAT GCGATC CGATCG GATCGC ATCGCA TCGCAT CGCATT GCATTC CATTCC ATTCCC TTCCCT TCCCTA CCCTAC CCTACG CTACGT TACGTG ACGTGG CGTGGT GTGGTA,3,118,ATGTGGGG G T TGTGGGGAGA A GGGAA AG TC G GAGACCT T A ACACTAT TT T AAATTA A T TTTTATAGGCAG TCCTTAG TGGC C A AGAGCGCTCA T G GCGCTCTCTC C C CTCTCTCCC T TCTCCCCTCT T C CCCCTAAACGA TC CTTTTTT T TATT CATTATA A T CATTATATAT ATT TATATTT T A ATGCATTTTT T T TTTTTTTGTG G TTAATTATGAGA A T TGTGAGAT CCT G GAGAT AATG GAAATGTGGTTGG TAGC TTGGAGA A GGGA ATAA A GTGGGAAAT AA A A AAAAACTTAA  AAAAAAACAC C A AAAACACCC A ACACCCCACT A C CCCCAAT T C TTCATATTTT T A ATATTTTTTT T TGT TTTTTGTG G TTTGTGCGC C T TGTGCGCCCC C G GCGCCCCACA TTTAT CCACATAT T C CAATTTT T A ATATTTTATATAT  TAAAATT T A ATATTTG G T TTGG TGGGG G T TG TAGGCGC  GGGGCGCACA A G GCATTCAAAA A CTTTCTAAATAT T A AATTATT  TA ATT ATTTTT T T TTTTTTTTTT T T TTTTTTTCC T TTTTCTCCCC  TCTCCCCTT TT C CCCCTCTTTT T C CTCTTTTATA A T TTTTGTATAT T T TATATATATA A A ATATATA AA A T TATAAAATAAAAC  CTAATATA TTA A ATATATATAT T T TATAT TTTT T T ATATTTTTTT TGGTTTTTCTC C T TTTTCTCGCG  AA TCTCGCGAGA A C CGCGAGAGAG G G GAGAGAGTAC  AGAGTGTCTC C G GTGTCTCAA T ATTCACAAAA A C CACAAAA A A AAAAAAATCCCT AATGAATATTTT T A ATATTTTTTT T T TTTTTTTTTT CT TTTTTTTT T T TTGTATT T T TTCG TC AG  GC TTTTTTTCTC C T TTTTCTCCCC C T TTTCCCCGCG  CCCCGCGCC C CGCGCGCGCG CAT GCGCGCGTT C CGCGTGTATA A GG TGTATACAC T A ATACTCT T AACTCTCTC C C CTCTCTCGTTT TCTCGCGAGA A C CGTT GAAAA  GAGAAAAAAA GAC AAAAAAAAAA A AT GAATT A AAAATATC CGC ATACATCTCGCG G T TCTCGCGCGC C C CGCGCGCGCG G G GCGCGCGAGA A CTC CGAGATCTTATCGAT GACGTC A TCATCTCGCG G TT CCGCGC C C CGCGCTT CA A GT CGCACATT C CACATATTT A ATATTTTCTTT GG TTTTCTCCCC C T TCTCCAT CC C C CCCCC TACT T C CCCCTCAATA A C CTCTATACT AC TTACACGCG G A ACACGTC  TTA CCGTGTGG G GTGTGTGGGG  TG GAGGTGT T G GGGGTT T,ATGTGGGGAGA A T TGTGGAC C G GGGAC GACT T GCCCGACACTCTTTT T A ACACTCTTTTATA A C CTAT TTATAGTATG T TTTTATAGAGCGC C T TATAGAGCGCTCT T A AGAGCGCTCTCTC AAT GCT ACTCTCCCC C C CTCTCTCCCT  TCTCCCCTCTTTT T C CCCCTCTTGTAAA T C CTCTTTTTTTATA A T TTTTTC TAG AT T T TT ACTATATTTT T TTATATTTTTTT T A ATATTTTGTG G T TTTTTTTGTGAGA A T TTTTGTGGATAT AT T TGTGAGATTG AGTGATATGTGGA C ATTTTTGGGGA TTA T TGTGGGGAGAAAA A G GGC CGAAAAAATAATTGAAAAAAAAAA A A AAAAAAAAAACCGC TA AAAAAAACACC AACCACA A A ACACC CCTCGAT T C CCCATATTTT CATTTTTT T A ATATTTTTTTGTG G TAC GGATTGTGCGC C T TTCTATCCGCCC T TGT TGCCCCAGTGA G GCGCCCCATCCAT T C CCCCATT ATTTT T C CACGTTTA TAATTTTATATAT TGAATTTT CCTTATATTTTGTG AAA ATATTTTATGGG T TTTTGGGAGGCGC C T TGTGGGGCCA A G GGGGCGCACAAAA  GCGCACAAAATTAAGA  CACAAAATATTTT AT  AACCTATTTTTTT  ATTTTTTTTTTTT  TTTTTATTGT TC C T TTTTTTTCCATCC TTA TTTCCCCTCT T T TCTCCCCTTCCT CCCACCTTTATTATA A C CTCTTTTATATAT G A TTTTATATGATTA A T TAG CATATAAAA A A ATAA AT TTCAT T TA ATAAAATATATA A A AA TTATAT AAT T A CAATATATATTTT T T TATATATTTTTGA TGGG GATTTTTC T TTTTCTTTCG G TAATTCGCGAGA A T TCTCGCGAGAGAG G C CGCGAGAGG GTTCT GCGCGAGCATGTCTC C A AGGTCTCA GTGTCTCACAAAA A T TCTCACAATTTAA A C CACAATGCAATCTTT A AAAAAC GATTTT T A AAAATTTTTT T A ATATTTTTTTTT T TTGC TTTTTTTT T TTTTT TTTTCATTTT TTATGTTTAAATTT TTTTTTTTTTCTC C T TTT TAATTGCT CC T TTTCCCCGCG G T TCTCCCCGCGCGC TTT CCCCGCGCGCGCG  CGCGCGCGCGTT G GCGCGCGTTTTTA A C CGATTGTATAC TTC G GTGTATACACTGA CTC TATACACTCTCTC C ACTTCTCTCGCG G C CTTCGCGACT A T TCCATCGAGAAAA  CGCGAGAAAAAAA A G GAGAAAAAAAATT A A AAAAAAAAAATAT TAT AAAATATCTC C A AAAATATCTCGCG TA  ATATCTCGCGCTTTC T TCTCGACTGCGCG TATCGCGCGCGAAT A G GCGCGCGAAT T C CGCGAGATATCTC C G GAGATATCTCGCG G A ATGG TCGGC C T TCTCGAC GCACA A C CGCGCGCAAGTCC T G GCCATATTTT T C CACATATTTTCGT C A ATATTTTCTCCC TTT TTCTCCCCCCC C T TCCTTCCCAATCT  CC GACCTCTAG A CCTACAC C CCTATACACGCG G TTACACGCGTTC T A ACACGCGTGTGTG G C CGCGTGTGGG  AT GTCA TGGGGTGT T T TGTTGGGT,ATGTGGGGAGACAC C TGA TGGGACCT T G GGGGAGACACTCTTTT T G GAGACCGCCTTTA A A ACACTCTTTTATAGAG G C CTCTTTTATAGAGCTAAC T TTTTATT AGCGCTCT T T TATAGAGCGCTCTCTC C AAGCGCTCTCGG CC C GGCTCTCTCCGCAT C CTCTCTT CCTCTTTT T T TCTCCCTTTT T CCCTCTTTTTTTATGGA C CTCTTTTGTT TATAT T TTTTTTTTATATTTT T T TTTTATATATTTTTT T TATAT TATTTTTTTG G A ATATTTTTCGTCCCGA ACG TGTTTTTGTGAGATAT T T TTTTGTGAGATATGTG  TGTGAGATGCATGGTCCG GCT ATGTGGGGAGA CAT ATATGTGGGGAGAAAA A T TGTGGGGAGAAAAAAA A GCGTGGA AAAAAAAAA G GAGAAAAAAC AC C A AACGCAAATCCACCCC  TTAAAGCAACCCCACA A A GGAACCCACATAT T A ACACCCCAATTT C CCCCACATATTTTTTT T C CACATAATTTTTTGTG TGA ATATTTTTTGCGC C T TTTTTTGCGCCCC C T TTTTGTGCC CCCAC T TGTGCGCCCATAT T G GCGCCCCACATTT T CCATATGTTATA A CG CATTTTATATAT T A ATATTTATCC TT T A TTTTATATTG G T TATATATTTTGTGGGG TCCTCGATTTGGGGCAATC TAAATTGGGCGCACA A T TTTGGGGC GACAAA GGGCGCAAATAT T GCAAAATTTAT CCAAAATCGATT T A AAATTATTTA GCGTT T A ATT CTTTTTTTTCTC C T TTTTTTTTACCTCCCC TTTTTTTTCA ACT T TC ATTCTCCCCTA CTAGT T TCTCCCGCCTTTTATA A C CCCCTCTTTTAAT ATT ATCTTTTAATAA TA T TTTTATATATATAAAA A T TATATATAGC AATAT T A CTATATAA CGTA A T TATAAAATATATATAT G AAATATATATATTTT GGT ATATATATATTTTTTT T T TATATATTTTTTC TC C A ATA A TTTTCTCGCG G TAAATTGTTCTCGCGAGA TG  TTTTCTCGCGAGAGAG G T TCTCGCGAGAGAGTTTTT C CGCGAGAGAGTGTCTC C GGAGAGTGTCTCACA ATT AGATCTCAAA A GGTCTCACAAAA A T TCCAAAAAAATAT AATGCGCAAAAAAATT AAAAAATATTTT T A AAATTTTTTTTCG T A ATATTCCATTTTTTTT T T TTA TTTTTTTT T TTTTTTTTTTTTT T TTTTTTTTC C T TTTTATTTTCCC T TTTTTTCCCCGCG G TGT TTCTCCCCGAAAC T ATCATGCG CCCCGCGCGCGCGTGT T C CGCGCTTTCGTGTAA G GCGCGT CGTATACAAAGCC CGCGTGTATACACTCT T G GTGTATACACTCTCTC C T TATACACTCTCTCGCG  ACCTCTCGCGAA C CTCTCCGAGAAAA A T TCTCGCGAAAAAA CTTAATCGAATC TTCATAA  GAGAAAAA AAAATAT T T AAAAAAAAT CATCTTCTTC AAAAAAATATCTCGCG G AGAAAATATCTCGCGCGC C A ATATCTCGACTCG CTA TCTCGCCT CA TTA C CGCGCGCGCGAGATAT T G GCGCGCGAGATGAATC C C CGATTGATATCTCGTT CGA GAGATATCGC GC C A ATGTCATTCA A T TCTCGCGCAACCAT GG CGCGCGCACCTTT T G GCGCACATATTTTCTC C C CATTCATTTTTATTTCCG ACA  TTTTCTCCCCCCCTCT T T TC AACCCCCTCTATA A CCCCCCTCTAAC C C CCATTCTATACACGCG G C CTG TCGTGT CCTTACACGCGTGTGTTT ACACGCGTGTGTGGGG AAA CGTTGGTGGGTG A GTTGGT AGTA,ATGTGGGGAGACACTTTC TGTGGGGAGACACTCTTTT  GGACTCTTA TTA A GTG GACCATCA TTAAA G A ACACTCTTTTAAGCGC C C CTCTTT ATAGAGCGCTCT T TTTTTTATATAGCGCTCTCTC C T TATTTAGCGCTCTCTCCC A AGAGCGCTTTAACCCCT CAT GTTTTTCCTCTCCCTTTT T C CTCTCTCCCCTCTTTTTTT T T TCTCCT TT GTTTTA ATT CCCCTCTTTTTTTATAGAT T C CTCTTTTAATTTT T T TTAAATATCCTTTTTT T T TTTTATATATT CGG TTG TTGTTG GCATTTTTCCTTGAGA A A AT TTTTTTTGTGAGATAT T T TTTTTTTGTGAATGGGAG T TTC GTGAGATATGGG G TT CGCTGATATGTGGGGAATTTAC GAGATATGTGGCGTGAACCA ATTTCTGGGAAA TTGGGGAGAAAAAAA A G GGGGAGAAAAAAAAAACC TGATAAAAAAAACACCAG TAT AAGGCAAAAACTTCCCACA A A AAAAAAACACCCCACATT A AAAACTCCAA CATTT C T ACACCCCAACTGA CATTT T C CCCCACATATTTTTA G GAG C CACATTTT TTGCGGC C AATTTTTTTGTGCCC C TTA TTT TATGCGCCCGTA T TTTTGTGCGCCT T TGGCCGGAGAAATTTT ATCGCCCCACATATTTTAATTA C CCCATATTTTATATAT T C CATTAATTTTATATATTTT T A ATATTTTACG ATTTG TTGTTAC AATTTTGAA GG G TTTATATATT CTTGGGC C A ATATTTTGTGGGGCGCACA A T TTTTGTGGATTGCACAAAA A TTTTGGCGCACAAC GAT T G GGGGCTC CAAAATATTTT TATGCACAAAATATTTTTTT T C CACAAAATATTTTTTTTTT T AAGTAATATTTTTTTTT TTC CGA ATAAATTTTTTTCCCC TTA TTTTTTTTTGATCCCCTCT T T TTTTTTTCTCCTT CTTT T TTTTCTCCCCTCTTTTATA A T GCTCCGCACTTTTATATAT T C CCC GTTATCGATATA C CTATTAAAA  TT TTCTCATATAAAATAT T T TATATATATAACTTTTATA A A ATATACATAATATATATAT  TATAAAATATATATATTTT  AAAATATAATTTGGTT T A ATATATATGGCAAATTCTC  TATATATTTTTTTCCG G A ATATTTTTTTCTCGC AGA A T TTTTTTTCTCGCGAGAGG T TTACCTATCGAGAGAGTGT T T TCTCGCGAGAGAGTTC  CGCGAGAG AATCACA A G GAGAGAGTGTCTCACAAAA A AAGTGTCTCACAAAA A G GTGTCTCACAAAAAAATAT  TCTCACAAAAAAATATTTT T CCT CAATTTAATATTAAACCTT ACCCG TTTGATTTTTTTTTT  AAAATATTTTTTTTTTTTT T A ATTTTTTT TTATTA TTTTTTTTTTTTTTT T T TTTTTTTTTTTTTTTTCTC C T TTTTTTTTTTCTCCCC  TTGA TTCTCCCCGCG G T TTTTTTTCCCGCGCGC AC  TTTTCTCCCCGCGCGCGTATATA TCTT CCGCGCGCGAG GT T C CCCCGCGCGCGCGTGTATA A C CGCGCCGTGTAAC C G GCGCGATCGTATACACTCT T C CGCGTGTAACTCTCTC C GGTATACACTCTCCG AAA TATACACTCTCTCGCGATTTA A ACACTCTCTCGCGAGAAAA A CTTGCTCTCGCGATTTTTA TCTTTCGACATAAAAAAAA A C CGCGAGAAAAAAATT TT G GAGAAAAAATTAATATCTC C A AAAAAAAAAATATCTCGCG G A AATTTAATATCTCGCGCGC C A AAAATTCGCGCGCGCG G A ATTG TCGCGCGCGCGAGA A T TCTCGCGCC CCGAGATAT T C CGCGCGCGCGA GCGCA GCGCGCGAAATTCGCG G CCCTCGAGATATCCGCGC TAGATCTCGCGCCCTA A ATATCTCGCGCCATAT ATT TCTCGCGCGCACATT TTT T C CGCGCCTAATTTTCTC C G TCGCATTTATTATGTCCCC GCG CACATTTCTCCCC C A ATATTTTCTCCCCTCT T T TTA A AACCTCTATA A T TCGGTCCCCCTCATTATAC AATCCCCCTTACACGCG G C CCTTGCTATACACGCGTGT  TGCTATACCCATG G T TATACACGGTGTGGGG G A ACACGCGTGTGGT T C CGCGTGTGTGGTCCGTA,"ID   RSMA_BACTN              Reviewed;         267 AA.
AC   Q8A0H8;
DT   04-AUG-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2003, sequence version 1.
DT   27-NOV-2024, entry version 117.
DE   RecName: Full=Ribosomal RNA small subunit methyltransferase A {ECO:0000255|HAMAP-Rule:MF_00607};
DE            EC=2.1.1.182 {ECO:0000255|HAMAP-Rule:MF_00607};
DE   AltName: Full=16S rRNA (adenine(1518)-N(6)/adenine(1519)-N(6))-dimethyltransferase {ECO:0000255|HAMAP-Rule:MF_00607};
DE   AltName: Full=16S rRNA dimethyladenosine transferase {ECO:0000255|HAMAP-Rule:MF_00607};
DE   AltName: Full=16S rRNA dimethylase {ECO:0000255|HAMAP-Rule:MF_00607};
DE   AltName: Full=S-adenosylmethionine-6-N', N'-adenosyl(rRNA) dimethyltransferase {ECO:0000255|HAMAP-Rule:MF_00607};
GN   Name=rsmA {ECO:0000255|HAMAP-Rule:MF_00607};
GN   Synonyms=ksgA {ECO:0000255|HAMAP-Rule:MF_00607};
GN   OrderedLocusNames=BT_4043;
OS   Bacteroides thetaiotaomicron (strain ATCC 29148 / DSM 2079 / JCM 5827 /
OS   CCUG 10774 / NCTC 10582 / VPI-5482 / E50).
OC   Bacteria; Bacteroidota; Bacteroidia; Bacteroidales; Bacteroidaceae;
OC   Bacteroides.
OX   NCBI_TaxID=226186;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 29148 / DSM 2079 / JCM 5827 / CCUG 10774 / NCTC 10582 /
RC   VPI-5482 / E50;
RX   PubMed=12663928; DOI=10.1126/science.1080029;
RA   Xu J., Bjursell M.K., Himrod J., Deng S., Carmichael L.K., Chiang H.C.,
RA   Hooper L.V., Gordon J.I.;
RT   ""A genomic view of the human-Bacteroides thetaiotaomicron symbiosis."";
RL   Science 299:2074-2076(2003).
CC   -!- FUNCTION: Specifically dimethylates two adjacent adenosines (A1518 and
CC       A1519) in the loop of a conserved hairpin near the 3'-end of 16S rRNA
CC       in the 30S particle. May play a critical role in biogenesis of 30S
CC       subunits. {ECO:0000255|HAMAP-Rule:MF_00607}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=adenosine(1518)/adenosine(1519) in 16S rRNA + 4 S-adenosyl-L-
CC         methionine = N(6)-dimethyladenosine(1518)/N(6)-
CC         dimethyladenosine(1519) in 16S rRNA + 4 S-adenosyl-L-homocysteine + 4
CC         H(+); Xref=Rhea:RHEA:19609, Rhea:RHEA-COMP:10232, Rhea:RHEA-
CC         COMP:10233, ChEBI:CHEBI:15378, ChEBI:CHEBI:57856, ChEBI:CHEBI:59789,
CC         ChEBI:CHEBI:74411, ChEBI:CHEBI:74493; EC=2.1.1.182;
CC         Evidence={ECO:0000255|HAMAP-Rule:MF_00607};
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000255|HAMAP-Rule:MF_00607}.
CC   -!- SIMILARITY: Belongs to the class I-like SAM-binding methyltransferase
CC       superfamily. rRNA adenine N(6)-methyltransferase family. RsmA
CC       subfamily. {ECO:0000255|HAMAP-Rule:MF_00607}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AE015928; AAO79148.1; -; Genomic_DNA.
DR   RefSeq; NP_812954.1; NC_004663.1.
DR   RefSeq; WP_008760928.1; NZ_UYXG01000005.1.
DR   AlphaFoldDB; Q8A0H8; -.
DR   SMR; Q8A0H8; -.
DR   STRING; 226186.BT_4043; -.
DR   PaxDb; 226186-BT_4043; -.
DR   DNASU; 1073424; -.
DR   EnsemblBacteria; AAO79148; AAO79148; BT_4043.
DR   GeneID; 60925217; -.
DR   KEGG; bth:BT_4043; -.
DR   PATRIC; fig|226186.12.peg.4105; -.
DR   eggNOG; COG0030; Bacteria.
DR   HOGENOM; CLU_041220_0_1_10; -.
DR   InParanoid; Q8A0H8; -.
DR   OrthoDB; 9814755at2; -.
DR   Proteomes; UP000001414; Chromosome.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0052908; F:16S rRNA (adenine(1518)-N(6)/adenine(1519)-N(6))-dimethyltransferase activity; IEA:UniProtKB-EC.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0000179; F:rRNA (adenine-N6,N6-)-dimethyltransferase activity; IBA:GO_Central.
DR   GO; GO:0031167; P:rRNA methylation; IBA:GO_Central.
DR   FunFam; 1.10.8.100:FF:000001; Ribosomal RNA small subunit methyltransferase A; 1.
DR   FunFam; 3.40.50.150:FF:000157; Ribosomal RNA small subunit methyltransferase A; 1.
DR   Gene3D; 1.10.8.100; Ribosomal RNA adenine dimethylase-like, domain 2; 1.
DR   Gene3D; 3.40.50.150; Vaccinia Virus protein VP39; 1.
DR   HAMAP; MF_00607; 16SrRNA_methyltr_A; 1.
DR   InterPro; IPR001737; KsgA/Erm.
DR   InterPro; IPR023165; rRNA_Ade_diMease-like_C.
DR   InterPro; IPR020596; rRNA_Ade_Mease_Trfase_CS.
DR   InterPro; IPR020598; rRNA_Ade_methylase_Trfase_N.
DR   InterPro; IPR011530; rRNA_adenine_dimethylase.
DR   InterPro; IPR029063; SAM-dependent_MTases_sf.
DR   NCBIfam; TIGR00755; ksgA; 1.
DR   PANTHER; PTHR11727; DIMETHYLADENOSINE TRANSFERASE; 1.
DR   PANTHER; PTHR11727:SF7; DIMETHYLADENOSINE TRANSFERASE-RELATED; 1.
DR   Pfam; PF00398; RrnaAD; 1.
DR   SMART; SM00650; rADc; 1.
DR   SUPFAM; SSF53335; S-adenosyl-L-methionine-dependent methyltransferases; 1.
DR   PROSITE; PS01131; RRNA_A_DIMETH; 1.
DR   PROSITE; PS51689; SAM_RNA_A_N6_MT; 1.
PE   3: Inferred from homology;
KW   Cytoplasm; Methyltransferase; Reference proteome; RNA-binding;
KW   rRNA processing; S-adenosyl-L-methionine; Transferase.
FT   CHAIN           1..267
FT                   /note=""Ribosomal RNA small subunit methyltransferase A""
FT                   /id=""PRO_0000101486""
FT   BINDING         13
FT                   /ligand=""S-adenosyl-L-methionine""
FT                   /ligand_id=""ChEBI:CHEBI:59789""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00607""
FT   BINDING         15
FT                   /ligand=""S-adenosyl-L-methionine""
FT                   /ligand_id=""ChEBI:CHEBI:59789""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00607""
FT   BINDING         40
FT                   /ligand=""S-adenosyl-L-methionine""
FT                   /ligand_id=""ChEBI:CHEBI:59789""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00607""
FT   BINDING         61
FT                   /ligand=""S-adenosyl-L-methionine""
FT                   /ligand_id=""ChEBI:CHEBI:59789""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00607""
FT   BINDING         85
FT                   /ligand=""S-adenosyl-L-methionine""
FT                   /ligand_id=""ChEBI:CHEBI:59789""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00607""
FT   BINDING         105
FT                   /ligand=""S-adenosyl-L-methionine""
FT                   /ligand_id=""ChEBI:CHEBI:59789""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00607""
SQ   SEQUENCE   267 AA;  30363 MW;  327763956D92CFE3 CRC64;
     MKLVKPKKFL GQHFLKDLKV AQDIADTVDT FPELPVLEVG PGMGVLTQFL VKKDRLVKVV
     EVDYESVAYL REAYPSLEDH IIEDDFLKMN LHRLFDGKPF VLTGNYPYNI SSQIFFKMLE
     NKDIIPCCTG MIQKEVAERI AAGPGSKTYG ILSVLIQAWY KVEYLFTVSE HVFNPPPKVK
     SAVIRMTRND TKELGCDEKL FKQVVKTTFN QRRKTLRNSI KPILGKDCPL TEDALFNKRP
     EQLSVEEFIS LTNQVEEALK TATASGN
//
",1405
TTCGTG TCGTGA CGTGAT GTGATG TGATGA GATGAG ATGAGC TGAGCC GAGCCT AGCCTG GCCTGC CCTGCT CTGCTG TGCTGG GCTGGC CTGGCC TGGCCC GGCCCT GCCCTG CCCTGG CCTGGG CTGGGG TGGGGG GGGGGG GGGGGT GGGGTG GGGTGG GGTGGG GTGGGA TGGGAT GGGATC GGATCG GATCGC ATCGCA TCGCAA CGCAAT GCAATG CAATGT AATGTA ATGTAT TGTATA GTATAC TATACG ATACGG TACGGC ACGGCG CGGCGT GGCGTT GCGTTG CGTTGC GTTGCG TTGCGG TGCGGG GCGGGC CGGGCG GGGCGC GGCGCT GCGCTG CGCTGC GCTGCG CTGCGC TGCGCG GCGCGC CGCGCT GCGCTG CGCTGC GCTGCC CTGCCG TGCCGG GCCGGC CCGGCC CGGCCG GGCCGG GCCGGG CCGGGT CGGGTG GGGTGG GGTGGA GTGGAT TGGATG GGATGC GATGCG ATGCGC TGCGCC GCGCCA CGCCAC GCCACC CCACCC CACCCC ACCCCT CCCCTC CCCTCA CCTCAT CTCATG TCATGC CATGCG ATGCGC TGCGCC GCGCCA CGCCAC GCCACA CCACAT CACATC ACATCC CATCCG ATCCGG TCCGGG CCGGGG CGGGGG GGGGGC GGGGCG GGGCGG GGCGGC GCGGCG CGGCGC GGCGCC GCGCCT CGCCTG GCCTGT CCTGTT CTGTTT TGTTTG GTTTGA TTTGAT TTGATG TGATGG GATGGT ATGGTT TGGTTC GGTTCG GTTCGC TTCGCT TCGCTG CGCTGG GCTGGC CTGGCT TGGCTT GGCTTT GCTTTC CTTTCA TTTCAT TTCATT TCATTA CATTAC ATTACG,2,145,TTCG TCGT CGTG GTGA TGAT GATG ATGA TGAG GAGC AGCC GCCT CCTG CTGC TGCT GCTG CTGG TGGC GGCC GCCC CCCT CCTG CTGG TGGG GGGG GGGG GGGG GGGT GGTG GTGG TGGG GGGA GGAT GATC ATCG TCGC CGCA GCAA CAAT AATG ATGT TGTA GTAT TATA ATAC TACG ACGG CGGC GGCG GCGT CGTT GTTG TTGC TGCG GCGG CGGG GGGC GGCG GCGC CGCT GCTG CTGC TGCG GCGC CGCG GCGC CGCT GCTG CTGC TGCC GCCG CCGG CGGC GGCC GCCG CCGG CGGG GGGT GGTG GTGG TGGA GGAT GATG ATGC TGCG GCGC CGCC GCCA CCAC CACC ACCC CCCC CCCT CCTC CTCA TCAT CATG ATGC TGCG GCGC CGCC GCCA CCAC CACA ACAT CATC ATCC TCCG CCGG CGGG GGGG GGGG GGGC GGCG GCGG CGGC GGCG GCGC CGCC GCCT CCTG CTGT TGTT GTTT TTTG TTGA TGAT GATG ATGG TGGT GGTT GTTC TTCG TCGC CGCT GCTG CTGG TGGC GGCT GCTT CTTT TTTC TTCA TCAT CATT ATTA TTAC TACG,TTCGT TCGTG CGTGA GTGAT TGATG GATGA ATGAG TGAGC GAGCC AGCCT GCCTG CCTGC CTGCT TGCTG GCTGG CTGGC TGGCC GGCCC GCCCT CCCTG CCTGG CTGGG TGGGG GGGGG GGGGG GGGGT GGGTG GGTGG GTGGG TGGGA GGGAT GGATC GATCG ATCGC TCGCA CGCAA GCAAT CAATG AATGT ATGTA TGTAT GTATA TATAC ATACG TACGG ACGGC CGGCG GGCGT GCGTT CGTTG GTTGC TTGCG TGCGG GCGGG CGGGC GGGCG GGCGC GCGCT CGCTG GCTGC CTGCG TGCGC GCGCG CGCGC GCGCT CGCTG GCTGC CTGCC TGCCG GCCGG CCGGC CGGCC GGCCG GCCGG CCGGG CGGGT GGGTG GGTGG GTGGA TGGAT GGATG GATGC ATGCG TGCGC GCGCC CGCCA GCCAC CCACC CACCC ACCCC CCCCT CCCTC CCTCA CTCAT TCATG CATGC ATGCG TGCGC GCGCC CGCCA GCCAC CCACA CACAT ACATC CATCC ATCCG TCCGG CCGGG CGGGG GGGGG GGGGC GGGCG GGCGG GCGGC CGGCG GGCGC GCGCC CGCCT GCCTG CCTGT CTGTT TGTTT GTTTG TTTGA TTGAT TGATG GATGG ATGGT TGGTT GGTTC GTTCG TTCGC TCGCT CGCTG GCTGG CTGGC TGGCT GGCTT GCTTT CTTTC TTTCA TTCAT TCATT CATTA ATTAC TTACG,TTCGTG TCGTGA CGTGAT GTGATG TGATGA GATGAG ATGAGC TGAGCC GAGCCT AGCCTG GCCTGC CCTGCT CTGCTG TGCTGG GCTGGC CTGGCC TGGCCC GGCCCT GCCCTG CCCTGG CCTGGG CTGGGG TGGGGG GGGGGG GGGGGT GGGGTG GGGTGG GGTGGG GTGGGA TGGGAT GGGATC GGATCG GATCGC ATCGCA TCGCAA CGCAAT GCAATG CAATGT AATGTA ATGTAT TGTATA GTATAC TATACG ATACGG TACGGC ACGGCG CGGCGT GGCGTT GCGTTG CGTTGC GTTGCG TTGCGG TGCGGG GCGGGC CGGGCG GGGCGC GGCGCT GCGCTG CGCTGC GCTGCG CTGCGC TGCGCG GCGCGC CGCGCT GCGCTG CGCTGC GCTGCC CTGCCG TGCCGG GCCGGC CCGGCC CGGCCG GGCCGG GCCGGG CCGGGT CGGGTG GGGTGG GGTGGA GTGGAT TGGATG GGATGC GATGCG ATGCGC TGCGCC GCGCCA CGCCAC GCCACC CCACCC CACCCC ACCCCT CCCCTC CCCTCA CCTCAT CTCATG TCATGC CATGCG ATGCGC TGCGCC GCGCCA CGCCAC GCCACA CCACAT CACATC ACATCC CATCCG ATCCGG TCCGGG CCGGGG CGGGGG GGGGGC GGGGCG GGGCGG GGCGGC GCGGCG CGGCGC GGCGCC GCGCCT CGCCTG GCCTGT CCTGTT CTGTTT TGTTTG GTTTGA TTTGAT TTGATG TGATGG GATGGT ATGGTT TGGTTC GGTTCG GTTCGC TTCGCT TCGCTG CGCTGG GCTGGC CTGGCT TGGCTT GGCTTT GCTTTC CTTTCA TTTCAT TTCATT TCATTA CATTAC ATTACG,TTCGTGA TCGTGAT CGTGATG GTGATGA TGATGAG GATGAGC ATGAGCC TGAGCCT GAGCCTG AGCCTGC GCCTGCT CCTGCTG CTGCTGG TGCTGGC GCTGGCC CTGGCCC TGGCCCT GGCCCTG GCCCTGG CCCTGGG CCTGGGG CTGGGGG TGGGGGG GGGGGGT GGGGGTG GGGGTGG GGGTGGG GGTGGGA GTGGGAT TGGGATC GGGATCG GGATCGC GATCGCA ATCGCAA TCGCAAT CGCAATG GCAATGT CAATGTA AATGTAT ATGTATA TGTATAC GTATACG TATACGG ATACGGC TACGGCG ACGGCGT CGGCGTT GGCGTTG GCGTTGC CGTTGCG GTTGCGG TTGCGGG TGCGGGC GCGGGCG CGGGCGC GGGCGCT GGCGCTG GCGCTGC CGCTGCG GCTGCGC CTGCGCG TGCGCGC GCGCGCT CGCGCTG GCGCTGC CGCTGCC GCTGCCG CTGCCGG TGCCGGC GCCGGCC CCGGCCG CGGCCGG GGCCGGG GCCGGGT CCGGGTG CGGGTGG GGGTGGA GGTGGAT GTGGATG TGGATGC GGATGCG GATGCGC ATGCGCC TGCGCCA GCGCCAC CGCCACC GCCACCC CCACCCC CACCCCT ACCCCTC CCCCTCA CCCTCAT CCTCATG CTCATGC TCATGCG CATGCGC ATGCGCC TGCGCCA GCGCCAC CGCCACA GCCACAT CCACATC CACATCC ACATCCG CATCCGG ATCCGGG TCCGGGG CCGGGGG CGGGGGC GGGGGCG GGGGCGG GGGCGGC GGCGGCG GCGGCGC CGGCGCC GGCGCCT GCGCCTG CGCCTGT GCCTGTT CCTGTTT CTGTTTG TGTTTGA GTTTGAT TTTGATG TTGATGG TGATGGT GATGGTT ATGGTTC TGGTTCG GGTTCGC GTTCGCT TTCGCTG TCGCTGG CGCTGGC GCTGGCT CTGGCTT TGGCTTT GGCTTTC GCTTTCA CTTTCAT TTTCATT TTCATTA TCATTAC CATTACG,"ID   PHAAB_RHIME             Reviewed;         999 AA.
AC   Q52978; Q52979; Q8RTE9; Q92LV7;
DT   13-APR-2004, integrated into UniProtKB/Swiss-Prot.
DT   13-APR-2004, sequence version 2.
DT   05-FEB-2025, entry version 136.
DE   RecName: Full=Probable K(+)/H(+) antiporter subunit A/B;
DE   AltName: Full=pH adaptation potassium efflux system protein A/B;
DE            Short=Pha system subunit A/B;
GN   Name=phaAB; Synonyms=phaA, phaA1, phaB; OrderedLocusNames=R02910;
GN   ORFNames=SMc03179;
OS   Rhizobium meliloti (strain 1021) (Ensifer meliloti) (Sinorhizobium
OS   meliloti).
OC   Bacteria; Pseudomonadota; Alphaproteobacteria; Hyphomicrobiales;
OC   Rhizobiaceae; Sinorhizobium/Ensifer group; Sinorhizobium.
OX   NCBI_TaxID=266834;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=41;
RX   PubMed=9680201; DOI=10.1046/j.1365-2958.1998.00868.x;
RA   Putnoky P., Kereszt A., Nakamura T., Endre G., Grosskopf E., Kiss P.,
RA   Kondorosi A.;
RT   ""The pha gene cluster of Rhizobium meliloti involved in pH adaptation and
RT   symbiosis encodes a novel type of K+ efflux system."";
RL   Mol. Microbiol. 28:1091-1101(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=1021;
RX   PubMed=11481430; DOI=10.1073/pnas.161294398;
RA   Capela D., Barloy-Hubler F., Gouzy J., Bothe G., Ampe F., Batut J.,
RA   Boistard P., Becker A., Boutry M., Cadieu E., Dreano S., Gloux S.,
RA   Godrie T., Goffeau A., Kahn D., Kiss E., Lelaure V., Masuy D., Pohl T.,
RA   Portetelle D., Puehler A., Purnelle B., Ramsperger U., Renard C.,
RA   Thebault P., Vandenbol M., Weidner S., Galibert F.;
RT   ""Analysis of the chromosome sequence of the legume symbiont Sinorhizobium
RT   meliloti strain 1021."";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:9877-9882(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=1021;
RX   PubMed=11474104; DOI=10.1126/science.1060966;
RA   Galibert F., Finan T.M., Long S.R., Puehler A., Abola P., Ampe F.,
RA   Barloy-Hubler F., Barnett M.J., Becker A., Boistard P., Bothe G.,
RA   Boutry M., Bowser L., Buhrmester J., Cadieu E., Capela D., Chain P.,
RA   Cowie A., Davis R.W., Dreano S., Federspiel N.A., Fisher R.F., Gloux S.,
RA   Godrie T., Goffeau A., Golding B., Gouzy J., Gurjal M., Hernandez-Lucas I.,
RA   Hong A., Huizar L., Hyman R.W., Jones T., Kahn D., Kahn M.L., Kalman S.,
RA   Keating D.H., Kiss E., Komp C., Lelaure V., Masuy D., Palm C., Peck M.C.,
RA   Pohl T.M., Portetelle D., Purnelle B., Ramsperger U., Surzycki R.,
RA   Thebault P., Vandenbol M., Vorhoelter F.J., Weidner S., Wells D.H.,
RA   Wong K., Yeh K.-C., Batut J.;
RT   ""The composite genome of the legume symbiont Sinorhizobium meliloti."";
RL   Science 293:668-672(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-926.
RC   STRAIN=JJ1c10;
RA   Watson R.J., Heys R.;
RT   ""Sinorhizobium meliloti phaA gene segment."";
RL   Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Part of a K(+) efflux system which is required for the
CC       adaptation of R.meliloti to alkaline pH as well as for the infection
CC       process during symbiotic nodule development.
CC   -!- SUBUNIT: May form a heterooligomeric complex that consists of six
CC       subunits: PhaAB, PhaC, PhaD, PhaE, PhaF and PhaG.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Multi-pass membrane
CC       protein {ECO:0000305}.
CC   -!- SIMILARITY: In the N-terminal section; belongs to the CPA3 antiporters
CC       (TC 2.A.63) subunit A family. {ECO:0000305}.
CC   -!- SIMILARITY: In the C-terminal section; belongs to the CPA3 antiporters
CC       (TC 2.A.63) subunit B family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA63735.1; Type=Frameshift; Note=Produces two separate ORFs named phaA and phaB.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X93358; CAA63734.1; ALT_FRAME; Genomic_DNA.
DR   EMBL; X93358; CAA63735.1; ALT_FRAME; Genomic_DNA.
DR   EMBL; AL591688; CAC47489.1; -; Genomic_DNA.
DR   EMBL; AF465791; AAL76258.1; -; Genomic_DNA.
DR   RefSeq; NP_387016.1; NC_003047.1.
DR   AlphaFoldDB; Q52978; -.
DR   SMR; Q52978; -.
DR   TCDB; 2.A.63.1.1; the monovalent cation (k(+) or na(+)):proton antiporter-3 (cpa3) family.
DR   EnsemblBacteria; CAC47489; CAC47489; SMc03179.
DR   KEGG; sme:SMc03179; -.
DR   PATRIC; fig|266834.11.peg.4431; -.
DR   eggNOG; COG1009; Bacteria.
DR   eggNOG; COG2111; Bacteria.
DR   HOGENOM; CLU_007100_2_0_5; -.
DR   OrthoDB; 9811798at2; -.
DR   Proteomes; UP000001976; Chromosome.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0015297; F:antiporter activity; IEA:UniProtKB-KW.
DR   GO; GO:0008324; F:monoatomic cation transmembrane transporter activity; IEA:InterPro.
DR   GO; GO:0006813; P:potassium ion transport; IEA:UniProtKB-KW.
DR   GO; GO:1902600; P:proton transmembrane transport; IEA:UniProtKB-KW.
DR   InterPro; IPR050616; CPA3_Na-H_Antiporter_A.
DR   InterPro; IPR005281; CPA3_sub_B.
DR   InterPro; IPR007182; MnhB.
DR   InterPro; IPR005663; MrpA/MnhA1/PhaAB.
DR   InterPro; IPR025383; MrpA_C/MbhD.
DR   InterPro; IPR046806; MrpA_C/MbhE.
DR   InterPro; IPR001750; ND/Mrp_TM.
DR   InterPro; IPR001516; Proton_antipo_N.
DR   NCBIfam; TIGR00940; 2a6301s01; 1.
DR   NCBIfam; TIGR00943; 2a6301s02; 1.
DR   PANTHER; PTHR43373; NA(+)/H(+) ANTIPORTER SUBUNIT; 1.
DR   PANTHER; PTHR43373:SF1; NA(+)_H(+) ANTIPORTER SUBUNIT A; 1.
DR   Pfam; PF13244; MbhD; 1.
DR   Pfam; PF20501; MbhE; 1.
DR   Pfam; PF04039; MnhB; 1.
DR   Pfam; PF00361; Proton_antipo_M; 1.
DR   Pfam; PF00662; Proton_antipo_N; 1.
DR   PRINTS; PR01434; NADHDHGNASE5.
PE   3: Inferred from homology;
KW   Antiport; Cell membrane; Hydrogen ion transport; Ion transport; Membrane;
KW   Potassium; Potassium transport; Reference proteome; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN           1..999
FT                   /note=""Probable K(+)/H(+) antiporter subunit A/B""
FT                   /id=""PRO_0000217075""
FT   TRANSMEM        31..48
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        63..85
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        106..128
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        138..160
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        162..181
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        191..213
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        233..255
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        270..292
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        299..321
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        336..358
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        389..411
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        442..464
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        488..510
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        530..552
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        604..621
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        636..653
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        660..682
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        686..708
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        729..751
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        788..807
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        846..868
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        878..900
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        913..935
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        955..977
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   REGION          1..20
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   CONFLICT        122
FT                   /note=""A -> V (in Ref. 1; CAA63734)""
FT                   /evidence=""ECO:0000305""
FT   CONFLICT        188
FT                   /note=""G -> A (in Ref. 1; CAA63734)""
FT                   /evidence=""ECO:0000305""
SQ   SEQUENCE   999 AA;  108790 MW;  9857B829580C2286 CRC64;
     MTRPASVLAG PKSRPPIHSQ GDKTIEYAEK LLSVFILVPF AGSLIAIFFP SDQRGAISWF
     AGAIALVCFL VTAGLYPYVA SGGVLHYRID WVPELGLNFT LRMDGFAWLF SALITAIGVL
     VALYARYYMA EEDPVPRFFA LFLAFMGSML GVVLSGNLIL LAVFWELTSI VSFLLIGYWH
     HNAHARDGAR MALTITGTGG LAMFVGLIII GKIVGSYELD AVLASGDAIR NHPLYGTVLV
     LVLLGALTKS AQFPFHFWLP HAMAAPTPVS AYLHSATMVK AGVFLLVRFW PVMAGTEAWF
     WIVGLAGLTT LLLGAYFAIF QQDLKGLLAY STISHLGLIT VLLSLGSPLA AVAAVFHIVN
     HATFKASLFM AAGIIDHESG TRDIRRLGGL FHFMPITATL AMVASAAMAG VPLLNGFLSK
     EMFFAEAIET HLVNPLDTVT PYVATIAGMF AVTYSLRFIH GVFFGRPPAD LPRKPHEPPR
     WMRAPLDFLV LACLVVGIIP AQTIGPFLHT AVLSVLREGT PDYSLSVWHG WNIPLIMSFV
     ALSGGIGLYF LMRSYLATAV EGPPVFRLLQ GQRIFERVLV TLSWKWARWL EQRLGTRRLQ
     PQMRLLVFLA LAAGASPLLL GNFELPPLVI RGIDPAFALL WAIGIACAIG SAYQAKFHRL
     ASLVLLGGAG LVTCITFVWL SAPDLAVTQL LVEIVTTVLI LLGLRWLPKR IEEPVAAEDI
     SIRVRLRRLR DLLLAIGAGG GMMLIAYTVM TRPLPETIAS YFLERAYREG GGTNVVNVIL
     VDFRGFDTLG EIAVLCIVAL TVFALLLRFR PQSDSLEAPE QQKVQNAFDD DHPDRAAGDS
     VAEYLFIPAV IMRWMFPVTG MLAAFLFLRG HDLPGGGFAA GIAMSIGFIL QYMSGGTRWV
     EERLRIHPLR WMSIGLLVAT ATGVGSWFFG YPFLTSHAQY ASLPVVGKFP LASAILFDLG
     VFSLVLGATV LILIALAHQS VRAPRAHAKA ARSDKEAVR
//
",31303
ACTAAA CTAAAG TAAAGA AAAGAA AAGAAG AGAAGG GAAGGT AAGGTG AGGTGC GGTGCC GTGCCA TGCCAC GCCACT CCACTA CACTAC ACTACT CTACTT TACTTG ACTTGT CTTGTG TTGTGG TGTGGT GTGGTT TGGTTA GGTTAC GTTACT TTACTT TACTTA ACTTAC CTTACC TTACCC TACCCC ACCCCA CCCCAA CCCAAA CCAAAA CAAAAT AAAATG AAATGC AATGCT ATGCTG TGCTGT GCTGTT CTGTTG TGTTGT GTTGTT TTGTTA TGTTAA GTTAAA TTAAAA TAAAAT AAAATT AAATTT AATTTA ATTTAT TTTATT TTATTG TATTGT ATTGTC TTGTCC TGTCCA GTCCAG TCCAGC CCAGCA CAGCAT AGCATG GCATGT CATGTC ATGTCA TGTCAC GTCACA TCACAA CACAAT ACAATT CAATTC AATTCA ATTCAG TTCAGA TCAGAA CAGAAG AGAAGT GAAGTA AAGTAG AGTAGG GTAGGA TAGGAC AGGACC GGACCT GACCTG ACCTGA CCTGAG CTGAGC TGAGCA GAGCAT AGCATA GCATAG CATAGT ATAGTC TAGTCT AGTCTT GTCTTG TCTTGC CTTGCC TTGCCG TGCCGA GCCGAA CCGAAT CGAATA GAATAC AATACC ATACCA TACCAT ACCATA CCATAA CATAAT ATAATG TAATGA AATGAA ATGAAT TGAATC GAATCT AATCTG ATCTGG TCTGGC CTGGCT TGGCTT GGCTTG GCTTGA CTTGAA TTGAAA TGAAAA GAAAAC AAAACC AAACCA AACCAT ACCATT,0,136,ACTA CTAA TAAA AAAG AAGA AGAA GAAG AAGG AGGT GGTG GTGC TGCC GCCA CCAC CACT ACTA CTAC TACT ACTT CTTG TTGT TGTG GTGG TGGT GGTT GTTA TTAC TACT ACTT CTTA TTAC TACC ACCC CCCC CCCA CCAA CAAA AAAA AAAT AATG ATGC TGCT GCTG CTGT TGTT GTTG TTGT TGTT GTTA TTAA TAAA AAAA AAAT AATT ATTT TTTA TTAT TATT ATTG TTGT TGTC GTCC TCCA CCAG CAGC AGCA GCAT CATG ATGT TGTC GTCA TCAC CACA ACAA CAAT AATT ATTC TTCA TCAG CAGA AGAA GAAG AAGT AGTA GTAG TAGG AGGA GGAC GACC ACCT CCTG CTGA TGAG GAGC AGCA GCAT CATA ATAG TAGT AGTC GTCT TCTT CTTG TTGC TGCC GCCG CCGA CGAA GAAT AATA ATAC TACC ACCA CCAT CATA ATAA TAAT AATG ATGA TGAA GAAT AATC ATCT TCTG CTGG TGGC GGCT GCTT CTTG TTGA TGAA GAAA AAAA AAAC AACC ACCA CCAT CATT,ACTAA CTAAA TAAAG AAAGA AAGAA AGAAG GAAGG AAGGT AGGTG GGTGC GTGCC TGCCA GCCAC CCACT CACTA ACTAC CTACT TACTT ACTTG CTTGT TTGTG TGTGG GTGGT TGGTT GGTTA GTTAC TTACT TACTT ACTTA CTTAC TTACC TACCC ACCCC CCCCA CCCAA CCAAA CAAAA AAAAT AAATG AATGC ATGCT TGCTG GCTGT CTGTT TGTTG GTTGT TTGTT TGTTA GTTAA TTAAA TAAAA AAAAT AAATT AATTT ATTTA TTTAT TTATT TATTG ATTGT TTGTC TGTCC GTCCA TCCAG CCAGC CAGCA AGCAT GCATG CATGT ATGTC TGTCA GTCAC TCACA CACAA ACAAT CAATT AATTC ATTCA TTCAG TCAGA CAGAA AGAAG GAAGT AAGTA AGTAG GTAGG TAGGA AGGAC GGACC GACCT ACCTG CCTGA CTGAG TGAGC GAGCA AGCAT GCATA CATAG ATAGT TAGTC AGTCT GTCTT TCTTG CTTGC TTGCC TGCCG GCCGA CCGAA CGAAT GAATA AATAC ATACC TACCA ACCAT CCATA CATAA ATAAT TAATG AATGA ATGAA TGAAT GAATC AATCT ATCTG TCTGG CTGGC TGGCT GGCTT GCTTG CTTGA TTGAA TGAAA GAAAA AAAAC AAACC AACCA ACCAT CCATT,ACTAAA CTAAAG TAAAGA AAAGAA AAGAAG AGAAGG GAAGGT AAGGTG AGGTGC GGTGCC GTGCCA TGCCAC GCCACT CCACTA CACTAC ACTACT CTACTT TACTTG ACTTGT CTTGTG TTGTGG TGTGGT GTGGTT TGGTTA GGTTAC GTTACT TTACTT TACTTA ACTTAC CTTACC TTACCC TACCCC ACCCCA CCCCAA CCCAAA CCAAAA CAAAAT AAAATG AAATGC AATGCT ATGCTG TGCTGT GCTGTT CTGTTG TGTTGT GTTGTT TTGTTA TGTTAA GTTAAA TTAAAA TAAAAT AAAATT AAATTT AATTTA ATTTAT TTTATT TTATTG TATTGT ATTGTC TTGTCC TGTCCA GTCCAG TCCAGC CCAGCA CAGCAT AGCATG GCATGT CATGTC ATGTCA TGTCAC GTCACA TCACAA CACAAT ACAATT CAATTC AATTCA ATTCAG TTCAGA TCAGAA CAGAAG AGAAGT GAAGTA AAGTAG AGTAGG GTAGGA TAGGAC AGGACC GGACCT GACCTG ACCTGA CCTGAG CTGAGC TGAGCA GAGCAT AGCATA GCATAG CATAGT ATAGTC TAGTCT AGTCTT GTCTTG TCTTGC CTTGCC TTGCCG TGCCGA GCCGAA CCGAAT CGAATA GAATAC AATACC ATACCA TACCAT ACCATA CCATAA CATAAT ATAATG TAATGA AATGAA ATGAAT TGAATC GAATCT AATCTG ATCTGG TCTGGC CTGGCT TGGCTT GGCTTG GCTTGA CTTGAA TTGAAA TGAAAA GAAAAC AAAACC AAACCA AACCAT ACCATT,ACTAAAG CTAAAGA TAAAGAA AAAGAAG AAGAAGG AGAAGGT GAAGGTG AAGGTGC AGGTGCC GGTGCCA GTGCCAC TGCCACT GCCACTA CCACTAC CACTACT ACTACTT CTACTTG TACTTGT ACTTGTG CTTGTGG TTGTGGT TGTGGTT GTGGTTA TGGTTAC GGTTACT GTTACTT TTACTTA TACTTAC ACTTACC CTTACCC TTACCCC TACCCCA ACCCCAA CCCCAAA CCCAAAA CCAAAAT CAAAATG AAAATGC AAATGCT AATGCTG ATGCTGT TGCTGTT GCTGTTG CTGTTGT TGTTGTT GTTGTTA TTGTTAA TGTTAAA GTTAAAA TTAAAAT TAAAATT AAAATTT AAATTTA AATTTAT ATTTATT TTTATTG TTATTGT TATTGTC ATTGTCC TTGTCCA TGTCCAG GTCCAGC TCCAGCA CCAGCAT CAGCATG AGCATGT GCATGTC CATGTCA ATGTCAC TGTCACA GTCACAA TCACAAT CACAATT ACAATTC CAATTCA AATTCAG ATTCAGA TTCAGAA TCAGAAG CAGAAGT AGAAGTA GAAGTAG AAGTAGG AGTAGGA GTAGGAC TAGGACC AGGACCT GGACCTG GACCTGA ACCTGAG CCTGAGC CTGAGCA TGAGCAT GAGCATA AGCATAG GCATAGT CATAGTC ATAGTCT TAGTCTT AGTCTTG GTCTTGC TCTTGCC CTTGCCG TTGCCGA TGCCGAA GCCGAAT CCGAATA CGAATAC GAATACC AATACCA ATACCAT TACCATA ACCATAA CCATAAT CATAATG ATAATGA TAATGAA AATGAAT ATGAATC TGAATCT GAATCTG AATCTGG ATCTGGC TCTGGCT CTGGCTT TGGCTTG GGCTTGA GCTTGAA CTTGAAA TTGAAAA TGAAAAC GAAAACC AAAACCA AAACCAT AACCATT,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",606
CCGAGT CGAGTC GAGTCT AGTCTC GTCTCG TCTCGA CTCGAG TCGAGT CGAGTT GAGTTG AGTTGA GTTGAG TTGAGA TGAGAC GAGACA AGACAG GACAGC ACAGCG CAGCGC AGCGCC GCGCCC CGCCCA GCCCAA CCCAAA CCAAAT CAAATC AAATCG AATCGT ATCGTT TCGTTA CGTTAC GTTACG TTACGC TACGCC ACGCCC CGCCCT GCCCTT CCCTTC CCTTCG CTTCGT TTCGTG TCGTGC CGTGCG GTGCGG TGCGGG GCGGGT CGGGTC GGGTCG GGTCGG GTCGGA TCGGAA CGGAAC GGAACT GAACTT AACTTA ACTTAC CTTACC TTACCC TACCCG ACCCGA CCCGAC CCGACG CGACGA GACGAG ACGAGG CGAGGA GAGGAA AGGAAT GGAATT GAATTT AATTTC ATTTCG TTTCGC TTCGCT TCGCTA CGCTAC GCTACC CTACCT TACCTT ACCTTA CCTTAG CTTAGG TTAGGA TAGGAC AGGACC GGACCG GACCGT ACCGTT CCGTTA CGTTAT GTTATA TTATAG TATAGT ATAGTT TAGTTA AGTTAC GTTACG TTACGG TACGGC ACGGCC CGGCCG GGCCGC GCCGCC CCGCCG CGCCGT GCCGTT CCGTTT CGTTTA GTTTAC TTTACT TTACTG TACTGG ACTGGG CTGGGG TGGGGC GGGGCT GGGCTT GGCTTC GCTTCA CTTCAA TTCAAT TCAATT CAATTC AATTCA ATTCAA TTCAAT TCAATG CAATGC AATGCT ATGCTT TGCTTT GCTTTG CTTTGA,3,133,CCGA CGAG GAGT AGTC GTCT TCTC CTCG TCGA CGAG GAGT AGTT GTTG TTGA TGAG GAGA AGAC GACA ACAG CAGC AGCG GCGC CGCC GCCC CCCA CCAA CAAA AAAT AATC ATCG TCGT CGTT GTTA TTAC TACG ACGC CGCC GCCC CCCT CCTT CTTC TTCG TCGT CGTG GTGC TGCG GCGG CGGG GGGT GGTC GTCG TCGG CGGA GGAA GAAC AACT ACTT CTTA TTAC TACC ACCC CCCG CCGA CGAC GACG ACGA CGAG GAGG AGGA GGAA GAAT AATT ATTT TTTC TTCG TCGC CGCT GCTA CTAC TACC ACCT CCTT CTTA TTAG TAGG AGGA GGAC GACC ACCG CCGT CGTT GTTA TTAT TATA ATAG TAGT AGTT GTTA TTAC TACG ACGG CGGC GGCC GCCG CCGC CGCC GCCG CCGT CGTT GTTT TTTA TTAC TACT ACTG CTGG TGGG GGGG GGGC GGCT GCTT CTTC TTCA TCAA CAAT AATT ATTC TTCA TCAA CAAT AATG ATGC TGCT GCTT CTTT TTTG TTGA,CCGAG CGAGT GAGTC AGTCT GTCTC TCTCG CTCGA TCGAG CGAGT GAGTT AGTTG GTTGA TTGAG TGAGA GAGAC AGACA GACAG ACAGC CAGCG AGCGC GCGCC CGCCC GCCCA CCCAA CCAAA CAAAT AAATC AATCG ATCGT TCGTT CGTTA GTTAC TTACG TACGC ACGCC CGCCC GCCCT CCCTT CCTTC CTTCG TTCGT TCGTG CGTGC GTGCG TGCGG GCGGG CGGGT GGGTC GGTCG GTCGG TCGGA CGGAA GGAAC GAACT AACTT ACTTA CTTAC TTACC TACCC ACCCG CCCGA CCGAC CGACG GACGA ACGAG CGAGG GAGGA AGGAA GGAAT GAATT AATTT ATTTC TTTCG TTCGC TCGCT CGCTA GCTAC CTACC TACCT ACCTT CCTTA CTTAG TTAGG TAGGA AGGAC GGACC GACCG ACCGT CCGTT CGTTA GTTAT TTATA TATAG ATAGT TAGTT AGTTA GTTAC TTACG TACGG ACGGC CGGCC GGCCG GCCGC CCGCC CGCCG GCCGT CCGTT CGTTT GTTTA TTTAC TTACT TACTG ACTGG CTGGG TGGGG GGGGC GGGCT GGCTT GCTTC CTTCA TTCAA TCAAT CAATT AATTC ATTCA TTCAA TCAAT CAATG AATGC ATGCT TGCTT GCTTT CTTTG TTTGA,CCGAGT CGAGTC GAGTCT AGTCTC GTCTCG TCTCGA CTCGAG TCGAGT CGAGTT GAGTTG AGTTGA GTTGAG TTGAGA TGAGAC GAGACA AGACAG GACAGC ACAGCG CAGCGC AGCGCC GCGCCC CGCCCA GCCCAA CCCAAA CCAAAT CAAATC AAATCG AATCGT ATCGTT TCGTTA CGTTAC GTTACG TTACGC TACGCC ACGCCC CGCCCT GCCCTT CCCTTC CCTTCG CTTCGT TTCGTG TCGTGC CGTGCG GTGCGG TGCGGG GCGGGT CGGGTC GGGTCG GGTCGG GTCGGA TCGGAA CGGAAC GGAACT GAACTT AACTTA ACTTAC CTTACC TTACCC TACCCG ACCCGA CCCGAC CCGACG CGACGA GACGAG ACGAGG CGAGGA GAGGAA AGGAAT GGAATT GAATTT AATTTC ATTTCG TTTCGC TTCGCT TCGCTA CGCTAC GCTACC CTACCT TACCTT ACCTTA CCTTAG CTTAGG TTAGGA TAGGAC AGGACC GGACCG GACCGT ACCGTT CCGTTA CGTTAT GTTATA TTATAG TATAGT ATAGTT TAGTTA AGTTAC GTTACG TTACGG TACGGC ACGGCC CGGCCG GGCCGC GCCGCC CCGCCG CGCCGT GCCGTT CCGTTT CGTTTA GTTTAC TTTACT TTACTG TACTGG ACTGGG CTGGGG TGGGGC GGGGCT GGGCTT GGCTTC GCTTCA CTTCAA TTCAAT TCAATT CAATTC AATTCA ATTCAA TTCAAT TCAATG CAATGC AATGCT ATGCTT TGCTTT GCTTTG CTTTGA,CCGAGTC CGAGTCT GAGTCTC AGTCTCG GTCTCGA TCTCGAG CTCGAGT TCGAGTT CGAGTTG GAGTTGA AGTTGAG GTTGAGA TTGAGAC TGAGACA GAGACAG AGACAGC GACAGCG ACAGCGC CAGCGCC AGCGCCC GCGCCCA CGCCCAA GCCCAAA CCCAAAT CCAAATC CAAATCG AAATCGT AATCGTT ATCGTTA TCGTTAC CGTTACG GTTACGC TTACGCC TACGCCC ACGCCCT CGCCCTT GCCCTTC CCCTTCG CCTTCGT CTTCGTG TTCGTGC TCGTGCG CGTGCGG GTGCGGG TGCGGGT GCGGGTC CGGGTCG GGGTCGG GGTCGGA GTCGGAA TCGGAAC CGGAACT GGAACTT GAACTTA AACTTAC ACTTACC CTTACCC TTACCCG TACCCGA ACCCGAC CCCGACG CCGACGA CGACGAG GACGAGG ACGAGGA CGAGGAA GAGGAAT AGGAATT GGAATTT GAATTTC AATTTCG ATTTCGC TTTCGCT TTCGCTA TCGCTAC CGCTACC GCTACCT CTACCTT TACCTTA ACCTTAG CCTTAGG CTTAGGA TTAGGAC TAGGACC AGGACCG GGACCGT GACCGTT ACCGTTA CCGTTAT CGTTATA GTTATAG TTATAGT TATAGTT ATAGTTA TAGTTAC AGTTACG GTTACGG TTACGGC TACGGCC ACGGCCG CGGCCGC GGCCGCC GCCGCCG CCGCCGT CGCCGTT GCCGTTT CCGTTTA CGTTTAC GTTTACT TTTACTG TTACTGG TACTGGG ACTGGGG CTGGGGC TGGGGCT GGGGCTT GGGCTTC GGCTTCA GCTTCAA CTTCAAT TTCAATT TCAATTC CAATTCA AATTCAA ATTCAAT TTCAATG TCAATGC CAATGCT AATGCTT ATGCTTT TGCTTTG GCTTTGA,"ID   YCX91_PHAAO             Reviewed;          91 AA.
AC   Q3BAI2;
DT   25-JUL-2006, integrated into UniProtKB/Swiss-Prot.
DT   22-NOV-2005, sequence version 1.
DT   05-FEB-2025, entry version 27.
DE   RecName: Full=Uncharacterized protein ORF91;
OS   Phalaenopsis aphrodite subsp. formosana (Moth orchid).
OG   Plastid; Chloroplast.
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliopsida; Liliopsida; Asparagales; Orchidaceae;
OC   Epidendroideae; Vandeae; Aeridinae; Phalaenopsis.
OX   NCBI_TaxID=308872;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=cv. Taisugar TS-97;
RX   PubMed=16207935; DOI=10.1093/molbev/msj029;
RA   Chang C.-C., Lin H.-C., Lin I.-P., Chow T.-Y., Chen H.-H., Chen W.-H.,
RA   Cheng C.-H., Lin C.-Y., Liu S.-M., Chang C.-C., Chaw S.-M.;
RT   ""The chloroplast genome of Phalaenopsis aphrodite (Orchidaceae):
RT   comparative analysis of evolutionary rate with that of grasses and its
RT   phylogenetic implications."";
RL   Mol. Biol. Evol. 23:279-291(2006).
CC   -!- SUBCELLULAR LOCATION: Plastid, chloroplast.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY916449; AAW82572.1; -; Genomic_DNA.
DR   RefSeq; YP_358636.1; NC_007499.1.
DR   AlphaFoldDB; Q3BAI2; -.
DR   GeneID; 3741793; -.
DR   GO; GO:0009507; C:chloroplast; IEA:UniProtKB-SubCell.
DR   AntiFam; ANF00025; Antisense to 23S rRNA.
PE   4: Predicted;
KW   Chloroplast; Plastid.
FT   CHAIN           1..91
FT                   /note=""Uncharacterized protein ORF91""
FT                   /id=""PRO_0000246135""
SQ   SEQUENCE   91 AA;  10596 MW;  C770491A1FF96EE8 CRC64;
     MQVVRIFTDM SISPSLSPRQ CPDRYAFRAG RNLPDKEFRY LRTVLVTAAV HRGFGRRLPC
     HQVTNFLDLP ALGRRQPPYM VLRLCGDLCF W
//
",38552
GATGAC ATGACA TGACAC GACACT ACACTC CACTCT ACTCTA CTCTAC TCTACG CTACGT TACGTG ACGTGT CGTGTT GTGTTG TGTTGA GTTGAG TTGAGG TGAGGC GAGGCT AGGCTT GGCTTT GCTTTT CTTTTG TTTTGA TTTGAG TTGAGT TGAGTA GAGTAC AGTACT GTACTA TACTAC ACTACC CTACCA TACCAC ACCACA CCACAC CACACA ACACAA CACAAC ACAACT CAACTG AACTGA ACTGAT CTGATC TGATCC GATCCT ATCCTA TCCTAG CCTAGT CTAGTT TAGTTT AGTTTT GTTTTC TTTTCT TTTCTG TTCTGG TCTGGG CTGGGT TGGGTA GGGTAG GGTAGG GTAGGT TAGGTA AGGTAC GGTACA GTACAT TACATG,0,67,GATG ATGA TGAC GACA ACAC CACT ACTC CTCT TCTA CTAC TACG ACGT CGTG GTGT TGTT GTTG TTGA TGAG GAGG AGGC GGCT GCTT CTTT TTTT TTTG TTGA TGAG GAGT AGTA GTAC TACT ACTA CTAC TACC ACCA CCAC CACA ACAC CACA ACAA CAAC AACT ACTG CTGA TGAT GATC ATCC TCCT CCTA CTAG TAGT AGTT GTTT TTTT TTTC TTCT TCTG CTGG TGGG GGGT GGTA GTAG TAGG AGGT GGTA GTAC TACA ACAT CATG,GATGA ATGAC TGACA GACAC ACACT CACTC ACTCT CTCTA TCTAC CTACG TACGT ACGTG CGTGT GTGTT TGTTG GTTGA TTGAG TGAGG GAGGC AGGCT GGCTT GCTTT CTTTT TTTTG TTTGA TTGAG TGAGT GAGTA AGTAC GTACT TACTA ACTAC CTACC TACCA ACCAC CCACA CACAC ACACA CACAA ACAAC CAACT AACTG ACTGA CTGAT TGATC GATCC ATCCT TCCTA CCTAG CTAGT TAGTT AGTTT GTTTT TTTTC TTTCT TTCTG TCTGG CTGGG TGGGT GGGTA GGTAG GTAGG TAGGT AGGTA GGTAC GTACA TACAT ACATG,GATGAC ATGACA TGACAC GACACT ACACTC CACTCT ACTCTA CTCTAC TCTACG CTACGT TACGTG ACGTGT CGTGTT GTGTTG TGTTGA GTTGAG TTGAGG TGAGGC GAGGCT AGGCTT GGCTTT GCTTTT CTTTTG TTTTGA TTTGAG TTGAGT TGAGTA GAGTAC AGTACT GTACTA TACTAC ACTACC CTACCA TACCAC ACCACA CCACAC CACACA ACACAA CACAAC ACAACT CAACTG AACTGA ACTGAT CTGATC TGATCC GATCCT ATCCTA TCCTAG CCTAGT CTAGTT TAGTTT AGTTTT GTTTTC TTTTCT TTTCTG TTCTGG TCTGGG CTGGGT TGGGTA GGGTAG GGTAGG GTAGGT TAGGTA AGGTAC GGTACA GTACAT TACATG,GATGACA ATGACAC TGACACT GACACTC ACACTCT CACTCTA ACTCTAC CTCTACG TCTACGT CTACGTG TACGTGT ACGTGTT CGTGTTG GTGTTGA TGTTGAG GTTGAGG TTGAGGC TGAGGCT GAGGCTT AGGCTTT GGCTTTT GCTTTTG CTTTTGA TTTTGAG TTTGAGT TTGAGTA TGAGTAC GAGTACT AGTACTA GTACTAC TACTACC ACTACCA CTACCAC TACCACA ACCACAC CCACACA CACACAA ACACAAC CACAACT ACAACTG CAACTGA AACTGAT ACTGATC CTGATCC TGATCCT GATCCTA ATCCTAG TCCTAGT CCTAGTT CTAGTTT TAGTTTT AGTTTTC GTTTTCT TTTTCTG TTTCTGG TTCTGGG TCTGGGT CTGGGTA TGGGTAG GGGTAGG GGTAGGT GTAGGTA TAGGTAC AGGTACA GGTACAT GTACATG,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",35472
CCTATG CTATGC TATGCT ATGCTT TGCTTA GCTTAT CTTATT TTATTG TATTGG ATTGGC TTGGCA TGGCAC GGCACA GCACAT CACATT ACATTA CATTAG ATTAGA TTAGAA TAGAAG AGAAGA GAAGAG AAGAGC AGAGCT GAGCTC AGCTCA GCTCAT CTCATT TCATTG CATTGA ATTGAT TTGATG TGATGA GATGAG ATGAGG TGAGGA GAGGAT AGGATC GGATCA GATCAC ATCACG TCACGC CACGCT ACGCTA CGCTAT GCTATT CTATTG TATTGT ATTGTC TTGTCT TGTCTC GTCTCC TCTCCT CTCCTC TCCTCT CCTCTA CTCTAT TCTATT CTATTG TATTGG ATTGGG TTGGGC TGGGCC GGGCCA GGCCAG GCCAGA CCAGAA CAGAAT AGAATA GAATAC AATACT ATACTA TACTAT ACTATG CTATGC TATGCG ATGCGC TGCGCA GCGCAT CGCATA GCATAT CATATT ATATTC TATTCT ATTCTA TTCTAT TCTATC CTATCT TATCTT ATCTTT TCTTTC CTTTCG TTTCGT TTCGTT TCGTTG CGTTGA GTTGAC TTGACA TGACAA GACAAG ACAAGG CAAGGA AAGGAC AGGACT GGACTA GACTAG,3,106,CCTTCGTA C C CTCTATTGCA T TTATTC TG T GATGTGC TGTGCCT T G GCCTTCTTTT T C CTT TTA A T TTTATAT CTT TATATATTG TT A ATATTTTGTG AG CA TTGTGGGG T TTGGGGCGC C G GGGGCGCACA A G GCGCACACAC CAT CACACTGCA ATTTCTATCAAT T CTG GAGATTTT T A ATCT TTATA A T AGAG G T TATAGAGAGA G T AGAGAGAAA G GAGAAAAGG T AAAAGAGATC A A TTAGACATAG G G GAGAGAGCGC C AAGCGCTCT T GT TTC C C CTCTCTCACA A T TCC CCATAT T C CACATATTCTC ATATTTTGTG G T TTACATGAGA A T TGTGAGATAT TTC GAATGTG GG  ATGA  TGT AGAGAG G G GAGAGAGGGG G A AGAGGGGAGA TCT GGGGAGATAT T GGATTC C A ATTATTCAAT A T TCCACAC A C CACACACGATA AC ACACGCGCGC C C CGCGCGCTCT T G GCGCTTA ATCCTATATAT GACTATATTTT T AATTTTGTG A A TTTTGTGTGT T T TGGTCTC C G GTTTACT T T TCTCTT ATC C C CTAC CC  CG TCTCCCCTCT  CCCCTCTCTC  CTTCTCT T T TCTCTCTATA A C GACTATATAT T T TATATATTTT TGA ATATTTTG CAG T TTTTGTGGGG  TGTGGGGGG AG G GGGGCGC C G GGTCCGCCCC  GCGCCTTTCA A C CCCAGAG G CGAC TAAAGGA A AAGAGAAAA A G CTGAAAATAT T A AAAATTTATA A A ATATATACC T TA CAACTATGT A ACACTCTATA A C CTACATATAT T T TATATATGGA G A ATATTGC C TAAGACAGCGG G GCCGCGC C CC TCGCGCA TTA G GCGCACATAT T CTACCATATAA A ATATATATAT T T TATATGGATT ATTT GATG TTTTCTCTCT T T TCA GCTATA  CTCTATATAT T T CTGA ATCTCTCT T T TCTCTCTTTT T C CTGCTCCATT G ATTCTC C T TTTTCCTACG G T TCTCGGT T C CGCGTGTTTT  AT GTGTTTTGTG G T TTTTGGA A T TGTGAAC AC C GA C CATATCA A A ACACAAA A C CACAAAG G A AA TGAGGGG  AGAGGGGATG A G GGATTGACCTCC G GA AGACTCT T A ACACTTA  GA CTCTATAG,CCTTATTATT C CTCTATATGACC GG T TAATGTGCGC C A ATATGTGCCT T TTTCTGCGCTCTTTT T GGCTCTTTTATA A C CTCTTTTATATAT T TTG TTATATATTTT T TAG TATATT CATG CACATTTTG TGGG G T TTTTGTGGGGCCGTC T TGTGGGGCGCACA A G GGC TGCAG AAC T C AGGCA TTACACA A C CACACACACATAT TGA ACACACATTCTTT T C CACATATTA A AT TGTTATAGAG G TCACTTATATAGAGA TGT TATAGTA AA A A AGGAAAAGAG  GAGGCAAGGA A AAAGAGACACAG G A AGGAGAGCC GT GGAGAGCGCTCT T A AGAGCGCTCTC TCC G GCGCTA TTCAA C CTCTCTCACA AT T T TCTCACATATTTT T CCATATT TATG G A CAATTTTGTGAA T TTTTGTGAGATAT T T TGTGAGATATGTG ACG GATC ATGGA CCT ATATGGACGAGAG G T TG TTAGG TCG G GAGAGAGGGGAA A GCAGGGGATAGAT T GGGAGATATCTC  TT GAGATATCTCA GGA A ATATCTCACACAC C T TCTCAGAGACGCG G CCT CACG GCGC ACACGCGCGCTCT T C CGCGCGCTCTAGAAA G GCGCTCTACTAAT C GCTATATATTTTGT T TAATTTTGG A ATATTTTGTGTAT T T TTTTGA TGTCTC C TTGGTGTGTCTCTCT  GA GTGTCTCCGATATGTC TCTCTCTCTCC C C CTCTCTCCCCTCT T T TCCGTCATCTCTC C CACTA ACTCTCTCT  GT CTCTCATAGCA GACTCCTATCTCTATATGT T C CTCTATATATTTT T T TATATATTTTGTG G A ATTTGGG G TTT GGGGG G TATTTGGGGGGC C G GGGGCGCCCC C G GGGGCGCCCCACCT GCGCCCCACAGAG G C CCCCACAGAGAGA  CAAGAGAAAA A A AG AAGAAAATAT T G GAGAAATATA A A AAAATATATACAC C A ATATATACACTTC T T TAACTCTATA A A ACACTCTAT C CTCTAGAATG  TATATATGTGCGC C A ATATGTGCGCGCG  TGTGCTGGCGCGC C G GCGCGCGCGCACA A CCGC TCCATAT T G GCGCACATCT TA  CACATATATATAT T ACA ATAATTTT T T TAATTTTCTC C A ATATTTTCTCTTCTGAGG TTCTGT TA  TCTT CTATATAT T C CTCTATATATC ATC TTGATATATCTCTCT T A ATATCTCTTT T TATTTCTT C CTCTTTTTTTCTC C T TTTTTTTCCG TTC TTTCGCGTCTAGG TCGGC GTTTT T CT CTCCGTTTTGTG G G CGGTTTTGTGAGA A T TTTTGTGAC T TG TAT TACAA G GAAGAACACAAAA A A ACACACAAAAGTTGG C CACAAAGG AAAAGAGGGGAGA  AGGGAGACAC C GGGAATG CCCT T GGACACTCTATA A A ACACTCTATAG,CCTCTATATATGTG G C CTCTAATGGC C T TATATATGTGCGCTT A TGATGTGCGCTCTTT TTTAGCTCTT ATTA AAG GCTGCCTTCGCTATGGCT C CTCTTTTATATTG TT T T TTG ATATATTTTGTG G T TATATTTGTGG ATATTTTGTGGGGCGC C T TTTGGGGCGCAA GA TGCATGGGGCGCACACTATCAG GGGGCGCACACCA  GCCTCA TACACATAT  CACACACACATC TGAAT A ACACACATATTGGCTA A C CACATATTTACG A ATATTTTATACAGAGA  TTTTATAGAGAACAA TCCTTAGAGAGAAAAGAG G A GAAGA GTAAGAGAGA  GAGAAA GAGAAG G A AAAAGAGAGAGAGCGC C A AGAGAAGCTATCT T G GAGAGAGCGCTCTCTC C A AGAGCCTCTCACA A G GCGCTGGCCATAT T CAT CTCTCACATATTTT T T TCTCACATATTTTGTG  CACATATTTTGTGAGA A A ATATTGCGTGAGATT T TTTGAGATATGATT TGTGAGATATGTGAGA CTA GAA TTC TGAGAGAG GCC ATATGTGAGAGAGGGG  TGTGAGAGT AGA A GT CGAGAGGGGAGATAT  AGAGGGGAGATATCTC CTA GGGGAGATATCTCACA A G AGGACATCTCACACC A ATATCTCACACACGT A TCTCACACG TTTAGC C C CACACACGCT GGA ACACGCGCGCTCA TA A C CGCGCGCTTATT AT G GCGCTCTAGACATTTT T CCTAC GTATATTTTGTG G T TACT ATTTTGTGTGT T ATA ATT TATG GTCTC C T TTTTGTGTGTCTCTCT T T TGTGTGTCTCTA CATGCTA GTGTCTCTCTCTCCCC C T TCTCTCTCTCCCCTCT TTT CTCTCTCC TACTCTC C T TCTCCCCTCTCTCTCT T C CCCTCTCTCTATA  TGCTCC TGCTATTT T TCCTA TAATTTT  GACATCTATGCATTTTGTG G T TAT AATTTTGTGG GGG A ATATTTTGTGGGGGACG TTTTGTGGGGGTTAGC  TGTGGGGGA G TCCC C GGG GGGGGCGCCCCACA A G GGAT GCCCCAC GAG G G GCGCCCCAA CA C CCCCACAGAGAGAAAA T A CACAGAGAGAAAATAT  AGAGAAATATATA CTC GAGAAAATATATTAAC C A AACTAATATACACTCT CAG ATATATACACTCTAA T TATAGACTCTAGCAT A ACAT TATATGTG G C CTCTATATATGTGCGC ACTTATATGTATGCGCG  ATATGTGCGCGCGCGC TATTGCTTGCGCGCACA A G GCTGACGCTAT CTAT T C CGCGCGCACATATATA A GGCACATATATATAT T CGTTCATATAAC TT TAT ATATATATA GTTCTC C T TATATTTCCT G T ATATTTTCTCTCAATA CAC TTTTCTCTCTATATAT T TG ATCTCAAC CATCTC C C CTCTA AAATCTCTTATT TTTGTATATCTCT CT ATATCTCTCTTTTTTT T T TCTCTCTTTTTTTCTC TAT CTCTTT CTTCTCGCG G T TTTTTTTCCGTGT T TTTCTCGCGTGTTTT T T TCTCGCGT CATTGTGTG C CGCGTGTTTTGTGAGA GAAGTTTTGGCGGACAC C TTTGTGACTAACACA A T TGTGAGATACACAAAA A G GAGACACAAAGAG G A ACCAAAAGAGGGG G C CAGACAAGAGGGGAGA A ATATAAGAGGGGAGACAC C A AGGGAGACCT T G GGGGAGACACTCTA ATA G GATATACTAAT,CCTCTAATGTGCGC C C CTTATCTTTGCCT T T TATATATGTGCCTTG G ATATGCTCGCTCTTTTAA T TGTGCGCTTATAT T G GCGCTGCATATATTTT T C CTCTTTTATATTGATTGTG G T TTTTATATATTCTATGGGG G T TATATATTTTGTGGGGCGC C A ATATTTTGTGGA CGCACA A T TTTTGTGGGGCTTACACATTC T TGTGGGGCACACACGCACTAA GGA GGCGCACACACAAT T G GCCACTCCCATATTTT T C CACACACACATATTC GTA GAT ACACAATCTTATAGAG G C CACATATT TCTAGAGAGA TGAATTTTATAGAGAGAA TAA T TTAGCTAGTT GAAAAG ACG T TATCAAGAGAAAAGAGAGA A A AGGAAAAGAGAGAGAG T A GAGAAAAGAGAGAGAGCGC GAC AAAAGAGAGAGTTAGCTCT  AGAGAGAGAGCGCTCTC GGC G GAAGCCTCA TCA A A AGAGCGCTCTATCACATAT T G GCGCTCTCCATATT GAT C CTCTCCATATTTTGT GG T TCTCACATATTTTGTGAGA A C CATTGAT  ATATTTTGTGATATATGTG G T TTTTGATTA AATGTGA TGA T TGAT GCAATGTCGTATATA GAAT ATGTGAGAGGG G A ATATGTGAGAGAGGGGAGA A T GG GCGAGAGGTCGAT T G GAGAGAGGGGAATTATCTC C A AGAGGGGAGATATCGG CA A GGGAATCTCACACATTC GGATATCTCACACACGTC G AGGGT TTCATGTACGCGC AC TCTCAACGCGCGCTCT T C CACACACGAG GCTAGATA A AC TACGCGCCCACTATATAT T C CGCGCGCTCTATATGATTATT G GCGCTCTATATATTTTG CT CTTATATTTTGTGTGT T T TAGGGATTTTGTGTTATTC  ATATTTTGCACGTCTCTCT T T TTTTGTGTGTCTCTCTCC T TGTGTGTCCTTCTCTCC GGC G GTGTCTCTCTCT TCCTCT  ATATTTCTTCCCCTTGGTC C C CTGCAACACCTTCTCCA TCTCCCCTTCTCA A CCCTT TTCTTTGTATAT T C CTCTCTCTCTATATTT ATCCTATCTCTATATATTTTGTG G CGGACTATATATTTTGTAGG T TATATAC TTGCTCTT GG G A ATATTTGGGGGGGCGC C T TTTTGTGG ATGGCGCCC T TGTGGGGCGCCGCTA GTC GGGGGCCCACAGAG GGCCCACAGAGAGA A G GCGCCATAGTTAGAGAAAA GGC CCCCACAGAGAAGGAATGCAT C CAAGAGAAAATCT TA A A AGCTAAATTG TACAC TTA GAGAAG GACT AAAATATATACACTAG TA A AATAACTCTATATTGATGC TATACACTTATATGTG G AACTCTATATATGTGCGC C CCTACTAGATATGTGCGCGCG G TTTCTATATGCTTGCGCGCC AATGTGCGCGCGCCTCCA A TTGCGCGGATCATAT  GCGCGGACTGACATATATA A C CGCGCGCACATATATATGATTG A AGCACATATAGAGATTTT  CACATATATATATTTTC ATTATATTTCTCT T T TA TCTATTCTCTATA A A ATAC TTCTCTCTCTATAT T T TTAGGTCTCTATATATCC TTTACTATATATCAGGCT T CCTATATATCTCTCTTTT T T TATATATCTCTCTTTTTTT T TCATTCTTGCTTTTTCTC C T TCTCTCTTTTTTTCCG G C CTTCTTTTTTCGATCGTGT T T TTA CTCGGTTTT TCC TTTTCTCGCGTGTTTTGATAG TTGA TGCGCTTGGA TTC CGCGTCAGTTGTGAGACAC C G GTGTTTTGTGAGACACACA A T TTTTGTGAGACACACAAAA TCACGTAT GACACACAA TCG GAGAC AACACAAAAGTCTGG G ACGCACAAAGAGGGA A C CACAAAAGTTCGGAGACAC C A AAAAGAGGGGAGACACTT A AGGAAGGAGTTACTCTATA A G GG CTGACACTCTA,"ID   PRS4_SCHPO              Reviewed;         448 AA.
AC   P36612;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   05-FEB-2025, entry version 179.
DE   RecName: Full=26S proteasome regulatory subunit 4 homolog;
DE   AltName: Full=Protein mts2;
GN   Name=mts2; ORFNames=SPBC4.07c;
OS   Schizosaccharomyces pombe (strain 972 / ATCC 24843) (Fission yeast).
OC   Eukaryota; Fungi; Dikarya; Ascomycota; Taphrinomycotina;
OC   Schizosaccharomycetes; Schizosaccharomycetales; Schizosaccharomycetaceae;
OC   Schizosaccharomyces.
OX   NCBI_TaxID=284812;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=972 / ATCC 24843;
RX   PubMed=8247131; DOI=10.1038/366355a0;
RA   Gordon C.B., McGurk G., Dillon P., Rosen C., Hastie N.D.;
RT   ""Defective mitosis due to a mutation in the gene for a fission yeast 26S
RT   protease subunit."";
RL   Nature 366:355-357(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=972 / ATCC 24843;
RX   PubMed=11859360; DOI=10.1038/nature724;
RA   Wood V., Gwilliam R., Rajandream M.A., Lyne M.H., Lyne R., Stewart A.,
RA   Sgouros J.G., Peat N., Hayles J., Baker S.G., Basham D., Bowman S.,
RA   Brooks K., Brown D., Brown S., Chillingworth T., Churcher C.M., Collins M.,
RA   Connor R., Cronin A., Davis P., Feltwell T., Fraser A., Gentles S.,
RA   Goble A., Hamlin N., Harris D.E., Hidalgo J., Hodgson G., Holroyd S.,
RA   Hornsby T., Howarth S., Huckle E.J., Hunt S., Jagels K., James K.D.,
RA   Jones L., Jones M., Leather S., McDonald S., McLean J., Mooney P.,
RA   Moule S., Mungall K.L., Murphy L.D., Niblett D., Odell C., Oliver K.,
RA   O'Neil S., Pearson D., Quail M.A., Rabbinowitsch E., Rutherford K.M.,
RA   Rutter S., Saunders D., Seeger K., Sharp S., Skelton J., Simmonds M.N.,
RA   Squares R., Squares S., Stevens K., Taylor K., Taylor R.G., Tivey A.,
RA   Walsh S.V., Warren T., Whitehead S., Woodward J.R., Volckaert G., Aert R.,
RA   Robben J., Grymonprez B., Weltjens I., Vanstreels E., Rieger M.,
RA   Schaefer M., Mueller-Auer S., Gabel C., Fuchs M., Duesterhoeft A.,
RA   Fritzc C., Holzer E., Moestl D., Hilbert H., Borzym K., Langer I., Beck A.,
RA   Lehrach H., Reinhardt R., Pohl T.M., Eger P., Zimmermann W., Wedler H.,
RA   Wambutt R., Purnelle B., Goffeau A., Cadieu E., Dreano S., Gloux S.,
RA   Lelaure V., Mottier S., Galibert F., Aves S.J., Xiang Z., Hunt C.,
RA   Moore K., Hurst S.M., Lucas M., Rochet M., Gaillardin C., Tallada V.A.,
RA   Garzon A., Thode G., Daga R.R., Cruzado L., Jimenez J., Sanchez M.,
RA   del Rey F., Benito J., Dominguez A., Revuelta J.L., Moreno S.,
RA   Armstrong J., Forsburg S.L., Cerutti L., Lowe T., McCombie W.R.,
RA   Paulsen I., Potashkin J., Shpakovski G.V., Ussery D., Barrell B.G.,
RA   Nurse P.;
RT   ""The genome sequence of Schizosaccharomyces pombe."";
RL   Nature 415:871-880(2002).
CC   -!- FUNCTION: The 26S proteasome is involved in the ATP-dependent
CC       degradation of ubiquitinated proteins. The regulatory (or ATPase)
CC       complex confers ATP dependency and substrate specificity to the 26S
CC       complex.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000305}. Nucleus {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the AAA ATPase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Z29366; CAA82554.1; -; mRNA.
DR   EMBL; CU329671; CAB58406.1; -; Genomic_DNA.
DR   PIR; S39348; S39348.
DR   RefSeq; NP_595480.1; NM_001021391.2.
DR   AlphaFoldDB; P36612; -.
DR   SMR; P36612; -.
DR   BioGRID; 277455; 30.
DR   ComplexPortal; CPX-9077; 26S proteasome complex.
DR   IntAct; P36612; 1.
DR   STRING; 284812.P36612; -.
DR   iPTMnet; P36612; -.
DR   PaxDb; 4896-SPBC4.07c.1; -.
DR   EnsemblFungi; SPBC4.07c.1; SPBC4.07c.1:pep; SPBC4.07c.
DR   GeneID; 2540939; -.
DR   KEGG; spo:2540939; -.
DR   PomBase; SPBC4.07c; -.
DR   VEuPathDB; FungiDB:SPBC4.07c; -.
DR   eggNOG; KOG0726; Eukaryota.
DR   HOGENOM; CLU_000688_2_3_1; -.
DR   InParanoid; P36612; -.
DR   OMA; QDDTDPM; -.
DR   PhylomeDB; P36612; -.
DR   Reactome; R-SPO-1236978; Cross-presentation of soluble exogenous antigens (endosomes).
DR   Reactome; R-SPO-350562; Regulation of ornithine decarboxylase (ODC).
DR   Reactome; R-SPO-5687128; MAPK6/MAPK4 signaling.
DR   Reactome; R-SPO-5689603; UCH proteinases.
DR   Reactome; R-SPO-5689880; Ub-specific processing proteases.
DR   Reactome; R-SPO-68949; Orc1 removal from chromatin.
DR   Reactome; R-SPO-69017; CDK-mediated phosphorylation and removal of Cdc6.
DR   Reactome; R-SPO-69601; Ubiquitin Mediated Degradation of Phosphorylated Cdc25A.
DR   Reactome; R-SPO-75815; Ubiquitin-dependent degradation of Cyclin D.
DR   Reactome; R-SPO-8854050; FBXL7 down-regulates AURKA during mitotic entry and in early mitosis.
DR   Reactome; R-SPO-8948751; Regulation of PTEN stability and activity.
DR   Reactome; R-SPO-8951664; Neddylation.
DR   Reactome; R-SPO-9755511; KEAP1-NFE2L2 pathway.
DR   Reactome; R-SPO-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   Reactome; R-SPO-9907900; Proteasome assembly.
DR   PRO; PR:P36612; -.
DR   Proteomes; UP000002485; Chromosome II.
DR   GO; GO:0000785; C:chromatin; IDA:PomBase.
DR   GO; GO:0005829; C:cytosol; HDA:PomBase.
DR   GO; GO:0005634; C:nucleus; HDA:PomBase.
DR   GO; GO:0005838; C:proteasome regulatory particle; IDA:PomBase.
DR   GO; GO:0008540; C:proteasome regulatory particle, base subcomplex; IDA:PomBase.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATP hydrolysis activity; NAS:PomBase.
DR   GO; GO:0036402; F:proteasome-activating activity; ISM:PomBase.
DR   GO; GO:0010498; P:proteasomal protein catabolic process; EXP:PomBase.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IBA:GO_Central.
DR   FunFam; 2.40.50.140:FF:000067; 26S protease regulatory subunit 4; 1.
DR   FunFam; 1.10.8.60:FF:000007; 26S proteasome regulatory subunit 4; 1.
DR   FunFam; 3.40.50.300:FF:000039; 26S proteasome regulatory subunit 4; 1.
DR   Gene3D; 1.10.8.60; -; 1.
DR   Gene3D; 2.40.50.140; Nucleic acid-binding proteins; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   InterPro; IPR050221; 26S_Proteasome_ATPase.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR041569; AAA_lid_3.
DR   InterPro; IPR003959; ATPase_AAA_core.
DR   InterPro; IPR003960; ATPase_AAA_CS.
DR   InterPro; IPR012340; NA-bd_OB-fold.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR032501; Prot_ATP_ID_OB_2nd.
DR   PANTHER; PTHR23073; 26S PROTEASOME REGULATORY SUBUNIT; 1.
DR   Pfam; PF00004; AAA; 1.
DR   Pfam; PF17862; AAA_lid_3; 1.
DR   Pfam; PF16450; Prot_ATP_ID_OB_C; 1.
DR   SMART; SM00382; AAA; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   PROSITE; PS00674; AAA; 1.
PE   2: Evidence at transcript level;
KW   ATP-binding; Cytoplasm; Nucleotide-binding; Nucleus; Proteasome;
KW   Reference proteome.
FT   CHAIN           1..448
FT                   /note=""26S proteasome regulatory subunit 4 homolog""
FT                   /id=""PRO_0000084684""
FT   REGION          1..58
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        1..10
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        19..31
FT                   /note=""Basic and acidic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   BINDING         232..239
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255""
SQ   SEQUENCE   448 AA;  50060 MW;  451AEEF6A24C29D4 CRC64;
     MGQAQSGNFS NFGDGANGDN KKDQKKDKPK YEPPVPTRTG RRKKKAQSGP DASAKLPTVI
     PTTRCRLRLL KMQRIHDHLL MEEEYVQNQE RLKPQDERTQ EERNRVDEIR GTPMSVGTLE
     EIIDDDHAIV STAGPEYYVS IMSFVDKDML EPGCSVLLHH KAMSIVGLLL DDTDPMINVM
     KLDKAPTESY ADIGGLESQI QEIKEAVELP LTHPELYEEM GIKPPKGVIL YGAPGTGKTL
     LAKAVANQTS ATFLRVVGSE LIQKYLGDGP RLVRQLFNAA EEHSPSIVFI DEIDAIGTKR
     YDAQSGAERE IQRTMLELLN QLDGFDTSQR DIKVIMATNR ISDLDPALIR PGRIDRKILF
     ENPDEATKRK IFTIHTSKMN LGEDVNLEEL IQCKDDLSGA EIKAIVSEAG LLALRERRMR
     VVMDDFRQAR EKVLKTKDEG GPAGGLYI
//
",23673
TATTTC ATTTCA TTTCAC TTCACA TCACAG CACAGA ACAGAG CAGAGC AGAGCA GAGCAA AGCAAC GCAACC CAACCA AACCAA ACCAAT CCAATT CAATTG AATTGA ATTGAT TTGATC TGATCT GATCTT ATCTTG TCTTGT CTTGTA TTGTAC TGTACC GTACCA TACCAA ACCAAA CCAAAC CAAACC AAACCA AACCAA ACCAAC CCAACC CAACCA AACCAT ACCATA CCATAT CATATC ATATCC TATCCA ATCCAA TCCAAA CCAAAC CAAACG AAACGC AACGCA ACGCAA CGCAAG GCAAGC CAAGCT AAGCTT AGCTTC GCTTCG CTTCGA TTCGAT TCGATA CGATAA GATAAT ATAATT TAATTT AATTTT ATTTTA TTTTAA TTTAAG TTAAGT TAAGTT AAGTTT AGTTTG GTTTGT TTTGTA TTGTAT TGTATG GTATGT TATGTG ATGTGA TGTGAT GTGATA TGATAA GATAAT ATAATA TAATAT AATATC ATATCA TATCAA ATCAAA TCAAAT CAAATT AAATTT AATTTG ATTTGC TTTGCT TTGCTG TGCTGA GCTGAT CTGATG TGATGA GATGAT ATGATT TGATTT GATTTA ATTTAA TTTAAA TTAAAC TAAACC AAACCA AACCAG ACCAGT CCAGTT CAGTTA AGTTAA GTTAAC TTAACT TAACTG AACTGG ACTGGT CTGGTT TGGTTA GGTTAT GTTATA TTATAA TATAAG ATAAGA TAAGAA AAGAAA AGAAAC GAAACC AAACCT AACCTG ACCTGC CCTGCT CTGCTT TGCTTC GCTTCA CTTCAA TTCAAG TCAAGA CAAGAG AAGAGA AGAGAG,0,142,TATT ATTT TTTC TTCA TCAC CACA ACAG CAGA AGAG GAGC AGCA GCAA CAAC AACC ACCA CCAA CAAT AATT ATTG TTGA TGAT GATC ATCT TCTT CTTG TTGT TGTA GTAC TACC ACCA CCAA CAAA AAAC AACC ACCA CCAA CAAC AACC ACCA CCAT CATA ATAT TATC ATCC TCCA CCAA CAAA AAAC AACG ACGC CGCA GCAA CAAG AAGC AGCT GCTT CTTC TTCG TCGA CGAT GATA ATAA TAAT AATT ATTT TTTT TTTA TTAA TAAG AAGT AGTT GTTT TTTG TTGT TGTA GTAT TATG ATGT TGTG GTGA TGAT GATA ATAA TAAT AATA ATAT TATC ATCA TCAA CAAA AAAT AATT ATTT TTTG TTGC TGCT GCTG CTGA TGAT GATG ATGA TGAT GATT ATTT TTTA TTAA TAAA AAAC AACC ACCA CCAG CAGT AGTT GTTA TTAA TAAC AACT ACTG CTGG TGGT GGTT GTTA TTAT TATA ATAA TAAG AAGA AGAA GAAA AAAC AACC ACCT CCTG CTGC TGCT GCTT CTTC TTCA TCAA CAAG AAGA AGAG GAGA AGAG,TATTT ATTTC TTTCA TTCAC TCACA CACAG ACAGA CAGAG AGAGC GAGCA AGCAA GCAAC CAACC AACCA ACCAA CCAAT CAATT AATTG ATTGA TTGAT TGATC GATCT ATCTT TCTTG CTTGT TTGTA TGTAC GTACC TACCA ACCAA CCAAA CAAAC AAACC AACCA ACCAA CCAAC CAACC AACCA ACCAT CCATA CATAT ATATC TATCC ATCCA TCCAA CCAAA CAAAC AAACG AACGC ACGCA CGCAA GCAAG CAAGC AAGCT AGCTT GCTTC CTTCG TTCGA TCGAT CGATA GATAA ATAAT TAATT AATTT ATTTT TTTTA TTTAA TTAAG TAAGT AAGTT AGTTT GTTTG TTTGT TTGTA TGTAT GTATG TATGT ATGTG TGTGA GTGAT TGATA GATAA ATAAT TAATA AATAT ATATC TATCA ATCAA TCAAA CAAAT AAATT AATTT ATTTG TTTGC TTGCT TGCTG GCTGA CTGAT TGATG GATGA ATGAT TGATT GATTT ATTTA TTTAA TTAAA TAAAC AAACC AACCA ACCAG CCAGT CAGTT AGTTA GTTAA TTAAC TAACT AACTG ACTGG CTGGT TGGTT GGTTA GTTAT TTATA TATAA ATAAG TAAGA AAGAA AGAAA GAAAC AAACC AACCT ACCTG CCTGC CTGCT TGCTT GCTTC CTTCA TTCAA TCAAG CAAGA AAGAG AGAGA GAGAG,TATTTC ATTTCA TTTCAC TTCACA TCACAG CACAGA ACAGAG CAGAGC AGAGCA GAGCAA AGCAAC GCAACC CAACCA AACCAA ACCAAT CCAATT CAATTG AATTGA ATTGAT TTGATC TGATCT GATCTT ATCTTG TCTTGT CTTGTA TTGTAC TGTACC GTACCA TACCAA ACCAAA CCAAAC CAAACC AAACCA AACCAA ACCAAC CCAACC CAACCA AACCAT ACCATA CCATAT CATATC ATATCC TATCCA ATCCAA TCCAAA CCAAAC CAAACG AAACGC AACGCA ACGCAA CGCAAG GCAAGC CAAGCT AAGCTT AGCTTC GCTTCG CTTCGA TTCGAT TCGATA CGATAA GATAAT ATAATT TAATTT AATTTT ATTTTA TTTTAA TTTAAG TTAAGT TAAGTT AAGTTT AGTTTG GTTTGT TTTGTA TTGTAT TGTATG GTATGT TATGTG ATGTGA TGTGAT GTGATA TGATAA GATAAT ATAATA TAATAT AATATC ATATCA TATCAA ATCAAA TCAAAT CAAATT AAATTT AATTTG ATTTGC TTTGCT TTGCTG TGCTGA GCTGAT CTGATG TGATGA GATGAT ATGATT TGATTT GATTTA ATTTAA TTTAAA TTAAAC TAAACC AAACCA AACCAG ACCAGT CCAGTT CAGTTA AGTTAA GTTAAC TTAACT TAACTG AACTGG ACTGGT CTGGTT TGGTTA GGTTAT GTTATA TTATAA TATAAG ATAAGA TAAGAA AAGAAA AGAAAC GAAACC AAACCT AACCTG ACCTGC CCTGCT CTGCTT TGCTTC GCTTCA CTTCAA TTCAAG TCAAGA CAAGAG AAGAGA AGAGAG,TATTTCA ATTTCAC TTTCACA TTCACAG TCACAGA CACAGAG ACAGAGC CAGAGCA AGAGCAA GAGCAAC AGCAACC GCAACCA CAACCAA AACCAAT ACCAATT CCAATTG CAATTGA AATTGAT ATTGATC TTGATCT TGATCTT GATCTTG ATCTTGT TCTTGTA CTTGTAC TTGTACC TGTACCA GTACCAA TACCAAA ACCAAAC CCAAACC CAAACCA AAACCAA AACCAAC ACCAACC CCAACCA CAACCAT AACCATA ACCATAT CCATATC CATATCC ATATCCA TATCCAA ATCCAAA TCCAAAC CCAAACG CAAACGC AAACGCA AACGCAA ACGCAAG CGCAAGC GCAAGCT CAAGCTT AAGCTTC AGCTTCG GCTTCGA CTTCGAT TTCGATA TCGATAA CGATAAT GATAATT ATAATTT TAATTTT AATTTTA ATTTTAA TTTTAAG TTTAAGT TTAAGTT TAAGTTT AAGTTTG AGTTTGT GTTTGTA TTTGTAT TTGTATG TGTATGT GTATGTG TATGTGA ATGTGAT TGTGATA GTGATAA TGATAAT GATAATA ATAATAT TAATATC AATATCA ATATCAA TATCAAA ATCAAAT TCAAATT CAAATTT AAATTTG AATTTGC ATTTGCT TTTGCTG TTGCTGA TGCTGAT GCTGATG CTGATGA TGATGAT GATGATT ATGATTT TGATTTA GATTTAA ATTTAAA TTTAAAC TTAAACC TAAACCA AAACCAG AACCAGT ACCAGTT CCAGTTA CAGTTAA AGTTAAC GTTAACT TTAACTG TAACTGG AACTGGT ACTGGTT CTGGTTA TGGTTAT GGTTATA GTTATAA TTATAAG TATAAGA ATAAGAA TAAGAAA AAGAAAC AGAAACC GAAACCT AAACCTG AACCTGC ACCTGCT CCTGCTT CTGCTTC TGCTTCA GCTTCAA CTTCAAG TTCAAGA TCAAGAG CAAGAGA AAGAGAG,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",12068
TTCATC TCATCG CATCGC ATCGCT TCGCTA CGCTAA GCTAAA CTAAAA TAAAAT AAAATT AAATTG AATTGC ATTGCT TTGCTG TGCTGC GCTGCC CTGCCT TGCCTA GCCTAC CCTACC CTACCA TACCAG ACCAGT CCAGTT CAGTTT AGTTTA GTTTAC TTTACC TTACCC TACCCA ACCCAC CCCACT CCACTC CACTCG ACTCGT CTCGTT TCGTTA CGTTAT GTTATC TTATCG TATCGA ATCGAT TCGATA CGATAC GATACT ATACTT TACTTA ACTTAC CTTACC TTACCG TACCGA ACCGAT CCGATG CGATGC GATGCA ATGCAT TGCATT GCATTA CATTAG ATTAGA TTAGAA TAGAAA AGAAAG GAAAGT AAAGTA AAGTAT AGTATT GTATTG TATTGT ATTGTG TTGTGA TGTGAA GTGAAT TGAATG GAATGT AATGTG ATGTGA TGTGAT GTGATT TGATTG GATTGC ATTGCC TTGCCG TGCCGG GCCGGT CCGGTT CGGTTT GGTTTT GTTTTT TTTTTT TTTTTC TTTTCG TTTCGG TTCGGG TCGGGC CGGGCT GGGCTT GGCTTT GCTTTA CTTTAC TTTACA TTACAG TACAGT ACAGTT CAGTTT AGTTTA GTTTAT TTTATA TTATAC TATACG ATACGT TACGTG ACGTGG CGTGGC GTGGCT TGGCTG GGCTGC GCTGCC CTGCCA TGCCAA GCCAAA CCAAAC CAAACC AAACCC AACCCC ACCCCG CCCCGC CCCGCG CCGCGA CGCGAC GCGACT CGACTG GACTGG ACTGGG CTGGGA TGGGAT GGGATC GGATCA GATCAC ATCACC TCACCC CACCCA ACCCAT CCCATA CCATAC,2,145,TTCA TCAT CATC ATCG TCGC CGCT GCTA CTAA TAAA AAAA AAAT AATT ATTG TTGC TGCT GCTG CTGC TGCC GCCT CCTA CTAC TACC ACCA CCAG CAGT AGTT GTTT TTTA TTAC TACC ACCC CCCA CCAC CACT ACTC CTCG TCGT CGTT GTTA TTAT TATC ATCG TCGA CGAT GATA ATAC TACT ACTT CTTA TTAC TACC ACCG CCGA CGAT GATG ATGC TGCA GCAT CATT ATTA TTAG TAGA AGAA GAAA AAAG AAGT AGTA GTAT TATT ATTG TTGT TGTG GTGA TGAA GAAT AATG ATGT TGTG GTGA TGAT GATT ATTG TTGC TGCC GCCG CCGG CGGT GGTT GTTT TTTT TTTT TTTT TTTC TTCG TCGG CGGG GGGC GGCT GCTT CTTT TTTA TTAC TACA ACAG CAGT AGTT GTTT TTTA TTAT TATA ATAC TACG ACGT CGTG GTGG TGGC GGCT GCTG CTGC TGCC GCCA CCAA CAAA AAAC AACC ACCC CCCC CCCG CCGC CGCG GCGA CGAC GACT ACTG CTGG TGGG GGGA GGAT GATC ATCA TCAC CACC ACCC CCCA CCAT CATA ATAC,TTCAT TCATC CATCG ATCGC TCGCT CGCTA GCTAA CTAAA TAAAA AAAAT AAATT AATTG ATTGC TTGCT TGCTG GCTGC CTGCC TGCCT GCCTA CCTAC CTACC TACCA ACCAG CCAGT CAGTT AGTTT GTTTA TTTAC TTACC TACCC ACCCA CCCAC CCACT CACTC ACTCG CTCGT TCGTT CGTTA GTTAT TTATC TATCG ATCGA TCGAT CGATA GATAC ATACT TACTT ACTTA CTTAC TTACC TACCG ACCGA CCGAT CGATG GATGC ATGCA TGCAT GCATT CATTA ATTAG TTAGA TAGAA AGAAA GAAAG AAAGT AAGTA AGTAT GTATT TATTG ATTGT TTGTG TGTGA GTGAA TGAAT GAATG AATGT ATGTG TGTGA GTGAT TGATT GATTG ATTGC TTGCC TGCCG GCCGG CCGGT CGGTT GGTTT GTTTT TTTTT TTTTT TTTTC TTTCG TTCGG TCGGG CGGGC GGGCT GGCTT GCTTT CTTTA TTTAC TTACA TACAG ACAGT CAGTT AGTTT GTTTA TTTAT TTATA TATAC ATACG TACGT ACGTG CGTGG GTGGC TGGCT GGCTG GCTGC CTGCC TGCCA GCCAA CCAAA CAAAC AAACC AACCC ACCCC CCCCG CCCGC CCGCG CGCGA GCGAC CGACT GACTG ACTGG CTGGG TGGGA GGGAT GGATC GATCA ATCAC TCACC CACCC ACCCA CCCAT CCATA CATAC,TTCATC TCATCG CATCGC ATCGCT TCGCTA CGCTAA GCTAAA CTAAAA TAAAAT AAAATT AAATTG AATTGC ATTGCT TTGCTG TGCTGC GCTGCC CTGCCT TGCCTA GCCTAC CCTACC CTACCA TACCAG ACCAGT CCAGTT CAGTTT AGTTTA GTTTAC TTTACC TTACCC TACCCA ACCCAC CCCACT CCACTC CACTCG ACTCGT CTCGTT TCGTTA CGTTAT GTTATC TTATCG TATCGA ATCGAT TCGATA CGATAC GATACT ATACTT TACTTA ACTTAC CTTACC TTACCG TACCGA ACCGAT CCGATG CGATGC GATGCA ATGCAT TGCATT GCATTA CATTAG ATTAGA TTAGAA TAGAAA AGAAAG GAAAGT AAAGTA AAGTAT AGTATT GTATTG TATTGT ATTGTG TTGTGA TGTGAA GTGAAT TGAATG GAATGT AATGTG ATGTGA TGTGAT GTGATT TGATTG GATTGC ATTGCC TTGCCG TGCCGG GCCGGT CCGGTT CGGTTT GGTTTT GTTTTT TTTTTT TTTTTC TTTTCG TTTCGG TTCGGG TCGGGC CGGGCT GGGCTT GGCTTT GCTTTA CTTTAC TTTACA TTACAG TACAGT ACAGTT CAGTTT AGTTTA GTTTAT TTTATA TTATAC TATACG ATACGT TACGTG ACGTGG CGTGGC GTGGCT TGGCTG GGCTGC GCTGCC CTGCCA TGCCAA GCCAAA CCAAAC CAAACC AAACCC AACCCC ACCCCG CCCCGC CCCGCG CCGCGA CGCGAC GCGACT CGACTG GACTGG ACTGGG CTGGGA TGGGAT GGGATC GGATCA GATCAC ATCACC TCACCC CACCCA ACCCAT CCCATA CCATAC,TTCATCG TCATCGC CATCGCT ATCGCTA TCGCTAA CGCTAAA GCTAAAA CTAAAAT TAAAATT AAAATTG AAATTGC AATTGCT ATTGCTG TTGCTGC TGCTGCC GCTGCCT CTGCCTA TGCCTAC GCCTACC CCTACCA CTACCAG TACCAGT ACCAGTT CCAGTTT CAGTTTA AGTTTAC GTTTACC TTTACCC TTACCCA TACCCAC ACCCACT CCCACTC CCACTCG CACTCGT ACTCGTT CTCGTTA TCGTTAT CGTTATC GTTATCG TTATCGA TATCGAT ATCGATA TCGATAC CGATACT GATACTT ATACTTA TACTTAC ACTTACC CTTACCG TTACCGA TACCGAT ACCGATG CCGATGC CGATGCA GATGCAT ATGCATT TGCATTA GCATTAG CATTAGA ATTAGAA TTAGAAA TAGAAAG AGAAAGT GAAAGTA AAAGTAT AAGTATT AGTATTG GTATTGT TATTGTG ATTGTGA TTGTGAA TGTGAAT GTGAATG TGAATGT GAATGTG AATGTGA ATGTGAT TGTGATT GTGATTG TGATTGC GATTGCC ATTGCCG TTGCCGG TGCCGGT GCCGGTT CCGGTTT CGGTTTT GGTTTTT GTTTTTT TTTTTTC TTTTTCG TTTTCGG TTTCGGG TTCGGGC TCGGGCT CGGGCTT GGGCTTT GGCTTTA GCTTTAC CTTTACA TTTACAG TTACAGT TACAGTT ACAGTTT CAGTTTA AGTTTAT GTTTATA TTTATAC TTATACG TATACGT ATACGTG TACGTGG ACGTGGC CGTGGCT GTGGCTG TGGCTGC GGCTGCC GCTGCCA CTGCCAA TGCCAAA GCCAAAC CCAAACC CAAACCC AAACCCC AACCCCG ACCCCGC CCCCGCG CCCGCGA CCGCGAC CGCGACT GCGACTG CGACTGG GACTGGG ACTGGGA CTGGGAT TGGGATC GGGATCA GGATCAC GATCACC ATCACCC TCACCCA CACCCAT ACCCATA CCCATAC,"ID   Y1263_SYNY3             Reviewed;         310 AA.
AC   P74068;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1997, sequence version 1.
DT   05-FEB-2025, entry version 137.
DE   RecName: Full=Uncharacterized transporter sll1263;
GN   OrderedLocusNames=sll1263;
OS   Synechocystis sp. (strain ATCC 27184 / PCC 6803 / Kazusa).
OC   Bacteria; Bacillati; Cyanobacteriota; Cyanophyceae; Synechococcales;
OC   Merismopediaceae; Synechocystis.
OX   NCBI_TaxID=1111708;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 27184 / PCC 6803 / Kazusa;
RX   PubMed=8905231; DOI=10.1093/dnares/3.3.109;
RA   Kaneko T., Sato S., Kotani H., Tanaka A., Asamizu E., Nakamura Y.,
RA   Miyajima N., Hirosawa M., Sugiura M., Sasamoto S., Kimura T., Hosouchi T.,
RA   Matsuno A., Muraki A., Nakazaki N., Naruo K., Okumura S., Shimpo S.,
RA   Takeuchi C., Wada T., Watanabe A., Yamada M., Yasuda M., Tabata S.;
RT   ""Sequence analysis of the genome of the unicellular cyanobacterium
RT   Synechocystis sp. strain PCC6803. II. Sequence determination of the entire
RT   genome and assignment of potential protein-coding regions."";
RL   DNA Res. 3:109-136(1996).
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Multi-pass membrane
CC       protein {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the cation diffusion facilitator (CDF)
CC       transporter (TC 2.A.4) family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; BA000022; BAA18144.1; -; Genomic_DNA.
DR   PIR; S75583; S75583.
DR   AlphaFoldDB; P74068; -.
DR   SMR; P74068; -.
DR   IntAct; P74068; 1.
DR   STRING; 1148.gene:10499016; -.
DR   PaxDb; 1148-1653229; -.
DR   EnsemblBacteria; BAA18144; BAA18144; BAA18144.
DR   KEGG; syn:sll1263; -.
DR   eggNOG; COG0053; Bacteria.
DR   InParanoid; P74068; -.
DR   PhylomeDB; P74068; -.
DR   Proteomes; UP000001425; Chromosome.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0015086; F:cadmium ion transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0015093; F:ferrous iron transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0015341; F:zinc efflux active transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0006882; P:intracellular zinc ion homeostasis; IBA:GO_Central.
DR   FunFam; 1.20.1510.10:FF:000001; Ferrous-iron efflux pump FieF; 1.
DR   FunFam; 3.30.70.1350:FF:000002; Ferrous-iron efflux pump FieF; 1.
DR   Gene3D; 1.20.1510.10; Cation efflux protein transmembrane domain; 1.
DR   Gene3D; 3.30.70.1350; Cation efflux protein, cytoplasmic domain; 1.
DR   InterPro; IPR002524; Cation_efflux.
DR   InterPro; IPR027470; Cation_efflux_CTD.
DR   InterPro; IPR036837; Cation_efflux_CTD_sf.
DR   InterPro; IPR027469; Cation_efflux_TMD_sf.
DR   InterPro; IPR050291; CDF_Transporter.
DR   NCBIfam; TIGR01297; CDF; 1.
DR   PANTHER; PTHR43840; MITOCHONDRIAL METAL TRANSPORTER 1-RELATED; 1.
DR   PANTHER; PTHR43840:SF15; MITOCHONDRIAL METAL TRANSPORTER 1-RELATED; 1.
DR   Pfam; PF01545; Cation_efflux; 1.
DR   Pfam; PF16916; ZT_dimer; 1.
DR   SUPFAM; SSF160240; Cation efflux protein cytoplasmic domain-like; 1.
DR   SUPFAM; SSF161111; Cation efflux protein transmembrane domain-like; 1.
PE   3: Inferred from homology;
KW   Cell membrane; Membrane; Reference proteome; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN           1..310
FT                   /note=""Uncharacterized transporter sll1263""
FT                   /id=""PRO_0000206138""
FT   TRANSMEM        10..30
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        44..64
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        78..98
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        113..133
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        161..181
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   REGION          285..310
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        285..297
FT                   /note=""Basic and acidic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
SQ   SEQUENCE   310 AA;  33324 MW;  822C5946CBEC7122 CRC64;
     MTARLARPYA VLSIGAALAT MGLKLGAYAI TGSVGLLSDA LESTVNLASA IVAFWALSLA
     ATPADSEHPF GHSKAEYFSS GLEGAFIFVA ALGIGYSAVE RLLSPRPLDQ NALGIALAIA
     ATALNGTVAW ILWRAGKRLN SIALRADSQH LMTDVWTSVG VVVAVALIFV TGWEWLDPLI
     ALGVGFNVLW TGTHLLRETI SSLMDQSLPP AQLQAITSCF LPYEDQGVRF HLLQTRQAGS
     QSFISFHVLV PGHWTVQRGH DLCEAIETAI AERITGSRVT THLEPLEDPK SWQHPDEFPP
     SAPLNRDKPN
//
",41191
CCGATG CGATGA GATGAC ATGACG TGACGG GACGGT ACGGTG CGGTGC GGTGCA GTGCAC TGCACA GCACAT CACATG ACATGA CATGAA ATGAAC TGAACC GAACCC AACCCG ACCCGG CCCGGT CCGGTG CGGTGC GGTGCT GTGCTC TGCTCT GCTCTT CTCTTG TCTTGA CTTGAA TTGAAG TGAAGC GAAGCC AAGCCG AGCCGC GCCGCA CCGCAG CGCAGA GCAGAG CAGAGC AGAGCG GAGCGA AGCGAG GCGAGA CGAGAT GAGATC AGATCG GATCGG ATCGGC TCGGCT CGGCTC GGCTCG GCTCGC CTCGCA TCGCAG CGCAGG GCAGGT CAGGTC AGGTCG GGTCGT GTCGTG TCGTGG CGTGGT GTGGTC TGGTCC GGTCCA GTCCAG TCCAGG CCAGGG CAGGGC AGGGCC GGGCCG GGCCGC GCCGCG CCGCGT CGCGTG GCGTGA CGTGAT GTGATC TGATCG GATCGG ATCGGC TCGGCA CGGCAA GGCAAT GCAATG CAATGC AATGCC ATGCCA TGCCAA GCCAAG CCAAGG CAAGGC AAGGCG AGGCGT GGCGTC GCGTCC CGTCCG GTCCGC TCCGCC CCGCCT CGCCTA GCCTAT CCTATC CTATCA TATCAG ATCAGG TCAGGC CAGGCC AGGCCA GGCCAT GCCATG CCATGA CATGAA ATGAAG TGAAGC GAAGCC AAGCCG AGCCGC GCCGCA CCGCAA CGCAAT GCAATT CAATTG AATTGA ATTGAT TTGATG TGATGA GATGAA ATGAAG TGAAGG GAAGGC AAGGCC AGGCCG GGCCGT GCCGTG CCGTGC CGTGCT GTGCTT TGCTTG GCTTGA CTTGAT,2,142,CCGA CGAT GATG ATGA TGAC GACG ACGG CGGT GGTG GTGC TGCA GCAC CACA ACAT CATG ATGA TGAA GAAC AACC ACCC CCCG CCGG CGGT GGTG GTGC TGCT GCTC CTCT TCTT CTTG TTGA TGAA GAAG AAGC AGCC GCCG CCGC CGCA GCAG CAGA AGAG GAGC AGCG GCGA CGAG GAGA AGAT GATC ATCG TCGG CGGC GGCT GCTC CTCG TCGC CGCA GCAG CAGG AGGT GGTC GTCG TCGT CGTG GTGG TGGT GGTC GTCC TCCA CCAG CAGG AGGG GGGC GGCC GCCG CCGC CGCG GCGT CGTG GTGA TGAT GATC ATCG TCGG CGGC GGCA GCAA CAAT AATG ATGC TGCC GCCA CCAA CAAG AAGG AGGC GGCG GCGT CGTC GTCC TCCG CCGC CGCC GCCT CCTA CTAT TATC ATCA TCAG CAGG AGGC GGCC GCCA CCAT CATG ATGA TGAA GAAG AAGC AGCC GCCG CCGC CGCA GCAA CAAT AATT ATTG TTGA TGAT GATG ATGA TGAA GAAG AAGG AGGC GGCC GCCG CCGT CGTG GTGC TGCT GCTT CTTG TTGA TGAT,CCGAT CGATG GATGA ATGAC TGACG GACGG ACGGT CGGTG GGTGC GTGCA TGCAC GCACA CACAT ACATG CATGA ATGAA TGAAC GAACC AACCC ACCCG CCCGG CCGGT CGGTG GGTGC GTGCT TGCTC GCTCT CTCTT TCTTG CTTGA TTGAA TGAAG GAAGC AAGCC AGCCG GCCGC CCGCA CGCAG GCAGA CAGAG AGAGC GAGCG AGCGA GCGAG CGAGA GAGAT AGATC GATCG ATCGG TCGGC CGGCT GGCTC GCTCG CTCGC TCGCA CGCAG GCAGG CAGGT AGGTC GGTCG GTCGT TCGTG CGTGG GTGGT TGGTC GGTCC GTCCA TCCAG CCAGG CAGGG AGGGC GGGCC GGCCG GCCGC CCGCG CGCGT GCGTG CGTGA GTGAT TGATC GATCG ATCGG TCGGC CGGCA GGCAA GCAAT CAATG AATGC ATGCC TGCCA GCCAA CCAAG CAAGG AAGGC AGGCG GGCGT GCGTC CGTCC GTCCG TCCGC CCGCC CGCCT GCCTA CCTAT CTATC TATCA ATCAG TCAGG CAGGC AGGCC GGCCA GCCAT CCATG CATGA ATGAA TGAAG GAAGC AAGCC AGCCG GCCGC CCGCA CGCAA GCAAT CAATT AATTG ATTGA TTGAT TGATG GATGA ATGAA TGAAG GAAGG AAGGC AGGCC GGCCG GCCGT CCGTG CGTGC GTGCT TGCTT GCTTG CTTGA TTGAT,CCGATG CGATGA GATGAC ATGACG TGACGG GACGGT ACGGTG CGGTGC GGTGCA GTGCAC TGCACA GCACAT CACATG ACATGA CATGAA ATGAAC TGAACC GAACCC AACCCG ACCCGG CCCGGT CCGGTG CGGTGC GGTGCT GTGCTC TGCTCT GCTCTT CTCTTG TCTTGA CTTGAA TTGAAG TGAAGC GAAGCC AAGCCG AGCCGC GCCGCA CCGCAG CGCAGA GCAGAG CAGAGC AGAGCG GAGCGA AGCGAG GCGAGA CGAGAT GAGATC AGATCG GATCGG ATCGGC TCGGCT CGGCTC GGCTCG GCTCGC CTCGCA TCGCAG CGCAGG GCAGGT CAGGTC AGGTCG GGTCGT GTCGTG TCGTGG CGTGGT GTGGTC TGGTCC GGTCCA GTCCAG TCCAGG CCAGGG CAGGGC AGGGCC GGGCCG GGCCGC GCCGCG CCGCGT CGCGTG GCGTGA CGTGAT GTGATC TGATCG GATCGG ATCGGC TCGGCA CGGCAA GGCAAT GCAATG CAATGC AATGCC ATGCCA TGCCAA GCCAAG CCAAGG CAAGGC AAGGCG AGGCGT GGCGTC GCGTCC CGTCCG GTCCGC TCCGCC CCGCCT CGCCTA GCCTAT CCTATC CTATCA TATCAG ATCAGG TCAGGC CAGGCC AGGCCA GGCCAT GCCATG CCATGA CATGAA ATGAAG TGAAGC GAAGCC AAGCCG AGCCGC GCCGCA CCGCAA CGCAAT GCAATT CAATTG AATTGA ATTGAT TTGATG TGATGA GATGAA ATGAAG TGAAGG GAAGGC AAGGCC AGGCCG GGCCGT GCCGTG CCGTGC CGTGCT GTGCTT TGCTTG GCTTGA CTTGAT,CCGATGA CGATGAC GATGACG ATGACGG TGACGGT GACGGTG ACGGTGC CGGTGCA GGTGCAC GTGCACA TGCACAT GCACATG CACATGA ACATGAA CATGAAC ATGAACC TGAACCC GAACCCG AACCCGG ACCCGGT CCCGGTG CCGGTGC CGGTGCT GGTGCTC GTGCTCT TGCTCTT GCTCTTG CTCTTGA TCTTGAA CTTGAAG TTGAAGC TGAAGCC GAAGCCG AAGCCGC AGCCGCA GCCGCAG CCGCAGA CGCAGAG GCAGAGC CAGAGCG AGAGCGA GAGCGAG AGCGAGA GCGAGAT CGAGATC GAGATCG AGATCGG GATCGGC ATCGGCT TCGGCTC CGGCTCG GGCTCGC GCTCGCA CTCGCAG TCGCAGG CGCAGGT GCAGGTC CAGGTCG AGGTCGT GGTCGTG GTCGTGG TCGTGGT CGTGGTC GTGGTCC TGGTCCA GGTCCAG GTCCAGG TCCAGGG CCAGGGC CAGGGCC AGGGCCG GGGCCGC GGCCGCG GCCGCGT CCGCGTG CGCGTGA GCGTGAT CGTGATC GTGATCG TGATCGG GATCGGC ATCGGCA TCGGCAA CGGCAAT GGCAATG GCAATGC CAATGCC AATGCCA ATGCCAA TGCCAAG GCCAAGG CCAAGGC CAAGGCG AAGGCGT AGGCGTC GGCGTCC GCGTCCG CGTCCGC GTCCGCC TCCGCCT CCGCCTA CGCCTAT GCCTATC CCTATCA CTATCAG TATCAGG ATCAGGC TCAGGCC CAGGCCA AGGCCAT GGCCATG GCCATGA CCATGAA CATGAAG ATGAAGC TGAAGCC GAAGCCG AAGCCGC AGCCGCA GCCGCAA CCGCAAT CGCAATT GCAATTG CAATTGA AATTGAT ATTGATG TTGATGA TGATGAA GATGAAG ATGAAGG TGAAGGC GAAGGCC AAGGCCG AGGCCGT GGCCGTG GCCGTGC CCGTGCT CGTGCTT GTGCTTG TGCTTGA GCTTGAT,"ID   COBQ_BRASB              Reviewed;         492 AA.
AC   A5EGF9;
DT   29-APR-2008, integrated into UniProtKB/Swiss-Prot.
DT   12-JUN-2007, sequence version 1.
DT   05-FEB-2025, entry version 90.
DE   RecName: Full=Cobyric acid synthase {ECO:0000255|HAMAP-Rule:MF_00028};
GN   Name=cobQ {ECO:0000255|HAMAP-Rule:MF_00028};
GN   OrderedLocusNames=BBta_3138;
OS   Bradyrhizobium sp. (strain BTAi1 / ATCC BAA-1182).
OC   Bacteria; Pseudomonadota; Alphaproteobacteria; Hyphomicrobiales;
OC   Nitrobacteraceae; Bradyrhizobium.
OX   NCBI_TaxID=288000;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=BTAi1 / ATCC BAA-1182;
RX   PubMed=17540897; DOI=10.1126/science.1139548;
RA   Giraud E., Moulin L., Vallenet D., Barbe V., Cytryn E., Avarre J.-C.,
RA   Jaubert M., Simon D., Cartieaux F., Prin Y., Bena G., Hannibal L.,
RA   Fardoux J., Kojadinovic M., Vuillet L., Lajus A., Cruveiller S., Rouy Z.,
RA   Mangenot S., Segurens B., Dossat C., Franck W.L., Chang W.-S., Saunders E.,
RA   Bruce D., Richardson P., Normand P., Dreyfus B., Pignol D., Stacey G.,
RA   Emerich D., Vermeglio A., Medigue C., Sadowsky M.;
RT   ""Legumes symbioses: absence of nod genes in photosynthetic bradyrhizobia."";
RL   Science 316:1307-1312(2007).
CC   -!- FUNCTION: Catalyzes amidations at positions B, D, E, and G on
CC       adenosylcobyrinic A,C-diamide. NH(2) groups are provided by glutamine,
CC       and one molecule of ATP is hydrogenolyzed for each amidation.
CC       {ECO:0000255|HAMAP-Rule:MF_00028}.
CC   -!- PATHWAY: Cofactor biosynthesis; adenosylcobalamin biosynthesis.
CC       {ECO:0000255|HAMAP-Rule:MF_00028}.
CC   -!- SIMILARITY: Belongs to the CobB/CobQ family. CobQ subfamily.
CC       {ECO:0000255|HAMAP-Rule:MF_00028}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CP000494; ABQ35253.1; -; Genomic_DNA.
DR   RefSeq; WP_012043271.1; NC_009485.1.
DR   AlphaFoldDB; A5EGF9; -.
DR   STRING; 288000.BBta_3138; -.
DR   KEGG; bbt:BBta_3138; -.
DR   eggNOG; COG1492; Bacteria.
DR   HOGENOM; CLU_019250_2_2_5; -.
DR   OrthoDB; 9808302at2; -.
DR   UniPathway; UPA00148; -.
DR   Proteomes; UP000000246; Chromosome.
DR   GO; GO:0015420; F:ABC-type vitamin B12 transporter activity; IEA:UniProtKB-UniRule.
DR   GO; GO:0003824; F:catalytic activity; IEA:InterPro.
DR   GO; GO:0009236; P:cobalamin biosynthetic process; IEA:UniProtKB-UniRule.
DR   CDD; cd01750; GATase1_CobQ; 1.
DR   Gene3D; 3.40.50.880; -; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   HAMAP; MF_00028; CobQ; 1.
DR   InterPro; IPR029062; Class_I_gatase-like.
DR   InterPro; IPR002586; CobQ/CobB/MinD/ParA_Nub-bd_dom.
DR   InterPro; IPR033949; CobQ_GATase1.
DR   InterPro; IPR004459; CobQ_synth.
DR   InterPro; IPR011698; GATase_3.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   NCBIfam; TIGR00313; cobQ; 1.
DR   PANTHER; PTHR21343:SF1; COBYRIC ACID SYNTHASE; 1.
DR   PANTHER; PTHR21343; DETHIOBIOTIN SYNTHETASE; 1.
DR   Pfam; PF01656; CbiA; 1.
DR   Pfam; PF07685; GATase_3; 1.
DR   SUPFAM; SSF52317; Class I glutamine amidotransferase-like; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   PROSITE; PS51274; GATASE_COBBQ; 1.
PE   3: Inferred from homology;
KW   Cobalamin biosynthesis; Glutamine amidotransferase; Reference proteome.
FT   CHAIN           1..492
FT                   /note=""Cobyric acid synthase""
FT                   /id=""PRO_0000332322""
FT   DOMAIN          252..440
FT                   /note=""GATase cobBQ-type""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00028""
FT   ACT_SITE        334
FT                   /note=""Nucleophile""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00028""
FT   ACT_SITE        432
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00028""
SQ   SEQUENCE   492 AA;  51883 MW;  F416FD2A47ECDE9E CRC64;
     MPARAIMFQG TGSDVGKSLI VAGLARALTL RGLKVAPFKP QNMSNNAAVT ADGGEIGRAQ
     ALQARAARRP MTVHMNPVLL KPQSEIGSQV VVQGRVIGNA KASAYQAMKP QLMKAVLDSF
     HHLIADTDIA LVEGAGSASE INLRAGDIAN MGFAQATQIP VVLIGDIDRG GVIASLVGTQ
     AVLAPDDAAL IAGFLVNKFR GDPALFASGM SEIATRTRWT SLGLIPHFAD ARRLPAEDAL
     GLPGGGVWSR DRPKIAVLAY PRISNFDEFD PLRLEDGVDL QFLRPGTPIP GDAAVVILPG
     SKATIADLAA LREAGWDIDL QAHLRRGGRV LGICGGYQML GRMISDPDGH EGAPGAVAGL
     GLLDIETTLT GDKALRDVEG RLTQDEAPFR GYEMHIGRTD GPAAQHPFLV FSDGRRDGAV
     AAGGQIAGCY VHGLFADDHL RAHWLRGLGT TASGQSYDAD VDATLDALAA HLERYIDIDR
     ILDLARVPRA IT
//
",41849
ACTAAA CTAAAG TAAAGA AAAGAA AAGAAG AGAAGG GAAGGT AAGGTG AGGTGC GGTGCC GTGCCA TGCCAC GCCACT CCACTA CACTAC ACTACT CTACTT TACTTG ACTTGT CTTGTG TTGTGG TGTGGT GTGGTT TGGTTA GGTTAC GTTACT TTACTT TACTTA ACTTAC CTTACC TTACCC TACCCC ACCCCA CCCCAA CCCAAA CCAAAA CAAAAT AAAATG AAATGC AATGCT ATGCTG TGCTGT GCTGTT CTGTTG TGTTGT GTTGTT TTGTTA TGTTAA GTTAAA TTAAAA TAAAAT AAAATT AAATTT AATTTA ATTTAT TTTATT TTATTG TATTGT ATTGTC TTGTCC TGTCCA GTCCAG TCCAGC CCAGCA CAGCAT AGCATG GCATGT CATGTC ATGTCA TGTCAC GTCACA TCACAA CACAAT ACAATT CAATTC AATTCA ATTCAG TTCAGA TCAGAA CAGAAG AGAAGT GAAGTA AAGTAG AGTAGG GTAGGA TAGGAC AGGACC GGACCT GACCTG ACCTGA CCTGAG CTGAGC TGAGCA GAGCAT AGCATA GCATAG CATAGT ATAGTC TAGTCT AGTCTT GTCTTG TCTTGC CTTGCC TTGCCG TGCCGA GCCGAA CCGAAT CGAATA GAATAC AATACC ATACCA TACCAT ACCATA CCATAA CATAAT ATAATG TAATGA AATGAA ATGAAT TGAATC GAATCT AATCTG ATCTGG TCTGGC CTGGCT TGGCTT GGCTTG GCTTGA CTTGAA TTGAAA TGAAAA GAAAAC AAAACC AAACCA AACCAT ACCATT,0,136,ACTA CTAA TAAA AAAG AAGA AGAA GAAG AAGG AGGT GGTG GTGC TGCC GCCA CCAC CACT ACTA CTAC TACT ACTT CTTG TTGT TGTG GTGG TGGT GGTT GTTA TTAC TACT ACTT CTTA TTAC TACC ACCC CCCC CCCA CCAA CAAA AAAA AAAT AATG ATGC TGCT GCTG CTGT TGTT GTTG TTGT TGTT GTTA TTAA TAAA AAAA AAAT AATT ATTT TTTA TTAT TATT ATTG TTGT TGTC GTCC TCCA CCAG CAGC AGCA GCAT CATG ATGT TGTC GTCA TCAC CACA ACAA CAAT AATT ATTC TTCA TCAG CAGA AGAA GAAG AAGT AGTA GTAG TAGG AGGA GGAC GACC ACCT CCTG CTGA TGAG GAGC AGCA GCAT CATA ATAG TAGT AGTC GTCT TCTT CTTG TTGC TGCC GCCG CCGA CGAA GAAT AATA ATAC TACC ACCA CCAT CATA ATAA TAAT AATG ATGA TGAA GAAT AATC ATCT TCTG CTGG TGGC GGCT GCTT CTTG TTGA TGAA GAAA AAAA AAAC AACC ACCA CCAT CATT,ACTAA CTAAA TAAAG AAAGA AAGAA AGAAG GAAGG AAGGT AGGTG GGTGC GTGCC TGCCA GCCAC CCACT CACTA ACTAC CTACT TACTT ACTTG CTTGT TTGTG TGTGG GTGGT TGGTT GGTTA GTTAC TTACT TACTT ACTTA CTTAC TTACC TACCC ACCCC CCCCA CCCAA CCAAA CAAAA AAAAT AAATG AATGC ATGCT TGCTG GCTGT CTGTT TGTTG GTTGT TTGTT TGTTA GTTAA TTAAA TAAAA AAAAT AAATT AATTT ATTTA TTTAT TTATT TATTG ATTGT TTGTC TGTCC GTCCA TCCAG CCAGC CAGCA AGCAT GCATG CATGT ATGTC TGTCA GTCAC TCACA CACAA ACAAT CAATT AATTC ATTCA TTCAG TCAGA CAGAA AGAAG GAAGT AAGTA AGTAG GTAGG TAGGA AGGAC GGACC GACCT ACCTG CCTGA CTGAG TGAGC GAGCA AGCAT GCATA CATAG ATAGT TAGTC AGTCT GTCTT TCTTG CTTGC TTGCC TGCCG GCCGA CCGAA CGAAT GAATA AATAC ATACC TACCA ACCAT CCATA CATAA ATAAT TAATG AATGA ATGAA TGAAT GAATC AATCT ATCTG TCTGG CTGGC TGGCT GGCTT GCTTG CTTGA TTGAA TGAAA GAAAA AAAAC AAACC AACCA ACCAT CCATT,ACTAAA CTAAAG TAAAGA AAAGAA AAGAAG AGAAGG GAAGGT AAGGTG AGGTGC GGTGCC GTGCCA TGCCAC GCCACT CCACTA CACTAC ACTACT CTACTT TACTTG ACTTGT CTTGTG TTGTGG TGTGGT GTGGTT TGGTTA GGTTAC GTTACT TTACTT TACTTA ACTTAC CTTACC TTACCC TACCCC ACCCCA CCCCAA CCCAAA CCAAAA CAAAAT AAAATG AAATGC AATGCT ATGCTG TGCTGT GCTGTT CTGTTG TGTTGT GTTGTT TTGTTA TGTTAA GTTAAA TTAAAA TAAAAT AAAATT AAATTT AATTTA ATTTAT TTTATT TTATTG TATTGT ATTGTC TTGTCC TGTCCA GTCCAG TCCAGC CCAGCA CAGCAT AGCATG GCATGT CATGTC ATGTCA TGTCAC GTCACA TCACAA CACAAT ACAATT CAATTC AATTCA ATTCAG TTCAGA TCAGAA CAGAAG AGAAGT GAAGTA AAGTAG AGTAGG GTAGGA TAGGAC AGGACC GGACCT GACCTG ACCTGA CCTGAG CTGAGC TGAGCA GAGCAT AGCATA GCATAG CATAGT ATAGTC TAGTCT AGTCTT GTCTTG TCTTGC CTTGCC TTGCCG TGCCGA GCCGAA CCGAAT CGAATA GAATAC AATACC ATACCA TACCAT ACCATA CCATAA CATAAT ATAATG TAATGA AATGAA ATGAAT TGAATC GAATCT AATCTG ATCTGG TCTGGC CTGGCT TGGCTT GGCTTG GCTTGA CTTGAA TTGAAA TGAAAA GAAAAC AAAACC AAACCA AACCAT ACCATT,ACTAAAG CTAAAGA TAAAGAA AAAGAAG AAGAAGG AGAAGGT GAAGGTG AAGGTGC AGGTGCC GGTGCCA GTGCCAC TGCCACT GCCACTA CCACTAC CACTACT ACTACTT CTACTTG TACTTGT ACTTGTG CTTGTGG TTGTGGT TGTGGTT GTGGTTA TGGTTAC GGTTACT GTTACTT TTACTTA TACTTAC ACTTACC CTTACCC TTACCCC TACCCCA ACCCCAA CCCCAAA CCCAAAA CCAAAAT CAAAATG AAAATGC AAATGCT AATGCTG ATGCTGT TGCTGTT GCTGTTG CTGTTGT TGTTGTT GTTGTTA TTGTTAA TGTTAAA GTTAAAA TTAAAAT TAAAATT AAAATTT AAATTTA AATTTAT ATTTATT TTTATTG TTATTGT TATTGTC ATTGTCC TTGTCCA TGTCCAG GTCCAGC TCCAGCA CCAGCAT CAGCATG AGCATGT GCATGTC CATGTCA ATGTCAC TGTCACA GTCACAA TCACAAT CACAATT ACAATTC CAATTCA AATTCAG ATTCAGA TTCAGAA TCAGAAG CAGAAGT AGAAGTA GAAGTAG AAGTAGG AGTAGGA GTAGGAC TAGGACC AGGACCT GGACCTG GACCTGA ACCTGAG CCTGAGC CTGAGCA TGAGCAT GAGCATA AGCATAG GCATAGT CATAGTC ATAGTCT TAGTCTT AGTCTTG GTCTTGC TCTTGCC CTTGCCG TTGCCGA TGCCGAA GCCGAAT CCGAATA CGAATAC GAATACC AATACCA ATACCAT TACCATA ACCATAA CCATAAT CATAATG ATAATGA TAATGAA AATGAAT ATGAATC TGAATCT GAATCTG AATCTGG ATCTGGC TCTGGCT CTGGCTT TGGCTTG GGCTTGA GCTTGAA CTTGAAA TTGAAAA TGAAAAC GAAAACC AAAACCA AAACCAT AACCATT,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",606
CAATAT AATATG ATATGA TATGAG ATGAGT TGAGTA GAGTAT AGTATG GTATGG TATGGT ATGGTA TGGTAC GGTACT GTACTG TACTGA ACTGAA CTGAAG TGAAGA GAAGAT AAGATG AGATGA GATGAT ATGATT TGATTA GATTAC ATTACC TTACCA TACCAA ACCAAG CCAAGG CAAGGT AAGGTA AGGTAA GGTAAA GTAAAC TAAACC AAACCT AACCTT ACCTTT CCTTTG CTTTGG TTTGGA TTGGAA TGGAAT GGAATT GAATTT AATTTG ATTTGG TTTGGT TTGGTG TGGTGC GGTGCC GTGCCA TGCCAC GCCACT CCACTT CACTTC ACTTCT CTTCTG TTCTGC TCTGCT CTGCTG TGCTGC GCTGCT CTGCTC TGCTCT GCTCTT CTCTTC TCTTCA CTTCAA TTCAAC TCAACC CAACCT AACCTG ACCTGA CCTGAA CTGAAG TGAAGA GAAGAA AAGAAG AGAAGA GAAGAG AAGAGC AGAGCA GAGCAA AGCAAG GCAAGA CAAGAA AAGAAG AGAAGA GAAGAA AAGAAG AGAAGA GAAGAT AAGATT AGATTG GATTGG ATTGGT TTGGTT TGGTTA GGTTAG GTTAGA TTAGAT TAGATG AGATGA GATGAT ATGATG TGATGA GATGAT ATGATA TGATAG GATAGT ATAGTC TAGTCC AGTCCT GTCCTG TCCTGT CCTGTC CTGTCT TGTCTC GTCTCT TCTCTT CTCTTA TCTTAT CTTATA TTATAC TATACA ATACAC TACACA ACACAT CACATT ACATTC CATTCC ATTCCG TTCCGA TCCGAG CCGAGC CGAGCC GAGCCC AGCCCA GCCCAC CCCACG CCACGA CACGAG ACGAGA,0,145,CAAT AATA ATAT TATG ATGA TGAG GAGT AGTA GTAT TATG ATGG TGGT GGTA GTAC TACT ACTG CTGA TGAA GAAG AAGA AGAT GATG ATGA TGAT GATT ATTA TTAC TACC ACCA CCAA CAAG AAGG AGGT GGTA GTAA TAAA AAAC AACC ACCT CCTT CTTT TTTG TTGG TGGA GGAA GAAT AATT ATTT TTTG TTGG TGGT GGTG GTGC TGCC GCCA CCAC CACT ACTT CTTC TTCT TCTG CTGC TGCT GCTG CTGC TGCT GCTC CTCT TCTT CTTC TTCA TCAA CAAC AACC ACCT CCTG CTGA TGAA GAAG AAGA AGAA GAAG AAGA AGAG GAGC AGCA GCAA CAAG AAGA AGAA GAAG AAGA AGAA GAAG AAGA AGAT GATT ATTG TTGG TGGT GGTT GTTA TTAG TAGA AGAT GATG ATGA TGAT GATG ATGA TGAT GATA ATAG TAGT AGTC GTCC TCCT CCTG CTGT TGTC GTCT TCTC CTCT TCTT CTTA TTAT TATA ATAC TACA ACAC CACA ACAT CATT ATTC TTCC TCCG CCGA CGAG GAGC AGCC GCCC CCCA CCAC CACG ACGA CGAG GAGA,CAATA AATAT ATATG TATGA ATGAG TGAGT GAGTA AGTAT GTATG TATGG ATGGT TGGTA GGTAC GTACT TACTG ACTGA CTGAA TGAAG GAAGA AAGAT AGATG GATGA ATGAT TGATT GATTA ATTAC TTACC TACCA ACCAA CCAAG CAAGG AAGGT AGGTA GGTAA GTAAA TAAAC AAACC AACCT ACCTT CCTTT CTTTG TTTGG TTGGA TGGAA GGAAT GAATT AATTT ATTTG TTTGG TTGGT TGGTG GGTGC GTGCC TGCCA GCCAC CCACT CACTT ACTTC CTTCT TTCTG TCTGC CTGCT TGCTG GCTGC CTGCT TGCTC GCTCT CTCTT TCTTC CTTCA TTCAA TCAAC CAACC AACCT ACCTG CCTGA CTGAA TGAAG GAAGA AAGAA AGAAG GAAGA AAGAG AGAGC GAGCA AGCAA GCAAG CAAGA AAGAA AGAAG GAAGA AAGAA AGAAG GAAGA AAGAT AGATT GATTG ATTGG TTGGT TGGTT GGTTA GTTAG TTAGA TAGAT AGATG GATGA ATGAT TGATG GATGA ATGAT TGATA GATAG ATAGT TAGTC AGTCC GTCCT TCCTG CCTGT CTGTC TGTCT GTCTC TCTCT CTCTT TCTTA CTTAT TTATA TATAC ATACA TACAC ACACA CACAT ACATT CATTC ATTCC TTCCG TCCGA CCGAG CGAGC GAGCC AGCCC GCCCA CCCAC CCACG CACGA ACGAG CGAGA,CAATAT AATATG ATATGA TATGAG ATGAGT TGAGTA GAGTAT AGTATG GTATGG TATGGT ATGGTA TGGTAC GGTACT GTACTG TACTGA ACTGAA CTGAAG TGAAGA GAAGAT AAGATG AGATGA GATGAT ATGATT TGATTA GATTAC ATTACC TTACCA TACCAA ACCAAG CCAAGG CAAGGT AAGGTA AGGTAA GGTAAA GTAAAC TAAACC AAACCT AACCTT ACCTTT CCTTTG CTTTGG TTTGGA TTGGAA TGGAAT GGAATT GAATTT AATTTG ATTTGG TTTGGT TTGGTG TGGTGC GGTGCC GTGCCA TGCCAC GCCACT CCACTT CACTTC ACTTCT CTTCTG TTCTGC TCTGCT CTGCTG TGCTGC GCTGCT CTGCTC TGCTCT GCTCTT CTCTTC TCTTCA CTTCAA TTCAAC TCAACC CAACCT AACCTG ACCTGA CCTGAA CTGAAG TGAAGA GAAGAA AAGAAG AGAAGA GAAGAG AAGAGC AGAGCA GAGCAA AGCAAG GCAAGA CAAGAA AAGAAG AGAAGA GAAGAA AAGAAG AGAAGA GAAGAT AAGATT AGATTG GATTGG ATTGGT TTGGTT TGGTTA GGTTAG GTTAGA TTAGAT TAGATG AGATGA GATGAT ATGATG TGATGA GATGAT ATGATA TGATAG GATAGT ATAGTC TAGTCC AGTCCT GTCCTG TCCTGT CCTGTC CTGTCT TGTCTC GTCTCT TCTCTT CTCTTA TCTTAT CTTATA TTATAC TATACA ATACAC TACACA ACACAT CACATT ACATTC CATTCC ATTCCG TTCCGA TCCGAG CCGAGC CGAGCC GAGCCC AGCCCA GCCCAC CCCACG CCACGA CACGAG ACGAGA,CAATATG AATATGA ATATGAG TATGAGT ATGAGTA TGAGTAT GAGTATG AGTATGG GTATGGT TATGGTA ATGGTAC TGGTACT GGTACTG GTACTGA TACTGAA ACTGAAG CTGAAGA TGAAGAT GAAGATG AAGATGA AGATGAT GATGATT ATGATTA TGATTAC GATTACC ATTACCA TTACCAA TACCAAG ACCAAGG CCAAGGT CAAGGTA AAGGTAA AGGTAAA GGTAAAC GTAAACC TAAACCT AAACCTT AACCTTT ACCTTTG CCTTTGG CTTTGGA TTTGGAA TTGGAAT TGGAATT GGAATTT GAATTTG AATTTGG ATTTGGT TTTGGTG TTGGTGC TGGTGCC GGTGCCA GTGCCAC TGCCACT GCCACTT CCACTTC CACTTCT ACTTCTG CTTCTGC TTCTGCT TCTGCTG CTGCTGC TGCTGCT GCTGCTC CTGCTCT TGCTCTT GCTCTTC CTCTTCA TCTTCAA CTTCAAC TTCAACC TCAACCT CAACCTG AACCTGA ACCTGAA CCTGAAG CTGAAGA TGAAGAA GAAGAAG AAGAAGA AGAAGAG GAAGAGC AAGAGCA AGAGCAA GAGCAAG AGCAAGA GCAAGAA CAAGAAG AAGAAGA AGAAGAA GAAGAAG AAGAAGA AGAAGAT GAAGATT AAGATTG AGATTGG GATTGGT ATTGGTT TTGGTTA TGGTTAG GGTTAGA GTTAGAT TTAGATG TAGATGA AGATGAT GATGATG ATGATGA TGATGAT GATGATA ATGATAG TGATAGT GATAGTC ATAGTCC TAGTCCT AGTCCTG GTCCTGT TCCTGTC CCTGTCT CTGTCTC TGTCTCT GTCTCTT TCTCTTA CTCTTAT TCTTATA CTTATAC TTATACA TATACAC ATACACA TACACAT ACACATT CACATTC ACATTCC CATTCCG ATTCCGA TTCCGAG TCCGAGC CCGAGCC CGAGCCC GAGCCCA AGCCCAC GCCCACG CCCACGA CCACGAG CACGAGA,"ID   R1A_SARS                Reviewed;        4382 AA.
AC   P0C6U8; P59641;
DT   10-JUN-2008, integrated into UniProtKB/Swiss-Prot.
DT   10-JUN-2008, sequence version 1.
DT   05-FEB-2025, entry version 124.
DE   RecName: Full=Replicase polyprotein 1a;
DE            Short=pp1a;
DE   AltName: Full=ORF1a polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3;
DE              Short=PL-PRO;
DE              EC=3.4.19.12 {ECO:0000269|PubMed:17692280};
DE              EC=3.4.22.- {ECO:0000269|PubMed:12917450, ECO:0000269|PubMed:16306590, ECO:0000269|PubMed:17692280};
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:12917450};
DE     AltName: Full=Main protease;
DE              Short=Mpro;
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=RNA-capping enzyme subunit nsp9;
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE              EC=2.7.7.50;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=Non-structural protein 11;
DE              Short=nsp11;
GN   ORFNames=1a;
OS   Severe acute respiratory syndrome coronavirus (SARS-CoV).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=694009;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
OH   NCBI_TaxID=9675; Paguma larvata (Masked palm civet).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Urbani;
RX   PubMed=12730500; DOI=10.1126/science.1085952;
RA   Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R.,
RA   Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.-H., Tong S.,
RA   Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D.,
RA   Peret T.C.T., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S.,
RA   Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R.,
RA   Guenther S., Osterhaus A.D.M.E., Drosten C., Pallansch M.A., Anderson L.J.,
RA   Bellini W.J.;
RT   ""Characterization of a novel coronavirus associated with severe acute
RT   respiratory syndrome."";
RL   Science 300:1394-1399(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Tor2;
RX   PubMed=12730501; DOI=10.1126/science.1085953;
RA   Marra M.A., Jones S.J.M., Astell C.R., Holt R.A., Brooks-Wilson A.,
RA   Butterfield Y.S.N., Khattra J., Asano J.K., Barber S.A., Chan S.Y.,
RA   Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffith O.L., Leach S.R.,
RA   Mayo M., McDonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S.,
RA   Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.M.,
RA   Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K.,
RA   Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R.,
RA   Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A.,
RA   Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S.,
RA   Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M.,
RA   Skowronski D.M., Upton C., Roper R.L.;
RT   ""The genome sequence of the SARS-associated coronavirus."";
RL   Science 300:1399-1404(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate CUHK-Su10, and Isolate CUHK-W1;
RX   PubMed=12853594; DOI=10.1056/nejm200307103490216;
RA   Tsui S.K.W., Chim S.S.C., Lo Y.M.D.;
RT   ""Coronavirus genomic-sequence variations and the epidemiology of the severe
RT   acute respiratory syndrome."";
RL   N. Engl. J. Med. 349:187-188(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate GZ50, Isolate SZ16, and Isolate SZ3;
RX   PubMed=12958366; DOI=10.1126/science.1087139;
RA   Guan Y., Zheng B.J., He Y.Q., Liu X.L., Zhuang Z.X., Cheung C.L., Luo S.W.,
RA   Li P.H., Zhang L.J., Guan Y.J., Butt K.M., Wong K.L., Chan K.W., Lim W.,
RA   Shortridge K.F., Yuen K.Y., Peiris J.S.M., Poon L.L.M.;
RT   ""Isolation and characterization of viruses related to the SARS coronavirus
RT   from animals in southern China."";
RL   Science 302:276-278(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HKU-39849;
RX   PubMed=12876307; DOI=10.1177/15353702-0322807-13;
RA   Zeng F.Y., Chan C.W., Chan M.N., Chen J.D., Chow K.Y.C., Hon C.C.C.,
RA   Hui R.K.H., Li J., Li V.Y.Y., Wang C.Y., Wang P.Y., Guan Y., Zheng B.,
RA   Poon L.L.M., Chan K.H., Yuen K.Y., Peiris J.S.M., Leung F.C.;
RT   ""The complete genome sequence of severe acute respiratory syndrome
RT   coronavirus strain HKU-39849 (HK-39)."";
RL   Exp. Biol. Med. 228:866-873(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Sin2500, Isolate Sin2677, Isolate Sin2679, Isolate
RC   Sin2748, and Isolate sin2774;
RX   PubMed=12781537; DOI=10.1016/s0140-6736(03)13414-9;
RA   Ruan Y., Wei C.L., Ling A.E., Vega V.B., Thoreau H., Se Thoe S.Y.,
RA   Chia J.-M., Ng P., Chiu K.P., Lim L., Zhang T., Chan K.P., Oon L.E.L.,
RA   Ng M.L., Leo S.Y., Ng L.F.P., Ren E.C., Stanton L.W., Long P.M., Liu E.T.;
RT   ""Comparative full-length genome sequence analysis of 14 SARS coronavirus
RT   isolates and common mutations associated with putative origins of
RT   infection."";
RL   Lancet 361:1779-1785(2003).
RN   [7]
RP   ERRATUM OF PUBMED:12781537.
RA   Ruan Y., Wei C.L., Ling A.E., Vega V.B., Thoreau H., Se Thoe S.Y.,
RA   Chia J.-M., Ng P., Chiu K.P., Lim L., Zhang T., Chan K.P., Oon L.E.L.,
RA   Ng M.L., Leo S.Y., Ng L.F.P., Ren E.C., Stanton L.W., Long P.M., Liu E.T.;
RL   Lancet 361:1832-1832(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate ZJ01;
RX   PubMed=14527350;
RA   Li L., Wang Z., Lu Y., Bao Q., Chen S., Wu N., Cheng S., Weng J., Zhang Y.,
RA   Yan J., Mei L., Wang X., Zhu H., Yu Y., Zhang M., Li M., Yao J., Lu Q.,
RA   Yao P., Bo X., Wo J., Wang S., Hu S.;
RT   ""Severe acute respiratory syndrome-associated coronavirus genotype and its
RT   characterization."";
RL   Chin. Med. J. 116:1288-1292(2003).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate BJ01, Isolate BJ02, Isolate BJ03, Isolate BJ04, and
RC   Isolate GD01;
RA   Qin E., Zhu Q., Yu M., Fan B., Chang G., Si B., Yang B., Peng W., Jiang T.,
RA   Liu B., Deng Y., Liu H., Zhang Y., Wang C., Li Y., Gan Y., Li X., Lu F.,
RA   Tan G., Yang R., Cao W.S., Wang J., Chen W., Cong L., Deng Y., Dong W.,
RA   Han Y., Hu W., Lei M., Li C., Li G., Li G., Li H., Li S., Li S., Li W.,
RA   Li W., Lin W., Liu J., Liu Z., Lu H., Ni P., Qi Q., Sun Y., Tang L.,
RA   Tong Z., Wang J., Wang X., Wu Q., Xi Y., Xu Z., Yang L., Ye C., Ye J.,
RA   Zhang B., Zhang F., Zhang J., Zhang X., Zhou J., Yang H.;
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TW1;
RA   Yeh S.-H., Kao C.-L., Tsai C.-Y., Liu C.-J., Chen D.-S., Chen P.-J.;
RT   ""The complete genome of SARS coronavirus clone TW1."";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate FRA;
RX   PubMed=14645828; DOI=10.1126/science.302.5650.1504b;
RA   Eickmann M., Becker S., Klenk H.-D., Doerr H.W., Stadler K., Censini S.,
RA   Guidotti S., Masignani V., Scarselli M., Mora M., Donati C., Han J.H.,
RA   Song H.C., Abrignani S., Covacci A., Rappuoli R.;
RT   ""Phylogeny of the SARS coronavirus."";
RL   Science 302:1504-1505(2003).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Frankfurt-1;
RA   Thiel V., Hertzig T., Putics A., Ivanov K.A., Schelle B., Bayer S.,
RA   Scheiner B., Weinand H., Weissbrich B., Ziebuhr J.;
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWC;
RA   Yang J.-Y., Lin J.-H., Chiu S.-C., Wang S.-F., Lee S.C., Lin Y.-C.,
RA   Hsu C.-K., Chen H.-Y., Chang J.G., Chen P.-J., Su I.-J.;
RT   ""Genomic sequence of SARS isolate from the first fatal case in Taiwan."";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Shanghai QXC1;
RA   Yuan Z., Zhang X., Hu Y., Lan S., Wang H., Zhou Z., Wen Y.;
RT   ""Analysis of SARS coronavirus genome in Shanghai isolates."";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HSR 1;
RA   Canducci F., Clementi M., Poli G., Vicenzi E.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [16]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Taiwan TC1, Isolate Taiwan TC2, and Isolate Taiwan TC3;
RA   Chang J.-G.C., Lin T.-H., Chen C.-M., Lin C.-S., Chan W.-L., Shih M.-C.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [17]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWH, Isolate TWJ, Isolate TWK, Isolate TWS, and Isolate
RC   TWY;
RA   Shu H.Y., Wu K.M., Tsai S.F.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [18]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate AS;
RA   Balotta C., Corvasce S., Violin M., Galli M., Moroni M., Vigevani G.M.,
RA   Ruan Y.J., Salemi M.;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [19]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate ZJ01;
RA   Wang Z., Cheng S., Zhang Y.;
RL   Submitted (NOV-2003) to the EMBL/GenBank/DDBJ databases.
RN   [20]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA] OF 1-507 AND 1655-4382.
RC   STRAIN=Isolate Shanghai LY;
RA   Yuan Z., Zhang X., Hu Y., Lan S., Wang H., Zhou Z., Wen Y.;
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [21]
RP   PROTEOLYTIC CLEAVAGE (ISOFORM REPLICASE POLYPROTEIN 1A), CATALYTIC ACTIVITY
RP   (3C-LIKE PROTEINASE NSP5), AND CATALYTIC ACTIVITY (PAPAIN-LIKE PROTEASE
RP   NSP3).
RX   PubMed=12917450; DOI=10.1099/vir.0.19424-0;
RA   Thiel V., Ivanov K.A., Putics A., Hertzig T., Schelle B., Bayer S.,
RA   Weissbrich B., Snijder E.J., Rabenau H., Doerr H.W., Gorbalenya A.E.,
RA   Ziebuhr J.;
RT   ""Mechanisms and enzymes involved in SARS coronavirus genome expression."";
RL   J. Gen. Virol. 84:2305-2315(2003).
RN   [22]
RP   PROTEOLYTIC CLEAVAGE (ISOFORM REPLICASE POLYPROTEIN 1A).
RX   PubMed=15331731; DOI=10.1128/jvi.78.18.9977-9986.2004;
RA   Prentice E., McAuliffe J., Lu X., Subbarao K., Denison M.R.;
RT   ""Identification and characterization of severe acute respiratory syndrome
RT   coronavirus replicase proteins."";
RL   J. Virol. 78:9977-9986(2004).
RN   [23]
RP   PROTEOLYTIC CLEAVAGE (ISOFORM REPLICASE POLYPROTEIN 1A).
RC   STRAIN=Isolate Urbani;
RX   PubMed=15564471; DOI=10.1128/jvi.78.24.13600-13612.2004;
RA   Harcourt B.H., Jukneliene D., Kanjanahaluethai A., Bechill J.,
RA   Severson K.M., Smith C.M., Rota P.A., Baker S.C.;
RT   ""Identification of severe acute respiratory syndrome coronavirus replicase
RT   products and characterization of papain-like protease activity."";
RL   J. Virol. 78:13600-13612(2004).
RN   [24]
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), AND BIOPHYSICOCHEMICAL PROPERTIES (3C-LIKE PROTEINASE NSP5).
RX   PubMed=14561748; DOI=10.1074/jbc.m310875200;
RA   Fan K., Wei P., Feng Q., Chen S., Huang C., Ma L., Lai B., Pei J., Liu Y.,
RA   Chen J., Lai L.;
RT   ""Biosynthesis, purification, and substrate specificity of severe acute
RT   respiratory syndrome coronavirus 3C-like proteinase."";
RL   J. Biol. Chem. 279:1637-1642(2004).
RN   [25]
RP   CATALYTIC ACTIVITY (PAPAIN-LIKE PROTEASE NSP3), FUNCTION (PAPAIN-LIKE
RP   PROTEASE NSP3), PROTEOLYTIC CLEAVAGE (ISOFORM REPLICASE POLYPROTEIN 1A),
RP   COFACTOR (PAPAIN-LIKE PROTEASE NSP3), MUTAGENESIS OF CYS-1651; CYS-1688;
RP   CYS-1729; CYS-1732; CYS-1764; CYS-1766 AND ASP-1826, AND ACTIVE SITE
RP   (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=16306590; DOI=10.1128/jvi.79.24.15189-15198.2005;
RA   Barretto N., Jukneliene D., Ratia K., Chen Z., Mesecar A.D., Baker S.C.;
RT   ""The papain-like protease of severe acute respiratory syndrome coronavirus
RT   has deubiquitinating activity."";
RL   J. Virol. 79:15189-15198(2005).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=16226257; DOI=10.1016/j.febslet.2005.09.075;
RA   Lin C.W., Tsai F.J., Wan L., Lai C.C., Lin K.H., Hsieh T.H., Shiu S.Y.,
RA   Li J.Y.;
RT   ""Binding interaction of SARS coronavirus 3CL(pro) protease with vacuolar-H+
RT   ATPase G1 subunit."";
RL   FEBS Lett. 579:6089-6094(2005).
RN   [27]
RP   SUBUNIT (3C-LIKE PROTEINASE NSP5).
RX   PubMed=15507456; DOI=10.1074/jbc.m408211200;
RA   Chen S., Chen L., Tan J., Chen J., Du L., Sun T., Shen J., Chen K.,
RA   Jiang H., Shen X.;
RT   ""Severe acute respiratory syndrome coronavirus 3C-like proteinase N
RT   terminus is indispensable for proteolytic activity but not for enzyme
RT   dimerization. Biochemical and thermodynamic investigation in conjunction
RT   with molecular dynamics simulations."";
RL   J. Biol. Chem. 280:164-173(2005).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=17024178; DOI=10.1038/sj.emboj.7601368;
RA   Imbert I., Guillemot J.-C., Bourhis J.-M., Bussetta C., Coutard B.,
RA   Egloff M.-P., Ferron F., Gorbalenya A.E., Canard B.;
RT   ""A second, non-canonical RNA-dependent RNA polymerase in SARS
RT   coronavirus."";
RL   EMBO J. 25:4933-4942(2006).
RN   [29]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3).
RX   PubMed=17692280; DOI=10.1016/j.abb.2007.07.006;
RA   Lindner H.A., Lytvyn V., Qi H., Lachance P., Ziomek E., Menard R.;
RT   ""Selectivity in ISG15 and ubiquitin recognition by the SARS coronavirus
RT   papain-like protease."";
RL   Arch. Biochem. Biophys. 466:8-14(2007).
RN   [30]
RP   INTERACTION WITH ORF6 PROTEIN (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=17532020; DOI=10.1016/j.virol.2007.04.029;
RA   Kumar P., Gunalan V., Liu B., Chow V.T., Druce J., Birch C., Catton M.,
RA   Fielding B.C., Tan Y.J., Lal S.K.;
RT   ""The nonstructural protein 8 (nsp8) of the SARS coronavirus interacts with
RT   its ORF6 accessory protein."";
RL   Virology 366:293-303(2007).
RN   [31]
RP   TOPOLOGY (PAPAIN-LIKE PROTEASE NSP3), TOPOLOGY (NON-STRUCTURAL PROTEIN 4),
RP   AND TOPOLOGY (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=18842706; DOI=10.1128/jvi.01219-08;
RA   Oostra M., Hagemeijer M.C., van Gent M., Bekker C.P., te Lintelo E.G.,
RA   Rottier P.J., de Haan C.A.;
RT   ""Topology and membrane anchoring of the coronavirus replication complex:
RT   not all hydrophobic domains of nsp3 and nsp6 are membrane spanning."";
RL   J. Virol. 82:12392-12405(2008).
RN   [32]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=19369340; DOI=10.1128/jvi.02220-08;
RA   Frieman M., Ratia K., Johnston R.E., Mesecar A.D., Baric R.S.;
RT   ""Severe acute respiratory syndrome coronavirus papain-like protease
RT   ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and
RT   NF-kappaB signaling."";
RL   J. Virol. 83:6689-6705(2009).
RN   [33]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), AND INTERACTION WITH HOST PHB AND PHB2
RP   (NON-STRUCTURAL PROTEIN 2).
RX   PubMed=19640993; DOI=10.1128/jvi.00842-09;
RA   Cornillez-Ty C.T., Liao L., Yates J.R., Kuhn P., Buchmeier M.J.;
RT   ""Severe acute respiratory syndrome coronavirus nonstructural protein 2
RT   interacts with a host protein complex involved in mitochondrial biogenesis
RT   and intracellular signaling."";
RL   J. Virol. 83:10314-10318(2009).
RN   [34]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=19153232; DOI=10.1128/jvi.01505-08;
RA   Miknis Z.J., Donaldson E.F., Umland T.C., Rimmer R.A., Baric R.S.,
RA   Schultz L.W.;
RT   ""Severe acute respiratory syndrome coronavirus nsp9 dimerization is
RT   essential for efficient viral growth."";
RL   J. Virol. 83:3007-3018(2009).
RN   [35]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=22174690; DOI=10.1371/journal.ppat.1002433;
RA   Huang C., Lokugamage K.G., Rozovics J.M., Narayanan K., Semler B.L.,
RA   Makino S.;
RT   ""SARS coronavirus nsp1 protein induces template-dependent endonucleolytic
RT   cleavage of mRNAs: viral mRNAs are resistant to nsp1-induced RNA
RT   cleavage."";
RL   PLoS Pathog. 7:E1002433-E1002433(2011).
RN   [36]
RP   INTERACTION WITH PAPAIN-LIKE PROTEASE NSP3 (NON-STRUCTURAL PROTEIN 4),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 4), AND INTERACTION WITH
RP   NON-STRUCTURAL PROTEIN 6 (NON-STRUCTURAL PROTEIN 4).
RX   PubMed=21345958; DOI=10.1128/jvi.00042-11;
RA   Hagemeijer M.C., Ulasli M., Vonk A.M., Reggiori F., Rottier P.J.,
RA   de Haan C.A.;
RT   ""Mobility and interactions of coronavirus nonstructural protein 4."";
RL   J. Virol. 85:4572-4577(2011).
RN   [37]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=23035226; DOI=10.1128/jvi.01958-12;
RA   Lokugamage K.G., Narayanan K., Huang C., Makino S.;
RT   ""Severe acute respiratory syndrome coronavirus protein nsp1 is a novel
RT   eukaryotic translation inhibitor that represses multiple steps of
RT   translation initiation."";
RL   J. Virol. 86:13598-13608(2012).
RN   [38]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 7), AND FUNCTION (NON-STRUCTURAL PROTEIN
RP   8).
RX   PubMed=22039154; DOI=10.1093/nar/gkr893;
RA   te Velthuis A.J., van den Worm S.H., Snijder E.J.;
RT   ""The SARS-coronavirus nsp7+nsp8 complex is a unique multimeric RNA
RT   polymerase capable of both de novo initiation and primer extension."";
RL   Nucleic Acids Res. 40:1737-1747(2012).
RN   [39]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 10), AND INTERACTION WITH PROOFREADING
RP   EXORIBONUCLEASE NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=22635272; DOI=10.1073/pnas.1201130109;
RA   Bouvet M., Imbert I., Subissi L., Gluais L., Canard B., Decroly E.;
RT   ""RNA 3'-end mismatch excision by the severe acute respiratory syndrome
RT   coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complex."";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:9372-9377(2012).
RN   [40]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 4), FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND FUNCTION
RP   (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=23943763; DOI=10.1128/mbio.00524-13;
RA   Angelini M.M., Akhlaghpour M., Neuman B.W., Buchmeier M.J.;
RT   ""Severe acute respiratory syndrome coronavirus nonstructural proteins 3, 4,
RT   and 6 induce double-membrane vesicles."";
RL   MBio 4:0-0(2013).
RN   [41]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=24991833; DOI=10.4161/auto.29309;
RA   Cottam E.M., Whelband M.C., Wileman T.;
RT   ""Coronavirus NSP6 restricts autophagosome expansion."";
RL   Autophagy 10:1426-1441(2014).
RN   [42]
RP   REVIEW.
RX   PubMed=24410069; DOI=10.1089/dna.2013.2304;
RA   Angelini M.M., Neuman B.W., Buchmeier M.J.;
RT   ""Untangling membrane rearrangement in the nidovirales."";
RL   DNA Cell Biol. 33:122-127(2014).
RN   [43]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=24622840; DOI=10.1007/s13238-014-0026-3;
RA   Chen X., Yang X., Zheng Y., Yang Y., Xing Y., Chen Z.;
RT   ""SARS coronavirus papain-like protease inhibits the type I interferon
RT   signaling pathway through interaction with the STING-TRAF3-TBK1 complex."";
RL   Protein Cell 5:369-381(2014).
RN   [44]
RP   INTERACTION WITH NUP93 (HOST TRANSLATION INHIBITOR NSP1), AND FUNCTION
RP   (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=30943371; DOI=10.1139/bcb-2018-0394;
RA   Gomez G.N., Abrar F., Dodhia M.P., Gonzalez F.G., Nag A.;
RT   ""SARS coronavirus protein nsp1 disrupts localization of Nup93 from the
RT   nuclear pore complex."";
RL   Biochem. Cell Biol. 97:758-766(2019).
RN   [45]
RP   PROTEOLYTIC CLEAVAGE (ISOFORM REPLICASE POLYPROTEIN 1A), MASS SPECTROMETRY
RP   (NON-STRUCTURAL PROTEIN 8), MASS SPECTROMETRY (NON-STRUCTURAL PROTEIN 9),
RP   AND MASS SPECTROMETRY (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=32083638; DOI=10.1042/bcj20200029;
RA   Krichel B., Falke S., Hilgenfeld R., Redecke L., Uetrecht C.;
RT   ""Processing of the SARS-CoV pp1a/ab nsp7-10 region."";
RL   Biochem. J. 477:1009-1019(2020).
RN   [46]
RP   3D-STRUCTURE MODELING OF 3241-3540, AND CHARACTERIZATION (3C-LIKE
RP   PROTEINASE NSP5).
RX   PubMed=12746549; DOI=10.1126/science.1085658;
RA   Anand K., Ziebuhr J., Wadhwani P., Mesters J.R., Hilgenfeld R.;
RT   ""Coronavirus main proteinase (3CLpro) structure: basis for design of anti-
RT   SARS drugs."";
RL   Science 300:1763-1767(2003).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 4118-4230 (NON-STRUCTURAL PROTEIN
RP   9).
RC   STRAIN=Isolate Frankfurt-1;
RX   PubMed=12925794; DOI=10.1107/s0907444903016779;
RA   Campanacci V., Egloff M.-P., Longhi S., Ferron F., Rancurel C.,
RA   Salomoni A., Durousseau C., Tocque F., Bremond N., Dobbe J.C.,
RA   Snijder E.J., Canard B., Cambillau C.;
RT   ""Structural genomics of the SARS coronavirus: cloning, expression,
RT   crystallization and preliminary crystallographic study of the Nsp9
RT   protein."";
RL   Acta Crystallogr. D 59:1628-1631(2003).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 4118-4230.
RX   PubMed=15007178; DOI=10.1073/pnas.0307877101;
RA   Egloff M.-P., Ferron F., Campanacci V., Longhi S., Rancurel C.,
RA   Dutartre H., Snijder E.J., Gorbalenya A.E., Cambillau C., Canard B.;
RT   ""The severe acute respiratory syndrome-coronavirus replicative protein nsp9
RT   is a single-stranded RNA-binding subunit unique in the RNA virus world."";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:3792-3796(2004).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 4107-4230.
RX   PubMed=14962394; DOI=10.1016/j.str.2004.01.016;
RA   Sutton G., Fry E., Carter L., Sainsbury S., Walter T., Nettleship J.,
RA   Berrow N., Owens R., Gilbert R., Davidson A., Siddell S., Poon L.L.M.,
RA   Diprose J., Alderton D., Walsh M., Grimes J.M., Stuart D.I.;
RT   ""The nsp9 replicase protein of SARS-coronavirus, structure and functional
RT   insights."";
RL   Structure 12:341-353(2004).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 3837-4117 AND 3920-4117,
RP   INTERACTION WITH NON-STRUCTURAL PROTEIN 7 (NON-STRUCTURAL PROTEIN 8), AND
RP   INTERACTION WITH NON-STRUCTURAL PROTEIN 8 (NON-STRUCTURAL PROTEIN 7).
RX   PubMed=16228002; DOI=10.1038/nsmb999;
RA   Zhai Y., Sun F., Li X., Pang H., Xu X., Bartlam M., Rao Z.;
RT   ""Insights into SARS-CoV transcription and replication from the structure of
RT   the nsp7-nsp8 hexadecamer."";
RL   Nat. Struct. Mol. Biol. 12:980-986(2005).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 1002-1176.
RX   PubMed=16271890; DOI=10.1016/j.str.2005.07.022;
RA   Saikatendu K.S., Joseph J.S., Subramanian V., Clayton T., Griffith M.,
RA   Moy K., Velasquez J., Neuman B.W., Buchmeier M.J., Stevens R.C., Kuhn P.;
RT   ""Structural basis of severe acute respiratory syndrome coronavirus ADP-
RT   ribose-1''-phosphate dephosphorylation by a conserved domain of nsP3."";
RL   Structure 13:1665-1675(2005).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 1541-1854.
RX   PubMed=16581910; DOI=10.1073/pnas.0510851103;
RA   Ratia K., Saikatendu K.S., Santarsiero B.D., Barretto N., Baker S.C.,
RA   Stevens R.C., Mesecar A.D.;
RT   ""Severe acute respiratory syndrome coronavirus papain-like protease:
RT   structure of a viral deubiquitinating enzyme."";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:5717-5722(2006).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 4240-4362.
RC   STRAIN=Isolate Tor2;
RX   PubMed=16873246; DOI=10.1128/jvi.00467-06;
RA   Joseph J.S., Saikatendu K.S., Subramanian V., Neuman B.W., Brooun A.,
RA   Griffith M., Moy K., Yadav M.K., Velasquez J., Buchmeier M.J.,
RA   Stevens R.C., Kuhn P.;
RT   ""Crystal structure of nonstructural protein 10 from the severe acute
RT   respiratory syndrome coronavirus reveals a novel fold with two zinc-binding
RT   motifs."";
RL   J. Virol. 80:7894-7901(2006).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 4231-4378.
RX   PubMed=16873247; DOI=10.1128/jvi.00483-06;
RA   Su D., Lou Z., Sun F., Zhai Y., Yang H., Zhang R., Joachimiak A.,
RA   Zhang X.C., Bartlam M., Rao Z.;
RT   ""Dodecamer structure of severe acute respiratory syndrome coronavirus
RT   nonstructural protein nsp10."";
RL   J. Virol. 80:7902-7908(2006).
RN   [55]
RP   STRUCTURE BY NMR OF 13-127.
RX   PubMed=17202208; DOI=10.1128/jvi.01939-06;
RA   Almeida M.S., Johnson M.A., Herrmann T., Geralt M., Wuthrich K.;
RT   ""Novel beta-barrel fold in the nuclear magnetic resonance structure of the
RT   replicase nonstructural protein 1 from the severe acute respiratory
RT   syndrome coronavirus."";
RL   J. Virol. 81:3151-3161(2007).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3241-3546.
RG   RIKEN structural genomics initiative (RSGI);
RT   ""Crystal structure of Sars coronavirus main proteinase(3CLPRO)."";
RL   Submitted (JUL-2007) to the PDB data bank.
CC   -!- FUNCTION: [Isoform Replicase polyprotein 1a]: Multifunctional protein
CC       involved in the transcription and replication of viral RNAs. Contains
CC       the proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000305}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by interacting with the 40S ribosomal subunit. The nsp1-40S ribosome
CC       complex further induces an endonucleolytic cleavage near the 5'UTR of
CC       host mRNAs, targeting them for degradation. Viral mRNAs are not
CC       susceptible to nsp1-mediated endonucleolytic RNA cleavage thanks to the
CC       presence of a 5'-end leader sequence and are therefore protected from
CC       degradation. By suppressing host gene expression, nsp1 facilitates
CC       efficient viral gene expression in infected cells and evasion from host
CC       immune response (PubMed:23035226). May disrupt nuclear pore function by
CC       binding and displacing host NUP93 (PubMed:30943371).
CC       {ECO:0000269|PubMed:23035226, ECO:0000269|PubMed:30943371}.
CC   -!- FUNCTION: [Non-structural protein 2]: May play a role in the modulation
CC       of host cell survival signaling pathway by interacting with host PHB
CC       and PHB2 (PubMed:19640993). Indeed, these two proteins play a role in
CC       maintaining the functional integrity of the mitochondria and protecting
CC       cells from various stresses (PubMed:19640993).
CC       {ECO:0000269|PubMed:19640993}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. In addition,
CC       PL-PRO possesses a deubiquitinating/deISGylating activity and processes
CC       both 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:17692280). Plays a role in host membrane
CC       rearrangement that leads to creation of cytoplasmic double-membrane
CC       vesicles (DMV) necessary for viral replication (PubMed:23943763). Nsp3,
CC       nsp4 and nsp6 together are sufficient to form DMV (PubMed:23943763,
CC       PubMed:24410069). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:19369340, PubMed:24622840).
CC       Prevents also host NF-kappa-B signaling (PubMed:19369340,
CC       PubMed:24622840). {ECO:0000269|PubMed:16271890,
CC       ECO:0000269|PubMed:17692280, ECO:0000269|PubMed:19369340,
CC       ECO:0000269|PubMed:23943763, ECO:0000269|PubMed:24622840,
CC       ECO:0000303|PubMed:24410069}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in host membrane
CC       rearrangement that leads to creation of cytoplasmic double-membrane
CC       vesicles (DMV) necessary for viral replication (PubMed:23943763,
CC       PubMed:24410069). Alone appears incapable to induce membrane curvature,
CC       but together with nsp3 is able to induce paired membranes
CC       (PubMed:23943763). Nsp3, nsp4 and nsp6 together are sufficient to form
CC       DMV (PubMed:23943763, PubMed:24410069). {ECO:0000269|PubMed:23943763,
CC       ECO:0000303|PubMed:24410069}.
CC   -!- FUNCTION: [3C-like proteinase nsp5]: Cleaves the C-terminus of
CC       replicase polyprotein at 11 sites. Recognizes substrates containing the
CC       core sequence [ILMVF]-Q-|-[SGACN]. Also able to bind an ADP-ribose-1''-
CC       phosphate (ADRP). May cleave host ATP6V1G1 thereby modifying host
CC       vacuoles intracellular pH. {ECO:0000255|PROSITE-ProRule:PRU00772,
CC       ECO:0000269|PubMed:16226257}.
CC   -!- FUNCTION: [Non-structural protein 6]: Plays a role in host membrane
CC       rearrangement that leads to creation of cytoplasmic double-membrane
CC       vesicles (DMV) necessary for viral replication (PubMed:23943763). Nsp3,
CC       nsp4 and nsp6 together are sufficient to form DMV (PubMed:23943763,
CC       PubMed:24410069). Plays a role in the initial induction of
CC       autophagosomes from host endoplasmic reticulum. Later, limits the
CC       expansion of these phagosomes that are no longer able to deliver viral
CC       components to lysosomes (PubMed:24991833).
CC       {ECO:0000269|PubMed:23943763, ECO:0000269|PubMed:24991833,
CC       ECO:0000303|PubMed:24410069}.
CC   -!- FUNCTION: [Non-structural protein 7]: Forms a hexadecamer with nsp8 (8
CC       subunits of each) that may participate in viral replication by acting
CC       as a primase. Alternatively, may synthesize substantially longer
CC       products than oligonucleotide primers. {ECO:0000269|PubMed:22039154}.
CC   -!- FUNCTION: [Non-structural protein 8]: Forms a hexadecamer with nsp7 (8
CC       subunits of each) that may participate in viral replication by acting
CC       as a primase. Alternatively, may synthesize substantially longer
CC       products than oligonucleotide primers. {ECO:0000269|PubMed:22039154}.
CC   -!- FUNCTION: [RNA-capping enzyme subunit nsp9]: Catalytic subunit of viral
CC       RNA capping enzyme which catalyzes the RNA guanylyltransferase reaction
CC       for genomic and sub-genomic RNAs. The kinase-like NiRAN domain of NSP12
CC       transfers RNA to the amino terminus of NSP9, forming a covalent RNA-
CC       protein intermediate. Subsequently, the NiRAN domain transfers RNA to
CC       GDP, forming the core cap structure GpppA-RNA. The NSP14 and NSP16
CC       methyltransferases then add methyl groups to form functional cap
CC       structures. {ECO:0000250|UniProtKB:P0DTC1,
CC       ECO:0000269|PubMed:19153232}.
CC   -!- FUNCTION: [Non-structural protein 10]: Plays a pivotal role in viral
CC       transcription by stimulating both nsp14 3'-5' exoribonuclease and nsp16
CC       2'-O-methyltransferase activities. Therefore plays an essential role in
CC       viral mRNAs cap methylation. {ECO:0000269|PubMed:22635272}.
CC   -!- CATALYTIC ACTIVITY: [3C-like proteinase nsp5]:
CC       Reaction=TSAVLQ-|-SGFRK-NH2 and SGVTFQ-|-GKFKK the two peptides
CC         corresponding to the two self-cleavage sites of the SARS 3C-like
CC         proteinase are the two most reactive peptide substrates. The enzyme
CC         exhibits a strong preference for substrates containing Gln at P1
CC         position and Leu at P2 position.; EC=3.4.22.69;
CC         Evidence={ECO:0000269|PubMed:12917450, ECO:0000269|PubMed:14561748};
CC   -!- CATALYTIC ACTIVITY: [Papain-like protease nsp3]:
CC       Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide
CC         and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-
CC         residue protein attached to proteins as an intracellular targeting
CC         signal).; EC=3.4.19.12; Evidence={ECO:0000269|PubMed:12917450,
CC         ECO:0000269|PubMed:17692280};
CC   -!- CATALYTIC ACTIVITY: [RNA-capping enzyme subunit nsp9]:
CC       Reaction=a 5'-end diphospho-ribonuc",52854
GCCAAA CCAAAA CAAAAG AAAAGC AAAGCT AAGCTG AGCTGG GCTGGC CTGGCC TGGCCC GGCCCA GCCCAG CCCAGC CCAGCG CAGCGA AGCGAA GCGAAT CGAATG GAATGG AATGGT ATGGTG TGGTGT GGTGTC GTGTCT TGTCTG GTCTGG TCTGGA CTGGAA TGGAAG GGAAGC GAAGCC AAGCCA AGCCAA GCCAAC CCAACA CAACAG AACAGC ACAGCC CAGCCT AGCCTG GCCTGG CCTGGC CTGGCC TGGCCA GGCCAT GCCATC CCATCC CATCCA ATCCAG TCCAGG CCAGGT CAGGTG AGGTGC GGTGCA GTGCAT TGCATG GCATGG CATGGG ATGGGG TGGGGG GGGGGT GGGGTT GGGTTA GGTTAC GTTACG TTACGG TACGGC ACGGCT CGGCTA GGCTAC GCTACA CTACAC TACACG ACACGC CACGCG ACGCGT CGCGTG GCGTGA CGTGAT GTGATT TGATTT GATTTT ATTTTC TTTTCC TTTCCG TTCCGG TCCGGT CCGGTG CGGTGG GGTGGA GTGGAG TGGAGC GGAGCA GAGCAG AGCAGT GCAGTA CAGTAT AGTATT GTATTG TATTGG ATTGGC TTGGCG TGGCGC GGCGCG GCGCGA CGCGAC GCGACA CGACAA GACAAC ACAACC CAACCG AACCGC ACCGCC CCGCCT CGCCTG GCCTGA CCTGAA CTGAAC TGAACA GAACAT AACATG ACATGA CATGAT ATGATC TGATCC GATCCA ATCCAC TCCACG CCACGA CACGAA ACGAAG CGAAGG GAAGGC AAGGCA AGGCAC GGCACA GCACAC CACACA ACACAT CACATG ACATGG CATGGC ATGGCA TGGCAT GGCATT,3,145,GCCA CCAA CAAA AAAA AAAG AAGC AGCT GCTG CTGG TGGC GGCC GCCC CCCA CCAG CAGC AGCG GCGA CGAA GAAT AATG ATGG TGGT GGTG GTGT TGTC GTCT TCTG CTGG TGGA GGAA GAAG AAGC AGCC GCCA CCAA CAAC AACA ACAG CAGC AGCC GCCT CCTG CTGG TGGC GGCC GCCA CCAT CATC ATCC TCCA CCAG CAGG AGGT GGTG GTGC TGCA GCAT CATG ATGG TGGG GGGG GGGG GGGT GGTT GTTA TTAC TACG ACGG CGGC GGCT GCTA CTAC TACA ACAC CACG ACGC CGCG GCGT CGTG GTGA TGAT GATT ATTT TTTT TTTC TTCC TCCG CCGG CGGT GGTG GTGG TGGA GGAG GAGC AGCA GCAG CAGT AGTA GTAT TATT ATTG TTGG TGGC GGCG GCGC CGCG GCGA CGAC GACA ACAA CAAC AACC ACCG CCGC CGCC GCCT CCTG CTGA TGAA GAAC AACA ACAT CATG ATGA TGAT GATC ATCC TCCA CCAC CACG ACGA CGAA GAAG AAGG AGGC GGCA GCAC CACA ACAC CACA ACAT CATG ATGG TGGC GGCA GCAT CATT,GCCAA CCAAA CAAAA AAAAG AAAGC AAGCT AGCTG GCTGG CTGGC TGGCC GGCCC GCCCA CCCAG CCAGC CAGCG AGCGA GCGAA CGAAT GAATG AATGG ATGGT TGGTG GGTGT GTGTC TGTCT GTCTG TCTGG CTGGA TGGAA GGAAG GAAGC AAGCC AGCCA GCCAA CCAAC CAACA AACAG ACAGC CAGCC AGCCT GCCTG CCTGG CTGGC TGGCC GGCCA GCCAT CCATC CATCC ATCCA TCCAG CCAGG CAGGT AGGTG GGTGC GTGCA TGCAT GCATG CATGG ATGGG TGGGG GGGGG GGGGT GGGTT GGTTA GTTAC TTACG TACGG ACGGC CGGCT GGCTA GCTAC CTACA TACAC ACACG CACGC ACGCG CGCGT GCGTG CGTGA GTGAT TGATT GATTT ATTTT TTTTC TTTCC TTCCG TCCGG CCGGT CGGTG GGTGG GTGGA TGGAG GGAGC GAGCA AGCAG GCAGT CAGTA AGTAT GTATT TATTG ATTGG TTGGC TGGCG GGCGC GCGCG CGCGA GCGAC CGACA GACAA ACAAC CAACC AACCG ACCGC CCGCC CGCCT GCCTG CCTGA CTGAA TGAAC GAACA AACAT ACATG CATGA ATGAT TGATC GATCC ATCCA TCCAC CCACG CACGA ACGAA CGAAG GAAGG AAGGC AGGCA GGCAC GCACA CACAC ACACA CACAT ACATG CATGG ATGGC TGGCA GGCAT GCATT,GCCAAA CCAAAA CAAAAG AAAAGC AAAGCT AAGCTG AGCTGG GCTGGC CTGGCC TGGCCC GGCCCA GCCCAG CCCAGC CCAGCG CAGCGA AGCGAA GCGAAT CGAATG GAATGG AATGGT ATGGTG TGGTGT GGTGTC GTGTCT TGTCTG GTCTGG TCTGGA CTGGAA TGGAAG GGAAGC GAAGCC AAGCCA AGCCAA GCCAAC CCAACA CAACAG AACAGC ACAGCC CAGCCT AGCCTG GCCTGG CCTGGC CTGGCC TGGCCA GGCCAT GCCATC CCATCC CATCCA ATCCAG TCCAGG CCAGGT CAGGTG AGGTGC GGTGCA GTGCAT TGCATG GCATGG CATGGG ATGGGG TGGGGG GGGGGT GGGGTT GGGTTA GGTTAC GTTACG TTACGG TACGGC ACGGCT CGGCTA GGCTAC GCTACA CTACAC TACACG ACACGC CACGCG ACGCGT CGCGTG GCGTGA CGTGAT GTGATT TGATTT GATTTT ATTTTC TTTTCC TTTCCG TTCCGG TCCGGT CCGGTG CGGTGG GGTGGA GTGGAG TGGAGC GGAGCA GAGCAG AGCAGT GCAGTA CAGTAT AGTATT GTATTG TATTGG ATTGGC TTGGCG TGGCGC GGCGCG GCGCGA CGCGAC GCGACA CGACAA GACAAC ACAACC CAACCG AACCGC ACCGCC CCGCCT CGCCTG GCCTGA CCTGAA CTGAAC TGAACA GAACAT AACATG ACATGA CATGAT ATGATC TGATCC GATCCA ATCCAC TCCACG CCACGA CACGAA ACGAAG CGAAGG GAAGGC AAGGCA AGGCAC GGCACA GCACAC CACACA ACACAT CACATG ACATGG CATGGC ATGGCA TGGCAT GGCATT,GCCAAAA CCAAAAG CAAAAGC AAAAGCT AAAGCTG AAGCTGG AGCTGGC GCTGGCC CTGGCCC TGGCCCA GGCCCAG GCCCAGC CCCAGCG CCAGCGA CAGCGAA AGCGAAT GCGAATG CGAATGG GAATGGT AATGGTG ATGGTGT TGGTGTC GGTGTCT GTGTCTG TGTCTGG GTCTGGA TCTGGAA CTGGAAG TGGAAGC GGAAGCC GAAGCCA AAGCCAA AGCCAAC GCCAACA CCAACAG CAACAGC AACAGCC ACAGCCT CAGCCTG AGCCTGG GCCTGGC CCTGGCC CTGGCCA TGGCCAT GGCCATC GCCATCC CCATCCA CATCCAG ATCCAGG TCCAGGT CCAGGTG CAGGTGC AGGTGCA GGTGCAT GTGCATG TGCATGG GCATGGG CATGGGG ATGGGGG TGGGGGT GGGGGTT GGGGTTA GGGTTAC GGTTACG GTTACGG TTACGGC TACGGCT ACGGCTA CGGCTAC GGCTACA GCTACAC CTACACG TACACGC ACACGCG CACGCGT ACGCGTG CGCGTGA GCGTGAT CGTGATT GTGATTT TGATTTT GATTTTC ATTTTCC TTTTCCG TTTCCGG TTCCGGT TCCGGTG CCGGTGG CGGTGGA GGTGGAG GTGGAGC TGGAGCA GGAGCAG GAGCAGT AGCAGTA GCAGTAT CAGTATT AGTATTG GTATTGG TATTGGC ATTGGCG TTGGCGC TGGCGCG GGCGCGA GCGCGAC CGCGACA GCGACAA CGACAAC GACAACC ACAACCG CAACCGC AACCGCC ACCGCCT CCGCCTG CGCCTGA GCCTGAA CCTGAAC CTGAACA TGAACAT GAACATG AACATGA ACATGAT CATGATC ATGATCC TGATCCA GATCCAC ATCCACG TCCACGA CCACGAA CACGAAG ACGAAGG CGAAGGC GAAGGCA AAGGCAC AGGCACA GGCACAC GCACACA CACACAT ACACATG CACATGG ACATGGC CATGGCA ATGGCAT TGGCATT,"ID   ACDA_BACSU              Reviewed;         379 AA.
AC   P45867;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   05-FEB-2025, entry version 142.
DE   RecName: Full=Acyl-CoA dehydrogenase;
DE            EC=1.3.99.-;
GN   Name=acdA; Synonyms=acd; OrderedLocusNames=BSU37170;
OS   Bacillus subtilis (strain 168).
OC   Bacteria; Bacillati; Bacillota; Bacilli; Bacillales; Bacillaceae; Bacillus.
OX   NCBI_TaxID=224308;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=168;
RX   PubMed=9353933; DOI=10.1099/00221287-143-10-3313;
RA   Presecan E., Moszer I., Boursier L., Cruz Ramos H., De La Fuente V.,
RA   Hullo M.-F., Lelong C., Schleich S., Sekowska A., Song B.H., Villani G.,
RA   Kunst F., Danchin A., Glaser P.;
RT   ""The Bacillus subtilis genome from gerBC (311 degrees) to licR (334
RT   degrees)."";
RL   Microbiology 143:3313-3328(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=168;
RX   PubMed=9384377; DOI=10.1038/36786;
RA   Kunst F., Ogasawara N., Moszer I., Albertini A.M., Alloni G., Azevedo V.,
RA   Bertero M.G., Bessieres P., Bolotin A., Borchert S., Borriss R.,
RA   Boursier L., Brans A., Braun M., Brignell S.C., Bron S., Brouillet S.,
RA   Bruschi C.V., Caldwell B., Capuano V., Carter N.M., Choi S.-K.,
RA   Codani J.-J., Connerton I.F., Cummings N.J., Daniel R.A., Denizot F.,
RA   Devine K.M., Duesterhoeft A., Ehrlich S.D., Emmerson P.T., Entian K.-D.,
RA   Errington J., Fabret C., Ferrari E., Foulger D., Fritz C., Fujita M.,
RA   Fujita Y., Fuma S., Galizzi A., Galleron N., Ghim S.-Y., Glaser P.,
RA   Goffeau A., Golightly E.J., Grandi G., Guiseppi G., Guy B.J., Haga K.,
RA   Haiech J., Harwood C.R., Henaut A., Hilbert H., Holsappel S., Hosono S.,
RA   Hullo M.-F., Itaya M., Jones L.-M., Joris B., Karamata D., Kasahara Y.,
RA   Klaerr-Blanchard M., Klein C., Kobayashi Y., Koetter P., Koningstein G.,
RA   Krogh S., Kumano M., Kurita K., Lapidus A., Lardinois S., Lauber J.,
RA   Lazarevic V., Lee S.-M., Levine A., Liu H., Masuda S., Mauel C.,
RA   Medigue C., Medina N., Mellado R.P., Mizuno M., Moestl D., Nakai S.,
RA   Noback M., Noone D., O'Reilly M., Ogawa K., Ogiwara A., Oudega B.,
RA   Park S.-H., Parro V., Pohl T.M., Portetelle D., Porwollik S.,
RA   Prescott A.M., Presecan E., Pujic P., Purnelle B., Rapoport G., Rey M.,
RA   Reynolds S., Rieger M., Rivolta C., Rocha E., Roche B., Rose M., Sadaie Y.,
RA   Sato T., Scanlan E., Schleich S., Schroeter R., Scoffone F., Sekiguchi J.,
RA   Sekowska A., Seror S.J., Serror P., Shin B.-S., Soldo B., Sorokin A.,
RA   Tacconi E., Takagi T., Takahashi H., Takemaru K., Takeuchi M.,
RA   Tamakoshi A., Tanaka T., Terpstra P., Tognoni A., Tosato V., Uchiyama S.,
RA   Vandenbol M., Vannier F., Vassarotti A., Viari A., Wambutt R., Wedler E.,
RA   Wedler H., Weitzenegger T., Winters P., Wipat A., Yamamoto H., Yamane K.,
RA   Yasumoto K., Yata K., Yoshida K., Yoshikawa H.-F., Zumstein E.,
RA   Yoshikawa H., Danchin A.;
RT   ""The complete genome sequence of the Gram-positive bacterium Bacillus
RT   subtilis."";
RL   Nature 390:249-256(1997).
RN   [3]
RP   GENE NAME, AND INDUCTION.
RC   STRAIN=168;
RX   PubMed=17189250; DOI=10.1074/jbc.m606831200;
RA   Matsuoka H., Hirooka K., Fujita Y.;
RT   ""Organization and function of the YsiA regulon of Bacillus subtilis
RT   involved in fatty acid degradation."";
RL   J. Biol. Chem. 282:5180-5194(2007).
CC   -!- FUNCTION: Involved in the degradation of long-chain fatty acids.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 2,3-saturated acyl-CoA + A = a 2,3-dehydroacyl-CoA + AH2;
CC         Xref=Rhea:RHEA:48608, ChEBI:CHEBI:13193, ChEBI:CHEBI:17499,
CC         ChEBI:CHEBI:60015, ChEBI:CHEBI:65111;
CC   -!- COFACTOR:
CC       Name=FAD; Xref=ChEBI:CHEBI:57692; Evidence={ECO:0000250};
CC   -!- PATHWAY: Lipid metabolism; fatty acid beta-oxidation.
CC   -!- INDUCTION: Repressed by FadR in the absence of LCFAs (fatty acids of
CC       14-20 carbon atoms). When LCFAs are present in the medium, they are
CC       converted to long-chain acyl-CoAs, which antagonize FadR as to its
CC       binding to fadR boxes on target DNA and thus derepress transcription.
CC       {ECO:0000269|PubMed:17189250}.
CC   -!- SIMILARITY: Belongs to the acyl-CoA dehydrogenase family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Z49782; CAA89868.1; -; Genomic_DNA.
DR   EMBL; AL009126; CAB15745.1; -; Genomic_DNA.
DR   PIR; S55421; S55421.
DR   RefSeq; NP_391598.1; NC_000964.3.
DR   RefSeq; WP_003242719.1; NZ_OZ025638.1.
DR   AlphaFoldDB; P45867; -.
DR   SMR; P45867; -.
DR   STRING; 224308.BSU37170; -.
DR   PaxDb; 224308-BSU37170; -.
DR   EnsemblBacteria; CAB15745; CAB15745; BSU_37170.
DR   GeneID; 938457; -.
DR   KEGG; bsu:BSU37170; -.
DR   PATRIC; fig|224308.179.peg.4027; -.
DR   eggNOG; COG1960; Bacteria.
DR   InParanoid; P45867; -.
DR   OrthoDB; 9802447at2; -.
DR   PhylomeDB; P45867; -.
DR   BioCyc; BSUB:BSU37170-MONOMER; -.
DR   UniPathway; UPA00659; -.
DR   Proteomes; UP000001570; Chromosome.
DR   GO; GO:0003995; F:acyl-CoA dehydrogenase activity; IBA:GO_Central.
DR   GO; GO:0050660; F:flavin adenine dinucleotide binding; IEA:InterPro.
DR   GO; GO:0006635; P:fatty acid beta-oxidation; IEA:UniProtKB-UniPathway.
DR   CDD; cd01158; SCAD_SBCAD; 1.
DR   FunFam; 1.10.540.10:FF:000002; Acyl-CoA dehydrogenase FadE19; 1.
DR   FunFam; 1.20.140.10:FF:000004; Acyl-CoA dehydrogenase FadE25; 1.
DR   FunFam; 2.40.110.10:FF:000001; Acyl-CoA dehydrogenase, mitochondrial; 1.
DR   Gene3D; 1.10.540.10; Acyl-CoA dehydrogenase/oxidase, N-terminal domain; 1.
DR   Gene3D; 2.40.110.10; Butyryl-CoA Dehydrogenase, subunit A, domain 2; 1.
DR   Gene3D; 1.20.140.10; Butyryl-CoA Dehydrogenase, subunit A, domain 3; 1.
DR   InterPro; IPR006089; Acyl-CoA_DH_CS.
DR   InterPro; IPR006091; Acyl-CoA_Oxase/DH_mid-dom.
DR   InterPro; IPR046373; Acyl-CoA_Oxase/DH_mid-dom_sf.
DR   InterPro; IPR036250; AcylCo_DH-like_C.
DR   InterPro; IPR009075; AcylCo_DH/oxidase_C.
DR   InterPro; IPR013786; AcylCoA_DH/ox_N.
DR   InterPro; IPR037069; AcylCoA_DH/ox_N_sf.
DR   InterPro; IPR009100; AcylCoA_DH/oxidase_NM_dom_sf.
DR   PANTHER; PTHR43884; ACYL-COA DEHYDROGENASE; 1.
DR   PANTHER; PTHR43884:SF41; ACYL-COA DEHYDROGENASE; 1.
DR   Pfam; PF00441; Acyl-CoA_dh_1; 1.
DR   Pfam; PF02770; Acyl-CoA_dh_M; 1.
DR   Pfam; PF02771; Acyl-CoA_dh_N; 1.
DR   PIRSF; PIRSF016578; HsaA; 1.
DR   SUPFAM; SSF47203; Acyl-CoA dehydrogenase C-terminal domain-like; 1.
DR   SUPFAM; SSF56645; Acyl-CoA dehydrogenase NM domain-like; 1.
DR   PROSITE; PS00072; ACYL_COA_DH_1; 1.
DR   PROSITE; PS00073; ACYL_COA_DH_2; 1.
PE   2: Evidence at transcript level;
KW   FAD; Fatty acid metabolism; Flavoprotein; Lipid degradation;
KW   Lipid metabolism; Oxidoreductase; Reference proteome.
FT   CHAIN           1..379
FT                   /note=""Acyl-CoA dehydrogenase""
FT                   /id=""PRO_0000201182""
SQ   SEQUENCE   379 AA;  41446 MW;  4D09861D59718EF9 CRC64;
     MNFSLSEEHE MIRKLVRDFA KHEVAPTAAE RDEQERFDRE LFREMANLGL TGIPWPEDYG
     GIGSDYLAYV IAVEELSKVC ASTGVTLSAH ISLCSWPLFA FGTEEQKTEY LTQLALGEKI
     GAFALTEAGS GSDAGSMKTT AERIGDDYVL NGSKVFITNG GVADIYIVFA VTDPEKKKKG
     VTAFIVEKDF EGFFTGKKEK KLGIRSSPTT EIMFEDCVVP ASKRLGEEGE GFKIAMKTLD
     GGRNGIAAQA VGIAQGALDA ALQYAKERKQ FGKSIAEQQG IAFKLADMAT MIEASRLLTY
     QAAWLESSGL PYGKASAMSK LMAGDTAMKV TTEAVQIFGG YGYTKDYPVE RYMRDAKITQ
     IYEGTQEIQR LVISRMLAD
//
",23822
ATCGCT TCGCTG CGCTGC GCTGCC CTGCCT TGCCTA GCCTAC CCTACT CTACTT TACTTT ACTTTG CTTTGA TTTGAC TTGACC TGACCG GACCGC ACCGCG CCGCGA CGCGAT GCGATG CGATGA GATGAG ATGAGG TGAGGT GAGGTC AGGTCG GGTCGC GTCGCC TCGCCC CGCCCT GCCCTC CCCTCA CCTCAA CTCAAG TCAAGG CAAGGG AAGGGA AGGGAT GGGATT GGATTC GATTCC ATTCCA TTCCAC TCCACA CCACAA CACAAG ACAAGT CAAGTT AAGTTC AGTTCT GTTCTT TTCTTC TCTTCA CTTCAA TTCAAG TCAAGG CAAGGA AAGGAG AGGAGA GGAGAG GAGAGC AGAGCG GAGCGC AGCGCC GCGCCG CGCCGA GCCGAC CCGACG CGACGA GACGAG ACGAGG CGAGGA GAGGAG AGGAGC GGAGCG GAGCGC AGCGCA GCGCAA CGCAAG GCAAGC CAAGCA AAGCAC AGCACG GCACGC CACGCC ACGCCC CGCCCA GCCCAG CCCAGG CCAGGA CAGGAG AGGAGT GGAGTT GAGTTC AGTTCA GTTCAT TTCATC TCATCT CATCTC ATCTCT TCTCTT CTCTTA TCTTAC CTTACA TTACAT TACATC ACATCA CATCAA ATCAAC TCAACC CAACCT AACCTT ACCTTC CCTTCG CTTCGT TTCGTG TCGTGG CGTGGA,3,118,ATCG TCGC CGCT GCTG CTGC TGCC GCCT CCTA CTAC TACT ACTT CTTT TTTG TTGA TGAC GACC ACCG CCGC CGCG GCGA CGAT GATG ATGA TGAG GAGG AGGT GGTC GTCG TCGC CGCC GCCC CCCT CCTC CTCA TCAA CAAG AAGG AGGG GGGA GGAT GATT ATTC TTCC TCCA CCAC CACA ACAA CAAG AAGT AGTT GTTC TTCT TCTT CTTC TTCA TCAA CAAG AAGG AGGA GGAG GAGA AGAG GAGC AGCG GCGC CGCC GCCG CCGA CGAC GACG ACGA CGAG GAGG AGGA GGAG GAGC AGCG GCGC CGCA GCAA CAAG AAGC AGCA GCAC CACG ACGC CGCC GCCC CCCA CCAG CAGG AGGA GGAG GAGT AGTT GTTC TTCA TCAT CATC ATCT TCTC CTCT TCTT CTTA TTAC TACA ACAT CATC ATCA TCAA CAAC AACC ACCT CCTT CTTC TTCG TCGT CGTG GTGG TGGA,ATCGC TCGCT CGCTG GCTGC CTGCC TGCCT GCCTA CCTAC CTACT TACTT ACTTT CTTTG TTTGA TTGAC TGACC GACCG ACCGC CCGCG CGCGA GCGAT CGATG GATGA ATGAG TGAGG GAGGT AGGTC GGTCG GTCGC TCGCC CGCCC GCCCT CCCTC CCTCA CTCAA TCAAG CAAGG AAGGG AGGGA GGGAT GGATT GATTC ATTCC TTCCA TCCAC CCACA CACAA ACAAG CAAGT AAGTT AGTTC GTTCT TTCTT TCTTC CTTCA TTCAA TCAAG CAAGG AAGGA AGGAG GGAGA GAGAG AGAGC GAGCG AGCGC GCGCC CGCCG GCCGA CCGAC CGACG GACGA ACGAG CGAGG GAGGA AGGAG GGAGC GAGCG AGCGC GCGCA CGCAA GCAAG CAAGC AAGCA AGCAC GCACG CACGC ACGCC CGCCC GCCCA CCCAG CCAGG CAGGA AGGAG GGAGT GAGTT AGTTC GTTCA TTCAT TCATC CATCT ATCTC TCTCT CTCTT TCTTA CTTAC TTACA TACAT ACATC CATCA ATCAA TCAAC CAACC AACCT ACCTT CCTTC CTTCG TTCGT TCGTG CGTGG GTGGA,ATCGCT TCGCTG CGCTGC GCTGCC CTGCCT TGCCTA GCCTAC CCTACT CTACTT TACTTT ACTTTG CTTTGA TTTGAC TTGACC TGACCG GACCGC ACCGCG CCGCGA CGCGAT GCGATG CGATGA GATGAG ATGAGG TGAGGT GAGGTC AGGTCG GGTCGC GTCGCC TCGCCC CGCCCT GCCCTC CCCTCA CCTCAA CTCAAG TCAAGG CAAGGG AAGGGA AGGGAT GGGATT GGATTC GATTCC ATTCCA TTCCAC TCCACA CCACAA CACAAG ACAAGT CAAGTT AAGTTC AGTTCT GTTCTT TTCTTC TCTTCA CTTCAA TTCAAG TCAAGG CAAGGA AAGGAG AGGAGA GGAGAG GAGAGC AGAGCG GAGCGC AGCGCC GCGCCG CGCCGA GCCGAC CCGACG CGACGA GACGAG ACGAGG CGAGGA GAGGAG AGGAGC GGAGCG GAGCGC AGCGCA GCGCAA CGCAAG GCAAGC CAAGCA AAGCAC AGCACG GCACGC CACGCC ACGCCC CGCCCA GCCCAG CCCAGG CCAGGA CAGGAG AGGAGT GGAGTT GAGTTC AGTTCA GTTCAT TTCATC TCATCT CATCTC ATCTCT TCTCTT CTCTTA TCTTAC CTTACA TTACAT TACATC ACATCA CATCAA ATCAAC TCAACC CAACCT AACCTT ACCTTC CCTTCG CTTCGT TTCGTG TCGTGG CGTGGA,ATCGCTG TCGCTGC CGCTGCC GCTGCCT CTGCCTA TGCCTAC GCCTACT CCTACTT CTACTTT TACTTTG ACTTTGA CTTTGAC TTTGACC TTGACCG TGACCGC GACCGCG ACCGCGA CCGCGAT CGCGATG GCGATGA CGATGAG GATGAGG ATGAGGT TGAGGTC GAGGTCG AGGTCGC GGTCGCC GTCGCCC TCGCCCT CGCCCTC GCCCTCA CCCTCAA CCTCAAG CTCAAGG TCAAGGG CAAGGGA AAGGGAT AGGGATT GGGATTC GGATTCC GATTCCA ATTCCAC TTCCACA TCCACAA CCACAAG CACAAGT ACAAGTT CAAGTTC AAGTTCT AGTTCTT GTTCTTC TTCTTCA TCTTCAA CTTCAAG TTCAAGG TCAAGGA CAAGGAG AAGGAGA AGGAGAG GGAGAGC GAGAGCG AGAGCGC GAGCGCC AGCGCCG GCGCCGA CGCCGAC GCCGACG CCGACGA CGACGAG GACGAGG ACGAGGA CGAGGAG GAGGAGC AGGAGCG GGAGCGC GAGCGCA AGCGCAA GCGCAAG CGCAAGC GCAAGCA CAAGCAC AAGCACG AGCACGC GCACGCC CACGCCC ACGCCCA CGCCCAG GCCCAGG CCCAGGA CCAGGAG CAGGAGT AGGAGTT GGAGTTC GAGTTCA AGTTCAT GTTCATC TTCATCT TCATCTC CATCTCT ATCTCTT TCTCTTA CTCTTAC TCTTACA CTTACAT TTACATC TACATCA ACATCAA CATCAAC ATCAACC TCAACCT CAACCTT AACCTTC ACCTTCG CCTTCGT CTTCGTG TTCGTGG TCGTGGA,"ID   FRI2_MAIZE              Reviewed;         252 AA.
AC   P29390; Q43259;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   11-APR-2003, sequence version 2.
DT   05-FEB-2025, entry version 129.
DE   RecName: Full=Ferritin-2, chloroplastic;
DE            EC=1.16.3.1;
DE   AltName: Full=ZmFer2;
DE   Flags: Precursor;
GN   Name=FER2;
OS   Zea mays (Maize).
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliopsida; Liliopsida; Poales; Poaceae; PACMAD clade;
OC   Panicoideae; Andropogonodae; Andropogoneae; Tripsacinae; Zea.
OX   NCBI_TaxID=4577;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 44-72.
RC   STRAIN=cv. Missouri 17; TISSUE=Root, and Seed;
RX   PubMed=1627771; DOI=10.1007/bf00026783;
RA   Lobreaux S., Massenet O., Briat J.-F.;
RT   ""Iron induces ferritin synthesis in maize plantlets."";
RL   Plant Mol. Biol. 19:563-575(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=cv. B73; TISSUE=Seedling;
RX   PubMed=7649160; DOI=10.1111/j.1432-1033.1995.tb20739.x;
RA   Fobis-Loisy I., Loridon K., Lobreaux S., Lebrun M., Briat J.-F.;
RT   ""Structure and differential expression of two maize ferritin genes in
RT   response to iron and abscisic acid."";
RL   Eur. J. Biochem. 231:609-619(1995).
CC   -!- FUNCTION: Stores iron in a soluble, non-toxic, readily available form.
CC       Important for iron homeostasis. Has ferroxidase activity. Iron is taken
CC       up in the ferrous form and deposited as ferric hydroxides after
CC       oxidation.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=4 Fe(2+) + O2 + 4 H(+) = 4 Fe(3+) + 2 H2O;
CC         Xref=Rhea:RHEA:11148, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:15379, ChEBI:CHEBI:29033, ChEBI:CHEBI:29034; EC=1.16.3.1;
CC   -!- SUBUNIT: Oligomer of 24 subunits. There are two types of subunits: L
CC       (light) chain and H (heavy) chain. The major chain can be light or
CC       heavy, depending on the species and tissue type. The functional
CC       molecule forms a roughly spherical shell with a diameter of 12 nm and
CC       contains a central cavity into which the insoluble mineral iron core is
CC       deposited.
CC   -!- SUBCELLULAR LOCATION: Plastid, chloroplast. Plastid.
CC   -!- TISSUE SPECIFICITY: Ferritins accumulate in seed during maturation.
CC       Then, they are degraded during the first days of germination. Present
CC       in roots and leaves after iron treatment.
CC   -!- INDUCTION: By iron.
CC   -!- SIMILARITY: Belongs to the ferritin family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA43664.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X61392; CAA43664.1; ALT_INIT; mRNA.
DR   EMBL; X83077; CAA58147.1; -; Genomic_DNA.
DR   PIR; S24057; S24057.
DR   AlphaFoldDB; P29390; -.
DR   SMR; P29390; -.
DR   STRING; 4577.P29390; -.
DR   MaizeGDB; 25278; -.
DR   InParanoid; P29390; -.
DR   Proteomes; UP000007305; Unplaced.
DR   ExpressionAtlas; P29390; baseline and differential.
DR   GO; GO:0009507; C:chloroplast; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0008199; F:ferric iron binding; IBA:GO_Central.
DR   GO; GO:0008198; F:ferrous iron binding; IBA:GO_Central.
DR   GO; GO:0004322; F:ferroxidase activity; IEA:UniProtKB-EC.
DR   GO; GO:0006879; P:intracellular iron ion homeostasis; IEA:UniProtKB-KW.
DR   GO; GO:0006826; P:iron ion transport; IEA:InterPro.
DR   CDD; cd01056; Euk_Ferritin; 1.
DR   FunFam; 1.20.1260.10:FF:000006; Ferritin; 1.
DR   Gene3D; 1.20.1260.10; -; 1.
DR   InterPro; IPR001519; Ferritin.
DR   InterPro; IPR012347; Ferritin-like.
DR   InterPro; IPR009040; Ferritin-like_diiron.
DR   InterPro; IPR009078; Ferritin-like_SF.
DR   InterPro; IPR014034; Ferritin_CS.
DR   InterPro; IPR008331; Ferritin_DPS_dom.
DR   PANTHER; PTHR11431; FERRITIN; 1.
DR   PANTHER; PTHR11431:SF125; FERRITIN-1, CHLOROPLASTIC; 1.
DR   Pfam; PF00210; Ferritin; 1.
DR   SUPFAM; SSF47240; Ferritin-like; 1.
DR   PROSITE; PS00540; FERRITIN_1; 1.
DR   PROSITE; PS50905; FERRITIN_LIKE; 1.
PE   1: Evidence at protein level;
KW   Chloroplast; Direct protein sequencing; Iron; Iron storage; Metal-binding;
KW   Oxidoreductase; Plastid; Reference proteome; Transit peptide.
FT   TRANSIT         1..43
FT                   /note=""Chloroplast""
FT                   /evidence=""ECO:0000269|PubMed:1627771""
FT   CHAIN           44..252
FT                   /note=""Ferritin-2, chloroplastic""
FT                   /id=""PRO_0000008860""
FT   DOMAIN          81..234
FT                   /note=""Ferritin-like diiron""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00085""
FT   REGION          44..80
FT                   /note=""Extension peptide (EP)""
FT   BINDING         98
FT                   /ligand=""Fe cation""
FT                   /ligand_id=""ChEBI:CHEBI:24875""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00085""
FT   BINDING         133
FT                   /ligand=""Fe cation""
FT                   /ligand_id=""ChEBI:CHEBI:24875""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00085""
FT   BINDING         133
FT                   /ligand=""Fe cation""
FT                   /ligand_id=""ChEBI:CHEBI:24875""
FT                   /ligand_label=""2""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00085""
FT   BINDING         136
FT                   /ligand=""Fe cation""
FT                   /ligand_id=""ChEBI:CHEBI:24875""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00085""
FT   BINDING         182
FT                   /ligand=""Fe cation""
FT                   /ligand_id=""ChEBI:CHEBI:24875""
FT                   /ligand_label=""2""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00085""
FT   BINDING         216
FT                   /ligand=""Fe cation""
FT                   /ligand_id=""ChEBI:CHEBI:24875""
FT                   /ligand_label=""2""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00085""
FT   CONFLICT        217
FT                   /note=""G -> V (in Ref. 2; CAA58147)""
FT                   /evidence=""ECO:0000305""
FT   CONFLICT        251
FT                   /note=""A -> G (in Ref. 2; CAA58147)""
FT                   /evidence=""ECO:0000305""
SQ   SEQUENCE   252 AA;  27749 MW;  D181B4A8A86ADED0 CRC64;
     MMLRVSSSPA AAVANHLSGG AAATTAPARV TAQRSGVSLS AAAAAGKGKE VLSGVVFQPF
     EEIKGELALV PQSPDRSLAR HKFVDDCEAA INEQINVEYN ASYAYHSLFA YFDRDNVALK
     GFAKFFKESS DEEREHAEKL MEYQNKRGGR VRLQSIVAPL TEFDHPEKGD ALYAMELTLA
     LEKLVNEKLH SLHGVATRCN DPQLIDFIES EFLEEQGEAI NKVSKYVAQL RRVGNKGHGV
     WHFDQMLLQE AA
//
",37066
TGTAAA GTAAAA TAAAAC AAAACC AAACCT AACCTG ACCTGT CCTGTG CTGTGG TGTGGC GTGGCG TGGCGG GGCGGA GCGGAA CGGAAG GGAAGC GAAGCG AAGCGG AGCGGA GCGGAC CGGACA GGACAG GACAGA ACAGAT CAGATA AGATAC GATACG ATACGC TACGCA ACGCAA CGCAAA GCAAAG CAAAGT AAAGTG AAGTGA AGTGAC GTGACC TGACCA GACCAA ACCAAT CCAATA CAATAC AATACT ATACTT TACTTT ACTTTC CTTTCC TTTCCT TTCCTG TCCTGG CCTGGG CTGGGA TGGGAC GGGACA GGACAG GACAGA ACAGAT CAGATG AGATGC GATGCA ATGCAG TGCAGA GCAGAC CAGACG AGACGG GACGGT ACGGTT CGGTTA GGTTAC GTTACA TTACAA TACAAC ACAACC CAACCT AACCTG ACCTGT CCTGTC CTGTCC TGTCCA GTCCAA TCCAAC CCAACC CAACCT AACCTG ACCTGT CCTGTA CTGTAA TGTAAC GTAACG TAACGG AACGGT ACGGTG CGGTGA GGTGAA GTGAAG TGAAGG GAAGGA AAGGAA AGGAAC GGAACC GAACCA AACCAC ACCACT CCACTG CACTGT ACTGTA CTGTAA TGTAAC GTAACA TAACAG AACAGC ACAGCC CAGCCA AGCCAA GCCAAA CCAAAT CAAATG AAATGT AATGTG ATGTGG TGTGGC GTGGCA TGGCAC GGCACC GCACCT CACCTG ACCTGT CCTGTA CTGTAA TGTAAA GTAAAG TAAAGG AAAGGA AAGGAG AGGAGA GGAGAA GAGAAG AGAAGG GAAGGA AAGGAC AGGACG GGACGG GACGGG ACGGGT CGGGTA,3,145,TGTGTATA GTG GTGTATAAAA A T TATAAAA A AAAAAAAAA A A AAAAAAACAC C A AGAACACCAACTT  ACACCGGCCT T C CCCCTCA TG G C CT GGGT T T TGTGTTG G G GTAC TGGGG G TA ATGGGGCGC C G GGGGCGCGCG G G GCATACGGGG TG  CGGGAA G GGGGAAA  GAGC TG AGG AAAAGAGCGC C A AGAGCGCGCG  TA GCGCGCGGGG G CGTTCGGT GGA A GAC GGAGAC GAGACACAACTCAC ACACA GGAG G C CACAGAGAC AA A AGAGA GAGATATATA A A ATATATACGG C TG GTACACGCG G A ACACGCGCACCC C CGCGCCA A G GCGCACAAAA A C CACAATGGAA A A AAAAGAG  AAAAGAGTCTGT A AGGTGTG G GA AGTGTGAGA  TGTGAGACAC C G GACC C AAAAACCCCACA A C CCCCACAATAAA C CACAAA GT AACAATATA ACC ATGCGTACAC C T TATACACTCT T A ACACTCTTTT T C CT GAGA T T TTTTTTTCTC C T TTTTCC T TCTCCCCTCT T C CCCCTCTGG CG C ACCTGTGGGG G TG CTGGGG G GCAGGGGGGAGA  GGGGAGACC G GAGACACACA A A ACACACAG CAAGAGAAA A AGG GAT T G GAGATATGTG G A ATATGTGCGC C T TGTGCGCATA  GCGCACAGG C CACAGAGAC AA A AAAGAGACAC C G GAGACCG GAA ACACGCGGGG GT  CGCTGGT T G GG CGT G GTGTTA TT CTTATACAC  TATACCA A AAATAA GGG CACAAAACGACC A AAAACACCC AACCCCTCT T CCCTCTGTG  CTCTGTGTGT T T TGTGTC GCT  GACC C TTCCCCACA A C CCCCACAAAA A C CATGTAACAC C A AACACGC CC GTA ACACCCCTCT  AC TTGTAG A TG CTTGTG CT T TGTGTTA A G GTGTATAAAA A T TATAAAAC AAAACACGTG  ACACGGG G C CGGGTGT T G GGGGTGTGTG GAT GTGTGTGAGA A TT TTGAGAAAA AATAG GAAAAGTT  AAAAGAGGGAAG A AGGGAGA A G GGGGAGA AA A GTCCGAAAACAC C A AAAACACCCC C A ACACCCCACA A C CCCCACACAC C C CAA ACA GTCT A ACACTCTGTG G C CTACGTGTGT T T TGTGTC AA GGTATAAAA A T TAAA AACGTGAGA AACC ACACA A A ACACACAGAG GCA CACAGAGCGC  AGAGCGCCC G GCCA A C CCCAAA CAA  CAGA AAAAA  GT AA ACAATAT  AAAATATGTG G A ATATGGT T T TGTGT CTTG  GTGTGTGGGG G T TGAAACCTC G GGGGCG C CCA G GCGCACACAC C C CAAACACCCC  ACACCCCTCT CCTCCTAG G CGTGCTGTGTGT AAG TGTGTGTATA A GCCACGGTAAAA A T TATAAAAAAA  AAAAAAAGG A CTAAGAGGGG G A AGAGGG CGA A G GGGGAGAGAG G GTTTGAGAGACAAA A AGGAAAA A G GAG A TGG A AAAAGG AGG AC  AGAGGGGAGA A G GGGGAAC AC C G GAGACACGCG G AT CACGCGGGG  CGCGGA CGG G GTGTGGGGCAGT GGA GGGGTGTA,TGTAATTAACCT GTGTATAAAAAAA A TTAAAAAAAAA AAAAAAAAACAC CCT AAAAAAACACCC A AA CTCCTCT T A ACACCCTGTG G C CCCCTCTGTGTGT T CAATAC TG G T TGTGTGTGTGGGG G G GTGTGTGGGGCGC C T TGTGGGGCGCGCG C CGCAACCGG G G GCGCGG AGA A C CG TAG AGAATACA GGGACT AAGAG TGTGC GAAAAGAGCCAAC A AAAAGAGCGCGC TG A AGAGCGCGCGGGG  GCAC CGGGGAGA A C CGCGGGGAAC GGA ATACACA A GAA GACACGCAGAG C T ACACACAGAGAGA A C CACAGAGAGATAT T AAGAGATATAC CA G GAGATATATACAC C A ATATATACACGCG G T TATACACGAG C A ACACGCGCGCACA  AA GGGC C CA G GCGCACAAAA A C CACAAAAAAAGTAAG A AACCAAAGAGTGT T AAAGAGTGTGTG G A AGAGTGTGTGA CAA G GTGTGTGAGCGC T AATGAGACACCCC C G GAGACACCCCACA A A ACACCCCACAAAA AGG CCG CCAAAATAT T C CACAAAATATATA A A AA GGTCCC A ATATATACACTCT T T TAACTCTTT A ACACTCTTTTTTT T CCTTTTTTTCTC TA TTTTTCTCCCC CG GACTTCTCCCCTCAA TCAC CCTCTGTG G C CCCCACTGTGGG C CTCTGC AGGGGG G T TGTGGGGGGGAGA A G GGA AAAGGACAC C G GGGGAGACACAA G GA TTACACAGGGGG A ACACACAGAGAGA A C CACAGAGAT A AGAGAGATATGTG G G GAGATATGGGCC ACACATGTGCGCACCTG G TGTGCGCAG GC A GCGCACAGAGAGA  CACAGAGAG AAC C A AGACGCG G G GAAAGACGCGGGG G A ACACGCGGGGTGT T C CGGGTGTTTT T G GGAT GTTGTGTA A GGTTCGGTACAC C T TTTTAC GTGTA T TATACACACAAAA  GC ACCAAAACAC C C CACAAAACACCCC CAA AAAACACCCCTCT T A ACTGTCCTTG CCA CCTGGCTGCA GT T C CTCTGTGTGTCTC C TGTCTCCCC AA  GTGTCTCCCCACA A T TCC GCCAAA A C CCCCACAAAACAC CGCAACGGCCC C A AAAACACCGTACT T A ACACCCA CTGTG G C CCCCTG GGT C T CTGG TGTA G CCA T TGTGTGTATAAAA  GTGTATAAAACACCC TAGAAACACGCG G A AAAACACGCGGGG G A ACACGCGGGGTT CCGGGGTGTGTG G GTACGGTGTGTGAGA A G GTGTGTGAGAAAA A TGTATGAGAAAG A TGAAAAGAGGGTAGGA AAAAGA C CGGA A A AGAGGGGAGAAAA A G GG ACAACAC GAA GAGAAAACACCCC C A TGACCTGTCA A A ACACCCCTCACAC TA  CCAAAACTTGT CACACACTCTGTG GACGGAACTCTGC GGT T CAAATGTGTAT CA T TGTGTCCTTAAAA A G GTAG AC G A TATAAACACA A A AAAACACACAGG A ACACACAGA GGC AA  CACAGAGCGCCCC AG  AGGCCCCACA A G GCCCACAAA C CCCCACAAAAAAA A CGA T TAGGGTAGGT AAAAA CTATGTG G A AAAATATGTGTGT T AGACATGG T TGCCATGGGG G GTTATGG GAC T TGTGGGCACA A G GGGCACACAC TCCA AGCACACACCCC CAG CA ATAGACCTCT T AACCCCTCTGTG G CTA A GCTGTGTGT T CAACCTGTGTGTATA A T TGTGTGTATAAAA A G GTGTAAAAAA A T TATAAAAAAA AG G A AAAAAAAGAGGG AC AAAGAGGGA GGG AGAGGGGAGAGAG G G GGGGAGAG TAGA CTGGAGCAAGAAAA A A AGAGAGAAAAGAG  GAACCAAGCTGGG CGGCGGGACAGGCT A A AGAGGGGAGACAC C G GGGGAGACACGGCCG G GAGACCGGGG G A ACACATTAAG GG G C CGCGGGGGGGTGT T G GGGGT TG,GTATAAAAAATAA G GTTAATTTAAAAA T AAAAAAAAAAAACAC  AAAAAAAAAACACCC A AAAAAAACACCCCTCT T A AAAACACCCTGTG G A ACCGGCCTCTGTGTGT T C CCCCTCTGTGTGT GGAG C CTT CTGTGG G TA GTGTCT TGGGGCGC C G GTGTGGGCGCGCG  TGGGCGCGCGGGG G G GGACTGCGGGAAAC CA GCAGGCGGGAAAA A C CGCGGGGAGAAAAGAG G G GGGGAGAAAAGAGCGC C GGTAGAAAAGAGCGCGG A TGAGC AACGGGG G A AGAGCAA CGGGGAGA A G GCGATCGGGGAAC C C CGGACGGAGACACACA A G GGGGAGACACACAGAG G G GAGACACACAGAGAGA A A ACACACAGTGAGAT CACAGAGA GTTA A AAATGATATAACC ATC GTTTGCGATATACACGCG G A ATATAACGCGCCAAC T TATACACGGGACA A A ACACGCGCAC AA A C CGCGCGCACAAAAAAA A G GCGCACAAAAAAAGAG G CACCA A GAAAGAGTGT T A AAAAAAAGACCGTGTG  AAAAGAGTGTGTGAA AAGTGAATGAGACAC C GACCGTGTGAGAC CACC C T TGTGAGACCCAA G GAGACCCACAAG G ACCCACAAAATAT T C CCCCAAATATAAAC CACAAAATATATACAC C AAC AATTGTTACACTCT T A ATATACA AAGCTTTT T T TATACACTCTTTTTTT T A ACCTT GATTC TATGGCTTTTTTTCAAACC G C TTTAAACATCCCCTCT T T TTTTCTCCCCTCTG TCTCCCCTCTGTGGGG  CCCCTTGGGGGGG G CGA GGATGGGGGCTGGA A TAG TGGGGGGGAGACAC C G GGGGGGTTACAGTAA G GGGGAGACACACAG CG GAAG TTCCAGAGACCAACACAGAGAGATT CTCCCAGAGAGATATGTG G A AGAGAGATATGTGCGC G A GAGATACCTGC ATATGTGCGCACAGAG G T TGTGCGCATCCT CGCACAGAGAGACAC C CC TCAGAGAGACACGCG  AGCC CGGACGCGGGG AA  GATTAACGCGG GGTAAT A ACACGCGGGGTGACTT  GC CGCGGGGTGTTC CTA A GGGTGTTTTATAC AAC G GCGTTTACACAA TT CTTATACACACAAAA A TTACACAGGCAC C A ACTGTCAA GGACCAGATGACAAAACCCTCT T AAACCCTCTGTG G ATAACCTCTGGAGT CCCTCTGTGTGTCTC C C CTCTGTGTGTCTCCA G TGTGTGTCCA A GGATGTCGA CCACAAAA A T TCTCCCCACAAAACGAAC C CCCAAACCCC C C CAGC AACACCCCTCT T A AAAACACCCCT TAAAGG A ACACCCTGGT CTG CCCCTCAAGTATA A C CTAA GTAG GA T TGTGTTAAAAC GAC GCACTAAAACCG G T TATAAAACACGCGGGG G CG GACGCGGGGTGT GAC ACACGCGGGGTGTGTG  CAAACGGTGTGTGAGA  TGGGTGGTGTGC CAA A G GTGTGTGAA AAAGGAC AC TGAGAGG AGGG G GAGAATG AGGGCAGA A A AAAAGAGGGGAGAAAA  AGAGGCT AACGCAC G GGGGAGTGAACACCCC C GCACAACACCCA A A AACCTTACCCACAC AAC ACCACACACTGTGT C CCCCACACACTCTGTG  CACACACTCTGTGTGT G TACTCTGTGTGTATA A C CTCTGTGTGTAGCGA TTGTGTA ACAC C GGTATAAAACGGAA TTAAA CACACAGAG G A AAAACACACAGAGCC A ACCAAGCCCC C C CACAGAGCGCCCCACA A AAGCGCCCCACAAAA GCCCCACAAG CAA A CTG CCAAAAAATAT T C CAACAAAAAATATGAG G A AAAAAAATATGACAGT T A AAAGAATGTGTGTGTG G AATGTGTGTGTGGGG G T TGTGTGTG CTAACC GGTGTGGGGCGCACA A T TGTGGGGCGCACACAC C GGGAGGCGCAGAAACCCC C G GTGCACACCCTGAA TT CAGTAAACCTGTG CA  ACACCCCTCTGTGTGT T C CCCCTCTGTGTGTAA C CTCTGTGTGTAGT AA  TGTGTGTAAAAAA A G GT GAAAAAAGAG G TCTGTAAAAAAGGGG G A AAAAAAAGAGGGGAA A AAAAGAAG CCGAGTG C G AGAGGGGAGTGGA A G GGGGAGAGAGAGAAAA A G GAGAGGAAAAG AA AGAGAGAAAAGAGGGG A A GAGAAAAGGCGGA A AGCGAAGAGGGACC A AGAGGGGAGACCG G G GGG AGACACGACCG GAC GACCGGGGGAC G A ACACGCGGGGGGGTGT T C CGCGGGGGGGTCA ,GG GTAAAAAA A GGTATAAAAAAACAACAC C T TATAAG GAAAAACACCCC C A AAAAAAAACAAACCCAG CCCAC AAAAAAACACCGTACTGTG G A AAAACACCCCTTGTGT T A ACACCCCTCTGTGTGCA GGG C CCA CGGATGTTGGGG G C CT AGTGTGTG AA TAGTGAG TGTGTGGGCACTCG G GTAAGTGTGG TGGCGCGGGA G T TGAACGGCGCGCGGCTGGA A G GGCT GCGCGGGA CAAAA A G GCGCGCGGGGAGAACCTAG G C CGCGGGGAGAAAAGAGCC G GGGGAGAAAAGAGCGCGCG G GGAAAAGAGCGCGCGGGG G A AAGTTGCGCGGGGAGA A AAACAGCGCGCGGGGAGACAC C GGCGACAGGAGACACACA CGG CGGGA AAACACAGAG G G GG AGGACACACAGAGAGA A G GATTTA GGATAT G A ACACACAGAGAGAAATATA A C CACAGAGAGATATAAAAACACA  AGAGAGATATATACACGCG TTT GA CTATAACGGC C A ATATATACTGAATACA A TACTTACACGCGCGCACAAAA CAG ACACGCGCGCACAAAAAAA A CAGACGCGCACAAGTTAAGAG G G GCTCCGAAAAACAAGT T C CACAAAAAAAGAGTGTGTG G A AAAAAAAGAGTCT TGAGA A A AAAAGAGTGTGTGAGACAC C A AGAGTGTGTGAGACACCCC C G GTGTGTGAGACACCCA A T TGACGGACACCCCACAAAA A G GA GAAATTGTAATAT GTG ACACCCAAAATCGCTA CCTCTTAC CACG GATATACAC C CGTCCAAAATATATACGCGCT T A AAAATATATACCCA CCTT T A ATATAACTCCTGTATT T T TATACACTCTTTTTTTCTC C A ACACTCTTTTCTCCCC C C CTCTTACATCCCCTGGCT T TTG GTTCCCTCTGTG G T TTTTCTCCCCTCTGTGGGG G T TCTCCCCTCTGTGGGGGGG G C CCC TCTGGGAGA GATCTGTGGGGAGACAC  TGTGGGGGGGA TGAGGAATCC GGGGGAACCACACCTG GGTAGGATGTTAACAGAGAGA A G GAACACGGAGAGATAT T A ACACAAGAATGTG G C CACAG CGGATATGGC C ACTGAGAGATATGTGCGCAAAGA G GAGATTGCGCACAGT A ATATGTGCGCACAGAGAGA A TGACTGCGCACAGAGAGACAC C G GCGCAAGAGACACGCG G CGGGAGAGACACGGG G A AGAGAGACACGGGTGT T G GAGACACGCGGGGTC ATT T A ACACGG TGCCAAATTATA A C CG ACGGTGTTTACAC  GGGGTGTTTTATACACACA A G GTGTTTTATACACAACGGG A T TTTTATACACA AGAC GAC TATACACACAAAACACCCC C ACGGAAACAAAACACCCGGT CAAAAACACCCCTGGGTG G AGACAACACCCCTGACGT T ACCTCTGTGTGTCTC C C CCCCTCTGTGTGTCGCACC  CTCTGTGTGTCCCACA  TGTGT CAAACCCAA G GTGTCTCCCCACAAAC  TCTCCAA AAGAACAC CC C C CCCCACAAAACACCACGGTGGAA CACAAAACACCAACCTGTG G ATGGCTGCTGTGTGT T A ACACCCCTCTGTGTGTATA A CCT CCTTGTGTATAAAA A C CTCTGCAAGTA ACAC C T TGTGTCCTTAAAACACGCG G G GTGTAAC AAGTGTG T TATAAAACTGAGGTGT T A AAAACACGCGGGGTGTGTG G AACGA GTTTGTGTGAGA A C CGCGGGGTGTGGAAAA AGA GGGGTGTGCAGGAAAAG TGAAA GTGTGTGAGAAAAGAGGA C TGTGAGAAAAGACAGGAGG A G GAGAAAAGAGGGGAGAAAA A A AAAAGAGGGGAAGCAACACCC A AGAGGAATGAAAACACCCC C G GGGGAGATAACACCCCACA A GGACAACACCACTCACCCAC A AAAACACCCCACACACTT A ACACCCAAGC CTGTG G C CCCCAT AACTCTGTGTGT T C CACACACTTGTCAGGTGA A ACACTCTGTGTGTATAAAA A C CTCTGTGTTTTTAATACAC C TGGCTGTTAAAACACACCA GTGTATAAAACGCAAG G T TAGC A AACACAGTAAC A AAAACACACAGGCCC A GTACAGTAAGCGCCCCACA A C CACAGAGCGGTCCAAA  AGAGCGCCCCACAAAAAAA A G GCGCCCCACAAAATAT T C CCCCACAAATGTG G C CACAAAAAATGTGTGT T AAAAACCATGTGTGTGTG G A AAAATATGTGTTA TGGGG  ATATGTGTGTGTGGTGAACC TGGT T ATGGGGCGCACA A G GTACCGGCGCACACAC C T TGTGGGGCGCACACACCCC C G GGGGCA AACCCCTCT T G GCGCACACCCTCTGTG CCT CACACACCCCTTGTTGT ACCGGCTGTGTTA A CC TCCTCTGTGT GGTAAGATA C CTCTGTGTGTATAAACAA T TGTGTGTATAAAAAAAGGGA GTGTATAAAAAAAGAGGGG G T TATAAAAAAAGAGGGGAGA A A AACAAAAGAGGGGAGAGAG G AA GAAGAGGGGAGAGGA AAC AGGAAGGAGAGGAAAA A G GGGGAGAGAGAT CAG G G GAGAGAGAGAAAGGGG G AAGAAGGAAGAGGGGACAG GAAAGAGGGGAGACAC C A AAAAGAGGGGAGACACGCG G AGGAAGGGGAGACCGGGG G GTG GGAGACACGCGGCGGAA G G GAGACAATCGGGGTGT T A ACACGCGGGGGGGTGTA,"ID   DNAJ_CHLP8              Reviewed;         401 AA.
AC   B3QPW8;
DT   14-APR-2009, integrated into UniProtKB/Swiss-Prot.
DT   02-SEP-2008, sequence version 1.
DT   27-NOV-2024, entry version 88.
DE   RecName: Full=Chaperone protein DnaJ {ECO:0000255|HAMAP-Rule:MF_01152};
GN   Name=dnaJ {ECO:0000255|HAMAP-Rule:MF_01152};
GN   OrderedLocusNames=Cpar_1573;
OS   Chlorobaculum parvum (strain DSM 263 / NCIMB 8327) (Chlorobium vibrioforme
OS   subsp. thiosulfatophilum).
OC   Bacteria; Chlorobiota; Chlorobiia; Chlorobiales; Chlorobiaceae;
OC   Chlorobaculum.
OX   NCBI_TaxID=517417;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=DSM 263 / NCIMB 8327;
RG   US DOE Joint Genome Institute;
RA   Lucas S., Copeland A., Lapidus A., Glavina del Rio T., Dalin E., Tice H.,
RA   Bruce D., Goodwin L., Pitluck S., Schmutz J., Larimer F., Land M.,
RA   Hauser L., Kyrpides N., Mikhailova N., Zhao F., Li T., Liu Z., Overmann J.,
RA   Bryant D.A., Richardson P.;
RT   ""Complete sequence of Chlorobaculum parvum NCIB 8327."";
RL   Submitted (JUN-2008) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Participates actively in the response to hyperosmotic and
CC       heat shock by preventing the aggregation of stress-denatured proteins
CC       and by disaggregating proteins, also in an autonomous, DnaK-independent
CC       fashion. Unfolded proteins bind initially to DnaJ; upon interaction
CC       with the DnaJ-bound protein, DnaK hydrolyzes its bound ATP, resulting
CC       in the formation of a stable complex. GrpE releases ADP from DnaK; ATP
CC       binding to DnaK triggers the release of the substrate protein, thus
CC       completing the reaction cycle. Several rounds of ATP-dependent
CC       interactions between DnaJ, DnaK and GrpE are required for fully
CC       efficient folding. Also involved, together with DnaK and GrpE, in the
CC       DNA replication of plasmids through activation of initiation proteins.
CC       {ECO:0000255|HAMAP-Rule:MF_01152}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000255|HAMAP-
CC         Rule:MF_01152};
CC       Note=Binds 2 Zn(2+) ions per monomer. {ECO:0000255|HAMAP-
CC       Rule:MF_01152};
CC   -!- SUBUNIT: Homodimer. {ECO:0000255|HAMAP-Rule:MF_01152}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000255|HAMAP-Rule:MF_01152}.
CC   -!- DOMAIN: The J domain is necessary and sufficient to stimulate DnaK
CC       ATPase activity. Zinc center 1 plays an important role in the
CC       autonomous, DnaK-independent chaperone activity of DnaJ. Zinc center 2
CC       is essential for interaction with DnaK and for DnaJ activity.
CC       {ECO:0000255|HAMAP-Rule:MF_01152}.
CC   -!- SIMILARITY: Belongs to the DnaJ family. {ECO:0000255|HAMAP-
CC       Rule:MF_01152}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CP001099; ACF11971.1; -; Genomic_DNA.
DR   RefSeq; WP_012502804.1; NC_011027.1.
DR   AlphaFoldDB; B3QPW8; -.
DR   SMR; B3QPW8; -.
DR   STRING; 517417.Cpar_1573; -.
DR   KEGG; cpc:Cpar_1573; -.
DR   eggNOG; COG0484; Bacteria.
DR   HOGENOM; CLU_017633_0_7_10; -.
DR   OrthoDB; 9779889at2; -.
DR   Proteomes; UP000008811; Chromosome.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:InterPro.
DR   GO; GO:0031072; F:heat shock protein binding; IEA:InterPro.
DR   GO; GO:0051082; F:unfolded protein binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0051085; P:chaperone cofactor-dependent protein refolding; IEA:TreeGrafter.
DR   GO; GO:0006260; P:DNA replication; IEA:UniProtKB-KW.
DR   GO; GO:0042026; P:protein refolding; IEA:TreeGrafter.
DR   GO; GO:0009408; P:response to heat; IEA:InterPro.
DR   CDD; cd06257; DnaJ; 1.
DR   CDD; cd10747; DnaJ_C; 1.
DR   CDD; cd10719; DnaJ_zf; 1.
DR   FunFam; 1.10.287.110:FF:000034; Chaperone protein DnaJ; 1.
DR   FunFam; 2.60.260.20:FF:000005; Chaperone protein dnaJ 1, mitochondrial; 1.
DR   FunFam; 2.10.230.10:FF:000002; Molecular chaperone DnaJ; 1.
DR   Gene3D; 1.10.287.110; DnaJ domain; 1.
DR   Gene3D; 2.10.230.10; Heat shock protein DnaJ, cysteine-rich domain; 1.
DR   Gene3D; 2.60.260.20; Urease metallochaperone UreE, N-terminal domain; 2.
DR   HAMAP; MF_01152; DnaJ; 1.
DR   InterPro; IPR012724; DnaJ.
DR   InterPro; IPR002939; DnaJ_C.
DR   InterPro; IPR001623; DnaJ_domain.
DR   InterPro; IPR018253; DnaJ_domain_CS.
DR   InterPro; IPR008971; HSP40/DnaJ_pept-bd.
DR   InterPro; IPR001305; HSP_DnaJ_Cys-rich_dom.
DR   InterPro; IPR036410; HSP_DnaJ_Cys-rich_dom_sf.
DR   InterPro; IPR036869; J_dom_sf.
DR   NCBIfam; TIGR02349; DnaJ_bact; 1.
DR   PANTHER; PTHR43096:SF48; CHAPERONE PROTEIN DNAJ; 1.
DR   PANTHER; PTHR43096; DNAJ HOMOLOG 1, MITOCHONDRIAL-RELATED; 1.
DR   Pfam; PF00226; DnaJ; 1.
DR   Pfam; PF01556; DnaJ_C; 1.
DR   Pfam; PF00684; DnaJ_CXXCXGXG; 1.
DR   PRINTS; PR00625; JDOMAIN.
DR   SMART; SM00271; DnaJ; 1.
DR   SUPFAM; SSF46565; Chaperone J-domain; 1.
DR   SUPFAM; SSF57938; DnaJ/Hsp40 cysteine-rich domain; 1.
DR   SUPFAM; SSF49493; HSP40/DnaJ peptide-binding domain; 2.
DR   PROSITE; PS00636; DNAJ_1; 1.
DR   PROSITE; PS50076; DNAJ_2; 1.
DR   PROSITE; PS51188; ZF_CR; 1.
PE   3: Inferred from homology;
KW   Chaperone; Cytoplasm; DNA replication; Metal-binding; Repeat;
KW   Stress response; Zinc; Zinc-finger.
FT   CHAIN           1..401
FT                   /note=""Chaperone protein DnaJ""
FT                   /id=""PRO_1000137670""
FT   DOMAIN          4..69
FT                   /note=""J""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01152""
FT   REPEAT          170..177
FT                   /note=""CXXCXGXG motif""
FT   REPEAT          186..193
FT                   /note=""CXXCXGXG motif""
FT   REPEAT          212..219
FT                   /note=""CXXCXGXG motif""
FT   REPEAT          226..233
FT                   /note=""CXXCXGXG motif""
FT   ZN_FING         157..238
FT                   /note=""CR-type""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01152""
FT   BINDING         170
FT                   /ligand=""Zn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29105""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01152""
FT   BINDING         173
FT                   /ligand=""Zn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29105""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01152""
FT   BINDING         186
FT                   /ligand=""Zn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29105""
FT                   /ligand_label=""2""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01152""
FT   BINDING         189
FT                   /ligand=""Zn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29105""
FT                   /ligand_label=""2""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01152""
FT   BINDING         212
FT                   /ligand=""Zn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29105""
FT                   /ligand_label=""2""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01152""
FT   BINDING         215
FT                   /ligand=""Zn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29105""
FT                   /ligand_label=""2""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01152""
FT   BINDING         226
FT                   /ligand=""Zn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29105""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01152""
FT   BINDING         229
FT                   /ligand=""Zn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29105""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01152""
SQ   SEQUENCE   401 AA;  42765 MW;  9A84DCB522C81A00 CRC64;
     MKRDYYEILG VSRSADKDEI KKAYRKLALK YHPDKNPDNK EAEEKFKEAN EAYEVLSNDD
     KRRRYDQFGH AGVGSSAASG GGPGGFGGGG YADINDIFEM FTGGGRARGG GSPFSGFEDI
     FGGGFSGGGG RRARSTGIHG TDLKIRLKLT LEEIAKGVEK TLKIKKQVVC SECNGTGSKS
     GKTETCQTCH GSGEVRQASK TMFGQFVNIV ACPTCGGEGQ VVKDRCTSCY GEGIKQGEVT
     VKINVPAGVQ DGNYLTLQGQ GNAGPRGGAP GDLIVIIEEK PHDQFKRNGD DIIYDLAVGF
     PDLVLGTKVD VPTLDGHVKL TVPAGTQPNT MLRIGGKGIG HLKGGGSGDL YVRVNVFVPK
     DVSGKDKEML KELKKSSHIS PNHGEQDHEK SIFEKAKDIF G
//
",27207
ATCTAT TCTATT CTATTC TATTCG ATTCGG TTCGGC TCGGCG CGGCGG GGCGGA GCGGAG CGGAGT GGAGTT GAGTTC AGTTCG GTTCGG TTCGGC TCGGCC CGGCCA GGCCAG GCCAGC CCAGCT CAGCTG AGCTGG GCTGGG CTGGGC TGGGCG GGGCGG GGCGGT GCGGTC CGGTCA GGTCAG GTCAGC TCAGCC CAGCCT AGCCTT GCCTTT CCTTTC CTTTCG TTTCGG TTCGGC TCGGCG CGGCGC GGCGCG GCGCGT CGCGTT GCGTTG CGTTGA GTTGAT TTGATC TGATCG GATCGG ATCGGC TCGGCG CGGCGA GGCGAT GCGATT CGATTT GATTTC ATTTCT TTTCTA TTCTAT TCTATT CTATTT TATTTT ATTTTG TTTTGA TTTGAT TTGATC TGATCA GATCAT ATCATT TCATTC CATTCG ATTCGG TTCGGC TCGGCG CGGCGT GGCGTC GCGTCA CGTCAG GTCAGA TCAGAT CAGATG AGATGT GATGTG ATGTGC TGTGCG GTGCGC TGCGCC GCGCCT CGCCTG GCCTGT CCTGTT CTGTTG TGTTGC GTTGCG TTGCGC TGCGCG GCGCGA CGCGAT GCGATT CGATTT GATTTG ATTTGG TTTGGG TTGGGC TGGGCA GGGCAA GGCAAA GCAAAA CAAAAT AAAATT AAATTG AATTGC ATTGCC TTGCCG TGCCGC GCCGCT CCGCTT CGCTTC GCTTCG CTTCGG TTCGGC TCGGCG CGGCGA GGCGAT GCGATG CGATGG GATGGC ATGGCC TGGCCC GGCCCC GCCCCG CCCCGT CCCGTT CCGTTT CGTTTA GTTTAT TTTATT,3,139,ATCT TCTA CTAT TATT ATTC TTCG TCGG CGGC GGCG GCGG CGGA GGAG GAGT AGTT GTTC TTCG TCGG CGGC GGCC GCCA CCAG CAGC AGCT GCTG CTGG TGGG GGGC GGCG GCGG CGGT GGTC GTCA TCAG CAGC AGCC GCCT CCTT CTTT TTTC TTCG TCGG CGGC GGCG GCGC CGCG GCGT CGTT GTTG TTGA TGAT GATC ATCG TCGG CGGC GGCG GCGA CGAT GATT ATTT TTTC TTCT TCTA CTAT TATT ATTT TTTT TTTG TTGA TGAT GATC ATCA TCAT CATT ATTC TTCG TCGG CGGC GGCG GCGT CGTC GTCA TCAG CAGA AGAT GATG ATGT TGTG GTGC TGCG GCGC CGCC GCCT CCTG CTGT TGTT GTTG TTGC TGCG GCGC CGCG GCGA CGAT GATT ATTT TTTG TTGG TGGG GGGC GGCA GCAA CAAA AAAA AAAT AATT ATTG TTGC TGCC GCCG CCGC CGCT GCTT CTTC TTCG TCGG CGGC GGCG GCGA CGAT GATG ATGG TGGC GGCC GCCC CCCC CCCG CCGT CGTT GTTT TTTA TTAT TATT,ATCTA TCTAT CTATT TATTC ATTCG TTCGG TCGGC CGGCG GGCGG GCGGA CGGAG GGAGT GAGTT AGTTC GTTCG TTCGG TCGGC CGGCC GGCCA GCCAG CCAGC CAGCT AGCTG GCTGG CTGGG TGGGC GGGCG GGCGG GCGGT CGGTC GGTCA GTCAG TCAGC CAGCC AGCCT GCCTT CCTTT CTTTC TTTCG TTCGG TCGGC CGGCG GGCGC GCGCG CGCGT GCGTT CGTTG GTTGA TTGAT TGATC GATCG ATCGG TCGGC CGGCG GGCGA GCGAT CGATT GATTT ATTTC TTTCT TTCTA TCTAT CTATT TATTT ATTTT TTTTG TTTGA TTGAT TGATC GATCA ATCAT TCATT CATTC ATTCG TTCGG TCGGC CGGCG GGCGT GCGTC CGTCA GTCAG TCAGA CAGAT AGATG GATGT ATGTG TGTGC GTGCG TGCGC GCGCC CGCCT GCCTG CCTGT CTGTT TGTTG GTTGC TTGCG TGCGC GCGCG CGCGA GCGAT CGATT GATTT ATTTG TTTGG TTGGG TGGGC GGGCA GGCAA GCAAA CAAAA AAAAT AAATT AATTG ATTGC TTGCC TGCCG GCCGC CCGCT CGCTT GCTTC CTTCG TTCGG TCGGC CGGCG GGCGA GCGAT CGATG GATGG ATGGC TGGCC GGCCC GCCCC CCCCG CCCGT CCGTT CGTTT GTTTA TTTAT TTATT,ATCTAT TCTATT CTATTC TATTCG ATTCGG TTCGGC TCGGCG CGGCGG GGCGGA GCGGAG CGGAGT GGAGTT GAGTTC AGTTCG GTTCGG TTCGGC TCGGCC CGGCCA GGCCAG GCCAGC CCAGCT CAGCTG AGCTGG GCTGGG CTGGGC TGGGCG GGGCGG GGCGGT GCGGTC CGGTCA GGTCAG GTCAGC TCAGCC CAGCCT AGCCTT GCCTTT CCTTTC CTTTCG TTTCGG TTCGGC TCGGCG CGGCGC GGCGCG GCGCGT CGCGTT GCGTTG CGTTGA GTTGAT TTGATC TGATCG GATCGG ATCGGC TCGGCG CGGCGA GGCGAT GCGATT CGATTT GATTTC ATTTCT TTTCTA TTCTAT TCTATT CTATTT TATTTT ATTTTG TTTTGA TTTGAT TTGATC TGATCA GATCAT ATCATT TCATTC CATTCG ATTCGG TTCGGC TCGGCG CGGCGT GGCGTC GCGTCA CGTCAG GTCAGA TCAGAT CAGATG AGATGT GATGTG ATGTGC TGTGCG GTGCGC TGCGCC GCGCCT CGCCTG GCCTGT CCTGTT CTGTTG TGTTGC GTTGCG TTGCGC TGCGCG GCGCGA CGCGAT GCGATT CGATTT GATTTG ATTTGG TTTGGG TTGGGC TGGGCA GGGCAA GGCAAA GCAAAA CAAAAT AAAATT AAATTG AATTGC ATTGCC TTGCCG TGCCGC GCCGCT CCGCTT CGCTTC GCTTCG CTTCGG TTCGGC TCGGCG CGGCGA GGCGAT GCGATG CGATGG GATGGC ATGGCC TGGCCC GGCCCC GCCCCG CCCCGT CCCGTT CCGTTT CGTTTA GTTTAT TTTATT,ATCTATT TCTATTC CTATTCG TATTCGG ATTCGGC TTCGGCG TCGGCGG CGGCGGA GGCGGAG GCGGAGT CGGAGTT GGAGTTC GAGTTCG AGTTCGG GTTCGGC TTCGGCC TCGGCCA CGGCCAG GGCCAGC GCCAGCT CCAGCTG CAGCTGG AGCTGGG GCTGGGC CTGGGCG TGGGCGG GGGCGGT GGCGGTC GCGGTCA CGGTCAG GGTCAGC GTCAGCC TCAGCCT CAGCCTT AGCCTTT GCCTTTC CCTTTCG CTTTCGG TTTCGGC TTCGGCG TCGGCGC CGGCGCG GGCGCGT GCGCGTT CGCGTTG GCGTTGA CGTTGAT GTTGATC TTGATCG TGATCGG GATCGGC ATCGGCG TCGGCGA CGGCGAT GGCGATT GCGATTT CGATTTC GATTTCT ATTTCTA TTTCTAT TTCTATT TCTATTT CTATTTT TATTTTG ATTTTGA TTTTGAT TTTGATC TTGATCA TGATCAT GATCATT ATCATTC TCATTCG CATTCGG ATTCGGC TTCGGCG TCGGCGT CGGCGTC GGCGTCA GCGTCAG CGTCAGA GTCAGAT TCAGATG CAGATGT AGATGTG GATGTGC ATGTGCG TGTGCGC GTGCGCC TGCGCCT GCGCCTG CGCCTGT GCCTGTT CCTGTTG CTGTTGC TGTTGCG GTTGCGC TTGCGCG TGCGCGA GCGCGAT CGCGATT GCGATTT CGATTTG GATTTGG ATTTGGG TTTGGGC TTGGGCA TGGGCAA GGGCAAA GGCAAAA GCAAAAT CAAAATT AAAATTG AAATTGC AATTGCC ATTGCCG TTGCCGC TGCCGCT GCCGCTT CCGCTTC CGCTTCG GCTTCGG CTTCGGC TTCGGCG TCGGCGA CGGCGAT GGCGATG GCGATGG CGATGGC GATGGCC ATGGCCC TGGCCCC GGCCCCG GCCCCGT CCCCGTT CCCGTTT CCGTTTA CGTTTAT GTTTATT,"ID   TSSC1_PSEAE             Reviewed;         498 AA.
AC   Q9I748;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2001, sequence version 1.
DT   02-OCT-2024, entry version 104.
DE   RecName: Full=Type VI secretion system sheath protein TssC1 {ECO:0000303|PubMed:23341461};
DE   AltName: Full=Sheath protein HsiC1;
GN   Name=tssC1 {ECO:0000303|PubMed:23341461}; OrderedLocusNames=PA0084;
OS   Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM
OS   14847 / LMG 12228 / 1C / PRS 101 / PAO1).
OC   Bacteria; Pseudomonadota; Gammaproteobacteria; Pseudomonadales;
OC   Pseudomonadaceae; Pseudomonas.
OX   NCBI_TaxID=208964;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 /
RC   1C / PRS 101 / PAO1;
RX   PubMed=10984043; DOI=10.1038/35023079;
RA   Stover C.K., Pham X.-Q.T., Erwin A.L., Mizoguchi S.D., Warrener P.,
RA   Hickey M.J., Brinkman F.S.L., Hufnagle W.O., Kowalik D.J., Lagrou M.,
RA   Garber R.L., Goltry L., Tolentino E., Westbrock-Wadman S., Yuan Y.,
RA   Brody L.L., Coulter S.N., Folger K.R., Kas A., Larbig K., Lim R.M.,
RA   Smith K.A., Spencer D.H., Wong G.K.-S., Wu Z., Paulsen I.T., Reizer J.,
RA   Saier M.H. Jr., Hancock R.E.W., Lory S., Olson M.V.;
RT   ""Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic
RT   pathogen."";
RL   Nature 406:959-964(2000).
RN   [2]
RP   FUNCTION, INTERACTION WITH TSSB1, DISRUPTION PHENOTYPE, AND DOMAIN.
RX   PubMed=23341461; DOI=10.1074/jbc.m112.439273;
RA   Lossi N.S., Manoli E., Foerster A., Dajani R., Pape T., Freemont P.,
RA   Filloux A.;
RT   ""The HsiB1C1 (TssB-TssC) complex of the Pseudomonas aeruginosa type VI
RT   secretion system forms a bacteriophage tail sheathlike structure."";
RL   J. Biol. Chem. 288:7536-7548(2013).
RN   [3]
RP   INTERACTION WITH TSSA1.
RX   PubMed=27288401; DOI=10.15252/embj.201694024;
RA   Planamente S., Salih O., Manoli E., Albesa-Jove D., Freemont P.S.,
RA   Filloux A.;
RT   ""TssA forms a gp6-like ring attached to the type VI secretion sheath."";
RL   EMBO J. 35:1613-1627(2016).
RN   [4] {ECO:0007744|PDB:5N8N}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.28 ANGSTROMS) OF 38-498, FUNCTION, AND
RP   INTERACTION WITH TSSB1.
RX   PubMed=29307484; DOI=10.1016/j.str.2017.12.005;
RA   Salih O., He S., Planamente S., Stach L., MacDonald J.T., Manoli E.,
RA   Scheres S.H.W., Filloux A., Freemont P.S.;
RT   ""Atomic Structure of Type VI Contractile Sheath from Pseudomonas
RT   aeruginosa."";
RL   Structure 26:329-336.E3(2018).
CC   -!- FUNCTION: Core component of the H1 type VI (H1-T6SS) secretion system
CC       that plays a role in the release of toxins targeting both eukaryotic
CC       and prokaryotic species. Forms the sheath of the structure by
CC       assembling into tubules together with TssB1 resulting in the stacking
CC       of cogwheel-like structures showing predominantly a 12-fold symmetry
CC       (PubMed:23341461, PubMed:29307484). The sheath contracts to provide the
CC       energy needed for effector delivery (PubMed:29307484).
CC       {ECO:0000269|PubMed:23341461, ECO:0000269|PubMed:29307484}.
CC   -!- SUBUNIT: Forms a heterodimer with TssB1. Heterodimers assemble to form
CC       the sheath of the T6SS machinery (PubMed:23341461, PubMed:29307484).
CC       Interacts with TssA1 (PubMed:27288401). {ECO:0000269|PubMed:23341461,
CC       ECO:0000269|PubMed:27288401, ECO:0000269|PubMed:29307484}.
CC   -!- DOMAIN: The C-terminal region is required for cogwheel and tubule
CC       formation. {ECO:0000269|PubMed:23341461}.
CC   -!- DISRUPTION PHENOTYPE: Deletion mutant shows a clear reduction in E.
CC       coli killing and a lack of ability to secrete Hcp1, VgrG1a as well as
CC       Tse3. {ECO:0000269|PubMed:23341461}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AE004091; AAG03474.1; -; Genomic_DNA.
DR   PIR; A83635; A83635.
DR   RefSeq; NP_248774.1; NC_002516.2.
DR   RefSeq; WP_003111626.1; NZ_QZGE01000015.1.
DR   PDB; 5N8N; EM; 3.28 A; B/D/F/H/J/L/N/P/R/T/V/X/Z/b/d=38-498.
DR   PDBsum; 5N8N; -.
DR   AlphaFoldDB; Q9I748; -.
DR   SMR; Q9I748; -.
DR   STRING; 208964.PA0084; -.
DR   PaxDb; 208964-PA0084; -.
DR   GeneID; 879464; -.
DR   KEGG; pae:PA0084; -.
DR   PATRIC; fig|208964.12.peg.88; -.
DR   PseudoCAP; PA0084; -.
DR   HOGENOM; CLU_018386_1_0_6; -.
DR   InParanoid; Q9I748; -.
DR   OrthoDB; 9764000at2; -.
DR   PhylomeDB; Q9I748; -.
DR   BioCyc; PAER208964:G1FZ6-86-MONOMER; -.
DR   Proteomes; UP000002438; Chromosome.
DR   InterPro; IPR010269; T6SS_TssC-like.
DR   InterPro; IPR044032; TssC1_C.
DR   InterPro; IPR044031; TssC1_N.
DR   NCBIfam; TIGR03355; VI_chp_2; 1.
DR   PANTHER; PTHR35565; CYTOPLASMIC PROTEIN-RELATED; 1.
DR   PANTHER; PTHR35565:SF3; TYPE VI SECRETION SYSTEM SHEATH PROTEIN TSSC1; 1.
DR   Pfam; PF05943; VipB; 1.
DR   Pfam; PF18945; VipB_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Reference proteome.
FT   CHAIN           1..498
FT                   /note=""Type VI secretion system sheath protein TssC1""
FT                   /id=""PRO_0000449263""
FT   HELIX           40..54
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   STRAND          55..58
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   HELIX           66..69
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   HELIX           70..86
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   HELIX           89..106
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   STRAND          111..120
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   HELIX           123..132
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   HELIX           135..139
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   HELIX           142..148
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   HELIX           149..153
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   STRAND          161..169
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   HELIX           173..188
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   STRAND          193..197
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   TURN            199..203
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   STRAND          205..209
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   HELIX           219..221
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   HELIX           223..225
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   HELIX           226..232
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   STRAND          234..236
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   HELIX           237..239
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   STRAND          240..242
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   STRAND          254..258
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   STRAND          261..263
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   STRAND          274..277
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   HELIX           283..297
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   STRAND          298..301
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   TURN            306..309
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   STRAND          318..320
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   STRAND          328..330
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   STRAND          332..335
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   HELIX           339..347
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   STRAND          353..355
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   STRAND          362..365
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   HELIX           379..387
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   HELIX           391..411
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   HELIX           418..429
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   STRAND          438..440
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   HELIX           444..447
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   STRAND          450..459
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   STRAND          463..465
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   STRAND          467..475
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   STRAND          481..488
FT                   /evidence=""ECO:0007829|PDB:5N8N""
FT   TURN            493..496
FT                   /evidence=""ECO:0007829|PDB:5N8N""
SQ   SEQUENCE   498 AA;  55772 MW;  49CFFB364D447D36 CRC64;
     MAELSTENLA QGQTTTEQTS EFASLLLQEF KPKTERAREA VETAVRTLAE HALEQTSLIS
     NDAIKSIESI IAALDAKLTA QVNLIMHHAD FQQLESAWRG LHYLVNNTET DEQLKIRVLN
     ISKPELHKTL KKFKGTTWDQ SPIFKKLYEE EYGQFGGEPY GCLVGDYYFD QSPPDVELLG
     EMAKISAAMH APFISAASPT VMGMGSWQEL SNPRDLTKIF TTPEYAGWRS LRESEDSRYI
     GLTMPRFLAR LPYGAKTDPV EEFAFEEETD GADSSKYAWA NSAYAMAVNI NRSFKLYGWC
     SRIRGVESGG EVQGLPAHTF PTDDGGVDMK CPTEIAISDR REAELAKNGF MPLLHKKNTD
     FAAFIGAQSL QKPAEYDDPD ATANANLAAR LPYLFATCRF AHYLKCIVRD KIGSFKEKDE
     MQRWLQDWIL NYVDGDPAHS TETTKAQHPL AAAEVVVEEV EGNPGYYNSK FFLRPHYQLE
     GLTVSLRLVS KLPSAKEA
//
",25357
GACAAC ACAACC CAACCA AACCAG ACCAGA CCAGAT CAGATC AGATCG GATCGA ATCGAC TCGACA CGACAT GACATC ACATCC CATCCC ATCCCC TCCCCA CCCCAC CCCACC CCACCG CACCGG ACCGGC CCGGCA CGGCAC GGCACC GCACCC CACCCT ACCCTC CCCTCA CCTCAA CTCAAG TCAAGC CAAGCT AAGCTC AGCTCA GCTCAA CTCAAG TCAAGG CAAGGC AAGGCG AGGCGC GGCGCG GCGCGC CGCGCT GCGCTT CGCTTC GCTTCG CTTCGA TTCGAC TCGACA CGACAA GACAAC ACAACC CAACCG AACCGC ACCGCG CCGCGA CGCGAC GCGACG CGACGA GACGAA ACGAAG CGAAGC GAAGCG AAGCGC AGCGCT GCGCTG CGCTGT GCTGTT CTGTTT TGTTTC GTTTCC TTTCCC TTCCCA TCCCAA CCCAAC CCAACC CAACCA AACCAG ACCAGT CCAGTT CAGTTC AGTTCG GTTCGT TTCGTC TCGTCA CGTCAA GTCAAT TCAATG CAATGT AATGTG ATGTGC TGTGCG GTGCGC TGCGCC GCGCCT CGCCTG GCCTGC CCTGCT CTGCTG TGCTGG GCTGGC CTGGCC TGGCCC GGCCCA GCCCAG CCCAGA CCAGAC CAGACC AGACCT GACCTT ACCTTG CCTTGT CTTGTC TTGTCA TGTCAC GTCACA TCACAG,2,118,GACA ACAA CAAC AACC ACCA CCAG CAGA AGAT GATC ATCG TCGA CGAC GACA ACAT CATC ATCC TCCC CCCC CCCA CCAC CACC ACCG CCGG CGGC GGCA GCAC CACC ACCC CCCT CCTC CTCA TCAA CAAG AAGC AGCT GCTC CTCA TCAA CAAG AAGG AGGC GGCG GCGC CGCG GCGC CGCT GCTT CTTC TTCG TCGA CGAC GACA ACAA CAAC AACC ACCG CCGC CGCG GCGA CGAC GACG ACGA CGAA GAAG AAGC AGCG GCGC CGCT GCTG CTGT TGTT GTTT TTTC TTCC TCCC CCCA CCAA CAAC AACC ACCA CCAG CAGT AGTT GTTC TTCG TCGT CGTC GTCA TCAA CAAT AATG ATGT TGTG GTGC TGCG GCGC CGCC GCCT CCTG CTGC TGCT GCTG CTGG TGGC GGCC GCCC CCCA CCAG CAGA AGAC GACC ACCT CCTT CTTG TTGT TGTC GTCA TCAC CACA ACAG,GACAA ACAAC CAACC AACCA ACCAG CCAGA CAGAT AGATC GATCG ATCGA TCGAC CGACA GACAT ACATC CATCC ATCCC TCCCC CCCCA CCCAC CCACC CACCG ACCGG CCGGC CGGCA GGCAC GCACC CACCC ACCCT CCCTC CCTCA CTCAA TCAAG CAAGC AAGCT AGCTC GCTCA CTCAA TCAAG CAAGG AAGGC AGGCG GGCGC GCGCG CGCGC GCGCT CGCTT GCTTC CTTCG TTCGA TCGAC CGACA GACAA ACAAC CAACC AACCG ACCGC CCGCG CGCGA GCGAC CGACG GACGA ACGAA CGAAG GAAGC AAGCG AGCGC GCGCT CGCTG GCTGT CTGTT TGTTT GTTTC TTTCC TTCCC TCCCA CCCAA CCAAC CAACC AACCA ACCAG CCAGT CAGTT AGTTC GTTCG TTCGT TCGTC CGTCA GTCAA TCAAT CAATG AATGT ATGTG TGTGC GTGCG TGCGC GCGCC CGCCT GCCTG CCTGC CTGCT TGCTG GCTGG CTGGC TGGCC GGCCC GCCCA CCCAG CCAGA CAGAC AGACC GACCT ACCTT CCTTG CTTGT TTGTC TGTCA GTCAC TCACA CACAG,GACAAC ACAACC CAACCA AACCAG ACCAGA CCAGAT CAGATC AGATCG GATCGA ATCGAC TCGACA CGACAT GACATC ACATCC CATCCC ATCCCC TCCCCA CCCCAC CCCACC CCACCG CACCGG ACCGGC CCGGCA CGGCAC GGCACC GCACCC CACCCT ACCCTC CCCTCA CCTCAA CTCAAG TCAAGC CAAGCT AAGCTC AGCTCA GCTCAA CTCAAG TCAAGG CAAGGC AAGGCG AGGCGC GGCGCG GCGCGC CGCGCT GCGCTT CGCTTC GCTTCG CTTCGA TTCGAC TCGACA CGACAA GACAAC ACAACC CAACCG AACCGC ACCGCG CCGCGA CGCGAC GCGACG CGACGA GACGAA ACGAAG CGAAGC GAAGCG AAGCGC AGCGCT GCGCTG CGCTGT GCTGTT CTGTTT TGTTTC GTTTCC TTTCCC TTCCCA TCCCAA CCCAAC CCAACC CAACCA AACCAG ACCAGT CCAGTT CAGTTC AGTTCG GTTCGT TTCGTC TCGTCA CGTCAA GTCAAT TCAATG CAATGT AATGTG ATGTGC TGTGCG GTGCGC TGCGCC GCGCCT CGCCTG GCCTGC CCTGCT CTGCTG TGCTGG GCTGGC CTGGCC TGGCCC GGCCCA GCCCAG CCCAGA CCAGAC CAGACC AGACCT GACCTT ACCTTG CCTTGT CTTGTC TTGTCA TGTCAC GTCACA TCACAG,GACAACC ACAACCA CAACCAG AACCAGA ACCAGAT CCAGATC CAGATCG AGATCGA GATCGAC ATCGACA TCGACAT CGACATC GACATCC ACATCCC CATCCCC ATCCCCA TCCCCAC CCCCACC CCCACCG CCACCGG CACCGGC ACCGGCA CCGGCAC CGGCACC GGCACCC GCACCCT CACCCTC ACCCTCA CCCTCAA CCTCAAG CTCAAGC TCAAGCT CAAGCTC AAGCTCA AGCTCAA GCTCAAG CTCAAGG TCAAGGC CAAGGCG AAGGCGC AGGCGCG GGCGCGC GCGCGCT CGCGCTT GCGCTTC CGCTTCG GCTTCGA CTTCGAC TTCGACA TCGACAA CGACAAC GACAACC ACAACCG CAACCGC AACCGCG ACCGCGA CCGCGAC CGCGACG GCGACGA CGACGAA GACGAAG ACGAAGC CGAAGCG GAAGCGC AAGCGCT AGCGCTG GCGCTGT CGCTGTT GCTGTTT CTGTTTC TGTTTCC GTTTCCC TTTCCCA TTCCCAA TCCCAAC CCCAACC CCAACCA CAACCAG AACCAGT ACCAGTT CCAGTTC CAGTTCG AGTTCGT GTTCGTC TTCGTCA TCGTCAA CGTCAAT GTCAATG TCAATGT CAATGTG AATGTGC ATGTGCG TGTGCGC GTGCGCC TGCGCCT GCGCCTG CGCCTGC GCCTGCT CCTGCTG CTGCTGG TGCTGGC GCTGGCC CTGGCCC TGGCCCA GGCCCAG GCCCAGA CCCAGAC CCAGACC CAGACCT AGACCTT GACCTTG ACCTTGT CCTTGTC CTTGTCA TTGTCAC TGTCACA GTCACAG,"ID   MDTA_PECAS              Reviewed;         411 AA.
AC   Q6D2B2;
DT   01-MAR-2005, integrated into UniProtKB/Swiss-Prot.
DT   16-AUG-2004, sequence version 1.
DT   05-FEB-2025, entry version 102.
DE   RecName: Full=Multidrug resistance protein MdtA {ECO:0000255|HAMAP-Rule:MF_01422};
DE   AltName: Full=Multidrug transporter MdtA {ECO:0000255|HAMAP-Rule:MF_01422};
DE   Flags: Precursor;
GN   Name=mdtA {ECO:0000255|HAMAP-Rule:MF_01422};
GN   OrderedLocusNames=ECA3184;
OS   Pectobacterium atrosepticum (strain SCRI 1043 / ATCC BAA-672) (Erwinia
OS   carotovora subsp. atroseptica).
OC   Bacteria; Pseudomonadota; Gammaproteobacteria; Enterobacterales;
OC   Pectobacteriaceae; Pectobacterium.
OX   NCBI_TaxID=218491;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=SCRI 1043 / ATCC BAA-672;
RX   PubMed=15263089; DOI=10.1073/pnas.0402424101;
RA   Bell K.S., Sebaihia M., Pritchard L., Holden M.T.G., Hyman L.J.,
RA   Holeva M.C., Thomson N.R., Bentley S.D., Churcher L.J.C., Mungall K.,
RA   Atkin R., Bason N., Brooks K., Chillingworth T., Clark K., Doggett J.,
RA   Fraser A., Hance Z., Hauser H., Jagels K., Moule S., Norbertczak H.,
RA   Ormond D., Price C., Quail M.A., Sanders M., Walker D., Whitehead S.,
RA   Salmond G.P.C., Birch P.R.J., Parkhill J., Toth I.K.;
RT   ""Genome sequence of the enterobacterial phytopathogen Erwinia carotovora
RT   subsp. atroseptica and characterization of virulence factors."";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:11105-11110(2004).
CC   -!- SUBUNIT: Part of a tripartite efflux system composed of MdtA, MdtB and
CC       MdtC. {ECO:0000255|HAMAP-Rule:MF_01422}.
CC   -!- SUBCELLULAR LOCATION: Cell inner membrane {ECO:0000255|HAMAP-
CC       Rule:MF_01422}; Peripheral membrane protein {ECO:0000255|HAMAP-
CC       Rule:MF_01422}.
CC   -!- SIMILARITY: Belongs to the membrane fusion protein (MFP) (TC 8.A.1)
CC       family. {ECO:0000255|HAMAP-Rule:MF_01422}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; BX950851; CAG76082.1; -; Genomic_DNA.
DR   RefSeq; WP_011094706.1; NC_004547.2.
DR   AlphaFoldDB; Q6D2B2; -.
DR   SMR; Q6D2B2; -.
DR   STRING; 218491.ECA3184; -.
DR   GeneID; 57209869; -.
DR   KEGG; eca:ECA3184; -.
DR   PATRIC; fig|218491.5.peg.3225; -.
DR   eggNOG; COG0845; Bacteria.
DR   HOGENOM; CLU_018816_2_0_6; -.
DR   OrthoDB; 9783047at2; -.
DR   Proteomes; UP000007966; Chromosome.
DR   GO; GO:1990281; C:efflux pump complex; IEA:TreeGrafter.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0015562; F:efflux transmembrane transporter activity; IEA:TreeGrafter.
DR   FunFam; 2.40.420.20:FF:000001; Efflux RND transporter periplasmic adaptor subunit; 1.
DR   FunFam; 1.10.287.470:FF:000005; Multidrug resistance protein MdtA; 1.
DR   FunFam; 2.40.30.170:FF:000006; Multidrug resistance protein MdtA; 1.
DR   Gene3D; 2.40.30.170; -; 1.
DR   Gene3D; 2.40.420.20; -; 1.
DR   Gene3D; 2.40.50.100; -; 1.
DR   Gene3D; 1.10.287.470; Helix hairpin bin; 1.
DR   HAMAP; MF_01422; MdtA; 1.
DR   InterPro; IPR039562; MFP_biotin_lipoyl_2.
DR   InterPro; IPR022824; Multidrug-R_MdtA.
DR   InterPro; IPR006143; RND_pump_MFP.
DR   NCBIfam; TIGR01730; RND_mfp; 1.
DR   PANTHER; PTHR30469; MULTIDRUG RESISTANCE PROTEIN MDTA; 1.
DR   PANTHER; PTHR30469:SF12; MULTIDRUG RESISTANCE PROTEIN MDTA; 1.
DR   Pfam; PF13533; Biotin_lipoyl_2; 1.
DR   Pfam; PF13437; HlyD_3; 1.
DR   SUPFAM; SSF111369; HlyD-like secretion proteins; 1.
PE   3: Inferred from homology;
KW   Cell inner membrane; Cell membrane; Membrane; Reference proteome; Signal;
KW   Transport.
FT   SIGNAL          1..19
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01422""
FT   CHAIN           20..411
FT                   /note=""Multidrug resistance protein MdtA""
FT                   /id=""PRO_0000018702""
FT   REGION          31..58
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        31..49
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
SQ   SEQUENCE   411 AA;  44075 MW;  5D7DC832E2D87DED CRC64;
     MNAKRIRGLL ILAAVIAIAV LIWRHFTQTT PAAPGTSEQH AARTSHSENS GSGGGRRAAM
     RTLAPVQAAL TQSASVPHYL SGLGTVTAAN TVTLRSRVNG QLMALHFQEG QQVKVGDLLA
     EIDPRPFQVE LTQAQGQLAK DQAALLNTRQ DLARYQQLVK TNLISRQELD TQTAAVRQAE
     GALKADEGAV ASAQLQLDYS KITAPISGRI GLKQVDVGNY ITSGDTNGIV VITQTYPIDV
     VFTVPEAEIS TILNAQKSGQ PPVVEAWDRA NQKKLSQGIL LSMDNQIDTT TGTIKLKARF
     DNLDDALFPN QFVNIRMKVD TLKNAVVAPS AAVQMGNDGR FVWILNNKNE VSKRQVTTSI
     QYGQLVVVTA GLDADVQVVT DGIDRLTEGA KVEIVPSALT EKTPAIAGEK S
//
",28812
ACTATA CTATAG TATAGG ATAGGT TAGGTC AGGTCC GGTCCA GTCCAG TCCAGA CCAGAC CAGACA AGACAT GACATG ACATGT CATGTT ATGTTC TGTTCC GTTCCT TTCCTC TCCTCG CCTCGG CTCGGA TCGGAA CGGAAC GGAACT GAACTT AACTTG ACTTGT CTTGTC TTGTCG TGTCGG GTCGGC TCGGCG CGGCGT GGCGTT GCGTTG CGTTGT GTTGTC TTGTCC TGTCCT GTCCTG TCCTGC CCTGCT CTGCTG TGCTGA GCTGAA CTGAAA TGAAAT GAAATT AAATTG AATTGT ATTGTT TTGTTG TGTTGA GTTGAC TTGACA TGACAC GACACT ACACTG CACTGT ACTGTG CTGTGA TGTGAG GTGAGT TGAGTG GAGTGC AGTGCT GTGCTT TGCTTT GCTTTG CTTTGG TTTGGT TTGGTT TGGTTT GGTTTA GTTTAT TTTATG TTATGA TATGAT ATGATA TGATAA GATAAT ATAATA TAATAA AATAAG ATAAGC TAAGCT AAGCTT AGCTTA GCTTAA CTTAAA TTAAAG TAAAGC AAAGCA AAGCAC AGCACA GCACAT CACATA ACATAA CATAAA ATAAAG TAAAGA AAAGAC AAGACA AGACAA GACAAA ACAAAT CAAATC AAATCA AATCAG ATCAGC TCAGCT CAGCTC AGCTCA GCTCAA CTCAAT TCAATG CAATGC AATGCT ATGCTT TGCTTT GCTTTA CTTTAA TTTAAA TTAAAA TAAAAT AAAATG AAATGT AATGTT ATGTTT TGTTTT GTTTTA TTTTAT TTTATA TTATAA TATAAG ATAAGG TAAGGG AAGGGT AGGGTG GGGTGT GGTGTT GTGTTA TGTTAT GTTATC,0,145,ACTA CTAT TATA ATAG TAGG AGGT GGTC GTCC TCCA CCAG CAGA AGAC GACA ACAT CATG ATGT TGTT GTTC TTCC TCCT CCTC CTCG TCGG CGGA GGAA GAAC AACT ACTT CTTG TTGT TGTC GTCG TCGG CGGC GGCG GCGT CGTT GTTG TTGT TGTC GTCC TCCT CCTG CTGC TGCT GCTG CTGA TGAA GAAA AAAT AATT ATTG TTGT TGTT GTTG TTGA TGAC GACA ACAC CACT ACTG CTGT TGTG GTGA TGAG GAGT AGTG GTGC TGCT GCTT CTTT TTTG TTGG TGGT GGTT GTTT TTTA TTAT TATG ATGA TGAT GATA ATAA TAAT AATA ATAA TAAG AAGC AGCT GCTT CTTA TTAA TAAA AAAG AAGC AGCA GCAC CACA ACAT CATA ATAA TAAA AAAG AAGA AGAC GACA ACAA CAAA AAAT AATC ATCA TCAG CAGC AGCT GCTC CTCA TCAA CAAT AATG ATGC TGCT GCTT CTTT TTTA TTAA TAAA AAAA AAAT AATG ATGT TGTT GTTT TTTT TTTA TTAT TATA ATAA TAAG AAGG AGGG GGGT GGTG GTGT TGTT GTTA TTAT TATC,ACTAT CTATA TATAG ATAGG TAGGT AGGTC GGTCC GTCCA TCCAG CCAGA CAGAC AGACA GACAT ACATG CATGT ATGTT TGTTC GTTCC TTCCT TCCTC CCTCG CTCGG TCGGA CGGAA GGAAC GAACT AACTT ACTTG CTTGT TTGTC TGTCG GTCGG TCGGC CGGCG GGCGT GCGTT CGTTG GTTGT TTGTC TGTCC GTCCT TCCTG CCTGC CTGCT TGCTG GCTGA CTGAA TGAAA GAAAT AAATT AATTG ATTGT TTGTT TGTTG GTTGA TTGAC TGACA GACAC ACACT CACTG ACTGT CTGTG TGTGA GTGAG TGAGT GAGTG AGTGC GTGCT TGCTT GCTTT CTTTG TTTGG TTGGT TGGTT GGTTT GTTTA TTTAT TTATG TATGA ATGAT TGATA GATAA ATAAT TAATA AATAA ATAAG TAAGC AAGCT AGCTT GCTTA CTTAA TTAAA TAAAG AAAGC AAGCA AGCAC GCACA CACAT ACATA CATAA ATAAA TAAAG AAAGA AAGAC AGACA GACAA ACAAA CAAAT AAATC AATCA ATCAG TCAGC CAGCT AGCTC GCTCA CTCAA TCAAT CAATG AATGC ATGCT TGCTT GCTTT CTTTA TTTAA TTAAA TAAAA AAAAT AAATG AATGT ATGTT TGTTT GTTTT TTTTA TTTAT TTATA TATAA ATAAG TAAGG AAGGG AGGGT GGGTG GGTGT GTGTT TGTTA GTTAT TTATC,ACTATA CTATAG TATAGG ATAGGT TAGGTC AGGTCC GGTCCA GTCCAG TCCAGA CCAGAC CAGACA AGACAT GACATG ACATGT CATGTT ATGTTC TGTTCC GTTCCT TTCCTC TCCTCG CCTCGG CTCGGA TCGGAA CGGAAC GGAACT GAACTT AACTTG ACTTGT CTTGTC TTGTCG TGTCGG GTCGGC TCGGCG CGGCGT GGCGTT GCGTTG CGTTGT GTTGTC TTGTCC TGTCCT GTCCTG TCCTGC CCTGCT CTGCTG TGCTGA GCTGAA CTGAAA TGAAAT GAAATT AAATTG AATTGT ATTGTT TTGTTG TGTTGA GTTGAC TTGACA TGACAC GACACT ACACTG CACTGT ACTGTG CTGTGA TGTGAG GTGAGT TGAGTG GAGTGC AGTGCT GTGCTT TGCTTT GCTTTG CTTTGG TTTGGT TTGGTT TGGTTT GGTTTA GTTTAT TTTATG TTATGA TATGAT ATGATA TGATAA GATAAT ATAATA TAATAA AATAAG ATAAGC TAAGCT AAGCTT AGCTTA GCTTAA CTTAAA TTAAAG TAAAGC AAAGCA AAGCAC AGCACA GCACAT CACATA ACATAA CATAAA ATAAAG TAAAGA AAAGAC AAGACA AGACAA GACAAA ACAAAT CAAATC AAATCA AATCAG ATCAGC TCAGCT CAGCTC AGCTCA GCTCAA CTCAAT TCAATG CAATGC AATGCT ATGCTT TGCTTT GCTTTA CTTTAA TTTAAA TTAAAA TAAAAT AAAATG AAATGT AATGTT ATGTTT TGTTTT GTTTTA TTTTAT TTTATA TTATAA TATAAG ATAAGG TAAGGG AAGGGT AGGGTG GGGTGT GGTGTT GTGTTA TGTTAT GTTATC,ACTATAG CTATAGG TATAGGT ATAGGTC TAGGTCC AGGTCCA GGTCCAG GTCCAGA TCCAGAC CCAGACA CAGACAT AGACATG GACATGT ACATGTT CATGTTC ATGTTCC TGTTCCT GTTCCTC TTCCTCG TCCTCGG CCTCGGA CTCGGAA TCGGAAC CGGAACT GGAACTT GAACTTG AACTTGT ACTTGTC CTTGTCG TTGTCGG TGTCGGC GTCGGCG TCGGCGT CGGCGTT GGCGTTG GCGTTGT CGTTGTC GTTGTCC TTGTCCT TGTCCTG GTCCTGC TCCTGCT CCTGCTG CTGCTGA TGCTGAA GCTGAAA CTGAAAT TGAAATT GAAATTG AAATTGT AATTGTT ATTGTTG TTGTTGA TGTTGAC GTTGACA TTGACAC TGACACT GACACTG ACACTGT CACTGTG ACTGTGA CTGTGAG TGTGAGT GTGAGTG TGAGTGC GAGTGCT AGTGCTT GTGCTTT TGCTTTG GCTTTGG CTTTGGT TTTGGTT TTGGTTT TGGTTTA GGTTTAT GTTTATG TTTATGA TTATGAT TATGATA ATGATAA TGATAAT GATAATA ATAATAA TAATAAG AATAAGC ATAAGCT TAAGCTT AAGCTTA AGCTTAA GCTTAAA CTTAAAG TTAAAGC TAAAGCA AAAGCAC AAGCACA AGCACAT GCACATA CACATAA ACATAAA CATAAAG ATAAAGA TAAAGAC AAAGACA AAGACAA AGACAAA GACAAAT ACAAATC CAAATCA AAATCAG AATCAGC ATCAGCT TCAGCTC CAGCTCA AGCTCAA GCTCAAT CTCAATG TCAATGC CAATGCT AATGCTT ATGCTTT TGCTTTA GCTTTAA CTTTAAA TTTAAAA TTAAAAT TAAAATG AAAATGT AAATGTT AATGTTT ATGTTTT TGTTTTA GTTTTAT TTTTATA TTTATAA TTATAAG TATAAGG ATAAGGG TAAGGGT AAGGGTG AGGGTGT GGGTGTT GGTGTTA GTGTTAT TGTTATC,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",0
CAATAT AATATG ATATGA TATGAG ATGAGT TGAGTA GAGTAT AGTATG GTATGG TATGGT ATGGTA TGGTAC GGTACT GTACTG TACTGA ACTGAA CTGAAG TGAAGA GAAGAT AAGATG AGATGA GATGAT ATGATT TGATTA GATTAC ATTACC TTACCA TACCAA ACCAAG CCAAGG CAAGGT AAGGTA AGGTAA GGTAAA GTAAAC TAAACC AAACCT AACCTT ACCTTT CCTTTG CTTTGG TTTGGA TTGGAA TGGAAT GGAATT GAATTT AATTTG ATTTGG TTTGGT TTGGTG TGGTGC GGTGCC GTGCCA TGCCAC GCCACT CCACTT CACTTC ACTTCT CTTCTG TTCTGC TCTGCT CTGCTG TGCTGC GCTGCT CTGCTC TGCTCT GCTCTT CTCTTC TCTTCA CTTCAA TTCAAC TCAACC CAACCT AACCTG ACCTGA CCTGAA CTGAAG TGAAGA GAAGAA AAGAAG AGAAGA GAAGAG AAGAGC AGAGCA GAGCAA AGCAAG GCAAGA CAAGAA AAGAAG AGAAGA GAAGAA AAGAAG AGAAGA GAAGAT AAGATT AGATTG GATTGG ATTGGT TTGGTT TGGTTA GGTTAG GTTAGA TTAGAT TAGATG AGATGA GATGAT ATGATG TGATGA GATGAT ATGATA TGATAG GATAGT ATAGTC TAGTCC AGTCCT GTCCTG TCCTGT CCTGTC CTGTCT TGTCTC GTCTCT TCTCTT CTCTTA TCTTAT CTTATA TTATAC TATACA ATACAC TACACA ACACAT CACATT ACATTC CATTCC ATTCCG TTCCGA TCCGAG CCGAGC CGAGCC GAGCCC AGCCCA GCCCAC CCCACG CCACGA CACGAG ACGAGA,0,145,CAAT AATA ATAT TATG ATGA TGAG GAGT AGTA GTAT TATG ATGG TGGT GGTA GTAC TACT ACTG CTGA TGAA GAAG AAGA AGAT GATG ATGA TGAT GATT ATTA TTAC TACC ACCA CCAA CAAG AAGG AGGT GGTA GTAA TAAA AAAC AACC ACCT CCTT CTTT TTTG TTGG TGGA GGAA GAAT AATT ATTT TTTG TTGG TGGT GGTG GTGC TGCC GCCA CCAC CACT ACTT CTTC TTCT TCTG CTGC TGCT GCTG CTGC TGCT GCTC CTCT TCTT CTTC TTCA TCAA CAAC AACC ACCT CCTG CTGA TGAA GAAG AAGA AGAA GAAG AAGA AGAG GAGC AGCA GCAA CAAG AAGA AGAA GAAG AAGA AGAA GAAG AAGA AGAT GATT ATTG TTGG TGGT GGTT GTTA TTAG TAGA AGAT GATG ATGA TGAT GATG ATGA TGAT GATA ATAG TAGT AGTC GTCC TCCT CCTG CTGT TGTC GTCT TCTC CTCT TCTT CTTA TTAT TATA ATAC TACA ACAC CACA ACAT CATT ATTC TTCC TCCG CCGA CGAG GAGC AGCC GCCC CCCA CCAC CACG ACGA CGAG GAGA,CAATA AATAT ATATG TATGA ATGAG TGAGT GAGTA AGTAT GTATG TATGG ATGGT TGGTA GGTAC GTACT TACTG ACTGA CTGAA TGAAG GAAGA AAGAT AGATG GATGA ATGAT TGATT GATTA ATTAC TTACC TACCA ACCAA CCAAG CAAGG AAGGT AGGTA GGTAA GTAAA TAAAC AAACC AACCT ACCTT CCTTT CTTTG TTTGG TTGGA TGGAA GGAAT GAATT AATTT ATTTG TTTGG TTGGT TGGTG GGTGC GTGCC TGCCA GCCAC CCACT CACTT ACTTC CTTCT TTCTG TCTGC CTGCT TGCTG GCTGC CTGCT TGCTC GCTCT CTCTT TCTTC CTTCA TTCAA TCAAC CAACC AACCT ACCTG CCTGA CTGAA TGAAG GAAGA AAGAA AGAAG GAAGA AAGAG AGAGC GAGCA AGCAA GCAAG CAAGA AAGAA AGAAG GAAGA AAGAA AGAAG GAAGA AAGAT AGATT GATTG ATTGG TTGGT TGGTT GGTTA GTTAG TTAGA TAGAT AGATG GATGA ATGAT TGATG GATGA ATGAT TGATA GATAG ATAGT TAGTC AGTCC GTCCT TCCTG CCTGT CTGTC TGTCT GTCTC TCTCT CTCTT TCTTA CTTAT TTATA TATAC ATACA TACAC ACACA CACAT ACATT CATTC ATTCC TTCCG TCCGA CCGAG CGAGC GAGCC AGCCC GCCCA CCCAC CCACG CACGA ACGAG CGAGA,CAATAT AATATG ATATGA TATGAG ATGAGT TGAGTA GAGTAT AGTATG GTATGG TATGGT ATGGTA TGGTAC GGTACT GTACTG TACTGA ACTGAA CTGAAG TGAAGA GAAGAT AAGATG AGATGA GATGAT ATGATT TGATTA GATTAC ATTACC TTACCA TACCAA ACCAAG CCAAGG CAAGGT AAGGTA AGGTAA GGTAAA GTAAAC TAAACC AAACCT AACCTT ACCTTT CCTTTG CTTTGG TTTGGA TTGGAA TGGAAT GGAATT GAATTT AATTTG ATTTGG TTTGGT TTGGTG TGGTGC GGTGCC GTGCCA TGCCAC GCCACT CCACTT CACTTC ACTTCT CTTCTG TTCTGC TCTGCT CTGCTG TGCTGC GCTGCT CTGCTC TGCTCT GCTCTT CTCTTC TCTTCA CTTCAA TTCAAC TCAACC CAACCT AACCTG ACCTGA CCTGAA CTGAAG TGAAGA GAAGAA AAGAAG AGAAGA GAAGAG AAGAGC AGAGCA GAGCAA AGCAAG GCAAGA CAAGAA AAGAAG AGAAGA GAAGAA AAGAAG AGAAGA GAAGAT AAGATT AGATTG GATTGG ATTGGT TTGGTT TGGTTA GGTTAG GTTAGA TTAGAT TAGATG AGATGA GATGAT ATGATG TGATGA GATGAT ATGATA TGATAG GATAGT ATAGTC TAGTCC AGTCCT GTCCTG TCCTGT CCTGTC CTGTCT TGTCTC GTCTCT TCTCTT CTCTTA TCTTAT CTTATA TTATAC TATACA ATACAC TACACA ACACAT CACATT ACATTC CATTCC ATTCCG TTCCGA TCCGAG CCGAGC CGAGCC GAGCCC AGCCCA GCCCAC CCCACG CCACGA CACGAG ACGAGA,CAATATG AATATGA ATATGAG TATGAGT ATGAGTA TGAGTAT GAGTATG AGTATGG GTATGGT TATGGTA ATGGTAC TGGTACT GGTACTG GTACTGA TACTGAA ACTGAAG CTGAAGA TGAAGAT GAAGATG AAGATGA AGATGAT GATGATT ATGATTA TGATTAC GATTACC ATTACCA TTACCAA TACCAAG ACCAAGG CCAAGGT CAAGGTA AAGGTAA AGGTAAA GGTAAAC GTAAACC TAAACCT AAACCTT AACCTTT ACCTTTG CCTTTGG CTTTGGA TTTGGAA TTGGAAT TGGAATT GGAATTT GAATTTG AATTTGG ATTTGGT TTTGGTG TTGGTGC TGGTGCC GGTGCCA GTGCCAC TGCCACT GCCACTT CCACTTC CACTTCT ACTTCTG CTTCTGC TTCTGCT TCTGCTG CTGCTGC TGCTGCT GCTGCTC CTGCTCT TGCTCTT GCTCTTC CTCTTCA TCTTCAA CTTCAAC TTCAACC TCAACCT CAACCTG AACCTGA ACCTGAA CCTGAAG CTGAAGA TGAAGAA GAAGAAG AAGAAGA AGAAGAG GAAGAGC AAGAGCA AGAGCAA GAGCAAG AGCAAGA GCAAGAA CAAGAAG AAGAAGA AGAAGAA GAAGAAG AAGAAGA AGAAGAT GAAGATT AAGATTG AGATTGG GATTGGT ATTGGTT TTGGTTA TGGTTAG GGTTAGA GTTAGAT TTAGATG TAGATGA AGATGAT GATGATG ATGATGA TGATGAT GATGATA ATGATAG TGATAGT GATAGTC ATAGTCC TAGTCCT AGTCCTG GTCCTGT TCCTGTC CCTGTCT CTGTCTC TGTCTCT GTCTCTT TCTCTTA CTCTTAT TCTTATA CTTATAC TTATACA TATACAC ATACACA TACACAT ACACATT CACATTC ACATTCC CATTCCG ATTCCGA TTCCGAG TCCGAGC CCGAGCC CGAGCCC GAGCCCA AGCCCAC GCCCACG CCCACGA CCACGAG CACGAGA,"ID   R1A_SARS                Reviewed;        4382 AA.
AC   P0C6U8; P59641;
DT   10-JUN-2008, integrated into UniProtKB/Swiss-Prot.
DT   10-JUN-2008, sequence version 1.
DT   05-FEB-2025, entry version 124.
DE   RecName: Full=Replicase polyprotein 1a;
DE            Short=pp1a;
DE   AltName: Full=ORF1a polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3;
DE              Short=PL-PRO;
DE              EC=3.4.19.12 {ECO:0000269|PubMed:17692280};
DE              EC=3.4.22.- {ECO:0000269|PubMed:12917450, ECO:0000269|PubMed:16306590, ECO:0000269|PubMed:17692280};
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:12917450};
DE     AltName: Full=Main protease;
DE              Short=Mpro;
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=RNA-capping enzyme subunit nsp9;
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE              EC=2.7.7.50;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=Non-structural protein 11;
DE              Short=nsp11;
GN   ORFNames=1a;
OS   Severe acute respiratory syndrome coronavirus (SARS-CoV).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=694009;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
OH   NCBI_TaxID=9675; Paguma larvata (Masked palm civet).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Urbani;
RX   PubMed=12730500; DOI=10.1126/science.1085952;
RA   Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R.,
RA   Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.-H., Tong S.,
RA   Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D.,
RA   Peret T.C.T., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S.,
RA   Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R.,
RA   Guenther S., Osterhaus A.D.M.E., Drosten C., Pallansch M.A., Anderson L.J.,
RA   Bellini W.J.;
RT   ""Characterization of a novel coronavirus associated with severe acute
RT   respiratory syndrome."";
RL   Science 300:1394-1399(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Tor2;
RX   PubMed=12730501; DOI=10.1126/science.1085953;
RA   Marra M.A., Jones S.J.M., Astell C.R., Holt R.A., Brooks-Wilson A.,
RA   Butterfield Y.S.N., Khattra J., Asano J.K., Barber S.A., Chan S.Y.,
RA   Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffith O.L., Leach S.R.,
RA   Mayo M., McDonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S.,
RA   Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.M.,
RA   Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K.,
RA   Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R.,
RA   Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A.,
RA   Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S.,
RA   Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M.,
RA   Skowronski D.M., Upton C., Roper R.L.;
RT   ""The genome sequence of the SARS-associated coronavirus."";
RL   Science 300:1399-1404(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate CUHK-Su10, and Isolate CUHK-W1;
RX   PubMed=12853594; DOI=10.1056/nejm200307103490216;
RA   Tsui S.K.W., Chim S.S.C., Lo Y.M.D.;
RT   ""Coronavirus genomic-sequence variations and the epidemiology of the severe
RT   acute respiratory syndrome."";
RL   N. Engl. J. Med. 349:187-188(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate GZ50, Isolate SZ16, and Isolate SZ3;
RX   PubMed=12958366; DOI=10.1126/science.1087139;
RA   Guan Y., Zheng B.J., He Y.Q., Liu X.L., Zhuang Z.X., Cheung C.L., Luo S.W.,
RA   Li P.H., Zhang L.J., Guan Y.J., Butt K.M., Wong K.L., Chan K.W., Lim W.,
RA   Shortridge K.F., Yuen K.Y., Peiris J.S.M., Poon L.L.M.;
RT   ""Isolation and characterization of viruses related to the SARS coronavirus
RT   from animals in southern China."";
RL   Science 302:276-278(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HKU-39849;
RX   PubMed=12876307; DOI=10.1177/15353702-0322807-13;
RA   Zeng F.Y., Chan C.W., Chan M.N., Chen J.D., Chow K.Y.C., Hon C.C.C.,
RA   Hui R.K.H., Li J., Li V.Y.Y., Wang C.Y., Wang P.Y., Guan Y., Zheng B.,
RA   Poon L.L.M., Chan K.H., Yuen K.Y., Peiris J.S.M., Leung F.C.;
RT   ""The complete genome sequence of severe acute respiratory syndrome
RT   coronavirus strain HKU-39849 (HK-39)."";
RL   Exp. Biol. Med. 228:866-873(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Sin2500, Isolate Sin2677, Isolate Sin2679, Isolate
RC   Sin2748, and Isolate sin2774;
RX   PubMed=12781537; DOI=10.1016/s0140-6736(03)13414-9;
RA   Ruan Y., Wei C.L., Ling A.E., Vega V.B., Thoreau H., Se Thoe S.Y.,
RA   Chia J.-M., Ng P., Chiu K.P., Lim L., Zhang T., Chan K.P., Oon L.E.L.,
RA   Ng M.L., Leo S.Y., Ng L.F.P., Ren E.C., Stanton L.W., Long P.M., Liu E.T.;
RT   ""Comparative full-length genome sequence analysis of 14 SARS coronavirus
RT   isolates and common mutations associated with putative origins of
RT   infection."";
RL   Lancet 361:1779-1785(2003).
RN   [7]
RP   ERRATUM OF PUBMED:12781537.
RA   Ruan Y., Wei C.L., Ling A.E., Vega V.B., Thoreau H., Se Thoe S.Y.,
RA   Chia J.-M., Ng P., Chiu K.P., Lim L., Zhang T., Chan K.P., Oon L.E.L.,
RA   Ng M.L., Leo S.Y., Ng L.F.P., Ren E.C., Stanton L.W., Long P.M., Liu E.T.;
RL   Lancet 361:1832-1832(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate ZJ01;
RX   PubMed=14527350;
RA   Li L., Wang Z., Lu Y., Bao Q., Chen S., Wu N., Cheng S., Weng J., Zhang Y.,
RA   Yan J., Mei L., Wang X., Zhu H., Yu Y., Zhang M., Li M., Yao J., Lu Q.,
RA   Yao P., Bo X., Wo J., Wang S., Hu S.;
RT   ""Severe acute respiratory syndrome-associated coronavirus genotype and its
RT   characterization."";
RL   Chin. Med. J. 116:1288-1292(2003).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate BJ01, Isolate BJ02, Isolate BJ03, Isolate BJ04, and
RC   Isolate GD01;
RA   Qin E., Zhu Q., Yu M., Fan B., Chang G., Si B., Yang B., Peng W., Jiang T.,
RA   Liu B., Deng Y., Liu H., Zhang Y., Wang C., Li Y., Gan Y., Li X., Lu F.,
RA   Tan G., Yang R., Cao W.S., Wang J., Chen W., Cong L., Deng Y., Dong W.,
RA   Han Y., Hu W., Lei M., Li C., Li G., Li G., Li H., Li S., Li S., Li W.,
RA   Li W., Lin W., Liu J., Liu Z., Lu H., Ni P., Qi Q., Sun Y., Tang L.,
RA   Tong Z., Wang J., Wang X., Wu Q., Xi Y., Xu Z., Yang L., Ye C., Ye J.,
RA   Zhang B., Zhang F., Zhang J., Zhang X., Zhou J., Yang H.;
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TW1;
RA   Yeh S.-H., Kao C.-L., Tsai C.-Y., Liu C.-J., Chen D.-S., Chen P.-J.;
RT   ""The complete genome of SARS coronavirus clone TW1."";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate FRA;
RX   PubMed=14645828; DOI=10.1126/science.302.5650.1504b;
RA   Eickmann M., Becker S., Klenk H.-D., Doerr H.W., Stadler K., Censini S.,
RA   Guidotti S., Masignani V., Scarselli M., Mora M., Donati C., Han J.H.,
RA   Song H.C., Abrignani S., Covacci A., Rappuoli R.;
RT   ""Phylogeny of the SARS coronavirus."";
RL   Science 302:1504-1505(2003).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Frankfurt-1;
RA   Thiel V., Hertzig T., Putics A., Ivanov K.A., Schelle B., Bayer S.,
RA   Scheiner B., Weinand H., Weissbrich B., Ziebuhr J.;
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWC;
RA   Yang J.-Y., Lin J.-H., Chiu S.-C., Wang S.-F., Lee S.C., Lin Y.-C.,
RA   Hsu C.-K., Chen H.-Y., Chang J.G., Chen P.-J., Su I.-J.;
RT   ""Genomic sequence of SARS isolate from the first fatal case in Taiwan."";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Shanghai QXC1;
RA   Yuan Z., Zhang X., Hu Y., Lan S., Wang H., Zhou Z., Wen Y.;
RT   ""Analysis of SARS coronavirus genome in Shanghai isolates."";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HSR 1;
RA   Canducci F., Clementi M., Poli G., Vicenzi E.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [16]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Taiwan TC1, Isolate Taiwan TC2, and Isolate Taiwan TC3;
RA   Chang J.-G.C., Lin T.-H., Chen C.-M., Lin C.-S., Chan W.-L., Shih M.-C.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [17]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWH, Isolate TWJ, Isolate TWK, Isolate TWS, and Isolate
RC   TWY;
RA   Shu H.Y., Wu K.M., Tsai S.F.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [18]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate AS;
RA   Balotta C., Corvasce S., Violin M., Galli M., Moroni M., Vigevani G.M.,
RA   Ruan Y.J., Salemi M.;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [19]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate ZJ01;
RA   Wang Z., Cheng S., Zhang Y.;
RL   Submitted (NOV-2003) to the EMBL/GenBank/DDBJ databases.
RN   [20]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA] OF 1-507 AND 1655-4382.
RC   STRAIN=Isolate Shanghai LY;
RA   Yuan Z., Zhang X., Hu Y., Lan S., Wang H., Zhou Z., Wen Y.;
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [21]
RP   PROTEOLYTIC CLEAVAGE (ISOFORM REPLICASE POLYPROTEIN 1A), CATALYTIC ACTIVITY
RP   (3C-LIKE PROTEINASE NSP5), AND CATALYTIC ACTIVITY (PAPAIN-LIKE PROTEASE
RP   NSP3).
RX   PubMed=12917450; DOI=10.1099/vir.0.19424-0;
RA   Thiel V., Ivanov K.A., Putics A., Hertzig T., Schelle B., Bayer S.,
RA   Weissbrich B., Snijder E.J., Rabenau H., Doerr H.W., Gorbalenya A.E.,
RA   Ziebuhr J.;
RT   ""Mechanisms and enzymes involved in SARS coronavirus genome expression."";
RL   J. Gen. Virol. 84:2305-2315(2003).
RN   [22]
RP   PROTEOLYTIC CLEAVAGE (ISOFORM REPLICASE POLYPROTEIN 1A).
RX   PubMed=15331731; DOI=10.1128/jvi.78.18.9977-9986.2004;
RA   Prentice E., McAuliffe J., Lu X., Subbarao K., Denison M.R.;
RT   ""Identification and characterization of severe acute respiratory syndrome
RT   coronavirus replicase proteins."";
RL   J. Virol. 78:9977-9986(2004).
RN   [23]
RP   PROTEOLYTIC CLEAVAGE (ISOFORM REPLICASE POLYPROTEIN 1A).
RC   STRAIN=Isolate Urbani;
RX   PubMed=15564471; DOI=10.1128/jvi.78.24.13600-13612.2004;
RA   Harcourt B.H., Jukneliene D., Kanjanahaluethai A., Bechill J.,
RA   Severson K.M., Smith C.M., Rota P.A., Baker S.C.;
RT   ""Identification of severe acute respiratory syndrome coronavirus replicase
RT   products and characterization of papain-like protease activity."";
RL   J. Virol. 78:13600-13612(2004).
RN   [24]
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), AND BIOPHYSICOCHEMICAL PROPERTIES (3C-LIKE PROTEINASE NSP5).
RX   PubMed=14561748; DOI=10.1074/jbc.m310875200;
RA   Fan K., Wei P., Feng Q., Chen S., Huang C., Ma L., Lai B., Pei J., Liu Y.,
RA   Chen J., Lai L.;
RT   ""Biosynthesis, purification, and substrate specificity of severe acute
RT   respiratory syndrome coronavirus 3C-like proteinase."";
RL   J. Biol. Chem. 279:1637-1642(2004).
RN   [25]
RP   CATALYTIC ACTIVITY (PAPAIN-LIKE PROTEASE NSP3), FUNCTION (PAPAIN-LIKE
RP   PROTEASE NSP3), PROTEOLYTIC CLEAVAGE (ISOFORM REPLICASE POLYPROTEIN 1A),
RP   COFACTOR (PAPAIN-LIKE PROTEASE NSP3), MUTAGENESIS OF CYS-1651; CYS-1688;
RP   CYS-1729; CYS-1732; CYS-1764; CYS-1766 AND ASP-1826, AND ACTIVE SITE
RP   (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=16306590; DOI=10.1128/jvi.79.24.15189-15198.2005;
RA   Barretto N., Jukneliene D., Ratia K., Chen Z., Mesecar A.D., Baker S.C.;
RT   ""The papain-like protease of severe acute respiratory syndrome coronavirus
RT   has deubiquitinating activity."";
RL   J. Virol. 79:15189-15198(2005).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=16226257; DOI=10.1016/j.febslet.2005.09.075;
RA   Lin C.W., Tsai F.J., Wan L., Lai C.C., Lin K.H., Hsieh T.H., Shiu S.Y.,
RA   Li J.Y.;
RT   ""Binding interaction of SARS coronavirus 3CL(pro) protease with vacuolar-H+
RT   ATPase G1 subunit."";
RL   FEBS Lett. 579:6089-6094(2005).
RN   [27]
RP   SUBUNIT (3C-LIKE PROTEINASE NSP5).
RX   PubMed=15507456; DOI=10.1074/jbc.m408211200;
RA   Chen S., Chen L., Tan J., Chen J., Du L., Sun T., Shen J., Chen K.,
RA   Jiang H., Shen X.;
RT   ""Severe acute respiratory syndrome coronavirus 3C-like proteinase N
RT   terminus is indispensable for proteolytic activity but not for enzyme
RT   dimerization. Biochemical and thermodynamic investigation in conjunction
RT   with molecular dynamics simulations."";
RL   J. Biol. Chem. 280:164-173(2005).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=17024178; DOI=10.1038/sj.emboj.7601368;
RA   Imbert I., Guillemot J.-C., Bourhis J.-M., Bussetta C., Coutard B.,
RA   Egloff M.-P., Ferron F., Gorbalenya A.E., Canard B.;
RT   ""A second, non-canonical RNA-dependent RNA polymerase in SARS
RT   coronavirus."";
RL   EMBO J. 25:4933-4942(2006).
RN   [29]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3).
RX   PubMed=17692280; DOI=10.1016/j.abb.2007.07.006;
RA   Lindner H.A., Lytvyn V., Qi H., Lachance P., Ziomek E., Menard R.;
RT   ""Selectivity in ISG15 and ubiquitin recognition by the SARS coronavirus
RT   papain-like protease."";
RL   Arch. Biochem. Biophys. 466:8-14(2007).
RN   [30]
RP   INTERACTION WITH ORF6 PROTEIN (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=17532020; DOI=10.1016/j.virol.2007.04.029;
RA   Kumar P., Gunalan V., Liu B., Chow V.T., Druce J., Birch C., Catton M.,
RA   Fielding B.C., Tan Y.J., Lal S.K.;
RT   ""The nonstructural protein 8 (nsp8) of the SARS coronavirus interacts with
RT   its ORF6 accessory protein."";
RL   Virology 366:293-303(2007).
RN   [31]
RP   TOPOLOGY (PAPAIN-LIKE PROTEASE NSP3), TOPOLOGY (NON-STRUCTURAL PROTEIN 4),
RP   AND TOPOLOGY (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=18842706; DOI=10.1128/jvi.01219-08;
RA   Oostra M., Hagemeijer M.C., van Gent M., Bekker C.P., te Lintelo E.G.,
RA   Rottier P.J., de Haan C.A.;
RT   ""Topology and membrane anchoring of the coronavirus replication complex:
RT   not all hydrophobic domains of nsp3 and nsp6 are membrane spanning."";
RL   J. Virol. 82:12392-12405(2008).
RN   [32]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=19369340; DOI=10.1128/jvi.02220-08;
RA   Frieman M., Ratia K., Johnston R.E., Mesecar A.D., Baric R.S.;
RT   ""Severe acute respiratory syndrome coronavirus papain-like protease
RT   ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and
RT   NF-kappaB signaling."";
RL   J. Virol. 83:6689-6705(2009).
RN   [33]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), AND INTERACTION WITH HOST PHB AND PHB2
RP   (NON-STRUCTURAL PROTEIN 2).
RX   PubMed=19640993; DOI=10.1128/jvi.00842-09;
RA   Cornillez-Ty C.T., Liao L., Yates J.R., Kuhn P., Buchmeier M.J.;
RT   ""Severe acute respiratory syndrome coronavirus nonstructural protein 2
RT   interacts with a host protein complex involved in mitochondrial biogenesis
RT   and intracellular signaling."";
RL   J. Virol. 83:10314-10318(2009).
RN   [34]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=19153232; DOI=10.1128/jvi.01505-08;
RA   Miknis Z.J., Donaldson E.F., Umland T.C., Rimmer R.A., Baric R.S.,
RA   Schultz L.W.;
RT   ""Severe acute respiratory syndrome coronavirus nsp9 dimerization is
RT   essential for efficient viral growth."";
RL   J. Virol. 83:3007-3018(2009).
RN   [35]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=22174690; DOI=10.1371/journal.ppat.1002433;
RA   Huang C., Lokugamage K.G., Rozovics J.M., Narayanan K., Semler B.L.,
RA   Makino S.;
RT   ""SARS coronavirus nsp1 protein induces template-dependent endonucleolytic
RT   cleavage of mRNAs: viral mRNAs are resistant to nsp1-induced RNA
RT   cleavage."";
RL   PLoS Pathog. 7:E1002433-E1002433(2011).
RN   [36]
RP   INTERACTION WITH PAPAIN-LIKE PROTEASE NSP3 (NON-STRUCTURAL PROTEIN 4),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 4), AND INTERACTION WITH
RP   NON-STRUCTURAL PROTEIN 6 (NON-STRUCTURAL PROTEIN 4).
RX   PubMed=21345958; DOI=10.1128/jvi.00042-11;
RA   Hagemeijer M.C., Ulasli M., Vonk A.M., Reggiori F., Rottier P.J.,
RA   de Haan C.A.;
RT   ""Mobility and interactions of coronavirus nonstructural protein 4."";
RL   J. Virol. 85:4572-4577(2011).
RN   [37]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=23035226; DOI=10.1128/jvi.01958-12;
RA   Lokugamage K.G., Narayanan K., Huang C., Makino S.;
RT   ""Severe acute respiratory syndrome coronavirus protein nsp1 is a novel
RT   eukaryotic translation inhibitor that represses multiple steps of
RT   translation initiation."";
RL   J. Virol. 86:13598-13608(2012).
RN   [38]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 7), AND FUNCTION (NON-STRUCTURAL PROTEIN
RP   8).
RX   PubMed=22039154; DOI=10.1093/nar/gkr893;
RA   te Velthuis A.J., van den Worm S.H., Snijder E.J.;
RT   ""The SARS-coronavirus nsp7+nsp8 complex is a unique multimeric RNA
RT   polymerase capable of both de novo initiation and primer extension."";
RL   Nucleic Acids Res. 40:1737-1747(2012).
RN   [39]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 10), AND INTERACTION WITH PROOFREADING
RP   EXORIBONUCLEASE NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=22635272; DOI=10.1073/pnas.1201130109;
RA   Bouvet M., Imbert I., Subissi L., Gluais L., Canard B., Decroly E.;
RT   ""RNA 3'-end mismatch excision by the severe acute respiratory syndrome
RT   coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complex."";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:9372-9377(2012).
RN   [40]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 4), FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND FUNCTION
RP   (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=23943763; DOI=10.1128/mbio.00524-13;
RA   Angelini M.M., Akhlaghpour M., Neuman B.W., Buchmeier M.J.;
RT   ""Severe acute respiratory syndrome coronavirus nonstructural proteins 3, 4,
RT   and 6 induce double-membrane vesicles."";
RL   MBio 4:0-0(2013).
RN   [41]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=24991833; DOI=10.4161/auto.29309;
RA   Cottam E.M., Whelband M.C., Wileman T.;
RT   ""Coronavirus NSP6 restricts autophagosome expansion."";
RL   Autophagy 10:1426-1441(2014).
RN   [42]
RP   REVIEW.
RX   PubMed=24410069; DOI=10.1089/dna.2013.2304;
RA   Angelini M.M., Neuman B.W., Buchmeier M.J.;
RT   ""Untangling membrane rearrangement in the nidovirales."";
RL   DNA Cell Biol. 33:122-127(2014).
RN   [43]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=24622840; DOI=10.1007/s13238-014-0026-3;
RA   Chen X., Yang X., Zheng Y., Yang Y., Xing Y., Chen Z.;
RT   ""SARS coronavirus papain-like protease inhibits the type I interferon
RT   signaling pathway through interaction with the STING-TRAF3-TBK1 complex."";
RL   Protein Cell 5:369-381(2014).
RN   [44]
RP   INTERACTION WITH NUP93 (HOST TRANSLATION INHIBITOR NSP1), AND FUNCTION
RP   (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=30943371; DOI=10.1139/bcb-2018-0394;
RA   Gomez G.N., Abrar F., Dodhia M.P., Gonzalez F.G., Nag A.;
RT   ""SARS coronavirus protein nsp1 disrupts localization of Nup93 from the
RT   nuclear pore complex."";
RL   Biochem. Cell Biol. 97:758-766(2019).
RN   [45]
RP   PROTEOLYTIC CLEAVAGE (ISOFORM REPLICASE POLYPROTEIN 1A), MASS SPECTROMETRY
RP   (NON-STRUCTURAL PROTEIN 8), MASS SPECTROMETRY (NON-STRUCTURAL PROTEIN 9),
RP   AND MASS SPECTROMETRY (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=32083638; DOI=10.1042/bcj20200029;
RA   Krichel B., Falke S., Hilgenfeld R., Redecke L., Uetrecht C.;
RT   ""Processing of the SARS-CoV pp1a/ab nsp7-10 region."";
RL   Biochem. J. 477:1009-1019(2020).
RN   [46]
RP   3D-STRUCTURE MODELING OF 3241-3540, AND CHARACTERIZATION (3C-LIKE
RP   PROTEINASE NSP5).
RX   PubMed=12746549; DOI=10.1126/science.1085658;
RA   Anand K., Ziebuhr J., Wadhwani P., Mesters J.R., Hilgenfeld R.;
RT   ""Coronavirus main proteinase (3CLpro) structure: basis for design of anti-
RT   SARS drugs."";
RL   Science 300:1763-1767(2003).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 4118-4230 (NON-STRUCTURAL PROTEIN
RP   9).
RC   STRAIN=Isolate Frankfurt-1;
RX   PubMed=12925794; DOI=10.1107/s0907444903016779;
RA   Campanacci V., Egloff M.-P., Longhi S., Ferron F., Rancurel C.,
RA   Salomoni A., Durousseau C., Tocque F., Bremond N., Dobbe J.C.,
RA   Snijder E.J., Canard B., Cambillau C.;
RT   ""Structural genomics of the SARS coronavirus: cloning, expression,
RT   crystallization and preliminary crystallographic study of the Nsp9
RT   protein."";
RL   Acta Crystallogr. D 59:1628-1631(2003).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 4118-4230.
RX   PubMed=15007178; DOI=10.1073/pnas.0307877101;
RA   Egloff M.-P., Ferron F., Campanacci V., Longhi S., Rancurel C.,
RA   Dutartre H., Snijder E.J., Gorbalenya A.E., Cambillau C., Canard B.;
RT   ""The severe acute respiratory syndrome-coronavirus replicative protein nsp9
RT   is a single-stranded RNA-binding subunit unique in the RNA virus world."";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:3792-3796(2004).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 4107-4230.
RX   PubMed=14962394; DOI=10.1016/j.str.2004.01.016;
RA   Sutton G., Fry E., Carter L., Sainsbury S., Walter T., Nettleship J.,
RA   Berrow N., Owens R., Gilbert R., Davidson A., Siddell S., Poon L.L.M.,
RA   Diprose J., Alderton D., Walsh M., Grimes J.M., Stuart D.I.;
RT   ""The nsp9 replicase protein of SARS-coronavirus, structure and functional
RT   insights."";
RL   Structure 12:341-353(2004).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 3837-4117 AND 3920-4117,
RP   INTERACTION WITH NON-STRUCTURAL PROTEIN 7 (NON-STRUCTURAL PROTEIN 8), AND
RP   INTERACTION WITH NON-STRUCTURAL PROTEIN 8 (NON-STRUCTURAL PROTEIN 7).
RX   PubMed=16228002; DOI=10.1038/nsmb999;
RA   Zhai Y., Sun F., Li X., Pang H., Xu X., Bartlam M., Rao Z.;
RT   ""Insights into SARS-CoV transcription and replication from the structure of
RT   the nsp7-nsp8 hexadecamer."";
RL   Nat. Struct. Mol. Biol. 12:980-986(2005).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 1002-1176.
RX   PubMed=16271890; DOI=10.1016/j.str.2005.07.022;
RA   Saikatendu K.S., Joseph J.S., Subramanian V., Clayton T., Griffith M.,
RA   Moy K., Velasquez J., Neuman B.W., Buchmeier M.J., Stevens R.C., Kuhn P.;
RT   ""Structural basis of severe acute respiratory syndrome coronavirus ADP-
RT   ribose-1''-phosphate dephosphorylation by a conserved domain of nsP3."";
RL   Structure 13:1665-1675(2005).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 1541-1854.
RX   PubMed=16581910; DOI=10.1073/pnas.0510851103;
RA   Ratia K., Saikatendu K.S., Santarsiero B.D., Barretto N., Baker S.C.,
RA   Stevens R.C., Mesecar A.D.;
RT   ""Severe acute respiratory syndrome coronavirus papain-like protease:
RT   structure of a viral deubiquitinating enzyme."";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:5717-5722(2006).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 4240-4362.
RC   STRAIN=Isolate Tor2;
RX   PubMed=16873246; DOI=10.1128/jvi.00467-06;
RA   Joseph J.S., Saikatendu K.S., Subramanian V., Neuman B.W., Brooun A.,
RA   Griffith M., Moy K., Yadav M.K., Velasquez J., Buchmeier M.J.,
RA   Stevens R.C., Kuhn P.;
RT   ""Crystal structure of nonstructural protein 10 from the severe acute
RT   respiratory syndrome coronavirus reveals a novel fold with two zinc-binding
RT   motifs."";
RL   J. Virol. 80:7894-7901(2006).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 4231-4378.
RX   PubMed=16873247; DOI=10.1128/jvi.00483-06;
RA   Su D., Lou Z., Sun F., Zhai Y., Yang H., Zhang R., Joachimiak A.,
RA   Zhang X.C., Bartlam M., Rao Z.;
RT   ""Dodecamer structure of severe acute respiratory syndrome coronavirus
RT   nonstructural protein nsp10."";
RL   J. Virol. 80:7902-7908(2006).
RN   [55]
RP   STRUCTURE BY NMR OF 13-127.
RX   PubMed=17202208; DOI=10.1128/jvi.01939-06;
RA   Almeida M.S., Johnson M.A., Herrmann T., Geralt M., Wuthrich K.;
RT   ""Novel beta-barrel fold in the nuclear magnetic resonance structure of the
RT   replicase nonstructural protein 1 from the severe acute respiratory
RT   syndrome coronavirus."";
RL   J. Virol. 81:3151-3161(2007).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3241-3546.
RG   RIKEN structural genomics initiative (RSGI);
RT   ""Crystal structure of Sars coronavirus main proteinase(3CLPRO)."";
RL   Submitted (JUL-2007) to the PDB data bank.
CC   -!- FUNCTION: [Isoform Replicase polyprotein 1a]: Multifunctional protein
CC       involved in the transcription and replication of viral RNAs. Contains
CC       the proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000305}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by interacting with the 40S ribosomal subunit. The nsp1-40S ribosome
CC       complex further induces an endonucleolytic cleavage near the 5'UTR of
CC       host mRNAs, targeting them for degradation. Viral mRNAs are not
CC       susceptible to nsp1-mediated endonucleolytic RNA cleavage thanks to the
CC       presence of a 5'-end leader sequence and are therefore protected from
CC       degradation. By suppressing host gene expression, nsp1 facilitates
CC       efficient viral gene expression in infected cells and evasion from host
CC       immune response (PubMed:23035226). May disrupt nuclear pore function by
CC       binding and displacing host NUP93 (PubMed:30943371).
CC       {ECO:0000269|PubMed:23035226, ECO:0000269|PubMed:30943371}.
CC   -!- FUNCTION: [Non-structural protein 2]: May play a role in the modulation
CC       of host cell survival signaling pathway by interacting with host PHB
CC       and PHB2 (PubMed:19640993). Indeed, these two proteins play a role in
CC       maintaining the functional integrity of the mitochondria and protecting
CC       cells from various stresses (PubMed:19640993).
CC       {ECO:0000269|PubMed:19640993}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. In addition,
CC       PL-PRO possesses a deubiquitinating/deISGylating activity and processes
CC       both 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:17692280). Plays a role in host membrane
CC       rearrangement that leads to creation of cytoplasmic double-membrane
CC       vesicles (DMV) necessary for viral replication (PubMed:23943763). Nsp3,
CC       nsp4 and nsp6 together are sufficient to form DMV (PubMed:23943763,
CC       PubMed:24410069). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:19369340, PubMed:24622840).
CC       Prevents also host NF-kappa-B signaling (PubMed:19369340,
CC       PubMed:24622840). {ECO:0000269|PubMed:16271890,
CC       ECO:0000269|PubMed:17692280, ECO:0000269|PubMed:19369340,
CC       ECO:0000269|PubMed:23943763, ECO:0000269|PubMed:24622840,
CC       ECO:0000303|PubMed:24410069}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in host membrane
CC       rearrangement that leads to creation of cytoplasmic double-membrane
CC       vesicles (DMV) necessary for viral replication (PubMed:23943763,
CC       PubMed:24410069). Alone appears incapable to induce membrane curvature,
CC       but together with nsp3 is able to induce paired membranes
CC       (PubMed:23943763). Nsp3, nsp4 and nsp6 together are sufficient to form
CC       DMV (PubMed:23943763, PubMed:24410069). {ECO:0000269|PubMed:23943763,
CC       ECO:0000303|PubMed:24410069}.
CC   -!- FUNCTION: [3C-like proteinase nsp5]: Cleaves the C-terminus of
CC       replicase polyprotein at 11 sites. Recognizes substrates containing the
CC       core sequence [ILMVF]-Q-|-[SGACN]. Also able to bind an ADP-ribose-1''-
CC       phosphate (ADRP). May cleave host ATP6V1G1 thereby modifying host
CC       vacuoles intracellular pH. {ECO:0000255|PROSITE-ProRule:PRU00772,
CC       ECO:0000269|PubMed:16226257}.
CC   -!- FUNCTION: [Non-structural protein 6]: Plays a role in host membrane
CC       rearrangement that leads to creation of cytoplasmic double-membrane
CC       vesicles (DMV) necessary for viral replication (PubMed:23943763). Nsp3,
CC       nsp4 and nsp6 together are sufficient to form DMV (PubMed:23943763,
CC       PubMed:24410069). Plays a role in the initial induction of
CC       autophagosomes from host endoplasmic reticulum. Later, limits the
CC       expansion of these phagosomes that are no longer able to deliver viral
CC       components to lysosomes (PubMed:24991833).
CC       {ECO:0000269|PubMed:23943763, ECO:0000269|PubMed:24991833,
CC       ECO:0000303|PubMed:24410069}.
CC   -!- FUNCTION: [Non-structural protein 7]: Forms a hexadecamer with nsp8 (8
CC       subunits of each) that may participate in viral replication by acting
CC       as a primase. Alternatively, may synthesize substantially longer
CC       products than oligonucleotide primers. {ECO:0000269|PubMed:22039154}.
CC   -!- FUNCTION: [Non-structural protein 8]: Forms a hexadecamer with nsp7 (8
CC       subunits of each) that may participate in viral replication by acting
CC       as a primase. Alternatively, may synthesize substantially longer
CC       products than oligonucleotide primers. {ECO:0000269|PubMed:22039154}.
CC   -!- FUNCTION: [RNA-capping enzyme subunit nsp9]: Catalytic subunit of viral
CC       RNA capping enzyme which catalyzes the RNA guanylyltransferase reaction
CC       for genomic and sub-genomic RNAs. The kinase-like NiRAN domain of NSP12
CC       transfers RNA to the amino terminus of NSP9, forming a covalent RNA-
CC       protein intermediate. Subsequently, the NiRAN domain transfers RNA to
CC       GDP, forming the core cap structure GpppA-RNA. The NSP14 and NSP16
CC       methyltransferases then add methyl groups to form functional cap
CC       structures. {ECO:0000250|UniProtKB:P0DTC1,
CC       ECO:0000269|PubMed:19153232}.
CC   -!- FUNCTION: [Non-structural protein 10]: Plays a pivotal role in viral
CC       transcription by stimulating both nsp14 3'-5' exoribonuclease and nsp16
CC       2'-O-methyltransferase activities. Therefore plays an essential role in
CC       viral mRNAs cap methylation. {ECO:0000269|PubMed:22635272}.
CC   -!- CATALYTIC ACTIVITY: [3C-like proteinase nsp5]:
CC       Reaction=TSAVLQ-|-SGFRK-NH2 and SGVTFQ-|-GKFKK the two peptides
CC         corresponding to the two self-cleavage sites of the SARS 3C-like
CC         proteinase are the two most reactive peptide substrates. The enzyme
CC         exhibits a strong preference for substrates containing Gln at P1
CC         position and Leu at P2 position.; EC=3.4.22.69;
CC         Evidence={ECO:0000269|PubMed:12917450, ECO:0000269|PubMed:14561748};
CC   -!- CATALYTIC ACTIVITY: [Papain-like protease nsp3]:
CC       Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide
CC         and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-
CC         residue protein attached to proteins as an intracellular targeting
CC         signal).; EC=3.4.19.12; Evidence={ECO:0000269|PubMed:12917450,
CC         ECO:0000269|PubMed:17692280};
CC   -!- CATALYTIC ACTIVITY: [RNA-capping enzyme subunit nsp9]:
CC       Reaction=a 5'-end diphospho-ribonuc",52854
GAAATC AAATCA AATCAA ATCAAG TCAAGG CAAGGA AAGGAT AGGATG GGATGC GATGCT ATGCTA TGCTAC GCTACT CTACTC TACTCC ACTCCT CTCCTT TCCTTC CCTTCA CTTCAG TTCAGA TCAGAT CAGATT AGATTT GATTTT ATTTTG TTTTGT TTTGTT TTGTTC TGTTCG GTTCGC TTCGCG TCGCGC CGCGCT GCGCTA CGCTAC GCTACT CTACTG TACTGC ACTGCA CTGCAA TGCAAC GCAACG CAACGA AACGAT ACGATA CGATAC GATACC ATACCG TACCGA ACCGAT CCGATA CGATAC GATACA ATACAA TACAAG ACAAGC CAAGCC AAGCCT AGCCTC GCCTCA CCTCAC CTCACT TCACTC CACTCC ACTCCC CTCCCT TCCCTT CCCTTT CCTTTC CTTTCG TTTCGG TTCGGA TCGGAT CGGATG GGATGG GATGGC ATGGCT TGGCTT GGCTTA GCTTAT CTTATT TTATTG TATTGT ATTGTT TTGTTG TGTTGG GTTGGC TTGGCG TGGCGT GGCGTT GCGTTG CGTTGC GTTGCA TTGCAC TGCACT GCACTT CACTTC ACTTCT CTTCTT TTCTTG TCTTGC CTTGCT TTGCTG TGCTGT GCTGTT CTGTTT TGTTTT GTTTTT TTTTTC TTTTCA TTTCAG TTCAGA TCAGAG CAGAGC AGAGCG GAGCGC AGCGCT GCGCTT CGCTTC GCTTCC CTTCCA TTCCAA TCCAAA CCAAAA CAAAAT AAAATC AAATCA AATCAT ATCATA TCATAA CATAAC ATAACT TAACTC AACTCT ACTCTC CTCTCA TCTCAA CTCAAA TCAAAA CAAAAA AAAAAG,1,142,GAAA AAAT AATC ATCA TCAA CAAG AAGG AGGA GGAT GATG ATGC TGCT GCTA CTAC TACT ACTC CTCC TCCT CCTT CTTC TTCA TCAG CAGA AGAT GATT ATTT TTTT TTTG TTGT TGTT GTTC TTCG TCGC CGCG GCGC CGCT GCTA CTAC TACT ACTG CTGC TGCA GCAA CAAC AACG ACGA CGAT GATA ATAC TACC ACCG CCGA CGAT GATA ATAC TACA ACAA CAAG AAGC AGCC GCCT CCTC CTCA TCAC CACT ACTC CTCC TCCC CCCT CCTT CTTT TTTC TTCG TCGG CGGA GGAT GATG ATGG TGGC GGCT GCTT CTTA TTAT TATT ATTG TTGT TGTT GTTG TTGG TGGC GGCG GCGT CGTT GTTG TTGC TGCA GCAC CACT ACTT CTTC TTCT TCTT CTTG TTGC TGCT GCTG CTGT TGTT GTTT TTTT TTTT TTTC TTCA TCAG CAGA AGAG GAGC AGCG GCGC CGCT GCTT CTTC TTCC TCCA CCAA CAAA AAAA AAAT AATC ATCA TCAT CATA ATAA TAAC AACT ACTC CTCT TCTC CTCA TCAA CAAA AAAA AAAA AAAG,GAAAT AAATC AATCA ATCAA TCAAG CAAGG AAGGA AGGAT GGATG GATGC ATGCT TGCTA GCTAC CTACT TACTC ACTCC CTCCT TCCTT CCTTC CTTCA TTCAG TCAGA CAGAT AGATT GATTT ATTTT TTTTG TTTGT TTGTT TGTTC GTTCG TTCGC TCGCG CGCGC GCGCT CGCTA GCTAC CTACT TACTG ACTGC CTGCA TGCAA GCAAC CAACG AACGA ACGAT CGATA GATAC ATACC TACCG ACCGA CCGAT CGATA GATAC ATACA TACAA ACAAG CAAGC AAGCC AGCCT GCCTC CCTCA CTCAC TCACT CACTC ACTCC CTCCC TCCCT CCCTT CCTTT CTTTC TTTCG TTCGG TCGGA CGGAT GGATG GATGG ATGGC TGGCT GGCTT GCTTA CTTAT TTATT TATTG ATTGT TTGTT TGTTG GTTGG TTGGC TGGCG GGCGT GCGTT CGTTG GTTGC TTGCA TGCAC GCACT CACTT ACTTC CTTCT TTCTT TCTTG CTTGC TTGCT TGCTG GCTGT CTGTT TGTTT GTTTT TTTTT TTTTC TTTCA TTCAG TCAGA CAGAG AGAGC GAGCG AGCGC GCGCT CGCTT GCTTC CTTCC TTCCA TCCAA CCAAA CAAAA AAAAT AAATC AATCA ATCAT TCATA CATAA ATAAC TAACT AACTC ACTCT CTCTC TCTCA CTCAA TCAAA CAAAA AAAAA AAAAG,GAAATC AAATCA AATCAA ATCAAG TCAAGG CAAGGA AAGGAT AGGATG GGATGC GATGCT ATGCTA TGCTAC GCTACT CTACTC TACTCC ACTCCT CTCCTT TCCTTC CCTTCA CTTCAG TTCAGA TCAGAT CAGATT AGATTT GATTTT ATTTTG TTTTGT TTTGTT TTGTTC TGTTCG GTTCGC TTCGCG TCGCGC CGCGCT GCGCTA CGCTAC GCTACT CTACTG TACTGC ACTGCA CTGCAA TGCAAC GCAACG CAACGA AACGAT ACGATA CGATAC GATACC ATACCG TACCGA ACCGAT CCGATA CGATAC GATACA ATACAA TACAAG ACAAGC CAAGCC AAGCCT AGCCTC GCCTCA CCTCAC CTCACT TCACTC CACTCC ACTCCC CTCCCT TCCCTT CCCTTT CCTTTC CTTTCG TTTCGG TTCGGA TCGGAT CGGATG GGATGG GATGGC ATGGCT TGGCTT GGCTTA GCTTAT CTTATT TTATTG TATTGT ATTGTT TTGTTG TGTTGG GTTGGC TTGGCG TGGCGT GGCGTT GCGTTG CGTTGC GTTGCA TTGCAC TGCACT GCACTT CACTTC ACTTCT CTTCTT TTCTTG TCTTGC CTTGCT TTGCTG TGCTGT GCTGTT CTGTTT TGTTTT GTTTTT TTTTTC TTTTCA TTTCAG TTCAGA TCAGAG CAGAGC AGAGCG GAGCGC AGCGCT GCGCTT CGCTTC GCTTCC CTTCCA TTCCAA TCCAAA CCAAAA CAAAAT AAAATC AAATCA AATCAT ATCATA TCATAA CATAAC ATAACT TAACTC AACTCT ACTCTC CTCTCA TCTCAA CTCAAA TCAAAA CAAAAA AAAAAG,GAAATCA AAATCAA AATCAAG ATCAAGG TCAAGGA CAAGGAT AAGGATG AGGATGC GGATGCT GATGCTA ATGCTAC TGCTACT GCTACTC CTACTCC TACTCCT ACTCCTT CTCCTTC TCCTTCA CCTTCAG CTTCAGA TTCAGAT TCAGATT CAGATTT AGATTTT GATTTTG ATTTTGT TTTTGTT TTTGTTC TTGTTCG TGTTCGC GTTCGCG TTCGCGC TCGCGCT CGCGCTA GCGCTAC CGCTACT GCTACTG CTACTGC TACTGCA ACTGCAA CTGCAAC TGCAACG GCAACGA CAACGAT AACGATA ACGATAC CGATACC GATACCG ATACCGA TACCGAT ACCGATA CCGATAC CGATACA GATACAA ATACAAG TACAAGC ACAAGCC CAAGCCT AAGCCTC AGCCTCA GCCTCAC CCTCACT CTCACTC TCACTCC CACTCCC ACTCCCT CTCCCTT TCCCTTT CCCTTTC CCTTTCG CTTTCGG TTTCGGA TTCGGAT TCGGATG CGGATGG GGATGGC GATGGCT ATGGCTT TGGCTTA GGCTTAT GCTTATT CTTATTG TTATTGT TATTGTT ATTGTTG TTGTTGG TGTTGGC GTTGGCG TTGGCGT TGGCGTT GGCGTTG GCGTTGC CGTTGCA GTTGCAC TTGCACT TGCACTT GCACTTC CACTTCT ACTTCTT CTTCTTG TTCTTGC TCTTGCT CTTGCTG TTGCTGT TGCTGTT GCTGTTT CTGTTTT TGTTTTT GTTTTTC TTTTTCA TTTTCAG TTTCAGA TTCAGAG TCAGAGC CAGAGCG AGAGCGC GAGCGCT AGCGCTT GCGCTTC CGCTTCC GCTTCCA CTTCCAA TTCCAAA TCCAAAA CCAAAAT CAAAATC AAAATCA AAATCAT AATCATA ATCATAA TCATAAC CATAACT ATAACTC TAACTCT AACTCTC ACTCTCA CTCTCAA TCTCAAA CTCAAAA TCAAAAA CAAAAAG,"ID   AP3A_SARS2              Reviewed;         275 AA.
AC   P0DTC3;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 25.
DE   RecName: Full=ORF3a protein;
DE            Short=ORF3a;
DE   AltName: Full=Accessory protein 3a;
DE   AltName: Full=Protein 3a;
DE   AltName: Full=Protein U274;
DE   AltName: Full=Protein X1;
GN   ORFNames=3a;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   SUBCELLULAR LOCATION.
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [3]
RP   FUNCTION.
RX   PubMed=33157038; DOI=10.1016/j.cell.2020.10.039;
RA   Ghosh S., Dellibovi-Ragheb T.A., Kerviel A., Pak E., Qiu Q., Fisher M.,
RA   Takvorian P.M., Bleck C., Hsu V.W., Fehr A.R., Perlman S., Achar S.R.,
RA   Straus M.R., Whittaker G.R., de Haan C.A.M., Kehrl J., Altan-Bonnet G.,
RA   Altan-Bonnet N.;
RT   ""beta-Coronaviruses Use Lysosomes for Egress Instead of the Biosynthetic
RT   Secretory Pathway."";
RL   Cell 183:1520-1535(2020).
RN   [4]
RP   FUNCTION, INTERACTION WITH HOST VPS39, AND SUBCELLULAR LOCATION.
RX   PubMed=33422265; DOI=10.1016/j.devcel.2020.12.010;
RA   Miao G., Zhao H., Li Y., Ji M., Chen Y., Shi Y., Bi Y., Wang P., Zhang H.;
RT   ""ORF3a of the COVID-19 virus SARS-CoV-2 blocks HOPS complex-mediated
RT   assembly of the SNARE complex required for autolysosome formation."";
RL   Dev. Cell 56:427-442(2020).
RN   [5]
RP   FUNCTION, INTERACTION WITH HOST HMGB1 AND HOST HMOX1, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=35239449; DOI=10.1080/15548627.2022.2039992;
RA   Zhang X., Yang Z., Pan T., Long X., Sun Q., Wang P.H., Li X., Kuang E.;
RT   ""SARS-CoV-2 ORF3a induces RETREG1/FAM134B-dependent reticulophagy and
RT   triggers sequential ER stress and inflammatory responses during SARS-CoV-2
RT   infection."";
RL   Autophagy 0:0-0(2022).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.1 ANGSTROMS), FUNCTION, SUBUNIT,
RP   MUTAGENESIS OF 1-MET--LEU-41; 57-GLN-SER-58; GLN-57 AND GLN-116, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=34158638; DOI=10.1038/s41594-021-00619-0;
RA   Kern D.M., Sorum B., Mali S.S., Hoel C.M., Sridharan S., Remis J.P.,
RA   Toso D.B., Kotecha A., Bautista D.M., Brohawn S.G.;
RT   ""Cryo-EM structure of SARS-CoV-2 ORF3a in lipid nanodiscs."";
RL   Nat. Struct. Mol. Biol. 28:573-582(2021).
CC   -!- FUNCTION: Plays a role in viral egress via lysosomal trafficking
CC       (PubMed:33157038, PubMed:33422265). Forms homotetrameric ion channels
CC       (viroporins) localized at endosomes and lysosomes, that may induce
CC       deacidification of lysosomes, allowing safe egress of virions via
CC       lysosomal trafficking (PubMed:33157038, PubMed:33422265,
CC       PubMed:34158638). Also blocks autolysosome formation by binding and
CC       sequestering the host component VPS39 for homotypic fusion and protein
CC       sorting (HOPS) on late endosomes (PubMed:33422265). This prevents
CC       fusion of autophagosomes with lysosomes, disrupting autophagy and
CC       facilitating virus egress (PubMed:33422265). Induces host
CC       RETREG1/FAM134B-dependent reticulophagy by interacting with host HMGB1
CC       and enhancing the association between HMGB1 and host BECN1
CC       (PubMed:35239449). This induces endoplasmic reticulum stress and
CC       inflammatory responses and facilitates viral infection
CC       (PubMed:35239449). {ECO:0000269|PubMed:33157038,
CC       ECO:0000269|PubMed:33422265, ECO:0000269|PubMed:34158638,
CC       ECO:0000269|PubMed:35239449}.
CC   -!- SUBUNIT: Homodimer (PubMed:34158638), a subset forms homotetramer of
CC       two homodimers linked non covalently (PubMed:34158638). Interacts with
CC       M, S and E proteins. Also interacts with the accessory protein 7a (By
CC       similarity). Interacts with host VPS39, sequestering it on late
CC       endosomes (PubMed:33422265). Interacts with host HMGB1; the interaction
CC       enhances the association between HMGB1 and host BECN1, promoting
CC       reticulophagy (PubMed:35239449). Interacts with HMOX1; the interaction
CC       promotes ORF3A-induced autophagy but is unlikely to be involved in
CC       ORF3A-mediated induction of reticulophagy (PubMed:35239449).
CC       {ECO:0000250|UniProtKB:P59632, ECO:0000269|PubMed:33422265,
CC       ECO:0000269|PubMed:34158638, ECO:0000269|PubMed:35239449}.
CC   -!- INTERACTION:
CC       P0DTC3; P0DTC3: 3a; NbExp=4; IntAct=EBI-25475894, EBI-25475894;
CC       P0DTC3; P0DTD8: 7b; NbExp=3; IntAct=EBI-25475894, EBI-25475914;
CC       P0DTC3; Q9Y673: ALG5; Xeno; NbExp=4; IntAct=EBI-25475894, EBI-11725055;
CC       P0DTC3; Q01518: CAP1; Xeno; NbExp=3; IntAct=EBI-25475894, EBI-2808398;
CC       P0DTC3; P09601: HMOX1; Xeno; NbExp=4; IntAct=EBI-25475894, EBI-2806151;
CC       P0DTC3; Q12846: STX4; Xeno; NbExp=4; IntAct=EBI-25475894, EBI-744942;
CC       P0DTC3; Q8NBJ7: SUMF2; Xeno; NbExp=3; IntAct=EBI-25475894, EBI-723091;
CC       P0DTC3; Q9UH99: SUN2; Xeno; NbExp=3; IntAct=EBI-25475894, EBI-1044964;
CC       P0DTC3; Q9P2Y5: UVRAG; Xeno; NbExp=6; IntAct=EBI-25475894, EBI-2952704;
CC       P0DTC3; P51809: VAMP7; Xeno; NbExp=4; IntAct=EBI-25475894, EBI-1052205;
CC       P0DTC3; Q96JC1: VPS39; Xeno; NbExp=19; IntAct=EBI-25475894, EBI-1050197;
CC       P0DTC3; P49754: VPS41; Xeno; NbExp=4; IntAct=EBI-25475894, EBI-2130459;
CC       P0DTC3; Q8NAF0: ZNF579; Xeno; NbExp=2; IntAct=EBI-25475894, EBI-6164383;
CC   -!- SUBCELLULAR LOCATION: Virion {ECO:0000250|UniProtKB:P59632}. Host cell
CC       membrane {ECO:0000250|UniProtKB:P59632, ECO:0000269|PubMed:33060197,
CC       ECO:0000269|PubMed:34158638}; Multi-pass membrane protein
CC       {ECO:0000250|UniProtKB:P59632, ECO:0000269|PubMed:34158638}. Host
CC       endoplasmic reticulum membrane {ECO:0000269|PubMed:35239449}; Multi-
CC       pass membrane protein {ECO:0000269|PubMed:34158638}. Secreted
CC       {ECO:0000250|UniProtKB:P59632}. Host cytoplasm
CC       {ECO:0000250|UniProtKB:P59632, ECO:0000269|PubMed:33060197}. Host
CC       endosome {ECO:0000269|PubMed:33060197, ECO:0000269|PubMed:33422265}.
CC       Host lysosome {ECO:0000269|PubMed:33422265}. Note=The cell surface
CC       expressed protein can undergo endocytosis. The protein is secreted in
CC       association with membranous structures. {ECO:0000250|UniProtKB:P59632}.
CC   -!- DOMAIN: The second or the third transmembrane region are responsible
CC       for Golgi localization. {ECO:0000250|UniProtKB:P59632}.
CC   -!- PTM: Exists in both O-glycosylated and non-glycosylated forms. The
CC       glycosylated form is associated with the virion.
CC       {ECO:0000250|UniProtKB:P59632}.
CC   -!- POLYMORPHISM: Variant Omicron/BA.1 and BA.2 belong to a lineage first
CC       isolated in South Africa (November 2021). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/BQ.1.1 belongs to a lineage first
CC       isolated in Nigeria (November 2022). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/XBB.1.5 belongs to a lineage first
CC       isolated in United States (November 2022). It is the result of
CC       recombination between omicron BJ.1 and BM.1.1. Moreover XBB.1.5 do not
CC       express ORF8. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43417.1; -; Genomic_RNA.
DR   PDB; 6XDC; EM; 2.90 A; A/B=1-275.
DR   PDB; 7KJR; EM; 2.08 A; A/B=1-275.
DR   PDB; 8EQJ; EM; 3.00 A; A/B=1-275.
DR   PDB; 8EQT; EM; 3.40 A; A/B=1-275.
DR   PDB; 8EQU; EM; 2.80 A; A/B=1-275.
DR   PDB; 8T5P; X-ray; 2.50 A; G/H/I=36-40.
DR   PDB; 8T5Q; X-ray; 1.90 A; G/H/I=36-40.
DR   PDBsum; 6XDC; -.
DR   PDBsum; 7KJR; -.
DR   PDBsum; 8EQJ; -.
DR   PDBsum; 8EQT; -.
DR   PDBsum; 8EQU; -.
DR   PDBsum; 8T5P; -.
DR   PDBsum; 8T5Q; -.
DR   EMDB; EMD-22136; -.
DR   EMDB; EMD-22898; -.
DR   EMDB; EMD-28538; -.
DR   EMDB; EMD-28545; -.
DR   EMDB; EMD-28546; -.
DR   SMR; P0DTC3; -.
DR   BioGRID; 4383868; 1267.
DR   ComplexPortal; CPX-6098; SARS-CoV-2 3a complex.
DR   IntAct; P0DTC3; 468.
DR   MINT; P0DTC3; -.
DR   TCDB; 1.A.57.1.5; the human sars coronavirus viroporin (sars-vp) family.
DR   GlyGen; P0DTC3; 2 sites.
DR   iPTMnet; P0DTC3; -.
DR   DNASU; 43740569; -.
DR   KEGG; vg:43740569; -.
DR   AGR; RefSeq:YP_009724391; -.
DR   Reactome; R-HSA-9694322; Virion Assembly and Release.
DR   Reactome; R-HSA-9694614; Attachment and Entry.
DR   Reactome; R-HSA-9694635; Translation of Structural Proteins.
DR   Reactome; R-HSA-9694719; Maturation of protein 3a.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   Reactome; R-HSA-9733458; Induction of Cell-Cell Fusion.
DR   Reactome; R-HSA-9754560; SARS-CoV-2 modulates autophagy.
DR   Reactome; R-HSA-9755779; SARS-CoV-2 targets host intracellular signalling and regulatory pathways.
DR   PRO; PR:P0DTC3; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:DisProt.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0044165; C:host cell endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044174; C:host cell endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0044187; C:host cell lysosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:ComplexPortal.
DR   GO; GO:0055036; C:virion membrane; TAS:Reactome.
DR   GO; GO:0005891; C:voltage-gated calcium channel complex; IPI:ComplexPortal.
DR   GO; GO:0008076; C:voltage-gated potassium channel complex; IPI:ComplexPortal.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0140677; F:molecular function activator activity; IMP:DisProt.
DR   GO; GO:0005216; F:monoatomic ion channel activity; IEA:InterPro.
DR   GO; GO:0039520; P:induction by virus of host autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0140883; P:induction by virus of host reticulophagy; IDA:UniProtKB.
DR   GO; GO:0098662; P:inorganic cation transmembrane transport; IDA:ComplexPortal.
DR   CDD; cd21648; SARS-CoV-like_ORF3a; 1.
DR   DisProt; DP03003; -.
DR   InterPro; IPR046446; a/bCoV_VIROPORIN_3A-like_CD.
DR   InterPro; IPR046445; a/bCoV_VIROPORIN_3A-like_TM.
DR   InterPro; IPR024407; Protein_3a_bCoV.
DR   Pfam; PF11289; bCoV_viroporin; 1.
DR   PROSITE; PS51967; COV_VIROPORIN_3A_CD; 1.
DR   PROSITE; PS51966; COV_VIROPORIN_3A_TM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activation of host autophagy by virus; Glycoprotein;
KW   Host cell membrane; Host cytoplasm; Host endoplasmic reticulum;
KW   Host endosome; Host lysosome; Host membrane; Host-virus interaction;
KW   Ion channel; Ion transport; Membrane; Reference proteome; Secreted;
KW   Transmembrane; Transmembrane helix; Transport; Viral ion channel; Virion.
FT   CHAIN           1..275
FT                   /note=""ORF3a protein""
FT                   /id=""PRO_0000449650""
FT   TOPO_DOM        1..42
FT                   /note=""Extracellular""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   TRANSMEM        43..61
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   TOPO_DOM        62..67
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   TRANSMEM        68..93
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   TOPO_DOM        94..101
FT                   /note=""Extracellular""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   TRANSMEM        102..126
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   TOPO_DOM        127..275
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   DOMAIN          33..141
FT                   /note=""CoV 3a-like viroporin TM""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01311""
FT   DOMAIN          145..237
FT                   /note=""CoV 3a-like viroporin CD""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01312""
FT   REGION          1..39
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000305|PubMed:35108439""
FT   REGION          239..275
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000305|PubMed:35108439""
FT   SITE            133
FT                   /note=""Involved in polymerization""
FT                   /evidence=""ECO:0000250|UniProtKB:P59632""
FT   CARBOHYD        32
FT                   /note=""O-linked (GalNAc...) threonine; by host""
FT                   /evidence=""ECO:0000250|UniProtKB:P59632""
FT   CARBOHYD        34
FT                   /note=""O-linked (GalNAc...) threonine; by host""
FT                   /evidence=""ECO:0000255""
FT   VARIANT         26
FT                   /note=""S -> L (in strain: Delta/B.1.617.2 and
FT                   Kappa/B.1.617.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         42
FT                   /note=""P -> L (in strain: Iota/B.1.526)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         57
FT                   /note=""Q -> H (in strain: Beta/B.1.351, Epsilon/B.1.429,
FT                   Iota/B.1.526 and Mu/B.1.621)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         171
FT                   /note=""S -> L (in strain: Beta/B.1.351)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         223
FT                   /note=""T -> I (in strain: Omicron/BA.2, Omicron/BA.2.12.1,
FT                   Omicron/BA.2.75, Omicron/BA.4, Omicron/BA.5,
FT                   Omicron/BQ.1.1, Omicron/XBB.1.5, Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         253
FT                   /note=""S -> P (in strain: Gamma/P.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         257
FT                   /note=""Missing (in strain: Mu/B.1.621)""
FT                   /evidence=""ECO:0000305""
FT   MUTAGEN         1..41
FT                   /note=""Missing: Partial loss of Ca(2+) and NMDG(+)
FT                   permeability. Increased localization at host plasma
FT                   membrane.""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   MUTAGEN         57..58
FT                   /note=""QS->EL: Partial loss of Ca(2+) and NMDG(+)
FT                   permeability.""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   MUTAGEN         57
FT                   /note=""Q->H: No effect on ion permeability.""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   MUTAGEN         116
FT                   /note=""Q->L: Partial loss of Ca(2+) and NMDG(+)
FT                   permeability.""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   HELIX           44..60
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   HELIX           68..99
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   HELIX           103..105
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   HELIX           106..133
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   HELIX           137..140
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   STRAND          144..150
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   STRAND          155..160
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   STRAND          165..172
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   STRAND          183..186
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   STRAND          189..192
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   STRAND          199..204
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   STRAND          209..218
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   HELIX           220..223
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   STRAND          228..235
FT                   /evidence=""ECO:0007829|PDB:7KJR""
SQ   SEQUENCE   275 AA;  31123 MW;  4688E6D477E031C4 CRC64;
     MDLFMRIFTI GTVTLKQGEI KDATPSDFVR ATATIPIQAS LPFGWLIVGV ALLAVFQSAS
     KIITLKKRWQ LALSKGVHFV CNLLLLFVTV YSHLLLVAAG LEAPFLYLYA LVYFLQSINF
     VRIIMRLWLC WKCRSKNPLL YDANYFLCWH TNCYDYCIPY NSVTSSIVIT SGDGTTSPIS
     EHDYQIGGYT EKWESGVKDC VVLHSYFTSD YYQLYSTQLS TDTGVEHVTF FIYNKIVDEP
     EEHVQIHTID GSSGVVNPVM EPIYDEPTTT TSVPL
//
",28891
GGCCAG GCCAGG CCAGGA CAGGAC AGGACC GGACCT GACCTG ACCTGG CCTGGC CTGGCC TGGCCG GGCCGG GCCGGC CCGGCA CGGCAA GGCAAG GCAAGA CAAGAA AAGAAC AGAACT GAACTT AACTTC ACTTCT CTTCTA TTCTAC TCTACC CTACCG TACCGC ACCGCC CCGCCC CGCCCC GCCCCC CCCCCG CCCCGC CCCGCG CCGCGA CGCGAC GCGACA CGACAA GACAAG ACAAGG CAAGGC AAGGCT AGGCTG GGCTGC GCTGCT CTGCTG TGCTGC GCTGCC CTGCCG TGCCGC GCCGCC CCGCCA CGCCAA GCCAAG CCAAGT CAAGTA AAGTAC AGTACG GTACGC TACGCC ACGCCA CGCCAA GCCAAG CCAAGC CAAGCA AAGCAG AGCAGT GCAGTT CAGTTT AGTTTG GTTTGG TTTGGT TTGGTA TGGTAC GGTACG GTACGG TACGGT ACGGTG CGGTGA GGTGAA GTGAAC TGAACC GAACCT AACCTG ACCTGT CCTGTT CTGTTC TGTTCA GTTCAC TTCACC TCACCA CACCAT ACCATC CCATCG CATCGA ATCGAC TCGACG CGACGA GACGAG ACGAGC CGAGCT GAGCTG AGCTGT GCTGTT CTGTTC TGTTCG GTTCGG TTCGGT TCGGTG CGGTGG GGTGGC GTGGCT TGGCTG GGCTGG GCTGGA CTGGAC TGGACC GGACCA GACCAA ACCAAA CCAAAG CAAAGC AAAGCC AAGCCC AGCCCA GCCCAG CCCAGA CCAGAA CAGAAA AGAAAA GAAAAC AAAACC AAACCC AACCCA ACCCAT CCCATT CCATTT CATTTC ATTTCG TTTCGC TTCGCC TCGCCG CGCCGA GCCGAC,2,145,GGCC GCCA CCAG CAGG AGGA GGAC GACC ACCT CCTG CTGG TGGC GGCC GCCG CCGG CGGC GGCA GCAA CAAG AAGA AGAA GAAC AACT ACTT CTTC TTCT TCTA CTAC TACC ACCG CCGC CGCC GCCC CCCC CCCC CCCG CCGC CGCG GCGA CGAC GACA ACAA CAAG AAGG AGGC GGCT GCTG CTGC TGCT GCTG CTGC TGCC GCCG CCGC CGCC GCCA CCAA CAAG AAGT AGTA GTAC TACG ACGC CGCC GCCA CCAA CAAG AAGC AGCA GCAG CAGT AGTT GTTT TTTG TTGG TGGT GGTA GTAC TACG ACGG CGGT GGTG GTGA TGAA GAAC AACC ACCT CCTG CTGT TGTT GTTC TTCA TCAC CACC ACCA CCAT CATC ATCG TCGA CGAC GACG ACGA CGAG GAGC AGCT GCTG CTGT TGTT GTTC TTCG TCGG CGGT GGTG GTGG TGGC GGCT GCTG CTGG TGGA GGAC GACC ACCA CCAA CAAA AAAG AAGC AGCC GCCC CCCA CCAG CAGA AGAA GAAA AAAA AAAC AACC ACCC CCCA CCAT CATT ATTT TTTC TTCG TCGC CGCC GCCG CCGA CGAC,GGCCA GCCAG CCAGG CAGGA AGGAC GGACC GACCT ACCTG CCTGG CTGGC TGGCC GGCCG GCCGG CCGGC CGGCA GGCAA GCAAG CAAGA AAGAA AGAAC GAACT AACTT ACTTC CTTCT TTCTA TCTAC CTACC TACCG ACCGC CCGCC CGCCC GCCCC CCCCC CCCCG CCCGC CCGCG CGCGA GCGAC CGACA GACAA ACAAG CAAGG AAGGC AGGCT GGCTG GCTGC CTGCT TGCTG GCTGC CTGCC TGCCG GCCGC CCGCC CGCCA GCCAA CCAAG CAAGT AAGTA AGTAC GTACG TACGC ACGCC CGCCA GCCAA CCAAG CAAGC AAGCA AGCAG GCAGT CAGTT AGTTT GTTTG TTTGG TTGGT TGGTA GGTAC GTACG TACGG ACGGT CGGTG GGTGA GTGAA TGAAC GAACC AACCT ACCTG CCTGT CTGTT TGTTC GTTCA TTCAC TCACC CACCA ACCAT CCATC CATCG ATCGA TCGAC CGACG GACGA ACGAG CGAGC GAGCT AGCTG GCTGT CTGTT TGTTC GTTCG TTCGG TCGGT CGGTG GGTGG GTGGC TGGCT GGCTG GCTGG CTGGA TGGAC GGACC GACCA ACCAA CCAAA CAAAG AAAGC AAGCC AGCCC GCCCA CCCAG CCAGA CAGAA AGAAA GAAAA AAAAC AAACC AACCC ACCCA CCCAT CCATT CATTT ATTTC TTTCG TTCGC TCGCC CGCCG GCCGA CCGAC,GGCCAG GCCAGG CCAGGA CAGGAC AGGACC GGACCT GACCTG ACCTGG CCTGGC CTGGCC TGGCCG GGCCGG GCCGGC CCGGCA CGGCAA GGCAAG GCAAGA CAAGAA AAGAAC AGAACT GAACTT AACTTC ACTTCT CTTCTA TTCTAC TCTACC CTACCG TACCGC ACCGCC CCGCCC CGCCCC GCCCCC CCCCCG CCCCGC CCCGCG CCGCGA CGCGAC GCGACA CGACAA GACAAG ACAAGG CAAGGC AAGGCT AGGCTG GGCTGC GCTGCT CTGCTG TGCTGC GCTGCC CTGCCG TGCCGC GCCGCC CCGCCA CGCCAA GCCAAG CCAAGT CAAGTA AAGTAC AGTACG GTACGC TACGCC ACGCCA CGCCAA GCCAAG CCAAGC CAAGCA AAGCAG AGCAGT GCAGTT CAGTTT AGTTTG GTTTGG TTTGGT TTGGTA TGGTAC GGTACG GTACGG TACGGT ACGGTG CGGTGA GGTGAA GTGAAC TGAACC GAACCT AACCTG ACCTGT CCTGTT CTGTTC TGTTCA GTTCAC TTCACC TCACCA CACCAT ACCATC CCATCG CATCGA ATCGAC TCGACG CGACGA GACGAG ACGAGC CGAGCT GAGCTG AGCTGT GCTGTT CTGTTC TGTTCG GTTCGG TTCGGT TCGGTG CGGTGG GGTGGC GTGGCT TGGCTG GGCTGG GCTGGA CTGGAC TGGACC GGACCA GACCAA ACCAAA CCAAAG CAAAGC AAAGCC AAGCCC AGCCCA GCCCAG CCCAGA CCAGAA CAGAAA AGAAAA GAAAAC AAAACC AAACCC AACCCA ACCCAT CCCATT CCATTT CATTTC ATTTCG TTTCGC TTCGCC TCGCCG CGCCGA GCCGAC,GGCCAGG GCCAGGA CCAGGAC CAGGACC AGGACCT GGACCTG GACCTGG ACCTGGC CCTGGCC CTGGCCG TGGCCGG GGCCGGC GCCGGCA CCGGCAA CGGCAAG GGCAAGA GCAAGAA CAAGAAC AAGAACT AGAACTT GAACTTC AACTTCT ACTTCTA CTTCTAC TTCTACC TCTACCG CTACCGC TACCGCC ACCGCCC CCGCCCC CGCCCCC GCCCCCG CCCCCGC CCCCGCG CCCGCGA CCGCGAC CGCGACA GCGACAA CGACAAG GACAAGG ACAAGGC CAAGGCT AAGGCTG AGGCTGC GGCTGCT GCTGCTG CTGCTGC TGCTGCC GCTGCCG CTGCCGC TGCCGCC GCCGCCA CCGCCAA CGCCAAG GCCAAGT CCAAGTA CAAGTAC AAGTACG AGTACGC GTACGCC TACGCCA ACGCCAA CGCCAAG GCCAAGC CCAAGCA CAAGCAG AAGCAGT AGCAGTT GCAGTTT CAGTTTG AGTTTGG GTTTGGT TTTGGTA TTGGTAC TGGTACG GGTACGG GTACGGT TACGGTG ACGGTGA CGGTGAA GGTGAAC GTGAACC TGAACCT GAACCTG AACCTGT ACCTGTT CCTGTTC CTGTTCA TGTTCAC GTTCACC TTCACCA TCACCAT CACCATC ACCATCG CCATCGA CATCGAC ATCGACG TCGACGA CGACGAG GACGAGC ACGAGCT CGAGCTG GAGCTGT AGCTGTT GCTGTTC CTGTTCG TGTTCGG GTTCGGT TTCGGTG TCGGTGG CGGTGGC GGTGGCT GTGGCTG TGGCTGG GGCTGGA GCTGGAC CTGGACC TGGACCA GGACCAA GACCAAA ACCAAAG CCAAAGC CAAAGCC AAAGCCC AAGCCCA AGCCCAG GCCCAGA CCCAGAA CCAGAAA CAGAAAA AGAAAAC GAAAACC AAAACCC AAACCCA AACCCAT ACCCATT CCCATTT CCATTTC CATTTCG ATTTCGC TTTCGCC TTCGCCG TCGCCGA CGCCGAC,"ID   SUBI_ECOLI              Reviewed;         329 AA.
AC   P0AG78; P06997; Q2M8L3;
DT   01-APR-1988, integrated into UniProtKB/Swiss-Prot.
DT   20-DEC-2005, sequence version 1.
DT   05-FEB-2025, entry version 126.
DE   RecName: Full=Sulfate-binding protein;
DE   AltName: Full=Sulfate starvation-induced protein 2;
DE            Short=SSI2;
DE   Flags: Precursor;
GN   Name=sbp; OrderedLocusNames=b3917, JW3888;
OS   Escherichia coli (strain K12).
OC   Bacteria; Pseudomonadota; Gammaproteobacteria; Enterobacterales;
OC   Enterobacteriaceae; Escherichia.
OX   NCBI_TaxID=83333;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3158524; DOI=10.1111/j.1432-1033.1985.tb08934.x;
RA   Hellinga H.W., Evans P.R.;
RT   ""Nucleotide sequence and high-level expression of the major Escherichia
RT   coli phosphofructokinase."";
RL   Eur. J. Biochem. 149:363-373(1985).
RN   [2]
RP   SEQUENCE REVISION.
RA   Evans P.R.;
RL   Submitted (OCT-1986) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   SEQUENCE REVISION TO 152-164; 176-178 AND 201-203, AND MUTAGENESIS.
RX   PubMed=2002055; DOI=10.1016/s0021-9258(19)67775-6;
RA   Jacobson B.L., He J.J., Vermersch P.S., Lemon D.D., Quiocho F.A.;
RT   ""Engineered interdomain disulfide in the periplasmic receptor for sulfate
RT   transport reduces flexibility. Site-directed mutagenesis and ligand-binding
RT   studies."";
RL   J. Biol. Chem. 266:5220-5225(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   PubMed=8346018; DOI=10.1093/nar/21.15.3391;
RA   Plunkett G. III, Burland V., Daniels D.L., Blattner F.R.;
RT   ""Analysis of the Escherichia coli genome. III. DNA sequence of the region
RT   from 87.2 to 89.2 minutes."";
RL   Nucleic Acids Res. 21:3391-3398(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   PubMed=9278503; DOI=10.1126/science.277.5331.1453;
RA   Blattner F.R., Plunkett G. III, Bloch C.A., Perna N.T., Burland V.,
RA   Riley M., Collado-Vides J., Glasner J.D., Rode C.K., Mayhew G.F.,
RA   Gregor J., Davis N.W., Kirkpatrick H.A., Goeden M.A., Rose D.J., Mau B.,
RA   Shao Y.;
RT   ""The complete genome sequence of Escherichia coli K-12."";
RL   Science 277:1453-1462(1997).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RX   PubMed=16738553; DOI=10.1038/msb4100049;
RA   Hayashi K., Morooka N., Yamamoto Y., Fujita K., Isono K., Choi S.,
RA   Ohtsubo E., Baba T., Wanner B.L., Mori H., Horiuchi T.;
RT   ""Highly accurate genome sequences of Escherichia coli K-12 strains MG1655
RT   and W3110."";
RL   Mol. Syst. Biol. 2:E1-E5(2006).
RN   [7]
RP   PROTEIN SEQUENCE OF 20-31.
RC   STRAIN=K12 / EMG2;
RX   PubMed=9298646; DOI=10.1002/elps.1150180807;
RA   Link A.J., Robison K., Church G.M.;
RT   ""Comparing the predicted and observed properties of proteins encoded in the
RT   genome of Escherichia coli K-12."";
RL   Electrophoresis 18:1259-1313(1997).
RN   [8]
RP   PROTEIN SEQUENCE OF 20-29; 42-48; 256-263; 265-273 AND 277-282.
RC   STRAIN=K12 / MC4100 / ATCC 35695 / DSM 6574;
RX   PubMed=8774726; DOI=10.1111/j.1432-1033.1996.0773u.x;
RA   Quadroni M., Staudenmann W., Kertesz M.A., James P.;
RT   ""Analysis of global responses by protein and peptide fingerprinting of
RT   proteins isolated by two-dimensional gel electrophoresis. Application to
RT   the sulfate-starvation response of Escherichia coli."";
RL   Eur. J. Biochem. 239:773-781(1996).
CC   -!- FUNCTION: This protein specifically binds sulfate and is involved in
CC       its transmembrane transport.
CC   -!- SUBCELLULAR LOCATION: Periplasm.
CC   -!- INDUCTION: Repressed by sulfate or cysteine.
CC   -!- SIMILARITY: Belongs to the prokaryotic sulfate-binding protein family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X02519; CAA26357.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; L19201; AAB03049.1; -; Genomic_DNA.
DR   EMBL; U00096; AAC76899.1; -; Genomic_DNA.
DR   EMBL; AP009048; BAE77393.1; -; Genomic_DNA.
DR   PIR; S40860; BYEC.
DR   RefSeq; NP_418352.1; NC_000913.3.
DR   RefSeq; WP_001045689.1; NZ_SSUV01000029.1.
DR   AlphaFoldDB; P0AG78; -.
DR   SMR; P0AG78; -.
DR   BioGRID; 4261220; 42.
DR   ComplexPortal; CPX-4386; Sulfate/thiosulfate ABC transporter complex, sbp variant.
DR   DIP; DIP-35843N; -.
DR   IntAct; P0AG78; 11.
DR   STRING; 511145.b3917; -.
DR   TCDB; 3.A.1.6.1; the atp-binding cassette (abc) superfamily.
DR   PaxDb; 511145-b3917; -.
DR   EnsemblBacteria; AAC76899; AAC76899; b3917.
DR   GeneID; 93777981; -.
DR   GeneID; 948411; -.
DR   KEGG; ecj:JW3888; -.
DR   KEGG; eco:b3917; -.
DR   KEGG; ecoc:C3026_21175; -.
DR   PATRIC; fig|1411691.4.peg.2788; -.
DR   EchoBASE; EB0922; -.
DR   eggNOG; COG1613; Bacteria.
DR   HOGENOM; CLU_055615_0_1_6; -.
DR   InParanoid; P0AG78; -.
DR   OMA; DKHGTRK; -.
DR   OrthoDB; 9802127at2; -.
DR   PhylomeDB; P0AG78; -.
DR   BioCyc; EcoCyc:SBP-MONOMER; -.
DR   BioCyc; MetaCyc:SBP-MONOMER; -.
DR   PRO; PR:P0AG78; -.
DR   Proteomes; UP000000318; Chromosome.
DR   Proteomes; UP000000625; Chromosome.
DR   GO; GO:0035796; C:ATP-binding cassette (ABC) transporter complex, transmembrane substrate-binding subunit-containing; NAS:ComplexPortal.
DR   GO; GO:0016020; C:membrane; NAS:ComplexPortal.
DR   GO; GO:0030288; C:outer membrane-bounded periplasmic space; IDA:EcoCyc.
DR   GO; GO:0043199; F:sulfate binding; IDA:EcoCyc.
DR   GO; GO:1902358; P:sulfate transmembrane transport; NAS:ComplexPortal.
DR   GO; GO:0006790; P:sulfur compound metabolic process; IDA:EcoCyc.
DR   GO; GO:0015709; P:thiosulfate transport; NAS:ComplexPortal.
DR   CDD; cd01005; PBP2_CysP; 1.
DR   Gene3D; 3.40.190.10; Periplasmic binding protein-like II; 2.
DR   InterPro; IPR000957; Sulphate/thiosulphate-bd_CS.
DR   InterPro; IPR034408; Sulphate/thiosulphate_BS.
DR   InterPro; IPR005669; Thiosulph/SO4-bd.
DR   NCBIfam; TIGR00971; 3a0106s03; 1.
DR   PANTHER; PTHR30368; SULFATE-BINDING PROTEIN; 1.
DR   PANTHER; PTHR30368:SF2; SULFATE-BINDING PROTEIN; 1.
DR   Pfam; PF13531; SBP_bac_11; 1.
DR   SUPFAM; SSF53850; Periplasmic binding protein-like II; 1.
DR   PROSITE; PS00401; PROK_SULFATE_BIND_1; 1.
DR   PROSITE; PS00757; PROK_SULFATE_BIND_2; 1.
PE   1: Evidence at protein level;
KW   Direct protein sequencing; Periplasm; Reference proteome; Signal;
KW   Sulfate transport; Transport.
FT   SIGNAL          1..19
FT                   /evidence=""ECO:0000269|PubMed:8774726,
FT                   ECO:0000269|PubMed:9298646""
FT   CHAIN           20..329
FT                   /note=""Sulfate-binding protein""
FT                   /id=""PRO_0000031683""
FT   CONFLICT        185
FT                   /note=""V -> E (in Ref. 1; CAA26357)""
FT                   /evidence=""ECO:0000305""
SQ   SEQUENCE   329 AA;  36659 MW;  3353D36DE484C814 CRC64;
     MNKWGVGLTF LLAATSVMAK DIQLLNVSYD PTRELYEQYN KAFSAHWKQQ TGDNVVIRQS
     HGGSGKQATS VINGIEADVV TLALAYDVDA IAERGRIDKE WIKRLPDNSA PYTSTIVFLV
     RKGNPKQIHD WNDLIKPGVS VITPNPKSSG GARWNYLAAW GYALHHNNND QAKAQDFVRA
     LYKNVEVLDS GARGSTNTFV ERGIGDVLIA WENEALLAAN ELGKDKFEIV TPSESILAEP
     TVSVVDKVVE KKGTKEVAEA YLKYLYSPEG QEIAAKNYYR PRDAEVAKKY ENAFPKLKLF
     TIDEEFGGWT KAQKEHFANG GTFDQISKR
//
",24391
AATTGC ATTGCA TTGCAC TGCACT GCACTT CACTTT ACTTTT CTTTTG TTTTGA TTTGAA TTGAAT TGAATA GAATAT AATATG ATATGT TATGTC ATGTCT TGTCTC GTCTCT TCTCTC CTCTCA TCTCAG CTCAGC TCAGCC CAGCCT AGCCTT GCCTTT CCTTTT CTTTTC TTTTCT TTTCTT TTCTTA TCTTAT CTTATG TTATGG TATGGA ATGGAC TGGACC GGACCT GACCTT ACCTTG CCTTGA CTTGAA TTGAAG TGAAGG GAAGGA AAGGAA AGGAAA GGAAAA GAAAAC AAAACA AAACAG AACAGG ACAGGG CAGGGT AGGGTA GGGTAA GGTAAT GTAATT TAATTT AATTTC ATTTCA TTTCAA TTCAAA TCAAAA CAAAAA AAAAAT AAAATC AAATCT AATCTT ATCTTA TCTTAG CTTAGG TTAGGG TAGGGA AGGGAA GGGAAT GGAATT GAATTT AATTTG ATTTGT TTTGTG TTGTGT TGTGTT GTGTTT TGTTTA GTTTAA TTTAAG TTAAGA TAAGAA AAGAAT AGAATA GAATAT AATATT ATATTG TATTGA ATTGAT TTGATG TGATGG GATGGT ATGGTT TGGTTA GGTTAT GTTATT TTATTT TATTTT ATTTTA TTTTAA TTTAAA TTAAAA TAAAAT AAAATA AAATAT AATATA ATATAT TATATT ATATTC TATTCT ATTCTA TTCTAA TCTAAG CTAAGC TAAGCA AAGCAC AGCACA GCACAC CACACG ACACGC CACGCC ACGCCT CGCCTA GCCTAT CCTATT CTATTA TATTAA ATTAAT TTAATT TAATTT AATTTA ATTTAG TTTAGG TTAGGG TAGGGC AGGGCG GGGCGT,1,145,AAT CTTT T A ATATTTTGTG G TAC TTGTGCGC C T TGTGCGCAAA  GCATGCACAC GAA CACACACTCTA ACACTAA CTCT C CTTAATTTG GT TTTT AAT TGTT GGTTTTTGTG  TTTTGTGAGA CT  TGTGAGAAAA A G GAAATAT  AAAATATATA A A ATATATATAT T A TATATGGACT T CATGTGTT TG TTGTGTCC G GTGTCTCTCT T T TCTCTCTCTC  CTTCTCT TT  TCTCTTT TC C C CTCTCTCACA A T TCTCACAGG C CACAGAGCGC C AT TAGCATTCC C G GCGCCCCTT C CCCCTCTTTT T C CTCTTCT TT T T TTTTTTTTTT T T TTTTTTTCTC TTC TTTTCTCTCT T T TCTCTCTTTT G A CTCTTTTAA T TTTTATATAA  TATATGCATG G A ATATGTGGG T TGTGGGT GA A G GGGGAGACAC C G GAACCCC C AACCCCTTTTT C CCCCTCTTTT T A CTCTTTATG T TTTTGGA A T TGTGAGAAAA A GGAAAAGGGAAAGAGGGG G ATTCAGGGGAATAAC  GGAG GAAAT A G GGGAAAAAA TA A AAAAAAAAAA ATG AAAAAAACAC C A AAAACACACA  ACACAGA AG G C CACAGAGGGG  AGCACAGGGGGGG G GGGGGGTGGAT G GGGGTGTATA A G GTGTATAAAA GT  TACTTAATAT T A AAAATTT T A ATTAATTTTT T T TTTTTTTCTC C T TTTTCTCACA A TA GTCACAAGCG CACAAAAA ATTGTTTTAAAAAAT TA A AAAAAAAAAA A AAAA TCAT T T AAAATTTATC C A ATATCTCTCT  TCTCTCTT GGT C CTCTTTTATA A T TTTTATA G T TATAGAGGA AG ATAGAGGGGGGG G G GGGGAA G GGATGC CCA AAT GAGAAAATAT T T AAAATATTT A ATA CTTTTT ATT TTTTTTTGTG G T TTTTGTGTGT T T TGA AGTGTG TT  GTGTGTGTGT T T TGTGTT TTT T G GTGTTTTT TAT T TTTTTTTATATA T TTTTATAAAA AA  TTATTAAGAG CC AAGAGAGA ATTAGAGAAA G GAGAAAATAT T AGG AATTA A A ATGA TATAT T T TATATA ATT T A ATATTTTGG T TTTGACAGA TAATTGAGATAT T G GAGATGCCG AAA ATGTGGGG G T TGTGGGGTGT T G GAGGTGTTTT T G GTGTTTTATA A T TTTTAA GAT G A TATATTT T C ATTTTTT T T TTTTTTT T T TTTTTT ATA A T TTTTATAAAA A T TATAAAAAAA A A AAAAAAAAAA A A AAAAAAATAT TTA AAAATATATA A AATATG AT T T TATATATATA  ATAT T T TATATATTTT T A ATATTC TTC C T TTTG T T TCTCTCTAA C CTCTAAA A T TAAAGAG G AGGGAGCGC C A AGAGCGCACA A G GCGCACACTT C C CACACACACA A A ACACACACA GC C CA AGACGCG G A ACACGCGCGC C C CGCGCGG  AAC GGG GCCCCTCT TAT CCCCTCTATA ATTA TTATAT T A TAT CATTTT T A ATATTGC  AGA T TTTAACTTA T TATG AATAT T A AA TGGCCTT T A ATATTTTTTT T T TT TTTTATA A T TTATCTAGG T TATAGAGGG A AGAGGGGGGG G GTT GGGTTAC GGGCAA CG G G GCGCGCGT,AATAAATTGTG TTA ATATTTAAGG GC TGG TTTTGTGCGCACA A TTT TGCGCAC G GCGCACACACTAAAT C CACACACTTT T A ACACTCTTTTTTT T C CTCTTTTTG AT TAT ATTTTTTAATG G T TTTTTTTGTGAGA A TGA TTGTGAGAAAA A TTT TGAGAAAATAT T G GAGAAAATAATTA AG  AATATAT T A ATATATATATGG TTATATGT AATGTGTGTCTC TAT TGTGTGTCTCTCT  GTGTCTCTCTCTC  TA TCTCTCTCTCTT CG CGG TCTCTCTC AAG TCTCTCTCTGTCA A C AACTCCAGA AG TT TCTTAGCGC C C CACAGAGCGGGCC C A AGTCTGCCCCTCT CTTGCCCCT TCTT  CCCCTCTTTTTTT T CATTCTTTTTTTTTT AATTTTTTCTC C T TTTTTTTCTCTCT T T TTTTCCAGTT  AATCTCTTTTATA A C CTCTTTTATATAAGT T TTTTATATATGTG G T TAAAAATATGGTTAG A ATCGTTGG CTGA A T TGC TGC GACAC TTG GGGGAGACACCCC C G GAACCCCTCT T A ACACCCCTCTTTTGT CCCTCTT CATG G CATTCTTTT TGAGA A T TTTTGTGAGAAA T TGGAAAAGAG G G GAGAAAAGAGGG AT TAA AAATT A AA TAGGGGAGAAAA G T GGGGAGAATCAAA A G GATAAAAAAA A A AACT TAAAACAC C AAAAAACATTCA  CTAACACACAGAG G A ACACAT GGG  CT CATA AGGGGGGG G A AGGGGGGTGT T G GGGCCGGTGTATA A G GGT AGTAAA A G GTGTATAAAATAT T TC TATTATAATTTT  AAAATACAA CT AATTTTTTTCC T TTTTCTCACA  TTTCACAA TCATTAAAAA GTT CAAAAAAAAA A ATCAAT AAATCTTC AAAAAAAATT AAATATCAA ACG AAAATAAAT A ATATCAGC GCC GT T TCTCTCTTTTATA A C CTCTTTTATAGAG GAA TTTTATAGAGGGG G TGGCTAGAGGGGGGG G AAGGGGGGGA TTA GGGGGGAGAAAA TA  GGGGAGAAAATAT T G GAGAAAATTT T A AAAATATTTTTTT T A ATTTTTTGTG G T ATTTTATGTGTGT T TTTGTGTGTGTG G T TGTGTGTGTGTGT T G GTGTGTGTA CTT T T TGTCAGTTTTTATGT G GTGTTTTAA GA T TTTTTTTATAAAA A T TTGG TAAAAGTATAAATAAAAGGA A ATT AAGAGAGAAAA A A AGAGAGAAAATAT AGG GAGAA TTATACAG AAAATATATATAT T A ATATATATATTTT TCATAT CTTTGTG G A TTAGGTTGGA  TTCTATGAGATAT T T TGTGAGATATGG TG G GAGAT TGTGGTGC ATTTGTGG CCGT T T TGTGGGGTGTTTT T G GGGGTGTTTTATA A G GTGTTTTAAT T T TTTATATT TAT TTT T A CATTTTTTTT T T TTTTTTTTTTATA A T TTTTTTTATAAA T TTTTATAAAAAAA A TTAAAAAAAAAA  AATATAAAAATAT GGT AAAAAATATA A A AAAATATATATAGGT A ATATATATATATA A T TATATATAC TAT T A ATATGATTTAT TATATATTTTCTC C A ATATTTTCTCTCT T T TTTTCTCTGG TA TTG TAAA TTTTATCTATAAAT AG G T TAAAGT CGC C A AAC TAGCGCACA A A AGAGCGCAAC C G GCGCACACCA A C ATCACACACACAC C A ACACACACC ACG G CC GCACACGCGCGGAC A ACACGCGCGCCCC C C CGCGCGCCCCTCT T G GCGCCCCTCTATA  CCCCTCTATAT TT CTCTAAGCATTTT T T TATT ATTTTAA AATTTTAA GAA A T TTTTATAAAATAT GT  TATAAAATTTGTT T A AAAAT CTTTTTT T A ATATTTTTTTT AG TTTTTTTATAGG TTTATAGAGGGG G T TATAGATTG A AGGGGGGCGC TG  GGGGGGGCGCGCG G G GG TAGCGATG,T GAGGTTGTGCAAA ATATTTTGTGCGCACTTA T TTTTGTGCGCA TTG CC T TGTGCGCACACT CCT AAT GCGCACACACTCTTTT  CACACTAATCTTTTTT T A ACACTCTTGTGTT T C CTCTTTTTTTGTG  TTTTTTTTTTGTGAGA A T TTTTTTTGTGAGAAAA A T CTTTGTGAT GAATAT T T TGTGAGAAAAT AGTA A G GATATTTTATATATATGT ATTTAATTAATATATGTG G A ATATAAATATGATAGT T T TATATATGTGTTGATC C A ATATGTT GTCCT T TTGTGTCTCTTC C G GTGTCTCTCTCTCTA GT T TCTCTCTCAGGC CTAGTCTCTCGTTA TTCTCTCTCATT G C TT GGTCATTTAGCAACGA AAATCACAGAGCGCCCC C CAAAAGCGCCCCTT A AGGGCGCCCCTCTTTT T G GC GACCTCTTTTT CCAATTTTTT T CTA CTTTTTTTTTTCTC CACCAGTTTAGG TACT ATA TTTTTTTCTCTCTTTT T T TTTTCTCTCTTTTATA A T TC AACTTTTATATAA T C CTCTTTTATATATGTG G T TTTTATT TGGGG G T TATATATGTGGTG GGGA A ATATGTGGGGAGACAC C T TGGGAGACACC TAC G GGGGAGAC GGCCTCT T G GATTACT CCTCTT TG ACACCCTTTTGTG G C CCCCTTTGTGAGA A C CTCTTTTGGTCGAAAA A T TTTTGGAAAAGAG G T TGTGAGAAAGGGG G G GAAGGAAGAGGGGAGA A A AAAGGGGAGAAAA  AGAGGGGAGAAAAAAA A GTAAGGAGAA TCAAAAA A GGCCGAAAAAAAAGC AC C A AAAAAAAAAACACAA A AAAAAAACACACAGAG G AAACGAATC GG TAT ACACACAGAGGGGGGG  CAAGGGGGGGTGT T ATTGAGGCTTGGTGTAA GAAGGGGGGTGTATAAA GTTTGGTGTATAAAT T G GTGTATAAAATATTTT T TTAAAATATTTTTAGCT A AAAATATTTTCTC C A ATTAATTTGA CA A T TTTTTTTCTCACAAAA A TATCTTCTCAAAAAA A T TCTCACAAAAAGC AA ATTCAAAAAAAAAAAAA A AAAAAAACAGAATAT T A AAAAAAAAATCTC C A AAAAAAAT TTTCTCT  AAAATAG TCTTG TT T A ATTCTTTA CTA T TCTCTGA AGAAC CTTTTATAGAGGGG G TGAATTATAGAGGGGGGG G T TAAT TT GGGGGAGA  AGTTCGGGGGAGAAAA A GAGCT ATTTAAGAATAT GAATAGGGAGAAAATATTTT T GGAAAATATTTTTTATT A AAAATCC TTTTG G ATAAATTTTG GGT T TTTTTTTGTGTTTTCTTG T TTTGTGTGTGTGT T T TGTGTGTGTGTTT T GGTGTGTGTTTTTTT  TGTGTGTTTTTTTATA A GGACGTTGGATTATAATGTA T TTTTTTTAACT CAAG G T TTTAAAAGAGATCAATT ATAAGAG GAAAA  AAAAGAGAGAAAATAT T AATAAGAGAAT TTA A G GA TTAATATAGAAAT T ACCTATATATATTTATGGG ATATATAT CATG G T TATATATTTTGACGC TA AATTTTGTGAGATTGGT T TTTTGTGAGATGGAG T TGTGAGATATGT CGG G G GAGATAT ACAGGTGT T A ATATGTGGGGTGTTTGTTGGGGTGTTTTAACAACCCTCGGTGTTTTATATAT T G GTGTTTTATATATTTT T T TTTTATATATTTTTTT T TCAGTTT AATT T A ATATTTTTTTATA A T TTAATTTT GT GGAA A T TTTTATAAAAAA TTTAATAAAAAAAAA  TATAAAAAAAAAATAT T A AAAAAAAAATATA A A AAAAAAATATATATAT T AATACAGATATA A A ATATATATTGTTATAT T T TAATATATATTTT T A ATATATATATTTTCTC  TATATATTTTCTCTT A ATATTTTCTCTCTAA T TATTCCTATAAAA A T TCCTTCTATAAAAGATCGGG CTCTATAAAAGACCGC C T TAA AAAGGCACA A A AATCTAGCGCACACAC C A AGAGCGCACACA TCA GCACACACACACAC C CT CTA CACCG G A ACACACACTGACGCGC C C CACACACGCGCGCCCC C A ACACGCGCGCCCCTCT T C CGCGCGCCCCTCTATA A G GCGCCCCTCTATATAT TGG CCCCTCTATATATTAG ACT CTCTATATATTAT TA A T TTTATATTTTATAAAA A A ATATTTTATAAAATAT T T TTTTATAAAATATTATTT TTCTAATTTTTT T A AAAATATTTTTTTATA A A ATATTTTT CTG TTTTTTATAGAGGGG G T TTTTATAGAGGGGGGG G T TATAGGAAG CGGCC A AGAGGGGGAGCGCGCG G G GGGGGGGCGCGCGT,AATATTTTGA TGCACA A A ATAACGCATTTAC C TTTGTGCGCACACACTCT T T AATGCGCACACTTCCTTTT T GGCACACACTCTTTATTT T CTGGCACACTCTTTTTTTTGCAT A ACACTCTTTTTTTTTTGTG G C CTCTTTTTT TTTGTGAGA GAA TTTTTTTGTTAGAAAA TTT TTTTTTTGCA CA AATAT T T TTTTGTGAAT AATATATA A T TGTGAGAAAATATATATAT TAA GAGAAAATATATATAGGTG G A AAAT ATATATGACTGTGT T AG TATATATATTTC C T TATATATGTGTGTCTATCT  ATATGTGTGTCTCTCTCTC C T TGTGTGTCTCTCTCTCTCT T G GTGTCTCTCTCTCTCTCTC C TCAGTCTCTCTCTCTCTCACA A C CTGGTTCTCTCTCATC AG G T TCTCT AATCACAGT TGC C CCTCTCACAGAGCGCCCC C T TCTCACAGAGCGCCCCTCT A A CAAA GCCCCTCTTTT TTTAACGCCTA CTTTTTTT T GGCCCTTTTTTTTTT T C CCCCTCTTTTTTTTTTCTC C CTA CTTCACTTTC ATCTCT T T TTTTTA TTTC AGTT T T TTTTCTATTA TGC TTACTTCTCTTGATGGAT T TCTCTCTTTATTG G C CTTTGTTATATATGTGGGG G T TTTTATATATGCACGGAGA  GGTATATGAGGTATGACC A ATATGTGGGGA TTTAACC C T TGGGAGACACCCCTCT GA  GGGGAGACACCCCTCTTT G GATTCACCCCTTTGTG G AACCCCTCTTTTGTGAGA A C CCCCTCTTTTGTGAGAAA CTTTCTTTTGTGAGAAAAGG T TTTGAGAAAGGGG G T TGTGAGAAAAGAGGGGAA G GAGAAAAGAGGGGAGAAAA A A AAAAGCTTGGAGAAAAAA ACTTATGGGAGAAC TAAAAA A GA TGGAGAAAAAAAAAACAC AGG GAGAAAAAAAAGTAACATGA AAAAATATAACACAG A AAAAAAACACACAGGG G A AATGCACA TCAGGGGGAAA ACACACAGAGGGGGGGTGT T C CAAGGGGGGGTGTATA  AG ATGGGGGTAAGTAAAA A G GGGGTTAAAATAT T G GGCTCGTATAAAATATTTT ATA GTGTAT GAATGTCTT T TCGCTAAAATATTTTTTTCCAG AAAATATTTTTTTCTCACA A A ATATTTTTTTCTCACAAAA  TTTTTTTCTCACAAAAAA T TTTTCCAAAAAAAA AT TCTCACAA ATAAAAA A C CAAAGAAAAAA ACAATAT T A AAAAAAAAAAAAATATCTC C A AAAAAAAATCTATCTCTC GT ATATCAG TTTTTAGGT AATTAAATTATA A A ATATCTCT TATTATAGAG TT  TCTCTCTTTTATAGAGGG C CTCGTTTAGTTAGGGGGGG G T TTTAGAGGGGGGGAGA TA TAGTAGAGGGGGTTAGAAAA A A AGTTAGGGGGAGAAAATT G GGGGGGGAGAAAATATTTT  GGGGAGTGAATATTTAGAAACAC GAGAAAATATTTTTTTGTG  AAAATATTTTTTTGTGTGT T A ATATTTTTTTGGTGG T TTGAATGTGTGTGTT T TTTTGGGCGTGTGTGTTTT AGC TGTGTTGTGTTTT T G GTGTGTGTGTT CTAGGTA AAA TGGTTTTTTTATAAAA CTC GTTTTTCTTTATAAAAGAG G T TTTTTTTATAA AGAGAT GA T TTTGAAAGAGAGAAA T TATAA CC TAAATGAA AAAAGAGAGAAAATATATA A A AGAGAGAAAATATATCTAATT G GAGAAAATTATACATT T A AAAATATATATATTTTGTG G A ATATATTAATTTTGTAAGA A T TATATATTTTGTGAGATAT T A ATC GTGAGATATGTG G T TTTTGTGAGATATGTGGGG T A TGTGATTAATGTGGGGTGT T G GAGATATGTGGGTTTT G T ATATGTGGGGTGTTTTAAGCA T TGTGGGGTGTTTTATATAT T G GGGGTCAGTATATTTT T G GTGTTTTATTAATTTT T T TTTTATATATTTTTTTTTT T T TATATATTTTTTTTTTATA T CAA ATTTTTTTTTAAAA A TATGTTTTTTTTAACCAAA AGA T TTTTTTTATAAAAAA TAA ATTTAAAAAAATT T TATGAAAAAAAAATATATA A AAAAAATATATATAT T A AAAAAT GATA TTA A AAAATATATATATATATAT T A ATATATATATATATCAC TATATATA TGATTTTCTATTTC ATATATATATTTTCTCTCT T T TATCTTCTCTAGGCA AAGGATTTTCTCTCTATAAAA A T TTTTCCTATAAAAGAG G T TCTTTCTATAAT AAGCTTTC C CTCTATAAGCACA A TTAAAAGAGCTT CACAC TT A GAAGCCTGCA CAACATTGA AAA CCTGCAATT TTCACAC CT  GCGCACACACACACACGCG G C CACACTATAAAACGCGCGC C A ACCGCGCCCC C C CACACCGCGCCCCTCT AAG ACACGGCCCCTCTATA A C CG TAGCCCCTCTATATAT T G GCGCCCTATATTT AGAACAATTA TA C CTCTAATTTTATAAA T TAAATATTTTATAAAATT A ATATTTTATAAATTTT  TTTTATAAAATTTTTT GG  TAAATATTTTTTTATA A A AAAATAGCT ATTATAGAG G AATTTTTTTATAGAGGGG G TTA TTTTTATAGA AGG G T TTTTATAGAGGGGGTGTGC T GA T TAC AGGG CTGCGCG G A AGAGGGGGGGCGCGCTT,"ID   SPIKE_SARS2             Reviewed;        1273 AA.
AC   P0DTC2;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Spike glycoprotein {ECO:0000255|HAMAP-Rule:MF_04099};
DE            Short=S glycoprotein {ECO:0000255|HAMAP-Rule:MF_04099};
DE   AltName: Full=E2 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   AltName: Full=Peplomer protein {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S1 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S2 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S2' {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Flags: Precursor;
GN   Name=S {ECO:0000255|HAMAP-Rule:MF_04099}; ORFNames=2;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   FUNCTION (SPIKE PROTEIN S1), AND CLEAVAGE BETWEEN S2 AND S2' BY HOST
RP   TMPRSS2.
RX   PubMed=32142651; DOI=10.1016/j.cell.2020.02.052;
RA   Hoffmann M., Kleine-Weber H., Schroeder S., Krueger N., Herrler T.,
RA   Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A.,
RA   Mueller M.A., Drosten C., Poehlmann S.;
RT   ""SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a
RT   clinically proven protease inhibitor."";
RL   Cell 181:1-10(2020).
RN   [3]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, FUNCTION, AND MUTAGENESIS OF
RP   681-PRO--ALA-684.
RX   PubMed=32362314; DOI=10.1016/j.molcel.2020.04.022;
RA   Hoffmann M., Kleine-Weber H., Poehlmann S.;
RT   ""A multibasic cleavage site in the Spike protein of SARS-CoV-2 is essential
RT   for infection of human lung cells."";
RL   Mol. Cell 78:779-784(2020).
RN   [4]
RP   GLYCOSYLATION AT ASN-17; ASN-61; ASN-74; ASN-122; ASN-149; ASN-165;
RP   ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098; ASN-1134; ASN-1158; ASN-1173 AND
RP   ASN-1194, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=32366695; DOI=10.1126/science.abb9983;
RA   Watanabe Y., Allen J.D., Wrapp D., McLellan J.S., Crispin M.;
RT   ""Site-specific glycan analysis of the SARS-CoV-2 spike."";
RL   Science 369:330-333(2020).
RN   [5]
RP   GLYCOSYLATION AT ASN-61; ASN-74; ASN-122; ASN-149; ASN-165; ASN-234;
RP   ASN-282; THR-323; SER-325; ASN-331; ASN-343; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098 AND ASN-1194, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=32363391; DOI=10.1093/glycob/cwaa042;
RA   Shajahan A., Supekar N.T., Gleinich A.S., Azadi P.;
RT   ""Deducing the N- and O- glycosylation profile of the spike protein of novel
RT   coronavirus SARS-CoV-2."";
RL   Glycobiology 30:981-988(2020).
RN   [6]
RP   VARIANT GLY-614.
RX   PubMed=32820179; DOI=10.1038/s41598-020-70827-z;
RA   Isabel S., Grana-Miraglia L., Gutierrez J.M., Bundalovic-Torma C.,
RA   Groves H.E., Isabel M.R., Eshaghi A., Patel S.N., Gubbay J.B., Poutanen T.,
RA   Guttman D.S., Poutanen S.M.;
RT   ""Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein
RT   mutation now documented worldwide."";
RL   Sci. Rep. 10:14031-14031(2020).
RN   [7]
RP   VARIANT GLY-614, AND MUTAGENESIS OF ASP-614.
RX   PubMed=32697968; DOI=10.1016/j.cell.2020.06.043;
RG   Sheffield COVID-19 Genomics Group;
RA   Korber B., Fischer W.M., Gnanakaran S., Yoon H., Theiler J., Abfalterer W.,
RA   Hengartner N., Giorgi E.E., Bhattacharya T., Foley B., Hastie K.M.,
RA   Parker M.D., Partridge D.G., Evans C.M., Freeman T.M., de Silva T.I.,
RA   McDanal C., Perez L.G., Tang H., Moon-Walker A., Whelan S.P.,
RA   LaBranche C.C., Saphire E.O., Montefiori D.C.;
RT   ""Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases
RT   Infectivity of the COVID-19 Virus."";
RL   Cell 182:812-827(2020).
RN   [8]
RP   FUNCTION.
RX   PubMed=32817270; DOI=10.1126/science.abd5223;
RA   Turonova B., Sikora M., Schuermann C., Hagen W.J.H., Welsch S.,
RA   Blanc F.E.C., von Buelow S., Gecht M., Bagola K., Hoerner C.,
RA   van Zandbergen G., Landry J., de Azevedo N.T.D., Mosalaganti S.,
RA   Schwarz A., Covino R., Muehlebach M.D., Hummer G., Krijnse Locker J.,
RA   Beck M.;
RT   ""In situ structural analysis of SARS-CoV-2 spike reveals flexibility
RT   mediated by three hinges."";
RL   Science 370:203-208(2020).
RN   [9]
RP   GLYCOSYLATION.
RX   PubMed=32929138; DOI=10.1038/s41598-020-71748-7;
RA   Grant O.C., Montgomery D., Ito K., Woods R.J.;
RT   ""Analysis of the SARS-CoV-2 spike protein glycan shield reveals
RT   implications for immune recognition."";
RL   Sci. Rep. 10:14991-14991(2020).
RN   [10]
RP   GLYCOSYLATION AT ASN-17; ASN-61; ASN-74; ASN-122; ASN-149; ASN-165;
RP   ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098; ASN-1134; ASN-1158; ASN-1173 AND
RP   ASN-1194, IDENTIFICATION BY MASS SPECTROMETRY, SUBCELLULAR LOCATION, AND
RP   SUBUNIT.
RX   PubMed=32979942; DOI=10.1016/j.cell.2020.09.018;
RA   Yao H., Song Y., Chen Y., Wu N., Xu J., Sun C., Zhang J., Weng T.,
RA   Zhang Z., Wu Z., Cheng L., Shi D., Lu X., Lei J., Crispin M., Shi Y.,
RA   Li L., Li S.;
RT   ""Molecular Architecture of the SARS-CoV-2 Virus."";
RL   Cell 183:730-738(2020).
RN   [11]
RP   VARIANT GLY-614, AND MUTAGENESIS OF ASP-614.
RX   PubMed=33106671; DOI=10.1038/s41586-020-2895-3;
RA   Plante J.A., Liu Y., Liu J., Xia H., Johnson B.A., Lokugamage K.G.,
RA   Zhang X., Muruato A.E., Zou J., Fontes-Garfias C.R., Mirchandani D.,
RA   Scharton D., Bilello J.P., Ku Z., An Z., Kalveram B., Freiberg A.N.,
RA   Menachery V.D., Xie X., Plante K.S., Weaver S.C., Shi P.Y.;
RT   ""Spike mutation D614G alters SARS-CoV-2 fitness."";
RL   Nature 592:116-121(2020).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH HUMAN NRP1 AND NRP2.
RC   STRAIN=SARS-CoV-2/human/Liverpool/REMRQ001/2020;
RX   PubMed=33082294; DOI=10.1126/science.abd3072;
RA   Daly J.L., Simonetti B., Klein K., Chen K.E., Williamson M.K.,
RA   Anton-Plagaro C., Shoemark D.K., Simon-Gracia L., Bauer M., Hollandi R.,
RA   Greber U.F., Horvath P., Sessions R.B., Helenius A., Hiscox J.A.,
RA   Teesalu T., Matthews D.A., Davidson A.D., Collins B.M., Cullen P.J.,
RA   Yamauchi Y.;
RT   ""Neuropilin-1 is a host factor for SARS-CoV-2 infection."";
RL   Science 370:861-865(2020).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH HUMAN NRP1 AND NRP2.
RC   STRAIN=SARS-CoV-2/human/Finland/1/2020;
RX   PubMed=33082293; DOI=10.1126/science.abd2985;
RA   Cantuti-Castelvetri L., Ojha R., Pedro L.D., Djannatian M., Franz J.,
RA   Kuivanen S., van der Meer F., Kallio K., Kaya T., Anastasina M., Smura T.,
RA   Levanov L., Szirovicza L., Tobi A., Kallio-Kokko H., Oesterlund P.,
RA   Joensuu M., Meunier F.A., Butcher S.J., Winkler M.S., Mollenhauer B.,
RA   Helenius A., Gokce O., Teesalu T., Hepojoki J., Vapalahti O.,
RA   Stadelmann C., Balistreri G., Simons M.;
RT   ""Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity."";
RL   Science 370:856-860(2020).
RN   [14]
RP   INTERACTION WITH HUMAN ITGA5 AND ITGB1.
RX   PubMed=33102950; DOI=10.1016/j.jacbts.2020.10.003;
RA   Beddingfield B.J., Iwanaga N., Chapagain P.P., Zheng W., Roy C.J., Hu T.Y.,
RA   Kolls J.K., Bix G.J.;
RT   ""The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2
RT   Infection."";
RL   JACC Basic Transl. Sci. 6:1-8(2021).
RN   [15]
RP   VARIANT GLY-614.
RX   PubMed=33184236; DOI=10.1126/science.abe8499;
RA   Hou Y.J., Chiba S., Halfmann P., Ehre C., Kuroda M., Dinnon K.H. III,
RA   Leist S.R., Schaefer A., Nakajima N., Takahashi K., Lee R.E.,
RA   Mascenik T.M., Graham R., Edwards C.E., Tse L.V., Okuda K., Markmann A.J.,
RA   Bartelt L., de Silva A., Margolis D.M., Boucher R.C., Randell S.H.,
RA   Suzuki T., Gralinski L.E., Kawaoka Y., Baric R.S.;
RT   ""SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and
RT   transmission in vivo."";
RL   Science 370:1464-1468(2020).
RN   [16]
RP   VARIANT GLY-614.
RX   PubMed=33417835; DOI=10.1016/j.celrep.2020.108630;
RA   Gobeil S.M., Janowska K., McDowell S., Mansouri K., Parks R., Manne K.,
RA   Stalls V., Kopp M.F., Henderson R., Edwards R.J., Haynes B.F., Acharya P.;
RT   ""D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease
RT   Cleavage at the S1/S2 Junction."";
RL   Cell Rep. 34:108630-108630(2021).
RN   [17]
RP   VARIANTS 69-VAL--PHE-70 DEL; LYS-144 DEL; TYR-501; ASP-570; GLY-614;
RP   HIS-681; ILE-716; ALA-982 AND HIS-1118.
RC   STRAIN=20I/501Y.V1, Alpha, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [18]
RP   VARIANT TYR-501.
RX   PubMed=32732280; DOI=10.1126/science.abc4730;
RA   Gu H., Chen Q., Yang G., He L., Fan H., Deng Y.Q., Wang Y., Teng Y.,
RA   Zhao Z., Cui Y., Li Y., Li X.F., Li J., Zhang N.N., Yang X., Chen S.,
RA   Guo Y., Zhao G., Wang X., Luo D.Y., Wang H., Yang X., Li Y., Han G., He Y.,
RA   Zhou X., Geng S., Sheng X., Jiang S., Sun S., Qin C.F., Zhou Y.;
RT   ""Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy."";
RL   Science 369:1603-1607(2020).
RN   [19]
RP   VARIANT GLY-614, AND MUTAGENESIS OF GLY-614.
RX   PubMed=33636719; DOI=10.1038/s41586-021-03361-1;
RA   Zhou B., Thi Nhu Thao T., Hoffmann D., Taddeo A., Ebert N., Labroussaa F.,
RA   Pohlmann A., King J., Steiner S., Kelly J.N., Portmann J., Halwe N.J.,
RA   Ulrich L., Trueeb B.S., Fan X., Hoffmann B., Wang L., Thomann L., Lin X.,
RA   Stalder H., Pozzi B., de Brot S., Jiang N., Cui D., Hossain J., Wilson M.,
RA   Keller M., Stark T.J., Barnes J.R., Dijkman R., Jores J., Benarafa C.,
RA   Wentworth D.E., Thiel V., Beer M.;
RT   ""SARS-CoV-2 spike D614G change enhances replication and transmission."";
RL   Nature 5920:122-127(2021).
RN   [20]
RP   MUTAGENESIS OF ASN-165; ASN-234; ASN-331; ASN-343; LEU-452; ALA-475;
RP   VAL-483; PHE-490 AND HIS-519.
RX   PubMed=32730807; DOI=10.1016/j.cell.2020.07.012;
RA   Li Q., Wu J., Nie J., Zhang L., Hao H., Liu S., Zhao C., Zhang Q., Liu H.,
RA   Nie L., Qin H., Wang M., Lu Q., Li X., Sun Q., Liu J., Zhang L., Li X.,
RA   Huang W., Wang Y.;
RT   ""The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and
RT   Antigenicity."";
RL   Cell 182:1284-1294(2020).
RN   [21]
RP   FUNCTION, CLEAVAGE BETWEEN S1 AND S2 BY HOST CTSL, AND INTERACTION WITH
RP   HUMAN ACE2.
RX   PubMed=32221306; DOI=10.1038/s41467-020-15562-9;
RA   Ou X., Liu Y., Lei X., Li P., Mi D., Ren L., Guo L., Guo R., Chen T.,
RA   Hu J., Xiang Z., Mu Z., Chen X., Chen J., Hu K., Jin Q., Wang J., Qian Z.;
RT   ""Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and
RT   its immune cross-reactivity with SARS-CoV."";
RL   Nat. Commun. 11:1620-1620(2020).
RN   [22]
RP   INTERACTION WITH HUMAN ACE2.
RX   PubMed=33607086; DOI=10.1016/j.bpj.2021.02.007;
RA   Cao W., Dong C., Kim S., Hou D., Tai W., Du L., Im W., Zhang X.F.;
RT   ""Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2
RT   protein-protein interaction."";
RL   Biophys. J. 120:1011-1019(2021).
RN   [23]
RP   FUNCTION, AND CLEAVAGE BETWEEN S1 AND S2 BY HOST TMPRSS2.
RX   PubMed=33465165; DOI=10.1371/journal.ppat.1009212;
RA   Ou T., Mou H., Zhang L., Ojha A., Choe H., Farzan M.;
RT   ""Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated
RT   by TMPRSS2."";
RL   PLoS Pathog. 17:e1009212-e1009212(2021).
RN   [24]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH S PROTEIN.
RX   PubMed=33229438; DOI=10.1074/jbc.ra120.016175;
RA   Boson B., Legros V., Zhou B., Siret E., Mathieu C., Cosset F.L.,
RA   Lavillette D., Denolly S.;
RT   ""The SARS-CoV-2 Envelope and Membrane proteins modulate maturation and
RT   retention of the Spike protein, allowing assembly of virus-like
RT   particles."";
RL   J. Biol. Chem. 296:100111-100111(2020).
RN   [25]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, CLEAVAGE BETWEEN S2 AND S2' BY
RP   HOST TMPRSS2, MUTAGENESIS OF ALA-684, AND FUNCTION (SPIKE PROTEIN S2').
RX   PubMed=32703818; DOI=10.26508/lsa.202000786;
RA   Bestle D., Heindl M.R., Limburg H., Van Lam van T., Pilgram O., Moulton H.,
RA   Stein D.A., Hardes K., Eickmann M., Dolnik O., Rohde C., Klenk H.D.,
RA   Garten W., Steinmetzer T., Boettcher-Friebertshaeuser E.;
RT   ""TMPRSS2 and furin are both essential for proteolytic activation of SARS-
RT   CoV-2 in human airway cells."";
RL   Life. Sci Alliance 3:1-14(2020).
RN   [26]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, CLEAVAGE BETWEEN S2 AND S2' BY
RP   HOST TMPRSS2, CLEAVAGE BETWEEN S2 AND S2' BY HOST CSTL, AND FUNCTION (SPIKE
RP   PROTEIN S2').
RX   PubMed=34159616; DOI=10.15252/embj.2021107821;
RA   Koch J., Uckeley Z.M., Doldan P., Stanifer M., Boulant S., Lozach P.Y.;
RT   ""TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect
RT   host cells."";
RL   EMBO J. 40:1-20(2021).
RN   [27]
RP   VARIANTS PHE-18; ALA-80; GLY-215; ASN-417; LYS-484; TYR-501; GLY-614 AND
RP   VAL-701.
RC   STRAIN=20H/501Y.V2, B.1.351, and Beta;
RX   PubMed=33690265; DOI=10.1038/s41586-021-03402-9;
RA   Tegally H., Wilkinson E., Giovanetti M., Iranzadeh A., Fonseca V.,
RA   Giandhari J., Doolabh D., Pillay S., San E.J., Msomi N., Mlisana K.,
RA   von Gottberg A., Walaza S., Allam M., Ismail A., Mohale T., Glass A.J.,
RA   Engelbrecht S., Van Zyl G., Preiser W., Petruccione F., Sigal A.,
RA   Hardie D., Marais G., Hsiao M., Korsman S., Davies M.A., Tyers L.,
RA   Mudau I., York D., Maslo C., Goedhals D., Abrahams S., Laguda-Akingba O.,
RA   Alisoltani-Dehkordi A., Godzik A., Wibmer C.K., Sewell B.T., Lourenco J.,
RA   Alcantara L.C.J., Kosakovsky Pond S.L., Weaver S., Martin D.,
RA   Lessells R.J., Bhiman J.N., Williamson C., de Oliveira T.;
RT   ""Emergence of a SARS-CoV-2 variant of concern with mutations in spike
RT   glycoprotein."";
RL   Nature 592:438-443(2021).
RN   [28]
RP   POLYMORPHISM.
RX   PubMed=34142653; DOI=10.2807/1560-7917.es.2021.26.24.2100509;
RA   Campbell F., Archer B., Laurenson-Schafer H., Jinnai Y., Konings F.,
RA   Batra N., Pavlin B., Vandemaele K., Van Kerkhove M.D., Jombart T.,
RA   Morgan O., le Polain de Waroux O.;
RT   ""Increased transmissibility and global spread of SARS-CoV-2 variants of
RT   concern as at June 2021."";
RL   Eurosurveillance 26:0-0(2021).
RN   [29]
RP   VARIANTS ARG-452 AND PHE-453, AND MUTAGENESIS OF LEU-452; TYR-453 AND
RP   ASN-501.
RX   PubMed=34171266; DOI=10.1016/j.chom.2021.06.006;
RG   Genotype to Phenotype Japan (G2P-Japan) Consortium;
RA   Motozono C., Toyoda M., Zahradnik J., Saito A., Nasser H., Tan T.S.,
RA   Ngare I., Kimura I., Uriu K., Kosugi Y., Yue Y., Shimizu R., Ito J.,
RA   Torii S., Yonekawa A., Shimono N., Nagasaki Y., Minami R., Toya T.,
RA   Sekiya N., Fukuhara T., Matsuura Y., Schreiber G., Ikeda T., Nakagawa S.,
RA   Ueno T., Sato K.;
RT   ""SARS-CoV-2 spike L452R variant evades cellular immunity and increases
RT   infectivity."";
RL   Cell Host Microbe 0:0-0(2021).
RN   [30]
RP   VARIANT 69-VAL--PHE-70 DEL, AND MUTAGENESIS OF 69-HIS-VAL-70.
RX   PubMed=34166617; DOI=10.1016/j.celrep.2021.109292;
RG   COVID-19 Genomics UK (COG-UK) Consortium;
RA   Meng B., Kemp S.A., Papa G., Datir R., Ferreira I.A.T.M., Marelli S.,
RA   Harvey W.T., Lytras S., Mohamed A., Gallo G., Thakur N., Collier D.A.,
RA   Mlcochova P., Duncan L.M., Carabelli A.M., Kenyon J.C., Lever A.M.,
RA   De Marco A., Saliba C., Culap K., Cameroni E., Matheson N.J., Piccoli L.,
RA   Corti D., James L.C., Robertson D.L., Bailey D., Gupta R.K.;
RT   ""Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in
RT   the Alpha variant B.1.1.7."";
RL   Cell Rep. 35:109292-109292(2021).
RN   [31]
RP   VARIANTS ILE-13 AND CYS-152, POLYMORPHISM, AND MASS SPECTROMETRY (SIGNAL).
RX   PubMed=34210893; DOI=10.1126/science.abi7994;
RA   McCallum M., Bassi J., De Marco A., Chen A., Walls A.C., Di Iulio J.,
RA   Tortorici M.A., Navarro M.J., Silacci-Fregni C., Saliba C., Sprouse K.R.,
RA   Agostini M., Pinto D., Culap K., Bianchi S., Jaconi S., Cameroni E.,
RA   Bowen J.E., Tilles S.W., Pizzuto M.S., Guastalla S.B., Bona G.,
RA   Pellanda A.F., Garzoni C., Van Voorhis W.C., Rosen L.E., Snell G.,
RA   Telenti A., Virgin H.W., Piccoli L., Corti D., Veesler D.;
RT   ""SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern."";
RL   Science 373:648-654(2021).
RN   [32]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-1269 AND HIS-1271.
RX   PubMed=34504087; DOI=10.1038/s41467-021-25589-1;
RA   Cattin-Ortola J., Welch L.G., Maslen S.L., Papa G., James L.C., Munro S.;
RT   ""Sequences in the cytoplasmic tail of SARS-CoV-2 Spike facilitate
RT   expression at the cell surface and syncytia formation."";
RL   Nat. Commun. 12:5333-5333(2021).
RN   [33]
RP   PALMITOYLATION AT CYS-1235; CYS-1236; CYS-1240; CYS-1241; CYS-1243;
RP   CYS-1247; CYS-1248; CYS-1250; CYS-1253 AND CYS-1254.
RX   PubMed=34599882; DOI=10.1016/j.devcel.2021.09.016;
RA   Mesquita F.S., Abrami L., Sergeeva O., Turelli P., Qing E., Kunz B.,
RA   Raclot C., Paz Montoya J., Abriata L.A., Gallagher T., Dal Peraro M.,
RA   Trono D., D'Angelo G., van der Goot F.G.;
RT   ""S-acylation controls SARS-CoV-2 membrane lipid organization and enhances
RT   infectivity."";
RL   Dev. Cell 56:1-18(2021).
RN   [34] {ECO:0007744|PDB:6M17}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.90 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), DOMAIN, AND INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN S1).
RX   PubMed=32132184; DOI=10.1126/science.abb2762;
RA   Yan R., Zhang Y., Li Y., Xia L., Guo Y., Zhou Q.;
RT   ""Structural basis for the recognition of the SARS-CoV-2 by full-length
RT   human ACE2."";
RL   Science 367:1444-1448(2020).
RN   [35]
RP   SUPERANTIGEN, AND DOMAIN.
RX   PubMed=32989130; DOI=10.1073/pnas.2010722117;
RA   Cheng M.H., Zhang S., Porritt R.A., Noval Rivas M., Paschold L.,
RA   Willscher E., Binder M., Arditi M., Bahar I.;
RT   ""Superantigenic character of an insert unique to SARS-CoV-2 spike supported
RT   by skewed TCR repertoire in patients with hyperinflammation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 117:25254-25262(2020).
RN   [36]
RP   INTERACTION WITH HUMAN BILIRUBIN, INTERACTION WITH HUMAN BILIVERDIN, AND
RP   MUTAGENESIS OF ASN-121 AND ARG-190.
RX   PubMed=33888467; DOI=10.1126/sciadv.abg7607;
RA   Rosa A., Pye V.E., Graham C., Muir L., Seow J., Ng K.W., Cook N.J.,
RA   Rees-Spear C., Parker E., Dos Santos M.S., Rosadas C., Susana A., Rhys H.,
RA   Nans A., Masino L., Roustan C., Christodoulou E., Ulferts R., Wrobel A.G.,
RA   Short C.E., Fertleman M., Sanders R.W., Heaney J., Spyer M., Kjaer S.,
RA   Riddell A., Malim M.H., Beale R., MacRae J.I., Taylor G.P., Nastouli E.,
RA   van Gils M.J., Rosenthal P.B., Pizzato M., McClure M.O., Tedder R.S.,
RA   Kassiotis G., McCoy L.E., Doores K.J., Cherepanov P.;
RT   ""SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity."";
RL   Sci. Adv. 7:0-0(2021).
RN   [37]
RP   BIOTECHNOLOGY, AND MUTAGENESIS OF 682-ARG--ARG-685 AND 986-LYS-VAL-987.
RX   PubMed=34322129; DOI=10.3389/fimmu.2021.701501;
RA   Martinez-Flores D., Zepeda-Cervantes J., Cruz-Resendiz A.,
RA   Aguirre-Sampieri S., Sampieri A., Vaca L.;
RT   ""SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of
RT   New Viral Variants."";
RL   Front. Immunol. 12:701501-701501(2021).
RN   [38]
RP   GLYCOSYLATION AT THR-676 AND THR-678 BY HOST GALNT1, AND MUTAGENESIS OF
RP   SER-673; THR-676; THR-678; SER-680 AND PRO-681.
RX   PubMed=34732583; DOI=10.1073/pnas.2109905118;
RA   Zhang L., Mann M., Syed Z.A., Reynolds H.M., Tian E., Samara N.L.,
RA   Zeldin D.C., Tabak L.A., Ten Hagen K.G.;
RT   ""Furin cleavage of the SARS-CoV-2 spike is modulated by O-glycosylation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [39]
RP   REVIEW, PROTEOLITIC PROCESSING, FUNCTION (SPIKE PROTEIN S2), AND FUNCTION
RP   (SPIKE PROTEIN S2').
RX   PubMed=34561887; DOI=10.1111/1348-0421.12945;
RA   Takeda M.;
RT   ""Proteolytic activation of SARS-CoV-2 spike protein."";
RL   Microbiol. Immunol. 66:15-23(2022).
RN   [40]
RP   INTERACTION WITH HOST MBL2.
RX   PubMed=35102342; DOI=10.1038/s41590-021-01114-w;
RA   Stravalaci M., Pagani I., Paraboschi E.M., Pedotti M., Doni A.,
RA   Scavello F., Mapelli S.N., Sironi M., Perucchini C., Varani L.,
RA   Matkovic M., Cavalli A., Cesana D., Gallina P., Pedemonte N., Capurro V.,
RA   Clementi N., Mancini N., Invernizzi P., Bayarri-Olmos R., Garred P.,
RA   Rappuoli R., Duga S., Bottazzi B., Uguccioni M., Asselta R., Vicenzi E.,
RA   Mantovani A., Garlanda C.;
RT   ""Recognition and inhibition of SARS-CoV-2 by humoral innate immunity
RT   pattern recognition molecules."";
RL   Nat. Immunol. 23:275-286(2022).
RN   [41]
RP   FUNCTION (SPIKE PROTEIN S1), AND INTERACTION WITH HOST INTEGRIN (SPIKE
RP   PROTEIN S1).
RX   PubMed=35150743; DOI=10.1016/j.jbc.2022.101710;
RA   Liu J., Lu F., Chen Y., Plow E., Qin J.;
RT   ""Integrin mediates cell entry of the SARS-CoV-2 virus independent of
RT   cellular receptor ACE2."";
RL   J. Biol. Chem. 1:101710-101710(2022).
RN   [42]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [43]
RP   SUBUNIT.
RX   PubMed=36735681; DOI=10.1371/journal.pbio.3001959;
RA   Shilts J., Crozier T.W.M., Teixeira-Silva A., Gabaev I., Gerber P.P.,
RA   Greenwood E.J.D., Watson S.J., Ortmann B.M., Gawden-Bone C.M., Pauzaite T.,
RA   Hoffmann M., Nathan J.A., Poehlmann S., Matheson N.J., Lehner P.J.,
RA   Wright G.J.;
RT   ""LRRC15 mediates an accessory interaction with the SARS-CoV-2 spike
RT   protein."";
RL   PLoS Biol. 21:e3001959-e3001959(2023).
RN   [44]
RP   VARIANT ASN-405.
RX   PubMed=36851546; DOI=10.3390/v15020332;
RA   Bugatti A., Filippini F., Messali S., Giovanetti M., Ravelli C., Zani A.,
RA   Ciccozzi M., Caruso A., Caccuri F.;
RT   ""The D405N Mutation in the Spike Protein of SARS-CoV-2 Omicron BA.5
RT   Inhibits Spike/Integrins Interaction and Viral Infection of Human Lung
RT   Microvascular Endothelial Cells."";
RL   Viruses 15:0-0(2023).
RN   [45]
RP   MUTAGENESIS OF GLU-484.
RX   PubMed=37421949; DOI=10.1016/j.cell.2023.06.005;
RA   Baggen J., Jacquemyn M., Persoons L., Vanstreels E., Pye V.E., Wrobel A.G.,
RA   Calvaresi V., Martin S.R., Roustan C., Cronin N.B., Reading E.,
RA   Thibaut H.J., Vercruysse T., Maes P., De Smet F., Yee A., Nivitchanyong T.,
RA   Roell M., Franco-Hernandez N., Rhinn H., Mamchak A.A., Ah Young-Chapon M.,
RA   Brown E., Cherepanov P., Daelemans D.;
RT   ""TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry."";
RL   Cell 186:1-16(2023).
RN   [46] {ECO:0007744|PDB:6VSB}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.46 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN S1), SUBUNIT, AND
RP   GLYCOSYLATION.
RX   PubMed=32075877; DOI=10.1126/science.abb2507;
RA   Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.L., Abiona O.,
RA   Graham B.S., McLellan J.S.;
RT   ""Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation."";
RL   Science 367:1260-1263(2020).
RN   [47] {ECO:0007744|PDB:6VXX, ECO:0007744|PDB:6VYB}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.80 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), SUBUNIT (SPIKE PROTEIN S1), INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN
RP   S1), MUTAGENESIS OF 679-GLN--ALA-684, GLYCOSYLATION AT ASN-61; ASN-122;
RP   ASN-61; ASN-165; ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616;
RP   ASN-657; ASN-709; ASN-717; ASN-801; ASN-1074; ASN-1098 AND ASN-1134, AND
RP   DISULFIDE BOND.
RX   PubMed=32155444; DOI=10.1016/j.cell.2020.02.058;
RA   Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., Veesler D.;
RT   ""Structure, function, and antigenicity of the SARS-CoV-2 spike
RT   glycoprotein."";
RL   Cell 180:1-12(2020).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HOST ACE2.
RX   PubMed=32225176; DOI=10.1038/s41586-020-2180-5;
RA   Lan J., Ge J., Yu J., Shan S., Zhou H., Fan S., Zhang Q., Shi X., Wang Q.,
RA   Zhang L., Wang X.;
RT   ""Structure of the SARS-CoV-2 spike receptor-binding domain bound to the
RT   ACE2 receptor."";
RL   Nature 581:215-220(2020).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.68 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HOST ACE2, INTERACTION WITH HOST ACE2, AND MUTAGENESIS OF GLN-493 AND
RP   ASN-501.
RX   PubMed=32225175; DOI=10.1038/s41586-020-2179-y;
RA   Shang J., Ye G., Shi K., Wan Y., Luo C., Aihara H., Geng Q., Auerbach A.,
RA   Li F.;
RT   ""Structural basis of receptor recognition by SARS-CoV-2."";
RL   Nature 581:221-224(2020).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (3.08 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HUMAN ANTIBODY CR3022, AND DISULFIDE BOND.
RX   PubMed=32245784; DOI=10.1126/science.abb7269;
RA   Yuan M., Wu N.C., Zhu X., Lee C.D., So R.T.Y., Lv H., Mok C.K.P.,
RA   Wilson I.A.;
RT   ""A highly conserved cryptic epitope in the receptor-binding domains of
RT   SARS-CoV-2 and SARS-CoV."";
RL   Science 368:630-633(2020).
CC   -!- FUNCTION: [Spike protein S1]: Attaches the virion to the cell membrane
CC       by interacting with host receptor, initiating the infection. The major
CC       receptor is host ACE2 (PubMed:32142651, PubMed:32155444,
CC       PubMed:33607086). When S2/S2' has been cleaved, binding to the receptor
CC       triggers direct fusion at the cell membrane (PubMed:34561887). When
CC       S2/S2' has not been cleaved, binding to the receptor results in
CC       internalization of the virus by endocytosis leading to fusion of the
CC       virion membrane with the host endosomal membrane (PubMed:32075877,
CC       PubMed:32221306). Alternatively, may use NRP1/NRP2 (PubMed:33082294,
CC       PubMed:33082293) and integrin as entry receptors (PubMed:35150743). The
CC       use of NRP1/NRP2 receptors may explain the tropism of the virus in
CC       human olfactory epithelial cells, which express these molecules at high
CC       levels but ACE2 at low levels (PubMed:33082293). The stalk domain of S
CC       contains three hinges, giving the head unexpected orientational freedom
CC       (PubMed:32817270). {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:32075877, ECO:0000269|PubMed:32142651,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32221306,
CC       ECO:0000269|PubMed:32817270, ECO:0000269|PubMed:33082293,
CC       ECO:0000269|PubMed:33082294, ECO:0000269|PubMed:35150743,
CC       ECO:0000303|PubMed:33082293, ECO:0000305|PubMed:34561887}.
CC   -!- FUNCTION: [Spike protein S2]: Precursor of the fusion protein processed
CC       in the biosynthesis of the S protein and the formation of virus
CC       particle. Mediates fusion of the virion and cellular membranes by
CC       functioning as a class I viral fusion protein. Contains two viral
CC       fusion peptides that are unmasked after cleavage. The S2/S2' cleavage
CC       occurs during virus entry at the cell membrane by host TMPRSS2
CC       (PubMed:32142651) or during endocytosis by host CSTL (PubMed:32703818,
CC       PubMed:34159616). In either case, this triggers an extensive and
CC       irreversible conformational change leading to fusion of the viral
CC       envelope with the cellular cytoplasmic membrane, releasing viral
CC       genomic RNA into the host cell cytoplasm (PubMed:34561887). Under the
CC       current model, the protein has at least three conformational states:
CC       pre-fusion native state, pre-hairpin intermediate state, and post-
CC       fusion hairpin state. During fusion of the viral and target cell
CC       membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-
CC       hairpins structure and position the fusion peptide in close proximity
CC       to the C-terminal region of the ectodomain. Formation of this structure
CC       appears to promote apposition and subsequent fusion of viral and target
CC       cell membranes. {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:32703818, ECO:0000269|PubMed:34159616,
CC       ECO:0000305|PubMed:34561887}.
CC   -!- FUNCTION: [Spike protein S2']: Subunit of the fusion protein that is
CC       processed upon entry into the host cell. Mediates fusion of the virion
CC       and cellular membranes by functioning as a class I viral fusion
CC       protein. Contains a viral fusion peptide that is unmasked after S2
CC       cleavage. This cleavage can occur at the cell membrane by host TMPRSS2
CC       or during endocytosis by host CSTL (PubMed:32703818, PubMed:34159616).
CC       In either case, this triggers an extensive and irreversible
CC       conformational change that leads to fusion of the viral envelope with
CC       the cellular cytoplasmic membrane, releasing viral genomic RNA into the
CC       host cell cytoplasm (PubMed:34561887). Under the current model, the
CC       protein has at least three conformational states: pre-fusion native
CC       state, pre-hairpin intermediate state, and post-fusion hairpin state.
CC       During fusion of the viral and target cell membranes, the coiled coil
CC       regions (heptad repeats) adopt a trimer-of-hairpins structure and
CC       position the fusion peptide in close proximity to the C-terminal region
CC       of the ectodomain. Formation of this structure appears to promote
CC       apposition and subsequent fusion of viral and target cell membranes.
CC       {ECO:0000255|HAMAP-Rule:MF_04099, ECO:0000269|PubMed:32703818,
CC       ECO:0000269|PubMed:34159616, ECO:0000305|PubMed:34561887}.
CC   -!- SUBUNIT: [Spike glycoprotein]: Homotrimer; each monomer consists of a
CC       S1 and a S2 subunit (PubMed:32075877, PubMed:32155444,
CC       PubMed:32245784). The resulting peplomers protrude from the virus
CC       surface as spikes (PubMed:32979942). Interacts with ORF3a protein and
CC       ORF7a protein (By similarity) (PubMed:32075877, PubMed:32155444,
CC       PubMed:32245784, PubMed:32979942). There are an average of 26 +/-15
CC       spike trimers at the surface of virion particles (PubMed:32979942).
CC       Binds to host MBL2 (PubMed:35102342). This binding occurs via glycans
CC       and inhibits viral infectivity. Inhibition is effective against alpha,
CC       beta, gamma, and delta variants (PubMed:35102342). {ECO:0000255|HAMAP-
CC       Rule:MF_04099, ECO:0000269|PubMed:32075877,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32245784,
CC       ECO:0000269|PubMed:32979942, ECO:0000269|PubMed:35102342}.
CC   -!- SUBUNIT: [Spike protein S1]: Binds to host ACE2 (PubMed:32075877,
CC       PubMed:32132184, PubMed:32155444, PubMed:32221306, PubMed:32225175,
CC       PubMed:32225176, PubMed:33607086). RBD also interacts with the N-linked
CC       glycan on 'Asn-90' of ACE2 (PubMed:33607086). Cleavage of S generates a
CC       polybasic C-terminal sequence on S1 that binds to host Neuropilin-1
CC       (NRP1) and Neuropilin-2 (NRP2) receptors (PubMed:33082293,
CC       PubMed:33082294). Interacts with host integrin alpha-5/beta-1
CC       (ITGA5:ITGB1) and with ACE2 in complex with integrin alpha-5/beta-1
CC       (ITGA5:ITGB1) (PubMed:33102950). May interact via cytoplasmic c-
CC       terminus with M protein (PubMed:33229438). May interact (via N-
CC       terminus) with host bilirubin and biliverdin, thereby preventing
CC       antibody binding to the SARS-CoV-2 spike NTD via an allosteric
CC       mechanism (PubMed:33888467). May interact with host LRRC15, thereby
CC       allowing attachment to host cells (PubMed:36735681).
CC       {ECO:0000269|PubMed:32075877, ECO:0000269|PubMed:32132184,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32221306,
CC       ECO:0000269|PubMed:32225",2740
ATTGAA TTGAAT TGAATT GAATTG AATTGT ATTGTG TTGTGC TGTGCG GTGCGT TGCGTG GCGTGG CGTGGA GTGGAT TGGATG GGATGA GATGAG ATGAGG TGAGGC GAGGCT AGGCTG GGCTGG GCTGGT CTGGTT TGGTTC GGTTCT GTTCTA TTCTAA TCTAAA CTAAAT TAAATC AAATCT AATCTC ATCTCC TCTCCC CTCCCT TCCCTT CCCTTT CCTTTC CTTTCA TTTCAG TTCAGT TCAGTA CAGTAC AGTACG GTACGT TACGTC ACGTCG CGTCGA GTCGAT TCGATG CGATGT GATGTC ATGTCG TGTCGA GTCGAT TCGATA CGATAA GATAAT ATAATT TAATTA AATTAT ATTATA TTATAC TATACA ATACAG TACAGT ACAGTT CAGTTA AGTTAT GTTATG TTATGT TATGTG ATGTGT TGTGTT GTGTTT TGTTTG GTTTGT TTTGTC TTGTCT TGTCTT GTCTTT TCTTTT CTTTTA TTTTAC TTTACA TTACAA TACAAT ACAATT CAATTA AATTAA ATTAAT TTAATT TAATTG AATTGC ATTGCC TTGCCA TGCCAG GCCAGG CCAGGA CAGGAA AGGAAA GGAAAC GAAACA AAACAA AACAAA ACAAAA CAAAAT AAAATT AAATTG AATTGG ATTGGG TTGGGT TGGGTA GGGTAG GGTAGT GTAGTC TAGTCT AGTCTT GTCTTG TCTTGT CTTGTA TTGTAG TGTAGT GTAGTG TAGTGC AGTGCG GTGCGT TGCGTT GCGTTG CGTTGT GTTGTT TTGTTC TGTTCG GTTCGT TTCGTT TCGTTC CGTTCT GTTCTG TTCTGT TCTGTT CTGTTA TGTTAA,1,142,ATTG TTGA TGAA GAAT AATT ATTG TTGT TGTG GTGC TGCG GCGT CGTG GTGG TGGA GGAT GATG ATGA TGAG GAGG AGGC GGCT GCTG CTGG TGGT GGTT GTTC TTCT TCTA CTAA TAAA AAAT AATC ATCT TCTC CTCC TCCC CCCT CCTT CTTT TTTC TTCA TCAG CAGT AGTA GTAC TACG ACGT CGTC GTCG TCGA CGAT GATG ATGT TGTC GTCG TCGA CGAT GATA ATAA TAAT AATT ATTA TTAT TATA ATAC TACA ACAG CAGT AGTT GTTA TTAT TATG ATGT TGTG GTGT TGTT GTTT TTTG TTGT TGTC GTCT TCTT CTTT TTTT TTTA TTAC TACA ACAA CAAT AATT ATTA TTAA TAAT AATT ATTG TTGC TGCC GCCA CCAG CAGG AGGA GGAA GAAA AAAC AACA ACAA CAAA AAAA AAAT AATT ATTG TTGG TGGG GGGT GGTA GTAG TAGT AGTC GTCT TCTT CTTG TTGT TGTA GTAG TAGT AGTG GTGC TGCG GCGT CGTT GTTG TTGT TGTT GTTC TTCG TCGT CGTT GTTC TTCT TCTG CTGT TGTT GTTA TTAA,ATTGA TTGAA TGAAT GAATT AATTG ATTGT TTGTG TGTGC GTGCG TGCGT GCGTG CGTGG GTGGA TGGAT GGATG GATGA ATGAG TGAGG GAGGC AGGCT GGCTG GCTGG CTGGT TGGTT GGTTC GTTCT TTCTA TCTAA CTAAA TAAAT AAATC AATCT ATCTC TCTCC CTCCC TCCCT CCCTT CCTTT CTTTC TTTCA TTCAG TCAGT CAGTA AGTAC GTACG TACGT ACGTC CGTCG GTCGA TCGAT CGATG GATGT ATGTC TGTCG GTCGA TCGAT CGATA GATAA ATAAT TAATT AATTA ATTAT TTATA TATAC ATACA TACAG ACAGT CAGTT AGTTA GTTAT TTATG TATGT ATGTG TGTGT GTGTT TGTTT GTTTG TTTGT TTGTC TGTCT GTCTT TCTTT CTTTT TTTTA TTTAC TTACA TACAA ACAAT CAATT AATTA ATTAA TTAAT TAATT AATTG ATTGC TTGCC TGCCA GCCAG CCAGG CAGGA AGGAA GGAAA GAAAC AAACA AACAA ACAAA CAAAA AAAAT AAATT AATTG ATTGG TTGGG TGGGT GGGTA GGTAG GTAGT TAGTC AGTCT GTCTT TCTTG CTTGT TTGTA TGTAG GTAGT TAGTG AGTGC GTGCG TGCGT GCGTT CGTTG GTTGT TTGTT TGTTC GTTCG TTCGT TCGTT CGTTC GTTCT TTCTG TCTGT CTGTT TGTTA GTTAA,ATTGAA TTGAAT TGAATT GAATTG AATTGT ATTGTG TTGTGC TGTGCG GTGCGT TGCGTG GCGTGG CGTGGA GTGGAT TGGATG GGATGA GATGAG ATGAGG TGAGGC GAGGCT AGGCTG GGCTGG GCTGGT CTGGTT TGGTTC GGTTCT GTTCTA TTCTAA TCTAAA CTAAAT TAAATC AAATCT AATCTC ATCTCC TCTCCC CTCCCT TCCCTT CCCTTT CCTTTC CTTTCA TTTCAG TTCAGT TCAGTA CAGTAC AGTACG GTACGT TACGTC ACGTCG CGTCGA GTCGAT TCGATG CGATGT GATGTC ATGTCG TGTCGA GTCGAT TCGATA CGATAA GATAAT ATAATT TAATTA AATTAT ATTATA TTATAC TATACA ATACAG TACAGT ACAGTT CAGTTA AGTTAT GTTATG TTATGT TATGTG ATGTGT TGTGTT GTGTTT TGTTTG GTTTGT TTTGTC TTGTCT TGTCTT GTCTTT TCTTTT CTTTTA TTTTAC TTTACA TTACAA TACAAT ACAATT CAATTA AATTAA ATTAAT TTAATT TAATTG AATTGC ATTGCC TTGCCA TGCCAG GCCAGG CCAGGA CAGGAA AGGAAA GGAAAC GAAACA AAACAA AACAAA ACAAAA CAAAAT AAAATT AAATTG AATTGG ATTGGG TTGGGT TGGGTA GGGTAG GGTAGT GTAGTC TAGTCT AGTCTT GTCTTG TCTTGT CTTGTA TTGTAG TGTAGT GTAGTG TAGTGC AGTGCG GTGCGT TGCGTT GCGTTG CGTTGT GTTGTT TTGTTC TGTTCG GTTCGT TTCGTT TCGTTC CGTTCT GTTCTG TTCTGT TCTGTT CTGTTA TGTTAA,ATTGAAT TTGAATT TGAATTG GAATTGT AATTGTG ATTGTGC TTGTGCG TGTGCGT GTGCGTG TGCGTGG GCGTGGA CGTGGAT GTGGATG TGGATGA GGATGAG GATGAGG ATGAGGC TGAGGCT GAGGCTG AGGCTGG GGCTGGT GCTGGTT CTGGTTC TGGTTCT GGTTCTA GTTCTAA TTCTAAA TCTAAAT CTAAATC TAAATCT AAATCTC AATCTCC ATCTCCC TCTCCCT CTCCCTT TCCCTTT CCCTTTC CCTTTCA CTTTCAG TTTCAGT TTCAGTA TCAGTAC CAGTACG AGTACGT GTACGTC TACGTCG ACGTCGA CGTCGAT GTCGATG TCGATGT CGATGTC GATGTCG ATGTCGA TGTCGAT GTCGATA TCGATAA CGATAAT GATAATT ATAATTA TAATTAT AATTATA ATTATAC TTATACA TATACAG ATACAGT TACAGTT ACAGTTA CAGTTAT AGTTATG GTTATGT TTATGTG TATGTGT ATGTGTT TGTGTTT GTGTTTG TGTTTGT GTTTGTC TTTGTCT TTGTCTT TGTCTTT GTCTTTT TCTTTTA CTTTTAC TTTTACA TTTACAA TTACAAT TACAATT ACAATTA CAATTAA AATTAAT ATTAATT TTAATTG TAATTGC AATTGCC ATTGCCA TTGCCAG TGCCAGG GCCAGGA CCAGGAA CAGGAAA AGGAAAC GGAAACA GAAACAA AAACAAA AACAAAA ACAAAAT CAAAATT AAAATTG AAATTGG AATTGGG ATTGGGT TTGGGTA TGGGTAG GGGTAGT GGTAGTC GTAGTCT TAGTCTT AGTCTTG GTCTTGT TCTTGTA CTTGTAG TTGTAGT TGTAGTG GTAGTGC TAGTGCG AGTGCGT GTGCGTT TGCGTTG GCGTTGT CGTTGTT GTTGTTC TTGTTCG TGTTCGT GTTCGTT TTCGTTC TCGTTCT CGTTCTG GTTCTGT TTCTGTT TCTGTTA CTGTTAA,"ID   NS8_SARS2               Reviewed;         121 AA.
AC   P0DTC8;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 24.
DE   RecName: Full=ORF8 protein;
DE            Short=ORF8;
DE   AltName: Full=Non-structural protein 8;
DE            Short=ns8;
DE   Flags: Precursor;
GN   ORFNames=8;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=isolate 2019-nCoV_HKU-SZ-002a_2020;
RX   PubMed=31986261; DOI=10.1016/s0140-6736(20)30154-9;
RA   Chan J.F., Yuan S., Kok K.H., To K.K., Chu H., Yang J., Xing F., Liu J.,
RA   Yip C.C., Poon R.W., Tsoi H.W., Lo S.K., Chan K.H., Poon V.K., Chan W.M.,
RA   Ip J.D., Cai J.P., Cheng V.C., Chen H., Hui C.K., Yuen K.Y.;
RT   ""A familial cluster of pneumonia associated with the 2019 novel coronavirus
RT   indicating person-to-person transmission: a study of a family cluster."";
RL   Lancet 395:514-523(2020).
RN   [3]
RP   MISCELLANEOUS.
RX   PubMed=32854725; DOI=10.1186/s12985-020-01402-1;
RA   Michel C.J., Mayer C., Poch O., Thompson J.D.;
RT   ""Characterization of accessory genes in coronavirus genomes."";
RL   Virol. J. 17:131-131(2020).
RN   [4]
RP   MISCELLANEOUS.
RX   PubMed=32807944; DOI=10.1038/s41590-020-0773-7;
RA   Hachim A., Kavian N., Cohen C.A., Chin A.W.H., Chu D.K.W., Mok C.K.P.,
RA   Tsang O.T.Y., Yeung Y.C., Perera R.A.P.M., Poon L.L.M., Peiris J.S.M.,
RA   Valkenburg S.A.;
RT   ""ORF8 and ORF3b antibodies are accurate serological markers of early and
RT   late SARS-CoV-2 infection."";
RL   Nat. Immunol. 21:1293-1301(2020).
RN   [5]
RP   INTERACTION WITH HUMAN IL17RA, AND SUBCELLULAR LOCATION.
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [6]
RP   INTERACTION WITH HUMAN IL17RA, AND FUNCTION.
RX   PubMed=33723527; DOI=10.1016/j.isci.2021.102293;
RA   Lin X., Fu B., Yin S., Li Z., Liu H., Zhang H., Xing N., Wang Y., Xue W.,
RA   Xiong Y., Zhang S., Zhao Q., Xu S., Zhang J., Wang P., Nian W., Wang X.,
RA   Wu H.;
RT   ""Title: ORF8 contributes to cytokine storm during SARS-CoV-2 infection by
RT   activating IL-17 pathway."";
RL   IScience 1:102293-102293(2021).
RN   [7]
RP   VARIANT SER-84.
RX   PubMed=32615316; DOI=10.1016/j.meegid.2020.104445;
RA   Laha S., Chakraborty J., Das S., Manna S.K., Biswas S., Chatterjee R.;
RT   ""Characterizations of SARS-CoV-2 mutational profile, spike protein
RT   stability and viral transmission."";
RL   Infect. Genet. Evol. 85:104445-104445(2020).
RN   [8]
RP   VARIANT 28-HIS--ILE-121 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [9]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=34177923; DOI=10.3389/fimmu.2021.679482;
RA   Geng H., Subramanian S., Wu L., Bu H.F., Wang X., Du C., De Plaen I.G.,
RA   Tan X.D.;
RT   ""SARS-CoV-2 ORF8 Forms Intracellular Aggregates and Inhibits IFNgamma-
RT   Induced Antiviral Gene Expression in Human Lung Epithelial Cells."";
RL   Front. Immunol. 12:679482-679482(2021).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH HOST MHC-I.
RX   PubMed=34021074; DOI=10.1073/pnas.2024202118;
RA   Zhang Y., Chen Y., Li Y., Huang F., Luo B., Yuan Y., Xia B., Ma X.,
RA   Yang T., Yu F., Liu J., Liu B., Song Z., Chen J., Yan S., Wu L., Pan T.,
RA   Zhang X., Li R., Huang W., He X., Xiao F., Zhang J., Zhang H.;
RT   ""The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-
RT   regulating MHC-Iota."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:1-12(2021).
RN   [11]
RP   FUNCTION, SUBCELLULAR LOCATION, HOMODIMERIZATION, MUTAGENESIS OF CYS-20 AND
RP   ASN-78, DISULFIDE BOND, AND GLYCOSYLATION AT ASN-78.
RX   PubMed=35157849; DOI=10.1016/j.jbc.2022.101724;
RA   Matsuoka K., Imahashi N., Ohno M., Ode H., Nakata Y., Kubota M.,
RA   Sugimoto A., Imahashi M., Yokomaku Y., Iwatani Y.;
RT   ""SARS-CoV-2 accessory protein ORF8 is secreted extracellularly as a
RT   glycoprotein homodimer."";
RL   J. Biol. Chem. 1:101724-101724(2022).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH HUMAN IL17RA, AND
RP   MUTAGENESIS OF SER-24; TYR-42; VAL-62; ILE-71; ILE-76; LEU-84 AND GLU-106.
RX   PubMed=35343786; DOI=10.1128/mbio.00402-22;
RA   Wu X., Xia T., Shin W.J., Yu K.M., Jung W., Herrmann A., Foo S.S., Chen W.,
RA   Zhang P., Lee J.S., Poo H., Comhair S.A.A., Jehi L., Choi Y.K., Ensser A.,
RA   Jung J.U.;
RT   ""Viral Mimicry of Interleukin-17A by SARS-CoV-2 ORF8."";
RL   MBio 1:e0040222-e0040222(2022).
RN   [13]
RP   FUNCTION, MUTAGENESIS OF 1-MET--PHE-16 AND ASN-78, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=36689483; DOI=10.1371/journal.ppat.1011128;
RA   Lin X., Fu B., Xiong Y., Xing N., Xue W., Guo D., Zaky M., Pavani K.,
RA   Kunec D., Trimpert J., Wu H.;
RT   ""Unconventional secretion of unglycosylated ORF8 is critical for the
RT   cytokine storm during SARS-CoV-2 infection."";
RL   PLoS Pathog. 19:e1011128-e1011128(2023).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.61 ANGSTROMS) OF 18-121, AND DISULFIDE BOND.
RA   Nelson C.A., Hall P.D., Fremont D.H.;
RT   ""Crystal Structure of the SARS-CoV-2 ORF8 Protein."";
RL   Submitted (AUG-2020) to the PDB data bank.
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.04 ANGSTROMS) OF 18-121, DISULFIDE BOND, AND
RP   HOMODIMERIZATION.
RX   PubMed=33361333; DOI=10.1073/pnas.2021785118;
RA   Flower T.G., Buffalo C.Z., Hooy R.M., Allaire M., Ren X., Hurley J.H.;
RT   ""Structure of SARS-CoV-2 ORF8, a rapidly evolving immune evasion protein."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
CC   -!- FUNCTION: Plays a role in modulating the host immune response
CC       (PubMed:31986261, PubMed:35343786, PubMed:36689483). May act as a
CC       secreted virokine by mimicking interleukin-17A (IL17A), and thereby
CC       binding to the IL17RA receptor, leading to activation of the IL17
CC       pathway and increased secretion of pro-inflammatory factors
CC       (PubMed:35343786, PubMed:36689483). Contributes to the cytokine storm
CC       during SARS-CoV-2 infection when secreted by unconventional pathway
CC       (PubMed:33723527, PubMed:36689483). May act by down-regulating major
CC       histocompability complex class I (MHC-I) at cell surface
CC       (PubMed:34021074, PubMed:35157849). May inhibit expression of some
CC       members of the IFN-stimulated gene (ISG) family including hosts
CC       IGF2BP1/ZBP1, MX1 and MX2, and DHX58 (PubMed:34177923).
CC       {ECO:0000269|PubMed:33723527, ECO:0000269|PubMed:34021074,
CC       ECO:0000269|PubMed:34177923, ECO:0000269|PubMed:35157849,
CC       ECO:0000269|PubMed:35343786, ECO:0000269|PubMed:36689483,
CC       ECO:0000303|PubMed:31986261}.
CC   -!- SUBUNIT: Homodimer (PubMed:33361333, PubMed:35157849). Interacts with
CC       host IL17RA (PubMed:33060197, PubMed:35343786). Interacts with host
CC       IL17RC (PubMed:35343786). Interacts with host MHC-I (PubMed:34021074).
CC       {ECO:0000269|PubMed:33060197, ECO:0000269|PubMed:33361333,
CC       ECO:0000269|PubMed:33723527, ECO:0000269|PubMed:35157849,
CC       ECO:0000269|PubMed:35343786}.
CC   -!- INTERACTION:
CC       P0DTC8; P0DTC8: 8; NbExp=3; IntAct=EBI-25475900, EBI-25475900;
CC       P0DTC8; Q9UHI8: ADAMTS1; Xeno; NbExp=3; IntAct=EBI-25475900, EBI-2511802;
CC       P0DTC8; Q8N766: EMC1; Xeno; NbExp=3; IntAct=EBI-25475900, EBI-1044442;
CC       P0DTC8; P01892: HLA-A; Xeno; NbExp=5; IntAct=EBI-25475900, EBI-2839473;
CC       P0DTC8; Q96F46: IL17RA; Xeno; NbExp=3; IntAct=EBI-25475900, EBI-5591258;
CC       PRO_0000449655; PRO_0000449655 [P0DTC8]: 8; NbExp=2; IntAct=EBI-28965865, EBI-28965865;
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:35157849,
CC       ECO:0000269|PubMed:35343786}. Note=Is secreted during a normal viral
CC       infection by unconventional pathway (PubMed:35157849, PubMed:36689483).
CC       Its mRNA is expressed in cytoplasm and not spliced during a viral
CC       infection, but is spliced when expressed from cDNA in nucleus
CC       (PubMed:35157849). Splicing changes localization to host endosome
CC       and/or cytoplasm (PubMed:33060197, PubMed:34177923). May also localize
CC       in nucleus when fused with GFP (PubMed:34177923).
CC       {ECO:0000269|PubMed:33060197, ECO:0000269|PubMed:34177923,
CC       ECO:0000269|PubMed:35157849}.
CC   -!- PTM: Glycosylated by the host when secreted via the conventional
CC       pathway. The glycosylated form cannot bind IL17A and would not
CC       participate in the cytokine storm. {ECO:0000269|PubMed:36689483}.
CC   -!- POLYMORPHISM: Variant B.1.1.7 is also called Variant Of Concern (VOC)
CC       202012/01, Variant Under Investigation (VUI) 202012/01, or 20B/501Y.V1.
CC       {ECO:0000305|PubMed:33413740}.
CC   -!- POLYMORPHISM: Variant Omicron/BA.1 and BA.2 belong to a lineage first
CC       isolated in South Africa (November 2021). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/BQ.1.1 belongs to a lineage first
CC       isolated in Nigeria (November 2022). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/XBB.1.5 belongs to a lineage first
CC       isolated in United States (November 2022). It is the result of
CC       recombination between omicron BJ.1 and BM.1.1. Moreover XBB.1.5 do not
CC       express ORF8. {ECO:0000305}.
CC   -!- MISCELLANEOUS: Similar to some Bat coronavirus ns8 genes, but is
CC       entirely different from SARS ns8a or Ns8b (Probable). Elicits strong
CC       specific antibody response (PubMed:32807944).
CC       {ECO:0000269|PubMed:32807944, ECO:0000305|PubMed:32854725}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43422.1; -; Genomic_RNA.
DR   EMBL; MN938384; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   PDB; 7F5F; X-ray; 1.62 A; A=18-121.
DR   PDB; 7JTL; X-ray; 2.04 A; A/B=18-121.
DR   PDB; 7JX6; X-ray; 1.61 A; A/B=18-121.
DR   PDB; 7MX9; X-ray; 2.60 A; A=15-121.
DR   PDB; 7XMN; X-ray; 2.30 A; B=16-121.
DR   PDBsum; 7F5F; -.
DR   PDBsum; 7JTL; -.
DR   PDBsum; 7JX6; -.
DR   PDBsum; 7MX9; -.
DR   PDBsum; 7XMN; -.
DR   SMR; P0DTC8; -.
DR   BioGRID; 4383873; 1317.
DR   ComplexPortal; CPX-6147; SARS-CoV-2 ORF8 complex.
DR   IntAct; P0DTC8; 152.
DR   MINT; P0DTC8; -.
DR   GlyGen; P0DTC8; 1 site.
DR   iPTMnet; P0DTC8; -.
DR   KEGG; vg:43740577; -.
DR   AGR; RefSeq:YP_009724396; -.
DR   Reactome; R-HSA-448424; Interleukin-17 signaling.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   Reactome; R-HSA-9727281; Translation of Accessory Proteins.
DR   Reactome; R-HSA-983170; Antigen Presentation: Folding, assembly and peptide loading of class I MHC.
DR   PRO; PR:P0DTC8; -.
DR   Proteomes; UP000464024; Genome.
DR   Proteomes; UP000464747; Genome.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:ComplexPortal.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProt.
DR   GO; GO:0005764; C:lysosome; IDA:ComplexPortal.
DR   GO; GO:0005125; F:cytokine activity; IDA:UniProt.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0032688; P:negative regulation of interferon-beta production; IDA:ComplexPortal.
DR   GO; GO:0002891; P:positive regulation of immunoglobulin mediated immune response; IDA:ComplexPortal.
DR   GO; GO:0046776; P:symbiont-mediated suppression of host antigen processing and presentation of peptide antigen via MHC class I; IDA:ComplexPortal.
DR   GO; GO:0019049; P:virus-mediated perturbation of host defense response; IDA:UniProt.
DR   CDD; cd21641; ORF8-Ig_SARS-CoV-2-like; 1.
DR   InterPro; IPR022722; ORF8_betacoronavirus.
DR   InterPro; IPR044391; ORF8_SARS-CoV-2-like.
DR   InterPro; IPR046444; SARS_ORF8_IG.
DR   Pfam; PF12093; bCoV_NS8; 1.
DR   PROSITE; PS51964; SARS_ORF8_IG; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Disulfide bond;
KW   Evasion of host immunity by viral interleukin-like protein; Glycoprotein;
KW   Host-virus interaction; Reference proteome; Secreted; Signal;
KW   Viral immunoevasion.
FT   SIGNAL          1..15
FT                   /evidence=""ECO:0000255""
FT   CHAIN           16..121
FT                   /note=""ORF8 protein""
FT                   /id=""PRO_0000449655""
FT   DOMAIN          19..121
FT                   /note=""SARS ORF8 Ig-like""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01309""
FT   CARBOHYD        78
FT                   /note=""N-linked (GlcNAc...) (complex) asparagine; by host""
FT                   /evidence=""ECO:0000269|PubMed:35157849,
FT                   ECO:0000269|PubMed:36689483""
FT   DISULFID        20
FT                   /note=""Interchain""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01309,
FT                   ECO:0000269|PubMed:33361333, ECO:0000269|PubMed:35157849""
FT   DISULFID        25..90
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01309,
FT                   ECO:0000269|PubMed:33361333, ECO:0000269|Ref.14""
FT   DISULFID        37..102
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01309,
FT                   ECO:0000269|PubMed:33361333, ECO:0000269|Ref.14""
FT   DISULFID        61..83
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01309,
FT                   ECO:0000269|PubMed:33361333, ECO:0000269|Ref.14""
FT   VARIANT         2
FT                   /note=""K -> Q (in strain: Theta/P.3)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         8..121
FT                   /note=""Missing (in strain: Omicron/XBB.1.5,
FT                   Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         11
FT                   /note=""T -> I (in strain: Iota/B.1.526)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         11
FT                   /note=""T -> K (in strain: Mu/B.1.621)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         28..121
FT                   /note=""Missing (in strain: B.1.1.7)""
FT                   /evidence=""ECO:0000305|PubMed:33413740""
FT   VARIANT         38
FT                   /note=""P -> S (in strain: Mu/B.1.621)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         84
FT                   /note=""L -> S""
FT                   /evidence=""ECO:0000305, ECO:0000305|PubMed:32615316""
FT   VARIANT         92
FT                   /note=""E -> K (in strain: Gamma/P.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         119
FT                   /note=""D -> I (in strain: Delta/B.1.617.2)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         120..121
FT                   /note=""Missing (in strain: Delta/B.1.617.2)""
FT                   /evidence=""ECO:0000305""
FT   MUTAGEN         1..16
FT                   /note=""Missing: Partial loss of secretion.""
FT                   /evidence=""ECO:0000269|PubMed:36689483""
FT   MUTAGEN         20
FT                   /note=""C->A: Complete loss of dimerization.""
FT                   /evidence=""ECO:0000269|PubMed:35157849""
FT   MUTAGEN         24
FT                   /note=""S->L: Partial loss of hIL-17RC binding.""
FT                   /evidence=""ECO:0000269|PubMed:35343786""
FT   MUTAGEN         42
FT                   /note=""Y->H: Complete loss of hIL-17RA binding.""
FT                   /evidence=""ECO:0000269|PubMed:35343786""
FT   MUTAGEN         62
FT                   /note=""V->L: Partial loss of hIL-17RC binding.""
FT                   /evidence=""ECO:0000269|PubMed:35343786""
FT   MUTAGEN         71
FT                   /note=""I->D: Complete loss of hIL-17RC binding.""
FT                   /evidence=""ECO:0000269|PubMed:35343786""
FT   MUTAGEN         76
FT                   /note=""I->D: Complete loss of hIL-17RC binding.""
FT                   /evidence=""ECO:0000269|PubMed:35343786""
FT   MUTAGEN         78
FT                   /note=""N->D: Complete loss of N-glycosylation and of
FT                   secretion.""
FT                   /evidence=""ECO:0000269|PubMed:35157849""
FT   MUTAGEN         78
FT                   /note=""N->Q: Complete loss of glycosylation when secreted
FT                   by conventional route. Increases cytokine storm effects.""
FT                   /evidence=""ECO:0000269|PubMed:36689483""
FT   MUTAGEN         84
FT                   /note=""L->S: Complete loss of IL17RA binding.""
FT                   /evidence=""ECO:0000269|PubMed:35343786""
FT   MUTAGEN         106
FT                   /note=""E->P: Complete loss of hIL-17RA binding.""
FT                   /evidence=""ECO:0000269|PubMed:35343786""
FT   STRAND          19..25
FT                   /evidence=""ECO:0007829|PDB:7JX6""
FT   STRAND          29..32
FT                   /evidence=""ECO:0007829|PDB:7JX6""
FT   STRAND          41..49
FT                   /evidence=""ECO:0007829|PDB:7JX6""
FT   STRAND          57..70
FT                   /evidence=""ECO:0007829|PDB:7JX6""
FT   TURN            74..78
FT                   /evidence=""ECO:0007829|PDB:7F5F""
FT   STRAND          80..82
FT                   /evidence=""ECO:0007829|PDB:7JX6""
FT   TURN            83..86
FT                   /evidence=""ECO:0007829|PDB:7JX6""
FT   STRAND          87..91
FT                   /evidence=""ECO:0007829|PDB:7JX6""
FT   STRAND          96..105
FT                   /evidence=""ECO:0007829|PDB:7JX6""
FT   STRAND          112..120
FT                   /evidence=""ECO:0007829|PDB:7JX6""
SQ   SEQUENCE   121 AA;  13831 MW;  912AD9E147A64907 CRC64;
     MKFLVFLGII TTVAAFHQEC SLQSCTQHQP YVVDDPCPIH FYSKWYIRVG ARKSAPLIEL
     CVDEAGSKSP IQYIDIGNYT VSCLPFTINC QEPKLGSLVV RCSFYEDFLE YHDVRVVLDF
     I
//
",10975
CAATTA AATTAA ATTAAC TTAACA TAACAC AACACC ACACCA CACCAA ACCAAT CCAATA CAATAG AATAGC ATAGCA TAGCAG AGCAGT GCAGTC CAGTCC AGTCCA GTCCAG TCCAGA CCAGAT CAGATG AGATGA GATGAC ATGACC TGACCA GACCAA ACCAAA CCAAAT CAAATT AAATTG AATTGG ATTGGC TTGGCT TGGCTA GGCTAC GCTACT CTACTA TACTAC ACTACC CTACCG TACCGA ACCGAA CCGAAG CGAAGA GAAGAG AAGAGC AGAGCT GAGCTA AGCTAC GCTACC CTACCA TACCAG ACCAGA CCAGAC CAGACG AGACGA GACGAA ACGAAT CGAATT GAATTC AATTCG ATTCGG TTCGGG TCGGGG CGGGGT GGGGTG GGGTGG GGTGGG GTGGGG,1,70,CAAT AATT ATTA TTAA TAAC AACA ACAC CACC ACCA CCAA CAAT AATA ATAG TAGC AGCA GCAG CAGT AGTC GTCC TCCA CCAG CAGA AGAT GATG ATGA TGAC GACC ACCA CCAA CAAA AAAT AATT ATTG TTGG TGGC GGCT GCTA CTAC TACT ACTA CTAC TACC ACCG CCGA CGAA GAAG AAGA AGAG GAGC AGCT GCTA CTAC TACC ACCA CCAG CAGA AGAC GACG ACGA CGAA GAAT AATT ATTC TTCG TCGG CGGG GGGG GGGT GGTG GTGG TGGG GGGG,CAATT AATTA ATTAA TTAAC TAACA AACAC ACACC CACCA ACCAA CCAAT CAATA AATAG ATAGC TAGCA AGCAG GCAGT CAGTC AGTCC GTCCA TCCAG CCAGA CAGAT AGATG GATGA ATGAC TGACC GACCA ACCAA CCAAA CAAAT AAATT AATTG ATTGG TTGGC TGGCT GGCTA GCTAC CTACT TACTA ACTAC CTACC TACCG ACCGA CCGAA CGAAG GAAGA AAGAG AGAGC GAGCT AGCTA GCTAC CTACC TACCA ACCAG CCAGA CAGAC AGACG GACGA ACGAA CGAAT GAATT AATTC ATTCG TTCGG TCGGG CGGGG GGGGT GGGTG GGTGG GTGGG TGGGG,CAATTA AATTAA ATTAAC TTAACA TAACAC AACACC ACACCA CACCAA ACCAAT CCAATA CAATAG AATAGC ATAGCA TAGCAG AGCAGT GCAGTC CAGTCC AGTCCA GTCCAG TCCAGA CCAGAT CAGATG AGATGA GATGAC ATGACC TGACCA GACCAA ACCAAA CCAAAT CAAATT AAATTG AATTGG ATTGGC TTGGCT TGGCTA GGCTAC GCTACT CTACTA TACTAC ACTACC CTACCG TACCGA ACCGAA CCGAAG CGAAGA GAAGAG AAGAGC AGAGCT GAGCTA AGCTAC GCTACC CTACCA TACCAG ACCAGA CCAGAC CAGACG AGACGA GACGAA ACGAAT CGAATT GAATTC AATTCG ATTCGG TTCGGG TCGGGG CGGGGT GGGGTG GGGTGG GGTGGG GTGGGG,CAATTAA AATTAAC ATTAACA TTAACAC TAACACC AACACCA ACACCAA CACCAAT ACCAATA CCAATAG CAATAGC AATAGCA ATAGCAG TAGCAGT AGCAGTC GCAGTCC CAGTCCA AGTCCAG GTCCAGA TCCAGAT CCAGATG CAGATGA AGATGAC GATGACC ATGACCA TGACCAA GACCAAA ACCAAAT CCAAATT CAAATTG AAATTGG AATTGGC ATTGGCT TTGGCTA TGGCTAC GGCTACT GCTACTA CTACTAC TACTACC ACTACCG CTACCGA TACCGAA ACCGAAG CCGAAGA CGAAGAG GAAGAGC AAGAGCT AGAGCTA GAGCTAC AGCTACC GCTACCA CTACCAG TACCAGA ACCAGAC CCAGACG CAGACGA AGACGAA GACGAAT ACGAATT CGAATTC GAATTCG AATTCGG ATTCGGG TTCGGGG TCGGGGT CGGGGTG GGGGTGG GGGTGGG GGTGGGG,"ID   ORF9B_SARS2             Reviewed;          97 AA.
AC   P0DTD2;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   27-NOV-2024, entry version 24.
DE   RecName: Full=ORF9b protein;
DE            Short=ORF9b;
DE   AltName: Full=Accessory protein 9b;
DE   AltName: Full=ORF-9b;
DE   AltName: Full=Protein 9b;
GN   ORFNames=9b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.05 ANGSTROMS), INTERACTION WITH HUMAN
RP   TOMM70, AND SUBCELLULAR LOCATION.
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [3]
RP   FUNCTION, AND INTERACTION WITH HOST TOMM70.
RX   PubMed=32728199; DOI=10.1038/s41423-020-0514-8;
RA   Jiang H.W., Zhang H.N., Meng Q.F., Xie J., Li Y., Chen H., Zheng Y.X.,
RA   Wang X.N., Qi H., Zhang J., Wang P.H., Han Z.G., Tao S.C.;
RT   ""SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting
RT   TOM70."";
RL   Cell. Mol. Immunol. 17:998-1000(2020).
RN   [4]
RP   FUNCTION, MUTAGENESIS OF SER-53, SUBCELLULAR LOCATION, AND INTERACTION WITH
RP   HOST TOMM70.
RX   PubMed=34502139; DOI=10.3390/ijms22179233;
RA   Brandherm L., Kobas A.M., Kloehn M., Brueggemann Y., Pfaender S.,
RA   Rassow J., Kreimendahl S.;
RT   ""Phosphorylation of SARS-CoV-2 Orf9b Regulates Its Targeting to Two Binding
RT   Sites in TOM70 and Recruitment of Hsp90."";
RL   Int. J. Mol. Sci. 22:0-0(2021).
RN   [5] {ECO:0007744|PDB:6Z4U}
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS), AND HOMODIMERIZATION.
RA   Weeks S.D., De Graef S., Munawar A.;
RT   ""X-ray Crystallographic Structure of Orf9b from SARS-CoV-2."";
RL   Submitted (MAY-2020) to the PDB data bank.
RN   [6]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.20 ANGSTROMS) OF 1-97, AND INTERACTION
RP   WITH HOST TOMM70.
RX   PubMed=33990585; DOI=10.1038/s41467-021-23118-8;
RA   Gao X., Zhu K., Qin B., Olieric V., Wang M., Cui S.;
RT   ""Crystal structure of SARS-CoV-2 Orf9b in complex with human TOM70 suggests
RT   unusual virus-host interactions."";
RL   Nat. Commun. 12:2843-2843(2021).
CC   -!- FUNCTION: Plays a role in inhibiting the host innate immune response by
CC       targeting the mitochondrial-associated innate immune response. Acts by
CC       binding to host TOMM70, inhibiting its binding to HSP90AB1 thereby
CC       disrupting the interferon activation pathway.
CC       {ECO:0000269|PubMed:32728199, ECO:0000269|PubMed:34502139}.
CC   -!- SUBUNIT: Homodimer (Ref.5). Interacts with host TOMM70
CC       (PubMed:33060197, PubMed:32728199, PubMed:34502139, PubMed:33990585);
CC       the interaction occurs only with monomer (PubMed:33990585).
CC       {ECO:0000269|PubMed:32728199, ECO:0000269|PubMed:33060197,
CC       ECO:0000269|PubMed:33990585, ECO:0000269|PubMed:34502139,
CC       ECO:0000269|Ref.5}.
CC   -!- INTERACTION:
CC       P0DTD2; P0DTD2: 9b; NbExp=5; IntAct=EBI-25475909, EBI-25475909;
CC       P0DTD2; Q9Y6K9: IKBKG; Xeno; NbExp=3; IntAct=EBI-25475909, EBI-81279;
CC       P0DTD2; O94826: TOMM70; Xeno; NbExp=28; IntAct=EBI-25475909, EBI-2800236;
CC   -!- SUBCELLULAR LOCATION: Host cytoplasm {ECO:0000269|PubMed:32728199,
CC       ECO:0000269|PubMed:33060197, ECO:0000269|PubMed:34502139}. Host
CC       mitochondrion {ECO:0000269|PubMed:32728199,
CC       ECO:0000269|PubMed:33060197}.
CC   -!- POLYMORPHISM: Variant Omicron/BA.1 and BA.2 belong to a lineage first
CC       isolated in South Africa (November 2021). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/BQ.1.1 belongs to a lineage first
CC       isolated in Nigeria (November 2022). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/XBB.1.5 belongs to a lineage first
CC       isolated in United States (November 2022). It is the result of
CC       recombination between omicron BJ.1 and BM.1.1. Moreover XBB.1.5 do not
CC       express ORF8. {ECO:0000305}.
CC   -!- MISCELLANEOUS: The open reading frame (ORF) encoding for this protein
CC       overlaps with the N ORF. {ECO:0000269|PubMed:32015508}.
CC   -!- SIMILARITY: Belongs to the coronavirus group 2 protein 9b family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   PDB; 6Z4U; X-ray; 1.95 A; A/B=1-97.
DR   PDB; 7DHG; X-ray; 2.20 A; B=1-97.
DR   PDB; 7KDT; EM; 3.05 A; B=1-97.
DR   PDB; 7YE7; X-ray; 2.95 A; A/B/C/D=1-97.
DR   PDB; 7YE8; X-ray; 3.01 A; A/B/C/D=1-97.
DR   PDBsum; 6Z4U; -.
DR   PDBsum; 7DHG; -.
DR   PDBsum; 7KDT; -.
DR   PDBsum; 7YE7; -.
DR   PDBsum; 7YE8; -.
DR   EMDB; EMD-22829; -.
DR   SMR; P0DTD2; -.
DR   BioGRID; 4383874; 613.
DR   ComplexPortal; CPX-6100; SARS-CoV-2 9b complex.
DR   IntAct; P0DTD2; 94.
DR   MINT; P0DTD2; -.
DR   iPTMnet; P0DTD2; -.
DR   AGR; RefSeq:P0DTD2; -.
DR   Reactome; R-HSA-168928; DDX58/IFIH1-mediated induction of interferon-alpha/beta.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   Reactome; R-HSA-9727281; Translation of Accessory Proteins.
DR   PRO; PR:P0DTD2; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0033650; C:host cell mitochondrion; IEA:UniProtKB-SubCell.
DR   GO; GO:0031966; C:mitochondrial membrane; IDA:UniProt.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IDA:ComplexPortal.
DR   GO; GO:0098799; C:outer mitochondrial membrane protein complex; ISO:ComplexPortal.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0140311; F:protein sequestering activity; IDA:UniProt.
DR   GO; GO:0050687; P:negative regulation of defense response to virus; IDA:ComplexPortal.
DR   GO; GO:0090258; P:negative regulation of mitochondrial fission; ISO:ComplexPortal.
DR   GO; GO:2000786; P:positive regulation of autophagosome assembly; ISO:ComplexPortal.
DR   GO; GO:0039545; P:symbiont-mediated suppression of host cytoplasmic pattern recognition receptor signaling pathway via inhibition of MAVS activity; IDA:UniProt.
DR   GO; GO:0039502; P:symbiont-mediated suppression of host type I interferon-mediated signaling pathway; IDA:ComplexPortal.
DR   GO; GO:0019049; P:virus-mediated perturbation of host defense response; IEA:UniProtKB-KW.
DR   CDD; cd21955; SARS-CoV_ORF9b; 1.
DR   InterPro; IPR018542; Protein_9b_Betacoronavirus.
DR   InterPro; IPR037223; Protein_9b_SARS.
DR   Pfam; PF09399; bCoV_lipid_BD; 1.
DR   SUPFAM; SSF141666; SARS ORF9b-like; 1.
DR   PROSITE; PS51920; SARS_9B; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Host cytoplasm; Host mitochondrion; Host-virus interaction;
KW   Inhibition of host innate immune response by virus;
KW   Inhibition of host MAVS by virus; Inhibition of host RLR pathway by virus;
KW   Reference proteome; Viral immunoevasion.
FT   CHAIN           1..97
FT                   /note=""ORF9b protein""
FT                   /evidence=""ECO:0000250|UniProtKB:P59636""
FT                   /id=""PRO_0000449657""
FT   DOMAIN          8..97
FT                   /note=""9b""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01268""
FT   MOTIF           45..53
FT                   /note=""Nuclear export signal""
FT                   /evidence=""ECO:0000250|UniProtKB:P59636""
FT   VARIANT         10
FT                   /note=""P -> S (in strain: Omicron/BA.1, Omicron/BA.2,
FT                   Omicron/BA.2.12.1, Omicron/BA.4, Omicron/BA.5,
FT                   Omicron/XBB.1.5, Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         27..29
FT                   /note=""Missing (in strain: Omicron/BA.1, Omicron/BA.2,
FT                   Omicron/BA.2.12.1, Omicron/BA.4, Omicron/BA.5,
FT                   Omicron/XBB.1.5, Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         60
FT                   /note=""T -> A (in strain: Delta/B.1.617.2)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         77
FT                   /note=""Q -> E (in strain: Gamma/P.1)""
FT                   /evidence=""ECO:0000305""
FT   MUTAGEN         53
FT                   /note=""S->E: Complete loss of binding to host TOMM70.""
FT                   /evidence=""ECO:0000269|PubMed:34502139""
FT   HELIX           5..7
FT                   /evidence=""ECO:0007829|PDB:6Z4U""
FT   STRAND          12..15
FT                   /evidence=""ECO:0007829|PDB:6Z4U""
FT   STRAND          19..23
FT                   /evidence=""ECO:0007829|PDB:6Z4U""
FT   STRAND          40..42
FT                   /evidence=""ECO:0007829|PDB:6Z4U""
FT   STRAND          44..50
FT                   /evidence=""ECO:0007829|PDB:6Z4U""
FT   STRAND          52..61
FT                   /evidence=""ECO:0007829|PDB:6Z4U""
FT   STRAND          64..66
FT                   /evidence=""ECO:0007829|PDB:6Z4U""
FT   STRAND          68..74
FT                   /evidence=""ECO:0007829|PDB:6Z4U""
FT   STRAND          78..80
FT                   /evidence=""ECO:0007829|PDB:7YE7""
FT   HELIX           84..86
FT                   /evidence=""ECO:0007829|PDB:6Z4U""
FT   STRAND          89..96
FT                   /evidence=""ECO:0007829|PDB:6Z4U""
SQ   SEQUENCE   97 AA;  10797 MW;  62CFB65C1804545E CRC64;
     MDPKISEMHP ALRLVDPQIQ LAVTRMENAV GRDQNNVGPK VYPIILRLGS PLSLNMARKT
     LNSLEDKAFQ LTPIAVQMTK LATTEELPDE FVVVTVK
//
",6566
TTGCAA TGCAAC GCAACT CAACTG AACTGA ACTGAA CTGAAG TGAAGG GAAGGA AAGGAC AGGACC GGACCT GACCTG ACCTGA CCTGAC CTGACC TGACCG GACCGT ACCGTG CCGTGT CGTGTC GTGTCC TGTCCT GTCCTA TCCTAT CCTATG CTATGG TATGGC ATGGCC TGGCCA GGCCAG GCCAGG CCAGGT CAGGTT AGGTTG GGTTGA GTTGAG TTGAGG TGAGGC GAGGCC AGGCCG GGCCGT GCCGTT CCGTTC CGTTCA GTTCAC TTCACC TCACCA CACCAA ACCAAG CCAAGT CAAGTC AAGTCC AGTCCA GTCCAG TCCAGC CCAGCT CAGCTC AGCTCG GCTCGA CTCGAT TCGATG CGATGT GATGTG ATGTGA TGTGAA GTGAAC TGAACG GAACGA AACGAA ACGAAG CGAAGG GAAGGC AAGGCG AGGCGA GGCGAG GCGAGA CGAGAT GAGATC AGATCG GATCGT ATCGTC TCGTCA CGTCAC GTCACA TCACAG CACAGT ACAGTC CAGTCA AGTCAT GTCATC TCATCG CATCGG ATCGGC TCGGCC CGGCCC GGCCCC GCCCCA CCCCAA CCCAAC CCAACG CAACGG AACGGC ACGGCG CGGCGC GGCGCG GCGCGG CGCGGG GCGGGC CGGGCA GGGCAA GGCAAG GCAAGA CAAGAC AAGACC AGACCA GACCAC ACCACG CCACGC CACGCT ACGCTG CGCTGC GCTGCT CTGCTG TGCTGT GCTGTG CTGTGC TGTGCG GTGCGC TGCGCG GCGCGG CGCGGC GCGGCA CGGCAA GGCAAT GCAATG CAATGG AATGGG ATGGGC TGGGCC GGGCCT GGCCTG GCCTGT CCTGTT CTGTTG,2,145,TTGC TGCA GCAA CAAC AACT ACTG CTGA TGAA GAAG AAGG AGGA GGAC GACC ACCT CCTG CTGA TGAC GACC ACCG CCGT CGTG GTGT TGTC GTCC TCCT CCTA CTAT TATG ATGG TGGC GGCC GCCA CCAG CAGG AGGT GGTT GTTG TTGA TGAG GAGG AGGC GGCC GCCG CCGT CGTT GTTC TTCA TCAC CACC ACCA CCAA CAAG AAGT AGTC GTCC TCCA CCAG CAGC AGCT GCTC CTCG TCGA CGAT GATG ATGT TGTG GTGA TGAA GAAC AACG ACGA CGAA GAAG AAGG AGGC GGCG GCGA CGAG GAGA AGAT GATC ATCG TCGT CGTC GTCA TCAC CACA ACAG CAGT AGTC GTCA TCAT CATC ATCG TCGG CGGC GGCC GCCC CCCC CCCA CCAA CAAC AACG ACGG CGGC GGCG GCGC CGCG GCGG CGGG GGGC GGCA GCAA CAAG AAGA AGAC GACC ACCA CCAC CACG ACGC CGCT GCTG CTGC TGCT GCTG CTGT TGTG GTGC TGCG GCGC CGCG GCGG CGGC GGCA GCAA CAAT AATG ATGG TGGG GGGC GGCC GCCT CCTG CTGT TGTT GTTG,TTGCA TGCAA GCAAC CAACT AACTG ACTGA CTGAA TGAAG GAAGG AAGGA AGGAC GGACC GACCT ACCTG CCTGA CTGAC TGACC GACCG ACCGT CCGTG CGTGT GTGTC TGTCC GTCCT TCCTA CCTAT CTATG TATGG ATGGC TGGCC GGCCA GCCAG CCAGG CAGGT AGGTT GGTTG GTTGA TTGAG TGAGG GAGGC AGGCC GGCCG GCCGT CCGTT CGTTC GTTCA TTCAC TCACC CACCA ACCAA CCAAG CAAGT AAGTC AGTCC GTCCA TCCAG CCAGC CAGCT AGCTC GCTCG CTCGA TCGAT CGATG GATGT ATGTG TGTGA GTGAA TGAAC GAACG AACGA ACGAA CGAAG GAAGG AAGGC AGGCG GGCGA GCGAG CGAGA GAGAT AGATC GATCG ATCGT TCGTC CGTCA GTCAC TCACA CACAG ACAGT CAGTC AGTCA GTCAT TCATC CATCG ATCGG TCGGC CGGCC GGCCC GCCCC CCCCA CCCAA CCAAC CAACG AACGG ACGGC CGGCG GGCGC GCGCG CGCGG GCGGG CGGGC GGGCA GGCAA GCAAG CAAGA AAGAC AGACC GACCA ACCAC CCACG CACGC ACGCT CGCTG GCTGC CTGCT TGCTG GCTGT CTGTG TGTGC GTGCG TGCGC GCGCG CGCGG GCGGC CGGCA GGCAA GCAAT CAATG AATGG ATGGG TGGGC GGGCC GGCCT GCCTG CCTGT CTGTT TGTTG,TTGCAA TGCAAC GCAACT CAACTG AACTGA ACTGAA CTGAAG TGAAGG GAAGGA AAGGAC AGGACC GGACCT GACCTG ACCTGA CCTGAC CTGACC TGACCG GACCGT ACCGTG CCGTGT CGTGTC GTGTCC TGTCCT GTCCTA TCCTAT CCTATG CTATGG TATGGC ATGGCC TGGCCA GGCCAG GCCAGG CCAGGT CAGGTT AGGTTG GGTTGA GTTGAG TTGAGG TGAGGC GAGGCC AGGCCG GGCCGT GCCGTT CCGTTC CGTTCA GTTCAC TTCACC TCACCA CACCAA ACCAAG CCAAGT CAAGTC AAGTCC AGTCCA GTCCAG TCCAGC CCAGCT CAGCTC AGCTCG GCTCGA CTCGAT TCGATG CGATGT GATGTG ATGTGA TGTGAA GTGAAC TGAACG GAACGA AACGAA ACGAAG CGAAGG GAAGGC AAGGCG AGGCGA GGCGAG GCGAGA CGAGAT GAGATC AGATCG GATCGT ATCGTC TCGTCA CGTCAC GTCACA TCACAG CACAGT ACAGTC CAGTCA AGTCAT GTCATC TCATCG CATCGG ATCGGC TCGGCC CGGCCC GGCCCC GCCCCA CCCCAA CCCAAC CCAACG CAACGG AACGGC ACGGCG CGGCGC GGCGCG GCGCGG CGCGGG GCGGGC CGGGCA GGGCAA GGCAAG GCAAGA CAAGAC AAGACC AGACCA GACCAC ACCACG CCACGC CACGCT ACGCTG CGCTGC GCTGCT CTGCTG TGCTGT GCTGTG CTGTGC TGTGCG GTGCGC TGCGCG GCGCGG CGCGGC GCGGCA CGGCAA GGCAAT GCAATG CAATGG AATGGG ATGGGC TGGGCC GGGCCT GGCCTG GCCTGT CCTGTT CTGTTG,TTGCAAC TGCAACT GCAACTG CAACTGA AACTGAA ACTGAAG CTGAAGG TGAAGGA GAAGGAC AAGGACC AGGACCT GGACCTG GACCTGA ACCTGAC CCTGACC CTGACCG TGACCGT GACCGTG ACCGTGT CCGTGTC CGTGTCC GTGTCCT TGTCCTA GTCCTAT TCCTATG CCTATGG CTATGGC TATGGCC ATGGCCA TGGCCAG GGCCAGG GCCAGGT CCAGGTT CAGGTTG AGGTTGA GGTTGAG GTTGAGG TTGAGGC TGAGGCC GAGGCCG AGGCCGT GGCCGTT GCCGTTC CCGTTCA CGTTCAC GTTCACC TTCACCA TCACCAA CACCAAG ACCAAGT CCAAGTC CAAGTCC AAGTCCA AGTCCAG GTCCAGC TCCAGCT CCAGCTC CAGCTCG AGCTCGA GCTCGAT CTCGATG TCGATGT CGATGTG GATGTGA ATGTGAA TGTGAAC GTGAACG TGAACGA GAACGAA AACGAAG ACGAAGG CGAAGGC GAAGGCG AAGGCGA AGGCGAG GGCGAGA GCGAGAT CGAGATC GAGATCG AGATCGT GATCGTC ATCGTCA TCGTCAC CGTCACA GTCACAG TCACAGT CACAGTC ACAGTCA CAGTCAT AGTCATC GTCATCG TCATCGG CATCGGC ATCGGCC TCGGCCC CGGCCCC GGCCCCA GCCCCAA CCCCAAC CCCAACG CCAACGG CAACGGC AACGGCG ACGGCGC CGGCGCG GGCGCGG GCGCGGG CGCGGGC GCGGGCA CGGGCAA GGGCAAG GGCAAGA GCAAGAC CAAGACC AAGACCA AGACCAC GACCACG ACCACGC CCACGCT CACGCTG ACGCTGC CGCTGCT GCTGCTG CTGCTGT TGCTGTG GCTGTGC CTGTGCG TGTGCGC GTGCGCG TGCGCGG GCGCGGC CGCGGCA GCGGCAA CGGCAAT GGCAATG GCAATGG CAATGGG AATGGGC ATGGGCC TGGGCCT GGGCCTG GGCCTGT GCCTGTT CCTGTTG,"ID   LIVF_ECOLI              Reviewed;         237 AA.
AC   P22731; P76697; Q2M7B7;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1994, sequence version 2.
DT   27-NOV-2024, entry version 172.
DE   RecName: Full=High-affinity branched-chain amino acid transport ATP-binding protein LivF;
DE   AltName: Full=LIV-I protein F;
GN   Name=livF; OrderedLocusNames=b3454, JW3419;
OS   Escherichia coli (strain K12).
OC   Bacteria; Pseudomonadota; Gammaproteobacteria; Enterobacterales;
OC   Enterobacteriaceae; Escherichia.
OX   NCBI_TaxID=83333;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2195019; DOI=10.1016/s0021-9258(19)38417-0;
RA   Adams M.D., Wagner L.M., Graddis T.J., Landick R., Antonucci T.K.,
RA   Gibson A.L., Oxender D.L.;
RT   ""Nucleotide sequence and genetic characterization reveal six essential
RT   genes for the LIV-I and LS transport systems of Escherichia coli."";
RL   J. Biol. Chem. 265:11436-11443(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   PubMed=8041620; DOI=10.1093/nar/22.13.2576;
RA   Sofia H.J., Burland V., Daniels D.L., Plunkett G. III, Blattner F.R.;
RT   ""Analysis of the Escherichia coli genome. V. DNA sequence of the region
RT   from 76.0 to 81.5 minutes."";
RL   Nucleic Acids Res. 22:2576-2586(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   PubMed=9278503; DOI=10.1126/science.277.5331.1453;
RA   Blattner F.R., Plunkett G. III, Bloch C.A., Perna N.T., Burland V.,
RA   Riley M., Collado-Vides J., Glasner J.D., Rode C.K., Mayhew G.F.,
RA   Gregor J., Davis N.W., Kirkpatrick H.A., Goeden M.A., Rose D.J., Mau B.,
RA   Shao Y.;
RT   ""The complete genome sequence of Escherichia coli K-12."";
RL   Science 277:1453-1462(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RX   PubMed=16738553; DOI=10.1038/msb4100049;
RA   Hayashi K., Morooka N., Yamamoto Y., Fujita K., Isono K., Choi S.,
RA   Ohtsubo E., Baba T., Wanner B.L., Mori H., Horiuchi T.;
RT   ""Highly accurate genome sequences of Escherichia coli K-12 strains MG1655
RT   and W3110."";
RL   Mol. Syst. Biol. 2:E1-E5(2006).
RN   [5]
RP   IDENTIFICATION BY 2D-GEL.
RX   PubMed=9298644; DOI=10.1002/elps.1150180805;
RA   VanBogelen R.A., Abshire K.Z., Moldover B., Olson E.R., Neidhardt F.C.;
RT   ""Escherichia coli proteome analysis using the gene-protein database."";
RL   Electrophoresis 18:1243-1251(1997).
CC   -!- FUNCTION: Component of the leucine-specific transport system.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB18429.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; J05516; AAA83887.1; -; Genomic_DNA.
DR   EMBL; U00039; AAB18429.1; ALT_INIT; Genomic_DNA.
DR   EMBL; U00096; AAC76479.2; -; Genomic_DNA.
DR   EMBL; AP009048; BAE77839.1; -; Genomic_DNA.
DR   PIR; S47673; S47673.
DR   RefSeq; NP_417911.4; NC_000913.3.
DR   RefSeq; WP_000416891.1; NZ_SSZK01000008.1.
DR   AlphaFoldDB; P22731; -.
DR   SMR; P22731; -.
DR   BioGRID; 4261110; 30.
DR   BioGRID; 852270; 2.
DR   ComplexPortal; CPX-4316; Branched chain amino acid ABC transporter complex.
DR   ComplexPortal; CPX-4317; Branched chain amino acid, leucine-specific ABC transporter complex.
DR   IntAct; P22731; 13.
DR   STRING; 511145.b3454; -.
DR   TCDB; 3.A.1.4.1; the atp-binding cassette (abc) superfamily.
DR   PaxDb; 511145-b3454; -.
DR   EnsemblBacteria; AAC76479; AAC76479; b3454.
DR   GeneID; 86948307; -.
DR   GeneID; 947961; -.
DR   KEGG; ecj:JW3419; -.
DR   KEGG; eco:b3454; -.
DR   PATRIC; fig|511145.12.peg.3552; -.
DR   EchoBASE; EB0531; -.
DR   eggNOG; COG0410; Bacteria.
DR   HOGENOM; CLU_000604_1_2_6; -.
DR   InParanoid; P22731; -.
DR   OMA; IMMQKIM; -.
DR   OrthoDB; 9776369at2; -.
DR   PhylomeDB; P22731; -.
DR   BioCyc; EcoCyc:LIVF-MONOMER; -.
DR   BioCyc; MetaCyc:LIVF-MONOMER; -.
DR   PRO; PR:P22731; -.
DR   Proteomes; UP000000318; Chromosome.
DR   Proteomes; UP000000625; Chromosome.
DR   GO; GO:0055052; C:ATP-binding cassette (ABC) transporter complex, substrate-binding subunit-containing; NAS:ComplexPortal.
DR   GO; GO:0016020; C:membrane; NAS:ComplexPortal.
DR   GO; GO:0005524; F:ATP binding; ISM:EcoCyc.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IEA:InterPro.
DR   GO; GO:0015658; F:branched-chain amino acid transmembrane transporter activity; IDA:EcoCyc.
DR   GO; GO:0015188; F:L-isoleucine transmembrane transporter activity; IDA:EcoCyc.
DR   GO; GO:0015190; F:L-leucine transmembrane transporter activity; EXP:EcoCyc.
DR   GO; GO:0005304; F:L-valine transmembrane transporter activity; IDA:EcoCyc.
DR   GO; GO:0015803; P:branched-chain amino acid transport; IDA:EcoCyc.
DR   GO; GO:1903714; P:isoleucine transmembrane transport; IDA:EcoCyc.
DR   GO; GO:0015807; P:L-amino acid transport; IBA:GO_Central.
DR   GO; GO:1903785; P:L-valine transmembrane transport; IDA:EcoCyc.
DR   GO; GO:0015823; P:phenylalanine transport; IDA:EcoCyc.
DR   CDD; cd03224; ABC_TM1139_LivF_branched; 1.
DR   FunFam; 3.40.50.300:FF:000341; High-affinity branched-chain amino acid transport ATP-binding protein; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR030660; ABC_branched_ATPase_LivF/BraG.
DR   InterPro; IPR003439; ABC_transporter-like_ATP-bd.
DR   InterPro; IPR017871; ABC_transporter-like_CS.
DR   InterPro; IPR052156; BCAA_Transport_ATP-bd_LivF.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   PANTHER; PTHR43820; HIGH-AFFINITY BRANCHED-CHAIN AMINO ACID TRANSPORT ATP-BINDING PROTEIN LIVF; 1.
DR   PANTHER; PTHR43820:SF4; HIGH-AFFINITY BRANCHED-CHAIN AMINO ACID TRANSPORT ATP-BINDING PROTEIN LIVF; 1.
DR   Pfam; PF00005; ABC_tran; 1.
DR   PIRSF; PIRSF039137; ABC_branched_ATPase; 1.
DR   SMART; SM00382; AAA; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 1.
PE   1: Evidence at protein level;
KW   Amino-acid transport; ATP-binding; Nucleotide-binding; Reference proteome;
KW   Transport.
FT   CHAIN           1..237
FT                   /note=""High-affinity branched-chain amino acid transport
FT                   ATP-binding protein LivF""
FT                   /id=""PRO_0000092401""
FT   DOMAIN          6..237
FT                   /note=""ABC transporter""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00434""
FT   BINDING         38..45
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00434""
FT   CONFLICT        56
FT                   /note=""R -> G (in Ref. 1; AAA83887)""
FT                   /evidence=""ECO:0000305""
FT   CONFLICT        120
FT                   /note=""V -> A (in Ref. 1; AAA83887)""
FT                   /evidence=""ECO:0000305""
FT   CONFLICT        200
FT                   /note=""A -> G (in Ref. 1; AAA83887)""
FT                   /evidence=""ECO:0000305""
SQ   SEQUENCE   237 AA;  26310 MW;  7E4129E54ED1BD02 CRC64;
     MEKVMLSFDK VSAHYGKIQA LHEVSLHINQ GEIVTLIGAN GAGKTTLLGT LCGDPRATSG
     RIVFDDKDIT DWQTAKIMRE AVAIVPEGRR VFSRMTVEEN LAMGGFFAER DQFQERIKWV
     YELFPRLHER RIQRAGTMSG GEQQMLAIGR ALMSNPRLLL LDEPSLGLAP IIIQQIFDTI
     EQLREQGMTI FLVEQNANQA LKLADRGYVL ENGHVVLSDT GDALLANEAV RSAYLGG
//
",28256
ATTCCG TTCCGG TCCGGC CCGGCA CGGCAT GGCATT GCATTC CATTCT ATTCTC TTCTCT TCTCTC CTCTCT TCTCTT CTCTTC TCTTCT CTTCTT TTCTTA TCTTAA CTTAAA TTAAAA TAAAAA AAAAAT AAAATC AAATCC AATCCA ATCCAC TCCACA CCACAG CACAGC ACAGCT CAGCTC AGCTCC GCTCCT CTCCTT TCCTTC CCTTCC CTTCCG TTCCGG TCCGGT CCGGTA CGGTAC GGTACT GTACTG TACTGC ACTGCT CTGCTT TGCTTC GCTTCG CTTCGT TTCGTC TCGTCT CGTCTC GTCTCT TCTCTT CTCTTT TCTTTA CTTTAA TTTAAG TTAAGA TAAGAA AAGAAT AGAATG GAATGC AATGCT ATGCTC TGCTCC GCTCCT CTCCTC TCCTCT CCTCTA CTCTAC TCTACC CTACCA TACCAC ACCACT CCACTT CACTTG ACTTGC CTTGCA TTGCAA TGCAAT GCAATA CAATAA AATAAA ATAAAT TAAATT AAATTG AATTGC ATTGCA TTGCAA TGCAAA GCAAAT CAAATC AAATCC AATCCG ATCCGC TCCGCA CCGCAG CGCAGC GCAGCT CAGCTT AGCTTC GCTTCG CTTCGG TTCGGT TCGGTA CGGTAA GGTAAC GTAACT TAACTG AACTGG ACTGGC CTGGCT TGGCTT GGCTTA GCTTAG CTTAGC TTAGCC TAGCCC AGCCCC GCCCCG CCCCGT CCCGTT CCGTTA CGTTAC GTTACA TTACAT TACATC ACATCT CATCTT ATCTTC TCTTCC CTTCCG TTCCGC TCCGCG CCGCGC CGCGCA GCGCAG CGCAGG GCAGGA CAGGAC AGGACG GGACGA GACGAC ACGACT,3,145,ATTC TTCC TCCG CCGG CGGC GGCA GCAT CATT ATTC TTCT TCTC CTCT TCTC CTCT TCTT CTTC TTCT TCTT CTTA TTAA TAAA AAAA AAAA AAAT AATC ATCC TCCA CCAC CACA ACAG CAGC AGCT GCTC CTCC TCCT CCTT CTTC TTCC TCCG CCGG CGGT GGTA GTAC TACT ACTG CTGC TGCT GCTT CTTC TTCG TCGT CGTC GTCT TCTC CTCT TCTT CTTT TTTA TTAA TAAG AAGA AGAA GAAT AATG ATGC TGCT GCTC CTCC TCCT CCTC CTCT TCTA CTAC TACC ACCA CCAC CACT ACTT CTTG TTGC TGCA GCAA CAAT AATA ATAA TAAA AAAT AATT ATTG TTGC TGCA GCAA CAAA AAAT AATC ATCC TCCG CCGC CGCA GCAG CAGC AGCT GCTT CTTC TTCG TCGG CGGT GGTA GTAA TAAC AACT ACTG CTGG TGGC GGCT GCTT CTTA TTAG TAGC AGCC GCCC CCCC CCCG CCGT CGTT GTTA TTAC TACA ACAT CATC ATCT TCTT CTTC TTCC TCCG CCGC CGCG GCGC CGCA GCAG CAGG AGGA GGAC GACG ACGA CGAC GACT,ATTCC TTCCG TCCGG CCGGC CGGCA GGCAT GCATT CATTC ATTCT TTCTC TCTCT CTCTC TCTCT CTCTT TCTTC CTTCT TTCTT TCTTA CTTAA TTAAA TAAAA AAAAA AAAAT AAATC AATCC ATCCA TCCAC CCACA CACAG ACAGC CAGCT AGCTC GCTCC CTCCT TCCTT CCTTC CTTCC TTCCG TCCGG CCGGT CGGTA GGTAC GTACT TACTG ACTGC CTGCT TGCTT GCTTC CTTCG TTCGT TCGTC CGTCT GTCTC TCTCT CTCTT TCTTT CTTTA TTTAA TTAAG TAAGA AAGAA AGAAT GAATG AATGC ATGCT TGCTC GCTCC CTCCT TCCTC CCTCT CTCTA TCTAC CTACC TACCA ACCAC CCACT CACTT ACTTG CTTGC TTGCA TGCAA GCAAT CAATA AATAA ATAAA TAAAT AAATT AATTG ATTGC TTGCA TGCAA GCAAA CAAAT AAATC AATCC ATCCG TCCGC CCGCA CGCAG GCAGC CAGCT AGCTT GCTTC CTTCG TTCGG TCGGT CGGTA GGTAA GTAAC TAACT AACTG ACTGG CTGGC TGGCT GGCTT GCTTA CTTAG TTAGC TAGCC AGCCC GCCCC CCCCG CCCGT CCGTT CGTTA GTTAC TTACA TACAT ACATC CATCT ATCTT TCTTC CTTCC TTCCG TCCGC CCGCG CGCGC GCGCA CGCAG GCAGG CAGGA AGGAC GGACG GACGA ACGAC CGACT,ATTCCG TTCCGG TCCGGC CCGGCA CGGCAT GGCATT GCATTC CATTCT ATTCTC TTCTCT TCTCTC CTCTCT TCTCTT CTCTTC TCTTCT CTTCTT TTCTTA TCTTAA CTTAAA TTAAAA TAAAAA AAAAAT AAAATC AAATCC AATCCA ATCCAC TCCACA CCACAG CACAGC ACAGCT CAGCTC AGCTCC GCTCCT CTCCTT TCCTTC CCTTCC CTTCCG TTCCGG TCCGGT CCGGTA CGGTAC GGTACT GTACTG TACTGC ACTGCT CTGCTT TGCTTC GCTTCG CTTCGT TTCGTC TCGTCT CGTCTC GTCTCT TCTCTT CTCTTT TCTTTA CTTTAA TTTAAG TTAAGA TAAGAA AAGAAT AGAATG GAATGC AATGCT ATGCTC TGCTCC GCTCCT CTCCTC TCCTCT CCTCTA CTCTAC TCTACC CTACCA TACCAC ACCACT CCACTT CACTTG ACTTGC CTTGCA TTGCAA TGCAAT GCAATA CAATAA AATAAA ATAAAT TAAATT AAATTG AATTGC ATTGCA TTGCAA TGCAAA GCAAAT CAAATC AAATCC AATCCG ATCCGC TCCGCA CCGCAG CGCAGC GCAGCT CAGCTT AGCTTC GCTTCG CTTCGG TTCGGT TCGGTA CGGTAA GGTAAC GTAACT TAACTG AACTGG ACTGGC CTGGCT TGGCTT GGCTTA GCTTAG CTTAGC TTAGCC TAGCCC AGCCCC GCCCCG CCCCGT CCCGTT CCGTTA CGTTAC GTTACA TTACAT TACATC ACATCT CATCTT ATCTTC TCTTCC CTTCCG TTCCGC TCCGCG CCGCGC CGCGCA GCGCAG CGCAGG GCAGGA CAGGAC AGGACG GGACGA GACGAC ACGACT,ATTCCGG TTCCGGC TCCGGCA CCGGCAT CGGCATT GGCATTC GCATTCT CATTCTC ATTCTCT TTCTCTC TCTCTCT CTCTCTT TCTCTTC CTCTTCT TCTTCTT CTTCTTA TTCTTAA TCTTAAA CTTAAAA TTAAAAA TAAAAAT AAAAATC AAAATCC AAATCCA AATCCAC ATCCACA TCCACAG CCACAGC CACAGCT ACAGCTC CAGCTCC AGCTCCT GCTCCTT CTCCTTC TCCTTCC CCTTCCG CTTCCGG TTCCGGT TCCGGTA CCGGTAC CGGTACT GGTACTG GTACTGC TACTGCT ACTGCTT CTGCTTC TGCTTCG GCTTCGT CTTCGTC TTCGTCT TCGTCTC CGTCTCT GTCTCTT TCTCTTT CTCTTTA TCTTTAA CTTTAAG TTTAAGA TTAAGAA TAAGAAT AAGAATG AGAATGC GAATGCT AATGCTC ATGCTCC TGCTCCT GCTCCTC CTCCTCT TCCTCTA CCTCTAC CTCTACC TCTACCA CTACCAC TACCACT ACCACTT CCACTTG CACTTGC ACTTGCA CTTGCAA TTGCAAT TGCAATA GCAATAA CAATAAA AATAAAT ATAAATT TAAATTG AAATTGC AATTGCA ATTGCAA TTGCAAA TGCAAAT GCAAATC CAAATCC AAATCCG AATCCGC ATCCGCA TCCGCAG CCGCAGC CGCAGCT GCAGCTT CAGCTTC AGCTTCG GCTTCGG CTTCGGT TTCGGTA TCGGTAA CGGTAAC GGTAACT GTAACTG TAACTGG AACTGGC ACTGGCT CTGGCTT TGGCTTA GGCTTAG GCTTAGC CTTAGCC TTAGCCC TAGCCCC AGCCCCG GCCCCGT CCCCGTT CCCGTTA CCGTTAC CGTTACA GTTACAT TTACATC TACATCT ACATCTT CATCTTC ATCTTCC TCTTCCG CTTCCGC TTCCGCG TCCGCGC CCGCGCA CGCGCAG GCGCAGG CGCAGGA GCAGGAC CAGGACG AGGACGA GGACGAC GACGACT,"ID   YCX91_PHAAO             Reviewed;          91 AA.
AC   Q3BAI2;
DT   25-JUL-2006, integrated into UniProtKB/Swiss-Prot.
DT   22-NOV-2005, sequence version 1.
DT   05-FEB-2025, entry version 27.
DE   RecName: Full=Uncharacterized protein ORF91;
OS   Phalaenopsis aphrodite subsp. formosana (Moth orchid).
OG   Plastid; Chloroplast.
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliopsida; Liliopsida; Asparagales; Orchidaceae;
OC   Epidendroideae; Vandeae; Aeridinae; Phalaenopsis.
OX   NCBI_TaxID=308872;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=cv. Taisugar TS-97;
RX   PubMed=16207935; DOI=10.1093/molbev/msj029;
RA   Chang C.-C., Lin H.-C., Lin I.-P., Chow T.-Y., Chen H.-H., Chen W.-H.,
RA   Cheng C.-H., Lin C.-Y., Liu S.-M., Chang C.-C., Chaw S.-M.;
RT   ""The chloroplast genome of Phalaenopsis aphrodite (Orchidaceae):
RT   comparative analysis of evolutionary rate with that of grasses and its
RT   phylogenetic implications."";
RL   Mol. Biol. Evol. 23:279-291(2006).
CC   -!- SUBCELLULAR LOCATION: Plastid, chloroplast.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY916449; AAW82572.1; -; Genomic_DNA.
DR   RefSeq; YP_358636.1; NC_007499.1.
DR   AlphaFoldDB; Q3BAI2; -.
DR   GeneID; 3741793; -.
DR   GO; GO:0009507; C:chloroplast; IEA:UniProtKB-SubCell.
DR   AntiFam; ANF00025; Antisense to 23S rRNA.
PE   4: Predicted;
KW   Chloroplast; Plastid.
FT   CHAIN           1..91
FT                   /note=""Uncharacterized protein ORF91""
FT                   /id=""PRO_0000246135""
SQ   SEQUENCE   91 AA;  10596 MW;  C770491A1FF96EE8 CRC64;
     MQVVRIFTDM SISPSLSPRQ CPDRYAFRAG RNLPDKEFRY LRTVLVTAAV HRGFGRRLPC
     HQVTNFLDLP ALGRRQPPYM VLRLCGDLCF W
//
",64814
CCCAAG CCAAGG CAAGGT AAGGTT AGGTTT GGTTTA GTTTAC TTTACC TTACCC TACCCA ACCCAA CCCAAT CCAATA CAATAA AATAAT ATAATA TAATAC AATACT ATACTG TACTGC ACTGCG CTGCGT TGCGTC GCGTCT CGTCTT GTCTTG TCTTGG CTTGGT TTGGTT TGGTTC GGTTCA GTTCAC TTCACC TCACCG CACCGC ACCGCT CCGCTC CGCTCT GCTCTC CTCTCA TCTCAC CTCACT TCACTC CACTCA ACTCAA CTCAAC TCAACA CAACAT AACATG ACATGG CATGGC ATGGCA TGGCAA GGCAAG GCAAGG CAAGGA AAGGAA AGGAAG GGAAGA GAAGAC AAGACC AGACCT GACCTT ACCTTA CCTTAA CTTAAA TTAAAT TAAATT AAATTC AATTCC ATTCCC TTCCCT TCCCTC CCCTCG CCTCGA CTCGAG TCGAGG CGAGGA GAGGAC AGGACA GGACAA GACAAG,1,82,CCCCCAA CGTCCCTC TAA A C CACAAAAGT GG A AAAAGAGGGG G A AGAGGGGTGT T GAC GGTGTTTT AG  GTGTTTTTTT  TTTTTTA A T CCTTATACC TTACGCACC C AACCCCCCC C C CCCCC ACCA A CGGTCAAC TA CCAAAT T A AAAATATATA A A ATATATAAAA AGG TAAATAT T A AAAATATATA A A ATGACCCA GGC T TAG TACTCT T A ACACTCTGTG GAC GCCTGTGCCAAGCGCG G G GCGCGCGTGT T C CGCGT ACTC C G GT CCTCTCT CT  TCTCTCTTTT  CTCTTTTGTG G T TTTTGTGGGG G T TGTGG CCGAAT G GGGGTGTTAATT G GTGTTTTCTC C T TTTTC CTCA AA  TCTCACACAC C C CAACCCC C AGTCACCCCGCG G C CCCCGCGCC C CGCGCGCT TCTCG CTA TCTCAG C C CTCTCTCTCT T T TCCTCTC C CCTCTCACA A TA CTCAAATAC CAC CACACACTT TA T ACACTTCATC C C CTCTCTAACA A T TCTCACAAT AA C CACAAAACAC  AAAACACACA A AACACATAT T CCATATGTG G AATGTGGGG G T TG GAGC C G GGGGCACCCA A G GCGCACAAAA CT  CACAAAAGAG  AAAAGAGGGG G A AGAGGGGAGA A G GGGGAGAAAA A GGGCGT AAGG A AAAAGAGAGA A A AGCA AAAAC C G GAGACACCCC C A ACACCCCTCT C CCCACTTTT T CCTCCTTTTATA  TTTAAGC A TTAAAAAAA A A AAGACCACAT  AAATTTT T AATTTTCTC C T TTTTCTCCCC AA  TCCCCCC C C TTCCCCCTCT C A CCCCTCTCTC  CTCTCTCG TCT GCGAGA A CATACGAGAGG GGAGAGGGG G A AGGCTGGAGA A G GGGGA CGAC C G GAG CACACA A AACAAA A C CACAAAAG,CCCCCACAAAA A CTT AAGAG TGC CACAAAGGCC G A AAAAGTCAGGTGT ATT AGTCAGGTAATAT  GGGTTTTTTT  GTGTTTTTTTATA A TTTTTTAC GC T TTTTAA CACCCC AAT TATACACCCCCC AAAAACCCCCCCACA  CCCCCCCACAAAA A C CCCCACAAGTTAT TAC TGAATATATA A A AAAATATACT A A ATTAAC TAT T T TATAAAATATATA A A AAAATATATACAGGC A ATATATACACTCT T T TAGGAACTCTGTG G A AC TGCTGTGCGC C C CTCTGTGCGCGCG G TACTG CGCGCGTGT T G GCGCGCGTGTCTC C GCGTGTCTCTCT T G CTGTCCTTTT T TAAGCTTTTGT CGGACTTGG G TGA TTGTGGGGTGT T TTGGGGTGTTTT T G GGT CGTTGGTTC C G GTGTTTCACA A T TTACACACA GTCACACACCC C CACACACCCCGCG G ATG ACCCCGCGCGC C C CCAG CT T C AAGCTCGCCTCTC C G GCGCTCTCTCTAA T C CTCTCTCTCTCTC C T TCTCTCTCAGGCA CCT GTCTC CACACAC C T TCCCCCACTACCT T CCACACTCTCTC C A ACACTCTCTCA CGA C CTCCTTCACAAAA  TCTCACAAAACAC C C CATTGAACTTCCA A A AAAACACATT T A ACACACATATG AC CACATATGTGGGG G A ATATGTGGGGCGC AA  TGTC GGCGCAA G GGGGCGCACAAAA A G GCGCACAAAAGCCGG CCAAAAGAGGGG G A AAAAGTTAGAAGA A A AGAGGGGAGAA TC GGGGAGGAAAGAG G G GAGAAAAGAGAA A CG AGAGAGACC A CAAGAACCCC  GAGACACCCCT ACACCTACCTTTT T C CCCTCCTTTTATA  CTCTTAC TAAC TA T TTTTATAA ACAA A T TATAAAAAAATAT T AAAAATT CC AAAATT ATTCTGGC ACAATCCC T TTTTCTCCCCCCC C T TCTCCTCACCTCT GGT CCCCCCCTCTCTC C C CCCCT GACG G C CTCTCTCGCGAGA A T TCTCGCGAGAGAG G CCA GAGAGGGG G GCTCGAGAGGTG A A AGAGGGGAGACAC AC  GG CTGACACAA GAGGGACACACAAAA A A ACACACAA TC,CCCCCACAAAAGAG  CCCCACAAAAGAGGGG G C CACAAAAG TCGGTGT A C AAAAGAGGCTCT A AGAATGGTGG TTTT GAGAGGTGTTTTTTTATA A GAG GTTTTTTTATACAC C T TTTTTTTATACACCCC C T TTTTATACACCCGCCGCC TCAATACACCCCCCCACA A A ACACCCCCCCACAAA C CCCCCCCAACTAATAT T C CCCCACAAAATATATA A C CACAAAATATATAAAA A A AAAATATATAAAATG CT A ATATATAAAATATAGACA T TATAAAATATATACAC C A AAAGGATATACACTT A ATAAGTAC TACA TG G T TATACACTCTGTGCGC C ACTGTGCGCGCG G CGAACTGTTCGCGCGTGT T T TGGGCGCGCGTGTCTC C G GACGTGTCTCTCT T CATTCGTGACTCTTT T G GTGTCTCTCTTTTGG T TCTCTCTTTTGGTTCA  CTCTTTTGGGTGT  TTTTGCTCGTTTGCTGGTTCTGG GAGTTTGCTC C G GGCAAGTTTTCTCACA A G GTGTT CCCACAC TTCTCACACACCCC C T TCTCACACACCCCGCG G C CAACCCCGCGCGC A A ACACCCCGCCCGCTCT T CTAACGCGCTCTCTC C CGGACC GCT AATCTCT T G GCGCTCTCTCTGGTTC C C CTTCGTCTCTCTCACA  GT TCTCTCTCTCACACAC C CCTCTCACACACTCT T T AGTCACACACTTC C C CACACACTCTCTCAG C ACTCACAAAA A C CTCTCCAAAACAC C T TCTCACAAAACACAGCACAAAACACACATAT TCC AA ATACACATATGCAAG A ACACACATATGTGGGG G CAACCATATGTGGTT GC  CAATGTGGGGCGCACA A TTGGCC  CACAAAA A G GGGGCGCACCCAAGA TG G GCGCATG AAGAGGGG G C CACAAAAGAGGGGAGA TT AAGAGGGGAAC  AC TCAGG CGGAAAAGAG G G GGGGAGAAAAGATAGA A GGAAAAGAGAGAC CTC A AAAGA GGGACACCCC C A AGAGAGACACCCCTCT T G GATA ACCCCTCTTTT T A ACACCCCTCTTTTATA A CCCTTTATAAAA A C CTCTTTTATAACACAA A T TTTAAAATAT T TGA CCGAAAAATATTTT T A AAAAAGAGCTCTTCTC C AA CAAT TGTCCC A ATATTTTCTCCGGTC T TTTTCT ACCCCCTCT T T TCTCCCCCCCTCTCTC C C CCCCCCC CTCTCGCG G C CCCCTCTCTCGCGAGA T A CTATTCTCCGAAATAG G TAGGTCGCGAGAGAGGGG G CCGACAAGGA TA GCGAGAGGGGAAA  CGC A TGAGGGGAGACACACA A G GGGGAGACACACAAA G GAGTCACAGAG,CCCCCAAAGAC G C CCCCACAAAAGAGGGGTGT T C CACAAAAGAGGGGTGTTTT T A AAAGGCGCTCATTTTT T A AGAGGGGTGTTTTTAATTA  CA GGGGTTTTTTAAGGGTT GTGTTTTTTTATACCACCC C T TTTTTTACACCCCCCC C TC ATTAACCCCCCCACA A T TATACACCAGGCAAAA  ACACCCCCCCACAAAATAT T C CCCCCCCACAAAATATATA A C CCCAAAATATATAAAA A C CACAAAATTAAAATAT  AAC TATAAAGAATATTTA A A ATATATAACTCATATACAC C T TATAAAATATATACACTCT T A AATTAATATACGGTCTTG A ATATATACACTCTGGC TCG TATACCATCTGTGCGCGCG GGT ACACTCTGTGCGCGCGTGT T CCTG TGGCGCGTGTCTC TGCTGCCGTGTCTCTCT T G GCAGGCCCTTGTCTCTTCTTT C CGCGTGTC ACCTTG TTG G GATGG CTCTCTTTTGTGGGG G T TCCTTGTCTGGCTCGT T C CTCTTTTGTGGGGTGTTTT ATG TTTTGTGGACTGTTTTCGGAC T TGTGGGTTTCACA A G GGGGTGTTTAAC GC AAC C GT TGTTTTCTCAACCCC  TTTTCTCACACACCCCGCG G T TCTCAGGT TTCGCGC C C CACACACCCAAGCTCT T A ACACCCCGCGCGCTCTCACCC C CCGCTAAGTCTT C CGCGCGCTCTCTCTTC C G GCGCTCTCTCTCTCTCACA A C CTTCTCTCTCACACAC  CT TC CTCTCTCAACCT C CTCTCTCACTCTC  TCTCACACACTAATTCAA CCTCGGAACTGGACAAAA A A ACCTCTCACAAAACCATTCTCTCTCACAAAACACACA A TTCACCCACAAC AT T C CAAACTCTCATATGTG G A AAAACCATATG TCGG G AACAACAACT GTTGGGGCGC C CA GCATT TTGGGGCGCACA A A ATATGTGGGCACAAAA A T TGTGGGGCGCATC AAGAG G GT AGGCGCAAAGAGGGG G G GCGCACAAGACGGAGA A C CACAACTCGGAGAAAA A A AAACAAGGGGAGAAAAGAG G A AGAGGGGAGAAAAGAGAGA A G GGGAAAAGAGAGACATAC G GAGAAAAGAGAGACCC  TT AAAAGAGAGACCT  GG AGAGATAAACCCCTACCTT T G GAGACCAACCTCTTTA A A ACACCCCTCTTTTATAAAA  CCCCTGGAACTTAAAAAAA  CTTG TTATTCAAAAATAT T T TTTTATAAAAAAATATTTT T T TATAAGTTAATATTTTCTC CACTCAAAAAATATTTTCTCCCC C A AAAC TTCTCCCCCCC C A ATATTTTCTCCCCCCCTCT  GTTTCTCCCCTCTCTC C T TCTCCCCCCG  CATCGCCTGTCCGTCCTCTCC TCGAGA A C CCAATCTCTCGCGATTGAG  CTCTCTCGCGAGAGAGGGG GAG TCCGAGAGTTAGA  CGCGAGAGAGGCACGACAC  GAGAGAGGTC ACACA A ATTA AAGACACACAAAA A G GGGGAGACAAGCAAAAG,"ID   ORF9B_SARS2             Reviewed;          97 AA.
AC   P0DTD2;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   27-NOV-2024, entry version 24.
DE   RecName: Full=ORF9b protein;
DE            Short=ORF9b;
DE   AltName: Full=Accessory protein 9b;
DE   AltName: Full=ORF-9b;
DE   AltName: Full=Protein 9b;
GN   ORFNames=9b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.05 ANGSTROMS), INTERACTION WITH HUMAN
RP   TOMM70, AND SUBCELLULAR LOCATION.
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [3]
RP   FUNCTION, AND INTERACTION WITH HOST TOMM70.
RX   PubMed=32728199; DOI=10.1038/s41423-020-0514-8;
RA   Jiang H.W., Zhang H.N., Meng Q.F., Xie J., Li Y., Chen H., Zheng Y.X.,
RA   Wang X.N., Qi H., Zhang J., Wang P.H., Han Z.G., Tao S.C.;
RT   ""SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting
RT   TOM70."";
RL   Cell. Mol. Immunol. 17:998-1000(2020).
RN   [4]
RP   FUNCTION, MUTAGENESIS OF SER-53, SUBCELLULAR LOCATION, AND INTERACTION WITH
RP   HOST TOMM70.
RX   PubMed=34502139; DOI=10.3390/ijms22179233;
RA   Brandherm L., Kobas A.M., Kloehn M., Brueggemann Y., Pfaender S.,
RA   Rassow J., Kreimendahl S.;
RT   ""Phosphorylation of SARS-CoV-2 Orf9b Regulates Its Targeting to Two Binding
RT   Sites in TOM70 and Recruitment of Hsp90."";
RL   Int. J. Mol. Sci. 22:0-0(2021).
RN   [5] {ECO:0007744|PDB:6Z4U}
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS), AND HOMODIMERIZATION.
RA   Weeks S.D., De Graef S., Munawar A.;
RT   ""X-ray Crystallographic Structure of Orf9b from SARS-CoV-2."";
RL   Submitted (MAY-2020) to the PDB data bank.
RN   [6]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.20 ANGSTROMS) OF 1-97, AND INTERACTION
RP   WITH HOST TOMM70.
RX   PubMed=33990585; DOI=10.1038/s41467-021-23118-8;
RA   Gao X., Zhu K., Qin B., Olieric V., Wang M., Cui S.;
RT   ""Crystal structure of SARS-CoV-2 Orf9b in complex with human TOM70 suggests
RT   unusual virus-host interactions."";
RL   Nat. Commun. 12:2843-2843(2021).
CC   -!- FUNCTION: Plays a role in inhibiting the host innate immune response by
CC       targeting the mitochondrial-associated innate immune response. Acts by
CC       binding to host TOMM70, inhibiting its binding to HSP90AB1 thereby
CC       disrupting the interferon activation pathway.
CC       {ECO:0000269|PubMed:32728199, ECO:0000269|PubMed:34502139}.
CC   -!- SUBUNIT: Homodimer (Ref.5). Interacts with host TOMM70
CC       (PubMed:33060197, PubMed:32728199, PubMed:34502139, PubMed:33990585);
CC       the interaction occurs only with monomer (PubMed:33990585).
CC       {ECO:0000269|PubMed:32728199, ECO:0000269|PubMed:33060197,
CC       ECO:0000269|PubMed:33990585, ECO:0000269|PubMed:34502139,
CC       ECO:0000269|Ref.5}.
CC   -!- INTERACTION:
CC       P0DTD2; P0DTD2: 9b; NbExp=5; IntAct=EBI-25475909, EBI-25475909;
CC       P0DTD2; Q9Y6K9: IKBKG; Xeno; NbExp=3; IntAct=EBI-25475909, EBI-81279;
CC       P0DTD2; O94826: TOMM70; Xeno; NbExp=28; IntAct=EBI-25475909, EBI-2800236;
CC   -!- SUBCELLULAR LOCATION: Host cytoplasm {ECO:0000269|PubMed:32728199,
CC       ECO:0000269|PubMed:33060197, ECO:0000269|PubMed:34502139}. Host
CC       mitochondrion {ECO:0000269|PubMed:32728199,
CC       ECO:0000269|PubMed:33060197}.
CC   -!- POLYMORPHISM: Variant Omicron/BA.1 and BA.2 belong to a lineage first
CC       isolated in South Africa (November 2021). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/BQ.1.1 belongs to a lineage first
CC       isolated in Nigeria (November 2022). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/XBB.1.5 belongs to a lineage first
CC       isolated in United States (November 2022). It is the result of
CC       recombination between omicron BJ.1 and BM.1.1. Moreover XBB.1.5 do not
CC       express ORF8. {ECO:0000305}.
CC   -!- MISCELLANEOUS: The open reading frame (ORF) encoding for this protein
CC       overlaps with the N ORF. {ECO:0000269|PubMed:32015508}.
CC   -!- SIMILARITY: Belongs to the coronavirus group 2 protein 9b family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR   PDB; 6Z4U; X-ray; 1.95 A; A/B=1-97.
DR   PDB; 7DHG; X-ray; 2.20 A; B=1-97.
DR   PDB; 7KDT; EM; 3.05 A; B=1-97.
DR   PDB; 7YE7; X-ray; 2.95 A; A/B/C/D=1-97.
DR   PDB; 7YE8; X-ray; 3.01 A; A/B/C/D=1-97.
DR   PDBsum; 6Z4U; -.
DR   PDBsum; 7DHG; -.
DR   PDBsum; 7KDT; -.
DR   PDBsum; 7YE7; -.
DR   PDBsum; 7YE8; -.
DR   EMDB; EMD-22829; -.
DR   SMR; P0DTD2; -.
DR   BioGRID; 4383874; 613.
DR   ComplexPortal; CPX-6100; SARS-CoV-2 9b complex.
DR   IntAct; P0DTD2; 94.
DR   MINT; P0DTD2; -.
DR   iPTMnet; P0DTD2; -.
DR   AGR; RefSeq:P0DTD2; -.
DR   Reactome; R-HSA-168928; DDX58/IFIH1-mediated induction of interferon-alpha/beta.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   Reactome; R-HSA-9727281; Translation of Accessory Proteins.
DR   PRO; PR:P0DTD2; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0033650; C:host cell mitochondrion; IEA:UniProtKB-SubCell.
DR   GO; GO:0031966; C:mitochondrial membrane; IDA:UniProt.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IDA:ComplexPortal.
DR   GO; GO:0098799; C:outer mitochondrial membrane protein complex; ISO:ComplexPortal.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0140311; F:protein sequestering activity; IDA:UniProt.
DR   GO; GO:0050687; P:negative regulation of defense response to virus; IDA:ComplexPortal.
DR   GO; GO:0090258; P:negative regulation of mitochondrial fission; ISO:ComplexPortal.
DR   GO; GO:2000786; P:positive regulation of autophagosome assembly; ISO:ComplexPortal.
DR   GO; GO:0039545; P:symbiont-mediated suppression of host cytoplasmic pattern recognition receptor signaling pathway via inhibition of MAVS activity; IDA:UniProt.
DR   GO; GO:0039502; P:symbiont-mediated suppression of host type I interferon-mediated signaling pathway; IDA:ComplexPortal.
DR   GO; GO:0019049; P:virus-mediated perturbation of host defense response; IEA:UniProtKB-KW.
DR   CDD; cd21955; SARS-CoV_ORF9b; 1.
DR   InterPro; IPR018542; Protein_9b_Betacoronavirus.
DR   InterPro; IPR037223; Protein_9b_SARS.
DR   Pfam; PF09399; bCoV_lipid_BD; 1.
DR   SUPFAM; SSF141666; SARS ORF9b-like; 1.
DR   PROSITE; PS51920; SARS_9B; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Host cytoplasm; Host mitochondrion; Host-virus interaction;
KW   Inhibition of host innate immune response by virus;
KW   Inhibition of host MAVS by virus; Inhibition of host RLR pathway by virus;
KW   Reference proteome; Viral immunoevasion.
FT   CHAIN           1..97
FT                   /note=""ORF9b protein""
FT                   /evidence=""ECO:0000250|UniProtKB:P59636""
FT                   /id=""PRO_0000449657""
FT   DOMAIN          8..97
FT                   /note=""9b""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01268""
FT   MOTIF           45..53
FT                   /note=""Nuclear export signal""
FT                   /evidence=""ECO:0000250|UniProtKB:P59636""
FT   VARIANT         10
FT                   /note=""P -> S (in strain: Omicron/BA.1, Omicron/BA.2,
FT                   Omicron/BA.2.12.1, Omicron/BA.4, Omicron/BA.5,
FT                   Omicron/XBB.1.5, Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         27..29
FT                   /note=""Missing (in strain: Omicron/BA.1, Omicron/BA.2,
FT                   Omicron/BA.2.12.1, Omicron/BA.4, Omicron/BA.5,
FT                   Omicron/XBB.1.5, Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         60
FT                   /note=""T -> A (in strain: Delta/B.1.617.2)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         77
FT                   /note=""Q -> E (in strain: Gamma/P.1)""
FT                   /evidence=""ECO:0000305""
FT   MUTAGEN         53
FT                   /note=""S->E: Complete loss of binding to host TOMM70.""
FT                   /evidence=""ECO:0000269|PubMed:34502139""
FT   HELIX           5..7
FT                   /evidence=""ECO:0007829|PDB:6Z4U""
FT   STRAND          12..15
FT                   /evidence=""ECO:0007829|PDB:6Z4U""
FT   STRAND          19..23
FT                   /evidence=""ECO:0007829|PDB:6Z4U""
FT   STRAND          40..42
FT                   /evidence=""ECO:0007829|PDB:6Z4U""
FT   STRAND          44..50
FT                   /evidence=""ECO:0007829|PDB:6Z4U""
FT   STRAND          52..61
FT                   /evidence=""ECO:0007829|PDB:6Z4U""
FT   STRAND          64..66
FT                   /evidence=""ECO:0007829|PDB:6Z4U""
FT   STRAND          68..74
FT                   /evidence=""ECO:0007829|PDB:6Z4U""
FT   STRAND          78..80
FT                   /evidence=""ECO:0007829|PDB:7YE7""
FT   HELIX           84..86
FT                   /evidence=""ECO:0007829|PDB:6Z4U""
FT   STRAND          89..96
FT                   /evidence=""ECO:0007829|PDB:6Z4U""
SQ   SEQUENCE   97 AA;  10797 MW;  62CFB65C1804545E CRC64;
     MDPKISEMHP ALRLVDPQIQ LAVTRMENAV GRDQNNVGPK VYPIILRLGS PLSLNMARKT
     LNSLEDKAFQ LTPIAVQMTK LATTEELPDE FVVVTVK
//
",22990
CTTCAT TTCATC TCATCC CATCCA ATCCAG TCCAGA CCAGAT CAGATT AGATTC GATTCT ATTCTG TTCTGC TCTGCC CTGCCA TGCCAC GCCACT CCACTC CACTCT ACTCTT CTCTTG TCTTGT CTTGTT TTGTTA TGTTAG GTTAGT TTAGTG TAGTGA AGTGAC GTGACA TGACAT GACATT ACATTG CATTGA ATTGAC TTGACA TGACAT GACATC ACATCA CATCAC ATCACT TCACTT CACTTT ACTTTC CTTTCT TTTCTT TTCTTA TCTTAA CTTAAA TTAAAG TAAAGA AAAGAA AAGAAA AGAAAG GAAAGA AAAGAT AAGATG AGATGC GATGCT ATGCTC TGCTCC GCTCCA CTCCAT TCCATA CCATAT CATATA ATATAT TATATA,0,67,CTTC TTCA TCAT CATC ATCC TCCA CCAG CAGA AGAT GATT ATTC TTCT TCTG CTGC TGCC GCCA CCAC CACT ACTC CTCT TCTT CTTG TTGT TGTT GTTA TTAG TAGT AGTG GTGA TGAC GACA ACAT CATT ATTG TTGA TGAC GACA ACAT CATC ATCA TCAC CACT ACTT CTTT TTTC TTCT TCTT CTTA TTAA TAAA AAAG AAGA AGAA GAAA AAAG AAGA AGAT GATG ATGC TGCT GCTC CTCC TCCA CCAT CATA ATAT TATA ATAT TATA,CTTCA TTCAT TCATC CATCC ATCCA TCCAG CCAGA CAGAT AGATT GATTC ATTCT TTCTG TCTGC CTGCC TGCCA GCCAC CCACT CACTC ACTCT CTCTT TCTTG CTTGT TTGTT TGTTA GTTAG TTAGT TAGTG AGTGA GTGAC TGACA GACAT ACATT CATTG ATTGA TTGAC TGACA GACAT ACATC CATCA ATCAC TCACT CACTT ACTTT CTTTC TTTCT TTCTT TCTTA CTTAA TTAAA TAAAG AAAGA AAGAA AGAAA GAAAG AAAGA AAGAT AGATG GATGC ATGCT TGCTC GCTCC CTCCA TCCAT CCATA CATAT ATATA TATAT ATATA,CTTCAT TTCATC TCATCC CATCCA ATCCAG TCCAGA CCAGAT CAGATT AGATTC GATTCT ATTCTG TTCTGC TCTGCC CTGCCA TGCCAC GCCACT CCACTC CACTCT ACTCTT CTCTTG TCTTGT CTTGTT TTGTTA TGTTAG GTTAGT TTAGTG TAGTGA AGTGAC GTGACA TGACAT GACATT ACATTG CATTGA ATTGAC TTGACA TGACAT GACATC ACATCA CATCAC ATCACT TCACTT CACTTT ACTTTC CTTTCT TTTCTT TTCTTA TCTTAA CTTAAA TTAAAG TAAAGA AAAGAA AAGAAA AGAAAG GAAAGA AAAGAT AAGATG AGATGC GATGCT ATGCTC TGCTCC GCTCCA CTCCAT TCCATA CCATAT CATATA ATATAT TATATA,CTTCATC TTCATCC TCATCCA CATCCAG ATCCAGA TCCAGAT CCAGATT CAGATTC AGATTCT GATTCTG ATTCTGC TTCTGCC TCTGCCA CTGCCAC TGCCACT GCCACTC CCACTCT CACTCTT ACTCTTG CTCTTGT TCTTGTT CTTGTTA TTGTTAG TGTTAGT GTTAGTG TTAGTGA TAGTGAC AGTGACA GTGACAT TGACATT GACATTG ACATTGA CATTGAC ATTGACA TTGACAT TGACATC GACATCA ACATCAC CATCACT ATCACTT TCACTTT CACTTTC ACTTTCT CTTTCTT TTTCTTA TTCTTAA TCTTAAA CTTAAAG TTAAAGA TAAAGAA AAAGAAA AAGAAAG AGAAAGA GAAAGAT AAAGATG AAGATGC AGATGCT GATGCTC ATGCTCC TGCTCCA GCTCCAT CTCCATA TCCATAT CCATATA CATATAT ATATATA,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",11679
